Deployment	T052	C2825812
Parental	T099	C0030551
Family	T099	C0015576
Child	T100	C0008059
Adjustment	T055	C0376209
Military Families	T099	C3850016
military service	T097	C1550414
United States	T083	C0041703
wartime	T079	C1254367
deployments	T052	C2825812
stress	T033	C0038435
military families	T099	C3850016
Research	T062	C0035168
negative impact	T033	C1513916
deployment	T052	C2825812
well being	T078	C0018684
service	T097	C1550414
members	T098	C0680022
military	T097	C3245458
spouses	T099	C0162409
children	T100	C0008059
parental	T099	C0030551
deployments	T052	C2825812
adjustment	T055	C0376209
young children	T100	C0728836
families	T099	C3850016
deployment	T052	C2825812
deployment records	T170	C0034869
parent	T099	C0030551
reported	T170	C0684224
caregiving	T052	C1947933
military	T097	C3245458
parents	T099	C0030551
deployment	T052	C2825812
adjustment	T055	C0376209
military families	T099	C3850016
children	T100	C0008059
deployment	T052	C2825812
impaired	T169	C0221099
family functioning	T054	C0680051
marital	T033	C0024841
instability	T033	C1444783
Parental	T099	C0030551
depressive	T048	C0011570
posttraumatic stress symptoms	T048	C0038436
associated with	T080	C0332281
impairments	T169	C0221099
social	T054	C0035820
emotional	T033	C0849912
adjustment	T055	C0376209
young children	T100	C0728836
anxiety	T033	C0003467
childhood	T079	C0231335
adjustment	T055	C0376209
school-age children	T100	C2827631
parental	T099	C0030551
sensitivity	T041	C0312418
associated with	T080	C0332281
social	T054	C0035820
emotional outcomes	T033	C0849912
childhood	T079	C0231335
findings	T033	C0243095
preventive	T080	C1456501
military families	T099	C3850016
children	T100	C0008059
neutral	T077	C1254372
forbidden links	T077	C1254372
morphological	T082	C0543482
matches	T080	C1708943
assembly	T078	C0441833
mutualistic	T067	C1254366
hawkmoth	T204	C0599456
plant	T002	C0032098
networks	T169	C1882071
evolutionary ecology	T090	C0013546
co-evolutionary processes	T067	C1522240
patterns	T082	C0449774
interactions	T169	C1704675
species	T185	C1705920
community	T096	C0009462
level	T080	C0441889
Pollination	T040	C1522786
flowers	T002	C0330090
long corolla tubes	T002	C2699452
long-tongued hawkmoths	T204	C0599456
model	T075	C0026336
co-evolution	T045	C0015219
models	T075	C0026336
association	T080	C0439849
mouthparts' length	T081	C1444754
corolla	T002	C2699452
depth	T082	C0205125
flowers	T002	C0330090
trait	T032	C0599883
convergence	T052	C2700387
specialization	T090	C0037776
community	T096	C0009462
assessed	T052	C1516048
hawkmoths	T204	C0599456
pollinate plants	T002	C0032098
floral tube	T185	C2698828
lengths	T081	C1444754
proboscis	T204	C3463932
lengths	T081	C1444754
morphological	T082	C0543482
match	T080	C1708943
hypothesis	T078	C1512571
abundance	T080	C2346714
processes	T067	C1522240
neutral hypothesis	T078	C1512571
ecological trait	T032	C0599883
mismatches	T080	C1881865
constraints	T057	C2986806
forbidden links	T077	C1254372
hypothesis	T078	C1512571
processes	T067	C1522240
structure	T082	C0678594
hawkmoth	T204	C0599456
plant	T002	C0032098
mutualistic networks	T169	C1882071
communities	T096	C0009462
biogeographical regions	T083	C0017446
South America	T083	C0037713
convergence	T052	C2700387
morphological	T082	C0543482
traits	T032	C0599883
communities	T096	C0009462
distribution	T169	C1704711
morphological	T082	C0543482
hawkmoths	T204	C0599456
plants	T002	C0032098
morphological	T082	C0543482
match	T080	C1708943
hypothesis	T078	C1512571
communities	T096	C0009462
communities	T096	C0009462
biogeographical areas	T083	C0017446
interactions	T169	C1704675
neutral hypothesis	T078	C1512571
findings	T169	C2607943
co-evolution	T045	C0015219
evolution	T045	C0015219
long proboscises	T204	C3463932
flower tubes	T002	C0330090
morphological	T082	C0543482
traits	T032	C0599883
forbidden links	T077	C1254372
hypothesis	T078	C1512571
interactions	T169	C1704675
mutualistic partners	T078	C0441833
role	T077	C1705810
niche-based processes	T067	C1522240
Nosocomial pneumonia	T047	C0949083
methicillin-resistant Staphylococcus aureus	T007	C1265292
treated with	T061	C0332293
linezolid	T109	C0663241
vancomycin	T116	C0042313
economic analysis	T057	C0680954
resource use	T078	C1704738
Spanish	T083	C0037747
perspective	UnknownType	C0680951
Spanish	T083	C0037747
perspective	UnknownType	C0680951
study	T062	C2603343
healthcare resource utilization	T078	C1704738
HCRU	T078	C1704738
costs	T081	C0085552
treating	T169	C1522326
nosocomial pneumonia	T047	C0949083
NP	T047	C0949083
methicillin-resistant Staphylococcus aureus	T007	C1265292
MRSA	T007	C1265292
hospitalized adults	T033	C0701159
linezolid	T109	C0663241
vancomycin	T116	C0042313
renal failure	T047	C0035078
rate	T081	C1521828
economic outcomes	T169	C1274040
study groups	UnknownType	C0681860
post hoc evaluation	T058	C1254363
randomized	T062	C2986910
double-blind	T062	C0013072
multicenter phase 4 study	T062	C0282462
Nosocomial pneumonia	T047	C0949083
MRSA	T007	C1265292
hospitalized adults	T033	C0701159
modified intent to treat	T169	C1292734
mITT	T169	C1292734
population	T098	C1257890
linezolid	T109	C0663241
vancomycin	T116	C0042313
treated	T061	C0332293
patients	T101	C0030705
Costs	T081	C0085552
HCRU	T078	C1704738
patients	T101	C0030705
administered	T169	C1521801
linezolid	T109	C0663241
vancomycin	T116	C0042313
patients	T101	C0030705
renal failure	T047	C0035078
HCRU	T078	C1704738
outcomes	T169	C1274040
costs	T081	C0085552
costs	T081	C0085552
linezolid	T109	C0663241
vancomycin	T116	C0042313
treated	T061	C0332293
patients	T101	C0030705
renal failure	T047	C0035078
rate	T081	C1521828
linezolid	T109	C0663241
treated	T061	C0332293
patients	T101	C0030705
costs	T081	C0085552
patients	T101	C0030705
renal failure	T047	C0035078
patients	T101	C0030705
renal failure	T047	C0035078
HCRU	T078	C1704738
days	T079	C0439228
mechanical ventilation	T061	C0199470
days	T079	C0439228
ICU stay	T079	C1254367
days	T079	C0439228
hospital stay	T079	C3489408
days	T079	C0439228
cost	T081	C0085552
linezolid	T109	C0663241
vancomycin	T116	C0042313
treated	T061	C0332293
patients	T101	C0030705
costs	T081	C0085552
patient	T101	C0030705
day	T079	C0439228
cohorts	T098	C0599755
mortality	T081	C0392762
Spanish	T083	C0037747
perspective	UnknownType	C0680951
costs	T081	C0085552
linezolid	T109	C0663241
vancomycin	T116	C0042313
pneumonia	T047	C0032285
cohorts	T098	C0599755
drug cost	T081	C0085123
linezolid	T109	C0663241
offset	T081	C1711330
renal failure	T047	C0035078
adverse events	T046	C0877248
HERG1	T116	C1566128
potassium channel	T116	C0032824
expression	T045	C1171362
potentially	T080	C3245505
malignant disorders	T191	C0006826
oral mucosa	T023	C0026639
prognostic	T170	C0220901
relevance	T080	C2347946
oral squamous cell carcinoma	T191	C0585362
HERG1	T116	C1566128
potassium channel	T116	C0032824
critical	T080	C1511545
role	T077	C1705810
cell proliferation	T043	C0596290
HERG1 protein	T116	C1566128
expression	T045	C1171362
analyzed	T062	C0936012
immunohistochemistry	T060	C0021044
IHC	T060	C0021044
patients	T101	C0030705
oral leukoplakias	T191	C0023532
patients	T101	C0030705
oral squamous cell carcinomas	T191	C0585362
OSCC	T191	C0585362
HERG1	T028	C1416571
mRNA	T114	C0035696
levels	T080	C0441889
assessed	T052	C1516048
real-time reverse transcriptase-polymerase chain reaction	T063	C0599161
RT-PCR	T063	C0599161
patients	T101	C0030705
primary	T080	C0205225
head and neck squamous cell carcinoma	T191	C1168401
HNSCC	T191	C1168401
Statistically significant	T081	C0237881
associations	T080	C0439849
HERG1	T116	C1566128
expression	T045	C1171362
tobacco consumption	T055	C0543414
disease stage	T060	C0699749
tumor	T191	C0027651
differentiation	T043	C0007589
tumor recurrence	T191	C0521158
reduced	T080	C0392756
survival	T052	C0038952
no	T169	C1518422
association	T080	C0439849
HERG1	T116	C1566128
expression	T045	C1171362
risk	T078	C0035647
progression	T191	C0178874
oral leukoplakia	T191	C0023532
OSCC	T191	C0585362
high	T080	C0205250
proportion	T081	C1709707
tumors	T191	C0027651
increased	T081	C0205217
HERG1	T028	C1416571
mRNA	T114	C0035696
levels	T080	C0441889
compared	T052	C1707455
normal mucosa	T024	C0026724
nononcologic patients	T101	C0030705
Aberrant	T080	C0443127
HERG1	T116	C1566128
expression	T045	C1171362
increases	T169	C0442805
tumorigenesis progresses	T191	C0178874
oral hyperplasia	T046	C1400010
OSCC	T191	C0585362
Increased	T081	C0205217
HERG1	T028	C1416571
mRNA	T114	C0035696
levels	T080	C0441889
detected	T033	C0442726
OSCC	T191	C0585362
HNSCC	T191	C1168401
subsites	T082	C1710234
HERG1	T116	C1566128
expression	T045	C1171362
clinically	T080	C0205210
relevant	T080	C2347946
feature	T080	C2348519
tumor progression	T191	C0178874
potential	T080	C3245505
poor	T080	C2700379
prognostic	T170	C0220901
biomarker	T201	C0005516
OSCC	T191	C0585362
Nationwide	T082	C1254362
reduction	T081	C0547047
corneal transplantations	T061	C0010042
keratoconus	T047	C0022578
implementation	T052	C1708476
cross-linking	T061	C4065848
Keratoconus	T047	C0022578
corneal ectasia	T047	C0155135
irregular astigmatism	T047	C0152194
diminished vision	T047	C0042798
corneal scarring	T033	C0349702
patients	T101	C0030705
keratoconus	T047	C0022578
corneal transplant	T061	C0010042
Corneal cross-linking	T061	C4065848
CXL	T061	C4065848
treatment	T061	C0087111
corneal transplantation	T061	C0010042
investigated	T169	C1292732
introduction	T169	C0579004
CXL	T061	C4065848
corneal transplants	T061	C0010042
performed	T169	C0884358
annually	T079	C0332181
Data	T078	C1511726
transplantation procedures	T061	C0040732
performed	T169	C0884358
patients	T101	C0030705
age	T032	C0001779
years	T079	C0439234
Dutch National Organ Transplant Registry	T170	C0034975
corneal transplants	T061	C0010042
performed	T169	C0884358
introduction	T169	C0579004
CXL	T061	C4065848
compared	T052	C1707455
trend analysis	UnknownType	C0681702
annual	T079	C0332181
keratoplasties	T061	C0010042
performed	T169	C0884358
corneal transplants	T061	C0010042
performed	T169	C0884358
year	T079	C0439234
introduction	T169	C0579004
CXL	T061	C4065848
compared	T052	C1707455
year	T079	C0439234
introduction	T169	C0579004
CXL	T061	C4065848
transplants	T061	C0010042
Age	T032	C0001779
gender	T032	C0079399
visual acuity	T201	C0042812
patient	T101	C0030705
time periods	T079	C1948053
Trend analysis	UnknownType	C0681702
decrease	T081	C0547047
corneal transplants	T061	C0010042
corneal transplants	T061	C0010042
keratoconus	T047	C0022578
nationwide	T082	C1254362
introduction	T169	C0579004
CXL	T061	C4065848
reduction	T081	C0547047
corneal cross-linking	T061	C4065848
reduce	T080	C0392756
corneal transplantation	T061	C0010042
Basal	T040	C0678121
maximal	T080	C0205289
metabolic rates	T039	C0870882
response	T032	C0871261
temperature change	T080	C0450031
avian	T012	C0005595
species	T185	C1705920
birds	T012	C0005595
acclimation	T040	C0000934
acclimatization	T040	C0000934
temperature	T081	C0039476
basal	T040	C0678121
BMR	T040	C0678121
summit	T039	C0870882
Msum	T039	C0870882
maximal	T080	C0205289
MMR	T039	C0870882
metabolic rates	T039	C0870882
rate	T039	C0870882
species	T185	C1705920
phenotype	T032	C0031437
short-term	T079	C0443303
temperature	T081	C0039476
variations	T080	C0205419
aims	T078	C1947946
pattern	T082	C0449774
metabolic	T169	C0311400
temperature change	T080	C0450031
rates	T039	C0870882
exposure to	T080	C0332157
warm	T067	C0563030
cold environments	T067	C0241842
BMR	T040	C0678121
Msum	T039	C0870882
MMR	T039	C0870882
rates	T039	C0870882
thermal	T070	C0018837
acclimation	T040	C0000934
white-throated sparrows	T012	C1093387
Zonotrichia albicollis	T012	C1093387
black-capped chickadees	T012	C0326488
Poecile atricapillus	T012	C0326488
snow buntings	T012	C0326923
Plectrophenax nivalis	T012	C0326923
acclimation	T040	C0000934
day	T079	C0439228
days	T079	C0439228
acclimation	T040	C0000934
Birds	T012	C0005595
metabolic	T169	C0311400
phenotype	T032	C0031437
days	T079	C0439228
patterns	T082	C0449774
species	T185	C1705920
Sparrows	T012	C1093387
metabolic	T169	C0311400
increases	T169	C0442805
cold	T067	C0241842
thermoneutrality	T078	C0680444
chickadees	T012	C0326488
buntings	T012	C0326923
influenced	T077	C4054723
temperature	T081	C0039476
patterns	T082	C0449774
results	T033	C0683954
BMR	T040	C0678121
rates	T039	C0870882
warm	T067	C0563030
cold environments	T067	C0241842
Msum	T039	C0870882
MMR	T039	C0870882
limitations	T169	C0449295
rate	T039	C0870882
organ size	T032	C1450569
function	T169	C0542341
maximal	T080	C0205289
metabolic	T169	C0311400
capacity	T081	C1516240
lost	T169	C0745777
warm environment	T067	C0563030
gained	T081	C1517378
cold environment	T067	C0241842
temperature	T081	C0039476
stochasticity	T081	C0038347
northern latitudes	T083	C0017446
loss	T081	C1517945
thermogenic	T070	C0018837
capacity	T081	C1516240
warm	T067	C0563030
winter	T079	C0241737
days	T079	C0439228
birds	T012	C0005595
phenotype	T032	C0031437
cold	T067	C0241842
days	T079	C0439228
prime	T041	C3825344
calories	T081	C1556156
effects of	T080	C1704420
supraliminal priming	T041	C3825344
food consumption	T052	C2983605
moderating role	T170	C1704326
gender	T032	C0079399
eating restraint	T170	C0451424
intentions	T041	C0162425
action	T052	C3266814
weight control	T061	C0920298
research	T062	C0035168
weight control	T061	C0920298
conscious	T041	C0234421
intentions	T041	C0162425
Priming	T041	C3825344
subconscious	T041	C0038535
cognition	T041	C0009240
effects of	T080	C1704420
semantic priming	T169	C0871332
healthy	T080	C3898900
body image	T041	C0005891
goal-oriented words	T170	C0042926
food consumption	T052	C2983605
moderating role	T170	C1704326
restrained eating	T170	C0451424
gender	T032	C0079399
participants	T098	C0679646
experiment	T062	C0681814
sentence	T170	C0876929
priming	T041	C3825344
game	T056	C0150593
kilocalories	T081	C0439259
consumed	T061	C0513065
ANCOVA	T081	C0814908
priming	T041	C3825344
gender	T032	C0079399
restrained eating index	T170	C0451424
self-reported	T062	C2700446
BMI	T201	C1305855
interaction	T169	C1704675
priming	T041	C3825344
gender	T032	C0079399
priming	T041	C3825344
restrained eating index	T170	C0451424
effect of	T080	C1704420
priming	T041	C3825344
interaction	T169	C1704675
priming	T041	C3825344
gender	T032	C0079399
Females	T032	C0086287
kilocalories	T081	C0439259
priming	T041	C3825344
words	T170	C0042926
healthy	T080	C3898900
body image	T041	C0005891
females	T032	C0086287
prime	T041	C3825344
body image	T041	C0005891
prime	T041	C3825344
food intake	T040	C0013470
males	T032	C0086582
restrained eaters	T098	C0679646
priming	T041	C3825344
females	T032	C0086287
food intake	T040	C0013470
restrained	T098	C0679646
unrestrained eaters	T098	C0679646
priming	T041	C3825344
words	T170	C0042926
male's	T032	C0086582
healthy	T080	C3898900
body image	T041	C0005891
muscles	T024	C0026845
food intake	T040	C0013470
males	T032	C0086582
Neurotrophins	T116	C0027754
specific receptors	T116	C0254837
oviduct tracts	T023	C0029954
Japanese quail	T012	C0022345
Coturnix coturnix japonica	T012	C0022345
Neurotrophins	T116	C0027754
NGF	T116	C0027752
BDNF	T116	C0107103
NT-3	T116	C0083735
specific receptors	T116	C0254837
TrkA	T116	C0072482
TrkB	T116	C0084873
TrkC	T116	C0132300
studied	T062	C2603343
oviduct	T023	C0029954
egg laying	T040	C1622979
quails	T012	C0022345
Neurotrophins	T116	C0027754
NTs	T116	C0027754
development	T169	C1527148
maintenance	T169	C0587894
neuronal populations	T025	C0027882
central	T022	C3714787
peripheral nervous system	T022	C0206417
reproductive system	T022	C1261210
studied	T062	C2603343
morphological	T080	C0332437
organization	T039	C0029237
quail	T012	C0022345
oviduct	T023	C0029954
infundibulum	T023	C0227911
magnum	T023	C0229962
isthmus	T023	C0227909
uterus	T023	C0042149
vagina	T023	C0042232
analyzed	T062	C0936012
expression	T045	C1171362
localization	T043	C0007613
NTs	T116	C0027754
Trks receptors	T116	C0254837
tracts	T023	C0029954
western blotting	T059	C0005863
investigated	T169	C1292732
NTs	T116	C0027754
Trks receptors	T116	C0254837
expressed	T045	C1171362
oviductal tracts	T023	C0029954
immunohistochemistry	T060	C0021044
distribution	T043	C0872250
NTs	T116	C0027754
Trks	T116	C0254837
NGF	T116	C0027752
BDNF	T116	C0107103
NT3	T116	C0083735
lining	T082	C1254362
ductal epithelial cells	T025	C1512085
NGF	T116	C0027752
secretory cells	T025	C1519221
tubular glands	T023	C1179446
nervous fibers	T026	C0027749
vessel wall	T023	C0507777
TrkA	T116	C0072482
TrkB	T116	C0084873
lining	T082	C1254362
ductal epithelium	T024	C1512086
TrkA	T116	C0072482
TrkC	T116	C0132300
nervous fibers	T026	C0027749
vessel wall	T023	C0507777
oviductal tracts	T023	C0029954
NGF	T116	C0027752
BDNF	T116	C0107103
TrkA	T116	C0072482
TrkB	T116	C0084873
cells	T025	C0007634
lining	T082	C1254362
ductal epithelium	T024	C1512086
autocrine mechanism	T043	C3825249
action	T052	C3266814
liposomal	T109	C0023828
formulation	T077	C1705957
incorporation	T169	C0243126
retention	T169	C0333117
PNA oligomers	T114	C0600500
Liposomal	T109	C0023828
formulations	T077	C1705957
phospholipids	T109	C0031676
unsaturation degrees	T080	C0522535
head groups	T169	C0205245
cholesterol content have been tested	T059	C0201950
encapsulation	T067	C2348438
Peptide Nucleic Acid (PNA) oligomers	T114	C0600500
best loading capability	T081	C3714444
ER	T081	C0456603
liposomes	T109	C0023828
phosphatidylglycerol	T109	C0043840
DOPG	T109	C0043840
negatively charged	T196	C0003075
head group	T169	C0205245
insertion	T058	C0441587
cholesterol	T109	C0008377
DOPG	T109	C0043840
liposomes	T109	C0023828
decrease	T081	C0547047
PNA	T114	C0600500
loading	T052	C1708715
cholesterol	T109	C0008377
addition	T169	C1524062
PNA's	T114	C0600500
release	T070	C3850077
fetal bovine serum	T130	C3812213
liposomal	T109	C0023828
formulation	T077	C1705957
encapsulation	T067	C2348438
release properties	T070	C3850077
PEGylated	T109	C0032483
DOPG	T109	C0043840
liposomes	T109	C0023828
cholesterol	T109	C0008377
optimal formulation	T062	C0524527
loading	T052	C1708715
PNA-a210	T114	C0600500
Histopathology	T091	C0677043
filum terminale	T023	C0016109
children	T100	C0008059
without	T080	C0332288
tethered cord syndrome	T047	C0080218
elastic tissue	T024	C0013762
filum	T023	C0016109
compare	T052	C1707455
histologically	T169	C0205462
transected	T169	C0332847
fila	T023	C0016109
pediatric	T080	C1521725
patients	T101	C0030705
tethered cord syndrome	T047	C0080218
TCS	T047	C0080218
without	T080	C0332288
low	T029	C1548802
conus	T023	C0149601
collagenous	T024	C0225333
elastic tissue	T024	C0013762
fila	T023	C0016109
patients	T101	C0030705
TCS	T047	C0080218
minimal	T080	C0547040
cautery	T061	C0007471
filum	T023	C0016109
section	T059	C0700320
compared	T052	C1707455
fila	T023	C0016109
pediatric	T080	C1521725
cadavers	T017	C0006629
without	T080	C0332288
TCS	T047	C0080218
controls	T096	C0009932
Sections	T167	C1522472
fila	T023	C0016109
stained	T059	C0487602
H&E	T059	C0523207
Masson trichrome	T059	C1294297
Verhoeff von Gieson elastic stains	T059	C1294321
Gordon and Sweet's reticulin stain	T059	C1293950
Fila	T023	C0016109
controls	T096	C0009932
loose	T080	C0205407
fibrous connective tissue	T024	C1184823
FCT	T024	C1184823
thin	T080	C0205168
evenly dispersed	T169	C1704711
elastic fibers	T024	C0230899
EFs	T024	C0230899
Reticulin fibers	T116	C0035285
RFs	T116	C0035285
blood vessel walls	T023	C1180033
nerve	T024	C0027740
Fat	T109	C0015677
identified	T080	C0205396
microscopically	T080	C0205288
fila	T023	C0016109
fila	T023	C0016109
patients	T101	C0030705
TCS	T047	C0080218
dense FCT	T024	C0225333
EFs	T024	C0230899
normal	T080	C0205307
focally	T082	C0205234
diffusely	T080	C0332261
decreased	T081	C0205216
patients	T101	C0030705
fila	T023	C0016109
cauterized	T061	C0007471
resection	T061	C0728940
thick	T080	C1280412
coiled	T082	C1880179
EFs	T024	C0230899
Coiling	T082	C0444764
minimal	T080	C0547040
cautery	T061	C0007471
RFs	T116	C0035285
blood vessel walls	T023	C1180033
Fat	T109	C0015677
identified	T080	C0205396
patients	T101	C0030705
Findings	T033	C0243095
similar	T080	C2348205
conus	T023	C0149601
normal	T080	C0205307
low	T082	C0441994
fila	T023	C0016109
patients	T101	C0030705
TCS	T047	C0080218
conus	T023	C0149601
low	T082	C0441994
abnormal	T033	C0205161
FCT	T024	C1184823
EFs	T024	C0230899
decreased	T081	C0205216
patients	T101	C0030705
thick	T080	C1280412
coiled	T082	C1880179
EFs	T024	C0230899
patients	T101	C0030705
Coiling	T082	C0444764
EFs	T024	C0230899
abnormality	T033	C1704258
patients	T101	C0030705
result	T033	C0808233
cautery	T061	C0007471
artifactual	T068	C0085089
iatrogenic	T080	C0439669
coiling	T082	C0444764
Clinical value	T033	C2826293
pathologic examination	T060	C4086729
non-neoplastic kidney	T023	C0022646
patients	T101	C0030705
upper urinary tract	T022	C1278977
malignancies	T191	C4282132
surgical resection	T061	C0728940
care	T052	C1947933
treatment	T061	C0087111
upper urinary tract	T022	C1278977
malignancies	T191	C4282132
nephrectomy	T061	C0027695
risk factor	T033	C0035648
development	T169	C1527148
chronic kidney disease	T047	C1561643
CKD	T047	C1561643
study	T062	C2603343
histologic	T169	C0205462
evaluation	T058	C0220825
non-neoplastic kidney	T023	C0022646
early identification	T061	C0814435
kidney disease	T047	C0022658
prognostic	T170	C0220901
postoperative	T079	C0032790
renal	T023	C0022646
outcomes	T080	C0085415
retrospectively analyzed	T062	C0035363
patients	T101	C0030705
upper urinary tract	T022	C1278977
malignancies	T191	C4282132
uninephrectomy	T061	C0027695
uninephroureterectomy	T061	C0027732
pathologic	T169	C1521733
evaluation	T058	C0220825
non-neoplastic kidney	T023	C0022646
special stains	T061	C2038188
immunofluorescence	T059	C0079603
electron microscopic studies	T059	C0026019
degree	T081	C0449286
parenchymal	T023	C0933845
changes	T169	C0392747
patients	T101	C0030705
kidney	T023	C0022646
pathology	T091	C0030664
patients	T101	C0030705
glomerular abnormalities	T047	C1398788
diabetic nephropathy	T047	C0011881
vascular	T023	C0005847
nephropathy	T061	C0027695
reflux nephropathy	T047	C3495566
chronic pyelonephritis	T047	C0085697
histologic score	T081	C0449820
patients	T101	C0030705
Score	T081	C0449820
patients	T101	C0030705
Postoperative	T079	C0032790
estimated glomerular filtration rate	T059	C3811844
eGFR	T059	C3811844
months	T079	C0439231
patients	T101	C0030705
CKD	T047	C1561643
CKD	T047	C1561643
nephrectomized patients	T101	C0030705
risk factors	T033	C0035648
CKD	T047	C1561643
nephrectomized patients	T101	C0030705
Cox regression analysis	T170	C0034980
postoperative	T079	C0032790
AKI	T037	C2609414
preoperative	T079	C0445204
eGFR	T059	C3811844
histologic	T169	C0205462
non-neoplastic kidney	T023	C0022646
predictors	T078	C2698872
CKD	T047	C1561643
pathologic	T169	C1521733
evaluation	T058	C0220825
non-neoplastic kidney	T023	C0022646
diagnostic	T169	C0348026
prognostic	T170	C0220901
Phenotypes	T032	C0031437
Duchenne Muscular Dystrophy	T047	C0013264
Patient	T101	C0030705
Myoblasts	T025	C0596995
Human	T016	C0086418
iPSC	T025	C2717959
Model	T050	C0684309
Duchenne muscular dystrophy	T047	C0013264
DMD	T047	C0013264
genetic disease	T047	C0019247
animal models	T050	C0012644
DMD	T047	C0013264
human cell	T025	C0682523
patient	T101	C0030705
DYSTROPHIN	T028	C1414083
mutations	T045	C0596611
human	T016	C0086418
DMD	T047	C0013264
model	T050	C0684309
human induced pluripotent stem cells	T025	C3658289
hiPSCs	T025	C3658289
disease	T047	C0012634
related	T169	C1552599
phenotypes	T032	C0031437
patient	T101	C0030705
dependent	T080	C0851827
variation	T080	C0205419
genetic	T169	C0314603
pharmacological	T169	C0205464
chemical-compound	T103	C0220806
strategy	T062	C0035171
hiPSCs	T025	C3658289
myoblasts	T025	C0596995
myogenic transcriptional	T045	C0040649
program	T169	C3484370
striated	T080	C0205364
contractile	T026	C1752744
myofibers	T026	C3179197
muscle regeneration	T033	C1850849
in vivo	T082	C1515655
DMD	T047	C0013264
hiPSC	T025	C3658289
myoblasts	T025	C0596995
disease	T047	C0012634
related	T169	C1552599
phenotypes	T032	C0031437
patient	T101	C0030705
patient	T101	C0030705
variability	T077	C2827666
aberrant	T080	C0443127
inflammation	T046	C0021368
immune-response genes	T028	C0086344
collagens	T116	C0009325
BMP	T044	C1155364
TGFβ signaling	T044	C1155363
genetic	T169	C0314603
correction	T169	C1947976
pharmacological	T169	C0205464
SMAD	T116	C1571580
inhibition	T043	C1519312
DMD	T047	C0013264
hiPSC	T025	C3658289
myoblasts	T025	C0596995
genetically	T169	C0314603
isogenic	T080	C2348628
myoblasts	T025	C0596995
multi	T081	C0439064
nucleated	T080	C1979936
myotubes	T025	C0242697
human	T016	C0086418
DMD	T047	C0013264
model	T050	C0684309
hiPSC	T025	C3658289
disease modeling	T050	C0684309
SNAI1	T116	C4308198
promotes	T052	C0033414
development	T169	C1527148
HCC	T191	C2239176
enhancement	T052	C2349975
proliferation	T169	C1514485
inhibition of apoptosis	T043	C1512772
SNAI1	T116	C4308198
zinc-finger transcription factor	T116	C0040648
induction	T169	C0205263
epithelial-mesenchymal transition	T043	C1523298
EMT	T043	C1523298
cancers	T191	C0006826
SNAI1	T116	C4308198
proliferation	T169	C1514485
apoptosis	T043	C0162638
hepatocellular carcinoma	T191	C2239176
study	T062	C2603343
effects	T080	C1280500
mechanisms	T169	C0441712
SNAI1	T116	C4308198
proliferation	T169	C1514485
apoptosis	T043	C0162638
hepatocellular carcinoma	T191	C2239176
clinical	T080	C0205210
samples	T167	C0370003
cell lines	T025	C0085983
SNAI1	T116	C4308198
expressed	T045	C1171362
tissues	T024	C0040300
liver cancer	T191	C2239176
nontumor tissues	T024	C0040300
SNAI1	T116	C4308198
expressed	T045	C1171362
hepatoma cell lines HepG2	T025	C2717940
SMMC-7721	T025	C0085983
BEL-7402	T025	C0085983
human normal liver cell line L02	T025	C0682523
SNAI1	T116	C4308198
expression	T045	C1171362
distal metastasis	T046	C4255448
tumor capsule formation	T191	C0027671
histological differentiation	T201	C1511938
hepatocellular carcinoma	T191	C2239176
HCC	T191	C2239176
knockdown	T063	C2350567
SNAI1	T028	C1420267
lentiviral	T005	C0079679
vectors	T121	C1520007
RNAi	T045	C1136031
SNAI	T116	C4308198
cell proliferation	T169	C1514485
G1 arrest	T043	C3178834
downregulation	T044	C0013081
cyclin D1	T116	C0174680
cyclin A	T116	C0079184
knockdown	T063	C2350567
SNAI1	T028	C1420267
promoted	T052	C0033414
apoptosis	T043	C0162638
expression	T045	C1171362
Bcl-2	T116	C4042483
SNAI1	T116	C4308198
development	T169	C1527148
hepatocellular carcinoma	T191	C2239176
regulating the growth	T040	C1160191
apoptosis	T043	C0162638
tumor cells	T025	C0597032
Quantitative assessment	T081	C0034384
fluorescent proteins	T116	C0033684
fluorescent proteins	T116	C0033684
FPs	T116	C0033684
genetic labeling	T063	C1513384
molecules	T167	C0567416
cells	T025	C0007634
fluorescence microscopy	T059	C0026022
Genetic manipulations	T063	C0178659
FPs	T116	C0033684
blue to red spectral regions	T082	C1254362
autofluorescent	T059	C0544711
FPs	T116	C0033684
β-barrel structure	T087	C0599216
rigidity	T080	C0205556
chemical	T103	C0220806
environment	T082	C0014406
fluorescence	T070	C0016315
structure	T085	C0026383
FP	T116	C0033684
properties	T080	C0871161
FP	T116	C0033684
FP	T116	C0033684
FP	T116	C0033684
quantitatively	T081	C0392762
brightness	T070	C0678578
photostability	T033	C0243095
pH	T081	C0020283
stability	T080	C0205360
monomeric	T104	C0596973
properties	T080	C0871161
FPs	T116	C0033684
straightforward	T080	C1272701
comparison	T052	C1707455
FPs	T116	C0033684
spectral region	T082	C1254362
Consumption of fruits and vegetables	T040	C1271941
associated with	T080	C0332281
risk behaviors	T055	C0086931
adolescents	T100	C0205653
Northeast Brazil	T083	C0006137
prevalence	T081	C0220900
consumption of fruits and vegetables	T040	C1271941
association with	T080	C0332281
low	T080	C0205251
level	T080	C0441889
physical activity	T056	C0026606
exposure to	T080	C0332157
sedentary behavior	T033	C3824706
consumption	T052	C2983605
soft drinks	T168	C3489624
overweight	T184	C0497406
obesity	T047	C0028754
adolescents	T100	C0205653
cross-sectional school-based study	T062	C0010362
sample	T167	C0370003
students	T098	C0038492
years	T079	C1510829
state of Sergipe	T083	C1301808
Brazil	T083	C0006137
outcome	T169	C1274040
low	T080	C0205251
consumption of fruits and vegetables	T040	C1271941
servings/day	T079	C0439505
Independent variables	T169	C0870693
level	T080	C0441889
physical activity	T056	C0026606
sedentary behavior	T033	C3824706
consumption	T052	C2983605
soft drinks	T168	C3489624
overweight	T184	C0497406
obesity	T047	C0028754
Global Student Health Survey questionnaire	T170	C0034394
body mass	T058	C3698309
height	T032	C0005890
measurements	T058	C0947289
chi-square test	T170	C0008041
crude and adjusted binary logistic regression	T062	C0206031
significance level	T062	C0814896
prevalence	T081	C0220900
inadequate	T080	C0205412
consumption of fruits and vegetables	T040	C1271941
high	T080	C0205250
CI	T081	C0009667
Higher	T080	C0205250
low	T080	C0205251
consumption of fruits and vegetables	T040	C1271941
boys	T100	C0870221
exposed to	T080	C0332157
sedentary behavior	T033	C3824706
OR	T081	C0028873
CI	T081	C0009667
consumed	T052	C2983605
soft drinks	T168	C3489624
OR	T081	C0028873
CI	T081	C0009667
insufficiently	T080	C0231180
physical activity	T056	C0026606
OR	T081	C0028873
CI	T081	C0009667
girls	T100	C0870604
consumed	T052	C2983605
soft drinks	T168	C3489624
OR	T081	C0028873
CI	T081	C0009667
overweight	T184	C0497406
obesity	T047	C0028754
OR	T081	C0028873
CI	T081	C0009667
public policies	T064	C0034033
consumption of healthy foods	T052	C2983605
adolescents	T100	C0205653
Cobalamin	T114	C0086024
Protection	T033	C1545588
Oxidative Stress	T049	C0242606
Acidophilic	T169	C0333931
Iron-oxidizing Bacterium	T007	C0004611
Leptospirillum Group II CF-1	T007	C2758310
Leptospirillum	T007	C0995279
aerobic	T080	C1510824
iron-oxidizing bacteria	T007	C0004611
phylum Nitrospira	T007	C0995591
microbial	T001	C0599840
communities	T070	C1253910
catalyze	T070	C2350294
biomining	T057	C0026175
sulfidic ores	T104	C0567321
metal ions	T196	C0022023
microorganisms	T001	C0445623
metal	T197	C0025552
environments	T082	C0014406
concentrations	T081	C1446561
reactive oxygen species	T123	C0162772
ROS	T123	C0162772
Cobalamin	T114	C0086024
vitamin B12	T109	C0042845
cobalt	T123	C0009148
tetrapyrrole	T109	C0076335
cofactor	T123	C0178555
intramolecular rearrangement reactions	T067	C0596965
intracellular	T082	C0178719
antioxidant	T121	C0003402
investigated	T169	C1292732
effect	T080	C1280500
exogenous	T169	C0205228
cobalamin	T114	C0086024
oxidative stress	T049	C0242606
parameters	T077	C0549193
Leptospirillum group II strain CF-1	T007	C2758310
revealed	T080	C0443289
external supplementation	T168	C0681579
cobalamin	T114	C0086024
intracellular	T082	C0178719
ROSs	T123	C0162772
damage	T169	C1883709
biomolecules	T123	C0574031
stimulates	T070	C1948023
growth	T040	C0018270
survival of cells	T043	C0007620
oxidative stress	T049	C0242606
ferric ion	T196	C2346593
hydrogen peroxide	T121	C0020281
chromate	T197	C0008543
diamide	T109	C0011953
strain CF-1	T007	C0995279
oxidative stress	T049	C0242606
transcriptional activation	T045	C0162493
cbiA gene	T028	C0017337
CbiA	T116	C0033684
cobalamin	T114	C0086024
biosynthetic pathway	T044	C1721101
data	T078	C1511726
cobalamin	T114	C0086024
redox	T044	C0030012
protection	T033	C1545588
Leptospirillum strain CF-1	T007	C0995279
microorganism	T001	C0445623
oxidative	T169	C0311404
environmental conditions	T080	C0348080
mechanisms	T169	C0441712
protective	T033	C1545588
effect	T080	C1280500
cobalamin	T114	C0086024
oxidative stress	T049	C0242606
biomining	T057	C0026175
processes	T067	C1522240
effective	T080	C1704419
longitudinal study	T062	C0023981
childcare	T057	C0683807
services'	T057	C0557854
obesity	T047	C0028754
prevention policies and practices	T058	C1254363
obesogenic	T047	C0028754
environments	T082	C0014406
childcare	T057	C0683807
services	T057	C0557854
physical activity	T056	C0026606
nutrition-promoting practices	T062	C1521729
Australian	T098	C0238711
childcare	T057	C0683807
services	T057	C0557854
best-practice	T058	C1254363
healthy eating	T061	C0452415
physical activity	T056	C0026606
practices	T058	C1254363
socio-economic status	T080	C0086996
locality	T082	C1254362
randomly selected sample	T062	C0150105
supervisors	T097	C0403172
childcare	T057	C0683807
services	T057	C0557854
New South Wales	T083	C0027975
Australia	T083	C0004340
telephone survey	T062	C0681820
Supervisors	T097	C0403172
service's	T057	C0557854
practices	T058	C1254363
nutrition	T062	C1521729
physical activity	T056	C0026606
policies	T170	C0242456
staff	T097	C0851286
physical activity	T056	C0026606
nutrition	T062	C1521729
time	T079	C0040223
movement	T040	C0026649
skills	T055	C0678856
outdoor play	T056	C0032214
weekly	T079	C0332174
screen time opportunitie	T033	C4038978
non-sweetened beverages	T168	C0005329
prevalence	T081	C0220900
services	T057	C0557854
practice	T058	C1254363
services	T057	C0557854
practices	T058	C1254363
services	T057	C0557854
practice	T058	C1254363
locality	T082	C1254362
socio-economic status	T080	C0086996
Government	T092	C0018104
investment	T081	C3242637
obesity	T047	C0028754
prevention programmes	T058	C1254363
childcare	T057	C0683807
healthy eating	T061	C0452415
physical activity	T056	C0026606
practices	T058	C1254363
jurisdiction	T170	C0680647
practices	T058	C1254363
childcare	T057	C0683807
services	T057	C0557854
Isolation	T169	C0205409
characterization	T052	C1880022
Burkholderia sp. strain CCA53	T007	C4130454
ligninolytic	T044	C1156998
potential	T080	C3245505
Microbial	T001	C0599840
degradation	T040	C0699900
lignin	T109	C0023705
fermentable sugars	T109	C0242209
effective	T080	C1704419
utilization	T169	C0457083
biofuel	T109	C2717891
production	T057	C0033268
lignocellulosic	T109	C0064974
biomass	T081	C0005535
study	T062	C2603343
lignin-degrading	T044	C1156998
bacterium	T007	C0004611
isolated	T169	C0205409
leaf	T002	C0242724
soil	T167	C0037592
Burkholderia sp.	T007	C1264855
16S rRNA	T114	C3537372
gene sequencing	T059	C1294197
strain	T080	C0456178
CCA53	T007	C4130454
lignin-degrading	T044	C1156998
capability	T080	C2698977
assessed	T052	C1516048
growth	T040	C0018270
medium	T130	C0010454
alkali lignin	T109	C0023705
lignin	T109	C0023705
aromatic monomers	T104	C0596973
carbon	T196	C0007009
source	T033	C0449416
Alkali lignin	T109	C0023705
lignin	T109	C0023705
aromatic monomers	T104	C0596973
growth	T040	C0018270
strain	T080	C0456178
effective	T080	C1704419
utilization	T169	C0457083
p-hydroxybenzene monomers	T104	C0596973
findings	T033	C0243095
Burkholderia sp. strain CCA53	T007	C4130454
fragmentary activity	T052	C0441655
lignin degradation	T044	C1156998
Diagnostic	T169	C0348026
utility	T169	C0457083
conventional	T081	C0205214
techniques	T060	C0430022
endobronchial ultrasonography	T060	C2959489
guidance	T058	C0150600
transbronchial biopsy	T060	C0863477
Endobronchial ultrasonography	T060	C2959489
guide sheath	T074	C0025080
transbronchial biopsy	T060	C0863477
EBUS	T060	C2959489
GS	T074	C0025080
TBB	T060	C0863477
diagnose	T033	C0011900
peripheral pulmonary lesions	T033	C0577916
PPLs	T033	C0577916
study	T062	C2603343
diagnostic	T169	C0348026
utility	T169	C0457083
conventional	T081	C0205214
TBB	T060	C0863477
EBUS	T060	C2959489
GS	T074	C0025080
TBB	T060	C0863477
retrospective analysis	T062	C0035363
patients	T101	C0030705
conventional	T081	C0205214
TBB	T060	C0863477
EBUS	T060	C2959489
GS	T074	C0025080
TBB	T060	C0863477
PPL	T033	C0577916
multivariate analysis	T081	C0026777
association	T080	C0439849
clinical	T080	C0205210
factors	T169	C1521761
EBUS	T060	C2959489
probe	T074	C0182400
distance	T081	C0012751
sample size	T081	C0242618
area	T082	C0205146
diagnostic yield	T080	C0205556
patients	T101	C0030705
diagnosed	T033	C0011900
EBUS	T060	C2959489
GS	T074	C0025080
TBB	T060	C0863477
patients	T101	C0030705
diagnosed	T033	C0011900
EBUS	T060	C2959489
GS	T074	C0025080
TBB	T060	C0863477
diagnosed	T033	C0011900
conventional	T081	C0205214
TBB	T060	C0863477
Ground glass opacity	T033	C3827002
GGO	T033	C3827002
significant	T078	C0750502
factor	T169	C1521761
diagnostic yield	T080	C0205556
conventional	T081	C0205214
TBB	T060	C0863477
EBUS	T060	C2959489
GS	T074	C0025080
TBB	T060	C0863477
Multivariate analysis	T081	C0026777
receiver operator curves	T081	C0035787
distance	T081	C0012751
PPL	T033	C0577916
EBUS	T060	C2959489
probe	T074	C0182400
utility	T169	C0457083
conventional	T081	C0205214
TBB	T060	C0863477
conventional	T081	C0205214
TBB	T060	C0863477
EBUS	T060	C2959489
GS	T074	C0025080
TBB	T060	C0863477
procedure	T060	C0430022
diagnosis	T033	C0011900
ground glass opacity	T033	C3827002
PPLs	T033	C0577916
cases	T169	C0868928
distance	T081	C0012751
EBUS	T060	C2959489
probe	T074	C0182400
lesion	T033	C0577916
Active	T169	C0205177
diffusion	T070	C0012222
microtubule-based transport	T043	C2755890
myosin	T116	C0033684
forces	T067	C0441722
position	T082	C0733755
organelles	T026	C0029219
cells	T025	C0007634
distribution	T169	C1704711
peroxisomes	T026	C0752063
POs	T026	C0752063
lipid droplets	T026	C0230704
LDs	T026	C0230704
role	T077	C1705810
lipid	T109	C0023779
reactive oxygen species	T123	C0162772
homeostasis	T038	C0019868
distribution	T169	C1704711
diffusive motion	T070	C0012222
motility	T040	C0007608
role	T077	C1705810
fungus	T004	C0016832
Ustilago maydis	T004	C0446013
POs	T026	C0752063
LDs	T026	C0230704
diffusive motions	T070	C0012222
movements	T040	C0007608
ATP	T114	C0001480
bidirectional	T080	C1706937
endosome	T026	C0034850
motility	T040	C0007608
microtubule	T026	C0026046
associated	T080	C0332281
membrane	T026	C0596901
trafficking	T043	C0599896
enhances	T052	C2349975
diffusion	T070	C0012222
organelles	T026	C0029219
endosome transport	T043	C1156042
POs	T026	C0752063
LDs	T026	C0230704
growing cell end	T026	C3159038
pole-ward drift	T043	C0007613
anterograde delivery	T043	C0598952
secretory cargo	T116	C0597427
cell tip	T026	C1656978
myosin-5	T116	C0969679
Modelling	T062	C0870071
microtubule-based directed transport	T043	C2755890
active	T169	C0205177
diffusion	T070	C0012222
distribution	T169	C1704711
mobility	T043	C1516353
POs	T026	C0752063
mammalian	T015	C0024660
COS-7 cells	T025	C1257858
microtubules	T026	C0026046
F-actin	T116	C1180307
distribute	T169	C1704711
POs	T026	C0752063
cytoskeletal	T026	C0010853
forces	T067	C0441722
organelle	T026	C0029219
positioning	T082	C0733755
eukaryotes	T204	C0684063
catheter ablation	T061	C0162563
management	T058	C0376636
atrial fibrillation	T047	C0004238
Atrial fibrillation	T047	C0004238
electrical activation	T040	C1658783
pulmonary veins	T023	C0034090
Catheter ablation	T061	C0162563
radiofrequency	T061	C0850292
cryothermal energy	T061	C0010412
electrically	T169	C0442828
isolates	T169	C0205409
veins	T023	C0034090
left atrium	T023	C0225860
reducing	T080	C0392756
burden	T078	C2828008
atrial fibrillation	T047	C0004238
episodes	T079	C1254367
patient's	T101	C0030705
symptoms	T184	C1457887
Catheter ablation	T061	C0162563
antiarryhthmic drugs	T121	C0003195
patients	T101	C0030705
medical problems	T201	C1715372
obesity	T047	C0028754
hypertension	T047	C0020538
obstructive sleep apnoea	T047	C0520679
treated	T169	C1522326
ablation	T061	C0547070
treatment	T061	C0087111
potential	T080	C3245505
cure	T077	C1880198
patients	T101	C0030705
symptoms	T184	C1457887
procedural complications	T033	C0742724
Chinese Herbal	T080	C3146288
Mixture	T167	C0439962
Tien-Hsien Liquid	T109	C1528399
Augments	T081	C0205217
Anticancer	T080	C2986475
Immunity	T039	C0020964
Tumor Cell	T025	C0597032
Vaccinated	T033	C1116171
Mice	T015	C0025929
Chinese herbal	T080	C3146288
mixture	T167	C0439962
Tien-Hsien liquid	T109	C1528399
THL	T109	C1528399
anticancer	T080	C2986475
dietary supplement	T168	C0242295
years	T079	C0439234
previous	T079	C0205156
studies	T062	C2603343
THL	T109	C1528399
modulate	T082	C0443264
immune response	T042	C0301872
inhibit	T052	C3463820
tumor growth	T191	C0598934
study	T062	C2603343
evaluated	T058	C0220825
effect	T080	C1280500
THL	T109	C1528399
anticancer	T080	C2986475
immune response	T042	C0301872
mice	T015	C0025929
vaccinated	T033	C1116171
γ-ray	T070	C0017011
irradiated	T070	C1282930
tumor cells	T025	C0597032
antitumor	T080	C2986475
effect	T080	C1280500
THL	T109	C1528399
determined	T080	C0521095
mice	T015	C0025929
vaccinated	T033	C1116171
low-tumorigenic CT-26-low colon cancer cells	T025	C0085983
γ-ray-irradiated	T061	C2985557
high-tumorigenic CT-26-high colon cancer cells	T025	C0085983
number	T081	C0237753
natural killer (NK) cells	T025	C0022688
T lymphocytes	T025	C0039194
spleen	T023	C0037993
analyzed	T062	C0936012
flow cytometry	T059	C0016263
tumor	T191	C0027651
killing	T043	C0599733
activities	T052	C0441655
NK cells	T025	C0022688
cytotoxic T lymphocytes	T025	C0039195
CTLs	T025	C0039195
analyzed	T062	C0936012
flow cytometry	T059	C0016263
YAC-1	T025	C0085983
CT-26-high cells	T025	C0085983
target	T169	C1521840
cells	T025	C0007634
levels	T080	C0441889
IFN-γ	T116	C0021745
IL-2	T116	C0021756
TNF-α	T116	C1456820
determined by	T080	C0521095
ELISA	T059	C0014441
THL	T109	C1528399
suppressed	T169	C1260953
growth	T040	C0018270
CT-26-high tumor	T025	C0085983
mice	T015	C0025929
vaccinated	T033	C1116171
low-tumorigenic CT-26-low cells	T025	C0085983
γ-irradiated	T061	C2985557
CT-26-high cells	T025	C0085983
THL	T109	C1528399
increased	T081	C0205217
NK cells	T025	C0022688
CD4+ T lymphocytes	T025	C0039215
spleen	T023	C0037993
enhanced	T052	C2349975
tumor	T191	C0027651
killing	T043	C0599733
activities	T052	C0441655
NK cells	T025	C0022688
CTL	T025	C0039195
mice	T015	C0025929
vaccinated	T033	C1116171
γ-irradiated	T061	C2985557
CT-26-high cells	T025	C0085983
THL	T109	C1528399
increased	T081	C0205217
production	T169	C0205245
IFN-γ	T116	C0021745
IL-2	T116	C0021756
TNF-α	T116	C1456820
mice	T015	C0025929
vaccinated	T033	C1116171
γ-irradiated	T061	C2985557
CT-26-high cells	T025	C0085983
THL	T109	C1528399
enhance	T052	C2349975
antitumor	T080	C2986475
immune responses	T042	C0301872
mice	T015	C0025929
vaccinated	T033	C1116171
killed	T169	C0205245
tumor cells	T025	C0597032
results	T169	C1274040
THL	T109	C1528399
complementary medicine	T091	C1148474
cancer	T191	C0006826
patients	T101	C0030705
previously	T079	C0205156
treated	T169	C1522326
killed tumor cell vaccines	T116	C0376659
radiotherapy	T061	C1522449
chemotherapy	T061	C3665472
Timing	T079	C0449243
Ring Formation	T039	C0243056
Pinus halepensis	T002	C1028806
Arbutus unedo	T002	C1036425
Southern	T082	C1710133
Italy	T083	C0022277
Outlook	T201	C0420834
Analysis	T062	C0936012
Xylogenesis	T039	C0243056
Tree-Ring	T002	C0040811
Chronologies	T170	C0008717
Mediterranean	T083	C0282645
tree rings	T002	C0040811
characterized	T052	C1880022
intra-annual density fluctuations	T079	C0231241
IADFs	T079	C0231241
climate-driven	T070	C0008946
cambial activity	T039	C0243056
IADFs	T079	C0231241
structural	T082	C0678594
signals	T078	C0010439
information	T078	C1533716
relations	T080	C0439849
between	T082	C0205103
environmental	T082	C0014406
conditions	T080	C0348080
eco-physiological	T039	C0243056
processes	T067	C1522240
during	T079	C0347984
xylogenesis	T039	C0243056
intra-annual	T079	C0332181
resolution	T077	C2699488
unbiased	T062	C1711255
synchronization	T079	C0439580
IADF	T079	C0231241
position	T082	C0733755
tree	T002	C0040811
rings	T082	C0521164
seasonal	T079	C1254367
fluctuations	T184	C0231239
environmental	T082	C0014406
conditions	T080	C0348080
timing	T079	C0449243
cambial activity	T039	C0243056
wood	T167	C0043217
formation	T169	C1522492
species-	T080	C0205556
site-specific	T080	C0205556
processes	T067	C1522240
applied	T169	C4048755
microcoring technique	T169	C0449851
analyze	T062	C0936012
xylogenesis	T039	C0243056
Pinus halepensis	T002	C1028806
Arbutus unedo	T002	C1036425
attempt	T051	C1516084
study	T062	C2603343
xylogenesis	T039	C0243056
hardwood	T167	C0043217
species	T185	C1705920
frequent	T079	C0332183
IADFs	T079	C0231241
species	T185	C1705920
co-occur	T052	C1709305
site	T082	C0205145
southern	T082	C1710133
Italy	T083	C0022277
characterized	T052	C1880022
Mediterranean	T083	C0282645
climate	T070	C0008946
tree-ring dating	T062	C2350279
identification	T080	C0205396
IADFs	T079	C0231241
performed	T169	C0884358
traditional	T169	C0443324
dendroecological	T080	C0205556
analysis	T062	C0936012
analyzed	T062	C0936012
xylogenesis	T039	C0243056
during	T079	C0347984
summer	T079	C0241301
considered	T078	C0750591
constraint	T169	C0443288
xylogenesis	T039	C0243056
IADF	T079	C0231241
formation	T169	C1522492
different	T080	C1705242
phases	T079	C0205390
cell development	T043	C0815089
current	T079	C0521116
wood	T167	C0043217
increment	T081	C1705117
IADFs	T079	C0231241
formed	T169	C0205431
analyzed	T062	C0936012
phases	T079	C0205390
September	T079	C3828193
winter	T079	C0241737
verify	T169	C1711411
possible	T033	C0332149
formation	T169	C1522492
IADFs	T079	C0231241
fall	T079	C0238715
cell	T025	C3178867
production	T039	C0243056
differentiation	T043	C0007589
completed	T080	C0205197
calendar year	T079	C0456586
species	T185	C1705920
formed	T169	C0205431
IADFs	T079	C0231241
earlywood	T167	C0043217
cells	T025	C3178867
latewood	T167	C0043217
temporary	T079	C0205374
growth	T067	C2911660
restoration	T033	C0243095
triggered by	T080	C1444748
rain	T070	C0034640
events	T051	C0441471
during	T079	C0347984
period	T079	C1948053
summer	T079	C0241301
drought	T070	C0013140
calendar year	T079	C0456586
cells	T025	C3178867
phases	T079	C0205390
enlargement	T080	C0442800
secondary cell wall	T026	C1167351
deposition	T169	C0333562
occurred	T052	C1709305
A. unedo	T002	C1036425
sensitive	T169	C0332324
P. halepensis	T002	C1028806
IADF	T079	C0231241
formed	T169	C0205431
earlier	T079	C1279919
season	T079	C0036497
frequent	T079	C0332183
tree-ring	T002	C0040811
dendro-anatomical	T080	C0205556
analysis	T062	C0936012
tree-ring	T002	C0040811
xylogenesis	T039	C0243056
detect	T033	C0442726
period	T079	C1948053
IADF	T079	C0231241
formation	T169	C1522492
species	T185	C1705920
Results	T169	C1274040
functional	T169	C0205245
terms	T078	C1705313
environmental	T082	C0014406
conditions	T080	C0348080
triggering	T080	C1444748
IADFs	T079	C0231241
methodological	UnknownType	C0815254
terms	T078	C1705313
applicability	T169	C4048755
xylogenesis	T039	C0243056
analysis	T062	C0936012
Mediterranean	T083	C0282645
woods	T167	C0043217
formation	T169	C1522492
IADFs	T079	C0231241
uniform	T080	C0205375
stem	T002	C0242767
Emergence	T080	C0205556
family medicine	T091	C0015607
Ethiopia	T083	C0015024
international	T078	C1512888
collaborative	T054	C0282116
education model	T170	C3161035
Family Medicine	T091	C0015607
FM	T091	C0015607
specialty	T091	C0037778
Ethiopia	T083	C0015024
first seven family physicians	T097	C1704221
graduated	T098	C0588053
February	T080	C3830166
residency	T065	C0035182
programme	T170	C0010478
Addis Ababa University	T073	C0041740
Cooperation	T054	C0392337
Ethiopian	T098	C0239304
expatriate	T033	C3842568
decision-makers	T097	C0554244
physicians	T097	C0031831
begin	T079	C0439659
programme	T170	C0010478
Intentional	T078	C1512888
replacement	T169	C0559956
expatriates	T033	C3842568
Ethiopian	T098	C0239304
family physicians	T097	C1704221
begun	T079	C0439659
Barriers	T080	C0205556
lack of	T080	C0332268
understanding	T041	C0162340
FM	T091	C0015607
human	T169	C0024752
financial resources	T033	C0516918
scaling up	T081	C0392762
programme	T170	C0010478
Regular	T080	C0205272
programme	T170	C0010478
review	T080	C1704362
resident physician	T097	C1320928
involvement	T054	C0009476
FM	T091	C0015607
training programme	T065	C0040607
adapt	T080	C0205556
fit	T052	C2349186
Ethiopian	T098	C0239304
context	T078	C0449255
successes	T054	C0597535
result	T169	C1274040
support	T054	C0037438
advocacy	T054	C0150446
Federal Ministry of Health	T057	C0013562
Ethiopian	T098	C0239304
African	T098	C0027567
international	T078	C1512888
international primary care organisations	T093	C0596660
Experience	T041	C0596545
Women	T098	C0043210
Veterans	T098	C0042610
War	T052	C0043027
Issues surrounding mental health	T048	C4061796
women	T098	C0043210
veterans	T098	C0042610
Iraq	T083	C0022066
Afghanistan	T083	C0001732
wars	T052	C0043027
phenomenological	T078	C0871071
study	T062	C2603343
document	T170	C1301746
themes	UnknownType	C0869035
stories	T170	C0282574
women	T098	C0043210
veterans	T098	C0042610
war	T052	C0043027
Themes	UnknownType	C0869035
stories	T170	C0282574
sentiments	T055	C0683293
changed	T169	C0392747
view of self	T041	C0242498
permeating aggravation	T033	C0243095
confounding broken relationships	T054	C2371543
frequent deployments	T033	C2321230
change in military status	T033	C1550416
remembering	T041	C0034770
war	T052	C0043027
experiences	T041	C0596545
seeking opportunity for what is possible	T033	C0243095
Mental health issues	T048	C4061796
themes	UnknownType	C0869035
story	T170	C0282574
mental health	T041	C0025353
veterans	T098	C0042610
veterans	T098	C0042610
transition of coming back	T052	C2700061
Trajectories	T082	C0205134
Health	T078	C0018684
Behavioral Health Services	T058	C0009472
Use	T169	C0457083
Community	T096	C0009462
Corrections	T169	C1947976
Rural	T033	C0240919
Adults	T100	C0001675
trajectories	T082	C0205134
health	T078	C0018684
behavioral health services	T058	C0009472
utilization	T169	C0457083
community corrections-involved	T078	C0009463
CCI	T078	C0009463
adults	T100	C0001675
demographic	T078	C0011292
clinical	T080	C0205210
trajectories	T082	C0205134
latent class growth analysis	T062	C0936012
LCGA	T062	C0936012
services	T058	C0009472
rural	T033	C0240919
CCI	T078	C0009463
adults	T100	C0001675
medical	T169	C0205476
mental health	T041	C0025353
substance use	T078	C1705534
treatment utilization	UnknownType	C0815187
behavior	T053	C0004927
days	T079	C0439228
years	T079	C0439234
LCGA	T062	C0936012
1.5-year	T079	C0439234
trajectories	T082	C0205134
demographic	T078	C0011292
health services	T058	C0018747
rural	T033	C0240919
CCI	T078	C0009463
adults	T100	C0001675
medical services	T058	C0199168
users	T098	C1706077
users	T098	C1706077
users	T098	C1706077
mental health	T041	C0025353
substance use	T078	C1705534
services	T058	C0009472
Employment	T080	C0014003
gender	T032	C0079399
medication usage	T033	C0240320
depression	T048	C0011570
severity	T080	C0439793
membership	T055	C0680038
services	T058	C0009472
social workers	T097	C0037444
community services	T058	C0009472
providers	T097	C0018724
health services	T058	C0018747
CCI	T078	C0009463
CCI	T078	C0009463
adults	T100	C0001675
risk	T078	C0035647
prevention	T061	C0199176
intervention domains	T061	C0184661
Data set	T170	C0150098
interactomes	T044	C0872079
metabolic pathways	T169	C1291081
proteins	T116	C0033684
expressed	T045	C1171362
brains	T023	C0006104
Alzheimer׳s disease	T047	C0002395
Alzheimer׳s disease	T047	C0002395
dementia	T048	C0497327
elderly	T098	C0001792
frequency	T079	C0439603
worldwide	T098	C2700280
complex	T080	C0439855
interactions	T169	C1704675
genetic	T080	C0814299
environmental factors	T080	C0686732
molecular players	T116	C0033684
disease	T047	C0002395
data	T078	C1511726
article	T170	C1706852
protein expression	T045	C1171362
protein	T116	C0033684
extracts	T167	C2828366
cortex regions of brains	T029	C0458324
patients	T101	C0030705
Alzheimer׳s disease	T047	C0002395
normal brain	T023	C0006104
identified	T080	C0205396
iTRAQ-labeled	T130	C2986808
polypeptides	T116	C1305923
analyzed	T062	C0936012
proteins	T116	C0033684
expression level	T081	C3244092
KEGG metabolic pathways	T170	C3826812
mitochondrial complexes of the electron transport chain	T026	C1325653
ATP synthase	T116	C0949692
analyzed	T062	C0936012
over- and sub-expressed polypeptides	T116	C1305923
IPA software	T073	C0037585
Core I and Biomarkers I modules	T170	C0037589
Data	T078	C1511726
article	T170	C1706852
research	T062	C0035168
article	T170	C1706852
proteins	T116	C0033684
expressed	T045	C1171362
brains	T023	C0006104
Alzheimer's disease	T047	C0002395
iTRAQ labeling	T059	C0022885
tandem mass spectrometry	T063	C0599748
Emergency general surgery	T061	C2216322
specific frailty index	T170	C4075886
validation study	T062	C0681836
Assessment	T058	C0220825
operative risk	T078	C0747003
geriatric patients	T101	C0870602
emergency general surgery	T061	C2216322
EGS	T061	C2216322
Frailty	T033	C0424594
measure	T081	C0079809
risk assessment	T058	C0086930
surgical cases	T077	C1706256
study	T062	C2603343
validate	T062	C1519941
variable	T080	C0439828
emergency general surgery specific frailty index	T058	C4075415
EGSFI	T058	C4075415
collected	T078	C1516695
geriatric	T080	C1704440
age > 65	T100	C0522003
emergency general surgery	T061	C2216322
patients	T101	C0870602
year	T079	C0439234
Post-operative complications	T046	C0032787
collected	T078	C1516695
Frailty Index	T170	C4075886
calculated	T059	C1443182
patients	T101	C0030705
pre-admission	T079	C0559269
condition	T080	C0348080
variable	T080	C0439828
Rockwood Frailty Index	T170	C4075886
FI	T170	C4075886
EGSFI	T058	C4075415
regression model	T170	C0034980
complications	T046	C0032787
FI	T170	C4075886
ROC curve analysis	T081	C0035787
cutoff	T169	C1442160
frail	T033	C0871754
status	T080	C0449438
validated	T062	C1519941
results	T169	C1274040
patients	T101	C0030705
predicting	T078	C0681842
complications	T046	C0032787
patients	T101	C0030705
Validation	T062	C1519941
enrolled	T058	C1516879
study	T062	C2603343
Mean age	T032	C0001779
years	T079	C0439234
complications	T046	C0032787
common	T081	C0205214
complications	T046	C0032787
pneumonia	T047	C0032285
UTI	T047	C0042029
wound infection	T046	C0043241
Univariate analysis	T062	C0683962
variables	T080	C0439828
associated with	T080	C0332281
complications	T046	C0032787
EGSFI	T058	C4075415
cutoff	T169	C1442160
frailty score	T033	C4075885
ROC curve analysis	T081	C0035787
frail	T033	C0871754
status	T080	C0449438
patients	T101	C0030705
frail	T033	C0871754
non-frail	T033	C0871754
enrolled	T058	C1516879
validation	T062	C1519941
cohort	T098	C0599755
Frail	T033	C0871754
patients	T101	C0030705
post-operative complications	T046	C0032787
nonfrail patients	T101	C0870602
Frail	T033	C0871754
status	T080	C0449438
EGSFI	T058	C4075415
significant predictor	T078	C2698872
post-operative complications	T046	C0032787
OR	T081	C0028873
CI	T081	C0009667
Age	T032	C0001779
associated with	T080	C0332281
postoperative complications	T046	C0032787
OR	T081	C0028873
CI	T081	C0009667
variable	T080	C0439828
validated	T062	C1519941
EGSFI	T058	C4075415
bedside tool	T073	C4286058
frailty status	T033	C0424594
patients	T101	C0030705
emergency general surgery	T061	C2216322
Frail	T033	C0871754
status	T080	C0449438
EGSFI	T058	C4075415
independent predictor	T078	C2698872
post-operative complications	T046	C0032787
mortality	T081	C0205848
geriatric	T080	C1704440
emergency general surgery	T061	C2216322
patients	T101	C0870602
Prognostic Studies	T062	C0242481
Investigating	T169	C1292732
Effect	T080	C1280500
Patient Characteristic	T201	C1285579
Outcome of Disease	T033	C0679250
Epidemiologic	T169	C0014508
Characteristics	T080	C1521970
Pertussis	T047	C0043167
Central	T083	C0454714
Eastern European Countries	T083	C0015177
epidemiological survey	T062	C0376688
annual	T079	C0332181
incidence	T081	C0021149
pertussis	T047	C0043167
reported	T058	C0700287
Central	T083	C0454714
Eastern European countries	T083	C0015177
pertussis	T047	C0043167
reports	T170	C0025102
countries	T083	C0454664
features	T080	C2348519
country	T083	C0454664
annual	T079	C0332181
incidence	T081	C0021149
pertussis	T047	C0043167
countries	T083	C0454664
government institutions	T093	C2607850
national surveillance systems	T093	C1708333
reviewed	T080	C1709940
changes	T169	C0392747
pertussis	T047	C0043167
incidence rates	T081	C1708485
country	T083	C0454664
differences	T080	C1705242
similarities	T080	C2348205
countries	T083	C0454664
pertussis	T047	C0043167
surveillance	T169	C0220920
case definitions	T170	C0679227
detection	T033	C0442726
confirmation	T080	C0521091
pertussis	T047	C0043167
incidence	T081	C0021149
number of cases	T081	C0021149
pertussis	T047	C0043167
year	T079	C0439234
age group	T100	C0027362
population	T098	C1257890
year	T079	C0439234
age group	T100	C0027362
pertussis	T047	C0043167
immunization schedule	T061	C0020972
coverage	T169	C1999244
whole-cell pertussis vaccines	T121	C0031237
wP	T121	C0031237
acellular pertussis vaccines	T121	C0982332
aP	T121	C0982332
heterogeneity	T080	C0019409
reported	T058	C0700287
annual	T079	C0332181
incidence rates	T081	C1708485
countries	T083	C0454664
Reported	T058	C0700287
pertussis	T047	C0043167
incidence rates	T081	C1708485
population	T098	C1257890
highest	T080	C1522410
rates	T081	C1521828
reported	T058	C0700287
Estonia	T083	C0014908
lowest	T080	C1708760
Hungary	T083	C0020174
Serbia	T083	C0036708
burden	T078	C2828008
infants	T100	C0021270
year	T079	C0439234
Bulgaria	T083	C0006368
Hungary	T083	C0020174
Latvia	T083	C0023128
Romania	T083	C0035826
Serbia	T083	C0036708
countries	T083	C0454664
burden	T078	C2828008
older children	T100	C0008059
surveillance	T169	C0220920
adults	T100	C0001675
associated with	T080	C0332281
wP	T121	C0031237
aP vaccines	T121	C0982332
reported	T058	C0700287
pertussis	T047	C0043167
incidence rates	T081	C1708485
heterogeneity	T080	C0019409
reported	T058	C0700287
data	T078	C1511726
factors	T169	C1521761
surveillance	T169	C0220920
system	T169	C0449913
characteristics	T080	C1521970
capabilities	T080	C2698977
case definitions	T170	C0679227
type	T080	C0332307
pertussis	T047	C0043167
confirmation tests	T059	C0022885
public	T092	C0678367
awareness	T033	C1328734
disease	T047	C0043167
differences	T081	C1705241
magnitude	T081	C1704240
disease	T047	C0043167
factors	T169	C1521761
pertussis	T047	C0043167
detection	T033	C0442726
confirmation	T080	C0521091
surveillance programs	T062	C1515095
Europe	T083	C0015176
seroprevalence studies	T062	C0600367
protocols	T170	C0442711
methodologies	T062	C0086912
Identification	T080	C0205396
characterization	T052	C1880022
Dichelobacter nodosus	T007	C0314932
serogroup H	T170	C0449555
ovine	T015	C1123019
footrot	T047	C0016513
India	T083	C0021201
foot swabs	T167	C0183753
inter digital spaces	T030	C0230506
sheep	T015	C0036945
footrot	T047	C0016513
lesions	T033	C0221198
screened	T060	C1710031
rRNA	T114	C0035701
Dichelobacter nodosus	T007	C0314932
PCR	T063	C0032520
samples	T077	C2347026
positive	T033	C1514241
positive	T033	C1514241
samples	T077	C2347026
multiplex PCR	T063	C3179032
targeting fimA gene	T063	C0242613
identification	T080	C0205396
serogroups	T170	C0449543
D. nodosus	T007	C0314932
Serogroup H	T170	C0449555
serogroup B	T170	C0456771
samples	T077	C2347026
serogroup I	T170	C0449543
samples	T077	C2347026
serogroup H	T170	C0449555
identified	T080	C0205396
Indian subcontinent	T083	C0454693
phylogenetic analysis	T062	C1519068
sequence	T086	C0004793
serogroup H	T170	C0449555
sequences	T086	C0004793
GenBank	T170	C0598211
serotype H1	T170	C0449943
Conservation education	T065	C0013652
habitat	T082	C0871648
restoration	T169	C0205245
endangered	T098	C2717882
Sagalla caecilian	T011	C2999417
Boulengerula niedeni	T011	C2999417
Sagalla Hill	T083	C0022558
Kenya	T083	C0022558
Sagalla caecilian	T011	C2999417
Boulengerula niedeni	T011	C2999417
endangered	T098	C2717882
amphibian	T011	C0002668
endemic	UnknownType	C0681784
Sagalla Hill	T083	C0022558
Taita Hills	T083	C0022558
burrowing worm	T204	C0018893
species	T185	C1705920
soft	T080	C0205358
soil	T167	C0037592
high	T080	C0205250
moisture	T167	C0868994
organic matter	T167	C0439861
major	T080	C0205164
threats	T078	C0749385
Sagalla caecilian	T011	C2999417
soil erosion	T070	C1254365
caused	T169	C0678227
steep slopes	T082	C1254362
ground	T083	C0242744
water siphoning	T067	C1254366
soil hardening	T067	C1254366
exotic eucalyptus trees	T002	C0015148
study	T062	C2603343
better	T080	C0332272
understanding	T041	C0162340
local	T082	C0205276
people's	T098	C0027361
attitude	T041	C0004271
species	T185	C1705920
contribute	T052	C1880177
continued	T078	C0549178
conservation	T080	C2347858
restoration	T169	C0205245
remaining	T080	C1527428
habitat	T082	C0871648
study	T062	C2603343
found	T033	C0150312
Sagalla	T083	C0022558
people	T098	C0027361
aware	T041	C0004448
species	T185	C1705920
habits	T055	C0018464
soils	T167	C0037592
high	T080	C0205250
organic matter	T167	C0439861
found	T033	C0150312
Sagalla	T083	C0022558
people	T098	C0027361
organic	T080	C0747055
manure	T167	C0024765
cow	T015	C0007452
dung	T031	C0015733
farms	T082	C0557759
Habitat	T082	C0871648
restoration	T169	C0205245
planting	T052	C0441655
indigenous	T082	C0205276
plants	T002	C0032098
found	T033	C0150312
ongoing	T078	C0549178
especially	T080	C0205555
compounds	T103	C1706082
public institutions	T092	C1552744
private lands	UnknownType	C0681784
drought	T070	C0013140
found	T033	C0150312
seedlings	T002	C0242437
development	T169	C1527148
low	T080	C0205251
elevation	T082	C0702240
sites	T082	C0205145
destruction	T052	C1948029
livestock	T008	C2936506
during	T079	C0347984
dry	T080	C0205222
season	T079	C0036497
major	T080	C0205164
threat	T078	C0749385
study	T062	C2603343
recommended	T078	C0034866
future	T079	C0016884
habitat	T082	C0871648
restoration	T169	C0205245
initiative	T041	C0424093
include	T169	C0332257
strong	T080	C0442821
chain-link	T073	C3273359
fencing	T052	C0441655
seedlings	T002	C0242437
livestock	T008	C2936506
activity	T052	C0441655
preferred	T078	C0558295
habitats	T082	C0871648
species	T185	C1705920
valleys	T082	C0563004
systematic	T169	C0220922
planting	T052	C0441655
keystone plant	T002	C0032098
species	T185	C1705920
fig trees	T002	C0969754
Ficus	T002	C0969754
creates	T052	C1706214
microhabitats	T082	C0871648
better	T080	C0332272
general	T082	C0205246
woodlots	T082	C1254362
indigenous	T082	C0205276
trees	T002	C0040811
clinical	T080	C0205210
economic	T169	C0013557
burden	T078	C2828008
significant	T078	C0750502
bleeding	T046	C0019080
during	T079	C0347984
lung resection surgery	T061	C0396565
retrospective matched cohort analysis	T062	C2985505
real	T080	C0205238
world	T098	C2700280
data	T078	C1511726
objective	T080	C1571702
retrospective study	T062	C0035363
quantify	T081	C1709793
clinical	T080	C0205210
economic	T169	C0013557
burden	T078	C2828008
significant	T078	C0750502
bleeding	T046	C0019080
lung resection surgery	T061	C0396565
US	T083	C0041703
study	T062	C2603343
utilized	T169	C1524063
data	T078	C1511726
Premier Perspective Database(TM)	T170	C0242356
Adult	T100	C0001675
patients	T101	C0030705
primary pulmonary lobectomy	T061	C0189497
segmentectomy procedures	T061	C0189488
categorized	T052	C0871968
surgical approach	T169	C0449446
VATS	T061	C0752151
open	T061	C4283938
primary diagnosis	T080	C0332137
primary	T060	C0920688
metastatic lung cancer	T060	C0920688
non-lung cancer	T060	C0430022
Patients	T101	C0030705
units	T081	C0439148
blood products	T121	C0456388
at least	T080	C1524031
unit	T081	C0439148
PRBCs	T116	C2316467
significant	T078	C0750502
bleeding	T046	C0019080
cohort	T098	C0599755
units	T081	C0439148
non-significant	T033	C1273937
bleeding	T046	C0019080
cohort	T098	C0599755
blood products	T121	C0456388
no	T169	C1518422
bleeding	T046	C0019080
cohort	T098	C0599755
cohort analysis	T062	C0086027
performed	T169	C0884358
significant	T078	C0750502
bleeding	T046	C0019080
no	T169	C1518422
bleeding	T046	C0019080
cohort	T098	C0599755
matching variables	UnknownType	C0815175
hospital	T073	C0019994
lung cancer diagnosis	T060	C0920688
year of surgery	T079	C0439234
APR-DRG severity score	T081	C0457451
procedure type	T201	C0944777
approach	T169	C0449446
age	T032	C0001779
gender	T032	C0079399
All	T081	C0444868
patient	T101	C0030705
cohort	T098	C0599755
patients	T101	C0030705
significant	T078	C0750502
bleeding	T046	C0019080
non-significant	T033	C1273937
bleeding	T046	C0019080
no	T169	C1518422
bleeding	T046	C0019080
Overall	T080	C1561607
incidence	T081	C0021149
significant	T078	C0750502
chest	T029	C0817096
bleeding	T046	C0019080
Patients	T101	C0030705
significant	T078	C0750502
bleeding	T046	C0019080
cohort	T098	C0599755
non-significant	T033	C1273937
bleeding	T046	C0019080
cohort	T098	C0599755
days	T079	C0439228
days	T079	C0439228
longer	T080	C0205166
length of stay	T079	C0023303
hospital	T073	C0019994
compared	T052	C1707455
no	T169	C1518422
bleeding	T046	C0019080
cohort	T098	C0599755
Overall	T080	C1561607
hospital costs	T081	C0206174
significant	T078	C0750502
bleeding	T046	C0019080
cohort	T098	C0599755
higher	T080	C0205250
no	T169	C1518422
bleeding	T046	C0019080
cohort	T098	C0599755
covered	T169	C0439844
Medicare	T064	C0018717
years of age	T079	C1510829
greater	T081	C1704243
severity of illness	T080	C0521117
segmentectomy	T061	C2987624
Hospital costs	T081	C0206174
significant	T078	C0750502
bleeding	T046	C0019080
cohort	T098	C0599755
non-significant	T033	C1273937
bleeding	T046	C0019080
significantly	T078	C0750502
higher	T080	C0205250
no	T169	C1518422
bleeding	T046	C0019080
cohort	T098	C0599755
significant	T078	C0750502
bleeding	T046	C0019080
during	T079	C0347984
lung resection surgery	T061	C0396565
rare	T080	C0522498
patients	T101	C0030705
complication	T046	C0009566
stay	T079	C3489408
longer	T080	C0205166
hospital	T073	C0019994
cost	T081	C0206174
Laceration	T037	C0043246
branch of	T082	C1253959
profunda femoris artery	T023	C0226455
caused	T169	C0678227
spike	T033	C0243095
displaced	T082	C0012727
lesser trochanter	T023	C0223866
inter-trochanteric	T030	C0229984
femoral fracture	T037	C0015802
case report	T170	C0007320
Injury	T037	C3263722
femoral vessels	T023	C1116455
extremely	T080	C0205403
rare	T080	C0522498
complication	T046	C0009566
intertrochanteric	T030	C0229984
femoral fractures	T037	C0015802
cases	T169	C0220856
reported	T058	C0700287
vascular lesion	T047	C1402315
involves	T169	C1314939
superficial femoral artery	T023	C0447106
cases	T169	C0220856
involve	T169	C1314939
profunda femoris artery	T023	C0226455
report	T170	C0684224
case	T169	C0220856
acute bleeding	T046	C0333276
laceration	T037	C0043246
perforating	T033	C0549099
branch of	T082	C1253959
profunda femoris artery	T023	C0226455
caused	T169	C0678227
sharp	T033	C1444775
fragment of	T169	C0332255
displaced	T082	C0012727
lesser trochanter	T023	C0223866
intertrochanteric	T030	C0229984
femoral fracture	T037	C0015802
lesion	T033	C0221198
treated	T169	C1522326
transcatheter embolization	T061	C0203006
arterial injury	T037	C0340652
iatrogenic	T080	C0439669
occurring	T052	C1709305
intramedullary	T082	C2732619
internal fixation	T061	C0016642
frequently	T079	C0332183
injury	T037	C3263722
fracture	T037	C0016658
caused	T169	C0678227
sharp	T033	C1444775
bone fragment	T037	C3698366
damages	T169	C1883709
profunda femoris artery	T023	C0226455
perforating	T033	C0549099
branches	T082	C1253959
intertrochanteric	T030	C0229984
femoral fractures	T037	C0015802
avulsed	T037	C0262386
lesser trochanter	T023	C0223866
at risk	T080	C1444641
femoral vessel	T023	C1116455
injuries	T037	C3263722
caused	T169	C0678227
displaced	T082	C0012727
bone	T023	C0262950
spike	T033	C0243095
meticulous	T080	C0205556
clinical	T080	C0205210
laboratory monitoring	T058	C3165364
pre-	T079	C0445204
post-operatively	T079	C0032790
prevent serious complications	T061	C0547286
perivascular	T023	C0005847
tumor cells	T025	C0597032
integrin αvβ3	T116	C1138427
signaling	T044	C1514762
migration	T043	C1622501
endothelial cells	T025	C0225336
secretion	T043	C1327616
pro-angiogenic factors	T123	C0002976
tumor cells	T025	C0597032
stromal cells	T025	C0162597
perivascular	T023	C0005847
aggressive angiogenesis	T191	C1519670
glioblastoma	T191	C0017636
GBM	T191	C0017636
angiogenesis	T191	C1519670
brain	T023	C0006104
tumor cells	T025	C0597032
tumor cells	T025	C0597032
cancer stem	T025	C1956422
CSCs	T025	C1956422
endothelial cells	T025	C0225336
ECs	T025	C0225336
in vitro	T080	C1533691
binding	T044	C0597358
integrin αvβ3	T116	C1138427
expressed	T045	C0597360
ECs	T025	C0225336
RGD-peptide	T116	C0052350
L1CAM	T116	C0950625
expressed	T045	C1171362
CSCs	T025	C1956422
EC	T025	C0225336
network formation	T043	C0007613
migration	T043	C1622501
fibroblast growth factor	T116	C0016026
Activation	T052	C1879547
αvβ3	T116	C1138427
bone marrow tyrosine kinase on chromosome X	T116	C1384557
BMX	T116	C1453891
migration	T043	C1622501
binding	T044	C0597358
migration	T043	C1622501
RGD-peptide	T116	C0052350
treatment	T169	C1522326
mice	T015	C0025929
intracerebral	T082	C0442111
GBM	T191	C0017636
xenografts	T122	C0522537
Sox2	T116	C0300483
tumor cells	T025	C0597032
CSCs	T025	C1956422
ECs	T025	C0225336
integrin αvβ3	T116	C1138427
BMX	T116	C1453891
p130CAS	T116	C1451358
phosphorylation	T044	C1158886
ECs	T025	C0225336
vessel	T023	C0005847
surface area	T082	C0205146
regulation	T038	C1327622
angiogenesis	T191	C1519670
GBM	T191	C0017636
therapeutic	T169	C0302350
anti-angiogenic	T121	C0596087
Ocimum americanum	T002	C1483717
essential oil	T109	C0028910
pathogens	T001	C0450254
Aeromonas hydrophila	T007	C0085491
Gyrodactylus sp.	T204	C1211435
silver catfish	T013	C1939719
Rhamdia quelen	T013	C1194855
bactericidal activity	T034	C1271650
MIC-test	T059	C0427978
Ocimum americanum	T002	C1483717
inflorescences	T002	C2697680
essential oil	T109	C0028910
OAEO	T109	C0028910
Aeromonas hydrophila	T007	C0085491
OAEO	T109	C0028910
compound	T080	C0205198
oil	T109	C0028908
linalool	T109	C0064997
inhibitors	T120	C0243077
hemolysis	T046	C0019054
Aer. hydrophila	T007	C0085491
fish	T013	C1939719
erythrocytes	T025	C0014792
in vivo experiment	T062	C0681829
survival	T052	C0038952
fish	T013	C0016163
Rhamdia quelen	T013	C1194855
experimentally	T062	C0681814
infected	T033	C0439663
Aer. hydrophila	T007	C0085491
exposed	T080	C0332157
OAEO	T109	C0028910
experiment	T062	C0681814
in vitro	T062	C0681828
in vivo	T062	C0681829
OAEO	T109	C0028910
inflorescences	T002	C2697680
leaves	T002	C0242724
parasite Gyrodactylus sp.	T204	C1211435
OAEO	T109	C0028910
weak	T080	C1762617
in vitro	T062	C0681828
Aer. hydrophila	T007	C0085491
OAEO	T109	C0028910
inhibited	T052	C3463820
hemolysis	T046	C0019054
Aer. hydrophila	T007	C0085491
fish	T013	C1939719
erythrocytes	T025	C0014792
linalool	T109	C0064997
not present	T169	C0332197
hemolysis	T046	C0019054
inhibition activity	T052	C3463820
water	T121	C0043047
OAEO	T109	C0028910
promoted	T052	C0033414
survival	T052	C0038952
infected	T033	C0439663
fish	T013	C1939719
Aer. hydrophila	T007	C0085491
OAEO	T109	C0028910
effective	T080	C1704419
Gyrodactylus sp.	T204	C1211435
significantly reducing	T081	C4055638
parasites	T204	C0030498
fish	T013	C1939719
Interleukin-1β	T116	C0021753
Stress Granules	T026	C1325596
Sequester	T169	C0333312
COX-2	T116	C0387583
mRNA	T114	C0035696
Regulates	T038	C1327622
Stability	T080	C2350440
Translation	UnknownType	C0678935
Human	T016	C0086418
OA	T047	C0029408
Chondrocytes	T025	C0225369
Enhanced	T052	C2349975
expression	T045	C0017262
cyclooxygenase-2	T028	C1367485
COX-2	T028	C1367485
mRNA	T114	C0035696
IL-1β	T116	C0021753
stimulated	T061	C1292856
OA	T047	C0029408
chondrocytes	T025	C0225369
synthesis of protein	T044	C0597295
delayed	T079	C0205421
stress granules	T026	C1325596
SGs	T026	C1325596
ribonucleoprotein complexes	T026	C1167298
regulate	T038	C1327622
mRNA translation	UnknownType	C0678935
delayed	T079	C0205421
translation	UnknownType	C0678935
COX-2	T028	C1367485
mRNAs	T114	C0035696
IL-1β	T116	C0021753
stimulated	T061	C1292856
OA	T047	C0029408
chondrocytes	T025	C0225369
Stimulation	T061	C1292856
human	T016	C0086418
chondrocytes	T025	C0225369
IL-1β	T116	C0021753
stress response	T039	C0149784
genes	T028	C0017337
phosphorylation	T044	C1158886
eIF2α	T116	C0013733
triggered	T080	C1444748
assembly of SGs	T045	C2247634
immunofluorescence staining	T059	C0079603
SGs	T026	C1325596
markers	T201	C0005516
COX-2 protein	T116	C0387583
RNA	T114	C0035668
fluorescence in situ hybridization	T063	C0162789
RNA	T114	C0035668
immunoprecipitation	T059	C0021069
COX-2	T028	C1367485
mRNAs	T114	C0035696
sequestered	T169	C0333312
SGs	T026	C1325596
IL-1β	T116	C0021753
stimulated	T061	C1292856
OA	T047	C0029408
chondrocytes	T025	C0225369
No	T033	C1513916
increase	T169	C0442805
COX-2	T116	C0387583
protein expression	T045	C1171362
persistence	T079	C0439590
SGs	T026	C1325596
enhanced	T052	C2349975
expression	T045	C1171362
COX-2 protein	T116	C0387583
clearance	T080	C0449297
SGs	T026	C1325596
Inhibition	T052	C3463820
SGs	T026	C1325596
clearance	T080	C0449297
blocked	T169	C0332206
COX-2	T028	C1367485
mRNA	T114	C0035696
translation	UnknownType	C0678935
blocking	T169	C0332206
assembly of SGs	T045	C2247634
TIA-1	T116	C1429678
depletion	T169	C0333668
increased	T081	C0205217
production	T169	C0005572
COX-2	T116	C0387583
PGE2	T109	C0012472
assembly of SGs	T045	C2247634
sequestration	T169	C0333312
COX-2	T028	C1367485
mRNAs	T114	C0035696
human	T016	C0086418
OA	T047	C0029408
chondrocytes	T025	C0225369
pathological conditions	T184	C0039058
Post-transcriptional regulation	T045	C1514248
COX-2	T028	C1367485
mRNAs translation	UnknownType	C0678935
SGs	T026	C1325596
IL-1β	T116	C0021753
catabolic	T169	C0311402
response	T032	C0871261
therapeutically	T061	C0087111
OA	T047	C0029408
Spatio-Temporal Distribution	T169	C1704711
Bark	T002	C0949119
Ambrosia	T002	C0331432
Beetles	T204	C0009276
Brazilian	T083	C0006137
Tropical Dry Forest	T070	C0086312
Bark	T002	C0949119
ambrosia	T002	C0331432
beetles	T204	C0009276
host plants	UnknownType	C0868970
tunnels	T082	C1116506
assessed	T052	C1516048
beetle	T204	C0009276
community	T096	C0009462
dynamics	T102	C0237587
tropical dry forest	T070	C0086312
sites	T082	C0205145
early	T079	C1279919
intermediate	T079	C1254367
late	T079	C0205087
successional stages	T079	C1306673
resource	T078	C0035201
availability	T169	C0470187
seasonal variations	T079	C0036496
guild structure	T080	C0205556
collected	T078	C1516695
beetles	T204	C0009276
species	T185	C1705920
bark	T002	C0949119
beetle	T204	C0009276
species	T185	C1705920
ambrosia	T002	C0331432
beetle	T204	C0009276
species	T185	C1705920
Local	T082	C0205276
richness	T080	C0205556
bark	T002	C0949119
ambrosia	T002	C0331432
beetles	T204	C0009276
species	T185	C1705920
Bark	T002	C0949119
ambrosia	T002	C0331432
composition	T078	C1254370
successional stages	T079	C1306673
gradient	T081	C0812409
beta diversity	T080	C1880371
sites	T082	C0205145
species	T185	C1705920
bark	T002	C0949119
beetle	T204	C0009276
community	T096	C0009462
Bark	T002	C0949119
beetle	T204	C0009276
richness	T080	C0205556
abundance	T080	C2346714
intermediate stages	T079	C1306673
availability of	T169	C0470187
wood	T167	C0043217
spatial mechanism	T169	C0441712
Climate	T070	C0008946
factors	T169	C1521761
non-seasonal	T080	C0205556
Ambrosia	T002	C0331432
beetles	T204	C0009276
successional stages	T079	C1306673
increase	T169	C0442805
wood	T167	C0043217
increased	T081	C0205217
abundance	T080	C2346714
richness	T080	C0205556
dry	T079	C0036497
wet seasons	T079	C0036497
abundance	T080	C2346714
increased	T081	C0205217
air	T167	C0001861
moisture	T167	C0868994
temperatures	T081	C0039476
rainfall	T070	C0034640
bark	T002	C0949119
beetle	T204	C0009276
species	T185	C1705920
accumulation	T169	C0205245
sites	T082	C0205145
wood	T167	C0043217
production	T052	C0441655
fungi	T004	C0016832
host	UnknownType	C0868970
air	T167	C0001861
moisture	T167	C0868994
conditions	T080	C0348080
species	T185	C1705920
accumulation	T169	C0205245
ambrosia	T002	C0331432
biological	T080	C0205460
pattern	T080	C0205556
tropical rain forests	T070	C0086312
dry forest areas	T070	C0086312
Detection	T061	C1511790
Flat Aberrant Crypt Foci (Flat ACF)	T047	C1510713
A/J Min/+ Mouse	T050	C2986594
Flat aberrant crypt foci	T047	C1510713
flat ACF	T047	C1510713
mucin-depleted foci	T047	C3828884
MDF	T047	C3828884
preneoplastic colonic lesions	T047	C1514395
A/J Min/+ mouse model	T050	C2986594
colon carcinogenesis	T191	C0699790
detection	T061	C1511790
flat ACF	T047	C1510713
lesions	T033	C0221198
histological examination	T059	C0019637
MDF	T047	C3828884
Colons	T023	C0009368
stained with methylene blue	T059	C1319310
MB	T109	C0025746
flat ACF	T047	C1510713
detection	T061	C1511790
restained	T059	C0487602
high-iron diamine-alcian blue	T109	C0062712
HID-AB	T109	C0062712
MDF	T047	C3828884
detection	T061	C1511790
flat ACF	T047	C1510713
MB staining	T059	C1319310
fraction of	T081	C1264633
flat ACF	T047	C1510713
MDF	T047	C3828884
Flat ACF	T047	C1510713
MDF	T047	C3828884
severe dysplasia	T049	C0334048
lack of	T080	C0332268
mucus	T025	C1513729
goblet cells	T025	C0014597
accumulation	T033	C4055506
cytoplasmic	T026	C0521449
β-catenin	T116	C0105770
flat ACF	T047	C1510713
surface	T026	C0699040
biomarkers	T201	C0005516
Apc	T028	C0162832
colon carcinogenesis	T191	C0699790
Transcriptional enhancement	T045	C0162493
Smn	T028	C1420257
levels	T034	C0428479
motoneurons	T025	C0026609
axon	T026	C0004461
morphology	T080	C0332437
zebrafish	T013	C0043457
spinal muscular atrophy	T047	C0026847
SMA	T047	C0026847
Smn protein	T116	C1571507
defects	T033	C0241225
motoneurons	T025	C0026609
Smn expression	T045	C1171362
motoneurons	T025	C0026609
ex vivo zebrafish culture system	T074	C4305352
zebrafish	T013	C0043457
GFP	T116	C0120285
marked	T080	C1708632
motoneurons	T025	C0026609
Smn protein	T034	C0428479
smn mRNA	T114	C0035696
levels	T081	C0392762
motoneurons	T025	C0026609
cell	T025	C0007634
Smn levels	T034	C0428479
motoneurons	T025	C0026609
transcriptional activation	T045	C0162493
ETS family transcription factor Etv5b	T116	C0919488
smn transcription	T045	C0040649
motoneurons	T025	C0026609
Smn protein	T116	C1571507
motoneurons	T025	C0026609
axonogenesis	T042	C1160337
cell-autonomous manner	T043	C0007613
findings	T034	C0587081
motoneurons	T025	C0026609
Smn	T116	C1571507
evidence	T078	C3887511
increased	T081	C0205217
vulnerability	T201	C0012655
SMA conditions	T047	C0026847
Evaluation	T058	C0220825
axitinib	T109	C1700874
Response Evaluation Criteria in Solid Tumors	T170	C1709926
Choi criteria	T170	C0935549
treated	T033	C0332154
patients	T101	C0030705
metastatic renal cell carcinoma	T191	C0278678
Axitinib	T109	C1700874
tyrosine kinase inhibitor	T121	C1268567
vascular endothelial growth factor receptors	T116	C0148199
patients	T101	C0030705
Canada	T083	C0006823
Australia	T083	C0004340
approval	T170	C2346845
axitinib	T109	C1700874
countries	T083	C0454664
treatment	T061	C0087111
clear-cell metastatic renal cell carcinoma	T191	C2931852
mRCC	T191	C2931852
regimen	T061	C0040808
single-arm	T062	C2826346
open-label study	T062	C1709323
axitinib	T109	C1700874
efficacy	T062	C1707887
safety	T062	C1705187
quality of life	T078	C0034380
QoL	T078	C0034380
patients	T101	C0030705
mRCC	T191	C2931852
disease	T047	C0012634
progressed	T046	C0242656
first-line regimen	T061	C1708063
response rate	T079	C0237629
evaluated	T058	C0220825
Response Evaluation Criteria in Solid Tumors	T170	C1709926
RECIST	T170	C1709926
Choi criteria	T170	C0935549
Progression-free survival	T081	C0242792
overall survival	T081	C4086681
safety	T062	C1705187
QoL	T078	C0034380
study	T062	C2603343
statistics	T062	C2717898
patients	T101	C0030705
Canada	T083	C0006823
Australia	T083	C0004340
patients	T101	C0030705
sunitinib	T109	C1176020
therapy	T061	C0087111
patients	T101	C0030705
clear-cell carcinoma	T191	C0206681
nephrectomy	T061	C0027695
Liver	T023	C0023884
lung	T023	C0024109
lymph nodes	T023	C0024204
metastases	T191	C0027627
patient	T101	C0030705
brain metastasis	T191	C0220650
Median	T081	C0876920
axitinib	T109	C1700874
days	T079	C0439228
range	T081	C1514721
days	T079	C0439228
survival	T052	C0038952
months	T079	C0439231
patients	T101	C0030705
responses	T032	C0871261
RECIST	T170	C1709926
Choi criteria	T170	C0935549
patients	T101	C0030705
progressive	T046	C0242656
disease	T047	C0012634
RECIST	T170	C1709926
Choi criteria	T170	C0935549
progression	T046	C0242656
death	T040	C0011065
study	T062	C2603343
patients	T101	C0030705
study	T062	C2603343
drug	T121	C1254351
Fatigue	T184	C0015672
diarrhea	T184	C0011991
treatment	T061	C0087111
adverse events	T046	C0877248
mean	T081	C0444504
European	T083	C0015176
Quality of Life	T078	C0034380
score	T081	C0449820
baseline	T081	C1442488
treatment	T061	C0087111
patients	T101	C0030705
definitive	T079	C0443196
conclusions	T078	C1707478
safety	T062	C1705187
efficacy	T062	C1707887
axitinib	T109	C1700874
studies	T062	C2603343
patients	T101	C0030705
mRCC	T191	C2931852
patients	T101	C0030705
QoL	T078	C0034380
response rate	T079	C0237629
RECIST	T170	C1709926
Choi criteria	T170	C0935549
research	T062	C0008972
Biochemical	T169	C0205474
characteristics	T080	C1521970
AtFAR2	T116	C4307379
fatty acid reductase	T116	C0060094
Arabidopsis thaliana	T002	C0162740
fatty acyl-CoA	T114	C0001374
ACP substrates	T116	C0001369
fatty alcohols	T109	C0015694
Fatty alcohols	T109	C0015694
derivatives	T104	C0243072
important	T080	C3898777
deposition	T169	C0333562
functional	T169	C0205245
pollen wall	T026	C1820005
Mutations	T045	C0596611
genes	T028	C0017337
fatty acid reductases	T116	C0060094
FAR	T116	C0060094
fatty alcohol	T109	C0015694
production	T169	C0205245
abnormal	T033	C0205161
development	T169	C1527148
pollen	T002	C0032385
disrupted	T080	C0332454
AtFAR2 (MS2) gene	T028	C1428496
Arabidopsis thaliana	T002	C0162740
results	T169	C1274040
pollen	T002	C0032385
developing	T169	C1527148
abnormal	T033	C0205161
exine layer	T026	C1820006
reduced fertility	T033	C0243095
phenotype	T032	C0031437
AtFAR2	T116	C4307379
targeted	T169	C1521840
chloroplasts	T026	C0008266
purified form	T080	C0348078
specific	T080	C0205369
acyl-ACP substrates	T116	C0001369
data	T078	C1511726
in vitro	T080	C1533691
planta	T002	C0032098
characterizations	T052	C1880022
AtFAR2	T116	C4307379
A. thaliana	T002	C0162740
enzyme	T116	C0014442
C16:0-ACP	T116	C0001369
C16:0-CoA	T114	C0030239
substrates	T120	C0178623
C16:0-alcohol	T109	C0055152
AtFAR2	T116	C4307379
properties	T080	C0205556
substrate	T120	C0178623
specificity	T081	C0037791
AtFAR6	T116	C0060094
in vitro	T080	C1533691
data	T078	C1511726
chloroplast	T026	C0008266
localized	T082	C0392752
enzyme	T116	C0014442
AtFAR2	T116	C4307379
enzyme	T116	C0014442
exine layer	T026	C1820006
functionality	T169	C0542341
AtFAR6	T116	C0060094
functional	T169	C0205245
redundancy	T169	C1313915
AtFAR2	T116	C4307379
Comparing	T052	C1707455
Time Perception	T041	C0040226
Morphine	T109	C0026549
Derived	T080	C1441547
Drugs	T121	C0013227
Addicts	T101	C0858354
Controls	T096	C0009932
aim	T078	C1947946
study	T062	C2603343
compare	T052	C1707455
time perception	T041	C0040226
drug addicts	T033	C0700285
controls	T096	C0009932
drug addicts	T033	C0700285
selected	T052	C1707391
non-addict individuals	T098	C0237401
selected	T052	C1707391
control group	T096	C0009932
groups	T078	C0441833
tests	T170	C0392366
time	T079	C0040223
reproduction	T040	C0035150
time estimation	T079	C0871937
time	T079	C0040223
discrimination	T041	C0012632
significant	T078	C0750502
difference	T080	C1705242
addicts	T101	C0858354
group	T078	C0441833
control group	T096	C0009932
error	T080	C0743559
time	T079	C0040223
reproduction	T040	C0035150
time estimation	T079	C0871937
addict	T101	C0858354
group	T078	C0441833
comparison	T052	C1707455
control group	T096	C0009932
lower	T052	C2003888
reproduction	T040	C0035150
higher	T080	C0205250
reproduction	T040	C0035150
error	T080	C0743559
lower	T052	C2003888
estimation	T041	C0680844
higher	T080	C0205250
estimation	T041	C0680844
error	T080	C0743559
time	T079	C0040223
discrimination	T041	C0012632
significant	T078	C0750502
difference	T080	C1705242
errors	T080	C0743559
groups	T078	C0441833
images	T170	C1704922
drug consumption	UnknownType	C0678263
tools	T073	C0336791
normal	T080	C0205307
images	T170	C1704922
durations	T079	C0449238
normal	T080	C0205307
group	T078	C0441833
images	T170	C1704922
drug consumption	UnknownType	C0678263
tools	T073	C0336791
shorter	T081	C1806781
period	T079	C1948053
time	T079	C0040223
Time perception	T041	C0040226
different	T080	C1705242
morphine	T109	C0026549
derived	T080	C1441547
drugs	T121	C0013227
addicts	T101	C0858354
controls	T096	C0009932
Co-delivery	T169	C1705822
pemetrexed	T109	C0210657
miR-21 antisense oligonucleotide	T114	C0079925
lipid	T109	C0023779
polymer	T104	C0032521
hybrid nanoparticles	T073	C1450054
effects	T080	C1280500
glioblastoma	T191	C0017636
cells	T025	C0007634
Combination therapy	T061	C0009429
anticancer drugs	T109	C0003392
nucleic acid	T114	C0028606
multidrug resistance	T032	C0242640
cancer	T191	C0027651
apoptosis	T043	C0162638
study	T062	C2603343
lipid	T109	C0023779
polymer	T104	C0032521
hybrid nanoparticles	T073	C1450054
LPNs	T122	C1713964
pemetrexed	T109	C0210657
miR-21 antisense oligonucleotide	T114	C0079925
anti-miR-21	T114	C0079925
treatment	T169	C1522326
glioblastoma	T191	C0017636
aggressive	T191	C2945759
brain tumor	T191	C0006118
LPNs	T122	C1713964
particle size	T081	C0030608
distribution	T169	C1704711
zeta potential	T067	C0597697
measurements	T169	C0242485
encapsulation	T067	C2348438
efficiency	T081	C0013682
in vitro	T080	C1533691
release experiments	T062	C0681814
Morphology	T080	C0332437
LPNs	T122	C1713964
transmission electron microscopy	T059	C0678118
LPNs	T122	C1713964
hydrodynamic	T070	C2936194
size	T082	C0456389
sustained release	T169	C0391871
pemetrexed	T109	C0210657
Encapsulation	T067	C2348438
pemetrexed	T109	C0210657
LPNs	T122	C1713964
cellular uptake	T043	C0007613
confocal microscopy analysis	T059	C0242842
co-delivery	T169	C1705822
anti-miR-21	T114	C0079925
accumulation	T033	C4055506
LPNs	T122	C1713964
nucleus	T026	C0007610
U87MG cells	T025	C0007634
cytotoxicity	T049	C0596402
results	T169	C1274040
concentration	UnknownType	C0678563
anti-miR-21	T114	C0079925
LPNs	T122	C1713964
drug delivery systems	T074	C0085104
concentration	UnknownType	C0678563
anti-miR-21	T114	C0079925
treatment	T061	C0087111
glioblastoma	T191	C0017636
Expert	T097	C1522486
position paper	T170	C0282574
prolonged	T079	C0439590
dual antiplatelet therapy	T061	C1096021
secondary prevention	T061	C0679699
myocardial infarction	T047	C0027051
protective effect	T080	C1280500
dual antiplatelet therapy	T061	C1096021
DAPT	T061	C1096021
acute coronary syndrome	T047	C0948089
duration	T079	C0449238
debate	T052	C0870392
studies	T062	C2603343
prolonged	T079	C0439590
therapy	T061	C0087111
clinical	T080	C0205210
benefit	T081	C0814225
patients	T101	C0030705
acute coronary syndrome	T047	C0948089
position paper	T170	C0282574
Austrian	T098	C0337795
experts	T097	C1522486
current	T079	C0521116
evidence	T078	C3887511
studies	T062	C2603343
practical guide	T170	C0681467
patients	T101	C0030705
benefit	T081	C0814225
prolonged	T079	C0439590
DAPT	T061	C1096021
Medulloblastoma	T191	C0025149
molecular pathways	T044	C1704259
histopathological	T169	C0243140
classification	T185	C0008902
Malignant brain tumors	T191	C0153633
leading	T169	C1522538
cause	T169	C0015127
cancer	T191	C0006826
death	T033	C1306577
pediatric	T080	C1521725
patients	T101	C0030705
medulloblastoma	T191	C0025149
treatment	T061	C0087111
surgical resection	T061	C0015252
recommended	T078	C0034866
chemotherapy	T061	C3665472
neuroaxis	T022	C3714787
radiotherapy	T061	C1522449
improving	T080	C1272745
survival rate	T081	C0038954
survivors	T101	C0206194
treatment	T061	C0087111
induced	T169	C0205263
side effects	T046	C0879626
reduce	T080	C0392756
toxic effects	T037	C0600688
molecular-targeted treatment	T061	C2699893
Medulloblastoma	T191	C0025149
research	T062	C0035168
robust	T080	C2986815
articles	T170	C1706852
published	T057	C0034037
review	T170	C0282443
molecular	T080	C1521991
pathophysiology	T169	C0031847
neoplasm	T191	C0027651
pathological	T169	C1521733
classification	T185	C0008902
tumor biology	T062	C1519672
histological picture	T201	C1301121
Spatio-Temporal History	T062	C3494293
HIV-1 CRF35_AD	T034	C3656358
Afghanistan	T083	C0001732
Iran	T083	C0022065
HIV-1 Circulating Recombinant Form 35_AD	T005	C0019704
CRF35_AD	T034	C3656358
epidemiological	T091	C0014507
profile	T169	C2003903
Afghanistan	T083	C0001732
Iran	T083	C0022065
clade	T001	C0029235
Afghanistan	T083	C0001732
Iran	T083	C0022065
dissemination	T080	C0332261
Bayesian phylogeographic analysis	T081	C0242196
spatio-temporal dispersion pattern	T080	C0332261
clade	T001	C0029235
CRF35_AD	T034	C3656358
gag and pol sequences	T086	C0004793
Los Alamos	T083	C3829256
HIV database	T170	C0950132
sequences	T086	C0004793
Iran	T083	C0022065
sequences	T086	C0004793
Afghanistan	T083	C0001732
CRF35_AD	T034	C3656358
pol sequence	T086	C0004793
USA	T083	C0041703
Bayesian Markov Chain Monte Carlo algorithm	T170	C0002045
BEAST v1.8.1	T073	C0037585
Bayesian stochastic search variable selection method	T170	C0034980
Bayes factor values	T081	C1553908
CRF35_AD	T034	C3656358
sequences	T086	C0004793
parental sequences	T086	C0004793
Kenya	T083	C0022558
Uganda	T083	C0041573
subtype A1	T034	C3656358
sequences	T086	C0004793
Afghan	T083	C0001732
refugees	T098	C0034961
Pakistan	T083	C0030211
phylogenies	T078	C0031797
Afghan	T083	C0001732
Iranian	T083	C0022065
CRF35_AD	T034	C3656358
sequences	T086	C0004793
monophyletic cluster	T081	C1704332
cluster	T081	C1704332
cluster	T081	C1704332
bidirectional	T080	C1706937
dispersion	T080	C0332261
virus	T005	C0042776
Afghanistan	T083	C0001732
Iran	T083	C0022065
Afghanistan	T083	C0001732
Iran	T083	C0022065
epidemic	T047	C0277548
cluster	T081	C1704332
CRF35_AD	T034	C3656358
sequences	T086	C0004793
Afghan	T083	C0001732
refugees	T098	C0034961
living in	T082	C0337646
Pakistan	T083	C0030211
Afghan	T083	C0001732
Iranian	T083	C0022065
CRF35_AD	T034	C3656358
CRF35_AD	T034	C3656358
sequence	T086	C0004793
USA	T083	C0041703
Kenyan	T083	C0022558
subtype A1	T034	C3656358
sequences	T086	C0004793
CRF35_AD	T034	C3656358
Potential	T080	C3245505
factors	T169	C1521761
viral	T005	C0042776
Afghanistan	T083	C0001732
Iran	T083	C0022065
mass migration	T054	C0600210
Afghan	T083	C0001732
refugees	T098	C0034961
labours	T055	C0022867
Iran	T083	C0022065
extensive	T080	C0205231
preventive	T080	C1456501
Benefits	T081	C0814225
Combination Therapy	T061	C0009429
Esomeprazole	T109	C0937846
Rebamipide	T109	C0069562
Symptom	T184	C1457887
Improvement	T077	C2986411
Reflux Esophagitis	T047	C0014869
International	T078	C1512888
Multicenter Study	T062	C1096776
investigate	T169	C1292732
effects	T080	C1280500
esomeprazole	T109	C0937846
rebamipide	T109	C0069562
combination therapy	T061	C0009429
symptomatic	T184	C1457887
improvement	T077	C2986411
patients	T101	C0030705
reflux esophagitis	T047	C0014869
patients	T101	C0030705
reflux esophagitis	T047	C0014869
randomized	T062	C0206034
treatment regimens	T061	C0040808
esomeprazole	T109	C0937846
rebamipide	T109	C0069562
daily	T079	C0332173
combination therapy	T061	C0009429
group	T078	C0441833
esomeprazole	T109	C0937846
daily	T079	C0332173
monotherapy	T061	C0087111
group	T078	C0441833
symptom	T184	C1457887
questionnaire	T170	C0034394
evaluated	T169	C1292732
heartburn	T184	C0018834
acid regurgitation	T184	C0849747
upper gastrointestinal symptoms	T047	C0857493
efficacy	T080	C1280519
decrease	T081	C0547047
symptom score	T033	C3476546
decreases	T081	C0547047
symptom score	T033	C3476546
weeks	T079	C0439230
combination therapy	T061	C0009429
group	T078	C0441833
monotherapy	T061	C0087111
group	T078	C0441833
reflux	T047	C0014869
symptom	T184	C1457887
baseline	T081	C1442488
weeks	T079	C0439230
treatment	T061	C0087111
combination therapy	T061	C0009429
group	T078	C0441833
monotherapy	T061	C0087111
group	T078	C0441833
week	T079	C0439230
treatment	T061	C0087111
esomeprazole	T109	C0937846
rebamipide	T109	C0069562
combination therapy	T061	C0009429
effective	T080	C1704419
decreasing	T033	C0442797
symptoms	T184	C1457887
reflux esophagitis	T047	C0014869
esomeprazole	T109	C0937846
monotherapy	T061	C0087111
Integrating	T080	C0205195
Palliative Care	T091	C0030231
Pediatric Oncology	T091	C1518931
Evolving	T169	C0332253
Paradigm	T062	C0681797
Comprehensive	T058	C0009586
Cancer Care	T061	C0920687
integrating	T080	C0205195
palliative care	T091	C0030231
PC	T091	C0030231
cancer treatment	T061	C0920425
increased	T081	C0205217
PC	T091	C0030231
integrating	T080	C0205195
PC	T091	C0030231
comprehensive	T058	C0009586
cancer centers,	T073	C1516604
pediatric centers	T093	C0020017
year	T079	C0439234
establishing	T080	C0443211
PC	T091	C0030231
Quality of Life Service	T058	C0008079
QoLS	T058	C0008079
St. Jude Children's Research Hospital	T093	C1519168
records of patients	T170	C0025102
QoLS	T058	C0008079
March	T079	C3829202
December	T080	C3830550
Variables	T081	C1705098
year	T079	C0439234
statistics	T081	C1456551
diagnostic groups	T170	C0011928
QoLS	T058	C0008079
encounters	T058	C1512346
goals of care	T058	C2930505
duration of survival	T201	C2919551
location of death	T082	C2924451
QoLS	T058	C0008079
patient	T101	C0030705
encounters	T058	C1512346
increased	T081	C0205217
consults	T058	C0009818
increased	T081	C0205217
encounters	T058	C1512346
patient	T101	C0030705
increased	T081	C0205217
Goal of care	T058	C2930505
initial consultation	T058	C2065349
comfort	T041	C1331418
increasing	T169	C0442808
goal of cure	T170	C3897861
initial consult	T058	C2065349
death	T033	C1306577
increased	T081	C0205217
increased	T081	C0205217
outpatient	T101	C0029921
location of death	T082	C2924451
outpatient	T101	C0029921
deaths	T033	C1306577
increasing	T169	C0442808
majority	T080	C0205164
year	T079	C0439234
Hospital-wide	T080	C1510665
patients	T101	C0030705
PC	T091	C0030231
death	T033	C1306577
increased	T081	C0205217
approximately	T080	C0332232
QoLS	T058	C0008079
increase	T081	C0205217
referrals	T058	C0034927
encounters	T058	C1512346
patient	T101	C0030705
increased	T081	C0205217
clinical services	T058	C1704289
earlier	T079	C1279919
consultation	T058	C0009818
longer term	T079	C0443252
follow-up	T058	C1522577
increasing	T169	C0442808
outpatient	T101	C0029921
location of death	T082	C2924451
universal	T080	C0175671
PC	T091	C0030231
end-of-life	T058	C0039548
integration	T080	C0205195
PC	T091	C0030231
comprehensive	T058	C0009586
cancer center	T073	C1516604
care provision	T058	C3244104
time	T079	C0040223
model	T170	C3161035
programs	T058	C0679897
PROTECTIVE EFFECTS OF	T080	C1704420
DIPEPTIDYL PEPTIDASE-4 INHIBITORS	T121	C1827106
PROGRESSION	T046	C0242656
DIABETIC RETINOPATHY	T047	C0011884
PATIENTS	T101	C0030705
TYPE 2 DIABETES	T047	C0011860
investigate	T169	C1292732
effects of	T080	C1704420
dipeptidyl peptidase-4 inhibitors	T121	C1827106
DPP4	T121	C1827106
progression	T046	C0242656
diabetic retinopathy	T047	C0011884
DR	T047	C0011884
patients	T101	C0030705
Type 2 diabetes	T047	C0011860
DR	T047	C0011884
severity scale	T081	C0392762
medical records	T170	C0025102
patients	T101	C0030705
Type 2 diabetes	T047	C0011860
retrospectively	T080	C1514923
reviewed	T080	C1709940
Fundus photographs	T060	C0200189
graded	T185	C0441800
Early Treatment Diabetic Retinopathy Study methods	T170	C3899277
associations	T080	C0332281
baseline	T081	C1442488
risk factors	T033	C0035648
progression	T046	C0242656
DR	T047	C0011884
investigated	T169	C1292732
patients	T101	C0030705
treated	T169	C1522326
DPP4 inhibitors	T121	C1827106
treated	T169	C1522326
hypoglycemic agents	T121	C0020616
progression	T046	C0242656
retinopathy	T047	C0011884
Early Treatment Diabetic Retinopathy Study scale	T081	C0392762
treatment	T169	C1522326
DPP4 inhibitors	T121	C1827106
reduced	T080	C0392756
progression	T046	C0242656
DR	T047	C0011884
patients	T101	C0030705
propensity score	T081	C2718044
Treatment	T169	C1522326
DPP4 inhibitors	T121	C1827106
associated with	T080	C0332281
lower	T052	C2003888
risk	T078	C0035647
DR	T047	C0011884
progression	T046	C0242656
Treatment	T169	C1522326
DPP4 inhibitors	T121	C1827106
independent	T078	C0085862
protective factor	T169	C1521761
progression	T046	C0242656
DR	T047	C0011884
improving glycemic control	T033	C0243095
benefits	T081	C0814225
DPP4 inhibitors	T121	C1827106
reducing	T080	C0392756
DR	T047	C0011884
progression	T046	C0242656
preliminary	T079	C0439611
data	T078	C1511726
evaluation	T058	C0220825
DPP4 inhibitors	T121	C1827106
progression	T046	C0242656
DR	T047	C0011884
randomized	T062	C0034656
double-blind	T062	C0013072
placebo-controlled trial	T062	C0599724
Production	T057	C0033268
Laccase	T116	C0064566
Cochliobolus sp.	T004	C0009206
Isolated	T169	C0205409
Plastic	T167	C0032167
Dumped Soils	T167	C0037592
Ability	T032	C0085732
Degrade	UnknownType	C0678637
Low Molecular Weight PVC	T109	C0032624
man-made problems	T068	C2963156
ever	T079	C3887636
increasing	T169	C0442808
plastic	T167	C0032167
waste	T167	C0043045
filling	T052	C1708059
municipal solid waste	T167	C1550151
landfill sites	T073	C0563007
plastic	T167	C0032167
biodegradation	T070	C0005482
fungi	T004	C0016832
enzymes	T116	C0014442
plastic	T167	C0032167
degradation	T070	C0005482
laboratory conditions	T080	C2826637
ability	T032	C0085732
fungi	T004	C0016832
degrade	UnknownType	C0678637
low molecular weight polyvinyl chloride	T109	C0032624
PVC	T109	C0032624
enzyme laccase	T116	C0064566
isolated	T169	C0205409
fungal	T004	C0016832
species	T185	C1705920
Cochliobolus sp.	T004	C0009206
plastic	T167	C0032167
dumped soils	T167	C0037592
cultured	T059	C0200954
Czapek Dox Agar slants	T130	C0010454
effectiveness	T080	C1280519
fungal	T004	C0016832
species	T185	C1705920
degradation	T070	C0005482
low molecular weight polyvinyl chloride	T109	C0032624
PVC	T109	C0032624
laboratory conditions	T080	C2826637
FTIR	T062	C0206055
GC-MS	T059	C0024868
SEM	T059	C0026020
control	T167	C1550141
Cochliobolus sp.	T004	C0009206
PVC	T109	C0032624
Effects of	T080	C1704420
Cerium	T130	C0055114
Titanium Oxide	T121	C0145999
Nanoparticles	T073	C1721060
Soil	T167	C0037592
Nutrient	T168	C0678695
Composition	T201	C0486616
Barley	T002	C0331554
Hordeum vulgare L	T002	C0331554
Kernels	T168	C0453143
implications	T169	C0205245
metal nanoparticles	T073	C1721060
MeNPs)	T073	C1721060
unknown	T080	C0439673
many	T081	C0439064
food crops	T002	C0242775
purpose	T169	C1285529
study	T062	C2603343
effects of	T080	C1704420
cerium oxide	T130	C0055114
nCeO₂	T130	C0055114
titanium oxide	T121	C0145999
nTiO₂	T121	C0145999
nanoparticles	T073	C1721060
soil	T167	C0037592
nutritional parameters	T080	C1521739
barley	T002	C0331554
Hordeum vulgare L.	T002	C0331554
kernels	T168	C0453143
Mineral nutrients	T197	C0682741
amylose	T109	C0002732
β-glucans	T109	C1134651
amino acid	T116	C0002520
crude protein	T116	C0033684
CP	T116	C0033684
concentrations were measured	T081	C1446561
kernels	T168	C0453143
Whole	T081	C0444667
flour	T168	C0016260
ICP-AES/MS	T059	C2930679
HPLC	T059	C0008562
Elemental CHNS Analyzer	T073	C1706246
Ce	T109	C0007828
Ti	T196	C0040302
accumulation	T033	C4055506
MeNPs	T073	C1721060
treatments	T169	C1522326
control treatment	T169	C1522326
nCeO₂	T130	C0055114
nTiO₂	T121	C0145999
impact	T080	C4049986
composition	T201	C0486616
nutritional quality	T080	C3489446
barley	T002	C0331554
kernels	T168	C0453143
contrasting ways	T080	C0205556
MeNPs	T073	C1721060
β-glucans	T109	C1134651
unaffected	T077	C2986417
amylose	T109	C0002732
amino acids	T116	C0002520
CP	T116	C0033684
increased	T081	C0205217
amino acids	T116	C0002520
lysine	T116	C0024337
proline	T116	C0033382
largest increase	T169	C0442805
Potassium	T123	C0032821
S	T121	C0038774
negatively impacted	T080	C4049986
MeNPs	T073	C1721060
affected	T169	C0392760
nCeO₂	T130	C0055114
Zn	T059	C0373748
Mn concentrations	T059	C0373677
nTiO₂	T121	C0145999
nTiO₂	T121	C0145999
treatments	T169	C1522326
demonstrated	T052	C3687625
kernels	T168	C0453143
negatively affected	T033	C1513916
nCeO₂	T130	C0055114
nTiO₂	T121	C0145999
beneficial effects	T080	C0205556
MeNPs	T073	C1721060
negatively impact	T080	C4049986
malt	T168	C0024651
feed production	T090	C4042899
Quantifying	T081	C1709793
Contributions	T052	C1880177
Cortical Responses Evoked	T059	C0853990
Continuous Wrist Manipulation	T061	C1293270
Cortical responses	T059	C0853990
continuous stimuli	T039	C0542478
magneto-	T060	C0024489
electroencephalography	T060	C0013819
EEG	T060	C0013819
stimulated frequency	T079	C0237630
nonlinear behavior	T053	C0004927
analysis	T062	C0936012
techniques	T169	C0449851
linearity	T082	C0205132
contributions	T052	C1880177
cortical responses	T059	C0853990
goal of this paper	T170	C0018017
quantify	T081	C1709793
contributions	T052	C1880177
cortical response	T059	C0853990
continuous	T078	C0549178
sensory stimulation	T061	C0150763
EEG	T060	C0013819
cortical response evoked	T059	C0853990
continuous movement of the wrist joint	T033	C0575717
robotic manipulator	T073	C0336537
stimulus signals	T067	C0234402
several	T081	C0443302
sinusoids	T030	C0682624
periodic	T079	C0332182
cortical response	T059	C0853990
assess	T052	C1516048
contributions	T052	C1880177
Wrist dynamics	T061	C0454465
joint angle	T030	C0022417
torque	T067	C0376590
linearized	T082	C0205132
cortical response	T059	C0853990
nonparametric linear model	T081	C0242932
results	T033	C0683954
evoked cortical responses	T059	C0853990
linear	T082	C0205132
mechanical stimulus	T067	C0234402
cortical response	T033	C0596450
Using	T169	C1524063
melanopsin	T116	C0670514
study	T062	C2603343
G protein signaling	T044	C1517335
cortical	T023	C0007776
neurons	T025	C0027882
understanding	T041	C0162340
G protein-coupled receptors	T116	C0682972
GPCRs	T116	C0682972
central nervous system	T022	C3714787
CNS	T022	C3714787
tools	T073	C3273359
study	T062	C2603343
signaling	T038	C3537152
precise temporal	T079	C1547902
control	T169	C2587213
overcome	T052	C2983310
tested	T169	C0039593
bistable	T080	C0205360
mammalian	T015	C0024660
opsin	T116	C2355587
melanopsin	T116	C0670514
G protein signaling	T044	C1517335
CNS	T022	C3714787
neurons	T025	C0027882
used	T169	C1524063
biolistic	T063	C0376638
gene gun	T075	C0920531
transfect melanopsin	T116	C0670514
cortical	T023	C0007776
pyramidal cells	T025	C0206441
maintained	T169	C1314677
organotypic slice culture	T059	C0040284
Whole cell recordings	T062	C0242624
transfected neurons	T025	C0027882
blue light	T070	C0303896
effectively	T080	C1704419
activated	T169	C1515877
transfected melanopsin	T116	C0670514
elicit	T080	C0449265
biphasic	T079	C0205184
modulation	UnknownType	C0678672
membrane	T026	C0596901
excitability	T184	C0235169
associated with	T080	C0332281
activation	T169	C1515877
GPCRs	T116	C0682972
coupling	T169	C1948027
Gαq-11	T116	C1333650
exogenous	T169	C0205228
agonist	T121	C2987634
concentration	T081	C1446561
obtained	T169	C1301820
pulses	T067	C1947910
few	T081	C0205388
milliseconds	T079	C0439223
triggering	T080	C1444748
single	T081	C0205171
melanopsin	T116	C0670514
activation-deactivation cycle	T079	C1254367
resulting	T169	C1274040
temporal control	T169	C2587213
melanopsin	T116	C0670514
activation	T169	C1515877
compare	T052	C1707455
activation	T169	C1515877
kinetics	T070	C0022702
electrophysiological	T042	C2350527
response	T032	C0871261
intracellular	T082	C0178719
loops	T082	C0445022
melanopsin	T116	C0670514
5-HT2A receptor	T116	C0289174
light-activated	T067	C1254366
GPCR	T116	C0682972
interacting	T169	C1704675
5-HT2A receptor	T116	C0289174
interacting	T169	C1704675
proteins	T116	C0033684
resulting	T169	C1274040
chimera	T116	C0162768
expressed	T169	C0205245
weak	T080	C1762617
activity	T052	C0441655
validated	T062	C1519941
potential	T080	C3245505
usefulness	T080	C3827682
melanopsin	T116	C0670514
tool	T073	C3273359
study	T062	C2603343
G protein signaling	T044	C1517335
CNS	T022	C3714787
neurons	T025	C0027882
Maternal	T099	C0026591
vitamin D	T109	C0042866
levels	T080	C0441889
risk	T078	C0035647
perinatal death	T046	C0455986
association	T080	C0439849
maternal	T099	C0026591
vitamin D	T109	C0042866
levels	T080	C0441889
perinatal death	T046	C0455986
retrospective	T080	C1514923
cross-sectional study	T062	C0010362
singleton	T099	C1313913
births	T040	C0005615
weeks	T079	C0439230
perinatal death	T046	C0455986
control group	T096	C0009932
pregnancies	T040	C0032961
vitamin D	T109	C0042866
level	T080	C0441889
weeks	T079	C0439230
gestation	T040	C0032961
analysis	T062	C0936012
Maternal	T099	C0026591
vitamin D	T109	C0042866
levels	T080	C0441889
normal	T080	C0205307
deficient	T169	C0011155
insufficient	T080	C0231180
cohorts	T098	C0599755
variables	T080	C0439828
groups	T098	C0599755
perinatal deaths	T046	C0455986
controls	T096	C0009932
vitamin D	T109	C0042866
levels	T080	C0441889
perinatal death	T046	C0455986
cohort	T098	C0599755
control group	T096	C0009932
deaths	T040	C0011065
normal	T080	C0205307
deficient	T169	C0011155
insufficient	T080	C0231180
groups	T098	C0599755
maternal	T099	C0026591
vitamin D	T109	C0042866
levels	T080	C0441889
associated with	T080	C0332281
risk	T078	C0035647
perinatal demise	T046	C0455986
Effect	T080	C1280500
constitutive inactivation	T045	C0598496
myostatin gene	T028	C1333667
gain	T081	C1517378
muscle strength	T042	C0517349
postnatal growth	T040	C0243109
murine	T015	C0025929
models	T008	C0599779
effect	T080	C1280500
constitutive inactivation	T045	C0598496
gene encoding myostatin	T028	C1333667
gain	T081	C1517378
muscle performance	T042	C0517349
postnatal growth	T040	C0243109
murine	T015	C0025929
myostatin	T028	C1333667
knockout (KO) models	T008	C1171353
Lee model	T008	C0599779
KO(Lee	T015	C0206745
Grobet model	T008	C0599779
KO(Grobet)	T015	C0206745
measured	T080	C0444706
contraction	T039	C0026820
tibialis anterior muscle	T023	C0242690
in situ	T082	C0444498
Absolute maximal isometric force	T042	C0022205
increased	T081	C0205217
KO(Lee)	T015	C0206745
KO(Grobet) mice	T015	C0206745
compared	T052	C1707455
wild-type mice	T015	C0026809
absolute maximal power	T042	C0517349
increased	T081	C0205217
KO(Lee) mice	T015	C0206745
specific	T080	C0205369
maximal force	T042	C0517349
relative	T080	C0205345
maximal force	T042	C0517349
muscle	T024	C0026845
mass	T033	C0577559
decreased	T081	C0205216
male	T032	C0086582
female	T032	C0086287
KO mice	T015	C0206745
except	T169	C0332300
6-month	T079	C0439231
female	T032	C0086287
KO(Grobet) mice	T015	C0206745
specific	T080	C0205369
maximal power	T040	C2371225
reduced	T080	C0392756
male	T032	C0086582
KO(Lee) mice	T015	C0206745
Genetic inactivation	T045	C0598496
myostatin	T028	C1333667
increases	T169	C0442805
maximal force	T042	C0517349
power	T040	C2371225
return	T080	C0332156
reduces	T080	C0392756
muscle	T024	C0026845
quality	T080	C0332306
male	T032	C0086582
mice	T015	C0026809
Methylation	T044	C0376452
status	T080	C0449438
promoter region	T114	C0033413
human	T016	C0086418
frizzled 9 gene	T028	C1333589
acute myeloid leukemia	T191	C0023465
FZD9 gene	T028	C1333589
chromosome 7q11.23	T028	C4267768
tumor suppressor gene	T028	C0079427
study	T062	C2603343
examined	T033	C0332128
involvement	T169	C1314939
FZD9	T028	C1333589
promoter	T114	C0086860
methylation	T044	C0376452
downregulation	T044	C0013081
FZD9	T028	C1333589
expression	T045	C0017262
leukemia	T191	C0023418
cells	T025	C0007634
expression	T045	C0017262
FZD9 gene	T028	C1333589
absent	T169	C0332197
leukemic	T191	C0023418
cell lines	T025	C0085983
treatment	T169	C1522326
DNA demethylating agent	T109	C0029224
5-aza-2'-deoxycytidine	T109	C0029224
Bisulfite sequencing analysis	T063	C3831347
FZD9	T028	C1333589
promoter region	T114	C0033413
methylated	T044	C0376452
cell lines	T025	C0085983
FZD9 gene	T028	C1333589
expressed	T045	C0017262
DNA methylation	T044	C0025723
promoter region	T114	C0033413
inactivation	T169	C0544461
FZD9 gene	T028	C1333589
associated with	T080	C0332281
leukemia	T191	C0023418
DNA	T114	C0012854
methylated	T044	C0376452
peripheral blood mononuclear cells	T025	C1321301
Methylation	T044	C0376452
polymerase chain reaction analysis	T063	C0032520
promoter region	T114	C0033413
FZD9 gene	T028	C1333589
frequently	T079	C0332183
methylated	T044	C0376452
primary	T080	C0205225
relapse	T067	C0035020
acute myeloid leukemia	T191	C0023465
acute promyelocytic leukemia	T191	C0023487
methylation	T044	C0376452
B-cell	T025	C0004561
acute lymphocytic leukemia	T191	C0023449
study	T062	C2603343
methylation	T044	C0376452
profile	T059	C1979963
FZD9 gene	T028	C1333589
tumor-suppressor gene	T028	C0079427
acute myeloid leukemia	T191	C0023465
Identification	T080	C0205396
group	T078	C0441833
XTHs	T116	C1175650
genes	T028	C0017337
heavy metal	T196	C0347988
mercury	T131	C0025424
salinity and drought stresses	T067	C0871732
Medicago truncatula	T002	C0330774
Xyloglucan endotransglucosylase/hydrolases	T116	C1175650
XTH	T116	C1175650
enzymes	T116	C0014442
regulating	T038	C1327622
cell wall construction	T043	C1156159
extension	T169	C0231448
metabolism	T025	C3826603
study	T062	C0008972
XTH protein	T116	C1175650
genes	T028	C0017337
Medicago truncatula	T002	C0330774
genome	T028	C0017428
bioinformatics	T091	C1140694
microarray	T073	C1709016
RT-PCR	T063	C0599161
XTH	T116	C1175650
highly conserved domain	T087	C1514562
XTHs	T116	C1175650
Cys	T116	C0010654
C terminal region	T087	C1514562
potential	T080	C3245505
disulfide bonds	T087	C1511997
XTH	T116	C1175650
protein sequences	T087	C0002518
XTHs	T116	C1175650
families	T116	C1335532
family	T116	C1335532
groups	T078	C0441833
genomic location	T082	C1880951
XTH genes	T028	C0017337
M. truncatula	T002	C0330774
chromosomes	T026	C0008633
evolutional expansion	T038	C0282688
genes	T028	C0017337
localized	T082	C0392752
gene duplications	T045	C0017261
involvement	T169	C1314939
XTHs	T116	C1175650
heavy metals	T196	C0347988
abiotic stresses	T067	C0871732
XTH genes	T028	C0017337
heavy metal	T196	C0347988
Hg	T131	C0025424
Cu	T121	C0009968
salt and drought stresses	T067	C0871732
MtXTH genes	T028	C0017337
HgCl2	T121	C0025417
salt and drought stresses	T067	C0871732
expression	T045	C0017262
stresses	T067	C0871732
XTH genes	T028	C0017337
quantitative	T081	C0392762
RT-PCR	T063	C0599161
qRT-PCR	T063	C0599161
specified	T080	C0205369
expression	T045	C0017262
XTH gene	T028	C0017337
Medtr4g128580	T028	C0017337
MtXTH3	T028	C0017337
environmental stresses	T067	C0871732
MtXTH3	T028	C0017337
Hg	T131	C0025424
exposure	T080	C0332157
results	T169	C1274040
group	T078	C0441833
MtXTHs	T028	C0017337
expressed	T045	C1171362
environmental stresses	T067	C0871732
Vestibular disorders	T047	C0042594
nausea	T184	C0027497
head	T191	C0751177
neck	T191	C0746787
intensity-modulated radiation therapy	T061	C1512814
relationship	T080	C0439849
nausea	T184	C0027497
vestibular disorders	T047	C0042594
patients	T101	C0030705
treated with	T061	C0332293
intensity modulated radiation therapy	T061	C1512814
IMRT	T061	C1512814
head	T191	C0751177
neck cancer	T191	C0746787
prospective single-centre study	T062	C0033522
enrolled	T058	C1516879
patients	T101	C0030705
videonystagmography	T061	C0087111
radiation therapy	T061	C1522449
patient	T101	C0030705
Nausea	T184	C0027497
baseline	T081	C1442488
post-radiotherapy	T061	C1522449
videonystagmography	T061	C0087111
patients	T101	C0030705
videonystagmography	T061	C0087111
patients	T101	C0030705
vestibular damage	T033	C0235928
diagnosed	T033	C0011900
post-radiotherapy	T061	C1522449
irradiation	T070	C1282930
patients	T101	C0030705
nauseous	T184	C0027497
dizziness	T184	C0012833
univariate analysis	T062	C0683962
relationship	T080	C0439849
statistically significant	T081	C0237881
dose	T081	C0178602
vestibules	T030	C0042606
vestibular disorder	T047	C0042594
videonystagmography	T061	C0087111
odds ratio	T081	C0028873
OR	T081	C0028873
no	T033	C1513916
relationship	T080	C0439849
vestibular disorder	T047	C0042594
videonystagmography	T061	C0087111
nausea	T184	C0027497
Irradiation	T070	C1282930
vestibular system	T022	C0682674
IMRT	T061	C1512814
nausea	T184	C0027497
Youth	T100	C0087178
Internalizing Symptoms	T048	C1398215
Familias Unidas	UnknownType	C0814781
Intervention	UnknownType	C0683495
Variation	T081	C1705241
Response	T201	C0521982
Prevention programs	T170	C0679717
parenting	T054	C0085092
family functioning	T054	C0680051
reduce	T061	C0441610
poor behavioral	T184	C1398200
adolescents	T100	C0205653
substance use	T048	C0237123
HIV risk	T033	C0744979
internalizing problems	T048	C1398215
youth	T100	C0087178
programs	T170	C0679717
Familias Unidas	UnknownType	C0814781
family-focused intervention	UnknownType	C0683495
substance use	T048	C0237123
sexual risk	T033	C1563228
Hispanic	T098	C0086409
youth	T100	C0087178
reductions	T061	C0441610
internalizing symptoms	T048	C1398215
youth	T100	C0087178
intervention	UnknownType	C0683495
internalizing symptoms	T048	C1398215
individual-level data	UnknownType	C0814855
Familias Unidas	UnknownType	C0814781
trials	T062	C1515364
eighth grade	T033	C2135624
students	T098	C0038492
school population	T098	C0242445
ninth grade	T033	C2135625
students	T098	C0038492
school population	T098	C0242445
adolescents	T100	C0205653
conduct	T048	C0149654
aggression	T055	C0001807
attention problems	T033	C3843050
adolescents	T100	C0205653
delinquency	T048	C0522174
Causal inference growth mixture modeling	UnknownType	C0814921
class	T185	C0008902
model	T170	C3161035
classes	T185	C0008902
youth	T100	C0087178
low	T080	C0205251
medium	T081	C0439536
internalizing symptoms	T048	C1398215
baseline	T081	C1442488
intervention	UnknownType	C0683495
control	T096	C0009932
participants	T098	C0679646
reductions	T061	C0441610
internalizing symptoms	T048	C1398215
class	T185	C0008902
youth	T100	C0087178
high	T080	C0205250
levels	T080	C0441889
baseline	T081	C1442488
internalizing symptoms	T048	C1398215
steady	T080	C0205361
levels	T080	C0441889
internalizing symptoms	T048	C1398215
exposed to	T080	C0332157
intervention	UnknownType	C0683495
symptoms	T048	C1398215
control condition	T080	C0243148
Female gender	T032	C0086287
low	T080	C0205251
baseline	T081	C1442488
levels	T080	C0441889
parent	T099	C0030551
adolescent	T100	C0205653
communication	T054	C0009452
older age	T098	C1999167
high-risk	T033	C0332167
class	T185	C0008902
youth	T100	C0087178
initial risk levels	T080	C3166291
preventive intervention	UnknownType	C0683495
response	T201	C0521982
preventive interventions	UnknownType	C0683495
Acute Kidney Injury	T037	C2609414
Severity	T080	C0439793
Long-Term	T079	C0443252
Readmission	T058	C0030700
Mortality	T081	C0205848
Cardiac Surgery	T061	C0018821
Acute kidney injury	T037	C2609414
AKI	T037	C2609414
complication	T046	C0009566
cardiac surgery	T061	C0018821
AKI	T037	C2609414
severity	T080	C0439793
associated with	T080	C0332281
risk	T078	C0035647
short-term	T079	C0443303
long-term	T079	C0443252
patients	T101	C0030705
coronary artery bypass graft surgery	T061	C0010055
Northern New England biomarker registry	T170	C0034975
Patients	T101	C0030705
renal failure	T047	C0035078
died	T033	C1306577
index admission	T058	C0030673
Severity	T080	C0439793
AKI	T037	C2609414
Acute Kidney Injury Network	T185	C0008902
AKIN	T185	C0008902
cohort	T081	C0009247
national Medicare	T093	C0596896
state all-payer claims	T170	C0282574
readmissions	T058	C0030700
National Death Index	T170	C3889680
survival	T169	C0220921
Kaplan-Meier	T081	C1720943
multivariate Cox proportional hazards modeling	T081	C0010235
readmission	T058	C0030700
death	T033	C1306577
patients	T101	C0030705
AKI	T037	C2609414
AKIN	T185	C0008902
readmissions	T058	C0030700
deaths	T033	C1306577
AKI	T037	C2609414
patients	T101	C0030705
risk	T078	C0035647
readmission	T058	C0030700
confidence interval	T081	C0009667
CI	T081	C0009667
patients	T101	C0030705
risk	T078	C0035647
CI	T081	C0009667
patients	T101	C0030705
no	T033	C1513916
AKI	T037	C2609414
patients	T101	C0030705
AKI	T037	C2609414
patients	T101	C0030705
risk	T078	C0035647
mortality	T081	C0205848
CI	T081	C0009667
patients	T101	C0030705
risk	T078	C0035647
CI	T081	C0009667
Severity	T080	C0439793
AKI	T037	C2609414
AKIN	T185	C0008902
associated with	T080	C0332281
risk	T078	C0035647
readmission	T058	C0030700
mortality	T081	C0205848
AKI	T037	C2609414
perioperative period	T079	C2712230
long-term	T079	C0443252
patients	T101	C0030705
mortality	T081	C0205848
health care utilization	T058	C0030672
Association	T080	C0439849
abdominal fat	T024	C1563742
serum	T031	C0229671
amylase	T116	C0002712
older	T098	C0001792
cohort	T098	C0599755
Baltimore	T083	C0004716
Longitudinal Study	T062	C0023981
Aging	T040	C0001811
Abdominal fat	T024	C1563742
determinant	T169	C1521761
metabolic diseases	T047	C0025517
older	T098	C0001792
individuals	T098	C0237401
Obesity	T047	C0028754
diabetes	T047	C0011847
associated with	T080	C0332281
low	T080	C0205251
serum amylase (SA) levels	T033	C0729348
association	T080	C0439849
SA	T033	C0729348
metabolic disease	T047	C0025517
investigated	T169	C1292732
association	T080	C0439849
low	T080	C0205251
SA	T033	C0729348
diabetes	T047	C0011847
sex	T032	C1522384
specific	T080	C0205369
associations	T080	C0439849
serum	T031	C0229671
amylase	T116	C0002712
abdominal fat	T024	C1563742
older adults	T100	C0001675
community-dwelling	T056	C4045975
volunteers	T098	C0020155
Baltimore	T083	C0004716
Longitudinal Study	T062	C0023981
Aging	T040	C0001811
participants	T098	C0679646
age	T032	C0001779
years	T079	C0439234
assessed	T052	C1516048
abdominal fat	T024	C1563742
computed tomography	T060	C0040405
diabetes status	T033	C1317301
American Diabetes Association	T094	C1705019
criteria	T078	C0243161
Linear regression analyses	T081	C0023733
assessed	T052	C1516048
cross-sectional associations	T080	C0439849
abdominal fat	T024	C1563742
SA	T033	C0729348
logistic regression	T062	C0206031
assessed	T052	C1516048
odds	T081	C0028873
diabetes	T047	C0011847
low	T080	C0205251
SA	T033	C0729348
unadjusted analyses	T062	C0936012
individuals	T098	C0237401
lowest	T080	C0205251
SA	T033	C0729348
quartile	T080	C2828255
odds	T081	C0028873
diabetes	T047	C0011847
CI	T081	C0009667
quartile	T080	C2828255
association	T080	C0439849
significant	T078	C0750502
visceral adipose tissue area	T024	C1563740
VAT	T024	C1563740
abdominal subcutaneous adipose tissue	T024	C1563741
SAT	T024	C1563741
BMI	T201	C1305855
adjusted analyses	T062	C0936012
VAT	T024	C1563740
SAT	T024	C1563741
significantly	T078	C0750502
associated with	T080	C0332281
SA	T033	C0729348
sexes	T032	C1522384
women	T098	C0043210
SA	T033	C0729348
associated with	T080	C0332281
VAT	T024	C1563740
SAT	T024	C1563741
BMI	T201	C1305855
VAT	T024	C1563740
SAT	T024	C1563741
BMI	T201	C1305855
association	T080	C0439849
SA	T116	C0002712
diabetes	T047	C0011847
abdominal visceral fat	T024	C1563740
women	T098	C0043210
SA	T116	C0002712
associated with	T080	C0332281
VAT	T024	C1563740
BMI	T201	C1305855
SAT	T024	C1563741
mechanistic studies	T089	C2698671
SA's	T116	C0002712
metabolic diseases	T047	C0025517
Efficacy	T080	C1280519
Intravenous	T082	C0348016
Chlorothiazide	T109	C0008273
Refractory	T169	C0205269
Acute Decompensated Heart Failure	T047	C1609524
Unresponsive	T169	C0205269
Adjunct	T169	C1719882
Metolazone	T109	C0025854
efficacy	T080	C1280519
intravenous	T082	C0348016
chlorothiazide	T109	C0008273
patients	T101	C0030705
acute decompensated heart failure	T047	C1609524
ADHF	T047	C1609524
loop diuretic	T121	C0354100
resistant	T169	C0332325
refractory	T169	C0205269
metolazone	T109	C0025854
Retrospective cohort study	T062	C2985505
patients	T101	C0030705
controls	T096	C0009932
Large	T081	C0549177
academic	T092	C1510747
tertiary care hospital	T073	C0337954
patients	T101	C0030705
ADHF	T047	C1609524
inadequate	T080	C0205412
response	T032	C0871261
high-dose	T081	C0444956
loop diuretics	T121	C0354100
dose	T081	C0178602
oral	T082	C0442027
metolazone	T109	C0025854
greater	T081	C1704243
metolazone	T109	C0025854
index dose	T081	C0178602
dose	T081	C0178602
intravenous	T082	C0348016
chlorothiazide	T109	C0008273
chlorothiazide	T109	C0008273
index dose	T081	C0178602
metolazone	T109	C0025854
inadequate	T080	C0205412
institutional protocol	T170	C0442711
doses	T081	C0178602
metolazone	T109	C0025854
administered	T058	C0806914
dose	T081	C0178602
chlorothiazide	T109	C0008273
index dose	T081	C0178602
index dose	T081	C0178602
metolazone	T109	C0025854
index dose	T081	C0178602
administered	T058	C0806914
hours	T079	C0439227
chlorothiazide	T109	C0008273
index dose	T081	C0178602
Data	T078	C1511726
diuretic	T121	C0354100
doses	T081	C0178602
metolazone	T109	C0025854
chlorothiazide	T109	C0008273
analysis	T062	C0936012
dose	T081	C0178602
loop diuretic	T121	C0354100
intravenous	T082	C0348016
furosemide	T109	C0016860
hour	T079	C0439227
period	T079	C1948053
metolazone	T109	C0025854
index dose	T081	C0178602
stay	T079	C3489408
days	T079	C0439228
in-hospital mortality	T080	C0085556
patients	T101	C0030705
end point	T080	C2349179
net-negative	T033	C0205160
urine output	T201	C0232856
hours	T079	C0439227
index dose	T081	C0178602
patients	T101	C0030705
patients	T101	C0030705
chlorothiazide	T109	C0008273
metolazone	T109	C0025854
doses	T081	C0178602
hour	T079	C0439227
urine output	T201	C0232856
administration	T081	C0001555
metolazone	T109	C0025854
interquartile range	T081	C1711350
IQR	T081	C1711350
IQR	T081	C1711350
administration	T081	C0001555
chlorothiazide	T109	C0008273
Compared	T052	C1707455
metolazone	T109	C0025854
chlorothiazide	T109	C0008273
doses	T081	C0178602
increase	T169	C0442805
urine output	T201	C0232856
hours	T079	C0439227
dose	T081	C0178602
hours	T079	C0439227
dose	T081	C0178602
net-negative	T033	C0205160
urine output	T201	C0232856
hours	T079	C0439227
chlorothiazide	T109	C0008273
metolazone	T109	C0025854
dose	T081	C0178602
chlorothiazide	T109	C0008273
metolazone	T109	C0025854
intravenous	T082	C0348016
chlorothiazide	T109	C0008273
improved	T033	C0184511
diuresis	T042	C0012797
patients	T101	C0030705
ADHF	T047	C1609524
refractory	T169	C0205269
loop diuretic	T121	C0354100
adjunctive	T169	C1719882
oral	T082	C0442027
metolazone	T109	C0025854
Comparisons	T052	C1707455
Safety	T068	C0036043
Clinical	T080	C0205210
Outcomes	T169	C1274040
Multiple-level	T061	C0035139
Single-level Cervical Disk Replacement	T061	C0035139
Cervical Spondylosis	T047	C1384641
Systematic Review	T170	C1955832
Meta-analysis	T170	C0282458
systematic review	T170	C1955832
meta-analysis	T170	C0282458
study	T062	C2603343
evaluate	T169	C1292732
efficacy	T080	C1280519
safety	T068	C0036043
multiple-level cervical disk replacement	T061	C0035139
CDR	T061	C0035139
single-level CDR	T061	C0035139
treatment	T061	C0087111
cervical spondylosis	T047	C1384641
multiple-level CDR	T061	C0035139
anterior	T082	C0205094
decompression	T061	C1829459
fusion	T061	C1293131
cervical multiple-level spondylosis	T047	C1384641
efficacy	T080	C1280519
safety	T068	C0036043
multi-level CDR	T061	C0035139
single-level CDR	T061	C0035139
MEDLINE	T170	C0025141
EMBASE	T170	C0242356
Cochrane library databases	T170	C0242356
controlled studies	T062	C0681867
compared	T052	C1707455
clinical	T080	C0205210
outcomes	T169	C1274040
single-level	T061	C0035139
multiple-level CDR	T061	C0035139
treatment	T061	C0087111
cervical spondylosis	T047	C1384641
outcomes	T169	C1274040
analyzed	T062	C0936012
prevalence	T081	C0033105
heterotopic ossification	T046	C0029396
reoperation	T061	C0035110
preoperative	T079	C0445204
postoperative	T079	C0032790
Neck Disability Index scores	T033	C2959538
preoperative	T079	C0445204
postoperative	T079	C0032790
Visual Analog Scale scores	T201	C2960751
success	T080	C0679864
rate	T081	C1521828
Odom grading system	T185	C0008902
studies	T062	C2603343
patients	T101	C0030705
randomized controlled trials	T062	C0206035
prospective studies	T062	C0033522
retrospective studies	T062	C0035363
single-level	T061	C0035139
multiple-level	T061	C0035139
prevalence	T081	C0033105
heterotopic ossification	T046	C0029396
reoperation	T061	C0035110
rate	T081	C1521828
Neck Disability Index score	T033	C2959538
Visual Analog Scale score	T201	C2960751
success	T080	C0679864
rate	T081	C1521828
Odom grading system	T185	C0008902
meta-analysis	T170	C0282458
clinical	T080	C0205210
outcomes	T169	C1274040
multiple-level CDR	T061	C0035139
single-level CDR	T061	C0035139
cervical spondylosis	T047	C1384641
multiple-level CDR	T061	C0035139
effective	T080	C1704419
safe	T068	C0036043
single-level CDR	T061	C0035139
studies	T062	C2603343
evaluation	T062	C0015195
Evaluation	T058	C0220825
Effects of	T080	C1704420
Intravenous	T082	C0348016
Percutaneous	T082	C0522523
Low Level Laser Therapy	T061	C0279027
Management	T061	C0002766
Shoulder	T029	C0037004
Myofascial Pain Syndrome	T047	C0027073
Myofascial pain syndrome	T047	C0027073
MPS	T047	C0027073
treatment	T061	C0087111
treatment frame	T061	C0087111
efficient	T080	C0442799
treatment	T061	C0087111
modalities	T078	C0695347
effects of	T080	C1704420
intravenous	T082	C0348016
laser therapy	T061	C1955835
IVL	T061	C1955835
percutaneous	T082	C0522523
low level laser	T061	C0279027
PLLL	T061	C0279027
management	T061	C0002766
shoulder	T029	C0037004
MPS	T047	C0027073
randomized controlled trial	T062	C0206035
patients	T101	C0030705
inclusion criteria	T080	C1512693
control	T096	C0009932
IVL	T098	C1257890
PLLL	T098	C1257890
Control group	T096	C0009932
placebo	T062	C1706408
low level laser	T061	C0279027
IVL group	T098	C1257890
IVL therapy	T061	C1955835
PLLL group	T098	C1257890
PLLL therapy	T061	C0279027
patients	T101	C0030705
better	T080	C0332272
body posture	T032	C1262869
body mechanics	T022	C0598002
gentle massage	T061	C0150347
trigger points	T029	C0458343
stretching exercises	T061	C0600080
affected	T169	C0392760
muscle	T024	C0026845
trapezius	T023	C0224361
oral	T082	C0442027
nortriptyline	T109	C0028420
regimen	T061	C0040808
pain severity	T080	C1507013
functional disability	T033	C0872173
quality of life	T078	C0034380
Patients	T101	C0030705
Numeric Rating Scale	T170	C4050142
NRS	T170	C4050142
Pain Disability Index	T170	C0282574
PDI	T170	C0282574
Short Form Health Survey	T170	C0451286
SF-12	T170	C1519135
Data collected	T033	C4019276
analyzed	T062	C0936012
analysis of variance	T081	C0002780
ANOVA	T081	C0002780
Mann-Whitney	T170	C1708930
t tests	T170	C0871472
PDI	T170	C0282574
pain intensity	T201	C1320357
reduced	T080	C0392756
PLLL	T098	C1257890
IVL groups	T098	C1257890
control group	T096	C0009932
PDI	T170	C0282574
IVL group	T098	C1257890
PLLL group	T098	C1257890
statistically significant	T081	C0237881
quality of life	T078	C0034380
statistically significantly	T081	C0237881
IVL	T098	C1257890
PLLL groups	T098	C1257890
control group	T096	C0009932
IVL group	T098	C1257890
statistically significant	T081	C0237881
PLLL group	T098	C1257890
No side effects	T033	C1963761
intervention groups	T098	C2986530
Intravenous	T082	C0348016
laser	T061	C1955835
PLLL therapy	T061	C0279027
effect	T080	C1280500
pain severity	T080	C1507013
PDI	T170	C0282574
quality of life	T078	C0034380
no adverse event	T033	C1963761
intravenous	T082	C0348016
lasers	T061	C1955835
PLLL therapy	T061	C0279027
effective	T080	C1704419
modalities	T078	C0695347
managing	T061	C0002766
patients	T101	C0030705
shoulder	T029	C0037004
MPS	T047	C0027073
Structural	T082	C0678594
Insights	T041	C0233820
5-HT1A	T116	C0379900
D4	T116	C0114835
Selectivity	T070	C1510827
WAY-100635	T109	C0290799
Analogues	T104	C0243071
Molecular Modeling	T062	C0600115
Synthesis	T052	C1883254
in Vitro	T080	C1533691
Binding	T044	C1167622
5-HT1A receptors	T116	C0379900
therapeutic	T169	C0302350
target	T169	C1521840
selective	T080	C0205556
5-HT1A	T116	C0379900
ligands	T103	C0023688
WAY-100635	T109	C0290799
prototypical antagonist	T120	C0243076
receptors	T116	C0597357
compound	T080	C0205198
affinity	UnknownType	C0683185
D4 dopamine receptors	T116	C0114835
5-HT1A	T116	C0379900
D4	T116	C0114835
selectivity	T070	C1510827
WAY-100635	T109	C0290799
analogues	T104	C0243071
structural	T082	C0678594
In silico	T066	C3489666
investigations	T169	C1292732
interactions	T169	C1704675
5-HT1A	T116	C0379900
D4	T116	C0114835
selectivity	T070	C1510827
WAY-100635	T109	C0290799
analogues	T104	C0243071
hydrogen bond	T070	C0020276
Ser 7.36	T116	C0036720
D4 receptor	T116	C0114835
D4	T116	C0114835
affinity	UnknownType	C0683185
synthesized	T052	C1883254
aza	T109	C0004471
analogues	T104	C0243071
Ser 7.36	T116	C0036720
affinity	UnknownType	C0683185
aza	T109	C0004471
analogues	T104	C0243071
mutant	T049	C0596988
D4 receptor S7.36A	T116	C0114835
hydrogen bond	T070	C0020276
Ser 5.42 residue	T116	C0036720
D4	T116	C0114835
binding	T044	C1167622
Genomic analysis	T059	C3854164
nontypeable pneumococci	T007	C0038410
invasive pneumococcal disease	T047	C1320214
South Africa	T083	C0037712
capsular polysaccharide	T109	C1979807
virulence factor	T109	C1136170
Streptococcus pneumoniae	T007	C0038410
target	T169	C1521840
pneumococcal vaccines	T121	C0358314
pathogenic	T033	C3816499
pneumococci	T007	C0038410
serologically nontypeable	T170	C0449943
nontypeable pneumococci	T007	C0038410
NTPn	T007	C0038410
rarity	T080	C0522498
NTPn	T007	C0038410
characterized	T052	C1880022
data	T078	C1511726
organisms	T001	C0029235
disease	T047	C0012634
genotypically	T032	C0017431
characterize	T052	C1880022
NTPn	T007	C0038410
invasive pneumococcal disease	T047	C1320214
South Africa	T083	C0037712
Isolates	T123	C1764827
laboratory	T073	C0022877
based	T078	C1705938
surveillance	T169	C0220920
invasive pneumococcal disease	T047	C1320214
South Africa	T083	C0037712
characterized	T052	C1880022
genome analysis	T059	C3854164
ancestral	T169	C0439660
serotypes	T170	C0449943
serotypes	T170	C0449943
NTPn	T007	C0038410
Group I	T078	C0441833
NTPn	T007	C0038410
multilocus sequence typing	T062	C2936544
capsular region	T082	C1254362
sequence analyses	T059	C0162801
Antimicrobial resistance	T201	C1456627
patterns	T082	C0449774
mutations	T045	C0026882
potentially	T080	C3245505
nontypeability	T170	C0449943
identified	T080	C0205396
NTPn	T007	C0038410
Twenty-two	T081	C4284772
partial	T081	C0728938
capsular genes	T028	C0017337
Group I	T078	C0441833
complete	T080	C0205197
capsular deletion	T045	C0017260
replacement	T169	C0559956
genes	T028	C0017337
Group II	T078	C0441833
Seventy-nine	T081	C3828184
percent	T081	C0439165
NTPn	T007	C0038410
isolates	T123	C1764827
encapsulated	T080	C0205223
S. pneumoniae	T007	C0038410
serotypes	T170	C0449943
ancestral	T169	C0439660
serotypes	T170	C0449943
serotypes	T170	C0449943
13-valent pneumococcal conjugate vaccine	T121	C3152625
mutations	T045	C0026882
capsular region	T082	C1254362
Group I	T078	C0441833
NTPn	T007	C0038410
nontypeable	T170	C0449943
phenotype	T032	C0031437
Nonsusceptibility	T034	C2827756
tetracycline	T109	C0039644
erythromycin	T109	C0014806
NTPn	T007	C0038410
encapsulated	T080	C0205223
S. pneumoniae	T007	C0038410
NTPn	T007	C0038410
invasive pneumococcal disease	T047	C1320214
South Africa	T083	C0037712
Pre-hypertension	T047	C1696708
pre-diabetes	T047	C0362046
predicting	T078	C0681842
cardiovascular events	T033	C1320716
long term	T079	C0443252
study	T062	C2603343
pre-diabetes	T047	C0362046
pre-hypertension	T047	C1696708
predicting	T078	C0681842
cardiovascular events	T033	C1320716
population	T081	C0032659
cross-sectional survey	T062	C0010362
Iranian	T098	C1553355
population	T098	C0683971
years	T079	C0439234
Isfahan Province	T083	C0017446
random, multistage cluster-sampling	T062	C2347298
cohort	T098	C0599755
study outcome	T169	C2985619
unstable angina	T047	C0002965
UA	T047	C0002965
acute	T079	C0205178
occurrence	T079	C2745955
myocardial infarction	T047	C0027051
MI	T047	C0027051
sudden cardiac death	T046	C0085298
SCD	T046	C0085298
brain stroke	T047	C3844825
cardiovascular disease	T047	C0007222
CVD	T047	C0007222
assessment	T058	C0220825
diabetes state	T047	C0011849
diabetics	T033	C0241863
pre-diabetic	T033	C0243095
hypertension	T047	C0020538
pre-hypertension	T047	C1696708
pre-hypertension	T047	C1696708
pre-diabetes	T047	C0362046
gender	T032	C0079399
pre-hypertension	T047	C1696708
pre-diabetes	T047	C0362046
occurrence	T079	C2745955
MI	T047	C0027051
hazard ratio	T081	C2985465
HR	T081	C2985465
confidence interval	T081	C0009667
CI	T081	C0009667
COX regression models	T170	C3161035
pre-hypertension	T047	C1696708
UA	T047	C0002965
CVD	T047	C0007222
occurrence	T079	C2745955
HR	T081	C2985465
CI	T081	C0009667
HR	T081	C2985465
CI	T081	C0009667
pre-diabetes	T047	C0362046
gender	T032	C0079399
age	T032	C0001779
data	T078	C1511726
evidence	T078	C3887511
pre-hypertension	T047	C1696708
pre-diabetes	T047	C0362046
appearance	T080	C0700364
progression	T046	C0242656
MI	T047	C0027051
healthy individuals	T098	C1708335
predicting	T078	C0681842
pre-hypertension	T047	C1696708
occurrence	T079	C2745955
UA	T047	C0002965
CVD	T047	C0007222
pre-hypertension	T047	C1696708
pre-diabetes	T047	C0362046
pre-hypertension	T047	C1696708
pre-diabetes	T047	C0362046
predicting	T078	C0681842
cardiovascular events	T033	C1320716
Strategies	T065	C0683852
Successful	T080	C1272703
Clinical	T080	C0205210
Teaching	T065	C0220924
article	T170	C1706852
roles	T077	C1705810
adjunct clinical faculty	T097	C0015538
preceptors	T097	C0221457
teach	T065	C0039401
nursing students	T097	C0038496
new	T080	C0205314
graduates	T098	C0588053
apply	T169	C4048755
knowledge	T170	C0376554
clinical settings	T082	C3176918
article	T170	C1706852
teaching strategies	T065	C0683852
learning environment	T082	C1510556
Learned helplessness	T041	C0018897
Insights	T041	C0233820
neuroscience	T091	C0027910
Learned helplessness	T041	C0018897
failure	T169	C0231174
escape	T041	C0870509
shock	T046	C0036974
induced	T169	C0205263
aversive events	T169	C1510994
Seligman and Maier	T016	C0086418
theorized	T078	C0871935
animals	T008	C0003062
learned	T041	C0023185
outcomes	T169	C1274040
independent of	T169	C0332291
responses	T032	C0871261
learning	T041	C0023185
escape	T041	C0870509
learned helplessness	T041	C0018897
well-charted biologically	T080	C0205460
theory	T078	C0871935
Passivity	T055	C0679170
response	T032	C0871261
shock	T046	C0036974
learned	T041	C0023185
response	T032	C0871261
prolonged	T079	C0439590
aversive events	T169	C1510994
serotonergic activity	T044	C1148560
dorsal raphe nucleus	T023	C0175392
inhibits	T052	C3463820
escape	T041	C0870509
passivity	T055	C0679170
learning	T041	C0023185
control	T080	C0243148
medial prefrontal cortex	T023	C3498368
detection	T033	C0442726
control	T080	C0243148
automatic	T169	C0205554
inhibition	T052	C3463820
dorsal raphe nucleus	T023	C0175392
animals	T008	C0003062
learn	T041	C0023185
control	T080	C0243148
aversive events	T169	C1510994
passive	T080	C3686820
failure	T169	C0231174
learn	T041	C0023185
escape	T041	C0870509
reaction	T169	C0443286
prolonged	T079	C0439590
aversive stimulation	T061	C0870183
alterations	T078	C1515926
ventromedial prefrontal cortex	T023	C3850122
dorsal raphe	T023	C0175392
pathway	T077	C1705987
expectation	T078	C0679138
control	T080	C0243148
passivity	T055	C0679170
compensating	T080	C0205432
detection	T033	C0442726
expectation	T078	C0679138
control	T080	C0243148
treat	T169	C1292734
depression	T048	C0011570
peptide	T116	C0030956
human β thymosin	T116	C1999611
anti-biofilm	T024	C3548526
anti-biofilm agents	T121	C1254351
Staphylococcus spp.	T007	C4275190
Pseudomonas aeruginosa	T007	C0033809
antibiotics	T195	C0003232
biofilm	T007	C0081786
infections	T046	C3714514
infection	T046	C3714514
recurrence	T046	C2825055
chronicity	T079	C0547045
antimicrobial peptides	T116	C4084937
discover	T052	C1880355
anti-infective agents	T121	C0003204
active	T169	C0205177
pathogens	T001	C0450254
planktonic	T007	C0032071
biofilm	T007	C0081786
fragment	T116	C1335533
human thymosin β4	T116	C1999611
studied	T062	C2603343
MD simulation	T066	C2717775
conformations of the peptide	T082	C1518960
central hydrophobic core	T082	C0205099
peripheral	T082	C0205100
residues	T077	C1709915
interaction	T169	C1704675
models	T170	C3161035
biological membranes	T026	C0682529
eukaryotic	T204	C0684063
bacterial membrane	T026	C0682529
peptide	T116	C0030956
antimicrobial activity	T034	C1271650
in vitro	T062	C0681828
planktonic	T007	C0032071
biofilm	T007	C0081786
group	T078	C0441833
strains	T001	C1518614
Staphylococcus spp.	T007	C4275190
P. aeruginosa	T007	C0033809
strain	T001	C1518614
human thymosin β4	T116	C1999611
fragment	T116	C1335533
EIEKFDKSKLK	T087	C0002518
antibacterial activity	T044	C1149575
staphylococcal	T007	C0038170
strains	T001	C1518614
Pseudomonas aeruginosa	T007	C0033809
concentrations	T081	C0560150
biofilm formation	T043	C1325881
sub-inhibitory concentrations	T081	C0600495
activity	T052	C0441655
fragment	T116	C1335533
biofilm formation	T043	C1325881
conformations	T082	C1518960
MD simulations	T066	C2717775
interaction	T169	C1704675
bacterial membrane	T026	C0682529
Human thymosin β4	T116	C1999611
fragment	T116	C1335533
lead compound	T121	C1254351
recombinant derivatives	T116	C0034861
pharmaceutical	T091	C0008003
Structural	T082	C0678594
Basis	T169	C1527178
Simvastatin	T109	C0074554
Competitive Antagonism	T044	C0013159
Complement Receptor 3	T116	C0079785
complement system	T116	C0009498
innate immune response	T032	C0020969
infection	T047	C0009450
severe complications	T033	C3495031
inflammation	T046	C0021368
Small molecule	T109	C1328819
antagonists	T120	C0243076
complement receptor 3	T116	C0079785
CR3	T116	C0079785
structural	T082	C0678594
basis	T169	C1527178
mode of action	T169	C1524059
report	T170	C0684224
structure	T082	C0678594
human	T016	C0086418
CR3	T116	C0079785
ligand-binding I domain	T087	C0682969
complex	T104	C1704241
simvastatin	T109	C0074554
Simvastatin	T109	C0074554
targets	T169	C1521840
metal	T197	C0025552
ion-dependent	T080	C0205556
adhesion site	T082	C1254362
ligand-binding	T044	C1517880
conformation	T082	C0026377
CR3	T116	C0079785
I domain	T087	C1514562
contact with	T169	C0332158
chelated Mg(2+) ion	T109	C0719248
Simvastatin	T109	C0074554
antagonizes	T033	C0243095
I domain binding	T087	C0682969
complement fragments	T116	C0009498
iC3b	T116	C0369029
C3d	T116	C0056184
intercellular adhesion molecule-1	T116	C0063695
virtue	T078	C0042764
I domain's	T087	C1514562
distribution	T082	C0037775
binding kinetics	T039	C0031327
ligands	T103	C0023688
possible	T033	C0332149
ligand binding	T044	C1517880
kinetics	T039	C0031327
simvastatin	T109	C0074554
antagonism	T044	C0013159
static	T080	C0441463
cellular	T059	C0178539
experiments	T062	C0681814
simvastatin	T109	C0074554
reduced	T080	C0392756
adhesion	T067	C3714578
K562 cells	T025	C0600432
expressing	T045	C0597360
recombinant	T001	C1514798
CR3	T116	C0079785
primary	T080	C0205225
human	T016	C0086418
monocytes	T025	C0026473
endogenous	T169	C0205227
expression	T045	C0597360
receptor	T116	C0597357
Application	T058	C0185125
force	T067	C0441722
adhering	T067	C3714578
monocytes	T025	C0026473
effects of	T080	C1704420
simvastatin	T109	C0074554
concentration	T081	C1446561
drug	T121	C1254351
reduced	T080	C0392756
adhesion	T067	C3714578
compared	T052	C1707455
untreated	T080	C0205556
cells	T025	C0007634
ability	T032	C0085732
simvastatin	T109	C0074554
target	T169	C1521840
CR3	T116	C0079785
ligand binding	T044	C1517880
activated	T052	C1879547
conformation	T082	C0026377
novel	T080	C0205314
mechanism	T044	C0678659
anti-inflammatory effects	T080	C1515999
compound	T103	C1706082
CR3	T116	C0079785
conformation	T082	C0026377
pro-inflammatory	T080	C0205556
environments	T082	C0014406
report	T170	C0684224
designs	T090	C0013171
CR3	T116	C0079785
antagonists	T120	C0243076
identifies	T033	C0243095
druggable	T080	C0205556
receptors	T116	C0597357
characterization	T052	C1880022
ligand binding	T044	C1517880
kinetics	T039	C0031327
presence	T080	C3854307
antagonists	T120	C0243076
Common	T081	C0205214
Laboratory	T073	C0022877
Parameters	T033	C0449381
Differentiating	T169	C2945687
Community-Acquired	T047	C0694549
Healthcare-Associated Pneumonia	T047	C1443237
correct	T080	C2349182
diagnosis	T033	C0011900
healthcare-associated pneumonia	T047	C1443237
HCAP	T047	C1443237
community-acquired pneumonia	T047	C0694549
essential	T080	C0205224
selection	T052	C1707391
correct	T080	C2349182
empirical	T080	C1880496
antimicrobial	T121	C1136254
broad-spectrum	T077	C2827424
highly potent	T080	C3245505
antimicrobial therapies	T061	C0087111
resistant	T169	C0332325
strains	T001	C1518614
HCAP	T047	C1443237
treating	T169	C1522326
resistant	T169	C0332325
strains	T001	C1518614
associated with	T080	C0332281
community	T096	C0009462
long-term care facility	T073	C1708733
acquired infections	T046	C3714514
targeted	T169	C1521840
empirical approach	T062	C0871728
standard approach	T080	C0205556
today	T079	C0750526
differentiate	T169	C2945687
medical history	T033	C0262926
past	T079	C1444699
days	T079	C0439228
admission	T058	C0184666
Measurable	T169	C1513040
quantitative	T081	C0392762
assessment	T058	C0220825
assist	T080	C1269765
decision	T041	C0679006
measurable	T169	C1513040
method	T170	C0025663
differentiating	T169	C2945687
community-acquired	T047	C0694549
healthcare-associated pneumonias	T047	C1443237
records	T170	C0034869
patients	T101	C0030705
admitted	T058	C0184666
diagnosis	T033	C0011900
pneumonia	T047	C0032285
groups	T078	C0441833
cause of their disease	UnknownType	C0679232
common practice	T041	C0237607
routine	T080	C0205547
laboratory work	T059	C0022885
admittance	T058	C0184666
analyzed	T062	C0936012
logistical regression	T062	C0206031
Student's t-test	T081	C0871453
red blood cell distribution width	T059	C0427460
neutrophil	T025	C0027950
neutrophil -to- lymphocyte ratio	T081	C0456603
lymphocyte	T025	C0024264
routine parameters	T033	C0449381
blood count	T059	C0005771
assist	T080	C1269765
differentiating	T169	C2945687
community-acquired	T047	C0694549
healthcare-associated pneumonias	T047	C1443237
statistically significant parameters	T081	C0871428
medical history	T033	C0262926
chest radiography	T060	C0039985
other parameters	T033	C0449381
immediate	T079	C0205253
clinical impression	T033	C2973287
patient	T101	C0030705
pneumonia	T047	C0032285
quasi-experimental study	T062	C0681814
reminiscence program	T061	C0150321
autobiographical memory	T041	C0561843
older adults	T098	C0001792
cognitive impairment	T048	C0338656
past memories	T041	C0233793
reminiscence interventions	T061	C0150321
several decades	T081	C2981279
outcomes	T169	C1274040
mental health	T041	C0025353
older adults	T098	C0001792
studies	T062	C2603343
autobiographical memory	T041	C0561843
recall	T041	C0034770
older individuals	T098	C3826770
cognitive impairment	T048	C0338656
study	T062	C2603343
individual	T098	C0237401
reminiscence program	T061	C0150321
older persons	T098	C3826770
cognitive decline	T046	C0234985
nursing homes	T073	C0028688
cognition	T041	C0009240
autobiographical memory	T041	C0561843
mood	T041	C0026516
behavior	T053	C0004927
anxiety	T048	C0003469
pre-test and post-test design	T170	C0032919
single blinded assessment	T058	C0220825
participants	T098	C0679646
experimental group	T098	C1257890
control group	T096	C0009932
individual	T098	C0237401
reminiscence	T041	C0871247
sessions	T051	C1883016
outcome measures	T081	C0086749
examined	T033	C0332128
cognition	T041	C0009240
Montreal Cognitive Assessment	T170	C3496286
Autobiographical Memory Test	T170	C0392366
behavior	T053	C0004927
Alzheimer Disease Assessment Subscale Non-Cog	T170	C0450989
emotional status	T033	C0243095
Cornell Scale for Depression	T170	C0679604
Dementia	T048	C0497327
Geriatric Depression Scale	T170	C0451184
Geriatric Anxiety Inventory	T170	C0282574
Participants	T098	C0679646
reminiscence sessions	T051	C1883016
outcomes	T169	C1274040
control group	T096	C0009932
cognition	T041	C0009240
anxiety	T048	C0003469
depression	T048	C0011570
retrieved	T041	C0034770
autobiographical events	T051	C0441471
memories	T041	C0025260
events	T051	C0441471
recalling	T041	C0034770
events	T051	C0441471
recalled	T041	C0034770
events	T051	C0441471
reminiscence therapy	T061	C0150321
recall	T041	C0034770
autobiographical memory	T041	C0561843
Reminiscence therapy	T061	C0150321
cognitive function	T041	C0392335
anxiety	T048	C0003469
depressive symptoms	T184	C0086132
altered behavior	T055	C0542299
Economic Burden	T081	C1512163
Illness	T184	C0221423
Patients	T101	C0030705
Severe Asthma	T033	C0581126
Care Setting	T073	C4034203
pharmacotherapy	T061	C0013216
number	T081	C0237753
patients	T101	C0030705
severe asthma	T033	C0581126
inadequate	T080	C0205412
disease	T047	C0012634
control	T080	C0243148
Patients	T101	C0030705
severe asthma	T033	C0581126
experience	T041	C0596545
exacerbations	T033	C0349790
health care resources	T081	C0683535
assess	T052	C1516048
health care resource	T081	C0683535
utilization	T169	C0042153
costs	T081	C0085123
patients	T101	C0030705
persistent	T079	C0205322
severe asthma	T033	C0581126
experienced	T041	C0596545
exacerbations	T033	C0349790
patients	T101	C0030705
persistent	T079	C0205322
asthma	T047	C0004096
retrospective	T080	C1514923
analysis	T062	C0936012
national administrative claims database	T170	C0242356
identified	T080	C0205396
patients	T101	C0030705
aged	T032	C0001779
years	T079	C0439234
medical claim	UnknownType	C0586198
asthma	T047	C0004096
diagnosis	T033	C0011900
medical	T033	C2136534
pharmacy coverage	T033	C2114292
commercial	T170	C0680536
Medicare Advantage plan	T064	C3844556
Patients	T101	C0030705
assigned	T169	C1516050
cohorts	T098	C0599755
persistent asthma	T047	C3266628
PA	T047	C3266628
severe asthma	T033	C0581126
SA	T033	C0581126
algorithm	T170	C0002045
asthma	T047	C0004096
health care resource	T081	C0683535
use	T169	C0457083
pharmacy claims	T033	C2114292
controller medication	T121	C0013227
SA	T033	C0581126
patients	T101	C0030705
meet	T067	C1550543
PA	T047	C3266628
criteria	T078	C0243161
evidence	T078	C3887511
asthma exacerbations	T033	C0349790
Asthma	T047	C0004096
health care resource	T081	C0683535
utilization	T169	C0042153
costs	T081	C0085123
computed	T052	C1880157
asthma	T047	C0004096
medication	T058	C2081612
use	T169	C0457083
rescue	T169	C0039798
controller therapy	T169	C0039798
medical claims	UnknownType	C0586198
asthma	T047	C0004096
diagnosis	T033	C0011900
primary position	T082	C0444508
Adherence	T169	C1510802
controller therapy	T169	C0039798
assessed	T052	C1516048
days	T079	C0439228
proportion of days covered	T079	C1254367
PDC	T079	C1254367
claim	UnknownType	C0586198
controller therapy	T169	C0039798
Differences	T080	C1705242
PA	T047	C3266628
SA	T033	C0581126
cohorts	T098	C0599755
analyzed	T062	C0936012
t-test	T170	C0871472
continuous variables	T080	C0439828
chi-square test	T170	C0008041
categorical variables	T080	C0439828
Asthma	T047	C0004096
costs	T081	C0085123
analyzed	T062	C0936012
linear model	T081	C0023732
gamma distribution	T081	C1708185
log link	T081	C0026348
adjusted	T169	C0456081
patient	T101	C0030705
demographics	T185	C1698647
age	T032	C0001779
gender	T032	C0079399
region	T083	C0017446
insurance type	T170	C0680873
Quan-Charlson comorbidity score	T081	C0449820
patients	T101	C0030705
PA	T047	C3266628
patients	T101	C0030705
SA	T033	C0581126
patients	T101	C0030705
Compared	T052	C1707455
PA	T047	C3266628
cohort	T098	C0599755
SA	T033	C0581126
cohort	T098	C0599755
older	T098	C3826770
mean age	T032	C0001779
years	T079	C0439234
years	T079	C0439234
comorbidity score	T081	C0449820
asthma	T047	C0004096
medications	T058	C2081612
SA	T033	C0581126
cohort,	T098	C0599755
compared	T052	C1707455
PA	T047	C3266628
cohort	T098	C0599755
PDC	T079	C1254367
oral	T122	C1272919
inhaled	T040	C0004048
controller therapy	T061	C0087111
SA	T033	C0581126
cohort	T098	C0599755
compared	T052	C1707455
PA	T047	C3266628
cohort	T098	C0599755
SA	T033	C0581126
patients	T101	C0030705
greater mean count	T081	C1704243
asthma	T047	C0004096
hospitalizations	T058	C0019993
emergency room visits	T058	C0586082
ambulatory visits	T033	C4035875
asthma	T047	C0004096
costs	T081	C0010186
SA	T033	C0581126
PA	T047	C3266628
cohorts	T098	C0599755
asthma	T047	C0004096
costs	T081	C0010186
asthma	T047	C0004096
medication	T058	C2081612
costs	T081	C0010186
Adjusted	T169	C0456081
asthma	T047	C0004096
costs	T081	C0010186
cost ratio	T081	C0392762
SA	T033	C0581126
cohort	T098	C0599755
adjusted	T169	C0456081
asthma	T047	C0004096
medication	T058	C2081612
costs	T081	C0010186
SA	T033	C0581126
cohort	T098	C0599755
Patients	T101	C0030705
SA	T033	C0581126
experienced	T041	C0596545
exacerbations	T033	C0349790
use	T169	C0457083
controller medications	T061	C0087111
years	T079	C0439234
adherent	T169	C0334154
controller therapy	T169	C0039798
patients	T101	C0030705
PA	T047	C3266628
pharmacotherapy	T061	C0013216
SA	T033	C0581126
patients	T101	C0030705
adjusted	T169	C0456081
asthma	T047	C0004096
costs	T081	C0010186
adjusted	T169	C0456081
asthma	T047	C0004096
medication	T058	C2081612
costs	T081	C0010186
PA	T047	C3266628
patients	T101	C0030705
Patients	T101	C0030705
SA	T033	C0581126
consistently	T078	C0332290
health care	T058	C0086388
utilization	T169	C0042153
Funding	T081	C0243098
study	T062	C2603343
GlaxoSmithKline	T093	C1552903
GSK	T093	C1552903
authors	T097	C3812881
meet	T067	C1550543
criteria	T078	C0243161
authorship	T057	C0004351
International Committee for Medical Journal Editors	T096	C2699414
Albers	T170	C0805191
Forshag	T170	C0805191
Yancey	T170	C0805191
employees	T097	C0599987
GSK	T093	C1552903
GSK	T093	C1552903
Dalal	T170	C0805191
Nagar	T170	C0805191
Ortega	T170	C0805191
employees	T097	C0599987
GSK	T093	C1552903
time	T079	C0040223
research	T062	C0035168
Chastek	T170	C0805191
Korrer	T170	C0805191
employees	T097	C0599987
Optum	T093	C0596660
consulting fees	T081	C0015751
GSK	T093	C1552903
research	T062	C0035168
study	T062	C2603343
Study concept	T078	C0178566
design	T052	C1707689
contributed	T052	C1880177
Chastek	T170	C0805191
Nagar	T170	C0805191
Dalal	T170	C0805191
Korrer	T170	C0805191
data collection	T062	C0010995
Chastek	T170	C0805191
data interpretation	T081	C0010998
Chastek	T170	C0805191
Ortega	T170	C0805191
Forshag	T170	C0805191
Dalal	T170	C0805191
manuscript	T073	C0600659
Chastek	T170	C0805191
Dalal	T170	C0805191
revised	T169	C3244319
Albers	T170	C0805191
Yancy	T170	C0805191
assisted	T080	C1269765
authors	T097	C3812881
Differential regulation	T042	C1325907
spontaneous	T169	C0205359
evoked	T080	C1444748
inhibitory synaptic transmission	T042	C2255939
somatosensory cortex	T023	C0037658
retinoic acid	T109	C0040845
Retinoic acid	T109	C0040845
RA	T109	C0040845
developmental	T080	C0458003
morphogen	T121	C1254351
novel	T080	C0205314
synaptic	T043	C4236609
signaling molecule	T123	C1519315
mature	T079	C0205286
hippocampal	T023	C0019564
neurons	T025	C0027882
modulate	UnknownType	C0678672
excitatory	T042	C0234107
inhibitory synaptic transmission	T042	C2255939
homeostatic	T038	C0019868
synaptic plasticity	T042	C0027880
RA	T109	C0040845
modulating	UnknownType	C0678672
neural circuits	UnknownType	C0814033
outside	T082	C0205101
hippocampus	T023	C0019564
mode of RA's action	T169	C1524059
synapses	T030	C0039062
similar	T080	C2348205
within	T082	C0332285
hippocampal	T023	C0019564
RA	T109	C0040845
synaptic function	T043	C0027793
outside	T082	C0205101
hippocampus	T023	C0019564
novel	T080	C0205314
function	T169	C0542341
all-trans retinoic acid	T109	C0040845
inhibitory synapses	T026	C1512777
Acute	T079	C0205178
RA	T109	C0040845
treatment	T169	C1522326
increases	T169	C0442805
spontaneous	T169	C0205359
inhibitory synaptic transmission	T042	C2255939
L2/3 pyramidal neurons	T025	C0206441
somatosensory cortex	T023	C0037658
effect	T080	C1280500
expression	T045	C0597360
RA's receptor	T116	C0140279
RARα	T116	C0140279
pre- and post-synaptically	T043	C0027793
RA	T109	C0040845
evoked	T080	C1444748
inhibitory transmission	T042	C2255939
extracellular	T026	C0521119
activation of action potentials	T043	C4233793
presynaptic	T026	C0206181
interneurons	T025	C0021792
interneurons	T025	C0021792
pyramidal neurons	T025	C0206441
results	T033	C0683954
RA's	T109	C0040845
action	T052	C3266814
synapses	T030	C0039062
diverse	T080	C1880371
synaptic connection	T043	C0027793
excitatory	T042	C0234107
inhibitory	T042	C2255939
circuit	UnknownType	C0814033
hippocampal	T023	C0019564
cortical)	T023	C0007776
synaptic signaling	T043	C4236609
RA	T109	C0040845
regulation of synaptic plasticity	T042	C1326639
classic roles	T077	C1705810
brain development	T042	C1160340
retinoic acid	T109	C0040845
RA	T109	C0040845
regulate	T042	C1325907
excitatory	T042	C0234107
inhibitory transmission	T042	C2255939
adult	T100	C0001675
brain	T023	C0006104
authors	T097	C3812881
layer 2/3	T023	C0934502
L2/3	T023	C0934502
somatosensory cortex	T023	C0037658
S1	T023	C0037658
acute	T079	C0205178
RA	T109	C0040845
induces	T169	C0205263
increases	T169	C0442805
spontaneous	T169	C0205359
action-potential	T043	C0001272
evoked	T080	C1444748
transmission	T043	C0027793
retinoic acid receptor	T116	C0140279
RARα	T116	C0140279
presynaptic	T026	C0206181
PV	T116	C0030616
interneurons	T025	C0021792
postsynaptic	UnknownType	C0682686
pyramidal (PN) neurons	T025	C0206441
Utilization	T081	C0013223
Pattern	T082	C0449774
Drug Use	T041	C0871719
Traditional Chinese Medicine	T091	C0025131
Chinese	T091	C0025123
Western Medicine	T091	C1879848
Integrated Chinese-Western Medicine	T091	C0025118
Treatments	T061	C0087111
Allergic Rhinitis	T047	C2607914
National Health Insurance Program	T058	C1254363
Taiwan	T083	C0039260
Patients	T101	C0030705
Taiwan	T083	C0039260
allergic rhinitis	T047	C2607914
Western medicine	T091	C1879848
treatment	T061	C0087111
Traditional Chinese Medicine	T091	C0025131
treatment	T061	C0087111
integrated Chinese-Western medicine	T091	C0025118
treatment	T061	C0087111
pairwise comparison	T081	C0086766
Traditional Chinese Medicine	T091	C0025131
Western medicine	T091	C1879848
integrated Chinese-Western medicine	T091	C0025118
treatments	T061	C0087111
simultaneous	T079	C0521115
analysis	T062	C0936012
treatments	T061	C0087111
analyzed	T062	C0936012
patients	T101	C0030705
allergic rhinitis	T047	C2607914
treatments	T061	C0087111
demographic	T090	C0011298
characteristic	T080	C1521970
medical	T169	C0205476
use	T169	C0457083
drug use patterns	T041	C0871719
treatments	T061	C0087111
National Health Insurance Research Database	T170	C0282574
data source	T081	C0011001
patients	T101	C0030705
diagnosed	T033	C0011900
allergic rhinitis	T047	C2607914
International Classification of Diseases, Ninth Revision	T170	C2346503
Clinical Modification codes 470-478	T170	C0282574
Chi-square test	T170	C0008041
Tukey studentized range (honest significant difference) test	T170	C0392366
investigate	T169	C1292732
treatments	T061	C0087111
Visit frequency	T081	C0808393
allergic rhinitis	T047	C2607914
treatment	T061	C0087111
female	T098	C0043210
male	T098	C0025266
patients	T101	C0030705
treatment	T061	C0087111
Traditional Chinese Medicine	T091	C0025131
Western medicine	T091	C1879848
integrated Chinese-Western medicine	T091	C0025118
Persons	T098	C0027361
highest	T080	C1522410
proportion	T081	C1709707
visits	T058	C1512346
allergic rhinitis	T047	C2607914
Traditional Chinese Medicine	T091	C0025131
treatment	T061	C0087111
medical	T169	C0205476
person-time	T098	C0027361
daily	T079	C0332173
drug cost	T081	C0085123
person-time	T098	C0027361
lowest	T080	C1708760
total	T080	C0439810
expenditure	T081	C0015316
person-time	T098	C0027361
Western medicine	T091	C1879848
lowest	T080	C1708760
daily	T079	C0332173
drug cost	T081	C0085123
person-time	T098	C0027361
highest	T080	C1522410
total	T080	C0439810
expenditure	T081	C0015316
person-time	T098	C0027361
total	T080	C0439810
expenditure	T081	C0015316
person-time	T098	C0027361
daily	T079	C0332173
drug cost	T081	C0085123
person-time	T098	C0027361
medical	T169	C0205476
items	T071	C1551338
person-time	T098	C0027361
integrated Chinese-Western medicine	T091	C0025118
treatment	T061	C0087111
Traditional Chinese Medicine	T091	C0025131
Western medicine	T091	C1879848
treatments	T061	C0087111
patients	T101	C0030705
allergic rhinitis	T047	C2607914
integrated Chinese-Western medicine	T091	C0025118
treatment	T061	C0087111
visit frequency	T081	C0808393
integrated Chinese-Western medicine	T091	C0025118
highest	T080	C1522410
multiple-composition	T081	C0439064
medicines	T121	C0013227
frequently	T079	C0332183
single-composition	T081	C0205171
medicines	T121	C0013227
mar huang	T109	C0390643
Ephedra sinica Stapf	T002	C0950030
decrease	T081	C0547047
risk of	T078	C0035647
medications	T121	C0013227
TLR9	T028	C1423633
Deficiency	T169	C0011155
Accelerated	T169	C0521110
Renal Disease	T047	C0022658
Myeloid Lineage	T025	C0007634
Abnormalities	T033	C1704258
Pristane	T109	C0071986
Murine	T015	C0026809
Lupus	T047	C0012634
Systemic lupus erythematosus	T047	C0024141
SLE)	T047	C0024141
chronic	T079	C0205191
life-threatening	T033	C2826244
autoimmune disorder	T047	C0004364
organ	T023	C0178784
pathologies	T091	C0030664
kidney	T023	C0022646
destruction	T052	C1948029
murine	T015	C0026809
models	T050	C0012644
SLE	T047	C0024141
endosomal	T026	C1820047
TLRs	T116	C0670896
autoantibodies	T116	C0004358
clinical	T080	C0205210
disease	T047	C0012634
manifestations	T169	C0205319
TLR9	T028	C1423633
deficient	T169	C0011155
autoimmune	T046	C0443146
strains	T001	C1518614
disease	T047	C0012634
pathology	T091	C0030664
Injection	T061	C1533685
BALB/c mice	T015	C0025919
2,6,10,14-tetramethylpentadecane	T109	C0071986
TMPD	T109	C0071986
pristane	T109	C0071986
SLE-like disease	T047	C0012634
Tlr9(-/-)	T028	C1423633
BALB/c mice	T015	C0025919
injected i.p.	T061	C0021493
TMPD	T109	C0071986
autoimmunity	T046	C0004368
TLR	T116	C0670896
accumulation	T033	C4055506
TLR7	T028	C1336639
expressing	T045	C0017262
Ly6C(hi)	T129	C1530208
inflammatory	T169	C0333348
monocytes	T025	C0026473
site of injection	T082	C2700396
upregulation	T044	C0041904
IFN	T116	C0021747
gene expression	T045	C0017262
peritoneal cavity	T030	C1704247
myeloid lineage precursors	T025	C0007634
common myeloid progenitors	T025	C1956319
granulocyte	T025	C0018183
myeloid precursors	T025	C0007634
bone marrow	T024	C0005953
TMPD	T109	C0071986
injected	T061	C1533685
Tlr9(-/-)	T028	C1423633
BALB/c mice	T015	C0025919
autoantibody	T116	C0004358
RNA	T114	C0035668
neutrophil	T025	C0027950
cytoplasmic	T026	C0521449
Ags	T129	C0003320
myeloperoxidase	T116	C0027021
TMPD	T109	C0071986
injected	T061	C1533685
wild-type BALB/c mice	T015	C0025919
TMP	T109	C0071986
injected	T061	C1533685
Tlr9(-/-)	T028	C1423633
mice	T015	C0026809
wild-type mice	T015	C1520150
glomerular IgG	T116	C0020852
deposition	T169	C0333562
granulocytes	T025	C0018183
glomerulonephritis	T047	C0017658
reduced	T080	C0392756
lifespan	T102	C0870809
TLR7	T028	C1336639
response	T032	C0871261
self-antigens	T129	C0004359
model	T050	C0012644
autoimmunity	T046	C0004368
BALB/c	T015	C0025919
pristane	T109	C0071986
model	T050	C0012644
TLR7	T028	C1336639
models	T050	C0012644
SLE	T047	C0024141
negatively	T033	C0205160
TLR9	T028	C1423633
Effect	T080	C1280500
Xenotransplantation	T061	C0520484
Site	T082	C0205145
MicroRNA	T114	C1101610
Expression	T045	C0017262
Human	T016	C0086418
Colon Cancer	T191	C0699790
Stem Cells	T025	C0038250
Cancer stem cells	T025	C1956422
CSCs	T025	C1956422
high	T080	C0205250
tumorigenic	T191	C0007621
ability	T032	C0085732
patient-derived tumor xenografts	T050	C4050317
PDXs	T050	C4050317
PDXs	T050	C4050317
attractive	T080	C2346874
pre-clinical model	T170	C1514292
gene expression	T045	C0017262
biological behavior	T070	C0001398
cancer cells	T025	C0334227
tumor	T191	C0027651
change	T169	C0392747
establishment	T080	C0443211
PDXs	T050	C4050317
Human	T016	C0086418
colon cancer	T191	C0699790
PDX	T050	C4050317
established	T080	C0443211
passaged	T059	C1709474
subcutaneously	T082	C0443315
orthotopically	T082	C0574893
murine	T015	C0025929
intestine	T023	C0021853
Histology	T091	C0019638
flow cytometric	T059	C0016263
profile	T059	C1979963
surgical	T061	C0543467
specimen	T077	C2347026
PDX	T050	C4050317
analyzed	T062	C0936012
CSCs	T025	C1956422
isolated	T169	C0205409
tumors	T191	C0027651
microRNA	T114	C1101610
miRNA	T114	C1101610
expression	T045	C0017262
analyzed	T062	C0936012
semi-quantitative polymerase chain reaction	T059	C2733022
surgical	T061	C0543467
specimens	T077	C2347026
PDXs	T050	C4050317
histologically	T091	C0019638
similar	T080	C2348205
size	T082	C0456389
CSC	T025	C1956422
population	T098	C1257890
increased	T081	C0205217
expression	T045	C0017262
miRNA	T114	C1101610
CSCs	T025	C1956422
changed	T169	C0392747
passaged	T059	C1709474
PDXs	T050	C4050317
Expression	T045	C0017262
oncogenic	T131	C0007090
miRNAs	T114	C1101610
highly	T080	C0205250
up-regulated	T044	C0041904
CSCs	T025	C1956422
orthotopically	T082	C0574893
passaged	T059	C1709474
PDXs	T050	C4050317
xenotransplantation	T061	C0520484
site	T082	C0205145
number	T081	C0237753
tumor	T191	C0027651
passages	T059	C1709474
affect	T041	C0001721
miRNA	T114	C1101610
expression	T045	C0017262
human	T016	C0086418
colon	T023	C0009368
CSCs	T025	C1956422
Chemosensitivity	T033	C2347610
Cardiovascular Risk	T033	C1113685
Ventilatory Response	T201	C1321070
Exercise	T056	C0015259
COPD	T047	C0024117
COPD	T047	C0024117
elevated	T080	C3163633
cardiovascular risk	T033	C1113685
potentiated	T080	C1704419
ventilatory response	T201	C1321070
exercise	T056	C0015259
carotid	T023	C0741968
chemoreceptor	T025	C0008010
CC	T025	C0008010
activity	T042	C0234208
sensitivity	T042	C0234208
sensitivity	T042	C0234208
clinical conditions	T201	C0683325
sympathetic	T022	C0039044
vasoconstrictor outflow	T046	C1456863
predictive	T080	C0681890
mortality	T033	C1306577
CC	T025	C0008010
activity	T042	C0234208
sensitivity	T042	C0234208
functional	T169	C0205245
significance	T078	C0750502
not been well examined	T080	C0332129
COPD	T047	C0024117
CC	T025	C0008010
activity	T042	C0234208
sensitivity	T042	C0234208
elevated	T080	C3163633
COPD	T047	C0024117
increased	T081	C0205217
pulse wave velocity	T081	C3494431
marker	T201	C0005516
CV risk	T033	C1113685
ventilatory response	T201	C1321070
exercise	T056	C0015259
COPD	T047	C0024117
patients	T101	C0030705
healthy	T080	C3898900
controls	T096	C0009932
examined	T033	C0332128
Participants	T098	C0679646
baseline	T081	C1442488
cardiopulmonary exercise	T060	C2959886
pulmonary function testing	T060	C0024119
CC	T025	C0008010
activity	T042	C0234208
evaluated	T058	C0220825
drop in	T033	C0085639
ventilation	T039	C0035203
breathing	T039	C0035203
O2	T121	C0030054
CC	T025	C0008010
sensitivity	T042	C0234208
ventilatory response to hypoxia	T060	C0199505
pO2	T059	C1283004
Peripheral	T082	C0205100
arterial stiffness	T039	C0599949
evaluated	T058	C0220825
measurement	T169	C0242485
pulse wave velocity	T081	C3494431
PWV	T081	C3494431
applanation tonometry	T060	C0430862
breathing	T039	C0035203
room air	T033	C3846005
chemoreceptor	T025	C0008010
inhibition	T052	C3463820
breathing	T039	C0035203
100%	T081	C3817553
O2	T121	C0030054
CC	T025	C0008010
activity	T042	C0234208
CC	T025	C0008010
sensitivity	T042	C0234208
PWV	T081	C3494431
ventilatory response	T201	C1321070
exercise	T056	C0015259
COPD	T047	C0024117
controls	T096	C0009932
CC	T025	C0008010
sensitivity	T042	C0234208
PWV	T081	C3494431
CC	T025	C0008010
activity	T042	C0234208
CC	T025	C0008010
sensitivity	T042	C0234208
ventilatory response	T201	C1321070
exercise	T056	C0015259
COPD	T047	C0024117
CC	T025	C0008010
breathing	T039	C0035203
100%	T081	C3817553
O2	T121	C0030054
PWV	T081	C3494431
COPD	T047	C0024117
no effect	T080	C1301751
controls	T096	C0009932
CC	T025	C0008010
activity	T042	C0234208
sensitivity	T042	C0234208
elevated	T080	C3163633
COPD	T047	C0024117
cardiovascular risk	T033	C1113685
CC	T025	C0008010
activity	T042	C0234208
sensitivity	T042	C0234208
potentiated	T080	C1704419
ventilatory response	T201	C1321070
exercise	T056	C0015259
Isolation of Cells	T059	C0007616
Specialized	T077	C1704211
Anticancer	T109	C0003392
Alkaloid Metabolism	T044	C1158456
Fluorescence-Activated Cell Sorting	T059	C0079366
Plant	T002	C0032098
specialized	T077	C1704211
metabolism	T040	C0025519
complex	T080	C0439855
cell	T025	C0007634
specific	T080	C0205369
compartmentation	T043	C0007583
biosynthesis	T169	C0005572
plant	T002	C0032098
natural products	T123	C1566558
manipulation	T169	C0392747
pathways	T077	C1705987
isolate	T059	C0220862
characterize	T052	C1880022
specific	T080	C0205369
cell types	T170	C0449475
Catharanthus roseus	T002	C0331124
medicinal	T121	C0013227
terpenoid indole alkaloids	T109	C1449663
anticancer	T109	C0003392
vinblastine	T109	C0042670
vincristine	T109	C0042679
biosynthetic steps	T169	C0005572
specialized	T077	C1704211
mesophyll cells	T025	C2936408
idioblasts	T025	C3178867
optical	T090	C0029144
fluorescence	T070	C0016315
alkaloid	T109	C0301258
accumulating	T033	C4055506
C. roseus	T002	C0331124
leaf	T002	C0242724
idioblasts	T025	C3178867
characterized	T052	C1880022
methodology	T078	C3266812
isolation	T059	C0220862
idioblast	T025	C3178867
protoplasts	T025	C0033731
fluorescence-activated cell sorting	T059	C0079366
autofluorescence	T059	C0544711
cells	T025	C0007634
omic strategies	T062	C0035171
identification	T080	C0205396
candidate genes	T028	C0017337
biosynthesis	T169	C0005572
pathway	T077	C1705987
regulation	T038	C1327622
transmembrane transport	T043	C1519624
anticancer	T033	C0243095
alkaloids	T109	C0301258
C. roseus	T002	C0331124
Interaction	T169	C1704675
Antimicrobial Peptides	T116	C4084937
Rhesus θ-Defensin	T116	C1450181
Porcine	T015	C3665571
Protegrin-1	T116	C0300260
Anionic Phospholipid Monolayers	T109	C0031676
Langmuir isotherm	T170	C0282574
Brewster angle microscopy	T059	C0026018
BAM	T059	C0026018
neutron reflectivity studies	T062	C0242481
model	T170	C0596899
bacterial cell membranes	T026	C0007603
antimicrobial peptides	T116	C4084937
Rhesus θ-defensin 1	T116	C1450181
RTD-1	T116	C1450181
porcine	T015	C3665571
protegrin 1	T116	C0300260
PG-1	T116	C0300260
peptides	T116	C0030956
interacted	T169	C1704675
monolayers	T109	C0031676
air	T167	C0001861
water	T121	C0043047
phosphatidylethanolamine	T109	C1450468
phosphatidylglycerol	T109	C0031614
approximate	T080	C0332232
cell membranes	T026	C0007603
Gram positive bacteria	T007	C0018154
Langmuir film	T167	C1561572
measurements	T169	C0242485
peptides	T116	C0030956
perturb	T169	C0332453
lipid monolayers	T109	C0031676
surface pressure	T070	C0004180
BAM	T059	C0026018
small domains	T087	C1514562
lipid films	T170	C0596899
monolayer	T109	C0031676
surface pressure	T070	C0004180
PG-1	T116	C0300260
RTD-1	T116	C1450181
interaction	T169	C1704675
monolayer	T109	C0031676
RTD-1	T116	C1450181
neutron reflectivity studies	T075	C0026336
PG-1	T116	C0300260
RTD-1	T116	C1450181
model	T170	C0596899
amphiphilic	T121	C0002671
PG-1	T116	C0300260
embedded	T059	C1707903
lipid film	T170	C0596899
lipid acyl chains	T120	C1254355
thickness	T080	C1280412
lipid headgroup layer	T120	C1254355
RTD-1	T116	C1450181
lipid acyl chains	T120	C1254355
PG-1	T116	C0300260
thickness	T080	C1280412
lipid headgroup layer	T120	C1254355
peptides	T116	C0030956
anionic lipid monolayers	T109	C0031676
hemolytic activities	T059	C0009542
differing propensities	T081	C2718044
transmembrane	T026	C1167322
pores	T026	C1325742
Development	T039	C0243107
chrysin	T109	C0055661
poloxamer	T109	C0600615
toxicity	T080	C0040539
evaluation	T058	C0220825
fish	T013	C0016163
embryos	T018	C0013935
Poloxamer	T109	C0600615
micelles	T109	C0025938
micelles	T109	C0025938
safety	T068	C0036043
efficacy	T080	C1280519
water	T121	C0043047
insoluble	T080	C0205556
drugs	T121	C0013227
Chrysin	T109	C0055661
anticancer	T080	C2986475
anti-inflammatory	T080	C1515999
antioxidant	T039	C3179302
anti-aromatase activities	T044	C1148560
water	T121	C0043047
insoluble	T080	C0205556
properties	T080	C0871161
pharmaceutical application	T091	C0039429
chrysin	T109	C0055661
poloxamer	T109	C0600615
micelles	T109	C0025938
poloxamers	T109	C0600615
Pluronic F-68	T109	C0032254
Pluronic F-127	T109	C0032253
chrysin	T109	C0055661
Pluronic F-68	T109	C0032254
micelles	T109	C0025938
CS-P68	T109	C0025938
chrysin	T109	C0055661
Pluronic F-127	T109	C0032253
micelles	T109	C0025938
CS-P127	T109	C0025938
increase	T169	C0442805
aqueous	T080	C0599956
solubility	T080	C0037628
chrysin	T109	C0055661
results	T169	C1274040
polymer	T104	C0032521
drug	T121	C0013227
polymer	T104	C0032521
size	T082	C0456389
characteristics	T080	C1521970
micelles	T109	C0025938
micelle system	T109	C0025938
CS-P68	T109	C0025938
CS-P127	T109	C0025938
drug	T121	C0013227
polymer	T104	C0032521
ratios	T081	C0456603
nanosize-range diameter	T081	C1301886
in vivo study	T062	C0681829
zebrafish	T013	C0043457
eggs	T025	C0029974
toxicity	T080	C0040539
CS-P68	T109	C0025938
CS-P127	T109	C0025938
dose response	T078	C1546996
CS-P68	T109	C0025938
CS-P127	T109	C0025938
drug dose	T081	C0678766
less	T080	C0547044
zebrafish	T013	C0043457
embryo	T018	C0013935
growth	T040	C0018270
study	T062	C2603343
enhanced	T052	C2349975
water solubility	T081	C0597682
chrysin	T109	C0055661
Chrysin	T109	C0055661
poloxamer	T109	C0600615
micelles	T109	C0025938
in vivo studies	T062	C0681829
mammalian	T015	C0024660
animals	T008	C0003062
humans	T016	C0086418
Adenoviral	T005	C0001483
Delivery	T061	C0011209
Tumor Necrosis Factor-α	T116	C1456820
Interleukin-2	T116	C0021756
Adoptive Cell Therapy	T061	C0079613
Immunosuppressive	T121	C0021081
Melanoma	T191	C0025202
Adoptive T-cell transfer	T061	C0376517
treatment approach	UnknownType	C0679624
metastatic cancer	T191	C0027627
efficacy	T080	C1280519
solid tumors	T191	C0280100
toxic	T080	C1407029
adoptive T-cell therapies	T061	C0079613
benefit	T081	C0814225
modalities	T078	C0695347
full	T080	C0443225
potential	T080	C3245505
excessive	T080	C0442802
toxicity	T080	C0040539
aimed	T078	C1947946
improve	T080	C1272745
efficacy	T080	C1280519
safety	T080	C0205556
adoptive T-cell transfer	T061	C0376517
adenoviral vectors	T114	C1510800
delivery	T169	C1705822
immunomodulatory	T061	C1963758
murine	T015	C0026809
cytokines	T116	C0079189
B16.OVA	T025	C0029974
melanoma tumors	T050	C0004565
tumors	T191	C0027651
concomitant	T079	C0521115
T-cell receptor	T116	C0034790
transgenic OT-I	T015	C0025936
transgenic OT-I T-cell transfer	T061	C0376517
adenoviruses	T005	C0001483
cytokine	T116	C0079189
injected	T169	C0449894
B16.OVA	T025	C0029974
tumors	T191	C0027651
safety	T080	C0205556
virus-mediated	T005	C0042776
virus-mediated cytokine delivery	T061	C0011209
cytokine	T116	C0079189
Antitumor	T080	C2986475
efficacy	T080	C1280519
enhanced	T052	C2349975
adenoviruses	T005	C0001483
murine	T015	C0026809
interleukin-2	T116	C0021756
mIL-2	T116	C0021756
tumor necrosis factor-α	T116	C1456820
mTNFα	T116	C1456820
T-cell transfer	T061	C0376517
viruses	T005	C0042776
improvement	T077	C2986411
efficacy	T080	C1280519
triple	T081	C0205174
combination	T080	C0205195
mIL-2	T116	C0021756
mTNFα	T116	C1456820
OT-I T-cells	T025	C0039194
Mechanistic studies	T169	C0441712
mIL-2	T116	C0021756
important	T080	C3898777
role	T077	C1705810
activating	T052	C1879547
T-cells	T025	C0039194
tumor	T191	C0027651
mTNFα	T116	C0041368
chemokine	T116	C0282554
expression	T045	C1171362
adenovirus	T005	C0001483
treatments	T061	C0087111
enhanced	T052	C2349975
tumor	T191	C0027651
OT-I T-cells	T025	C0039194
demonstrated	T052	C3687625
SPECT/CT imaging	T060	C3472245
(111)In-labeled cells	T025	C0007634
results	T169	C1274040
suggest	T078	C1705535
cytokine-coding	T116	C0079189
adenoviruses	T005	C0001483
improving	T080	C1272745
efficacy	T080	C1280519
adoptive T-cell therapies	T061	C0079613
Maternal	T033	C1858460
Legacy	T081	C0242538
Female	T032	C0086287
Identity	T054	C3826248
Offspring	T099	C0680063
Sex Ratio	T081	C0036893
Loggerhead Sea Turtle	T014	C0999068
organisms	T001	C0029235
temperature-dependent	T081	C0039476
sex determination	T038	C1367886
incubation environment	T082	C0014406
offspring	T099	C0680063
sex ratios	T081	C0036893
global	T080	C2348867
temperatures	T081	C0039476
warmed	T070	C0687712
organisms	T001	C0029235
adjust	T033	C2364069
climate change	T070	C2718051
degree	T080	C0441889
mothers	T099	C0026591
influence	T077	C4054723
sex ratios	T081	C0036893
offspring	T099	C0680063
years	T079	C0439234
nesting data	T078	C1511726
individual	T098	C0237401
female	T032	C0086287
loggerhead sea turtles	T014	C0999068
Caretta caretta	T014	C0999068
Bald Head Island	T083	C0022130
North Carolina	T083	C0028407
maternal	T033	C1858460
identity	T054	C3826248
nest	T082	C1254362
sex ratio	T081	C0036893
univariate	T062	C0683962
multivariate predictive models	T062	C0242481
variability	T077	C2827666
nest	T082	C1254362
sex ratios	T081	C0036893
mothers	T099	C0026591
consistency	T080	C0332529
mothers	T099	C0026591
spatial	T082	C1254362
temporal	T079	C0040223
thermal variation	T070	C2584332
individual	T098	C0237401
nesting preferences	T054	C0027776
divergences	T082	C0443204
nest	T082	C1254362
sex ratios	T081	C0036893
female's	T032	C0086287
nest	T082	C1254362
sex ratios	T081	C0036893
environmental	T082	C0014406
conditions	T080	C0348080
constrained	T077	C1707494
individuals	T098	C0237401
mitigate	T067	C1553901
environmental change	T033	C4060636
loggerhead	T014	C0999068
populations	T098	C1257890
female-biased	T078	C0242568
offspring	T099	C0680063
sex ratios	T081	C0036893
maternal behavioral	T054	C0024919
critical	T080	C1511545
species	T185	C1705920
vulnerable	T169	C0231204
extinction	T070	C3826380
RhoA	T116	C0643681
Activity	T044	C1537044
Worse	T033	C1457868
Overall Survival	T081	C4086681
Patients	T101	C0030705
Surgical Resection	T061	C0015252
Lauren	T185	C3829311
Diffuse-Type Gastric Adenocarcinoma	T191	C0279635
RHOA	T028	C0812234
mutations	T045	C0596611
Lauren	T185	C3829311
diffuse-type gastric adenocarcinoma	T191	C0279635
GA	T191	C0278701
intestinal-type GA	T191	C0279633
RhoA	T116	C0643681
activity	T044	C1537044
prognostic	T201	C1514474
overall survival	T081	C4086681
OS	T081	C4086681
patients	T101	C0030705
GA	T191	C0278701
Retrospective review	T062	C0035363
GA	T191	C0278701
patients	T101	C0030705
curative resection	T061	C1511562
single institution	T093	C2607850
Tissue	T024	C0040300
microarrays	T073	C1709016
surgical specimens	T059	C1254419
phosphorylated	T116	C1519061
RhoA	T116	C0643681
marker	T201	C0005516
RhoA	T116	C0643681
signaling	T043	C2611812
OS	T081	C4086681
Kaplan-Meier method	T062	C2827659
multivariate analysis	T081	C0026777
Cox proportional hazards regression modeling	T081	C0010235
patients	T101	C0030705
diffuse-type GA	T191	C0279635
patients	T101	C0030705
intestinal-type GA	T191	C0279633
intestinal-type GA	T191	C0279633
diffuse-type GA	T191	C0279635
tumors	T191	C0027651
associated with	T080	C0332281
tumor size	T082	C0475440
advanced tumor, node, metastasis (TNM) classification system stage	T185	C1515169
patients	T101	C0030705
diffuse-type GA	T191	C0279635
RhoA	T116	C0643681
activity	T044	C1537044
associated with	T080	C0332281
worse	T033	C1457868
OS	T081	C4086681
RhoA	T116	C0643681
activity	T044	C1537044
OS	T081	C4086681
OS	T081	C4086681
patients	T101	C0030705
intestinal-type GA	T191	C0279633
OS	T081	C4086681
multivariate analysis	T081	C0026777
diffuse-type GA	T191	C0279635
patients	T101	C0030705
RhoA	T116	C0643681
activity	T044	C1537044
prognostic factor	T201	C1514474
OS	T081	C4086681
hazard ratio	T081	C2985465
confidence interval	T081	C0009667
RhoA	T116	C0643681
activity	T044	C1537044
worse	T033	C1457868
OS	T081	C4086681
patients	T101	C0030705
diffuse-type GA	T191	C0279635
curative surgical resection	T061	C1511562
genomic studies	T091	C0887950
RhoA	T116	C0643681
therapeutic	T061	C0087111
target	T169	C1521840
diffuse-type GA	T191	C0279635
Doxifluridine	T114	C0048808
conjugated	T082	C0522529
2-5A	T114	C0045143
analog	T104	C0243071
strong	T080	C0442821
RNase L	T116	C0071795
activation	T045	C0599177
ability	T080	C2698977
tumor suppressive	T044	C1519692
effect	T080	C1280500
RNase L	T116	C0071795
activated	T045	C0599177
2',5'-oligoadenylates	T114	C0045143
2-5A	T114	C0045143
subnanomolar	T081	C0392762
levels	T080	C0441889
cleave	T082	C0205242
single-stranded RNA	T114	C3272452
reported	T170	C0684224
hypothesis	T078	C1512571
introduction	T169	C0579004
8-methyladenosine	T114	C0100309
terminus	T082	C1705315
2-5A tetramer	T114	C0092311
shifts	T169	C0333051
2-5A	T114	C0045143
binding site	T192	C0005456
RNase L	T116	C0071795
study	T062	C2603343
synthesized	T052	C1883254
modified	T169	C0392747
2-5A	T114	C0045143
analog	T104	C0243071
8-methyladenosine	T114	C0100309
terminus	T082	C1705315
doxifluridine	T114	C0048808
conjugated	T082	C0522529
8-methyladenosine	T114	C0100309
substituted	T052	C1706204
2-5A	T114	C0045143
analog	T104	C0243071
significantly more	T081	C4055637
effective	T080	C1704419
activator	T052	C1879547
RNase L	T116	C0071795
parent	T077	C2699423
monophophorylated	T044	C1327237
2-5A tetramer	T114	C0092311
tumor suppressive	T044	C1519692
effect	T080	C1280500
against	T080	C0521124
human	T016	C0086418
cervical cancer	T191	C4048328
cells	T025	C0007634
Video Laryngoscopy	T074	C2363575
Advantages	T080	C0205556
Direct Laryngoscopy	T060	C0392823
during	T079	C0347984
Cardiopulmonary Resuscitation	T061	C0007203
Interruption	T079	C1512900
chest compressions	T058	C4032596
minimized	T080	C0392756
negative	T033	C0205160
effects	T080	C1280500
survival	T081	C0038954
randomized	T062	C0034656
controlled	T169	C2587213
cross-over study	T062	C0150097
aimed	T078	C1947946
analyze	T062	C0936012
effectiveness	T080	C1280519
Macintosh	T074	C1531939
Miller	T074	C1532566
McCoy	T074	C0563580
McGrath laryngoscopes	T074	C0180453
during	T079	C0347984
chest compressions	T058	C4032596
scope	T077	C1710028
cardiopulmonary resuscitation	T061	C0007203
scenario	T169	C0683579
time	T079	C0040223
required	T169	C1514873
successful	T080	C1272703
tracheal intubation	T061	C0021932
number of attempts	T201	C3163850
dental trauma	T037	C1301685
severity	T080	C0439793
need	T080	C0027552
optimization	T052	C2698650
manoeuvres	T052	C0441655
recorded	T033	C0243095
during	T079	C0347984
cardiopulmonary resuscitation	T061	C0007203
chest compressions	T058	C4032596
experience	T041	C0596545
computer games	T073	C0870328
during	T079	C0347984
years	T079	C0439234
participants	T098	C0679646
recorded	T033	C0243095
McCoy laryngoscope	T074	C0563580
shortest time	T079	C0040223
successful	T080	C1272703
tracheal intubation	T061	C0021932
presence	T033	C0150312
chest compressions	T058	C4032596
During	T079	C0347984
use	T169	C0042153
McCoy laryngoscopes	T074	C0563580
fewer	T081	C0205388
tracheal intubation	T061	C0021932
attempts	T051	C1516084
lower incidence	T081	C0021149
dental trauma	T037	C1301685
lower	T052	C2003888
visual analogue scale scores	T201	C2960751
intubation	T061	C0021925
recorded	T033	C0243095
Participants	T098	C0679646
experienced	T041	C0596545
computer game	T073	C0870328
players	T098	C1257890
Macintosh	T074	C1531939
McCoy	T074	C0563580
McGrath	T074	C0180453
achieved	T033	C0432600
successful	T080	C1272703
tracheal intubation	T061	C0021932
significantly	T078	C0750502
shorter time	T079	C0040223
during	T079	C0347984
resuscitation	T061	C0035273
chest compressions	T058	C4032596
Dental trauma	T037	C1301685
incidence	T081	C0021149
number	T081	C0237753
tracheal intubation	T061	C0021932
attempts	T051	C1516084
significant	T078	C0750502
difference	T080	C1705242
four	T081	C0205450
laryngoscopes	T074	C0180453
rate	T081	C1521828
playing	T052	C0441655
computer games	T073	C0870328
McGrath video laryngoscopes	T074	C2363575
advantages	T080	C0205556
direct laryngoscopes	T060	C0392823
smooth	T080	C0205556
successful	T080	C1272703
tracheal intubation	T061	C0021932
during	T079	C0347984
rhythmic chest compressions	T058	C4032596
McCoy laryngoscope	T074	C0563580
provided	T052	C1999230
tracheal intubation	T061	C0021932
shorter time	T079	C0040223
fewer	T081	C0205388
attempts	T051	C1516084
laryngoscope	T074	C0180453
increase	T169	C0442805
success rate	T081	C1521828
resuscitation	T061	C0035273
nurse-patient communication	T054	C0870983
nursing students	T097	C0038496
Effective communication skills	T032	C0870313
pivotal factors	T169	C1521761
positive interpersonal relationships	T054	C0021797
nursing undergraduates	T097	C0038496
perspectives	UnknownType	C0678958
communicating	T169	C0205196
patients	T101	C0030705
study	T062	C2603343
nursing students'	T097	C0038496
perspectives	UnknownType	C0678958
experiences	T041	C0596545
nurse-patient communication	T054	C0870983
clinical	T080	C0205210
placement	T080	C1524072
participants	T098	C0679646
second-year undergraduates	T098	C0682177
first-year master's students	T098	C0682177
Interviews	T052	C0021822
Cantonese	T171	C0023008
Chinese	T171	C0008120
English	T171	C0376245
content analysis	T062	C0681915
approach	T082	C0449445
data	T078	C1511726
themes	UnknownType	C0869035
interview data	T078	C1511726
nurse-patient communication	T054	C0870983
reveals	T080	C0443289
students	T098	C0038492
nurse-patient communication	T054	C0870983
conversation contents	T033	C0582166
content of the conversations	T033	C0582166
students	T098	C0038492
patients	T101	C0030705
theme	UnknownType	C0869035
self-reflection	T033	C0243095
nurse-patient communication	T054	C0870983
themes	UnknownType	C0869035
communication pattern in different	T033	C4061885
hospital settings	T073	C0019994
nurse-patient communication	T054	C0870983
students'	T098	C0038492
communication styles	T080	C0205556
hospitals	T073	C0019994
encounter	T053	C1947978
improve	T033	C0184511
students'	T098	C0038492
communication skills	T032	C0870313
educators	T097	C0259853
clinical staff	T097	C0851286
students	T098	C0038492
enhance	T052	C2349975
students'	T098	C0038492
reflective skills	T055	C0678856
confidence	T041	C1704726
understanding	T041	C0162340
students'	T098	C0038492
difficulties	T080	C0332218
nurse-patient communication	T054	C0870983
experience	T041	C0596545
skills	T055	C0678856
educators	T097	C0259853
recommendations	T078	C0034866
improve	T033	C0184511
communication skills	T032	C0870313
clinical practice	T057	C0205897
study	T062	C2603343
reveal	T080	C0443289
students'	T098	C0038492
nurse-patient communication	T054	C0870983
skills	T032	C0870313
improved	T033	C0184511
hippocampal	T023	C0019564
volume loss	T033	C0243095
marker	T201	C0005516
memory deficits	T048	C0233794
repeated stress	T033	C0038435
Exposure to	T080	C0332157
severe	T080	C0205082
prolonged	T079	C0439590
stress	T033	C0038435
detrimental effects	T033	C0243095
hippocampus	T023	C0019564
relatively	T080	C0205345
little	T081	C0700321
known	T080	C0205309
gradual	T080	C0439833
changes	T169	C0392747
hippocampal structure	T023	C0019564
behavioral	T053	C0004927
consequences	T169	C0686907
repeated stress	T033	C0038435
Behavioral analyses	T058	C1160858
chronic stress	UnknownType	C1510527
decline	T081	C0547047
spatial memory	T041	C0814087
impact	T080	C4049986
stress	T033	C0038435
concurrent	T079	C0205420
volumetric measurements	T081	C0079809
animals	T008	C0003062
reduction	T080	C0392756
hippocampal	T023	C0019564
volumes	T081	C0392762
stressed	T033	C0038435
animals	T008	C0003062
unstressed counterparts	T033	C0231300
stress	T033	C0038435
animals	T008	C0003062
behaviorally	T053	C0004927
worst	T080	C1522166
affected	T169	C1292725
chronic stress	UnknownType	C1510527
suffered	T048	C0683278
early loss in hippocampal volume	T033	C0243095
hippocampal	T023	C0019564
volume	T081	C0392762
stress	T033	C0038435
induced	T169	C0205263
memory deficits	T048	C0233794
risk factor	T033	C0035648
cognitive impairments	T048	C0338656
stress-related psychiatric disorders	T048	C0599909
Association	T080	C0439849
C9orf72	T028	C1428691
Repeats	T086	C0004793
Risk	T078	C0035647
Alzheimer's Disease	T047	C0002395
Amyotrophic Lateral Sclerosis	T047	C0002736
Meta-Analysis	T062	C0920317
C9orf72	T028	C1428691
genetic	T169	C0314603
cause	T169	C0015127
amyotrophic lateral sclerosis	T047	C0002736
ALS	T047	C0002736
frontotemporal dementia	T047	C0338451
FTD	T047	C0338451
Caucasian populations	T098	C0043157
relationship	T080	C0439849
C9orf72	T028	C1428691
repeats	T086	C0004793
Alzheimer's disease	T047	C0002395
AD	T047	C0002395
not clear	T033	C3845108
articles	T170	C0282420
assessing	T052	C1516048
C9orf72	T028	C1428691
ethnicities	T080	C0243103
ALS	T047	C0002736
meta-analysis	T062	C0920317
investigate	T169	C1292732
relationship	T080	C0439849
C9orf72	T028	C1428691
repeat expansions	T049	C1257790
repeats	T086	C0004793
intermediate	T082	C0205103
repeat copies	T086	C0004793
repeats	T086	C0004793
AD	T047	C0002395
ALS	T047	C0002736
results	T169	C1274040
positive	T033	C1446409
correlations	T080	C1707520
C9orf72	T028	C1428691
repeat expansions	T049	C1257790
risk	T078	C0035647
Alzheimer's disease	T047	C0002395
OR	T081	C0028873
CI	T081	C0009667
p	T081	C1709380
intermediate	T082	C0205103
repeat copies	T086	C0004793
C9orf72 gene	T028	C1428691
associated with	T080	C0332281
risk	T078	C0035647
disease	T047	C0012634
C9orf72	T028	C1428691
repeat expansions	T049	C1257790
positively	T033	C1446409
correlated	T080	C1707520
risk	T078	C0035647
familial	T047	C1862939
sporadic ALS	T047	C1862941
OR	T081	C0028873
CI	T081	C0009667
p	T081	C1709380
OR	T081	C0028873
CI	T081	C0009667
p	T081	C1709380
positive	T033	C1446409
correlation	T080	C1707520
gene variations	T070	C0042333
ALS	T047	C0002736
risk	T078	C0035647
Caucasians	T098	C0043157
Asians	T098	C0078988
OR	T081	C0028873
CI	T081	C0009667
p	T081	C1709380
OR	T081	C0028873
CI	T081	C0009667
p	T081	C1709380
validation	T062	C1519941
pressure	T067	C0033095
MRI	T074	C0336660
pain tolerance	T033	C0162703
device	T074	C0025080
behavioral	T053	C0004927
emotional	T041	C0013987
effects	T080	C1280500
pain	T184	C0030193
functional Magnetic Resonance Imaging	T060	C0376335
fMRI	T060	C0376335
MRI	T074	C0336660
compatible	T080	C1524057
pressure	T067	C0033095
algometer	T074	C0025080
elicit	T080	C0449265
pain	T184	C0030193
MRI	T074	C0336660
apparatus	T074	C0025080
incremental	T081	C1705117
measurable	T169	C1513040
pressure	T067	C0033095
scanning bore	T074	C0183115
device	T074	C0025080
pressure	T067	C0033095
pain	T184	C0030193
test	T059	C0022885
MRI	T074	C0336660
incompatible	T080	C1524057
algometer	T074	C0025080
AlgoMed	T074	C0025080
pain tolerance	T033	C0162703
tested	T059	C0022885
pressure	T067	C0033095
pain	T184	C0030193
MRI	T074	C0336660
environment	T082	C0014406
brain	T023	C0006104
activation	T052	C1879547
neural networks	T023	C0242406
pain	T184	C0030193
test	T059	C0022885
pain	T184	C0030193
scanned	T060	C0441633
MRI scanner	T074	C0336660
validity and reliability	T080	C0035036
device	T074	C0025080
pain tolerance	T033	C0162703
device	T074	C0025080
pain tolerance	T033	C0162703
algometer	T074	C0025080
device	T074	C0025080
BOLD	T042	C1655730
insula	T023	C0021640
BA 13	T023	C2326439
anterior cingulate gyrus	T023	C0175190
BA 24	T029	C2334367
pressure	T067	C0033095
increased	T081	C0205217
parametrically	UnknownType	C0681933
increased	T081	C0205217
thermal	T061	C2032530
electrical	T061	C2032523
mechanical	T061	C0699886
pain applications	T184	C0521491
Behavioral	T053	C0004927
functional	T169	C0205245
data	T078	C1511726
device	T074	C0025080
administering	T061	C1533734
pressure	T067	C0033095
pain	T184	C0030193
MRI	T074	C0336660
environments	T082	C0014406
MRI	T074	C0336660
device	T074	C0025080
instrument	T074	C0348000
measure	T169	C0242485
administer	T169	C1621583
pressure	T067	C0033095
pain	T184	C0030193
Anti-Inflammatory Properties	T080	C1515999
Menthol	T109	C0025368
Menthone	T109	C0065950
Schistosoma mansoni Infection	T047	C0036330
Schistosomiasis	T047	C0036323
parasitic disease	T047	C0030499
species	T185	C1705920
trematode worms	T204	C3662558
people	T098	C0027361
affected	T169	C0392760
drug development	T091	C0872152
essential	T080	C0205224
parasite	T204	C0030498
resistant	T039	C1514892
Praziquantel	T109	C0032911
drug	T121	C0013227
infection	T046	C3714514
study	T062	C2603343
evaluated	T058	C0220825
parasitological	T080	C0205468
immunological	T169	C0205470
histological	T169	C0205462
parameters	T033	C0449381
mice	T015	C0025929
infected	T033	C0439663
Schistosoma mansoni	T204	C0036319
treated with	T061	C0332293
herbal commercial medicine	T121	C2240391
drug	T121	C0013227
menthol	T109	C0025368
menthone	T109	C0065950
treatment regimen	T061	C0040808
herbal medicine	T121	C2240391
decreased	T081	C0205216
S. mansoni	T204	C0036319
eggs	T204	C0686887
feces	T031	C0015733
liver	T023	C0023884
intestine	T023	C0021853
reduced	T080	C0392756
hepatic granulomas	T047	C0745754
observed	T169	C1441672
reduction	T061	C0441610
blood eosinophilia	T047	C0014457
decrease	T081	C0205216
IL-4	T116	C0021758
IL-10	T116	C0085295
blood levels	T031	C0005768
treatment	T061	C0087111
schistosomiasis	T047	C0036323
treatment	T061	C0087111
herbal medicine	T121	C2240391
immunomodulatory	T080	C0205556
anti-inflammatory action	T080	C1515999
animal model	T008	C0599779
schistosomiasis	T047	C0036323
contributing	T052	C1880177
decrease	T081	C0205216
pathological	T169	C1521733
effects	T080	C1280500
S. mansoni infection	T047	C0036330
Catastrophic	T047	C0007397
health expenditure	T081	C0015318
comparative analysis	T062	C0683941
empty-nest	T078	C0870492
non-empty-nest	T078	C1254370
households	T099	C0020052
seniors	T098	C0001792
Shandong, China	T083	C0008115
aim	T078	C1947946
study	T062	C2603343
compare	T052	C1707455
catastrophic	T047	C0007397
health expenditure	T081	C0015318
CHE	T081	C0015318
prevalence	T081	C0683919
determinants	T169	C1521761
empty-nest	T078	C0870492
non-empty-nest	T078	C1254370
elderly	T098	C0001792
households	T099	C0020052
Shandong province of China	T083	C0008115
total	T080	C0439810
elderly	T098	C0001792
households	T099	C0020052
included	T169	C0332257
analysis	T062	C0936012
CHE	T081	C0015318
incidence	T081	C0021149
elderly	T098	C0001792
households	T099	C0020052
CHE	T081	C0015318
incidence	T081	C0021149
empty-nest	T078	C0870492
singles	T033	C1549113
empty-nest	T078	C0870492
couples	T099	C0010222
statistically	T081	C0871425
higher	T080	C0205250
non-empty-nest	T078	C1254370
elderly	T098	C0001792
households	T099	C0020052
inverse association	T077	C1708567
observed	T169	C1441672
CHE	T081	C0015318
incidence	T081	C0021149
income level	T080	C0870689
elderly	T098	C0001792
household	T099	C0020052
types	T080	C0332307
Factors	T169	C1521761
including	T169	C0332257
household	T099	C0020052
elderly members	T098	C0001792
non-communicable chronic diseases	T047	C0008679
elderly	T098	C0001792
household members	T099	C0015578
hospitalised	T033	C0701159
past year	T079	C4086728
lower	T052	C2003888
household	T099	C0020052
income	T081	C0021162
significant	T078	C0750502
risk factors	T033	C0035648
CHE	T081	C0015318
household	T099	C0020052
types	T080	C0332307
Health insurance	T058	C0021682
status	T080	C0449438
significant	T078	C0750502
determinant	T169	C1521761
CHE	T081	C0015318
empty-nest	T078	C0870492
singles	T033	C1549113
non-empty-nest	T078	C1254370
households	T099	C0020052
CHE	T081	C0015318
incidence	T081	C0021149
elderly	T098	C0001792
households	T099	C0020052
high	T080	C0205250
China	T083	C0008115
Empty-nest	T078	C0870492
households	T099	C0020052
higher	T080	C0205250
risk	T078	C0035647
CHE	T081	C0015318
non-empty-nest	T078	C1254370
households	T099	C0020052
findings	T033	C0243095
suggest	T078	C1705535
special	T080	C0205555
insurance	T058	C0021682
broaden	T082	C0332464
coverage	T078	C1551362
health services	T058	C0018747
heighten	T080	C0442803
reimbursement rate	T058	C0554896
empty-nest	T078	C0870492
elderly	T098	C0001792
health insurance	T058	C0021682
schemes	T170	C1519193
Financial	T080	C2350008
social protection	T064	C0242457
interventions	T058	C0262765
essential	T080	C0205224
identifie	T080	C0205396
at-risk	T080	C1444641
subgroups	T185	C1515021
elderly	T098	C0001792
households	T099	C0020052
agonistic autoantibodies	T116	C0004358
type-1 angiotensin II receptor	T116	C0529330
pathogenesis	T046	C0699748
retinopathy	T047	C0035309
preeclampsia	T046	C0032914
investigate	T169	C1292732
mechanism	T169	C0441712
AT1-AA	T129	C0021054
retinopathy	T047	C0035309
preeclampsia	T046	C0032914
positive rate	T081	C1521828
titer	T081	C0475208
AT1-AA	T129	C0021054
plasma	T031	C0032105
women	T098	C0043210
severe preeclampsia	T046	C0341950
pregnant women	T098	C0033011
AT1-AA	T129	C0021054
titer	T081	C0475208
correlated	T080	C1707520
retinopathy	T047	C0035309
preeclampsia	T046	C0032914
rat	T015	C0034721
model	T008	C0887965
intravenous injection	T169	C0021494
AT1-AA	T129	C0021054
plasma	T031	C0032105
patient	T101	C0030705
severe preeclampsia	T046	C0341950
plasma	T031	C0032105
titer	T081	C0475208
positive rate	T081	C1521828
AT1-AA	T129	C0021054
women	T098	C0043210
severe preeclampsia	T046	C0341950
pregnant women	T098	C0033011
antibody	T116	C0003241
titer	T081	C0475208
preeclampsia	T046	C0032914
retinopathy	T047	C0035309
correlated	T080	C1707520
TNF-α	T116	C1456820
VEGF	T116	C1256770
animal experiment	T062	C0205664
results	T169	C1274040
modeled rats	T015	C0034721
symptoms	T184	C1457887
symptoms	T184	C1457887
human	T016	C0086418
preeclampsia	T046	C0032914
retinopathy	T047	C0035309
Ocular fundus	T023	C4071854
examination	T058	C0582103
retinal microvascular abnormalities	T033	C0035300
hemorrhaging	T046	C0019080
leakage	T033	C4281748
severe preeclampsia	T046	C0341950
Morphological changes	T082	C1254362
edema	T184	C0013604
thickening	T033	C0205400
INL	T023	C1512784
ONL	T023	C0507777
pigment atrophy	T033	C0243095
TNF-α	T116	C1456820
VEGF	T116	C1256770
vitreous humor	T031	C0229096
retina	T023	C0035298
model rats	T015	C0034721
studies	T062	C2603343
results	T169	C1274040
abnormal expression	T045	C0017262
AT1-AA	T129	C0021054
damage	T169	C1883709
retinal capillary endothelial cells	T025	C0225336
vascular permeability	T042	C0162337
resulting in	T169	C0332294
retinopathy	T047	C0035309
Characterizing	T052	C1880022
sexual function	T040	C0278092
patients	T101	C0030705
generalized anxiety disorder	T048	C0270549
pooled analysis	T062	C0242481
vilazodone	T109	C1530072
studies	T062	C0002783
Vilazodone	T109	C1530072
reduce	T080	C0392756
core symptoms	T184	C1457887
generalized anxiety disorder	T048	C0270549
GAD	T048	C0270549
randomized	T062	C0206035
double-blind	T062	C0013072
placebo-controlled trials	T062	C0599724
sexual dysfunction	T047	C0549622
SD	T047	C0549622
GAD	T048	C0270549
post hoc analysis	T062	C0242481
trials	T062	C0008976
evaluate	T058	C0220825
effects of	T080	C1704420
vilazodone	T109	C1530072
sexual functioning	T040	C0278092
GAD	T048	C0270549
patients	T101	C0030705
Data	T078	C1511726
pooled	T169	C2349200
fixed-dose trial	T062	C0008976
vilazodone	T109	C1530072
mg/day	T081	C0439422
NCT01629966	T170	C0282574
flexible-dose studies	T062	C0242481
vilazodone	T109	C1530072
mg/day	T081	C0439422
NCT01766401	T170	C0282574
NCT01844115	T170	C0282574
adults	T100	C0001675
GAD	T048	C0270549
Sexual functioning	T040	C0278092
assessed	T052	C1516048
Changes in Sexual Functioning Questionnaire	T170	C0034394
CSFQ	T170	C0034394
Outcomes	T062	C0086750
mean change from baseline to end of treatment	T081	C0392762
EOT	T080	C0205556
CSFQ total score	T033	C2960025
percentage	T081	C0439165
patients	T101	C0030705
shifting	T169	C0333051
SD	T047	C0549622
baseline	T081	C1442488
CSFQ total score	T033	C2960025
males	T098	C0025266
females	T098	C0043210
normal functioning	T033	C4296962
EOT	T080	C0205556
Treatment-emergent adverse events	T046	C0877248
sexual functioning	T040	C0278092
analyzed	T062	C0936012
total	T080	C0439810
patients	T101	C0030705
analyses	T062	C0936012
SD	T047	C0549622
baseline	T081	C1442488
females	T098	C0043210
placebo	T122	C1696465
vilazodone	T109	C1530072
males	T098	C0025266
placebo	T122	C1696465
vilazodone	T109	C1530072
CSFQ total score	T033	C2960025
improvement	T077	C2986411
females	T098	C0043210
placebo	T122	C1696465
vilazodone	T109	C1530072
males	T098	C0025266
placebo	T122	C1696465
vilazodone	T109	C1530072
no statistically significant differences	T033	C3842396
treatment	T169	C1522326
groups	T078	C0441833
percentage	T081	C0439165
patients	T101	C0030705
shifted	T169	C0333051
SD	T047	C0549622
baseline	T081	C1442488
normal	T080	C0205307
sexual functioning	T040	C0278092
EOT	T080	C0205556
males	T098	C0025266
placebo	T122	C1696465
vilazodone	T109	C1530072
females	T098	C0043210
placebo	T122	C1696465
vilazodone	T109	C1530072
no statistical testing	T033	C3841003
erectile dysfunction	T047	C0242350
delayed ejaculation	T046	C0234047
vilazodone	T109	C1530072
treated	T169	C1522326
males	T098	C0025266
no treatment-emergent adverse events	T033	C1963761
sexual functioning	T040	C0278092
occurred	T052	C1709305
patients	T101	C0030705
treatment	T169	C1522326
group	T078	C0441833
Approximately	T080	C0332232
patients	T101	C0030705
vilazodone	T109	C1530072
GAD	T048	C0270549
studies	T062	C0002783
SD	T047	C0549622
baseline	T081	C1442488
Vilazodone	T109	C1530072
placebo	T122	C1696465
effects	T080	C1280500
CSFQ	T170	C0034394
outcomes	T062	C0086750
females	T098	C0043210
males	T098	C0025266
limited	T169	C0439801
adverse impact	T046	C0879626
sexual functioning	T040	C0278092
vilazodone	T109	C1530072
Biogeochemical	T169	C0205474
Controls	T080	C0243148
Uranium	T196	C0041928
Bioavailability	T081	C0005508
Dissolved Phase	T080	C1948047
Natural	T169	C0205296
Freshwaters	T167	C0016710
risks	T078	C0035647
associated with	T080	C0332281
uranium	T196	C0041928
U	T196	C0041928
mining	T057	C0026175
processing	T052	C1709694
investigated	T169	C1292732
biogeochemical	T169	C0205474
controls	T080	C0243148
U	T196	C0041928
bioavailability	T081	C0005508
freshwater	T167	C0016710
species	T185	C1705920
Lymnaea stagnalis	T204	C0323913
Gastropoda	T204	C0324023
Bioavailability	T081	C0005508
dissolved U(VI)	T196	C0041928
characterized	T052	C1880022
controlled	T169	C2587213
laboratory	T073	C0022877
experiments	T062	C0681814
water	T121	C0043047
hardness	T080	C0018599
pH	T081	C0020283
presence	T033	C0150312
complexing ligands	T103	C0023688
dissolved natural organic matter	T167	C0567360
DOM	T167	C0567360
Results	T034	C0456984
dissolved U	T196	C0041928
bioavailable	T080	C0935763
geochemical conditions	T090	C0017448
tested	T169	C0039593
Uranium	T196	C0041928
uptake	T039	C0243144
rates	T081	C1521828
first order kinetics	UnknownType	C0878685
environmental	T082	C0014406
concentrations	T081	C1446561
Uranium	T196	C0041928
uptake	T039	C0243144
rates	T081	C1521828
L. stagnalis	T204	C0323913
saturation	T070	C0522534
uptake	T039	C0243144
kinetics	T070	C0022702
exposure	T080	C0332157
concentrations	T081	C1446561
suggesting	T078	C1705535
uptake	T039	C0243144
ion channels	T116	C0022009
U	T196	C0041928
uptake	T039	C0243144
constants	T081	C1547014
Ca	T121	C0006675
uptake	T039	C0243144
rates	T081	C1521828
suggest	T078	C1705535
U	T196	C0041928
Ca	T121	C0006675
membrane transporters	T116	C0596902
U	T196	C0041928
bioavailability	T081	C0005508
decreases	T033	C0442797
increasing	T169	C0442808
pH	T081	C0020283
increasing	T169	C0442808
Ca	T121	C0006675
Mg	T123	C0024467
concentrations	T081	C1446561
DOM	T167	C0567360
present	T033	C0150312
ions	T196	C0022023
U	T196	C0041928
uptake	T039	C0243144
rates	T081	C1521828
Speciation modeling	T062	C0870071
formation	T169	C1522492
constants	T081	C1547014
U	T196	C0041928
ternary complexes	T104	C1254350
reveals	T080	C0443289
aqueous	T080	C0599956
concentration	T081	C1446561
dicarbonato U	T196	C0041928
species	T185	C1705920
U	T196	C0041928
bioavailability	T081	C0005508
L. stagnalis	T204	C0323913
free-ion activity	T052	C0441655
Interleukin-21	T116	C0962190
pathogenesis	T046	C0699748
type I autoimmune hepatitis	T047	C4303164
follicular	T023	C1571705
helper T (Tfh) cells	T025	C0018894
interleukin (IL)-21	T116	C0962190
peripheral blood	T031	C0229664
human	T016	C0086418
murine	T015	C0026809
models	T050	C0012644
autoimmune hepatitis	T047	C0241910
AIH	T047	C0241910
IL-21	T116	C0962190
type-I cytokine family	T116	C0079189
immune system	T022	C0020962
B cell activation	T043	C1155003
plasma cell differentiation	T043	C1817697
immunoglobulin production	T038	C0003261
serum	T031	C0229671
IL-21	T116	C0962190
levels	T080	C0441889
patients	T101	C0030705
type I AIH	T047	C4303164
clinical	T080	C0205210
laboratory	T073	C0022877
parameters	T077	C0549193
histology	T091	C0019638
Japanese	T098	C1556094
patients	T101	C0030705
liver disease	T047	C0023895
AIH	T047	C0241910
primary biliary cholangitis	T047	C0008312
drug-induced liver injury	T047	C0860207
acute hepatitis B	T047	C0276609
chronic hepatitis C	T047	C0524910
non-alcoholic steatohepatitis	T047	C3241937
viral hepatitis	T047	C0042721
healthy volunteers	T098	C1708335
Serum	T031	C0229671
IL-21	T116	C0962190
levels	T080	C0441889
enzyme-linked immunosorbent assay	T059	C0014441
Real-time polymerase chain reaction	T063	C1709846
mRNA	T114	C0035696
levels	T080	C0441889
Bcl-6	T028	C1332399
IL-21	T028	C1416406
CXCR5	T028	C1332421
Tfh-related factors	T116	C0033684
peripheral	T082	C0205100
mononuclear cells	T025	C0806987
diagnosis	T033	C0011900
AIH	T047	C0241910
male-to-female ratio	T033	C0243095
cirrhosis	T047	C0023890
severe	T080	C0205082
disease	T047	C0012634
IL-21	T116	C0962190
levels	T080	C0441889
increased	T081	C0205217
serum	T031	C0229671
patients	T101	C0030705
AIH	T047	C0241910
other liver diseases	UnknownType	C0156194
controls	T096	C0009932
serum	T031	C0229671
IL-21	T116	C0962190
levels	T080	C0441889
increased	T081	C0205217
severe	T080	C0205082
AIH	T047	C0241910
Serum	T031	C0229671
IL-21	T116	C0962190
levels	T080	C0441889
serum	T031	C0229671
bilirubin levels	T059	C0344395
grading of necroinflammatory activity	T033	C1954433
serum albumin levels	T034	C0728877
patients	T101	C0030705
AIH	T047	C0241910
patients	T101	C0030705
biochemical	T169	C0205474
remission	T033	C0544452
AIH	T047	C0241910
serum	T031	C0229671
IL-21	T116	C0962190
levels	T080	C0441889
elevated	T080	C3163633
correlated	T080	C1707520
positively	T033	C1514241
serum IgG levels	T059	C2732508
Expression	T045	C1171362
Tfh-related factors	T116	C0033684
Bcl-6	T116	C1448774
IL-21	T116	C0962190
peripheral blood mononuclear cells	T025	C1321301
patients	T101	C0030705
AIH	T047	C0241910
higher	T080	C0205250
healthy volunteers	T098	C1708335
IL-21	T116	C0962190
pathogenesis	T046	C0699748
AIH	T047	C0241910
AIH	T047	C0241910
therapy	T169	C0039798
Resistance	T169	C4281815
Exercise	T056	C0015259
Pregnancy	T040	C0032961
Outcome	T033	C0032972
health benefits	T081	C0086387
exercise	T056	C0015259
traditional advice	T058	C0150600
rest	T056	C0035253
pregnancy	T040	C0032961
changed	T169	C0392747
healthy	T080	C3898900
active	T169	C0205177
pregnancy	T040	C0032961
exercise	T056	C0015259
life	T078	C0376558
pregnant woman	T098	C0033011
benefits	T081	C0814225
combination	T080	C0205195
resistance	T169	C4281815
aerobic exercises	T061	C0001701
studies	T062	C2603343
resistance	T169	C4281815
training programs	T065	C0040607
no adverse	T184	C0853204
outcomes	T033	C0032972
ocular prosthesis	T074	C0015417
rehabilitation	T061	C0034991
child	T100	C0008059
retinoblastoma	T191	C0035335
maxillofacial prosthodontist	T061	C2193570
important	T080	C3898777
management of a patient	T058	C1610129
anopthalmosis	T019	C0003119
Prosthetic management	T061	C0087111
anopthalmic defect	T019	C0003119
ocular prosthesis	T074	C0015417
eye	T023	C0015392
patient's	T101	C0030705
self-confidence	T041	C0237529
rehabilitating	T169	C0034992
society	T092	C0037455
fabrication	T061	C0087111
ocular prosthesis	T074	C0015417
case report	T170	C0007320
technique	T169	C0449851
fabrication	T061	C0087111
ocular prosthesis	T074	C0015417
child	T100	C0008059
lost	T169	C0745777
eye	T023	C0015392
enucleation	T061	C0014392
retinoblastoma	T191	C0035335
rehabilitation	T061	C0034991
self-image	T058	C2712201
child	T100	C0008059
Pulmonary function	T042	C0231921
health-related quality of life	T078	C4279947
year	T079	C0439234
follow up	T058	C1522577
cardiac surgery	T061	C0018821
Pulmonary function	T042	C0231921
severely	T080	C0205082
reduced	T080	C0392756
early	T079	C1279919
period	T079	C1948053
cardiac surgery	T061	C0018821
impairments	T046	C0684336
months	T079	C0439231
after surgery	T079	C0032790
Evaluation	T058	C0220825
pulmonary function	T042	C0231921
lacking	T080	C0332268
prospective study	T062	C0033522
pulmonary function	T042	C0231921
health-related quality of life	T078	C4279947
investigated	T169	C1292732
year	T079	C0439234
cardiac surgery	T061	C0018821
Pulmonary function	T042	C0231921
measurements	T169	C0242485
health-related quality of life	T078	C4279947
SF-36	T170	C1519136
dyspnoea	T184	C0013404
subjective	T080	C0439655
breathing	T039	C0035203
coughing	T184	C0010200
ability	T032	C0085732
pain	T184	C0030193
evaluated	T058	C0220825
before	T079	C0332152
year	T079	C0439234
after surgery	T079	C0032790
patients	T101	C0030705
coronary artery bypass grafting	T061	C0010055
valve surgery	T061	C0543467
surgery	T061	C0543467
year	T079	C0439234
after surgery	T079	C0032790
forced vital capacity	T201	C0231958
forced expiratory volume	T042	C0016529
decreased	T081	C0205216
compared	T052	C1707455
preoperative	T079	C0445204
values	T081	C1522609
Saturation of peripheral oxygen	T042	C2317096
unchanged	T033	C0442739
year	T079	C0439234
postoperatively	T079	C0032790
compared	T052	C1707455
baseline	T081	C1442488
improved	T033	C0184511
health-related quality of life	T078	C4279947
year	T079	C0439234
after surgery	T079	C0032790
improvements	T077	C2986411
aspects	T080	C1879746
SF-36	T170	C1519136
Sternotomy	T061	C0185792
pain	T184	C0030193
low	T080	C0205251
year	T079	C0439234
postoperatively	T079	C0032790
at rest	T169	C0443144
deep breath	T184	C1321587
coughing	T184	C0010200
pulmonary function	T042	C0231921
associated with	T080	C0332281
dyspnoea	T184	C0013404
limitations	T169	C0449295
impaired	T046	C0684336
subjective	T080	C0439655
breathing	T039	C0035203
coughing	T184	C0010200
ability	T032	C0085732
year	T079	C0439234
cardiac surgery	T061	C0018821
static	T080	C0441463
dynamic	T169	C0729333
lung function measurements	T060	C0024119
decreased	T081	C0205216
health-related quality of life	T078	C4279947
improved	T033	C0184511
comparison	T052	C1707455
preoperative	T079	C0445204
values	T081	C1522609
Measured	T080	C0444706
levels	T080	C0441889
pain	T184	C0030193
low	T080	C0205251
saturation of peripheral oxygen	T042	C2317096
same	T080	C0445247
preoperatively	T079	C0445204
Impact	T080	C4049986
Soil	T167	C0037592
Salinity	T081	C0392762
Structure	T082	C0678594
Bacterial	T007	C0004611
Endophytic	T004	C1265415
Community	T096	C0009462
Identified	T080	C0205396
Roots	T002	C0242726
Caliph Medic	T002	C0330774
Medicago truncatula	T002	C0330774
forage crop	T002	C0032098
Caliph medic	T002	C0330774
Medicago truncatula	T002	C0330774
model legume plant	T062	C1514135
molecular characterization	T052	C1880022
interaction	T169	C1704675
rhizobia	T007	C0004611
plants	T002	C0032098
endophytic microbiome	T001	C1956108
plant	T002	C0032098
Endophytic	T004	C1265415
bacteria	T007	C0004611
plants	T002	C0032098
requirements	T169	C1514873
growth	T040	C0597252
development	T040	C0597252
bacteria	T007	C0004611
mechanism	T169	C0441712
salinity stress	T070	C1254365
adaptation	T038	C0392673
plants	T002	C0032098
isolation	T059	C0220862
utilization	T169	C0042153
bacteria	T007	C0004611
Caliph medic	T002	C0330774
farming	T082	C0557759
bacterial	T007	C0004611
OTUs	T185	C0008902
identified	T080	C0205396
interior	T082	C0205102
roots	T002	C0242726
plant	T002	C0032098
pyrosequencing	T059	C2732543
small ribosomal subunit gene	T028	C0017337
16S rDNA	T028	C0017337
cultivation-independent approach	T059	C0022885
differential	T080	C0443199
abundance	T080	C2346714
bacteria	T007	C0004611
plants	T002	C0032098
salinity stress	T070	C1254365
high-quality reads	T081	C0392762
sequencing	T059	C1294197
libraries	T028	C0017272
control	T024	C0040300
salinity-treated tissues	T024	C0040300
Statistical analysis	T062	C0871424
abundance	T080	C2346714
OTUs	T185	C0008902
roots	T002	C0242726
exposed to	T080	C0332157
salinity stress	T070	C1254365
Sequence analysis	T059	C0162801
identified	T080	C0205396
species	T185	C1705920
growth-promoting bacteria	T007	C0004611
marine	T001	C0599383
salt-stressed soil-borne bacteria	T007	C0004611
nitrogen-fixing bacterial	T007	C4277688
isolates	T123	C1764827
bacteria	T007	C0004611
community	T096	C0009462
salinity stress	T070	C1254365
Caliph medic	T002	C0330774
association	T080	C0439849
endophytes	T004	C1265415
salt stress conditions	T070	C1254365
model plant	T062	C1514135
evidence	T078	C3887511
growth promoting activity	T052	C0441655
group	T078	C0441833
endophytic	T004	C1265415
bacteria	T007	C0004611
isolated	T169	C0205409
plant roots	T002	C0242726
cultivation-dependent approach	T059	C0022885
isolates	T123	C1764827
ACC-deaminase	T116	C0044278
ammonia	T121	C0002607
IAA	T109	C0936060
solubilize	T169	C0205245
Zn+2	T121	C0043481
PO4-3	T121	C1601799
data	T078	C1511726
occurrence	T079	C2745955
cultivation-independent techniques	T059	C0022885
bacteria	T007	C0004611
endophytic	T004	C1265415
bacteria	T007	C0004611
Caliph medic	T002	C0330774
normal	T080	C0205307
saline	T167	C0036082
conditions	T080	C0348080
Cancer Stem Cells	T025	C1956422
CML	T191	C0023473
Transcriptional	T045	C0040649
Therapy	T061	C0087111
Leukemia	T191	C0023418
stem cells	T025	C1956422
LSCs	T025	C1956422
therapies	T061	C0087111
chronic myeloid leukemia	T191	C0023473
CML	T191	C0023473
molecular network	T044	C1148560
critical	T169	C0231242
CML	T191	C0023473
LSC	T025	C1956422
survival	T043	C0007620
transcriptional regulators	T116	C0040648
p53	T028	C0079419
c-Myc	T116	C0314684
eradication	T045	C2248542
Crocetin	T109	C0056501
improves	T033	C0184511
quality	T080	C0332306
in vitro	T080	C1533691
produced	T169	C0205245
bovine	T015	C3667982
embryos	T018	C0013935
blastocyst development	T039	C1326531
cryotolerance	T080	C1704410
apoptosis	T043	C0162638
assess	T058	C0184514
effect	T080	C1280500
supplementation	T061	C0087111
bovine	T015	C3667982
culture medium	T130	C0010454
natural antioxidant	T121	C0003402
crocetin	T109	C0056501
in vitro	T080	C1533691
blastocyst development	T039	C1326531
quality	T080	C0332306
evaluated	T058	C0220825
cryotolerance	T080	C1704410
apoptosis index	T170	C0918012
total cells number	T059	C0007584
allocation	T052	C1706778
Abattoir	T073	C0000715
oocytes	T025	C0029045
matured	T079	C0205286
fertilized	T169	C0232904
in vitro	T080	C1533691
standard procedure	T077	C1710183
hours	T079	C0439227
IVF	T061	C0015915
presumptive	T080	C3640893
zygotes	T018	C0043544
cultured	T059	C0430400
synthetic oviduct	T023	C0029954
fluid medium	T167	C1705217
crocetin	T109	C0056501
humidified air	T061	C0508271
CO2	T123	C0007012
O2	T121	C0030054
N2	T123	C0028158
Day	T079	C0439228
embryo yields	T081	C0392762
assessed	T052	C1516048
blastocysts	T018	C1281743
Cryotop method	T170	C0025663
ethylene glycol	T109	C0015083
DMSO	T109	C0012403
sucrose	T109	C0038636
blastocysts	T018	C1281743
Day	T079	C0439228
absence	T169	C0332197
control	T096	C0009932
presence	T033	C0150312
crocetin	T109	C0056501
terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling	T063	C1515232
differential staining	T059	C0487602
evaluate	T058	C0220825
apoptotic rate	T081	C1521828
allocation	T052	C1706778
cells	T025	C0007634
inner cell mass	T018	C1283994
ICM	T018	C1283994
trophectoderm	T018	C0041178
TE	T018	C0041178
lineages	T077	C1881379
Embryo development	T042	C0013936
crocetin group	T078	C0441833
control	T096	C0009932
total	T080	C0439810
embryo	T018	C0013935
output	T033	C4263297
grade 1	T185	C1275673
2	T185	C1275673
blastocysts	T018	C1281743
percentage	T078	C1549488
fast-developing embryos	T042	C0013936
increased	T081	C0205217
crocetin group	T078	C0441833
control	T096	C0009932
enrichment of culture medium	T130	C3503937
crocetin	T109	C0056501
improved	T033	C0184511
embryo	T018	C0013935
cryotolerance	T080	C1704410
control	T096	C0009932
hatching	T040	C0598016
rates	T081	C1521828
hours	T079	C0439227
postwarming culture	T130	C0010454
crocetin	T109	C0056501
decreased	T081	C0205216
percentage	T078	C1549488
apoptotic	T080	C1516044
cells	T025	C0007634
blastocysts	T018	C1281743
control	T096	C0009932
ICM	T018	C1283994
TE	T018	C0041178
total	T080	C0439810
total	T080	C0439810
cells	T025	C0007634
crocetin	T109	C0056501
control	T096	C0009932
enrichment of bovine culture medium	T130	C3503937
crocetin	T109	C0056501
increased	T081	C0205217
blastocyst yield	T081	C0392762
quality	T080	C0332306
improved	T033	C0184511
chronology	T170	C0008717
embryo development	T042	C0013936
increased	T081	C0205217
resistance	T169	C4281815
cryopreservation	T059	C0519951
reduced incidence	T081	C0021149
apoptosis	T043	C0162638
Matrix solid-phase dispersion	T059	C0022885
liquid chromatography-tandem mass spectrometry	T059	C4049918
determination	T059	C1148554
paraben	T109	C0030398
preservatives	T122	C0033086
mollusks	T204	C0026391
method for the extraction	T170	C0449341
determination	T059	C1148554
parabens	T109	C0030398
esters	T109	C0014898
4-hydroxybenzoic acid	T109	C0048323
preservatives	T122	C0033086
personal care products	T167	C4288402
pharmaceuticals	T121	C1254351
chlorinated derivatives	T109	C0020247
mono-	T109	C0066415
di-chloro methyl paraben	T109	C0066415
mollusk	T204	C0026391
samples	T077	C2347026
matrix solid-phase dispersion	T059	C0022885
MSPD	T059	C0022885
liquid chromatography-tandem mass spectrometry	T059	C4049918
MSPD parameters	T170	C2825207
solvent	T130	C0037638
solid support	T130	C1254353
clean-up sorbent	T130	C1254353
optimized	T052	C2698650
parabens	T109	C0030398
investigated	T169	C1292732
precleaning	T052	C1947930
sorbents	T130	C1254353
freeze-dried	T059	C0016698
mollusk	T204	C0026391
dispersed	T082	C0332624
silica	T122	C0037098
packed	T052	C2828395
cartridge	T170	C1553461
C18	T109	C0029224
clean-up sorbent	T130	C1254353
cartridge	T170	C1553461
acetonitrile	T109	C0050456
evaporated	T070	C0596539
reconstituted	T052	C0441655
methanol	T109	C0001963
analysis	T062	C0936012
validation	T062	C1519941
recoveries	T052	C0237820
analytes	T167	C0443354
precision	T080	C1706245
limits of detection	T081	C2718050
quantification	T081	C0392762
LOD	T081	C2718050
LOQ	T062	C1519941
dry weight	T081	C1439839
levels	T080	C0441889
methodology	T170	C0969625
mussel	T204	C0026871
clam	T204	C0008894
cockle	T204	C0453050
samples	T077	C2347026
Methyl paraben	T109	C0066415
LOQ	T081	C0392762
samples	T077	C2347026
clam	T204	C0008894
sample	T077	C2347026
concentrations	T081	C1446561
dry weight	T081	C1439839
Ethyl paraben	T109	C0059788
LOQ	T081	C0392762
mussel	T204	C0026871
cockle	T204	C0453050
samples	T077	C2347026
concentration level	T081	C1446561
n-Propyl paraben	T109	C0072238
LOQ	T081	C0392762
mussel	T204	C0026871
sample	T077	C2347026
reconstructive	T061	C0524865
overlapping stent	T074	C0038257
LEO+	T074	C0038257
SILK	T074	C0025080
treatment	T061	C0087111
intracranial	T029	C0524466
circumferential	T082	C0205113
fusiform aneurysms	T190	C0333099
posterior	T082	C1254362
circulation	T039	C0005775
Intracranial	T029	C0524466
circumferential	T082	C0205113
fusiform aneurysms	T190	C0333099
posterior	T082	C1254362
circulation	T039	C0005775
arterial branches	T023	C0003842
perforating	T033	C0549099
vessels	T023	C0005847
vessels	T023	C0005847
difficult	T080	C0332218
treat	T169	C1522326
endovascular	T029	C0524425
reconstruction technique	T061	C0524865
telescoping self-expandable stent	T074	C4042807
LEO+	T074	C0038257
flow-diverter device	T074	C0025080
SILK	T074	C0025080
different	T080	C1705242
surgical times	T079	C3494201
patients	T101	C0030705
circumferential	T082	C0205113
fusiform aneurysm	T190	C0333099
aneurysm	T047	C0002940
posterior cerebral artery	T023	C0149576
diagnosed	T033	C0011900
headache	T184	C0018681
partially	T081	C0728938
thrombosed aneurysm	T047	C1265766
lower	T029	C1548802
basilar artery	T023	C0004811
diagnosed	T033	C0011900
ischemia	T046	C0022116
brain stem	T023	C0006121
Endovascular	T029	C0524425
treatment	T061	C0524865
vascular	T023	C0005847
reconstruction technique	T061	C0524865
different	T080	C1705242
surgical times	T079	C3494201
overlapping; a telescoped self-expandable stent	T061	C2937236
LEO+	T074	C0038257
flow-diverter device	T074	C0025080
SILK	T074	C0025080
Angiographic	T060	C0002978
control	T080	C0243148
months	T079	C0439231
arterial patency	T201	C1508228
flow	T070	C0806140
maintenance	T052	C0024501
arterial branches	T023	C0003842
perforating	T033	C0549099
vessels	T023	C0005847
thrombosis	T046	C0040053
aneurysm	T047	C0002940
combined	T080	C0205195
different	T080	C1705242
surgical times	T079	C3494201
self-expandable stent	T074	C4042807
flow-diverter device	T074	C0025080
successful	T080	C1272703
patients	T101	C0030705
complications	T046	C0009566
procedure	T169	C2700391
long-term	T079	C0443252
follow-up	T058	C1522577
arterial	T023	C0003842
vascular	T023	C0005847
reconstruction	T061	C0524865
maintenance	T052	C0024501
cerebral perfusion	T061	C3162005
complete	T080	C0205197
aneurysm	T047	C0002940
occlusion	T169	C0441597
month	T079	C0439231
angiographic	T060	C0002978
follow-up	T058	C1522577
aneurysm recanalization	T037	C3854508
intra-stent stenosis	T046	C1261287
Circumferential	T082	C0205113
fusiform aneurysm	T190	C0333099
posterior	T082	C1254362
circulation	T039	C0005775
arterial branches	T023	C0003842
perforating	T033	C0549099
vessels	T023	C0005847
brain stem	T023	C0006121
treated	T169	C1522326
arterial	T023	C0003842
reconstruction technique	T061	C0524865
different	T080	C1705242
surgical times	T079	C3494201
self-expandable stent	T074	C4042807
LEO+	T074	C0038257
flow-diverter device	T074	C0025080
SILK	T074	C0025080
minimizing	T080	C0392756
risk	T078	C0035647
complications	T046	C0009566
failure	T169	C0231175
endovascular	T029	C0524425
technique	T061	C0524865
potential	T080	C3245505
arterial reconstruction	T061	C2937236
thrombosis	T046	C0040053
aneurysmatic sac	T047	C0002940
flow	T070	C0806140
maintenance	T052	C0024501
eloquent arteries	T023	C0003842
cerebral aneurysm	T047	C0917996
Polysaccharide	T109	C0032595
Specific	T080	C0205369
Memory B Cells	T025	C0682638
Protection	T033	C1545588
Experimental	T080	C1517586
Human	T016	C0086418
Pneumococcal	T007	C0038410
Carriage	T033	C0853960
previously	T079	C0205156
experimental	T080	C1517586
pneumococcal	T007	C0038410
carriage	T033	C0853960
enhances	T052	C2349975
immunity	T039	C0020964
protects	T033	C1545588
healthy	T080	C3898900
adults	T100	C0001675
against	T080	C0521124
carriage	T033	C0853960
reacquisition	T052	C1706701
rechallenge	T061	C2347900
homologous	T032	C0301883
strain	T001	C1518614
naturally	T169	C0205296
acquired	T080	C0439661
pneumococcal protein	T116	C0004627
polysaccharide	T109	C0032595
PS	T109	C0032595
specific	T080	C0205369
immunity	T039	C0020964
protection	T033	C1545588
against	T080	C0521124
carriage	T033	C0853960
acquisition	T052	C1706701
heterologous challenge	T039	C3658217
healthy volunteers	T098	C1708335
naturally	T169	C0205296
colonized	T025	C1947989
pneumococcus	T007	C0038410
clearance	T080	C0449297
natural	T169	C0205296
carriage	T033	C0853960
episode	T079	C0332189
heterologous	T032	C0301884
6B strain	T007	C1688613
cohort	T098	C0599755
volunteers	T098	C1708335
6BPS	T109	C0032595
specific	T080	C0205369
PspA	T116	C0071312
specific	T080	C0205369
PspC	T116	C2000489
specific	T080	C0205369
IgG	T116	C0020852
IgA	T116	C0020835
plasma	T025	C0032112
memory B-cell populations	T025	C0682638
before	T079	C0332152
after	T079	C0687676
experimental	T080	C1517586
pneumococcal	T007	C0038410
inoculation	T061	C2987620
Heterologous challenge	T039	C3658217
6B	T007	C1688613
carriage	T033	C0853960
volunteers	T098	C1708335
previous	T079	C0205156
natural	T169	C0205296
pneumococcal	T007	C0038410
carriage	T033	C0853960
Protection	T033	C1545588
carriage	T033	C0853960
associated with	T080	C0332281
high	T080	C0205250
circulating	T169	C0175630
6BPS	T109	C0032595
IgG	T116	C0020852
secreting	T043	C1327616
memory B cells	T025	C0682638
baseline	T081	C1442488
associations	T080	C0439849
protection	T033	C1545588
carriage	T033	C0853960
baseline	T081	C1442488
levels	T080	C0441889
6BPS	T109	C0032595
IgG	T116	C0020852
serum	T031	C0229671
nasal wash	T031	C0206289
PspA	T116	C0071312
specific	T080	C0205369
PspC	T116	C2000489
specific	T080	C0205369
memory B cells	T025	C0682638
plasma cells	T025	C0032112
volunteers	T098	C1708335
not develop	T033	C0243095
carriage	T033	C0853960
circulating	T169	C0175630
6BPS	T109	C0032595
memory B cells	T025	C0682638
decreased	T081	C0205216
6BPS	T109	C0032595
plasma cells	T025	C0032112
increased	T081	C0205217
postinoculation	T033	C0231291
naturally	T169	C0205296
acquired	T080	C0439661
PS	T109	C0032595
specific	T080	C0205369
memory B cells	T025	C0682638
not levels	T033	C0243095
circulating	T169	C0175630
IgG	T116	C0020852
pneumococcal	T007	C0038410
exposure	T080	C0332157
associated with	T080	C0332281
protection	T033	C1545588
against	T080	C0521124
carriage	T033	C0853960
acquisition	T052	C1706701
Hounsfield unit	T081	C1552985
recovery	T052	C0237820
clinical	T080	C0205210
cone beam CT	T060	C1956110
images	T078	C1551337
thorax	T029	C0817096
image guided radiation therapy	T061	C3179062
comprehensive	T080	C1880156
artefact	T068	C0085089
correction	T169	C1947976
method	T170	C0025663
clinical	T080	C0205210
cone beam CT	T060	C1956110
CBCT	T060	C1956110
images	T078	C1551337
image guided radiation therapy	T061	C3179062
IGRT	T061	C3179062
method	T170	C0025663
reduce	T080	C0392756
artefacts	T068	C0085089
recover	T052	C0237820
CT	T060	C0040405
Hounsfield units	T081	C1552985
HU	T081	C1552985
reconstructed	T066	C0020912
CBCT	T060	C1956110
images	T078	C1551337
lung cancer	T191	C0242379
patients	T101	C0030705
Projection image	T078	C1551337
artefact	T068	C0085089
corrections	T169	C1947976
image lag	T068	C0085089
detector scatter	T068	C0085089
body scatter	T068	C0085089
beam hardening	T033	C2828112
CBCT	T060	C1956110
images	T078	C1551337
lung cancer	T191	C0242379
patients	T101	C0030705
Image quality	T080	C0806487
evaluated	T058	C0220825
visual	T169	C0234621
appearance	T080	C0700364
reconstructed	T066	C0020912
images	T078	C1551337
HU	T081	C1552985
CT	T060	C0040405
images	T078	C1551337
total volume	T081	C0449468
HU	T081	C1552985
error	T080	C0743559
Artefacts	T068	C0085089
reduced	T080	C0392756
CT	T060	C0040405
HUs	T081	C1552985
recovered	T052	C0237820
artefact	T068	C0085089
corrected	T080	C0205202
CBCT	T060	C1956110
images	T078	C1551337
Visual inspection	T058	C3669138
confirms	T033	C0750484
artefacts	T068	C0085089
suppressed	T169	C1260953
method	T170	C0025663
HU	T081	C1552985
root mean square	T081	C2347976
difference	T081	C1705241
reconstructed	T066	C0020912
CBCTs	T060	C1956110
reference	T077	C1706462
CT	T060	C0040405
images	T078	C1551337
reduced	T080	C0392756
artefact	T068	C0085089
corrections	T169	C1947976
compared	T052	C1707455
standard	T080	C1442989
clinical	T080	C0205210
CBCT	T060	C1956110
reconstruction	T066	C0020912
artefact	T068	C0085089
correction	T169	C1947976
method	T170	C0025663
clinical	T080	C0205210
CBCT	T060	C1956110
images	T078	C1551337
IGRT	T061	C3179062
HU	T081	C1552985
values	T081	C1522609
recovered	T052	C0237820
corrected	T080	C0205202
CBCT	T060	C1956110
images	T078	C1551337
method	T170	C0025663
post processing	T170	C0449935
clinical	T080	C0205210
projection images	T078	C1551337
patient	T101	C0030705
specific	T080	C0205369
optimisation	T052	C2698650
tool	T170	C0037589
image	T078	C1551337
quality	T080	C0332306
improvement	T077	C2986411
large	T081	C0549177
numbers	T081	C0237753
CBCT	T060	C1956110
images	T078	C1551337
Risk Factors	T033	C0035648
Infection	T046	C3714514
Knee Arthroscopy	T060	C1304878
Analysis	T062	C0936012
Cases	T169	C0868928
United States	T083	C0041703
Databases	T170	C0242356
identify	T080	C0205396
quantify	T081	C1709793
patient-	T033	C0035648
procedure-related risk factors	T033	C0035648
post-arthroscopic	T079	C1254367
knee infections	T047	C1400580
dataset	T170	C0150098
administrative health care database	T170	C0242356
years	T079	C0439234
insurers	T092	C0021675
Medicare	T064	C0018717
random sample	T062	C0150105
knee arthroscopies	T060	C1304878
performed	T169	C0884358
patients	T101	C0030705
aged	T032	C0001779
years	T079	C0439234
Current Procedural Terminology (CPT) codes	T170	C1136322
CPT code	T170	C1136322
high-	T058	C1292781
low-complexity procedure	T058	C1292781
incisions	T061	C0184898
operative time	T079	C3494201
infections	T046	C3714514
CPT code	T170	C1136322
incision	T061	C0184898
drainage	T061	C0013103
days	T079	C0439228
surgery	T169	C0038895
Superficial infections	T046	C3714514
International Classification of Diseases, Ninth Revision infection codes	T170	C2346503
record	T170	C0034869
incision	T061	C0184898
drainage	T061	C0013103
Patients	T101	C0030705
age	T032	C0001779
sex	T032	C1522384
body mass index	T201	C1305855
tobacco use	T055	C0543414
presence	T080	C3854307
diabetes	T047	C0011847
Charlson Comorbidity Index	T081	C1516737
patients	T101	C0030705
arthroscopic knee procedures	T060	C1304878
postoperative infections	T046	C0392618
Superficial infections	T046	C3714514
Tobacco use	T055	C0543414
morbid obesity	T047	C0028756
risk factors	T033	C0035648
deep	T046	C3714514
superficial infections	T046	C3714514
relative risk	T081	C0242492
infection rates	T046	C3714514
patients	T101	C0030705
high-complexity arthroscopies	T060	C1304878
men	T098	C0025266
obese	T047	C0028754
patients	T101	C0030705
diabetic	T047	C0011847
patients	T101	C0030705
younger	T079	C0332239
patients	T101	C0030705
relative risk	T081	C0242492
Charlson Comorbidity Index	T081	C1516737
associated with	T080	C0332281
superficial	T046	C3714514
total infections	T046	C3714514
Post-arthroscopic	T079	C1254367
knee infections	T047	C1400580
morbidly obese	T047	C0028756
patients	T101	C0030705
tobacco users	T033	C3853727
patients	T101	C0030705
complex procedures	T058	C1292781
men	T098	C0025266
obese patients	T101	C0030705
diabetic patients	T101	C0030705
young patients	T101	C0030705
patients	T101	C0030705
comorbidity	T078	C0009488
population	T081	C0032659
preoperative counseling	T058	C0920638
aid surgeons	T097	C0582175
patient selection	T062	C0242802
infection prevention	T061	C0547605
individuals	T098	C0237401
inherent risk	T078	C0035647
cross-sectional study	T062	C0010362
Association	T080	C0439849
prenatal	T100	C0678804
exposure to	T080	C0332157
tetrachloroethylene	T109	C0039637
PCE	T109	C0039637
polycystic ovary syndrome	T047	C0032460
reproductive disorders	T047	C1659749
cape cod	T083	C0017446
health study	T062	C0008972
retrospective cohort study	T062	C0035363
Tetrachloroethylene	T109	C0039637
PCE	T109	C0039637
organic	T080	C0747055
lipophilic	T081	C0598631
solvent	T130	C0037638
neuroendocrine	T022	C0027912
toxicity	T080	C0040539
objective	T170	C0018017
study	T062	C2603343
association	T080	C0439849
prenatal	T100	C0678804
early childhood	T079	C0599196
exposure to	T080	C0332157
PCE	T109	C0039637
contaminated	T169	C0205279
drinking water	T167	C0599638
development	T039	C0243107
adult-onset	T033	C1853562
Polycystic Ovary Syndrome	T047	C0032460
PCOS	T047	C0032460
endometriosis	T047	C0014175
difficulty conceiving	T033	C0013418
miscarriage	T046	C0000786
exposed	T080	C0332157
unexposed	T098	C2349018
female	T032	C0086287
participants	T098	C0679646
completed	T080	C0205197
questionnaires	T170	C0034394
demographic	T078	C0011292
lifestyle	T054	C0023676
characteristics	T080	C1521970
reproductive disorders	T047	C1659749
Residential locations	T082	C0442506
prenatal	T100	C0678804
period	T079	C1948053
age	T032	C0001779
estimate	T081	C0750572
PCE	T109	C0039637
exposure	T080	C0332157
water modeling software	T073	C0037585
exposure to	T080	C0332157
PCE	T109	C0039637
adjusted risk ratio	T081	C0242492
PCOS	T047	C0032460
CI	T081	C0009667
statistically significan	T081	C0237881
associations	T080	C0439849
observed	T169	C1441672
increasing	T169	C0442808
levels	T080	C0441889
exposure	T080	C0332157
PCOS	T047	C0032460
reproductive disorders	T047	C1659749
associations	T080	C0439849
found	T033	C0150312
adult	T100	C0001675
women	T098	C0043210
exposure to	T080	C0332157
PCE	T109	C0039637
contaminated	T169	C0205279
drinking water	T167	C0599638
adult-onset	T033	C1853562
reproductive disorders	T047	C1659749
Host plant	T002	C0032098
sexual attractiveness	T001	C0029235
female	T032	C0086287
white-spotted longicorn beetle	T204	C0009276
Anoplophora malasiaca	T204	C1229576
Anoplophora malasiaca	T204	C1229576
Coleoptera	T204	C0009276
Cerambycidae	T204	C1005233
landscape	T082	C0870781
crop	T002	C0242775
trees	T002	C0040811
Japan	T083	C0022341
precopulatory	T080	C0205556
responses	T032	C0871261
A. malasiaca	T204	C1229576
populations	T098	C1257890
mandarin orange	T002	C0884217
willow	T002	C0995181
blueberry trees	T002	C0950036
males	T032	C0086582
host plant	T002	C0032098
population	T098	C1257890
females	T032	C0086287
willow	T002	C0995181
blueberry	T002	C0950036
populations	T081	C0032659
males	T032	C0086582
blueberry	T002	C0950036
willow	T002	C0995181
populations	T098	C1257890
females	T032	C0086287
mandarin orange	T002	C0884217
population	T081	C0032659
antennae	T023	C2936203
female	T032	C0086287
populations	T098	C1257890
sex pheromones	T123	C0036863
elytra	T023	C0229962
females	T032	C0086287
mandarin orange	T002	C0884217
population	T081	C0032659
chemicals	T103	C0220806
males	T032	C0086582
populations	T081	C0032659
β-Elemene	T109	C1101268
mandarin orange	T002	C0884217
females	T032	C0086287
rejection	T080	C1548437
response	T032	C0871261
willow	T002	C0995181
males	T032	C0086582
female	T032	C0086287
repellent	T131	C0544309
males	T032	C0086582
host plant	T002	C0032098
populations	T081	C0032659
host plant	T002	C0032098
female's	T032	C0086287
sexual attractiveness	T001	C0029235
Molecular	T080	C1521991
detection	T061	C1511790
infection	T046	C3714514
homogeneity	T080	C1881065
impact	T080	C4049986
miltefosine	T109	C0068006
treatment	T169	C1522326
Syrian golden hamster	T015	C0018561
Leishmania donovani	T204	C0023273
L. infantum	T204	C0023272
visceral leishmaniasis	T047	C0023290
Control	T169	C2587213
visceral leishmaniasis	T047	C0023290
Leishmania infantum	T204	C0023272
Leishmania donovani	T204	C0023273
chemotherapy	T061	C3665472
compromised	T033	C2945640
antileishmanial compounds	T121	C0304339
evaluation	T058	C0220825
novel	T080	C0205314
drugs	T121	C1254351
Syrian golden hamster	T015	C0018561
clinically	T080	C0205210
relevant	T080	C2347946
laboratory model	T170	C0086272
study	T062	C2603343
molecular parasite detection assays	T059	C1294355
targeting	T169	C1521840
cathepsin-like cysteine protease B	T116	C0699919
CPB	T116	C0699919
DNA	T114	C0012854
rRNA	T114	C0035701
absolute	T080	C0205344
amastigote	T204	C0686878
quantification	T081	C1709793
target	T169	C1521840
organs	T023	C0178784
liver	T023	C0023884
spleen	T023	C0037993
quantitative PCR	T063	C1709846
(qPCR) techniques	T063	C1709846
correlation	T080	C1707520
microscopic reading	T059	C0369671
Giemsa-stained	T059	C0523205
tissue	T024	C0040300
smears	T059	C1272593
multiple	T081	C0439064
single	T081	C0205171
tissue pieces	T024	C0040300
detection	T033	C0442726
methods	T170	C0025663
homogeneity	T080	C1881065
infection	T046	C3714514
liver	T023	C0023884
spleen	T023	C0037993
robustness	T080	C2986815
whole organ burdens	T081	C0005884
small	T081	C0700321
single	T081	C0205171
tissue piece	T024	C0040300
Comparison	T052	C1707455
pre	T079	C3539075
post-treatment	T079	C2709088
burdens	T078	C2828008
infected	T033	C0439663
hamsters	T015	C0018561
detection	T033	C0442726
methods	T170	C0025663
revealed	T080	C0443289
parasite	T204	C0030498
reduction	T080	C0392756
spleen	T023	C0037993
compared	T052	C1707455
liver	T023	C0023884
organ	T023	C0178784
dependent	T080	C0851827
clearance	T080	C0449297
efficacy	T080	C1280519
miltefosine	T109	C0068006
conclusion	T078	C1707478
study	T062	C2603343
hamster	T015	C0018561
high	T080	C0205250
homogeneity	T080	C1881065
infection	T046	C3714514
liver	T023	C0023884
spleen	T023	C0037993
molecular	T080	C1521991
detection	T061	C1511790
methods	T170	C0025663
assessment	T058	C0220825
low	T080	C0205251
post-treatment	T079	C2709088
tissue	T024	C0040300
burdens	T078	C2828008
Approximate	T080	C0332232
Bayesian computation	T081	C1553908
estimating	T081	C0750572
number concentrations	T081	C1446561
monodisperse	T080	C0205556
nanoparticles	T073	C1450054
suspension	T167	C1382107
optical microscopy	T059	C0026018
present	T078	C0449450
approximate	T080	C0332232
Bayesian computation	T081	C1553908
scheme	T170	C1519193
estimating	T081	C0750572
number concentrations	T081	C1446561
monodisperse	T080	C0205556
diffusing	T070	C0012222
nanoparticles	T073	C1450054
suspension	T167	C1382107
optical particle tracking microscopy	T059	C0026018
method	T169	C0449851
based	T078	C1705938
probability distribution	T081	C3826440
time	T079	C0040223
spent	T081	C0680968
particle	T104	C0597177
inside	T082	C0205102
detection	T061	C1511790
region	T082	C0205147
method	T169	C0449851
suspensions	T167	C1382107
well-controlled	T169	C3853142
reference	T077	C1706462
particles	T104	C0597177
usefulness	T080	C3827682
application	T169	C4048755
gene therapy	T061	C0017296
applying	T169	C4048755
method	T169	C0449851
estimate	T081	C0750572
number concentrations	T081	C1446561
plasmid	T114	C0032136
DNA molecules	T114	C0012854
average number	T081	C1510992
DNA molecules	T114	C0012854
complexed	T104	C1704241
liposomal	T109	C0023828
drug delivery	T074	C0085104
particles	T104	C0597177
Gestational age	T032	C0017504
stillbirth	T033	C0595939
risk	T078	C0035647
Indigenous	T102	C1512704
non	T169	C1518422
Indigenous	T102	C1512704
women	T098	C0043210
Queensland	T083	C0034391
Australia	T083	C0004340
population based study	T062	C1709599
Australia	T083	C0004340
stillbirth	T033	C0595939
rates	T081	C1521828
Aboriginal	T098	C0935542
Torres Strait Islander	T098	C1257890
Indigenous Australian	T098	C3826690
non	T169	C1518422
Indigenous	T102	C1512704
women	T098	C0043210
Diabetes	T047	C0011847
hypertension	T047	C0020538
antepartum haemorrhage	T046	C0269608
small-for-gestational age	T046	C0235991
SGA	T046	C0235991
identified	T080	C0205396
important	T080	C3898777
rates	T081	C1521828
Indigenous	T102	C1512704
women	T098	C0043210
study	T062	C2603343
gestational age	T032	C0017504
risk	T078	C0035647
stillbirth	T033	C0595939
associated with	T080	C0332281
conditions	T080	C0348080
Indigenous	T102	C1512704
non	T169	C1518422
Indigenous	T102	C1512704
women	T098	C0043210
Retrospective	T080	C1514923
population-based study	T062	C1709599
singleton	T099	C1313913
births	T081	C0005608
weeks	T079	C0439230
gestation	T040	C0032961
grams	T081	C0439208
birthweight	T032	C0005612
Queensland	T083	C0034391
July	T080	C3829447
December	T080	C3830550
data	T078	C1511726
Queensland	T083	C0034391
Perinatal	T079	C0178795
Data Collection	T062	C0010995
routinely-maintained database	T170	C0242356
data	T078	C1511726
births	T081	C0005608
Queensland	T083	C0034391
Multivariate logistic regression	T062	C0206031
adjusted odds ratios	T081	C0028873
aOR	T081	C0028873
confidence intervals	T081	C0009667
maternal	T033	C1858460
demographic	T078	C0011292
pregnancy factors	T033	C3533185
births	T081	C0005608
analysed	T062	C0936012
Indigenous	T102	C1512704
women	T098	C0043210
non	T169	C1518422
Indigenous	T102	C1512704
women	T098	C0043210
Stillbirth	T033	C0595939
rates	T081	C1521828
CI	T081	C0009667
CI	T081	C0009667
births	T081	C0005608
Indigenous	T102	C1512704
non	T169	C1518422
Indigenous	T102	C1512704
women	T098	C0043210
gestational	T079	C0439671
age groups	T100	C0027362
antepartum haemorrhage	T046	C0269608
SGA	T046	C0235991
pre-existing diabetes	T033	C2114054
pre-existing hypertension	T033	C2114056
associated with	T080	C0332281
increased	T081	C0205217
risk	T078	C0035647
stillbirth	T033	C0595939
pre-eclampsia	T046	C0032914
eclampsia	T047	C0013537
risk	T078	C0035647
stillbirth	T033	C0595939
gestational diabetes	T047	C0085207
study	T062	C2603343
gestational age	T032	C0017504
stillbirth	T033	C0595939
risk	T078	C0035647
Indigenous	T102	C1512704
non	T169	C1518422
Indigenous	T102	C1512704
women	T098	C0043210
risk	T078	C0035647
term gestations	T040	C0032961
appropriate	T080	C1548787
responsive	T169	C0205342
healthcare	T058	C0086388
stillbirth	T033	C0595939
risk	T078	C0035647
Indigenous	T102	C1512704
women	T098	C0043210
Defining	T058	C0509805
Describing	T170	C0678257
Categorizing	T052	C0871968
Public Health Infrastructure	T058	C0699943
Priorities	T079	C0439607
Tropical Cyclone	T070	C0337000
Flood	T070	C0016248
Storm	T070	C1254365
Tornado	T070	C0040476
Tsunami-Related Disasters	T070	C0027485
study	T062	C2603343
literature review	T170	C0282441
databases	T170	C0242356
define	T058	C0509805
describe	T170	C0678257
categorize	T052	C0871968
public health infrastructure	T058	C0699943
PHI	T058	C0699943
priorities	T079	C0439607
tropical cyclone	T070	C0337000
flood	T070	C0016248
storm	T070	C1254365
tornado	T070	C0040476
tsunami-related disasters	T070	C0027485
publication databases	T170	C0993637
define	T058	C0509805
describe	T170	C0678257
categorize	T052	C0871968
PHI	T058	C0699943
discuss	T054	C2584313
tropical cyclone	T070	C0337000
flood	T070	C0016248
storm	T070	C1254365
tornado	T070	C0040476
tsunami-related disasters	T070	C0027485
impact	T080	C4049986
PHI	T058	C0699943
data	T078	C1511726
aggregation	T169	C0332621
articles	T170	C1706852
data	T078	C1511726
grouped	T169	C1522242
PHI	T058	C0699943
themes	UnknownType	C0869035
prioritized	T079	C0439607
articles	T170	C1706852
PHI	T058	C0699943
categorized	T052	C0871968
themes	UnknownType	C0869035
descriptors	T170	C0282354
priority	T079	C0439607
PHI	T058	C0699943
workforce	T169	C0024752
water	T167	C0599638
sanitation	T090	C0036172
equipment	T073	C0014672
communication	T054	C0009452
physical structure	T073	C0556997
power	T073	C0032865
governance	T089	C0220842
prevention	T080	C2700409
supplies	T169	C1561604
service	T057	C0557854
transport	T073	C1317949
surveillance	T169	C0220920
review	T170	C0282443
workforce	T169	C0024752
thematic areas	UnknownType	C0869035
PHI	T058	C0699943
disasters	T070	C0027485
workforce	T169	C0024752
health services	T058	C0018747
post-disaster	T079	C1254367
PHI	T058	C0699943
PHI	T058	C0699943
priorities	T079	C0439607
disaster	T070	C0027485
Fragment	T116	C1335533
Discovery	T052	C1880355
5-Arylisatin	T109	C0022115
Inhibitors	T121	C1513016
Matrix Metalloproteinases 2	T116	C0172537
13	T116	C0255672
Matrix metalloproteinases	T116	C0623362
MMPs	T116	C0623362
pathologies	T046	C0699748
MMP-2	T116	C0172537
MMP-13	T116	C0255672
cancer progression	T046	C1947901
study	T062	C2603343
structure-based screening	T058	C1710032
metalloproteinase	T116	C0623362
fragments	T116	C1335533
computational model	T066	C0009609
fragment	T116	C1335533
set	T077	C1705195
EDASA Scientific compound library	T170	C0282574
fragments	T116	C1335533
biological assay	T059	C0005507
validate	T062	C1519941
model	T066	C0009609
scaffolds	T116	C1179132
activity	T052	C0441655
assay	T059	C0005507
isatin-based compounds	T109	C0022115
fragments	T116	C1335533
design	T052	C1707689
MMP inhibitors	T121	C1513016
micromolar activity	T052	C0441655
chemical synthesis	T070	C0007987
flexible	T080	C0443220
creative access	T082	C0444454
analogues	T104	C0002776
Incidence	T081	C0021149
environmental	T080	C0686732
genetic factors	T080	C0814299
congenital cataract	T019	C0009691
Children	T100	C0008059
Lahore	UnknownType	C0681784
incidence	T081	C0021149
environmental	T080	C0686732
genetic factors	T080	C0814299
congenital cataract	T019	C0009691
infants	T100	C0021270
descriptive study	T062	C0008972
Layton Rahmatullah Benevolent Trust	T093	C1708333
Lahore	UnknownType	C0681784
Pakistan	T083	C0030211
children	T100	C0008059
years	T079	C1510829
age	T032	C0001779
rubella syndrome	T047	C0748452
herpes simplex	T047	C0019348
birth trauma	T033	C2145877
trisomy 21	T049	C3537167
Nance-Horan syndrome	T047	C0796085
Lowe's syndrome	T047	C0028860
cases	T081	C0021149
patients	T101	C0030705
diagnosed	T033	C0011900
congenital cataract	T019	C0009691
aged	T032	C0001779
years	T079	C1510829
years	T079	C1510829
years	T079	C1510829
Bilateral congenital cataract	T047	C3277059
patients	T101	C0030705
unilateral congenital cataract	T047	C3640028
Environmental factors	T080	C0686732
cases	T081	C0021149
genetic factors	T080	C0814299
Congenital cataract	T019	C0009691
predominated	T080	C0332251
boys	T100	C0870221
girls	T100	C0870604
diagnosis	T033	C0011900
therapy	T061	C0087111
technology	T090	C0039421
long-term	T079	C0443252
permanent	T079	C0205355
care	T052	C1947933
Transcriptome	T086	C3178810
Metabolome	T070	C2350399
Analyses	T062	C0936012
Glucosinolates	T109	C0017767
Broccoli Cultivars	T002	C0330498
Jasmonate	T109	C1176128
Treatment	T169	C1522326
Induction	T169	C0205263
Glucosinolate	T109	C0017767
Defense	T077	C1880266
Trichoplusia ni	T204	C0998450
Hübner	T170	C0805191
Lepidopteran	T204	C0023338
larvae	T204	C0023047
growth	T040	C0018270
influenced	T077	C4054723
host	T001	C1167395
plant	T002	C0032098
glucosinolate	T109	C0017767
GS	T109	C0017767
concentrations	T081	C1446561
influenced	T077	C4054723
phytohormone	T116	C0032082
jasmonate	T109	C1176128
JA	T109	C1176128
insect	T204	C0021585
resistance	T169	C4281815
biomarkers	T045	C0017393
lepidopteran	T204	C0023338
pests	T008	C0869004
transcriptome	T086	C3178810
metabolome	T070	C2350399
analyses	T062	C0936012
JA	T109	C1176128
treatments	T169	C1522326
broccoli cultivars	T002	C0330498
Green Magic	T002	C0330498
VI-158	T002	C0330498
induced	T169	C0205263
indole GSs	T109	C0017767
neoglucobrassicin	T109	C2975109
glucobrassicin	T109	C0061370
test	T169	C0039593
inducible	T169	C0205263
GSs	T109	C0017767
growth	T040	C0018270
cabbage looper	T204	C0684063
Trichoplusia ni	T204	C0998450
cabbage looper larvae	T204	C0023047
plants	T002	C0032098
JA	T109	C1176128
treatments	T169	C1522326
days	T079	C0439228
treatment	T169	C1522326
days	T079	C0439228
feeding	T052	C2987508
weight	T081	C0043100
larvae	T204	C0023047
survival rate	T081	C0038954
decrease	T081	C0547047
increasing	T169	C0442805
JA	T109	C1176128
concentrations	T081	C1446561
broccoli cultivars	T002	C0330498
JA	T109	C1176128
inducible	T169	C0205263
GSs	T109	C0017767
measured	T080	C0444706
high performance liquid chromatography	T059	C0008562
Neoglucobrassicin	T109	C2975109
Green Magic	T002	C0330498
glucobrassicin	T109	C0061370
VI-158	T002	C0330498
leaves	T002	C0242724
increased	T081	C0205217
dose-dependent	T081	C1512045
glucosinolates	T109	C0017767
hydrolysis	T070	C0020291
products	T071	C1514468
inverse	T080	C0439850
correlations	T080	C1707520
larval	T204	C0023047
weight	T081	C0043100
survival	T052	C0038952
days	T079	C0439228
treatment	T169	C1522326
positively	T033	C1446409
correlated	T080	C1707520
days	T079	C0439228
pupation	T040	C1326578
JA	T109	C1176128
inducible	T169	C0205263
glucosinolates	T109	C0017767
influence	T077	C4054723
growth	T040	C0018270
survival	T052	C0038952
cabbage looper larvae	T204	C0023047
Transcriptome profiling	T059	C0752248
changes	T169	C0392747
glucosinolate	T109	C0017767
hydrolysis	T070	C0020291
product	T071	C1514468
concentrations	T081	C1446561
JA	T109	C1176128
treatments	T169	C1522326
genes	T028	C0017337
GS	T109	C0017767
metabolism	T040	C0025519
differentiate	T169	C2945687
broccoli cultivars	T002	C0330498
pattern	T082	C0449774
transcriptional	T045	C0040649
response	T032	C0871261
JA	T109	C1176128
treatments	T169	C1522326
change	T169	C0392747
indole GS	T109	C0017767
concentrations	T081	C1446561
transcripts	T114	C1519595
transcription factor	T116	C0040648
MYB122	T116	C0040648
biosynthesis	T169	C0005572
genes	T028	C0017337
CYP79B2	T028	C0017337
UGT74B1	T028	C0017337
SUR1	T028	C1412082
SOT16	T028	C0017337
SOT17	T028	C0017337
SOT18	T028	C0017337
indole glucosinolate	T104	C1254350
modification	T033	C3840684
gene	T028	C0017337
IGMT1	T028	C0017337
glucosinolate	T109	C0017767
hydrolysis	T070	C0020291
TGG1	T028	C0017337
TGG2	T028	C0017337
ESM1	T028	C1414460
increased	T081	C0205217
Green Magic	T002	C0330498
UGT74B1	T028	C0017337
MYB122	T028	C0017337
increased	T081	C0205217
VI-158	T002	C0330498
metabolite	T123	C0870883
transcript	T114	C1519595
biomarker	T045	C0017393
transcriptome profiling	T059	C0752248
identify	T080	C0205396
genes	T028	C0017337
formation	T169	C1522492
indole GS	T109	C0017767
hydrolysis	T070	C0020291
products	T071	C1514468
metabolite	T123	C0870883
transcript	T114	C1519595
biomarkers	T045	C0017393
effective	T080	C1704419
marker	T045	C0017393
assisted	T080	C1269765
breeding	T040	C0006159
resistance	T169	C4281815
lepidopteran	T204	C0023338
pests	T008	C0869004
broccoli	T002	C0330498
Brassica vegetables	T168	C0453113
clinical prognosis	T033	C1317293
implants	T074	C0021102
super-erupted	T047	C3839493
dentition	T023	C0011443
teeth	T023	C0040426
missing	T020	C0080233
super-eruption of teeth	T047	C3839493
opposing arch	T082	C1254362
area	T082	C0205146
occlusal plane	T042	C0524544
missing teeth	T020	C0080233
implants	T074	C0021102
oral surgeon	T097	C0260272
super-erupted teeth	T023	C0040426
treated	T169	C1522326
normalize	T062	C1882115
occlusal plane	T042	C0524544
study	T062	C0008972
evaluated	T058	C0220825
clinical prognosis	T033	C1317293
dentition	T023	C0011443
implant placement	T061	C0021107
prosthetic treatment	T061	C0204076
completed	T080	C0205197
occlusal plane	T042	C0524544
super-erupted teeth	T023	C0040426
opposing arch	T082	C1254362
treatment	T169	C1522326
super-erupted teeth	T023	C0040426
patients	T101	C0030705
males	T032	C0086582
females	T032	C0086287
treated	T169	C1522326
implants	T074	C0021102
prosthetics	T074	C0175649
super-erupted	T047	C3839493
dentition	T023	C0011443
Seoul	T083	C3850150
National University Bundang Hospital	T073	C0019994
implants	T074	C0021102
crestal bone loss	T047	C0002382
survival rates	T081	C0038954
surgical	T046	C0274311
prosthetic complications	T046	C0274320
months	T079	C0439231
prosthetic loading	T061	C0204076
case	T077	C1706256
cover screw	T074	C0021102
implant surgery	T061	C0543467
crestal bone loss	T047	C0002382
implants	T074	C0021102
survived	T067	C3179277
survival rate	T081	C0038954
prosthetic complication	T046	C0274320
case	T077	C1706256
clinical results	T034	C0456984
prosthetic complications	T046	C0274320
crestal bone loss	T047	C0002382
implant	T074	C0021102
survival rates	T081	C0038954
implants	T074	C0021102
super-erupted opposing tooth	T023	C0040426
Evaluation	T080	C0034375
Mathisen's technique	T169	C0449851
ureteral reimplantation	T061	C0401287
children	T100	C0008059
primary	T080	C0205225
vesicoureteral reflux	T047	C0042580
cross-trigonal ureteral reimplantation (Cohen)	T061	C0401296
technique	T169	C0449851
children	T100	C0008059
non-physiological transfer	T041	C0025361
ureteral orifices	T030	C0447577
endoscopic ureteral operations	T061	C0401343
later	T079	C0205087
life	T078	C0376558
described	T078	C1552738
alternative	T077	C1523987
method	T169	C0449851
ureteral reimplantation	T061	C0401287
lateralization	T169	C0542341
neohiatus	T082	C1254362
orthotopic	T082	C0574893
course	T079	C0750729
submucosal ureter	T023	C0227684
evaluated	T052	C1516048
success	T080	C0679864
complication	T078	C2362589
rates	T081	C1521828
techniques	T169	C0449851
applied	T169	C4048755
sequentially	T169	C1519249
departments	T092	C1704729
consecutive	T080	C1707491
patients	T101	C0030705
ureters	T098	C2348561
males	T098	C0025266
females	T098	C0043210
Mathisen reimplantation	T061	C0401287
compared	T052	C1707455
consecutive	T080	C1707491
patients	T101	C0030705
ureters	T098	C2348561
males	T098	C0025266
females	T098	C0043210
Cohen reimplantation	T061	C0401296
Inclusion	T080	C1512693
criteria	T078	C0243161
primary	T080	C0205225
vesicoureteral reflux	T047	C0042580
VUR	T047	C0042580
previous	T079	C0205156
intervention	T061	C0184661
Reflux	T047	C0042580
grades	T185	C1511980
ureters	T098	C2348561
VUR ≥ III	T033	C3274338
ureters	T098	C2348561
VUR ≥ III	T033	C3274338
complicating	T169	C1522701
factors	T169	C1521761
ureteroceles	T020	C0041960
megaureters	T190	C0521620
posterior urethral valves	T019	C0238506
groups	T078	C0441833
comparable	T052	C1707455
Cohen's reimplantation	T061	C0401296
immediate	T079	C0205253
complications	T046	C0009566
intervention	T061	C0184661
during	T079	C0347984
follow-up	T058	C1522577
mean	T081	C0444504
months	T079	C0439231
patients	T101	C0030705
suffered	T048	C0683278
febrile urinary tract infections	T047	C3875265
UTIs	T047	C3875265
diagnosed	T033	C0011900
persisting	T078	C0549178
VUR	T047	C0042580
Persistent	T078	C0549178
hydronephroses	T047	C0020295
SFU	T047	C0020295
patients	T101	C0030705
reimplantation	T061	C0401287
Mathisen's technique	T169	C0449851
patients	T101	C0030705
suffered	T048	C0683278
significant	T078	C0750502
intravesical bleeding	T047	C1390213
follow-up	T058	C1522577
mean	T081	C0444504
months	T079	C0439231
patients	T101	C0030705
suffered	T048	C0683278
febrile UTIs	T047	C3875265
patients	T101	C0030705
diagnosed	T033	C0011900
persisting	T078	C0549178
VUR	T047	C0042580
mean	T081	C0444504
follow-up	T058	C1522577
months	T079	C0439231
patients	T101	C0030705
persistent	T078	C0549178
VUR	T047	C0042580
high-grade	T080	C0205556
VUR	T047	C0042580
compared	T052	C1707455
whole group	T078	C0441833
patients	T101	C0030705
persistent	T078	C0549178
hydronephroses	T047	C0020295
SFU	T047	C0020295
Mathisen's technique	T169	C0449851
ureteral reimplantation	T061	C0401287
significantly	T078	C0750502
patients	T101	C0030705
ureterorenal units	T081	C1519795
lower	T082	C0441994
success	T080	C0679864
rate	T081	C1521828
patients	T101	C0030705
ureterorenal units	T081	C1519795
comparison	T052	C1707455
Cohen's technique	T169	C0449851
patients	T101	C0030705
ureterorenal units	T081	C1519795
intervention	T061	C0184661
obstruction	T046	C0028778
persistent	T078	C0549178
hydronephrosis	T047	C0020295
Cohen group	T078	C0441833
orthotopic	T082	C0574893
ureteral orifice	T030	C0447577
bladder neck	T023	C0227716
Mathisen's reimplantation	T061	C0401287
cross-trigonal ureteral reimplantation	T061	C0401296
reliable	T170	C3858758
VUR	T047	C0042580
correction	T169	C1947976
patient selection	T062	C0242802
technique	T169	C0449851
prove essential	T080	C0205224
difficulties	T080	C0332218
ectopic	T082	C0574895
ureteral orifices	T030	C0447577
Cohen technique	T169	C0449851
long-term	T079	C0443252
follow-up	T058	C1522577
concept	T078	C0178566
anatomic	T080	C0220784
orthotopic	T082	C0574893
ureteral reimplantation	T061	C0401287
technique	T169	C0449851
use of	T169	C1524063
neonatal	T079	C2939425
extracorporeal life support	T061	C0015357
pediatric	T080	C1521725
cardiac intensive care unit	T073	C0587446
evaluate	T058	C0220825
extracorporeal life support system	T061	C0015357
ECLS	T061	C0015357
neonates	T100	C0021289
pediatric	T080	C1521725
cardiac intensive care unit	T073	C0587446
neonates	T100	C0021289
ECLS	T061	C0015357
evaluated	T058	C0220825
median	T081	C0876920
age	T032	C0001779
days	T079	C0439228
range	T081	C1514721
days	T079	C0439228
median	T081	C0876920
body weight	T032	C0005910
range	T081	C1514721
Venoarterial	T082	C0450124
ECLS	T061	C0015357
performed	T169	C0884358
Ascendan aorta	T023	C0003956
right atrial	T023	C0225844
cannulation	T061	C0917707
patients	T101	C0030705
neck	T029	C0027530
cannulation	T061	C0917707
patients	T101	C0030705
performed	T169	C0884358
ECLS	T061	C0015357
E-CPR	T061	C0007203
patients	T101	C0030705
inability to wean	T033	C0243095
cardiopulmonary bypass	T061	C0007202
CPB	T061	C0007202
patients	T101	C0030705
respiratory insufficiency	T046	C0035229
hypoxia	T046	C0242184
patients	T101	C0030705
low cardiac output	T046	C0600177
LCOS	T046	C0600177
patients	T101	C0030705
Median	T081	C0876920
duration	T079	C0449238
ECLS	T061	C0015357
days	T079	C0439228
range	T081	C1514721
Hemorrhagic	T080	C0333275
complications	T046	C0009566
renal complications	T046	C1408259
pulmonary complications	T046	C0281169
infectious	T047	C0009450
complications	T046	C0009566
neurologic complications	T046	C0235029
mechanical complications	T046	C0009566
patients	T101	C0030705
Weaning	T033	C0043084
successful	T080	C1272703
patients	T101	C0030705
patients	T101	C0030705
successfully	T080	C1272703
discharged	T058	C0030685
ECLS	T061	C0015357
important	T080	C3898777
treatment option	T061	C0683525
performed	T169	C0884358
successfully	T080	C1272703
centers	T073	C0475309
world	T098	C2700280
maintain	T052	C0024501
life support	T061	C0521300
patients	T101	C0030705
unresponsive to medical treatment	T169	C0205269
utilization	T169	C0042153
modality	T078	C0695347
newborns	T100	C0021289
congenital heart disease	T019	C0152021
Medicare	T064	C0018717
claims	T170	C3242446
indicators	T169	C1522602
healthcare	T058	C0086388
utilization	T169	C0042153
differences	T080	C1705242
hospitalization	T058	C0019993
ischemic stroke	T047	C0948008
Race	T098	C0034510
gender	T032	C0079399
caregiving	T052	C1947933
effects	T080	C1280500
Background	T077	C1706907
Differences	T080	C1705242
healthcare	T058	C0086388
utilization	T169	C0042153
stroke	T047	C0948008
race	T098	C0034510
gender	T032	C0079399
differences	T080	C1705242
stroke	T047	C0948008
factors	T169	C1521761
reduce	T080	C0392756
post	T079	C0687676
acute stroke	T047	C0751956
care costs	T081	C0086600
systematic	T169	C0220922
differences	T080	C1705242
Medicare	T064	C0018717
claims	T170	C3242446
healthcare	T058	C0086388
utilization	T169	C0042153
hospitalization	T058	C0019993
ischemic stroke	T047	C0948008
US	T083	C0041703
population	T098	C1257890
sample	T096	C0681850
Claims	T170	C3242446
examined	T033	C0332128
six-month	T079	C0439231
period	T079	C1948053
hospitalization	T058	C0019993
ischemic stroke	T047	C0948008
survivors	T101	C0206194
years	T079	C0439234
older	T098	C0001792
REasons	T078	C0392360
Geographic	T078	C1171306
Racial Differences	T033	C0682075
Stroke	T047	C0948008
REGARDS	T047	C0948008
Statistical analyses	T062	C0871424
examined	T033	C0332128
differences	T080	C1705242
post	T079	C0687676
acute healthcare	T058	C0679878
utilization	T169	C0042153
pre	T079	C0332152
stroke	T047	C0948008
utilization	T169	C0042153
function	T169	C0542341
race	T098	C0034510
African-American	T098	C0085756
White	T098	C0007457
gender	T032	C0079399
age	T032	C0001779
stroke belt	UnknownType	C0681784
residence	T082	C0237096
income	T081	C0021162
Medicaid dual-eligibility	T064	C3494385
Charlson comorbidity index	T170	C3714916
person	T098	C0027361
lived	T052	C2982691
available	T169	C0470187
caregiver	T097	C0085537
women	T098	C0043210
men	T098	C0025266
receive	T080	C1514756
home health care	T058	C3845073
emergency department services	T058	C0374899
post	T079	C0687676
acute care	T058	C0679878
period	T079	C1948053
effects	T080	C1280500
maintained	T169	C1314677
further	T082	C1517331
adjustment	T169	C0456081
acute stroke	T047	C0751956
severity	T080	C0439793
African-Americans	T098	C0085756
home health care	T058	C3845073
visits	T058	C1512346
Whites	T098	C0007457
patients	T101	C0030705
received	T080	C1709850
home health care	T058	C3845073
co-residing	T052	C2982691
caregiver	T097	C0085537
associated with	T080	C0332281
reduced	T080	C0392756
acute hospitalization	T058	C0019993
length of stay	T079	C0023303
post	T079	C0687676
acute emergency department	T058	C0586082
primary care physician visits	T058	C3251682
Underutilization of healthcare	T055	C4042758
stroke	T047	C0948008
long-term	T079	C0443252
stroke	T047	C0948008
women	T098	C0043210
African-Americans	T098	C0085756
epidemiologically	T169	C0014508
sample	T096	C0681850
Caregiver	T097	C0085537
availability	T169	C0470187
contribute	T052	C1880177
reduced	T080	C0392756
formal care	T052	C1947933
cost	T081	C0010186
post	T079	C0687676
acute	T058	C0679878
period	T079	C1948053
dynamic global vegetation models	T170	C3161035
seasonality	T079	C0683922
carbon fluxes	T070	C2936196
Amazon basin	T083	C0017446
data	T078	C1511726
model	T170	C3161035
intercomparison	UnknownType	C0683958
forest	T070	C0086312
response	T032	C0871261
long-term	T079	C0443252
climate change	T070	C2718051
dynamic global vegetation models	T170	C3161035
DGVMs	T170	C3161035
ecosystem	T070	C0162358
response	T032	C0871261
short-term	T079	C0443303
variations	T079	C0036496
environmental drivers	T082	C0014406
seasonal patterns	T079	C0683922
dataset	T170	C0150098
forests	T070	C0086312
Brasil flux network	T170	C0242356
dry-season	T079	C0036497
intensities	T080	C0522510
lengths	T081	C1444754
models	T170	C3161035
IBIS	T170	C3161035
ED2	T170	C3161035
JULES	T170	C3161035
CLM3.5	T170	C3161035
seasonality	T079	C0683922
carbon exchanges	T070	C2936196
Amazonian	T083	C0017446
tropical forests	T070	C0086312
DGVMs	T170	C3161035
gross primary productivity	T081	C0033269
GPP	T081	C0033269
photosynthetic capacity	T081	C1516240
Pc	T081	C1516240
fluxes	T070	C2348693
Models	T170	C3161035
dry-season	T079	C0036497
declines	T081	C0547047
GPP	T081	C0033269
equatorial Amazon	T083	C0017446
Manaus K34	T083	C0017446
Santarem K67	T083	C0017446
Caxiuanã CAX	T083	C0017446
GPP	T081	C0033269
Model	T170	C3161035
dry-season	T079	C0036497
GPP	T081	C0033269
reductions	T080	C0392756
environmental	T082	C0014406
factor	T169	C1521761
soil water stress	T033	C0038435
photosynthetic infrastructure	T070	C0031764
Pc	T081	C1516240
dry-season	T079	C0036497
GPP	T081	C0033269
biological	T080	C0205460
leaf	T002	C0242724
abscission	T040	C1177284
Pc	T081	C1516240
environmental	T082	C0014406
radiation	T070	C0851346
models	T170	C3161035
net ecosystem exchange	T081	C0392762
NEE	T081	C0392762
respiration	T039	C0035203
Re	T039	C0035203
southern Amazon	T083	C0017446
forest	T070	C0086312
dry-season	T079	C0036497
declines	T081	C0547047
GPP	T081	C0033269
Re	T039	C0035203
DGVMs	T170	C3161035
simulations	T062	C0679083
models	T170	C3161035
photosynthesis	T070	C0031764
southern Amazonia	T083	C0017446
biophysical processes	T038	C1511162
light-harvesting	T044	C1158303
adaptations	T070	C0001398
leaf area index	T170	C0918012
LAI	T170	C0918012
leaf	T002	C0242724
assimilation	T038	C3714634
rate	T081	C1521828
leaf demography	T090	C0011298
leaf	T002	C0242724
wood	T002	C0032098
equatorial Amazon	T083	C0017446
carbon flux	T070	C2936196
model	T170	C3161035
flux	T070	C2348693
seasonality	T079	C0683922
tropical forests	T070	C0086312
biophysical mechanisms	T044	C1148560
model developments	T170	C0920595
Blood Pressure	T040	C0005823
All-Cause Mortality	T033	C0007465
Level	T080	C0441889
Cognitive Function	T041	C0392335
Elderly	T098	C0001792
Results	T033	C0683954
Population-Based Study	T062	C1709599
Rural Greece	T083	C0018226
study	T062	C1709599
aimed	T078	C1947946
investigate	T169	C1292732
effect	T080	C1280500
blood pressure	T040	C0005823
BP	T040	C0005823
mortality	T033	C1306577
levels	T080	C0441889
cognitive function	T041	C0392335
associations	T080	C0439849
brachial	T082	C0445456
systolic BP	T201	C0871470
diastolic BP	T201	C0428883
mean arterial pressure	T033	C0428886
MAP	T033	C0428886
pulse pressure	T040	C0949236
all-cause mortality	T033	C0007465
prospectively explored	T033	C0243095
follow-up	T058	C1522577
years	T079	C0439234
community-dwelling	T056	C4045975
individuals	T098	C0237401
≥60 years	T033	C4062292
adjusted Cox models	T081	C0010234
stratified	T080	C0205363
cognitive impairment	T048	C0338656
Mini-Mental State Examination	T060	C0451306
MMSE	T060	C0451306
No association	T080	C0205556
brachial	T082	C0445456
BP	T040	C0005823
variables	T080	C0439828
mortality	T033	C1306577
total	T080	C0439810
sample	T167	C0370003
quartiles analysis	T062	C0871424
MAP	T033	C0428886
highest quartile	T080	C2828255
compared	T052	C1707455
second	T081	C0205436
associated with	T080	C0332281
mortality	T033	C1306577
hazard ratio	T081	C2985465
confidence intervals	T081	C0009667
cognitively impaired	T048	C0338656
individuals	T098	C0237401
fractional-polynomials approach	T062	C0242481
BP	T040	C0005823
confirmed	T033	C0750484
finding	T033	C0243095
further	T082	C1517331
solely	T081	C0205171
MMSE	T060	C0451306
subcohort	T081	C0009247
U-shaped trends	T079	C0040833
MAP	T033	C0428886
systolic BP	T201	C0871470
increased	T081	C0205217
mortality risk	T078	C0035647
extremely	T080	C0205403
low or high values	T080	C0205556
pattern	T082	C0449774
evident	T078	C3887511
patients	T101	C0030705
MMSE	T060	C0451306
Elderly	T098	C0001792
individuals	T098	C0237401
cognitive impairment	T048	C0338656
more	T081	C0205172
susceptible	T169	C0231204
detrimental effects	T046	C0879626
low	T080	C0205251
elevated	T080	C3163633
MAP	T033	C0428886
systolic BP	T201	C0871470
Hypovitaminosis D	T047	C0042870
Cardiometabolic Risk	T078	C0035647
Women	T098	C0043210
PCOS	T047	C0032460
Women	T098	C0043210
Polycystic Ovary Syndrome	T047	C0032460
PCOS	T047	C0032460
metabolic disturbances	T047	C0746556
insulin resistance	T046	C0021655
hypertension	T047	C0020538
atherogenic dyslipidemia	T047	C0242339
Accumulating	T033	C4055506
Vitamin D deficiency	T047	C0042870
PCOS	T047	C0032460
associated with	T080	C0332281
metabolic	T047	C0025517
endocrinal dysfunctions	T047	C1397856
PCOS	T047	C0032460
women	T098	C0043210
PCOS	T047	C0032460
risk	T078	C0035647
cardiovascular disease	T047	C0007222
study	T062	C2603343
Vitamin D	T109	C0042866
metabolic	T047	C0025517
endocrinal dysregulations	T047	C1397856
women	T098	C0043210
PCOS	T047	C0032460
early identification	T061	C0814435
prevention	T061	C0679698
symptomatic	T169	C0231220
cardiac disease	T047	C0018799
women	T098	C0043210
PCOS	T047	C0032460
Rotterdam criteria	T170	C0679228
healthy control	T080	C2986479
PCOS	T047	C0032460
Vitamin D	T109	C0042866
cardiometabolic risk factors	T033	C0035648
fasting plasma glucose	T034	C1318375
insulin resistance	T046	C0021655
dyslipidemia	T047	C0242339
hs-CRP	T033	C0742906
endocrinal	T169	C0521425
parameters	T077	C0549193
hyperandrogenism	T047	C0206081
correlation studies	T062	C0010101
Vitamin D	T109	C0042866
cardiometabolic risk factor	T033	C0035648
PCOS	T047	C0032460
statistically analysed	T062	C0871424
SPSS software version 16	T073	C0037585
unpaired student's t-test	T170	C1710574
Pearson's correlation coefficient	T081	C0871052
Vitamin D	T109	C0042866
healthy controls	T080	C2986479
Hyperinsulinemia	T047	C0020459
insulin resistance	T046	C0021655
dyslipidemia	T047	C0242339
study	T062	C2603343
Vitamin D	T109	C0042866
insulin	T116	C0021641
Homeostatic Model of Assessment- Insulin Resistance Index	T059	C3639411
HOMA-IR	T059	C3639411
Hypovitaminosis D	T047	C0042870
PCOS	T047	C0032460
metabolic	T047	C0025517
hormonal disorders	T033	C3263685
PCOS	T047	C0032460
impaired fasting glucose	T033	C1272092
IR	T046	C0021655
dyslipidemia	T047	C0242339
Cardio vascular risks	T078	C0035647
PCOS	T047	C0032460
observational studies	T170	C3658316
randomized control trials	T062	C0206035
hypothesis	T078	C1512571
Family	T099	C0015576
close	T033	C1821461
friends	T098	C0079382
closer	T033	C1821461
social support	T054	C0037438
resilience	T055	C0683253
older	T098	C0001792
spousal	T099	C0162409
dementia	T048	C0497327
carers	T097	C1305660
Spousal	T099	C0162409
dementia	T048	C0497327
carers	T097	C1305660
support	T054	C0037438
needs	T080	C0027552
disengage	T080	C0205556
existing	T077	C2987476
social networks	T098	C0150775
time	T079	C0040223
caring	T055	C0150499
disease progresses	T046	C0242656
support	T054	C0037438
resources	T078	C0035201
resilience	T055	C0683253
carers	T097	C1305660
relationship	T080	C0439849
complex	T080	C0439855
relationship type	T169	C2826982
social support	T054	C0037438
resilience	T055	C0683253
availability	T169	C0470187
function	T169	C0542341
perceived functional aspects	T169	C0205245
support	T054	C0037438
older	T098	C0001792
spousal	T099	C0162409
dementia	T048	C0497327
carers	T097	C1305660
in-depth qualitative interviews	T052	C0021822
spousal	T099	C0162409
carers	T097	C1305660
carer	T097	C1305660
support groups	T095	C0036606
North West England	T083	C0014282
Family	T099	C0015576
friends	T098	C0079382
functions	T169	C0542341
resilient	T098	C0679646
non-resilient participants	T098	C0679646
Family support	T061	C0150232
perceived	T041	C0030971
created	T052	C1706214
feelings	T041	C1527305
over-dependence	T080	C0205556
Participants	T098	C0679646
resist involvement	T169	C1314939
grandchildren	T099	C0337548
narrow and low-level support functions	T054	C0037438
Friend	T098	C0079382
support	T054	C0037438
perceived	T041	C0030971
helpful	T080	C3898897
circumstances	T080	C0851364
Neighbours	T098	C1553702
crisis management	T061	C0262762
perceptions	T041	C0030971
moderate	T080	C0205081
effect	T080	C1280500
support	T054	C0037438
resilience	T055	C0683253
Family	T061	C0150232
friend	T098	C0079382
support	T054	C0037438
sufficient	T080	C0205410
resilience	T055	C0683253
Support functions	T054	C0037438
resilience	T055	C0683253
perceived	T041	C0030971
need	T080	C0027552
Implications	T033	C0243095
findings	T169	C2607943
Measure Up Pressure Down: Provider Toolkit	T058	C0205787
Improve	T077	C2986411
Hypertension	T047	C0020538
Control	T040	C1753303
Hypertension	T047	C0020538
risk factors	T033	C0035648
heart disease	T047	C0018799
stroke	T047	C0038454
kidney failure	T047	C0035078
diabetes complications	T047	C0342257
Americans	T098	C0596070
adults	T100	C0001675
high blood pressure	T047	C0020538
cost	T081	C0087112
associated with	T080	C0332281
treating	T061	C0087111
condition	T047	C0020538
Measure Up Pressure Down: Provider Toolkit	T058	C0205787
Improve	T077	C2986411
Hypertension	T047	C0020538
Control	T040	C1753303
resource	T078	C0018741
developed	T169	C1527148
American Medical Group Foundation	T093	C1708333
partnership	T092	C1711206
American Medical Group Association	T093	C1708333
goal	T170	C0018017
toolkit	T170	C1301746
health care practitioners	T097	C1709627
work	T057	C0043227
together	T080	C1883357
team	T096	C0871489
control	T040	C1753303
rate	T081	C1521828
high blood pressure	T047	C0020538
patient population	T101	C0030705
toolkit	T170	C1301746
health educators	T097	C1136362
clinic administrators	T097	C0019949
physicians	T097	C0031831
students	T098	C0038492
clinic staff	T097	C0851286
resource	T078	C0018741
developing	T169	C1527148
infrastructure	T062	C1512763
treat	T061	C0087111
individuals	T098	C0027361
high blood pressure	T047	C0020538
chronic conditions.	T047	C0008679
Potentiation	T061	C0279023
LPS	T109	C0023810
Induced	T046	C0007994
Apoptotic Cell Death	T043	C0162638
Human Hepatoma HepG2 Cells	T025	C2717940
Aspirin	T109	C0004057
ROS	T123	C0162772
Mitochondrial Dysfunction	T033	C4021734
Protection	T033	C1545588
N-Acetyl Cysteine	T116	C0001047
Cytotoxicity	T049	C0596402
inflammation	T046	C0021368
associated	T046	C0243082
toxic	T080	C1407029
responses	T032	C0871261
observed	T169	C1441672
induced	T169	C0205263
bacterial	T080	C0521009
lipopolysaccharides	T109	C0023810
LPS	T109	C0023810
in vitro	T080	C1533691
in vivo	T082	C1515655
nonsteroidal anti-inflammatory drugs	T121	C0003211
NSAIDs	T121	C0003211
aspirin	T109	C0004057
reported	T058	C0700287
inflammation	T046	C0021368
associated diseases	T046	C0243083
cancer	T191	C0006826
diabetes	T047	C0011847
cardiovascular disorders	T047	C0007222
molecular	T080	C1521991
mechanisms	T169	C0441712
studies	T062	C0008972
aspirin	T109	C0004057
treated	T061	C0332293
HepG2 cells	T025	C2717940
cell cycle arrest	T043	C1155873
induction	T169	C0205263
apoptosis	T043	C0162638
associated with	T080	C0332281
mitochondrial dysfunction	T033	C4021734
study	T062	C0008972
HepG2 cells	T025	C2717940
treated with	T061	C0332293
LPS	T109	C0023810
combination	T080	C0205195
aspirin	T109	C0004057
induces	T169	C0205263
subcellular	T026	C0729605
toxic responses	T043	C3549372
increase	T169	C0442805
reactive oxygen species	T123	C0162772
ROS	T123	C0162772
oxidative stress	T049	C0242606
mitochondrial respiratory dysfunction	T033	C4021734
apoptosis	T043	C0162638
LPS	T109	C0023810
Aspirin	T109	C0004057
induced	T169	C0205263
toxicity	T037	C0600688
attenuated	T052	C0599946
pre-treatment	T079	C2709094
cells	T025	C0007634
N-acetyl cysteine	T116	C0001047
NAC	T116	C0001047
oxidative stress	T049	C0242606
glutathione	T116	C0017817
dependent	T080	C0851827
redox-homeostasis	T043	C1156287
mitochondria	T026	C0026237
compared	T052	C1707455
extra	T082	C1254362
mitochondrial	T026	C0026237
cellular compartments	T026	C1166607
Pre-treatment	T079	C2709094
HepG2 cells	T025	C2717940
NAC	T116	C0001047
protection	T033	C1545588
redox homeostasis	T043	C1156287
mitochondrial dysfunction	T033	C4021734
results	T033	C0683954
altered	T169	C0392747
redox metabolism	T043	C1156287
oxidative stress	T049	C0242606
mitochondrial	T026	C0026237
function	T169	C0542341
HepG2 cells	T025	C2717940
LPS	T109	C0023810
aspirin	T109	C0004057
induced	T169	C0205263
cytotoxicity	T049	C0596402
results	T033	C0683954
pharmacological	T169	C0205464
toxicological	T169	C0205472
therapeutic properties	T169	C0039798
NSAIDs	T121	C0003211
cancer cells	T025	C0334227
exposed	T080	C0332157
bacterial endotoxins	T109	C0014264
Placental	T018	C0032043
Pathologic	T169	C0205469
Associations	T080	C0439849
Morbidly Adherent Placenta	T046	C0405107
Pathogenesis	T046	C0699748
pathology	T169	C0205469
morbidly adherent placenta	T046	C0405107
MAP	T046	C0405107
placental	T018	C0032043
pathology	T169	C0205469
implantation site	T082	C0230992
pathology	T169	C0205469
associated with	T080	C0332281
MAP	T046	C0405107
single	T081	C0205171
institution	T093	C2607850
retrospective case-control study	T062	C0035363
placentas	T018	C0032043
patients	T101	C0030705
delivered	T033	C0566687
MAP	T046	C0405107
cases	T077	C1706256
clinical	T080	C0205210
intervention	T058	C1273869
delivery	T061	C0011209
spontaneous	T169	C0205359
placental delivery	T061	C0404381
manual extraction	T061	C0391874
placenta	T018	C0032043
Controls	T096	C0009932
patients	T101	C0030705
placentas	T018	C0032043
examination	T058	C0582103
history	T033	C0032967
maternal	T099	C0026591
malignancy	T191	C0006826
no	T033	C1513916
clinical	T080	C0205210
suspicion	T078	C0750491
accreta	T046	C0032044
Placental	T018	C0032043
pathologic findings	T033	C1317598
maternal vascular underperfusion	T047	C0012634
MVU	T047	C0012634
acute inflammation	T033	C0333361
chronic inflammation	T046	C0021376
fetal	T018	C0015965
vascular obstruction	T047	C1096458
hemorrhage	T046	C0019080
bivariable and multivariable analyses	UnknownType	C0814907
categories	T170	C0683312
pathologic	T169	C0205469
changes	T169	C0392747
MAP	T046	C0405107
placentas	T018	C0032043
control	T096	C0009932
placentas	T018	C0032043
chronic basal inflammation	T046	C0021376
changes	T169	C0392747
MVU	T047	C0012634
retromembranous	T046	C0019080
intervillous hemorrhage	T046	C0269801
multivariable analyses	T081	C0026777
confounders	T169	C0009673
chronic basal villitis	T047	C1300128
aOR	T081	C0028873
plasma cell deciduitis	T033	C3899627
aOR	T081	C0028873
increased syncytial knots	T033	C3898771
aOR	T081	C0028873
aOR	T081	C0028873
increased perivillous fibrin	T033	C0243095
aOR	T081	C0028873
subchorionic	T046	C0087086
intervillous thrombi	T033	C3898711
aOR	T081	C0028873
associated with	T080	C0332281
MAP	T046	C0405107
MAP	T046	C0405107
associated with	T080	C0332281
intraparenchymal placental hemorrhage	T046	C0542014
villous	T080	C1519984
changes	T169	C0392747
MVU	T047	C0012634
lymphoplasmacytic infiltrate	T033	C1334467
implantation site	T082	C0230992
basal chronic inflammatory infiltrate	T033	C1333036
MAP	T046	C0405107
copper	T121	C0009968
responsive	T169	C0205342
self	T078	C0036588
cleaving	T082	C0205242
DNAzyme	T114	C0540193
immobilizing	T169	C0205245
Cu(2+)	T121	C0009968
responsive	T169	C0205342
self	T078	C0036588
cleaving	T082	C0205242
DNAzyme	T114	C0540193
PET	T109	C0032485
conical multinanochannels	T122	C0005479
control	T169	C2587213
ion transport	T043	C0162585
regulating	T038	C1327622
surface	T082	C0205148
charge	T032	C1706211
density	T081	C0178587
channels	T122	C0005479
High-Intensity Intermittent Training	T056	C4277545
Positively	T033	C1446409
Affects	T080	C1280500
Aerobic	T061	C0001701
Anaerobic Performance	T056	C3841233
Judo	T056	C0079650
Athletes	T097	C0238703
Exercise Mode	T056	C0015259
effects	T080	C1280500
high-intensity intermittent training	T056	C4277545
HIIT	T056	C4277545
lower	T023	C1268088
upper-body	T023	C1268087
graded exercise	T056	C0015259
high-intensity intermittent exercise	T056	C4277545
HIIE	T056	C4277545
performance	T052	C1882330
physiological	T169	C0205463
muscle damage	T020	C0410158
markers responses	T033	C0243095
judo	T056	C0079650
athletes	T097	C0238703
subjects	T098	C0080105
randomly allocated	T062	C0034656
control group	T096	C0009932
HIIT	T056	C4277545
groups	T078	C0441833
tested pre- and post	T170	C0032919
lower-body	T023	C1268088
cycle-ergometer	T061	C2107077
cycle-ergometer	T061	C2107077
uchi-komi	T169	C0449851
judo technique entrance	T169	C0449851
HIIT	T056	C4277545
upper-body	T023	C1268087
group	T078	C0441833
increase	T169	C0442805
maximal aerobic power	T201	C2371107
upper-body	T023	C1268087
exercise test	T033	C0429687
lower-body	T023	C1268088
group	T078	C0441833
increased	T169	C0442805
power	T201	C2371107
onset blood lactate	T109	C3824990
upper-body	T023	C1268087
exercise test	T033	C0429687
uchi-komi group	T078	C0441833
increased	T169	C0442805
upper	T023	C1268087
lower-body	T023	C1268088
lower-body	T023	C1268088
increased	T169	C0442805
lower-body	T023	C1268088
HIIE	T056	C4277545
decrease	T081	C0547047
delta blood lactate	T109	C3824990
uchi-komi training	T065	C0559197
group	T078	C0441833
upper-body	T023	C1268087
training	T065	C0220931
group	T078	C0441833
Training	T065	C0220931
testosterone-cortisol	T081	C4035023
ratio	T081	C0456603
increased	T169	C0442805
lower-body	T023	C1268088
HIIE	T056	C4277545
lower-body	T023	C1268088
uchi-komi (61.4%) training	T065	C0559197
groups	T078	C0441833
short-duration	T080	C0439593
HIIT	T056	C4277545
regular judo training	T065	C0220931
increase	T169	C0442805
upper-body	T023	C1268087
aerobic power	T201	C2371107
lower	T023	C1268088
upper-body	T023	C1268087
HIIE	T056	C4277545
performance	T052	C1882330
Microbiomes	T001	C1956108
Muricea californica	T204	C1093383
M. fruticosa	T204	C1011258
Comparative Analyses	T062	C0683941
Eastern Pacific	T083	C0030168
Octocorals	T204	C0997913
Octocorals	T204	C0997913
understudied	T062	C2603343
microbial	T001	C0599840
diversity	T080	C1880371
scleractinian	T204	C0997908
reef-building coral microbiomes	T001	C1956108
examined	T033	C0332128
threats	T078	C0749385
climate change	T070	C2718051
Muricea californica	T204	C1093383
Muricea fruticosa	T204	C1011258
co-occurring species	T185	C1705920
gorgonian octocoral	T204	C0997913
abundantly found	T033	C0150312
kelp	T204	C0036500
forests	T070	C0086312
southern California	T083	C0006754
excellent basis	T169	C1527178
octocoral	T204	C0997913
microbiomes	T001	C1956108
host	T001	C1167395
specific	T080	C0205369
Illumina MiSeq amplicon sequencing	T170	C2348563
replicate samples	T169	C1609629
microbiomes	T001	C1956108
multiple colonies	T081	C0439158
species	T185	C1705920
Muricea	T204	C1093383
measure	T081	C0079809
inter-	T025	C1947989
intra-colony	T025	C1947989
microbiome	T001	C1956108
variabilities	T077	C2827666
microbiomes	T001	C1956108
sea water	T167	C0036499
zoanthids	T204	C0684063
benthic invertebrate	T204	C0021948
analysis	T062	C0936012
bacterial taxa	T170	C0682467
associate with	T080	C0332281
octocorals	T204	C0997913
first report	T170	C0684224
microbiomes	T001	C1956108
species	T185	C1705920
Muricea	T204	C1093383
microbiomes	T001	C1956108
isolated	T169	C0205409
sample type	T080	C2347029
distinct	T080	C1705242
octocoral	T204	C0997913
species	T185	C1705920
type	T080	C0332307
predicting	T078	C0681842
composition	T201	C0486616
Muricea	T204	C1093383
microbiome	T001	C1956108
Bacterial taxa	T170	C0682467
compositional differences	T081	C1705241
distinct	T080	C1705242
strains	T001	C1518614
Mycoplasma	T007	C0026934
associated with	T080	C0332281
M. californica	T204	C1093383
M. fruticosa	T204	C1011258
abundance	T080	C2346714
Spirochaetes	T007	C1222582
observed	T169	C1441672
M. californica	T204	C1093383
greater	T081	C1704243
diversity	T080	C1880371
γ-Proteobacteria	T007	C0751988
associated with	T080	C0332281
M. fruticosa	T204	C1011258
bacterial taxa	T170	C0682467
differences	T081	C1705241
presence	T033	C0150312
photosymbiont-containing invertebrate	T204	C0021948
microbiomes	T001	C1956108
2,8-Dihydroxyadenine	T114	C0045643
Nephropathy	T047	C0022658
Cause	T169	C0015127
End-Stage Renal Disease	T047	C0022661
Renal Transplant	T061	C0022671
Adenine phosphoribosyltransferase	T116	C0001414
Adenine phosphoribosyltransferase deficiency	T047	C0268120
autosomal recessive disorder	T047	C3899988
uric acid	T109	C0041980
metabolism	T040	C0025519
formation	T169	C1522492
excretion	T039	C0221102
2,8-dihydroxyadenine	T114	C0045643
urine	T031	C0042036
solubility	T080	C0037628
2,8-dihydroxyadenine	T114	C0045643
precipitation	T070	C0032931
formation	T169	C1522492
urinary crystals	T034	C0151579
renal stones	T047	C0022650
Patients	T101	C0030705
disorder	T047	C0012634
recurrent nephrolithiasis	T047	C1737262
nephropathy secondary	T047	C4288763
crystal	T031	C1533132
precipitation	T070	C0032931
renal parenchyma	T023	C0227628
disease	T047	C0012634
underdiagnosed	T033	C0243095
recur	T067	C0034897
renal transplant	T061	C0022671
causing	T169	C0015127
graft failure	T046	C1262018
clinical	T080	C0205210
manifestations	T169	C0205319
chemical	T070	C0243178
radiologic features	T033	C1948139
uric acid	T109	C0041980
uric acid stones	T031	C0006736
lack of awareness	T033	C0589402
clinicians	T097	C0871685
causes	T169	C0015127
underdiagnoses	T033	C0243095
treatable	T169	C1522326
disease	T047	C0012634
Allopurinol	T109	C0002144
xanthine dehydrogenase	T116	C0043316
inhibitor	T121	C0014432
treatment	T169	C0039798
fluid intake	T201	C0429791
dietary modifications	T061	C0086153
adenine phosphoribosyl transferase	T116	C0001414
adenine phosphoribosyl transferase deficiency	T047	C0268120
urolithiasis	T047	C0451641
children	T100	C0008059
patients	T101	C0030705
recurrent urolithiasis	UnknownType	C0750009
patients	T101	C0030705
urolithiasis	T047	C0451641
associated with	T080	C0332281
renal failure	T047	C0035078
cause	T169	C0015127
patients	T101	C0030705
end-stage renal disease	T047	C0022661
renal transplant recipients	T101	C0376387
female patient	T032	C0150905
late diagnosis	T080	C2718037
2,8-dihydroxyadenine	T114	C0045643
nephropathy	T047	C0022658
end-stage renal disease	T047	C0022661
native	T169	C0302891
nephrectomy	T061	C0027695
renal transplant	T061	C0022671
prevented	T080	C1456501
recurrence	T046	C2825055
graft	T061	C0022671
Social capital	T169	C1510639
healthy	T080	C3898900
ageing	T040	C0001811
Indonesia	T083	C0021247
large	T081	C0549177
international	T078	C1512888
literature	T170	C0023866
positive	T033	C1446409
association	T080	C0439849
social capital	T169	C1510639
measures	T081	C0079809
physical	T033	C0517226
mental health	T041	C0025353
research	T062	C0035168
links	T080	C0439849
social capital	T169	C1510639
healthy	T080	C3898900
ageing	T040	C0001811
developing country	T080	C0011750
environment	T082	C0014406
universal social security coverage	T064	C0037435
absent	T169	C0332197
health infrastructure	T078	C0018684
poor	T080	C0542537
test	T169	C0039593
model	T170	C3161035
linkages	T185	C0332280
social capital	T169	C1510639
health outcomes	T170	C1550208
older adults	T098	C0001792
Indonesia	T083	C0021247
data	T078	C1511726
Indonesian Family Life Survey-East	T170	C0038951
IFLS-East	T170	C0038951
multivariate regression analysis	T170	C0034980
social capital	T169	C1510639
role	T077	C1705810
mitigating	T080	C0205556
poor health	T033	C0683321
older	T098	C0001792
individuals	T098	C0237401
aged	T032	C0001779
years	T079	C0439234
Indonesia	T083	C0021247
vulnerable provinces	T083	C1514578
test	T169	C0039593
robustness	T080	C2986815
social capital	T169	C1510639
variables	T080	C0439828
health	T078	C0018684
measures	T081	C0079809
self-assessed	T052	C1516048
health	T078	C0018684
Activities of Daily Living	T056	C0001288
ADL	T056	C0001288
measures	T081	C0079809
chronic illness	T047	C0008679
mental health	T041	C0025353
measures	T081	C0079809
demographic	T090	C0011298
groups	T078	C0441833
controlling	T169	C2587213
array	T082	C1510941
socio-economic	T080	C0086996
demographic	T090	C0011298
geographic	T082	C1517526
characteristics	T080	C1521970
findings	T033	C0243095
access	T082	C0444454
social capital	T169	C1510639
measures	T081	C0079809
neighbourhood	T098	C1553702
trust	T054	C0237935
community participation	T054	C0009476
associated with	T080	C0332281
higher	T080	C0205250
degree	T081	C0449286
physical mobility	T040	C0871081
independence	T078	C0085862
mental well-being	T041	C0025353
older	T098	C0001792
individuals	T098	C0237401
influence	T077	C4054723
chronic illnesses	T047	C0008679
results	T169	C1274040
consistent	T078	C0332290
estimate	T081	C0750572
samples	T096	C0681850
gender	T032	C0079399
rural	T033	C0240919
urban	T080	C2700386
residence	T082	C0237096
age	T032	C0001779
categories	T170	C0683312
policy	T170	C0242456
results	T169	C1274040
social capital	T169	C1510639
measures	T169	C1879489
moderating	T080	C1881878
influence	T077	C4054723
poor health	T033	C0683321
Activities of Daily Living	T056	C0001288
Modulation	T082	C0443264
Interleukins	T116	C0021764
Sepsis	T047	C0036690
Associated	T080	C0332281
Clotting Disorders	T047	C0005779
Hemostatic Derangement	T047	C0005779
Interleukins	T116	C0021764
central	T082	C0205099
role	T077	C1705810
immune system	T022	C0020962
involved	T169	C1314939
immunological	T047	C0021053
inflammatory	T047	C1290884
infectious disease	T047	C0009450
states	T169	C1442792
sepsis syndrome	T047	C0036690
Levels	T080	C0441889
interleukins	T116	C0021764
correlate	T080	C1707520
overall survival	T081	C4086681
directly	T080	C1947931
indirectly	T080	C0439852
affect	T041	C0001721
regulators	T121	C0005525
coagulation	T042	C0005778
fibrinolysis	T039	C0016017
hemostasis	T042	C0019116
thrombosis	T046	C0040053
hypothesis	T078	C1512571
sepsis-associated coagulopathies	T047	C0005779
SACs	T047	C0005779
interleukins	T116	C0021764
upregulated	T044	C0041904
hemostatic imbalance	T047	C0005779
thrombogenic mediators	T123	C0574031
profiled	T169	C2003903
levels	T080	C0441889
interleukins	T116	C0021764
IL-1α	T116	C0600251
IL-1β	T116	C0021753
IL-2	T116	C0021756
IL-4	T116	C0021758
IL-6	T116	C0021760
IL-8	T116	C0079633
IL-10	T116	C0085295
in addition to	T169	C0332287
d-dimer	T116	C0060323
DD	T116	C0060323
patients	T101	C0030705
SAC	T047	C0005779
normal	T080	C0205307
donors	T098	C0005795
observed	T169	C1441672
highest	T080	C1522410
increase	T169	C0442805
interleukins	T116	C0021764
IL-6	T116	C0021760
322-fold	T081	C1880833
IL-8	T116	C0079633
48-fold	T081	C1880833
IL-10	T116	C0085295
72-fold	T081	C1880833
DD	T116	C0060323
18-fold	T081	C1880833
suggests	T078	C1705535
interleukins	T116	C0021764
IL-6	T116	C0021760
IL-10	T116	C0085295
association with	T080	C0332281
coagulopathy	T047	C0005779
fibrinolytic dysregulation	UnknownType	C0543673
sepsis	T047	C0036690
considered	T078	C0750591
candidates	T116	C0021764
potential	T080	C3245505
therapeutic	T169	C0302350
targets	T169	C1521840
SAC	T047	C0005779
Thymosin β4	T116	C0076616
Development	T169	C1527148
Repair	T040	C0043240
Engineering	T169	C0205245
Cardiovascular System	T022	C0007226
cardiovascular disease	T047	C0007222
clinical trials	T062	C0008976
test	T169	C0039593
therapies	T061	C0087111
treating	T169	C1522326
heart	T023	C0018787
myocardial infarction	T047	C0027051
MI	T047	C0027051
heart failure	T047	C0018801
doctors	T097	C0031831
patients	T101	C0030705
repair the heart	T061	C0189919
ventricular contractility	T042	C1258017
systemic disease	T047	C0442893
vascular disorders	T047	C0042373
stroke	T047	C0038454
peptides	T116	C0030956
thymosin β4	T116	C0076616
Tβ4	T116	C0076616
cardiovascular	T029	C3887460
niche	T030	C0333343
fetal development	T042	C4246208
injuries	T037	C0018805
MI	T047	C0027051
neovasculogenesis	T191	C0027671
paracrine signals	T043	C0525011
endogenous	T169	C0205227
endogenous stem cell	T025	C4084729
wound repair	T040	C0043240
research	T062	C0035168
in vivo	T082	C1515655
administration	T061	C1533734
Tβ4	T116	C0076616
injections	T061	C1533685
coatings	T121	C0304222
implants	T074	C0021102
cell differentiation	T043	C0007589
Tβ4	T116	C0076616
administration	T061	C1533734
angiogenesis	T042	C0302600
wound healing	T040	C0043240
heart	T023	C0018787
MI	T047	C0027051
brain	T023	C0006104
stroke	T047	C0038454
adult stem cells	T025	C1171322
cardiac	T023	C0018787
lineage	T078	C0282637
implantation	T061	C0021107
heart	T023	C0018787
contractility	T042	C1258017
survival	T169	C0220921
clinical trials	T062	C0008976
in vivo	T082	C1515655
effect	T080	C1280500
therapies	T061	C0087111
human	T016	C0086418
patients	T101	C0030705
goal	T170	C0018017
people	T098	C0027361
cardiovascular disease	T047	C0007222
Yersinia ruckeri	T007	C1257868
Isolates	T123	C3494793
Recovered from	T080	C0521108
Diseased	T047	C0012634
Atlantic Salmon	T013	C0327949
Salmo salar	T013	C0327949
Scotland	T083	C0036453
Rainbow Trout	T013	C0036108
Oncorhynchus mykiss	T013	C0036108
Represent	T052	C1882932
Subpopulations	T098	C1257890
Yersinia ruckeri	T007	C1257868
etiological agent	T169	C1314792
enteric redmouth	T047	C0275759
ERM	T047	C0275759
disease	T047	C0012634
salmonids	T013	C0036129
Enteric redmouth disease	T047	C0275759
associated with	T080	C0332281
rainbow trout	T013	C0036108
Oncorhynchus mykiss	T013	C0036108
Walbaum	T013	C0036108
incidence	T081	C0021149
Atlantic salmon	T013	C0327949
Salmo salar	T013	C0327949
increasing	T169	C0442808
Yersinia ruckeri	T007	C1257868
isolates	T123	C3494793
recovered from	T080	C0521108
diseased	T047	C0012634
Atlantic salmon	T013	C0327949
poorly characterized	T052	C1880022
relationship	T080	C0439849
isolates	T123	C3494793
associated with	T080	C0332281
species	T185	C1705920
Phenotypic	T032	C0031437
Y. ruckeri	T007	C1257868
isolates	T123	C3494793
infected	T033	C0439663
Atlantic salmon	T013	C0327949
Scotland	T083	C0036453
isolates	T123	C3494793
infected	T033	C0439663
rainbow trout	T013	C0036108
characterized	T052	C1880022
Biotyping	T059	C0441707
serotyping	T059	C0036759
comparison	T052	C1707455
outer membrane	T026	C1167331
protein profiles	T034	C3463810
Y. ruckeri	T007	C1257868
clones	T024	C1522642
associated with	T080	C0332281
Atlantic salmon	T013	C0327949
associated with	T080	C0332281
rainbow trout	T013	C0036108
Atlantic salmon	T013	C0327949
clones	T024	C1522642
rainbow trout	T013	C0036108
findings	T033	C0243095
subpopulations	T098	C1257890
Y. ruckeri	T007	C1257868
associated with	T080	C0332281
species	T185	C1705920
O serotype	T170	C0449549
56 biotype 1	T170	C0449562
Atlantic salmon	T013	C0327949
isolates	T123	C3494793
serotype	T170	C0449943
increased prevalence	T081	C1512456
Rainbow trout	T013	C0036108
isolates	T123	C3494793
represented	T052	C1882932
biotype 2	T170	C0449562
serotype O1	T170	C0449549
ERM	T047	C0275759
species	T185	C1705920
United Kingdom	T083	C0041700
biotype 2	T170	C0449562
serotype O8	T170	C0449549
isolates	T123	C3494793
rainbow trout	T013	C0036108
vaccines	T121	C0042210
serotypes O1 and O8	T170	C0449549
rainbow trout	T013	C0036108
Atlantic salmon	T013	C0327949
Scotland	T083	C0036453
Vaccination	T061	C0042196
Atlantic salmon	T013	C0327949
bacterial	T007	C0004611
Yersinia ruckeri	T007	C1257868
increasing	T169	C0442808
incidence	T081	C0021149
vaccine	T121	C0042210
salmon	T013	C0036110
vaccines	T121	C0042210
rainbow trout	T013	C0036108
serotypes	T170	C0449943
species	T185	C1705920
serotypes	T170	C0449943
infection	T046	C3714514
Atlantic salmon	T013	C0327949
strains	T013	C0327949
relationships	T080	C0439849
recovered from	T080	C0521108
rainbow trout	T013	C0036108
Y. ruckeri	T007	C1257868
isolates	T123	C3494793
recovered from	T080	C0521108
diseased	T047	C0012634
Atlantic salmon	T013	C0327949
Scotland	T083	C0036453
rainbow trout	T013	C0036108
isolates	T123	C3494793
species	T185	C1705920
represent	T052	C1882932
subpopulations	T098	C1257890
O serotype	T170	C0449549
significant	T078	C0750502
proportion	T081	C1709707
disease	T047	C0012634
Atlantic salmon	T013	C0327949
findings	T033	C0243095
development of improved vaccines	T062	C0597634
Y. ruckeri	T007	C1257868
CD84	T116	C0666283
CLL	T191	C0023434
microenvironment	T070	C3494179
interactions	T043	C0007582
Chronic lymphocytic leukemia	T191	C0023434
CLL	T191	C0023434
malignant disease	T047	C0442867
mature lymphocytes	T025	C1513026
Signals	T067	C1710082
CLL	T191	C0023434
microenvironment	T070	C3494179
promote	T052	C0033414
progression of the disease	T046	C0242656
induce	T169	C0205263
drug resistance	T038	C0013203
phenomenon	T067	C1882365
dependent	T080	C0851827
malignant B cells	T191	C0079731
stromal cells	T025	C1518246
CD84	T116	C0666283
signaling lymphocyte activation molecule family	T116	C4277631
immunoreceptors	T116	C0597357
self-associates	T044	C1819957
orthogonal homophilic dimer	T104	C0596448
CD84	T116	C0666283
CLL	T191	C0023434
cells	T025	C0007634
microenvironment	T070	C3494179
promoting	T052	C0033414
cell survival	T043	C0007620
in vitro	T080	C1533691
results	T169	C1274040
CD84 expressed	T045	C1171362
CLL	T191	C0023434
cells	T025	C0007634
interact	T169	C1704675
CD84 expressed	T045	C1171362
cells	T025	C0007634
microenvironment	T070	C3494179
inducing	T169	C0205263
cell survival	T043	C0007620
Blocking	T169	C0332206
CD84	T116	C0666283
in vitro	T080	C1533691
in vivo	T082	C1515655
disrupt	T080	C0332454
interaction	T169	C1704675
CLL	T191	C0023434
cells	T025	C0007634
microenvironment	T070	C3494179
resulting in	T169	C0332294
induced	T169	C0205263
cell death	T043	C0007587
findings	T033	C0243095
novel	T080	C0205314
therapeutic	T169	C0302350
blockade	T121	C3540676
CD84	T116	C0666283
dependent	T080	C0851827
survival	T043	C0007620
pathway	T044	C1704259
Aurantimonas endophytica sp. nov.	T007	C1207105
endophytic bacterium	T004	C1265415
roots	T002	C0242726
Anabasis elatior (C. A. Mey.) Schischk	T002	C3012678
orange-coloured	T080	C1313858
aerobic	T080	C1510824
motile	T033	C1979933
short-rods bacterial strain	T007	C0004611
EGI 6500337T	T007	C0004611
root	T002	C0242726
halophyte	T002	C2350261
Anabasis elatior (C. A. Mey.) Schischk	T002	C3012678
Urumqi	T083	C0017446
Xinjiang province	T083	C0017446
north-west China	T083	C0008115
Growth	T040	C0018270
pH	T081	C0020283
pH	T081	C0020283
NaCl	T121	C0037494
Phylogenetic tree	T080	C1519069
16S rRNA	T114	C3537372
gene sequences	T086	C0162327
strain EGI 6500337T	T007	C0004611
genera Aurantimonas	T007	C1207105
Aureimonas	T007	C1894985
family Aurantimonadaceae	T007	C1494877
16S rRNA	T114	C3537372
gene sequence	T086	C0162327
strain EGI 6500337T	T007	C0004611
Aurantimonas coralicida DSM 14790T	T007	C1207106
Aurantimonas manganoxydans DSM 21871T	T007	C2783928
Strain EGI 6500337T	T007	C0004611
Q-10	T109	C0034435
isoprenoid quinone	T109	C0034435
fatty acids	T109	C0015684
C18:1 7c	T109	C2599892
C19:0 8c cyclo	T109	C0015684
lipid profile	T109	C0023779
strain EGI 6500337T	T007	C0004611
diphosphatidylglycerol	T109	C0023779
phosphatidylglycerol	T109	C0031619
phosphatidylcholine	T109	C1959616
phosphatidylethanolamine	T109	C0031618
genus Aurantimonas	T007	C1207105
DNA	T114	C0012854
G+C content	T081	C1135899
strain EGI 6500337T	T007	C0004611
DNA	T114	C0012854
DNA	T114	C0012854
strain EGI 6500337T	T007	C0004611
Aurantimonas coralicida DSM 14790T	T007	C1207106
phylogenetic analysis	T062	C1519068
chemotaxonomic data	T078	C1511726
phenotypic characteristics	T032	C0031437
strain EGI 6500337T	T007	C0004611
genus Aurantimonas	T007	C1207105
Aurantimonas endophytica sp. nov.	T007	C1207105
strain	T007	C0004611
EGI 6500337T	T007	C0004611
KCTC 52296T	T007	C0004611
CPCC 100904T	T007	C0004611
Assessment	T058	C0220825
classification	T185	C0008902
protocol deviations	T033	C1705236
Deviations	T033	C1705236
trial protocol	T170	C2599718
clinical trials	T062	C0008976
classified	T185	C0008902
deviations	T033	C1705236
violations	T062	C1709750
impact	T080	C4049986
trial	T062	C0008976
deviations	T033	C1705236
classified	T185	C0008902
grades from 1 to 5	T185	C0008902
deviation	T033	C1705236
Grade 1	T033	C0687695
no	T033	C1513916
impact	T080	C4049986
subjects'	T098	C2349001
well-being	T033	C0424578
quality of data	T080	C0242483
deviation	T033	C1705236
Grade 5	T185	C0441804
death	T033	C1306577
subject	T098	C2349001
classification	T185	C0008902
deviations	T033	C1705236
deviations	T033	C1705236
Grades 1 and 2	T185	C0008902
Grades 3 and 4	T185	C0008902
deviations	T033	C1705236
death of the subject	T033	C3897054
classification	T185	C0008902
trial	T062	C0008976
managers	T097	C0335141
occurrence	T079	C2745955
deviations	T033	C1705236
impact	T080	C4049986
Fabrication	T067	C1254366
modelling	T062	C0870071
fractal	T082	C0205148
biomimetic	T082	C0205148
micro	T082	C0205148
nano-topographical surfaces	T082	C0205148
Natural	T169	C0205296
surface topographies	UnknownType	C0459111
hierarchical features	T080	C2348519
micro	T077	C1254372
nanoscale	T077	C1254372
modern	T079	C1254367
tissue engineering	T061	C0596171
biomaterial	T122	C0005479
design	T052	C1707689
limitations	T169	C0449295
cell's microenvironment	T070	C3179020
human body	T016	C0242821
fractal topographical cues	T029	C0005898
cell	T025	C0007634
behaviour	T053	C0004927
recreating	T169	C0205245
biomimetic	T082	C0870781
fractal topographies	T082	C0870781
in vitro	T080	C1533691
trivial process	T067	C1522240
fabrication methods	T067	C1254366
fail	T169	C0231175
control	T080	C0243148
spatial resolution	T082	C1254362
features	T080	C2348519
different	T080	C1705242
lengths	T081	C1444754
scales	T074	C0183110
biomimetic properties	T080	C0871161
method	T170	C0025663
accurately	T080	C0443131
reproducing	T169	C0205245
micro	T082	C0870781
nanoscale topography	T082	C0870781
human	T016	C0086418
biological tissue	T024	C0457457
synthetic polymer	T109	C0440257
fabrication process	T067	C1254366
biological tissue	T024	C0457457
surface	T082	C0205148
characterised	T052	C1880022
atomic force microscopy	T059	C0242849
AFM	T059	C0242849
spatial	T082	C1254362
data	T078	C1511726
grayscale 'digital photomask'	T071	C2827989
maskless grayscale optical lithography	T057	C0599199
modified deep reactive ion etching	T067	C1254366
replica molding	T067	C1254366
accurately	T080	C0443131
fractal topography	T082	C0870781
acellular dermal matrix	T024	C3494272
ADM	T024	C3494272
polydimethylsiloxane	T109	C0137758
PDMS	T109	C0137758
Characterisation	T052	C1880022
AFM	T059	C0242849
different	T080	C1705242
length	T081	C1444754
scales	T074	C0183110
nano	T082	C0870781
micro-topographical	T082	C0870781
features	T080	C2348519
fractal dimension	T081	C0439534
native	T169	C0302891
ADM	T024	C3494272
reproduced	T169	C0205245
PDMS	T109	C0137758
fractal topography	T082	C0870781
biological surfaces	T082	C0205148
synthetic materials	T073	C0440251
novel	T080	C0205314
fabrication process	T067	C1254366
medical device	T074	C0025080
biocompatibility	T044	C0596177
performance	T052	C1882330
Investigating	T169	C1292732
Effects of	T080	C1704420
Acidic pH	T081	C0020283
Proliferation	T043	C0596290
Invasion	T046	C2699153
Drug	T121	C1254351
Induced	T169	C0205263
Apoptosis	T043	C0162638
Lymphoblastic Leukemia	T191	C0023448
extracellular	T030	C0015352
pH	T081	C0020283
tumors	T191	C0027651
tumor progression	T191	C0178874
normal	T080	C0205307
tissues	T024	C0040300
study	T062	C2603343
investigate	T169	C1292732
effects of	T080	C1704420
extracellular	T030	C0015352
acidic pH	T081	C0020283
proliferation	T043	C0596290
invasion	T046	C2699153
drug	T121	C1254351
induced	T169	C0205263
apoptosis	T043	C0162638
acute lymphoblastic cells	T025	C0883208
cells	T025	C0883208
different	T080	C1705242
pH	T081	C0020283
pH	T081	C0020283
pH	T081	C0020283
days	T079	C0439228
Cell proliferation	T043	C0596290
assessed	T052	C1516048
MTT assay	T062	C2986858
cell invasion	T046	C2699153
invasion assay	T059	C0022885
gene expression analysis	T063	C1880945
MMP-9	T116	C0165519
Drug	T121	C1254351
induced	T169	C0205263
apoptosis	T043	C0162638
exposure to	T080	C0332157
doxorubicin	T109	C0013089
annexin V	T116	C0059249
PI	T109	C0033470
staining	T059	C0487602
gene expression analysis	T063	C1880945
BAX pro-apoptotic protein	T116	C0219474
growth	T043	C0007595
invasion	T046	C2699153
leukemic	T191	C0023418
cells	T025	C0007634
pH	T081	C0020283
cells	T025	C0007634
pH	T081	C0020283
resistant	T169	C0332325
apoptosis	T043	C0162638
doxorubicin	T109	C0013089
acidic pH	T081	C0020283
increases	T169	C0442805
proliferation	T043	C0596290
invasion	T046	C2699153
reduces	T080	C0392756
drug	T121	C1254351
induced	T169	C0205263
apoptosis	T043	C0162638
acute lymphoblastic leukemia	T191	C0023449
Extracellular	T030	C0015352
acidity	T081	C0020283
leukemic	T191	C0023418
cells	T025	C0007634
manipulation	T169	C0205245
extracellular liquid	T031	C0015349
therapeutic strategy	T061	C0087111
leukemia	T191	C0023418
acute lymphoblastic leukemia	T191	C0023449
Gold	T121	C0018026
Nanosponge	T074	C0441126
Multistimuli-Responsive Drug Vehicles	T122	C0042444
Targeted	T169	C1521840
Chemo-Photothermal Therapy	T061	C0087111
Gold	T121	C0018026
nanosponge	T074	C0441126
multistimuli-responsive drug vehicles	T122	C0042444
chemo-photothermal therapy	T061	C0087111
drug	T121	C1254351
delivery	T169	C1705822
release	T169	C0391871
nonspecific	T078	C0750540
systemic	T169	C0205373
spread	T080	C0332261
drugs	T121	C0013227
enhancing	T052	C2349975
therapeutic efficiency	T080	C2348767
acute	T079	C0205178
side effects	T046	C0041755
Hemodynamic	T042	C0019010
transient cognitive impairment	T048	C0338656
transient ischemic attack	T047	C0007787
minor stroke	T047	C0038454
transcranial Doppler study	T060	C0554756
Transient cognitive impairment	T048	C0338656
TCI	T048	C0338656
Mini Mental State Evaluation	T060	C0451306
score	T081	C0449820
transient ischemic attack	T047	C0007787
minor stroke	T047	C0038454
identify	T080	C0205396
patients	T101	C0030705
risk	T078	C0035647
dementia	T048	C0497327
aimed	T078	C1947946
replicate	T080	C1883725
TCI	T048	C0338656
Montreal Cognitive Assessment	T170	C3496286
MoCA	T170	C3496286
compare	T052	C1707455
persistent Mild Cognitive Impairment	T048	C1270972
PMCI	T048	C1270972
global	T080	C2348867
cerebral	T023	C0228174
hemodynamic	T042	C0019010
changes	T169	C0392747
transient	T079	C0205374
impairment	T169	C0221099
patients	T101	C0030705
transient ischemic attack	T047	C0007787
minor stroke	T047	C0038454
assessed	T052	C1516048
MoCA	T170	C3496286
transcranial Doppler ultrasound	T060	C0206077
acutely	T079	C0205178
compared	T052	C1707455
patients	T101	C0030705
TCI	T048	C0338656
baseline	T081	C1442488
MoCA	T170	C3496286
points	T081	C1552961
increase	T169	C0442805
PMCI	T048	C1270972
MoCA	T170	C3496286
points	T081	C1552961
increase	T169	C0442805
no cognitive impairment	T033	C4230628
NCI	T033	C4230628
MoCA	T170	C3496286
patients	T101	C0030705
PMCI	T048	C1270972
TCI	T048	C0338656
NCI	T033	C4230628
baseline	T081	C1442488
TCI	T048	C0338656
patients	T101	C0030705
higher systolic blood pressure	T033	C0277884
lower	T080	C0205251
cerebral blood flow velocities	T081	C0005798
end-diastolic velocity	T081	C0439830
mean flow velocity	T033	C4287833
NCI	T033	C4230628
clinical	T080	C0205210
hemodynamic	T042	C0019010
profiles	T059	C1979963
PMCI	T048	C1270972
Systolic BP fell	T033	C0277885
baseline	T081	C1442488
mean	T081	C0444504
reduction	T061	C0441610
end-diastolic velocity	T081	C0439830
mean flow velocity	T033	C4287833
increased	T169	C0442805
mean	T081	C0444504
increase	T169	C0442805
changes	T169	C0392747
not differ	T033	C3842396
patients	T101	C0030705
TCI	T048	C0338656
PMCI	T048	C1270972
NCI	T033	C4230628
TCI	T048	C0338656
detectable	T201	C3830527
MoCA	T170	C3496286
transient ischemic attack	T047	C0007787
minor stroke	T047	C0038454
clinical	T080	C0205210
hemodynamic	T042	C0019010
profile	T059	C1979963
PMCI	T048	C1270972
TCI	T048	C0338656
not appear	T169	C0332197
exaggerated	T080	C0442801
acute	T079	C0205178
reversible	T169	C0205343
global	T080	C2348867
hemodynamic	T042	C0019010
changes	T169	C0392747
Apixaban	T109	C1831808
Twice	T081	C1948050
Daily	T079	C0332173
Clinical	T080	C0205210
Outcomes	T169	C1274040
Patients	T101	C0030705
Atrial Fibrillation	T047	C0004238
Advanced	T080	C0205179
Age	T032	C0001779
Low	T080	C0205251
Body Weight	T032	C0005910
High	T080	C0205250
Creatinine	T109	C0010294
Secondary Analysis	UnknownType	C0683944
Randomized Clinical Trial	T062	C0206034
Apixaban	T109	C1831808
Reduction	T080	C0392756
Stroke	T047	C0038454
Thromboembolic Complications	T046	C0040038
Atrial Fibrillation	T047	C0004238
ARISTOTLE	T062	C0008976
trial	T062	C0008976
dose	T081	C0178602
apixaban	T109	C1831808
twice	T081	C1948050
daily	T079	C0332173
patients	T101	C0030705
dose	T081	C0178602
reduction	T080	C0392756
years	T079	C0439234
weight	T032	C0005910
creatinine level	T033	C0428279
level	T080	C0441889
reduced	T080	C0392756
dose	T081	C0178602
apixaban	T109	C1831808
twice	T081	C1948050
daily	T079	C0332173
patients	T101	C0030705
dose	T081	C0178602
reduction	T080	C0392756
twice	T081	C1948050
daily	T079	C0332173
dose	T081	C0178602
apixaban	T109	C1831808
frequency	T079	C0439603
dose	T081	C0178602
reduction	T080	C0392756
effects of	T080	C1704420
twice	T081	C1948050
daily	T079	C0332173
dose	T081	C0178602
apixaban	T109	C1831808
stroke	T047	C0038454
systemic embolism	UnknownType	C0149876
bleeding	T046	C0019080
patients	T101	C0030705
dose	T081	C0178602
reduction	T080	C0392756
patients	T101	C0030705
ARISTOTLE trial	T062	C0008976
analysis	T062	C0936012
stroke	T047	C0038454
systemic embolism	UnknownType	C0149876
bleeding	T046	C0019080
hazard ratios	T081	C2985465
HRs	T081	C2985465
CIs	T081	C0009667
evaluated	T058	C0220825
Interactions	T169	C1704675
effects of	T080	C1704420
apixaban	T109	C1831808
warfarin	T109	C0043031
dose	T081	C0178602
reduction	T080	C0392756
assessed	T052	C1516048
patient	T101	C0030705
ARISTOTLE trial	T062	C0008976
follow-up	T058	C1522577
Data	T078	C1511726
Analysis	T062	C0936012
bleeding	T046	C0019080
study	T062	C2603343
drug treatment	T061	C0013216
Analysis	T062	C0936012
stroke	T047	C0038454
systemic embolism	UnknownType	C0149876
intention	T080	C1283828
treat	T169	C1522326
patients	T101	C0030705
dose	T081	C0178602
reduction	T080	C0392756
twice	T081	C1948050
daily	T079	C0332173
dose	T081	C0178602
apixaban	T109	C1831808
warfarin	T109	C0043031
dose	T081	C0178602
reduction	T080	C0392756
patients	T101	C0030705
stroke	T047	C0038454
systemic embolism	UnknownType	C0149876
HR	T081	C2985465
CI	T081	C0009667
bleeding	T046	C0019080
HR	T081	C2985465
CI	T081	C0009667
dose	T081	C0178602
reduction	T080	C0392756
benefit	T081	C0814225
twice	T081	C1948050
daily	T079	C0332173
dose	T081	C0178602
apixaban	T109	C1831808
warfarin	T109	C0043031
stroke	T047	C0038454
systemic embolism	UnknownType	C0149876
patients	T101	C0030705
dose	T081	C0178602
reduction	T080	C0392756
HR	T081	C2985465
CI	T081	C0009667
dose	T081	C0178602
reduction	T080	C0392756
HR	T081	C2985465
CI	T081	C0009667
benefit	T081	C0814225
twice	T081	C1948050
daily	T079	C0332173
dose	T081	C0178602
apixaban	T109	C1831808
warfarin	T109	C0043031
bleeding	T046	C0019080
patients	T101	C0030705
dose	T081	C0178602
reduction	T080	C0392756
HR	T081	C2985465
CI	T081	C0009667
dose	T081	C0178602
reduction	T080	C0392756
HR	T081	C2985465
CI	T081	C0009667
dose	T081	C0178602
reduction	T080	C0392756
age	T032	C0001779
body weight	T032	C0005910
creatinine level	T033	C0428279
level	T080	C0441889
creatinine	T109	C0010294
clearance	T201	C1382187
Patients	T101	C0030705
atrial fibrillation	T047	C0004238
age	T032	C0001779
body weight	T032	C0005910
renal dysfunction	T033	C3279454
risk	T078	C0035647
stroke	T047	C0038454
systemic embolism	UnknownType	C0149876
bleeding	T046	C0019080
benefits	T081	C0814225
twice	T081	C1948050
daily	T079	C0332173
dose	T081	C0178602
apixaban	T109	C1831808
warfarin	T109	C0043031
patients	T101	C0030705
twice	T081	C1948050
daily	T079	C0332173
dose	T081	C0178602
apixaban	T109	C1831808
patients	T101	C0030705
dose	T081	C0178602
reduction	T080	C0392756
Transition	T052	C2700061
Hospital	T073	C0019994
Home	T082	C0442519
Preterm Infants	T100	C4048294
Families	T099	C0015576
day	T079	C0439228
discharge	T058	C0030685
neonatal intensive care unit	T073	C0021709
NICU	T073	C0021709
parents	T099	C0030551
newborn infants	T100	C0021289
joy	T041	C0018592
happiness	T041	C0018592
home	T082	C0442519
feeling	T041	C1527305
parents	T099	C0030551
scheduled routines	T080	C0205547
hospital	T073	C0019994
monitor alarms	T033	C2091666
clinical rounds	T033	C1456356
numerous	T081	C0439064
tests	T059	C0022885
happens	T052	C1709305
little patients	T101	C0030705
families	T099	C0015576
leave	T052	C1706081
NICU	T073	C0021709
happens	T052	C1709305
leaving	T052	C1706081
hospital	T073	C0019994
life	T078	C0376558
perceived	T041	C0030971
normal	T080	C0205307
article	T170	C0282420
summary	T170	C1706244
research	T062	C0035168
vulnerable population	T098	C0949366
high-risk	T033	C0332167
preterm infants	T100	C4048294
families	T099	C0015576
postdischarge	T058	C0586003
evidence	T078	C3887511
transition	T052	C2700061
home	T082	C0442519
hospital discharge	T058	C0586003
phenomenon	T067	C1882365
families	T099	C0015576
experience	T041	C0596545
challenging	T080	C0205556
attention	T058	C1283164
clinicians	T097	C0871685
researchers	T097	C0687734
effective	T080	C1704419
efficient	T080	C0442799
high-quality care	T058	C0034379
Visual Analytics	T060	C0042825
Pattern Discovery	T041	C1518918
Home Care	T058	C0994454
Clinical Relevance	T080	C2347946
Quality Improvement	T057	C2936612
Visualization	T041	C0175631
cognitive load of information	T081	C0870301
interpret	T169	C1285553
assess large amounts of data	T058	C0184514
home health data	T170	C3878819
visual analysis techniques	T060	C3536884
clinically salient	T080	C0449440
associations	T078	C0750490
patient characteristics	T201	C0815172
problem-oriented health outcomes	T170	C1550208
older adult home health patients	T058	C1443513
home health service	T058	C0184605
Knowledge	T170	C0376554
Behavior	T053	C0004927
Status ratings	T081	C0681889
discharge	T058	C0030685
admission	T058	C0030673
discharge	T058	C0030685
Omaha System	T170	C1140113
dataset	T170	C0150098
patient data	T170	C2707520
home health agencies	T093	C0019859
SPSS Visualization Designer v1.0	T170	C0037589
visually analyze patterns	T060	C0042825
heat maps	T078	C1609081
histograms	T073	C2348974
Visualizations	T041	C0175631
clinical salience	T033	C2826293
tested	T169	C0039593
correlation analysis	T062	C0010101
patients	T101	C0030705
female	T032	C0086287
visualizations	T041	C0175631
meaningful patterns	T078	C1609081
bivariate associations	UnknownType	C0681927
associations	T078	C0750490
associations	T078	C0750490
Charlson co-morbidity index	T170	C3714916
urinary	T080	C1524119
diagnoses and problems	T047	C0338067
visual analysis	T060	C0042825
association	T078	C0750490
home health episode	T058	C0085554
Charlson co-morbidity index	T170	C3714916
behavior or status outcomes	T033	C0243095
patients	T101	C0030705
impaired urinary function	T047	C0871563
visual analysis	T060	C0042825
subgroups	T185	C1515021
older home health patient population	T081	C2361270
data patterns	T078	C1609081
clinicians	T097	C0871685
patient improvement	T057	C3858649
home health interventions	T058	C1553498
patient outcomes	T058	C0030698
Transforming Growth Factor Beta 1	T116	C1704256
TGF-β1	T116	C1704256
Thyroid Cancer	T191	C0007115
Patients	T101	C0030705
Peripheral Blood	T031	C0229664
Transforming growth factor beta	T116	C0040690
TGF-β	T116	C0040690
pathophysiological	T169	C0031847
conditions	T080	C0348080
cancer	T191	C0006826
level	T080	C0441889
TGF-β	T116	C0040690
patients	T101	C0030705
differentiated thyroid cancer	T191	C1337013
DTC	T191	C1337013
examined	T033	C0332128
study	T062	C2603343
TGF-β	T116	C0040690
concentration	T081	C1446561
serum samples	T031	C1550100
PHA	T116	C0031858
stimulated	T044	C0038337
whole blood	T031	C0370231
culture	T059	C0200949
in vitro	T080	C1533691
analyze	T062	C0936012
TGF-β1	T116	C1704256
levels	T080	C0441889
leukocyte	T025	C0023516
lymphocyte	T025	C0024264
platelets	T025	C0005821
counts	T059	C0007584
histological	T169	C0205462
thyroid cancer	T191	C0007115
stage of disease	T060	C0699749
TGF-β1	T116	C1704256
DTC	T191	C1337013
patients	T101	C0030705
healthy	T080	C3898900
controls	T096	C0009932
duoSet ELISA Development kit	T074	C0812225
human TGF-β1	T116	C0080222
concentration	T081	C1446561
TGF-β1	T116	C1704256
serum samples	T031	C1550100
groups	T098	C1257890
platelet	T025	C0005821
counts	T059	C0007584
statistically significant	T081	C0237881
serum concentrations	T081	C0683149
TGF-β1	T116	C1704256
DTC	T191	C1337013
patients	T101	C0030705
control subjects	T096	C0009932
PHA	T116	C0031858
stimulated	T044	C0038337
whole blood	T031	C0370231
cultures	T059	C0200949
DTC	T191	C1337013
patients	T101	C0030705
TGF-β1	T116	C1704256
controls	T096	C0009932
studies	T062	C2603343
significance	T078	C0750502
in vitro	T080	C1533691
findings	T033	C0243095
P-glycoprotein	T116	C0242643
traffics	T169	C0205245
nucleus	T026	C0007610
plasma membrane	T026	C0007603
rat brain	T023	C1882598
endothelium	T024	C0014257
inflammatory pain	T184	C0234251
P-glycoprotein	T116	C0242643
PgP	T116	C0242643
drug	T121	C1254351
efflux pump	T024	C3824504
blood-brain barrier	T023	C0005854
endothelial cells	T025	C0225336
clinical	T080	C0205210
obstacle	T080	C0679881
central nervous system	T022	C3714787
drug delivery	T061	C0087111
Identifying	T058	C1254363
PgP	T116	C0242643
regulatory pathways	T169	C1514829
central nervous system	T022	C3714787
drug delivery	T061	C0087111
PgP activity	T044	C1753353
increases	T169	C0442805
rat brain	T023	C1882598
microvessels	T023	C2350570
concomitant	T079	C0521115
decreased	T081	C0205216
central nervous system	T022	C3714787
drug delivery	T061	C0087111
acute	T079	C0205178
peripheral	T082	C0205100
inflammatory pain	T184	C0234251
PgP	T116	C0242643
traffics	T169	C0205245
luminal	T082	C0524462
plasma membrane	T026	C0007603
microvessel	T023	C2350570
endothelial cells	T025	C0225336
intracellular	T082	C0178719
stores	T169	C1698986
peripheral	T082	C0205100
inflammatory pain	T184	C0234251
immunofluorescence microscopy	T059	C0079604
detected	T033	C0442726
PgP	T116	C0242643
endothelial cell	T025	C0225336
nuclei	T026	C0007610
luminal	T082	C0524462
plasma membrane	T026	C0007603
control animals	T008	C1511501
peripheral	T082	C0205100
inflammatory pain	T184	C0234251
luminal	T082	C0524462
PgP	T116	C0242643
staining	T059	C0487602
increased	T081	C0205217
staining	T059	C0487602
nucleus	T026	C0007610
decreased	T081	C0205216
Biochemical analysis	T059	C3495389
nuclear	T026	C0007610
PgP	T116	C0242643
content	T077	C0456205
visual observations	T169	C0199219
Peripheral	T082	C0205100
inflammatory pain	T184	C0234251
increased	T081	C0205217
endothelial cell	T025	C0225336
luminal	T082	C0524462
staining	T059	C0487602
polymerase 1 and transcript release factor	T028	C1419128
cavin1	T028	C1419128
serum deprivation response protein	T028	C1419916
cavin2	T028	C1419916
caveolar scaffold proteins	T116	C0033684
caveolin1	T116	C0033684
protein kinase C delta binding protein	T028	C1418917
cavin3	T028	C1418917
location	T082	C0450429
data	T078	C1511726
PgP	T116	C0242643
traffics	T169	C0205245
stores	T169	C1698986
nucleus	T026	C0007610
endothelial cell	T025	C0225336
luminal membrane	T026	C0597895
peripheral	T082	C0205100
inflammatory pain	T184	C0234251
observation	T062	C0302523
peripheral	T082	C0205100
inflammatory pain	T184	C0234251
inhibits	T052	C3463820
central nervous system	T022	C3714787
drug	T121	C1254351
uptake	T039	C0243144
novel	T080	C0205314
regulatory mechanism	T033	C0243095
PgP activity	T044	C1753353
rat brain	T023	C1882598
Functional	T169	C0205245
Impairment	T169	C0221099
Children	T100	C0008059
Externalizing Behavior Disorders	T048	C0004930
Psychometric	T060	C0033920
Properties	T080	C0871161
Weiss Functional Impairment Rating Scale-Parent Report	T170	C0282574
German	T083	C0017480
Clinical Sample	T167	C0370003
psychometric	T060	C0033920
properties	T080	C0871161
German	T083	C0017480
Weiss Functional Impairment Rating Scale-Parent Report	T170	C0282574
WFIRS-P	T170	C0282574
clinical sample	T167	C0370003
children	T100	C0008059
years	T079	C0439234
externalizing behavior disorders	T048	C0004930
Data	T078	C1511726
collected	T169	C1516698
clinical trials	T062	C0008976
Factorial validity	T080	C0871742
reliability	T081	C2347947
divergent validity	T081	C0392762
symptoms	T184	C1457887
ADHD	T048	C1263846
oppositional defiant disorder	T048	C0029121
ODD	T048	C0029121
assessed	T052	C1516048
Confirmatory factor analyses	T080	C0870334
revealed	T080	C0443289
bifactor model	T170	C3161035
consistent with	T078	C0332290
theoretical assumption	T078	C0871935
general construct	T185	C2827421
impairment	T169	C0221099
additional	T169	C1524062
specific factors	T169	C1521761
satisfactory	T080	C0205410
data fit	T078	C1511726
Model	T170	C3161035
reliability	T081	C2347947
estimates	T081	C0750572
general construct	T185	C2827421
specific factors	T169	C1521761
variance	T080	C1711260
consistencies	T080	C0332529
correlations	T080	C1707520
Correlations	T080	C1707520
WFIRS-P Scales	T170	C0282574
ADHD	T048	C1263846
ODD	T048	C0029121
symptoms	T184	C1457887
low	T080	C0205251
moderate	T080	C0205081
results	T169	C1274040
factorial validity	T080	C0871742
reliability	T081	C2347947
divergent validity	T081	C0392762
WFIRS-P	T170	C0282574
Canadians	T098	C1257890
Americans	T098	C0596070
learn	T041	C0023185
health care systems	T093	C0018696
papers	T170	C0282420
comparing	T052	C1707455
Canadian	T098	C1257890
US	T083	C0041703
healthcare systems	T093	C0018696
health policy	T089	C0018735
experts	T097	C0009817
recommended	T078	C0034866
Americans	T098	C0596070
implement	T052	C1708476
single-payer system	T058	C0282487
healthcare expenditures	T081	C0015318
paper	T170	C0282420
country	T083	C0454664
significant	T078	C0750502
philosophic	T080	C2986477
structural	T082	C0678594
change	T169	C0392747
healthcare system	T093	C0018696
learned	T041	C0023185
breakthrough	T080	C0444503
model	T083	C0006823
Canada	T083	C0006823
Western Europe	T083	C0043129
USA	T083	C0041703
implement	T052	C1708476
universal	T080	C0175671
health insurance	T058	C0021682
Americans	T098	C0596070
uninsured	T098	C0087134
minimal	T080	C0547040
coverage	T078	C1551362
medical expenditures	T081	C0015318
USA	T083	C0041703
smart cards	T073	C1519382
evaluate eligibility	T058	C0013893
process	T067	C1522240
health insurance claims	T058	C3824919
resulting in	T169	C0332294
estimated	T081	C0750572
reduction	T080	C0392756
US	T083	C0041703
health expenditures	T081	C0015318
effecting	T080	C1280500
access	T080	C0018748
quality of care	T058	C0034379
result	T169	C1274040
loss	T081	C1517945
white-collar jobs	T090	C0028811
hospitals	T073	C0019994
physician offices	T073	C0031834
insurance companies	T078	C1549448
long-term	T079	C0443252
economic	T169	C0013557
gain	T081	C1517378
Canada	T083	C0006823
functions	T169	C0542341
multi-payer	T092	C2348942
reimbursement system	T170	C0035002
federal	T092	C0015737
provincial	T083	C1514578
tax	T081	C0039371
supported	T077	C1521721
plan	T058	C0679909
provinces	T083	C1514578
universal coverage	T078	C0376640
hospital	T073	C0019994
physician services	T058	C0587569
residents	T098	C2347958
employer-paid	T081	C3824871
health insurance	T058	C0021682
benefits	T081	C0814225
effective	T080	C1280519
reimburse	T080	C0205432
pharmaceuticals	T058	C0031321
dental	T058	C0011365
healthcare services	T058	C0018747
USA	T083	C0041703
Western European countries	T083	C0043129
implementing	T052	C1708476
upper-income	T080	C0871944
Canadians	T098	C1257890
federal	T092	C0015737
provincial	T083	C1514578
plan	T058	C0679909
private	T092	C0679727
insurance coverage	T078	C0376629
hospital	T073	C0019994
physician	T058	C0587569
pharmaceutical	T058	C0031321
dental	T058	C0011365
healthcare services	T058	C0018747
revenues	T081	C0681042
private sector	T098	C0033176
eliminate	T052	C1883720
specialists	T097	C1611835
medical staffs	T097	C0025106
prompt	T169	C0871157
admissions	T058	C0184666
elective cases	T033	C0745036
private	T073	C0033173
wings of hospitals	T073	C0019994
increase	T081	C0205217
funding	T081	C0243098
currently	T079	C0521116
undercapitalized	T033	C0243095
system	T169	C0449913
enhance	T052	C2349975
sluggish	T033	C3842079
operations	T052	C3241922
competition	T057	C0013550
two-tier approach	T170	C0025663
USA	T083	C0041703
Canada	T083	C0006823
private insurance	T064	C3845555
legal	T169	C1301860
recommended	T078	C0034866
western European countries	T083	C0043129
percentagea	T081	C0439165
Canada	T083	C0006823
public	T092	C0678367
funding	T081	C0243098
health expenditures	T081	C0015318
attempts	T051	C1516084
implement	T052	C1708476
result	T169	C1274040
political	T057	C0032379
rancor	T041	C0542301
Canadians	T098	C1257890
effective	T080	C1280519
efficient	T080	C0442799
delivery of care	T058	C0011211
long-term	T079	C0443252
fiscal	T064	C0681005
agree	T033	C3641827
privatization	T064	C0033180
healthcare system	T093	C0018696
Americans	T098	C0596070
smart card	T073	C1519382
insurance eligibility	UnknownType	C0680867
controls	T169	C2587213
pharmaceuticals	T121	C1254351
Optimal	T080	C2698651
Duration	T079	C0449238
Coronary Ligation	T061	C0396819
Reperfusion	T061	C0027054
Reperfusion Injury	T037	C0035126
Study	T062	C2603343
Rat	T015	C0034721
Model	T075	C0026339
Reperfusion injury	T037	C0035126
RI	T037	C0035126
important	T080	C3898777
impact	T080	C4049986
clinical	T080	C0205210
prognosis	T201	C3854082
patients	T101	C0030705
acute myocardial injury	T037	C0746730
coronary	T082	C1522318
blood flow	T039	C0232338
reestablished	T080	C0443211
studies	T062	C2603343
investigated	T169	C1292732
timeframe	T079	C0332168
coronary occlusion	T047	C0151814
reperfusion	T061	C0027054
effects	T080	C1280500
RI	T037	C0035126
rats	T015	C0034721
groups	T078	C0441833
coronary ligation	T061	C0396819
period	T079	C1948053
group	T078	C0441833
subgroups	T078	C0441833
different	T080	C1705242
reperfusion	T061	C0027054
periods	T079	C1948053
baseline	T081	C1442488
subgroup	T078	C0441833
animals	T008	C0003062
protocols	T170	C0542547
designed	T052	C1707689
ligation	T061	C0023690
reperfusion	T061	C0027054
periods	T079	C1948053
Evans blue	T109	C0015205
2,3,5-triphenyltetrazolium chloride	T109	C0146883
different	T080	C1705242
myocardial injury	T037	C0746730
areas	T082	C0205146
area	T082	C0205146
at risk	T080	C1444641
AAR	T082	C0205146
myocardial necrosis	T047	C1442837
differences	T080	C1705242
ratios	T081	C0456603
necrotic	T042	C0027540
area	T082	C0205146
AAR	T082	C0205146
subgroup	T078	C0441833
baseline	T081	C1442488
averaged	T081	C1510992
calculate	T052	C1441506
overall	T080	C1561607
value	T081	C1522609
heart	T023	C0018787
RI	T037	C0035126
percentages	T081	C0439165
significant	T078	C0750502
differences	T080	C1705242
different	T080	C1705242
time points	T079	C2348792
reperfusion	T061	C0027054
different	T080	C1705242
time points	T079	C2348792
ligation	T061	C0023690
effects	T080	C1280500
different	T080	C1705242
time courses	T079	C0449247
RI	T037	C0035126
group	T078	C0441833
highest	T080	C1522410
RI	T037	C0035126
difference	T080	C1705242
baseline	T081	C1442488
group	T078	C0441833
Maximal	T080	C0205289
RI	T037	C0035126
timeframe	T079	C0332168
animal model	T075	C0026339
result	T169	C1274040
assess	T052	C1516048
benefits	T081	C0814225
RI therapies	T061	C0035124
experimental rat model	T050	C0012644
Derivation	T080	C1441547
Predictive	T080	C0681890
Score	T081	C0449820
Hemorrhagic	T046	C0019080
Progression	T169	C0449258
Cerebral Contusions	T037	C0750971
Moderate	T037	C3508473
Severe Traumatic Brain Injury	T037	C3508474
traumatic brain injury	T037	C0876926
TBI	T037	C0876926
hemorrhagic	T046	C0019080
progression	T169	C0449258
contusions	T037	C0009938
HPCs	T037	C0009938
frequently	T079	C0332183
established	T080	C0443211
predictive	T080	C0681890
score	T081	C0449820
high-risk	T033	C0332167
patients	T101	C0030705
HPC	T037	C0009938
Consecutive	T080	C1707491
patients	T101	C0030705
hospitalized	T033	C0701159
moderate	T037	C3508473
severe TBI	T037	C3508474
primary outcome	T080	C3274433
HPC	T037	C0009938
increase	T169	C0442805
contusion	T037	C0009938
volume	T081	C0449468
absolute	T080	C0205344
increase	T169	C0442805
serial imaging	UnknownType	C0203640
Logistic regression models	T081	C0023965
created	T052	C1706214
risk factors	T033	C0035648
HPC	T037	C0009938
HPC	T037	C0009938
Score	T081	C0449820
derived	T080	C1441547
final model	T170	C3161035
patients	T101	C0030705
patients	T101	C0030705
HPC	T037	C0009938
univariate analyses	T062	C0683962
HPC	T037	C0009938
associated with	T080	C0332281
older age	T032	C0001779
higher initial blood pressure	T033	C0436789
antiplatelet medications	T121	C0085826
anticoagulants	T121	C0003280
subarachnoid hemorrhage	T047	C0038525
SAH	T047	C0038525
subdural hematoma	T046	C0018946
SDH	T046	C0018946
skull fracture	T037	C0037304
frontal	T023	C0016732
contusion	T037	C0009938
larger	T081	C0549177
contusion	T037	C0009938
volume	T081	C0449468
shorter interval	T079	C1272706
injury	T037	C0178314
initial CT	T060	C0040405
final model	T170	C3161035
SAH	T047	C0038525
OR	T081	C0028873
CI	T081	C0009667
SDH	T046	C0018946
OR	T081	C0028873
CI	T081	C0009667
skull fracture	T037	C0037304
OR	T081	C0028873
CI	T081	C0009667
associated with	T080	C0332281
HPC	T037	C0009938
factors	T169	C1521761
HPC	T037	C0009938
Score	T081	C0449820
derived	T080	C1441547
SAH	T047	C0038525
SDH	T046	C0018946
skull fracture	T037	C0037304
score	T081	C0449820
receiver operating curve	T081	C0035787
Patients	T101	C0030705
score	T081	C0449820
incidence	T081	C0021149
HPC	T037	C0009938
patients	T101	C0030705
score	T081	C0449820
incidence	T081	C0021149
HPC	T037	C0009938
HPC	T037	C0009938
Score	T081	C0449820
risk	T078	C0035647
stratification	T169	C1514984
HPC	T037	C0009938
patients	T101	C0030705
moderate	T037	C3508473
severe TBI	T037	C3508474
Expressing	T055	C0565975
sexuality	T053	C0036915
nursing homes	T073	C0028688
experience	T055	C0683573
older women	T098	C0043210
qualitative study	T062	C0949415
nursing homes	T073	C0028688
barriers	T080	C4045969
expression	T055	C0565975
sexuality	T053	C0036915
exist	T077	C2987476
lack of privacy	T033	C2712041
attitudes	T041	C0004271
staff	T097	C0028698
family	T099	C0015576
sexual partner	T098	C0036911
physical limitations	T033	C0243095
study	T062	C0949415
lived experience	T055	C0683573
sexuality	T053	C0036915
elderly Spanish women	T098	C3161473
nursing homes	T073	C0028688
qualitative phenomenological approach	T062	C0949415
Data	T078	C1511726
collected	T062	C0010995
month period	T079	C0439231
sampling	T078	C0870078
Spanish residents	T098	C2347958
nursing homes	T073	C0028688
Madrid	T083	C0017446
Data	T078	C1511726
unstructured and semi-structured interviews	T052	C0021822
data	T078	C1511726
analyzed	T062	C0936012
thematic analysis	T062	C0242481
female	T032	C0086287
residents	T098	C2347958
themes	UnknownType	C0869035
data	T078	C1511726
expressing	T055	C0565975
sexuality	T053	C0036915
sexuality	T053	C0036915
duty	T058	C0028702
vows	T079	C1254367
Female	T032	C0086287
residents	T098	C2347958
manage	T058	C0184516
sexuality	T053	C0036915
Nursing Homes	T073	C0028688
expression	T055	C0565975
sexuality	T053	C0036915
older female	T032	C0086287
nursing home	T073	C0028688
residents	T098	C2347958
Xylan-based	T109	C0062221
temperature	T081	C0039476
pH	T081	C0020283
sensitive	T169	C0332324
hydrogels	T122	C0600484
drug controlled release	T122	C1707506
Xylan-based	T109	C0062221
temperature	T081	C0039476
pH	T081	C0020283
sensitive	T169	C0332324
hydrogels	T122	C0600484
crosslinking copolymerization	T044	C1880180
xylan	T109	C0062221
N-isopropylacrylamide	T109	C0083668
NIPAm	T109	C0083668
acrylic acid	T109	C1321887
AA	T109	C1321887
N,Ń-methylenebis-acrylamide	T109	C0067314
MBA	T109	C0067314
cross-linker	T130	C0034760
2,2-dimethoxy-2-phenylacetophenone	T109	C1121773
photoinitiator	T109	C0029224
ultraviolet irradiation	T070	C0041625
influence	T077	C4054723
NIPAm	T109	C0083668
AA	T109	C1321887
MBA	T109	C0067314
xylan-based	T109	C0062221
hydrogels	T122	C0600484
morphology	T080	C0332437
interactions	T169	C1704675
hydrogels	T122	C0600484
characterized	T052	C1880022
SEM	T059	C0026020
FTIR	T062	C0206055
lower critical solution temperature	T081	C0039476
LCST	T081	C0039476
hydrogels	T122	C0600484
investigated	T169	C1292732
DSC	T059	C0006780
results	T033	C0683954
LCST	T081	C0039476
hydrogels	T122	C0600484
AA	T109	C1321887
drug	T121	C0013227
encapsulation	T067	C2348438
efficiency	T081	C0013682
hydrogels	T122	C0600484
cumulative	T080	C1511559
release	T070	C3850077
rate	T081	C1521828
acetylsalicylic acid	T109	C0004057
intestinal	T023	C0021853
gastric fluid	T031	C2828094
Xylan-based	T109	C0062221
hydrogels	T122	C0600484
biocompatible	T080	C1524057
NIH3T3 cell	T025	C0007600
MTT assay	T062	C2986858
drug carriers	T122	C0013161
intestinal	T023	C0021853
targeted	T169	C1521840
oral drug delivery	T061	C0001563
Isolation	T059	C0220862
prebiotic	T109	C2717875
activity	T169	C0205177
water-soluble	T130	C0492715
polysaccharides	T109	C0032594
fractions	T081	C1264633
bamboo shoots	T168	C4040751
Phyllostachys praecox	T002	C1639319
water-soluble	T130	C0492715
polysaccharides	T109	C0032594
bamboo shoots	T168	C4040751
Phyllostachys praecox	T002	C1639319
WBP	T109	C0032594
isolated	T169	C0205409
characterizations	T185	C0243175
prebiotic	T109	C2717875
activities	T169	C0205177
investigated	T169	C1292732
yield	T081	C0392762
WBP	T109	C0032594
hot-water	T197	C0337023
extraction	T059	C0684295
fractions	T081	C1264633
WBP-1	T109	C0032594
WBP-2	T109	C0032594
molecular weight	T081	C0026385
chromatography	T059	C0008550
polysaccharides	T109	C0032594
fractions	T081	C1264633
heteropolysaccharides-protein complexes	T104	C1704241
amino acids	T116	C0002520
protein	T116	C0033684
rhamnose	T109	C0035417
arabinose	T109	C0003682
xylose	T109	C0043375
mannose	T109	C0024742
glucose	T109	C0017725
galactose	T109	C0016945
molar ratios	T081	C2825550
polysaccharide	T109	C0032594
α-	T078	C0006999
β-glycosidic linkages	T078	C0006999
sugar	T109	C0007004
FTIR	T062	C0206055
NMR spectra	T060	C0877853
WBP-1	T109	C0032594
WBP-2	T109	C0032594
Bifidobacterium adolescentis	T007	C0314972
Bifidobacterium bifidum	T007	C0314974
production	T169	C0205245
organic acids	T109	C0369760
polysaccharides	T109	C0032594
potential	T080	C3245505
prebiotic	T109	C2717875
properties	T080	C0871161
nutraceutical	T033	C0243095
antinutritional properties	T033	C0243095
barnyard	T002	C1075468
finger millet	T168	C0026145
varieties	T077	C1254372
Himalayan region	UnknownType	C0681784
varieties	T077	C1254372
barnyard	T002	C1075468
Echinochloa frumentacea	T002	C1075468
finger	T002	C0997163
Eleusine coracana	T002	C0997163
northwestern Himalaya	UnknownType	C0681784
investigated	T169	C1292732
nutraceutical	T033	C0243095
antinutritional properties	T033	C0243095
Barnyard millet	T168	C0026145
amount	T081	C1265611
crude fiber	T109	C2348013
total dietary fiber	T168	C0012173
tryptophan	T116	C0041249
content	T077	C0456205
total carotenoids	T109	C0007271
α-tocopherol	T109	C0969677
finger millet	T168	C0026145
finger millet	T168	C0026145
amount	T081	C1265611
methionine	T116	C0025646
ascorbic acid	T109	C0003968
barnyard millet	T168	C0026145
secondary metabolites	T123	C0870883
biological functions	T038	C3714634
barnyard millet	T168	C0026145
amount	T081	C1265611
polyphenols	T109	C0071649
tannins	T109	C0039294
ortho-dihydroxy phenol	T109	C0029224
content	T077	C0456205
finger millet	T168	C0026145
antinutitional compounds	T109	C0029224
barnyard millet	T168	C0026145
phytic acid	T109	C0031855
content	T077	C0456205
finger millet	T168	C0026145
no significant difference	T033	C3842396
trypsin inhibition activity	T044	C1148560
barnyard millet	T168	C0026145
finger millet	T168	C0026145
varieties	T077	C1254372
Barnyard millet	T168	C0026145
acid phosphatase	T116	C0001109
α-galactosidase	T116	C0016955
α-amylase inhibitor activity	T044	C1152556
finger millet	T168	C0026145
Finger millet seeds	T168	C0026145
calcium	T121	C0006675
content	T077	C0456205
amount	T081	C1265611
manganese	T123	C0024706
content	T077	C0456205
barnyard millet seeds	T168	C0026145
barnyard millet	T168	C0026145
varieties	T077	C1254372
finger millet	T168	C0026145
varieties	T077	C1254372
Polymorphisms	T086	C0752046
Inflammatory	T169	C0333348
Mediator Genes	T028	C0017337
Risk	T078	C0035647
Preeclampsia	T046	C0032914
Taiyuan	UnknownType	C0681784
China	T083	C0008115
Excessive	T080	C0442802
maternal	T033	C1858460
inflammatory response	T046	C1155266
pathogenesis	T046	C0699748
preeclampsia	T046	C0032914
epidemiologic studies	T062	C0002783
investigated	T169	C1292732
associations	T080	C0439849
genetic variations	T070	C0042333
inflammatory	T169	C0333348
mediator genes	T028	C0017337
preeclampsia	T046	C0032914
risk	T078	C0035647
studies	T062	C0002783
single-nucleotide polymorphisms	T086	C0752046
IL-1A	T028	C1708430
IL-1B	T028	C1334112
IL-1R1	T116	C0391754
IL-2RA	T116	C1101536
IL-5RA	T116	C1704269
IL-6	T028	C1334122
IL-6R	T116	C0063717
TNFSF11	T028	C1367028
TNFRSF11A	T028	C1420805
IL-28RA	T028	C1425622
IRAK4	T028	C1334137
KIT genes	T028	C1416655
risk	T078	C0035647
preeclampsia	T046	C0032914
clinical	T080	C0205210
subtypes	T185	C0449560
nested case-control study	T062	C0027775
preeclampsia	T046	C0032914
cases	T077	C1706256
controls	T096	C0009932
IL-1R1	T116	C0391754
IL-5RA	T116	C1704269
IL-6R	T116	C0063717
TNFSF11	T028	C1367028
associated with	T080	C0332281
risk	T078	C0035647
preeclampsia	T046	C0032914
significant	T078	C0750502
associations	T080	C0439849
preeclampsia	T046	C0032914
overall	T080	C1561607
late-onset	T079	C4025592
preeclampsia	T046	C0032914
severe	T080	C0205082
preeclampsia	T046	C0032914
IL-6R	T116	C0063717
rs2229238	T170	C0282574
TNFSF11	T028	C1367028
rs9525643	T170	C0282574
polymorphisms	T086	C0752046
associated with	T080	C0332281
risk	T078	C0035647
preeclampsia	T046	C0032914
TNFSF11	T028	C1367028
rs2200287	T170	C0282574
rs2148072	T170	C0282574
polymorphisms	T086	C0752046
associated with	T080	C0332281
risk	T078	C0035647
preeclampsia	T046	C0032914
study	T062	C2603343
evidence	T078	C3887511
genetic variations	T070	C0042333
inflammatory	T169	C0333348
mediator genes	T028	C0017337
IL-1R1	T116	C0391754
IL-6R	T116	C0063717
TNFSF11	T028	C1367028
IL-5RA	T116	C1704269
associated with	T080	C0332281
preeclampsia	T046	C0032914
risk	T078	C0035647
risk	T078	C0035647
preeclampsia	T046	C0032914
subtypes	T185	C0449560
school	T073	C0036375
bonding	T041	C0237497
African American	T098	C0085756
adolescents	T100	C0205653
low-income communities	T098	C0024045
latent class analysis	T062	C0242481
Positive	T033	C1446409
school	T073	C0036375
bonding	T041	C0237497
significant	T078	C0750502
precursor	T078	C1709634
students	T098	C0038492
school	T073	C0036375
success	T054	C0597535
African American	T098	C0085756
youth	T100	C0087178
lower	T080	C0205251
school	T073	C0036375
success	T054	C0597535
White counterparts	T098	C1257890
study	T062	C2603343
correlates	T080	C1707520
school	T073	C0036375
bonding	T041	C0237497
African American	T098	C0085756
youth	T100	C0087178
recruited	T052	C2949735
community settings	T096	C0009462
Chicago	T083	C0008044
Major	T080	C0205164
findings	T033	C0243095
negative peer norms	T033	C1513916
exposure to	T080	C0332157
community violence	T033	C4061413
poor	T080	C2700379
mental health	T041	C0025353
negatively	T033	C0205160
correlated	T080	C1707520
school	T073	C0036375
bonding	T041	C0237497
parental monitoring	UnknownType	C0814580
positive self-regard	T033	C1821524
future	T079	C0016884
orientation	T041	C0029266
correlated	T080	C1707520
higher	T080	C0205250
school	T073	C0036375
motivation	T041	C0026605
Students	T098	C0038492
classified	T185	C0008902
high	T080	C0205250
moderate	T080	C0205081
school	T073	C0036375
bonding	T041	C0237497
live	T052	C2982691
parents	T099	C0030551
experience	T041	C0596545
higher	T080	C0205250
levels	T080	C0441889
parental monitoring	UnknownType	C0814580
exhibit positive self-regard	T033	C1821524
findings	T033	C0243095
DEPRESSION	T048	C0011570
ANXIETY	T048	C0003469
STRESS	T048	C0038443
ASSOCIATED	T080	C0332281
FACTORS	T169	C1521761
CORPS MEMBERS	T098	C0680022
KEBBI STATE	UnknownType	C0681784
Depression	T048	C0011570
anxiety	T048	C0003469
stress	T048	C0038443
health problems	T033	C1446377
associated with	T080	C0332281
negative	T033	C1513916
health	T078	C0018684
consequences	T169	C0686907
national youth service	T092	C1561598
characterized	T052	C1880022
experiences	T041	C0596545
life style	T054	C0023676
adjustments	T055	C0376209
corps member	T098	C0680022
psychological factors	T041	C0033898
corps members	T098	C0680022
study	T062	C2603343
prevalence	T081	C0683921
depression	T048	C0011570
anxiety	T048	C0003469
stress	T048	C0038443
associated	T080	C0332281
factors	T169	C1521761
corps members	T098	C0680022
Kebbi state	UnknownType	C0681784
cross-sectional study	T062	C0010362
corps members	T098	C0680022
local government areas	UnknownType	C0681785
state	T083	C1301808
local government areas	UnknownType	C0681785
participants	T098	C0679646
simple random sampling	T062	C0681878
Data	T078	C1511726
May	T079	C3812381
June	T079	C3829443
self-administered questionnaire	T170	C0034394
Data analysis	T057	C0010992
chi-square test	T170	C0008041
relationship	T080	C0439849
categorical variables	T080	C0439828
multivariate logistic regression	T062	C0206031
factors	T169	C1521761
depression	T048	C0011570
anxiety	T048	C0003469
stress	T048	C0038443
response rate	T079	C0237629
respondents	T098	C0282122
males	T032	C0086582
single	T098	C0037179
years	T079	C1510829
age	T032	C0001779
prevalences	T081	C0033105
depression	T048	C0011570
anxiety	T048	C0003469
stress	T048	C0038443
respondents	T098	C0282122
factors	T169	C1521761
depression	T048	C0011570
North central	T083	C0017446
OR	T081	C0028873
CI	T081	C0009667
South-south	T083	C0017446
perception	T041	C0030971
earning	T081	C0680989
income	T081	C0021162
OR	T081	C0028873
CI	T081	C0009667
CI	T081	C0009667
anxiety	T048	C0003469
male gender	T032	C0086582
OR	T081	C0028873
CI	T081	C0009667
North central	T083	C0017446
risk factors	T033	C0035648
OR	T081	C0028873
CI	T081	C0009667
years	T079	C1510829
age	T032	C0001779
risk factor	T033	C0035648
stress	T048	C0038443
OR	T081	C0028873
CI	T081	C0009667
schooled	T033	C0013658
towns	T083	C1555315
residence	T082	C0237096
stressed	T041	C0564404
OR	T081	C0028873
CI	T081	C0009667
factors	T169	C1521761
significant association	T080	C0439849
outcome variables	T080	C0439828
multivariate analysis	T081	C0026777
conclusion	T078	C1707478
prevalences	T081	C0033105
depression	T048	C0011570
anxiety	T048	C0003469
stress	T048	C0038443
high	T080	C0205250
corps members	T098	C0680022
Kebbi state	UnknownType	C0681784
study	T062	C2603343
national level	T082	C0681788
problem	T033	C0033213
Trans-oral	T082	C0442366
fine needle aspiration cytology	T060	C2236896
cervical (C1 and C2) vertebral	T023	C0223098
lesions	T033	C0221198
diagnostic approach	T060	C0430022
Fine needle aspiration (FNA) cytology	T060	C2236896
non-invasive	T169	C0205303
diagnosing	T033	C0011900
superficial	T033	C1336528
deep-seated neoplastic	T191	C0027651
non-neoplastic lesions	T033	C0221198
diagnostic utility	T169	C0348026
trans-oral	T082	C0442366
FNA	T060	C2236896
cervical (C1 and C2) vertebral	T023	C0223098
paravertebral	T029	C0446501
lesions	T033	C0221198
FNA	T060	C2236896
cervical vertebral	T023	C0223098
paravertebral	T029	C0446501
lesions	T033	C0221198
trans-oral route	T082	C0442366
image-guidance	T058	C1254363
cytology	T091	C0010819
department	T092	C1704729
PGIMER	T092	C0035172
Chandigarh	UnknownType	C0681784
diagnosis	T033	C0011900
diagnosis	T033	C0011900
granulomatous inflammation	T046	C0553697
tuberculosis	T047	C0041296
Trans-oral	T082	C0442366
FNA	T060	C2236896
outpatient procedure	T061	C1299353
C1 and C2 vertebral	T023	C0223098
paravertebral	T029	C0446501
lesions	T033	C0221198
clinically	T201	C0683325
radiologically	T091	C0039431
early diagnosis	T060	C0596473
management of these patients	T058	C1610129
Neonatal infections	T047	C0854706
Case definition	T170	C1704788
guidelines	T170	C0162791
data collection	T062	C0010995
analysis	T062	C0936012
presentation	T078	C0449450
immunisation	T061	C0020971
safety data	T078	C1511726
Maternal	T033	C1858460
vaccination	T061	C0042196
research	T062	C0035168
definitions	T170	C1704788
safety standards	T170	C2828392
GAIA group	T097	C1522486
Brighton Collaboration	T097	C1522486
definitions	T170	C1704788
maternal	T033	C1858460
vaccine	T121	C0042210
research	T062	C0035168
study	T062	C2603343
definitions	T170	C1704788
neonatal infections	T047	C0854706
neonatal infections	T047	C0854706
GAIA	T097	C1522486
working group	T098	C1883562
literature	T170	C0023866
review	T169	C0565989
Medline	T170	C0025141
EMBASE	T170	C0242356
Cochrane collaboration	T169	C1882071
definitions	T170	C1704788
neonatal	T169	C1882071
public health networks	T169	C1882071
criteria	T078	C0243161
derived	T080	C1441547
consensus process	T054	C0376298
definitions	T170	C1704788
neonatal	T100	C0021289
blood stream infections	T046	C2316160
BSI	T046	C2316160
meningitis	T047	C0025289
lower respiratory tract infections	T047	C0149725
LRTI	T047	C0149725
definition	T170	C1704788
definitions	T170	C1704788
data collection	T062	C0010995
analysis	T062	C0936012
presentation	T078	C0449450
harmonized	T062	C0150103
Brighton Collaboration	T097	C1522486
GAIA	T097	C1522486
format	T170	C1301627
international standards	T170	C2828392
study	T062	C2603343
reporting	T062	C0011000
Beneficial	T081	C0814225
effects	T080	C1280500
dark chocolate	T168	C3853217
exercise	T056	C0015259
capacity	T081	C1516240
sedentary	T080	C0205254
subjects	T098	C2349001
mechanisms	T169	C0441712
double blind	T062	C0013072
randomized	T062	C0034656
placebo controlled	T062	C1706408
trial	T062	C0008976
heart failure	T047	C0018801
patients	T101	C0030705
consumption	T039	C1947907
(-)-epicatechin	T121	C1881340
(-)-Epi	T121	C1881340
cocoa	T168	C0009209
skeletal muscle	T024	C0242692
SkM	T024	C0242692
mitochondrial	T026	C0026237
structure	T082	C0678594
decrease	T081	C0547047
biomarkers	T201	C0005516
oxidative stress	T049	C0242606
effects	T080	C1280500
exercise	T056	C0015259
capacity	T081	C1516240
mechanisms	T169	C0441712
normal	T080	C0205307
sedentary	T080	C0205254
subjects	T098	C2349001
normal	T080	C0205307
sedentary	T080	C0205254
subjects	T098	C2349001
years old	T100	C0001675
randomized	T062	C0034656
placebo	T061	C0032042
dark chocolate	T168	C3853217
DC	T168	C3853217
groups	T078	C0441833
consumed	T052	C2983605
months	T079	C0439231
Subjects	T098	C2349001
treatment	T061	C0087111
bicycle ergometry	T060	C0857787
assess	T058	C0184514
VO2 max	T033	C0429693
work	T057	C0043227
SkM biopsy	T060	C2315740
assess	T058	C0184514
mitochondrial	T026	C0026237
density	T081	C0178587
function	T169	C0542341
oxidative stress	T049	C0242606
blood sampling	T060	C0005834
assess	T058	C0184514
metabolic	T169	C0311400
endpoints	T080	C2349179
subjects	T098	C2349001
trial	T062	C0008976
DC	T168	C3853217
VO2 max	T033	C0429693
increased	T169	C0442805
increase	T169	C0442805
work	T057	C0043227
watts	T081	C0439261
placebo	T061	C0032042
DC	T168	C3853217
increases	T169	C0442805
HDL	T116	C0023821
decreased	T081	C0205216
triglycerides	T109	C0041004
DC	T168	C3853217
SkM	T024	C0242692
significant	T078	C0750502
increases	T169	C0442805
protein	T116	C0033684
LKB1	T116	C1431123
AMPK	T116	C2350345
PGC1α	T116	C1452082
active	T169	C0205177
phosphorylated	T044	C0031715
AMPK	T116	C2350345
LKB1	T116	C1431123
citrate synthase activity	T044	C2258114
mitochondrial	T026	C0026237
density	T081	C0178587
DC	T168	C3853217
significant	T078	C0750502
increases	T169	C0442805
SkM	T024	C0242692
glutathione	T116	C0017817
decreases	T081	C0547047
protein carbonylation	T044	C1563721
work	T057	C0043227
VO2 max	T033	C0429693
DC	T168	C3853217
activation	T052	C1879547
SkM	T024	C0242692
mitochondria	T026	C0026237
efficiency	T081	C0013682
clinical studies	T062	C0008972
observations	T062	C0302523
Reduction	T080	C0392756
Hospital-Wide	T073	C0019994
Clinical Laboratory Specimen Identification	T059	C0200344
Errors	T080	C0743559
Process Interventions	UnknownType	C0814452
Year	T079	C0439234
Retrospective Observational Study	T062	C0035363
Accurate	T080	C0443131
patient identification	T058	C1269815
specimen labeling	T058	C1254363
crucial steps	T077	C1254372
prevention	T062	C1706420
medical errors	T080	C0376531
improving	T080	C1272745
patient safety	T058	C1113679
patient specimen	T031	C1292459
identification	T080	C0205396
errors	T080	C0743559
occurred	T052	C1709305
outpatient department	T082	C1547116
OPD	T082	C1547116
emergency department	T073	C0562508
ED	T073	C0562508
inpatient department	T082	C1547116
IPD	T082	C1547116
bed	T073	C0004916
academic medical center	T073	C0000872
Taiwan	T083	C0039260
documented	T058	C1301725
analyzed	T058	C1254363
reduce	T080	C0392756
errors	T080	C0743559
series	T081	C0205549
strategies	T170	C0679716
restrictive specimen acceptance policy	T089	C0680575
ED	T073	C0562508
IPD	T082	C1547116
computer-assisted	T059	C2362103
barcode	T170	C0004738
positive patient identification system	T073	C0009612
ED	T073	C0562508
IPD	T082	C1547116
automated	T169	C0205554
sample labeling	T058	C1254363
combined	T080	C0205195
electronic identification systems	T058	C3687093
introduced	T169	C1292748
OPD	T082	C1547116
specimens	T031	C1550655
collected	T169	C1516698
identified	T033	C0243095
patient identification	T058	C1269815
errors	T080	C0743559
errors	T080	C0743559
specimens	T031	C1550655
collected	T169	C1516698
interventions	T058	C1273869
relative	T080	C0205345
reduction	T080	C0392756
total number	T081	C4288115
rate	T081	C1521828
institutional identification	T058	C1254363
errors	T080	C0743559
ED	T073	C0562508
IPD	T082	C1547116
OPD	T082	C1547116
year	T079	C0439234
period	T079	C1948053
errors	T080	C0743559
before	T079	C0332152
interventions	T058	C1273869
after	T079	C0687676
interventions	T058	C1273869
relative	T080	C0205345
reductions	T080	C0392756
Accurate	T080	C0443131
patient identification	T058	C1269815
patient safety	T058	C1113679
health	T078	C0018684
settings	T081	C1318139
data collected	T033	C4019276
study	T062	C2603343
restrictive specimen acceptance policy	T089	C0680575
computer-generated	T059	C0022885
positive identification systems	T073	C0009612
reduce	T080	C0392756
patient identification	T058	C1269815
errors	T080	C0743559
Management	T058	C0376636
skin and soft-tissue infections	T047	C0852000
teaching hospital	T073	C0020027
severity-of-illness tool	T169	C0449851
Skin and soft-tissue infections	T047	C0852000
SSTIs	T047	C0852000
diverse	T080	C1880371
range	T081	C1514721
infections	T046	C3714514
severity	T080	C0439793
Clinical Resource Efficiency Support Team (CREST) scoring system	T170	C0162791
stratifies	T185	C0008902
patients	T101	C0030705
classes	T185	C0008902
severe	T080	C0205082
severe	T080	C0205082
Standardized Early Warning Score	T170	C2919819
SEWS	T170	C2919819
objective	T078	C2985627
study	T062	C2603343
CREST	T170	C0162791
hospitalized patients	T101	C0870668
SSTIs	T047	C0852000
disease severity	T080	C0521117
evaluate	T058	C0220825
antibiotic	T195	C0003232
retrospective	T062	C0035363
hypothesis	T078	C1512571
evaluation	T058	C0220825
hospitalized patients	T101	C0870668
SSTIs	T047	C0852000
admitted	T058	C0184666
CREST	T170	C0162791
empirical	T080	C1880496
antimicrobial	T121	C1136254
categorized	T052	C0871968
over-treatment	T058	C4046039
under-treatment	T061	C0087111
patients	T101	C0030705
inclusion criteria	T080	C1512693
patients	T101	C0030705
classified	T185	C0008902
CREST	T170	C0162791
class I	T185	C1550329
class I	T185	C1550329
Over-treatment	T058	C4046039
severe	T080	C0205082
classes	T185	C0008902
class I	T185	C1550329
class II	T185	C1550329
percent	T081	C0439165
class I	T185	C1550329
over-treated	T058	C4046039
intravenous	T169	C1522726
antibiotic	T195	C0003232
oral therapy	T061	C0559681
broad-spectrum antibiotics	T195	C0003232
class II	T185	C1550329
over-treated	T058	C4046039
broad-spectrum antibiotics	T195	C0003232
clinical failure	T033	C3640841
patients	T101	C0030705
response	T201	C0521982
class II	T185	C1550329
class III	T185	C1550329
class IV	T185	C1550329
Retrospective	T080	C1514923
application	T058	C0185125
CREST	T170	C0162791
management	T058	C0376636
SSTIs	T047	C0852000
CREST	T170	C0162791
severe	T080	C0205082
SSTIs	T047	C0852000
treated	T061	C0087111
outpatient	T101	C0029921
Breakthrough	T080	C0444503
viridans streptococcal bacteremia	T047	C0152965
allogeneic hematopoietic stem cell transplant	T061	C4255274
recipients	T101	C0376387
receiving	T080	C1514756
levofloxacin	T109	C0282386
prophylaxis	T061	C0199176
Japanese	T083	C0022341
hospital	T073	C0019994
Breakthrough	T080	C0444503
viridans streptococcal bacteremia	T047	C0152965
VSB	T047	C0152965
patients	T101	C0030705
hematological malignancy	T191	C0376545
receiving	T080	C1514756
levofloxacin	T109	C0282386
prophylaxis	T061	C0199176
major	T080	C0205164
blood stream infection	T047	C0004610
BSI	T047	C0004610
occurring	T052	C1709305
during	T079	C0347984
febrile neutropenia	T047	C0746883
clinical data	T170	C1516606
focused	T169	C1285542
VSB	T047	C0152965
allogeneic hematopoietic stem cell transplant	T061	C4255274
allo-HSCT	T061	C4255274
recipients	T101	C0376387
lacking	T080	C0332268
medical records	T170	C0025102
allo-HSCT	T061	C4255274
recipients	T101	C0376387
received	T080	C1514756
oral	T169	C1527415
levofloxacin	T109	C0282386
prophylaxis	T061	C0199176
Toranomon Hospital	T073	C0019994
reviewed	T080	C1709940
evaluate	T058	C0220825
breakthrough	T080	C0444503
VSB	T047	C0152965
viridans streptococcal	T007	C1140704
VGS	T007	C1140704
species	T185	C1705920
identified	T080	C0205396
using	T169	C1524063
sodA gene	T028	C0017337
sequencing	T059	C1294197
assessed	T052	C1516048
drug susceptibility	T038	C1326871
allo-HSCT	T061	C4255274
recipients	T101	C0376387
levofloxacin	T109	C0282386
prophylaxis	T061	C0199176
breakthrough	T080	C0444503
VSB	T047	C0152965
recipients	T101	C0376387
VSB	T047	C0152965
treated	T169	C1522326
cefepime	T109	C0055003
based	T169	C1527178
piperacillin/tazobactam	T121	C0250480
based	T169	C1527178
regimen	T061	C0040808
susceptibility	T038	C1326871
rates	T081	C1521828
VGS	T007	C1140704
strains	T001	C1518614
levofloxacin	T109	C0282386
cefepime	T109	C0055003
piperacillin/tazobactam	T121	C0250480
meropenem	T109	C0066005
vancomycin	T116	C0042313
MIC50	T059	C0427978
minimum inhibitory concentration	T059	C0427978
MIC90	T059	C0427978
ceftazidim	T109	C0007559
higher	T080	C0205250
MIC90	T059	C0427978
anti-pseudomonal beta-lactams	T121	C1254351
APBLs	T121	C1254351
VGS	T007	C1140704
strain	T001	C1518614
penicillin	T109	C0220892
MIC	T059	C0427978
Etest	T059	C3850116
no	T169	C1518422
cases	T169	C0868928
acute respiratory distress syndrome	T033	C1848829
ARDS	T033	C1848829
associated with	T080	C0332281
VSB	T047	C0152965
rate	T081	C1521828
viridans group streptococcal shock syndrome	T047	C0152965
high	T080	C0205250
30-day	T079	C0439228
mortality rate	T081	C0205848
VSB	T047	C0152965
group	UnknownType	C0681860
not	T169	C1518422
differ	T080	C1705242
significantly	T078	C0750502
BSI	T047	C0004610
without	T080	C0332288
VSB	T047	C0152965
group	UnknownType	C0681860
non	T169	C1518422
BSI	T047	C0004610
group	UnknownType	C0681860
VSB	T047	C0152965
not	T169	C1518422
risk factor	T033	C0035648
mortality	T081	C0205848
60 days	T079	C0439228
following	T079	C0332282
allo-HSCT	T061	C4255274
APBL	T121	C1254351
increased	T081	C0205217
anti-VGS activity	T033	C0243095
APBL-VA	T033	C0243095
monotherapy	T061	C0087111
optimal	T080	C2698651
treating	T169	C1522326
VGS	T007	C1140704
strains	T001	C1518614
anti-gram-positive agent	T121	C1254351
APBL-VA	T033	C0243095
treating	T169	C1522326
VSB	T047	C0152965
local	T082	C0205276
factors	T169	C1521761
susceptibility	T038	C1326871
results	T169	C1274040
breakthrough	T080	C0444503
VSB	T047	C0152965
not	T169	C1518422
major	T080	C0205164
cause of death	T033	C0007465
allo-HSCT	T061	C4255274
beta-lactam	T109	C0282215
non-susceptible VGS	T007	C1140704
ARDS	T033	C1848829
rare	T080	C0522498
splenorrhaphy	T061	C1261005
hemodynamically unstable	T047	C0948268
child	T100	C0008059
splenorrhaphy	T061	C1261005
splenectomy	T061	C0037995
postsplenectomy	T046	C3854596
sepsis	T047	C0243026
splenorrhaphy	T061	C1261005
familiarity	T041	C0600269
procedure	T061	C0087111
splenectomies	T061	C0037995
splenorrhaphies	T061	C1261005
trauma	T037	C3714660
pediatric surgeon	T097	C0586905
perform	T169	C0884358
career	T057	C0178534
Pediatric Health Information System (PHIS) Database	T170	C0242356
patients	T101	C0030705
years	T079	C0439234
International Classification of Diseases 9th Edition	T170	C2346503
diagnosis code	T170	C1550350
splenic injury	T037	C0160405
Age	T032	C0001779
gender	T032	C0079399
grade	T185	C0441800
splenic injury	T037	C0160405
operations	T061	C0543467
performed	T169	C0884358
extracted	T078	C1516695
pediatric surgeons	T097	C0586905
hospital	T073	C0019994
children	T100	C0008059
identified	T080	C0205396
splenectomy	T061	C0037995
splenorrhaphy	T061	C1261005
surgeon	T097	C0582175
performed	T169	C0884358
splenectomies	T061	C0037995
splenorrhaphies	T061	C1261005
trauma	T037	C3714660
rates	T081	C1521828
constant	T080	C1948059
surgeon	T097	C0582175
perform	T169	C0884358
splenectomies	T061	C0037995
splenorrhaphies	T061	C1261005
trauma	T037	C3714660
year	T079	C0439234
surgical career	T057	C0178534
Nonoperative management	T061	C0161969
experience level	T080	C0870520
pediatric surgeons	T097	C0586905
perform	T169	C0884358
splenectomy	T061	C0037995
splenorrhaphy	T061	C1261005
Vestibular	T030	C0042606
inter-stimulus interval	T079	C0870743
effects	T080	C1280500
sound evoked potentials	T042	C0015215
central	T082	C0205099
origin	T079	C0439659
presence	T033	C0150312
vestibular	T030	C0042606
contributions	T052	C1880177
auditory evoked potentials	T042	C0015215
AEPs	T042	C0015215
vestibular	T030	C0042606
threshold	T081	C0004312
vestibular evoked myogenic potentials	T034	C2936453
VEMPs	T034	C2936453
deflection	T082	C0012727
labeled	T080	C1708632
prior	T079	C0332152
long	T080	C0205166
latency	T079	C0242465
AEPs	T042	C0015215
report	T058	C0700287
results	T033	C2825142
experiment	T062	C0681814
effect of	T080	C1704420
inter-stimulus interval	T079	C0870743
ISI	T079	C0870743
regularity	T080	C0449581
potentials	T042	C0015214
above	T082	C1282910
below	T082	C0542339
VEMP	T034	C2936453
threshold	T081	C0004312
healthy	T080	C3898900
right-handed	T032	C0344333
subjects	T098	C2349001
evoked potentials	T042	C0015214
sound stimulation	T061	C0001164
above	T082	C1282910
below	T082	C0542339
vestibular	T030	C0042606
threshold	T081	C0004312
stimulus	T067	C0234402
rates	T081	C1521828
ISIs	T079	C0870743
intervals	T079	C0870743
presented	T078	C0449450
regular	T080	C0205272
irregular	T080	C0205271
ANOVA	T081	C0002780
global field power	T081	C0392762
GFP	T081	C0392762
intensity	T081	C0237686
ISI	T079	C0870743
regularity	T080	C0449581
significant	T078	C0750502
ANOVA	T081	C0002780
effects of	T080	C1704420
intensity	T081	C0237686
effects	T080	C1280500
interactions	T169	C1704675
additional	T169	C1524062
effects of	T080	C1704420
ISI	T079	C0870743
intensity	T081	C0237686
evidence of	T169	C0332120
non	T169	C1518422
linear	T082	C0205132
interactions	T169	C1704675
ISI	T079	C0870743
intensity	T081	C0237686
source analysis	T062	C0936012
consistent with	T078	C0332290
prior	T079	C0332152
above	T082	C1282910
vestibular	T030	C0042606
threshold	T081	C0004312
in addition to	T169	C0332287
bilateral	T082	C0238767
superior	T082	C1282910
temporal cortex	T023	C0039485
ocular	T023	C0015392
cerebellar	T023	C0007765
cingulate	T023	C0228272
sources	T033	C0449416
statistical analysis	T062	C0871424
source	T033	C0449416
currents	T070	C1705970
interactions	T169	C1704675
intensity	T081	C0237686
ISI	T079	C0870743
sensitivity	T081	C0036667
vestibular	T030	C0042606
sources	T033	C0449416
specific	T080	C0205369
vestibular	T030	C0042606
preference	T078	C0558295
stimulus	T067	C0234402
rates	T081	C1521828
associated with	T080	C0332281
locomotion	T040	C0023946
rates	T081	C1521828
ISIs	T079	C0870743
saccular	T082	C0205137
afferents	T082	C0205115
increased	T081	C0205217
gain	T081	C1517378
reflexes	T042	C0034929
sensitive	T169	C0332324
Systematic Review	T170	C1955832
Diagnostic	T169	C0348026
Prognostic Value	T080	C1514475
Urinary	T080	C1524119
Protein	T116	C0033684
Biomarkers	T201	C0005516
Urothelial Bladder Cancer	T191	C0751571
cystoscopy	T060	C0010702
gold-standard	T080	C0150110
detecting	T033	C0442726
tumours	T191	C0027651
urinary bladder	T023	C0005682
bladder tumours	T191	C0005695
recur	T067	C0034897
progress	T046	C0242656
patients	T101	C0030705
cystoscopies	T060	C0010702
long-term	T079	C0443252
surveillance	T058	C0733511
procedure	T061	C0184661
patient	T101	C0030705
healthcare providers	T097	C0018724
identification	T080	C0205396
validation	T062	C1519941
bladder tumour	T191	C0005695
molecular markers	T201	C0005516
urine	T031	C0042036
tumour	T191	C0027651
detection	T033	C0442726
reliance	T055	C0599403
cystoscopy	T060	C0010702
biomarkers	T201	C0005516
Proteins	T116	C0033684
studied class of biomolecule	UnknownType	C0681852
researchers	T097	C0035173
urinary	T080	C1524119
biomarkers	T201	C0005516
comprehensive systematic review	T170	C1955832
literature	T170	C0023866
database	T170	C0242356
proteins	T116	C0033684
investigated	T058	C0220825
proteins	T116	C0033684
sensitivity and specificity	T081	C0036668
bladder cancer	T191	C0005695
detection	T033	C0442726
investigation	T058	C0220825
investigation	T058	C0220825
investigated	T058	C0220825
prognostic markers	T080	C1514475
biomarkers	T201	C0005516
rigorous validation	T062	C0681836
preventing	T169	C1292733
proteins	T116	C0033684
disease	T047	C0012634
biomarker	T201	C0005516
large-scale efforts	UnknownType	C0814860
validation	T062	C0681836
Qualitative Study	T062	C0949415
Decision-Making	T041	C0011109
Hopes	T041	C0392347
Realities	T078	C0871222
Adults	T100	C0001675
Type 1 Diabetes	T047	C0011854
Islet Cell Transplantation	T061	C0079646
individuals	T098	C0237401
type 1 diabetes	T047	C0011854
pancreatic islet transplantation	T061	C0079646
IT	T061	C0079646
hypoglycemia	T047	C0020615
optimizes glycemia	T061	C3267174
systemic immunosuppression	T061	C0021079
candidates	T098	C1257890
recipients	T101	C0376387
transplantation	T061	C0040732
waiting list	T033	C0586018
recipients	T101	C0376387
posttransplant	T079	C1254367
qualitative	T080	C0205556
research design	T062	C0035171
interviews	T058	C0683518
adults	T100	C0001675
pretransplant	T079	C1254367
posttransplant	T079	C1254367
UK	T083	C0041700
centers	T073	C0475309
Canadian	T083	C0006823
center	T073	C0475309
Interviews	T058	C0683518
audio-recorded	T058	C2316646
inductive thematic analysis	T062	C0936012
Interviewees	T098	C0489844
years	T079	C0439234
duration	T079	C0449238
diabetes	T047	C0011847
years	T079	C0439234
women	T098	C0043210
expectations	T078	C0679138
hopes	T041	C0392347
realities	T078	C0871222
decision-making	T041	C0011109
hospital stay	T079	C3489408
follow-up	T058	C1522577
hypoglycemic episodes	T047	C0745153
reduced	T080	C0392756
insulin	T116	C0021641
complications	T046	C0009566
psychological well-being	T033	C0424578
interviewees	T098	C0489844
decision-making	T041	C0011109
clinicians	T097	C0871685
family	T099	C0015576
stressful	T169	C0231297
immunosuppressant	T121	C0021081
side effects	T046	C0879626
severe	T080	C0205082
interviewees	T098	C0489844
no	T033	C1513916
regrets	T041	C0080101
Posttransplant	T079	C1254367
interviewees	T098	C0489844
confidence	T041	C0237529
freedom from hypoglycemia	T033	C0243095
glycemic control	T061	C3267174
insulin	T116	C0021641
transplant	T061	C0040732
hopes	T041	C0392347
insulin-free	T033	C0243095
interviews	T058	C0683518
IT	T061	C0079646
IT	T061	C0079646
candidates	T098	C1257890
nanocomposite	T080	C0205199
bone	T023	C0262950
strength	T081	C0237897
damage	T169	C1883709
resistance	T169	C4281815
human bone	T023	C0277764
amorphous	T080	C1979848
mineral	T197	C0026162
precursor	T078	C1709634
formation	T169	C1522492
nanocrystalline	T073	C1721058
apatite	T197	C0003522
amorphous	T080	C1979848
mineral	T197	C0026162
transmission electron microscopy	T059	C0678118
amorphous	T080	C1979848
calcium phosphate	T121	C0006711
regions	T029	C0005898
disordered phase	T082	C1254362
trabecular bone	T024	C0222660
Nanomechanical experiments	T062	C0681814
cylindrical	T082	C0946010
samples	T167	C0370003
diameters	T081	C1301886
bone's	T023	C0262950
ordered	T082	C1254362
disordered phases	T082	C1254362
transition	T052	C2700061
plastic	T070	C0678558
deformation	T033	C0575133
brittle	T033	C3810845
failure	T037	C0016658
strength	T081	C0237897
smaller	T080	C0547044
samples	T167	C0370003
transition	T052	C2700061
failure	T169	C0231174
mechanism	T169	C0441712
suppression	T169	C1260953
extrafibrillar	T026	C0225328
shearing	T061	C0205013
samples	T167	C0370003
smaller	T080	C0547044
stronger	T080	C0442821
size effect	T081	C0814843
sample-size	T081	C0242618
scaling	T052	C1947916
findings	T033	C0243095
multi-scale nature	T078	C0349590
bone	T023	C0262950
biomineralization	T042	C0006660
process	T067	C1522240
Assessing	T052	C1516048
physiological	T169	C0205463
relevance	T080	C2347946
architectures	T082	C0678594
p7 protein	T116	C0257097
hepatitis C virus	T005	C0220847
environments	T082	C0014406
viroporin	T038	C3820740
p7	T116	C0257097
hepatitis C virus	T005	C0220847
multimeric channels	T116	C0022009
ion transport	T043	C0162585
endoplasmic reticulum membrane	T026	C0230770
subject	T078	C1706203
studies	T062	C2603343
molecular assembly	T044	C0872376
ion channel	T116	C0022009
structural	T082	C0678594
characteristics	T080	C1521970
p7	T116	C0257097
monomer	T104	C0596973
Structural	T082	C0678594
investigation	T169	C1292732
p7	T116	C0257097
detergent	T120	C0011740
environments	T082	C0014406
analyze	T062	C0936012
molecular dynamics simulations	T066	C2717775
structure	T082	C0678594
p7	T116	C0257097
monomer	T104	C0596973
sequence	T087	C0002518
conformation	T082	C0026377
environment	T082	C0014406
conductance	UnknownType	C0678840
models	T075	C0026339
hexameric	T104	C1254350
p7	T116	C0257097
ion channel	T116	C0022009
ion translocation	T043	C0162585
lipid bilayer	T026	C0023768
models	T075	C0026339
cations	T104	C0007447
position	T082	C1550045
orientation	T082	C1704322
acidic or basic residues	T077	C1709915
ion	T196	C0022023
selectivity	T052	C1707391
conductance	UnknownType	C0678840
channel	T116	C0022009
packing	T044	C1148560
monomers	T104	C0596973
channel	T116	C0022009
collapse	T067	C0332521
pore	T026	C1325742
ion translocation	T043	C0162585
physiological	T169	C0205463
relevance	T080	C2347946
p7	T116	C0257097
ion channel	T116	C0022009
models	T075	C0026339
multimeric structures	T082	C0678594
environments	T082	C0014406
genome	T028	C0017428
DNA-binding	T045	C1148673
profile	T059	C1979963
BarR	T116	C0033684
β-alanine	T116	C0000392
responsive	T169	C0205342
transcription factor	T116	C0040648
archaeon	T194	C0003732
Sulfolobus acidocaldarius	T194	C0085459
Leucine-responsive Regulatory Protein	T116	C0125575
Lrp	T116	C0125575
family	T116	C1335532
family	T116	C1335532
regulatory transcription factors	T116	C0040648
prokaryotes	T001	C0686817
BarR	T116	C0033684
Lrp	T116	C0125575
transcription factor	T116	C0040648
archaeon	T194	C0003732
Sulfolobus acidocaldarius	T194	C0085459
activates	T052	C1879547
expression	T045	C0017262
β-alanine aminotransferase gene	T028	C0017337
β-alanine degradation	T044	C1156738
Lrp	T116	C0125575
transcription factors	T116	C0040648
BarR	T116	C0033684
not responsive	T033	C0237284
α-amino acids	T116	C0311462
β-alanine	T116	C0000392
β-alanine aminotransferase gene	T028	C0017337
BarR	T116	C0033684
β-alanine	T116	C0000392
precursor	T116	C0014436
coenzyme A	T114	C0009226
metabolite	T123	C0870883
aim	T078	C1947946
study	T062	C2603343
DNA-binding	T045	C1148673
characteristics	T080	C1521970
BarR	T116	C0033684
regulon	T028	C0206522
local	T082	C0205276
genome	T028	C0017428
genome-wide binding profile	T059	C2986505
BarR	T116	C0033684
chromatin immunoprecipation	T059	C1328856
high-throughput sequencing	T063	C2936621
ChIP-seq	T063	C2936621
genomic	T028	C0017428
binding	T044	C1167622
loci	T082	C1708726
binding regions	T045	C3158196
BarR protein	T116	C0033684
in vitro	T080	C1533691
electrophoretic mobility shift assays	T059	C0949632
conserved	T086	C0009802
semi-palindromic	T114	C2350254
binding motif	T087	C1514535
genomic sites	T028	C0017428
intergenic regions	T114	C0887859
promoter	T114	C0086860
qRT-PCR analysis	T059	C2733022
operon	T028	C0029073
activation	T045	C0599177
BarR	T116	C0033684
glutamine synthase operon	T028	C0029073
Lrp	T116	C0125575
transcription factors	T116	C0040648
BarR	T116	C0033684
ChIP-seq profile	T034	C3463810
β-alanine aminotransferase promoter region	T114	C0033413
combination	T080	C0205195
binding motif	T087	C1514535
operator structure	T114	C0086734
complicated	T169	C0231242
multiple (major and auxiliary) operators	T114	C0086734
BarR	T116	C0033684
limited	T169	C0439801
regulon	T028	C0206522
glutamine synthase genes	T028	C0017337
β-alanine aminotransferase	T028	C0017337
Regulation	T038	C1327622
glutamine synthase	T116	C0017801
β-alanine	T044	C1156837
α-amino acid metabolism	T044	C3547146
S. acidocaldarius	T194	C0085459
BarR	T116	C0033684
regulon	T028	C0206522
Lrp	T116	C0125575
regulators	T077	C1704735
GH32 family	T116	C0017976
activity	T044	C0243102
topological	T082	C0026377
protein contact networks	T169	C3178902
Protein Contact Networks methodology	T169	C3178902
border region	T082	C1254362
domains to substrate binding	T087	C0682969
Glycoside hydrolases	T116	C0017976
GH	T116	C0017976
enzymes	T116	C0014442
hydrolyze	T070	C0020291
glycosidic bond	T044	C0813982
carbohydrates	T109	C0007004
carbohydrate	T109	C0007004
non-carbohydrate moiety	T104	C1254350
enzymes	T116	C0014442
biological processes	T038	C3714634
plants	T002	C0032098
GH32 family	T116	C0017976
enzymes	T116	C0014442
sequence	T087	C0002518
structure	T116	C0596527
substrate	T120	C0178623
preferences	T078	C0558295
kinetic properties	T169	C0220865
Structural	T116	C1510464
topological	T082	C0026377
proteins	T116	C0033684
GH32 family	T116	C0017976
Protein Contact network	T169	C3178902
PCN	T169	C3178902
3D structures	T082	C0026377
contact networks	T169	C3178902
amino-acid residues	T087	C0002518
PCN	T169	C3178902
functional	T169	C0205245
domains	T087	C1514562
structural	T116	C1510464
GH32 enzymes	T116	C0017976
allosteric	T169	C0002146
activation	T044	C0014429
binding of the border (cleft) region	T044	C1517880
domains	T087	C1514562
allosteric	T169	C0002146
enzymatic activity	T044	C0243102
GH32 family	T116	C0017976
biochemical studies	T059	C0430027
topological signature	T082	C0026377
affinity	T070	C1510827
enzymes	T116	C0017976
substrates	T120	C0178623
Grasping	T040	C0220843
Moon	T083	C0079853
Enhancing	T052	C2349975
Access	T082	C0444454
Careers	T057	C0178534
Health Professions	T091	C0018722
former	T078	C0750523
HHS	T093	C0041711
secretary	T097	C0341647
reflects	T041	C0558058
minorities	T098	C0026192
doctors	T097	C0031831
health professionals	T097	C1704312
Multivariate	T081	C0026777
Imaging	T060	C0011923
Genetics Study	T062	C2827447
MRI	T060	C0024485
Gray Matter	T024	C0018220
Volume	T081	C0449468
SNPs	T086	C0752046
Biological	T080	C0205460
Pathways	T077	C1705987
Correlated	T080	C1707520
Brain	T023	C0006104
Structural	T082	C0678594
Differences	T081	C1705241
Attention Deficit Hyperactivity Disorder	T048	C1263846
Attention deficit hyperactivity disorder	T048	C1263846
ADHD	T048	C1263846
prevalent	T081	C0220900
neurodevelopmental disorder	T048	C1535926
affecting	T169	C0392760
children	T100	C0008059
adolescents	T100	C0205653
adults	T100	C0001675
etiology	T169	C1314792
result	T169	C1274040
diverse	T080	C1880371
pathophysiologies	T046	C0277785
affect	T169	C0392760
structure	T082	C0678594
function	T169	C0542341
specific	T080	C0205369
brain circuits	UnknownType	C0682723
neurobiological abnormalities	T047	C0027765
ADHD	T048	C1263846
reduced	T080	C0392756
fronto-striatal-cerebellar gray matter	T023	C3850014
GM	T024	C0018220
volume	T081	C0449468
genetic	T169	C0314603
correlates	T080	C1707520
unknown	T080	C0439673
study	T062	C2603343
T1-weighted MR images of brain structure	T060	C2454640
adolescents	T100	C0205653
ADHD	T048	C1263846
diagnosed	T033	C0011900
multivariate parallel independent component analysis	T081	C0026777
Para-ICA	T081	C0026777
technique	T169	C0449851
imaging	T060	C0011923
genetic	T169	C0314603
relationships	T080	C0439849
regional	T082	C0205147
GM	T024	C0018220
volume	T081	C0449468
single nucleotide polymorphism	T086	C0752046
data	T078	C1511726
Para-ICA analyses	T081	C0026777
genetic data	T170	C0872179
MR	T060	C0024485
data	T078	C1511726
iterative cross-validation	T062	C0681935
stability	T080	C0205360
ICA	T081	C0026777
solutions	T077	C2699488
partial correlation analyses	UnknownType	C0678931
controlling	T067	C2239193
age	T032	C0001779
sex	T032	C1522384
ethnicity	T080	C0243103
genotype-phenotype	T032	C0678920
component	T077	C1705248
pairs	T080	C1709450
ADHD	T048	C1263846
non-ADHD	T033	C0243095
groups	T078	C0441833
Bonferroni correction	T081	C2347434
multiple	T081	C0439064
comparisons	T052	C1707455
brain	T023	C0006104
phenotype	T032	C0031437
component	T077	C1705248
structures	T082	C0678594
abnormally low	T080	C1299352
volume	T081	C0449468
ADHD	T048	C1263846
studies	T062	C2603343
associated with	T080	C0332281
ADHD	T048	C1263846
symptom severity	T033	C1319166
performance	T052	C1882330
cognitive tests	T170	C0392366
patients	T101	C0030705
diagnosed	T033	C0011900
disorder	T047	C0012634
Pathway analysis	T170	C0868995
genotype	T032	C0017431
component	T077	C1705248
biological	T080	C0205460
pathways	T077	C1705987
structural	T082	C0678594
abnormalities	T033	C1704258
ADHD	T048	C1263846
pathways	T077	C1705987
dopaminergic neurotransmission	T042	C0234101
neurodevelopment	T042	C0599855
hypothesized	T078	C1512571
abnormal	T033	C0205161
ADHD	T048	C1263846
pathways	T077	C1705987
glutamatergic	T043	C1523698
GABA-eric physiological systems	T042	C0234105
ADHD	T048	C1263846
sleep abnormalities	T184	C0037317
Clinicopathological	T058	C0282421
Immunohistochemical	T059	C1441616
Verruciform Xanthoma	T047	C3872816
Lower Gingiva	T023	C0227123
Case Report	T170	C0085973
Verruciform xanthoma	T047	C3872816
VX	T047	C3872816
benign lesion	T191	C0086692
oral mucosa	T023	C0026639
slow-growing	T033	C4086857
asymptomatic	T033	C0231221
lesion	T191	C0086692
gingival margin	T029	C1184544
masticatory	T169	C0005654
mucosa	T024	C0026724
hard palate	T023	C0226901
tongue	T023	C0040408
buccal mucosa	T023	C1578559
floor of the mouth	T029	C0026638
alveolar mucosa	T029	C4239924
soft palate	T023	C0030219
junction	T082	C0205144
hard	T023	C0226901
soft palate	T023	C0030219
lesion	T191	C0086692
skin	T022	C1123023
genital organs	T023	C0017420
Clinically	T080	C0205210
VX	T047	C3872816
sessile	T033	C1335952
pedunculated appearance	T033	C1335371
papule	T033	C0332563
single plaque	T033	C2221189
verrucous	T191	C0206706
papillomatous	T191	C0030354
mucosal	T024	C0026724
growth	T042	C1621966
colour	T080	C0009393
white	T080	C0220938
pink	T080	C0332585
grey	T080	C1269776
yellow	T080	C0221205
thickness	T080	C1280412
epidermis	T024	C0014520
clinical	T080	C0205210
findings	T033	C0243095
VX	T047	C3872816
verrucous carcinoma	T191	C0206706
benign tumours	T191	C0086692
squamous papilloma	T191	C0205874
verruca vulgaris	T047	C0043037
mucosal fibroma	T191	C0016045
clinical	T080	C0205210
histopathological	T169	C0243140
examinations	T058	C0031809
accurate differential diagnosis	T060	C0011906
Histologically	T169	C0205462
VX	T047	C3872816
parakeratosis	T047	C0030436
rete ridges	T024	C1516920
accumulation	T033	C4055506
foam cells	T025	C0016390
xanthoma cells	T025	C1520164
clinicopathological	T058	C0282421
immunohistochemical	T059	C1441616
findings	T033	C0243095
VX	T047	C3872816
lower gingiva	T023	C0227123
male patient	T032	C0150904
MicroRNA 101b	T028	C2825314
Downregulated	T044	C0013081
Prefrontal Cortex	T023	C0162783
Genetic Model	T170	C0026343
Depression	T048	C0011581
Targets	T169	C1521840
Glutamate Transporter	T116	C0061467
SLC1A1	T116	C1529079
EAAT3	T116	C1529079
in Vitro	T080	C1533691
MicroRNAs	T114	C1101610
miRNAs	T114	C1101610
small	T081	C0700321
regulatory	T077	C1704735
molecules	T167	C0567416
translational repression	T045	C1519619
base pairing with target mRNAs	T044	C2263416
Cumulative	T080	C1511559
evidence	T078	C3887511
changes	T169	C0392747
miRNA	T028	C2825314
expression	T045	C0017262
pathophysiology	T169	C0031847
treatment	T061	C0087111
neuropsychiatric disorders	T047	C2015799
major depressive disorder	T048	C1269683
MDD	T048	C1269683
miRNA	T028	C2825314
expression	T045	C0017262
assay	T059	C0005507
simultaneously	T079	C0521115
miRNAs	T028	C2825314
profile	T059	C1979963
prefrontal cortex	T023	C0162783
PFC	T023	C0162783
genetic rat model	T170	C0026343
MDD	T048	C1269683
Flinders Sensitive Line	T170	C0026343
FSL	T170	C0026343
controls	T096	C0009932
Flinders Resistant Line	T170	C0026343
FRL	T170	C0026343
Gene expression	T045	C0017262
data	T078	C1511726
PFC	T023	C0162783
FSL	T170	C0026343
FRL	T170	C0026343
animals	T008	C0003062
mRNA	T114	C0035696
target	T169	C1521840
selection	T052	C1707391
Luciferase reporter assays	T059	C0005507
verify	T169	C1711411
miRNA	T028	C2825314
targets	T169	C1521840
in vitro	T080	C1533691
identified	T080	C0205396
miRNAs	T028	C2825314
downregulated	T044	C0013081
PFC	T023	C0162783
FSL model	T170	C0026343
compared	T052	C1707455
controls	T096	C0009932
identified	T080	C0205396
miRNAs	T028	C2825314
miR-101b	T028	C2825314
conserved	T080	C2347858
rat	T015	C0086893
human	T016	C0086418
downregulated	T044	C0013081
PFC	T023	C0162783
depressed	T184	C1579931
suicide	T033	C0038661
subjects	T096	C0681850
combination	T080	C0205195
in silico	T066	C3489666
in vitro	T080	C1533691
analyses	T062	C0936012
miR-101b	T028	C2825314
targets	T169	C1521840
neuronal	T025	C0027882
glutamate transporter	T116	C0061467
SLC1A1	T116	C1529079
EAAC1	T116	C1529079
EAAT3	T116	C1529079
mRNA	T114	C0035696
protein levels	T034	C0428479
SLC1A1	T116	C1529079
upregulated	T044	C0041904
PFC	T023	C0162783
FSL model	T170	C0026343
miRNAs	T028	C2825314
associated with	T080	C0332281
depression-like states	T033	C0344315
preclinical study	T062	C1709631
replicated	T169	C0205173
human	T016	C0086418
association	T080	C0439849
miR-101	T028	C2825314
depression	T048	C0011581
targets	T169	C1521840
miR-101b	T028	C2825314
glutamate transporter	T116	C0061467
preclinical	T080	C1709630
data	T078	C1511726
hypothesis	T078	C1512571
glutamatergic	T121	C0242899
dysregulation	T033	C0243095
etiology	T169	C1314792
depression	T048	C0011581
Practical Guide	T097	C0181090
Forensic Nursing	T091	C1721027
Incorporating	T169	C0332257
forensic	T091	C1721027
principles	T081	C1882460
nursing practice	T058	C0028687
Amar Angela F	T016	C0086418
Sekula L Kathleen	T016	C0086418
Practical Guide	T097	C0181090
Forensic Nursing	T091	C1721027
forensic	T091	C1721027
principles	T081	C1882460
nursing practice	T058	C0028687
George Bernard Shaw	T016	C0086418
Britons	T098	C0337925
Americans	T098	C0596070
divided	T169	C0332849
common language	T171	C0023008
fascinating publication	T073	C0034036
roles and responsibilities	T170	C3890565
forensic nurses	T097	C0028661
US	T083	C0041703
Incidence	T081	C0021149
Diabetes Mellitus	T047	C0011849
Obesity	T047	C0028754
Overlap	T079	C1948020
Comorbidities	T078	C0009488
HIV+	T034	C0019699
Hispanics	T098	C0086409
Initiating	T169	C1704686
Antiretroviral Therapy	T061	C1963724
Cardiovascular disease	T047	C0007222
CVD	T047	C0007222
health	T078	C0018684
threat	T078	C0749385
HIV+	T034	C0019699
patients	T101	C0030705
antiretroviral therapy	T061	C1963724
ART	T061	C1963724
cardiometabolic	T047	C0025517
comorbidities	T078	C0009488
predictors of risk	T033	C0035648
Data	T078	C1511726
incidence	T081	C0021149
metabolic	T169	C0311400
comorbidities	T078	C0009488
HIV+	T034	C0019699
individuals	T098	C0237401
initiating	T169	C1704686
ART	T061	C1963724
low	T080	C0870823
middle income	T080	C0870890
countries	T083	C0454664
LMICs	T083	C0454664
particularly	T080	C0205556
Hispanics	T098	C0086409
examined	T033	C0332128
incidence	T081	C0021149
diabetes	T047	C0011847
obesity	T047	C0028754
prospective cohort	T098	C0599755
initiating	T169	C1704686
ART	T061	C1963724
Dominican Republic	T083	C0013014
Participants	T098	C0679646
years	T079	C0439234
initiating	T169	C1704686
ART	T061	C1963724
days	T079	C0439228
study	T062	C2603343
enrollment	T058	C1516879
examined	T033	C0332128
incidence	T081	C0021149
impaired fasting glucose	T033	C1272092
IFG	T033	C1272092
diabetes mellitus	T047	C0011849
DM	T047	C0011849
overweight, and obesity	T047	C1561826
Fasting plasma glucose	T059	C0583513
FPG	T059	C0583513
IFG	T033	C1272092
FPG	T059	C0583513
diagnosis	T062	C1704656
medical record	T170	C0025102
hypoglycemic medication	T121	C0020616
DM	T047	C0011849
Overweight and obesity	T047	C1561826
BMI	T201	C1305855
Dyslipidemia	T047	C0242339
total cholesterol	T109	C0543421
use of	T169	C1524063
lipid-lowering medication	T121	C0003367
Framingham risk equation	T170	C3176199
used	T033	C1273517
determine	T080	C0521095
ten-year	T079	C0439234
CVD	T047	C0007222
risk	T058	C0086930
end of observation	T062	C0302523
initiating	T169	C1704686
ART	T061	C1963724
DM	T047	C0011849
IFG	T033	C1272092
baseline	T081	C1442488
DM	T047	C0011849
person	T098	C0027361
years	T079	C0439234
follow up	T058	C1522577
PYFU	T058	C1522577
IFG	T033	C1272092
PYFU	T058	C1522577
baseline	T081	C1442488
obese	T047	C0028754
overweight	T184	C0497406
obese	T047	C0028754
PYFU	T058	C1522577
overweight	T184	C0497406
PYFU	T058	C1522577
Median	T082	C2939193
observation	T058	C0700325
periods	T079	C1948053
diabetes	T047	C0011847
obesity	T047	C0028754
analyses	T062	C0936012
months	T079	C0439231
months	T079	C0439231
Increased	T081	C0205217
CVD	T047	C0007222
risk	T058	C0086930
10-year Framingham risk score	T033	C4086295
present	T033	C0150312
cohort	T098	C0599755
cohort	T098	C0599755
cardiometabolic comorbidity	T078	C0009488
Hispanic	T098	C0086409
cohort	T098	C0599755
LMIC	T083	C0454664
incidences	T081	C0021149
IFG	T033	C1272092
DM	T047	C0011849
overweight	T184	C0497406
obesity	T047	C0028754
similar	T080	C2348205
higher than	T080	C0205250
found	T033	C0150312
high income	T033	C0948433
countries	T083	C0454664
cardiometabolic disorders	T047	C0025517
affected	T169	C0392760
initiating	T169	C1704686
ART	T061	C1963724
Care models	T170	C0596657
cardiovascular risk	T047	C0850624
reduction	T061	C0441610
HIV	T047	C0019693
treatment programs	T058	C0679841
needed	T080	C0027552
prevent	T169	C1292733
CVD	T047	C0007222
associated	T080	C0332281
mortality	T081	C0205848
vulnerable population	T098	C0949366
Laparoscopic Approach	T060	C0031150
Thermoablation Microwave	T061	C3854551
Treatment	T061	C0087111
Hepatocellular Carcinoma	T191	C2239176
Experience	T041	C0596545
surgical therapy	T061	C0543467
hepatocellular carcinoma	T191	C2239176
HCC	T191	C2239176
liver transplantation	T061	C0023911
LT	T061	C0023911
hepatic resection	T061	C0400440
small	T081	C0700321
percentage	T081	C0439165
patients	T101	C0030705
procedures	T169	C2700391
Microwave thermal ablation	T061	C3854551
MWTA	T061	C3854551
effective	T080	C1280519
alternative	T077	C1523987
treatment	T061	C0087111
HCC	T191	C2239176
complicates	T169	C0231242
cirrhotic liver disease	T047	C0023890
final	T079	C3853528
procedure	T169	C2700391
downstaging	T060	C0430022
patients	T101	C0030705
LT	T061	C0023911
combination	T080	C0205195
resective	T061	C0015252
surgery	T061	C0543467
oncological	T191	C0027651
radicality	T080	C0439807
retrospective study	T062	C0035363
evaluate	T058	C0220825
experience	T041	C0596545
laparoscopic approach	T060	C0031150
MWTA	T061	C3854551
cohort	T098	C0599755
consecutive	T080	C1707491
patients	T101	C0030705
MWTA	T061	C3854551
laparoscopic approach	T060	C0031150
demographic data	T062	C0011289
Barcelona clinic liver cancer stage	T185	C3899974
severity	T080	C0439793
cirrhotic liver disease	T047	C0023890
size	T082	C0456389
ablated	T061	C0547070
lesion	T033	C0221198
duration	T079	C0449238
procedure	T169	C2700391
complications	T169	C0231242
days	T079	C0439228
surgery	T061	C0543467
MWTA	T061	C3854551
hepatic	T029	C0205054
parenchymal	T024	C4277702
insertions	T058	C0441587
mean	T081	C0444504
patient	T101	C0030705
mean	T081	C0444504
duration	T079	C0449238
surgery	T061	C0543467
minutes	T079	C0439232
blood loss	T033	C3163616
procedures	T169	C2700391
necrosis	T042	C0027540
CT scan	T060	C0040405
patients	T101	C0030705
mean	T081	C0444504
hospital stay	T079	C3489408
days	T079	C0439228
complications	T169	C0231242
postablation	T079	C1292448
syndrome	T047	C0039082
peritoneal fluid	T031	C0003964
transient	T079	C0205374
jaundice	T047	C0022354
patients	T101	C0030705
no mortality	T033	C0243095
Laparoscopic	T060	C0031150
MWTA	T061	C3854551
effective	T080	C1280519
treatment	T061	C0087111
unresectable	T201	C1519810
HCC	T191	C2239176
percutaneous	T082	C0522523
procedure	T169	C2700391
Structured	T082	C0678594
Instruction	T170	C1442085
Modified	T169	C0392747
Storybooks	UnknownType	C0814818
Teach	T065	C0039401
Morphosyntax	T090	C0023741
Vocabulary	T170	C0042926
Preschoolers	T100	C0008100
Deaf	T101	C3824904
Hard of Hearing	T101	C0525064
Children	T100	C0008059
deaf	T101	C3824904
hard of hearing	T101	C0525064
D	T101	C3824904
HH	T101	C0525064
at risk	T080	C1444641
diminished	T081	C0205216
morphosyntactical	T090	C0023741
vocabulary	T170	C0042926
development	T169	C1527148
effects of	T080	C1704420
repeated	T169	C0205341
reading	T056	C0034754
combined	T080	C0205195
structured	T082	C0678594
instruction	T170	C1442085
Targets	T169	C1521840
morphosyntactical form	T090	C0023741
vocabulary words	T170	C0042926
Participants	T098	C0679646
preschoolers	T100	C0008100
D	T101	C3824904
HH	T101	C0525064
receiving	T080	C1514756
instruction	T170	C1442085
oral	T082	C0442027
Data	T078	C1511726
multiple	T081	C0439064
baseline design	T062	C0282121
children	T100	C0008059
acquired	T052	C1706701
targeted	T169	C1521840
skills	T055	C0678856
generalization	T041	C0237635
skills	T055	C0678856
untrained	T033	C0243095
context	T078	C0449255
Implications	T080	C0205556
teaching	T065	C0039401
young	T079	C0332239
children	T100	C0008059
D	T101	C3824904
HH	T101	C0525064
using	T169	C1524063
repeated	T169	C0205341
storybook	UnknownType	C0814818
reading	T056	C0034754
Application	T058	C0185125
BRAF V600E	T033	C3250916
mutation	T045	C0026882
specific	T080	C0205369
immunohistochemistry	T060	C0021044
diagnosis	T033	C0011900
gastrointestinal stromal tumors	T191	C0238198
evaluate	T058	C0220825
BRAF V600E	T033	C3250916
allele	T028	C0002085
specific	T080	C0205369
antibody	T116	C0003241
diagnosis	T033	C0011900
gastrointestinal stromal tumors	T191	C0238198
GISTs	T191	C0238198
BRAF V600E	T033	C3250916
mutation	T045	C0026882
specific	T080	C0205369
immunohistochemistry	T060	C0021044
BRAF	T028	C0812241
sequencing	T169	C1561491
consecutive	T080	C1707491
GISTs	T191	C0238198
cases	T169	C0868928
KIT	T049	C1511353
PDGFRA mutations	T049	C1518782
cases	T169	C0868928
KIT	T028	C1416655
PDGFRA wild	T028	C1705319
GISTs	T191	C0238198
GISTs	T191	C0238198
men	T098	C0025266
women	T098	C0043210
mean	T081	C2347634
age	T032	C0001779
tumors	T191	C0027651
stomach	T023	C0038351
cases	T169	C0868928
small bowel	T023	C0021852
cases	T169	C0868928
peritoneal cavity	T030	C1704247
case	T169	C0868928
Strong	T080	C0442821
diffuse	T082	C0205219
cytoplasmic	T026	C0521449
BRAF	T116	C1259929
staining	T033	C1704680
noted	T080	C4288581
cases	T169	C0868928
cases	T169	C0868928
weak	T080	C1762617
staining	T033	C1704680
cases	T169	C0868928
no	T169	C0332197
staining	T033	C1704680
cases	T169	C0868928
strong	T080	C0442821
BRAF	T116	C1259929
immunostain	T130	C0038128
confirmed	T080	C0521093
BRAF mutations	T049	C1511021
cases	T169	C0868928
stomach	T023	C0038351
case	T169	C0868928
small intestine	T023	C0021852
tumors	T191	C0027651
spindle cell	T025	C0682540
morphology	T080	C0332437
case	T169	C0868928
progressive disease	T047	C1335499
No	T169	C0332197
BRAF mutations	T049	C1511021
detected	T033	C0442726
cases	T169	C0868928
weak	T080	C1762617
negative	T033	C0205160
BRAF	T116	C1259929
immunostain	T130	C0038128
BRAF V600E	T033	C3250916
mutation	T045	C0026882
specific	T080	C0205369
immunohistochemistry	T060	C0021044
highly sensitive	T080	C0439822
specific	T080	C0205369
marker	T201	C0005516
detecting	T033	C0442726
BRAF-mutated	T049	C1511021
GISTs	T191	C0238198
pegylated liposomal etoposide nanoparticles	T109	C0015133
breast cancer cell lines	T025	C1512505
efficacy of	T080	C1280519
pegylated liposomal etoposide nanoparticles	T109	C0015133
T-47D	T050	C3897399
MCF-7 breast cancer cell lines	T025	C0596890
Pegylated liposomal etoposide NPs	T109	C0015133
reverse phase evaporation method	T070	C0596539
size	T082	C0456389
size distribution	T082	C0037775
zeta potential	T067	C0597697
NPs	T109	C0015133
Zetasizer instrument	T074	C0348000
cytotoxicity	T049	C0596402
NPs	T109	C0015133
methyl thiazol tetrazolium assay	T062	C2986858
release pattern of the drug from the vesicles	UnknownType	C0360812
dialysis method	T061	C3483167
Drug loading	UnknownType	C0678767
encapsulation efficiency	T067	C2348438
EE	T067	C2348438
mean size	T082	C0456389
size distribution	T082	C0037775
zeta potential	T067	C0597697
pegylated liposomal etoposide NPs	T109	C0015133
Drug loading	UnknownType	C0678767
EE	T067	C2348438
etoposide release in the formulation	T073	C1707824
cytotoxicity effect	T049	C0596402
etoposide NPs	T109	C0015133
T-47D	T050	C3897399
MCF-7 cell lines of breast cancer	T025	C0596890
antitumor activity	T080	C2986475
free drug	T081	C0678752
Liposome-based NPs	T109	C0015133
drug delivery system	T074	C0085104
Bindex(®) ultrasound device	T074	C1875843
reliability	T081	C2347947
cortical bone	T023	C0222652
thickness	T080	C1280412
measures	T081	C0079809
relationship	T080	C0439849
regional	T082	C0205147
bone mineral density	T201	C0005938
Bindex(®) quantitative ultrasound (QUS) device	T074	C1875843
study	T062	C2603343
analyzed	T062	C0936012
relative	T080	C0205345
absolute	T080	C0205344
intra- and inter-session reliability	T081	C2347947
relationship	T080	C0439849
data	T078	C1511726
Bindex(®)-QUS	T074	C1875843
bone mineral density	T201	C0005938
BMD	T201	C0005938
measured	T080	C0444706
dual-energy x-ray absorptiometry	T060	C1510486
skeletal sites	T082	C1282387
young	T098	C0080105
healthy subjects	T098	C1708335
age	T032	C0001779
years	T079	C1510829
Bindex(®)-QUS	T074	C1875843
calculates	T052	C1441506
density index	T201	C0005938
thickness	T080	C1280412
cortical bone	T023	C0222652
measured	T080	C0444706
distal radius	T023	C0588207
distal	T023	C0588200
proximal tibia	T023	C0588198
data	T078	C1511726
relative	T080	C0205345
absolute	T080	C0205344
intra-	T081	C2347947
ICC	T081	C0392762
CV	T081	C0681921
inter-session reliability	T081	C2347947
ICC	T081	C0392762
CV	T081	C0681921
density index	T201	C0005938
highest	T080	C1522410
positive	T033	C1446409
correlations	T080	C1707520
cortical	T023	C0222652
thickness	T080	C1280412
BMD	T201	C0005938
distal radius	T023	C0588207
distal tibia	T023	C0588200
data	T078	C1511726
Bindex(®)-QUS	T074	C1875843
parameters	T033	C0449381
measurement	T169	C0242485
sessions	T077	C1883017
measurements	T169	C0242485
BMD	T201	C0005938
specific	T080	C0205369
skeletal sites	T082	C1282387
Bindex(®)-QUS	T074	C1875843
measurement	T169	C0242485
skeletal adaptations	T039	C2248552
Botulinum Toxin	T116	C0006055
Refractory Pain	T184	C0030200
Symptoms	T184	C1457887
Parkinsonism	T047	C0242422
Parkinson's disease	T047	C0030567
PD	T047	C0030567
parkinsonian syndromes	T047	C0242422
chronic	T079	C0205191
progressive	T169	C0205329
neurodegenerative diseases	T047	C0524851
disease	T047	C0012634
motor	T184	C0426980
non-motor symptoms	T184	C1457887
burden	T078	C2828008
symptom	T184	C1457887
relief	T033	C0564405
quality of life	T078	C0034380
improvement	T077	C2986411
goal	T170	C0018017
treatment	T061	C0087111
Botulinum toxins	T116	C0006055
BTX	T116	C0006055
effective	T080	C1704419
treatment	T061	C0087111
modality	T078	C0695347
neurological conditions	T047	C0027765
potential	T080	C3245505
usefulness	T080	C3827682
BTX	T116	C0006055
population	T098	C1257890
performed	T169	C0884358
retrospective	T080	C1514923
chart review	T058	C0541653
patients	T101	C0030705
clinical diagnosis	T060	C0332140
idiopathic PD	T047	C0865475
atypical parkinsonism	T047	C4302185
treatment	T169	C0039798
BTX injections	T061	C1321035
center	T093	C1708333
symptoms	T184	C1457887
Response	T032	C0871261
BTX	T116	C0006055
assessed	T052	C1516048
subjective Clinical Global Impression	T170	C3639708
Records	T170	C0034869
patients	T101	C0030705
reviewed	T080	C1709940
idiopathic PD	T047	C0865475
diagnosis	T033	C0011900
patients	T101	C0030705
indication	T078	C3146298
BTX	T116	C0006055
treatment	T061	C0087111
pain	T184	C0030193
indications	T078	C3146298
treatment	T061	C0087111
functional impairment	T033	C4062321
resulting	T169	C0678226
dystonia	T184	C0013421
sialorrhea	T047	C0037036
freezing of gait	T184	C0860515
camptocormia	T020	C0264162
pain	T184	C0030193
indication	T078	C3146298
patients	T101	C0030705
PD	T047	C0030567
reported	T058	C0700287
benefits	T081	C0814225
BTX injections	T061	C1321035
benefit	T081	C0814225
maintained	T169	C1314677
last recorded visit	T058	C1512346
difference	T080	C1705242
outcome	T169	C1274040
compared	T052	C1707455
injection	T061	C0021485
results	T169	C1274040
patients	T101	C0030705
atypical parkinsonism	T047	C4302185
results	T169	C1274040
efficacy	T080	C1280519
different	T080	C1705242
uses	T169	C0457083
BTX	T116	C0006055
symptomatic	T169	C0231220
treatment	T169	C1522326
patients	T101	C0030705
parkinsonism	T047	C0242422
advanced	T080	C0205179
stages	T079	C1306673
disease	T047	C0012634
suggest	T078	C1705535
BTX	T116	C0006055
treatment	T061	C0087111
role	T077	C1705810
treatment	T169	C1522326
pain	T184	C0030193
population	T098	C1257890
Chronic exposure to	T033	C0743284
haloperidol	T109	C0018546
olanzapine	T109	C0171023
shape changes	T033	C1562006
rat	T015	C0034693
hippocampus	T023	C0019564
grey-matter	T024	C0018220
volume loss	T169	C0205245
brain abnormalities	T190	C4021085
schizophrenia	T048	C0036341
SCZ	T048	C0036341
volume and shape deformation	T033	C1562006
hippocampus	T023	C0019564
chronic antipsychotic medication	T121	C0040615
exposure	T033	C0743284
chronic exposure	T033	C0743284
relevant doses	T081	C0178602
haloperidol	T109	C0018546
HAL	T109	C0018546
olanzapine	T109	C0171023
OLZ	T109	C0171023
rat	T015	C0034693
hippocampal	T029	C3496509
volume and shape	T033	C0243095
ex vivo	T169	C2348480
structural MRI	T060	C0024485
brain retained inside the cranium	T023	C0037303
distortions	T190	C0332482
dissection	T061	C0012737
tensor-based morphometry	T059	C0200760
TBM	T059	C0200760
elastic surface-based shape deformation analysis	T062	C0936012
hippocampus	T023	C0019564
post-mortem	T060	C0004398
brain tissue	T023	C0459385
Chronic exposure	T033	C0743284
HAL	T109	C0018546
OLZ	T109	C0171023
hippocampus	T023	C0019564
exploratory thresholds	T060	C0430009
post-mortem	T060	C0004398
shape deformation analysis	T062	C0936012
HAL	T109	C0018546
OLZ	T109	C0171023
exposure	T033	C0743284
divergent shape deformations	T033	C1562006
rat	T015	C0034693
hippocampus	T023	C0019564
dorsal hippocampus	T023	C0019564
HAL	T109	C0018546
exposure	T033	C0743284
inward shape deformation	T033	C1562006
OLZ	T109	C0171023
exposure	T033	C0743284
outward shape deformation	T033	C1562006
outward shape deformations	T033	C1562006
drugs	T121	C0013227
ventral hippocampus	T023	C0019564
hippocampal	T023	C0019564
shape changes	T033	C1562006
Chronic exposure	T033	C0743284
HAL	T109	C0018546
OLZ	T109	C0171023
rat	T015	C0034693
hippocampal shape	T023	C0175202
Shear	T070	C1254365
extensional properties	T070	C1254365
kefiran	T109	C0628688
Kefiran	T109	C0628688
neutral polysaccharide	T109	C0032594
glucose	T109	C0017725
galactose	T109	C0016945
Lactobacillus kefiranofaciens	T007	C0317649
kefir grains	T168	C4280055
health promoting properties	T070	C1254365
shear	T070	C1254365
extensional properties	T070	C1254365
different	T080	C1705242
kefiran	T109	C0628688
aqueous dispersions	T167	C0439861
assessed	T052	C1516048
compared	T052	C1707455
neutral gums	T109	C0029224
food	T168	C0016452
cosmetic	T073	C0010164
pharmaceutics industries	T093	C0013185
methylcellulose	T109	C0025729
locust bean gum	T200	C3190255
guar gum	T109	C0061996
Kefiran	T109	C0628688
shear flow characteristics	T070	C1254365
neutral gums	T109	C0029224
lower	T080	C0205251
viscosities	T070	C0042784
concentration	T081	C0392762
gum	T109	C0029224
system	T169	C0449913
correlation	T080	C1707520
dynamic and steady shear properties	T070	C1254365
master curve	T082	C0205134
apparent	T078	C0750489
complex	T080	C0439855
viscosities	T070	C0042784
extensional properties	T070	C1254365
gums	T109	C0029224
capillary break-up rheometer	T073	C0699733
kefiran	T109	C0628688
solutions	T167	C0037633
extensional properties	T070	C1254365
behaviour	T080	C1521970
Newtonian	T080	C0205556
Air	T167	C0001861
tamponade	T169	C0332459
heart	T023	C0018787
Pneumopericardium	T047	C0032319
rare disease	T047	C0678236
presence	T033	C0150312
air	T167	C0001861
gas	T104	C0017110
pericardial sac	T023	C0031050
etiological factors	T169	C1521761
chest trauma	T037	C0039980
barotrauma	T037	C0004760
air	T167	C0001861
fistulas	T190	C0016169
pericardium	T023	C0031050
surrounding	T082	C1282914
structures	T082	C0678594
secondary gas production	T169	C0205245
microorganisms	T001	C0445623
pericardial sac	T023	C0031050
iatrogenic	T080	C0439669
factors	T169	C1521761
spontaneous	T169	C0205359
pneumopericardium	T047	C0032319
considered	T078	C0750591
harmless	T080	C0205556
temporary	T079	C0205374
state	T169	C1442792
review of	T169	C0699752
clinical cases	T077	C1706256
presence	T033	C0150312
air	T167	C0001861
pericardium	T023	C0031050
cardiac tamponade	T047	C0007177
life-threatening	T033	C2826244
hemodynamic	T042	C0019010
disturbances	T080	C2699787
present	T033	C0150312
year-old	T079	C1510829
patient	T101	C0030705
chronic	T079	C0205191
bronchopericardial	T023	C1186133
fistula	T190	C0016169
cardiac arrest	T047	C0018790
air	T167	C0001861
tamponade	T169	C0332459
heart	T023	C0018787
Complete	T080	C0205197
Chloroplast Genome	T028	C1955992
Sequence	T086	C0314659
Medicinal Plant	T002	C0032100
Swertia mussotii	T002	C1624947
PacBio RS II Platform	T074	C1609455
Swertia mussotii	T002	C1624947
medicinal plant	T002	C0032100
great	T081	C0549177
economic	T081	C0392762
medicinal value	T121	C1254351
Qinghai Tibetan Plateau	UnknownType	C0681784
complete	T080	C0205197
chloroplast (cp) genome	T028	C1955992
S. mussotii	T002	C1624947
size	T081	C3178847
pair	T080	C1709450
inverted repeat (IR) regions	T114	C2350250
separate	T080	C0443299
large single-copy (LSC) region	T086	C0314659
small single-copy (SSC) region	T086	C0314659
S. mussotii	T002	C1624947
cp genome	T028	C1955992
encodes	T052	C2700640
protein-coding genes	T028	C3839127
transfer RNA	T114	C0035711
tRNA	T114	C0035711
genes	T028	C0017337
ribosomal RNA (rRNA) genes	T028	C0035899
GC content	T081	C1135899
S. mussotii	T002	C1624947
cp genes	T028	C1955992
genomes	T028	C0017428
Gentianales	T002	C1080874
species	T185	C1705920
analysis	T062	C0936012
repeat structure	T086	C0314659
repeats	T086	C0314659
palindromic repeats	T114	C2350254
detected	T033	C0442726
S. mussotii	T002	C1624947
cp genome	T028	C1955992
SSRs	T114	C1519302
S. mussotii	T002	C1624947
cp genome	T028	C1955992
majority	T080	C0205164
mononucleotides	T114	C0028630
Gentianales	T002	C1080874
species	T185	C1705920
entire	T081	C0439751
cp genome	T028	C1955992
comparison study	T062	C1579762
S. mussotii	T002	C1624947
species	T185	C1705920
Gentianaceae	T002	C0950077
complete	T080	C0205197
cp genome	T028	C1955992
sequence	T086	C0314659
intragenic	T028	C0017337
information	T078	C1533716
cp	T026	C0008266
genetic engineering	T063	C0017387
medicinal plant	T002	C0032100
Meta-Analysis	T062	C0920317
Experiments	T062	C0681814
Evaluating	T058	C1261322
Effects of	T080	C1704420
Rapamycin	T109	C0072980
Life Span	T102	C0870809
Laboratory Mouse	T015	C0025929
Rapamycin	T109	C0072980
effects	T080	C1280500
aging	T040	C0001811
mice	T015	C0025929
applied	T169	C4048755
healthy	T080	C3898900
aging	T040	C0001811
humans	T016	C0086418
study	T062	C2603343
analyzed	T062	C0936012
raw	T080	C1709843
data	T078	C1511726
survival studies	T062	C0038953
rapamycin	T109	C0072980
control	T167	C1550141
treated	T169	C1522326
mice	T015	C0025929
goals	T170	C0018017
estimating	T081	C0750572
summary	T170	C1706244
statistics	T170	C0600673
identifying	T080	C0205396
factors	T169	C1521761
associated with	T080	C0332281
effect size	T081	C0814843
heterogeneity	T080	C0019409
Meta-analysis	T062	C0920317
demonstrated	T080	C0443289
significant	T078	C0750502
heterogeneity	T080	C0019409
studies	T059	C0947630
hazard ratio	T081	C2985465
(HR)	T081	C2985465
estimates	T081	C0750572
ranging	T081	C1514721
confidence interval	T081	C0009667
[CI]	T081	C0009667
CI	T081	C0009667
Sex	T032	C1522384
major	T080	C0205164
factor	T169	C1521761
accounting	T169	C0586014
effect size	T081	C0814843
variation	T080	C0205419
mortality	T081	C0205848
decreased	T081	C0205216
more	T081	C0205172
females	T032	C0086287
HR	T081	C2985465
CI	T081	C0009667
compared	T052	C1707455
males	T032	C0086582
HR	T081	C2985465
CI	T081	C0009667
Rapamycin	T109	C0072980
effects	T080	C1280500
genotype	T032	C0017431
dependent	T080	C1701901
stronger	T080	C0442821
survivorship	T079	C0038955
increases	T169	C0442805
hybrid	T001	C0020205
mice	T015	C0025929
CI	T081	C0009667
relative	T080	C0205345
pure	T001	C0599804
inbred strains	T015	C0025927
CI	T081	C0009667
Number	T081	C0237753
needed	T169	C1514873
treat	T169	C1522326
applied	T169	C4048755
effect size	T081	C0814843
metric	T081	C0025867
identified	T080	C0205396
senescence	T033	C0231337
age	T032	C0001779
peak	T080	C0444505
treatment	T169	C0039798
benefit	T081	C0814225
results	T169	C1274040
provide	T052	C1999230
synthesis	T052	C1883254
existing	T077	C2987476
data	T078	C1511726
support	T077	C1521721
translation	T062	C3494164
findings	T033	C0243095
mouse	T015	C0025929
primate species	T015	C0033147
rapamycin's	T109	C0072980
effect	T080	C1280500
survival	T052	C0038952
depends	T080	C1701901
sex	T032	C1522384
genotype	T032	C0017431
factors	T169	C1521761
treatment	T169	C0039798
response	T032	C0871261
Transfusion medicine	T091	C1273858
medical education	T065	C0013631
analysis	T062	C0936012
curricular grids	UnknownType	C0681363
Brazil	T083	C0006137
review	T078	C1552617
current literature	T170	C0023866
Blood transfusions	T061	C0005841
medical procedures	T058	C0199171
world	T098	C2700280
education	T065	C0013621
transfusion medicine	T091	C1273858
vital	T080	C0442732
medical care	T033	C0496675
promote	T052	C0033414
practice	T057	C0033284
blood	T031	C0005767
doctors	T097	C0031831
investigate	T169	C1292732
teaching	T065	C0039401
transfusion medicine	T091	C1273858
medical schools	T073	C0036378
Brazil	T083	C0006137
websites	T170	C2349146
Brazilian	T098	C1257890
medical schools	T073	C0036378
operation	T052	C3241922
curricula	T170	C0010478
medical courses	T065	C0013652
investigated	T169	C1292732
transfusion medicine discipline	T091	C1273858
analyzed	T062	C0936012
description of content	T170	C0678257
transfusion medicine	T091	C1273858
disciplines	T090	C1518533
medical school	T073	C0036378
information	T078	C1533716
curriculum	T170	C0010478
medical schools	T073	C0036378
published	T057	C0034037
curriculum	T170	C0010478
disciplines of transfusion medicine	T091	C1273858
hematology	T091	C0018943
discipline of transfusion medicine	T091	C1273858
curricular grid	UnknownType	C0681363
Education	T065	C0013621
transfusion medicine	T091	C1273858
fundamental importance	T080	C3898777
safe and efficient transfusion practices	T061	C1879316
Deficiencies	T169	C0011155
medical	T169	C0205476
knowledge	T170	C0376554
deficiency	T169	C0011155
teaching	T065	C0039401
basics	T169	C1527178
prospective studies	T062	C0033522
assess	T058	C0184514
knowledge	T170	C0376554
transfusion medicine	T091	C1273858
Brazilian	T098	C1257890
medical schools	T073	C0036378
importance	T080	C3898777
training	T065	C0220931
transfusion medicine	T091	C1273858
medical students	T097	C0038495
Advanced	T080	C0205179
interlocking systems	T074	C0025080
improve	T033	C0184511
heavy	T080	C0439539
load-bearing	T032	C1318107
characteristics	T080	C1521970
flexible	T080	C0443220
intramedullary nailing	T061	C0021885
Flexible	T080	C0443220
intramedullary nailing	T061	C0021885
FIN	T061	C0021885
minimally invasive	T061	C0282624
widespread	T082	C0205391
standard	T080	C1442989
method	T061	C0087111
osteosynthesis	T061	C0016643
pediatric	T080	C1521725
long bone fractures	T033	C0240231
unstable fractures	T037	C0559876
lower extremity	T023	C0023216
interlocking systems	T074	C0025080
axial	T082	C0205131
shortening	T061	C0441636
subsequent	T079	C0332282
perforation	T046	C1881710
nail	T074	C0441224
insertion site	T082	C0449682
study	T062	C0008972
screw	T074	C0005975
interlocking systems	T074	C0025080
FINs	T061	C0021885
Hofer TwinPlug	T074	C0038932
titanium	T196	C0040302
interlocking screws	T074	C0441273
Hofer FixPlug	T074	C0038932
titanium	T196	C0040302
interlocking screw	T074	C0441273
Hofer Plug	T074	C0038932
titanium	T196	C0040302
interlocking screw	T074	C0441273
Hofer Plug	T074	C0038932
titanium	T196	C0040302
interlocking screw	T074	C0441273
comparison	T052	C1707455
stainless steel	T122	C0038126
nails	T074	C0441224
screw	T074	C0005975
experimentally investigated	T169	C1292732
cadaveric	T017	C0006629
lamb	T015	C1123019
tibiae	T023	C0588199
load	T052	C1708715
characteristics	T080	C1521970
failure	T066	C0014678
modes	T169	C1513371
heavy	T080	C0439539
loading	T052	C1708715
specimens	T167	C0370003
sequential	T080	C1705294
axial	T082	C0205131
cyclic	T079	C1511572
loading	T052	C1708715
cycles	T079	C1511572
stepwise increase	T169	C0442805
load	T052	C1708715
amplitude	T082	C2346753
failure	T066	C0014678
Migration	T067	C1881827
locking screws	T074	C0441273
internal	T082	C0205102
damage	T037	C0010957
bone tissue	T024	C0391978
micro-computed tomography (CT) imaging	T060	C0729619
Ender nails	T074	C0441224
failed	T169	C0231175
average	T081	C1510992
peak	T080	C0444505
load	T052	C1708715
TwinPlugs	T074	C0038932
FixPlugs	T074	C0038932
Plugs	T074	C0038932
Plugs	T074	C0038932
TwinPlugs	T074	C0038932
FixPlugs	T074	C0038932
Plugs	T074	C0038932
failed	T169	C0231175
loading	T052	C1708715
cycles	T079	C1511572
Ender nails	T074	C0441224
Plugs	T074	C0038932
abrupt	T080	C1276802
failure	T066	C0014678
prior	T079	C0332152
indication	T078	C3146298
axial	T082	C0205131
stability	T080	C0205360
FIN	T061	C0021885
improved	T033	C0184511
screw	T074	C0005975
plugs	T074	C0038932
simultaneously	T079	C0521115
eye-locked system	T073	C1704459
Ender nails	T074	C0441224
biomechanical	T070	C3658372
results	T033	C0683954
plug	T074	C0038932
interlocking systems	T074	C0025080
screws	T074	C0005975
conventional	T080	C0439858
Ender nails	T074	C0441224
plugs	T074	C0038932
screws	T074	C0005975
Surgical	T061	C0543467
Guidance	T061	C1959633
Multiplexed Molecular Imaging	T060	C1537028
Tissues	T024	C0040300
Labeled	T130	C1522485
SERS	T070	C1720804
Nanoparticles	T073	C1450054
imaging	T060	C0011923
cell-surface receptors	T116	C0034800
biomarkers)	T201	C0005516
presence	T033	C0150312
cancer	T191	C0006826
sensitivity	T169	C0332324
specificity	T081	C1511884
heterogeneities	T080	C0019409
expression of protein	T045	C1171362
biomarkers	T123	C0041366
tumors	T191	C0027651
molecular imaging	T060	C1537028
technologies	T058	C0752188
multiplexed panel	T130	C1254353
cancer biomarkers	T123	C0041366
surface-enhanced Raman-scattering	T070	C1720804
SERS	T070	C1720804
nanoparticles	T073	C1450054
NPs	T073	C1450054
sensitive	T169	C0332324
multiplexed biomarker	T130	C1254353
detection	T061	C1511790
review	T170	C0282443
tumor	T191	C0027651
imaging	T060	C0011923
SERS	T070	C1720804
NPs	T073	C1450054
structure	T082	C0678594
optical properties	T070	C1254365
SERS	T070	C1720804
NPs	T073	C1450054
imaging	T060	C0011923
administration	T169	C1621583
NPs	T073	C1450054
tissue	T024	C0040300
topical	T082	C0332237
systemic	T169	C0205373
optical configuration	UnknownType	C0678647
imaging	T060	C0011923
Raman imaging systems	T059	C1257898
spectral demultiplexing methods	T060	C1537028
quantifying	T081	C1709793
NP	T073	C1450054
concentrations	T081	C1446561
disambiguation	T080	C2346729
specific	T080	C0205369
nonspecific	T078	C0750540
ratiometric imaging	T060	C0011923
targeted	T169	C1521840
untargeted	T167	C1550141
control	T167	C1550141
NP	T073	C1450054
Expression	T045	C0017262
methylation	T044	C0376452
posttraumatic stress disorder	T048	C0038436
resilience	T055	C0683253
evidence	T078	C3887511
role	T077	C1705810
odorant receptors	T116	C0164313
Post-traumatic stress disorder	T048	C0038436
PTSD	T048	C0038436
potentially	T080	C3245505
disabling disorder	T047	C0596452
people	T098	C0027361
exposed to	T080	C0332157
severe	T080	C0205082
trauma	T037	C3714660
Twin studies	T170	C1096782
genetic	T169	C0314603
factors	T169	C1521761
variance	T080	C1711260
PTSD	T048	C0038436
specific	T080	C0205369
role	T077	C1705810
genetic	T169	C0314603
factors	T169	C1521761
pathogenesis	T046	C0699748
PTSD	T048	C0038436
genome-wide	T063	C2350277
gene expression	T045	C0017262
DNA methylation	T044	C0376452
profiles	T081	C0237801
participants	T098	C0679646
PTSD	T048	C0038436
participants	T098	C0679646
resilient	T055	C0683253
severity	T080	C0392364
trauma	T037	C3714660
exposure	T080	C0332157
genes	T028	C0017337
differentially	T080	C0443199
expressed	T045	C0017262
adjusted	T169	C0456081
fold-change	T081	C1880833
upregulated	T044	C0041904
PTSD	T048	C0038436
odorant/olfactory receptor	T116	C0164313
genes	T028	C0017337
up-regulated	T044	C0041904
PTSD	T048	C0038436
genes	T028	C0017337
immune activation	T043	C1155000
Gamma-Aminobutyric Acid A (GABAA) receptor	T116	C0206518
vitamin D synthesis	T044	C1157731
adjusted	T169	C0456081
significance	T078	C0750502
DNA methylation	T044	C0376452
increased	T081	C0205217
gene expression	T045	C0017262
important	T080	C3898777
role	T077	C1705810
PTSD	T048	C0038436
expression	T045	C0017262
consequence of	T169	C0686907
DNA methylation	T044	C0376452
role	T077	C1705810
odorant receptor	T116	C0164313
expression	T045	C0597360
independent	T169	C0332291
replication	T045	C0598312
Absorption Characteristics	T169	C0220777
Vertebrate	T010	C0042567
Non	T169	C1518422
Visual	T169	C0234621
Opsin, Opn3	T116	C0967413
animals	T008	C0003062
possess	T078	C3154893
multiple	T081	C0439064
opsins	T116	C2355587
sense	T040	C0042789
light	T070	C0023693
visual	T169	C0234621
non	T169	C1518422
visual functions	T040	C0042789
spectral	T081	C1883073
characteristics	T080	C1521970
non	T169	C1518422
visual	T169	C0234621
opsins	T116	C2355587
vertebrate	T010	C0042567
Opn3s	T116	C0967413
distributed	T169	C1704711
vertebrates	T010	C0042567
successfully	T080	C1272703
expressed	T045	C1171362
zebrafish	T013	C0043457
Opn3	T116	C2355587
mammalian	T015	C0024660
cultured cells	T025	C0007635
measured	T080	C0444706
absorption spectrum spectroscopically	T059	C0037812
incubated	T059	C1439852
11-cis retinal	T109	C0085717
zebrafish	T013	C0043457
Opn3	T116	C2355587
blue-sensitive photopigment	T109	C0035323
absorption	T043	C0234682
maximum	T081	C0806909
Opn3	T116	C0967413
converts	T169	C0439836
all-trans retinal-bearing	T109	C0035331
photoproduct	T167	C1550506
absorption spectrum	T059	C0037812
similar	T080	C2348205
dark state	T042	C0010985
brief	T079	C1879313
blue-light	T070	C0303896
irradiation	T070	C1282930
photoproduct	T167	C1550506
blue-shift	T081	C0449819
in position	T082	C1550045
isosbestic point	T081	C0449819
irradiation	T070	C1282930
cAMP	T114	C0001455
dependent	T169	C3244310
luciferase	T116	C0024075
reporter	T130	C1522485
assay	T059	C1510438
investigate	T169	C1292732
light	T070	C0023693
dependent	T169	C3244310
cAMP	T114	C0001455
responses	T043	C1657589
cultured cells	T025	C0007635
expressing	T045	C1171362
zebrafish	T013	C0043457
pufferfish	T013	C0936076
anole	T014	C0327220
chicken	T012	C0008051
Opn3	T116	C2355587
wild type	T028	C1883559
opsins	T116	C2355587
responses	T043	C1657589
cells	T025	C0007634
expressing	T045	C1171362
chimera	T001	C0008109
mutants	T116	C1564139
WT Opn3s	T116	C0967413
third intracellular	T082	C0178719
loops	T087	C0002518
replaced	T169	C0559956
third intracellular	T082	C0178719
loop	T087	C0002518
Gs-coupled	T116	C0289372
jellyfish	T204	C0022381
opsin	T116	C2355587
displayed	T169	C0870432
light	T070	C0023693
dependent	T169	C3244310
changes	T081	C0443172
cAMP	T114	C0001455
Opn3	T116	C0967413
activating	T045	C0599177
G protein(s)	T116	C0086376
light	T070	C0023693
dependent	T169	C3244310
assay	T059	C1510438
measure	T081	C0079809
relative	T080	C0205345
wavelength	T081	C0449819
dependent	T169	C3244310
response	T032	C0871261
cells	T025	C0007634
expressing	T045	C1171362
Opn3	T116	C0967413
chimeras	T001	C0008109
multiple	T081	C0439064
quantally	T170	C0034385
matched	T080	C1708943
stimuli	T067	C0234402
inferred	T078	C3245504
spectral sensitivity	T041	C0871405
curve	T082	C0205134
zebrafish	T013	C0043457
Opn3	T116	C2355587
accurately	T080	C0443131
matched	T080	C1708943
measured	T080	C0444706
absorption spectrum	T059	C0037812
spectral sensitivity	T041	C0871405
curve	T082	C0205134
mouse	T015	C0026809
anole	T014	C0327220
Opn3	T116	C2355587
zebrafish	T013	C0043457
Opn3	T116	C2355587
chicken	T012	C0008051
pufferfish	T013	C0936076
Opn3-JiL3	T116	C1564139
chimeras	T001	C0008109
blue-sensitive pigments	T116	C0381986
vertebrate	T010	C0042567
Opn3s	T116	C0967413
blue-sensitive G protein-coupled pigments	T116	C0289372
cAMP	T114	C0001455
dependent	T169	C3244310
luciferase	T116	C0024075
reporter	T130	C1522485
assay	T059	C1510438
chimeric	T001	C0008109
opsins	T116	C2355587
third intracellular	T082	C0178719
loop	T087	C0002518
jellyfish	T204	C0022381
opsin	T116	C2355587
estimating	T081	C0750572
absorption spectra	T059	C0037812
opsins	T116	C2355587
signaling cascades	T043	C2611812
absorption spectra	T059	C0037812
difficult	T080	C0332218
Effectiveness	T080	C1280519
offloading	T061	C2922211
methods	T061	C0087111
preventing	T061	C0679698
primary	T080	C0205225
diabetic foot ulcers	T047	C1456868
adults	T100	C0001675
diabetes	T047	C0011847
systematic review	T170	C1955832
incidence	T081	C0021149
foot ulceration	T047	C0085119
diabetes	T047	C0011847
increasing	T169	C0442808
foot care	T061	C0150240
professionals	T097	C0679924
offloading	T061	C2922211
management strategies	T058	C1254363
excess	T080	C1979886
pressure	T081	C4284008
prevent	T061	C0679698
diabetic foot ulcers	T047	C1456868
DFUs	T047	C1456868
measures	T081	C0079809
padding	T061	C0455069
insoles	T074	C0493044
orthotic devices	T074	C0029365
footwear	T073	C0336894
evidence	T078	C3887511
effectiveness	T080	C1280519
offloading	T061	C2922211
preventing	T061	C0679698
primary	T080	C0205225
ulceration	T047	C0085119
diabetes	T047	C0011847
evidence	T078	C3887511
methods	T061	C0087111
offloading	T061	C2922211
prevent	T061	C0679698
development	T169	C1527148
reduce	T080	C0392756
risk	T078	C0035647
primary	T080	C0205225
foot ulceration	T047	C0085119
adults	T100	C0001675
diabetes	T047	C0011847
question	T078	C0681799
addressed	T170	C0376649
review	T170	C0282443
effectiveness	T080	C1280519
methods	T061	C0087111
offloading	T061	C2922211
preventing	T061	C0679698
primary	T080	C0205225
DFUs	T047	C1456868
adults	T100	C0001675
diabetes	T047	C0011847
Adults	T100	C0001675
years	T079	C0439234
diabetes mellitus	T047	C0011849
age	T032	C0001779
gender	T032	C0079399
ethnicity	T080	C0243103
duration	T079	C0449238
type	T080	C0332307
diabetes	T047	C0011847
history	T033	C1287400
DFUs	T047	C1456868
clinical setting	T082	C3176918
Interventions	T061	C0184661
methods	T061	C0087111
offloading	T061	C2922211
Studies	T062	C2603343
interventions	T061	C0184661
usual	T080	C3538928
practice	T061	C0087111
prevention	T061	C0679698
DFUs	T047	C1456868
excluded	T078	C1554077
primary	T080	C0205225
outcome	T169	C1274040
primary	T080	C0205225
foot ulceration	T047	C0085119
secondary	T081	C0205436
outcome	T169	C1274040
plantar	T029	C0230463
pressure	T081	C4284008
review	T170	C0282443
quantitative	T081	C0392762
study designs	T062	C0035171
literature	T170	C0023866
databases	T170	C0242356
studies	T062	C2603343
English	T171	C0376245
JBI-MAStARI extraction tool	T170	C0037589
data	T078	C1511726
Results	T169	C1274040
summarized	T170	C1553398
narrative	UnknownType	C0815257
tables	T170	C1706074
studies	T062	C2603343
effectiveness	T080	C1280519
offloading	T061	C2922211
interventions	T061	C0184661
inclusion criteria	T080	C1512693
evidence	T078	C3887511
footwear	T073	C0336894
prototype shoe plus polyurethane	T073	C0036988
cork insole	T073	C3873740
prevent	T061	C0679698
skin	T022	C1123023
orthotic devices	T074	C0029365
reduction	T080	C0392756
grade	T080	C0205082
number	T081	C0237753
calluses	T020	C0457978
shoe plus	T073	C0036988
insole	T073	C3873740
plantar	T029	C0230463
pressure	T081	C4284008
risk	T078	C0035647
skin ulceration	T047	C0085119
evidence	T078	C3887511
population	T098	C1257890
adults	T100	C0001675
diabetes	T047	C0011847
history	T033	C1287400
DFU	T047	C1456868
footwear	T073	C0336894
orthotic devices	T074	C0029365
plantar	T029	C0230463
pressure	T081	C4284008
prevent	T061	C0679698
primary	T080	C0205225
DFU	T047	C1456868
evidence	T078	C3887511
effectiveness	T080	C1280519
offloading	T061	C2922211
Punch	T048	C0004930
injury	T037	C0043251
self-harm	T037	C0424366
young people	T100	C0087178
Punch	T048	C0004930
injuries	T037	C0043251
form	T080	C0348078
self-harm	T037	C0424366
characterised	T052	C1880022
intentional	T080	C1283828
act of striking	T052	C0441655
object	T072	C0347997
closed	T169	C0587267
fist	T072	C0336667
aimed	T078	C1947946
characteristics	T080	C1521970
trends	T079	C1521798
young people	T100	C0087178
presenting	T078	C0449450
injuries	T037	C0043251
sustained	T169	C0443318
punch	T048	C0004930
mechanism	T169	C0441712
comprehensive	T080	C1880156
retrospective review	T062	C0035363
medical records	T170	C0025102
completed	T080	C0205197
young people	T100	C0087178
aged	T032	C0001779
years	T079	C0439234
presenting	T078	C0449450
Central London Emergency Department	T093	C1708333
12-month period	T079	C4082117
subset of the total group	T185	C1515021
identified	T080	C0205396
punch	T048	C0004930
injury	T037	C0043251
subgroup	T185	C1515021
punch	T048	C0004930
injury	T037	C0043251
presentations	T078	C0449450
identified	T080	C0205396
subgroup	T185	C1515021
male	T032	C0086582
female	T032	C0086287
ratio	T081	C0456603
presentations	T078	C0449450
associated with	T080	C0332281
fracture	T037	C0016658
patients	T101	C0030705
re-presented	T078	C0449450
punch	T048	C0004930
injury	T037	C0043251
victim of violence	T033	C2711168
psychiatric	T169	C0205487
presentation	T078	C0449450
conclusion	T078	C1707478
male preponderance	T033	C0243095
observed	T169	C1441672
frequent	T079	C0332183
re-presentations	T078	C0449450
high-risk	T033	C0332167
circumstances	T169	C0868928
screening	T058	C1710032
mental health	T041	C0025353
social	T169	C0728831
substance misuse	T033	C4061432
identified	T080	C0205396
research	T062	C0035168
needed	T080	C0027552
targeted	T169	C1521840
effective	T080	C1704419
interventions	T058	C1273869
group	T100	C0087178
Delayed	T079	C0205421
Recognition	T041	C1285650
Deterioration	T033	C0563273
Patients	T101	C0030705
General Wards	T073	C0043030
Human	T016	C0086418
Monitoring	T058	C1283169
Failures	T169	C0231175
Root Cause Analysis	T080	C3179036
ICU Admissions	T058	C0583239
ICU admission	T058	C0583239
inpatient	T101	C0021562
serious adverse event	T033	C1519255
SAE	T033	C1519255
root causes	T080	C3179036
ICU-admissions	T058	C0583239
healthcare worker	T097	C0018724
organisational	T080	C0220885
technical	T097	C0402239
disease	T047	C0012634
patient	T101	C0030705
ICU admissions	T058	C0583239
general wards	T073	C0043030
Root-Cause Analysis Tool	T080	C3179036
PRISMA-medical	T058	C0199168
Track and Trigger System (MEWS)	T057	C0681689
hospital	T073	C0019994
protocol	T061	C0008971
Track and Trigger system	T057	C0681689
deterioration	T033	C0563273
general hospital wards	T073	C0043030
patients	T101	C0030705
ICU	T073	C0021708
Retrospective observational study	T062	C1518527
patients	T101	C0030705
admitted	T058	C0184666
Intensive Care Unit	T073	C0021708
general nursing ward	T058	C0204637
PRISMA-analysis	T062	C0936012
root causes	T080	C3179036
ICU admissions	T058	C0583239
protocol	T061	C0008971
early warning score system	T033	C2919393
root causes	T080	C3179036
root causes	T080	C3179036
healthcare worker	T097	C0018724
failures	T169	C0231175
monitoring	T058	C1283169
patient	T101	C0030705
disease	T047	C0012634
patient	T101	C0030705
organisational	T080	C0220885
root causes	T080	C3179036
patients	T101	C0030705
vital parameters	T077	C0549193
doctor	T097	C0031831
vital parameter	T077	C0549193
ICU admission	T058	C0583239
MEWS	T057	C0681689
documented	T058	C1301725
in-depth analysis	T062	C0936012
ICU admissions	T058	C0583239
general ward	T073	C0043030
healthcare worker	T097	C0018724
root causes	T080	C3179036
monitoring	T058	C1283169
failures	T169	C0231175
clinically deteriorating	T033	C0563273
patients	T101	C0030705
ICU admissions	T058	C0583239
monitoring	T058	C1283169
patients	T101	C0030705
phosphodiesterase 10A inhibitor	T121	C0031638
non-human primates	T015	C0237798
therapeutic approach	T169	C0039798
schizophrenia	T048	C0036341
side effect profile	T046	C0879626
Schizophrenia	T048	C0036341
symptoms	T184	C1457887
associated with	T080	C0332281
alterations in basal ganglia-cortical networks	T047	C0004782
cyclic nucleotides	T114	C0028631
cAMP	T114	C0001455
cGMP	T114	C0018338
signaling pathways	T044	C0037080
Phosphodiesterase 10A (PDE10A) inhibitors	T121	C0031638
therapeutic agents	T121	C1611640
schizophrenia	T048	C0036341
regulation of cAMP	T044	C2613288
cGMP	T044	C2612051
striatum	T023	C0010097
PDE10A	T116	C1447737
signaling mechanisms	T044	C0037080
striatal-cortical network	UnknownType	C0682726
cognitive function	T041	C0392335
non-human primates	T015	C0237798
NHPs	T015	C0237798
PDE10A inhibitor	T121	C0031638
FRM-6308	T121	C0031638
high potency	T121	C1656349
human recombinant PDE10A	T116	C1447737
in vitro	T062	C0681828
behavioral effects	T033	C0243095
FRM-6308	T121	C0031638
dose range	T081	C0178602
rhesus monkeys	T015	C0024400
standardized motor disability scale	T033	C4228195
primates	T015	C0033147
motor tasks	T061	C0556033
drug effects on the nervous system" (DENS) scale	UnknownType	C0678802
neuronal	T129	C0521390
metabolic effects	T039	C2945675
FRM-6308	T121	C0031638
[(18)F]-fluorodeoxyglucose PET imaging	T060	C2315783
FRM-6308	T121	C0031638
motor system	UnknownType	C0682711
s.c. doses	T169	C0021499
NHPs	T015	C0237798
FDG	T109	C0046056
SUV	T081	C2348529
striatum	T023	C0010097
cortical	T029	C1181303
Higher doses	T081	C0444956
sedation	T033	C0235195
occasional involuntary movements	T184	C0427086
tolerance after repeated exposures	T033	C0743284
FRM-6308	T121	C0031638
adequate pharmacological profile	T061	C1320678
clinical trials	T062	C0008976
antipsychotic efficacy	T039	C3179403
PDE10A	T116	C1447737
inhibition	T052	C3463820
treatment	T169	C1522326
schizophrenia	T048	C0036341
patients	T101	C0030705
Agglomeration	T081	C1704332
Luminescent	T070	C1450275
Porous	T082	C1881977
Silicon	T196	C0037107
Nanoparticles	T073	C1450054
Colloidal Solutions	T122	C0009361
prepared	T033	C4082130
colloidal solutions	T122	C0009361
clusters	T081	C1704332
porous	T082	C1881977
silicon	T196	C0037107
nanoparticles	T073	C1450054
methanol	T109	C0001963
water	T121	C0043047
phosphate-buffered saline	T167	C0036082
PBS	T167	C0036082
size	T082	C0456389
nanoclusters	T081	C1704332
highly	T080	C0205250
porous	T082	C1881977
"cauliflower"-like structure	T082	C0678594
porous	T082	C1881977
silicon	T196	C0037107
nanoparticles	T073	C1450054
interconnected	T082	C0449379
nanocrystals	T073	C1721058
size	T082	C0456389
strong	T080	C0442821
visible	T080	C0205379
luminescence	T070	C1450275
orange	T080	C1313858
red	T080	C1260956
spectral	T077	C2827424
region	T082	C0205147
Hydrophilic behaviour	T080	C0475370
good	T080	C0205170
solubility	T080	C0037628
nanoclusters	T081	C1704332
water	T121	C0043047
water	T121	C0043047
based	T078	C1705938
solutions	T167	C0037633
obtained	T169	C1301820
hydrogen peroxide	T121	C0020281
etching	T070	C2350458
solution	T167	C0037633
preparation	T052	C1521827
after-bath	T169	C1549544
hydrogen peroxide	T121	C0020281
simple	T080	C0205352
filtration	T068	C0016107
solutions	T167	C0037633
syringe filters	T074	C0180875
extracted	T080	C0849355
smaller	T081	C0700321
nanoclusters	T081	C1704332
sizes	T082	C0456389
approx	T080	C0332232
nanoclusters	T081	C1704332
water	T121	C0043047
PBS solution	T167	C0036082
pH neutral	T080	C1882074
prone	T169	C0231204
agglomeration	T081	C1704332
confirmed	T033	C0750484
zeta potential	T067	C0597697
measurements	T169	C0242485
samples	T167	C0370003
ambient conditions	T080	C1879688
several	T081	C0443302
typical	T080	C3538928
nanocluster	T081	C1704332
size	T082	C0456389
increased	T081	C0205217
approx	T080	C0332232
stable	T080	C0205360
freshly	T080	C0443224
filtered	T077	C1704449
aged	T079	C2362314
samples	T167	C0370003
agglomerated	T081	C1704332
porous	T082	C1881977
silicon	T196	C0037107
nanoparticles	T073	C1450054
porous	T082	C1881977
silicon	T196	C0037107
water	T121	C0043047
PBS solutions	T167	C0036082
biological	T080	C0205460
studies	T062	C2603343
luminescent	T070	C1450275
markers	T201	C0005516
living cells	T025	C0007634
Development	T169	C1527148
liquid chromatography-tandem mass spectrometry	T059	C4049918
method	T169	C0449851
quantitative analysis	UnknownType	C0681919
trace	T081	C0442822
d-amino acids	T116	C0002520
d-Amino acids	T116	C0002520
recently	T079	C0332185
attention	T041	C0004268
research fields	T062	C0242481
including	T169	C0332257
medical	T169	C0205476
clinical	T080	C0205210
food industry	T057	C0524863
important	T080	C3898777
biological functions	T038	C3714634
l-amino acid	T116	C0002520
chiral	T067	C3539649
amino acid	T116	C0002520
separation	T059	C1441514
techniques	T169	C0449851
require	T169	C1514873
complicated	T169	C0231242
derivatization	T067	C0596319
procedures	T169	C0025664
desirable	T080	C0205556
chromatographic	T080	C0205556
detectability	T033	C0442726
aim	T078	C1947946
research	T062	C0035168
develop	T169	C1527148
highly sensitive	T080	C0439822
analytical method	T170	C0178476
enantioseparation	T059	C1441514
chiral	T067	C3539649
amino acids	T116	C0002520
derivatization	T067	C0596319
process	T067	C1522240
liquid chromatography-tandem mass spectrometry	T059	C4049918
LC-MS/MS	T059	C4049918
optimizing	T052	C2698650
MS/MS	T059	C2123592
parameters	T077	C0549193
established	T080	C0443211
quantification	T081	C1709793
method	T169	C0449851
simultaneous	T079	C0521115
analysis	T062	C0936012
d-amino acids	T116	C0002520
high sensitivity	T067	C2346484
reproducibility	T080	C1514863
applied	T169	C4048755
method	T169	C0449851
food sample	T167	C0444315
vinegar	T109	C0148405
validation	T062	C1519941
quantified	T081	C1709793
trace levels	T081	C0442822
d-amino acids	T116	C0002520
samples	T167	C0370003
results	T034	C0456984
applicability	T080	C1706839
feasibility	T080	C0205556
LC-MS/MS	T059	C4049918
method	T169	C0449851
novel	T080	C0205314
effective	T080	C1704419
d-amino acid	T116	C0002520
measurement	T169	C0242485
biological samples	T077	C2347026
Multi-center Evaluation of the Accuracy of the Contrast MEdium INduced Pd/Pa RaTiO	T170	C0282574
FFR	T201	C1299469
MEMENTO	T170	C0282574
FFR	T201	C1299469
Study	T062	C2603343
Adenosine	T114	C0001443
administration	T061	C1533734
maximal	T080	C0205289
hyperaemia	T047	C0020452
fractional flow reserve	T201	C1299469
FFR	T201	C1299469
assessment	T058	C0220825
accuracy	T080	C0443131
Pd	T034	C1254360
Pa	T034	C0456180
ratio	T081	C0456603
submaximal	T080	C0205556
hyperaemia	T047	C0020452
non-ionic contrast medium	T130	C1875544
contrast FFR	T201	C1299469
cFFR	T201	C1299469
FFR	T201	C1299469
resting	T033	C0679218
Pd	T034	C1254360
Pa	T034	C0456180
collaborative	T062	C0681804
patients	T101	C0030705
hospitals	T073	C0019994
four	T081	C0205450
European countries	UnknownType	C0681784
Italy	T083	C0022277
Spain	T083	C0037747
France	T083	C0016674
Portugal	T083	C0032729
Resting	T033	C0679218
Pd	T034	C1254360
Pa	T034	C0456180
cFFR	T201	C1299469
FFR	T201	C1299469
coronary stenoses	T047	C0242231
functionally	T169	C0205245
pressure wires	T074	C0025080
cFFR	T201	C1299469
intracoronary injection	T169	C1554869
contrast medium	T130	C0009924
FFR	T201	C1299469
administration	T061	C1533734
adenosine	T114	C0001443
Resting	T033	C0679218
Pd	T034	C1254360
Pa	T034	C0456180
cFFR	T201	C1299469
higher	T080	C0205250
FFR	T201	C1299469
correlation	T080	C1707520
Bland-Altman analysis	T170	C0282574
cFFR	T201	C1299469
FFR	T201	C1299469
CI	T081	C0009667
ROC curve	T081	C0035787
analysis	T062	C0936012
accuracy	T080	C0443131
cFFR	T201	C1299469
FFR	T201	C1299469
CI	T081	C0009667
resting	T033	C0679218
Pd	T034	C1254360
Pa	T034	C0456180
CI	T081	C0009667
cFFR	T201	C1299469
FFR	T201	C1299469
hybrid approach	T170	C0282574
lower	T080	C0205251
lesions	T033	C0221198
adenosine	T114	C0001443
resting	T033	C0679218
Pd	T034	C1254360
Pa	T034	C0456180
FFR	T201	C1299469
hybrid approach	T170	C0282574
cFFR	T201	C1299469
accurate	T080	C0443131
functional	T169	C0205245
coronary stenosis	T047	C0242231
adenosine	T114	C0001443
FFR	T201	C1299469
stenoses	T046	C1261287
time	T079	C0040223
costs	T081	C0010186
Transfemoral aortic valve implantation	T061	C0021107
repositionable Lotus valve	T074	C0184252
treatment	T061	C0087111
patients	T101	C0030705
symptomatic	T169	C0231220
severe	T080	C0205082
aortic stenosis	T047	C0003507
results	T169	C1274040
single-centre experience	T041	C0237607
study	T062	C2603343
evaluate	T058	C0220825
day	T079	C0439228
results	T169	C1274040
repositionable Lotus valve	T074	C0184252
patients	T101	C0030705
transfemoral aortic valve implantation	T061	C0021107
single-centre experience	T041	C0237607
patients	T101	C0030705
severe	T080	C0205082
symptomatic	T169	C0231220
aortic stenosis	T047	C0003507
NCT02162069	T170	C3274381
procedures	T169	C2700391
general anaesthesia	T061	C0002915
transfemoral approach	T061	C0087111
Patients	T101	C0030705
days	T079	C0439228
Patients	T101	C0030705
received	T080	C1514756
Lotus device	T074	C0184252
Mean oversizing	T081	C0392762
annulus	T026	C2262860
left ventricular outflow tract	T023	C4284103
LVOT	T023	C4284103
groups	T078	C0441833
no residual	UnknownType	C0746917
moderate	T080	C0205081
severe	T080	C0205082
aortic regurgitation	T047	C0003504
rate of mild aortic regurgitation	T081	C0392762
aortic regurgitation	T047	C0003504
valve	T023	C0003501
embolisation	T061	C0190360
second	T081	C0205436
valve	T023	C0003501
no conversion	T033	C0243095
surgery	T061	C0543467
pacemaker implantation	T061	C0189842
complete	T047	C0151517
third degree	T047	C0151517
type II (Mobitz) second degree atrioventricular block	T047	C0155700
patients	T101	C0030705
implanted devices	T061	C0948629
days	T079	C0439228
rates	T081	C1521828
all-cause mortalit	T081	C0205848
stroke	T047	C0038454
low	T080	C0205251
patients	T101	C0030705
severe	T080	C0205082
aortic stenosis	T047	C0003507
transfemoral TAVI	T061	C3509486
repositionable Lotus valve	T074	C0184252
associated with	T080	C0332281
high	T080	C0205250
rate	T081	C1521828
device	T074	C0025080
success	T080	C0679864
moderate	T080	C0205081
severe	T080	C0205082
residual	T080	C1609982
aortic regurgitation	T047	C0003504
low	T080	C0205251
rates	T081	C1521828
major	T080	C0205164
vascular complications	T047	C1393529
mortality	T081	C0205848
days	T079	C0439228
Comparison	T052	C1707455
Measured	T080	C0444706
Concentration	T081	C0457929
3H	T196	C0041119
Kalpakkam Environment	UnknownType	C0681784
Predicted Atmospheric Dispersion Model	T075	C0026336
field	T082	C3539073
measurements	T169	C0242485
3H	T196	C0041119
HTO	T197	C0077315
air	T070	C0935443
moisture	T167	C0868994
Madras Atomic Power Station	T073	C0562516
compared	T052	C1707455
atmospheric dispersion modeling	T075	C0026336
Air 3H samples	T167	C1546536
collected	T078	C1516695
sectors	T083	C1708237
site	T082	C0205145
boundary	T185	C2828371
operating	T052	C3241922
reactors	T073	C0028591
period	T079	C1948053
y	T079	C0439234
compared	T052	C1707455
Gaussian Plume model	T075	C0026336
predictions	T078	C0681842
measured	T080	C0444706
value	T081	C1522609
slight	T080	C2937276
variation	T080	C0205419
observed	T169	C1441672
methods	T170	C0025663
uncertainty	T033	C0087130
measurement	T169	C0242485
air	T167	C0001861
3H	T196	C0041119
concentration	T081	C0457929
measurement	T169	C0242485
site-specific	T082	C0449604
meteorological parameters	T070	C0025594
radiation dose	T081	C4019308
imparted	T169	C0332289
members of public	T092	C0678367
levels	T080	C0441889
observed	T169	C1441672
station	T073	C0562516
technical specification limit	T169	C0439801
3H	T196	C0041119
aureocin A70	T116	C1101398
promising agent	T120	C0450442
food biopreservation	T057	C0016484
Aureocin A70	T116	C1101398
bacteriocin	T116	C0004641
inhibits the growth	T040	C2249823
Gram-positive bacteria	T007	C0018154
Listeria monocytogenes	T007	C0023861
strains	T001	C1518614
food	T168	C0016452
food safety	T057	C1456535
Aureocin A70	T116	C1101398
bactericidal	T195	C0004635
lytic	T080	C0439680
listerial	T007	C0023861
strains	T001	C1518614
antibacterial activity	T052	C0441655
aureocin A70	T116	C1101398
UHT-treated	T061	C3179136
skimmed milk	T168	C0349375
inoculated	T059	C1439852
food	T168	C0016452
L. monocytogenes L12 strain	T007	C0023861
storage	T169	C1698986
Aureocin A70	T116	C1101398
reduction	T070	C0301630
listerial	T007	C0023861
viable cell counts	T059	C0007584
incubation	T059	C1439852
Aureocin A70	T116	C1101398
toxic	T080	C1407029
Vero	T025	C0042542
L-929 cell lines	T025	C0007634
hemolytic activity	T049	C0302110
sheep	T015	C0036945
red blood cells	T025	C0014792
Aureocin A70	T116	C1101398
Aureocin A70	T116	C1101398
susceptibility	T081	C1547045
simulated	T070	C1948023
gastric juice	T031	C0017133
bile salts	T109	C0005404
gastrointestinal conditions	T033	C4061136
entrapment	T044	C2825784
aureocin A70	T116	C1101398
alginate	T109	C0102137
gelatin matrix	T116	C1533434
bacteriocin	T116	C0004641
low-density polyethylene plastic	T109	C0752344
aureocin A70	T116	C1101398
bioactive	T167	C3714412
packaging	T052	C2828395
control the growth	T040	C2249823
bacteria	T007	C0004611
aureocin A70	T116	C1101398
promising alternative	T120	C0450442
food applications	T057	C0016484
Folate	T109	C0178638
conjugated	T082	C0522529
gene	T028	C0017337
carrying	T045	C0872177
microbubbles	T074	C1258018
focused ultrasound	T061	C1517281
concurrent	T079	C0205420
blood-brain barrier	T023	C0005854
opening	T082	C1254362
local	T082	C0205276
gene delivery	T045	C0872177
Previous	T079	C0205156
studies	T062	C2603343
circulating	T169	C0175630
DNA	T114	C0012854
encapsulated	T080	C0205223
microbubbles	T074	C1258018
MBs	T074	C1258018
combined	T080	C0205195
focused ultrasound	T061	C1517281
FUS	T061	C1517281
used	T169	C1524063
local	T082	C0205276
blood-brain barrier	T023	C0005854
BBB	T023	C0005854
opening	T082	C1254362
gene delivery	T045	C0872177
studies	T062	C2603343
focused	T169	C1285542
increase	T169	C0442805
efficiency	T081	C0013682
gene delivery	T045	C0872177
brain tumors	T191	C0006118
released	T169	C0391871
gene	T028	C0017337
penetrating	T169	C0205321
BBB	T023	C0005854
use of	T169	C1524063
folate	T109	C0178638
cationic MBs	T074	C1258018
FCMBs	T074	C1258018
combined	T080	C0205195
FUS	T061	C1517281
trigger	T080	C1444748
BBB	T023	C0005854
FCMBs	T074	C1258018
nanometer	T081	C0439202
sized	T082	C0456389
vesicles	T026	C1622418
transported	T043	C0005528
brain	T023	C0006104
parenchyma	T023	C0933845
FCMBs	T074	C1258018
aggregate	T080	C0205418
tumor cells	T025	C0597032
overexpressed	T045	C1514559
folate receptor	T116	C2955669
enhancing	T052	C2349975
gene delivery	T045	C0872177
folate	T116	C2955669
stimulated	T070	C1948023
endocytosis	T043	C0014139
results	T169	C1274040
confirmed	T080	C0521093
FCMBs	T074	C1258018
carry	T045	C0872177
DNA	T114	C0012854
surface	T082	C0205148
MB	T074	C1258018
shell	T080	C1948022
good	T080	C0205170
targeting	T169	C1521840
ability	T081	C1516240
C6 glioma cells	T025	C0007634
FUS	T061	C1517281
parameters	T077	C0549193
FCMBs	T074	C1258018
enhanced	T052	C2349975
gene delivery	T045	C0872177
confirmed by	T080	C0521093
cell	T025	C0007634
experiments	T062	C0681814
center frequency	T081	C1705502
acoustic pressure	T081	C4284008
pulse	T067	C1947910
repetition	T169	C0205341
frequency	T081	C1705502
cycle	T079	C1511572
number	T081	C0237753
exposure	T080	C0332157
time	T079	C0040223
FCMBs	T074	C1258018
concentration	T081	C1446561
In vivo	T082	C1515655
data	T078	C1511726
indicated	T033	C1444656
FCMBs	T074	C1258018
better	T080	C0332272
gene	T028	C0017337
transfection	T045	C0314641
efficiency	T081	C0013682
MBs	T074	C1258018
without	T080	C0332288
folate	T116	C2955669
conjugation	T043	C1160466
traditional	T169	C0443324
approach	T082	C0449445
directly	T080	C1947931
injecting	T061	C1533685
gene	T028	C0017337
study	T062	C2603343
novel	T080	C0205314
development	T169	C1527148
multifunctional	T169	C0205245
MBs	T074	C1258018
FUS	T061	C1517281
triggered	T080	C1444748
gene delivery	T045	C0872177
therapy	T061	C0087111
Modulation	T082	C0443264
IL-6	T116	C0021760
induced	T169	C0205263
RANKL	T116	C0666364
expression	T045	C1171362
arthritic	T047	C0003864
synovium	T023	C0039099
transcription factor SOX5	T116	C2350546
Receptor activator of nuclear factor κB ligand	T116	C0666364
RANKL	T116	C0666364
critically	T080	C1511545
bone erosion	T046	C0587240
rheumatoid arthritis	T047	C0003873
RA	T047	C0003873
previously	T079	C0205156
younger age	T032	C0001779
RA	T047	C0003873
RANKL	T116	C0666364
SNP	T086	C0752046
elevated	T080	C3163633
binding	T052	C1145667
transcription factor SOX5	T116	C2350546
study	T062	C2603343
regulation	T043	C1157519
SOX5	T116	C2350546
RANKL	T116	C0666364
expression	T045	C1171362
RA	T047	C0003873
synovial	T023	C0039099
fibroblasts	T025	C0016030
SF	T025	C0016030
development	T169	C1527148
bone erosion	T046	C0587240
collagen-induced arthritis	T050	C0971858
CIA	T050	C0971858
mouse	T015	C0026809
data	T170	C0150098
indicated	T033	C1444656
SOX5	T116	C2350546
synovium	T023	C0039099
synovial fluid	T031	C0039097
RA	T047	C0003873
compared	T052	C1707455
osteoarthritis	T047	C0029408
patients	T101	C0030705
Pro-inflammatory	T169	C0333348
cytokines	T116	C0079189
upregulated	T044	C0041904
SOX5	T116	C2350546
RANKL	T116	C0666364
expression	T045	C1171362
RA	T047	C0003873
SF	T025	C0016030
fibroblast cell line	UnknownType	C0682524
MH7A	T025	C0007634
Overexpression	T045	C1514559
SOX5	T116	C2350546
resulted	T169	C1274040
significantly increased	T081	C0205217
RANKL	T116	C0666364
knockdown	T063	C2350567
SOX5	T028	C1420328
resulted	T169	C1274040
diminished	T081	C0205216
IL-6	T116	C0021760
RANKL	T116	C0666364
upregulation	T044	C0041904
MH7A cells	T025	C0007634
Chromatin immunoprecipitation	T059	C1328856
ChIP	T059	C1328856
approximately	T080	C0332232
RANKL-specific DNA	T114	C0012854
anti-SOX5 immunoprecipitate	T129	C0301871
IL-6	T116	C0021760
treated	T169	C1522326
MH7A cells	T025	C0007634
compared	T052	C1707455
untreated cells	T033	C0243095
silencing	T045	C0598496
SOX5 gene	T028	C1420328
significantly diminished	T081	C0205216
RANKL	T116	C0666364
positive	T033	C1514241
cells	T025	C0007634
bone erosion	T046	C0587240
CIA	T050	C0971858
mice	T015	C0026809
findings	T033	C0243095
suggest	T078	C1705535
SOX5	T116	C2350546
regulator	T077	C1704735
IL-6	T116	C0021760
induced	T169	C0205263
RANKL	T116	C0666364
expression	T045	C1171362
RA	T047	C0003873
SF	T025	C0016030
Intracameral	T082	C1636767
cefuroxime	T109	C0007562
prevention	T061	C0679698
postoperative endophthalmitis	T047	C1282227
experience	T041	C0596545
Hong Kong	T083	C0019907
study	T062	C2603343
effect	T080	C1280500
introducing	T169	C0579004
intracameral	T082	C1636767
cefuroxime	T109	C0007562
compounded	T058	C0013164
hospital pharmacy	T093	C0260123
postoperative endophthalmitis	T047	C1282227
tertiary eye centre	T093	C0596660
Hong Kong	T083	C0019907
cataract surgeries	T061	C2939459
routine	T080	C0205547
use	T169	C0457083
intracameral	T082	C1636767
cefuroxime	T109	C0007562
cataract surgery	T061	C2939459
cefuroxime	T109	C0007562
aliquots	T081	C1510844
hospital pharmacy	T093	C0260123
aseptic	T080	C0232920
aseptic compounding	T058	C0013164
rates	T081	C1521828
postoperative endophthalmitis	T047	C1282227
Group	UnknownType	C0681860
no	T169	C0332197
intracameral	T082	C1636767
cefuroxime	T109	C0007562
Group	UnknownType	C0681860
intracameral	T082	C1636767
cefuroxime	T109	C0007562
eyes	T023	C0015392
Group	UnknownType	C0681860
Group	UnknownType	C0681860
postoperative endophthalmitis	T047	C1282227
Group	UnknownType	C0681860
endophthalmitis	T047	C0014236
Group	UnknownType	C0681860
rate	T081	C1521828
reduction	T080	C0392756
statistically significant	T081	C0237881
endophthalmitis	T047	C0014236
positive culture	T033	C0159125
Organisms	T001	C0029235
Group G Streptococcus	T007	C0318162
Group B Streptococcus	T007	C0038402
Staphylococcus aureus	T007	C0038172
Serratia marcescens	T007	C0036766
coagulase-negative Staphylococcus	T007	C0445625
Antibiotic susceptibility	T033	C0427965
testing results	T034	C0456984
organisms	T001	C0029235
susceptible	T169	C0231204
penicillin group	T109	C0030842
No adverse events	T033	C2699517
use	T169	C0457083
intracameral	T082	C1636767
cefuroxime	T109	C0007562
use	T169	C0457083
intracameral	T082	C1636767
cefuroxime	T109	C0007562
reduce	T081	C0547047
rate	T081	C1521828
postoperative endophthalmitis	T047	C1282227
tertiary centre	T093	C0596660
Hong Kong	T083	C0019907
use	T169	C0457083
aseptic	T080	C0232920
aseptic compounding	T058	C0013164
cefuroxime	T109	C0007562
aliquots	T081	C1510844
hospital pharmacy	T093	C0260123
assessment	T058	C1261322
treatment	T061	C0087111
internationally	T078	C1512888
adopted children	T099	C0337541
anorectal malformation	T190	C3495676
ARM	T190	C3495676
internationally	T078	C1512888
adopted children	T099	C0337541
congenital birth defects	T019	C0000768
colorectal	T082	C0555952
diagnoses	T060	C0430022
children	T100	C0008059
anorectal malformation	T190	C3495676
ARM	T190	C3495676
reoperation	T061	C0035110
Knowledge	T033	C0518904
complications	T046	C0009566
ARM	T190	C3495676
surgery	T061	C0543467
treatment	T061	C0087111
algorithms	T170	C0002045
patients	T101	C0030705
past medical	T033	C0455458
surgical history	T033	C0744961
adopted	T033	C0425382
population	T098	C1257890
investigations	T058	C1261322
indications	T078	C3146298
rate	T081	C1521828
reoperation	T061	C0035110
adopted children	T099	C0337541
ARM	T190	C3495676
patients	T101	C0030705
males	T032	C0086582
reoperative surgery	T061	C0035110
anus	T023	C0003461
outside	T082	C0205101
sphincter	T023	C1409894
males	T032	C0086582
females	T032	C0086287
Anal stricture	T019	C0266229
rectal prolapse	T047	C0034888
retained	T169	C0333118
vaginal septum	T019	C0431649
strictured	T046	C1261287
vaginal introitus	T030	C0458952
reoperative surgery	T061	C0035110
rate	T081	C1521828
internationally	T078	C1512888
adopted child	T099	C0337541
ARM	T190	C3495676
children	T100	C0008059
complications	T046	C0009566
repair	T058	C1705181
surgical care	T058	C0520254
children	T100	C0008059
fluorescent	T070	C0016315
gold	T121	C0018026
nanoclusters	T073	C1721060
food proteins	T116	C0012177
detection	T061	C1511790
food	T168	C0016452
contaminants	T167	C2827365
bioactive nutrients	T167	C3714412
nanotechnology	T090	C0872323
food	T168	C0016452
Ultra-small gold nanoclusters	T073	C1721060
Au NCs	T073	C1721060
nanomaterials	T073	C1450053
Au NCs	T073	C1721060
food proteins	T116	C0012177
environmentally friendly preparation	T057	C2350565
fluorescence	T070	C0016315
photo-stability	T080	C0205556
biocompatibility	T044	C0596177
protein-Au hybrids	T073	C1721059
nano-bio-food interface	T093	C1708333
single metal atoms	T196	C0567415
plasmonic	T062	C2603343
metal nanoparticles	T073	C1721060
hybrid system	T122	C1881073
biomacromolecule	T167	C1179809
inorganic	T077	C1881215
ions	T196	C0022023
synthesis	T052	C1883254
optical properties	T080	C0871161
Au NCs	T073	C1721060
food proteins	T116	C0012177
detection	T061	C1511790
food	T168	C0016452
contaminants	T167	C2827365
bioactive nutrients	T167	C3714412
food proteins	T116	C0012177
gold nanoclusters	T073	C1721060
synthesis	T052	C1883254
Sub-lethal effects	T033	C3151529
dietary	T168	C0012155
neonicotinoid insecticide	T131	C1997222
exposure	T080	C0332157
honey bee queen	T204	C0323351
fecundity	T040	C0015895
colony	T025	C1947989
development	T039	C0243107
factors	T169	C1521761
negatively	T033	C0205160
honey bee	T204	C0323351
Apis mellifera L.	T204	C0323351
health	T078	C0018684
pervasive	T082	C0205391
systemic	T169	C0205373
neonicotinoid insecticides	T131	C1997222
consumption	T039	C1947907
contaminated	T169	C0205279
nectar	T123	C2717960
pollen	T002	C0032385
treated	T169	C1522326
plants	T002	C0032098
neonicotinoids	T131	C1997222
foraging	T055	C2752984
learning	T041	C0023185
memory	T041	C0025260
worker bees	T204	C0004923
neonicotinoids	T131	C1997222
queen bees	T204	C0004923
trophallaxis	T054	C0237876
food	T168	C0016452
sharing	T054	C0237876
assess	T058	C0184514
queen	T204	C0004923
productivity	T081	C0033269
small	T081	C0700321
colonies	T025	C1947989
sizes	T082	C0456389
bees	T204	C0004923
fed	T052	C2987508
imidacloprid	T109	C0218499
syrup	T168	C0458173
weeks	T079	C0439230
adverse effects	T046	C0879626
imidacloprid	T109	C0218499
queens	T204	C0004923
egg-laying	T040	C1622979
locomotor activity	T040	C0023946
worker bees	T204	C0004923
foraging	T055	C2752984
hygienic	T091	C0020405
activities	T052	C0441655
colony	T025	C1947989
development	T040	C0678723
brood	T204	C0004923
pollen	T002	C0032385
treated	T169	C1522326
colonies	T025	C1947989
less	T080	C0547044
colony	T025	C1947989
size	T082	C0456389
increased	T081	C0205217
larger	T081	C1704243
colony	T025	C1947989
populations	T098	C1257890
pesticide exposure	T033	C2220281
study	T062	C2603343
adverse effects	T046	C0879626
imidacloprid	T109	C0218499
queen bee	T204	C0004923
fecundity	T040	C0015895
behavior	T053	C0004927
improves	T080	C1272747
understanding	T041	C0162340
neonicotinoids	T131	C1997222
impair	T169	C0221099
colony	T025	C1947989
functioning	T169	C0205245
data	T078	C1511726
risk-mitigation efforts	T170	C4296788
reducing	T080	C0392756
neonicotinoid	T131	C1997222
exposure	T080	C0332157
early spring	T079	C0241232
colonies	T025	C1947989
smallest	T081	C0700321
queens	T204	C0004923
vulnerable	T169	C0231204
exposure	T080	C0332157
Therapeutic applications	T169	C0039798
CRISPR	T114	C3658200
RNA-guided	T114	C0082774
genome editing	T063	C4279981
programmable nuclease	T116	C0597094
genome editing	T063	C4279981
technologies	T090	C0039421
targeted	T169	C1521840
gene	T028	C0017337
disruption	T169	C0332453
correction	T061	C1720855
in vitro	T080	C1533691
in vivo	T082	C1515655
genome editing	T063	C4279981
target	T169	C1521840
genomic sites	T082	C1880951
gene function	T045	C0314627
animals	T008	C0003062
plants	T002	C0032098
programmable nucleases	T116	C0597094
type II clustered regularly interspaced short palindromic repeats	T114	C3658200
CRISPR	T114	C3658200
CRISPR-associated nuclease 9 (Cas9) system	T044	C3658355
research	T062	C0035168
medicine	T091	C0025118
biotechnology	T091	C0005574
CRISPR-Cas9	T044	C3658355
gene editing	T063	C4279981
therapeutic purposes	T169	C0039798
patient	T101	C0030705
stem cells	T025	C0038250
animal models	T008	C0599779
therapeutic approaches	T169	C0039798
delivery methods	T061	C0565867
biomedical	T091	C1879848
applications	T169	C0039798
therapeutic applications	T169	C0039798
CRISPR-Cas9 system	T044	C3658355
Design	T052	C1707689
characteristics	T080	C1521970
cytotoxic	T169	C1511636
fibroblast growth factor 1	T116	C0079349
conjugate	T121	C1254351
fibroblast growth factor receptor	T116	C0060369
targeted cancer therapy	T061	C3854476
Fibroblast growth factor receptors	T116	C0060369
FGFRs	T116	C0060369
cancer therapy	T061	C0920425
targets	T169	C1521840
overexpressed	T045	C1514559
multiple	T081	C0439064
tumors	T191	C0027651
breast	T191	C1458155
prostate	T191	C0033578
bladder	T191	C0005695
lung cancer	T191	C0242379
natural ligand	T044	C1749457
FGFR	T116	C0060369
engineered variant	T116	C0034861
fibroblast growth factor 1	T116	C0079349
FGF1V	T116	C0079349
conjugated	T082	C0522529
potent cytotoxic drug	T121	C0304497
monomethyl auristatin E	T116	C1565020
MMAE	T116	C1565020
targeting agent	T043	C0599894
cancer cells	T025	C0334227
overexpressing	T045	C1514559
FGFRs	T116	C0060369
antibodies	T116	C0003241
antibody-drug conjugates	T061	C2346828
FGF1V-valine-citrulline-MMAE conjugate	T121	C1254351
stability profile	T044	C1327386
bound	T044	C1167622
FGFRs	T116	C0060369
cell surface	T026	C0699040
specifically	T080	C0205369
efficiently	T080	C0442799
released	T169	C1283071
drug (MMAE)	T116	C1565020
cleavage	T044	C0597304
lysosomal protease cathepsin B	T116	C0699919
conjugate	T121	C1254351
prominent	T080	C0205402
cytotoxic effect	T049	C0596402
cell lines	T025	C0334227
expressing	T045	C0597360
FGFR	T116	C0060369
FGF1V-vcMMAE	T121	C1254351
cytotoxic	T169	C1511636
concentrations	T081	C1446561
lower	T052	C2003888
MMAE	T116	C1565020
FGFR	T116	C0060369
cells	T025	C0334227
lacking	T080	C0332268
FGFR	T116	C0060369
did not show	T033	C1513916
increased	T081	C0205217
mortality	T043	C0007587
morphology	T080	C0332437
surface hydroxyl	T197	C0700307
toxicity	T037	C0600688
BiOCl	T121	C0053787
human	T016	C0086418
HaCaT cells	T025	C0022567
bismuth oxychloride	T121	C0053787
nanomaterials	T185	C1881976
BiOCls	T121	C0053787
pollutant	T131	C0599786
removal	T052	C1883720
Residues	T131	C0599786
environmental remediations	T069	C3853059
hazardous materials	T131	C0018626
human	T016	C0086418
health risks	T058	C0086930
BiOCls	T121	C0053787
study	T062	C2603343
physicochemical properties	T080	C0871161
cytotoxicity	T049	C0596402
BiOCls	T121	C0053787
human	T016	C0086418
skin	T022	C1123023
cell line	T025	C0007634
HaCaT	T025	C0022567
morphology	T080	C0332437
surface hydroxyl	T197	C0700307
toxicity	T037	C0600688
BiOCls	T121	C0053787
Microsphere-shaped	T082	C0332479
BiOCl	T121	C0053787
toxicity	T037	C0600688
nanosheet-shaped	T082	C0332479
BiOCl	T121	C0053787
weaker particle-membrane interactions	T043	C0007613
surface hydroxyl	T197	C0700307
microsphere-shaped	T082	C0332479
BiOCl	T121	C0053787
toxicity	T037	C0600688
interaction	T043	C0007613
cell membrane	T026	C0007603
microsphere-shaped	T082	C0332479
BiOCl	T121	C0053787
surface hydroxyl	T197	C0700307
nanosheet-shaped	T082	C0332479
BiOCl	T121	C0053787
cell membrane	T026	C0007603
damage	T049	C0599732
PI	T109	C0033470
PI uptake	T059	C0005507
LDH	T116	C0022917
LDH release	T059	C0005507
mechanism	T043	C0007613
"chemical" mechanism	T043	C1623221
oxidative stress paradigm	T062	C0681797
ROS	T123	C0162772
GSH	T116	C0017817
physical	T169	C0205485
damage	T049	C0599732
cell membrane	T026	C0007603
physical	T043	C1623221
"chemical" response	T043	C1623221
cell death	T043	C0007587
experiments	T062	C0681814
MMP	T043	C1720920
cell cycle arrest	T043	C1155873
apoptosis	T043	C0162638
necrosis	T042	C0027540
toxicological aspects	T080	C0040539
BiOCls	T121	C0053787
Data	T078	C1511726
rational design	T052	C1707689
BiOCls	T121	C0053787
unintended consequences	T080	C0205556
application potentials	T080	C3245505
Reduced	T080	C0392756
haemodynamic coupling	T042	C4042905
exercise	T056	C0015259
associated with	T080	C0332281
vascular stiffening	T046	C3178781
pulmonary arterial hypertension	T047	C2973725
Inadequate	T080	C0205412
right ventricular	T023	C0225883
RV	T023	C0225883
pulmonary arterial	T023	C0034052
PA	T023	C0034052
functional	T169	C0205245
responses	T169	C0205245
exercise	T056	C0015259
pulmonary arterial hypertension	T047	C2973725
PAH	T047	C2973725
study	T062	C2603343
invasive	T061	C0683468
catheterisation	T061	C0007430
echocardiography	T060	C0013516
assess	T052	C1516048
RV	T023	C0225883
RV function	T042	C0080311
ventricular	T023	C0018827
vascular	T023	C0005847
coupling	T042	C1254358
subjects	T098	C0080105
PAH	T047	C2973725
subjects	T098	C0080105
PAH	T047	C2973725
right heart	T029	C0225808
catheterisation	T061	C0007430
Doppler echocardiography	T060	C0013520
rest	T056	C0035253
incremental	T081	C1705117
exercise	T056	C0015259
cardiac MRI	T060	C0412692
rest	T056	C0035253
Measurements	T169	C0242485
rest	T056	C0035253
haemodynamics	T042	C0019010
RV function	T042	C0080311
coupling efficiency	T081	C0013682
η	T081	C0013682
Measurements	T169	C0242485
incremental	T081	C1705117
exercise	T056	C0015259
pulmonary vascular resistance	T033	C0456261
Z0	T033	C0456261
characteristic impedance	T060	C0007185
ZC	T060	C0007185
measure	T169	C0242485
proximal	T082	C0205107
PA	T023	C0034052
stiffness	T039	C0599949
proximal	T082	C0205107
distal	T082	C0205108
patients	T101	C0030705
PAH	T047	C2973725
proximal	T082	C0205107
PAs	T023	C0034052
significantly	T078	C0750502
stiffer	T033	C0205400
maximum	T081	C0806909
exercise	T056	C0015259
ZC	T060	C0007185
rest	T056	C0035253
decreased	T081	C0205216
rest	T056	C0035253
Z0	T033	C0456261
exercise	T056	C0015259
resistance-compliance (RC) time	T081	C0392762
decreased	T081	C0205216
exercise	T056	C0015259
rest	T056	C0035253
patients	T101	C0030705
resting	T056	C0035253
coupling efficiency	T081	C0013682
η	T081	C0013682
stiffer	T033	C0205400
proximal	T082	C0205107
PAs	T023	C0034052
rest	T056	C0035253
maximum	T081	C0806909
exercise	T056	C0015259
level	T080	C0441889
reduction	T080	C0392756
maximum	T081	C0806909
exercise	T056	C0015259
PAH	T047	C2973725
exercise	T056	C0015259
proximal	T082	C0205107
distal	T082	C0205108
PA	T023	C0034052
stiffening	T039	C0599949
Z0	T033	C0456261
decreased	T081	C0205216
RC time	T081	C0392762
exercise	T056	C0015259
Stiff PAs	T023	C0034052
rest	T056	C0035253
haemodynamic coupling	T042	C4042905
reduced	T080	C0392756
pulmonary vascular	T023	C0459963
contributes	T052	C1880177
maximum	T081	C0806909
exercise	T056	C0015259
level	T080	C0441889
Altered pH gradient	T081	C1138565
plasma membrane	T026	C0007603
osteosarcoma	T191	C0029463
cells	T025	C0007634
mechanism	T169	C0441712
drug resistance	T038	C0013203
therapy	T061	C0087111
osteosarcoma	T191	C0029463
OS	T191	C0029463
primary bone malignancy	T191	C4282132
combination of surgery and chemotherapy	T061	C0920442
Multidrug resistance	T032	C0242640
P-glycoprotein	T116	C0242643
P-gp	T116	C0242643
overexpression	T045	C1514559
treatment failure	T033	C0162643
progression	T046	C0242656
OS	T191	C0029463
mechanisms	T169	C0441712
acidic extracellular pH	T081	C0020283
pHe	T081	C0020283
sarcomas	T191	C1261473
doxorubicin	T109	C0013089
DXR	T109	C0013089
cytotoxicity	T049	C0596402
reduced	T080	C0392756
P-gp	T028	C0376623
OS	T191	C0029463
cells cultured	T025	C0007635
pHe	T081	C0020283
Short-time	T079	C0443303
exposure to	T080	C0332157
pHe	T081	C0020283
significantly increased	T081	C1707919
acidity	T034	C0368606
lysosomes	T026	C0024369
combination	T080	C0205195
DXR	T109	C0013089
omeprazole	T109	C0028978
proton pump inhibitor	T121	C0358591
lysosomal acidity	T043	C1156062
significantly enhanced	T081	C1707919
DXR	T109	C0013089
cytotoxicity	T049	C0596402
OS	T191	C0029463
xenografts	T122	C0522537
combination treatment	T061	C0013218
DXR	T109	C0013089
omeprazole	T109	C0028978
significantly reduced	T038	C3890174
tumor volume	T081	C0475276
body weight loss	T033	C1262477
impaired toxicity	T037	C0013221
DXR	T109	C0013089
pHe	T081	C0020283
increased	T081	C0205217
autophagy	T043	C0004391
lysosomal acidification	T043	C1156062
SNARF	T130	C0084578
staining	T059	C0487602
reversal	T169	C0443290
pH gradient	T081	C1138565
plasma membrane	T026	C0007603
ΔpHcm	T081	C1138565
reduced	T080	C0392756
DXR	T109	C0013089
intracellular	T082	C0178719
accumulation	T033	C4055506
reversal	T169	C0443290
ΔpHcm	T081	C1138565
OS	T191	C0029463
cells	T025	C0007634
resistance	T169	C4281815
DXR	T109	C0013089
cisplatin	T121	C0008838
methotrexate	T109	C0025677
vincristine	T109	C0042679
OS	T191	C0029463
cells	T025	C0007634
short-term	T079	C0443303
acidosis	T046	C0001122
resistance	T169	C4281815
chemotherapeutic drugs	T109	C0003392
reversal	T169	C0443290
ΔpHcm	T081	C1138565
buffer	T121	C0006353
therapies	T061	C0087111
regimens	T170	C2945654
proton pump inhibitors	T121	C0358591
combination	T080	C0205195
concentrations	T081	C1446561
anticancer agents	T109	C0003392
novel	T080	C0205314
overcome	T052	C2983310
drug resistance	T038	C0013203
Boston Keratoprosthesis Type 1	T074	C1261333
Randomized Controlled Trial	T062	C0206035
Fresh	T080	C0443224
Frozen	T080	C1548793
Corneal Donor Carriers	T101	C0030705
Long-Term	T079	C0443252
Follow-up	T058	C1522577
compare	T052	C1707455
long-term	T079	C0443252
clinical outcomes	T169	C1274040
fresh	T080	C0443224
frozen	T080	C1548793
corneal graft carriers	T101	C0030705
Boston Keratoprosthesis type 1	T074	C1261333
B-KPro	T074	C1261333
nonblinded	T077	C2986424
randomized controlled trial.	T062	C0206035
participants	T098	C0679646
initial	T079	C0205265
study protocol	T170	C2348563
months	T079	C0439231
extension	T169	C0231448
phase	T079	C0205390
follow-up visits	T058	C0589121
months	T079	C0439231
patients	T101	C0030705
B-KPro surgery	T061	C0176217
experienced surgeon	T097	C0582175
Hospitalier de l'Université de Montréal	T073	C0020028
allograft carrier	T024	C0348047
Patients	T101	C0030705
excluded	T052	C2828389
previously	T079	C0205156
B-KPro	T074	C1261333
implantation	T061	C0021107
Participants	T098	C0679646
randomized	T033	C3815594
receive	T080	C1514756
B-KPro	T074	C1261333
frozen	T080	C1548793
fresh	T080	C0443224
corneal graft carrier	T024	C0348047
tissue	T024	C0040300
availability	T169	C0470187
day	T079	C0439228
surgery	T061	C0543467
eye bank	T073	C0015394
outcome measure	T081	C0086749
device retention	T033	C0243095
months	T079	C0439231
surgical feasibility	T033	C0243095
visual acuity	T201	C0042812
VA	T201	C0042812
complications	T046	C0009566
eyes	T023	C0015392
patients	T101	C0030705
initial	T079	C0205265
study protocol	T170	C2348563
eyes	T023	C0015392
randomized	T062	C0034656
fresh	T080	C0443224
frozen	T080	C1548793
carrier grafts	T024	C0348047
eyes	T023	C0015392
months	T079	C0439231
follow-up	T058	C1522577
extension	T169	C0231448
eyes	T023	C0015392
frozen	T080	C1548793
eyes	T023	C0015392
fresh	T080	C0443224
carrier graft	T024	C0348047
no differences	T033	C3842396
baseline	T081	C1442488
characteristics	T080	C1521970
patients	T101	C0030705
extension	T169	C0231448
phase	T079	C0205390
months	T079	C0439231
VA	T201	C0042812
fresh group	T078	C0441833
improved	T033	C0184511
baseline	T081	C1442488
frozen group	T078	C0441833
improved	T033	C0184511
baseline	T081	C1442488
Device retention	T033	C0243095
months	T079	C0439231
months	T079	C0439231
differences	T080	C1705242
rate	T081	C1521828
complications	T046	C0009566
groups	T078	C0441833
Fresh	T080	C0443224
frozen	T080	C1548793
corneal donors	T098	C0524358
clinical outcomes	T169	C1274040
carriers	T024	C0348047
B-KPro	T074	C1261333
differences	T080	C1705242
device retention	T033	C0243095
visual rehabilitation	T033	C0243095
rates	T081	C1521828
complications	T046	C0009566
months	T079	C0439231
Impact	T080	C4049986
Educational Intervention	T061	C0281163
Improve	T033	C0184511
Antibiotic	T195	C0003232
Prescribing	T058	C2239117
Nurse Practitioners	T097	C0028657
Pediatric	T100	C0008059
Urgent Care Center	T073	C1710587
pediatric visits	T058	C1444717
antibiotic	T195	C0003232
prescription	T058	C0033080
educational sessions	T065	C1276369
reduce	T080	C0392756
inappropriate	T080	C1548788
antibiotic	T195	C0003232
use	T169	C0457083
Intervention study	T170	C1096775
evaluating	T058	C0220825
antibiotic	T195	C0003232
prescribing	T058	C2239117
educational sessions	T065	C1276369
urinary tract infection	T047	C0042029
skin	T047	C0037278
soft tissue infection	T047	C0149778
pharyngitis	T047	C0031350
upper respiratory tract infection	T047	C0041912
acute otitis media	T047	C0271429
acute bacterial sinusitis	T047	C0275556
nurse practitioners	T097	C0028657
urgent care centers	T073	C1710587
enrolled	T058	C1516879
study	T062	C2603343
rate	T081	C1521828
inappropriate	T080	C1548788
antibiotic	T195	C0003232
use	T169	C0457083
intervention	T061	C0184661
decrease	T081	C0547047
inappropriate	T080	C1548788
antibiotic	T195	C0003232
prescribing	T058	C2239117
educational session	T065	C1276369
inappropriate	T080	C1548788
antibiotic	T195	C0003232
prescribing	T058	C2239117
wrong dosage	T033	C3845820
not indicated	T033	C1444655
Educational sessions	T065	C1276369
improvement	T077	C2986411
inappropriate	T080	C1548788
antibiotic	T195	C0003232
use	T169	C0457083
stewardship	T170	C1554086
interventions	T061	C0184661
reduce	T080	C0392756
antibiotic	T195	C0003232
use	T169	C0457083
Zika Virus	T005	C0318793
Disrupts	T080	C0332454
Phospho-TBK1	T116	C1449326
Localization	T043	C1159772
Mitosis	T043	C0026255
Human	T016	C0086418
Neuroepithelial	T080	C1518280
Stem Cells	T025	C0038250
Radial Glia	T025	C3661481
mechanisms	T169	C0441712
Zika virus	T005	C0318793
ZIKV	T005	C0318793
microcephaly	T019	C0025958
neurodevelopment	T042	C0599855
defects	T169	C1457869
poorly	T080	C0205169
understood	T041	C0162340
derivation	T080	C1441547
characterization	T052	C1880022
single-cell RNA-seq	T086	C0162327
neocortical	T023	C0175173
spinal cord	T023	C0037925
neuroepithelial	T080	C1518280
stem (NES) cells	T025	C0038250
early	T079	C1279919
human	T016	C0086418
neurodevelopment	T042	C0599855
ZIKV	T005	C0318793
neuropathogenesis	T047	C1518296
human	T016	C0086418
NES cells	T025	C0038250
organotypic	T080	C0205556
fetal	T018	C0015965
brain	T023	C0006104
slices	T167	C1519355
ZIKV	T005	C0318793
infected	T033	C0439663
micrencephalic	T019	C0025958
brain	T023	C0006104
ZIKV	T005	C0318793
infects	T033	C0439663
neocortical	T023	C0175173
spinal	T023	C0037925
NES cells	T025	C0038250
fetal	T018	C0015965
radial glial cells	T025	C3661481
RGCs	T025	C3661481
disrupted	T080	C0332454
mitoses	T043	C0026255
supernumerary	T081	C1883702
centrosomes	T026	C0242608
structural	T082	C0678594
disorganization	T033	C4061689
cell death	T043	C0007587
ZIKV infection	T047	C0276289
NES cells	T025	C0038250
RGCs	T025	C3661481
centrosomal	T026	C0242608
depletion	T169	C0333668
mitochondrial	T026	C0026237
sequestration	T169	C0443301
phospho-TBK1	T116	C1449326
mitosis	T043	C0026255
nucleoside analogs	T114	C1579410
inhibit	T052	C3463820
ZIKV	T005	C0318793
replication	T043	C0042774
NES cells	T025	C0038250
ZIKV	T005	C0318793
induced	T169	C0205263
pTBK1	T116	C1449326
relocalization	T043	C0007613
cell death	T043	C0007587
established	T080	C0443211
model system	T170	C3161035
human	T016	C0086418
neural stem cells	T025	C1113654
cellular	T025	C0007634
molecular	T080	C1521991
mechanisms	T169	C0441712
neurodevelopmental	T042	C0599855
defects	T169	C1457869
associated with	T080	C0332281
ZIKV infection	T047	C0276289
potential	T080	C3245505
treatment	T061	C0087111
Prevalence	T081	C0033105
HPV	T005	C0021344
genotypes	T032	C0017431
cervical adenocarcinoma	T191	C0279672
study	T062	C2603343
Greek	T098	C0337806
women	T098	C0043210
study	T062	C2603343
prevalence	T081	C0033105
human papillomavirus	T005	C0021344
HPV	T005	C0021344
genotypes	T032	C0017431
cervical adenocarcinomas	T191	C0279672
Greek	T098	C0337806
women	T098	C0043210
study group	UnknownType	C0681860
adenocarcinoma	T191	C0001418
cases	T077	C1706256
in situ	T191	C0007099
invasive	T191	C1334274
HPV DNA	T114	C3872595
amplified	T045	C0683230
polymerase chain reaction	T063	C0032520
PCR	T063	C0032520
HPV	T005	C0021344
genotypes	T032	C0017431
identified	T080	C0205396
reverse hybridization	T063	C0221902
high prevalence	T081	C0033105
HPV infection	T047	C0343641
in situ	T191	C0007099
invasive (94.83%) adenocarcinomas	T191	C1334274
cancers	T191	C0006826
unusual morphology	T080	C0332437
HPV 16	T005	C0999806
commonest	T081	C0205214
strain	T001	C1518614
HPV 18	T005	C0999807
cases	T077	C1706256
HPV 52 positive	T005	C3641016
co-infection	T047	C0275524
HPV 16	T005	C0999806
18	T005	C0999807
strains	T001	C1518614
exception	T077	C1705847
HPV 66	T005	C3641020
co-infections	T047	C0275524
age difference	T100	C0699810
HPV	T005	C0021344
strain	T001	C1518614
positivity	T033	C1446409
HPV DNA	T114	C3872595
large majority	T054	C0680220
cervical adenocarcinomas	T191	C0279672
studies	T062	C0008972
HPV 52	T005	C3641016
commonly	T081	C0205214
encountered	T058	C0422301
strain	T001	C1518614
HPV 16	T005	C0999806
HPV 18	T005	C0999807
help	T080	C1269765
decision making	T041	C0011109
vaccination	T061	C0042196
policy	T170	C0242456
prevention	T080	C2700409
HPV infection	T047	C0343641
Greece	T083	C0018226
Glucose metabolism	T044	C0596620
weighted imaging	T060	C0011923
chemical exchange-sensitive MRI	T060	C0024485
2-deoxyglucose	T109	C4049845
2DG	T109	C4049845
brain	T023	C0006104
Sensitivity	T081	C1511883
biological	T080	C0205460
sources	T033	C0449416
Recent proof-of-principle studies	T062	C2603343
uptake	T039	C0243144
metabolism	T040	C0025519
2-deoxy-D-glucose	T109	C4049845
2DG	T109	C4049845
chemical exchange-sensitive spin-lock (CESL) MRI approach	T060	C0024485
dynamic	T169	C0729333
in vivo	T082	C1515655
CESL MRI	T060	C0024485
healthy	T080	C3898900
rat	T015	C0086893
brains	T023	C0006104
intravenous injection	T169	C0021494
2DG	T109	C4049845
2DG	T109	C4049845
doses	T081	C0178602
2DG	T109	C4049845
CESL	T060	C0024485
signals	T067	C1710082
increased	T081	C0205217
injection	T061	C1533685
dose	T081	C0178602
2DG	T109	C4049845
transport	T043	C0005528
metabolism	T040	C0025519
2DG	T109	C4049845
CESL	T060	C0024485
2DG	T109	C4049845
higher	T080	C0205250
isoflurane	T109	C0022180
level	T080	C0441889
reduces	T080	C0392756
glucose metabolism	T044	C0596620
increases	T169	C0442805
blood flow	T039	C0232338
2DG	T109	C4049845
CESL	T060	C0024485
measured	T080	C0444706
isoflurane	T109	C0022180
2DG	T109	C4049845
CESL	T060	C0024485
signal	T067	C1710082
reduced	T080	C0392756
higher	T080	C0205250
isoflurane	T109	C0022180
2DG	T109	C4049845
phosphorylation	T044	C0031715
intracellular space	T030	C0682581
regional heterogeneities	T102	C0086833
glucose metabolism	T044	C0596620
2DG	T109	C4049845
CESL	T060	C0024485
higher	T080	C0205250
cortex	T023	C0007776
corpus callosum	T023	C0010090
CESL MRI	T060	C0024485
injection	T061	C1533685
non-transportable mannitol	T109	C0024730
2DG	T109	C4049845
CESL	T060	C0024485
decreased	T081	C0205216
increased	T081	C0205217
spin-lock pulse power	T081	C3854080
2DG	T109	C4049845
CESL	T060	C0024485
chemical	T103	C0220806
exchange	T201	C4019011
processes	T067	C1522240
extravascular space	T082	C1254362
2DG	T109	C4049845
CESL MRI	T060	C0024485
signals	T067	C1710082
glucose transport	T043	C0178666
metabolism	T044	C0596620
biomarker	T201	C0005516
metabolic	T169	C0311400
studies	T062	C2603343
normal	T023	C0006104
diseased	T047	C0012634
brains	T023	C0006104
Parental	T099	C0030551
perceptions	T041	C0030971
children´s agency	T092	C0237463
Parental warmth	UnknownType	C0814578
school achievement	T055	C0700132
adjustment	T055	C0376209
study	T062	C2603343
Swedish	T098	C1710263
mothers'	T099	C0026591
fathers'	T099	C0015671
warmth	UnknownType	C0814578
children	T100	C0008059
children´s agency	T092	C0237463
agency	T092	C0237463
children's	T100	C0008059
school achievement	T055	C0700132
Swedish	T098	C1710263
children's	T100	C0008059
mothers	T099	C0026591
fathers	T099	C0015671
interviewed	T052	C0021822
time points	T079	C1442880
children	T100	C0008059
years	T079	C0439234
warmth	UnknownType	C0814578
children	T100	C0008059
children's agency	T092	C0237463
children's	T100	C0008059
school achievement	T055	C0700132
Parental warmth	UnknownType	C0814578
Time	T079	C0040223
correlated	T080	C1707520
child agency	T092	C0237463
Time	T079	C0040223
correlated	T080	C1707520
child	T100	C0008059
academic achievement	T055	C0700132
Time	T079	C0040223
girls	T100	C0870604
boys	T100	C0870221
study	T062	C2603343
Swedish	T098	C1710263
parents' warmth	UnknownType	C0814578
perceptions	T041	C0030971
children's agency	T092	C0237463
child	T100	C0008059
problems	T033	C0033213
academic achievement	T055	C0700132
findings	T033	C0243095
year	T079	C0439234
longitudinal study	T062	C0023981
boys	T100	C0870221
girls	T100	C0870604
child agency	T092	C0237463
parental warmth	UnknownType	C0814578
children's	T100	C0008059
adjustment	T055	C0376209
Vasopressin	T116	C0042413
regulates the growth	T043	C0596286
biliary epithelium	T025	C3686472
polycystic liver disease	T019	C0158683
neurohypophysial hormone	T116	C0032017
arginine vasopressin	T116	C0003779
AVP	T116	C0003779
receptor	T116	C0597357
V1a	T116	C0284725
V1b	T116	C0284726
V2	T116	C0162829
liver	T023	C0023884
AVP	T116	C0003779
involved	T169	C1314939
ureogenesis	T044	C0597619
glycogenolysis	T044	C0596624
neoglucogenesis	T044	C0598530
regeneration	T042	C0034963
presence	T033	C0150312
AVP	T116	C0003779
biliary epithelium	T025	C3686472
Cholangiocytes	T025	C3686472
target cells	T025	C0221284
animal models	T050	C0012644
cholestasis	T047	C0008370
bile duct	T023	C0005400
ligation	T061	C0023690
BDL	T061	C0023690
human	T016	C0086418
pathologies	T091	C0030664
polycystic liver disease	T019	C0158683
characterized	T052	C1880022
presence	T033	C0150312
cysts	T047	C0010709
biliary epithelium	T025	C3686472
In vivo	T082	C1515655
liver	T023	C0023884
fragments	T031	C0486805
BDL	T061	C0023690
mice	T015	C0025929
rats	T015	C0034721
liver samples	T024	C0586689
ADPKD	T019	C0085413
patients	T101	C0030705
intrahepatic	T082	C1512948
bile duct	T023	C0005400
mass	T033	C0577559
immunohistochemistry	T060	C0021044
cytokeratin-19	T116	C0010803
expression	T045	C0597360
V1a	T116	C0284725
V1b	T116	C0284726
V2	T116	C0162829
immunohistochemistry	T060	C0021044
immunofluorescence	T059	C0079603
real-time PCR	T063	C1709846
In vitro	T080	C1533691
mouse	T015	C0025929
cholangiocytes	T025	C3686472
H69	T025	C0007634
non-malignant	T080	C1518371
human	T016	C0086418
cholangiocytes	T025	C3686472
LCDE	T025	C0007634
human	T016	C0086418
cholangiocytes	T025	C3686472
cystic epithelium	T190	C0259770
stimulated	T044	C0038337
vasopressin	T116	C0042413
presence	T033	C0150312
AVP antagonists	T116	C1719946
OPC-31260	T109	C0171458
Tolvaptan	T109	C1176308
cellular growth	T043	C0007595
MTT assay	T059	C0201596
cAMP	T114	C0001455
Cholangiocytes	T025	C3686472
V2 receptor	T116	C0162829
upregulated	T044	C0041904
BDL	T061	C0023690
ADPKD	T019	C0085413
liver samples	T024	C0586689
Administration	T061	C1533734
AVP	T116	C0003779
increased	T081	C0205217
proliferation	T043	C0596290
cAMP	T114	C0001455
cholangiocytes	T025	C3686472
LCDE cells	T025	C0007634
no effect	T080	C1301751
proliferation	T043	C0596290
mouse	T015	C0025929
cholangiocytes	T025	C3686472
H69 cells	T025	C0007634
Increases	T169	C0442805
blocked	T169	C0332206
preincubation	T059	C1441618
AVP antagonists	T116	C1719946
results	T169	C1274040
AVP	T116	C0003779
receptors	T116	C0597357
modulation	UnknownType	C0544633
proliferation rate	T034	C0812425
biliary epithelium	T025	C3686472
Central Corneal Thickness	T201	C1720164
Reproducibility	T081	C0035149
Instruments	T073	C1518597
assess	T058	C0184514
ultrasonic	T074	C1875843
US	T074	C1875843
optical instruments	T073	C1518597
measurement	T169	C0242485
central corneal thickness	T201	C1720164
CCT	T201	C1720164
evaluate	T058	C0220825
intra- and inter-operator reproducibility	T081	C0035149
cross-sectional study	T062	C0010362
CCT	T201	C1720164
healthy	T080	C3898900
eyes	T023	C0015392
spectral-domain optical coherence tomography (SD-OCT) devices	T074	C3876157
one time-domain OCT	T074	C4052697
Scheimpflug camera	T074	C0179543
US-based instrument	T074	C1875843
Inter- and intra-operator reproducibility	T080	C1514863
evaluated	T058	C0220825
intraclass correlation coefficient	T081	C0010100
ICC	T081	C0010100
coefficient of variation	T081	C0681921
CV	T081	C0681921
Bland-Altman test	T170	C0870616
analysis	T062	C0936012
Instrument	T074	C0348000
instrument	T074	C0348000
reproducibility	T081	C0035149
ANOVA	T081	C0002780
tested	T169	C0039593
devices	T074	C0025080
systemic	T169	C0205373
bias	T078	C0242568
random	T080	C0439605
error	T080	C0743559
structural equation model	T062	C0681947
CCT	T201	C1720164
instruments	T074	C0348000
instrument	T074	C0348000
instrument	T074	C0348000
correlation test	T170	C1707521
high	T080	C0205250
values	T080	C0042295
investigated	T169	C1292732
devices	T074	C0025080
correlation coefficient	T081	C0010100
range	T081	C1514721
p values	T081	C1709380
Topcon-Spectral OCT/SLO Opko	T073	C1518597
Cirrus HD-OCT Zeiss-RS-3000 Nidek	T073	C1518597
SS-1000 CASIA	T073	C1518597
Spectral OCT/SLO Opko	T073	C1518597
ICC	T081	C0010100
CV	T081	C0681921
inter- and intra-operator reproducibility	T080	C1514863
optic	T090	C0029144
devices	T074	C0025080
US	T074	C1875843
device	T074	C0025080
Bland-Altman	T170	C0870616
analysis	T062	C0936012
biases	T078	C0242568
intra- and inter-operator reproducibility	T080	C1514863
scale	T170	C0349674
bias	T078	C0242568
instruments	T074	C0348000
interfere with	T169	C0521102
CCT	T201	C1720164
monitoring	T058	C1283169
optimal	T080	C2698651
monitoring	T058	C1283169
device	T074	C0025080
Predictors	T078	C2698872
neurologic	T046	C0006110
nonneurologic death	T033	C1306577
patients	T101	C0030705
brain metastasis	T191	C0220650
treated	T169	C1522326
upfront stereotactic radiosurgery	T061	C0085203
whole-brain radiation therapy	T061	C1520143
study	T062	C2603343
factors	T169	C1521761
predictive	T080	C0681890
neurologic death	T046	C0006110
patients	T101	C0030705
brain metastasis	T191	C0220650
treated	T169	C1522326
upfront stereotactic radiosurgery	T061	C0085203
SRS	T061	C0085203
whole brain radiation therapy	T061	C1520143
WBRT	T061	C1520143
competing risk	T078	C0035647
nonneurologic death	T033	C1306577
retrospective	T080	C1514923
single-institution	T093	C2607850
analysis	T062	C0936012
patients	T101	C0030705
brain metastasis	T191	C0220650
treated	T169	C1522326
SRS	T061	C0085203
WBRT	T061	C1520143
Competing risks analysis	T080	C0814767
hazard ratios	T081	C2985465
HRs	T081	C2985465
neurologic	T046	C0006110
nonneurologic death	T033	C1306577
predictor	T078	C2698872
patients	T101	C0030705
treated	T169	C1522326
upfront SRS	T061	C0085203
neurologic death	T046	C0006110
nonneurologic death	T033	C1306577
Multivariate competing risks analysis	T081	C0026777
increased	T081	C0205217
hazard	T081	C2985465
neurologic death	T046	C0006110
diagnosis-specific graded prognostic assessment	T170	C0282574
DS-GPA	T170	C0282574
melanoma	T191	C0025202
histology	T059	C0344441
increased	T081	C0205217
brain metastases	T191	C0220650
decreased	T081	C0205216
hazard	T081	C2985465
SRS	T061	C0085203
dose	T081	C0178602
Targeted agents	T121	C1254351
decreased	T081	C0205216
HR	T081	C2985465
neurologic death	T046	C0006110
years	T079	C0439234
increased	T081	C0205217
hazard	T081	C2985465
nonneurologic death	T033	C1306577
age	T032	C0001779
nonmelanoma histology	T059	C0344441
extracranial disease	T047	C0012634
progressive	T169	C0205329
systemic disease	T047	C0442893
Melanoma	T191	C0025202
DS-GPA	T170	C0282574
number	T081	C0237753
brain metastases	T191	C0220650
SRS	T061	C0085203
dose	T081	C0178602
predictive	T080	C0681890
neurologic death	T046	C0006110
age	T032	C0001779
nonmelanoma histology	T059	C0344441
systemic disease	T047	C0442893
predictive	T080	C0681890
nonneurologic death	T033	C1306577
Targeted agents	T121	C1254351
delay	T079	C0205421
neurologic death	T046	C0006110
Pharmacological Actions	T038	C0007992
Glucagon-Like Peptide-1	T116	C0061355
Gastric Inhibitory Polypeptide	T116	C0017132
Glucagon	T116	C0017687
Glucagon family	T116	C0017687
peptide hormones	T116	C0597192
brain-gut peptides	T116	C0030956
pleiotropic actions	T045	C2936488
interactions	T045	C0596610
unique members of class B1	T185	C0008902
G protein-coupled receptors	T116	C0682972
GPCRs	T116	C0682972
regulators	T077	C1704735
hormonal	T080	C0458083
homeostasis	T038	C0019868
drug targets	T074	C0085104
metabolic disorders	T047	C0025517
type-2 diabetes mellitus	T047	C0011860
T2DM	T047	C0011860
obesity	T047	C0028754
dysregulations of the nervous systems	T047	C0027765
migraine	T047	C0149931
anxiety	T048	C0003469
depression	T048	C0011570
neurodegeneration	T049	C0027746
psychiatric disorders	T048	C0004936
cardiovascular diseases	T047	C0007222
overview	T170	C0814812
pharmacological actions	T038	C0007992
therapeutic advances	T061	C0087111
glucagon-like peptide-1	T116	C0061355
GLP-1	T116	C0061355
gastric inhibitory polypeptide	T116	C0017132
GIP	T116	C0017132
glucagon	T116	C0017687
Endemic	T082	C1254362
hydrothermal vent	T070	C3178903
species	T185	C1705920
identified	T080	C0205396
ocean	T170	C1547972
seed bank	T002	C4042839
Hydrothermal vent	T070	C3178903
systems	T169	C0449913
microbial	T001	C0599840
communities	T096	C0009462
several	T081	C0443302
microorganisms	T001	C0445623
considered	T078	C0750591
endemic	T082	C1254362
habitat	T082	C0871648
unclear	T033	C3845108
organisms	T001	C0029235
colonize	T033	C4289767
geographically	T083	C0017446
distant	T082	C0443203
hydrothermal	T080	C0205556
environments	T082	C0014406
16S rRNA	T114	C3537372
gene sequences	T086	C0162326
compare	T052	C1707455
bacterial	T080	C0521009
communities	T096	C0009462
Atlantic	T083	C0004167
hydrothermal vent	T070	C3178903
samples	T077	C2347026
available	T169	C0470187
global	T080	C2348867
ocean	T170	C1547972
samples	T167	C0370003
Analysing	T062	C0936012
sequences	T086	C0162326
obtained	T169	C1301820
16S rRNA	T114	C3537372
genes	T028	C0017337
genera	T185	C1708235
ocean waters	T170	C1547972
contained	T169	C0332256
vent	T070	C0043187
suggests	T078	C1705535
previously	T079	C0205156
observed	T169	C1441672
vent	T070	C0043187
exclusiveness	T033	C0243095
cases	T169	C0868928
probably	T078	C0750492
artefact	T033	C0243095
lower	T052	C2003888
sequencing	T059	C1294197
depth	T080	C0205556
findings	T033	C0243095
role	T170	C1704326
ocean	T170	C1547972
seed bank	T002	C4042839
predicament	T033	C0243095
species	T185	C1705920
expected	T170	C1517001
endemic	T082	C1254362
vent	T070	C0043187
systems	T169	C0449913
able	T033	C1299581
colonize	T033	C4289767
geographically	T083	C0017446
distant	T082	C0443203
hydrothermal	T080	C0205556
habitats	T082	C0871648
contribute	T052	C1880177
understanding	T041	C0162340
Cerebral toxoplasmosis	T047	C0085315
patients	T101	C0030705
acquired immune deficiency syndrome	T047	C0001175
neurological emergency department	T073	C0562508
tertiary hospital	T073	C0337954
Cerebral toxoplasmosis	T047	C0085315
cause	T169	C0015127
space	T082	C1883067
brain lesion	T047	C0221505
patients	T101	C0030705
HIV/AIDS	T047	C0497169
Brazil	T083	C0006137
post-HAART era	T079	C0681698
high	T080	C0205250
rates	T081	C1521828
morbidity	T081	C0026538
mortality	T081	C0205848
study	T062	C2603343
case series	T062	C0150093
patients	T101	C0030705
diagnosed	T033	C0011900
cerebral toxoplasmosis	T047	C0085315
clinical	T080	C0205210
features	T080	C1521970
brain imaging	T060	C0203860
cerebrospinal fluid	T031	C0007806
aspects	T080	C1879746
analyzed	T062	C0936012
Cerebral toxoplasmosis	T047	C0085315
diagnosis	T033	C0011900
infection	T046	C3714514
human immunodeficiency virus	T005	C0019682
HIV	T005	C0019682
patients	T101	C0030705
HIV seropositive	T034	C0019699
time	T079	C0040223
diagnosis	T033	C0011900
cerebral toxoplasmosis	T047	C0085315
reported	T058	C0700287
antiretroviral therapy	T061	C1963724
receiving	T080	C1514756
primary	T080	C0205225
prophylaxis	T061	C0199176
toxoplasmosis	T047	C0085315
Headache	T184	C0018681
strength deficit	T184	C1457887
fever	T184	C0015967
signs and symptoms	T184	C0037088
study	T062	C2603343
patients	T101	C0030705
changes	T169	C0392747
consistent with	T078	C0332290
toxoplasmosis	T047	C0085315
CT	T060	C0040405
MRI	T060	C0024485
CSF samples	T031	C1292530
positive	T033	C1446409
indirect haemagglutination test	T059	C0022885
reaction	T169	C0443286
Toxoplasma gondii IgG	T116	C0370074
ELISA	T059	C0014441
positive	T033	C1446409
direct haemagglutination test	T059	C0022885
patients	T101	C0030705
first-line treatment	T061	C1708063
toxoplasmosis	T047	C0085315
Cerebral toxoplasmosis	T047	C0085315
relevant	T080	C2347946
neurological disease	T047	C0027765
individuals	T098	C0237401
AIDS	T047	C0001175
admitted	T058	C0184666
neurology	T091	C0027855
emergency departments	T073	C0562508
Early diagnosis	T060	C0596473
initiation	T169	C1704686
empiric treatment	T033	C0749647
antiretroviral therapy	T061	C1963724
prognosis	T058	C0033325
Maf1	T028	C1825934
regulation	T038	C1327622
yeast	T004	C0043393
RNA polymerase III	T116	C0035680
correlated	T080	C1707520
CCA addition at the 3' end of tRNA	T045	C1158763
tRNA precursors	T114	C0041133
eukaryotic cells	T025	C0015161
tRNA synthesis	T045	C1622985
negatively	T033	C0205160
regulated	T038	C1327622
protein Maf1	T116	C0536951
yeast	T004	C0043393
humans	T016	C0086418
Maf1	T028	C1825934
yeast	T004	C0043393
Saccharomyces cerevisiae	T004	C0036025
repression	T045	C0920533
trna transcription	T045	C1158829
cells	T025	C0007634
medium	T130	C0010454
glucose	T109	C0017725
medium	T130	C0010454
glycerol	T109	C0017861
non-fermentable	T044	C0015852
carbon	T196	C0007009
source	T033	C0449416
strain	T001	C1518614
deleted	T033	C2069771
gene	T028	C0017337
encoding	T052	C2700640
Maf1	T028	C1825934
maf1Δ	T028	C1825934
viable	T080	C0443348
tRNA precursors	T114	C0041133
study	T062	C2603343
tRNA precursors	T114	C0041133
analysed	T062	C0936012
RNA-Seq	T059	C0917793
Northern hybridization	T059	C0599862
wild type	T028	C1883559
strain	T001	C1518614
maf1Δ	T028	C1825934
mutant	T028	C0678941
glucose	T109	C0017725
medium	T130	C0010454
repressive conditions	T080	C0348080
negative	T033	C0205160
effect	T080	C1280500
maf1Δ	T028	C1825934
mutant	T028	C0678941
addition of the auxiliary CCA nucleotides to the 3' end of pre-tRNAs	T045	C1158763
cells	T025	C0007634
growth	T040	C0018270
conditions	T080	C0348080
effect	T080	C1280500
reduced	T080	C0392756
overexpression	T045	C1514559
yeast	T004	C0043393
CCA1 gene	T028	C1413163
encoding	T052	C2700640
ATP(CTP):tRNA nucleotidyltransferase	T116	C0077328
CCA sequence	T086	C0004793
export	T067	C0699789
tRNA precursors	T114	C0041133
nucleus	T026	C0007610
tRNA charging	T045	C1327001
amino acids	T116	C0002520
Data	T078	C1511726
CCA-addition to intron -containing end-processed tRNA precursors	T045	C1158763
intron	T114	C0021920
limiting step	T077	C1261552
tRNA maturation	T045	C1158762
Maf1	T028	C1825934
RNA polymerase III	T116	C0035680
Pol III	T116	C0035680
repression	T045	C0920533
correlation	T080	C1707520
CCA	T086	C0004793
synthesis	T044	C1157592
Pol III	T116	C0035680
regulation	T038	C1327622
Maf1	T028	C1825934
coordination	T169	C0700114
tRNA transcription	T045	C1158829
processing	T045	C1158762
regulation of translation	T043	C1157519
Pre-existing	T080	C2347662
renal	T023	C0022646
lesions	T033	C0221198
renal	T023	C0022646
trauma	T037	C3714660
diagnosis	T062	C1704656
accountability	T078	C0078889
cases	T077	C1706256
Pre-existing	T080	C2347662
renal	T023	C0022646
lesions	T033	C0221198
PERL	T033	C0221198
patho-physiology	T169	C0031847
trauma	T037	C3714660
radiographic imaging	T060	C0457276
influence	T077	C4054723
therapeutic	T061	C0087111
aims	T078	C1947946
study	T062	C2603343
PERL	T033	C0221198
blunt	T080	C1997138
renal	T023	C0022646
trauma	T037	C3714660
conservative management	T061	C0459914
partial permanent disability	T033	C2080701
PPD	T033	C2080701
medical records	T170	C0025102
patients	T101	C0030705
PERL	T033	C0221198
blunt	T080	C1997138
renal	T023	C0022646
trauma	T037	C3714660
patient	T101	C0030705
pre-existing	T080	C2347662
renal	T023	C0022646
clinical	T080	C0205210
symptoms	T184	C1457887
CT scan	T060	C0040405
study	T062	C2603343
findings	T033	C0243095
injuries	T037	C3263723
therapeutic	T061	C0087111
accountability	T078	C0078889
PPD	T033	C2080701
men	T098	C0025266
women	T098	C0043210
mean	T081	C0444504
age	T032	C0001779
years	T079	C0439234
years	T079	C0439234
Renal	T023	C0022646
trauma	T037	C3714660
traffic accident	T037	C0000932
patients	T101	C0030705
Renal	T023	C0022646
severity	T080	C0439793
trauma	T037	C3714660
trauma	T037	C3714660
trauma	T037	C3714660
abdominal organs	T023	C0446633
patients	T101	C0030705
Urinary stones	T031	C0042018
patients	T101	C0030705
pelvi-ureteric junction obstruction	T046	C0521619
horseshoe kidny	T019	C0221353
ectopic kidney	T019	C0238207
urinary tract carcinoma	T191	C2007041
nephrectomy	T061	C0027695
cases	T077	C1706256
hemodynamic instability	T047	C0948268
Ureteral stenting	T074	C0183518
cases	T077	C1706256
patients	T101	C0030705
operated	T061	C0543467
renal	T023	C0022646
pathology	T059	C0919386
conservative treatment	T061	C0459914
cases	T077	C1706256
PPD	T033	C2080701
renal	T023	C0022646
trauma	T037	C3714660
cases	T077	C1706256
PERL	T033	C0221198
renal	T023	C0022646
trauma	T037	C3714660
cases	T077	C1706256
patient's	T101	C0030705
findings	T033	C0243095
therapeutic	T061	C0087111
PERL	T033	C0221198
severity	T080	C0439793
damage	T169	C1883709
hemo-dynamically stable	T033	C0578150
patient	T101	C0030705
Accountability	T078	C0078889
PPD	T033	C2080701
PERL	T033	C0221198
renal injuries	T037	C0160420
severity	T080	C0439793
Polymeric	T104	C0032521
Nanostructure	T073	C1450053
Multifunctional Components	T077	C1705248
Tumor	T191	C0027651
Targeted Delivery	T063	C0920677
Antiangiogenic	T039	C3179230
Gene	T028	C0017337
Tumor Growth	T191	C0598934
Suppression	T080	C2700409
Nucleic acid-based	T114	C0028606
therapy	T061	C0087111
revolutionary methodology	T078	C3266812
treatment	T169	C1522326
diseases	T047	C0012634
protein	T116	C0033684
dysfunction	T077	C3887504
lack of	T080	C0332268
systemically	T169	C0205373
applicable	T080	C1706839
synthetic delivery systems	T063	C0920677
local applications	T046	C1393254
DNA-based	T114	C0012854
therapy	T061	C0087111
poor bioavailability	T081	C0005508
systemic administrations	UnknownType	C0678812
multiple	T081	C0439064
chemistry-based strategies	T059	C3178923
manufacture	T057	C0870840
gene delivery formulations	T063	C0920677
improved	T033	C0184511
tolerability	T080	C4053931
DNA	T114	C0012854
enzymatic	T044	C1511131
degradation	T044	C0314674
biological	T080	C0205460
milieu	T082	C0014406
prolonged retention	T043	C1753315
distinctive multilayered	T080	C0205556
functional	T169	C0205245
architecture	T082	C1254362
plasmid DNA	T114	C0032136
pDNA	T114	C0032136
electrostatically complexed	T067	C2348396
cationic	T104	C0007447
poly(lysine)	T116	C0032426
polyplex	T104	C0032521
interior	T082	C0205102
pDNA	T114	C0032136
reservoir	T082	C1254362
cross-linked	T070	C0178576
redox	T044	C0030012
responsive	T169	C0205342
disulfide	T104	C0012771
cross-linking	T169	C0332220
occurrence	T079	C2745955
polyplex	T104	C0032521
disassembly	T052	C1707798
exchange reaction	T044	C1148560
biological	T080	C0205460
charged components	T196	C0022023
pDNA	T114	C0032136
reservoir	T082	C1254362
sequential	T080	C1705294
thermoresponsive	T169	C0205245
poly(N-isopropylacrylamide)	T109	C0071490
palisade	T033	C1704513
intermediate barrier	T033	C1704513
biocompatible	T122	C0005479
hydrophilic	T080	C0475370
poly(ethylene glycol)	T109	C0032483
PEG	T109	C0032483
shell	T080	C1948022
accessibility	T080	C0814423
biological	T080	C0205460
species	T185	C1705920
nuclease	T116	C0597094
degradation	T169	C0243125
pDNA	T114	C0032136
investigations	T058	C0220825
strategies	T041	C0679199
blood	T031	C0005767
retention	T046	C0268000
method	T170	C0025663
therapy	T061	C0087111
ligand cyclic (Arg-Gly-Asp) peptide	T116	C1685100
PEG	T109	C0032483
tumor	T191	C0027651
targeted	T169	C1521840
delivery	T077	C1524066
gene expression	T045	C0017262
antiangiogenic	T039	C3179230
gene	T028	C0017337
targeted	T169	C1521840
tumor cells	T025	C0597032
exerting	T040	C0015264
antiangiogenesis	T039	C3179230
tumors	T191	C0027651
abrogation	T079	C2746065
tumor growth	T191	C0598934
potential	T080	C3245505
gene delivery system	T063	C0920677
treatment	T169	C1522326
intractable	T169	C0205269
diseases	T047	C0012634
Evaluation	T058	C0220825
VIDAS Anti-HCV Assay	T059	C0005507
Detection	T061	C1511790
Hepatitis C Virus Infection	T047	C4288963
Anti-hepatitis C virus antibody	T116	C0166049
anti-HCV	T116	C0166049
assays	T059	C0005507
screening	T058	C1710032
HCV	T005	C0220847
HCV -infected persons	T098	C0027361
VIDAS Anti-HCV Assay	T059	C0005507
France	T083	C0016674
enzyme-linked fluorescence test	T059	C0022885
principle	T078	C0178566
Korea	T083	C0022771
clinical	T080	C0205210
performance	T052	C1882330
VIDAS assay	T059	C0005507
HCV-positive	T034	C1112419
HCV-negative	T034	C1619717
blood samples	T031	C0178913
Architect anti-HCV	T059	C0005507
Abbott Laboratories	T093	C1552881
USA	T083	C0041703
COBAS TaqMan HCV real-time PCR	T063	C1709846
Roche Diagnostics	T092	C3828314
USA	T083	C0041703
Procleix Ultrio Plus Assay	T059	C0005507
USA	T083	C0041703
Human Serum Bank	T093	C0597886
HSB	T093	C0597886
VIDAS	T059	C1553144
discrepant results	T033	C1290905
recombinant immunoblot assay	T059	C2987205
RIBA	T059	C2987205
agreement rates	T081	C1521828
HCV-positive	T034	C1112419
HCV-negative	T034	C1619717
samples	T031	C0178913
VIDAS assay	T059	C0005507
HSB	T093	C0597886
confidence interval	T081	C0009667
CI	T081	C0009667
CI	T081	C0009667
discrepant	T033	C1290905
samples	T031	C0178913
positive	T033	C1446409
Core 2+	T129	C0019166
NS3-2 2+	T129	C0021054
samples	T031	C0178913
negative	T033	C0205160
NS4 2+	T129	C0021054
RIBA	T059	C2987205
correlation	T080	C1707520
titers	T081	C0475208
VIDAS	T059	C1553144
Architect assays	T059	C0005507
VIDAS anti-HCV assay	T059	C0005507
VIDAS	T059	C1553144
automated immunoassay platform	T059	C0020980
laboratories	T073	C0022877
Architect anti-HCV	T059	C0005507
COBAS PCR assays	T063	C1709846
HCV infection	T047	C4288963
Weakly test-positive (ambiguous)	T034	C0456984
samples	T031	C0178913
anti-HCV	T116	C0166049
RIBA	T059	C2987205
HCV RNA assay	T059	C1272251
Reassembly of Excitable Domains	T042	C1254358
CNS	T022	C3714787
Axon Regeneration	T042	C1621980
Action potential initiation	T043	C4236548
propagation	T043	C4236672
myelinated axons	UnknownType	C0682682
ion channel clustering	T043	C1660767
axon initial segments	T026	C1179989
(AIS	T026	C1179989
nodes of Ranvier	T030	C0034667
Disruption	T169	C0332453
injury	T037	C3263723
impairs	T169	C1883709
nervous system function	T042	C0027767
injured	T169	C0332664
CNS	T022	C3714787
axons	T026	C0004461
refractory	T040	C0034954
regeneration	T042	C1621980
robust	T080	C2986815
long-distance	T081	C0012751
regeneration	T042	C1621980
remyelination	T042	C0334220
reestablishment	T042	C1254358
AIS	T026	C1179989
nodes of Ranvier	T030	C0034667
unknown	T080	C0439673
mouse	T015	C0025929
optic nerve	T023	C0029130
crush	T037	C0332679
model	T050	C0012644
CNS	T022	C3714787
traumatic injury	T037	C3263723
analysis	T062	C0936012
AIS	T026	C1179989
node	T030	C0034667
disruption	T169	C0332453
nerve crush	T037	C0161479
disruption	T169	C0332453
AIS	T026	C1179989
loss	T081	C1517945
nodes	T030	C0034667
crush	T037	C0332679
loss	T081	C1517945
nodes	T030	C0034667
injury	T037	C3263723
Genetic deletion	T045	C0017260
tumor suppressor phosphatase and tensin homolog	T028	C0694888
Pten	T028	C0694888
retinal ganglion cells	T025	C0035316
RGCs	T025	C0035316
stimulation	T043	C0007613
RGCs	T025	C0035316
inflammation	T046	C0021368
cAMP	T114	C0001455
regeneration	T042	C1621980
treatmen	T062	C3161471
reestablishment	T042	C1254358
RGC	T025	C0035316
AIS	T026	C1179989
remyelination	T042	C0334220
reassembly	T042	C1254358
nodes	T030	C0034667
regions proximal	T082	C0205107
within	T082	C0332285
distal	T082	C0205108
crush	T037	C0332679
site	T029	C1515974
Remyelination	T042	C0334220
near the retina	T029	C0459620
progressed	T169	C1272688
distally	T082	C0205108
electron microscopy	T059	C0026019
axons	T026	C0004461
grew	T043	C0007595
rapidly	T080	C0456962
remyelination	T042	C0334220
nodal ion channel clustering	T043	C1660767
slower	T080	C0439834
genetic deletion	T045	C0017260
ankyrinG	T116	C1384562
RGCs	T025	C0035316
block	T169	C0332206
AIS	T026	C1179989
reassembly	T042	C1254358
axon regeneration	T042	C1621980
neuronal polarity	T082	C0085304
not required	T033	C0243095
axon regeneration	T042	C1621980
regenerating	T042	C1621980
CNS	T022	C3714787
axons	T026	C0004461
remyelinated	T042	C0334220
reassemble	T042	C1254358
AIS	T026	C1179989
nodes of Ranvier	T030	C0034667
regenerated	T042	C1621980
CNS	T022	C3714787
axons	T026	C0004461
capacity	T081	C1516240
remyelinate	T042	C0334220
reassemble	T042	C1254358
axon initial segments	T026	C1179989
nodes of Ranvier	T030	C0034667
rapid	T080	C0456962
efficient	T080	C0442799
action potential propagation	T043	C4236672
Clinicopathological	T091	C0030667
kinesin family member 18A	T116	C1610793
expression	T045	C1171362
invasive breast cancer	T191	C0853879
kinesin	T116	C0085139
motor proteins	T116	C1720835
targets	T169	C1521840
cancer therapy	T061	C0920425
Kinesins	T116	C0085139
microtubule	T116	C0026042
motor proteins	T116	C1720835
diverse functions	T169	C0542341
cell	T025	C0007634
transport	T043	C0005528
vesicles	T026	C1622418
organelles	T026	C0029219
chromosomes	T026	C0008633
protein complexes	T116	C1180347
movement of microtubules	T043	C1156033
expression	T045	C1171362
kinesin family member 18A	T116	C1610793
KIF18A	T116	C1610793
member of kinesin superfamily	T116	C0085139
investigated	T169	C1292732
breast cancer	T191	C0006142
immunohistochemistry	T060	C0021044
breast cancer	T191	C0006142
KIF18A	T116	C1610793
expression level	T081	C3244092
associated with	T080	C0332281
lymph node metastasis	T191	C0686619
patients	T101	C0030705
KIF18A	T116	C1610793
expression	T045	C1171362
survival	T052	C0038952
patients	T101	C0030705
KIF18A	T116	C1610793
expression	T045	C1171362
disease-free survival	T081	C0242793
Multivariate analysis	T081	C0026777
venous invasion	T033	C1710625
hazard ratio	T081	C2985465
confidence interval	T081	C0009667
KIF18A	T116	C1610793
expression	T045	C1171362
hazard ratio	T081	C2985465
confidence interval	T081	C0009667
predictive factors	T170	C0683956
lymph node metastasis	T191	C0686619
KIF18A	T116	C1610793
predictive	T170	C0683956
marker	T201	C0005516
lymph node metastasis	T191	C0686619
breast cancer	T191	C0006142
curative adjuvant	T033	C3846124
treatment	T061	C0087111
inflammatory chronic disease	T047	C1290886
influences	T077	C4054723
infliximab	T116	C0666743
pharmacokinetics	T169	C0031328
Infliximab	T116	C0666743
anti-tumor necrosis factor	T121	C1562242
monoclonal antibody	T116	C0003250
chronic inflammatory diseases	T047	C1290886
rheumatoid arthritis	T047	C0003873
RA	T047	C0003873
psoriatic arthritis	T047	C0003872
PsA	T047	C0003872
ankylosing spondylitis	T047	C0038013
AS	T047	C0038013
Crohn's disease	T047	C0010346
CD	T047	C0010346
ulcerative colitis	T047	C0009324
UC	T047	C0009324
Infliximab	T116	C0666743
pharmacokinetics	T169	C0031328
patients	T101	C0030705
influence	T077	C4054723
underlying disease	T047	C0012634
assessed	T052	C1516048
influence	T077	C4054723
cohort	T098	C0599755
patients monitored	T058	C0030695
assay	T059	C1510438
Infliximab	T116	C0666743
concentrations	T081	C1446561
determined	T080	C0521095
samples collected	T059	C0200345
treatment	T169	C1522326
initiation	T169	C1704686
patients	T101	C0030705
treated	T169	C1522326
RA	T047	C0003873
PsA	T047	C0003872
AS	T047	C0038013
CD	T047	C0010346
UC	T047	C0009324
Infliximab	T116	C0666743
pharmacokinetics	T169	C0031328
analyzed	T062	C0936012
population	T098	C1257890
elimination	T033	C2735304
rate constant	T081	C2986811
AS	T047	C0038013
patients	T101	C0030705
volume of distribution	T081	C0683148
V	T081	C0683148
elimination	T033	C2735304
clearance	T080	C0449297
CL	T080	C0449297
CD	T047	C0010346
UC	T047	C0009324
patients	T101	C0030705
AS	T047	C0038013
CL	T080	C0449297
AS	T047	C0038013
RA	T047	C0003873
patients	T101	C0030705
CL	T080	C0449297
AS	T047	C0038013
patients	T101	C0030705
Simulations	T062	C0679083
methotrexate	T109	C0025677
dosing	T081	C0178602
regimen	T061	C0040808
RA	T047	C0003873
patients	T101	C0030705
target	T169	C1521840
concentration	T081	C1446561
target	T169	C1521840
concentrations	T081	C1446561
approximately	T080	C0332232
RA	T047	C0003873
patients	T101	C0030705
cotreated	T169	C1522326
methotrexate	T109	C0025677
CD	T047	C0010346
UC	T047	C0009324
patients	T101	C0030705
dosing	T081	C0178602
regimens	T061	C0040808
development	T169	C1527148
dosing	T081	C0178602
optimization	T052	C2698650
concentration measurements	T081	C1446561
International	T078	C1512888
validation	T062	C1519941
urinary	T031	C1610733
biomarker	T201	C0005516
panel	T059	C0022885
active	T169	C0205177
lupus nephritis	T047	C0024143
children	T100	C0008059
markers	T201	C0005516
juvenile-onset systemic lupus erythematosus	T047	C1274834
JSLE	T047	C1274834
disease activity	T060	C4065474
lupus nephritis	T047	C0024143
LN	T047	C0024143
novel	T080	C0205314
urine	T031	C0042036
biomarkers	T201	C0005516
detecting	T061	C1511790
LN	T047	C0024143
flares	T184	C1517205
biomarker	T201	C0005516
panels	T059	C0022885
diagnostic accuracy	T080	C0598285
aim	T078	C1947946
study	T062	C2603343
assess	T052	C1516048
biomarker	T201	C0005516
panel	T059	C0022885
active	T169	C0205177
LN	T047	C0024143
international	T078	C1512888
JSLE	T047	C1274834
cohorts	T098	C0599755
urinary	T031	C1610733
biomarkers	T201	C0005516
vascular cell adhesion molecule-1	T116	C0078056
VCAM-1	T116	C0078056
monocyte chemoattractant protein 1	T116	C0128897
MCP-1	T116	C0128897
lipocalin-like prostaglandin D synthase	T116	C0072296
LPGDS	T116	C0072296
transferrin	T116	C0040679
TF	T116	C0040679
ceruloplasmin	T116	C0007841
alpha-1-acid glycoprotein	T116	C0029297
AGP	T116	C0029297
neutrophil gelatinase-associated lipocalin	T116	C0215955
NGAL	T116	C0215955
quantified	T081	C0392762
cross-sectional study	T062	C0010362
participants	T098	C0679646
UK	T083	C0041700
JSLE	T047	C1274834
Cohort Study	T081	C0009247
Cohort 1	T098	C0599755
Einstein Lupus	T093	C1708333
Cohort	T098	C0599755
Cohort 2	T098	C0599755
Binary	T080	C1706942
logistic regression modelling	T062	C0206031
receiver operating characteristic	T081	C0034772
curve analysis	T081	C0392762
area under the curve	T081	C0376690
AUC	T081	C0376690
assess	T052	C1516048
combinations	T080	C0205195
biomarkers	T201	C0005516
diagnostic accuracy	T080	C0598285
JSLE	T047	C1274834
patients	T101	C0030705
cohorts	T098	C0599755
active	T169	C0205177
LN	T047	C0024143
LN	T047	C0024143
Urinary	T031	C1610733
AGP	T116	C0029297
ceruloplasmin	T116	C0007841
VCAM-1	T116	C0078056
MCP-1	T116	C0128897
LPGDS	T116	C0072296
levels	T080	C0441889
significantly higher	T081	C4055637
patients	T101	C0030705
active	T169	C0205177
LN	T047	C0024143
non	T169	C1518422
LN	T047	C0024143
patients	T101	C0030705
cohorts	T098	C0599755
Urinary	T031	C1610733
TF	T116	C0040679
patient	T101	C0030705
Cohort 2	T098	C0599755
Cohort 1	T098	C0599755
optimal	T080	C2698651
biomarker	T201	C0005516
panel	T059	C0022885
AGP	T116	C0029297
ceruloplasmin	T116	C0007841
LPGDS	T116	C0072296
TF	T116	C0040679
AUC	T081	C0376690
active	T169	C0205177
LN	T047	C0024143
Cohort 2	T098	C0599755
markers	T201	C0005516
optimal	T080	C2698651
urine	T031	C0042036
biomarker	T201	C0005516
panel	T059	C0022885
AUC	T081	C0376690
international	T078	C1512888
JSLE	T047	C1274834
cohorts	T098	C0599755
urinary	T031	C1610733
AGP	T116	C0029297
ceruloplasmin	T116	C0007841
LPGDS	T116	C0072296
TF	T116	C0040679
active	T169	C0205177
LN	T047	C0024143
children	T100	C0008059
interleukin 18 (IL-18) receptor	T116	C0666963
immunoreactive	T022	C0020962
neurons	T025	C0027882
retrosplenial cortex	T023	C4085586
IL18	T028	C1334109
knockout mice	T015	C0206745
Interleukin 18	T116	C0383327
IL-18	T116	C0383327
inflammatory	T169	C0333348
immune response	T042	C0301872
immune response	T042	C0301872
lymphocytes	T025	C0024264
Delay in learning or memory	T079	C1254367
IL-18	T028	C1334109
knockout mouse	T015	C0206745
IL-18	T116	C0383327
immunoreactive	T022	C0020962
neurons	T025	C0027882
retrosplenial cortex	T023	C4085586
RSC	T023	C4085586
subiculum	T023	C2950582
neurons	T025	C0027882
IL-18 receptor	T116	C0666963
ultrastructure	T078	C0041623
IL-18 receptor	T116	C0666963
immunoreactive	T022	C0020962
neurons	T025	C0027882
RSC	T023	C4085586
IL-18 receptor	T116	C0666963
immunoreactive	T022	C0020962
neurons	T025	C0027882
IL-18	T028	C1334109
knockout mouse	T015	C0206745
IL-18 receptor	T116	C0666963
immunoreactive	T022	C0020962
neurons	T025	C0027882
layer V of the granular RSC	T029	C3498609
neurons	T025	C0027882
oval nucleus	T026	C0007610
cytoplasm	T026	C0010834
free ribosomes	T026	C0035553
endoplasmic reticulum	T026	C0014239
mitochondria	T026	C0026237
Nissl bodies	T026	C0028117
axosomatic terminals	T030	C1180004
IL-18 receptor	T116	C0666963
immunoreactive	T022	C0020962
neurons	T025	C0027882
RSC	T023	C4085586
IL-18	T028	C1334109
knockout mouse	T015	C0206745
small electron-dense	T085	C0596488
neurons	T025	C0027882
layer V	T029	C3498609
nucleus	T026	C0007610
cytoplasm	T026	C0010834
electron-dense	T085	C0596488
mitochondria	T026	C0026237
rough endoplasmic reticulum	T026	C0230779
swollen	T033	C0038999
IL-18 receptor	T116	C0666963
immunoreactive	T022	C0020962
neurons	T025	C0027882
degenerating	T033	C2673328
degeneration	T049	C0027746
IL18-receptor	T116	C0666963
immunoreactive	T022	C0020962
neurons	T025	C0027882
RSC	T023	C4085586
abnormal behaviors	T048	C0233514
IL-18	T028	C1334109
knockout mice	T015	C0206745
genetic	T169	C0314603
variability	T077	C2827666
water	T121	C0043047
use	T169	C0457083
efficiency	T081	C0013682
inter	T079	C1548610
intra cultivar	T002	C0032098
genetic diversity	T070	C0042333
grapevines	T002	C0330100
Genetic	T169	C0314603
improvement	T077	C2986411
crop	T002	C0242775
Water	T121	C0043047
Use	T169	C0457083
Efficiency	T081	C0013682
WUE	T081	C0013682
goal	T078	C1571704
increasing	T169	C0442808
water	T121	C0043047
scarcity	T169	C0231179
sustainable	T169	C0443318
agriculture	T090	C0001829
grapevines	T002	C0330100
subject	T078	C1706203
relevant	T080	C2347946
distribution	T169	C1704711
semi-arid	T070	C0011673
areas	T082	C0205146
cultivars	T002	C0032098
difficult	T080	C0332218
introduce	T169	C1292748
viticulture	UnknownType	C0681558
consumer	T098	C1707496
appreciation	T077	C2346843
wine	T168	C0043188
taste	T081	C1547046
Clones	T024	C1522642
cultivars	T002	C0032098
accepted	T080	C1272684
intra-cultivar	T002	C0032098
genetic	T169	C0314603
variability	T077	C2827666
WUE	T081	C0013682
compares	T052	C1707455
field	T090	C0001829
variability	T077	C2827666
water	T121	C0043047
use	T169	C0457083
efficiency	T081	C0013682
WUEi	T081	C0013682
collection	T169	C1516698
cultivars	T002	C0032098
contrast	T080	C1979874
collection	T169	C1516698
clones	T024	C1522642
Tempranillo cultivar	T002	C0032098
results	T169	C1274040
clonal	T080	C1704387
variability	T077	C2827666
WUEi	T081	C0013682
around	T078	C0750503
inter-cultivar	T002	C0032098
assessment	T052	C1516048
clonal	T080	C1704387
selection	T052	C1707391
WUE	T081	C0013682
WUEi	T081	C0013682
data	T078	C1511726
stem	T002	C0242767
water	T121	C0043047
potential	T080	C3245505
stomatal conductance	T039	C1326524
possible	T033	C0332149
identify	T080	C0205396
cultivars	T002	C0032098
clones	T024	C1522642
confidence intervals	T081	C0009667
linear regression	T081	C0023733
significantly higher	T081	C4055637
lower	T081	C4055638
WUEi	T081	C0013682
values	T081	C1522609
results	T169	C1274040
contribute	T052	C1880177
genetic	T169	C0314603
improvement	T077	C2986411
grapevine	T002	C0330100
WUE	T081	C0013682
isolating	T059	C0220862
primary	T080	C0205225
hepatocytes	T025	C0227525
mini pigs	T015	C0039011
porcine	T015	C0039005
hepatocyte	T025	C0227525
isolation	T059	C0220862
development	T169	C1527148
bioartificial liver devices	T074	C0336562
hepatocyte transplantation	T061	C1998344
Serva collagenase NB grades	T116	C0162745
collagenases	T116	C0162745
tissue	T024	C0040300
isolation	T059	C0220862
N-acetylcysteine	T116	C0001047
NAC	T116	C0001047
viability	T080	C0443348
human	T016	C0086418
hepatocytes	T025	C0227525
effectiveness	T080	C1280519
collagenases	T116	C0162745
effect of	T080	C1704420
NAC	T116	C0001047
hepatocyte	T025	C0227525
isolation	T059	C0220862
porcine	T015	C0039005
liver tissue	T023	C0736268
Porcine	T015	C0039005
hepatocytes	T025	C0227525
isolated	T059	C0220862
perfusion method	T061	C0031001
mini pigs	T015	C0039011
Serva NB 4	T116	C0162745
group	T078	C0441833
Serva NB 8	T116	C0162745
group	T078	C0441833
NB 8	T116	C0162745
NAC	T116	C0001047
group	T078	C0441833
Viability	T080	C0443348
hepatocytes	T025	C0227525
spheroids formation	T033	C1844596
rocker culture	T059	C0430400
serum-free medium	T130	C0085414
Metabolic function	T040	C0025519
gene expression	T045	C0017262
albumin	T116	C0001924
urea	T109	C0041942
synthesis	T038	C0220781
hepatocyte	T025	C0227525
isolation	T059	C0220862
Cells	T025	C0007634
NB 8	T116	C0162745
NAC	T116	C0001047
group	T078	C0441833
viability	T080	C0443348
NB 8	T116	C0162745
group	T078	C0441833
NB 4	T116	C0162745
group	T078	C0441833
cell	T025	C0007634
cells	T025	C0007634
NB 8	T116	C0162745
NAC	T116	C0001047
group	T078	C0441833
cells	T025	C0007634
NB 8	T116	C0162745
group	T078	C0441833
cells	T025	C0007634
NB 4	T116	C0162745
group	T078	C0441833
secretion	T038	C0036536
albumin	T116	C0001924
NB 8	T116	C0162745
NAC	T116	C0001047
group	T078	C0441833
NB 8	T116	C0162745
group	T078	C0441833
NB 4	T116	C0162745
group	T078	C0441833
injury	T037	C0178314
hepatocytes	T025	C0227525
NB 8	T116	C0162745
NAC	T116	C0001047
group	T078	C0441833
means ± SD	T081	C0444504
collagenase Serva NB 8	T116	C0162745
NAC	T116	C0001047
porcine	T015	C0039005
hepatocyte	T025	C0227525
isolation	T059	C0220862
viable cells	T025	C1441322
Endothermal venous ablation	T061	C2242647
saphenous vein	T023	C0036186
patients	T101	C0030705
anticoagulation therapy	T061	C0003281
study	T062	C2603343
risks	T078	C0035647
bleeding	T046	C0019080
deep venous thrombosis	T047	C0149871
DVT	T047	C0149871
endovenous heat induced thrombosis	T046	C0042487
EHIT	T046	C0042487
failure	T169	C0231174
ablation	T061	C0547070
patients	T101	C0030705
ablation	T061	C0547070
oral anticoagulation	T061	C0003281
compared	T052	C1707455
patients	T101	C0030705
group A	T185	C0441835
endovenous ablation	T061	C2242647
saphenous veins	T023	C0036186
oral anticoagulation	T061	C0003281
patients	T101	C0030705
group B	T185	C0441836
endovenous ablation	T061	C2242647
time period	T079	C1948053
anticoagulation	T061	C0003281
demographic data	T081	C0392762
history of	T033	C0332119
DVT	T047	C0149871
Clinical	T080	C0205210
Etiologic	T080	C0205556
Anatomic	T080	C0220784
Pathologic	T169	C1521733
CEAP	T080	C0205556
classification	T185	C0008902
VCSS	T081	C0392762
Venous Clinical Severity Score	T081	C0392762
indications	T078	C3146298
anticoagulation	T061	C0003281
anticoagulants	T121	C0003280
bleeding	T046	C0019080
DVT	T047	C0149871
EHIT	T046	C0042487
failure	T169	C0231174
ablation	T061	C0547070
Patients	T101	C0030705
group A	T185	C0441835
older	T098	C3826770
men	T098	C0025266
DVT	T047	C0149871
PE	T047	C0034065
CEAP	T080	C0205556
VCSS	T081	C0392762
group B	T185	C0441836
anticoagulation	T061	C0003281
warfarin	T109	C0043031
direct oral inhibitors	T121	C1254351
DOIs	T121	C1254351
rate	T081	C1521828
failure	T169	C0231174
ablation	T061	C0547070
days	T079	C0439228
Group A	T185	C0441835
Group B	T185	C0441836
one month	T079	C4082115
EHIT	T046	C0042487
cases	T169	C0868928
group A	T185	C0441835
days	T079	C0439228
group B	T185	C0441836
1 month	T079	C4082115
DVT	T047	C0149871
SVT	T047	C0039240
hematoma	T046	C0018944
wound infection	T046	C0043241
rates	T081	C1521828
groups	T078	C0441833
Ablation	T061	C0547070
saphenous veins	T023	C0036186
patients	T101	C0030705
oral anticoagulation	T061	C0003281
risk	T078	C0035647
bleeding	T046	C0019080
hematoma	T046	C0018944
incidence	T081	C0021149
EHIT	T046	C0042487
incidence	T081	C0021149
failure	T169	C0231174
ablation	T061	C0547070
Variation analysis	T062	C0242481
PRIM1 gene	T028	C1335259
Chinese	T098	C0152035
patients	T101	C0030705
primary ovarian insufficiency	T047	C0085215
genetic susceptibility	T032	C0314657
primary ovarian insufficiency	T047	C0085215
POI	T047	C0085215
natural	T040	C0856856
early menopause	T047	C0025322
delivered	T169	C1705822
genetic mechanisms	T169	C0017399
POI	T047	C0085215
PRIM1	T028	C1335259
DNA replication	T045	C0598312
synthesizing	T052	C1883254
RNA primers	T114	C0073429
Okazaki fragments	T114	C0069390
associated with	T080	C0332281
age	T032	C0001779
natural menopause	T040	C0856856
early menopause	T047	C0025322
POI	T047	C0085215
European	T098	C0239307
women	T098	C0043210
study	T062	C2603343
investigate	T169	C1292732
mutations	T045	C0026882
PRIM1	T028	C1335259
POI	T047	C0085215
Chinese	T098	C0152035
women	T098	C0043210
exons	T114	C0015295
exon-intron boundaries	T114	C0028606
PRIM1 gene	T028	C1335259
sequenced	T059	C1294197
Han Chinese	UnknownType	C0814942
women	T098	C0043210
POI	T047	C0085215
mutations	T045	C0026882
identified	T080	C0205396
perturbations	T169	C0332453
PRIM1 gene	T028	C1335259
POI	T047	C0085215
Chinese	T098	C0152035
women	T098	C0043210
Selection	T052	C1707391
marker gene	T028	C0017337
reference library	T073	C0023621
wetland	T070	C1721088
plants	T002	C0032098
metabarcoding	T062	C2936547
analyze	T062	C0936012
diet	T168	C0012155
wintering	T079	C0241737
herbivorous	T008	C0562691
waterbirds	T012	C0005595
Food	T168	C0016452
availability	T169	C0470187
diet	T168	C0012155
selection	T052	C1707391
factors	T169	C1521761
influencing	T077	C4054723
abundance	T080	C2346714
distribution	T169	C1704711
wild	T170	C0445392
waterbirds	T012	C0005595
changes	T169	C0392747
waterbird	T012	C0005595
population	T081	C0032659
feed on	T052	C3853577
analyzing	T062	C0936012
diet	T168	C0012155
difficult	T080	C0332218
inefficient	T169	C0231185
methods	T169	C0025664
microhistologic observation	T059	C0019637
diet	T168	C0012155
greater white-fronted goose Anser albifrons	T012	C1015285
bean goose Anser fabalis	T012	C1015285
obligate herbivores	T008	C0562691
wintering	T079	C0241737
China	T083	C0008115
Middle	T083	C0017446
Lower Yangtze River floodplain	T083	C0017446
selected	T052	C1707391
suitable	T080	C3900053
marker gene	T028	C0017337
wetland	T070	C1721088
plants	T002	C0032098
geese	T012	C0017225
wintering period	T079	C0241737
candidate genes	T028	C0017337
rbcL	T028	C0017337
rpoC1	T028	C0017337
rpoB	T028	C0017337
matK	T028	C1334485
trnH-psbA	T087	C2936548
trnL	T028	C1421162
UAA	T086	C1956149
atpF-atpH	T087	C2936548
psbK-psbI	T087	C2936548
selection	T052	C1707391
analysis	T062	C0936012
representative	T052	C1882932
sequences	T086	C0162326
NCBI	T092	C1705803
comparison	T052	C1707455
amplification	T045	C0017256
efficiency	T081	C0013682
plant	T002	C0032098
samples	T167	C0370003
wintering area	T083	C0017446
trnL gene	T028	C1421162
c/h primers	T114	C0206416
local	T082	C0205276
plant	T002	C0032098
reference library	T073	C0023621
constructed	T185	C2827421
gene	T028	C0017337
DNA metabarcoding	T062	C2936547
discovered	T052	C1880355
food items	T168	C0016452
feces	T031	C0015733
birds	T012	C0005595
dietary	T168	C0012155
sequences	T086	C0162326
specie	T185	C1705920
level	T080	C0441889
greater white-fronted goose	T012	C1015285
sequences	T086	C0162326
Poaceae spp.	T002	C0018210
Carex spp	T002	C1000671
sequences	T086	C0162326
bean goose	T012	C1064115
Carex spp	T002	C1000671
samples	T167	C0370003
microhistology	T059	C0019637
consistent	T078	C0332290
food composition	T168	C0459115
metabarcoding	T062	C2936547
results	T169	C1274040
greater white-fronted goose	T012	C1015285
Poaceae	T002	C0018210
bean goose	T012	C1064115
taxa	T077	C1515221
discovered	T052	C1880355
microhistologic analysis	T059	C0019637
taxa	T077	C1515221
matched	T080	C1708943
methods	T169	C0025664
DNA metabarcoding	T062	C2936547
taxonomically	T169	C0008903
detailed information	T078	C1533716
Discrepancies	T033	C1290905
biased	T078	C0242568
PCR	T063	C0032520
amplification	T045	C0017256
metabarcoding	T062	C2936547
discriminating	T054	C2987623
power	T081	C3854080
marker genes	T028	C0017337
monocots	T002	C0331451
biases	T078	C0242568
microhistologic analysis	T059	C0019637
diet	T168	C0012155
differences	T080	C1705242
geese	T012	C0017225
species	T185	C1705920
ecological	T070	C0162358
significance	T078	C0750502
study	T062	C2603343
DNA metabarcoding	T062	C2936547
perspectives	T170	C0683498
studies	T062	C2603343
herbivorous	T008	C0562691
waterbird	T012	C0005595
diets	T168	C0012155
inter-specific interactions	T169	C1704675
investigate	T169	C1292732
interactions	T169	C1704675
herbivores	T008	C0562691
plants	T002	C0032098
microhistologic analysis	T059	C0019637
metabarcoding methods	T062	C2936547
information	T078	C1533716
Expressions	T045	C1171362
CD8	T129	C0085358
TILs	T025	C0079722
PD-L1	T116	C0965245
Foxp3	T116	C1504797
TILs	T025	C0079722
stage I NSCLC	T191	C0278504
adjuvant chemotherapy	T061	C0085533
decisions	T041	C0679006
adjuvant chemotherapy	T061	C0085533
recommended	T078	C0034866
patients	T101	C0030705
high risk	T033	C0332167
stage I non-small cell lung cancer	T191	C0278504
NSCLC	T191	C0007131
identifying	T080	C0205396
high risk	T033	C0332167
patients	T101	C0030705
study	T062	C2603343
aims	T078	C1947946
identify	T080	C0205396
patient	T101	C0030705
cohorts	T098	C0599755
adjuvant chemotherapy	T061	C0085533
tumor	T191	C0027651
micro-immune	T169	C0439662
environment	T082	C0014406
CD8	T129	C0085358
TILs	T025	C0079722
significantly associated with	T080	C0332281
disease-free survival	T081	C0242793
DFS	T081	C0242793
overall survial	T081	C4086681
OS	T081	C4086681
Patients	T101	C0030705
high risk factors	T033	C1830377
DFS	T081	C0242793
compared	T052	C1707455
patients	T101	C0030705
high	T080	C0205250
CD8	T129	C0085358
TILs	T025	C0079722
DFS	T081	C0242793
patients	T101	C0030705
low	T080	C0205251
CD8	T129	C0085358
TILs	T025	C0079722
risk factors	T033	C1830377
no correlation	T033	C0243095
PD-L1	T116	C0965245
expressions	T045	C1171362
survival	T169	C0220921
PD-L1	T116	C0965245
highly	T080	C0205250
expressed	T045	C1171362
men	T098	C0025266
squamous	T080	C1182670
well differentiated	T080	C0205615
carcinoma	T191	C0278504
Foxp3	T116	C1504797
TILs	T025	C0079722
low	T080	C0205251
Foxp3	T116	C1504797
high	T080	C0205250
CD8	T129	C0085358
TILs	T025	C0079722
associated with	T080	C0332281
prolonged	T079	C0439590
DFS	T081	C0242793
patients	T101	C0030705
surgically resected	T080	C1521996
stage I NSCLC	T191	C0278504
included	T169	C0332257
immunohistochemistry	T060	C0021044
CD8	T129	C0085358
tumor infiltrating lymphocytes	T025	C0079722
TILs	T025	C0079722
programmed death ligand-1	T116	C0965245
PD-L1	T116	C0965245
forkhead box P3	T116	C1504797
Foxp3	T116	C1504797
TILs	T025	C0079722
CD8	T129	C0085358
TILs	T025	C0079722
effective	T080	C1704419
Patients	T101	C0030705
surgically resected	T080	C1521996
stage I NSCLC	T191	C0278504
CD8	T129	C0085358
TILs	T025	C0079722
adjuvant chemotherapy	T061	C0085533
high risk	T033	C0332167
twins discordant	T046	C2609166
affective disorders	T048	C0001723
anterior callosal	T023	C0226208
white matter	T024	C0682708
microstructure	T082	C0678594
neurobiological	T091	C0027817
mechanisms	T169	C0441712
risk	T078	C0035647
affective disorders	T048	C0001723
group of individuals	T098	C0027361
family history	T033	C0241889
major depressive	T048	C1269683
MDD	T048	C1269683
bipolar disorder	T048	C0005586
BD	T048	C0005586
white matter	T024	C0682708
fiber tracts	T023	C3499212
cingulum bundle	T023	C0228272
uncinate fasciculus	T023	C0228271
anterior limb of the internal capsule	T023	C0152342
corpus callosum	T023	C0010090
brain regions	T029	C1273723
affective disorders	T048	C0001723
mono	T099	C0041432
dizygotic twins	T099	C0041429
co-twin	T099	C0041427
diagnosed	T033	C0011900
MDD	T048	C1269683
BD	T048	C0005586
high-risk	T098	C1257890
healthy	T080	C3898900
twins	T099	C0872326
co-twin	T099	C0041427
no familial history of	T033	C0332123
affective disorders	T048	C0001723
diffusion tensor imaging study	T060	C1537007
high-risk group	T098	C1257890
fractional anisotropy	T060	C2348041
FA	T060	C2348041
water	T121	C0043047
diffusion	T070	C0012222
directionality	T169	C1707761
radial	T077	C0442038
diffusivity	T077	C3899378
anterior region of corpus callosum	T023	C0152325
low-risk group	T098	C1257890
abnormality	T033	C1704258
zygosity	T169	C1710709
depressive disorder	T048	C0011581
co-twin	T099	C0041427
anterior callosal fiber	T023	C0010090
FA	T060	C2348041
high-risk group	T098	C1257890
interhemispheric communication	T041	C0870728
left	T023	C0228194
right frontal regions	T023	C0228193
mood regulation	T041	C2370884
anterior callosal	T023	C0010090
FA	T060	C2348041
vulnerability	UnknownType	C0679109
marker	T201	C0005516
affective disorders	T048	C0001723
individuals	T098	C0237401
familial risk	T078	C0035647
Study of Aversive	T061	C0004415
Instrumental Learning	T041	C0009651
Strains	T001	C1518614
Performance	T052	C1882330
Neuroendocrine	T022	C0027912
Immunologic Systems	T022	C0020962
avoidance	T041	C0870186
response	T032	C0871261
pathological	T169	C1521733
anxiety	T033	C0003467
normal daily functions	T169	C0542341
performance	T052	C1882330
active avoidance	T041	C0871637
AA	T041	C0871637
rat strains	T015	C1514734
Sprague-Dawley	T015	C2699239
SD	T015	C2699239
Wistar	T015	C2700262
performers	T169	C1550480
evaluated	T058	C0220825
anxiety	T033	C0003467
traits	T032	C0599883
elevated plus maze	T073	C0870866
EPM	T073	C0870866
corticosterone levels	T059	C0857657
motor activity	T038	C0234130
open field test	T059	C0022885
plasma levels	T059	C0022885
Interleukin-6	T116	C0021760
IL-6	T116	C0021760
Interleukin-1Beta	T116	C0021753
IL-1beta	T116	C0021753
Nerve Growth Factor Beta	T116	C0027753
NGF-beta	T116	C0027753
Tumor Necrosis Factor-Alpha	T116	C0041368
TNF-alpha	T116	C0041368
cytokine-induced neutrophil chemoattractant 1	T116	C0378112
CINC-1	T116	C0378112
performers	T169	C1550480
immunologic system	T022	C0020962
aversive learning	T061	C0004415
Behavioral criteria	T170	C2986890
subpopulations	T098	C1257890
SD	T015	C0034715
Wistar rats	T015	C0034716
behavioral scores	T170	C2986890
AA	T041	C0871637
test	T170	C0392366
animals	T008	C0003062
tested	T170	C0392366
anxiety	T033	C0003467
behavior	T053	C0004927
EPM	T073	C0870866
motor activity	T038	C0234130
open-field test	T059	C0022885
Plasma corticosterone levels	T059	C0857657
measured	T080	C0444706
avoidance	T041	C0870186
test	T170	C0392366
Cytokine levels	T059	C2699541
IL-6	T116	C0021760
IL-1beta	T116	C0021753
NGF-beta	T116	C0027753
TNF-alpha	T116	C0041368
CINC-1	T116	C0378112
measured	T080	C0444706
plasma	T031	C0032105
Wistar rats	T015	C0034716
Wistar rats	T015	C0034716
SD rats	T015	C0034715
performance	T052	C1882330
associated with	T080	C0332281
anxiety	T033	C0003467
behavior	T053	C0004927
EPM	T073	C0870866
performers	T169	C1550480
levels of corticosterone	T059	C0857657
control animals	T008	C1511501
corticosterone levels	T059	C0857657
hypocortisolism	T047	C0001403
performance	T052	C1882330
CINC-1	T116	C0378112
levels	T080	C0441889
performers	T169	C1550480
immunologic system	T022	C0020962
activation	T052	C1879547
learning deficits	T048	C0851265
complex	T080	C0439855
interactions	T169	C1704675
neuroimmune	UnknownType	C0682644
consequences	T169	C0686907
performance	T052	C1882330
Costing	T169	C0220812
healthy' food baskets	T168	C0453857
Australia	T083	C0004340
systematic review	T170	C1955832
food	T168	C0016452
price	T081	C0080045
affordability	T081	C0814630
monitoring tools	T170	C0282574
protocols	T170	C0442711
methods	T170	C0025663
systematic review	T170	C1955832
similarities	T080	C2348205
differences	T080	C1705242
metrics	T081	C0025867
results	T169	C1274040
recently	T079	C0332185
currently	T079	C0521116
tools	T170	C0282574
protocols	T170	C0442711
methods	T170	C0025663
monitoring	T058	C1283169
Australian	T083	C0004340
healthy food	T168	C0453857
prices	T081	C0080045
affordability	T081	C0814630
Electronic databases	T170	C0242356
peer-reviewed literature	T170	C0023866
online grey literature	T170	C0023866
systematically	T169	C0220922
searched	T052	C1706202
PRISMA	T062	C0242481
articles	T170	C1706852
reports	T170	C0684224
healthy food	T168	C0453857
diet price assessment tools	T170	C0282574
protocols	T170	C0442711
methods	T170	C0025663
results	T169	C1274040
retail pricing	T081	C0080045
National	UnknownType	C0681784
state	T083	C1301808
regional	T082	C0205147
local areas	T083	C0017446
Australia	T083	C0004340
Assessment tools	T170	C0282574
protocols	T170	C0442711
methods	T170	C0025663
measure	T081	C0079809
price	T081	C0080045
'healthy' foods	T168	C0453857
diets	T168	C0012155
identified	T080	C0205396
surveys	T170	C0038951
healthy' food	T168	C0453857
pricing	T081	C0080045
food pricing tools	T170	C0282574
multiple areas	T082	C4266465
time periods	T079	C1948053
minor	T080	C0205165
food pricing tools	T170	C0282574
single survey area	T082	C0445260
time period	T079	C1948053
Analysis	T062	C0936012
methodological	T078	C3266812
differences	T080	C1705242
included	T169	C0332257
foods	T168	C0016452
reference households	T099	C0020052
availability	T169	C0470187
quality measures	T170	C3242457
household income	T033	C0557163
sources	T033	C0449416
store	T073	C0680165
sampling methods	T170	C0449370
data collection	T062	C0010995
protocols	T170	C0442711
analysis methods	T062	C3900047
results	T169	C1274040
Healthy' food	T168	C0453857
price	T081	C0080045
assessment	T052	C1516048
methods	T170	C0025663
Australia	T083	C0004340
lack	T080	C0332268
comparability	T052	C1707455
metrics	T081	C0025867
healthy' diet	T168	C0012155
recommended	T078	C0034866
Australian Dietary Guidelines	T170	C3658297
Assessment	T052	C1516048
price	T081	C0080045
price differential	T078	C1549478
affordability	T081	C0814630
healthy	T061	C0452415
recommended	T078	C0034866
current	T079	C0521116
(unhealthy) diets	T055	C3805118
provide	T052	C1999230
robust	T080	C2986815
data	T078	C1511726
health and fiscal policy	T064	C0681005
Australia	T083	C0004340
INFORMAS	T170	C0282574
optimal	T080	C2698651
potential	T080	C3245505
development	T169	C1527148
methods	T170	C0025663
Consecutive	T080	C1707491
Endovascular Treatment	T061	C2936204
Ruptured	T169	C0443294
Small	T081	C0700321
Anterior Communicating Artery Aneurysms	T047	C0740386
Small	T081	C0700321
aneurysms	T047	C0740386
anterior communicating artery	T023	C0149562
anatomy	T017	C0700276
endovascular technologies	T061	C2936204
coil embolization	T061	C0189713
small	T081	C0700321
aneurysm	T047	C0740386
treatment	T169	C1522326
safety	T068	C0036043
efficacy	T080	C1280519
small	T081	C0700321
anterior communicating artery aneurysms	T047	C0740386
long-term clinical	T080	C0085415
radiographic outcomes	T080	C0085415
consecutive	T080	C1707491
patients	T101	C0030705
ruptured	T169	C0443294
small	T081	C0700321
anterior communicating artery aneurysms	T047	C0740386
endovascular coil embolization techniques	T061	C0189713
neuroendovascular database	T170	C0242356
small	T081	C0700321
ruptured	T169	C0443294
anterior communicating artery aneurysms	T047	C0740386
patients	T101	C0030705
ruptured	T169	C0443294
small	T081	C0700321
anterior communicating artery aneurysms	T047	C0740386
consecutively	T080	C1707491
coil embolization	T061	C0189713
diameter	T081	C1301886
aneurysm occlusion	T061	C0189724
aneurysms	T047	C0740386
aneurysm occlusion	T061	C0189724
aneurysms	T047	C0740386
Intraoperative	T079	C0456904
perforation	T033	C0549099
patients	T101	C0030705
clinical worsening	T078	C1546960
external ventricular drain	T061	C0844106
thromboembolic event	T046	C0040038
patient	T101	C0030705
clinical worsening	T078	C1546960
radiologic infarct	T046	C0021308
follow-up	T058	C1522577
months	T079	C0439231
follow-up	T058	C1522577
months	T079	C0439231
consecutive	T080	C1707491
endovascular treatments	T061	C2936204
ruptured	T169	C0443294
small	T081	C0700321
anterior communicating artery aneurysms	T047	C0740386
coil embolization	T061	C0189713
small	T081	C0700321
aneurysms	T047	C0740386
location	T082	C0450429
complications	T046	C0009566
recanalization	T061	C0034771
Factors	T169	C1521761
affecting	T169	C0392760
formation	T169	C1522492
nitrogenous disinfection	T061	C0012683
by-products	T104	C0684298
chlorination	T057	C2728946
aspartic acid	T116	C0004015
drinking water	T167	C0599638
formation	T169	C1522492
nitrogenous disinfection	T061	C0012683
by-products	T104	C0684298
N-DBPs	T104	C0684298
chlorination	T057	C2728946
aspartic acid	T116	C0004015
Asp	T116	C0004015
investigated	T169	C1292732
dichloroacetonitrile	T109	C0057843
DCAN	T109	C0057843
N-DBPs	T104	C0684298
dichloroacetamide	T109	C0045293
DCAcAm	T109	C0045293
chloropicrin	T109	C0055437
TCNM	T109	C0055437
chlorination	T057	C2728946
Asp	T116	C0004015
formation	T169	C1522492
DCAN	T109	C0057843
DCAcAm	T109	C0045293
TCNM	T109	C0055437
increasing	T169	C0442808
decreasing	T033	C0442797
chlorination	T057	C2728946
Asp	T116	C0004015
increasing	T169	C0442808
contact time	T079	C1254367
dosage	T081	C0178602
chlorine	T131	C0008209
formation	T169	C1522492
DCAN	T109	C0057843
DCAcAm	T109	C0045293
TCNM	T109	C0055437
yields	T081	C0392762
DCAN	T109	C0057843
DCAcAm	T109	C0045293
Cl2	T131	C0008209
Asp	T116	C0004015
molar ratio	T081	C2825550
yield	T081	C0392762
TCNM	T109	C0055437
increased	T081	C0205217
increasing	T169	C0442808
Cl2	T131	C0008209
Asp	T116	C0004015
molar ratio	T081	C2825550
TCNM	T109	C0055437
ratio	T081	C2825550
Cyanogen chloride	T109	C0056659
CNCl	T109	C0056659
Cl2	T131	C0008209
Asp	T116	C0004015
molar ratio	T081	C2825550
N-DBPs	T104	C0684298
formation	T169	C1522492
pH	T081	C0020283
DCAN	T109	C0057843
formation	T169	C1522492
increased	T081	C0205217
increasing	T169	C0442808
pH	T081	C0020283
decreased	T081	C0205216
increasing	T169	C0442808
pH	T081	C0020283
DCAcAm	T109	C0045293
TCNM	T109	C0055437
increased	T081	C0205217
increasing	T169	C0442808
pH	T081	C0020283
decreased	T081	C0205216
temperatures	T081	C0039476
reduced	T080	C0392756
formation	T169	C1522492
DCAN	T109	C0057843
DCAcAm	T109	C0045293
increased	T081	C0205217
TCNM	T109	C0055437
formation	T169	C1522492
DCAN	T109	C0057843
DCAcAm	T109	C0045293
formation	T169	C1522492
decreased	T081	C0205216
stable	T080	C0205360
TCNM	T109	C0055437
formation	T169	C1522492
increased	T081	C0205217
increasing	T169	C0442808
chlorine	T131	C0008209
contact time	T079	C1254367
chloramination	T067	C1254366
N-nitrosodimethylamine	T109	C0012431
NDMA	T109	C0012431
chloramination	T067	C1254366
Asp	T116	C0004015
increased	T081	C0205217
prolonged	T079	C0439590
chloramination	T067	C1254366
contact time	T079	C1254367
bromide ions	T121	C3848571
enhanced	T052	C2349975
yields	T081	C0392762
haloacetonitriles	T109	C0001004
N-DBPs	T104	C0684298
brominated species	T109	C0029224
Midodrine	T109	C0026078
tolvaptan	T109	C1176308
patients	T101	C0030705
cirrhosis	T047	C0023890
refractory	T033	C3532188
recurrent ascites	UnknownType	C0741243
randomised	T062	C0034656
pilot study	T062	C0031928
Splanchnic arterial vasodilatation	T042	C1372887
sodium	T047	C0020488
water retention	T033	C0542203
cirrhotic ascites	T047	C0401037
Midodrine	T109	C0026078
tolvaptan	T109	C1176308
patients	T101	C0030705
combination	T061	C0013218
midodrine	T109	C0026078
tolvaptan	T109	C1176308
ascites	T047	C0401037
evaluate	T058	C0220825
safety	T068	C0036043
efficacy	T080	C1280519
midodrine	T109	C0026078
tolvaptan	T109	C1176308
combination	T061	C0013218
refractory	T033	C3532188
recurrent ascites	UnknownType	C0741243
cirrhotics	T047	C0023890
cirrhotic	T080	C0439686
patients	T101	C0030705
refractory	T033	C3532188
recurrent ascites	UnknownType	C0741243
randomised	T062	C0034656
midodrine	T109	C0026078
tolvaptan	T109	C1176308
medical therapy	T061	C0418981
SMT	T061	C0418981
SMT	T061	C0418981
significant increase in urinary volume	T033	C1287298
urinary sodium	T047	C3671887
months	T079	C0439231
groups	T098	C1257890
SMT	T061	C0418981
worsening	T080	C0332271
renal	T033	C0232805
hepatic function	T042	C0232741
group	T098	C1257890
deterioration	T067	C0868945
model for end-stage liver disease	T185	C3826979
MELD	T185	C3826979
Midodrine	T109	C0026078
combination	T061	C0013218
midodrine	T109	C0026078
tolvaptan	T109	C1176308
tolvaptan	T109	C1176308
SMT	T061	C0418981
ascites	T047	C0401037
months	T079	C0439231
combination therapy	T061	C0013218
midodrine	T109	C0026078
ascites	T047	C0401037
month	T079	C0439231
morbidity	T081	C0026538
mortality	T081	C0205848
groups	T098	C1257890
SMT	T061	C0418981
pilot study	T062	C0031928
midodrine	T109	C0026078
combination	T061	C0013218
tolvaptan	T109	C1176308
ascites	T047	C0401037
renal	T047	C1565489
hepatic dysfunction	T046	C0086565
combination therapy	T061	C0013218
ascites	T047	C0401037
midodrine	T109	C0026078
tolvaptan	T109	C1176308
Acute Complicated Sinusitis	T047	C0149512
Years	T079	C0439234
Experience	T041	C0596545
University Hospital	T073	C0020028
West Indies	T083	C0043122
Complicated sinusitis	T047	C0149512
rare	T047	C0678236
patient	T101	C0030705
unfavourable outcome	T169	C1274040
data	T078	C1511726
condition	T047	C0012634
Caribbean	T083	C0043122
study	T062	C2603343
clinical characteristics	T201	C0683325
treatment outcomes	T080	C0085415
patients	T101	C0030705
admitted	T058	C0184666
condition	T047	C0012634
retrospective	T080	C1514923
chart review	UnknownType	C0553620
patients	T101	C0030705
admitted	T058	C0184666
University Hospital of the West Indies	T073	C0020028
UHWI	T073	C0020028
complicated sinusitis	T047	C0149512
data	T078	C1511726
analysed	T062	C0936012
SPSS statistics 22 software	T170	C0600673
patients	T101	C0030705
males	T032	C0086582
females	T032	C0086287
mean	T081	C0444504
SD	T081	C0871420
age	T032	C0001779
years	T079	C1510829
orbital	T030	C0029180
complications	T046	C0009566
intracranial	T029	C0524466
complications	T046	C0009566
common	T081	C0205214
organisms	T001	C0029235
isolated	T169	C0205409
streptococcus	T007	C0038402
common	T081	C0205214
sensitivity	T032	C0237865
amoxicillin	T109	C0002645
clavulinic acid	T109	C0055860
patients	T101	C0030705
external	T082	C0205101
surgical approach	T169	C0449446
mean	T081	C0444504
SD	T081	C0871420
hospital stay	T079	C3489408
days	T079	C0439228
patients	T101	C0030705
endoscopic approach	T082	C0442418
mean	T081	C0444504
SD	T081	C0871420
hospital stay	T079	C3489408
days	T079	C0439228
no	T033	C0205160
statistical difference	T081	C1705241
mean	T081	C0444504
hospital stay	T079	C3489408
groups	T078	C0441833
mean	T081	C0444504
duration	T079	C0449238
hospital stay	T079	C3489408
treated medically	T058	C0237726
days	T079	C0439228
days	T079	C0439228
surgical	T169	C0449446
group	T078	C0441833
mean	T081	C0444504
difference	T081	C1705241
days	T079	C0439228
Acute complicated sinusitis	T047	C0149512
commonly	T081	C0205214
adolescent males	T100	C0001589
common	T081	C0205214
complication	T046	C0009566
orbital	T030	C0029180
Surgical treatment	T061	C0543467
patients	T101	C0030705
fail	T169	C0231175
medical	T169	C0205476
management	T057	C1273870
endoscopic approach	T082	C0442418
proteomic analysis	T059	C0022885
alterations	T078	C1515926
development	T040	C0597252
photosynthesis	T070	C0031764
proteins	T116	C0033684
diploid	T032	C0012568
triploid	T049	C3536727
rice	T002	C1140671
Polyploidy	T049	C0032578
influences	T077	C4054723
rice	T002	C1140671
Oryza sativa L.	T002	C1140671
morphology	T080	C0332437
physiology	T039	C0031843
rice	T002	C1140671
domestication	T078	C0175819
agricultural traits	T032	C0599883
Diploid	T032	C0012568
DP	T032	C0012568
triploid	T049	C3536727
TP	T049	C3536727
rice	T002	C1140671
differences	T080	C1705242
morphological	T080	C0332437
parameters	T033	C0449381
plant	T002	C0032098
height	T032	C0489786
leaf	T002	C0242724
length	T081	C1444754
leaf	T002	C0242724
width	T081	C0487742
physiological	T169	C0205463
index	T170	C0918012
chlorophyll	T109	C0008260
content	T077	C0456205
mechanisms	T169	C0441712
morphological	T080	C0332437
differences	T080	C1705242
proteomic	T116	C0033684
changes	T169	C0392747
DP	T032	C0012568
TP	T049	C3536727
tandem mass tags (TMT) mass spectrometry (MS)	T059	C2123592
MS	T059	C0037813
changes	T169	C0392747
protein expression	T045	C1171362
DP	T032	C0012568
TP	T049	C3536727
photosynthesis	T070	C0031764
metabolic pathways	T169	C1291081
associated with	T080	C0332281
proteomic alteration	T044	C1514563
DP	T032	C0012568
TP	T049	C3536727
biological process	T038	C3714634
pathway enrichment analysis	T059	C0022885
abundance	T080	C2346714
chloroplast proteins	T116	C3178938
pathways	T044	C1704259
identified	T080	C0205396
TP	T049	C3536727
Quantitative real-time PCR analysis	T063	C3179034
chloroplast proteins	T116	C3178938
ATPF	T116	C0033684
PSAA	T116	C0033684
PSAB	T116	C0084235
PSBB	T116	C0033684
RBL	T116	C0033684
TP	T049	C3536727
abundance	T080	C2346714
DP	T032	C0012568
study	T062	C2603343
morphology	T080	C0332437
physiology	T039	C0031843
proteomic profiling	T059	C1327760
alteration	T078	C1515926
DP	T032	C0012568
TP	T049	C3536727
molecular mechanisms	T044	C3537153
ATPF	T116	C0033684
PSAA	T116	C0033684
PSAB	T116	C0084235
PSBB	T116	C0033684
RBL	T116	C0033684
expression	T045	C1171362
changes	T169	C0392747
TP	T049	C3536727
development	T040	C0597252
growth	T040	C0597252
rice	T002	C1140671
photosynthesis	T070	C0031764
metabolic pathways	T169	C1291081
Correlation	T080	C1707520
cardiopulmonary exercise testing	T060	C2959886
parameters	T077	C0549193
quality of life	T078	C0034380
stable	T033	C0677946
COPD	T047	C0024117
patients	T101	C0030705
relationships	T080	C0439849
Cardio-pulmonary exercise testing	T060	C2959886
CPET	T060	C2959886
parameters	T077	C0549193
patients	T101	C0030705
daily symptoms	T033	C0436354
activities	T056	C0871707
disease	T047	C0012634
social	T080	C0162468
emotional impact	T201	C1514593
correlation	T080	C1707520
COPD	T047	C0024117
daily symptoms	T033	C0436354
quality of life	T078	C0034380
St. George's Respiratory Questionnaire	T170	C0451500
SGRQ	T170	C0451500
COPD	T047	C0024117
severity index	T170	C4053940
BODE-index	T170	C4053940
CPET	T060	C2959886
parameters	T077	C0549193
Symptom	T184	C1457887
CPET	T060	C2959886
consecutive	T080	C1707491
COPD	T047	C0024117
GOLD I-III	T060	C0699749
exacerbation	T047	C0740304
phase	T079	C0205390
SGRQ	T170	C0451500
patient	T101	C0030705
SGRQ-score	T201	C3472502
correlated	T080	C1707520
negatively	T033	C0205160
FEV1	T060	C0849974
predicted	T078	C0681842
maximal work-rate	T033	C0744679
%WR-max	T033	C0744679
V'O2	T033	C0429627
WR	T201	C0018810
breathing reserve	T081	C0392762
did not correlate	T033	C0243095
Peak-V'O2	T033	C0429693
leg fatigue was the main cause for stopping the test	T033	C2036296
Peak-V'O2	T033	C0429693
%WR-max	T033	C0744679
HR-Reserve	T081	C0392762
Breathing reserve	T081	C0392762
significant	T081	C0237881
correlation	T080	C1707520
BODE-index	T170	C4053940
∆VO2	T033	C0429627
∆WR	T201	C0018810
breathing-reserve	T081	C0392762
relationships	T080	C0439849
CPET	T060	C2959886
parameter	T077	C0549193
daily	T079	C0332173
subjective complaints	T041	C2936631
COPD	T047	C0024117
CPET	T060	C2959886
because of leg fatigue	T033	C2036296
earlier stages	T079	C2363430
COPD	T047	C0024117
negative	T033	C0205160
correlation	T080	C1707520
∆VO2	T033	C0429627
∆WR	T201	C0018810
BODE-index	T170	C4053940
COPD	T047	C0024117
progression	T046	C0242656
negative past history	T033	C3699386
comorbidities	T078	C0009488
cardiac	T033	C0262402
musculoskeletal problems	T033	C0026859
Intrapartum	T079	C0456337
Cervical Laceration	T037	C0007851
Pregnancy Outcomes	T033	C0032972
objective	T170	C0018017
study	T062	C2603343
pregnancy outcomes	T033	C0032972
cervical insufficiency	T047	C1401059
preterm birth	T033	C0151526
pregnancy	T040	C0032961
following	T079	C0332282
intrapartum	T079	C0456337
cervical laceration	T037	C0007851
cohort	T098	C0599755
women	T098	C0043210
consecutive	T080	C1707491
singleton pregnancies	T040	C0341899
weeks	T079	C0439230
gestation	T040	C0032961
tertiary health care system	T093	C0018696
Cervical laceration	T037	C0007851
cases	T077	C1706256
identified	T080	C0205396
ICD9 codes	T170	C1550213
included	T169	C0332257
suture repair	T061	C0087111
required	T169	C1514873
study	T062	C2603343
women	T098	C0043210
confirmed	T033	C0750484
cervical laceration	T037	C0007851
delivery	T040	C0005615
lacerations	T037	C0043246
vaginal delivery	T061	C1541822
(VD)	T061	C1541822
cesarean delivery	T061	C0007876
(CD)	T061	C0007876
median	T081	C0876920
gestational age	T032	C0017504
delivery	T040	C0005615
weeks	T079	C0439230
median	T081	C0876920
birth weight	T032	C0005612
differ	T080	C1705242
VD	T061	C1541822
CD	T061	C0007876
pregnancy	T040	C0032961
women	T098	C0043210
prophylactic	T169	C0445202
cerclage	T061	C0195681
carried	T052	C0206243
term	T040	C0233324
delivered	T033	C0151526
weeks	T079	C0439230
total	T080	C0439810
women	T098	C0043210
delivered	T033	C0151526
pregnancy	T040	C0032961
weeks	T079	C0439230
prior	T079	C0332152
term	T040	C0233324
VD	T061	C1541822
prior	T079	C0332152
weeks	T079	C0439230
VD	T061	C1541822
case	T077	C1706256
recurrent	T079	C2945760
cervical laceration	T037	C0007851
occurring	T052	C1709305
setting	T169	C0868928
vaginal deliveries	T061	C1541822
Obstetric	T169	C0205484
cervical lacerations	T037	C0007851
uncommon	T080	C0522498
Complications	T046	C0009566
following	T079	C0332282
pregnancy	T040	C0032961
low	T080	C0205251
lack	T080	C0332268
prophylactic	T169	C0445202
cerclage	T061	C0195681
Wnt Pathway	T044	C1520113
Activator	T109	C3659232
Induces Apoptosis	T043	C1326205
Cell Death	T043	C0007587
Mouse Monocytic Leukemia	T191	C1521831
Cells	T025	C0007634
Wnt agonist,	T109	C3659232
2-amino-4-[3,4-(methylenedioxy)benzylamino]-6-(3-methoxyphenyl) pyrimidine	T109	C3659232
cell-permeable	T043	C0007605
pyrimidine compound	T109	C3659232
Wnt	T116	C0753137
leukemic mouse cell lines	T025	C1517806
RAW 264.7	T025	C4042840
J774.1	T025	C1517806
Wnt agonist	T109	C3659232
Wnt agonist	T109	C3659232
cell death	T043	C0007587
Wnt agonist	T109	C3659232
inhibition	T052	C3463820
GSK-3β	T116	C0244988
activity	T044	C0243102
induced	T169	C0205263
β-catenin accumulation	T044	C1511110
nucleus	T026	C0007610
Wnt agonist	T109	C3659232
caspase-independent cell death	T043	C3820502
cell death ER stress signaling	T043	C2610698
Wnt agonist	T109	C3659232
induced apoptotic cell death	T043	C1326205
RAW 264.7 cells	T025	C4042840
Extracorporeal membrane oxygenation	T061	C0015357
outcomes	T169	C1274040
children	T100	C0008059
hemophagocytic lymphohistiocytosis	T047	C0024291
Pediatric	T080	C1521725
patients	T101	C0030705
hemophagocytic lymphohistiocytosis	T047	C0024291
HLH	T047	C0024291
refractory	T169	C0205269
respiratory	T047	C1145670
cardiac failure	T047	C0018801
consideration	T033	C0518609
extracorporeal membrane oxygenation	T061	C0015357
ECMO	T061	C0015357
support	T074	C0183683
purposes	T169	C1285529
study	T062	C0008972
use	T169	C0457083
outcomes	T080	C0085415
ECMO	T061	C0015357
pediatric	T080	C1521725
HLH	T047	C0024291
patients	T101	C0030705
identify	T080	C0205396
risk factors	T033	C0035648
hospital mortality	T080	C0085556
compare	T052	C1707455
ECMO	T061	C0015357
use	T169	C0457083
outcomes	T080	C0085415
ECMO	T061	C0015357
population	T098	C1257890
Pediatric	T080	C1521725
patients	T101	C0030705
years	T079	C1510829
diagnosis	T033	C0011900
HLH	T047	C0024291
Extracorporeal Life Support Organization	T058	C3161508
ELSO	T058	C3161508
Registry	T170	C0034975
included	T169	C0332257
data	T078	C1511726
children	T100	C0008059
HLH	T047	C0024291
ELSO	T058	C3161508
registry	T170	C0034975
included	T169	C0332257
study	T062	C0008972
cases	T077	C1706256
occurred	T052	C1709305
last	T079	C0205156
decade	T081	C2981279
HLH	T047	C0024291
patients	T101	C0030705
respiratory	T047	C1145670
indication	T078	C3146298
ECMO	T061	C0015357
cardiac	T047	C0018801
indication	T078	C3146298
E	T082	C0442087
CPR	T061	C0007203
cardiac failure	T047	C0018801
respiratory	T047	C1145670
ECMO	T061	C0015357
patients	T101	C0030705
VA ECMO	T061	C3863606
Compared	T052	C1707455
pediatric	T080	C1521725
patients	T101	C0030705
ELSO	T058	C3161508
registry	T170	C0034975
study period	T079	C0489652
HLH	T047	C0024291
patients	T101	C0030705
hospital survival	T169	C0220921
HLH	T047	C0024291
p	T081	C1709380
pediatric	T080	C1521725
HLH	T047	C0024291
patients	T101	C0030705
ECMO	T061	C0015357
risk factors	T033	C0035648
mortality	T081	C0178686
identified	T080	C0205396
development	T169	C1527148
hemorrhagic	T080	C0333275
complication	T046	C0009566
ECMO	T061	C0015357
associated with	T080	C0332281
decreased	T081	C0547047
mortality	T081	C0178686
p	T081	C1709380
Comparing	T052	C1707455
HLH	T047	C0024291
patients	T101	C0030705
respiratory failure	T047	C1145670
patients	T101	C0030705
immune compromised conditions	T201	C4284394
survival rate	T081	C0038954
HLH	T047	C0024291
immune compromised	T201	C4284394
p	T081	C1709380
HLH	T047	C0024291
uncommon	T080	C0522498
indication	T078	C3146298
ECMO	T061	C0015357
patients	T101	C0030705
increased	T081	C0205217
mortality	T081	C0178686
compared	T052	C1707455
pediatric	T080	C1521725
ECMO	T061	C0015357
population	T098	C1257890
data	T078	C1511726
decision-making	T041	C0011109
ECMO	T061	C0015357
pediatric	T080	C1521725
HLH	T047	C0024291
patients	T101	C0030705
Gut microbiome	T001	C2985398
alterations	T078	C1515926
patients	T101	C0030705
stage 4	T080	C0205585
hepatitis C	T047	C0019196
Hepatitis C virus	T005	C0220847
HCV	T005	C0220847
liver diseases	T047	C0023895
cirrhosis	T047	C0023890
cancer	T191	C0006826
worldwide	T078	C0043236
HCV	T005	C0220847
epidemiology	T062	C0002783
pathophysiology	T046	C0277785
therapy	T169	C0039798
reciprocal interactions	T040	C0596935
HCV infection	T047	C4288963
HCV	T005	C0220847
chronic liver diseases	T047	C0341439
human	T016	C0086418
gut microbiome	T001	C2985398
Egypt	T083	C0013715
world's	T098	C2700280
highest prevalence	T081	C1512456
HCV infections	T047	C4288963
study	T062	C2603343
gut microbial community	T001	C2985398
composition	T201	C0486616
Egyptian	T098	C0337801
HCV	T005	C0220847
patients	T101	C0030705
patients	T101	C0030705
liver	T023	C0023884
state	T169	C1442792
stool samples	T031	C1550661
stage 4	T080	C0205585
HCV	T005	C0220847
patients	T101	C0030705
healthy individuals	T098	C1708335
high-throughput	T060	C0872186
16S rRNA gene sequencing	T059	C1294197
Illumina MiSeq	T074	C0348000
alpha-diversity	T080	C0282469
healthy persons'	T098	C1708335
gut microbiomes	T001	C2985398
higher	T080	C0205250
HCV	T005	C0220847
patients	T101	C0030705
phylum Bacteroidetes	T007	C0995456
HCV	T005	C0220847
patients	T101	C0030705
healthy individuals	T098	C1708335
higher	T080	C0205250
abundance	T080	C2346714
Firmicutes	T007	C1254144
Proteobacteria	T007	C0751985
Actinobacteria	T007	C0600148
Genus	T185	C1708235
analysis	T062	C0936012
abundance	T080	C2346714
Prevotella	T007	C0242946
Faecalibacterium	T007	C1229075
higher	T080	C0205250
HCV	T005	C0220847
patients	T101	C0030705
Ruminococcus	T007	C0318074
Clostridium	T007	C0009054
healthy group	T078	C0441833
higher	T080	C0205250
abundance	T080	C2346714
Bacteroidetes	T007	C0995456
HCV	T005	C0220847
patients	T101	C0030705
Prevotella	T007	C0242946
overabundance	T080	C2346714
probiotic genus	T007	C0525033
Bifidobacterium	T007	C0005380
microbiotas	T001	C2985398
healthy individuals	T098	C1708335
study	T062	C2603343
phyla	T185	C1709533
genera	T185	C1708235
stage 4	T080	C0205585
HCV	T005	C0220847
patients	T101	C0030705
healthy individuals	T098	C1708335
microbiome	T001	C1956108
chronic hepatitis C	T047	C0524910
bacterial translocation	T043	C0282583
liver's	T023	C0023884
impaired role	T033	C0231410
digestion	T040	C0012238
protein synthesis	T044	C0597295
microbiome	T001	C1956108
composition	T201	C0486616
capabilities	T080	C2698977
patients	T101	C0030705
biomarker	T201	C0005516
Prevotella	T007	C0242946
Faecalibacterium	T007	C1229075
Bifidobacterium	T007	C0005380
Peptide	T116	C0030956
Interference	T070	C0042730
PB2	T116	C0753209
eIF4G1	T116	C1505487
Interaction	T044	C0872079
Inhibits	T052	C3463820
Influenza A Viruses	T005	C0029347
Replication	T043	C0042774
in Vitro	T062	C0681828
in Vivo	T062	C0681829
Influenza viruses	T005	C0029341
obligate parasites	T204	C0562628
hijack the host cellular system	T043	C1154502
influenza virus PB2	T116	C1611366
host eukaryotic translation initiation factor 4-γ 1	T116	C1505487
eIF4G1	T116	C1505487
viral mRNA translation	T046	C1154505
peptide	T116	C0030956
interference	T070	C0042730
PB2	T116	C0753209
eIF4G1	T116	C1505487
interaction	T044	C0872079
inhibited	T052	C3463820
virus replication	T043	C0042774
in vitro	T062	C0681828
in vivo	T062	C0681829
intranasal administration	T061	C0001560
peptide	T116	C0030956
protection	T033	C1545588
lethal	T033	C3151529
challenges	T058	C0805586
influenza A viruses	T005	C0029347
BALB/c mice	T015	C0025919
H1N1	T005	C1615607
H5N1	T005	C1613950
H7N9 influenza virus subtypes	T005	C3658219
Mapping	T063	C0949728
PB2 protein	T116	C0753209
eIF4G1	T116	C1505487
binding sites	T192	C0005456
PB2 cap	T116	C0753209
binding domain	T044	C1149343
Virtual docking analysis	T170	C3494274
inhibitory	T052	C3463820
peptide	T116	C0030956
associated with	T080	C0332281
amino acid residues	T116	C0002520
PB2	T116	C0753209
cap-binding activity	T059	C0201711
PB2	T116	C0753209
eIF4G1	T116	C1505487
interactive site	T192	C0005456
druggable	T121	C1254351
influenza	T047	C0021400
therapeutics	T061	C0087111
DRG1	T028	C1414151
oncogene	T028	C0029016
lung adenocarcinoma	T191	C0152013
promotes	T052	C0033414
tumor progression	T191	C0178874
spindle checkpoint signaling	T043	C3156402
regulation	T038	C1327622
GTP binding protein 1	T116	C1430718
DRG1	T116	C0905573
DRG family	T116	C1335532
regulating cell growth	T043	C0596286
molecular basis	T078	C1853126
DRG1	T116	C0905573
cell proliferation regulation	T043	C1156235
DRG1	T116	C0905573
tumor progression	T191	C0178874
DRG1	T116	C0905573
lung adenocarcinomas	T191	C0152013
expressed	T045	C1171362
lung	T023	C0024109
tissues	T024	C0040300
DRG1	T028	C1414151
knockdown	T063	C2350567
growth inhibition	T043	C2244509
tumor cells	T025	C0597032
cells	T025	C0007634
M phase	T043	C0007591
Overexpression	T045	C1171362
DRG1	T116	C0905573
chromosome	T026	C0008633
missegregation	T045	C0314627
tumorigenesis	T191	C0007621
ectopic	T045	C1512167
DRG1	T028	C1414151
taxol	T109	C0678133
induced	T169	C0205263
apoptosis	T043	C0162638
lung adenocarcinoma	T191	C0152013
cells	T025	C0007634
Mechanistic	T022	C0598002
analyses	T062	C0936012
DRG1	T116	C0905573
localizes	T082	C0392752
mitotic spindles	T026	C0026258
dividing cells	T025	C0230517
binds	T044	C1167622
spindle checkpoint signaling	T043	C3156402
proteins	T116	C1335962
in vivo	T082	C1515655
studies	T062	C2603343
DRG1	T028	C1414151
tumorigenesis	T191	C0007621
mechanism	T169	C0441712
DRG1	T028	C1414151
taxol	T109	C0678133
Gelsolin	T116	C0061187
Onychophora	T204	C1001576
Tardigrada	T204	C1010027
variability	T077	C2827666
Ecdysozoa	T204	C3578917
Rearrangements	T067	C0596965
filamentous actin network	T116	C1180307
range	T081	C1514721
actin binding proteins	T116	C0001239
gelsolin proteins	T116	C0061187
actin filaments	T026	C0025979
fast growing	T033	C4086299
nucleate	T044	C1155976
actin assembly	T043	C2610250
calcium	T121	C0006675
dependent	T080	C0851827
gelsolin	T116	C0061187
onychophoran	T204	C1001576
Peripatoides novaezealandiae	T204	C1083155
eutardigrade	T204	C1010027
Hypsibius dujardini	T204	C1465325
cDNA	T114	C0006556
P. novaezealandiae	T204	C1083155
obtained	T169	C1301820
coding sequence	T028	C0079941
open reading frame	T028	C0079941
bp	T044	C0600436
encodes	T052	C2700640
protein	T116	C0033684
amino acids	T116	C0002520
calculated	T052	C1441506
molecular mass	T081	C3152252
sequence	T087	C0002518
comprised	T052	C2700400
segments	T082	C0441635
analysis	T062	C0936012
data	T078	C1511726
TardiBase	T170	C0242356
reveals	T080	C0443289
gelsolin	T116	C0061187
eutardigrade	T204	C1010027
Hypsibius dujardini	T204	C1465325
segments	T082	C0441635
coding sequence	T028	C0079941
bp	T044	C0600436
amino acids	T116	C0002520
calculated	T052	C1441506
molecular mass	T081	C3152252
Peripatoides	T204	C1014425
Hypsibius	T204	C1481832
gelsolin	T116	C0061187
revealed	T080	C0443289
conserved	T086	C0009802
binding motifs	T116	C1956035
G-actin	T116	C0016890
F-actin	T116	C1180307
phosphatidylinositol 4,5-bisphosphate	T109	C0070798
PIP2	T109	C0070798
type-1	T192	C0005456
type-2	T192	C0005456
Ca(2+)	T121	C0596235
binding sites	T192	C0005456
result	T169	C1274040
binding	T044	C1167622
calcium ions	T121	C0596235
gelsolin proteins	T116	C0061187
lack	T080	C0332268
C-terminal	T087	C1514562
latch-helix	T082	C1704821
rapid	T080	C0456962
activation	T052	C1879547
Ca(2+) range	T059	C0201925
gelsolin	T116	C0061187
segments	T082	C0441635
present	T033	C0150312
ancestor	T099	C0870134
ecdysozoan	T204	C3578917
Panarthropoda	T204	C1039396
Onychophora	T204	C1001576
Tardigrada	T204	C1010027
Arthropoda	T204	C0003903
primarily	T080	C0205225
gelsolin	T116	C0061187
studied	T062	C2603343
Chordata	T008	C0920312
reveals	T080	C0443289
segments	T082	C0441635
Mapping	T059	C0030944
molecular data	T170	C0026382
well-established	T080	C0443211
phylogeny	T078	C0031797
revealed	T080	C0443289
gelsolin	T116	C0061187
segments	T082	C0441635
correlate	T080	C1707520
phylogenetic	T078	C0031797
lineage	T077	C1881379
functional	T169	C0205245
alter	T169	C0392747
kinetics	T070	C0022702
actin polymerization	T043	C1155982
MiR-424-5p	T028	C1537908
participates	T169	C0679823
esophageal squamous cell carcinoma	T191	C0279626
invasion	T046	C0027626
metastasis	T191	C0027627
SMAD7	T028	C1334470
pathway	T044	C0037080
EMT	T043	C1523298
ESCC	T191	C0279626
life-threatening	T033	C2826244
disease	T047	C0012634
invasion	T046	C0027626
metastasis	T191	C0027627
early stage	T079	C2363430
detect	T033	C0442726
molecular	T080	C1521991
mechanisms	T169	C0441712
invasion	T046	C0027626
metastasis	T191	C0027627
ESCC	T191	C0279626
evidence	T078	C3887511
deregulation	T052	C1880287
miR-424-5p	T028	C1537908
role	T077	C1705810
cancers	T191	C0006826
role	T077	C1705810
functional	T169	C0205245
mechanism	T169	C0441712
ESCC	T191	C0279626
seldom	T080	C0522498
expression levels	T081	C3244092
miR-424-5p	T028	C1537908
detected	T033	C0442726
ESCC	T191	C0279626
tissues	T024	C0040300
cell lines	T025	C0085983
real-time PCR methods	T063	C1709846
invasion	T046	C0027626
metastasis	T191	C0027627
proliferation	T043	C0596290
ESCC	T191	C0279626
cell lines	T025	C0085983
transfected	T045	C0314641
miR-424-5p	T028	C1537908
analyzed	T062	C0936012
transwell invasion assay	T059	C1510438
wound healing assay	T059	C1510438
cell proliferation assay	T062	C3899698
target gene	T028	C0017337
miR-424-5p	T028	C1537908
verified	T169	C1711411
luciferase activity assay	T059	C1510438
role	T077	C1705810
miR-424-5p	T028	C1537908
EMT	T043	C1523298
investigated	T169	C1292732
real-time PCR	T063	C1709846
western blot assay	T059	C0949466
expression levels	T081	C3244092
miR-424-5p	T028	C1537908
decreased	T081	C0205216
ESCC	T191	C0279626
tissues	T024	C0040300
cell lines	T025	C0085983
expression levels	T081	C3244092
miR-424-5p	T028	C1537908
lymph node	T023	C0024204
metastasis	T191	C0027627
ESCC	T191	C0279626
tissues	T024	C0040300
miR-424-5p	T028	C1537908
EC-1 cells	T025	C0597032
miR-424-5p	T028	C1537908
decrease	T081	C0547047
invasion	T046	C0027626
metastasis	T191	C0027627
proliferation	T043	C0596290
EC-1 cells	T025	C0597032
role	T077	C1705810
inhibition	T052	C3463820
invasion	T046	C0027626
metastasis	T191	C0027627
ESCC	T191	C0279626
cells	T025	C0597032
tissues	T024	C0040300
SMAD7	T028	C1334470
target gene	T028	C0017337
miR-424-5p	T028	C1537908
luciferase activity assay	T059	C1510438
miR-424-5p	T028	C1537908
negatively	T033	C0205160
regulate	T045	C0017263
SMAD7	T028	C1334470
expression	T045	C0017262
EMT	T043	C1523298
SMAD7	T028	C1334470
overexpression	T045	C0017262
SMAD7	T028	C1334470
enhance	T052	C2349975
miR-424-5p	T028	C1537908
anti-EMT	T033	C0243095
function	T169	C0542341
results	T169	C1274040
miR-424-5p	T028	C1537908
SMAD7	T028	C1334470
pathway	T044	C0037080
ESCC	T191	C0279626
invasion	T046	C0027626
metastasis	T191	C0027627
up-regulation	T044	C0041904
miR-424-5p	T028	C1537908
preventing	T169	C1292733
tumor invasion	T033	C1269955
metastasis	T191	C0027627
Double-Network Hydrogel	T109	C0063083
Tunable	T080	C0205556
Mechanical Performance	T052	C1882330
Biocompatibility	T044	C0596177
Fabrication	T170	C3494260
Stem Cells	T025	C0038250
Encapsulated Fibers	T109	C0225326
3D Assemble	T082	C1254362
Fabrication	T170	C3494260
cell	T025	C0038250
encapsulated fibers	T109	C0225326
contribute	T052	C1880177
tissue engineering	T061	C0596171
regenerative medicine	T091	C1257974
existing	T080	C2347662
methods	T169	C0449851
unavoidability	T080	C0205556
cell damaging	T049	C0599732
conditions	T080	C0348080
sophisticated equipment	T073	C0681588
unavailability	T080	C0686905
materials	T167	C0520510
mechanical	T169	C0443254
biological	T080	C0205460
expectations	T078	C0679138
work	T057	C0043227
simple	T080	C0205352
method	T169	C0449851
proposed	T080	C1553874
prepare	T052	C1521827
cell	T025	C0038250
encapsulated fibers	T109	C0225326
tunable	T080	C0205556
mechanical strength	T081	C0039526
stretching behavior	T080	C0871161
diameter	T081	C1301886
microstructure	T104	C1254350
hydrogel	T109	C0063083
fibers	T109	C0225326
optimal	T080	C2698651
combination	T080	C0205195
alginate	T109	C0102137
poly(N-iso-propylacrylamide)-poly(ethylene glycol)	T122	C0005479
double-network hydrogel	T109	C0063083
stiffness	T184	C0427008
flexibility	T080	C0242808
create	T052	C1706214
variety	T077	C2346866
three dimensional structures	T082	C0026377
parallel helical	T082	C1254362
different	T080	C1705242
knots without crack	T082	C1254362
hydrogel	T109	C0063083
fibers	T109	C0225326
better	T080	C0332272
compatibility	T044	C0596177
indicated	T033	C1444656
viability	T080	C0443348
proliferation	T169	C1514485
expression	T169	C0205245
pluripotency	T169	C1514185
markers	T201	C0005516
embryonic stem cells	T025	C0596508
encapsulated	T080	C0205223
4-day	T033	C3840892
culture	T059	C0430400
double-network hydrogel	T109	C0063083
possesses	T048	C0850310
specific	T080	C0205369
quick	T080	C0456962
responses	T032	C0871261
alginate lyase	T116	C0051154
EDTA	T109	C0013618
environmental temperature	T081	C2983601
degradation	T169	C0243125
fibers	T109	C0225326
fibrous assemblies	T082	C1254362
cells	T025	C0038250
encapsulated	T080	C0205223
subsequent	T079	C0332282
assay	T059	C1510438
treatment	T061	C0087111
Synchronous	T079	C0439580
vitellogenin	T116	C0042896
expression	T045	C1171362
sexual maturation	T040	C0036887
migration	T039	C1533574
negatively	T033	C0205160
correlated	T080	C1707520
juvenile hormone	T125	C0022439
levels	T080	C0441889
Mythimna separata	T204	C1477488
migration	T039	C1533574
pests	T008	C0869004
different	T080	C1705242
seasonal	T079	C0036497
habitats	T082	C0871648
lead	T169	C1522538
crop	T002	C0242775
damage	T169	C1883709
Reproductive	T040	C0035150
immaturity	T080	C0205252
migratory process	T039	C1533574
oogenesis	T042	C0029047
flight syndrome	T047	C0039082
mechanism	T169	C0441712
reproductive development	T040	C0597375
migration	T039	C1533574
migration	T039	C1533574
unpredictably	T033	C0562453
vitellogenin gene	T028	C0017337
MsVg	T028	C0017337
key	T077	C1706198
regulatory enzyme genes	T028	C0017362
MsJhamt	T028	C0017337
MsJheh	T028	C0017337
MsJhe	T028	C0017337
juvenile hormone	T125	C0022439
JH	T125	C0022439
synthesis	T052	C1883254
degradation	T044	C0314674
identified	T080	C0205396
characterized	T052	C1880022
Mythimna separata	T204	C1477488
relative expression	T045	C0017262
MsVg	T028	C0017337
response	T032	C0871261
seasonal	T079	C0036497
changes	T169	C0392747
correlated	T080	C1707520
stages	T079	C1306673
ovarian development	T042	C1160267
low levels	T080	C0441889
JH	T125	C0022439
titer	T081	C0475208
not differ	T033	C3842396
male	T032	C0086582
moths	T204	C0026593
increased	T081	C0205217
female adults	T098	C0043210
migratory season	T039	C1533574
consistent with	T078	C0332290
changes	T169	C0392747
mRNA	T114	C0035696
levels	T080	C0441889
MsJhamt	T028	C0017337
MsJheh	T028	C0017337
MsJhe	T028	C0017337
JH	T125	C0022439
titer	T081	C0475208
negatively	T033	C0205160
seasonal	T079	C0036497
levels	T080	C0441889
vitellogenin	T116	C0042896
mRNA	T114	C0035696
transcripts	T114	C1519595
ovarian development	T042	C1160267
migrating	T039	C1533574
M. separata	T204	C1477488
synchrony	T079	C0439580
MsVg expression	T045	C0017262
sexual maturation	T040	C0036887
potential	T080	C3245505
MsVg	T028	C0017337
transcript	T114	C1519595
levels	T080	C0441889
index	T170	C0918012
adult	T100	C0001675
reproductive	T040	C0035150
status	T080	C0449438
level	T080	C0441889
JH	T125	C0022439
sexual maturity	T040	C0036887
correlated	T080	C1707520
JH	T125	C0022439
regulating	T038	C1327622
MsVg expression	T045	C0017262
reproduction	T040	C0035150
seasonal	T079	C0036497
northern and southern migration	T039	C1533574
migration	T039	C1533574
Functional Result	T169	C1274040
Cochlear Implantation	T061	C0302559
Children	T100	C0008059
Adults	T100	C0001675
Single-sided Deafness	T047	C0521785
Patients	T101	C0030705
single-sided deafness	T047	C0521785
SSD	T047	C0521785
reduced	T080	C0392756
binaural hearing	T042	C0596169
sound localization	T041	C0037710
speech	T040	C0037817
noise discrimination	T041	C0234747
Cochlear implantation	T061	C0302559
patients	T101	C0030705
SSD	T047	C0521785
alternative	T077	C1523987
hearing devices	T074	C0018768
contralateral	T082	C0441988
signal	T067	C1710082
Application	T058	C0185125
children	T100	C0008059
retrospectively	T062	C0035363
children	T100	C0008059
adults	T100	C0001675
SSD	T047	C0521785
treated with	T061	C0332293
cochlear implantation	T061	C0302559
outcome	T169	C1274040
adult	T100	C0001675
patients	T101	C0030705
control group	T096	C0009932
patients	T101	C0030705
bilateral profound hearing loss	T047	C0018775
cochlear implant	T074	C0009199
mean	T033	C3533236
speech recognition	T041	C0597498
score	T081	C0449820
monosyllabic	T170	C0282574
monosyllabic words	T170	C0042926
adults	T100	C0001675
multisyllabic	T170	C0282574
cochlear implant	T074	C0009199
CI	T074	C0009199
improved hearing	T033	C0429200
noise	T067	C0028263
SSD	T047	C0521785
patients	T101	C0030705
improvement	T077	C2986411
speech reception threshold	T201	C0234742
Sound localization	T041	C0037710
angle detection error	T170	C0282574
improved	T077	C2986411
CI	T074	C0009199
word recognition	T041	C0871615
score	T081	C0449820
monosyllabic	T170	C0282574
monosyllabic words	T170	C0042926
logarithm	T081	C2986775
duration of deafness	T079	C0449238
deafness	T033	C0011053
improvement	T077	C2986411
speech reception threshold	T201	C0234742
RMS angle detection error	T170	C0282574
CI	T074	C0009199
SSD	T047	C0521785
patients	T101	C0030705
CI	T074	C0009199
hearing	T039	C0018767
situations	T080	C0348080
Patients	T101	C0030705
SSD	T047	C0521785
improve	T080	C1272747
cochlear implantation	T061	C0302559
CHOROIDAL VASCULARITY INDEX	T081	C0392762
Optical Coherence Tomography	T060	C0920367
Parameter	T077	C0549193
Patients	T101	C0030705
Exudative Age-Related Macular Degeneration	T047	C0271084
choroidal	T023	C0008520
structural	T082	C0678594
exudative age-related macular degeneration	T047	C0271084
AMD	T047	C0242383
choroidal vascularity index	T081	C0392762
computed	T052	C1880157
spectral domain optical coherence tomography	T060	C0920367
depth imaging	T060	C0011923
case series	T062	C0150093
consecutive	T080	C1707491
patients	T101	C0030705
unilateral	T082	C0205092
exudative AMD	T047	C0271084
Choroidal	T023	C0008520
images	T060	C0011923
luminal	T082	C0524462
area	T082	C0205146
Choroidal vascularity index	T081	C0392762
ratio	T081	C0456603
luminal	T082	C0524462
area	T082	C0205146
area	T082	C0205146
Mean	T081	C0444504
choroidal vascularity index	T081	C0392762
mean	T081	C0444504
choroidal thickness	T081	C0392762
study	T062	C2603343
eyes	T023	C0015392
patient	T101	C0030705
AMD	T047	C0242383
Student's t-test	T081	C0871453
significantly lower	T081	C4055638
choroidal vascularity index	T081	C0392762
eyes	T023	C0015392
exudative AMD	T047	C0271084
Luminal area	T082	C0524462
decreased	T081	C0205216
eyes	T023	C0015392
exudative AMD	T047	C0271084
no significant difference	T033	C3842396
area	T082	C0205146
study	T062	C2603343
eyes	T023	C0015392
Eyes	T023	C0015392
exudative AMD	T047	C0271084
reduced	T080	C0392756
choroidal vascularity index	T081	C0392762
differences	T080	C1705242
eyes	T023	C0015392
Choroidal vascularity index	T081	C0392762
potential	T080	C3245505
noninvasive tool	T033	C0243095
studying	T062	C2603343
structural	T082	C0678594
choroid	T023	C0008520
choroidal disease	T047	C0008521
exudative AMD	T047	C0271084
Comparison	T052	C1707455
Esophageal	T201	C2316724
Rectal	T033	C0489749
Gastrointestinal	T029	C0809794
Temperatures	T081	C0039476
Passive Rest	T056	C0035253
Exercise	T056	C0015259
Heat	T070	C0018837
Influence	T077	C4054723
Hydration	T033	C1321013
esophageal	T201	C2316724
rectal	T033	C0489749
gastrointestinal	T029	C0809794
temperatures	T081	C0039476
TES	T201	C2316724
TRE	T033	C0489749
TGI	T081	C0039476
exercise-induced	T184	C0239313
hyperthermia	T184	C0015967
hydration states	T033	C1321013
study	T062	C0008972
TES	T201	C2316724
TRE	T033	C0489749
TGI	T081	C0039476
passive rest	T056	C0035253
exercise-induced	T184	C0239313
hyperthermia	T184	C0015967
hydration states	T033	C1321013
euhydrated	T033	C0231162
EU	T033	C0231162
hypohydrated	T047	C0011175
HY	T047	C0011175
Randomized-crossover design	T062	C0242817
Controlled	T067	C2239193
laboratory setting	T073	C0022877
recreationally	T056	C0034872
active	T169	C0205177
male	T032	C0086582
participants	T098	C0679646
SD	T081	C0871420
age	T032	C0001779
height	T032	C0489786
body mass	T032	C0005910
body fat	T201	C0344335
Participants	T098	C0679646
trials	T062	C0008976
EU	T033	C0231162
HY	T047	C0011175
bout	T079	C0741605
treadmill exercise	T056	C2712999
ranging	T081	C1514721
grade	T185	C0441800
minute	T079	C0439232
jog	T056	C0022400
ranging	T081	C1514721
hot environment	T067	C0241922
ambient temperature	T070	C0428692
relative humidity	T081	C0428696
wet bulb globe temperature	T169	C0242485
passive rest	T056	C0035253
Root mean squared difference	T081	C2347976
RMSD	T081	C2347976
variance	T080	C1711260
temperature readings	T032	C0005903
time points	T079	C0439547
TRE	T033	C0489749
TGI	T081	C0039476
TRE	T033	C0489749
TES	T201	C2316724
TGI	T081	C0039476
TES	T201	C2316724
EU	T033	C0231162
HY	T047	C0011175
RMSD	T081	C2347976
three-way repeated measures ANOVA	T081	C0002780
analysis	T062	C0936012
effects	T080	C1280500
Tukey's HSD	T170	C0237913
RMSD values	T081	C2347976
device	T074	C0025080
comparisons	T052	C1707455
significantly	T081	C0237881
EU	T033	C0231162
TRE	T033	C0489749
TGI	T081	C0039476
TRE	T033	C0489749
TES	T201	C2316724
TGI	T081	C0039476
TES	T201	C2316724
HY	T047	C0011175
TRE	T033	C0489749
TGI	T081	C0039476
TRE	T033	C0489749
TES	T201	C2316724
TGI	T081	C0039476
TES	T201	C2316724
minute	T079	C0439232
bout	T079	C0741605
passive rest	T056	C0035253
TRE	T033	C0489749
TGI	T081	C0039476
TES	T201	C2316724
EU	T033	C0231162
HY	T047	C0011175
trials	T062	C0008976
passive rest	T056	C0035253
exercise	T056	C0015259
heat	T070	C0018837
TRE	T033	C0489749
TGI	T081	C0039476
body temperature	T032	C0005903
euhydration	T033	C0231162
hypohydrated	T047	C0011175
exercise	T056	C0015259
clinical significance	T033	C2826293
Annexin A1	T116	C0103403
Aβ1-42	T116	C0169424
blood-brain barrier disruption	T061	C1831732
inhibition	T044	C0021469
RhoA-ROCK signaling pathway	T044	C0037080
blood-brain barrier	T023	C0005854
BBB	T023	C0005854
brain capillary	T023	C4242462
endothelial cells	T025	C0225336
homeostasis	T038	C0019868
brain	T023	C0006104
blood	T031	C0005767
parenchyma	T023	C0933845
central nervous system	T022	C1269563
CNS	T022	C1269563
disruption of the BBB	T061	C1831732
neurodegenerative diseases	T047	C0524851
Alzheimer's disease	T047	C0002395
AD	T047	C0002395
Annexin A1	T116	C0103403
ANXA1	T116	C0103403
anti-inflammatory messenger	T116	C0169911
expressed	T045	C1171362
brain endothelial cells	T025	C0225336
BBB	T023	C0005854
mechanism	T044	C0678659
BBB	T023	C0005854
AD	T047	C0002395
β-Amyloid 1-42	T116	C0169424
Aβ42	T116	C0169424
BBB disruption	T061	C1831732
human recombinant ANXA1	T116	C0034861
hrANXA1	T116	C0034861
murine	T109	C0591833
brain endothelial cell line bEnd.3.	T025	C0225336
ANXA1	T116	C0103403
bEnd.3 cells	T025	C0225336
capillaries	T023	C0006901
5XFAD mice	T001	C1514798
human serum	T031	C0229671
patients	T101	C0030705
AD	T047	C0002395
mechanism	T044	C0678659
ANXA1	T116	C0103403
BBB	T023	C0005854
AD	T047	C0002395
RhoA-ROCK signaling pathway	T044	C0037080
Aβ42	T116	C0169424
bEnd.3 cells	T025	C0225336
capillaries	T023	C0006901
5XFAD mice	T001	C1514798
RhoA	T116	C0643681
activated	T045	C0599177
RhoA inhibitors	T080	C1999216
Aβ42	T116	C0169424
BBB disruption	T061	C1831732
overexpressed	T045	C1171362
RhoA-GTP	T116	C0084340
RhoA	T116	C0643681
ANXA1	T116	C0103403
pericytes	T025	C0598800
cocultured	T059	C0282547
bEnd.3 cells	T025	C0225336
Aβ42	T116	C0169424
RhoA activation	T045	C0599177
bEnd.3 cells	T025	C0225336
inhibited	T080	C0311403
secretion	T038	C0036536
ANXA1	T116	C0103403
pericytes	T025	C0598800
ANXA1	T116	C0103403
Aβ42	T116	C0169424
BBB disruption	T061	C1831732
inhibition	T044	C0021469
RhoA-ROCK signaling pathway	T044	C0037080
ANXA1	T116	C0103403
therapeutic reagent	T121	C1611640
breakdown of the BBB	T061	C1831732
AD	T047	C0002395
Association	T080	C0439849
kidney disease	T047	C0022658
obstructive sleep apnea	T047	C0520679
population study	T062	C0681876
men	T098	C0025266
determine	T059	C1148554
relationship	T080	C0439849
obstructive sleep apnea	T047	C0520679
OSA	T047	C0520679
chronic kidney disease	T047	C1561643
CKD	T047	C1561643
population studies	T062	C0681876
association	T080	C0439849
sparse	T079	C0521114
conflicting	T033	C0855281
confined	T169	C0443288
studies	T062	C2603343
administrative	T033	C3845829
data	T078	C1511726
Cross-sectional analysis	T062	C0010362
participants	T098	C0679646
Men Androgens Inflammation Lifestyle Environment and Stress (MAILES) study	T081	C0009247
aged	T032	C0001779
Renal	T023	C0022646
data	T078	C1511726
men	T098	C0025266
prior	T079	C0332152
OSA	T047	C0520679
diagnosis	T033	C0011900
in-home	T082	C0442519
polysomnography	T060	C0162701
Embletta X100	T074	C0182339
CKD	T047	C1561643
estimated glomerular filtration rate	T059	C3811844
eGFR	T059	C3811844
eGFR	T059	C3811844
albuminuria	T033	C0001925
albumin creatinine ratio	T059	C1655929
CKD	T047	C1561643
Stage	T079	C1306673
Stage	T079	C1306673
predominantly	T080	C0332251
mild severity	T033	C1513302
significant	T078	C0750502
association	T080	C0439849
OSA	T047	C0520679
odds ratio	T081	C0028873
OR	T081	C0028873
confidence interval	T081	C0009667
CI	T081	C0009667
severe	T080	C0205082
OSA	T047	C0520679
OR	T081	C0028873
respiratory	T169	C0521346
arousal	T039	C0233972
index	T170	C0918012
OR	T081	C0028873
measures	T081	C0079809
hypoxemia	T033	C0700292
adjustment	T169	C0456081
age	T032	C0001779
hypertension	T047	C0020538
diabetes	T047	C0011847
smoking	T055	C0037369
obesity	T047	C0028754
NSAID	T121	C3536840
use	T169	C0457083
association	T080	C0439849
CKD	T047	C1561643
daytime sleepiness	T033	C0541854
men	T098	C0025266
CKD	T047	C1561643
OSA	T047	C0520679
not significantly	T033	C1273937
more	T081	C0205172
likely	T081	C0033204
report	T058	C0700287
symptoms	T184	C1457887
sleepiness	T033	C0013144
snoring	T184	C0037384
apneas	T046	C0003578
identified	T080	C0205396
STOP OSA screening questionnaire	T062	C1134635
men	T098	C0025266
OSA	T047	C0520679
Predominantly	T080	C0332251
mild	T080	C2945599
CKD	T047	C1561643
associated with	T080	C0332281
severe	T080	C0205082
OSA	T047	C0520679
arousals	T041	C0003808
population studies	T062	C0681876
examining	T033	C0332128
longitudinal	T082	C0205127
relationship	T080	C0439849
CKD	T047	C1561643
OSA	T047	C0520679
warranted	T169	C0205245
methods	T170	C0025663
needed	T080	C0027552
identify	T041	C0020792
OSA	T047	C0520679
CKD	T047	C1561643
few	T081	C0205388
symptoms	T184	C1457887
vitronectin	T116	C0055023
migration-enhancing factor	T123	C0574031
cancer cells	T025	C0597032
chaperoned	T116	C0243041
fibrinogen	T116	C0016006
metastasis	T046	C4255448
cancer cells	T025	C0597032
fibrinogen	T116	C0016006
lymphatics	T022	C0024235
body cavities	T030	C0333343
Diluted	T169	C1948037
plasma	T031	C0032105
migration	T043	C1622501
malignant cell lines	T025	C0334227
pro-metastatic factors	T169	C1521761
factor(s)	T169	C1521761
diluted	T169	C1948037
plasma	T031	C0032105
phenomenon	T067	C1882365
heat	T070	C0018837
inactivation	T169	C0544461
dialysis	T070	C0011945
proteinase K	T116	C0059256
treatment	T169	C1522326
molecular size filtration studies	T068	C0016107
pro-migratory activity	T052	C0441655
diluted	T169	C1948037
plasma	T031	C0032105
protein	T116	C0033684
GαI protein-coupled receptors	T116	C0682972
p42/44 MAPK	T116	C0752312
AKT signaling	T044	C1623484
cells	T025	C0007634
pro-migratory activity	T052	C0441655
plasma	T031	C0032105
plasma concentrations	T081	C0683150
serum	T031	C0229671
fibrinogen	T116	C0016006
chaperone	T116	C0243041
protein(s)	T116	C0033684
pro-migratory protein(s)	T116	C0033684
diluted	T169	C1948037
plasma	T031	C0032105
fibrinogen	T116	C0016006
serum	T031	C0229671
gel filtration	T059	C0008559
hydrophobic interaction chromatography	T059	C0008550
mass spectrometry analysis	T059	C0037813
protein	T116	C0033684
in vitro	T080	C1533691
experiments	T062	C0681814
pro-migratory factor	T123	C0574031
chaperoned	T116	C0243041
fibrinogen	T116	C0016006
vitronectin	T116	C0055023
fibrinogen	T116	C0016006
mechanism	T044	C0678659
metastasis	T046	C4255448
cancer cells	T025	C0597032
lymphatics	T022	C0024235
body cavities	T030	C0333343
concentration	T081	C1264643
fibrinogen	T116	C0016006
vitronectin	T116	C0055023
migration	T043	C1622501
tumor cells	T025	C0597032
Development	T169	C1527148
initial	T079	C0205265
validation	T062	C1519941
Respirator	T074	C3824912
Comfort	T041	C1331418
Wearing Experience	T041	C0596545
Function	T169	C0542341
Instrument	T074	C0348000
R-COMFI	T074	C0348000
Filtering face-piece respirators	T074	C3824912
FFRs	T074	C3824912
protect	T033	C1545588
health care personnel	T097	C0018724
airborne particles	T131	C1510837
clinical studies	T062	C0008972
FFR	T074	C3824912
adherence	T169	C1510802
low	T080	C0205251
part	T082	C0449719
discomfort	T184	C2364135
intolerance	T040	C0231199
objective	T170	C0018017
study	T062	C0681814
initially	T079	C0205265
evaluate	T052	C1516048
psychometric properties	T080	C0871161
instrument	T074	C0348000
designed	T057	C0014677
measure	T081	C0079809
comfort	T041	C1331418
tolerability	T080	C4053931
FFRs	T074	C3824912
Instrument	T074	C0348000
literature reviews	T170	C0282441
focus groups	T096	C0016400
several	T081	C0443302
iterations	T033	C1854293
ranking	T170	C0699794
experts	T097	C0009817
Psychometric evaluation	T060	C0033920
instrument	T074	C0348000
Rasch partial credit model	T170	C3161035
PCM	T170	C3161035
analysis	T062	C0936012
Pivot anchoring	T170	C0282574
threshold	T080	C0449864
difficulty	T080	C0332218
analyses	T062	C0936012
point	T081	C1552961
participants	T098	C0679646
possessing	T078	C3154893
trait	T032	C0599883
trait	T032	C0599883
final	T079	C3853528
instrument	T074	C0348000
completed	T080	C0205197
health care personnel	T097	C0018724
Veterans	T098	C0042610
Health Administration facilities	T058	C2936317
data	T078	C1511726
analyzed	T062	C0936012
Rasch PCM	T170	C3161035
removed	T080	C0849355
violated the assumption of independence	T080	C0205556
mis-fitting	T080	C0205556
not relevant	T080	C2347946
Category	T170	C0683312
function	T169	C0542341
analysis	T062	C0936012
categories	T170	C0683312
progressed	T169	C1272688
monotonically	T080	C0205556
Principal components analysis	T081	C0429865
existence	T081	C1547035
subscales	T081	C0392762
Discomfort	T184	C2364135
Wearing Experience	T041	C0596545
Function	T169	C0542341
Final	T079	C3853528
reliability	T081	C2347947
analyses	T062	C0936012
scale	T081	C0392762
moderate	T080	C0205081
high person reliability	T081	C2347947
reliability	T081	C2347947
instrument	T074	C0348000
contained	T169	C0332256
knowledge	T041	C0162340
instrument	T074	C0348000
evidence	T078	C3887511
reliability and validity	T080	C0035036
assess	T052	C1516048
discomfort	T184	C2364135
tolerance	T080	C1704410
FFRs	T074	C3824912
health care personnel	T097	C0018724
published	T057	C0034037
psychometrically sound measure	T081	C0079809
comfort	T041	C1331418
tolerability	T080	C4053931
FFRs	T074	C3824912
Respirator	T074	C3824912
Comfort	T041	C1331418
Wearing Experience	T041	C0596545
Function	T169	C0542341
Instrument	T074	C0348000
R-COMFI	T074	C0348000
significance	T078	C0750502
instrument	T074	C0348000
respirators	T074	C3824912
adherence	T169	C1510802
practice	T041	C0032893
R-COMFI	T074	C0348000
within	T082	C0332285
VA healthcare system	T093	C0018696
psychometrically sound instrument	T074	C0348000
evaluate	T052	C1516048
comfort	T041	C1331418
tolerability	T080	C4053931
respirators	T074	C3824912
developmental	T080	C0458003
Kidney transplant recipients	T033	C4304779
nonrenal solid organ transplantation	T061	C0029216
alloreactivity	T039	C0301873
risk	T078	C0035647
infection	T046	C3714514
kidney transplant recipients	T033	C4304779
KTRs	T033	C4304779
nonrenal solid organ transplantation	T061	C0029216
SOT	T061	C0029216
patient	T101	C0030705
allograft	T061	C0040739
outcomes	T080	C0085415
infections	T046	C3714514
alloreactivity	T039	C0301873
studied	T062	C2603343
KTRs	T033	C4304779
nonrenal SOT	T061	C0029216
KTRs	T033	C4304779
KTRs	T033	C4304779
Samples	T031	C0504082
pretransplantation	T079	C1254367
post-transplantation	T079	C1254367
Alloreactive	T039	C0301873
CMV-specific	T005	C0010825
T cells	T025	C0039194
interferon-γ ELISPOT assay	T059	C0920508
Patient	T101	C0030705
survival	T052	C0038952
KTRs	T033	C4304779
SOT	T061	C0029216
KTRs	T033	C4304779
death	T040	C0011065
allograft	T061	C0040739
survival	T052	C0038952
KTRs	T033	C4304779
SOT	T061	C0029216
KTRs	T033	C4304779
KTRs	T033	C4304779
SOT	T061	C0029216
5-year	T079	C0439234
death	T040	C0011065
allograft	T061	C0040739
survival	T052	C0038952
KTRs	T033	C4304779
KTRs	T033	C4304779
SOT	T061	C0029216
panel-reactive antibodies	T059	C1141951
frequencies	T079	C0439603
alloreactive	T039	C0301873
T cells	T025	C0039194
acute rejections	T033	C3273245
KTRs	T033	C4304779
KTRs	T033	C4304779
SOT	T061	C0029216
incidences	T081	C0021149
EBV viremia	T047	C1701919
PTLD	T191	C0432487
sepsis	T047	C0243026
death	T040	C0011065
sepsis	T047	C0243026
CMV-specific	T005	C0010825
cellular immunity	T040	C0020966
associated with	T080	C0332281
CMV	T005	C0010825
replication	T043	C0042774
KTRs	T033	C4304779
patient	T101	C0030705
allograft	T061	C0040739
outcomes	T080	C0085415
KTRs	T033	C4304779
SOT	T061	C0029216
KTRs	T033	C4304779
alloreactivity	T039	C0301873
allograft	T061	C0040739
outcomes	T080	C0085415
KTRs	T033	C4304779
SOT	T061	C0029216
infectious complications	T047	C0940933
overimmunosuppression	T047	C4048329
Improved	T033	C0184511
protocol	T170	C0442711
isolation	T059	C0220862
follicular dendritic cells	T025	C0242245
Follicular dendritic cells	T025	C0242245
FDCs	T025	C0242245
lymphoid organs	T023	C0502330
role	T077	C1705810
humoral immune response	T043	C1155229
isolation	T061	C0204727
FDCs	T025	C0242245
difficult	T080	C0332218
small	T081	C0700321
population size	T081	C0032683
fragility	T049	C0302113
mechanical	T070	C0038442
chemical stresses	T070	C1254365
genetic	T169	C0314603
biochemical	T169	C0205474
characteristics	T080	C1521970
FDCs	T025	C0242245
unclear	T033	C3845108
FDCs	T025	C0242245
ICAM-1(+)	T116	C0063695
cells	T025	C0007634
CD45	T116	C0054961
(-)	T033	C0205160
non-hematopoietic cell fraction	T026	C0805525
mouse spleen	T024	C1519474
cell separation	T059	C0007616
combination	T080	C0205195
enzymes	T116	C0014442
new	T080	C0205314
combination	T080	C0205195
enzymes	T116	C0014442
FDCs	T025	C0242245
CD45	T116	C0054961
(-)	T033	C0205160
ICAM-1(+)	T116	C0063695
CD21	T116	C0056184
35(+)	T116	C0009552
cell fraction	T026	C0805525
CD45	T116	C0054961
(-)	T033	C0205160
ICAM-1(+)	T116	C0063695
CD21	T116	C0056184
35(+)	T116	C0009552
cells	T025	C0007634
mouse spleen	T024	C1519474
antigen	T129	C0003320
in vivo	T082	C1515655
days	T079	C0439228
CD45	T116	C0054961
(-)	T033	C0205160
ICAM-1(+)	T116	C0063695
CD21	T116	C0056184
35(+)	T116	C0009552
cells	T025	C0007634
isolated	T169	C0205409
spleen of mice	T024	C1519474
cognate antigen	T129	C0003320
enhanced	T052	C2349975
survival	T043	C0007620
proliferation	T169	C1514485
antigen-specific B cells	T025	C0007634
in vitro	T080	C1533691
improved	T033	C0184511
protocol	T170	C0442711
isolation	T059	C0220862
FDCs	T025	C0242245
analysis	T062	C0936012
FDCs	T025	C0242245
in vitro	T080	C1533691
in vivo	T082	C1515655
Dental	T080	C0226984
enamel defects	T033	C2750331
German	T098	C1556085
medieval	T079	C0242321
early-modern-age	T079	C0242818
populations	T098	C1257890
Aim	T078	C1947946
study	T062	C2603343
investigate	T169	C1292732
frequency	T079	C0439603
type	T080	C0332307
developmental defects of enamel	T033	C2750331
DDE	T033	C2750331
medieval	T079	C0242321
early-modern-age	T079	C0242818
population	T098	C1257890
Thuringia, Germany	T083	C0017480
skeletons	T022	C0816871
subdivided	T169	C0332849
single	T081	C0205171
burials	T052	C0006407
individuals	T098	C0237401
buried	T052	C0006407
groups	T078	C0441833
examined	T033	C0332128
DDE	T033	C2750331
classified	T185	C0008902
teeth	T023	C0040426
DDE	T033	C2750331
index	T170	C0918012
Molar-incisor-hypomineralisation	T047	C2350038
MIH	T047	C2350038
type	T080	C0332307
DDE	T033	C2750331
recorded	T170	C0034869
European Academy of Paediatric Dentistry	T092	C0000877
EAPD	T092	C0000877
criteria	T078	C0243161
DDE	T033	C2750331
individuals	T098	C0237401
single	T081	C0205171
burials	T052	C0006407
group	T078	C0441833
burials	T052	C0006407
Hypoplastic	T169	C0543481
pits	T033	C1860853
frequent	T079	C0332183
defect	T169	C1457869
primary teeth	T023	C3266841
linear enamel hypoplasia	T047	C0011351
LEH	T047	C0011351
permanent teeth	T023	C1720362
individuals	T098	C0237401
hypomineralised	T047	C0085511
permanent tooth	T023	C0348070
MIH	T047	C2350038
permanent molar	T023	C0026367
permanent incisors	T023	C3161464
Second primary molars	T023	C0227108
affected	T169	C0392760
children	T100	C0008059
juveniles	T100	C3146221
individual	T098	C0237401
affected	T169	C0392760
molars	T023	C0026367
incisors	T023	C0021156
combination	T080	C0205195
Endogenous	T169	C0205227
factors	T169	C1521761
nutritional deficiencies	T047	C0162429
health problems	T033	C1398682
early	T079	C1279919
childhood	T079	C0231335
aetiological	T169	C1314792
reasons	T078	C0392360
DDE	T033	C2750331
MIH	T047	C2350038
frequency	T079	C0439603
DDE	T033	C2750331
MIH	T047	C2350038
masked	T062	C0150108
extended	T082	C0231449
carious lesions	T047	C0011334
dental wear	T037	C2717979
ante-mortem	T033	C0243095
tooth loss	T020	C0080233
Breast Cancer	T191	C0006142
Detection Rate	T081	C0392762
Incidence	T081	C0021149
Prevalence	T081	C0220900
Interval	T079	C1272706
Cancer	T191	C0006826
Mammography Screening	T061	C0203028
Times	T079	C0040223
Thai	T098	C0337910
Women	T098	C0043210
guideline	T170	C0162791
American Cancer Society	T094	C0002455
mammography	T060	C0024671
MMG	T060	C0024671
women	T098	C0043210
Thailand	T083	C0039725
opportunistic mammography screening	T058	C0422389
limited	T169	C0439801
data	T078	C1511726
incidence	T081	C0021149
breast cancer	T191	C0006142
study	T062	C0008972
estimate	T081	C0750572
breast cancer	T191	C0006142
detection	T058	C1516193
incident	T067	C1551358
prevalence rates	T081	C0220900
Thai	T098	C0337910
women	T098	C0043210
opportunistic mammography screening	T058	C0422389
women	T098	C0043210
years	T079	C0439234
procedure	T058	C0220908
detection rate	T081	C0392762
observation	T062	C0302523
number	T081	C0237753
women	T098	C0043210
positive findings	T033	C0586815
total number	T081	C4288115
women	T098	C0043210
screened	T060	C0199230
incidence rate	T081	C1708485
calculated	T169	C0444686
MMG	T060	C0024671
detected	T033	C0442726
MMG	T060	C0024671
women	T098	C0043210
MMGs	T060	C0024671
person	T098	C0027361
duration	T079	C0449238
interval	T079	C1272706
years	T079	C0439234
breast cancer	T191	C0006142
detected	T033	C0442726
women	T098	C0043210
detection rate	T081	C0392762
persons	T098	C0027361
prevalence rate	T081	C0220900
breast cancer	T191	C0006142
person	T098	C0027361
incidence	T081	C0021149
detected	T033	C0442726
person	T098	C0027361
interval	T079	C1272706
women	T098	C0043210
detected	T033	C0442726
MMG	T060	C0024671
women	T098	C0043210
Opportunistic mammography screening	T058	C0422389
Thailand	T083	C0039725
detected	T033	C0442726
breast cancer	T191	C0006142
women	T098	C0043210
cancer detection	T058	C1516193
interval	T079	C1272706
screening mammogram	T061	C0203028
groundwater	T082	C0596631
vulnerability	T080	C0332157
Daule aquifer	T070	C3178977
Ecuador	T083	C0013593
susceptibility index method	T059	C0871511
Guayas region	T083	C0017446
Ecuador	T083	C0013593
national crops	T002	C0242775
agricultural activities	T090	C0001829
groundwater	T082	C0596631
nitrate	T197	C0699857
contamination	T078	C2349974
fertiliser	T073	C0015919
water	T121	C0043047
needs	T080	C0027552
susceptibility index assessment method	T059	C0871511
agricultural activities	T090	C0001829
groundwater	T082	C0596631
quality	T080	C0332306
aquifer	T070	C3178977
Guayas	T083	C0017446
river basin	T082	C0205146
Ecuador	T083	C0013593
DRASTIC method	T059	C0871511
land use	UnknownType	C0814835
areas	T082	C0205146
highly	T080	C0205250
vulnerable	T080	C0332157
contamination	T078	C2349974
irrigation	T068	C2936278
perimeters	T082	C1295726
paddy fields	T082	C0562975
alluvial deposits	T197	C0055863
moderately	T080	C0205081
vulnerable	T080	C0332157
low	T080	C0205251
vulnerability	T080	C0332157
areas	T082	C0205146
aquatic environments	T067	C0563034
forests	T070	C0086312
semi-natural zones	T082	C1710706
water bodies	T067	C2584335
Daule aquifer	T070	C3178977
vulnerability	T080	C0332157
wide	T082	C0332464
flat topography	T082	C0870781
aquifer	T070	C3178977
high risk of contamination	T033	C4060526
nitrates	T197	C0699857
good	T080	C0205170
agricultural practices	T090	C0001829
monitoring network to control	T033	C0243095
nitrates	T197	C0699857
concentrations	T081	C1446561
groundwater	T082	C0596631
quality	T080	C0332306
drinking	T167	C0599638
purposes	T169	C1285529
Heterogeneous	T080	C0019409
depression	T048	C0011570
trajectories	T079	C1254367
multiple sclerosis	T047	C0026769
patients	T101	C0030705
Trajectories	T079	C1254367
depression	T048	C0011570
heterogeneous	T080	C0019409
Multiple Sclerosis	T047	C0026769
MS	T047	C0026769
patients	T101	C0030705
trajectories	T079	C1254367
clinicians	T097	C0871685
progression	T169	C0449258
depression	T048	C0011570
MS	T047	C0026769
patients	T101	C0030705
Latent class growth analysis	T062	C0681947
LCGA	T062	C0681947
MS	T047	C0026769
patients	T101	C0030705
electronic health records (EHR) data base	T170	C2362543
subgroups	T098	C1257890
MS	T047	C0026769
patients	T101	C0030705
depression screening	T061	C0740218
PHQ-9	T170	C1718207
Latent	T080	C0205275
trajectory	T079	C1254367
group	T098	C1257890
baseline	T081	C1442488
clinical characteristics	T201	C0683325
subgroups	T098	C1257890
high	T080	C0205250
participants	T098	C0679646
moderate	T080	C0205081
low	T080	C0205251
variable	T080	C0439828
depression level	T033	C1319226
trajectories	T079	C1254367
subpopulation	T098	C1257890
trajectories	T079	C1254367
high	T080	C0205250
moderate	T080	C0205081
low	T080	C0205251
MS	T047	C0026769
disability	T033	C0231170
baseline	T081	C1442488
trajectory	T079	C1254367
moderate	T080	C0205081
depression	T048	C0011570
threshold	T080	C0449864
LCGA	T062	C0681947
MS	T047	C0026769
patients	T101	C0030705
template	T078	C1705542
EHR data base	T170	C2362543
heterogeneous	T080	C0019409
depression screening	T061	C0740218
trajectories	T079	C1254367
Clinicians	T097	C0871685
information	T078	C1533716
monitor patients	T058	C0030695
high	T080	C0205250
unstable	T033	C0443343
depression levels	T033	C1319226
PLA2 gene	T028	C0017337
humoral immune responses	T043	C1155229
Bactrocera dorsalis (Hendel)	T204	C1001509
phospholipase A2 (PLA2) gene	T028	C0017337
encodes	T052	C2700640
enzyme	T116	C0014442
catalyzes	T169	C0205245
hydrolysis	T070	C0020291
phospholipids	T109	C0031676
PLs	T109	C0031676
sn-2 position	T082	C0733755
role	T170	C1704326
humoral immune responses	T043	C1155229
study	T062	C2603343
investigated	T169	C1292732
expression profile	T081	C1956267
PLA2	T028	C0017337
different	T080	C1705242
tissues	T024	C0040300
developmental stages	T079	C0870411
Bactrocera dorsalis (Hendel)	T204	C1001509
transcriptional	T045	C0040649
level	T080	C0441889
PLA2	T028	C0017337
high	T080	C0205250
egg	T042	C1254358
mature stage	T042	C1326793
testis	T023	C0039597
tissue	T024	C0040300
Bacterial infection	T047	C0004623
expression	T045	C0017262
PLA2	T028	C0017337
up-regulation	T044	C0041904
fat body	T023	C0015665
Silencing	T045	C0598496
PLA2	T028	C0017337
influenced	T077	C4054723
expression	T045	C0017262
immune-related genes	T028	C0017337
MyD88	T028	C1417530
defensin	T116	C0057256
Toll pathway	T044	C1155478
relish	T116	C0033684
diptericin	T116	C0033684
Imd pathway	T077	C2753278
expression	T045	C0017262
MyD88	T028	C1417530
defensin	T116	C0057256
down-regulated	T044	C0013081
ds-PLA2	T028	C0017337
group	T078	C0441833
ds-egfp	T116	C1258415
group	T078	C0441833
B. dorsalis	T204	C1001509
infected	T033	C0439663
L. monocytogenes	T007	C0023861
S. aureus	T007	C0038172
PLA2	T028	C0017337
activation	T045	C0017255
Toll pathway	T044	C1155478
infection	T046	C3714514
L. monocytogenes	T007	C0023861
E. coli	T007	C0014834
activate	T169	C1515877
Imd pathway	T077	C2753278
increase	T169	C0442805
mRNA	T114	C0035696
levels	T080	C0441889
relish	T116	C0033684
diptericin	T116	C0033684
ds-PLA2	T028	C0017337
group	T078	C0441833
increases	T169	C0442805
ds-egfp	T116	C1258415
group	T078	C0441833
Imd pathway	T077	C2753278
repressed	T169	C0205245
silencing	T045	C0598496
PLA2	T028	C0017337
development	T169	C1527148
lipid droplets	T026	C0230704
fat body	T023	C0015665
cells	T025	C0007634
influenced	T077	C4054723
silencing	T045	C0598496
PLA2	T028	C0017337
PLA2	T028	C0017337
function	T169	C0542341
fat body	T023	C0015665
tissue	T024	C0040300
PLA2	T028	C0017337
PLA2 gene	T028	C0017337
humoral immune responses	T043	C1155229
reducing	T080	C0392756
lipid storage	T043	C1159705
fat body	T023	C0015665
cells	T025	C0007634
B. dorsalis	T204	C1001509
Gambling disorders	T048	C0030662
gambling	T055	C0016995
psychiatric	T169	C0205487
comorbidity	T078	C0009488
Thai general population	T098	C0337910
National Mental Health Survey	T170	C3481515
prevalence	T081	C0033105
problem	T048	C0850474
pathological gambling	T048	C0030662
gender	T032	C0079399
age-group	T100	C0027362
gambling types	T055	C0016995
comorbidities	T078	C0009488
psychiatric disorders	T048	C0004936
Thai general population	T098	C0337910
participants	T098	C0679646
Thailand's	T083	C0039725
National Mental Health Survey	T170	C3481515
multistage stratified cluster survey	T170	C0038951
Composite International Diagnostic Interview	T170	C0451085
Diagnoses	T033	C0011900
problem	T048	C0850474
pathological gambling	T048	C0030662
psychiatric disorders	T048	C0004936
DSM-IV-TR criteria	T170	C0220952
criteria	T078	C0243161
gamblers	T055	C0858352
lifetime	T079	C4071830
single year loss	T081	C1517945
USD	T081	C0562019
gambling	T055	C0016995
lifetime	T079	C4071830
prevalence rates	T081	C0033105
pathological	T048	C0030662
problem gambling	T048	C0850474
confidence interval	T081	C0009667
CI	T081	C0009667
CI	T081	C0009667
gambling	T055	C0016995
playing lotteries	T055	C0018464
standard error	T081	C1710181
SE	T081	C1710181
prevalence	T081	C0033105
females	T032	C0086287
older age groups	T098	C0001792
psychiatric disorders	T048	C0004936
pathological gamblers	T048	C0030662
alcohol abuse	T048	C0085762
nicotine dependence	T048	C0028043
drug use disorder	T048	C0013222
Pathological gambling	T048	C0030662
major depressive episodes	T048	C0024517
drug dependence	T048	C1510472
intermittent explosive disorder	T048	C0021776
pathological gambling	T048	C0030662
major depressive episode	T048	C0024517
adjusted odds ratio	T081	C0028873
AOR	T081	C0028873
CI	T081	C0009667
recognition	T041	C0524637
gambling disorders	T048	C0030662
public health	T170	C3244304
Thailand	T083	C0039725
culturally	T169	C0220814
preventive	T080	C1456501
pathological gamblers	T048	C0030662
substance use disorders	T048	C0038586
major depression	T048	C1269683
Synovial sarcoma	T191	C0039101
hypopharynx	T029	C0020629
pediatric	T080	C1521725
patient	T101	C0030705
Case report	T170	C0085973
Synovial sarcoma	T191	C0039101
SS	T191	C0039101
soft tissue	T024	C0225317
sarcoma	T191	C1261473
head and neck sarcomas	T191	C1827431
SS	T191	C0039101
Head	T029	C0018670
Neck	T029	C0027530
pediatric	T080	C1521725
population	T098	C1257890
SS	T191	C0039101
rare	T080	C0522498
head & neck malignancy	T191	C1827431
boy	T100	C0870221
diagnosed	T033	C0011900
SS	T191	C0039101
hypopharynx	T029	C0020629
treated by	T061	C0332293
surgical excision	T061	C0728940
post operative	T033	C0241311
radio	T061	C1522449
chemotherapy	T061	C3665472
anatomical location	T029	C0923870
functional	T169	C0205245
challenges	T058	C0805586
swallowing	T040	C0011167
phonation	T042	C0031577
respiration	T039	C0035203
pediatric	T080	C1521725
population	T098	C1257890
Pre-operative	T079	C0445204
post-operative	T033	C0241311
histopathological	T169	C0243140
diagnosis	T033	C0011900
SS	T191	C0039101
Optimal	T080	C2698651
treatment	T061	C0087111
Head	T029	C0018670
Neck	T029	C0027530
SS	T191	C0039101
functional	T169	C0205245
oncologic	T091	C0205478
aspects	T080	C1879746
SS	T191	C0039101
rare	T080	C0522498
head & neck malignancy	T191	C1827431
pediatric	T080	C1521725
population	T098	C1257890
multifaceted	T082	C0205291
challenges	T058	C0805586
post-operative	T033	C0241311
histopathological	T169	C0243140
diagnosis	T033	C0011900
optimal	T080	C2698651
modality	T078	C0695347
treatment	T061	C0087111
Clinical judgment	T170	C0237512
pediatric	T080	C1521725
population	T098	C1257890
tumor free margins	T034	C0332648
organ preservation	T061	C0029209
head	T029	C0018670
neck	T029	C0027530
region	T029	C0005898
Ocular hypotensive	T047	C0028841
effect	T080	C1280500
EP3	T116	C1449580
FP	T116	C0662784
agonist	T121	C2987634
ONO-9054	T109	C4277062
Xalatan	T109	C0593887
day	T079	C0439228
double-masked	T062	C0013072
randomised	T080	C0439605
study	T062	C2603343
ONO-9054	T109	C4277062
reduction	T080	C0392756
intraocular pressure	T042	C0021888
IOP	T042	C0021888
patients	T101	C0030705
ocular hypertension	T047	C0028841
OHT	T047	C0028841
open-angle glaucoma	T047	C0017612
OAG	T047	C0017612
study	T062	C2603343
EP3	T116	C1449580
FP	T116	C0662784
agonist	T121	C2987634
ONO-9054	T109	C4277062
FP	T116	C0662784
agonist	T121	C2987634
Xalatan	T109	C0593887
Adults	T100	C0001675
OAG	T047	C0017612
OHT	T047	C0028841
IOP	T042	C0021888
ONO-9054	T109	C4277062
Xalatan	T109	C0593887
daily	T079	C0332173
days	T079	C0439228
Day	T079	C0439228
IOP	T042	C0021888
ONO-9054	T109	C4277062
Xalatan	T109	C0593887
IOPs	T042	C0021888
decrease	T081	C0547047
IOP	T042	C0021888
ONO-9054	T109	C4277062
day	T079	C0439228
IOP	T042	C0021888
reduction	T080	C0392756
ONO-9054	T109	C4277062
Xalatan	T109	C0593887
post hoc analyses	T062	C0936012
IOPs	T042	C0021888
day	T079	C0439228
ONO-9054	T109	C4277062
Xalatan	T109	C0593887
IOP	T042	C0021888
ONO-9054	T109	C4277062
Xalatan	T109	C0593887
post hoc analysis	T062	C0936012
ONO-9054	T109	C4277062
IOP	T042	C0021888
IOPs	T042	C0021888
Xalatan	T109	C0593887
ONO-9054	T109	C4277062
IOP	T042	C0021888
Xalatan	T109	C0593887
Whole-body strength training	T061	C0872279
Huber Motion Lab	T073	C0014672
traditional strength training	T061	C0872279
cardiac rehabilitation	T061	C0700431
randomized controlled study	T062	C0681867
Isometric strengthening	T061	C0022206
patients	T101	C0030705
coronary heart disease	T047	C0010068
CHD	T047	C0010068
potential side effects	T046	C0879626
lack	T080	C0332268
appropriate	T080	C1548787
reliable	T170	C3858758
devices	T073	C0699733
modes	T169	C1513371
resistance training	T061	C0872279
mode	T169	C1513371
Huber Motion Lab	T073	C0014672
HML	T073	C0014672
traditional strength training	T061	C0872279
TST	T061	C0872279
CHD	T047	C0010068
patients	T101	C0030705
cardiac rehabilitation	T061	C0700431
patients	T101	C0030705
HML	T073	C0014672
TST	T061	C0872279
Patients	T101	C0030705
blinded	T062	C0150108
evaluation	T058	C0220825
rehabilitation program	T061	C0034991
testing for cardiopulmonary exercise	T060	C2959886
maximal isometric voluntary contraction	T060	C0430022
endothelial	T024	C0014257
function	T042	C1254358
body composition	T032	C0005885
weeks	T079	C0439230
training	T065	C0220931
groups	T078	C0441833
body composition	T032	C0005885
anthropometric	T062	C0003188
characteristics	T080	C1521970
endothelial	T024	C0014257
function	T042	C1254358
HML	T073	C0014672
peak	T080	C0444505
power output	T070	C0445194
maximal	T080	C0205289
heart rate	T201	C0018810
gain	T081	C1517378
force	T067	C0441722
measured	T080	C0444706
greater	T081	C1704243
training	T056	C0015259
protocols	T170	C2348563
CHD	T047	C0010068
patients	T101	C0030705
training protocol	T170	C2348563
isometric contractions	T042	C0022205
passive	T080	C3686820
recovery	T040	C2004454
HML	T073	C0014672
rehabilitation programs	T061	C0034991
patients	T101	C0030705
CHD	T047	C0010068
functional outcomes	T080	C0205556
Percutaneous coronary intervention	T061	C1532338
heart surgery	T061	C0018821
learning	T041	C0023185
needs of patients	T169	C0686904
Jordan	T083	C0022418
prioritize	T079	C0549179
perceived	T041	C0030971
learning	T041	C0023185
needs of patients	T169	C0686904
percutaneous coronary intervention	T061	C1532338
open-heart surgery	T061	C0189745
learning	T041	C0023185
post-cardiac intervention	T061	C0184661
patients	T101	C0030705
health education programmes	T058	C0679897
patient	T101	C0030705
central care	T058	C1279810
design	T052	C1707689
convenience	T080	C3831015
sample	T098	C1257890
patients	T101	C0030705
percutaneous coronary intervention	T061	C1532338
patients	T101	C0030705
open-heart surgery	T061	C0189745
patients	T101	C0030705
Participants	T098	C0679646
Patient	T101	C0030705
Learning Needs Scale	T170	C0282574
Data	T078	C1511726
Patients	T101	C0030705
groups	T078	C0441833
health and recovery related information	T058	C0846605
learning need	T041	C0023185
topics	T170	C1555712
priority	T079	C0549179
learning	T041	C0023185
patient groups	T101	C0030705
information	T078	C1533716
wound care	T061	C0886052
priority	T079	C0549179
learning	T041	C0023185
topic	T170	C1555712
physical activity	T056	C0026606
learning	T041	C0023185
needs	T080	C0027552
groups	T078	C0441833
educational secondary prevention programmes	T170	C0679717
patients	T101	C0030705
headings	T170	C0038545
needs	T080	C0027552
cardiac	T023	C0018787
interventional procedure	T061	C0184661
wound care	T061	C0886052
medications	T058	C2081612
learning	T041	C0023185
needs	T080	C0027552
patients	T101	C0030705
health policy	T089	C0018735
decision makers	T097	C0242170
topics	T170	C1555712
time	T079	C0040223
hospital discharge	T058	C0586003
policy	T089	C0018735
patients	T101	C0030705
learning	T041	C0023185
needs	T080	C0027552
establishment	T073	C0442594
managerial support	T054	C0037438
patients	T101	C0030705
learning	T041	C0023185
needs	T080	C0027552
discharge	T058	C0586003
health services	T058	C0018747
support	T054	C0037438
patients	T101	C0030705
hospital discharge	T058	C0586003
Secondary prevention programmes	T170	C0679717
health education	T065	C0018701
topics	T170	C1555712
patients	T101	C0030705
priority	T079	C0549179
patients' needs	T169	C0686904
patients	T101	C0030705
information	T078	C1533716
needs	T080	C0027552
learning	T041	C0023185
environment	T082	C0014406
patients	T101	C0030705
families	T099	C0015576
Complications	T046	C0009566
Events	T051	C0441471
Hepatectomy	T061	C0019144
Living-Related Liver Donation	T061	C1318453
Italian	T083	C0022277
Single Center	T073	C0475309
Report	T170	C0684224
Cases	T169	C0868928
healthy	T080	C3898900
individuals	T098	C0237401
liver living donors	T098	C0348050
complications	T046	C0009566
surgery	T061	C0543467
complications	T046	C0009566
living donor	T098	C0348050
management	T057	C1273870
safety	T068	C0036043
retrospective study	T062	C0035363
database	T170	C0242356
analysis	T062	C0936012
perioperative	T079	C1518988
medium-term	T079	C1254367
long-term	T079	C0443252
complications	T046	C0009566
events	T051	C0441471
single center	T073	C0475309
liver resections	T061	C0019144
adult	T100	C0001675
adult	T100	C0001675
living-donor	T098	C0348050
liver transplantation	T061	C0023911
living donors	T098	C0348050
surgery	T061	C0543467
No	T033	C1513916
living donor	T098	C0348050
mortality	T081	C0178686
patients	T101	C0030705
complication	T046	C0009566
patients	T101	C0030705
mild	T080	C2945599
long-term	T079	C0443252
dysfunction	T077	C3887504
hepatectomies	T061	C0019144
events	T051	C0441471
strategy	T041	C0679199
assessment	T058	C0220825
living donor	T098	C0348050
complications	T046	C0009566
selection	T052	C1707391
center	T073	C0475309
patient outcome	T078	C1547647
reports	T170	C0684224
Tooth wear	T037	C2717979
quantify	T081	C1709793
intra-specific	T080	C0205369
variations	T080	C0205419
diet	T168	C0012155
chewing	T042	C0024888
movements	T040	C0026649
mammals	T015	C0024660
tooth	T023	C0040426
function	T169	C0542341
efficiency	T081	C0013682
mechanical	T070	C0376706
properties	T080	C0871161
food	T168	C0016452
chewing	T042	C0024888
dynamics	T169	C0729333
aspects	T080	C1879746
studied	T062	C2603343
intra-specific	T080	C0205369
3D	T082	C0450363
dental	T023	C1550246
surface	T082	C0205148
texture	T080	C0449582
analysis	T062	C0936012
sample	T077	C2347026
field voles	T015	C0042947
Microtus agrestis	T015	C1002449
Finnish Lapland	T083	C0016132
seasons	T079	C0036497
localities	T083	C2828208
test	T169	C0039593
inter-population	T098	C1257890
variations	T080	C0205419
intra-individual	T098	C1257890
variation	T080	C0205419
chewing	T042	C0024888
dynamics	T169	C0729333
analysing	T062	C0936012
facets	T082	C0205148
second upper molars	T023	C4082818
results	T033	C0683954
localities	T083	C2828208
environments	T082	C0014406
voles	T015	C0042947
feed	T052	C2987508
texture	T080	C0449582
data	T078	C1511726
diets	T168	C0012155
variable	T080	C0439828
concentrations	T081	C1446561
abrasives	T120	C0450125
textures	T080	C0449582
buccal facets	T029	C1540415
isotropic	T067	C1882365
direction	T082	C0449738
deviates	T082	C0012727
mesial	T029	C1708982
chewing	T042	C0024888
direction	T082	C0449738
lingual	T023	C0040408
facets	T082	C0205148
interpret	T169	C1285553
results	T033	C0683954
food	T168	C0016452
chewing	T042	C0024888
movements	T040	C0026649
food particles	T168	C0311119
lingual	T023	C0040408
molars	T023	C0026367
dental microwear	T037	C2717979
analysis	T062	C0936012
fossils	T167	C0016614
homologous	T032	C0301883
facets	T082	C0205148
molar	T023	C0026367
functional unit	T169	C0205245
Human cathelicidin LL-37	T116	C3891304
antibiofilm effect	T033	C0243095
EGCG	T109	C0059438
Streptococcus mutans	T007	C0038409
Streptococcus mutans	T007	C0038409
biofilms	T007	C0081786
resistance	T169	C4281815
mechanism	T169	C0441712
antimicrobial agents	T121	C1136254
human	T016	C0086418
oral cavity	T030	C0226896
human cathelicidin LL-37	T116	C3891304
inhibitory effects	T080	C1280500
biofilm formation	T043	C1325881
S. mutans	T007	C0038409
interaction	T169	C1704675
lipoteichoic acid	T109	C0065067
LTA	T109	C0065067
antibacterial	T033	C0243095
biofilm	T007	C0081786
dispersal abilities	T082	C0332624
(-)-Epigallocatechin gallate	T109	C0059438
EGCG	T109	C0059438
tea	T168	C0039400
catechins	T109	C0007404
anti-infective potential	T033	C0243095
inhibit the growth	T040	C2249823
microorganisms	T001	C0445623
biofilm formation	T043	C1325881
evaluated	T058	C0220825
LL-37	T116	C3891304
EGCG	T109	C0059438
antibiofilm effect	T033	C0243095
EGCG	T109	C0059438
S. mutans	T007	C0038409
biofilm formation	T043	C1325881
S. mutans	T007	C0038409
strains	T001	C1518614
children's	T100	C0008059
saliva	T031	C0036087
tested	T169	C0039593
biofilm formation	T043	C1325881
assay	T059	C0005507
antibiofilm effect	T033	C0243095
EGCG	T109	C0059438
LL-37	T116	C3891304
analyzed	T062	C0936012
biofilm	T007	C0081786
eradication	T080	C2700409
concentration	T081	C1446561
assay	T059	C0005507
emission-scanning electron microscopy	T059	C0026020
interaction	T169	C1704675
EGCG	T109	C0059438
LL-37	T116	C3891304
LTA	T109	C0065067
S. mutans	T007	C0038409
quartz crystal microbalance analysis	T062	C2936414
EGCG	T109	C0059438
planktonic	T007	C0032071
S. mutans	T007	C0038409
biofilm formation	T043	C1325881
bacteria cells	T007	C0004611
biofilms	T007	C0081786
concentration	T081	C1446561
EGCG	T109	C0059438
LTA	T109	C0065067
LL-37	T116	C3891304
bactericidal activity	T039	C0544570
EGCG	T109	C0059438
biofilm formation	T043	C1325881
biofilms	T007	C0081786
quantitative	T081	C0392762
crystal violet	T109	C0017440
staining	T059	C0487602
emission-scanning electron microscopy	T059	C0026020
quartz crystal microbalance analysis	T062	C2936414
LL-37	T116	C3891304
interacted	T169	C1704675
EGCG	T109	C0059438
binding	T044	C1167622
EGCG	T109	C0059438
LTA	T109	C0065067
S. mutans	T007	C0038409
LL-37	T116	C3891304
antibiofilm effect	T033	C0243095
EGCG	T109	C0059438
S. mutans	T007	C0038409
dental treatment	T061	C0011331
LL-37	T116	C3891304
antibiofilm compound	T121	C1254351
Discovery	T052	C1880355
Orally	T030	C0226896
Efficacious	T080	C1704419
Phosphoinositide-3-Kinase delta	T116	C1450115
Inhibitors	T121	C0014432
Improved	T033	C0184511
Metabolic	T169	C0311400
Stability	T080	C0205360
Aberrant signaling	T038	C3537152
phosphoinositide-3-kinase delta	T116	C1450115
PI3K-delta	T116	C1450115
pathologies	T046	C0677042
hematological malignancies	T191	C0376545
rheumatoid arthritis	T047	C0003873
discovery	T052	C1880355
optimization	T052	C2698650
in vivo	T082	C1515655
evaluation	T058	C0220825
pyridine-containing	T109	C0576798
PI3K-delta	T116	C1450115
inhibitors	T121	C0014432
discovery	T052	C1880355
35	T121	C1254351
inhibitor	T121	C0014432
PI3K-delta	T116	C1450115
pharmacokinetic profile	T169	C0031328
efficacious	T080	C1704419
rodent model	T050	C1519106
rheumatoid arthritis	T047	C0003873
Mobile phone	T073	C1136360
use	T169	C0457083
behavioural problems	T048	C0233514
concentration	T041	C0086045
capacity	T081	C1516240
adolescents	T100	C0205653
prospective study	T062	C0033522
study	T062	C2603343
investigate	T169	C1292732
exposure to	T080	C0332157
radiofrequency electromagnetic fields	T070	C0013835
RF-EMF	T070	C0013835
mobile phones	T073	C1136360
wireless communication devices	T073	C3825042
behavioural problems	T048	C0233514
concentration	T041	C0086045
capacity	T081	C1516240
adolescents	T100	C0205653
HERMES	T062	C0681814
Health	T078	C0018684
Effects	T080	C1280500
Related	T080	C0439849
Mobile phonE	T073	C1136360
adolescentS	T100	C0205653
sample	T096	C0681850
Swiss	T098	C0241315
adolescents	T100	C0205653
aged	T032	C0001779
years	T079	C0439234
Behavioural problems	T048	C0233514
assessed	T052	C1516048
Strengths and Difficulties Questionnaire	T170	C3472494
SDQ	T170	C3472494
concentration	T041	C0086045
capacity	T081	C1516240
adolescents	T100	C0205653
measured	T080	C0444706
standardized computerized cognitive test	T170	C0237892
FAKT	T170	C0282574
Cross-sectional	T062	C0010362
longitudinal	T062	C0023981
1year	T079	C0439234
follow-up	T033	C0589120
analyses	T062	C0936012
performed	T169	C0884358
investigate	T169	C1292732
associations	T080	C0439849
behavioural problems	T048	C0233514
concentration	T041	C0086045
capacity	T081	C1516240
different	T080	C1705242
exposure	T080	C0332157
measures	T081	C0079809
self-reported	T062	C2700446
operator	T097	C0335223
wireless communication device	T073	C3825042
cumulative	T080	C1511559
RF-EMF	T070	C0013835
brain	T023	C0006104
whole body	T017	C0444584
measured	T080	C0444706
RF-EMF	T070	C0013835
exposure	T080	C0332157
cross-sectional analyses	T062	C0010362
behavioural problems	T048	C0233514
associated with	T080	C0332281
self-reported	T170	C0684224
wireless device	T073	C0699733
use	T169	C0457083
measures	T081	C0079809
operator	T097	C0335223
mobile phone	T073	C1136360
use	T169	C0457083
measures	T081	C0079809
concentration	T041	C0086045
capacity	T081	C1516240
associated with	T080	C0332281
self-reported	T062	C2700446
operator	T097	C0335223
exposures	T080	C0332157
longitudinal analyses	T062	C0023981
absence	T169	C0332197
associations	T080	C0439849
lack	T080	C0332268
consistent	T078	C0332290
exposure	T080	C0332157
patterns	T082	C0449774
longitudinal analyses	T062	C0023981
behavioural problems	T048	C0233514
concentration	T041	C0086045
capacity	T081	C1516240
affected	T169	C0392760
wireless communication devices	T073	C3825042
RF-EMF	T070	C0013835
exposure	T080	C0332157
Information	T078	C1533716
bias	T078	C0242568
explanations	T170	C0681841
cross-sectional findings	T062	C0010362
Twisting method	T169	C0449851
reducing	T080	C0392756
friction	T070	C0162691
insertion	T061	C0021107
sheath	T074	C1299426
introducer	T074	C0179695
sheathless guiding catheter	T074	C0221799
sheathless system	T169	C0449913
inserts	T058	C0441587
catheter	T074	C0179724
directly	T080	C1947931
artery	T023	C0003842
reduce	T080	C0392756
puncture	T067	C1881711
site	T082	C0230992
complications	T046	C0274317
2-Fr reduction	T080	C0332519
outer diameter	T082	C4086674
gap	T082	C3887622
dilator	T074	C0180431
guiding catheter	T074	C0221799
sheathless system	T169	C0449913
larger	T081	C0549177
gap	T082	C3887622
dilator	T074	C0180431
sheath	T074	C1299426
introducer system	T074	C0179695
insertion	T061	C0021107
resistance	T067	C1880315
twisting method	T169	C0449851
rapid	T080	C0456962
alternating	T169	C0332270
rotation	T169	C0035868
device	T074	C0025080
insertion	T061	C0021107
insertion	T061	C0021107
reduce	T080	C0392756
insertion	T061	C0021107
resistance	T067	C1880315
effective	T080	C1704419
sheathless system	T169	C0449913
larger	T081	C0549177
gap	T082	C3887622
effect of	T080	C1704420
size	T082	C0456389
reduction	T080	C0332519
sheathless system	T169	C0449913
effect of	T080	C1704420
insertion	T061	C0021107
resistance	T067	C1880315
reduction	T080	C0392756
twisting method	T169	C0449851
insertion	T061	C0021107
simulator	T074	C0183309
compared	T052	C1707455
insertion	T061	C0021107
resistance	T067	C1880315
5-Fr sheath	T074	C1299426
introducer	T074	C0179695
5-Fr sheathless system	T169	C0449913
twisting method	T169	C0449851
insertion	T061	C0021107
simulator	T074	C0183309
sheath	T074	C1299426
introducer	T074	C0179695
sheathless system	T169	C0449913
mock	T033	C0562577
artery	T023	C0003842
5-mm urethane	T074	C2721056
1-mm rubber sheet	T074	C0183069
electrical motor	T073	C1705994
twisting	T169	C0449851
motion	T070	C0026597
crank shaft	T073	C1705197
Insertion	T061	C0021107
resistance	T067	C1880315
penetration	T169	C0205321
measured	T080	C0444706
tension meter	T074	C1706378
insertion	T061	C0021107
resistance	T067	C1880315
5-Fr sheathless system	T169	C0449913
5-Fr sheath	T074	C1299426
introducer	T074	C0179695
resistance	T067	C1880315
reduced	T080	C0392756
twisting	T169	C0449851
sheathed	T074	C0179724
sheathless catheters	T074	C0179724
conclusion	T078	C1707478
benefits	T081	C0814225
twisting	T169	C0449851
insertion	T061	C0021107
sheathless guiding catheter	T074	C0221799
reduction	T080	C0392756
puncture	T067	C1881711
site	T082	C0230992
complications	T046	C0274317
Unconventional	T080	C2700116
Protein Secretion	T043	C1159339
Plants	T002	C0032098
Unconventional	T080	C2700116
protein secretion	T043	C1159339
UPS	T043	C1159339
describes	T078	C1552738
secretion pathways	T043	C1159342
several	T081	C0443302
canonical	T081	C0870245
secretion	T038	C0036536
plasma membrane	T026	C0007603
involve	T169	C1314939
secretion	T038	C0036536
proteins	T116	C0033684
alternatives	T077	C1523987
conventional	T080	C3538928
secretion	T038	C0036536
primarily	T080	C0205225
observed	T169	C1441672
studied	T062	C0008972
yeast	T004	C0043393
animal cells	T025	C0007634
sessile	T080	C0205348
plants	T002	C0032098
unique	T080	C1710548
adapt to adverse conditions	T040	C0001400
environmental challenges	T082	C0557737
attention	T041	C0004268
unconventional	T080	C2700116
secretion pathways	T043	C1159342
plant cells	T025	C3178867
proteins	T116	C0033684
identified	T080	C0205396
proteomic studies	T091	C0872252
UPS	T043	C1159339
pathways	T077	C1705987
plants	T002	C0032098
induction	T169	C0205263
UPS	T043	C1159339
pathways	T077	C1705987
correlated	T080	C1707520
pathogenesis	T046	C0699748
stress responses	T039	C2350025
UPS	T043	C1159339
comprehensively	T080	C1880156
organizing	T169	C1300196
proteins	T116	C0033684
apoplast	T026	C1325756
UPS	T043	C1159339
establishment	T080	C0443211
collection	T169	C1516698
plant proteins	T116	C0032089
UPS	T043	C1159339
pathways	T077	C1705987
endomembrane	T026	C1167315
trafficking	T043	C0599896
several	T081	C0443302
novel	T080	C0205314
enabling	T041	C1171285
technologies	T090	C0039421
vesicle	T026	C1622418
proteomics	T091	C0872252
chemical	T103	C0220806
genomics	T091	C0887950
potential	T080	C3245505
dissecting	T169	C0205239
secretion pathways	T043	C1159342
providing	T052	C1999230
information	T078	C1533716
induce	T169	C0205263
Neospora caninum	T204	C0242906
Axis Deer	T015	C0999597
Axis axis	T015	C0325211
Fallow Deer	T015	C0325214
Dama dama	T015	C0325214
Northern	T082	C1709269
Mexico	T083	C0025885
Serum samples	T031	C1550100
axis deer	T015	C0999597
Axis axis	T015	C0325211
fallow deer	T015	C0325214
Dama dama	T015	C0325214
enzyme-linked immunosorbent assay	T059	C0014441
Neospora caninum antibodies	T116	C0807090
axis	T015	C0325211
fallow deer	T015	C0325214
positive	T033	C1514241
N. caninum antibodies	T116	C0807090
ABBA study	T062	C2603343
bulimia nervosa	T048	C2267227
binge eating disorder	T048	C0596170
randomised controlled trial	T062	C0206035
symptoms	T184	C1457887
bulimia nervosa	T048	C2267227
BN	T048	C2267227
binge eating disorder	T048	C0596170
BED	T048	C0596170
recurrent episodes of binge eating	T033	C1843777
negative psychological	T048	C1306597
physical consequences	T033	C1446390
BN/BED	T048	C0013473
patients	T101	C0030705
tendencies towards food	T040	C0003618
cognitive bias	T078	C0237494
information processing	T041	C0700301
Cognitive bias modification	T061	C3162263
CBM	T061	C3162263
biases	T078	C0242568
treating	T061	C0087111
mental disorders	T048	C0004936
alcohol addiction	T048	C0001973
alcohol cues	UnknownType	C0679056
relapse	T067	C0035020
rates	T081	C1521828
CBM	T061	C3162263
bias modification	T169	C1554963
data	T078	C1511726
proof-of-concept study	T062	C2603343
people	T098	C0027361
food craving	T055	C0872380
CBM	T169	C1554963
treatment approach	UnknownType	C0679624
BN/BED	T048	C0013473
BN/BED	T048	C0013473
addictive disorders	T048	C0085281
rationale	T078	C2699007
bias modification	T169	C1554963
sham training	T062	C3897046
bias modification	T169	C1554963
binge-eating episodes	T033	C1843777
BN/BED	T048	C0013473
patients	T101	C0030705
pre-treatment	T079	C2709094
CBM	T061	C3162263
global	T080	C2348867
eating disorder psychopathology	T048	C0556019
trait	T032	C0599883
cue-elicited food craving	T055	C0872380
food intake	T040	C0013470
attentional bias	T041	C4277667
visual food cues	T078	C0010439
Treatment acceptance	T061	C3468361
attrition rates	UnknownType	C0814623
responses	T170	C1706817
double-blind	T062	C0013072
randomised	T062	C0034656
placebo-controlled	T062	C0599724
parallel-group superiority trial	T078	C0680731
BN/BED	T048	C0013473
patients	T101	C0030705
bias towards food	T078	C0242568
implicit learning paradigm	T062	C0681797
Patients	T101	C0030705
sham	T062	C3897046
similar task	T057	C3540678
food cues	T078	C0010439
bias	T078	C0242568
public registration	T170	C3897463
randomisation	T062	C0034656
central study office	T097	C1522486
standardisation of the treatments	T062	C0038136
blinding of assessors	T062	C0150108
randomised controlled trial	T062	C0206035
bias modification	T169	C1554963
clinical BN/BED sample	T062	C0008976
bias modification	T169	C1554963
BN/BED	T048	C0013473
treatment	T061	C0087111
Protein	T116	C0033684
Design	T052	C1707689
Nanostructural Engineering	T059	C0033629
Remarks	T170	C0282411
chapter	T170	C0005990
conclusions	T170	C1830648
book	T170	C0006002
research	T062	C0035168
field	UnknownType	C0683945
protein	T116	C0033684
design	T052	C1707689
nanostructural engineering	T059	C0033629
research field	UnknownType	C0683945
multidisciplinary	T080	C0205556
research efforts	T062	C0035168
design	T052	C1707689
synthetic protein	T116	C0597552
nanostructures	T073	C1450053
functional	T169	C0205245
materials	T167	C0520510
progress	T169	C1272688
chapters	T170	C0005990
book	T170	C0006002
examples	T077	C1707959
advances	T079	C3854260
use of	T169	C1524063
proteins	T116	C0033684
peptides	T116	C0030956
building blocks	T077	C1254372
fabrication	T067	C1254366
architectures	T077	C1254372
functional	T169	C0205245
nanostructures	T073	C1450053
assemblies	T052	C1706853
materials	T167	C0520510
strategies	T169	C0025664
prepare	T052	C1521827
functional	T169	C0205245
protein	T116	C0033684
nanostructures	T073	C1450053
nanostructured materials	T073	C1450053
devices	T073	C0699733
aspects	T080	C1879746
research	T062	C0035168
community	T096	C0009462
developments	T062	C0035170
Synthesis	T052	C1883254
characterization	T052	C1880022
drug	T121	C1254351
loading	T052	C1708715
property	T080	C0871161
Monomethoxy-Poly(ethylene glycol)-Poly(ε-caprolactone)-Poly(D,L-lactide) (MPEG-PCLA) copolymers	T104	C0032521
Amphiphilic block copolymers	T104	C0032521
drug delivery systems	T074	C0085104
monomethoxy-poly (ethylene glycol)-poly (ε-caprolactone-co-D,L-lactide) (MPEG-PCLA) copolymers	T104	C0032521
composition	T070	C0243176
poly (ε-caprolactone)	T109	C0137734
PCL	T109	C0137734
poly (D,L-lactide)	T122	C0071444
PDLLA	T122	C0071444
ring-opening copolymerization	T044	C1880180
ε-CL	T109	C0908527
D,L-LA	T109	C0293984
MPEG	T109	C0066763
stannous octoate	T109	C0963887
structure	T082	C0678594
molecular weight	T081	C0026385
characterized	T052	C1880022
nuclear magnetic resonance	T070	C0028580
NMR	T070	C0028580
gel permeation chromatography	T059	C0008559
GPC	T059	C0008559
crystallinity	T104	C0444626
hydrophilicity	T080	C0475370
thermal	T070	C0018837
stability	T080	C0205360
hydrolytic	T070	C0020291
degradation behavior	T169	C0243125
amphiphilic MPEG-PCLA copolymers	T104	C0032521
properties	T080	C0871161
composition	T070	C0243176
PCLA	T109	C1744269
clinical applications	T201	C0683325
drug	T121	C1254351
loading	T052	C1708715
properties	T080	C0871161
Docetaxel	T109	C0246415
DTX	T109	C0246415
MPEG-PCLA	T104	C0032521
micelles	T109	C0025938
high	T080	C0205250
loading	T052	C1708715
capacity	T081	C1516240
encapsulation	T067	C2348438
efficiency	T081	C0013682
lyophilized	T080	C0205556
DTX	T109	C0246415
MPEG-PCLA	T104	C0032521
micelles	T109	C0025938
MPEG-PCL	T104	C0032521
micelles	T109	C0025938
re-dissolved	T169	C0205245
normal saline	T121	C0445115
DTX	T109	C0246415
MPEG-PCLA	T104	C0032521
micelles	T109	C0025938
enhanced	T052	C2349975
antitumor	T080	C2986475
activity	T052	C0441655
DTX	T109	C0246415
DTX	T109	C0246415
micelles	T109	C0025938
slower	T080	C0439834
sustained	T169	C0443318
release	T169	C1283071
behavior	T080	C0871161
in vitro	T080	C1533691
higher	T080	C0205250
DTX	T109	C0246415
concentration	T081	C1264643
retention time	T081	C0392762
in vivo	T082	C1515655
MPEG-PCLA copolymer	T104	C0032521
ratio	T081	C0456603
PCL	T109	C0137734
PDLLA	T122	C0071444
drug delivery carrier	T122	C0013161
DTX	T109	C0246415
Thyroid cancer	T191	C0007115
burden	T081	C1516167
Central	T083	C0007674
South America	T083	C0037713
Incidence	T081	C0021149
thyroid cancer	T191	C0007115
TC	T191	C0007115
rapidly	T080	C0456962
increasing	T169	C0442808
worldwide	T078	C0043236
TC	T191	C0007115
burden	T081	C1516167
Central	T083	C0007674
South America	T083	C0037713
CSA	T083	C0002454
geographic patterns	T082	C0442527
trends	T079	C0040833
TC	T191	C0007115
sex	T032	C0079399
CSA	T083	C0002454
regional	UnknownType	C0683928
national-level	T082	C0681788
incidence	T081	C1708485
data	T078	C1511726
population-based cancer registries	T170	C1514227
countries	T083	C0454664
cancer deaths	T081	C1516192
WHO	T093	C0043237
mortality	T081	C0205848
database	T170	C0242356
countries	T083	C0454664
world	T098	C2700280
age-standardized incidence rates	T081	C1706747
ASRs	T081	C1706747
age-standardized mortality rates	T081	C1706748
ASMRs	T081	C1706748
person	T098	C0027361
years	T079	C0439234
ASRs	T081	C1706747
histological subtype	T201	C0449574
estimated the annual percentage change	T081	C0023732
EAPC	T081	C0023732
time trends	T079	C0040833
CSA	T083	C0002454
countries	T083	C0454664
TC	T191	C0007115
incidence	T081	C1708485
mortality rates	T081	C0205848
highest	T080	C1522410
TC	T191	C0007115
ASRs	T081	C1706747
females	T032	C0086287
males	T032	C0086582
Ecuador	T083	C0013593
Brazil	T083	C0006137
Costa Rica	T083	C0010182
Colombia	T083	C3245499
highest	T080	C1522410
ASMRs	T081	C1706748
Ecuador	T083	C0013593
Colombia	T083	C3245499
Mexico	T083	C0025885
Peru	T083	C0031238
Panama	T083	C0030266
females	T032	C0086287
males	T032	C0086582
Papillary TC	T191	C0238463
diagnosed	T033	C0011900
histological subtype	T201	C0449574
incidence pattern	T081	C1708485
TC	T191	C0007115
Argentinean	T098	C0238689
Brazilian	T033	C0238815
Chilean	T098	C0239045
Costa Rican	T098	C0239127
females	T032	C0086287
TC	T191	C0007115
incidence	T081	C1708485
increased	T081	C0205217
annually	T079	C0332181
papillary TC	T191	C0238463
increased	T081	C0205217
annually	T079	C0332181
mortality	T081	C0205848
stable	T080	C0205360
males	T032	C0086582
trends	T079	C0040833
TC	T191	C0007115
stable	T080	C0205360
TC	T191	C0007115
occurred	T052	C1709305
frequently	T079	C0332183
females	T032	C0086287
males	T032	C0086582
overall	T080	C1561607
high	T080	C0205250
incidence	T081	C1708485
low	T080	C0205251
mortality	T081	C0205848
TC	T191	C0007115
suggest	T078	C1705535
subclinical disease	T047	C0277544
improved	T080	C0332272
detection methods	T170	C0449335
Histopathological	T169	C0243140
Evaluation	T058	C0220825
Effectiveness	T080	C1280519
Glycyrrhizic Acid	T109	C0061751
Radioprotector	T061	C1318473
Development	T169	C1527148
Radiation-Induced Lung Fibrosis	T047	C0340126
Radiotherapy	T061	C1522449
thorax	T029	C0817096
lung inflammation	T047	C0032285
fibrosis	T047	C0034069
aim	T078	C1947946
study	T062	C2603343
investigate	T169	C1292732
glycyrrhizic acid	T109	C0061751
GLA	T109	C0061751
development	T169	C1527148
lung fibrosis	T047	C0034069
irradiated	T061	C1522449
animals	T008	C0003062
Wistar rats	T015	C0034716
groups	T078	C0441833
Group A	T078	C0441833
rats	T015	C0034693
thoracic irradiation	T061	C2169121
Rats	T015	C0034693
group B	T078	C0441833
GLA	T109	C0061751
irradiation	T061	C1522449
Group C	T078	C0441833
GLA	T109	C0061751
irradiation	T061	C1522449
Group D	T078	C0441833
GLA	T109	C0061751
irradiation	T061	C1522449
GLA	T109	C0061751
administered	T169	C1521801
dose	T081	C0178602
body weight	T032	C0005910
intraperitoneal injection	T061	C0021493
thoracic irradiation	T061	C2169121
Radiation therapy	T061	C1522449
Cobalt-60	T130	C0303395
animals	T008	C0003062
thoracic irradiation	T061	C2169121
lungs	T023	C0024109
dissected	T169	C0205239
histopathological	T169	C0243140
evaluation	T058	C0220825
Histopathologically	T169	C0243140
decrease	T081	C0547047
thickening	T033	C0205400
alveolar	T023	C0225695
bronchial wall	T023	C1180039
fibrous bands	T020	C0334163
collagen	T116	C0009325
animals	T008	C0003062
group B	T078	C0441833
animals	T008	C0003062
group A	T078	C0441833
experimental study	T062	C0681814
administration	T081	C0001555
GLA	T109	C0061751
thoracic irradiation	T061	C2169121
protective agent	T121	C0033613
radiation-induced fibrosis	T047	C0340126
animals	T008	C0003062
model	T050	C0012644
Avulsions	T037	C0262386
Triceps Brachii	T023	C0559502
injuries	T037	C3263722
surgical treatment	T061	C0543467
study	T062	C2603343
clinical presentations	T170	C2708283
intra -operative	T079	C0456904
findings	T033	C0243095
treatments	T061	C0087111
outcome	T169	C1274040
treatment	T061	C0087111
injuries	T037	C3263722
patients	T101	C0030705
avulsion	T037	C0262386
distal end	T082	C0205108
triceps brachii (TB) tendon	T023	C0448542
patients	T101	C0030705
rupture	T037	C3203359
avulsion	T037	C0262386
distal end	T082	C0205108
TB tendon	T023	C0448542
medical records	T170	C0025102
imaging files	T170	C0242193
clinical	T080	C0205210
outcomes	T169	C1274040
follow up visit	T058	C0589121
clinical	T080	C0205210
outcomes	T169	C1274040
Mayo Elbow Score	T170	C0282574
follow-up visit	T058	C0589121
patients	T101	C0030705
male	T032	C0086582
injury	T037	C3263722
left hand	T023	C0230371
hand	T023	C0018563
age	T032	C0001779
years	T079	C0439234
bony	T169	C0443157
fleck	T037	C0009938
elbow	T029	C0013769
lateral radiograph	T060	C0202571
patients	T101	C0030705
injuries	T037	C3263722
intra-articular	T082	C0442108
fractures	T037	C0016658
medial collateral ligament rupture	T037	C0840716
V-Y plasty	T061	C0087111
distal	T082	C0205108
TB	T023	C0559502
patients	T101	C0030705
surgery	T061	C0543467
TB tendon	T023	C0448542
rupture	T037	C3203359
diagnosis	T062	C1704656
upper -extremity trauma	UnknownType	C0749817
injuries	T037	C3263722
Prolyl-4-hydroxylase 2	T116	C1451071
3	T116	C2002278
murine	T109	C0591833
erythropoietin	T116	C0014822
brain	T023	C0006104
pericytes	T025	C0598800
response	T033	C1704632
systemic	T169	C0205373
hypoxia	T046	C0242184
increased	T081	C0205217
production of red blood cells	T042	C0014819
hypoxia-inducible factor	T116	C0215848
HIF	T116	C0215848
induction	T169	C0205263
erythropoietin	T116	C0014822
EPO	T116	C0014822
EPO	T116	C0014822
glycoprotein hormone	T109	C0312438
normal erythropoiesis	T042	C0014819
peritubular	T082	C0456918
renal interstitial fibroblast-like cells	T025	C1514842
cellular markers	T201	C0005516
neuronal cells	T025	C0027882
pericytes	T025	C0598800
investigate	T169	C1292732
EPO	T116	C0014822
functional	T169	C0205245
feature	T080	C2348519
pericytes	T025	C0598800
gene targeting	T063	C0242613
von Hippel-Lindau	T047	C0019562
prolyl-4-hydroxylase domain (PHD)/HIF	T116	C3658213
cell	T025	C0007634
expressing	T045	C1171362
neural glial antigen 2	T116	C1311695
molecular marker	T201	C0005516
pericytes	T025	C0598800
multiple organs	T023	C0178784
pericytes	T025	C0598800
brain	T023	C0006104
EPO	T116	C0014822
mice	T015	C0026809
genetic	T169	C0314603
HIF	T116	C0215848
activation	T052	C1879547
systemic	T169	C0205373
hypoxia	T046	C0242184
induction	T169	C0205263
Epo	T116	C0014822
high-resolution	T059	C1719039
in situ hybridization	T063	C0162788
brain	T023	C0006104
pericytes	T025	C0598800
cellular source	T025	C0007634
Epo	T116	C0014822
hypoxic	T046	C0242184
brain	T023	C0006104
Epo	T116	C0014822
expressing	T045	C1171362
cells	T025	C0007634
Epo	T116	C0014822
transcription	T045	C0040649
brain	T023	C0006104
pericytes	T025	C0598800
HIF-2	T116	C0215848
PHD2	T116	C1451071
PHD3	T116	C2002278
oxygen	T121	C0030054
2-oxoglutarate	T109	C1291208
prolyl-4-hydroxylases	T116	C3658213
HIF	T116	C0215848
activity	T044	C0243102
experimental	T080	C1517586
evidence	T078	C3887511
pericytes	T025	C0598800
brain	T023	C0006104
oxygen sensors	T074	C0183211
hypoxia	T046	C0242184
EPO	T116	C0014822
findings	T169	C2607943
EPO	T116	C0014822
functional	T169	C0205245
feature	T080	C2348519
pericytes	T025	C0598800
brain	T023	C0006104
kidney	T023	C0022646
Patient Satisfaction	T080	C0030702
Pharmacist	T097	C0031323
Collaborative	T054	C0282116
Follow-Up Care	T058	C3899107
Ambulatory	T078	C1561561
Rheumatology Clinic	T073	C3812871
Patient satisfaction	T080	C0030702
pharmacist	T097	C0031323
intervention	T061	C0184661
general outpatient clinics	T073	C0029916
nurse-led care	T058	C0086584
rheumatology clinics	T073	C3812871
patient satisfaction	T080	C0030702
care	T058	C0017313
pharmacist	T097	C0031323
physician	T097	C0031831
collaborative model	T170	C0596657
traditional physician model	T170	C0596657
rheumatology clinic	T073	C3812871
cross-sectional survey	T062	C0010362
inflammatory arthritis	T047	C0003864
patients	T101	C0030705
follow-up visit	T058	C0589121
Edmonton	UnknownType	C0681784
Alberta	UnknownType	C0681784
Canada	T083	C0006823
ten-week period	T062	C2347804
Patient satisfaction	T080	C0030702
Leeds Satisfaction Questionnaire	T058	C4039173
Likert scale	T170	C0451267
six dimensions	T082	C0454192
satisfaction	T080	C0030702
collaborative care	T058	C0086388
traditional physician models	T170	C0596657
patients	T101	C0030705
questionnaire	T170	C1879301
collaborative care	T058	C0086388
traditional physician model	T170	C0596657
respondents	T098	C0282122
female	T032	C0086287
mean score for satisfaction	T170	C0451370
six dimensions	T082	C0454192
collaborative care group	T093	C1273804
traditional physician group	T097	C0031831
Patient satisfaction	T080	C0030702
collaborative care group	T093	C1273804
No difference	T033	C3842396
participants	T098	C0679646
pharmacist	T097	C0031323
collaborative care model	T170	C0596657
high expectations	T078	C0679138
care of patients	T058	C0030677
inflammatory arthritis	T047	C0003864
pharmacists	T097	C0031323
collaborative care	T058	C0086388
care for patients	T058	C0030677
rheumatology clinics	T073	C3812871
Ontology	T090	C1518584
High	T080	C0205250
Level	T080	C0441889
Context	T078	C0449255
Inference	T041	C0679201
Human Behavior	T055	C3826173
Identification	T080	C0205396
progress	T169	C1280477
automatic	T169	C0205554
identification	T080	C0205396
individual	T098	C0237401
primitives	T170	C3645627
human behavior	T055	C3826173
activities	T056	C0026606
locations	T082	C0450429
complex	T080	C0439855
nature	T169	C1262865
human behavior	T055	C3826173
contextual	T078	C0449255
information	T078	C1533716
ontology	T090	C1518584
method	T170	C0025663
low	T080	C0205251
level	T080	C0441889
primitives	T170	C3645627
behavior	T053	C0004927
activity	T056	C0026606
locations	T082	C0450429
emotions	T041	C0013987
unprecedented	T080	C0439673
date	T079	C0011008
high	T080	C0205250
level	T080	C0441889
context	T078	C0449255
information	T078	C1533716
contributes	T052	C1880177
ontology	T090	C1518584
low	T080	C0205251
level	T080	C0441889
high	T080	C0205250
level	T080	C0441889
context	T078	C0449255
information	T078	C1533716
relationships	T080	C0439849
framework	T077	C1709697
ontology	T090	C1518584
models	T170	C3161035
high	T080	C0205250
level	T080	C0441889
contexts	T078	C0449255
event	T051	C0441471
erroneously	T080	C0205556
detected	T033	C0442726
low	T080	C0205251
evel	T080	C0441889
context	T078	C0449255
inference	T041	C0679201
relevant	T080	C2347946
set	T041	C0036849
users	T098	C1706077
instances	T078	C1550608
scenarios	T169	C0683579
users	T098	C1706077
Characterization	T052	C1880022
exposure	T037	C0014412
epidemiological studies	T062	C0002783
air pollution	T069	C0001873
biodegradable	T080	C0205556
wastes	T167	C0043045
Misclassification	T185	C0008902
comparison	T052	C1707455
exposure	T037	C0014412
assessment	T058	C0220825
strategies	T062	C0035171
exposure	T037	C0014412
environmental	T082	C0014406
epidemiologists	T097	C1516908
misclassification	T185	C0008902
exposures	T037	C0014412
population	T098	C1257890
epidemiological studies	T062	C0002783
air pollution	T069	C0001873
biodegradable	T080	C0205556
wastes	T167	C0043045
objective	T078	C2985627
study	T062	C2603343
investigate	T169	C1292732
exposure	T037	C0014412
air pollution	T069	C0001873
biodegradable	T080	C0205556
wastes	T167	C0043045
analyzing	T062	C0936012
misclassification	T185	C0008902
exposure	T037	C0014412
surrogates	T096	C1551364
differentia	T080	C0443199
misclassification	T185	C0008902
effects	T080	C1280500
misclassification	T185	C0008902
health	T078	C0018684
effect	T080	C1280500
estimates	T081	C0750572
interpretation	T169	C1285553
epidemiological	T062	C0002783
results	T033	C0683954
exposure	T037	C0014412
health outcomes	T170	C1550208
cross validation	T062	C0681935
exposure	T037	C0014412
assessment	T058	C0220825
studied	T062	C2603343
ammonia	T121	C0002607
concentrations	T081	C1446561
residence	T082	C0237096
Metric I	T081	C0025867
distance	T081	C0012751
source	T033	C0449416
Metric II	T081	C0025867
sources	T033	C0449416
distances	T081	C0012751
residence	T082	C0237096
Metric IIIa	T081	C0025867
b	T081	C0025867
location	T082	C0450429
region	T083	C0017446
Metric IV	T081	C0025867
Exposure-response models	T170	C3161035
Metric I	T081	C0025867
goodness-of-fit	T080	C0870608
IV	T081	C0025867
III	T081	C0025867
II	T081	C0025867
Metric I	T081	C0025867
Metric IV	T081	C0025867
results	T033	C0683954
exposure	T037	C0014412
misclassification	T185	C0008902
analysis	T062	C0936012
interpretation	T169	C1285553
health	T078	C0018684
effect	T080	C1280500
estimates	T081	C0750572
Metric IIIb	T081	C0025867
IIIa	T081	C0025867
II	T081	C0025867
study	T062	C2603343
NH3	T121	C0002607
concentrations	T081	C1446561
estimations	T081	C0750572
exposure	T037	C0014412
surrogates	T096	C1551364
surrogates	T096	C1551364
distance	T081	C0012751
source	T033	C0449416
populations	T098	C1257890
studies	T062	C2603343
De Ritis Ratio (AST/ALT)	T201	C0364051
Significant Prognostic Factor	T201	C1514474
Patients	T101	C0030705
Upper Tract Urothelial Cancer	T191	C0751571
Treated	T169	C1522326
Surgery	T169	C0038895
investigated	T169	C1292732
clinical prognostic value	T170	C0220901
preoperative	T079	C0445204
De Ritis ratio (aspartate aminotransferase [AST]/alanine aminotransferase [ALT])	T201	C0364051
postsurgical	T033	C0231287
survival	T052	C0038952
outcomes	T169	C1274040
patients	T101	C0030705
upper tract urothelial cancer	T191	C0751571
UTUC	T191	C0751571
retrospectively analyzed	T062	C0035363
data	T078	C1511726
patients	T101	C0030705
radical nephrouretectomy	T061	C0027732
UTUC	T191	C0751571
Multivariate regression	T080	C0681923
tests	T170	C0392366
possible associations	T080	C0439849
adverse pathologic events	T046	C0030660
AST/ALT	T201	C0364051
postoperative	T079	C0032790
progression	T169	C0449258
survival	T052	C0038952
tested	T169	C0039593
Kaplan-Meier analyses	T081	C1720943
Cox proportional hazards models	T081	C0010235
receiver operator characteristic curve	T081	C0034772
AST/ALT	T201	C0364051
cancer-specific mortality	T081	C1516192
patients	T101	C0030705
AST/ALT	T201	C0364051
AST/ALT	T201	C0364051
patients	T101	C0030705
AST/ALT	T201	C0364051
Kaplan-Meier analyses	T081	C1720943
AST/ALT	T201	C0364051
progression-free survival	T081	C0242792
PFS	T081	C0242792
cancer-specific survival	T081	C0038954
CSS	T081	C0038954
overall survival	T081	C4086681
AST/ALT	T201	C0364051
associated with	T080	C0332281
T stage	T185	C0475455
hazard ratio	T081	C2985465
HR	T081	C2985465
confidence interval	T081	C0009667
CI	T081	C0009667
higher cellular grade	T185	C0441800
HR	T081	C2985465
CI	T081	C0009667
multivariate regression	T080	C0681923
tests	T170	C0392366
multivariate Cox analyses	T081	C0026777
AST/ALT	T201	C0364051
independent predictor	T078	C2698872
PFS	T081	C0242792
HR	T081	C2985465
CI	T081	C0009667
CSS	T081	C0038954
HR	T081	C2985465
overall survival	T081	C4086681
HR	T081	C2985465
CI	T081	C0009667
preoperative	T079	C0445204
AST/ALT	T201	C0364051
significant predictor	T078	C2698872
worse	T033	C1457868
postoperative	T079	C0032790
survival	T052	C0038952
patients	T101	C0030705
surgically treated	T061	C0543467
UTUC	T191	C0751571
prospective studies	T062	C0033522
prognostic value	T170	C0220901
preoperative	T079	C0445204
AST/ALT	T201	C0364051
Molecular simulation	T066	C2717775
study	T062	C2603343
concentration	T081	C1446561
effects of	T080	C1704420
rofecoxib	T109	C0762662
POPC	T109	C0044576
bilayer	T026	C0023768
interactions	T044	C0687133
rofecoxib	T109	C0762662
POPC	T109	C0044576
(1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine)	T109	C0044576
bilayer	T026	C0023768
studied	T062	C2603343
using	T169	C1524063
all-atom molecular dynamics simulation	T066	C2717775
method	T170	C0025663
POPC	T109	C0044576
bilayer	T026	C0023768
systems	T169	C0449913
different	T080	C1705242
number	T081	C0237753
rofecoxib	T109	C0762662
molecules	T167	C0567416
constructed	T169	C0205431
simulate	T080	C1883725
different	T080	C1705242
drug	T121	C1254351
concentration	T081	C1446561
free energy	T070	C0678591
rofecoxib	T109	C0762662
passing	T077	C2828360
pure	T080	C0205556
POPC	T109	C0044576
bilayer	T026	C0023768
minima	T080	C1524031
high	T080	C0205250
concentration	T081	C1446561
model	T170	C0026344
minimum	T080	C1524031
free energy	T070	C0678591
bilayer	T026	C0023768
center	T082	C0205099
energy change	UnknownType	C0678592
bulk water	T121	C3663211
POPC	T109	C0044576
bilayer	T026	C0023768
increases	T169	C0442805
central	T082	C0205099
barrier	T046	C0028778
cross	T077	C2828360
hydrophobic core	T120	C1254355
bilayer	T026	C0023768
slightly	T080	C0750482
decreases	T081	C0547047
suggesting	T078	C1705535
increasing	T169	C0442808
drug	T121	C1254351
concentration	T081	C1446561
favorable	T033	C0278250
rofecoxib	T109	C0762662
partition	T169	C1534709
bilayer	T026	C0023768
pass	T077	C2828360
bialyer	T026	C0023768
center	T082	C0205099
Energy	T081	C1442080
analysis	T062	C0936012
stabilization	T080	C0205360
selected	T052	C1707391
rofecoxib	T109	C0762662
pre-inserted	T169	C1883719
rofecoxib	T109	C0762662
molecule	T167	C0567416
van der Waals interaction	T067	C2346563
energy	T081	C1442080
predicted	T078	C0681842
permeability	T070	C0031164
rofecoxib	T109	C0762662
high	T080	C0205250
concentration	T081	C1446561
model	T170	C0026344
weakens	T080	C1762617
compared	T052	C1707455
low	T080	C0205251
concentration	T081	C1446561
model	T170	C0026344
Short-term Variability	T077	C2827666
Vitamin D	T109	C0042866
Biomarkers	T201	C0005516
Quantifying	T081	C1709793
variability	T077	C2827666
biomarkers	T201	C0005516
important	T080	C3898777
variability	T077	C2827666
misclassification	T185	C0008902
individuals	T098	C0237401
variability	T077	C2827666
important	T080	C3898777
markers	T201	C0005516
vitamin D metabolism	T044	C1159433
repeatability study	T062	C2603343
Atherosclerosis	T047	C0004153
Risk	T078	C0035647
Communities study participants	T098	C1997894
female	T032	C0086287
black	T098	C0005680
age	T032	C0001779
Fasting	T033	C1976106
serum	T031	C0229671
weeks	T079	C0439230
Vitamin D binding protein	T116	C0042872
VDBP	T116	C0042872
25-hydroxyvitamin D	T109	C0535968
25(OH)D	T109	C0535968
measured	T080	C0444706
LC-MS	T059	C0872318
fibroblast growth factor	T116	C0016026
FGF23	T116	C0016026
parathyroid hormone	T116	C0030520
PTH	T116	C0030520
enzyme-linked immunoassay	T059	C0086231
calcium	T121	C0006675
phosphorus	T196	C0031705
Roche Cobas 6000	T059	C0022885
Free	T080	C1996904
bioavailable	T080	C0935763
25(OH)D	T109	C0535968
calculated	T052	C1441506
calculated	T052	C1441506
within-person CV	T081	C0681921
CVW	T081	C0681921
intraclass correlation coefficient	T081	C1707429
ICC	T081	C1707429
Spearman rank correlation coefficient	T081	C0242929
r	T081	C0242929
percent	T081	C0439165
reclassified	T080	C0205542
CVW	T081	C0681921
lowest	T080	C1708760
calcium	T121	C0006675
albumin	T116	C0001924
25(OH)D	T109	C0535968
VDBP	T116	C0042872
phosphorus	T196	C0031705
intermediate	T034	C1550465
free	T080	C1996904
25(OH)D	T109	C0535968
bioavailable	T080	C0935763
25(OH)D	T109	C0535968
highest	T080	C1522410
PTH	T116	C0030520
FGF23	T116	C0016026
Reclassification	T185	C0008902
highest	T080	C1522410
PTH	T116	C0030520
VDBP	T116	C0042872
phosphorus	T196	C0031705
ICC	T081	C1707429
r	T081	C0242929
highest	T080	C1522410
25(OH)D	T109	C0535968
free	T080	C1996904
25(OH)D	T109	C0535968
bioavailable	T080	C0935763
25(OH)D	T109	C0535968
PTH	T116	C0030520
lower	T080	C0205251
approximately	T080	C0332232
biomarkers	T201	C0005516
week	T079	C0439230
short-term variability	T077	C2827666
assessed	T052	C1516048
CVW	T081	C0681921
quite low	T080	C0205251
VDBP	T116	C0042872
calcium	T121	C0006675
phosphorus	T196	C0031705
fairly high	T080	C0205250
FGF23	T116	C0016026
PTH	T116	C0030520
multiple measurements	T169	C0242485
FGF23	T116	C0016026
PTH	T116	C0030520
minimize	T080	C1524031
misclassification	T185	C0008902
results	T169	C1274040
insight	T041	C0233820
potential	T080	C3245505
misclassification	T185	C0008902
vitamin D	T109	C0042866
markers	T201	C0005516
research	T062	C0035168
clinical settings	T169	C4086198
Fabrication	T067	C1522240
gelatin methacrylate	T109	C0029224
nanohydroxyapatite	T197	C0020326
microgel	T122	C0017243
arrays	T082	C1510941
periodontal tissue regeneration	T061	C1448477
Periodontitis	T047	C0031099
chronic infectious disease	T047	C0151317
major cause	T033	C1333617
tooth loss	T020	C0080233
oral health	T058	C0029162
issues	T033	C0033213
world	T098	C2700280
Periodontal tissue regeneration	T061	C1448477
ultimate goal	T170	C0018017
dentists	T097	C0011441
researchers	T097	C0035173
fabrication	T067	C1522240
methods	T170	C0025663
focused	T169	C1285542
top-down tissue engineering	T061	C0596171
strategy	T041	C0679199
drawbacks	T080	C0205556
remain	T033	C0243095
low throughput	T080	C0205556
diffusion	T070	C0012222
properties	T080	C0871161
resulting	T169	C0332294
large sample size	T081	C0242618
Gelatin methacrylate	T109	C0029224
GelMA	T109	C0029224
photocrosslinkable	T070	C0178576
biocompatible	T122	C0005479
hydrogel	T109	C0063083
capacities	T081	C1516240
enabling	T041	C1171285
cell encapsulation	T059	C3831155
regeneration of functional tissues	T042	C1623047
novel	T080	C0205314
method	T169	C0449851
fabricate	T067	C1522240
GelMA	T109	C0029224
nanohydroxylapatite	T197	C0020326
nHA	T197	C0020326
microgel	T122	C0017243
arrays	T082	C1510941
photocrosslinkable	T070	C0178576
strategy	T041	C0679199
viability	T043	C0007620
proliferation	T043	C0596290
osteogenic differentiation	T043	C1159974
in vivo	T082	C1515655
osteogenesis	T042	C0029433
human	T016	C0086418
periodontal ligament	T023	C0031093
stem cells	T025	C0038250
hPDLSCs	T025	C0038250
encapsulated	T080	C0205223
microgels	T122	C0017243
evaluated	T058	C0220825
results	T169	C1274040
suggested	T078	C1705535
microgels	T122	C0017243
provide	T052	C1999230
potential	T080	C3245505
periodontal tissue repair and regeneration	T061	C1448477
Microgel	T122	C0017243
arrays	T082	C1510941
fabricated	T067	C1522240
blending	T068	C0678946
different	T080	C1705242
weight ratios	T081	C2919747
GelMA	T109	C0029224
nHA	T197	C0020326
hPDLSCs	T025	C0038250
encapsulated	T080	C0205223
GelMA	T109	C0029224
nHA	T197	C0020326
microgels	T122	C0017243
ratios	T081	C0456603
systematic	T169	C0220922
evaluation	T058	C0220825
cell viability	T043	C0007620
proliferation	T043	C0596290
osteogenic differentiation	T043	C1159974
In vivo	T082	C1515655
osteogenesis	T042	C0029433
nude mice	T015	C0025932
GelMA	T109	C0029224
nHA	T197	C0020326
microgels	T122	C0017243
appropriate	T080	C1548787
microarchitecture	T080	C0205556
mechanical strength	T078	C0808080
surface	T082	C0205148
roughness	T080	C0205556
cell adhesion	T043	C0007577
proliferation	T043	C0596290
GelMA	T109	C0029224
nHA	T197	C0020326
microgels	T122	C0017243
enhanced	T052	C2349975
osteogenic differentiation	T043	C1159974
hPDLSCs	T025	C0038250
elevating	T080	C3163633
expression levels	T081	C3244092
osteogenic biomarker	T201	C0005516
genes	T028	C0017337
ALP	T028	C0017337
BSP	T028	C1415840
OCN	T028	C1412791
RUNX2	T028	C1419771
In vivo	T082	C1515655
ectopic	T082	C0574895
transplantation	T061	C0040732
results	T169	C1274040
GelMA	T109	C0029224
nHA	T197	C0020326
microgels	T122	C0017243
increased	T081	C0205217
mineralized tissue	T024	C0040300
formation	T169	C1522492
abundant	T080	C2346714
vascularization	T169	C0042382
compared	T052	C1707455
GelMA group	T109	C0029224
GelMA	T109	C0029224
nHA	T197	C0020326
microgels	T122	C0017243
hPDLSCs	T025	C0038250
viability	T043	C0007620
proliferation	T043	C0596290
osteogenic differentiation	T043	C1159974
in vitro	T080	C1533691
further	T082	C1517331
promoted	T052	C0033414
new	T080	C0205314
bone formation	T042	C0029433
in vivo	T082	C1515655
GelMA	T109	C0029224
nHA	T197	C0020326
microgels	T122	C0017243
provide	T052	C1999230
potential	T080	C3245505
periodontal tissue regeneration	T061	C1448477
Esomeprazole	T109	C0937846
rabeprazole	T109	C0378482
triple	T081	C0205174
therapy	T061	C0087111
Helicobacter pylori	T007	C0079488
regardless	T080	C3641650
clarithromycin	T109	C0055856
susceptibility	T169	C1264642
CYP2C19	T028	C1332828
genotypes	T032	C0017431
study	T062	C2603343
assess	T052	C1516048
efficacy	T080	C1280519
esomeprazole	T109	C0937846
triple	T081	C0205174
therapy	T061	C0087111
compared	T052	C1707455
rabeprazole	T109	C0378482
triple	T081	C0205174
therapy	T061	C0087111
CYP2C19	T028	C1332828
genotype	T032	C0017431
clarithromycin	T109	C0055856
susceptibility	T169	C1264642
status	T080	C0449438
eradication therapy of Helicobacter pylori	T061	C0559761
H. pylori	T007	C0079488
Japan	T083	C0022341
H. pylori	T007	C0079488
infected patients	T101	C0030705
randomly	T080	C0439605
allocated	T052	C1706778
patients	T101	C0030705
EAC group	T101	C0030705
esomeprazole	T109	C0937846
clarithromycin	T109	C0055856
amoxicillin	T109	C0002645
week	T079	C0439230
drugs	T121	C0013227
given	T169	C1947971
twice daily	T079	C0585361
RAC group	T101	C0030705
rabeprazole	T109	C0378482
clarithromycin	T109	C0055856
amoxicillin	T109	C0002645
week	T079	C0439230
drugs	T121	C0013227
given	T169	C1947971
twice daily	T079	C0585361
H. pylori	T007	C0079488
eradication rate	T081	C1521828
PP analyses	T062	C0936012
CI	T081	C0009667
EAC group	T101	C0030705
CI	T081	C0009667
RAC group	T101	C0030705
differences	T080	C1705242
eradication rates	T081	C1521828
clarithromycin	T109	C0055856
clarithromycin -resistant	T046	C0860039
sensitive	T169	C0332324
strains	T007	C0004611
CI	T081	C0009667
CI	T081	C0009667
EAC group	T101	C0030705
CI	T081	C0009667
CI	T081	C0009667
RAC group	T101	C0030705
eradication rate	T081	C1521828
clarithromycin	T109	C0055856
sensitive	T169	C0332324
strains	T007	C0004611
higher	T080	C0205250
resistant strains	T046	C0860039
both	T080	C1706086
groups	T078	C0441833
EAC	T101	C0030705
RAC	T101	C0030705
therapies	T061	C0087111
efficacy	T080	C1280519
regardless	T080	C3641650
CYP2C19	T028	C1332828
genotype	T032	C0017431
clarithromycin	T109	C0055856
susceptibility	T169	C1264642
status	T080	C0449438
Japan	T083	C0022341
Early	T079	C1279919
Response Monitoring	T058	C1822578
Cancer	T191	C0006826
Antiangiogenesis Therapy	T061	C0281318
Noninvasive	T185	C2986496
PET Molecular Imaging	T060	C0032743
Multifactorial	T033	C1837655
Bioparameters	T077	C0549193
Antiangiogenesis therapy	T061	C0281318
AAT	T061	C0281318
survival	T052	C0038952
patients	T101	C0030705
clinical settings	T082	C3176918
early	T079	C1279919
therapeutic effects	T201	C1527144
cancer	T191	C0006826
AAT	T061	C0281318
early	T079	C1279919
response monitoring	T058	C1822578
AAT	T061	C0281318
efficacy	T080	C2348767
anti-angiogenic drug	T121	C0596087
sunitinib	T109	C1176020
U87MG tumors	T191	C0027651
noninvasive	T185	C2986496
positron emission computed tomography (PET) molecular imaging	T060	C1699633
multifactorial	T033	C1837655
bioparameters	T077	C0549193
U87MG tumor	T191	C0027651
mice	T015	C0025929
intragastric	T082	C0442113
injections	T061	C0021485
sunitinib	T109	C1176020
vehicle	T122	C0042444
Longitudinal	T082	C0205127
MicroPET/CT scans	T060	C1699633
(18)F-FDG	T109	C0046056
(18)F-FMISO,	T109	C3661419
(18)F-ML-10	T109	C2700345
(18)F-Alfatide II	T116	C3852643
metabolism	T040	C0025519
hypoxia	T046	C0242184
apoptosis	T043	C0162638
angiogenesis	T191	C1519670
therapy	T061	C0087111
Tumor tissues	T024	C0475358
mice	T015	C0025929
immunohistochemical	T059	C1441616
IHC	T059	C1441616
biomarkers	T123	C0041365
Glut-1	T116	C1527589
CA-IX	T116	C2351139
TUNEL	T063	C0872284
ανβ3	T116	C1138427
CD31	T116	C0081939
PET imaging	T060	C1699633
tumor sizes	T082	C0475440
mouse	T015	C0025929
weights	T032	C0005910
tumor	T191	C0027651
uptake	T039	C0243144
tumor	T191	C0027651
muscle	T024	C0026845
T	T191	C0027651
M	T024	C0026845
tumor growth	T191	C0598934
ratios	T081	C0456603
TGR	T081	C0456603
statistical analyses	T062	C0871424
Sunitinib	T109	C1176020
U87MG tumor growth	T191	C0598934
tumor size	T082	C0475440
sunitinib	T109	C1176020
treatment	T061	C1533734
control group	T096	C0009932
uptakes	T039	C0243144
(18)F-FMISO	T109	C3661419
hypoxia	T046	C0242184
(18)F-ML-10	T109	C2700345
apoptosis	T043	C0162638
(18)F-Alfatide II	T116	C3852643
angiogenesis	T191	C1519670
tumor	T191	C0027651
lesions	T033	C0221198
early	T079	C1279919
early stage	T079	C2363430
sunitinib	T109	C1176020
treatment	T061	C1533734
uptake	T039	C0243144
(18)F-FDG	T109	C0046056
glucose metabolism	T044	C0596620
late stage	T079	C1279941
PET imaging	T060	C1699633
ex vivo	T169	C2348480
IHC	T059	C1441616
biomarkers	T123	C0041365
PET imaging	T060	C1699633
(18)F-Alfatide II	T116	C3852643
(18)F-FMISO	T109	C3661419
TGR	T081	C0456603
(18)F-FDG	T109	C0046056
(18)F-ML-10	T109	C2700345
TGR	T081	C0456603
tumor	T191	C0027651
uptake	T039	C0243144
PET	T060	C1699633
MVD	T080	C3272839
TGR	T081	C0456603
(18)F-Alfatide II	T116	C3852643
PET	T060	C1699633
early	T079	C1279919
response	T058	C1822578
therapeutic efficacy	T080	C2348767
anti-angiogenic drug	T121	C0596087
sunitinib	T109	C1176020
U87MG tumors	T191	C0027651
early	T079	C1279919
response monitoring	T058	C1822578
efficacy	T080	C2348767
cancer	T191	C0006826
AAT	T061	C0281318
noninvasive	T185	C2986496
PET molecular imaging	T060	C0032743
multifactorial	T033	C1837655
bioparameters	T077	C0549193
angiogenesis	T191	C1519670
imaging	T060	C0011923
(18)F-Alfatide II	T116	C3852643
RGD	T116	C0052350
research priorities	T062	C0376368
nurses	T097	C0028661
children's	T100	C0008059
hospital	T073	C0019994
United Kingdom	T083	C0041700
study	T062	C2603343
research priority	T062	C0376368
efficiency	T081	C0013682
impact	T080	C4049986
research activity	T062	C0079816
nurses	T097	C0028661
children's	T100	C0008059
healthcare institution	T093	C1274109
clinical staff	T097	C0025106
coherent	T033	C4068804
transparent	T080	C0205556
consensus	T054	C0376298
nurse-led research agenda	T062	C0681798
research topics	UnknownType	C0681795
nurses	T097	C0028661
modified nominal group technique	T062	C0035177
consensus method	T170	C0025663
participants	T098	C0679646
nurses	T097	C0028661
clinical areas	T078	C1547541
ranked	T170	C0699794
priorities	T062	C0376368
divisional heads	T097	C0018676
nursing	T091	C0028677
staff	T097	C0025106
clinical areas	T078	C1547541
divisional priorities	T062	C0376368
Nursing Research Working Group	T097	C0027363
divisions' priorities	T062	C0376368
voted	T055	C0042978
research priorities	T062	C0376368
organization	T093	C1274109
research topics	UnknownType	C0681795
ranking	T170	C0699794
priorities	T062	C0376368
Divisional level	T092	C2919030
organizational priorities	T062	C0376368
patient	T101	C0030705
hospital system	T073	C0019994
play	T056	C0032214
staff wellbeing	T078	C0018684
patient care	T058	C0017313
productivity	T081	C0033269
team work	T057	C0043227
service	T057	C0557854
supporting parents	T099	C0030551
parent	T099	C0030551
priorities	T062	C0376368
clinical teams	T058	C0086390
patient-specific nurse-led research agenda	T062	C0681798
Organizational priorities	T062	C0376368
management structures	T090	C3273539
subgroup	T097	C0027363
Nursing Research Working Group	T097	C0027363
priorities	T062	C0376368
nurse-led research activity	T062	C0079816
inquiry	T052	C2987583
Accurate	T080	C0443131
Lungs	T023	C0024109
Segmentation	T058	C0700381
CT	T060	C0040405
Chest	T029	C0817096
Images	T170	C1704254
Adaptive Appearance-Guided Shape Modeling	T062	C0870071
accurately	T080	C0443131
segment	T058	C0700381
pathological	T169	C1521733
healthy	T080	C3898900
lungs	T023	C0024109
reliable	T080	C0205423
computer-aided disease diagnostics	T060	C0011905
stack	T082	C3272897
chest	T029	C0817096
CT	T060	C0040405
scans	T060	C0441633
modeled	T062	C0870071
spatially inhomogeneous	T082	C1254362
joint 3D Markov-Gibbs random field	T080	C0205556
MGRF	T080	C0205556
voxel-wise	T077	C2700259
lung	T023	C0024109
chest	T029	C0817096
CT	T060	C0040405
image	T170	C1704254
signals	T067	C1710082
intensities	T081	C0871362
proposed	T080	C1553874
MGRF	T080	C0205556
integrates	T066	C1705422
visual	T169	C0234621
appearance	T080	C0700364
sub-models	T075	C0026336
lung	T023	C0024109
submodel	T075	C0026336
appearance	T080	C0700364
submodel	T075	C0026336
original	T078	C0205313
CT	T060	C0040405
image	T170	C1704254
Gaussian scale space (GSS) filtered version	T080	C0205556
signal	T067	C1710082
empirical	T080	C1880496
marginal	T080	C1947914
probability distribution	T081	C3826440
signals	T067	C1710082
linear combination of discrete Gaussians	T080	C0205556
LCDG	T080	C0205556
positive dominant and multiple sign-alternate subordinate DGs	T080	C0205556
LCDGs	T080	C0205556
lungs	T023	C0024109
chest	T029	C0817096
tissues	T024	C0040300
appearance	T080	C0700364
submodel	T075	C0026336
quantifies	T081	C1709793
conditional	T080	C1701901
pairwise	T081	C0392762
intensity	T081	C0871362
dependencies	T170	C3669743
original	T078	C0205313
GSS-filtered	T080	C0205556
images	T170	C1704254
submodel	T075	C0026336
training data	T078	C1511726
segmentation	T058	C0700381
lung	T023	C0024109
chest	T029	C0817096
appearances	T080	C0700364
accuracy	T080	C0443131
proposed	T080	C1553874
segmentation	T058	C0700381
quantitatively	T081	C0392762
assessed	T052	C1516048
databases	T170	C0242356
ISBI VESSEL12 challenge	T170	C0242356
MICCAI LOLA11 challenge	T170	C0242356
database	T170	C0242356
CT	T060	C0040405
images	T170	C1704254
lung	T023	C0024109
pathologies	T169	C0205469
scanners	T074	C0183115
protocols	T061	C0040808
Quantitative	T081	C0392762
assessment	T052	C1516048
Dice similarity coefficients	T081	C0392762
95-percentile bidirectional Hausdorff distances	T081	C0392762
percentage volume differences	T081	C0392762
accuracy	T080	C0443131
model	T075	C0026336
database	T170	C0242356
VESSEL12 database	T170	C0242356
accuracy	T080	C0443131
accuracy	T080	C0443131
approach	T078	C3266812
verified	T169	C1711411
blind	T170	C1561605
evaluation	T170	C0015196
LOLA11	T170	C0242356
competition	T052	C3687609
average	T081	C1510992
segmentation	T058	C0700381
state-of-the-art	T080	C0205314
techniques	T169	C0449851
compared	T052	C1707455
Influence	T077	C4054723
Different	T080	C1705242
Levels	T079	C1306673
Lipoic Acid Synthase	T028	C1424272
Gene Expression	T045	C0017262
Diabetic Nephropathy	T047	C0011881
Oxidative stress	T049	C0242606
pathogenesis	T046	C0699748
diabetic nephropathy	T047	C0011881
DN	T047	C0011881
outcomes	T169	C1274040
clinical trials	T062	C0008976
role	T077	C1705810
antioxidants	T121	C0003402
kidney	T023	C0022646
during	T079	C0347984
development	T169	C1527148
diabetic nephropathy	T047	C0011881
generated	T052	C3146294
novel	T080	C0205314
genetic antioxidant mouse model	T050	C2986594
over- or under-expression	T045	C0017262
lipoic acid synthase gene	T028	C1424272
Lias	T028	C1424272
models	T050	C2986594
mated	T040	C1260875
Ins2Akita/+ mice	T015	C0025929
type I diabetic	T047	C0836995
mouse model	T050	C2986594
compare	T052	C1707455
major	T080	C0205164
pathologic changes	T034	C4086730
oxidative stress	T049	C0242606
status	T080	C0449438
mice	T015	C0025929
results	T169	C1274040
Ins2Akita/+ mice	T015	C0025929
under-expressed	T045	C0017262
Lias gene	T028	C1424272
higher	T080	C0205250
oxidative stress	T049	C0242606
more	T081	C0205172
severe	T080	C0205082
DN	T047	C0011881
features	T080	C2348519
albuminuria	T033	C0001925
glomerular basement membrane thickening	T033	C0445347
mesangial matrix expansion	T033	C3553722
Ins2Akita/+ mice	T015	C0025929
highly	T080	C0205250
expressed	T045	C0017262
Lias gene	T028	C1424272
display	T169	C0870432
lower	T080	C0205251
oxidative stress	T049	C0242606
less	T080	C0547044
DN	T047	C0011881
pathologic changes	T034	C4086730
study	T062	C2603343
demonstrates	T052	C3687625
endogenous	T169	C0205227
antioxidant	T121	C0003402
capacity	T081	C1516240
effective strategy for prevention	UnknownType	C0679723
treatment	T169	C1522326
DN	T047	C0011881
Assessment	T052	C1516048
genetic	T169	C0314603
relationship	T080	C0439849
Rhododendron	T002	C0330429
cultivars	T077	C1883525
amplified fragment length polymorphism	T063	C1955927
inter-simple sequence repeat	UnknownType	C0684192
markers	T086	C0012872
Genetic	T169	C0314603
relationships	T080	C0439849
Rhododendron	T002	C0330429
cultivars	T077	C1883525
China	T083	C0008115
assessed	T052	C1516048
inter-simple sequence repeat	UnknownType	C0684192
ISSR	UnknownType	C0684192
amplified fragment length polymorphism	T063	C1955927
AFLP	T063	C1955927
markers	T086	C0012872
ISSR	UnknownType	C0684192
primers	T114	C0206416
polymorphic	T080	C1882417
AFLP	T063	C1955927
primer pairs	T114	C0206416
polymorphism	T080	C1882417
polymorphic	T080	C1882417
products	T071	C1514468
cluster analysis	T062	C0009085
similarities	T080	C2348205
results	T169	C1274040
ISSR	UnknownType	C0684192
AFLP	T063	C1955927
cultivars	T077	C1883525
clustered	T169	C0332227
branches	T078	C1254370
branch	T078	C1254370
cultivars	T077	C1883525
cultivars	T077	C1883525
groups	T078	C0441833
branch	T078	C1254370
cluster	T081	C1704332
results	T169	C1274040
genetic	T169	C0314603
relationships	T080	C0439849
cultivars	T077	C1883525
related	T080	C0439849
morphological	T082	C0543482
characteristics	T080	C1521970
flowering	T040	C1820370
phase	T079	C0205390
results	T169	C1274040
study	T062	C2603343
classification	T185	C0008902
Rhododendron	T002	C0330429
cultivars	T077	C1883525
flowering	T040	C1820370
phase	T079	C0205390
cluster	T081	C1704332
results	T169	C1274040
select	T052	C1707391
breeding	T040	C0006159
Spontaneous activity	T039	C0443158
correlated	T080	C1707520
coding	T052	C2700640
density	T081	C0178587
primary auditory cortex	T029	C2954070
Sensory neurons	T025	C0027883
sensory modalities	T067	C0234402
processing	T052	C1709694
spontaneous firing rates	T039	C1254359
SFRs	T039	C1254359
sensory stimuli	UnknownType	C0683107
functional	T169	C0205245
significance	T078	C0750502
spontaneous activity	T039	C0443158
studies	T062	C2603343
auditory system	T022	C0587901
spontaneous activity	T039	C0443158
correlated	T080	C1707520
physiological	T169	C0205463
anatomic	T080	C0220784
neurons	T025	C0027882
SFRs	T039	C1254359
encoding	T052	C2700640
auditory stimuli	T039	C0178490
SFRs	T039	C1254359
tinnitus	T033	C0040264
auditory areas	T023	C0004302
ototoxic	T037	C1407041
substances	T167	C0439861
noise	T067	C0028263
trauma	T037	C3714660
study	T062	C2603343
recorded single-unit activity	T059	C1537057
primary auditory cortex	T029	C2954070
marmoset	T015	C0006764
monkeys	T015	C0026447
wide-band random-spectrum stimuli	T067	C0234402
white Gaussian noise	T170	C3161035
WGN	T170	C3161035
divergences	T082	C0443204
stimulus	T067	C0234402
encoding	T052	C2700640
spontaneous activity	T039	C0443158
activation	T052	C1879547
suppression	T169	C1260953
wide-band stimuli	T067	C0234402
response	T032	C0871261
WGN	T170	C3161035
response latencies	T079	C0242465
WGN	T170	C3161035
correlated	T080	C1707520
activation	T052	C1879547
response	T032	C0871261
stimulus	T067	C0234402
spontaneous spiking	T039	C0443158
stimulus	T067	C0234402
processing	T052	C1709694
primary auditory cortex	T029	C2954070
malfunction	T169	C0231174
tinnitus	T033	C0040264
Systematic mapping	T062	C0079435
functional	T169	C0205245
enhancer	T114	C0014290
promoter	T114	C2350877
connections	T169	C0205245
CRISPR	T114	C3658200
CRISPR interference	T059	C0200924
Gene expression	T045	C0017262
mammals	T015	C0024660
regulated	T045	C0017263
noncoding elements	T114	C0021920
physiology	T039	C0031843
disease	T047	C0012634
functions	T169	C0542341
target genes	T028	C0017337
noncoding elements	T114	C0021920
unknown	T080	C0439673
high-throughput approach	T170	C0872047
clustered regularly interspaced short palindromic repeats	T114	C3658200
clustered regularly interspaced short palindromic repeats (CRISPR) interference	T059	C0200924
CRISPR	T114	C3658200
CRISPRi	T059	C0200924
regulatory elements	T114	C0021920
target genes	T028	C0017337
assess	T058	C0184514
megabase	T081	C1533164
sequence	T086	C0004793
transcription factors	T116	C0040648
MYC	T116	C1137610
GATA1	T116	C1530719
distal	T082	C0205108
enhancers	T114	C0014290
control	T080	C0243148
gene expression	T045	C0017262
cellular proliferation	T043	C0596290
Quantitative	T081	C0392762
features	T080	C2348519
chromatin	T116	C0008546
state	T169	C1442792
chromosome	T026	C0008633
conformation	T033	C1299941
enhancers	T114	C0014290
MYC	T116	C1137610
elements	T086	C0004793
strategy	T169	C0449851
enhancer	T114	C0014290
promoter	T114	C2350877
connectivity	T169	C0205245
CRISPRi	T059	C0200924
approach	T169	C1292724
dissect	T169	C0205239
transcriptional networks	T044	C1720950
interpret	T169	C1285553
contributions	T052	C1880177
noncoding genetic variation	T070	C0042333
human	T016	C0086418
disease	T047	C0012634
Proliferation	T043	C0596290
effects of	T080	C1704420
gastrodin	T109	C0061139
RSC96 Schwann cells	T025	C0036387
regulating	T038	C1327622
ERK1	T116	C0082529
2	T116	C0170168
PI3K	T116	C0044602
signaling pathways	T044	C0037080
proliferation	T043	C0596290
migration	T043	C1622501
Schwann cells	T025	C0036387
SCs	T025	C0036387
process	T067	C1522240
peripheral nerve repair	T061	C0196777
promotion	T052	C0033414
growth	T043	C0007595
SCs	T025	C0036387
cell based therapy	T061	C3658313
Gastrodin	T109	C0061139
GAS	T109	C0061139
Chinese traditional	T091	C0025124
herbal medicine	T121	C2240391
Gastrodia elata Blume	T002	C1040858
reported	T058	C0700287
associated with	T080	C0332281
neuroprotective properties	T043	C0598958
GAS	T109	C0061139
activated	T052	C1879547
MAPK	T116	C0752312
PI3K	T116	C0044602
signaling pathways	T044	C0037080
growth	T043	C0007595
nerve cells	T025	C0027882
reported	T058	C0700287
hypothesis	T078	C1512571
GAS	T109	C0061139
SCs	T025	C0036387
growth	T043	C0007595
effect of	T080	C1704420
GAS	T109	C0061139
rat	T015	C0034693
RSC96 Schwann cells	T025	C0036387
SCs	T025	C0036387
mechanism	T169	C0441712
concentration	T081	C1446561
GAS	T109	C0061139
treatment	T061	C0087111
RSC96 SCs	T025	C0036387
cell proliferation	T043	C0596290
gene expression	T045	C0017262
neurotrophic factors	T116	C0027754
Regulation of	T038	C1327622
MAPK	T116	C0752312
PI3K	T116	C0044602
signaling pathways	T044	C0037080
phosphorylation	T044	C1158886
ERK1	T116	C0082529
2	T116	C0170168
Akt	T116	C0164786
GAS	T109	C0061139
promote	T052	C0033414
proliferation	T043	C0596290
RSC96 SCs	T025	C0036387
dose	T081	C0178602
time	T079	C0040223
concentration	T081	C1446561
Exploration	T061	C1280903
mechanism	T169	C0441712
GAS	T109	C0061139
SCs	T025	C0036387
metabolism	T043	C1524026
inhibiting	T052	C3463820
ERK1	T116	C0082529
2	T116	C0170168
phosphorylation	T044	C1158886
activating	T052	C1879547
Akt	T116	C0164786
phosphorylation	T044	C1158886
RSC96 SCs	T025	C0036387
treatment	T061	C0087111
peripheral nerve injuries	T037	C0262593
influenza A virus (H7N9)	T005	C3658219
anti-neuraminidase	T033	C0243095
monoclonal antibody	T116	C0003250
prophylactic and therapeutic activity	T061	C0199176
in vivo	T082	C1515655
Zoonotic	T047	C0043528
A(H7N9) avian influenza viruses	T005	C3658219
China	T083	C0008115
threat	T078	C0749385
human	T016	C0086418
public health	T058	C0699943
infected	T033	C0439663
individuals	T098	C0237401
mortality rate	T081	C0205848
Treatment options	T061	C0683525
infected	T033	C0439663
A(H7N9)	T005	C3658219
neuraminidase (NA) inhibitors	T121	C1443650
influenza viruses	T005	C0029341
A(H7N9)	T005	C3658219
resistant	T169	C0332325
drugs	T121	C0013227
monoclonal antibodies	T116	C0003250
strategy	T041	C0679199
influenza virus	T005	C0029341
infection	T046	C3714514
murine	T015	C0026809
monoclonal antibody	T116	C0003250
3c10-3	T129	C3849272
NA	T116	C1545516
A(H7N9)	T005	C3658219
prophylactic	T169	C0445202
systemic administration	UnknownType	C0678812
3c10-3	T129	C3849272
wild-type	T028	C1883559
A/Anhui/1/2013	T005	C0029347
H7N9	T005	C3658219
infection	T046	C3714514
treatment	T061	C0087111
systemic	T169	C0205373
dose	T081	C0178602
3c10-3	T129	C3849272
A(H7N9)	T005	C3658219
dose	T081	C0178602
time	T079	C0040223
dependent	T169	C3244310
protection	T033	C1545588
mice	T015	C0026809
therapeutic	T169	C0302350
potential	T080	C3245505
3c10-3	T129	C3849272
Epitope mapping	T059	C0242831
3c10-3	T129	C3849272
binds	T044	C1167622
enzyme	T116	C0014442
active site	T169	C0205681
NA	T116	C1545516
functional	T169	C0205245
3c10-3	T129	C3849272
enzyme activity	T044	C0243102
NA	T116	C1545516
spread	T080	C0332261
virus	T005	C0042776
cultured cells	T025	C0007635
Affinity	T070	C1510827
analysis	T062	C0936012
3c10-3	T129	C3849272
binds	T044	C1167622
recombinant	T116	C0034861
NA	T116	C1545516
wild-type	T028	C1883559
A/Anhui/1/2013	T005	C0029347
variant	T080	C0205419
NA	T116	C1545516
mutation	T045	C0026882
NAI	T121	C1443650
resistance	T169	C4281815
3c10-3	T129	C3849272
potential	T080	C3245505
therapeutic	T169	C0302350
A(H7N9)	T005	C3658219
infections	T046	C3714514
alternative	T077	C1523987
combination	T080	C0205195
NA	T116	C1545516
antiviral inhibitors	T121	C0003451
Mechanisms	T169	C0441712
ear	T023	C0013443
trauma	T037	C3714660
reconstructive	T061	C0524865
techniques	T169	C0449851
consecutive	T080	C1707491
patients	T101	C0030705
Acquired	T080	C0439661
auricular	T023	C1549094
deformities	T190	C0302142
diminish	T081	C0205216
facial esthetics	T032	C0871976
psychological distress	T048	C0815107
injuries	T037	C3263723
applied reconstructive	T061	C0524865
techniques	T169	C0449851
academic hospital	T073	C0000872
Netherlands	T083	C0027778
retrospective	T080	C1514923
chart review	UnknownType	C0553620
patients	T101	C0030705
auricular	T023	C1549094
reconstruction	T061	C0524865
acquired deformity	T020	C0221430
Data	T078	C1511726
gender	T032	C0079399
affected side	T033	C3166323
cause of injury	T033	C0552510
anatomical region	T029	C0005898
surgeries	T061	C0543467
cartilage	T024	C0007301
skin cover used	T074	C3874019
analyzed	T062	C0936012
patients	T101	C0030705
Acquired	T080	C0439661
auricular	T023	C1549094
deformities	T190	C0302142
bite injuries	T037	C0005658
traffic accidents	T037	C0000932
burns	T037	C0006434
post-otoplasty	T061	C0868838
complications	T046	C0009566
upper third of the auricle	T023	C0502136
injured	T169	C0332664
entire auricle	T023	C0013453
cases	T169	C0868928
reconstruction	T061	C0524865
costal cartilage	T024	C0222787
cutaneous cover	T082	C0221912
postauricular skin flap	T061	C0395655
cases	T169	C0868928
study	T062	C2603343
treatment	T169	C0039798
acquired	T080	C0439661
auricular	T023	C1549094
deformities	T190	C0302142
results	T169	C1274040
studies	T062	C2603343
literature	T170	C0023866
Bite wounds	T037	C0561546
acquired	T080	C0439661
auricular	T023	C1549094
injuries	T037	C3263723
upper third	T023	C0502136
reconstructions	T061	C0524865
costal cartilage	T024	C0222787
postauricular flap	T023	C0440884
deformity	T190	C0302142
Anatomic	T080	C0220784
assessment	T058	C0220825
left main bifurcation	T082	C1254362
dynamic bifurcation angles	T082	C1254362
computed tomography angiography	T060	C1536105
left main coronary artery	T023	C1261082
LMCA	T023	C1261082
anatomy	T017	C0700276
diagnosis	T080	C1704338
therapeutic	T061	C0087111
investigate	T169	C1292732
LMCA	T023	C1261082
anatomy	T017	C0700276
128-multisliced coronary computed-tomography-angiography	T060	C1536105
CCTA	T060	C1536105
patients	T101	C0030705
LMCA	T023	C1261082
CCTA	T060	C1536105
studies	T062	C0008972
study	T062	C2603343
Anatomical features	T017	C0700276
LMCA	T023	C1261082
cross-sectional areas	T082	C0552389
LMCA	T023	C1261082
ostial	T030	C0444567
LMCA	T023	C1261082
distal	T082	C0205108
LAD ostial	T023	C3898617
LCX	T023	C0815994
ostial	T030	C0444567
LMCA	T023	C1261082
bifurcation angles	T082	C1254362
BA	T082	C1254362
LMCA	T023	C1261082
LCX	T023	C0815994
BA	T082	C1254362
LMCA	T023	C1261082
LAD	T023	C3898617
BA	T082	C1254362
LAD	T023	C3898617
LCX	T023	C0815994
BA	T082	C1254362
end-diastole	T079	C1562146
end-systole	T079	C1563001
age	T032	C0001779
males	T032	C0086582
RCA	T023	C0226042
dominant	T169	C1527180
patients	T101	C0030705
LMCA	T023	C1261082
length	T081	C1444754
LMCA	T023	C1261082
ostial	T030	C0444567
LMCA	T023	C1261082
distal	T082	C0205108
LAD ostial	T023	C3898617
LCX	T023	C0815994
ostial	T030	C0444567
areas	T082	C0205146
LMCA	T023	C1261082
ostial	T030	C0444567
distal	T082	C0205108
area	T082	C0205146
LMCA	T023	C1261082
distal	T082	C0205108
LAD ostial	T023	C3898617
area	T082	C0205146
LMCA	T023	C1261082
distal	T082	C0205108
LCX	T023	C0815994
ostial	T030	C0444567
area ratios	T081	C1442066
patients	T101	C0030705
patients	T101	C0030705
Systolic motion	T070	C0026597
LMCA	T023	C1261082
BAs	T082	C1254362
systolic motion	T070	C0026597
LMCA	T023	C1261082
LAD	T023	C3898617
patients	T101	C0030705
LAD	T023	C3898617
LCX	T023	C0815994
patients	T101	C0030705
Patients	T101	C0030705
LAD	T023	C3898617
LCX	T023	C0815994
BA	T082	C1254362
LMCA	T023	C1261082
LAD ostial	T023	C3898617
area	T082	C0205146
LCX	T023	C0815994
ostial	T030	C0444567
area	T082	C0205146
diastolic-to-systolic range	T081	C1514721
DSR	T081	C1514721
LAD	T023	C3898617
LCX	T023	C0815994
BA	T082	C1254362
patients	T101	C0030705
LAD	T023	C3898617
LCX	T023	C0815994
BA	T082	C1254362
LMCA	T023	C1261082
T-shaped distal	T082	C0205108
BA	T082	C1254362
LMCA	T023	C1261082
LAD ostial	T023	C3898617
area	T082	C0205146
LCX	T023	C0815994
ostial	T030	C0444567
area	T082	C0205146
DSR	T081	C1514721
distal	T082	C0205108
BA	T082	C1254362
patients	T101	C0030705
Y-shaped distal	T082	C0205108
BA	T082	C1254362
findings	T033	C0243095
LMCA	T023	C1261082
bifurcation stenting	T061	C2348535
stents	T074	C0038257
LMCA	T023	C1261082
three	T081	C0205449
perspective study	T062	C2603343
home	T082	C0442519
nursing home residents	T098	C0682287
residents	T098	C0682287
care professionals	T097	C0018724
relatives	T099	C0080103
home	T082	C0442519
nursing home residents	T098	C0682287
multifactorial	T033	C1837655
phenomenon	T067	C1882365
important	T080	C3898777
quality	T080	C0332306
living	T078	C0376558
purpose	T169	C1285529
study	T062	C2603343
investigate	T169	C1292732
factors	T169	C1521761
influencing	T077	C4054723
home	T082	C0442519
older adults	T098	C3826770
residing	T052	C2982691
nursing home	T073	C0028688
residents	T098	C0682287
relatives	T099	C0080103
care professionals	T097	C0018724
participants	T098	C0679646
residents	T098	C0682287
relatives	T099	C0080103
care professionals	T097	C0018724
nursing homes	T073	C0028688
Netherlands	T083	C0027778
qualitative study	T062	C0949415
subsequent	T079	C0332282
interviews	T052	C0021822
focus groups	T096	C0016400
data	T078	C1511726
open ended coding	T080	C2827655
axial coding	T080	C0205556
selective coding	T080	C0205556
home	T082	C0442519
nursing home residents	T098	C0682287
influenced	T077	C4054723
factors	T169	C1521761
building	T073	C1999269
interior design	T073	C0021751
eating	T055	C0392339
drinking	T055	C0013124
autonomy	T078	C0085862
control	T169	C2587213
involvement	T169	C1314939
relatives	T099	C0080103
activities	T052	C0441655
quality of care	T058	C0034379
Residents	T098	C0682287
relatives	T099	C0080103
importance	T080	C3898777
nature	T078	C0349590
outdoors	T083	C1709359
coping strategies	T055	C0009967
Relatives	T099	C0080103
care professionals	T097	C0018724
organization	T092	C0029246
facilitation	T058	C0262752
care	T052	C1947933
residents	T098	C0682287
home	T082	C0442519
nursing home residents	T098	C0682287
influenced	T077	C4054723
multitude	T081	C0439064
factors	T169	C1521761
psychology	T169	C1524060
residents	T098	C0682287
social and built environmental contexts	T078	C0037414
holistic	T078	C0683249
factors	T169	C1521761
influence	T077	C4054723
home	T082	C0442519
residents	T098	C0682287
optimize	T052	C2698650
home	T082	C0442519
study	T062	C0949415
nursing home	T073	C0028688
nature	T078	C0349590
residence	T082	C0237096
place	T082	C0442504
people	T098	C0027361
numerous	T081	C0439064
one health	T091	C4277525
national health policies	T170	C0027458
developing countries	T080	C0011750
India's	T083	C0021201
Globally	T080	C2348867
threat	T078	C0749385
infectious diseases	T047	C0009450
emerging infectious diseases	T047	C0872315
originating	T079	C0439659
human	T016	C0086418
animal	T008	C0003062
environment	T082	C0014406
interface	T169	C1704675
health systems	T064	C1456613
pathogen	T001	C0450254
emergence	T047	C0872315
Asia	T083	C0003980
Africa	T083	C0001737
Latin America	T083	C0023122
policy frameworks	T170	C0242456
threat	T078	C0749385
urgent	T079	C0439609
Emergence of diseases	T047	C0872315
avian influenza	T047	C0016627
Ebola virus disease	T047	C0282687
threatened	T078	C0749385
social	T169	C0728831
disruption	T169	C0332453
established	T080	C0443211
intersectoral coordination/collaboration	T058	C4277663
events	T051	C0441471
initiation	T169	C1704686
establishing	T080	C0443211
institutionalised	T033	C0562359
collaborative frameworks	T054	C0282116
India	T083	C0021201
One Health approach	T091	C4277525
disease prevention and control	T058	C0085557
gains	T081	C1517378
influenza	T047	C0021400
control	T067	C2239193
infectious diseases	T047	C0009450
Intersectoral coordination	T058	C4277663
reactive	T080	C0205332
threats	T078	C0749385
systemic	T169	C0205373
failure	T169	C0231175
sustain	T169	C0443318
coordinated	T169	C0700114
response	T169	C0443286
draft	T170	C1547277
National Health Policy	T170	C0027458
failed	T169	C0231175
establish	T080	C0443211
intersectoral coordination	T058	C4277663
disease control approaches	T058	C0085557
linkages	T185	C0332280
human	T016	C0086418
health	T078	C0018684
animal	T008	C0003062
health	T078	C0018684
husbandry	T090	C0003052
agriculture	T090	C0001829
environmental	T082	C0014406
sectors	T083	C1708237
duplicative	T169	C0205173
weak response systems	T033	C0243095
absence	T169	C0332197
health impact assessment	T058	C3494320
development	T169	C1527148
agenda	T170	C0681473
policies	T170	C0242456
negative	T033	C0205160
effects	T080	C1280500
health	T078	C0018684
wellbeing of man	T170	C3813622
animal	T008	C0003062
environment	T082	C0014406
Lack of attention	T033	C1398138
capacity	T081	C1516240
critical	T080	C1511545
sectors	T083	C1708237
raised	T080	C0442818
challenges	T058	C0805586
deploying	T052	C2825812
mitigation	T067	C1553901
strategies	T041	C0679199
developing countries	T080	C0011750
India	T083	C0021201
portion	T082	C0449719
world's	T098	C2700280
poorest	T080	C0542537
livestock farmers	T097	C0335415
absence	T169	C0332197
policy	T170	C0242456
discourse	T054	C0009452
One Health approach	T091	C4277525
development	T169	C1527148
health policies	T089	C0018735
hurdle	T046	C0009566
eliminating	T052	C1883720
poverty	T102	C0032854
poverty	T102	C0032854
related	T080	C0439849
diseases	T047	C0012634
adoption	T080	C0332162
One Health approaches	T091	C4277525
health	T078	C0018684
sectoral	T082	C0439741
policies	T170	C0242456
critical	T080	C1511545
policy	T170	C0242456
India	T083	C0021201
developing countries	T080	C0011750
establish	T080	C0443211
preparedness	T033	C1318963
plans	T041	C0032074
encourage	T169	C1511253
policy environment	T064	C0282166
assessment	T058	C0220825
mitigation	T067	C1553901
downstream	T082	C0522506
impacts	T080	C4049986
agenda	T170	C0681473
incorporated	T169	C0243126
Assessment	T058	C0220825
demographic	T078	C0011292
pathoanatomic risk factors	T033	C0035648
recurrent	T079	C2945760
patellofemoral	T030	C0447801
instability	T033	C0022410
WARPS/STAID classification	T185	C0008902
clinical	T080	C0205210
assessment	T058	C0220825
features	T080	C2348519
anatomic	T080	C0220784
characteristics	T080	C1521970
subsets	T185	C1515021
patients	T101	C0030705
patellofemoral instability	T033	C0427262
population	T101	C0030705
purpose of this study	UnknownType	C0681832
demographics	T185	C1698647
prevalence	T081	C0220900
risky	T080	C1444641
pathoanatomies	T080	C1384516
patients	T101	C0030705
WARPS	T185	C0008902
STAID	T185	C0008902
recurrent	T079	C2945760
patellofemoral	T030	C0447801
instability	T033	C0022410
WARPS/STAID classification	T185	C0008902
Banff Patella Instability Instrument	T170	C0282574
BPII	T170	C0282574
Marx activity scale	T170	C0282574
Patellar	T023	C0030647
Instability Severity Score	T170	C0021504
ISS	T170	C0021504
patients	T101	C0030705
recurrent	T079	C2945760
patellofemoral	T030	C0447801
instability	T033	C0022410
WARPS	T185	C0008902
STAID subtype	T185	C0008902
patients	T101	C0030705
assessed	T052	C1516048
Clinical data	T170	C1516606
assessment	T058	C0220825
demographic	T078	C0011292
risk factors	T033	C0035648
sex	T032	C0079399
BMI	T201	C1305855
bilaterality	T082	C0238767
symptoms	T184	C1457887
affected	T082	C0449642
limb side	T023	C0015385
age	T032	C0001779
dislocation	T037	C0856775
pathoanatomic risk factors	T033	C0035648
TT-TG distance	T081	C0012751
patella	T023	C0030647
height	T032	C1317145
grade	T185	C0441800
trochlear dysplasia	T047	C4274287
Beighton score	T033	C4273179
rotational abnormalities	T033	C1704258
tibia	T023	C0040184
femur	T023	C0015811
Patients	T101	C0030705
BPII	T170	C0282574
Marx activity scale	T170	C0282574
ISS	T170	C0021504
calculated	T059	C1443182
clinical assessment data	T170	C1516606
Patients	T101	C0030705
WARPS	T185	C0008902
STAID subtypes	T185	C0008902
comparative analysis	T062	C0683941
t test	T170	C0871472
demographics	T185	C1698647
pathoanatomic risk factors	T033	C0035648
groups	UnknownType	C0681860
Convergent validity	T080	C1510594
Pearson r correlation coefficient	T081	C0871052
WARPS/STAID	T081	C0457451
ISS scores	T170	C0021504
Demographic risk factors	T078	C0011292
associated with	T080	C0332281
WARPS subtype	T185	C0008902
female sex	T032	C0086287
age	T032	C0001779
dislocation	T037	C0856775
bilaterality	T082	C0238767
Pathoanatomic risk factors	T033	C0035648
associated with	T080	C0332281
WARPS subtype	T185	C0008902
trochlear dysplasia	T047	C4274287
TT-TG distance	T081	C0012751
ligamentous laxity	T046	C0158359
rotational abnormalities	T033	C1704258
t test	T170	C0871472
ISS	T170	C0021504
WARPS subtype	T185	C0008902
STAID subtype	T185	C0008902
relationship	T080	C0439849
WARPS/STAID	T081	C0457451
ISS scores	T170	C0021504
Pearson r correlation coefficient	T081	C0871052
relationship	T080	C0439849
study	T062	C0008972
statistically significant	T081	C0237881
evidence	T078	C3887511
demographics	T185	C1698647
pathoanatomies	T080	C1384516
WARPS	T185	C0008902
STAID	T185	C0008902
patellofemoral	T030	C0447801
instability	T033	C0022410
subtypes	T185	C0449560
quality-of-life	T078	C0034380
activity level	T033	C0683317
subtypes	T185	C0449560
WARPS/STAID score	T081	C0457451
convergent validity	T080	C1510594
ISS	T170	C0021504
divergent validity	T081	C2349101
BPII score	T170	C0282574
Marx activity scale	T170	C0282574
study	T062	C0008972
WARPS/STAID classification	T185	C0008902
ISS	T170	C0021504
patients	T101	C0030705
recurrent	T079	C2945760
patellofemoral	T030	C0447801
instability	T033	C0022410
Expression	T045	C1171362
caspase 3	T116	C0291573
ovarian follicle	T023	C0018120
cells	T025	C0007634
lizard	T014	C0023916
Podarcis sicula	T014	C1025381
caspase 3	T116	C0291573
previtellogenesis	T042	C0042895
ovarian	T023	C0205065
follicular epithelium	T024	C0040300
lizard	T014	C0023916
Podarcis sicula	T014	C1025381
localization	T169	C0475264
caspase 3	T116	C0291573
enzyme assay	T059	C2717977
Western blotting	T059	C0005863
immunocytochemistry	T059	C0242349
fragment	T080	C1708096
caspase 3	T028	C1413132
cloned	T059	C0598888
species	T185	C1705920
sequenced	T169	C1561491
in situ hybridization	T063	C0162788
localize	T082	C0392752
messengers	UnknownType	C0815028
phylogenetic survey	T062	C1519068
homology	T080	C2697616
reptilian	T014	C0035161
caspases	T116	C0010656
follicle	T023	C1571705
cells	T025	C0007634
expressed	T045	C1171362
caspase	T116	C0010656
mRNA	T114	C0035696
caspase 3	T116	C0291573
transcribed	T045	C0040649
stem phase	T079	C0205390
translated	T044	C0597295
cell differentiation	T043	C0007589
proform protein	T116	C0033684
differentiated (nurse) stage	T080	C0205615
activated	T045	C0599177
previtellogenesis	T042	C0042895
degeneration of cells	T046	C0333467
protein sequence	T087	C0002518
reptilian	T014	C0035161
caspases 3	T116	C0291573
epithelial cells	T025	C0014597
ovarian follicle	T023	C0018120
caspase 3	T116	C0291573
nurse stage	T080	C0205615
apoptosis	T043	C0162638
Increased	T081	C0205217
acute	T079	C0205178
mortality	T081	C0205848
chemoradiotherapy	T061	C0436307
locally advanced head and neck cancer	T191	C0278996
patients	T101	C0030705
years	T079	C1510829
Concurrent chemoradiotherapy	T061	C3178775
CRT	T061	C3178775
standard of care	T061	C2936643
sites	T082	C0205145
locally advanced head and neck squamous cell carcinomas	T191	C1168401
LAHNC	T191	C1168401
meta-analysis	T062	C0920317
chemotherapy	T061	C3665472
survival	T169	C0220921
patients	T101	C0030705
years	T079	C1510829
elderly	T098	C0001792
patients	T101	C0030705
treated	T169	C1522326
CRT	T061	C3178775
increased	T081	C0205217
toxicity	T037	C0600688
improvements	T077	C2986411
survival	T169	C0220921
single-institution	T093	C2607850
IRB-approved	T170	C2346499
retrospective study	T062	C0035363
patients	T101	C0030705
treated	T169	C1522326
CRT	T061	C3178775
LAHNC	T191	C1168401
Multivariate models	T081	C0026348
death	T033	C1306577
months	T079	C0439231
death	T033	C1306577
time	T079	C0040223
logistic regression	T062	C0206031
Cox modeling	T062	C0870071
Patients	T101	C0030705
years	T079	C1510829
treated	T169	C1522326
concurrent	T079	C0205420
cisplatin	T121	C0008838
weeks	T079	C0439230
weekly	T079	C0439230
carboplatin	T109	C0079083
patients	T101	C0030705
years	T079	C1510829
Patients	T101	C0030705
years	T079	C1510829
increased	T081	C0205217
toxicity	T037	C0600688
treatment	T061	C0087111
hospitalizations	T058	C0019993
PEG removal	T061	C0087111
follow-up	T058	C1522577
death	T033	C1306577
proportion	T081	C1709707
patients	T101	C0030705
years	T079	C1510829
months	T079	C0439231
CRT	T061	C3178775
Patients	T101	C0030705
increased	T081	C0205217
risk	T078	C0035647
death	T033	C1306577
months	T079	C0439231
CRT	T061	C3178775
odds ratio	T081	C0028873
CI	T081	C0009667
survival	T169	C0220921
time	T079	C0040223
hazard ratio	T081	C2985465
CI	T081	C0009667
Patients	T101	C0030705
years	T079	C1510829
treated	T169	C1522326
toxic	T080	C1407029
chemotherapy	T061	C3665472
rates	T081	C1521828
hospitalization	T058	C0019993
treatment	T061	C0087111
increased	T081	C0205217
rates	T081	C1521828
acute	T079	C0205178
mortality	T081	C0205848
CRT	T061	C3178775
efficacy	T080	C1280519
chemoradiotherapy	T061	C0436307
elderly	T098	C0001792
patients	T101	C0030705
prospective setting	T080	C0205556
Food security	T080	C3178753
nutritional status	T033	C0392209
children	T100	C0008059
foster care	T073	C0599759
nutritional status	T033	C0392209
foster children	T099	C0337544
quality	T080	C0332306
daily menus	T168	C0016452
group homes	T073	C0018257
Food Security	T080	C3178753
organizations	T092	C1561598
study	T062	C2603343
children	T100	C0008059
group homes	T073	C0018257
group A	UnknownType	C0681860
children	T100	C0008059
general population	T098	C0683971
group B	UnknownType	C0681860
nutritional status	T033	C0392209
BMI percentiles	T033	C2227318
Mean	T081	C0444504
percentiles	T081	C1264641
groups	UnknownType	C0681860
statistical analysis	T062	C0871424
nutritional	T033	C0392209
caloric daily distributions	T033	C2164132
organization	T092	C1561598
recall method	T170	C0025663
questionnaire	T170	C0034394
Food Security	T080	C3178753
analysis	T062	C0936012
mean	T081	C0444504
BMI	T201	C1305855
age	T032	C0001779
percentiles	T081	C1264641
differences	T033	C3842396
group A	UnknownType	C0681860
group B	UnknownType	C0681860
average	T081	C1510992
daily	T079	C0332173
nutrient	T033	C0392209
calorie distribution	T033	C0392209
group homes	T073	C0018257
nearly optimal	T033	C0243095
excess	T080	C1979886
proteins	T168	C0453858
deficiency	T169	C0011155
PUFAs	T109	C0032615
low intake	T033	C0231353
iron	T033	C0518043
calcium	T201	C0489458
organizations	T092	C1561598
High Food Security	T080	C3178753
Nutritional conditions	T033	C0392209
foster children	T099	C0337544
children	T100	C0008059
general population	T098	C0683971
Foster care	T073	C0599759
necessary conditions	T080	C0337645
growth	T040	C0018270
Incontinence	T047	C0021167
dermatitis	T047	C0011603
reducing	T080	C0392756
adverse events	T046	C0879626
Incontinence	T047	C0021167
dermatitis	T047	C0011603
IAD	T047	C0011603
problem	T033	C0033213
patients	T101	C0030705
faecal	T047	C0015732
urinary incontinence	T046	C0042024
Urine	T031	C0042036
skin	T022	C1123023
flora	T033	C0314761
permeability	T070	C0031164
stratum corneum	T024	C0221921
faecal	T031	C0015733
enzymes	T116	C0014442
skin	T022	C1123023
skin damage	T184	C0849640
Faecal	T031	C0015733
bacteria	T007	C0004611
penetrate	T169	C0205321
skin	T022	C1123023
risk	T078	C0035647
secondary infection	T047	C0442886
IAD	T047	C0011603
prevented	T061	C0199176
healed	T169	C0205249
appropriate	T080	C1548787
skin cleansing	T061	C0455082
skin protection	T201	C1543231
appropriate	T080	C1548787
containment devices	T074	C0181299
HARTMANN incontinence pads	T074	C0085099
fluids	T167	C0302908
IAD	T047	C0011603
skin's	T022	C1123023
acidic pH	T081	C0020283
acidic pH	T081	C0020283
skin	T022	C1123023
barrier function	T042	C2246986
infection	T046	C3714514
acidic pH	T081	C0020283
skin	T022	C1123023
damage	T169	C1883709
Feasibility	T062	C0015730
transition	T052	C2700061
intervention	T061	C0184661
aimed	T078	C1947946
adolescents	T100	C0205653
chronic illness	T047	C0008679
International	T078	C1512888
guidelines	T170	C0162791
transition	T052	C2700061
programmes	T058	C0043113
adolescents	T100	C0205653
chronic illness	T047	C0008679
inadequate	T080	C0205412
transition	T052	C2700061
poor disease control	T033	C0421179
risk	T078	C0035647
lacking	T080	C0332268
outpatient follow-up	T058	C0589125
investigate	T169	C1292732
feasibility	T062	C0015730
transition	T052	C2700061
intervention	T061	C0184661
aimed	T078	C1947946
adolescents	T100	C0205653
chronic illness	T047	C0008679
focusing	T041	C0589098
declines	T055	C1136454
drop-outs	T098	C0030686
no-shows	T081	C4042858
advantages	T078	C1254370
disadvantages	T078	C1254370
participating	T169	C0679823
adolescents	T100	C0205653
juvenile idiopathic arthritis	T047	C3495559
JIA	T047	C3495559
participate	T169	C0679823
randomised controlled trial	T062	C0206035
RCT	T062	C0206035
transition	T052	C2700061
intervention	T061	C0184661
Reasons	T078	C0392360
decline	T055	C1136454
drop-outs	T098	C0030686
calculated	T169	C0444686
Adolescents	T100	C0205653
experiences	T041	C0596545
advantages	T078	C1254370
disadvantages	T078	C1254370
participating	T169	C0679823
reasons	T078	C0392360
no-shows	T081	C4042858
investigated	T169	C1292732
focus groups	T096	C0016400
telephone interviews	T062	C0021823
analysed	T062	C0936012
thematic	T062	C0949415
analysis	T062	C0936012
patients	T101	C0030705
declined to participate	T055	C1136454
intervention	T061	C0184661
dropped out	T098	C0030686
intervention	T061	C0184661
Unspecified	T080	C0205370
declines	T055	C1136454
practical issues	T033	C0033213
common	T081	C0205214
reason	T078	C0392360
decline	T055	C1136454
do not wish to continue	T053	C0004927
common	T081	C0205214
reason	T078	C0392360
drop-out	T098	C0030686
Reasons	T078	C0392360
no-shows	T081	C4042858
forgetting	T048	C0598853
Advantages	T078	C1254370
participating	T169	C0679823
participating	T169	C0679823
without	T080	C0332288
parents	T099	C0030551
trust	T054	C0237935
confidentiality	T078	C0009669
agenda	T170	C0681473
responsiveness	T169	C0205342
Disadvantages	T078	C1254370
unclear	T033	C3845108
aim	T078	C1947946
study	T062	C2603343
JIA	T047	C3495559
conversations	T054	C0871703
transport	T056	C0040802
issues	T033	C0033213
adolescents	T100	C0205653
difficulties	T033	C1299586
understanding	T041	C0162340
aim	T078	C1947946
intervention	T061	C0184661
participants	T100	C0205653
conversations	T054	C0871703
trust	T054	C0237935
confidentiality	T078	C0009669
communication	T054	C0009452
adolescents	T100	C0205653
programmes	T058	C0043113
preferences	T078	C0558295
cooperation	T054	C0392337
parents	T099	C0030551
health care providers	T097	C0018724
High-Throughput Analysis	T060	C0872186
IgG N-Glycome	T116	C0208205
UPLC	T059	C0008565
FLR	T074	C0180919
biological	T080	C0205460
clinical	T080	C0205210
relevance	T080	C2347946
glycosylation	T070	C0017982
apparent	T078	C0750489
large scale studies	T062	C2603343
glycome	T109	C2348869
Glycans	T109	C0032594
immunoglobulin G	T116	C0020852
IgG	T116	C0020852
essential	T080	C0205224
function	T039	C0031843
IgG	T116	C0020852
glycosylation	T070	C0017982
change	T169	C0392747
processes	T067	C1522240
IgG	T116	C0020852
glycoproteins	T116	C0017968
approaches	T082	C0449445
liquid chromatography	T059	C0008565
capillary gel electrophoresis	T059	C0596607
mass spectrometry	T059	C0037813
study	T062	C2603343
IgG	T116	C0020852
glycosylation	T070	C0017982
Generation	T052	C3146294
high-quality	T080	C0205556
glycomics	T090	C1512223
data	T078	C1511726
high-throughput	T170	C0872047
reproducible	T081	C0035149
robust	T080	C2986815
sample preparation	T059	C3824791
accurate	T080	C0443131
quantitative analysis	UnknownType	C0681919
chapter	T078	C1552857
protocol	T170	C2348563
high-throughput	T170	C0872047
IgG N-glycan	T116	C0208205
release	T169	C1283071
fluorescent labeling	T059	C0022885
cleanup	T169	C0243114
analysis	T062	C0936012
fluorescently labeled	T080	C1708632
IgG N-glycans	T116	C0208205
hydrophilic interaction liquid chromatography	T059	C0008565
HILIC	T059	C0008565
ultra performance liquid chromatography	T059	C0008565
UPLC	T059	C0008565
fluorescence	T070	C0016315
FLR	T074	C0180919
detection	T061	C1511790
Biomimetic	T073	C1136386
whitlockite	T122	C0078483
inorganic	T077	C1881215
nanoparticles	T073	C1450054
in situ	T082	C0444498
remodeling	T042	C0085268
bone regeneration	T042	C0005972
Bone remodeling	T042	C0085268
complex	T080	C0439855
signaling pathway	T044	C0037080
osteoblasts	T025	C0029418
osteoclasts	T025	C0029431
mechanisms	T169	C0441712
homeostasis	T038	C0019868
growth	T043	C0007595
differentiation	T043	C0007589
signaling pathways	T044	C0037080
cells	T025	C0007634
bone	T023	C0262950
extracellular matrices	T024	C0015350
bone remodeling	T042	C0085268
ionic	T196	C0022023
concentration	T081	C1446561
elucidated	T052	C2986669
synthetic	T052	C1883254
whitlockite	T122	C0078483
WH: Ca18Mg2(HPO4)2(PO4)12)	T122	C0078483
nanoparticles	T073	C1450054
recapitulate	T169	C0205341
bone regeneration	T042	C0005972
stimulating	T070	C1948023
osteogenic differentiation	T043	C0007589
prohibiting	T169	C1292733
osteoclastic	T025	C0029431
activity	T052	C0441655
transforming	T043	C0040682
hydroxyapatite	T197	C0020326
HAP	T197	C0020326
neo bone tissues	T024	C0391978
PO4(3-)	T121	C1601799
Mg(2+)	T121	C2346927
physiological	T169	C0205463
conditions	T080	C0348080
structural analysis	T062	C0242481
phase	T079	C0205390
transformation	T043	C0040682
WH	T122	C0078483
HAP	T197	C0020326
factor	T169	C1521761
bone regeneration	T042	C0005972
denser	T080	C0439794
hierarchical	T169	C0699032
neo-bone	T023	C0262950
structure	T082	C0678594
findings	T033	C0243095
living	T078	C0376558
bone	T023	C0262950
minerals	T197	C0026162
actively	T169	C0205177
communicate	T043	C0007582
induce	T169	C0205263
self-healing	T042	C1254358
bone	T023	C0262950
minerals	T197	C0026162
passive	T080	C3686820
cellular	T025	C0007634
mineralization	T042	C1254358
inactivation	T169	C0544461
dentin	T031	C0011429
proteases	T116	C1947941
crosslinkers	T130	C0010360
reversible	T169	C0205343
Inactivation	T169	C0544461
dentin	T031	C0011429
proteases	T116	C1947941
crosslinkers	T130	C0010360
suggested	T078	C1705535
prevent	T080	C2700409
degradation	T044	C0314674
dentin	T031	C0011429
collagen	T116	C0009325
hybrid	T116	C0598148
layer	T082	C1254362
not known	T080	C0439673
inhibition	T052	C3463820
reversible	T169	C0205343
aim	T078	C1947946
study	T062	C2603343
evaluate	T052	C0441655
inactivation	T169	C0544461
effect	T080	C1280500
crosslinkers	T130	C0010360
dentin	T031	C0011429
protease	T116	C1947941
activity	T044	C0243102
period	T079	C1948053
Demineralized dentin beams	T122	C0296481
treated with	T169	C1522326
glutaraldehyde	T109	C0017814
GA1	T109	C0017814
glutaraldehyde	T109	C0017814
GA5	T109	C0017814
grape seed extract	T109	C0772454
GS1	T109	C0772454
grape seed extract	T109	C0772454
GS5	T109	C0772454
sumac berry extract	T002	C4047315
S	T002	C4047315
20μM curcumin	T109	C0010467
CR20	T109	C0010467
curcumin	T109	C0010467
CR200	T109	C0010467
Untreated	T033	C0243095
beams	T122	C0296481
control	T096	C0009932
beams	T122	C0296481
incubated	T059	C1439852
incubation media	T130	C0358514
analyze	T062	C0936012
solubilized	T080	C1948047
telopeptide	T116	C0030956
ICTP	T116	C1101784
CTX	T116	C1173299
fragments	T116	C0030935
indicators	T169	C1522602
MMP	T116	C0623362
cathepsin K	T116	C0284930
degradation	T044	C0314674
incubation	T059	C1439852
relative	T080	C0205345
MMP	T116	C0623362
activity	T044	C1148560
dentin beams	T122	C0296481
generic	T077	C1705810
MMP	T116	C0623362
assay	T059	C2717977
Data	T078	C1511726
analyzed	T062	C0936012
repeated-measures	T062	C0871881
ANOVA	T081	C0002780
treated	T169	C1522326
groups	T078	C0441833
significant	T078	C0750502
decrease	T081	C0547047
CTX	T116	C1173299
dentin	T031	C0011429
ICTP	T116	C1101784
dentin	T031	C0011429
fragments	T116	C0030935
incubation	T059	C1439852
compared	T052	C1707455
control	T096	C0009932
dentin	T031	C0011429
GA5	T109	C0017814
GS5	T109	C0772454
CR200	T109	C0010467
maintained	T169	C1314677
inhibitory	T052	C3463820
effect	T080	C1280500
incubation	T059	C1439852
results	T034	C1254595
dry mass loss	T067	C1254366
relative	T080	C0205345
MMP	T116	C0623362
activity	T044	C1148560
results	T033	C0683954
study	T062	C2603343
long-term effect	T067	C0023983
crosslinker	T130	C0010360
dose dependent	T081	C1512045
Inhibition	T044	C0021469
STEP61	T116	C3883719
ameliorates	T080	C0205556
deficits	T080	C2987487
mouse	T015	C0025929
hiPSC	T025	C3658289
schizophrenia	T048	C0036341
models	T050	C0012644
brain	T023	C0006104
specific	T080	C0205369
tyrosine phosphatase	T116	C0085536
STEP	T116	C3883719
STriatal-Enriched protein tyrosine Phosphatase	T116	C3883719
regulator	T077	C1704735
synaptic function	T043	C0027793
STEP	T116	C3883719
synaptic	T030	C0039062
strengthening	T080	C0205556
increasing	T081	C0205217
N-methyl D-aspartate glutamate receptor	T116	C0080093
NMDAR	T116	C0080093
internalization	T067	C0599281
dephosphorylation	T044	C3160734
GluN2B	T116	C1741283
inactivation	T044	C0314679
kinases	T116	C0031727
extracellular signal-regulated kinase 1	T116	C0082529
2	T116	C0170168
Fyn	T116	C1530914
STEP61	T116	C3883719
elevated	T080	C3163633
cortex	T023	C1176472
Nrg1(+/-)	T028	C1367656
knockout	T050	C1522225
mouse model	T050	C2986594
schizophrenia	T048	C0036341
SZ	T048	C0036341
Genetic	T169	C0314603
reduction	T061	C0441610
pharmacological	T169	C0205464
inhibition	T052	C3463820
STEP	T116	C3883719
prevents	T169	C1292733
NMDARs	T116	C0080093
synaptic membranes	T026	C0039063
behavioral deficits	T048	C0004930
Nrg1(+/-)	T028	C1367656
mice	T015	C0025929
STEP61 protein	T116	C3883719
increased	T081	C0205217
cortical	T023	C1176472
lysates	T072	C1881488
central nervous system	T022	C3714787
specific	T080	C0205369
ErbB2	T116	C0069515
4	T116	C0214098
mouse model	T050	C2986594
SZ	T048	C0036341
human induced pluripotent stem cell	T025	C3658289
hiPSC	T025	C3658289
forebrain	T023	C0085140
neurons	T025	C0027882
Ngn2	T028	C1422204
induced	T169	C0205263
excitatory neurons	T025	C0027882
independent	T169	C0332291
SZ	T048	C0036341
patient	T101	C0030705
cohorts	T098	C0599755
selected	T052	C1707391
SZ	T048	C0036341
models	T050	C0012644
increased	T081	C0205217
STEP61	T116	C3883719
protein levels	T059	C0542493
reduced	T080	C0392756
ubiquitination	T044	C1519751
degradation	T044	C0597297
convergent	T080	C0205556
findings	T033	C0243095
mouse	T015	C0025929
hiPSC	T025	C3658289
SZ	T048	C0036341
models	T050	C0012644
provide	T052	C1999230
evidence	T078	C3887511
STEP61	T116	C3883719
dysfunction	T077	C3887504
SZ	T048	C0036341
Incident	T067	C1551358
fracture	T037	C0016658
associated with	T080	C0332281
increased	T081	C0205217
risk	T078	C0035647
mortality	T081	C0205848
frailty	T033	C0424594
status	T080	C0449438
elderly	T098	C0001792
Japanese	T098	C1556094
men	T098	C0025266
Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Cohort Study	T081	C0009247
Frail	T033	C0871754
elderly	T098	C0001792
individuals	T098	C0237401
elevated	T080	C3163633
risks	T078	C0035647
fracture	T037	C0016658
mortality	T081	C0205848
incident	T067	C1551358
fractures	T037	C0016658
associated with	T080	C0332281
increased	T081	C0205217
risk	T078	C0035647
death	T033	C1306577
pre-fracture	T037	C0016658
frailty	T033	C0424594
status	T080	C0449438
physical performance tests	T060	C0679543
laboratory tests	T059	C0022885
geriatric	T080	C1704440
diseases	T047	C0012634
community-dwelling	T056	C4045975
elderly	T098	C0001792
Japanese	T098	C1556094
men	T098	C0025266
fractures	T037	C0016658
increase	T169	C0442805
risk	T078	C0035647
mortality	T081	C0205848
frailty	T033	C0424594
complicate	T169	C0231242
association	T080	C0439849
false-positive result	T033	C1112254
evaluated	T058	C0220825
association	T080	C0439849
pre-fracture	T037	C0016658
levels	T080	C0441889
frailty	T033	C0424594
examined	T033	C0332128
community-dwelling	T056	C4045975
ambulatory	T169	C0439841
men	T098	C0025266
aged	T032	C0001779
years	T079	C1510829
baseline	T081	C1442488
Fujiwara-kyo Osteoporosis Risk in Men Study	T081	C0009247
frailty	T033	C0424594
status	T080	C0449438
activities of daily living	T056	C0001288
ADL	T056	C0001288
physical performance tests	T060	C0679543
grip strength	T081	C0429271
one-foot standing balance with eyes open	T033	C0516711
timed 10-m walk	T060	C2315460
laboratory sera tests	T059	C0022885
sera	T031	C0229671
Participants	T098	C0679646
years	T079	C0439234
incident	T067	C1551358
clinical	T080	C0205210
fractures	T037	C0016658
death	T033	C1306577
Effects of	T080	C1704420
incident	T067	C1551358
fracture	T037	C0016658
death	T033	C1306577
Cox proportional hazards model	T081	C0033489
fracture	T037	C0016658
follow-up	T058	C1522577
time-dependent predictor	T078	C2698872
frailty status indices	T170	C4075886
covariates	T080	C0205556
identified	T080	C0205396
fractures	T037	C0016658
men	T098	C0025266
deaths	T033	C1306577
follow-up	T058	C1522577
period	T079	C1948053
median	T082	C2939193
follow-up	T058	C1522577
years	T079	C0439234
Participants	T098	C0679646
incident	T067	C1551358
fractures	T037	C0016658
not have significantly worse	T033	C0243095
frailty	T033	C0424594
statuses	T080	C0449438
significantly	T078	C0750502
higher	T080	C0205250
cumulative	T080	C1511559
mortality rate	T081	C0205848
fractures	T037	C0016658
Age-adjusted	T081	C4300468
hazard ratio	T081	C2985465
HR	T081	C2985465
death	T033	C1306577
incident	T067	C1551358
fracture	T037	C0016658
confidence interval	T081	C0009667
physical performance	T032	C2607857
decreased	T081	C0205216
significant	T078	C0750502
HR	T081	C2985465
no significant change	T033	C0442739
laboratory test results	T034	C1254360
Exclusion	T052	C2828389
deaths	T033	C1306577
months	T079	C0439231
follow-up	T058	C1522577
not alter	T033	C0243095
results	T034	C0456984
Incident	T067	C1551358
clinical	T080	C0205210
fracture	T037	C0016658
associated with	T080	C0332281
elevated	T080	C3163633
risk	T078	C0035647
death	T033	C1306577
independently	T033	C1299583
pre-fracture	T037	C0016658
levels	T080	C0441889
frailty	T033	C0424594
community-dwelling	T056	C4045975
elderly	T098	C0001792
men	T098	C0025266
Total Energy Expenditure	T033	C0429629
Obese	T047	C0028754
Kuwaiti Primary School	T073	C0036375
Children	T100	C0008059
Assessed	T052	C1516048
Doubly-Labeled Water Technique	T169	C0449851
pilot study	T062	C0031928
assess	T052	C1516048
total energy expenditure	T033	C0429629
TEE	T033	C0429629
obese	T047	C0028754
years	T079	C0439234
Kuwaiti	T098	C1257890
children	T100	C0008059
girls	T100	C0870604
boys	T100	C0870221
Total body water	T033	C0429632
TBW	T033	C0429632
TEE	T033	C0429629
assessed	T052	C1516048
doubly-labeled water technique	T169	C0449851
TBW	T033	C0429632
intercept	T081	C3146232
elimination rate	T033	C0231360
deuterium	T196	C0011744
TEE	T033	C0429629
difference	T081	C1705241
elimination rates	T033	C0231360
(18)O	T121	C0030061
deuterium	T196	C0011744
TBW	T033	C0429632
estimate	T081	C0750572
fat-free mass	T033	C0424679
FFM	T033	C0424679
hydration	T067	C0596317
factors	T169	C1521761
ages	T032	C0001779
gender	T032	C0079399
Fat mass	T032	C3656665
FM	T032	C3656665
calculated	T052	C1441506
difference	T081	C1705241
body weight	T032	C0005910
FFM	T033	C0424679
Body weight	T032	C0005910
statistically different	T081	C1705241
TBW	T033	C0429632
significantly higher	T080	C0205250
boys	T100	C0870221
girls	T100	C0870604
girls	T100	C0870604
significantly higher	T080	C0205250
estimated	T081	C0750572
FM	T032	C3656665
TEE	T033	C0429629
significantly higher	T080	C0205250
boys	T100	C0870221
girls	T100	C0870604
Estimated	T081	C0750572
physical activity level	T033	C3694575
PAL	T033	C3694575
significantly higher	T080	C0205250
boys	T100	C0870221
results	T169	C1274040
dataset	T170	C0150098
TEE	T033	C0429629
years	T079	C0439234
obese	T047	C0028754
Kuwaiti	T098	C1257890
children	T100	C0008059
gender differences	T032	C0036866
school based interventions	T058	C0679800
childhood obesity	T047	C2362324
Mesenchymal stromal cells	T025	C3178844
clinical	T080	C0205210
kidney transplantation	T061	C0022671
tolerant	T169	C0231198
Progress	T169	C1280477
improvement	T077	C2986411
short-term	T079	C0443303
long-term	T079	C0443252
outcomes	T080	C0085415
kidney transplantation	T061	C0022671
plateau	T081	C2964353
consequences of	T169	C0686907
efficient	T080	C0442799
nonspecific	T078	C0750540
immunosuppressive drugs	T121	C0021081
cell therapy	T061	C0302189
mesenchymal stromal cells	T025	C3178844
alternative	T077	C1523987
strategy	T170	C0679716
therapy	T061	C0087111
therapies	T061	C0087111
controlled	T169	C2587213
tapering	T058	C0441640
immunosuppressive medication	T121	C0021081
ambition	T041	C0870128
generating	T052	C3146294
donor	T098	C0013018
immune regulation	T040	C1327458
tolerance	T046	C0020963
alloimmunity	T042	C0598604
direct	T080	C0439851
indirect	T080	C0439852
semi-direct	T080	C0205556
alloantigen	T129	C0002131
donor	T098	C0013018
immune regulation	T040	C1327458
mechanisms	T169	C0441712
mesenchymal stromal cells	T025	C3178844
alloimmunity	T042	C0598604
interaction	T043	C0007582
antigen presenting cells	T025	C0003315
dendritic cells	T025	C0011306
critical	T080	C1511545
importance	T080	C3898777
current	T079	C0521116
status	T080	C0449438
clinical trials	T062	C0008976
mesenchymal stromal cells	T025	C3178844
kidney transplantation	T061	C0022671
therapeutic strategies	T061	C0087111
contribute	T052	C1880177
control	T080	C0243148
alloreactivity	T042	C0598604
organ transplantation	T061	C0029216
Facilitating factors	T169	C1521761
barriers	T080	C4045969
malaria	T047	C0024530
research	T062	C0035168
utilization	T169	C0042153
policy development	T064	C0242440
Malawi	T083	C0024548
Research	T062	C0035168
determinants	T169	C1521761
health	T078	C0018684
providing	T052	C1999230
evidence	T078	C3887511
policy development	T064	C0242440
successful	T080	C1272703
Utilization	T169	C0042153
research	T062	C0035168
intricate	T080	C0439855
process	T067	C1522240
contextual factors	UnknownType	C0683580
enhancing	T052	C2349975
factors	T169	C1521761
barriers	T080	C4045969
research	T062	C0035168
utilization	T169	C0042153
malaria	T047	C0024530
policy development	T064	C0242440
Malawi	T083	C0024548
Qualitative	T080	C0205556
research	T062	C0035168
interviews	T052	C0021822
informants	T098	C0870704
malaria	T047	C0024530
researchers	T097	C0035173
policy makers	T097	C0242170
programme	T057	C0683739
managers	T097	C0335141
key stakeholders	T098	C1257890
Purposive sampling	T062	C0681880
snowballing techniques	T062	C2348215
identifying	T080	C0205396
informants	T098	C0870704
Interview	T052	C0021822
transcripts	T170	C0034869
entered	T080	C1521975
QSR Nvivo 11 software	T073	C0037585
analysis	T062	C0936012
Respondents	T098	C0282122
identified	T080	C0205396
global	T080	C2348867
efforts	T052	C0441655
knowledge translation	T062	C3494164
local	T082	C0205276
political will	T068	C0032380
conducive	T080	C3898897
research	T062	C0035168
utilization	T169	C0042153
factors	T169	C1521761
availability of	T169	C0470187
research	T062	C0035168
availability of	T169	C0470187
local	T082	C0205276
researchers	T097	C0035173
stakeholders	T098	C1257890
supporting	T077	C1521721
knowledge translation	T062	C3494164
barriers	T080	C4045969
lack	T080	C0332268
researcher	T097	C0035173
public	T092	C0678367
engagement	T033	C2937292
politics	T057	C0032379
researchers'	T097	C0035173
lack	T080	C0332268
communication skills	T032	C0870313
lack	T080	C0332268
research	T062	C0035168
collaborations	T054	C0282116
funder driven research	T062	C0681805
unknown	T080	C0439673
World Health Organization	T093	C0043237
policy	T170	C0242456
lack	T080	C0332268
malaria	T047	C0024530
research	T062	C0035168
repository	T073	C3847505
identified	T080	C0205396
facilitating factors	T169	C1521761
malaria	T047	C0024530
research	T062	C0035168
utilization	T169	C0042153
policy development	T064	C0242440
Malawi	T083	C0024548
factors	T169	C1521761
systematically	T169	C0220922
coordinated	T169	C0700114
identified	T080	C0205396
barriers	T080	C4045969
improve	T033	C0184511
malaria	T047	C0024530
research	T062	C0035168
utilization	T169	C0042153
policy development	T064	C0242440
Malaria	T047	C0024530
research	T062	C0035168
implementation	T052	C1708476
evidence-based	T078	C3887511
reduce	T080	C0392756
malaria	T047	C0024530
burden	T078	C2828008
paradigm shift	T062	C0681797
malaria	T047	C0024530
control	T169	C2587213
elimination	T052	C1948029
Malawi	T083	C0024548
Altered	T169	C0392747
interregional	T029	C0005898
correlations	T080	C1707520
serotonin transporter	T116	C0170657
availability	T169	C0470187
cerebral glucose	T109	C1988487
glucose metabolism	T044	C0596620
schizophrenia	T048	C0036341
high-resolution PET	T060	C0032743
[(11)C]DASB	T109	C1570551
[(18)F]FDG	T109	C0046056
interregional	T029	C0005898
correlations	T080	C1707520
serotonin transporter	T116	C0170657
SERT	T116	C0170657
availability	T169	C0470187
glucose metabolism	T044	C0596620
7-Tesla magnetic resonance imaging	T060	C0024485
MRI	T060	C0024485
high-resolution positron emission tomography	T060	C0032743
PET	T060	C0032743
(11)C-3-amino-4-(2-dimethylaminomethylphenylthio)benzonitrile	T109	C1570551
[(11)C]DASB	T109	C1570551
[(18)F]fluorodeoxyglucose	T109	C0046056
[(18)F]FDG	T109	C0046056
antipsychotic-free patients	T101	C0030705
schizophrenia	T048	C0036341
disrupted	T080	C0332454
functional connectivity	T169	C1707489
schizophrenia	T048	C0036341
patients	T101	C0030705
schizophrenia	T048	C0036341
healthy controls	T080	C2986479
high-resolution PET	T060	C0032743
MRI	T060	C0024485
binding potential	T067	C2986841
BPND	T067	C2986841
[(11)C]DASB	T109	C1570551
standardized uptake value ratio	T081	C3897504
SUVR	T081	C3897504
[(18)F]FDG	T109	C0046056
SERT	T116	C0170657
availability	T169	C0470187
region of interest	T082	C0807727
ROI	T082	C0807727
analyses	T062	C0936012
region	T029	C1273723
anterior	T082	C0205094
hippocampus	T023	C0019564
SERT	T116	C0170657
availability	T169	C0470187
patients	T101	C0030705
schizophrenia	T048	C0036341
controls	T096	C0009932
ROI	T082	C0807727
voxel	T077	C2700259
analyses	T062	C0936012
[(18)F]FDG	T109	C0046056
SUVR values	T081	C3897504
patients	T101	C0030705
controls	T096	C0009932
right superior frontal gyrus	T023	C2338731
medial part	T082	C0442056
left superior frontal gyrus	T023	C2334005
interregional	T029	C0005898
correlations	T080	C1707520
[(11)C]DASB	T109	C1570551
BPND	T067	C2986841
[(18)F]FDG	T109	C0046056
SUVR	T081	C3897504
positive	T033	C1514241
correlations	T080	C1707520
brain regions	T029	C1273723
control subjects	T096	C0009932
patients	T101	C0030705
schizophrenia	T048	C0036341
patients	T101	C0030705
control subjects	T096	C0009932
correlations	T080	C1707520
SERT	T116	C0170657
availability	T169	C0470187
parietal	T023	C0030560
temporal cortices	T023	C0039485
glucose metabolism	T044	C0596620
posterior cingulate cortex	T023	C0175191
abnormal	T033	C0205161
functional connectivity	T169	C1707489
higher-order cortical regions	T029	C0458324
schizophrenia	T048	C0036341
role	T077	C1705810
posterior cingulate gyrus	T023	C0175191
circuitry	UnknownType	C0260041
pathophysiology	T169	C0031847
schizophrenia	T048	C0036341
Urticarial	T047	C0042109
exanthema	T184	C0015230
hepatitis B	T047	C0019163
pregnant woman	T098	C0033011
polymorphic eruption	T047	C0031736
pregnancy	T040	C0032961
Hepatitis B virus (HBV) infection in pregnant women	T047	C3854623
western countries	T083	C0017446
cutaneous	T082	C0221912
manifestation of	T080	C1280464
HBV infection	T047	C0019163
dermatosis	T047	C0037274
pregnancy	T040	C0032961
woman	T098	C0043210
pregnancy	T040	C0032961
pruritic rash	T047	C0033771
erythematous plaques	T033	C0332477
purple centre	T033	C0243095
Serology testing	T059	C0036743
acute HBV infection	T047	C0019163
biopsy	T060	C0005558
superficial	T082	C0205124
interstitial perivascular inflammatory infiltrate	T033	C3810076
lymphocytes	T025	C0024264
eosinophils	T025	C0014467
diagnosis	T033	C0011900
exanthema	T184	C0015230
acute hepatitis B infection	T047	C0019163
patient	T101	C0030705
delivered	T033	C0559563
clinically healthy boy	T033	C0686744
first dose	T081	C0178602
HBV vaccine	T061	C0474232
intravenous specific immunoglobulin	T116	C0085297
second dose	T081	C0178602
infected	T033	C0439663
HBV	T005	C0019169
HBV	T047	C0019163
exanthema	T184	C0015230
pregnant woman	T098	C0033011
newborn	T100	C0021289
vertical transmission	T046	C0242648
cirrhosis	T047	C1623038
hepatocellular carcinoma	T191	C2239176
Mutant Prevention Concentration	T061	C1273380
Mutant Selection Window	T081	C0001555
Topical Antimicrobial Agents	T121	C1136255
Propionibacterium acnes	T007	C0033477
mutant prevention concentration	T061	C1273380
MPC	T061	C1273380
mutant selection window	T081	C0001555
MSW	T081	C0001555
antimicrobial agents	T121	C1136254
pathogenic	T001	C0450254
bacteria	T007	C0004611
antimicrobial	T121	C1136254
therapies	T061	C0087111
MPCs	T061	C1273380
topical antimicrobial agents	T121	C1136255
Propionibacterium acnes	T007	C0033477
Staphylococcus aureus	T007	C0038172
skin infections	T047	C0162627
MSWs	T081	C0001555
MPCs	T061	C1273380
nadifloxacin	T109	C0286402
clindamycin	T109	C0008947
clindamycin	T109	C0008947
MPC	T061	C1273380
lowest	T080	C1708760
P. acnes	T007	C0033477
nadifloxacin	T109	C0286402
MPC	T061	C1273380
lowest	T080	C1708760
S. aureus	T007	C0038172
Calculations	T057	C1956058
minimum inhibitory concentrations	T034	C1304747
MPCs	T061	C1273380
clindamycin	T109	C0008947
lowest	T080	C1708760
MSW	T081	C0001555
P. acnes	T007	C0033477
S. aureus	T007	C0038172
Nadifloxacin	T109	C0286402
MSWs	T081	C0001555
higher	T080	C0205250
P. acnes	T007	C0033477
S. aureus	T007	C0038172
P. acnes	T007	C0033477
resistance	T038	C0013203
fluoroquinolones	T109	C0949665
S. aureus	T007	C0038172
topical application	T061	C0683174
clindamycin	T109	C0008947
resistant	T038	C0013203
P. acnes	T007	C0033477
S. aureus	T007	C0038172
colectomy	T061	C0009274
colon perforation	T037	C0347646
kayexalate	T109	C0124498
administration	T061	C1533734
literature review	T170	C0282441
rare	T080	C0522498
complication	T046	C0009566
Kayexalate	T109	C0124498
ion exchange resin	T121	C0022014
treat	T061	C0087111
patients	T101	C0030705
hyperkalemia	T033	C0020461
Bowel ulceration	T047	C0009324
necrosis	T042	C0027540
rare	T080	C0522498
complication	T046	C0009566
kayexalate	T109	C0124498
administration	T061	C1533734
concomitant	T079	C0521115
administration	T061	C1533734
sorbitol	T109	C0037688
damage	T169	C1883709
bowel	T023	C0021853
kayexalate	T109	C0124498
administration	T061	C1533734
bowel necrosis	T047	C2243080
sorbitol	T109	C0037688
critically ill	T047	C0010340
patient	T101	C0030705
colectomy	T061	C0009274
colonic necrosis	T047	C3671268
oral	T082	C0442027
kayexalate	T109	C0124498
administration	T061	C1533734
pathologic process	T046	C0030660
review the literature	T170	C0282441
progression	T046	C0242656
Total	T080	C0439810
Arsenic	T121	C0003818
Cadmium	T131	C0006632
Lead	T131	C0023175
Determination	T059	C1148554
Brazilian Rice	T168	C0035567
Samples	T167	C0370003
ICP-MS	T059	C1553183
study	T062	C2603343
investigating	T169	C1292732
method	T170	C0025663
rice	T168	C0035567
sample	T167	C0370003
preparation	T052	C1521827
validating	T062	C1519941
applying	T169	C0205245
method	T170	C0025663
monitoring	T169	C0205245
concentration	T081	C1446561
total	T080	C0439810
arsenic	T121	C0003818
cadmium	T131	C0006632
lead	T131	C0023175
rice	T168	C0035567
Inductively Coupled Plasma Mass Spectrometry	T059	C1553183
ICP-MS	T059	C1553183
rice	T168	C0035567
sample	T167	C0370003
preparation	T052	C1521827
procedures	T169	C2700391
analytical method	T170	C0178476
validated	T062	C1519941
measuring	T169	C0242485
parameters	T033	C0449381
limit of detection	T081	C2718050
LOD	T081	C2718050
limit of quantification	T081	C1709793
LOQ	T081	C1709793
linearity	T081	C0392762
relative bias	T078	C0242568
repeatability	T080	C0205556
sample	T167	C0370003
preparation	T052	C1521827
recoveries	T033	C0683340
spiked samples	T167	C0370003
acceptable range	T081	C1514721
muffle furnace	T073	C1708110
heating block	T074	C0181153
hot plate	T074	C0182315
microwave	T073	C0336756
Validation	T062	C1519941
parameters	T033	C0449381
method	T170	C0025663
total	T080	C0439810
arsenic	T121	C0003818
cadmium	T131	C0006632
lead	T131	C0023175
method	T170	C0025663
analyzing	T062	C0936012
rice	T168	C0035567
samples	T167	C0370003
polished	T168	C0035567
brown	T168	C0452710
parboiled	T168	C0035567
Brazilian population	T081	C0032659
total	T080	C0439810
arsenic	T121	C0003818
cadmium	T131	C0006632
lead	T131	C0023175
contents	T077	C0456205
legislative	T170	C2937257
values	T080	C0042295
total	T080	C0439810
arsenic	T121	C0003818
brown rice	T168	C0452710
sample	T167	C0370003
study	T062	C2603343
monitoring	T169	C0205245
programs	T169	C3484370
study	T062	C2603343
type	T080	C0332307
cereal	T168	C0007757
Public Health	T170	C3244304
Safety Precautions	T058	C0150755
Operating Procedures	T170	C3889288
BSL-4	T170	C1443939
Laboratory	T073	C0022877
Biosafety Level 4	T170	C1443939
Suit Laboratory	T073	C0022877
Suite Entry and Exit Procedures	T170	C0442711
Biosafety level 4	T170	C1443939
BSL-4	T170	C1443939
suit laboratories	T073	C0022877
designed	T052	C1707689
study	T062	C2603343
high-consequence pathogens	T001	C0450254
infection	T046	C3714514
prophylaxes	T061	C0199176
treatment	T061	C0087111
laboratories	T073	C0022877
custom-designed	T052	C1707689
airtight doors	T073	C0557698
supply	T169	C1561604
exhaust airflow systems	T073	C3273359
negative-pressure environment	T074	C1961760
positive-pressure ("space") suits	T073	C0376610
laboratory	T073	C0022877
specialists	T097	C0035173
pathogenic agents	T001	C0450254
training	T065	C0220931
safety protocols	T170	C0677563
standard operating procedures	T170	C3889288
Researchers	T097	C0035173
majority	T080	C0205164
work	T057	C0043227
BSL-2	T170	C1443937
laboratories	T073	C0022877
BSL-4	T170	C1443939
suit laboratories	T073	C0022877
high-consequence pathogen	T001	C0450254
Collaborators	T094	C2827395
scientists	T097	C0402112
BSL-4	T170	C1443939
projects	T062	C0700032
challenges	T033	C0033213
associated with	T080	C0332281
BSL-4	T170	C1443939
research	T062	C0035168
experimental	T080	C1517586
technical	T169	C0449851
limitations	T169	C0449295
BSL-4	T170	C1443939
laboratory	T073	C0022877
space	T082	C1883067
increased	T081	C0205217
duration	T079	C0449238
experiments	T062	C0681814
entering	T169	C0205245
exiting	T169	C0205245
BSL-4	T170	C1443939
suit laboratories	T073	C0022877
complex	T080	C0439855
time-consuming	T080	C3827829
compared	T052	C1707455
BSL-2	T170	C1443937
BSL-3	T170	C1443938
laboratories	T073	C0022877
article	T170	C1706852
address	T170	C0376649
biosafety	T068	C0036043
concerns	T078	C2699424
entrance and exit procedures	T170	C0442711
BSL-4	T170	C1443939
laboratory	T073	C0022877
NIH	T093	C0027468
NIAID	T093	C1513895
Integrated Research Facility	T073	C0598009
procedures	T170	C0442711
BSL-4	T170	C1443939
laboratory	T073	C0022877
positive-pressure suits	T073	C0376610
laboratory	T073	C0022877
air pressure	T070	C0001876
resistant	T169	C0332325
doors	T073	C0557698
air-supply hoses	T074	C0181222
moving	T040	C0560560
exiting	T169	C0205245
BSL-4	T170	C1443939
suit laboratories	T073	C0022877
chemical	T103	C0220806
shower	T073	C0541748
removing	T052	C1883720
storing	T169	C1698986
positive-pressure suits	T073	C0376610
Masters Athletes	T097	C0682271
Successful Aging	T040	C0001811
Global population	T098	C1257890
aging	T040	C0001811
raised academic interest	T033	C0243095
successful aging	T040	C0001811
public policy	T064	C0034033
consensus	T054	C0376298
successful aging	T040	C0001811
successful aging	T040	C0001811
late-life process of change	T048	C0233441
high physical	T033	C0516981
psychological	T041	C0233398
cognitive	T041	C0392335
social functioning	T054	C0037395
Masters athletes	T097	C0682271
systematically train	T080	C2673163
compete in	T054	C0679932
organized forms of team	T096	C0871489
individual sport	T056	C0681652
older adults	T098	C0001792
Masters athletes	T097	C0682271
successful aging	T040	C0001811
aging status	T033	C0518170
comprehensive	T080	C1880156
multidimensional	T082	C2347299
successful aging	T040	C0001811
successful aging literature	T170	C0023866
successful aging	T040	C0001811
literature	T170	C0023866
masters athletes	T097	C0682271
successful aging	T040	C0001811
experimental research	T062	C0681814
mutualism	T070	C0599514
plant parasitic nematode	T204	C0321773
Bursaphelenchus xylophilus	T204	C0997987
bacterium	T007	C0004611
Serratia quinivorans BXF1	T007	C0445754
plant-growth	T040	C0597252
pine	T002	C0330186
endophyte	T004	C1265415
antagonistic	T120	C0243076
effects	T080	C1280500
study	T062	C2603343
Serratia quinivorans BXF1	T007	C0445754
bacterium	T007	C0004611
Bursaphelenchus xylophilus	T204	C0997987
plant parasitic nematode	T204	C0321773
pine	T002	C0330186
wilt disease	T047	C0032080
strain BXF1	T007	C0445754
pine	T002	C0330186
wilt disease	T047	C0032080
strain BXF1	T007	C0445754
in vitro	T080	C1533691
nematode	T204	C1704319
reproduction	T040	C0035150
bacteria	T007	C0004611
nematode	T204	C1704319
chitinase gene (Bxcht-1)	T028	C0017337
expression	T045	C0017262
bacterial	T007	C0004611
chitinase	T116	C0008145
nematode	T204	C1704319
reproduction	T040	C0035150
strain BXF1	T007	C0445754
colonize	T033	C4289767
nematode	T204	C1704319
cuticle	T023	C0596796
nematode	T204	C1704319
xenobiotic	T123	C0043335
stress	T046	C0449430
strain BXF1	T007	C0445754
tomato	T002	C0032098
pine	T002	C0330186
plant-growth	T040	C0597252
colonize	T033	C4289767
plant-growth	T040	C0597252
endophyte	T004	C1265415
strain BXF1	T007	C0445754
wilting symptoms	T184	C1457887
pine	T002	C0330186
shoot	T002	C2700376
artificial incisions	T169	C3496294
bacterium	T007	C0004611
antagonistic	T120	C0243076
activities	T052	C0441655
fungi	T004	C0016832
bacteria	T007	C0004611
Pinus pinaster	T002	C1028819
B. xylophilus	T204	C0997987
symbiotic community	T001	C0562641
pine	T002	C0330186
wilt disease	T047	C0032080
symptoms	T184	C1457887
bacteria	T007	C0004611
BXF1	T007	C0445754
plant-growth	T040	C0597252
antagonistic	T120	C0243076
effects	T080	C1280500
B. xylophilus	T204	C0997987
bacterial	T007	C0004611
endophytic community	T004	C1265415
host	T001	C1167395
pine	T002	C0330186
Habitual physical activity	UnknownType	C0815170
associated with	T080	C0332281
anthropometric	T081	C0815129
androgenic	T121	C0002844
profile	T059	C1979963
PCOS	T047	C0032460
cross-sectional study	T062	C0010362
effect	T080	C1280500
habitual physical activity	UnknownType	C0815170
PA	T056	C0026606
metabolic	T039	C3853758
hormonal profiles	T060	C3495938
women	T098	C0043210
polycystic ovary syndrome	T047	C0032460
Anthropometric	T081	C0815129
metabolic	T059	C0696138
hormonal assessment	T060	C0430022
habitual PA	UnknownType	C0815170
digital pedometer	T074	C2709220
women	T098	C0043210
PCOS	T047	C0032460
body mass index	T201	C1305855
BMI	T201	C1305855
controls	T096	C0009932
PA	T056	C0026606
number of steps	T081	C1651669
sedentary	T080	C0205254
BMI	T201	C1305855
women	T098	C0043210
PCOS	T047	C0032460
women	T098	C0043210
waist circumference	T201	C0455829
WC	T201	C0455829
lipid accumulation product	T081	C3658347
LAP	T081	C3658347
sedentary	T080	C0205254
PCOS	T047	C0032460
women	T098	C0043210
control group	T096	C0009932
women	T098	C0043210
WC	T201	C0455829
insulin	T116	C0021641
LAP	T081	C3658347
sedentary controls	T096	C0009932
PCOS	T047	C0032460
androgen	T121	C0002844
sedentary women	T098	C0043210
control group	T096	C0009932
free androgen index	T034	C1261412
FAI	T034	C1261412
sedentary women	T098	C0043210
Homeostasis model assessment	T058	C1829779
insulin resistance	T046	C0021655
predictors	T078	C2698872
FAI	T034	C1261412
associated with	T080	C0332281
FAI	T034	C1261412
Habitual PA	UnknownType	C0815170
associated with	T080	C0332281
anthropometric	T081	C0815129
androgenic	T121	C0002844
profile	T059	C1979963
PCOS	T047	C0032460
Geolocalization	T083	C0017446
Influenza	T047	C0021400
Outbreak	T067	C0012652
Acute Care	T058	C0679878
Population	T098	C1257890
Layered-Surveillance	T169	C0220920
Approach	T082	C0449445
layered-surveillance	T169	C0220920
approach	T082	C0449445
localize	T082	C0392752
influenza	T047	C0021400
clusters	T081	C0012641
acute care	T058	C0679878
population	T098	C1257890
system	T169	C0449913
syndromic	T047	C0039082
surveillance screen	T058	C1444548
rapid polymerase chain reaction testing	T059	C1658604
second	T081	C0205436
geolocalization	T083	C0017446
cluster analysis	T062	C0009085
patients	T101	C0030705
identified	T080	C0205396
clusters	T081	C0012641
at-risk populations	T098	C0242444
high-yield	T081	C0392762
targets	T169	C1521840
preventive medical interventions	T061	C3836383
prospective observational surveillance study	T062	C0033522
Patients	T101	C0030705
screened	T058	C0220908
clinical decision guideline	T170	C0282451
sensitivity	T081	C0036667
specificity	T081	C0037791
influenza	T047	C0021400
Patients	T101	C0030705
points	T081	C1552961
signs and symptoms	T184	C0037088
past	T079	C1444637
days	T079	C0439228
cough	T184	C0010200
headache	T184	C0018681
subjective fever	UnknownType	C0743979
documented fever	T184	C0015967
triage	T061	C0040861
temperature	T081	C0039476
Patients	T101	C0030705
scoring	T081	C0449820
indicated	T033	C1444656
influenza	T047	C0021400
testing	T169	C0039593
Patients	T101	C0030705
tested	T169	C0039593
Xpert Flu	T059	C1510438
Cepheid	T073	C0683757
Sunnyvale	T083	C0017446
CA	T083	C0006754
rapid polymerase chain reaction test	T059	C1658604
Positive	T033	C1446409
results	T169	C1274040
mapped	T170	C3858752
ArcGIS	T170	C0815319
ESRI	T073	C0683757
Redlands	T083	C0017446
CA	T083	C0006754
analyzed	T062	C0936012
kernel density estimation	T062	C4279908
heat maps	T073	C0024779
patients	T101	C0030705
tested	T169	C0039593
Xpert Flu	T059	C1510438
retrievable	T080	C0205556
addresses	T170	C1442065
Phoenix metro area	UnknownType	C0815251
tested	T169	C0039593
positive for influenza A	T034	C2748182
tested	T169	C0039593
positive for influenza B	T034	C2748175
influenza A virus	T005	C0029347
clear cluster	T081	C1704332
pattern	T082	C0449774
patient	T101	C0030705
population	T098	C1257890
densest cluster	T081	C1704332
located	T082	C0450429
square-mile	T081	C1552923
region	T083	C0017446
southeast	T082	C1711190
hospital	T073	C0019994
layered-surveillance	T169	C0220920
approach	T082	C0449445
effective	T080	C1704419
localizing	T082	C0392752
cluster	T081	C1704332
influenza A	T047	C2062441
outbreak	T067	C0012652
region	T083	C0017446
house	T073	C2003847
high-yield	T081	C0392762
target	T169	C1521840
population	T098	C1257890
public health intervention	T058	C0699943
collaborative	T054	C0282116
hospital	T073	C0019994
Maricopa County	T083	C3829199
Department of Public Health	T073	C3897811
perform	T169	C0884358
community	T096	C0009462
vaccination	T061	C0042196
events	T051	C0441471
influenza	T047	C0021400
season	T079	C0036497
reduce	T080	C0392756
burden	T078	C2828008
disease	T047	C0012634
patient	T101	C0030705
population	T098	C1257890
system	T169	C0449913
future	T079	C0016884
investigations	T058	C0220825
at-risk populations	T098	C0242444
Heart rate	T201	C0018810
variability	T077	C2827666
Pre-deployment	T079	C1254367
predictor	T078	C2698872
post-deployment	T079	C1254367
PTSD	T048	C0038436
symptoms	T184	C1457887
Heart rate	T201	C0018810
variability	T077	C2827666
autonomic nervous system	T022	C0004388
activity	T052	C0441655
study	T062	C2603343
pre-deployment	T079	C1254367
HRV	T039	C2350828
post-deployment	T079	C1254367
post-traumatic stress disorder	T048	C0038436
PTSD	T048	C0038436
symptoms	T184	C1457887
Army National Guard soldiers	T097	C0524647
Warriors Achieving Resilience (WAR) study	T062	C2603343
outcome	T169	C1274040
PTSD	T048	C0038436
symptom	T184	C1457887
severity	T080	C0392364
PTSD	T048	C0038436
Checklist	T170	C0451524
Military	T097	C3245458
version	T170	C0333052
PCL	T170	C0451524
baseline	T081	C1442488
month	T079	C0439231
post-deployment	T079	C1254367
Heart rate	T201	C0018810
variability	T077	C2827666
predictor	T078	C2698872
variables	T080	C0439828
high frequency power	T081	C3854080
HF	T081	C3854080
standard deviation	T081	C0871420
cardiac inter-beat	T042	C0425583
interval	T079	C1272706
SDNN	T079	C1272706
linear mixed models	T170	C3161035
pre-deployment	T079	C1254367
PCL	T170	C0451524
ln(HF) interaction	T081	C0237688
Pre-deployment	T079	C1254367
SDNN	T079	C1272706
predictor	T078	C2698872
post-deployment	T079	C1254367
PCL	T170	C0451524
Covariates	T080	C0439828
age	T032	C0001779
pre-deployment	T079	C1254367
PCL	T170	C0451524
race	T098	C0034510
ethnicity	T098	C0015031
marital status	T102	C0024819
tobacco use	T055	C0543414
childhood abuse	T048	C0008060
pre-deployment	T079	C1254367
traumatic brain injury	T037	C0876926
combat zone	T082	C1710706
deployment	T052	C2825812
Pre-deployment	T079	C1254367
heart rate	T201	C0018810
variability	T077	C2827666
post-deployment	T079	C1254367
PTSD	T048	C0038436
symptoms	T184	C1457887
pre-deployment	T079	C1254367
PCL	T170	C0451524
scores	T081	C0449820
neuronal	T025	C0027882
PI(3,4,5)P3	T109	C0765553
program	T169	C3484370
oligodendrocyte	T025	C0028944
precursor	T078	C1709634
recruitment	T052	C2949735
myelination	T043	C0596991
molecular trigger	T044	C1148560
CNS	T022	C3714787
myelination	T043	C0596991
unknown	T080	C0439673
targeting	T169	C1521840
Pten	T116	C1530899
cerebellar granule cells	T025	C0007634
activating	T052	C1879547
AKT1	T116	C0285558
mTOR	T116	C0293060
pathway	T044	C0086982
increased	T081	C0205217
normally	T080	C0205307
unmyelinated axons	T026	C1179986
expression	T045	C1171362
numerous	T081	C0439064
genes	T028	C0017337
encoding	T052	C2700640
regulatory proteins	T116	C0815047
expansion	T043	C0007595
genetically wild-type	T028	C1883559
oligodendrocyte	T025	C0028944
progenitor cells	T025	C0038250
oligodendrocyte	T025	C0028944
differentiation	T043	C0007589
de novo	T078	C1515568
myelination	T043	C0596991
parallel fibers	T026	C3546707
neuronal	T025	C0027882
program	T169	C3484370
phosphoinositide	T109	C0031621
PI(3,4,5)P3	T109	C0765553
trigger	T044	C1148560
steps	T077	C1261552
myelination	T043	C0596991
microglial	T025	C0206116
response	T032	C0871261
biodiesel exhaust	T109	C0012151
healthy	T080	C3898900
hypertensive	T047	C0020538
rats	T015	C0034721
evidence	T078	C3887511
suggests	T078	C1705535
deleterious	T169	C0001688
role	T077	C1705810
urban	T083	C0442529
air pollution	T069	C0001873
central nervous system (CNS) diseases	T047	C0007682
neurodevelopmental disorders	T048	C1535926
Microglia	T025	C0206116
innate	T032	C0020969
immune cells	T025	C0312740
sentinels	T109	C0950580
brain	T023	C0006104
common	T081	C0205214
source	T033	C0449426
neuroinflammation	UnknownType	C0683396
air pollution	T069	C0001873
induced	T169	C0205263
CNS effects	T047	C0007682
renewable energy	T169	C3178762
soy-based biofuel	T109	C2717891
increasing	T169	C0442808
public	T098	C0027361
interest	T041	C0543488
little	T081	C0700321
information	T078	C1533716
soy biofuel	T109	C2717891
affect	T080	C1280500
brain	T023	C0006104
people	T098	C0027361
preexisting disease conditions	T033	C0521987
male	T032	C0086582
spontaneously hypertensive rats	T015	C0034705
SHR	T015	C0034705
normotensive	T033	C2712122
Wistar Kyoto (WKY) rats	T015	C0034709
exposed to	T080	C0332157
100% Soy-based Biodiesel Exhaust	T109	C0012151
100SBDE	T109	C0012151
inhalation	T040	C0004048
day	T079	C0439228
weeks	T079	C0439230
days	T079	C0439228
week	T079	C0439230
Ionized calcium-binding adapter molecule-1	T116	C1455000
IBA-1	T116	C1455000
staining	T059	C0487602
microglia	T025	C0206116
substantia nigra	T023	C0038590
revealed	T080	C0443289
significant	T078	C0750502
changes	T169	C0392747
morphology	T080	C0332437
100SBDE	T109	C0012151
exposure	T080	C0332157
rats	T015	C0034721
both	T080	C1706086
genotypes	T032	C0017431
SHR	T015	C0034705
less	T081	C0439092
sensitive	T169	C0332324
Aconitase activity	T044	C4234382
inhibited	T080	C0311403
frontal cortex	T023	C0016733
cerebellum	T023	C0007765
WKY rats	T015	C0034709
exposed to	T080	C0332157
100SBDE	T109	C0012151
No	T169	C1518422
consistent	T080	C0332529
changes	T169	C0392747
occurred	T079	C2745955
pro-inflammatory	T169	C0333348
cytokine	T116	C0079189
expression	T045	C1171362
nitrated protein	T116	C0033684
arginase1	T116	C0003763
expression	T045	C1171362
brain regions	T029	C1273723
rat strain	T015	C0034721
exposed to	T080	C0332157
100SBDE	T109	C0012151
IBA-1	T116	C1455000
mRNA expression	T045	C1515670
not	T169	C1518422
modified	T169	C0392747
CX3CR1	T116	C1870161
mRNA expression	T045	C1515670
lower	T080	C0205251
striatum	T023	C0010097
100SBDE	T109	C0012151
exposed rats	T015	C0034721
regardless	T080	C3641650
genotype	T032	C0017431
suggesting	T078	C1705535
downregulation	T044	C0013081
fractalkine receptor	T116	C0663627
microglia	T025	C0206116
brain region	T029	C1273723
data	T078	C1511726
indicate	T078	C0392360
microglia	T025	C0206116
detecting	T033	C0442726
responding	T032	C0871261
100SBDE	T109	C0012151
exposure	T080	C0332157
changes	T169	C0392747
morphology	T080	C0332437
reduced	T080	C0392756
expression	T045	C1171362
CX3CR1	T116	C1870161
regardless	T080	C3641650
genetic background	T032	C4042916
activation	UnknownType	C0678666
response	T032	C0871261
atypical	T080	C0205182
traditional	T169	C0443324
inflammatory markers	T201	C0005516
M1	T025	C0024432
M2	T025	C4086555
activation	UnknownType	C0678666
brain	T023	C0006104
Pre-Activation Negativity	T033	C0243095
PrAN	T033	C0243095
Brain	T023	C0006104
Potentials	T080	C3245505
Unfolding Words	T041	C0025361
event-related potential	T042	C0282171
ERP	T042	C0282171
effect	T080	C1280500
pre-activation negativity	T033	C0243095
PrAN	T033	C0243095
index	T170	C0918012
degree of pre-activation	T081	C0392762
word	T078	C1705313
internal	T082	C0205102
morphemes	T170	C0870914
speech	T040	C0037817
processing	T052	C1709694
lexical competition	T067	C1882365
measures	T081	C0079809
word-initial speech fragments	T068	C0037829
WIFs	T068	C0037829
statistical analyses	T062	C0871424
ERP	T042	C0282171
data	T078	C1511726
experiments	T062	C0681814
PrAN	T033	C0243095
lexical competition	T067	C1882365
degree	T081	C0449286
predictive	T080	C0681890
certainty	T080	C0205423
negativity	T033	C0205160
larger	T081	C0549177
fewer	T081	C0205388
lexical	T078	C1705313
competitors	T098	C1257890
Angiotensin-converting enzyme insertion/deletion polymorphism	T033	C4015787
association with	T080	C0332281
obesity	T047	C0028754
disorders	T047	C0012634
Egyptian	T098	C0337801
females	T032	C0086287
case-control observational study	T062	C1518527
WHO	T093	C0043237
report	T170	C0684224
obesity	T047	C0028754
cause of death	T033	C0007465
worldwide	T079	C1254367
prevalence	T081	C0220900
Egyptian	T098	C0337801
female	T098	C0043210
obesity	T047	C0028754
obesity	T047	C0028754
influenced	T077	C4054723
genetics	T169	C0314603
adipose tissue	T024	C0001527
renin-angiotensin system	T022	C0035096
over-activated	T169	C0205245
obesity	T047	C0028754
effect of	T080	C1704420
angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism	T033	C4015787
obesity	T047	C0028754
disorders	T047	C0012634
populations	T098	C1257890
effect	T080	C1280500
ACE activity	T044	C2258685
objective	T170	C0018017
study	T062	C2603343
association	T080	C0439849
ACE I/D polymorphism	T033	C4015787
obesity	T047	C0028754
disorders	T047	C0012634
hypertension	T047	C0020538
insulin resistance	T046	C0021655
metabolic syndrome	T047	C0524620
Egyptian	T098	C0337801
females	T032	C0086287
Eighty	T081	C3816958
female	T098	C0043210
volunteers	T098	C0020155
blood pressure	T058	C3826646
body measurements	T060	C0203910
recorded	T169	C0205245
fasting	T033	C0015663
blood sample	T031	C0178913
quantitation	T081	C1709793
glucose	T109	C0017725
lipid profile	T059	C0430044
insulin,	T116	C0021641
leptin	T116	C0299583
identification	T080	C0205396
ACE I/D polymorphs	T033	C4015787
Subjects	T098	C0080105
hypertension	T047	C0020538
obesity states	T033	C4060989
Comparisons	T052	C1707455
continuous	T078	C0549178
parameters	T033	C0449381
independent	T078	C0085862
sample t-test	T170	C1709321
groups	T078	C0441833
frequencies	T081	C0017270
ACE	T116	C1452534
genotypes	T032	C0017431
alleles	T028	C0002085
association	T080	C0439849
gene polymorphism	T045	C0678951
metabolic	T169	C0311400
parameters	T033	C0449381
assessed	T052	C1516048
chi-square	T170	C0008041
Fisher's exact test	T170	C1708064
Genotype	T032	C0017431
frequencies	T081	C0017270
Hardy-Weinberg equilibrium	T081	C1547026
groups	T078	C0441833
Genotype	T032	C0017431
distribution	T169	C1704711
controls	T096	C0009932
cases	T077	C1706256
disorders	T047	C0012634
DD carriers	T033	C0007294
higher	T080	C0205250
parameters	T033	C0449381
blood pressure	T040	C0005823
lipid profile	T059	C0430044
insulin resistance	T046	C0021655
diastolic blood pressure	T201	C0428883
significant	T078	C0750502
I-carriers	T033	C0007294
susceptible	T169	C0231204
hypertension	T047	C0020538
DD carriers	T033	C0007294
normal	T080	C0205307
waist/hip ratio	T032	C0205682
OR	T081	C0028873
CI	T081	C0009667
normal	T080	C0205307
conicity index	T034	C1254595
OR	T081	C0028873
CI	T081	C0009667
DD genotype carriers	T033	C0007294
significant	T078	C0750502
association	T080	C0439849
insulin resistance	T046	C0021655
high body mass index	T033	C0231254
OR	T081	C0028873
CI	T081	C0009667
waist circumference	T201	C0455829
OR	T081	C0028873
CI	T081	C0009667
waist/height ratio	T033	C1821269
OR	T081	C0028873
CI	T081	C0009667
variations	T070	C0042333
percentages	T081	C0439165
DD	T033	C0007294
I-carriers	T033	C0007294
effect of	T080	C1704420
ACE I/D	T033	C4015787
association	T080	C0439849
sample	T167	C0370003
Egyptian	T098	C0337801
females	T032	C0086287
ACE I/D polymorphism	T033	C4015787
not significantly	T033	C1273937
associated with	T080	C0332281
obesity	T047	C0028754
disorders	T047	C0012634
I allele	T028	C0002085
hypertension	T047	C0020538
subjects	T098	C0080105
normal	T080	C0205307
waist/hip ratio	T032	C0205682
conicity index	T034	C1254595
DD genotype carriers	T033	C0007294
Expressed	T045	C0017262
microRNA	T114	C1101610
associated with	T080	C0332281
high	T080	C0205250
rate	T081	C1521828
egg production	T042	C0029965
chicken	T012	C0008051
ovarian follicles	T023	C0018120
MicroRNA	T114	C1101610
miRNA	T114	C1101610
noncoding RNA	T114	C0887909
nucleotides	T114	C0028630
length	T081	C1444754
function	T169	C0542341
post-transcriptionally regulate	T045	C1514248
gene expression	T045	C0017262
organisms	T001	C0029235
Tissue	T024	C0040300
miRNA	T114	C1101610
expression	T045	C0017262
studies	T062	C2603343
functions	T169	C0542341
miRNAs	T114	C1101610
miRNAs	T114	C1101610
chicken	T012	C0008051
ovarian tissue	T024	C1518744
days	T079	C0439228
age	T032	C0001779
miRNA	T114	C1101610
analysis	T062	C0936012
ovarian tissues	T024	C1518744
chickens	T012	C0008051
low	T080	C0205251
high	T080	C0205250
rates	T081	C1521828
egg production	T042	C0029965
high-throughput sequencing	T063	C2936623
low	T080	C0205251
rate	T081	C1521828
egg production	T042	C0029965
chickens	T012	C0008051
high	T080	C0205250
rate	T081	C1521828
egg production	T042	C0029965
chickens	T012	C0008051
expressed	T045	C0017262
miRNAs	T114	C1101610
miRNAs	T114	C1101610
miRNAs	T114	C1101610
pathways	T044	C0037080
reproduction	T040	C0035150
regulation	T045	C0017263
steroid hormone biosynthesis	T044	C0597517
dopaminergic synapse	T030	C0039062
expression	T045	C0017262
regulated	T045	C0017263
miRNAs	T114	C1101610
quantitative real-time polymerase chain reaction	T063	C3179034
RT-qPCR	T063	C3179034
miRNAs	T114	C1101610
gga-miR-34b	T028	C1537746
gga-miR-34c	T028	C1537747
gga-miR-216b	T028	C2239687
regulate	T045	C0017263
proliferation	T043	C0596290
cell cycle	T043	C0007586
apoptosis	T043	C0162638
metastasis	T046	C4255448
expressed	T045	C0017262
ovaries	T023	C0029939
chickens	T012	C0008051
high	T080	C0205250
rates	T081	C1521828
egg production	T042	C0029965
miRNAs	T114	C1101610
ovary	T023	C0029939
development	T038	C0242290
reproductive management	T040	C0035150
chicken	T012	C0008051
up-regulated	T044	C0041904
miRNA	T114	C1101610
gga-miR-200a-3p	T028	C1537838
reproduction	T040	C0035150
regulation	T045	C0017263
pathways	T044	C0037080
miRNA	T114	C1101610
reproductive management	T040	C0035150
chicken	T012	C0008051
Air pollution	T069	C0001873
neighbourhood	T082	C1254362
maternal	T033	C1858460
level	T080	C0441889
factors	T169	C1521761
modify	T169	C3242344
effect	T080	C1280500
smoking	T055	C0037369
birth weight	T032	C0005612
multilevel analysis	T062	C0814909
British Columbia	T083	C0006193
Canada	T083	C0006823
Maternal	T033	C1858460
smoking	T055	C0037369
pregnancy	T040	C0032961
negatively	T033	C0205160
impacts	T080	C4049986
fetal growth	T039	C0743925
effect	T080	C1280500
homogenous	T082	C0439713
population	T081	C0032659
relationship	T080	C0439849
cigarette use	T055	C0694535
fetal growth	T039	C0743925
modified	T033	C3840684
social	T078	C0037414
physical environment	T082	C0557720
Birth records	T073	C0005609
BC Perinatal Database Registry	T170	C0242356
Maternal	T033	C1858460
smoking status	T201	C1519386
self-reported	T062	C0681906
number	T081	C0449788
cigarettes	T073	C0677453
smoked	T055	C0037369
per day	T079	C0439505
first prenatal care visit	T061	C1504204
Census	T081	C0007663
dissemination	T082	C0205221
areas	T083	C0017446
DAs	T083	C0017446
neighbourhood	T082	C1254362
level	T080	C0441889
units	T081	C0439148
individual	T098	C0237401
births	T040	C0005615
residential postal codes	T078	C1552677
assign	T169	C1516050
exposure to	T080	C0332157
particulate	T131	C1510837
air pollution	T069	C0001873
neighbourhood	T082	C1254362
level	T080	C0441889
attributes	T078	C0449234
socioeconomic status	T080	C0086996
SES	T080	C0086996
proportion	T081	C1709707
post-secondary education	T170	C0683860
immigrant	T098	C0282163
density	T081	C0178587
living	UnknownType	C0023913
rural place	T082	C0178837
Random	T080	C0439605
coefficient	T081	C1707429
models	T170	C3161035
cigarettes	T073	C0677453
/day	T079	C0439505
modeled	T170	C3161035
random	T080	C0439605
slope	T081	C0807955
estimate	T081	C0750572
DA	T083	C0017446
variability	T077	C2827666
test	T169	C0039593
cross-level	T080	C0441889
interactions	T169	C1704675
neighbourhood	T082	C1254362
level	T080	C0441889
variables	T080	C0439828
continuous	T078	C0549178
birth weight	T032	C0005612
significant	T078	C0750502
negative	T033	C0205160
association	T080	C0439849
maternal	T033	C1858460
smoking	T055	C0037369
birth weight	T032	C0005612
significant	T078	C0750502
DA	T083	C0017446
intercept	T081	C3146232
variability	T077	C2827666
birth weight	T032	C0005612
DA	T083	C0017446
slope	T081	C0807955
variability	T077	C2827666
maternal	T033	C1858460
smoking	T055	C0037369
birth weight	T032	C0005612
inclusion	T080	C1512693
DA	T083	C0017446
level	T080	C0441889
variables	T080	C0439828
cross-level	T080	C0441889
interactions	T169	C1704675
High	T080	C0205250
DA	T083	C0017446
level	T080	C0441889
SES	T080	C0086996
strong	T080	C0442821
positive	T033	C1446409
association	T080	C0439849
birth weight	T032	C0005612
effect	T080	C1280500
moderated	T080	C1881878
increased	T169	C0442805
cigarettes	T073	C0677453
/day	T079	C0439505
heavy smokers	T033	C0459847
largest	T081	C0443228
increases	T169	C0442805
birth weight	T032	C0005612
rising	T169	C0442805
neighbourhood	T082	C1254362
education levels	T033	C1553770
Increased	T169	C0442805
levels	T080	C0441889
PM2.5	T131	C1510837
immigrant	T098	C0282163
density	T081	C0178587
negatively	T033	C0205160
associated with	T080	C0332281
birth weight	T032	C0005612
positive	T033	C1446409
interactions	T169	C1704675
increased	T169	C0442805
levels	T080	C0441889
smoking	T055	C0037369
maternal age	T079	C0024915
suspected	T078	C0750491
drug	T048	C0242510
alcohol use	T055	C0001948
negative	T033	C0205160
interactions	T169	C1704675
increased	T169	C0442805
levels	T080	C0441889
maternal	T033	C1858460
smoking	T055	C0037369
Maternal	T033	C1858460
smoking	T055	C0037369
negative	T033	C0205160
dose-response association	T038	C0678790
birth weight	T032	C0005612
highly	T080	C0205250
variable	T080	C0439828
neighbourhood	T082	C1254362
evidence	T078	C3887511
effect	T080	C1280500
modification	T033	C3840684
neighbourhood	T082	C1254362
level	T080	C0441889
factors	T169	C1521761
results	T169	C1274040
suggest	T078	C1705535
individual	T098	C0237401
behaviours	T053	C0004927
limited	T169	C0439801
success	T054	C0597535
improving	T080	C1272745
outcomes	T169	C1274040
without	T080	C0332288
contextual	T041	C0237482
influences	T077	C4054723
neighbourhood	T082	C1254362
level	T080	C0441889
studies	T062	C2603343
corroborate	T080	C1456348
findings	T033	C0243095
understand	T041	C0162340
neighbourhood	T082	C1254362
level	T080	C0441889
attributes	T078	C0449234
interact	T169	C1704675
smoking	T055	C0037369
affect	T041	C0001721
birth outcomes	T201	C1286282
Individual	T098	C0237401
Leg Muscle	T023	C0224456
Contributions	T052	C1880177
Walking	T056	C0080331
Effects	T080	C1280500
Age	T032	C0001779
Walking Speed	T032	C2009910
study	T062	C2603343
examined	T033	C0332128
contributions	T052	C1880177
individual	T098	C0237401
muscles	T024	C0026845
cost of transport	T169	C0220812
COT	T169	C0220812
walking speeds	T032	C2009910
healthy young	T100	C0238598
elderly subjects	T098	C0001792
participants	T098	C0679646
young aged	T100	C0238598
old aged	T098	C1999167
COT	T169	C0220812
mean oxygen consumption	T201	C0030055
steady state walking	T056	C0080331
Electromyography	T060	C0013839
signals	T067	C1710082
leg muscles	T023	C0224456
cumulative activity required to traverse a unit of distance	T056	C0001288
CMAPD	T056	C0001288
muscle	T024	C0026845
speed	T081	C0678536
old group	T098	C1999167
CMAPD	T056	C0001288
correlated	T080	C1707520
COT	T169	C0220812
optimal speed	T081	C0678536
muscles	T024	C0026845
Soleus	T023	C0242694
CMAPD	T056	C0001288
speed	T081	C0678536
young group	T100	C0238598
aging	T040	C0001811
Greater energy cost	T169	C0220812
walking	T056	C0080331
older	T098	C0001792
individuals	T098	C0237401
energy cost	T169	C0220812
lower limb muscles	T023	C2362789
Glycated Hemoglobin	T116	C0017853
HbA1c	T116	C0017853
Correlation	T080	C1707520
Severity	T080	C0439793
Coronary Artery Disease	T047	C0010054
Non-diabetic	T033	C0241863
Patients	T101	C0030705
Hospital based	T073	C0019994
Study	T062	C2603343
North-Eastern India	T083	C0017446
Glycated Hemoglobin (HbA1c) levels	T034	C1261236
predictive	T080	C0681890
cardiovascular disease	T047	C0007222
mortality	T081	C0178686
patients	T101	C0030705
diabetes mellitus	T047	C0011849
HbA1c	T116	C0017853
Coronary Artery Disease	T047	C0010054
CAD	T047	C0010054
non-diabetics	T033	C0241863
inconsistent	T080	C0442809
evaluate	T058	C0220825
correlation	T080	C1707520
HbA1c level	T034	C1261236
severity	T080	C0439793
CAD	T047	C0010054
non-diabetic patients	T101	C0030705
SYNTAX score	T081	C0449820
cohort	T098	C0599755
CAD	T047	C0010054
angiography	T060	C0002971
Gauhati Medical College	T093	C1708333
Guwahati, Assam	T083	C0017446
India	T083	C0021201
tertiary care hospital	T073	C0337954
North-Eastern India	T083	C0017446
data	T078	C1511726
non-diabetic patients	T101	C0030705
CAD	T047	C0010054
angiography	T060	C0002971
Patients	T101	C0030705
groups	T078	C0441833
interquartiles	T080	C2828255
HbA1c levels	T034	C1261236
Severity	T080	C0439793
CAD	T047	C0010054
assessed	T052	C1516048
SYNTAX score	T081	C0449820
number of coronary vessels diseased	T081	C3275120
quartiles	T080	C2828255
HbA1c	T116	C0017853
SYNTAX score	T081	C0449820
diseased vessels	T081	C3275120
patients	T101	C0030705
study	T062	C2603343
age	T032	C0001779
males	T032	C0086582
hypertensives	T033	C0857121
smokers	T033	C0337664
dyslipidemic	T033	C0243095
CAD	T047	C0010054
severity	T080	C0439793
SYNTAX score	T081	C0449820
vessels	T023	C0005847
quartiles	T080	C2828255
p-values	T081	C1709380
Increase	T169	C0442805
HbA1c level	T034	C1261236
correlated	T080	C1707520
disease severity	T080	C0521117
SYNTAX score	T081	C0449820
increase	T169	C0442805
diseased vessels	T081	C3275120
p-value	T081	C1709380
HbA1c level	T034	C1261236
increases	T169	C0442805
Age	T032	C0001779
gender	T032	C0079399
hypertension	T047	C0020538
dyslipidemia	T047	C0242339
quartiles	T080	C2828255
smoking	T055	C0037369
predictor	T078	C2698872
severity	T080	C0439793
CAD	T047	C0010054
SYNTAX score	T081	C0449820
clinical study	T062	C0008972
correlation	T080	C1707520
HbA1c	T116	C0017853
severity	T080	C0439793
CAD	T047	C0010054
SYNTAX score	T081	C0449820
vessels	T023	C0005847
non- diabetes	T033	C0243095
Relation	T080	C0439849
Face	T041	C0870537
Object Recognition	T041	C0599621
Developmental Prosopagnosia	T048	C0751842
Dissociation	T048	C0086168
Systematic	T169	C0220922
Association	T080	C0439849
debate	T052	C0870392
face recognition	T041	C0870537
object recognition	T041	C0599621
separate	T080	C0443299
domains	T169	C1880389
Clarification	T052	C2986669
issue	T033	C0033213
important	T080	C3898777
theoretical	T078	C0871935
implications	T080	C0205556
face recognition	T041	C0870537
example	T077	C1707959
domain	T169	C1880389
specificity	T081	C0037791
mind	T078	C0695534
brain	T023	C0006104
important	T080	C3898777
source	T033	C0449416
input	T077	C1708517
debate	T052	C0870392
individuals	T098	C0027361
developmental prosopagnosia	T048	C0751842
suggesting	T078	C1705535
face recognition	T041	C0870537
selectively impaired	T169	C0221099
selectivity	T080	C0205556
hypothesis	T078	C1512571
test	T169	C0039593
performance	T052	C1882330
individuals	T098	C0027361
developmental prosopagnosia	T048	C0751842
visual object processing	T041	C0589087
involving	T169	C1314939
regular	T080	C0205272
degraded	T033	C1457868
drawings	T170	C0013113
individuals	T098	C0027361
dissociation	T048	C0086168
face	T041	C0870537
object recognition	T041	C0599621
group	UnknownType	C0681860
significantly	T078	C0750502
affected	T169	C0392760
degradation	T033	C1457868
objects	T072	C0347997
control	T096	C0009932
participants	T098	C0679646
positive	T033	C1446409
correlations	T080	C1707520
severity	T080	C0439793
face recognition	T041	C0870537
impairment	T169	C0221099
degree	T081	C0449286
impaired	T169	C0221099
performance	T052	C1882330
degraded	T033	C1457868
objects	T072	C0347997
face	T041	C0870537
object	T041	C0599621
deficits	T080	C2987487
related	T080	C0439849
coincidental	T079	C0205420
evidence	T078	C3887511
literature	T170	C0023866
developmental prosopagnosia	T048	C0751842
domain	T169	C1880389
specific	T080	C0205369
face recognition	T041	C0870537
Reduced Chest	T033	C0577943
Abdominal Wall	T023	C0836916
Mobility	T080	C0449580
Relationship	T080	C0439849
Lung Function	T039	C0035245
Respiratory	T169	C0521346
Muscle Strength	T042	C0517349
Exercise Tolerance	T201	C0162521
Subjects	T096	C0681850
COPD	T047	C0024117
air-flow	T039	C0231999
limitation	T169	C0449295
patients	T101	C0030705
COPD	T047	C0024117
reduction	T080	C0392756
vital capacity	T201	C0042834
respiratory	T169	C0521346
muscle strength	T042	C0517349
exercise capacity	T201	C0162521
chest	T029	C0817096
abdominal wall	T023	C0836916
mobility	T080	C0449580
unknown	T080	C0439673
prevalence	T081	C0033106
patients	T101	C0030705
COPD	T047	C0024117
reduced chest	T033	C0577943
abdominal wall	T023	C0836916
mobility	T080	C0449580
investigate	T169	C1292732
effect	T080	C1280500
reduced chest	T033	C0577943
abdominal wall	T023	C0836916
mobility	T080	C0449580
pulmonary function	T039	C0035245
respiratory	T169	C0521346
muscle strength	T042	C0517349
exercise capacity	T201	C0162521
elderly	T098	C0001792
male	T032	C0086582
subjects	T096	C0681850
COPD	T047	C0024117
chest	T029	C0817096
abdominal wall	T023	C0836916
mobility	T080	C0449580
FVC	T034	C3714541
FEV1	T060	C0849974
FEV1/FVC	T059	C3815113
maximal inspiratory pressure	T060	C4083126
PImax	T060	C4083126
maximal expiratory pressure	T060	C4082175
PEmax	T060	C4082175
6-min walk distance	T060	C0430515
6MWD	T060	C0430515
assessed	T052	C1516048
Chest	T023	C0205076
abdominal wall	T023	C0836916
mobility	T080	C0449580
measured	T080	C0444706
breathing	T040	C0004048
movement scale	T059	C0022885
regions	T029	C0005898
upper chest	T029	C0446469
lower chest	T029	C0446470
abdomen	T029	C0000726
Reduced mobility	T033	C0700572
value	T081	C1522609
lower	T052	C2003888
lower limit of the normal scale	T081	C1518030
unpaired t test	T170	C1710574
Mann-Whitney test	T170	C1708930
multiple regression analysis	T080	C0681923
performed	T169	C0884358
percentages	T081	C0439165
subjects	T096	C0681850
reduced mobility	T033	C0700572
upper chest	T029	C0446469
lower chest	T029	C0446470
abdomen	T029	C0000726
subjects	T096	C0681850
reduced mobility	T033	C0700572
significantly low	T081	C4055638
FVC	T034	C3714541
FEV1	T060	C0849974
6MWD	T060	C0430515
region	T029	C0005898
significantly low	T081	C4055638
FEV1/FVC	T059	C3815113
PImax	T060	C4083126
PEmax	T060	C4082175
abdominal region	T029	C1720043
compared	T052	C1707455
mobility	T080	C0449580
FVC	T034	C3714541
6MWD	T060	C0430515
associated with	T080	C0332281
scale values	T080	C0042295
region	T029	C0005898
abdominal	T029	C0000726
scale value	T080	C0042295
subjects	T096	C0681850
COPD	T047	C0024117
reduced chest	T033	C0577943
abdominal wall	T023	C0836916
mobility	T080	C0449580
associated with	T080	C0332281
FVC	T034	C3714541
abdominal wall	T023	C0836916
mobility	T080	C0449580
compared	T052	C1707455
chest wall	T023	C0205076
mobility	T080	C0449580
associated with	T080	C0332281
6MWD	T060	C0430515
FGF21	T116	C3887831
biomarker	T201	C0005516
mitochondrial translation	T045	C2245743
mtDNA	T114	C0012929
maintenance	T052	C0024501
disorders	T047	C0012634
mitochondrial myopathy	T019	C0162670
serum	T031	C0229671
biomarkers	T201	C0005516
diagnostic use	T060	C0011933
analyzed	T062	C0936012
serum	T031	C0229671
FGF21	T116	C3887831
S-FGF21	T116	C3887831
GDF15	T116	C1431343
patients	T101	C0030705
mitochondrial diseases	T047	C0751651
nonmitochondrial disorders	T047	C0012634
partially	T081	C0728938
overlapping	T079	C1948020
mitochondrial disorder	T047	C0751651
phenotypes	T032	C0031437
meta-analysis	T062	C0920317
S-FGF21	T116	C3887831
mitochondrial disease	T047	C0751651
analyzed	T062	C0936012
S-Fgf21	T116	C3887831
skeletal muscle	T024	C0242692
Fgf21	T116	C3887831
expression	T045	C0017262
mouse	T015	C0025929
models	T008	C0599779
different	T080	C1705242
muscle	T024	C0026845
manifesting	T169	C0205319
mitochondrial dysfunctions	T033	C4021734
S-FGF21	T116	C3887831
increases	T169	C0442805
primary	T080	C0205225
mitochondrial myopathy	T019	C0162670
patients	T101	C0030705
mitochondrial translation	T045	C2245743
defects	T019	C0000768
mitochondrial DNA (mtDNA) deletions	T033	C4313882
controls	T096	C0009932
mice	T015	C0025929
mtDNA deletions	T033	C4313882
patients	T101	C0030705
mice	T015	C0025929
structural respiratory chain subunit or assembly factor defects	T019	C0000768
low	T080	C0205251
induction	T169	C0205263
human	T016	C0086418
mice	T015	C0025929
not significant	T033	C1273937
Overall	T080	C1561607
specificities	T081	C0037791
FGF21	T116	C3887831
GDF15	T116	C1431343
patients	T101	C0030705
mitochondrial myopathy	T019	C0162670
sensitivities	T081	C1511883
GDF15	T116	C1431343
increased	T081	C0205217
nonmitochondrial conditions	T080	C0348080
S-FGF21	T116	C3887831
specific	T080	C0205369
biomarker	T201	C0005516
muscle	T024	C0026845
manifesting	T169	C0205319
defects	T019	C0000768
mitochondrial translation	T045	C2245743
mitochondrial	T026	C0026237
transfer-RNA	T114	C0035711
mutations	T045	C0026882
primary	T080	C0205225
secondary	T080	C0175668
mtDNA deletions	T033	C4313882
causes	T169	C0015127
mitochondrial disease	T047	C0751651
normal	T080	C0205307
S-FGF21	T116	C3887831
not	T033	C1513916
exclude	T169	C0332196
structural respiratory chain complex or assembly factor defects	T019	C0000768
diagnostics	T060	C0430022
study	T062	C2603343
Class III	T170	C0441887
evidence	T078	C3887511
elevated	T080	C3163633
S-FGF21	T116	C3887831
patients	T101	C0030705
mitochondrial myopathies	T019	C0162670
patients	T101	C0030705
conditions	T080	C0348080
FGF21	T116	C3887831
GDF15	T116	C1431343
mitochondrial myopathy	T019	C0162670
myopathies	T047	C0026848
effects of	T080	C1704420
captopril	T116	C0006938
lipopolysaccharide	T109	C0023810
induced	T169	C0205263
learning	T048	C0023186
memory impairments	T048	C0233794
brain	T023	C0006104
cytokine	T116	C0079189
levels	T080	C0441889
oxidative	T169	C0311404
damage	T037	C0010957
rats	T015	C0034721
Renin-angiotensin system	T022	C0035096
inflammation	T046	C0021368
learning	T041	C0023185
memory	T041	C0025260
effects of	T080	C1704420
captopril	T116	C0006938
lipopolysaccharide	T109	C0023810
LPS	T109	C0023810
induced	T169	C0205263
learning	T048	C0023186
memory impairments	T048	C0233794
hippocampal	T023	C0019564
cytokine	T116	C0079189
levels	T080	C0441889
brain tissues	T023	C0459385
oxidative	T169	C0311404
damage	T037	C0010957
investigated	T169	C1292732
rats	T015	C0034721
saline	T167	C0036082
Control	T096	C0009932
LPS	T109	C0023810
captopril	T116	C0006938
LPS	T109	C0023810
treatment	T061	C0087111
days	T079	C0439228
behavioral experiments	T060	C0683444
behavioral tests	T060	C0683444
LPS	T109	C0023810
injection	T061	C1533685
behavioral experiment	T060	C0683444
Administration	T061	C1533734
LPS	T109	C0023810
prolonged	T079	C0439590
latency	T080	C0205275
Morris water maze (MWM) test	T060	C0683444
latency	T080	C0205275
dark compartment	T058	C3649443
passive avoidance	T041	C0871047
PA	T041	C0871047
test	T060	C0683444
Pretreatment	T052	C3539076
doses	T081	C0178602
captopril	T116	C0006938
improved	T080	C1272745
performances	T052	C1882330
rats	T015	C0034721
MWM	T060	C0683444
prolonged	T079	C0439590
latency	T080	C0205275
dark	T058	C3649443
PA	T041	C0871047
test	T060	C0683444
LPS	T109	C0023810
increased	T081	C0205217
IL-6	T116	C0021760
TNF-α	T116	C1456820
malondialdehyde	T109	C0024643
MDA	T109	C0024643
nitric oxide	T121	C0028128
NO	T121	C0028128
metabolites	T123	C0870883
hippocampal	T023	C0019564
tissues	T023	C0459385
prevented	T061	C0199176
captopril	T116	C0006938
thiol	T123	C0574031
superoxide dismutase	T116	C0038838
SOD	T116	C0038838
catalase	T116	C0007367
CAT	T116	C0007367
hippocampus	T023	C0019564
LPS	T109	C0023810
group	T078	C0441833
control	T096	C0009932
enhanced	T052	C2349975
aniamls	T008	C0003062
pretreated	T052	C3539076
captopril	T116	C0006938
captopril	T116	C0006938
improved	T080	C1272745
LPS	T109	C0023810
induced	T169	C0205263
learning	T048	C0023186
memory impairments	T048	C0233794
rats	T015	C0034721
attenuating	T052	C0599946
hippocampal	T023	C0019564
cytokine	T116	C0079189
levels	T080	C0441889
improving	T080	C1272745
brain tissues	T023	C0459385
oxidative	T169	C0311404
damage	T037	C0010957
criteria	T078	C0243161
Targeted therapy	T061	C2985566
gastric cancer	T191	C0024623
Gastric cancer	T191	C0024623
cancer	T191	C0006826
Surgery	T061	C0543467
multimodal therapy	T061	C0009429
curative therapy	T033	C1273390
targeted therapy	T061	C2985566
years	T079	C0439234
implication	T169	C1314939
HER2	T028	C0242957
angiogenesis	T042	C0302600
targeted therapies	T061	C2985566
treatment	T061	C0087111
gastric cancer	T191	C0024623
resistance	T169	C4281815
monoclonal antibodies	T116	C0003250
comprehensive	T080	C1880156
comparative	T062	C1579762
literature	T170	C0023866
research	T062	C0035168
evaluate	T058	C0220825
HER2	T028	C0242957
angiogenesis	T042	C0302600
targeted therapy	T061	C2985566
gastric cancer	T191	C0024623
trastuzumab	T116	C0728747
ramucirumab	T116	C2742502
agents	T109	C0003392
therapy	T061	C0087111
patients	T101	C0030705
gastric cancer	T191	C0024623
targeted therapies	T061	C2985566
gastric cancer	T191	C0024623
resistance	T169	C4281815
targeted therapy	T061	C2985566
second-line treatment	T061	C1710038
chemotherapy	T061	C3665472
results	T033	C0808233
first-line treatment	T061	C1708063
therapeutic agents	T121	C1611640
combinations	T121	C0013162
first-line treatment	T061	C1708063
gastric cancer	T191	C0024623
clinical trials	T062	C0008976
Serum C-Reactive Protein	T059	C1277266
Children	T100	C0008059
Liver Disease	T047	C0023895
Ascites	T033	C0003962
diagnosis	T062	C1704656
peritonitis	T046	C0031154
complication	T046	C0009566
cirrhosis	T047	C0023890
study	T062	C2603343
serum C-reactive protein levels	T059	C1277266
diagnostic factor	T201	C1511876
spontaneous bacterial peritonitis	T047	C0275551
SBP	T047	C0275551
child patients	T101	C0030705
liver disease	T047	C0023895
study	T062	C2603343
children	T100	C0008059
diagnosed	T062	C1704656
liver disease	T047	C0023895
ascites	T033	C0003962
admission	T058	C0184666
Nemazee Teaching Hospital	T073	C0020027
Shiraz	T083	C0017446
Iran	T083	C0022065
examined	T033	C0332128
Patients	T101	C0030705
spontaneous bacterial peritonitis	T047	C0275551
sterile ascetic fluid groups	T031	C0682554
PMN count	T059	C0948762
ascetic fluids	T031	C0682554
Routine laboratory tests	T059	C0022885
C-reactive protein (CRP) levels	T059	C1277266
patients	T101	C0030705
Accuracy	T080	C0443131
sensitivity, and specificity	T081	C0036668
CRP	T059	C1277266
diagnosis	T062	C1704656
SBP	T047	C0275551
cirrhotic	T047	C1623038
patients	T101	C0030705
patients	T101	C0030705
SBP	T047	C0275551
male	T098	C0025266
mean age	T032	C0001779
years	T079	C0439234
patients	T101	C0030705
SBP	T047	C0275551
male	T098	C0025266
mean age	T032	C0001779
years	T079	C0439234
Cell counts	T059	C0007584
protein levels	T034	C0428479
albumin levels	T034	C0428519
lactate dehydrogenize (LDH) levels	T059	C0428346
ascetic fluid	T031	C0682554
serum samples	T031	C1550100
SBP	T047	C0275551
SBP	T047	C0275551
CRP	T059	C1277266
SBP	T047	C0275551
SBP	T047	C0275551
sensitivity and specificity	T081	C0036668
CRP	T059	C1277266
diagnosis	T062	C1704656
SBP	T047	C0275551
PMN count	T059	C0948762
cultured ascites	T033	C0003962
CRP	T059	C1277266
SBP	T047	C0275551
PMN count	T059	C0948762
cultured ascites	T033	C0003962
study	T062	C2603343
CRP	T059	C1277266
sensitivity and specificity	T081	C0036668
diagnosis	T062	C1704656
SBP	T047	C0275551
cirrhotic	T047	C1623038
children	T100	C0008059
bacterial	T080	C0521009
plant	T002	C0032098
ferredoxin	T116	C0015858
receptor	T116	C0597357
FusA	T116	C0059038
Iron	T121	C0302583
nutrient	T168	C0678695
bacterial infection	T047	C0004623
host	T001	C1167395
pathogen	T001	C0450254
Gram-negative bacteria	T007	C0018150
TonB	T116	C1437205
outer membrane	T026	C1167331
receptors	T116	C0597357
iron	T121	C0302583
infection	T046	C3714514
receptors	T116	C0597357
iron	T121	C0302583
iron-scavenging siderophores	T109	C0142281
direct interaction	T169	C1704675
extraction	T061	C0185115
host	T001	C1167395
proteins	T116	C0033684
Characterization	T052	C1880022
receptors	T116	C0597357
pathogenesis	T046	C0699748
virulence	T038	C0042765
TonB	T116	C1437205
receptors	T116	C0597357
discovery	T052	C1880355
FusA	T116	C0059038
TonB	T116	C1437205
receptor	T116	C0597357
phytopathogenic Pectobacterium spp.	T007	C0030745
iron	T121	C0302583
plant	T002	C0032098
ferredoxin	T116	C0015858
crystal structure	T104	C0444626
FusA	T116	C0059038
binding	T044	C1167622
ferredoxin	T116	C0015858
extracellular loops	T026	C0243092
extensive	T080	C0205231
interactions	T169	C1704675
ferredoxin	T116	C0015858
function	T169	C0542341
FusA	T116	C0059038
homologues	T085	C0162774
clinically important	T080	C3898777
pathogens	T001	C0450254
iron-containing proteins	T116	C0033684
iron	T121	C0302583
source	T033	C0449416
bacterial	T080	C0521009
pathogens	T001	C0450254
Antigen	T129	C0003320
Masking	T070	C0005520
Fixation	T059	C0085254
Embedding	T059	C1707903
Dissected	T169	C0205239
Antigen	T129	C0003320
masking	T070	C0005520
processed	T067	C1522240
tissue	T024	C0040300
multiple	T081	C0439064
factors	T169	C1521761
dissect	T169	C0205239
antigenicity	T038	C3714634
step	T077	C1261552
processing	T052	C1709694
frozen sections	T024	C0016741
proxies	T096	C0600420
whole tissue	T024	C0040300
antigen	T129	C0003320
masking	T070	C0005520
fixation	T059	C0085254
times	T079	C0040223
room temperature	T080	C2348236
antigens	T129	C0003320
fixation	T059	C0085254
times	T079	C0040223
detection	T033	C0442726
antigen	T129	C0003320
retrieval	T058	C1514918
AR	T058	C1514918
Ki-67	T116	C0208804
bcl-2	T129	C1317122
ER	T116	C1545287
transfer	T169	C0205245
graded alcohol	T109	C0001975
series	T081	C0205549
staining effect	T033	C1704680
treating	T169	C1522326
sections	T024	C0016741
detergents	T120	C0011740
polymeric	T104	C0032521
immunohistochemical	T059	C1441616
detection	T033	C0442726
system	T169	C0449913
tissue	T024	C0040300
structures	T082	C0678594
masking	T070	C0005520
clearing agent	T120	C4055226
paraffin	T109	C0030415
embedding	T059	C1707903
step	T077	C1261552
non-freezable	T080	C0205556
water	T121	C0043047
removal	T052	C1883720
AR	T058	C1514918
masking	T070	C0005520
fixation	T059	C0085254
time	T079	C0040223
paraffin	T109	C0030415
embedding	T059	C1707903
AR	T058	C1514918
destroys	T052	C1948029
epitopes	T129	C0003316
routine	T080	C0205547
processing	T052	C1709694
Processed	T067	C1522240
frozen sections	T024	C0016741
investigate	T169	C1292732
fixation	T059	C0085254
processing	T052	C1709694
requirements	T169	C1514873
antigens	T129	C0003320
routine	T080	C0205547
specimens	T167	C0370003
Synthesis	T052	C1883254
1,2-Dioxetanes	T109	C0212353
Thermochemiluminescent Labels	T130	C1522485
Ultrasensitive Bioassays	T059	C0005507
Rational Prediction	T078	C0681842
Olefin	T109	C0002068
Photooxygenation	T067	C1254366
Outcome	T169	C1274040
Chemometric Approach	T059	C0022885
thermochemiluminescent (TCL) molecules	T167	C0567416
bioanalytical assays	T059	C0005507
design	T052	C1707689
synthesis	T052	C1883254
library	T073	C0023621
olefins	T109	C0002068
photooxygenation	T067	C1254366
1,2-dioxetane-based	T109	C0212353
TCL labels	T130	C1522485
optimized properties	T080	C0871161
Fluorine	T123	C0016330
acridan	T109	C0283001
1,2-dioxetanes	T109	C0212353
3- and/or 6-position	T082	C1254362
2,7-difluorinated acridan dioxetane	T109	C0029224
fluorescence quantum yield	T081	C0392762
unsubstituted dioxetane	T109	C0029224
synthesized	T052	C1883254
olefins	T109	C0002068
singlet oxygen addition	T067	C1254366
rationale	T078	C2699007
photooxygenation	T067	C1254366
TCL dioxetanes	T109	C0029224
chemometric approach	T059	C0022885
principal component analysis	T062	C0936012
linear discriminant analysis	T062	C0936012
structural	T082	C0678594
electronic molecular descriptors	T170	C0282354
DFT optimizations	T052	C2698650
olefins	T109	C0002068
approach	T082	C0449445
steric and electronic parameters	T077	C0549193
dioxetane	T109	C0029224
formation	T169	C1522492
revealed	T080	C0443289
Prostate external beam radiotherapy	T061	C2367589
combined	T080	C0205195
high-dose-rate brachytherapy	T061	C0454270
dose	T081	C0178602
volume	T081	C0449468
parameters	T033	C0449381
deformably-registered plans	T170	C0002045
correlate	T080	C1707520
late	T079	C0205087
gastrointestinal complications	T046	C0161819
Derivation	T080	C1441547
dose	T081	C0178602
volume	T081	C0449468
correlated	T080	C1707520
toxicity	T080	C0040539
multi-modal treatments	T061	C0087111
difficult	T080	C0332218
voxel-by-voxel dose accumulation	T059	C0022885
data	T078	C1511726
single	T081	C0205171
institution	T073	C0018704
cohort	T098	C0599755
long	T080	C0205166
follow-up	T058	C1522577
investigation	T169	C1292732
rectal	T082	C0205052
dose	T081	C0178602
volume	T081	C0449468
effects	T080	C1280500
gastrointestinal toxicities	T033	C1142499
phase	T079	C0205390
combined	T080	C0205195
external beam radiotherapy	T061	C2367589
EBRT	T061	C2367589
high-dose-rate (HDR) brachytherapy	T061	C0454270
prostate treatment	T061	C0194790
patients	T101	C0030705
EBRT	T061	C2367589
fractions	T081	C1264633
Gy	T081	C0556636
HDR	T061	C0454270
TG43 algorithm	T170	C0002045
fractions	T081	C1264633
Gy	T081	C0556636
Results	T033	C0683954
Late Effects of Normal Tissues - Subjective, Objective, Management and Analytic toxicity assessments	T170	C0450973
median	T081	C0876920
follow-up	T058	C1522577
months	T079	C0439231
HDR	T061	C0454270
CT	T060	C0040405
EBRT	T061	C2367589
CT	T060	C0040405
Doses	T081	C0178602
corrected	T080	C0205202
dose fractionation	T061	C0524811
Rectum	T023	C0034896
dose-volume histogram	T170	C3827011
DVH	T170	C3827011
parameters	T033	C0449381
calculated	T052	C1441506
Distribution-adding	T170	C0025663
parameters	T033	C0449381
calculated	T052	C1441506
EBRT	T061	C2367589
dose	T081	C0178602
distribution	T169	C1704711
HDR	T061	C0454270
dose	T081	C0178602
distribution	T169	C1704711
Parameter-adding	T170	C0025663
EBRT	T061	C2367589
DVH	T170	C3827011
parameters	T033	C0449381
added	T169	C1524062
HDR	T061	C0454270
DVH	T170	C3827011
parameters	T033	C0449381
Logistic regressions	T062	C0206031
Mann-Whitney U-tests	T081	C0242927
correlate	T080	C1707520
parameters	T033	C0449381
late	T079	C0205087
peak	T080	C0444505
toxicity	T080	C0040539
dichotomised	T169	C0332849
grade	T185	C0441800
Gy	T081	C0556636
dose	T081	C0178602
regions	T082	C0205147
distribution-adding	T170	C0025663
significantly	T078	C0750502
correlated	T080	C1707520
rectal bleeding	T046	C0267596
urgency	T047	C0085606
tenesmus	T184	C0232726
stool frequency	T033	C0426642
Additionally	T169	C1524062
urgency	T047	C0085606
tenesmus	T184	C0232726
anorectal pain	T184	C0581362
associated with	T080	C0332281
Gy	T081	C0556636
Gy	T081	C0556636
dose	T081	C0178602
regions	T082	C0205147
distribution-adding	T170	C0025663
Parameter-adding	T170	C0025663
low	T080	C0205251
mid	T082	C0444598
dose	T081	C0178602
region	T082	C0205147
significantly	T078	C0750502
correlated	T080	C1707520
stool frequency	T033	C0426642
proctitis	T047	C0033246
study	T062	C0681814
confirms	T033	C0750484
significant	T078	C0750502
dose-histogram	T170	C3827011
effects	T080	C1280500
gastrointestinal toxicities	T033	C1142499
including	T169	C0332257
deformable registration	T170	C0002045
combine	T080	C0205195
phases	T079	C0205390
EBRT	T061	C2367589
HDR	T061	C0454270
prostate cancer	T191	C0376358
treatment	T061	C0087111
findings	T033	C0243095
distribution-adding	T170	C0025663
cases	T169	C0868928
consistent with	T078	C0332290
parameter-adding	T170	C0025663
mid	T082	C0444598
high	T080	C0205250
dose	T081	C0178602
range	T081	C1514721
near	T080	C1706276
maximum	T081	C0806909
doses	T081	C0178602
important	T080	C3898777
rectal bleeding	T046	C0267596
distribution-adding	T170	C0025663
mid	T082	C0444598
high	T080	C0205250
dose	T081	C0178602
range	T081	C1514721
important	T080	C3898777
stool frequency	T033	C0426642
urgency	T047	C0085606
tenesmus	T184	C0232726
additional	T169	C1524062
studies	T062	C2603343
variety	T077	C2346866
institutions	T078	C1272753
variety	T077	C2346866
dose accumulation methods	T059	C0022885
inter-fraction motion management	T058	C1254363
Prescription	T170	C1521941
opioids	T109	C0242402
breathlessness	T184	C0013404
end-stage	T080	C0205088
COPD	T047	C0024117
population-based study	T062	C1709599
Low-dose	T081	C0445550
opioids	T109	C0242402
relieve	T169	C1301676
breathlessness	T184	C0013404
late-stage	T079	C1279941
COPD	T047	C0024117
fear	T041	C0015726
complications	T046	C0009566
symptom control	T061	C1274136
study	T062	C2603343
period	T079	C1948053
indications	T078	C3146298
opioids	T109	C0242402
prescribed	T058	C0278329
people	T098	C0027361
end-stage	T080	C0205088
COPD	T047	C0024117
study	T062	C2603343
longitudinal	T062	C0023981
population-based study	T062	C1709599
patients	T101	C0030705
long-term oxygen therapy	T061	C0418996
LTOT	T061	C0418996
COPD	T047	C0024117
Sweden	T083	C0038995
dispensed	T058	C1880359
opioid	T109	C0242402
prescriptions	T170	C1521941
national Prescribed Drugs Register	T170	C0282574
days	T079	C0439228
LTOT	T061	C0418996
LTOT	T061	C0418996
withdrawal	T052	C2349954
death	T040	C0011065
study end	T079	C2983670
dispensed quantity	T081	C0805077
date of dispensing	T033	C0243095
indications	T078	C3146298
pain	T184	C0030193
breathlessness	T184	C0013404
COPD	T047	C0024117
patients	T101	C0030705
women	T098	C0043210
follow-up	T058	C1522577
interquartile range	T081	C1711350
years	T079	C0439234
patients	T101	C0030705
dispensed	T058	C1880359
opioid	T109	C0242402
prescription	T058	C0033080
prescriptions	T058	C0033080
prescribed	T058	C0278329
opioids	T109	C0242402
tramadol	T109	C0040610
oxycodone	T109	C0030049
morphine	T109	C0026549
codeine	T109	C0009214
dispensed quantity	T081	C0805077
interquartile range	T081	C1711350
daily doses	T081	C2348070
prescription	T058	C0033080
sample	T167	C0370003
indication	T078	C3146298
pain	T184	C0030193
breathlessness	T184	C0013404
opioids	T109	C0242402
relief	T169	C1301676
breathlessness	T184	C0013404
study	T062	C2603343
opioids	T109	C0242402
prescribed	T058	C0278329
relieve	T169	C1301676
breathlessness	T184	C0013404
oxygen-dependent	T042	C1655730
COPD	T047	C0024117
symptom control	T061	C1274136
study	T062	C2603343
baseline	T081	C1442488
morphine	T109	C0026549
In Vivo	T082	C1515655
3-Dimensional	T082	C0450363
Strain Mapping	T052	C1283195
Confirms	T080	C0521093
Large	T081	C0549177
Optic Nerve Head	T023	C0029127
Deformations	T190	C0302142
Following	T079	C0332282
Horizontal Eye Movements	T039	C0015413
measure	T081	C0079809
lamina cribrosa	T023	C0229114
LC	T023	C0229114
strains	T190	C0302142
deformations	T190	C0302142
following	T079	C0332282
abduction	T039	C0231456
adduction	T169	C0231457
healthy subjects	T098	C1708335
compare	T052	C1707455
resulting	T169	C1274040
relatively	T080	C0205345
high	T080	C0205250
acute	T079	C0205178
intraocular pressure	T042	C0021888
IOP	T042	C0021888
elevation	T082	C0702240
total	T080	C0439810
eyes	T023	C0015392
healthy subjects	T098	C1708335
included	T052	C2700399
eyes	T023	C0015392
peripapillary atrophy	T033	C1719838
PPA	T033	C1719838
each	T081	C1457900
subject	T096	C0681850
optic nerve heads	T023	C0029127
ONHs	T023	C0029127
imaged	T170	C1704922
optical coherence tomography	T060	C0920367
OCT	T060	C0920367
baseline	T081	C1442488
twice	T081	C1948050
different	T080	C1705242
gaze	T074	C0590323
positions	T082	C0733755
adduction	T169	C0231457
abduction	T039	C0231456
following	T079	C0332282
acute	T079	C0205178
IOP	T042	C0021888
elevation	T082	C0702240
approximately	T080	C0332232
Hg	T131	C0025424
baseline	T081	C1442488
ophthalmodynamometry	T060	C0029085
Strains	T190	C0302142
LC	T023	C0229114
loading scenarios	T169	C0683579
mapped	T170	C3858752
three-dimensional	T082	C0450363
tracking	T082	C0546881
algorithm	T170	C0002045
eyes	T023	C0015392
LC	T023	C0229114
strains	T190	C0302142
induced	T169	C0205263
adduction	T169	C0231457
abduction	T039	C0231456
significantly higher	T081	C4055637
control	T096	C0009932
strains	T190	C0302142
measured	T080	C0444706
repeated	T169	C0205341
baseline	T081	C1442488
acquisitions	T052	C1706701
Strains	T190	C0302142
LC	T023	C0229114
adduction	T169	C0231457
average	T081	C1510992
higher	T080	C0205250
abduction	T039	C0231456
difference	T080	C1705242
statistically significant	T081	C0237881
Strains	T190	C0302142
LC	T023	C0229114
induced	T169	C0205263
IOP	T042	C0021888
elevations	T082	C0702240
average	T081	C1510992
Hg	T131	C0025424
significantly higher	T081	C4055637
control	T096	C0009932
strains	T190	C0302142
Gaze	T074	C0590323
induced	T169	C0205263
LC	T023	C0229114
strains	T190	C0302142
PPA	T033	C1719838
group	T101	C0030705
average	T081	C1510992
larger	T081	C0549177
non-PPA group	T101	C0030705
relationship	T080	C0439849
statistically significant	T081	C0237881
results	T033	C0683954
confirm	T080	C1456348
horizontal eye movements	T039	C0015413
generate	T080	C0205556
significant	T078	C0750502
ONH	T023	C0029127
strains	T190	C0302142
consistent with	T078	C0332290
previous	T079	C0205156
estimations	T041	C0680844
finite element analysis	T170	C0600552
Further studies	T062	C2603343
possible	T033	C0332149
ONH	T023	C0029127
strains	T190	C0302142
induced	T169	C0205263
eye movements	T039	C0015413
axonal loss	T033	C1832338
optic neuropathies	T047	C0029132
Simultaneously	T079	C0521115
Targeting	T169	C1521840
Myofibroblast Contractility	T043	C4235370
Extracellular Matrix	T024	C0015350
Cross-Linking	T169	C0332220
Therapeutic Concept	T169	C0302350
Airway	T023	C0458827
Fibrosis	T046	C0016059
Fibrosis	T046	C0016059
solid organ transplantation	T061	C0029216
irreversible	T079	C0205355
process	T067	C1522240
major	T080	C0205164
graft dysfunction	T046	C1167870
death	T040	C0011065
limited	T169	C0439801
therapies	T061	C0087111
remodeling	UnknownType	C0678692
characterized	T052	C1880022
aberrant	T080	C0443127
accumulation	T033	C4055506
contractile myofibroblasts	T025	C0225360
deposit	T169	C0333562
excessive	T080	C0442802
extracellular matrix	T024	C0015350
ECM	T024	C0015350
increase	T169	C0442805
tissue stiffness	T184	C2017125
Studies	T062	C2603343
stiff	T184	C0427008
ECM	T024	C0015350
promotes	T052	C0033414
fibroblast	T025	C0016030
myofibroblast	T025	C0225360
differentiation	T043	C0007589
stimulating	T052	C1879547
ECM	T024	C0015350
production	T052	C1883254
positive feedback loop	UnknownType	C0678664
perpetuates	T080	C0205556
fibrosis	T046	C0016059
hypothesized	T078	C1512571
simultaneously	T079	C0521115
targeting	T169	C1521840
myofibroblast contractility	T043	C4235370
relaxin	T116	C0035031
ECM	T024	C0015350
stiffness	T184	C0427008
lysyl oxidase	T116	C0024375
inhibitors	T121	C0014432
feedback loop	T039	C0678663
reversing	T169	C1555029
established	T080	C0443211
fibrosis	T046	C0016059
test	T169	C0039593
orthotopic tracheal transplantation	T061	C0040732
OTT	T061	C0040732
mouse model	T050	C2986594
robust	T080	C2986815
fibrotic	T169	C0334129
airway	T023	C0458827
remodeling	UnknownType	C0678692
Mice	T015	C0025929
established	T080	C0443211
fibrosis	T046	C0016059
treated	T169	C1522326
saline	T167	C0036082
mono-	T061	C0520016
combination therapies	T061	C0013218
monotherapies	T061	C0520016
no effect	T080	C1301751
combining these agents	T121	C0013162
decreased	T081	C0205216
collagen	T116	C0009325
deposition	T169	C0333562
promoted	T052	C0033414
re-epithelialization	T042	C0334221
remodeled airways	T033	C2717792
Relaxin	T116	C0035031
inhibited	T080	C0311403
myofibroblast	T025	C0225360
differentiation	T043	C0007589
contraction	T046	C1140999
matrix	T024	C0015350
stiffness	T184	C0427008
dependent	T169	C3244310
prostaglandin E2	T109	C3813211
PGE2	T109	C3813211
effect	T080	C1280500
combination therapy	T061	C0013218
PGE2 receptor	T116	C0034835
knockout	T015	C0206745
PGE2	T109	C3813211
inhibited	T080	C0311403
OTT	T061	C0040732
mice	T015	C0025929
study	T062	C2603343
revealed	T080	C0443289
synergistic	T080	C2986495
roles	T077	C1705810
cellular contractility	T046	C1140999
tissue stiffness	T184	C2017125
maintenance	T052	C0024501
fibrotic	T169	C0334129
tissue	T024	C0040300
therapeutic	T169	C0302350
principle	UnknownType	C0678989
fibrosis	T046	C0016059
Systemic matrix metalloproteinase-8	T116	C1721358
response	T038	C3714634
chronic tonsillitis	T047	C0149517
development	T169	C1527148
diseases	T047	C0012634
coronary heart disease	T047	C0010068
low-grade	T080	C1282907
systemic	T169	C0205373
inflammation	T046	C0021368
Data	T078	C1511726
potential	T080	C3245505
long-term	T079	C0443252
health	T078	C0018684
effects	T080	C1280500
chronic tonsillitis	T047	C0149517
inflammatory	T046	C0021368
conditions	T080	C0348080
systemic matrix metalloproteinase	T116	C1721358
(MMP)-8	T116	C1721358
response	T038	C3714634
head and neck cancer	T191	C0278996
high	T080	C0205250
plasma	T031	C0032105
level	T080	C0441889
tissue inhibitor of metalloproteinase	T116	C0145947
(TIMP)-1	T116	C0145947
predicts	T078	C0681842
poor prognosis	T033	C0278252
S-MMP-8	T116	C1721358
immunofluorometric assay	T059	C0016350
S-TIMP-1	T116	C0145947
immunosorbent assay	T059	C1532280
consecutive	T080	C1707491
patients	T101	C0030705
tonsillectomy	T061	C0040423
benign tonsillar disease	T191	C0153936
control	T096	C0009932
patients	T101	C0030705
tonsillar squamous cell carcinoma	T191	C0280317
Tonsillar	T023	C0040421
human papillomavirus	T005	C0021344
HPV	T005	C0021344
PCR	T063	C0032520
patients	T101	C0030705
benign tonsillar disease	T191	C0153936
chronic tonsillitis	T047	C0149517
hypertrophy	T046	C0020564
associated with	T080	C0332281
systemic MMP-8	T116	C1721358
response	T038	C3714634
patients	T101	C0030705
benign tonsillar disease	T191	C0153936
patients	T101	C0030705
tonsillar squamous cell carcinoma	T191	C0280317
significantly higher	T081	C4055637
concentrations	T081	C1446561
S-MMP-8	T116	C1721358
S-TIMP-1	T116	C0145947
S-MMP-8	T116	C1721358
S-TIMP-1	T116	C0145947
tonsillar	T023	C0040421
HPV	T005	C0021344
positivity	T033	C1514241
Addressing	T170	C0376649
holistic health	T078	C0019844
work	T057	C0043227
empowerment	T054	C0679959
through	T169	C0332273
body-mind-spirit intervention program	T058	C0679897
helping	T054	C0018896
professionals	T097	C0679924
continuous	T078	C0549178
education	T065	C0013621
pilot study	T062	C0031928
effectiveness	T080	C1280519
body-mind-spirit (BMS) intervention program	T058	C0679897
improving	T080	C1272745
holistic well-being	T078	C0019844
work	T057	C0043227
empowerment	T054	C0679959
helping	T054	C0018896
professionals	T097	C0679924
continuous	T078	C0549178
education	T065	C0013621
helping	T054	C0018896
professionals	T097	C0679924
postgraduate study	T065	C0597274
participants	T098	C0679646
attended	T169	C1456498
BMS intervention program	T058	C0679897
holistic approach	T078	C0683249
health	T078	C0018684
well-being	T078	C0018684
levels	T080	C0441889
physical distress	T033	C0231303
daily functioning	T054	C0037395
affect	T041	C0001721
spirituality	T078	C0237104
psychologica	T169	C0205486
empowerment	T054	C0679959
work	T057	C0043227
intervention	T058	C1273869
Participants	T098	C0679646
levels	T080	C0441889
negative affect	T033	C0243095
physical distress	T033	C0231303
spiritually disoriented	T033	C0243095
intervention	T058	C1273869
Enhanced	T052	C2349975
levels	T080	C0441889
daily functioning	T054	C0037395
positive affect	T041	C0018592
spiritual resilience	UnknownType	C0683811
tranquility	T041	C0522165
participants	T098	C0679646
empowered	T041	C0562342
work	T057	C0043227
work	T057	C0043227
BMS intervention program	T058	C0679897
positive	T033	C0243095
measurable	T169	C1513040
effec	T080	C1280500
participants	T098	C0679646
holistic well-being	T078	C0019844
empowerment	T054	C0679959
work	T057	C0043227
Educators	T097	C0259853
fields	T077	C2346620
holistic	T078	C0019844
practices	T041	C0032893
curriculum	T170	C0010478
practitioners	T097	C1709627
professionals	T097	C0679924
clients	T096	C0008942
patients	T101	C0030705
Successful Restoration	T061	C0399059
Mutilated	T037	C0332811
Primary Incisors	T023	C0021156
Zirconia	T074	C3503915
Crowns	T074	C3853546
Two Year	T079	C0439234
Results	T169	C1274040
manuscript	T073	C0600659
reliable technique	T169	C0449851
restoring	T061	C0399059
mutilated	T037	C0332811
primary anterior teeth	T023	C0021156
glass ionomer post	T122	C0017597
zirconia	T074	C3503915
crowns	T074	C3853546
long-term	T079	C0443252
esthetic	T061	C0010163
restoration	T061	C0399059
primary anterior teeth	T023	C0021156
Children	T100	C0008059
years	T079	C0439234
decayed	T047	C0011334
upper primary incisors	T023	C0021156
Fuji IX	T122	C0671561
intracanal space	T061	C0282543
depth	T082	C0205125
core	T082	C0444669
supragingivally	T061	C0086959
Crown preparations	T061	C0399013
cores	T082	C0444669
Zirconia	T074	C3503915
crowns	T074	C3853546
Nusmile	T170	C0947322
Houston Texas	T083	C3812709
USA	T083	C0041703
fitted	T067	C3714578
cemented	T031	C0011343
cores	T082	C0444669
patients	T101	C0030705
recalled	T061	C1707680
regular intervals	T079	C1272706
children	T100	C0008059
restorations	T061	C0399059
study	T062	C2603343
overall survival	T081	C4086681
restorations	T061	C0399059
months	T079	C0439231
months	T079	C0439231
Kaplan-Meier survival analysis	T062	C0038953
median survival time	T079	C2986586
mean survival time	T081	C0086595
months	T079	C0439231
clinical technique	T058	C0376583
reliable	T170	C3858758
restoration	T061	C0399059
decayed	T047	C0011334
primary incisors	T023	C0021156
zirconia	T074	C3503915
crowns	T074	C3853546
technique	T169	C0449851
superior esthetic	T080	C0004898
restorations	T061	C0399059
gingival response	T033	C0541981
months	T079	C0439231
Reimbursement	T170	C3242446
Knee Surgery	T061	C0187769
Medicare Access and Children's Health Insurance Program Reauthorization Act of 2015	T089	C4277549
Health care cost	T081	C0085552
nation's	T092	C1555720
gross domestic product	T081	C2936646
economic burdens	T081	C1512163
physicians	T097	C0031831
patients	T101	C0030705
total joint replacement	T061	C0185317
procedures	T061	C0184661
health care environment	T093	C0565997
knee surgeons	T097	C0334891
health care reforms	T064	C0206597
Medicare Access and Children's Health Insurance Program Reauthorization Act	T089	C4277549
value-based payment reform	T064	C0206597
knee surgeons	T097	C0334891
contextual framework	T078	C1254370
health care legislation	T089	C0018719
health policy	T089	C0018735
comprehensive	T080	C1880156
summary	T170	C1706244
Merit-Based Incentive Payment Systems	T170	C0282574
Alternative Payment Models reimbursement models	T170	C0282574
Empty	T080	C1880497
Capsids	T017	C0006933
Macrophage	T025	C0024432
Inhibition	T052	C3463820
Depletion	T169	C0333668
Increase	T169	C0442805
rAAV	T121	C1520007
Transgene	T028	C0282641
Expression	T045	C0017262
Joints	T030	C0022417
Healthy	T080	C3898900
Arthritic	T047	C0003864
Mice	T015	C0025929
Gene therapy	T061	C0017296
potential	T080	C3245505
treat	T061	C0087111
rheumatic diseases	T047	C0035435
presence	T033	C0150312
macrophages	T025	C0024432
joint	T030	C0022417
adeno-associated viral	T005	C0001417
vector	T121	C1520007
gene delivery	T077	C1524066
arthritic	T047	C0003864
healthy	T080	C3898900
mice	T015	C0025929
administration of agents	T058	C2348003
influence	T077	C4054723
macrophage	T025	C0024432
activity	T052	C0441655
number	T081	C0237753
addition	T169	C1883712
empty	T080	C1880497
decoy capsids	T017	C0006933
improve	T033	C0184511
efficacy	T080	C1280519
recombinant	T001	C1514798
adeno-associated viral	T005	C0001417
vector	T121	C1520007
transgene	T028	C0282641
expression	T045	C0017262
joint	T030	C0022417
Pretreatment	T052	C3539076
triamcinolone	T109	C0040864
clodronate	T109	C0162357
liposomes	T109	C0023828
improved	T033	C0184511
luciferase	T116	C0024075
expression	T045	C0017262
period	T079	C1948053
weeks	T079	C0439230
Similar	T080	C2348205
results	T033	C0683954
empty	T080	C1880497
decoy capsids	T017	C0006933
added	T169	C1524062
full	T080	C0443225
genome	T028	C0017428
capsids	T017	C0006933
ratio	T081	C0456603
study	T062	C0008972
assess	T052	C1516048
duration	T079	C0449238
expression	T045	C0017262
investigate	T169	C1292732
combination	T080	C0205195
approaches	T169	C1292724
observed	T169	C1441672
synergistic	T080	C2986495
enhancement	T052	C2349975
gene expression	T045	C0017262
sustained	T169	C0443318
weeks	T079	C0439230
enhancement	T052	C2349975
gene expression	T045	C0017262
route of administration	T169	C0013153
triamcinolone	T109	C0040864
intra-articular	T082	C0442108
intramuscular	T082	C0442117
healthy	T080	C3898900
mice	T015	C0025929
combination	T080	C0205195
improved	T033	C0184511
expression	T045	C0017262
transgene	T028	C0282641
serotype	T170	C0449943
data	T078	C1511726
gene therapy	T061	C0017296
joint	T030	C0022417
tissues	T024	C0040300
abundance	T080	C2346714
macrophages	T025	C0024432
Inhibitory	T052	C3463820
Septum	UnknownType	C0814033
Lateral Hypothalamus	T029	C0020654
Circuit	UnknownType	C0814033
Suppresses	T169	C1260953
Feeding	T055	C0015745
Feeding behavior	T055	C0015745
orchestrated	T169	C1300196
neural circuits	UnknownType	C0814033
hypothalamus	T023	C0020663
hindbrain	T023	C0035507
relative	T080	C0205345
influence	T077	C4054723
cognitive	T169	C1516691
emotional	T041	C0013987
brain circuits	UnknownType	C0682723
feeding	T055	C0015745
circuitry	UnknownType	C0260041
hypothalamus	T023	C0020663
hindbrain	T023	C0035507
unclear	T033	C3845108
using	T169	C1524063
cell-type	T170	C0449475
genetic methods	T062	C0017395
circuit mapping	T060	C0006117
behavior	T053	C0004927
assays	T059	C0005507
neural circuits	UnknownType	C0814033
septal nucleus	T023	C0175232
lateral hypothalamus	T029	C0020654
LH	T029	C0020654
neural regulation	T042	C0598959
food intake	T040	C0013470
mice	T015	C0025929
chemogenetic	T169	C0205245
optogenetic	T169	C0205245
activation	T052	C1879547
septal	T082	C0442004
vesicular GABA transporter	T116	C1453453
vGAT	T116	C1453453
containing	T169	C0332256
neurons	T025	C0027882
LH	T029	C0020654
reduced	T080	C0392756
food intake	T040	C0013470
mice	T015	C0025929
chemogenetic	T169	C0205245
inhibition	T052	C3463820
septal	T082	C0442004
vGAT	T116	C1453453
neurons	T025	C0027882
increased	T081	C0205217
food intake	T040	C0013470
investigated	T169	C1292732
unknown	T080	C0439673
neural circuit	UnknownType	C0814033
originating	T079	C0439659
septal	T082	C0442004
vGAT	T116	C1453453
neurons	T025	C0027882
subset	T185	C1515021
vGAT	T116	C1453453
neurons	T025	C0027882
LH	T029	C0020654
area	T082	C0205146
involved	T169	C1314939
homeostatic	T038	C0019868
hedonic	T038	C3714634
control	T080	C0243148
energy states	T033	C0516979
data	T078	C1511726
reveal	T080	C0443289
inhibitory	T052	C3463820
septohypothalamic	T029	C0005898
feeding circuit	UnknownType	C0814033
therapeutic	T169	C0302350
target	T169	C1521840
treatment	T169	C1522326
eating disorders	T048	C0013473
anorexia nervosa	T048	C0003125
septum	UnknownType	C0814033
hypothalamus	T023	C0020663
control	T080	C0243148
food intake	T040	C0013470
negatively	T033	C0205160
brain regions	T029	C1273723
control	T080	C0243148
feeding	T055	C0015745
emotion	T041	C0013987
related	T169	C1552599
behaviors	T053	C0004927
findings	T033	C0243095
reveal	T080	C0443289
unknown	T080	C0439673
neural circuitry	UnknownType	C0260041
emotional aspects	T078	C0243152
food intake	T040	C0013470
provide	T052	C1999230
insights	T041	C0233820
development	T169	C1527148
therapeutic	T169	C0302350
targets	T169	C1521840
treatment	T169	C1522326
eating disorders	T048	C0013473
Human	T016	C0086418
Umbilical Cord Blood	T031	C0162371
Derived	T078	C1550535
Neural Stem Cell Line	T025	C0007600
Screening	T058	C0220908
Model	T075	C0026339
Toxicity	T037	C0600688
aim	T078	C1947946
investigate	T169	C1292732
human	T016	C0086418
neural stem cell	T025	C1113654
NSC	T025	C1113654
line	T025	C0007600
derived	T078	C1550535
human	T016	C0086418
umbilical cord blood	T031	C0162371
hUCB	T031	C0162371
toxicity	T037	C0600688
study	T062	C2603343
Toxicity	T037	C0600688
neurotoxic	T131	C0260049
environmental	T082	C0014406
xenobiotics	T123	C0043335
methyl mercury chloride	T109	C0066402
CH3HgCl	T109	C0066402
lead acetate	T121	C0064711
CH3COOPb	T121	C0064711
chlorpyrifos	T109	C0013328
CP	T109	C0013328
non-neurotoxic	T033	C0243095
insecticide	T131	C0021576
dichlorvos	T109	C0012087
non-neurotoxic	T033	C0243095
drugs	T121	C1254351
theophylline	T109	C0039771
acetaminophen	T109	C0000970
assessed	T052	C1516048
differentiation	T169	C2945687
neuronal	T129	C0521390
glial cell lines	T025	C0027836
derived	T078	C1550535
hUCB	T031	C0162371
observed	T169	C1441672
CH3HgCl	T109	C0066402
toxic	T080	C1407029
human	T016	C0086418
NSCs	T025	C0007600
comparison	T052	C1707455
CH3COOPb	T121	C0064711
CP	T109	C0013328
minimum inhibitory concentration (MIC) value	T034	C1304747
NSCs	T025	C0007600
staining process	T059	C0487602
acridine orange	T109	C0001185
ethidium bromide	T109	C0019873
AO	T109	C0001185
EB	T109	C0019873
staining	T059	C0487602
3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide	T109	C0094912
MTT	T109	C0094912
assay	T059	C1510438
Hoechst staining	T059	C1441607
CH3HgCl	T109	C0066402
CP	T109	C0013328
CH3COOPb	T121	C0064711
CH3HgCl	T109	C0066402
LC25	T081	C0392762
value	T080	C0042295
staining method	T059	C0487602
CP	T109	C0013328
LC25	T081	C0392762
value	T080	C0042295
CH3COOPb	T121	C0064711
LC25	T081	C0392762
values	T080	C0042295
LC50	T081	C1443965
values	T080	C0042295
ranged	T081	C1514721
CH3HgCl	T109	C0066402
CP	T109	C0013328
CH3COOPb	T121	C0064711
Theophylline	T109	C0039771
acetaminophen	T109	C0000970
dichlorvos	T109	C0012087
impact	T080	C4049986
viability	T080	C0443348
NSCs	T025	C0007600
hUCB	T031	C0162371
NSC	T025	C0007600
model	T075	C0026339
toxicity	T037	C0600688
study	T062	C2603343
MiR 221	T028	C1537859
222	T028	C1537860
tamoxifen	T109	C0039286
resistance	T038	C0013203
Breast cancer	T191	C0007104
cancer	T191	C0006826
women	T098	C0043210
early detection	T060	C0596473
treatment	T061	C0087111
mortality rate	T081	C0205848
lung cancer	T191	C0242379
breast carcinomas	T191	C0678222
ER+	T033	C1971473
antiestrogens	T121	C0014930
tamoxifen	T109	C0039286
tamoxifen	T109	C0039286
patients	T101	C0030705
patients	T101	C0030705
respond poorly	T033	C1320680
therapy	T061	C0087111
recurrence	T067	C0034897
tamoxifen	T109	C0039286
resistance	T038	C0013203
Drug resistance	T038	C0013203
clinical	T080	C0205210
successful treatment	T201	C0521982
breast cancer	T191	C0007104
unsuccessful treatments	T033	C0438286
acquired	T080	C0439661
resistance	T038	C0013203
MultiDrug Resistance	T032	C0242640
(MDR)	T032	C0242640
MicroRNAs	T114	C1101610
noncoding RNAs	T114	C0887909
gene expression	T045	C0017262
miRNAs	T114	C1101610
cancer	T191	C0006826
therapeutic targets	T104	C1513403
biomarkers	T201	C0005516
miRNA	T114	C1101610
deregulation	T052	C1880287
breast cancer	T191	C0007104
reports	T170	C0684224
miRNAs	T114	C1101610
studies	T062	C2603343
miRNAs	T114	C1101610
antiestrogen therapy	T061	C0854638
tamoxifen	T109	C0039286
molecules	T167	C0567416
drug resistance	T038	C0013203
RNA molecules	T114	C0035668
miRNAs	T114	C1101610
breast cancer	T191	C0007104
pathogenesis	T046	C0699748
cancer	T191	C0006826
drug resistance	T038	C0013203
mechanisms	T169	C0441712
oncomirs	T114	C1101610
miR 221	T028	C1537859
222	T028	C1537860
cell cycle deregulation	T049	C1516331
breast cancer	T191	C0007104
oncomiRs	T114	C1101610
resistance	T038	C0013203
tamoxifen	T109	C0039286
emphasized	T080	C3898777
Ultra-low activities	T052	C0441655
radioisotope	T196	C0034595
permission	T080	C0521104
tracking	T082	C0546881
drosophilid fly	T204	C0013138
natural habitat	T082	C0557745
species	T185	C1705920
ecology	T090	C0013546
movement	T040	C0026649
time	T079	C0040223
space	T082	C1883067
biology	T091	C0005532
conservation	T080	C2347858
tools	T073	C0336791
tracking	T082	C0546881
animals	T008	C0003062
millimetre-sized insects	T204	C0021585
tracking	T082	C0546881
labelling procedures	T062	C0022261
ultra-low	T052	C0441655
permission	T080	C0521104
exempt activities	T052	C0441655
metastable isomer	T070	C0022203
radionuclide	T196	C0034595
Technetium-99	T130	C0303612
labelling	T062	C0022261
field detection	T033	C0243095
mountain	T083	C0442533
fly	T204	C1704307
Drosophila nigrosparsa	T204	C3766101
activity	T052	C0441655
label	T062	C0022261
flies	T204	C0012578
detect single individuals	T033	C0243095
radiation protection	T061	C0034533
monitors	T059	C0034532
methodology	T078	C3266812
small-sized	T033	C0748864
low-mobility	T033	C0243095
animals	T008	C0003062
light	T070	C0023693
weather	T070	C0043085
conditions	T080	C0348080
visual contact	T033	C0243095
target	T169	C1521840
organism	T001	C0029235
Injury surveillance	T057	C0681625
female	T032	C0086287
adult	T100	C0001675
Zumba	T058	C1254363
dancers	T097	C0335079
patterns	T082	C0449774
injury	T037	C0043251
injury	T037	C0043251
incidence rates	T081	C1708485
associated	T080	C0332281
Zumba	T058	C1254363
Zumba	T058	C1254363
dancers	T097	C0335079
web-based	T073	C0282111
survey	T170	C0038951
demographic	T078	C0011292
background	T077	C1706907
yr	T079	C0439234
retrospective	T080	C1514923
injury	T037	C0043251
history	T169	C0019665
questions	T170	C1522634
Inclusion	T080	C1512693
criteria	T078	C0243161
respondents	T098	C0282122
aged	T032	C0001779
yr	T079	C0439234
group	T098	C1257890
classes	T170	C0456387
Zumba	T058	C1254363
registered instructor	T097	C0556993
class	T170	C0456387
participant	T098	C0679646
Binomial logistic regression analysis	UnknownType	C0681925
odds	T081	C0028873
injury	T037	C0043251
Zumba	T058	C1254363
Mann-Whitney tests	T170	C1708930
groups	T098	C1257890
survey	T170	C0038951
response rate	T081	C1521828
respondents	T098	C0282122
female	T032	C0086287
registered instructors	T097	C0556993
class	T170	C0456387
participants	T098	C0679646
sustained	T169	C0443318
injury	T037	C0043251
Zumba	T058	C1254363
year	T079	C0439234
odds	T081	C0028873
injury	T037	C0043251
CI	T081	C0009667
greater	T081	C1704243
registered instructors	T097	C0556993
class	T170	C0456387
participants	T098	C0679646
Zumba	T058	C1254363
dancers	T097	C0335079
CI	T081	C0009667
greater	T081	C1704243
odds	T081	C0028873
injury	T037	C0043251
h	T079	C0439227
Zumba	T058	C1254363
moderate to vigorous physical activity	T056	C0015259
MVPA	T056	C0015259
week	T079	C0439230
injury	T037	C0043251
incidence rate	T081	C1708485
registered instructors	T097	C0556993
class	T170	C0456387
participants	T098	C0679646
CI	T081	C0009667
CI	T081	C0009667
injuries	T037	C0043251
h	T079	C0439227
exposure	T080	C0205556
Zumba	T058	C1254363
low risk	T081	C3538919
injury	T037	C0043251
registered instructors	T097	C0556993
increased risk	T080	C1444641
injury	T037	C0043251
MVPA	T056	C0015259
participated	T169	C0679823
weekly	T079	C0332174
Clinical	T080	C0205210
Features	T080	C2348519
Smokers	T033	C0337664
Radiological	T060	C0807679
Emphysema	T047	C0034067
Airway	T023	C0458827
Limitation	T169	C0449295
clinical characteristics	T201	C0683325
patients	T101	C0030705
emphysema	T047	C0034067
airway	T023	C0458827
limitations	T169	C0449295
unknown	T080	C0439673
goal	T170	C0018017
study	T062	C2603343
compare	T052	C1707455
clinical	T080	C0205210
features	T080	C2348519
current	T033	C3241966
former smokers	T033	C0337671
airflow	T039	C0231999
limitation	T169	C0449295
radiologic	T060	C0807679
emphysema	T047	C0034067
chest CT scans	T060	C0202823
control group	T096	C0009932
current	T033	C3241966
ex-smokers	T033	C0337671
emphysema	T047	C0034067
Subjects	T096	C0681850
anthropometric characteristics	T060	C2459906
provided	T052	C1999230
medical history	T033	C0262926
low-dose	T081	C0445550
chest CT scanning	T060	C0202823
parameters	T033	C0449381
pulmonary function tests	T060	C0024119
diffusion capacity for carbon monoxide	T060	C1516251
Dlco	T060	C1516251
Medical Research Council dyspnea score	T170	C4288768
COPD assessment test	T170	C4284282
CAT	T170	C4284282
6-min walk test	T060	C0430515
6MWT	T060	C0430515
comparison	T052	C1707455
CT	T060	C0040405
confirmed	T033	C0750484
emphysema	T047	C0034067
subjects	T096	C0681850
emphysema	T047	C0034067
group	T098	C2348561
comparisons	T052	C1707455
revealed	T080	C0443289
proportion	T081	C1709707
patients	T101	C0030705
emphysema	T047	C0034067
low-dose	T081	C0445550
chest CT scanning	T060	C0202823
abnormal Dlco	T033	C4073173
value	T081	C1522609
decrease	T081	C0547047
percentage	T081	C0439165
oxygen saturation	T044	C0369768
6MWT	T060	C0430515
altered	T169	C0392747
quality of life	T078	C0034380
CAT	T170	C4284282
score	T081	C0449820
analysis	T062	C0936012
CAT questionnaire	T170	C4284282
revealed	T080	C0443289
patients	T101	C0030705
emphysema	T047	C0034067
score	T081	C0449820
chest tightness	T184	C0232292
limitation	T169	C0449295
activities	T052	C0441655
home	T082	C0442519
compared	T052	C1707455
no emphysema	T033	C0243095
exacerbations	T033	C4086268
year	T079	C0439234
significant	T078	C0750502
proportion	T081	C1709707
smokers	T033	C0337664
emphysema	T047	C0034067
low-dose	T081	C0445550
chest CT scanning	T060	C0202823
airway	T023	C0458827
limitation	T169	C0449295
alterations	T078	C1515926
quality of life	T078	C0034380
exacerbations	T033	C4086268
Dlco	T060	C1516251
values	T081	C1522609
oxygen saturation	T044	C0369768
6MWT test	T060	C0430515
Anti-tumor activity	T042	C1516031
SL4	T109	C4278992
breast cancer cells	T025	C1512505
induction	T169	C0205263
G2/M arrest	T044	C1517345
modulation	UnknownType	C0678672
MAPK	T116	C0752312
p21	T116	C0288472
signaling pathway	T043	C0037083
SL4	T109	C4278992
chalcone	T109	C0007935
compound	T103	C1706082
retard	T080	C0521111
tumor invasion	T033	C1269955
angiogenesis	T191	C1519670
suppressing	T169	C1260953
HIF1	T116	C0215848
activity	T052	C0441655
induce	T169	C0205263
apoptosis	T043	C0162638
promoting	T052	C0033414
ROS	T123	C0162772
release	T169	C1283071
report	T170	C0684224
SL4	T109	C4278992
inhibit	T052	C3463820
proliferation	T043	C0596290
different	T080	C1705242
types	T080	C0332307
breast cancer cell	T025	C1512505
in vitro	T080	C1533691
in vivo	T082	C1515655
inducing	T169	C0205263
G2/M cell cycle arrest	T044	C1517345
results	T033	C0683954
SL4	T109	C4278992
exhibited	T169	C0870432
strong	T080	C0442821
anti-proliferative	T109	C0003392
activity	T052	C0441655
human	T016	C0086418
breast cancer	T191	C0678222
cell lines	T025	C0085983
IC50 values	T081	C0600495
lower	T052	C2003888
studies	T062	C2603343
indicated	T033	C1444656
SL4	T109	C4278992
induced	T169	C0205263
G2/M arrest	T044	C1517345
cell lines	T025	C0085983
Mechanistically	T022	C0598002
SL4	T109	C4278992
reduces	T080	C0392756
expression	T045	C0017262
cyclin A2	T116	C0297674
cdc25C	T116	C0213045
decreases	T081	C0547047
activity	T044	C1537044
cdc2	T116	C0080054
cyclin B1	T116	C0385333
complex	T104	C1704241
SL4	T109	C4278992
treatment	T061	C1533734
resulted in	T169	C0332294
increase	T169	C0442805
p21	T028	C0249197
mRNA	T114	C0035696
protein	T116	C0033684
levels	T080	C0441889
activation	T043	C2259058
MAPK signaling pathways	T043	C1518102
TGF-β pathway	T044	C1155363
SP600125	T109	C0968383
PD98059	T109	C0298346
inhibitors	T120	C0243077
JNK kinase	T116	C0291988
ERK kinase	T116	C0600388
significantly	T078	C0750502
blocked	T169	C0332206
SL4	T109	C4278992
induced	T169	C0205263
G2/M phase arrest	T044	C1517345
upregulation	T044	C0041904
p21	T116	C0288472
SL4	T109	C4278992
suppressed	T169	C1260953
growth	T043	C0007595
established	T080	C0443211
breast tumors	T191	C1458155
nude mice	T015	C0025932
upregulation	T044	C0041904
p21	T116	C0288472
downregulation	T044	C0013081
cdc25C	T116	C0213045
displayed	T169	C0870432
safety	T068	C0036043
profile	T169	C2003903
findings	T033	C0243095
demonstrate	T080	C0443211
potential	T080	C3245505
value	T080	C1264628
SL4	T109	C4278992
multi-target anti-tumor drug candidate	T109	C0003392
Identification	T080	C0205396
In-Chain-Functionalized Compounds	T103	C1706082
Methyl-Branched Alkanes	T109	C0002065
Cuticular	T002	C2699479
Waxes	T122	C0043076
Triticum aestivum cv. Bethlehem	T002	C1123020
cuticular	T002	C2699479
waxes	T122	C0043076
flag leaf	T002	C0242724
blades	T002	C2700402
peduncles	T002	C2698753
Triticum aestivum cv. Bethlehem	T002	C1123020
investigated	T169	C1292732
novel	T080	C0205314
wax compounds	T122	C0043076
wax compound	T122	C0043076
classes	T185	C1705943
detected	T033	C0442726
structures	T170	C0220807
gas chromatography-mass spectrometry	T059	C0024868
derivatives	T104	C0243072
series of homologs	T081	C0205549
differing	T080	C1705242
two methylene units	T104	C1254350
homologous series	T081	C0205549
homologs with single methylene unit	T104	C1254350
waxes	T122	C0043076
flag leaf	T002	C0242724
blades	T002	C2700402
secondary alcohols	UnknownType	C0682927
predominantly	T080	C1542147
C27	UnknownType	C0682927
C33	UnknownType	C0682927
primary	T109	C0017951
secondary diols	T109	C0017951
predominantly	T080	C1542147
C28	T109	C0017951
esters of primary	T109	C0014898
secondary diols	T109	C0014898
predominantly	T080	C1542147
C50	T109	C0014898
C28 diol	T109	C0017945
C22 acid	T109	C0369760
secondary hydroxyl group positions	T104	C1254350
7-	T109	C0014898
8-hydroxy-2-alkanol esters	T109	C0014898
predominantly	T080	C1542147
C35	T109	C0014898
7-	T109	C0014898
8-oxo-2-alkanol esters	T109	C0014898
predominantly	T080	C1542147
C35	T109	C0014898
4-alkylbutan-4-olides	T109	C0022947
predominantly	T080	C1542147
C28	T109	C0022947
flag leaf	T002	C0242724
peduncle	T002	C2698753
wax	T122	C0043076
series	T081	C0205549
even	T104	C1254350
odd-numbered alkane homologs	T104	C1254350
leaf	T002	C0242724
peduncle	T002	C2698753
waxes	T122	C0043076
internal methyl branch	T104	C1254350
C-11	T109	C0029224
C-13 of homologs with even total carbon number	T109	C0029224
C-12 of odd-numbered homologs	T109	C0029224
Biosynthetic pathways	T044	C1721101
compounds	T080	C0205198
structural	T170	C0220807
features	T080	C2348519
chain length	T081	C0596310
profiles	T169	C2003903
wheat	T002	C1510495
wax compound	T122	C0043076
Pupillary response	T040	C4067879
abnormalities	T033	C1704258
depressive disorders	T048	C0011581
Depressive disorders	T048	C0011581
lack	T080	C0332268
objective	T080	C1571702
physiological	T169	C0205463
measurements	T169	C0242485
characterize	T052	C1880022
affected population	T201	C4285581
study	T062	C0008972
relevant	T080	C2347946
mechanisms	T169	C0441712
melanopsin	T116	C0670514
mediated	T041	C0870868
light signaling pathway	T044	C0037080
seasonal variation	T079	C0036496
measured	T080	C0444706
pupillometry	T060	C0260180
prospectively studied	T062	C0033522
melanopsin	T116	C0670514
mediated	T041	C0870868
pupillary constriction	T042	C3537108
participants	T101	C0030705
major depressive disorder	T048	C1269683
MDD	T048	C1269683
control	T096	C0009932
summer and winter solstices	T079	C1254367
melanopsin	T116	C0670514
mediated response	T041	C0870868
measured	T080	C0444706
pupil's sustained constriction	T033	C0728710
high intensity	UnknownType	C0683109
blue light	T070	C0303896
stimulus	T067	C0234402
attenuated	T052	C0599946
MDD	T048	C1269683
controls	T096	C0009932
p	T081	C1709380
participants	T101	C0030705
MDD	T048	C1269683
significantly	T078	C0750502
reduced	T080	C0392756
transient	T079	C0205374
pupillary response	T040	C4067879
low intensity	UnknownType	C0683108
red	T070	C0563227
p	T081	C1709380
blue light	T070	C0303896
p	T081	C1709380
high intensity	UnknownType	C0683109
red	T070	C0563227
blue light	T070	C0303896
pupillary constriction	T042	C3537108
response	T040	C4067879
high intensity	UnknownType	C0683109
blue light	T070	C0303896
increasing	T169	C0442808
daylight	T070	C0023693
hours	T079	C0439227
p	T081	C1709380
objectively	T080	C1571702
measured	T080	C0444706
estimated	T081	C0750572
light exposure	T051	C1689916
Melanopsin	T116	C0670514
mediated	T041	C0870868
impairments	T169	C0221099
pupil response	T040	C4067879
biological marker	T201	C0005516
vulnerability	T033	C1821973
depression	T048	C0011570
low light	UnknownType	C0683108
conditions	T080	C0348080
Assessment	T058	C0220825
responses	T032	C0871261
light	T070	C0023693
stimuli	T067	C0234402
response	T032	C0871261
low intensity light	UnknownType	C0683108
study	T062	C0008972
neurobiology	T091	C0027817
MDD	T048	C1269683
mood disorders	T048	C0525045
Long Noncoding RNAs	T114	C2982391
Cardiovascular Pathology	T047	C0741949
Diagnosis	T062	C1704656
Therapy	T061	C0087111
mammalian	T015	C0024660
genomes	T028	C0017428
encode	T052	C2700640
transcripts	T114	C1519595
translated into proteins	T045	C1519614
purpose	T169	C1285529
majority	T080	C0205164
noncoding ribonucleic acids	T114	C0887909
(RNAs)	T114	C0887909
paradoxical	T080	C0205310
growing	T169	C0442808
evidence	T078	C3887511
demonstrates	T052	C3687625
long noncoding RNAs	T114	C2982391
dynamically	T169	C0729333
expressed	T045	C0017262
different	T080	C1705242
cell types	T025	C0007634
diseases	T047	C0012634
developmental stages	T079	C0870411
execute	T052	C1705848
wide variety	T077	C2346866
regulatory roles	T077	C1704735
virtually	T080	C0205556
step	T077	C1261552
gene expression	T045	C0017262
translation	T045	C1519614
long noncoding RNAs	T114	C2982391
influence	T077	C4054723
gene expression	T045	C0017262
epigenetic modulations	T045	C1516924
regulating	T045	C0017263
alternative splicing	T045	C0002345
molecular sponges	T080	C0205556
abundance	T080	C2346714
long noncoding RNAs	T114	C2982391
cardiovascular system	T022	C0007226
complex	T080	C0439855
regulatory network	T044	C1720950
governing	T067	C2239193
physiology	T039	C1254359
pathology	T046	C0030660
heart	T023	C0018787
multifaceted	T082	C0205291
functions	T169	C0542341
long noncoding RNAs	T114	C2982391
current literature	T170	C0023866
cardiac development	T039	C2263229
disease	T047	C0012634
Furthermore	T082	C1517331
enormous	T080	C0205231
long noncoding RNAs	T114	C2982391
potentially	T080	C3245505
avenues	T082	C1254362
diagnosis	T062	C1704656
prevention	T061	C0199176
heart failure	T047	C0018801
futuristic prospects	T079	C1552610
long noncoding RNAs	T114	C2982391
biomarkers	T201	C0005516
therapeutic	T169	C0302350
targets	T114	C0028622
treatment	T061	C0087111
cardiovascular disorders	T047	C0007222
Flexible	T080	C0443220
Coordination	T169	C0700114
Stationary	T080	C0439835
Mobile	T169	C0231435
Conversations	T054	C0871703
Gaze	T033	C0553544
Resource Allocation	T081	C0086914
Multiple Joint Activities	T056	C0026606
Gaze	T033	C0553544
coordinating	T169	C0700114
face-to-face	T169	C1553514
social interactions	T033	C0037420
gaze	T033	C0553544
social interactions	T033	C0037420
co-occur	T052	C1709305
joint activities	T056	C0026606
investigated	T169	C1292732
walking	T056	C0080331
talking	T056	C0234856
assessed	T052	C1516048
gaze	T033	C0553544
allocated	T052	C1706778
targets	T098	C0039309
mobile	T169	C0231435
conversations	T054	C0871703
allocation	T052	C1706778
gaze	T033	C0553544
targets	T098	C0039309
affects	T041	C0001721
conversational	T054	C0871703
coordination	T169	C0700114
reduced	T080	C0392756
availability of	T169	C0470187
gaze	T033	C0553544
conversational	T054	C0871703
coordination	T169	C0700114
affects	T041	C0001721
conversational	T054	C0871703
performance	T055	C0597198
content	T077	C0456205
experimental study	T062	C0681814
videotaped	T073	C0042654
conditions	T080	C0449910
mobility	T033	C0425245
standing still	T082	C0231472
talking	T056	C0234856
walking along a straight-line itinerary	T060	C0522230
talking	T056	C0234856
walking	T056	C0080331
complex itinerary	T080	C0439855
walking	T056	C0080331
complex itinerary	T080	C0439855
no conversational	T033	C0243095
task	T057	C3540678
Gaze	T033	C0553544
partners	T098	C0026767
substantially reduced	T080	C0392756
mobile	T169	C0231435
conversations	T054	C0871703
gaze	T033	C0553544
coordinate	T169	C0700114
conversation	T054	C0871703
displays	T169	C0870432
mutual	T080	C1709100
orientation	T082	C1704322
conversational	T054	C0871703
performance	T055	C0597198
content	T077	C0456205
different	T080	C1705242
stationary	T080	C0439835
mobile	T169	C0231435
conditions	T080	C0449910
Results	T034	C0456984
phenomena	T067	C1882365
joint activities	T056	C0026606
Sepsis	T047	C0243026
Clinical Criteria	T080	C1516637
Emergency Department	T073	C0562508
Patients	T101	C0030705
Admitted	T058	C0184666
Intensive Care Unit	T073	C0021708
External Validation Study	T062	C0681836
Quick Sequential Organ Failure Assessment	T033	C3494459
Quick Sequential Organ Failure Assessment	T033	C3494459
qSOFA	T033	C3494459
prognostic score	T081	C0449821
patients	T101	C0030705
sepsis	T047	C0243026
aim	T078	C1947946
area under the receiver operating curve	T081	C0035787
AUROC	T081	C0035787
sensitivity	T081	C0036667
specificity	T081	C0037791
likelihood ratios	T081	C0150102
qSOFA	T033	C3494459
systemic inflammation response syndrome	T047	C0242966
SIRS	T047	C0242966
in-hospital mortality	T080	C0085556
emergency department	T073	C0562508
ED	T073	C0562508
patients	T101	C0030705
suspected infection	T046	C3714514
admitted	T058	C0184666
intensive care units	T073	C0021708
ICUs	T073	C0021708
retrospective cohort chart review study	T062	C2985505
ED	T073	C0562508
patients	T101	C0030705
admitted	T058	C0184666
ICU	T073	C0021708
suspected infection	T046	C3714514
August	T080	C3831448
February	T080	C3830166
patients	T101	C0030705
body fluid cultures sampled	T031	C1292527
ED	T073	C0562508
antibiotic administration	T061	C0199779
antibiotics administered	T061	C0199779
ED	T073	C0562508
Trained chart abstractors	T097	C1522486
study	T062	C2603343
double-entered data	T078	C1511726
patient's	T101	C0030705
electronic medical record	T170	C2362543
demographic characteristics	T102	C0683970
vital signs	T201	C0518766
laboratory study results	T059	C0681827
physical examination	T058	C0031809
findings	T033	C0243095
in-hospital mortality	T080	C0085556
AUROC	T081	C0035787
sensitivity	T081	C0036667
specificity	T081	C0037791
likelihood ratios	T081	C0150102
qSOFA	T033	C3494459
SIRS	T047	C0242966
in-hospital mortality	T080	C0085556
patients	T101	C0030705
admitted	T058	C0184666
ICU	T073	C0021708
presumed sepsis	T047	C0243026
died during hospitalization	T033	C3260027
AUROC	T081	C0035787
confidence interval	T081	C0009667
CI	T081	C0009667
SIRS	T047	C0242966
CI	T081	C0009667
qSOFA	T033	C3494459
qSOFA	T033	C3494459
in-hospital mortality	T080	C0085556
sensitivity	T081	C0036667
specificity	T081	C0037791
positive likelihood ratio	T081	C0150102
negative likelihood ratio	T081	C0150102
ED	T073	C0562508
patients	T101	C0030705
admitted	T058	C0184666
ICU	T073	C0021708
SIRS	T047	C0242966
qSOFA	T033	C3494459
prognostic value	T081	C0449821
in-hospital mortality	T080	C0085556
prognostic values	T081	C0449821
Sepsis-3 guidelines	T170	C0282451
ICU	T073	C0021708
encounters	T170	C3889614
Repetitive transcranial magnetic stimulation	T061	C0872259
cognitive function	T041	C0392335
Alzheimer's disease	T047	C0002395
patients	T101	C0030705
Repetitive transcranial magnetic stimulation	T061	C0872259
rTMS	T061	C0872259
intervention	T061	C0184661
neurological disorders	T047	C0027765
prospective	T062	C0033522
randomized	T062	C0034656
double-blind	T062	C0013072
placebo-controlled trial	T062	C1706408
investigates	T169	C1292732
rTMS	T061	C0872259
cases	T169	C0868928
Alzheimer's disease	T047	C0002395
AD	T047	C0002395
participants	T098	C0679646
mild	T080	C2945599
moderate	T080	C0205081
groups	T098	C1257890
Neuropsychological tests	T060	C0027902
AD Assessment Scale	T170	C0450989
cognitive subscale	T170	C0282574
ADAS	T170	C0450989
cog	T170	C0282574
Mini-Mental State Examination	T060	C0451306
MMSE	T060	C0451306
Montreal Cognitive Assessment	T170	C3496286
MoCA	T170	C3496286
World Health Organization University of California-Los Angeles, Auditory Verbal Learning Test	T170	C0589055
WHO-UCLA AVLT	T170	C0589055
weeks	T079	C0439230
intervention	T061	C0184661
data	T078	C1511726
AD	T047	C0002395
patients	T101	C0030705
interaction effect	UnknownType	C0548930
ADAS	T170	C0450989
cog	T170	C0282574
MMSE	T060	C0451306
WHO-UCLA AVLT	T170	C0589055
score	T081	C0449820
rTMS	T061	C0872259
group	T098	C1257890
compared	T052	C1707455
baselines	T081	C1442488
weeks	T079	C0439230
treatment	T061	C0087111
MoCA	T170	C3496286
scores	T081	C0449820
ameliorated	T033	C0184511
mild	T080	C2945599
AD	T047	C0002395
patients	T101	C0030705
rTMS	T061	C0872259
subgroup analysis	T062	C0936012
rTMS	T061	C0872259
memory	T041	C0025260
language	T171	C0023008
mild	T080	C2945599
AD	T047	C0002395
patients	T101	C0030705
moderate	T080	C0205081
AD	T047	C0002395
patients	T101	C0030705
findings	T033	C0243095
repetitive transcranial magnetic stimulation	T061	C0872259
cognitive function	T041	C0392335
memory	T041	C0025260
language	T171	C0023008
level	T080	C0441889
AD	T047	C0002395
patients	T101	C0030705
mild	T080	C2945599
stage	T079	C0205390
AD	T047	C0002395
rTMS	T061	C0872259
adjuvant therapy	T061	C0677850
cholinesterase inhibitors	T109	C0008425
mild	T080	C2945599
stage	T079	C0205390
AD	T047	C0002395
patients	T101	C0030705
Novel	T080	C0205314
Insulin/Glucose	T081	C1719133
Model	T170	C3161035
Mixed-Meal Test	T059	C0202098
Patients	T101	C0030705
Type 1 Diabetes	T047	C0011854
Insulin Pump	T074	C1140609
Therapy	T061	C0087111
Current	T079	C0521116
closed-loop insulin delivery methods	T074	C0181334
glucose-insulin (G/I) system	T081	C1719133
mostly	T078	C0750554
complex	T080	C0439855
studies	T062	C0008972
employing	T033	C0557351
glucose tracer technology	T074	C0726401
tested	T169	C0039593
performance	T052	C1882330
minimal model	T170	C3161035
GLUKINSLOOP 2.0	T170	C3161035
G/I system	T081	C1719133
characterize	T052	C1880022
glucose and insulin	T081	C1719133
dynamics	T070	C3826426
multiple	T081	C0439064
mixed meal tests	T059	C0202098
MMT	T059	C0202098
different	T080	C1705242
sizes	T082	C0456389
patients	T101	C0030705
type 1 diabetes	T047	C0011854
T1D	T047	C0011854
insulin pump	T074	C1140609
therapy	T061	C0087111
continuous subcutaneous insulin infusion	T061	C0393124
CSII	T061	C0393124
GLUKINSLOOP 2.0	T170	C3161035
identified	T080	C0205396
G/I system	T081	C1719133
provided	T052	C1999230
G/I	T081	C1719133
time-courses	T079	C0449247
acceptable	T080	C1879533
reproducibility	T080	C1514863
G/I system	T081	C1719133
parameters	T033	C0449381
repeated	T169	C0205341
studies	T062	C0008972
identical	T080	C0205280
double-sized	T081	C0392762
MMTs	T059	C0202098
model	T170	C3161035
provide	T052	C1999230
description	T170	C0678257
G/I system	T081	C1719133
T1D	T047	C0011854
patients	T101	C0030705
CSII	T061	C0393124
applied	T169	C4048755
"virtual" patients	T058	C1553497
results	T034	C0456984
relevant	T080	C2347946
improving	T080	C1272745
closed-loop	T169	C0443183
CSII	T061	C0393124
Impact	T080	C4049986
White Matter Hyperintensities	T046	C2938912
Cognition	T041	C0009240
Memory Clinic	T073	C0442592
Patients	T101	C0030705
Small Vessel Disease	T047	C2733158
impact	T080	C4049986
small vessel disease	T047	C2733158
SVD	T047	C2733158
cognition	T041	C0009240
focus	T082	C0205234
white matter hyperintensity	T046	C2938912
WMH	T046	C2938912
volume	T081	C0449468
extent	T082	C0439792
WMH	T046	C2938912
location	T029	C1515974
relates	T080	C0439849
cognitive performance	T041	C0392335
received	T080	C1514756
less	T081	C0439092
attention	T041	C0004268
functionally	T169	C0205245
important	T080	C3898777
relation	T080	C0439849
WMH	T046	C2938912
location	T029	C1515974
cognition	T041	C0009240
memory clinic	T073	C0442592
cohort	T098	C0599755
patients	T101	C0030705
sporadic	T079	C0205422
SVD	T047	C2733158
patients	T101	C0030705
SVD	T047	C2733158
memory clinics	T073	C0442592
Assumption-free region of interest-based analyses	T062	C0936012
based	T169	C1527178
white matter	T024	C0682708
tracts	T023	C1185740
voxel	T077	C2700259
wise	T169	C1527178
analyses	T062	C0936012
used	T169	C1524063
association	T080	C0439849
WMH	T046	C2938912
location	T029	C1515974
executive functioning	T041	C0935584
visuomotor speed	T041	C0025361
memory	T041	C0025260
Region of interest-based analyses	T062	C0936012
WMHs	T046	C2938912
located	T029	C1515974
within	T082	C0332285
anterior thalamic radiation	T023	C2338170
forceps minor	T023	C0152325
inversely	T080	C0439850
associated with	T080	C0332281
executive functioning	T041	C0935584
visuomotor speed	T041	C0025361
independent of	T169	C0332291
total	T080	C0439810
WMH	T046	C2938912
volume	T081	C0449468
Memory	T041	C0025260
associated with	T080	C0332281
WMH	T046	C2938912
volume	T081	C0449468
forceps minor	T023	C0152325
independent of	T169	C0332291
total	T080	C0439810
WMH	T046	C2938912
volume	T081	C0449468
independent assumption-free voxel-wise analysis	T062	C0936012
identified	T080	C0205396
voxels	T077	C2700259
same	T080	C0445247
tracts	T023	C1185740
Region of interest-based analyses	T062	C0936012
WMH	T046	C2938912
volume	T081	C0449468
within	T082	C0332285
anterior thalamic radiation	T023	C2338170
variance	T080	C1711260
executive functioning	T041	C0935584
compared	T052	C1707455
total	T080	C0439810
WMH	T046	C2938912
volume	T081	C0449468
WMH	T046	C2938912
volume	T081	C0449468
within	T082	C0332285
forceps minor	T023	C0152325
variance	T080	C1711260
visuomotor speed	T041	C0025361
variance	T080	C1711260
memory	T041	C0025260
compared	T052	C1707455
total	T080	C0439810
WMH	T046	C2938912
volume	T081	C0449468
findings	T033	C0243095
identify	T080	C0205396
anterior thalamic radiation	T023	C2338170
forceps minor	T023	C0152325
white matter	T024	C0682708
tracts	T023	C1185740
WMHs	T046	C2938912
associated with	T080	C0332281
cognitive impairment	T048	C0338656
memory clinic	T073	C0442592
patients	T101	C0030705
SVD	T047	C2733158
WMH	T046	C2938912
volumes	T081	C0449468
tracts	T023	C1185740
variance	T080	C1711260
cognition	T041	C0009240
total	T080	C0439810
WMH	T046	C2938912
importance	T080	C3898777
lesion location	T033	C2184261
functional	T169	C0205245
consequences of	T169	C0686907
WMHs	T046	C2938912
Natural	T169	C0205296
competence	T080	C0086035
transformation	T045	C0040683
molecular biologists	T097	C0260017
artificial	T080	C2004457
transformation of bacteria	T045	C0040683
context	T078	C0449255
laboratory	T073	C0022877
cloning	T062	C0009015
experiments	T062	C0681814
natural	T169	C0205296
competence	T080	C0086035
transformation	T045	C0040683
specific	T080	C0205369
physiological	T169	C0205463
state	T169	C1442792
prokaryotes	T001	C0686817
genetic material	T028	C0440471
surroundings	T082	C1282914
absorbed	T169	C0205245
DNA	T114	C0012854
recombined	T080	C0205195
organism's	T001	C0029235
genome	T028	C0017428
natural	T169	C0205296
transformation	T045	C0040683
consequence	T169	C0686907
natural	T169	C0205296
competence	T080	C0086035
transformation	T045	C0040683
primary	T080	C0205225
mode	T169	C1513371
horizontal gene transfer	T045	C0887912
HGT	T045	C0887912
prokaryotes	T001	C0686817
conjugation	T045	C0009757
direct	T080	C1947931
cell	T025	C0007634
cell	T025	C0007634
transfer	T078	C3244299
DNA	T114	C0012854
specialized	T077	C1704211
conjugal pilus	T026	C0242435
phage	T005	C0004651
transduction	T045	C0040667
DNA	T114	C0012854
transfer	T078	C3244299
viruses	T005	C0042776
HGT	T045	C0887912
bacterial	T080	C0521009
evolution	T045	C0015219
past	T079	C1444637
research	T062	C0035168
HGT	T045	C0887912
natural	T169	C0205296
competence	T080	C0086035
transformation	T045	C0040683
contributes	T052	C1880177
pathogens	T001	C0450254
spread	T080	C0332261
virulence factors	T109	C1136170
natural	T169	C0205296
competence	T080	C0086035
transformation	T045	C0040683
investigating	T169	C1292732
exchange	T045	C1749881
pathogenic	T033	C3816499
traits	T032	C0599883
pneumococci	T007	C0038410
increase	T169	C0442805
abundance	T080	C2346714
spread	T080	C0332261
multidrug-resistant microbes	T007	C4076168
research	T062	C0035168
HGT	T045	C0887912
Three-dimensional constructive interference in steady-state (3D-CISS) sequences	T169	C1275506
Phase-contrast MRI	T060	C0024485
arrested hydrocephalus	T047	C0270718
three-dimensional constructive interference in steady-state (3D-CISS) sequences	T169	C1275506
phase-contrast magnetic resonance imaging	T060	C0024485
PC-MRI	T060	C0024485
patients	T101	C0030705
arrested hydrocephalus	T047	C0270718
Prospective study	T062	C0033522
patients	T101	C0030705
arrested hydrocephalus	T047	C0270718
patients	T101	C0030705
PC-MRI	T060	C0024485
3D-CISS	T169	C1275506
assessment	T058	C0220825
aqueduct	T030	C0228168
Axial	T082	C0205131
through-plane	T082	C1254362
sagittal	T082	C0205129
in-plane	T082	C1254362
PC-MRI	T060	C0024485
sagittal	T082	C0205129
3D-CISS	T169	C1275506
assess	T058	C0184514
cerebral aqueduct	T030	C0007769
spontaneous	T169	C0205359
third ventriculostomy	T061	C0844213
Aqueductal	T030	C0228168
patency	T082	C0175566
graded	T185	C0441800
3D-CISS	T169	C1275506
PC-MRI	T060	C0024485
Quantitative analysis	T059	C0200767
aqueduct	T030	C0228168
PC-MRI	T060	C0024485
obstruction	T046	C0028778
aqueductal	T030	C0228168
obstruction	T046	C0028778
ventricular obstruction	T047	C0042512
ventricular obstruction	T047	C0042512
arrest	T079	C0237477
hydrocephalus	T047	C0020255
spontaneous	T169	C0205359
third ventriculostomy	T061	C0844213
endoscopic third ventriculostomy	T061	C0844212
ventriculo-peritoneal shunt	T074	C3874496
detected	T033	C0442726
patients	T101	C0030705
positive	T033	C1446409
correlation	T080	C1707520
moderate	T080	C0205081
agreement	T054	C0680240
grading	T185	C0441800
PC-MRI	T060	C0024485
3D-CISS sequences	T169	C1275506
mean peak systolic velocity	T081	C0392762
CSF	T031	C0007806
stroke volume	T201	C0038455
mean flow	T081	C0392762
3D-CISS	T169	C1275506
PC-MRI	T060	C0024485
non-invasive	T169	C0205303
diagnosis	T033	C0011900
cause	T169	C0015127
arrested hydrocephalus	T047	C0270718
Historical	T079	C0681698
Environment	T082	C0014406
Modern Population Genetics	T090	C0017404
Biogeography	T090	C2936603
Island	T083	C0022130
Endemic	T169	C0243130
Lizard	T014	C0023916
Xantusia riversiana reticulata	T014	C0999100
restricted distribution	T169	C1704711
isolation	T169	C0205409
island	T083	C0022130
endemics	T169	C0243130
genetic	T070	C0042333
phenotypic	T032	C0031437
diversity	T080	C1880371
conservation	T080	C2347858
management	T090	C3273539
agencies	T092	C0237463
isolated	T169	C0205409
species	T185	C1705920
sensitive	T169	C0332324
life history	T032	C0598779
traits	T032	C0599883
high risk	T033	C0332167
adverse effects	T046	C0879626
genetic drift	T045	C0917892
habitat	T082	C0871648
degradation	T169	C0243125
non-native wildlife	T008	C0003070
study	T062	C2603343
population	T098	C1257890
genetic diversity	T070	C0042333
structure	T082	C0678594
stability	T080	C0205360
island giant	T014	C0023916
Xantusia riversiana	T014	C0999100
Island Night Lizard	T014	C0023916
San Clemente Island	T083	C0022130
California	T083	C0006754
removal	T052	C1883720
feral goats	T015	C1510458
DNA	T114	C0012854
microsatellites	T114	C1519302
population	T098	C1257890
genetically	T169	C0314603
robust	T080	C2986815
historical	T079	C0681698
grazing	T040	C3178952
population sizes	T081	C0032683
genetic diversity	T070	C0042333
sampling	T078	C0870078
locations	T083	C0017446
habitat	T082	C0871648
degree of degradation	T080	C0205556
site-specific	T082	C0449604
patterns	T082	C0449774
genetic variation	T070	C0042333
genetic diversity	T070	C0042333
mainland congeners	T014	C0035161
management	T090	C3273539
island	T083	C0022130
endemic	T169	C0243130
high	T080	C0205250
low	T080	C0205251
elevation areas	T082	C0702240
repositories	T073	C3847505
genetic diversity	T070	C0042333
case study	T170	C0085973
low-dispersal	T070	C1254365
coastal	T082	C0557760
organisms	T001	C0029235
future	T079	C0016884
climate change	T070	C2718051
Rhesus	T015	C0024400
Cytomegalovirus Infection	T047	C0010823
Cynomolgus Macaques	T015	C0024399
Cytomegaloviruses	T005	C0010825
CMV	T005	C0010825
co-evolution	T045	C0015219
adaptation	T038	C0392673
host	T001	C1167395
species	T185	C1705920
infection	T046	C3714514
primates	T015	C0033147
genome	T028	C0017428
phylogenetic analysis	T062	C1519068
CMV	T005	C0010825
isolates	T123	C1764827
nonhuman primate	T015	C0237798
species	T185	C1705920
Indian-origin	T033	C0425361
rhesus macaques	T015	C0024400
RM	T015	C0024400
Mauritian	T083	C0024944
cynomolgus macaques	T015	C0024399
MCM	T015	C0024399
lineage	T077	C1881379
species of origin	T033	C0449420
MCM	T015	C0024399
CMV	T005	C0010825
isolates	T123	C1764827
genetic diversity	T070	C0042333
primate	T015	C0033147
host	T001	C1167395
ability	T032	C0085732
Rhesus	T015	C0024400
CMV	T005	C0010825
RhCMV	T005	C0010825
laboratory strain	T025	C0007635
replicate	T080	C1883725
MCM	T015	C0024399
fibroblasts	T025	C0016030
inhibit antigen presentation	T039	C2250749
MCM	T015	C0024399
T cells	T025	C0039194
in vitro	T080	C1533691
RhCMV	T005	C0010825
infect	T046	C3714514
MCM	T015	C0024399
in vivo	T082	C1515655
host	T001	C1167395
CD8+ T	T025	C0242629
NK cells	T025	C0022688
RhCMV	T005	C0010825
clone	T024	C1522642
genetically	T169	C0314603
repaired	T058	C1705181
express	T045	C0017262
homologues	T028	C1334043
HCMV	T005	C0010825
anti-apoptosis	T043	C1512772
gene UL36	T116	C0210337
epithelial cell tropism	T039	C4277517
genes UL128	T116	C2605215
UL130	T116	C1608605
infected	T046	C3714514
MCM	T098	C1257890
induction	T045	C0017391
transgene	T028	C0282641
T cells	T025	C0039194
virus shedding	T046	C0162633
Recombinant variants	T116	C0034861
RhCMV	T005	C0010825
expression	T045	C0017262
UL36	T116	C0210337
UL128	T116	C2605215
UL130	T116	C1608605
MCM	T098	C1257890
infection	T046	C3714514
species	T185	C1705920
restriction	T169	C0443288
hosts	T001	C1167395
cell tropism	T039	C4277517
apoptosis	T043	C0162638
determinants	T169	C1521761
CMV	T005	C0010825
transmission	T043	C1160716
primate	T015	C0033147
species	T185	C1705920
macaque	T015	C0024398
model	T170	C3161035
human	T016	C0086418
CMV	T005	C0010825
infection	T046	C3714514
immunology	T091	C0152036
MCM	T098	C1257890
nonhuman primate	T015	C0237798
species	T185	C1705920
host	T001	C1167395
immunogenetics	T091	C0021005
Mildly	T080	C2945599
raised	T080	C0442818
tricuspid regurgitant velocity	T033	C2059632
pregnant women	T098	C0033011
sickle cell disease	T047	C0002895
associated with	T080	C0332281
poor	T080	C0542537
obstetric	T169	C0205484
outcome	T169	C1274040
observational cross-sectional study	T062	C0010362
Pulmonary hypertension	T046	C0020542
associated with	T080	C0332281
mortality	T081	C0024923
pregnancy	T040	C0032961
patients	T101	C0030705
sickle cell disease	T047	C0002895
pulmonary hypertension	T046	C0020542
Tricuspid regurgitant velocity	T033	C2059632
echocardiography	T060	C0013516
screening	T058	C1710032
pulmonary hypertension	T046	C0020542
non-pregnant	T033	C0232973
population	T098	C1257890
pilot study	T062	C0031928
non-invasive	T169	C0205303
screening test	T058	C0871311
pulmonary hypertension	T046	C0020542
pregnancy	T040	C0032961
tricuspid regurgitant velocity	T033	C2059632
associated with	T080	C0332281
poor	T080	C0542537
outcomes	T169	C1274040
cross-sectional study	T062	C0010362
tertiary referral centre	T073	C0587437
multidisciplinary clinic	T093	C0242933
pregnant women	T098	C0033011
sickle cell disease	T047	C0002895
Women	T098	C0043210
sickle cell disease	T047	C0002895
pulmonary hypertension	T046	C0020542
singleton	T099	C1313913
pregnancies	T040	C0032961
echocardiography	T060	C0013516
tricuspid regurgitant velocity	T033	C2059632
pregnancy	T040	C0032961
pregnancies	T040	C0032961
tricuspid regurgitant velocity	T033	C2059632
no significant	T033	C1273937
characteristics	T080	C1521970
sickle cell	T025	C0221283
complications	T046	C0009566
medical	T169	C0205476
co-morbidities	T081	C0026538
women	T098	C0043210
tricuspid regurgitant velocity	T033	C2059632
obstetric	T169	C0205484
perinatal	T079	C0178795
outcomes	T169	C1274040
tricuspid regurgitant velocity	T033	C2059632
randomized trial	T062	C0206034
TLR-2	T116	C0754728
agonist	T121	C2987634
CADI-05	T109	C2703083
targeting	T169	C1521840
desmocollin-3	T116	C1453561
advanced	T080	C0205179
non-small-cell lung cancer	T191	C0007131
Randomized controlled trial	T062	C0206035
evaluate	T058	C0220825
synergy	T044	C0013215
taxane	T109	C0215136
platinum	T196	C0032207
chemotherapy	T061	C3665472
CADI-05	T109	C2703083
Toll like receptor-2	T116	C0754728
agonist	T121	C2987634
targeting	T169	C1521840
desmocollin-3	T116	C1453561
first-line therapy	T061	C1708063
advanced	T080	C0205179
non-small-cell lung cancer	T191	C0007131
NSCLC	T191	C0007131
Patients	T101	C0030705
advanced	T080	C0205179
NSCLC	T191	C0007131
randomized	T033	C3815594
cisplatin-paclitaxel	T061	C0280455
chemotherapy	T061	C3665472
group	T078	C0441833
cisplatin-paclitaxel	T061	C0280455
CADI-05	T109	C2703083
chemoimmunotherapy	T061	C2986423
group	T078	C0441833
CADI-05	T109	C2703083
administered	T169	C1621583
week	T079	C0439230
chemotherapy	T061	C3665472
days	T079	C0439228
cycle	T061	C1302181
month	T079	C0439231
months	T079	C0439231
disease progression	T046	C0242656
Overall survival	T081	C4086681
log-rank test	T170	C0392366
Computed tomography	T060	C0040405
baseline	T081	C1442488
cycles	T061	C1302181
cycles	T061	C1302181
Response rate	T079	C0237629
evaluated	T058	C0220825
Response Evaluation Criteria in Solid Tumors	T170	C1709926
criteria	T078	C0243161
independent radiologist	T097	C0260194
intention-to-treat analysis	T062	C2718028
survival	T052	C0038952
benefit	T081	C0814225
groups	T078	C0441833
days	T079	C0439228
hazard ratio	T081	C2985465
confidence interval	T081	C0009667
subgroup analysis	T062	C0936012
improvement	T077	C2986411
median survival	T079	C2986586
days	T079	C0439228
squamous NSCC	T191	C0027671
chemoimmunotherapy	T061	C2986423
hazard ratio	T081	C2985465
patients	T101	C0030705
cycles	T061	C1302181
chemotherapy	T061	C3665472
improved	T077	C2986411
median	T081	C0444504
overall survival	T081	C4086681
days	T079	C0439228
days	T079	C0439228
hazard ratio	T081	C2985465
chemoimmunotherapy	T061	C2986423
group	T078	C0441833
chemotherapy	T061	C3665472
group	T078	C0441833
associated with	T080	C0332281
improved	T077	C2986411
survival	T052	C0038952
year	T079	C0439234
chemoimmunotherapy	T061	C2986423
group	T078	C0441833
Systemic adverse events	T046	C0877248
identical	T080	C0205280
group	T078	C0441833
survival	T052	C0038952
benefit	T081	C0814225
addition	T169	C1883712
CADI-05	T109	C2703083
combination	T080	C0205195
cisplatin-paclitaxel	T061	C0280455
patients	T101	C0030705
advanced	T080	C0205179
NSCLC	T191	C0007131
squamous cell subset	T025	C0221910
survival	T052	C0038952
Sex Life	T078	C0376558
Impact	T080	C4049986
Operative	T169	C0038895
Intervention	T061	C0184661
Sex Life-related Pain	T184	C0030193
Degenerative	T046	C0011164
Spinal	T023	C0037949
Analysis	T062	C0936012
SPORT Study	T062	C2603343
study	T062	C2603343
therapeutic retrospective cohort study	T062	C2985505
study	T062	C2603343
sexual function	T040	C0278092
patients	T101	C0030705
spinal stenosis	T020	C0037944
SPS	T020	C0037944
degenerative spondylolisthesis	T047	C0264184
DS	T047	C0264184
impact	T080	C4049986
operative	T169	C0038895
sexual function	T040	C0278092
patients	T101	C0030705
nonoperative	T169	C0039798
operative	T169	C0038895
treatment	T169	C0039798
patients	T101	C0030705
SPS	T020	C0037944
DS	T047	C0264184
sexual function	T040	C0278092
Demographic	T090	C0011298
treatment	T169	C0039798
follow-up	T058	C1522577
data	T078	C1511726
patients	T101	C0030705
SPORT study	T062	C2603343
patients	T101	C0030705
sexual life relevant	T078	C0441833
SLR	T078	C0441833
sexual life not relevant (NR) group	T078	C0441833
Univariate	T062	C0683962
multivariate analysis	T081	C0026777
patient	T101	C0030705
characteristics	T080	C1521970
NR	T078	C0441833
SLR group	T078	C0441833
Operative	T169	C0038895
treatment	T169	C0039798
groups	T078	C0441833
nonoperative	T169	C0039798
group	T078	C0441833
impact	T080	C4049986
surgery	T061	C0543467
sexual function	T040	C0278092
patients	T101	C0030705
sex life	T078	C0441833
patients	T101	C0030705
NR group	T078	C0441833
patients	T101	C0030705
SLR group	T078	C0441833
Patients	T101	C0030705
older	T098	C0001792
female	T032	C0086287
unmarried	T098	C0037179
stenotic levels	T080	C0441889
central stenosis	T169	C0476189
NR group	T078	C0441833
patients	T101	C0030705
analysis	T062	C0936012
operative	T169	C0038895
nonoperative	T169	C0039798
treatment	T169	C0039798
follow-up	T058	C1522577
operative	T169	C0038895
groups	T078	C0441833
percentage	T081	C0439165
patients	T101	C0030705
pain	T184	C0030193
sex life	T078	C0441833
nonoperative	T169	C0039798
group	T078	C0441833
nonoperative	T169	C0039798
years	T079	C0439234
follow-up	T058	C1522577
Sex life	T078	C0376558
patients	T101	C0030705
DS	T047	C0264184
SPS	T020	C0037944
operative	T169	C0038895
treatment	T169	C0039798
improved	T033	C0184511
sex life-related pain	T184	C0030193
Functional analyses	T062	C0936012
OcRhS1	T116	C0033684
OcUER1	T116	C0033684
UDP-L-rhamnose	T114	C0609108
biosynthesis	T169	C0005572
Ornithogalum caudatum	T002	C0331605
UDP-L-rhamnose	T114	C0609108
UDP-Rha	T114	C0609108
sugar donor	T121	C1254351
synthesis	T169	C0005572
rhamnose	T109	C0035417
compounds	T103	C1706082
plants	T002	C0331605
enzymes	T116	C0014442
encoding	T052	C2700640
genes	T028	C0017337
UDP-Rha	T114	C0609108
biosynthesis	T169	C0005572
plants	T002	C0331605
genes	T028	C0017337
encoding	T052	C2700640
rhamnose synthase	T116	C0014442
RhS	T116	C0014442
bi-functional	T116	C0443560
UDP-4-keto-6-deoxy-D-glucose	T116	C0014442
UDP-4K6DG	T116	C0014442
3, 5-epimerase/UDP-4-keto-L-rhamnose	T116	C0014442
UDP-4KR	T116	C0014442
4-keto-reductase	T116	C0014442
UER	T116	C0014442
Ornithogalum caudatum	T002	C0331605
RNA	T114	C0035668
Seq data	T170	C0026382
OcRhS1 gene	T028	C0017337
ORF	T028	C0079941
open reading frame	T028	C0079941
encoding	T052	C2700640
tri-functional RhS enzyme	T026	C1750262
In vitro	T080	C1533691
enzymatic assays	T059	C2717977
revealed	T080	C0443289
OcRhS1	T116	C0033684
UDP-D-glucose	T109	C0077887
UDP-Glc	T109	C0077887
UDP-Rha	T114	C0609108
consecutive	T080	C1707491
reactions	T169	C0443286
Biochemical	T169	C0205474
evidences	T169	C0332120
recombinant OcRhS1	T116	C0034861
temperature range	T081	C0457171
Km	T081	C1706312
value	T081	C1522609
OcRhS1	T116	C0033684
UDP-Glc	T109	C0077887
OcRhS1	T116	C0033684
multi-domain protein	T116	C2326433
cofactor-binding motifs	T044	C1323251
cofactors	T044	C1323251
OcRhS1	T116	C0033684
research	T062	C0035168
N-terminal portion of OcRhS1	T116	C0033684
OcRhS1-N	T116	C0033684
metabolize	T169	C0205245
UDP-Glc	T109	C0077887
UDP-4K6DG	T114	C1254348
OcUER1	T028	C0017337
ORF	T028	C0079941
encoding	T052	C2700640
polypeptide	T116	C1305923
aa	T116	C0002520
OcUER1	T116	C0033684
carboxy-terminal domain of OcRhS1	T116	C0033684
OcRhS1-C	T116	C0033684
UDP-4K6DG	T114	C1254348
UDP-Rha	T114	C0609108
UDP-Glc	T109	C0077887
bio-transformed	T169	C0220798
UDP-Rha	T114	C0609108
OcRhS1-N	T116	C0033684
OcUER1	T116	C0033684
biochemical assay	T059	C0005507
expression profiles	T034	C3463810
OcRhS1	T116	C0033684
OcUER1	T116	C0033684
revealed	T080	C0443289
biosynthesis	T169	C0005572
rhamnose	T109	C0035417
polysaccharides	T109	C0032594
O. caudatum	T002	C0331605
antibody	T116	C0003241
acquisition	T052	C1706701
merozoite	T204	C0444659
antigens	T129	C0003320
malaria	T047	C0024530
immunity	T039	C0020964
surveillance	T058	C0733511
Antibodies	T116	C0003241
acquired human immunity	T039	C0678209
Plasmodium falciparum (Pf) malaria	T047	C0024535
merozoites	T204	C0444659
blood	T031	C0005767
replication	T043	C0007590
disease	T047	C0024530
Merozoites	T204	C0444659
antigens	T129	C0003320
immune system	T022	C0020962
antibodies	T116	C0003241
responses	T039	C1314973
antigens	T129	C0003320
acquired	T080	C0439661
boosted	T169	C1511253
acquisition	T052	C1706701
antibodies	T116	C0003241
antigens	T129	C0003320
infection	T046	C3714514
acquisition	T052	C1706701
immunity	T039	C0020964
responses	T039	C1314973
merozoite	T204	C0444659
antigens	T129	C0003320
children	T100	C0008059
adults	T100	C0001675
age	T032	C0001779
malaria	T047	C0024530
antibodies	T116	C0003241
age	T032	C0001779
infection	T046	C3714514
responses	T039	C1314973
age	T032	C0001779
infection	T046	C3714514
antibody	T116	C0003241
acquisition	T052	C1706701
antigens	T129	C0003320
antigen	T129	C0003320
malaria	T047	C0024530
hypothesis	T078	C1512571
Antigen	T129	C0003320
responses	T039	C1314973
response	T039	C1314973
antibodies	T116	C0003241
acquired	T080	C0439661
childhood	T079	C0231335
late response	T079	C0205087
response	T039	C1314973
antigen	T129	C0003320
responses	T039	C1314973
infection	T046	C3714514
responses	T039	C1314973
acquisition	T052	C1706701
human	T016	C0086418
immunity	T039	C0020964
malaria	T047	C0024530
malaria vaccines	T121	C0206255
merozoite	T204	C0444659
antigens	T129	C0003320
antigens	T129	C0003320
malaria	T047	C0024530
surveillance	T058	C0733511
Variety	T077	C2346866
DNA Replication Activity	T045	C0598312
Cyanobacteria	T007	C1047211
Correlates	T039	C0871083
Respiration Activity	T039	C0035203
Dark	T070	C0010986
Cyanobacteria	T007	C1047211
light	T070	C0023693
cell growth	T043	C0007595
cellular	T025	C0007634
energy	T081	C1442080
photosynthesis	T070	C0031764
Synechococcus elongatus PCC 7942	T007	C1003877
cyanobacteria	T007	C1047211
DNA replication	T045	C0598312
photosynthetic electron transport	T044	C0013846
critical signal	T067	C1710082
regulatory	T038	C1327622
mechanism	T169	C0441712
DNA replication	T045	C0598312
conservation	T080	C2347858
regulatory mechanism	T169	C0441712
investigated	T169	C1292732
cyanobacteria	T007	C1047211
regulatory	T038	C1327622
signal	T067	C1710082
light	T070	C0023693
regulation	T038	C1327622
DNA replication	T045	C0598312
light	T070	C0023693
dark	T070	C0010986
model	T075	C0026336
cyanobacteria	T007	C1047211
S. elongatus PCC 7942	T007	C1003877
Synechocystis sp. PCC 6803	T007	C0995541
Anabaena sp. PCC 7120	T007	C1047885
DNA replication activity	T045	C0598312
Synechocystis	T007	C0995541
Anabaena	T007	C1047885
retained	T169	C0333118
cells	T025	C0007634
transferred to	T033	C4049693
dark	T070	C0010986
decreased	T081	C0205216
S. elongatus	T007	C1003877
Glycogen metabolism	T044	C0599784
respiration	T039	C0035203
Synechocystis	T007	C0995541
Anabaena	T007	C1047885
S. elongatus	T007	C1003877
dark	T070	C0010986
DNA replication activity	T045	C0598312
Synechocystis	T007	C0995541
Anabaena	T007	C1047885
reduced	T081	C0205216
S. elongatus	T007	C1003877
inhibition	T052	C3463820
respiratory	T169	C0521346
electron transport	T044	C0013846
dark	T070	C0010986
disparity	T033	C1290905
DNA replication	T045	C0598312
dark	T070	C0010986
cyanobacteria	T007	C1047211
difference	T080	C1705242
activity	T169	C0205177
respiratory	T169	C0521346
electron transport	T044	C0013846
Radiosensitization	T061	C0279024
non-small-cell lung cancer	T191	C0007131
cells	T025	C0334227
xenografts	T061	C0520484
interactive effects	T169	C1704675
pemetrexed	T109	C0210657
methoxyamine	T109	C0066156
anti-folate	T121	C1254351
pemetrexed	T109	C0210657
radiosensitizer	T121	C0034541
pre-clinical models	T170	C1514292
pemetrexed	T109	C0210657
effective	T080	C1704419
base-excision-repair	T045	C1158530
inhibitor	T080	C1999216
methoxyamine	T109	C0066156
tested	T169	C0039593
methoxyamine	T109	C0066156
enhances	T052	C2349975
pemetrexed	T109	C0210657
radiosensitization	T061	C0279024
lung adenocarcinoma	T191	C0152013
xenografts	T061	C0520484
A549	T025	C4277577
H1299 cells	T025	C0334227
cell cycle	T043	C0007586
distribution	T169	C1704711
flow cytometry	T059	C0016263
radiosensitization	T061	C0279024
clonogenic assay	T059	C0041372
DNA repair	T045	C0012899
neutral comet assay	T063	C0751980
repair protein	T044	C1159338
activation	T045	C0599177
H460 cells	T025	C0334227
Xenografts	T061	C0520484
nude mice	T015	C0025932
received drug	T033	C0332154
radiation	T070	C0851346
tumor growth	T191	C0598934
caliper	T074	C0175720
in vivo	T062	C0681829
toxicity	T037	C0600688
animal weight	T032	C0005910
Exposure to	T080	C0332157
pemetrexed	T109	C0210657
methoxyamine	T109	C0066156
H1299	T025	C0334227
H460	T025	C0334227
A549	T025	C4277577
irradiation	T070	C1282930
accumulation	T033	C4055506
cells	T025	C0334227
radiosensitive G1/S border	T082	C1254362
dose	T081	C0178602
enhancement	T052	C2349975
factors	T169	C1521761
inactivation	T169	C0544461
dose	T081	C0178602
Radiosensitization	T061	C0279024
DNA double-strand-break rejoining	T045	C3155842
DNA-PKcs	T116	C0212694
tumor-growth	T191	C0598934
rate	T079	C0449249
tumor-growth	T191	C0598934
delay	T079	C0205421
methoxyamine	T109	C0066156
pemetrexed	T109	C0210657
pre-irradiation	T070	C1282930
mice	T015	C0025932
treatment	T169	C1522326
methoxyamine	T109	C0066156
pemetrexed	T109	C0210657
patients	T101	C0030705
non-squamous non-small-cell lung cancer	T191	C2585890
language	T171	C0023008
social interaction	T033	C0037420
Communication	T054	C0009452
chronic	T079	C0205191
non-fluent aphasia	T048	C0349390
Clinical research	T062	C0008972
massed practice	T170	C0870850
rehabilitation	T061	C0034991
chronic	T079	C0205191
post-stroke	T079	C1254367
aphasia	T048	C0003537
massed practice	T170	C0870850
progress	T169	C1280477
speech-language therapy	T058	C0037831
neuroscience	T091	C0027910
language	T171	C0023008
communication	T054	C0009452
social interaction	T033	C0037420
synergistic effects	T080	C1280500
left perisylvian eloquent areas	T029	C3495412
communicative	T054	C0009452
language function	T041	C0233732
outcome	T169	C1274040
intensive aphasia therapy	T061	C0087111
individuals	T098	C0237401
left-hemisphere lesions	T033	C2026233
chronic	T079	C0205191
non-fluent aphasia	T048	C0349390
training	T065	C0220931
counterbalanced order	T080	C1705176
Intensive Language-Action Therapy	T061	C0023017
ILAT	T061	C0023017
Constraint-Induced Aphasia Therapy	T061	C0087111
verbal utterances	T061	C2202690
communication	T054	C0009452
social interaction	T033	C0037420
Naming Therapy	T073	C0037585
speech production per se	T060	C0037827
training	T065	C0220931
duration	T079	C0449238
days	T079	C0439228
therapy	T061	C0087111
materials	T167	C0520510
number of utterances	T033	C0243095
treatment groups	T061	C0087111
aphasia	T048	C0003537
test battery	T060	C0204458
language	T171	C0023008
performance	T055	C0597198
ILAT	T061	C0023017
method	T170	C0025663
Naming Therapy	T073	C0037585
language	T171	C0023008
treatment	T061	C0087111
training	T065	C0220931
massed practice	T170	C0870850
chronic	T079	C0205191
post-stroke	T079	C1254367
aphasia	T048	C0003537
language	T171	C0023008
communication	T054	C0009452
social interaction	T033	C0037420
intensive aphasia therapy	T061	C0087111
miR-27b	T028	C1537730
inhibits	T052	C3463820
gastric cancer	T191	C0699791
metastasis	T191	C0027627
targeting	T169	C1521840
NR2F2	T116	C1506576
Increasing	T169	C0442808
attention	T041	C0004268
down-regulation	T044	C0013081
miRNAs	T114	C1101610
cancer process	T191	C0007097
Nuclear receptor subfamily 2	T116	C1506576
NR2F2	T116	C1506576
COUP-TFII	T116	C1506576
involved	T169	C1314939
development	T169	C1527148
types	T080	C0332307
cancers	T191	C0007097
role	T077	C1705810
gastric cancer	T191	C0699791
experiment	T062	C0681814
oncomine	T170	C0242356
Kaplan-meier database	T170	C0242356
revealed	T080	C0443289
NR2F2	T116	C1506576
up-regulated	T044	C0041904
gastric cancer	T191	C0699791
high	T080	C0205250
NR2F2	T116	C1506576
expression	T045	C1171362
contributed	T052	C1880177
poor	T080	C0542537
survival	T081	C0038954
MicroRNA-27b	T028	C1537730
targeted	T169	C1521840
down-regulated	T044	C0013081
NR2F2	T116	C1506576
human	T016	C0086418
gastric cancer	T191	C0699791
tissues	T024	C0040300
cells	T025	C1518174
ectopic expression	T045	C1512167
miR-27b	T028	C1537730
inhibited	T080	C0311403
gastric cancer	T191	C0699791
cell proliferation	T043	C0596290
tumor growth	T191	C0598934
in vitro	T080	C1533691
in vivo	T082	C1515655
Assays	T059	C0005507
suggested	T078	C1705535
overexpression	T045	C0017262
miR-27b	T028	C1537730
promote	T052	C0033414
MGC-803 cells	T025	C0007634
migration	T043	C1622501
invasion	T046	C2699153
retard	T080	C0521111
metastasis	T191	C0027627
liver	T023	C0023884
down-regulation	T044	C0013081
miR-27b	T028	C1537730
GES-1 cells	T025	C0007634
proliferation	T043	C0596290
metastasis	T191	C0027627
in vitro	T080	C1533691
findings	T033	C0243095
reveal	T080	C0443289
miR-27b	T028	C1537730
tumor suppressor	T028	C0079427
gastric cancer	T191	C0699791
biomarker	T201	C0005516
improving	T080	C1272745
patients	T101	C0030705
survival	T081	C0038954
Promoting	T052	C0033414
Healthy	T080	C3898900
Growth	T040	C0018270
Feeding	T052	C2987508
Obesity	T047	C0028754
Need	T080	C0027552
Evidence	T078	C3887511
Infant	T100	C0021270
Nutritional Supplement	T168	C0242295
Developmental Origins of Health and Disease	T170	C0282574
DOHaD	T170	C0282574
growth	T040	C0018270
infancy	T079	C0231330
childhood	T079	C0231335
lifespan	T102	C0870809
health	T078	C0018684
Evidence of	T169	C0332120
long-term	T079	C0443252
health	T078	C0018684
risks	T078	C0035647
small	T081	C0700321
neonates	T100	C0021289
grow	T067	C0870861
rapidly	T080	C0456962
interventions	T058	C1273869
healthy	T080	C3898900
growth	T040	C0018270
weight gain	T033	C0043094
healthy	T080	C3898900
growth	T040	C0018270
essential	T080	C0205224
infant	T100	C0021270
young	T079	C0332239
child	T100	C0008059
feeding	T052	C2987508
industries	T057	C0021267
Liquid	T167	C0302908
nutritional supplements	T168	C0242295
formulated	T168	C0016497
undernourished	T047	C0162429
children	T100	C0008059
increasingly	T169	C0442808
marketed	T057	C0683746
consumed	T052	C2983605
children	T100	C0008059
Clarifying	T052	C2986669
promoting	T052	C0033414
healthy	T080	C3898900
growth	T040	C0018270
important	T080	C3898777
Evidence	T078	C3887511
social	T169	C0728831
beliefs	T078	C0004951
cultural	T169	C0220814
practices	T041	C0237607
supplementary feeding	T061	C0038847
specific	T080	C0205369
concerns	T078	C2699424
long-term	T079	C0443252
health	T078	C0018684
consequences of	T169	C0686907
associated	T080	C0332281
altered	T169	C0392747
feeding	T052	C2987508
culture	T169	C0220814
reduced	T080	C0392756
dietary	T168	C0012155
variety	T077	C2346866
weight gain	T033	C0043094
Reassessing	T052	C1516048
evidence for	T169	C0332120
relevance	T080	C2347946
dietary supplements'	T168	C0242295
promoting	T052	C0033414
healthy	T080	C3898900
growth	T040	C0018270
healthy	T080	C3898900
children	T100	C0008059
needed	T080	C0027552
global	T080	C2348867
obesity	T047	C0028754
opportunity	T062	C0683937
intervention approaches	T061	C0184661
small	T081	C0700321
children	T100	C0008059
rapid	T080	C0456962
growth	T040	C0018270
risk	T078	C0035647
chronic disease	T047	C0008679
Scientific	T090	C0036397
health care	T058	C0086388
partnerships	T092	C1711206
needed	T080	C0027552
governmental	UnknownType	C0680773
populations	T098	C1257890
overconsumption	T052	C0441655
important	T080	C3898777
On-Site	T082	C0205145
Fertility Preservation Services	T061	C1171194
Adolescents	T100	C0205653
Young Adults	T100	C0238598
Comprehensive Cancer Center	T093	C1708333
Adolescents	T100	C0205653
young adults	T100	C0238598
AYAs	T100	C0027362
cancer treatments	T061	C0920425
impair fertility	T046	C0021359
counseling	T058	C0010210
risk of infertility	T033	C1171162
fertility preservation	T061	C1171194
FP	T061	C1171194
treatment	T061	C0087111
survivorship	T079	C0038955
objective	T170	C0018017
AYA	T100	C0027362
patient	T101	C0030705
population	T098	C1257890
on-site fertility consultation service	T058	C0009818
comprehensive cancer center	T093	C1708333
factors	T169	C1521761
patients	T101	C0030705
FP treatment	T061	C3839343
retrospective chart review	T062	C0035363
AYA	T100	C0027362
women	T098	C0043210
consultation	T058	C0009818
MD Anderson Fertility Preservation and Family Building Service	T058	C0018747
service	T057	C0557854
Records	T170	C0025102
AYA	T100	C0027362
patients	T101	C0030705
reviewed	T080	C1709940
age	T032	C0001779
ethnicity	T098	C0015031
cancer type	T033	C0872066
gravidity	T033	C0600457
parity	T033	C0030563
survivorship	T079	C0038955
status	T080	C0449438
FP treatment	T061	C3839343
Patients	T101	C0030705
Caucasian	T098	C0043157
Hispanic	T098	C0086409
African American	T098	C0085756
women	T098	C0043210
FP	T061	C1171194
cancer treatment	T061	C0920425
options	T169	C1518601
family building	T058	C0009861
survivorship	T079	C0038955
cancer types	T033	C0872066
hematologic	T191	C0376545
breast	T191	C0678222
gynecologic	T191	C0699889
Patients	T101	C0030705
on-site fertility consultation service	T058	C0009818
ethnically	T080	C0243103
diverse	T080	C1880371
fertility counseling	T065	C1689849
treatment	T061	C0087111
survivorship	T079	C0038955
pre- and postcancer treatment	T061	C0920425
referral	T058	C0034927
group	T078	C0441833
ethnically	T080	C0243103
diverse	T080	C1880371
Caucasian	T098	C0043157
women	T098	C0043210
FP treatment	T061	C3839343
women	T098	C0043210
ethnicities	T080	C0243103
Results	T169	C1274040
Multicenter	T062	C1096776
Randomized	T062	C0034656
Controlled Trial	T170	C0936233
Hydrogen Peroxide	T121	C0020281
Kit	T074	C0812225
Benzoyl Peroxide	T109	C0005088
Kit	T074	C0812225
Mild-to-moderate	T080	C1299392
Acne	T047	C0702166
evaluate	T058	C0220825
efficacy	T080	C1280519
tolerability	T062	C3274448
hydrogen peroxide	T121	C0020281
regimen	T061	C0040808
benzoyl peroxide	T109	C0005088
regimen	T061	C0040808
mild-to-moderate	T080	C1299392
acne	T047	C0702166
Methods	T170	C0025663
week	T079	C0439230
multicenter study	T062	C1096776
patients	T101	C0030705
randomized	T062	C0034656
hydrogen peroxide	T121	C0020281
benzoyl peroxide	T109	C0005088
regimen	T061	C0040808
primary outcome measure	T080	C3274433
clinical response	T033	C4055223
assessed	T052	C1516048
Global Acne Grading System	T058	C1273712
GAGS	T058	C1273712
baseline	T081	C1442488
weeks	T079	C0439230
weeks	T079	C0439230
Week	T079	C0439230
patient	T101	C0030705
self-satisfaction questionnaire	T170	C0034394
administered	T169	C1521801
Investigators	T097	C0035173
queried	T170	C1522634
assessment	T058	C0220825
tolerability	T062	C3274448
cosmetic	T073	C0010164
acceptability	T080	C0814633
Tolerability	T062	C3274448
measured	T080	C0444706
visit	T058	C1512346
treatment regimens	T061	C0040808
associated with	T080	C0332281
improvement	T077	C2986411
GAGS score	T081	C0449820
Week	T079	C0439230
compared	T052	C1707455
baseline	T081	C1442488
GAGS score	T081	C0449820
regimens	T061	C0040808
period	T079	C1948053
No significant adverse events	T033	C1963761
reported	T058	C0700287
observed	T169	C1441672
treatment arm	T062	C1522541
patients	T101	C0030705
investigators	T097	C0035173
regimens	T061	C0040808
effective	T080	C1704419
cosmetically	T073	C0010164
acceptable	T080	C0814633
hydrogen peroxide	T121	C0020281
regimen	T061	C0040808
comparable	T052	C1707455
efficacy	T080	C1280519
safety	T068	C0036043
cosmetic	T073	C0010164
acceptability	T080	C0814633
benzoyl peroxide	T109	C0005088
regimen	T061	C0040808
treatment	T061	C0087111
mild-to-moderate	T080	C1299392
acne	T047	C0702166
Multisensory Integration	T040	C0679019
Virtual Hand Illusion	T048	C0020903
Active Movement	T040	C0231481
sense of	T041	C0025361
sense of immersion	T033	C0243095
virtual reality	T066	C0871582
Perceptual illusions	T048	C2052872
perceived	T041	C0030971
virtual body	T066	C0871582
multisensory	T061	C2585668
virtual reality	T066	C0871582
Rubber Hand	T074	C0025080
Virtual Hand Illusions	T048	C0020903
visual	T061	C0556861
tactile stimulation	T061	C0152054
multisensory integration	T040	C0679019
Virtual Hand Illusion	T048	C0020903
active movement	T040	C0231481
virtual xylophone playing	T066	C0871582
synchronous	T079	C0439580
visual	T061	C0556861
tactile	T061	C0152054
auditory stimulation	T061	C0001164
sensory stimulations	T061	C0150763
multisensory integration	T040	C0679019
active movement	T040	C0231481
sense of	T041	C0025361
immersion in virtual reality	T066	C0871582
Obstructive	T169	C0549186
Acute Pancreatitis	T047	C0001339
PEG Tube	T074	C2985542
Migration	T033	C0549474
Percutaneous gastrostomy	T061	C0176751
method	T169	C0449851
enteral nutrition	T061	C0014327
patients	T101	C0030705
incapable	T033	C1550518
oral intake	T033	C0518037
oral intake	T033	C0518037
insufficient	T080	C0231180
metabolic	T169	C0311400
needs	T080	C0027552
total parenteral nutrition	T061	C0030548
enteral feeding	T058	C0086225
gut	T023	C0699819
mucosal	T024	C0026724
integrity	T080	C1947912
risk	T078	C0035647
bacterial translocation	T043	C0282583
gastrointestinal tract	T022	C0017189
Complications	T046	C0009566
bleeding	T046	C0019080
aspiration	T046	C0700198
internal organ injury	T037	C0332675
perforation	T047	C0151664
periostomal leaks	T047	C0341600
tube dislodgement	T037	C1608950
occlusion	T046	C0028778
Acute pancreatitis	T047	C0001339
percutaneous gastrostomy tube	T074	C2985542
migration	T033	C0549474
patient	T101	C0030705
acute	T079	C0205178
obstructive	T169	C0549186
pancreatitis	T047	C0030305
percutaneous gastrostomy tube	T074	C2985542
migration	T033	C0549474
Tractable	T080	C0205556
Method	T170	C0025663
Measuring	T080	C0444706
Nanomaterial	T073	C1450053
Risk	T078	C0035647
Bayesian Networks	T170	C3161035
banding	T061	C0185014
evaluation	T078	C1550157
potential	T080	C3245505
human	T016	C0086418
health risks	T061	C0679809
exposure to	T080	C0332157
nanomaterials	T073	C1450053
NMs	T073	C1450053
implementation	T052	C1708476
data	T078	C1511726
toxicological	T038	C4042799
measurements	T169	C0242485
risk	T078	C0035647
NMs	T073	C1450053
physicochemical	T070	C2350461
data	T078	C1511726
concentration	T081	C1446561
exposure route	UnknownType	C0683172
Bayesian networks	T170	C3161035
tool	T169	C0449851
NM	T073	C1450053
risk	T078	C0035647
tool	T169	C0449851
tractable	T080	C0205556
accessible	T080	C0205556
scalable	T081	C0392762
data	T078	C1511726
quality	T080	C0332306
data sets	T170	C0150098
data sets	T170	C0150098
data	T078	C1511726
values	T081	C1522609
probability distribution	T081	C3826440
tool	T169	C0449851
quality	T080	C0332306
data	T078	C1511726
risk	T078	C0035647
measurement	T169	C0242485
NMs	T073	C1450053
risk	T078	C0035647
potential	T080	C3245505
carbon nanotubes	T104	C1138408
silver	T196	C0037125
titanium dioxide	T121	C0076733
non-experts	T098	C0027361
risk	T078	C0035647
NMs	T073	C1450053
NM	T073	C1450053
risk	T078	C0035647
evaluated	T078	C1550157
tractable	T080	C0205556
quantitative	T081	C0392762
risk	T078	C0035647
Gender	T032	C0079399
Direction	T082	C0449738
Effect	T080	C1280500
Alcohol Problems	T048	C0549393
Internalizing Symptoms	T041	C0871786
Longitudinal Sample	T062	C0023981
College Students	T098	C0682177
Alcohol problems	T048	C0549393
internalizing symptoms	T041	C0871786
associated	T080	C0332281
relate	T080	C0439849
unclear	T033	C3845108
study	T062	C2603343
limitations	T169	C0449295
literature	T170	C0023866
comorbidity	T078	C0009488
alcohol problems	T048	C0549393
internalizing symptoms	T041	C0871786
investigating	T169	C1292732
direction	T082	C0449738
effect	T080	C1280500
phenotypes	T032	C0031437
gender differences	T032	C0036866
college students	T098	C0682177
data	T078	C1511726
longitudinal study	T062	C0023981
college students	T098	C0682177
United States	T083	C0041703
questionnaire-based	T170	C0034394
data	T078	C1511726
years	T079	C0439234
college	T073	C0557806
Cross-lagged models	T081	C2348012
direction	T082	C0449738
effect	T080	C1280500
internalizing symptoms	T041	C0871786
alcohol problems	T048	C0549393
effects	T080	C1280500
gender	T032	C0079399
investigated	T169	C1292732
multigroup modeling	T081	C0392762
significant	T078	C0750502
correlations	T080	C1707520
alcohol problems	T048	C0549393
internalizing symptoms	T041	C0871786
direction	T082	C0449738
effect	T080	C1280500
alcohol problems	T048	C0549393
internalizing symptoms	T041	C0871786
genders	T032	C0079399
relationship	T080	C0439849
age	T032	C0001779
males	T032	C0086582
alcohol problems	T048	C0549393
predicted	T078	C0681842
internalizing symptoms	T041	C0871786
internalizing symptoms	T041	C0871786
alcohol problems	T048	C0549393
females	T032	C0086287
relationship	T080	C0439849
alcohol problems	T048	C0549393
internalizing symptoms	T041	C0871786
relationship	T080	C0439849
alcohol problems	T048	C0549393
internalizing symptoms	T041	C0871786
complex	T080	C0439855
genders	T032	C0079399
males	T032	C0086582
phenotypes	T032	C0031437
predictive	T080	C0681890
females	T032	C0086287
relationship	T080	C0439849
alcohol problems	T048	C0549393
study	T062	C2603343
population-based sample	T081	C1709598
relationships	T080	C0439849
alcohol problems	T048	C0549393
internalizing symptoms	T041	C0871786
individuals	T098	C0027361
clinically diagnosed	T060	C0332140
mental health	T041	C0025353
substance use problems	T048	C0740858
Real-time	T079	C1550177
monitoring	T058	C1283169
vesicle	T026	C1622418
pH	T081	C0020283
endocytic	T043	C0014139
pathway	T044	C1704259
EGF	T116	C0242275
conjugated two-photon probe	T120	C2347609
ratiometric two-photon probe	T120	C2347609
BHS3	T120	C2347609
EGF	T116	C0242275
pH	T081	C0020283
sensitive	T169	C0332324
epidermal growth factor	T116	C0242275
EGF	T116	C0242275
real-time	T079	C1550177
monitoring	T058	C1283169
quantitative	T081	C0392762
analysis	T062	C0936012
acidic luminal	T030	C0524461
pH	T081	C0020283
values	T080	C0042295
endocytic	T043	C0014139
pathway activity	T044	C1704259
Two-photon microscopy imaging	T059	C1537066
BHS3	T120	C2347609
EGF	T116	C0242275
quantitative	T081	C0392762
analysis	T062	C0936012
pH	T081	C0020283
distributions	T169	C1704711
vesicles	T026	C1622418
dynamics	T070	C3826426
receptor-mediated endocytosis	T043	C0597361
real-time	T079	C1550177
Body burden	T081	C0005884
heavy metals	T196	C0347988
HIV	T033	C0744979
high risk population	T098	C0870646
USA	T083	C0041703
HIV	T033	C0744979
high risk population	T098	C0870646
threat	T078	C0749385
HIV infection	T047	C0019693
higher	T080	C0205250
chance	T080	C0237506
exposure to environmental contaminants	T037	C0522741
studies	T062	C2603343
examined	T080	C0332129
body burden	T081	C0005884
environmental pollutants	T131	C0014417
heavy metals	T196	C0347988
HIV	T033	C0744979
high risk populations	T098	C0870646
study	T062	C2603343
adults aged	T100	C0001675
high risk of	T033	C0332167
HIV infection	T047	C0019693
higher	T080	C0205250
blood levels of heavy metals	T033	C0495719
compared	T052	C1707455
low risk	T081	C3538919
HIV infection	T047	C0019693
United States	T083	C0041703
National Health and Nutrition Examination Survey	T062	C0376344
NHANES	T062	C0376344
compare	T052	C1707455
exposures to	T080	C0332157
heavy metals	T196	C0347988
cadmium	T131	C0006632
lead	T131	C0023175
mercury	T131	C0025424
HIV	T033	C0744979
risk status	T033	C1319831
results	T169	C1274040
people	T098	C0027361
high risk of	T033	C0332167
HIV	T033	C0744979
higher	T080	C0205250
blood concentrations	T034	C0427728
heavy metals	T196	C0347988
compared	T052	C1707455
lower	T080	C0205251
HIV risks	T033	C0744979
multivariate linear regression	T081	C0023733
models	T075	C0026336
HIV risk	T033	C0744979
associated with	T080	C0332281
increased	T081	C0205217
blood cadmium	T059	C0855870
lead	T059	C0853362
total mercury	T059	C0202414
adjusting	T169	C0456081
age	T032	C0001779
sex	T032	C0079399
race	T098	C0034510
education	UnknownType	C0683842
poverty	T102	C0032854
income	T081	C0021162
ratio	T081	C0456603
study	T062	C2603343
people	T098	C0027361
high risk of	T033	C0332167
HIV	T033	C0744979
higher	T080	C0205250
body burden	T081	C0005884
heavy metals	T196	C0347988
cadmium	T131	C0006632
lead	T131	C0023175
mercury	T131	C0025424
compared	T052	C1707455
low risk	T081	C3538919
HIV	T033	C0744979
longitudinal study	T062	C0023981
more	T081	C0205172
pollutants	T131	C0599786
warranted	T169	C1552821
potential	T080	C3245505
health	T078	C0018684
effects	T080	C1280500
elevated	T080	C3163633
pollutants	T131	C0599786
HIV-infected	T047	C0019693
HIV	T033	C0744979
high-risk populations	T098	C0870646
Fluorescence-	T059	C0079366
magnetic-activated cell sorting	T059	C0599662
strategies	T169	C0449851
separate	T080	C0443299
spermatozoa	T025	C0037868
plural	T081	C0439064
contributors	T098	C1257890
biological mixtures	T077	C2347026
human identification	T060	C0242954
method	T169	C0449851
distinguish	T080	C0443299
sperm cells	T025	C0037868
men	T098	C0025266
multi-suspect	T078	C0750491
sexual assault	T048	C0237236
cases	T169	C0868928
MACS	T059	C0599662
FACS	T059	C0079366
isolate	T059	C0220862
single	T081	C0205171
donor	T098	C0013018
sperm cells	T025	C0037868
forensic mixture samples	T167	C0370003
female	T098	C0043210
vaginal	T023	C0042232
epithelial cells	T025	C0014597
sperm cells	T025	C0037868
multiple	T081	C0439064
contributors	T098	C1257890
Sperms	T025	C0037868
vaginal swab	T167	C0444207
isolated	T169	C0205409
MACS	T059	C0599662
FITC	T109	C0085216
A kinase anchor protein 3	T116	C1309095
AKAP3	T116	C1309095
antibody	T116	C0003241
target individual	T098	C0237401
sperm cells	T025	C0037868
donors	T098	C0013018
separated	T080	C0443299
FACS	T059	C0079366
FITC	T109	C0085216
blood group A/B antigen	T116	C0302043
antibody	T116	C0003241
procedure	T169	C2700391
tested	T169	C0039593
mock	T033	C0562577
multi-suspect	T078	C0750491
sexual assault	T048	C0237236
samples	T167	C0370003
practical casework	T074	C0179660
sample	T167	C0370003
complete	T080	C0205197
single	T081	C0205171
donor	T098	C0013018
STR profiles	T114	C1519302
sperm	T025	C0037868
epithelial cell	T025	C0014597
sperm	T025	C0037868
mixtures	T167	C0439962
contributors	T098	C1257890
sperm	T025	C0037868
epithelial cells	T025	C0014597
sperm cells	T025	C0037868
mixtures	T167	C0439962
sensitivity	T081	C0036667
target cells	T034	C2939170
detected	T033	C0442726
cell number	T059	C0007584
blood types	T201	C1383165
individuals	T098	C0237401
procedure	T169	C2700391
forensic DNA analysis	T059	C0200898
multi-suspect	T078	C0750491
sexual assault	T048	C0237236
cases	T169	C0868928
use of	T169	C1524063
FACS	T059	C0079366
MACS	T059	C0599662
sperm	T025	C0037868
AKAP3	T116	C1309095
antigen	T129	C0003320
human	T016	C0086418
blood type antigen	T034	C0701817
Iron Stain	T059	C0918182
Assessing	T052	C1516048
Intracranial Hemorrhage	T047	C0151699
timing	T079	C0449243
red blood cells	T025	C0014792
organization	T169	C1300196
hemorrhage	T046	C0019080
significance	T081	C0237881
catabolism	T040	C0699900
heme	T109	C0018966
processing	T052	C1709694
iron	T121	C0302583
application	T169	C4048755
assigning	T169	C1516050
attempting	T051	C1516084
assign	T169	C1516050
time course	T079	C0449247
traumatic	T037	C3714660
events	T051	C0441471
contusions	T037	C0009938
hemorrhages	T046	C0019080
Attempts	T051	C1516084
date contusions	T037	C0009938
unsuccessful	T080	C1272705
macroscopic observation	T059	C1551402
microscopic observations	T059	C0369671
data	T078	C1511726
anatomically	T080	C0220784
imprecise	T080	C0205408
function	T169	C0542341
time	T079	C0040223
Intracranial lesions	T033	C0581296
significance	T081	C0237881
timing	T079	C0449243
organizing	T169	C1300196
hemorrhage	T046	C0019080
acute	T079	C0205178
life-threatening	T033	C2826244
nature	T078	C0349590
hemorrhages	T046	C0019080
medicolegal investigation	T060	C0420141
potential	T080	C3245505
crimes	T068	C0010325
Prussian Blue reaction	T059	C0033779
iron	T121	C0302583
histochemical	T059	C0019635
reaction	T169	C0443286
years	T079	C0439234
diagnostic test	T060	C0086143
chronicity	T079	C0547045
study	T062	C2603343
examined	T033	C0332128
Prussian Blue iron stain	T121	C0060234
living patients	T101	C0030705
intracranial hemorrhages	T047	C0151699
symptom onset	T079	C4086878
presence	T033	C0150312
Prussian Blue	T121	C0060234
reactivity	UnknownType	C0678596
correlated	T080	C1707520
chronicity	T079	C0547045
found	T033	C0243095
cases	T169	C0868928
intracranial hemorrhage	T047	C0151699
cases	T169	C0868928
focal iron	T121	C0302583
reactivity	UnknownType	C0678596
duration	T079	C0449238
symptom onset	T079	C4086878
surgery	T061	C0543467
cases	T169	C0868928
ranged	T081	C1514721
hours	T079	C0439227
days	T079	C0439228
cases	T169	C0868928
no iron reactivity	T033	C0243095
duration	T079	C0449238
symptom onset	T079	C4086878
surgery	T061	C0543467
hours	T079	C0439227
days	T079	C0439228
Prussian Blue reaction	T059	C0033779
unreliable	T078	C0749770
indicator	T130	C0021212
timing	T079	C0449243
intracranial hemorrhage	T047	C0151699
Prussian blue reaction	T059	C0033779
independent indicator	T130	C0021212
chronicity	T079	C0547045
valid	T080	C2349099
indicated	T033	C1444656
iron staining	T059	C1522279
timing	T079	C0449243
pre-existing	T080	C2347662
lesions	T033	C0221198
brain lesions	T047	C0221505
Prussian blue reaction	T059	C0033779
clinical	T080	C0205210
timing	T079	C0449243
neurologic decline	T033	C4314692
clinical data	T170	C1516606
accurate	T080	C0443131
susceptible	T169	C0231204
false positive results	T034	C0205557
Successful	T080	C1272703
Fetal Tele-Echo	T060	C0412564
Small Regional Hospital	T073	C0019994
Prenatal diagnosis	T060	C0033053
complex	T080	C0439855
congenital heart disease	T019	C0152021
CHD	T019	C0152021
improve	T033	C0184511
newborn	T033	C2239178
outcomes	T169	C1274040
prenatal diagnosis	T060	C0033053
access	T082	C0444454
fetal echocardiography	T060	C0412564
United States	T083	C0041703
clinical fetal tele-echo	T060	C0412564
King's Daughters Medical Center	T073	C0565990
KDMC	T073	C0565990
Ashland	T083	C3811365
KY	T083	C0022557
eastern Kentucky	T083	C0022557
congenital heart surgeon	T097	C0334892
study	T062	C2603343
fetal tele-echo	T060	C0412564
local sonographers	T097	C1954848
small regional hospital	T073	C0019994
accurately	T080	C0443131
efficiently	T080	C0442799
fetuses	T018	C0015965
complex	T080	C0439855
CHD	T019	C0152021
Medical records	T170	C0025102
reviewed	T080	C1709940
mother-infant pairs	T058	C0596977
fetal tele-echoes	T060	C0412564
performed	T169	C0884358
KDMC	T073	C0565990
interpreted	T169	C1285553
University of Louisville pediatric cardiology	T073	C0020028
Findings	T033	C0243095
fetal tele-echo	T060	C0412564
newborn	T100	C0021289
newborn	T100	C0021289
echo	T060	C0013516
clinical course	T079	C0449259
Correct	T080	C2349182
no difference	T033	C3842396
fetal tele-echo	T060	C0412564
newborn	T100	C0021289
echo	T060	C0013516
fetal tele-echo	T060	C0412564
newborn	T100	C0021289
Major Difference	T081	C1705241
affected	T169	C0392760
newborn	T100	C0021289
newborn	T033	C2239178
clinical course	T079	C0449259
Minor Difference	T081	C1705241
clinical course	T079	C0449259
mother-infant pairs	T058	C0596977
analyzed	T062	C0936012
Fetal tele-echoes	T060	C0412564
Correct	T080	C2349182
Correct	T080	C2349182
Major Differences	T081	C1705241
Minor Differences	T081	C1705241
complex	T080	C0439855
CHD	T019	C0152021
fetal tele-echo	T060	C0412564
sensitivity	T169	C0332324
specificity	T081	C0037791
fetal echocardiograms	T060	C0278336
mother-infant pair	T058	C0596977
Fetal tele-echocardiography	T060	C0412564
performed	T169	C0884358
local sonographers	T097	C1954848
small regional hospital	T073	C0019994
accurately	T080	C0443131
efficiently	T080	C0442799
fetuses	T018	C0015965
complex	T080	C0439855
CHD	T019	C0152021
Identification	T080	C0205396
mineral	T197	C0026162
binding	T052	C1145667
peptides	T116	C0030956
discriminate	T080	C0205235
chalcopyrite	T197	C0605435
enargite	T197	C0026162
separation	T080	C0443299
minerals	T197	C0026162
subsequent	T079	C0332282
extraction	T059	C0684295
metals	T197	C0025552
imperative	T080	C3898777
increasing	T169	C0442808
mineralogical	T197	C0026162
complexity	T080	C0439855
ore deposits	T197	C0026162
difficult	T080	C0332218
impossible	T033	C0243095
separate	T080	C0443299
slurries	T167	C1883043
solutions	T167	C0037633
containing	T169	C0332256
minerals	T197	C0026162
metals	T197	C0025552
Low	T080	C0205251
recovery	T052	C0237820
metal	T197	C0026162
typical	T080	C3538928
complex	T080	C0439855
deposits	T197	C0026162
significant	T078	C0750502
losses	T081	C1517945
tailings	T069	C0021265
In addition	T169	C0332287
minerals	T197	C0026162
impurities	T167	C2827365
toxic	T080	C1407029
difficult	T080	C0332218
costly	T169	C0220812
control	T169	C2587213
processing	T052	C1709694
concentrate	T080	C4283884
mineral	T197	C0026162
product	T071	C1514468
example	T077	C1707959
complex	T080	C0439855
significant	T078	C0750502
economic	T169	C0013557
environmental	T082	C0014406
costs	T081	C0010186
associated with	T080	C0332281
diluting	T169	C1948037
processing	T052	C1709694
copper	T121	C0009968
concentrates	T080	C4283884
containing	T169	C0332256
arsenic	T121	C0003818
mineral enargite	T197	C0026162
Cu3 AsS4	T197	C0026162
production	T057	C0033268
pure	T081	C1882508
copper	T121	C0009968
separation	T080	C0443299
problems	T033	C0033213
phage display	T063	C1519025
identify	T080	C0205396
peptides	T116	C0030956
selective	T080	C0205556
recognition	T080	C0205396
enargite	T197	C0026162
arsenic	T121	C0003818
free	T169	C0332296
copper sulfide	T197	C0389357
chalcopyrite	T197	C0605435
random	T080	C0439605
peptide phage display libraries	T116	C0751719
identification	T080	C0205396
enargite	T197	C0026162
selective	T080	C0205556
peptide	T116	C0030956
sequence MHKPTVHIKGPT	T087	C0002518
chalcopyrite	T197	C0605435
selective	T080	C0205556
peptide	T116	C0030956
sequence RKKKCKGNCCYTPQ	T087	C0002518
Mineral	T197	C0026162
binding	T052	C1145667
selectivity	T080	C0205556
binding	T052	C1145667
studies	T062	C2603343
zeta potential	T067	C0597697
determination	T059	C1148554
immunochemistry	T091	C0020986
Peptides	T116	C0030956
ability	T033	C1299581
discriminate	T080	C0205235
enargite	T197	C0026162
chalcopyrite	T197	C0605435
option	T169	C1518601
separation	T080	C0443299
arsenic	T121	C0003818
containing	T169	C0332256
contaminants	T167	C2827365
copper	T121	C0009968
concentrates	T080	C4283884
major	T080	C0205164
advance	T079	C3854260
replacement	T169	C0559956
reduction	T080	C0392756
toxic	T080	C1407029
collectors	T169	C1516698
reducing	T080	C0392756
level	T080	C0441889
arsenic	T121	C0003818
bearing	T052	C0206243
minerals	T197	C0026162
early	T079	C1279919
stages	T079	C1306673
mineral	T197	C0026162
processing	T052	C1709694
High-density lipoprotein	T116	C0023821
sphingosine-1-phosphate	T109	C0074992
heterozygous familial hypercholesterolaemia	T047	C0342882
Patients	T101	C0030705
heterozygous familial hypercholesterolaemia	T047	C0342882
FH	T047	C0342882
suffer	T184	C0751408
high plasma cholesterol	T033	C0858226
environment	T082	C0014406
oxidative stress	T049	C0242606
high-density lipoprotein	T116	C0023821
HDL	T116	C0023821
sphingosine-1-phosphate	T109	C0074992
S1P	T109	C0074992
HDL	T116	C0023821
S1P	T109	C0074992
HDL	T116	C0023821
protection against oxidative stress	T039	C3823580
statin treatment	T058	C1314135
case-control study	T062	C0007328
HDL	T116	C0023821
isolated	T169	C0205409
FH	T047	C0342882
patients	T101	C0030705
statin treatment	T058	C1314135
healthy controls	T080	C2986479
HDL	T116	C0023821
S1P	T109	C0074992
HDL	T116	C0023821
protect	T033	C1545588
cardiomyocytes	T025	C0225828
oxidative stress	T049	C0242606
in vitro	T062	C0681828
HDL	T116	C0023821
S1P	T109	C0074992
cell protection	T039	C0524828
HDL-cholesterol	T109	C0023822
apolipoprotein AI	T116	C0085201
HDL	T116	C0023821
cell protection	T039	C0524828
HDL	T116	C0023821
S1P	T109	C0074992
HDL	T116	C0023821
FH	T047	C0342882
patients	T101	C0030705
apolipoprotein AI	T116	C0085201
apolipoprotein M	T116	C1438565
FH	T047	C0342882
patients	T101	C0030705
Statin treatment	T058	C1314135
FH	T047	C0342882
environment	T082	C0014406
HDL	T116	C0023821
S1P	T109	C0074992
HDL	T116	C0023821
S1P	T109	C0074992
cell protection	T039	C0524828
Statin treatment	T058	C1314135
HDL	T116	C0023821
Moberg Picking-Up Test	T059	C1293918
patients	T101	C0030705
hand osteoarthritis	T047	C0263746
Clinical measurement	T058	C0947289
Moberg Pick-up Test	T059	C1293918
MPUT	T059	C1293918
functional performance	T033	C3853978
patients	T101	C0030705
hand	T023	C0018563
inflammatory disease	T047	C1290884
MPUT	T059	C1293918
hand osteoarthritis	T047	C0263746
OA	T047	C0263746
functional performance	T033	C3853978
MPUT	T059	C1293918
hand OA	T047	C0263746
patients	T101	C0030705
healthy controls	T080	C2986479
hand OA	T047	C0263746
patients	T101	C0030705
controls	T096	C0009932
MPUT	T059	C1293918
AUSCAN	T170	C3891717
Cochin questionnaires	T170	C0034394
grip	T033	C0518032
pinch strength	T060	C1720876
pain	T184	C0030193
visual analog scale	T060	C0042815
Likert scale	T170	C0451267
MPUT	T059	C1293918
MPUT	T059	C1293918
evaluation	T058	C1261322
OA	T047	C0263746
statistically significant	T081	C0237881
control group	T096	C0009932
OA	T047	C0263746
more	T081	C0205172
time	T079	C0040223
test	T170	C0392366
grip	T033	C0518032
pinch strength measurements	T060	C1720876
control group	T096	C0009932
OA	T047	C0263746
difficulty	T080	C0332218
control group	T096	C0009932
test	T170	C0392366
MPUT	T059	C1293918
test	T170	C0392366
functional performance	T033	C3853978
hand OA	T047	C0263746
Soymilk	T168	C3825658
residue	T077	C1709915
okara	T116	C0960549
natural	T169	C0205296
immobilization carrier	T080	C0205556
Lactobacillus plantarum	T007	C0317608
cells	T025	C0007634
enhances	T052	C2349975
soymilk	T168	C3825658
fermentation	T044	C0015852
glucosidic isoflavone	T109	C0022179
bioconversion	T169	C0439836
cell survival	T043	C0007620
simulated gastric	T080	C1704242
intestinal	T023	C0021853
conditions	T080	C0348080
Cell immobilization	T025	C0282542
alternative	T077	C1523987
microencapsulation	T061	C0025974
cells	T025	C0007634
liquid	T167	C0302908
medium	T167	C1705217
artificial	T080	C2004457
immobilization carriers	T080	C0205556
safety	T068	C0036043
risk	T078	C0035647
Okara	T116	C0960549
food-grade	T168	C0016452
byproduct	T167	C0439861
soymilk	T168	C3825658
production	T057	C0033268
prebiotics	T109	C2717875
Lactobacilli	T007	C0317608
health	T078	C0018684
enhancing	T052	C2349975
effects	T080	C1280500
host	T001	C1167395
study	T062	C2603343
okara	T116	C0960549
L. plantarum 70810 cells	T025	C0007634
okara-immobilized	T116	C0960549
L. plantarum 70810 cells	T025	C0007634
IL	T025	C0007634
soymilk	T168	C3825658
fermentation	T044	C0015852
glucosidic isoflavone	T109	C0022179
bioconversion	T169	C0439836
cell	T025	C0007634
resistance	T169	C4281815
simulated gastric	T080	C1704242
intestinal	T023	C0021853
stresses	T046	C0449430
Scanning electron microscopy	T059	C0026020
SEM	T059	C0026020
cells	T025	C0007634
adherence	T169	C1510802
surface	T082	C0205148
okara	T116	C0960549
Lactic acid	T109	C0064582
acetic acid	T109	C0000983
isoflavone	T109	C0022179
analyses	T062	C0936012
fermented	T168	C1827145
soymilk	T168	C3825658
performed	T169	C0884358
HPLC with UV detection	T059	C0201764
Viability	T080	C0443348
immobilized	T025	C0282542
free L. plantarum 70810 cells	T025	C0007634
FL	T025	C0007634
soymilk	T168	C3825658
fermentation	T044	C0015852
changes	T169	C0392747
pH	T034	C1304686
titrable acidity	T034	C0368606
viscosity	T070	C0042784
measured	T080	C0444706
conventional methods	T170	C0025663
in vitro	T080	C1533691
testing	T169	C0039593
gastrointestinal	T082	C0521362
resistance	T169	C4281815
fermented	T168	C1827145
soymilk	T168	C3825658
inoculated	T061	C2987620
FL	T025	C0007634
IL	T025	C0007634
aliquot	T081	C1510844
incubated	T059	C1439852
acidic MRS broth	T167	C1705217
gastric	T080	C1704242
pancreatic juices	T031	C0030296
bile salts	T109	C0005404
simulated gastric	T080	C1704242
intestinal	T023	C0021853
stresses	T046	C0449430
plate count of colony forming units	T059	C0201253
MRS agar	T130	C1720273
SEM	T059	C0026020
lactobacilli	T007	C0317608
cells	T025	C0007634
attached	T067	C3714578
surface	T082	C0205148
okara	T116	C0960549
Compared	T052	C1707455
FL	T025	C0007634
IL	T025	C0007634
higher	T080	C0205250
specific	T080	C0205369
growth rate	T079	C0449249
shorter	T081	C1806781
lag phase	T079	C0205390
growth	T040	C0018270
lactic	T109	C0064582
acetic acids	T109	C0000983
faster	T080	C0456962
decrease	T081	C0547047
pH	T034	C1304686
increase	T169	C0442805
titrable acidity	T034	C0368606
higher	T080	C0205250
soymilk	T168	C3825658
viscosity	T070	C0042784
IL	T025	C0007634
soymilk	T168	C3825658
daizein	T109	C0022179
genistein	T109	C0061202
compared	T052	C1707455
control	T167	C1550141
Compared	T052	C1707455
FL	T025	C0007634
IL	T025	C0007634
simulatedgastric	T080	C1704242
intestinal	T023	C0021853
stresses	T046	C0449430
in vitro	T080	C1533691
low pH	T033	C0728725
low pH plus	T033	C0728725
pepsin	T116	C0014442
pancreatin	T116	C0030304
bile salt	T109	C0005404
results	T169	C1274040
okara	T116	C0960549
immobilization carrier	T080	C0205556
enhance	T052	C2349975
growth	T040	C0018270
glucosidic isoflavone	T109	C0022179
bioconversion	T169	C0439836
activities	T052	C0441655
L. plantarum	T007	C0317608
soymilk	T168	C3825658
improve	T033	C0184511
cell survivability	T043	C0007620
simulated gastric	T080	C1704242
intestinal	T023	C0021853
conditions	T080	C0348080
visual stylet (Discopo)-guided	T061	C0543467
laryngeal mask airway placement	T061	C0396618
conventional blind technique	T061	C0442775
randomized	T062	C0034656
laryngeal mask airway (LMA) insertion	T061	C0396618
fiberoptic view	T082	C0449911
LMA	T074	C0162645
placement	T080	C1524072
Discopo visual stylet-guided insertion	T061	C0543467
conventional blind technique	T061	C0442775
randomized	T062	C0034656
controlled study	T062	C0681867
Operating room	T073	C0029064
university hospital	T073	C0020028
adult	T100	C0001675
patients	T101	C0030705
elective surgery	T061	C0206058
LMA	T074	C0162645
general anesthesia	T061	C0002915
Patients	T101	C0030705
randomly	T062	C0034656
groups	UnknownType	C0681860
GLMA group	UnknownType	C0681860
visual stylet-guided technique	T061	C0543467
BLMA group	UnknownType	C0681860
blind technique	T061	C0442775
placement	T080	C1524072
LMA	T074	C0162645
clinical test	T201	C3173977
fiberoptic	T073	C1708050
assessment	T058	C0220825
Unblinded data	T078	C1511726
insertion	T061	C0021107
success rate	T081	C1521828
LMA	T074	C0162645
position	T082	C1550045
fiberoptic view	T082	C0449911
LMA	T074	C0162645
anatomical position	T029	C0277809
hemodynamic responses	T042	C4042806
adverse	T169	C0001688
insertion	T061	C0021107
responses	T032	C0871261
bucking	T037	C0852885
breathholding	T033	C0235744
laryngospasm	T037	C0920061
Blinded data	T078	C1511726
postoperative	T079	C0032790
airway morbidity	T047	C1301933
blood staining	T031	C0005835
LMA	T074	C0162645
sore throat	T184	C0242429
hoarseness	T184	C0019825
Insertion	T061	C0021107
GLMA	UnknownType	C0681860
BLMA group	UnknownType	C0681860
GLMA	UnknownType	C0681860
BLMA	UnknownType	C0681860
patients	T101	C0030705
BLMA group	UnknownType	C0681860
reinsertion	T061	C0021107
GLMA group	UnknownType	C0681860
fiberoptic view	T082	C0449911
GLMA group	UnknownType	C0681860
groups	UnknownType	C0681860
hemodynamic stress responses	T039	C0149784
incidences	T081	C0021149
adverse	T169	C0001688
insertion	T061	C0021107
postoperative	T079	C0032790
airway morbidity	T047	C1301933
LMA	T074	C0162645
insertion	T061	C0021107
Discopo visual stylet	T061	C0543467
success rate	T081	C1521828
accuracy rate	T080	C0443131
LMA	T074	C0162645
placement	T080	C1524072
hemodynamic stress response	T039	C0149784
incidences	T081	C0021149
adverse events	T046	C0877248
Targeting	T169	C1521840
brain	T023	C0006104
peripheral plasticity	T042	C0027880
lipidome	T109	C0023779
acute	T079	C0205178
kainic acid	T109	C0022471
induced	T169	C0205263
epileptic seizures	T047	C0014544
mice	T015	C0025929
quantitative mass spectrometry	T059	C3525763
Epilepsy	T047	C0014544
chronic neurological disorder	T047	C1290882
manifested	T169	C0205319
types	T080	C0332307
human	T016	C0086418
population	T098	C1257890
molecular mechanisms	T044	C1148560
epileptogenesis	T047	C0014544
pharmacoresistance	T047	C2712961
epilepsy	T047	C0014544
patients	T101	C0030705
medical	T169	C0205476
care	T058	C0086388
evidence	T078	C3887511
lipid	T109	C0023779
signalling pathways	T044	C0037080
epileptogenesis	T047	C0014544
lipid	T109	C0023779
signals	T044	C0037080
potential	T080	C3245505
biomarkers	T201	C0005516
epileptic disorder	T047	C0014544
potential	T080	C3245505
therapeutic agents	T121	C1611640
targets	T169	C1521840
lipidomic	T109	C0023779
strategy	T062	C0035171
lipid	T109	C0023779
brain regions	T029	C1273723
periphery tissues	T024	C0040300
plasma	T031	C0032105
specific	T080	C0205369
acute	T079	C0205178
epileptic seizures	T047	C0014544
mice	T015	C0025929
seizure	T047	C0014544
induction	T169	C0205263
systemic	T062	C3494163
kainic acid	T109	C0022471
injection	T062	C3494163
compared	T052	C1707455
vehicle controls	T096	C0009932
levels	T080	C0441889
phospholipids	T109	C0031676
sphingomyelins	T109	C0037906
endocannabinoids	T109	C1172779
anandamide	T109	C0211726
AEA	T109	C0211726
2-arachidonoyl glycerol	T109	C0299477
2-AG	T109	C0299477
endocannabinoid	T109	C1172779
compounds	T103	C1706082
oleoylethanolamide	T109	C1454896
OEA	T109	C1454896
palmitoylethanolamide	T109	C0069964
PEA	T109	C0069964
arachidonic acid	T109	C0003695
AA	T109	C0003695
eicosanoids	T109	C0013725
fatty acyl	T123	C0574031
lipidome	T109	C0023779
pulverized	T062	C3494163
tissues	T023	C0459385
brain regions	T029	C1273723
kainic acid	T109	C0022471
induced	T169	C0205263
epileptic seizure	T047	C0014544
models	T075	C0026336
vehicle controls	T096	C0009932
hypothalamus	T023	C0020663
hippocampus	T023	C0019564
thalamus	T023	C0039729
striatum	T023	C0010097
cerebellum	T023	C0007765
cerebral cortex	T023	C0007776
peripheral	T082	C0205100
organs	T023	C0178784
heart	T023	C0018787
lungs	T023	C0024109
plasma	T031	C0032105
lipid	T109	C0023779
acute	T079	C0205178
epileptic seizures	T047	C0014544
compared	T052	C1707455
non-seizure controls	T096	C0009932
brain region	T029	C1273723
periphery tissue	T024	C0040300
specific	T080	C0205369
specific	T080	C0205369
plasma	T031	C0032105
lipid	T109	C0023779
marker candidates	T201	C0005516
research studies	T062	C0681814
drug discovery	T062	C0920472
response monitoring	T058	C0085421
Panitumumab	T116	C0879427
Encephalopathy	T047	C0085584
Intra-arterial	T169	C1561451
Application	T058	C0185125
Dislocated Central Venous Access Device	T074	C0025080
Acute	T079	C0205178
central nervous system	T022	C3714787
CNS	T022	C3714787
toxicity	T037	C3160947
immune	T169	C0439662
side effects	T046	C0879626
monoclonal antibodies	T116	C0003250
cancer therapy	T061	C0920425
patient	T101	C0030705
acute-onset encephalopathy	T033	C4014441
coma	T047	C0009421
administration	T169	C1621583
panitumumab	T116	C0879427
treatment	T061	C0087111
metastatic colorectal cancer	T191	C0948380
Echocardiography	T060	C0013516
drug	T121	C0013227
left cardiac ventricle	T023	C0225897
dislocated central venous line	T074	C0025080
Diffusion-weighted magnetic resonance imaging	T060	C0598801
cortical hyperintensities	T033	C3149362
frontal lobes	T023	C0016733
neurological condition	T047	C0027765
days	T079	C0439228
patient	T101	C0030705
died	T040	C0011065
weeks	T079	C0439230
administration	T169	C1621583
antibody	T116	C0003241
intra-arterial route	T169	C1561451
condition	T047	C0012634
Toxic encephalopathy	T037	C0149504
hitherto	T079	C0205156
complication	T046	C0009566
panitumumab	T116	C0879427
treatment	T061	C0087111
patients	T101	C0030705
CNS	T022	C3714787
symptoms	T184	C1457887
therapy	T061	C0087111
Abundance	T080	C2346714
Characterization	T052	C1880022
Microsatellites	T114	C1519302
Cattle	T015	C0007452
Y Chromosome	T026	C0043381
Microsatellites	T114	C1519302
simple sequence repeats	T114	C1519302
SSRs	T114	C1519302
organisms	T001	C0029235
genomic organization	T028	C1517495
function	T045	C0314627
characterize	T052	C1880022
abundance	T080	C2346714
SSRs	T114	C1519302
base-pairs	T044	C0600436
bp	T044	C0600436
cattle	T015	C0007452
Y chromsome	T026	C0043381
frequency	T079	C0439603
density	T081	C0178587
SSRs	T114	C1519302
Y chromosome	T026	C0043381
sequence	T086	C0162326
examined	T033	C0332128
SSRs	T114	C1519302
length	T081	C1444754
cattle	T015	C0007452
Y chromosome	T026	C0043381
sequence	T086	C0162326
SSRs	T114	C1519302
length	T086	C0162326
bp	T044	C0600436
frequency	T079	C0439603
density	T081	C0178587
bp	T044	C0600436
SSRs	T114	C1519302
cattle	T015	C0007452
Y chromosome	T026	C0043381
Mononucleotide repeats	T114	C0028630
length	T086	C0162326
bp	T044	C0600436
SSRs	T114	C1519302
di-	T114	C0282524
tetra-	T114	C0028630
tri-	T114	C0028630
penta-	T114	C0028630
hexa-nucleotide repeats	T114	C0028630
SSRs	T114	C1519302
dinucleotides	T114	C0028630
A	T114	C0001407
AC	T086	C0004793
AT	T086	C0004793
AAC	T086	C0004793
AGC	T086	C0004793
GTTT	T086	C0004793
CTTT	T086	C0004793
ATTT	T086	C0004793
AACTG	T086	C0004793
Y chromosome	T026	C0043381
study	T062	C2603343
cattle	T015	C0007452
Y chromosome	T026	C0043381
DNA	T114	C0012854
polymorphic	T080	C1882417
cattle	T015	C0007452
Y-chromosome	T026	C0043381
SSRs	T114	C1519302
Antenatal	T079	C2828394
Stressful Life Events	T051	C0038444
Postpartum	T079	C0086839
Depressive Symptoms	T184	C0086132
United States	T083	C0041703
Women's	T098	C0043210
Socioeconomic Status	T080	C0086996
Indices	T170	C0918012
State Level	T081	C1711201
women	T098	C0043210
suffer	T048	C0683278
postpartum depression	T048	C0221074
PPD	T048	C0221074
predictors	T078	C2698872
antenatal	T079	C2828394
stressful life event	T051	C0038444
SLE	T051	C0038444
experiences	T067	C0237609
association	T080	C0439849
women's	T098	C0043210
state-level	T081	C1711201
socioeconomic status	T080	C0086996
SES	T080	C0086996
PPD	T048	C0221074
study	T062	C0681814
association	T080	C0439849
antenatal	T079	C2828394
SLE	T051	C0038444
PPD	T048	C0221074
symptoms	T184	C1457887
moderated	T080	C1881878
women's	T098	C0043210
state-level	T081	C1711201
SES	T080	C0086996
Data	T078	C1511726
Pregnancy Risk Assessment Monitoring System	T170	C0038951
PRAMS	T170	C0038951
State-level	T081	C1711201
women's	T098	C0043210
employment	T080	C0014003
earnings	T081	C0680989
social	T169	C0728831
economic	T169	C0013557
autonomy	T078	C0085862
indices	T170	C0918012
indicators	T130	C0021212
Institute of Women's Policy Research	T092	C1561598
IWPR	T092	C1561598
Multilevel multivariable logistic regression analyses	UnknownType	C0681925
women	T098	C0043210
valid	T080	C2349099
responses	T032	C0871261
PPD	T048	C0221074
symptoms	T184	C1457887
prevalence	T081	C0220900
Illinois	T083	C0020898
Arkansas	T083	C0003790
Women	T098	C0043210
stressor	T078	C0597530
categories	T170	C0683312
partner	T098	C3887537
related	T033	C0445223
traumatic	T169	C0332663
emotional	T033	C0849912
financial	T081	C0376243
odds	T081	C0028873
adjusted odds ratio	T081	C0028873
aOR	T081	C0028873
confidence interval	T081	C0009667
CI	T081	C0009667
PPD	T048	C0221074
symptoms	T184	C1457887
odds	T081	C0028873
PPD	T048	C0221074
symptoms	T184	C1457887
decreased	T081	C0205216
increase	T169	C0442805
state-level	T081	C1711201
social	T169	C0728831
economic	T169	C0013557
autonomy	T078	C0085862
index	T170	C0918012
aOR	T081	C0028873
CI	T081	C0009667
cross-level interaction	T080	C0205556
stressor	T078	C0597530
categories	T170	C0683312
state-level	T081	C1711201
index	T170	C0918012
Screening	T169	C1305399
antenatal	T079	C2828394
SLEs	T051	C0038444
women	T098	C0043210
at risk	T080	C1444641
PPD	T048	C0221074
symptoms	T184	C1457887
odds	T081	C0028873
PPD	T048	C0221074
symptoms	T184	C1457887
decreased	T081	C0205216
increasing	T169	C0442805
state-level	T081	C1711201
social	T169	C0728831
economic	T169	C0013557
autonomy	T078	C0085862
women	T098	C0043210
states	T083	C1301808
indices	T170	C0918012
more vulnerable	T169	C0231204
antenatal	T079	C2828394
stressors	T078	C0597530
policy implications	UnknownType	C0814846
SES	T080	C0086996
women	T098	C0043210
states	T083	C1301808
Multi-component model	T075	C0026339
intramural hematoma	T046	C0333200
multi-component model	T075	C0026339
studying	T062	C2603343
interaction	T169	C1704675
blood flow	T039	C0232338
deforming	T033	C1562006
aortic wall	T023	C0507851
intramural hematoma	T046	C0333200
IMH	T046	C0333200
aortic wall	T023	C0507851
simulated	T062	C0679083
composite structure submodel	T075	C0026339
material properties	T080	C0205556
wall layers	T023	C0934502
IMH	T046	C0333200
poroelasticity submodel	T075	C0026339
pressure	T070	C0001876
hematoma	T046	C0018944
deformation	T033	C1562006
submodel	T075	C0026339
hematoma	T046	C0018944
aortic submodel	T075	C0026339
submodel	T075	C0026339
pulsatile blood flow	T067	C0034106
Model simulations	T062	C0679083
investigate	T169	C1292732
hematoma	T046	C0018944
permeability	T070	C0031164
patients	T101	C0030705
age	T032	C0001779
hematoma	T046	C0018944
wall stress	T033	C0038435
clinical data	T170	C1516606
simulations	T062	C0679083
hematoma	T046	C0018944
permeability	T070	C0031164
wall stress	T033	C0038435
blood coagulation	T042	C0005778
hematoma	T046	C0018944
mechanical stability	T033	C0243095
experimental	T080	C1517586
observations	T062	C0302523
coagulation	T042	C0005778
beneficial effect	T080	C1280500
patient	T101	C0030705
IMH	T046	C0333200
Impact of	T080	C4049986
Diabetes	T047	C0011847
Risk	T078	C0035647
Prostate Cancer	T191	C0376358
Development	T169	C1527148
Body Mass Index	T201	C1305855
Cohort Study	T081	C0009247
obesity	T047	C0028754
prostate cancer	T191	C0376358
without	T080	C0332288
diabetic	T047	C0011847
patients	T101	C0030705
data	T078	C1511726
Korean population	T098	C1556095
National Health Insurance System	T058	C0027452
NHIS	T058	C0027452
participants	T098	C0679646
health examinations	T061	C0260135
men ≥40 years old	T098	C0025266
without	T080	C0332288
prostate cancer	T191	C0376358
Multivariate adjusted	T081	C0026777
Cox regression analysis	T081	C0010235
hazard ratio	T081	C2985465
HR	T081	C2985465
confidence interval	T081	C0009667
CI	T081	C0009667
prostate cancer	T191	C0376358
body mass index	T201	C1305855
BMI	T201	C1305855
without	T080	C0332288
diabetes	T047	C0011847
HR	T081	C2985465
prostate cancer	T191	C0376358
diabetes	T047	C0011847
stratified	T080	C0205363
BMI	T201	C1305855
age	T032	C0001779
multivariable-adjusted models	T081	C0026777
population	T098	C1257890
without	T080	C0332288
diabetes	T047	C0011847
HR	T081	C2985465
prostate cancer	T191	C0376358
significantly increased	T081	C0205217
BMI	T201	C1305855
model adjusted for age and multiple variables	T081	C0026777
HR	T081	C2985465
population	T098	C1257890
diabetes	T047	C0011847
HR	T081	C2985465
prostate cancer	T191	C0376358
significantly increased	T081	C0205217
BMI	T201	C1305855
multivariable-adjusted model	T081	C0026777
marked decrease	T081	C0547047
HR	T081	C2985465
population	T098	C1257890
BMI	T201	C1305855
BMI	T201	C1305855
population	T098	C1257890
population	T098	C1257890
obesity	T047	C0028754
development	T169	C1527148
prostate cancer	T191	C0376358
risk increases	T033	C0332167
BMI	T201	C1305855
diabetes	T047	C0011847
Bioinformatic	T091	C1140694
Analysis	T062	C0936012
Codon	T086	C0009221
Usage	T169	C0457083
Phylogenetic Relationships	T080	C1519069
Genotypes	T032	C0017431
Hepatitis C Virus	T005	C0220847
hepatitis C virus	T005	C0220847
HCV	T005	C0220847
genotypes	T032	C0017431
study	T062	C2603343
phylogenetically investigate	T062	C1519068
genotypes	T032	C0017431
HCV	T005	C0220847
amino acid	T116	C0002520
codon	T086	C0009221
usage	T169	C0457083
structure of the virus	T017	C2717802
treatment regimes	T058	C0418956
codon	T086	C0009221
usage	T169	C0457083
genotypes	T032	C0017431
HCV	T005	C0220847
nucleotide sequence	T086	C0004793
investigated	T169	C1292732
website Gene Infinity	T170	C2349146
phylogenetic analysis	T062	C1519068
evolutionary relationship	T080	C0205556
HCV	T005	C0220847
genotypes	T032	C0017431
analyzed	T062	C0936012
MEGA 7 software	T073	C0037585
genotypes	T032	C0017431
HCV	T005	C0220847
groups	T078	C0441833
codon	T086	C0009221
usage	T169	C0457083
properties	T080	C0871161
group	T078	C0441833
genotypes 1 and 5	T032	C0017431
group	T078	C0441833
genotypes 2 and 6	T032	C0017431
similarity	T080	C2348205
codon	T086	C0009221
usage	T169	C0457083
similarity	T080	C2348205
codon	T086	C0009221
usage	T169	C0457083
phylogenetic analysis	T062	C1519068
resemblance	T080	C0205556
correlation	T080	C1707520
genotypes 1 and 4	T032	C0017431
HCV	T005	C0220847
GC	T114	C0028630
guanine	T114	C0018321
guanine - cytosine	T114	C0028630
cytosine	T109	C0010843
genome structure	T028	C0017428
codons	T086	C0009221
translation	UnknownType	C0678935
Genotypes 1 and 4	T032	C0017431
similarity	T080	C2348205
genome sequences	T085	C1254364
proteins	T116	C0033684
codons	T086	C0009221
gene expression	T045	C0017262
studies	T062	C2603343
approach	T082	C0449445
treatment	T169	C1522326
genotypes	T032	C0017431
codon	T086	C0009221
usage	T169	C0457083
properties	T080	C0871161
Chronic	T079	C0205191
adiponectin deficiency	T047	C2675518
Alzheimer's disease	T047	C0002395
cognitive impairments	T048	C0338656
pathologies	T091	C0030664
AMPK	T116	C2350345
cerebral	T023	C0006104
insulin resistance	T046	C0021655
aged	T032	C0001779
mice	T015	C0026809
Insulin resistance	T046	C0021655
pathogenesis	T046	C0699748
type 2 diabetes mellitus	T047	C0011860
T2DM	T047	C0011860
patients	T101	C0030705
risk	T078	C0035647
Alzheimer's disease	T047	C0002395
AD	T047	C0002395
insulin resistance	T046	C0021655
pathogenesis	T046	C0699748
GSK3β	T116	C0244989
activation	T044	C0014429
intra-	T026	C0175996
extracellular	T026	C0521119
amyloid-beta	T116	C3484390
Aβ	T116	C3484390
Adiponectin	T116	C0389071
APN	T116	C0389071
adipokine	T116	C1955907
anti-inflammatory effects	T080	C1515999
APN	T116	C0389071
insulin resistance	T046	C0021655
T2DM	T047	C0011860
APN	T116	C0389071
AD	T047	C0002395
study	T062	C2603343
adiponectin deficiency	T047	C2675518
adiponectin deficiency	T047	C2675518
cerebral	T023	C0006104
insulin resistance	T046	C0021655
cognitive decline	T048	C0338656
Alzheimer's-like pathology	T046	C0699748
mice	T015	C0026809
study	T062	C2603343
adiponectin	T116	C0389071
cognitive functions	T041	C0392335
adiponectin-knockout	T050	C1522225
(APN-KO) mice	T015	C0206745
chronic	T079	C0205191
APN deficiency	T047	C2675518
CNS	T022	C3714787
Behavioral tests	T060	C0683444
study	T062	C2603343
cognitions	T041	C0009240
male	T032	C0086582
APN-KO mice	T015	C0206745
Brains	T023	C0006104
tissue	T024	C0040300
lysates	T072	C1881488
study	T062	C2603343
molecular changes	T044	C1148560
brain	T023	C0006104
APN-KO mice	T015	C0206745
SH-SY5Y neuroblastoma cell line	T025	C0007600
study	T062	C2603343
molecular mechanism	T044	C3537153
APN	T116	C0389071
insulin treatment	T061	C0745343
Aged	T032	C0001779
APN	T116	C0389071
mice	T015	C0026809
spatial memory	T041	C0814087
learning	T041	C0023185
impairments	T046	C0684336
fear-conditioned	T041	C1510535
memory deficit	T048	C0233794
anxiety	T033	C0003467
mice	T015	C0026809
AD	T047	C0002395
pathologies	T046	C0699748
cerebral	T023	C0006104
Aβ42	T116	C0169424
Aβ	T116	C3484390
hyperphosphorylated Tau proteins	T116	C0085401
microgliosis	T046	C3686874
astrogliosis	T046	C0017639
cerebral	T023	C0006104
IL-1β	T116	C0021753
TNFα	T116	C1456820
neuronal apoptosis	T043	C1660771
synaptic	T030	C0229984
proteins levels	T034	C0428479
APN deficiency	T047	C2675518
neuronal	T129	C0521390
brain	T023	C0006104
AD	T047	C0002395
pathologies	T169	C1521733
APN	T116	C0389071
KO mice	T015	C0206745
AMPK	T116	C2350345
phosphorylation	T044	C0031715
insulin signaling	T044	C1512804
Akt	T116	C0014442
GSK3β	T116	C0244989
activation	T044	C0014429
hippocampus	T023	C0019564
frontal cortex	T023	C0016733
Aged	T032	C0001779
APN	T116	C0389071
mice	T015	C0026809
hippocampal	T023	C0019564
insulin resistance	T046	C0021655
pAkt	T116	C0014442
insulin injection	T061	C0199782
APN	T116	C0389071
treatment	T061	C0087111
SH-SY5Y cells	UnknownType	C0815000
insulin resistance	T046	C0021655
overexpressing	T045	C1171362
Aβ	T116	C3484390
pAkt	T116	C0014442
AdipoR1	T116	C1259440
insulin treatment	T061	C0745343
blocked	T046	C0028778
compound C	T103	C1706082
APN	T116	C0389071
neuronal	T129	C0521390
insulin sensitivity	T046	C0920563
AMPK	T116	C2350345
chronic	T079	C0205191
APN deficiency	T047	C2675518
AMPK	T116	C2350345
AD-like pathogenesis	T046	C0699748
aged	T032	C0001779
mice	T015	C0026809
cognitive impairments	T048	C0338656
psychiatric symptoms	T184	C0233401
inorganic phosphate	T121	C0031603
sag	T080	C1511741
unfused	T080	C0205257
tetanic contractions	T039	C0026820
skeletal muscle	T024	C0242692
hypothesis	T078	C1512571
cytosolic	T026	C1383501
inorganic phosphate	T121	C0031603
Pi	T121	C0031603
contraction	T039	C0026820
induced	T169	C0205263
reductions	T070	C0301630
twitch	T033	C0231530
duration	T079	C0449238
impair	T169	C0221099
force	T067	C0441722
decline	T080	C1511741
sag	T080	C1511741
unfused	T080	C0205257
tetanic contractions	T039	C0026820
fast-twitch muscle	T025	C0242873
five-state model	T075	C0026336
crossbridge cycling	T042	C2265877
simulate	T169	C0205173
twitch	T033	C0231530
unfused	T080	C0205257
tetanic contractions	T039	C0026820
Pi	T121	C0031603
concentration	T081	C1446561
Pi	T121	C0031603
increased	T081	C0205217
twitch	T033	C0231530
duration	T079	C0449238
decreased	T081	C0205216
progressive	T169	C0205329
reductions	T061	C0441610
sensitivity	T169	C0332324
Pi	T121	C0031603
Pi	T121	C0031603
increased	T081	C0205217
unfused	T080	C0205257
simulated	T062	C0679083
Pi	T121	C0031603
sag	T080	C1511741
pronounced	T080	C4288581
initial	T079	C0205265
Pi	T121	C0031603
low	T080	C0205251
magnitude	T081	C1704240
Pi	T121	C0031603
increase	T081	C0205217
large	T081	C0549177
Fast-twitch	T033	C0231530
extensor digitorum longus (EDL) muscles	T023	C0224464
sag-prone	T169	C0205245
Pi	T121	C0031603
slow-twitch	T033	C0231530
soleus muscles	T023	C0242694
sag	T080	C1511741
resistant	T039	C1514892
Pi	T121	C0031603
isolated	T169	C0205409
female	T032	C0086287
C57BL/6 mice	T015	C1521751
Muscles	T024	C0026845
incubated	T059	C1439852
solutions	T167	C0037633
glucose	T109	C0017725
pyruvate	T109	C0244104
typical	T080	C3538928
low	T080	C0205251
Pi	T121	C0031603
environments	T082	C0014406
Twitch	T033	C0231530
duration	T079	C0449238
pyruvate	T109	C0244104
glucose	T109	C0017725
muscles	T024	C0026845
Stimuli	T067	C0234402
applied	T169	C4048755
intervals	T079	C1272706
peak	T080	C0444505
twitch	T033	C0231530
tension	T033	C1442730
sag	T080	C1511741
glucose	T109	C0017725
pyruvate	T109	C0244104
EDL	T023	C0224464
pyruvate	T109	C0244104
glucose	T109	C0017725
glucose	T109	C0017725
pyruvate	T109	C0244104
soleus	T023	C0242694
pyruvate	T109	C0244104
glucose	T109	C0017725
Pi	T121	C0031603
crossbridge cycling	T042	C2265877
tenable mechanism	T169	C0441712
sag	T080	C1511741
low basal	T033	C1389277
Pi	T121	C0031603
fast-twitch	T033	C0231530
slow-twitch muscle	T033	C0231530
explanation	T170	C0681841
fiber-type	T025	C0242697
sag	T080	C1511741
Pancreatic Cancer	T191	C0235974
Survival Analysis	T062	C0038953
Study	T062	C2603343
Oklahoma	T083	C0028914
Pancreatic cancer	T191	C0235974
deadly cancers	T191	C0006826
Risk factors	T033	C0035648
associated with	T080	C0332281
disease	T047	C0012634
age	T032	C0001779
race	T098	C0034510
sex	T032	C0079399
smoking status	T201	C1519386
diabetes status	T033	C1317301
prospective analysis	T062	C0033522
risk factors	T033	C0035648
length of survival	T079	C0023980
pancreatic cancer patients	T101	C1516213
Oklahoma	T083	C0028914
Kaplan-Meier survival curves	T081	C1720944
created	T052	C1706214
log-rank test	T169	C0039593
difference	T080	C1705242
survival time	T201	C2919552
Cox proportional hazard regression models	T081	C0033489
strength of association	T080	C0205556
estimated	T081	C0750572
hazard ratios	T081	C2985465
median survival time	T079	C2986586
cohort	T098	C0599755
months	T079	C0439231
Significant	T078	C0750502
risk factors	T033	C0035648
reduced	T080	C0392756
survival times	T201	C2919552
age	T032	C0001779
stage at diagnosis	T185	C1514952
year of diagnosis	T201	C3173168
Results	T034	C0456984
research findings	T033	C0243095
noteworthy improvements	T077	C2986411
survival times	T201	C2919552
pancreatic cancer patients	T101	C1516213
Oklahoma	T083	C0028914
Length of survival	T079	C0023980
study period	T062	C2347804
significantly	T078	C0750502
associated with	T080	C0332281
risk factors	T033	C0035648
age	T032	C0001779
stage of diagnosis	T185	C1514952
Biochemical	T169	C0205474
proteomic	T091	C0872252
analyses	T062	C0936012
physiological response	T039	C0542478
housing	T073	C0020057
gilts	T015	C0039005
potential	T080	C3245505
stress	T046	C0449430
markers	T201	C0005516
objective	T080	C1571702
assessment	T058	C0220825
animal	T008	C0003062
stress	T046	C0449430
laboratory	T073	C0022877
biomarkers	T201	C0005516
serum	T031	C0229671
composition	T201	C0486616
gilts	T015	C0039005
housing	T073	C0020057
stalls	T073	C0020057
animal	T008	C0003062
discomfort	T184	C2364135
Blood	T031	C0005767
saliva samples	T031	C0438730
housing	T073	C0020057
Biochemical	T169	C0205474
analyses	T062	C0936012
adaptive	T169	C0231193
lipid	T109	C0023779
protein metabolism	T044	C0597299
housing	T073	C0020057
cortisol	T109	C0020268
muscular	T024	C0026845
markers	T201	C0005516
variability	T077	C2827666
animals	T008	C0003062
2D-DIGE	T059	C2936240
iTRAQ	T170	C0282574
proteomic	T091	C0872252
approaches	T057	C0039152
serum protein	T116	C0036825
composition	T201	C0486616
housing	T073	C0020057
gilts	T015	C0039005
techniques	T169	C0449851
alterations	T078	C1515926
homeostatic mechanisms	T040	C1561987
innate immune	T032	C0020969
redox	T044	C0030012
acute phase proteins	T116	C0001347
haptoglobin	T116	C0018595
apolipoprotein A-I	T116	C0085201
antioxidant	T121	C0003402
peroxiredoxin 2	T116	C1137156
2D-DIGE	T059	C2936240
proteins	T116	C0033684
innate immune system	T032	C0020969
lactotransferrin	T116	C0022942
protegrin 3	T116	C0300261
galectin 1	T116	C0252527
iTRAQ	T170	C0282574
oxidative stress	T049	C0242606
enzymes	T116	C0014442
peroxiredoxin 2	T116	C1137156
glutathione peroxidase 3	T116	C1436542
Proteomics	T091	C0872252
decrease	T080	C0392756
apolipoproteins	T116	C0003591
intracellular	T082	C0178719
proteins	T116	C0033684
serum	T031	C0229671
physical injury	T037	C1328749
tissues	T024	C0040300
Housing	T073	C0020057
gilts	T015	C0039005
stalls	T073	C0020057
lipid	T109	C0023779
protein catabolism	T044	C0597297
oxidative stress	T049	C0242606
innate immune system	T032	C0020969
tissue damage	T037	C0010957
stress assessment	T060	C4076401
gilts	T015	C0039005
score	T081	C0449820
lipid	T109	C0023779
metabolites	T123	C0870883
innate immunity	T032	C0020969
oxidative stress	T049	C0242606
markers	T201	C0005516
intracellular	T082	C0178719
proteins	T116	C0033684
Cultivation	T059	C1511556
microalgae	T204	C2936330
species	T185	C1705920
effluent	T167	C1550144
anaerobic digester	T075	C3856828
biodiesel	T109	C2717894
production	T057	C0033268
study	T062	C2603343
investigated	T169	C1292732
effluent	T167	C1550144
anaerobic digestion (AD) system	T075	C3856828
used	T169	C1524063
nutrients	T168	C0678695
source	T033	C0449416
microalgae	T204	C2936330
cultivation	T059	C1511556
effluent	T167	C1550144
treated	T169	C1522326
Nitrogen	T123	C0028158
phosphorus	T196	C0031705
AD	T075	C3856828
AD	T075	C3856828
effluent	T167	C1550144
microalgal	T204	C2936330
growth	T040	C0018270
removal	T080	C0849355
efficiency	T081	C0013682
different	T080	C1705242
algal	T204	C0002028
species	T185	C1705920
tested	T169	C0039593
Micractinium inermum	T002	C2669599
stood out	T169	C0205245
highest	T080	C1522410
biomass	T081	C0005535
FAME	T109	C0029224
productivity	T081	C0392762
dry	T080	C0205222
cell	T025	C0007634
weight	T032	C0005910
FAME	T109	C0029224
contents	T077	C0456205
concentrations	T081	C1446561
nutrients	T168	C0678695
decreased	T081	C0205216
over	T079	C0347984
time	T079	C0040223
FAME	T109	C0029224
contents	T077	C0456205
increased	T081	C0205217
quality	T080	C0332306
well	T080	C0205170
several	T081	C0443302
biodiesel	T109	C2717894
quality	T080	C0332306
standards	T080	C1442989
study	T062	C2603343
AD	T075	C3856828
effluent	T167	C1550144
cheap	T081	C0392762
nutrient	T168	C0678695
rich	T080	C0699759
medium	T081	C0439536
microalgae	T204	C2936330
cultivation	T059	C1511556
equally	T080	C0205163
importantly	T080	C3898777
microalgae	T204	C2936330
treatment	T169	C1522326
option	T169	C1518601
Antiviral activities	T033	C0243095
antimalarials	T121	C0003374
against	T080	C0521124
dengue virus type 2	T005	C0318759
Zika virus	T005	C0318793
previous	T079	C0205156
study,	T062	C2603343
antimalarial compounds	T121	C0003374
amodiaquine	T109	C0002641
AQ	T109	C0002641
derivatives	T104	C0243072
potent	T080	C1704419
anti-dengue viral (DENV) activity	T033	C0243095
stable	T080	C0205360
DENV2	T005	C0318759
Renilla luciferase	T116	C1450145
reporter	T028	C0206414
replicon	T114	C0035142
expressing	T045	C0017262
BHK-21 cells	T025	C0007634
infectivity	T080	C0030657
plaque	T059	C0032102
qRT-PCR assays	T063	C1514628
study	T062	C2603343
performed	T169	C0884358
molecular modeling	T062	C0600115
compounds	T121	C1254351
stereo-electronic properties	T080	C0205556
optimal	T080	C2698651
antiviral activity	T033	C0243095
similarity	T080	C2348205
stereo-electronic profiles	T080	C0205556
electrostatic potential profiles	T081	C0596484
compounds	T121	C1254351
in silico screening	T062	C0178605
compounds	T121	C1254351
literature	T170	C0023866
identified	T080	C0205396
additional	T169	C1524062
compounds	T121	C1254351
Quinacrine	T109	C0034403
QC	T109	C0034403
Mefloquine	T109	C0025153
MQ	T109	C0025153
GSK369796	T109	C3884469
antiviral activities	T033	C0243095
three compounds	T121	C1254351
high	T080	C0205250
anti-DENV activity	T033	C0243095
DENV2	T005	C0318759
replicon	T114	C0035142
expressing	T045	C0017262
cells	T025	C0007634
EC50 values	T081	C0392762
QC	T109	C0034403
MQ	T109	C0025153
GSK369796	T109	C3884469
infectivity assays	T059	C0032102
revealed	T080	C0443289
EC50 values	T081	C0392762
QC	T109	C0034403
MQ	T109	C0025153
GSK369796	T109	C3884469
mode of action	T169	C1524059
compounds	T121	C1254351
through	T169	C0332273
inhibition	T052	C3463820
autophagy	T043	C0004391
affecting	T169	C0392760
DENV2	T005	C0318759
replication	T043	C0042774
compounds	T121	C1254351
antiviral activity	T033	C0243095
against	T080	C0521124
Zika virus	T005	C0318793
ZIKV	T005	C0318793
EC50 values	T081	C0392762
QC	T109	C0034403
MQ	T109	C0025153
GSK369796	T109	C3884469
babies	T100	C0021270
fetal alcohol spectrum disorder	T019	C2985290
pathway	T077	C1705987
Alcohol	T168	C0001967
consumed	T055	C0001948
pregnancy	T040	C0032961
nation's	UnknownType	C0683734
preventable	T080	C2700409
cause	T169	C0015127
developmental disabilities	T048	C0008073
birth defects	T019	C0220810
babies	T100	C0021270
born	T040	C0005615
alcohol-related damage	T047	C3146244
World Health Organization	T093	C0043237
Fetal alcohol spectrum disorders	T019	C2985290
FASDs	T019	C2985290
autism	T048	C0004352
diagnosed	T033	C0011900
Genotyping	T059	C1285573
German	T098	C1556085
Austrian	T098	C0337795
Taylorella equigenitalis	T007	C0318205
isolates	T123	C1764827
repetitive extragenic palindromic (REP) PCR	T063	C0032520
pulsed-field gel electrophoresis	T059	C0085117
PFGE	T059	C0085117
total	T080	C0439810
Taylorella (T.) equigenitalis	T007	C0318205
T. asinigenitalis	T007	C1036797
field	T077	C1521738
isolates	T123	C1764827
collected	T169	C1516698
available	T169	C0470187
genotyping	T059	C1285573
REP- (repetitive extragenic palindromic) PCR	T063	C0032520
PFGE	T059	C0085117
pulsed-field gel electrophoresis	T059	C0085117
study	T062	C2603343
T. equigenitalis	T007	C0318205
field	T077	C1521738
isolates	T123	C1764827
breeds	T040	C0006159
German horses	T015	C0019944
revealed	T080	C0443289
spectrum	T077	C2827424
REP	T086	C0004793
rep-E1-E4	T032	C0017431
rep-E3a	T032	C0017431
PFGE	T059	C0085117
TE-A1-A9	T032	C0017431
TE-B1-B3	T032	C0017431
TE-C	T032	C0017431
TE-E1	T032	C0017431
TE-E2	T032	C0017431
genotypes	T032	C0017431
T. equigenitalis	T007	C0318205
field	T077	C1521738
isolates	T123	C1764827
obtained	T169	C1301820
Austrian Lipizzaner horses	T015	C0324170
differentiated	T080	C0205556
REP	T086	C0004793
rep-E1	T032	C0017431
rep-E3a	T032	C0017431
rep-E4	T032	C0017431
PFGE	T059	C0085117
genotypes	T032	C0017431
TE-A2	T032	C0017431
TE-A5	T032	C0017431
TE-D	T032	C0017431
isolated	T169	C0205409
Austrian Trotters	T015	C0019944
REP	T086	C0004793
PFGE	T059	C0085117
genotype	T032	C0017431
rep-E2/TE-A1	T032	C0017431
T. equigenitalis	T007	C0318205
isolate	T123	C1764827
recovered from	T080	C0521108
Holsteiner stallion	T015	C0019944
living	T078	C0376558
South Africa	T083	C0037712
revealed	T080	C0443289
REP	T086	C0004793
PFGE	T059	C0085117
genotype	T032	C0017431
rep-E1/TE-A5	T032	C0017431
exclusively	T078	C1548966
present	T033	C0150312
majority	T054	C0680220
Austrian Lipizzaner horses	T015	C0324170
study	T062	C2603343
strain	T001	C1518614
study	T062	C2603343
revealed	T080	C0443289
genotype	T032	C0017431
REP	T086	C0004793
PFGE	T059	C0085117
rep-E1/TE-F	T032	C0017431
strains	T001	C1518614
T. asinigenitalis	T007	C1036797
strain	T001	C1518614
separated	T080	C0443299
REP	T086	C0004793
rep-A1-A3	T032	C0017431
PFGE	T059	C0085117
genotypes	T032	C0017431
TA-A1	T032	C0017431
TA-A2	T032	C0017431
TA-A3	T032	C0017431
TA-B	T032	C0017431
TA-C	T032	C0017431
TA-D	T032	C0017431
Overall,	T080	C1561607
generated	T052	C3146294
REP	T086	C0004793
PFGE	T059	C0085117
genotypes	T032	C0017431
good	T080	C0205170
correlation	T080	C1707520
REP-PCR	T063	C0032520
suitable method	T059	C0871511
molecular epidemiological screening	T059	C1294203
T. equigenitalis	T007	C0318205
T. asinigenitalis	T007	C1036797
isolates	T123	C1764827
differentiated	T080	C0205556
detail	T080	C1522508
genotyping	T059	C1285573
PFGE	T059	C0085117
Urokinase	T116	C0042071
Urokinase Receptor	T116	C0071216
Mast Cells	T025	C0024880
Effects	T080	C1280500
Functional	T169	C0205245
Interaction	T169	C1704675
fMLF Receptors	T116	C0597357
Mast cell	T025	C0024880
basophils	T025	C0004827
express	T045	C0597360
high affinity receptor	T116	C0597357
IgE	T116	C0020846
FcɛRI	T116	C0020846
primary effector cells	T025	C0312740
allergic disorders	T046	C0020517
urokinase	T116	C0042071
uPA	T116	C0042071
plasminogen activation system	T044	C1622667
physiological	T039	C0031845
pathological events	T046	C0030660
cell migration	T043	C1622501
tissue remodelling	T042	C1254358
inflammation	T046	C0021368
wound healing	T040	C0043240
angiogenesis	T042	C0302600
metastasis	T046	C4255448
uPA	T116	C0042071
serine protease	T116	C2717971
uPAR	T116	C0071216
high affinity glycosyl-phosphatidyl-inositol (GPI)-anchored	T109	C0119748
receptor	T116	C0597357
uPAR	T116	C0071216
uPA	T116	C0042071
activity	T044	C0243102
cell surface	T026	C0699040
activates intracellular signaling	T044	C3822614
interactions	T169	C1704675
integrins	T116	C0021701
receptor tyrosine kinases	T116	C0206364
G-protein-coupled family	T116	C0872043
fMLF chemotaxis receptors	T116	C0597357
FPRs	T116	C0597357
investigated	T169	C1292732
expression	T045	C1171362
uPA	T116	C0042071
uPAR	T116	C0071216
functional	T169	C0205245
interaction	T169	C1704675
FPRs	T116	C0597357
human	T016	C0086418
mast cells	T025	C0024880
MCs	T025	C0024880
basophils	T025	C0004827
MCs	T025	C0024880
uPA	T116	C0042071
chemotaxis	T043	C0008018
MCs	T025	C0024880
uPAR	T116	C0071216
DII-DIII-uPAR	T116	C0071216
SRSRY sequence	T087	C0002518
FPRs	T116	C0597357
cell chemotaxis	T043	C2610454
MCs	T025	C0024880
mRNAs	T114	C0035696
FPRs	T116	C0597357
uPA	T116	C0042071
soluble peptide	T116	C0030956
uPAR84-95	T116	C0071216
SRSRY chemotactic sequence	T087	C0002518
uPAR	T116	C0071216
FPRs	T116	C0597357
MCs	T025	C0024880
chemotaxis	T043	C0008018
uPA	T116	C0042071
chemoattractant	T123	C0008013
MCs	T025	C0024880
exposure	T080	C0332157
chemotactic	T043	C0008018
epitope	T129	C0003316
uPAR	T116	C0071216
endogenous	T169	C0205227
ligand	T103	C0023688
FPRs	T116	C0597357
mechanism	T169	C0441712
VEGF-A	T116	C0078058
secretion	T038	C0036536
human	T016	C0086418
MCs	T025	C0024880
induced	T169	C0205263
uPA	T116	C0042071
uPAR84-95	T116	C0071216
stimulation.	T044	C1148560
Psychogenic non-epileptic seizure	T048	C1142430
patients	T101	C0030705
intellectual disability	T048	C3714756
choice	T052	C1707391
therapeutic intervention	T061	C0808232
studies	T062	C2603343
treatments	T061	C0087111
psychogenic non-epileptic seizure	T048	C1142430
PNES	T048	C1142430
neglecting	T033	C0243095
subgroup	T185	C1515021
patients	T101	C0030705
intellectual disability	T048	C3714756
ID	T048	C3714756
present	T079	C0521116
study	T062	C2603343
attempted	T051	C1516084
demonstrate	T169	C0205319
effects	T080	C1704420
preferred	T078	C0558295
therapeutic intervention	T061	C0808232
PNES	T048	C1142430
patients	T101	C0030705
ID	T048	C3714756
treated	T169	C1522326
Japanese municipal center	T093	C1708333
short	T081	C1806781
referral chain	T058	C0034927
examined	T033	C0332128
PNES	T048	C1142430
patients	T101	C0030705
ID	T048	C3714756
ID	T048	C3714756
group	T078	C0441833
PNES	T048	C1142430
patients	T101	C0030705
ID	T048	C3714756
non-ID	T033	C0243095
group	T078	C0441833
retrospectively	T080	C1514923
case charts	T170	C3842891
In addition to	T169	C0332287
examining	T033	C0332128
demographic	T090	C0011298
clinical data	T170	C1516606
effects of	T080	C1704420
different	T080	C1705242
therapeutic intervention	T061	C0808232
examined	T033	C0332128
function	T169	C0542341
decrease	T081	C0547047
disappearance	T079	C2746065
PNES	T048	C1142430
ID	T048	C3714756
group	T078	C0441833
Age	T032	C0001779
visit	T058	C1512346
PNES	T048	C1142430
onset	T080	C0332162
younger	T079	C0332239
ID	T048	C3714756
non-ID	T033	C0243095
group	T078	C0441833
PNES	T048	C1142430
ratio	T081	C0456603
visit	T058	C1512346
higher	T080	C0205250
non-ID	T033	C0243095
group	T078	C0441833
group	T078	C0441833
chi square	T081	C1552646
Psychosis	T048	C0033975
ID	T048	C3714756
group	T078	C0441833
chi square	T081	C1552646
cognitive therapy	T061	C0009244
pharmaco-therapeutic	T061	C0013216
similarly	T080	C2348205
distributed	T169	C1704711
groups	T078	C0441833
environmental	T082	C0014406
adjustment	T169	C0456081
introduced	T169	C1292748
ID	T048	C3714756
group	T078	C0441833
compared	T052	C1707455
non-ID	T033	C0243095
group	T078	C0441833
chi square	T081	C1552646
Brief	T079	C1879313
weekly	T079	C0332174
visit service	T058	C1512346
utilized	T169	C0042153
patients	T101	C0030705
ID	T048	C3714756
ID	T048	C3714756
chi square	T081	C1552646
Optimal	T080	C2698651
treatment	T061	C0087111
patient	T101	C0030705
subgroup	T185	C1515021
subject	T078	C1706203
future	T079	C0016884
prospective studies	T062	C0033522
Effect of	T080	C1704420
immunomodulatory regimen	T061	C1963758
cancer prevention	T061	C0281206
case report	T170	C0085973
present	T033	C0150312
case study	T170	C0085973
immunomodulatory regimen	T061	C1963758
cancer prevention	T061	C0281206
reported	T058	C0700287
patient	T101	C0030705
abnormally high	T080	C1299351
level	T080	C0441889
tumor markers	T123	C0041365
carbohydrate antigen-724	T109	C0248054
CA724	T109	C0248054
CA19-9	T109	C0006613
carcinoembryonic antigen	T116	C0007082
CEA	T116	C0007082
without	T080	C0332288
detectable	T201	C3830527
tumor	T191	C0027651
treated with	T061	C0332293
immunomodulatory therapy	T061	C1963758
infusion	T061	C0574032
cytokine-induced autologous killer cells	T025	C2348032
CIKs	T025	C2348032
request	T052	C1272683
patient	T101	C0030705
therapy	T061	C0087111
tumor markers	T123	C0041365
rapidly	T080	C0456962
decreased	T081	C0205216
normal reference level	T081	C0086715
slight	T080	C2937276
fluctuations	T079	C0231241
narrow	T080	C0333164
range	T081	C1514721
frequently	T079	C0332183
patient	T101	C0030705
monitored	T058	C0150369
months	T079	C0439231
present	T033	C0150312
day	T079	C0439228
no abnormality	T033	C3809765
observed	T169	C1441672
results	T033	C0808233
therapy	T061	C0087111
novel	T080	C0205314
effective	T080	C1704419
reliable	T080	C0205556
cancer prevention	T061	C0281206
regimen	T061	C0087111
prevention of malignancies	T061	C0281206
treatment	T061	C0087111
major	T080	C0205164
cancer	T191	C0006826
prophylactic regimen	T061	C0199176
patients	T101	C0030705
high risk of	T033	C0332167
cancer	T191	C0006826
relationships	T080	C0439849
rugby	T056	C0035945
players'	T098	C0679646
tackle	T053	C0018578
training	T065	C0220931
attitudes	T041	C0004271
behaviour	T053	C0004927
match tackle attitudes	T041	C0004271
behaviour	T053	C0004927
tackle	T053	C0018578
rugby	T056	C0035945
technical	T080	C0205556
physical	T169	C0205485
contest	T056	C0040595
players	T098	C0679646
player's	T098	C0679646
tolerate	T054	C0680282
contest	T056	C0040595
tackle	T053	C0018578
prerequisite	T078	C0679209
safe	UnknownType	C0814103
participation	T169	C0679823
success	T054	C0597535
rugby	T056	C0035945
relationship	T080	C0439849
tackle training	T065	C0220931
tackling	T053	C0018578
matches	T056	C0150593
rugby union	T056	C0035945
investigated	T169	C1292732
relationships	T080	C0439849
players'	T098	C0679646
training attitudes	T041	C0004271
behaviour	T053	C0004927
match attitudes	T041	C0004271
behaviour	T053	C0004927
tackling	T053	C0018578
rugby union	T056	C0035945
questionnaire	T170	C0034394
assess	T058	C0184514
attitude	T041	C0004271
behaviours	T053	C0004927
frequency	T080	C1561548
quantity	T081	C1265611
junior	T078	C1708595
players	T098	C0679646
5-point Likert Scale	T170	C0451267
Questionnaires	T170	C0034394
players	T098	C0679646
schools	T073	C0036375
tournament	T056	C0040595
schools	T073	C0036375
analysis	T062	C0936012
Associations	T041	C0004083
training attitudes	T041	C0004271
behaviours	T053	C0004927
tested	T169	C0039593
χ(2) test, Cramer's V and τ-b	T170	C0392366
technique	T169	C0449851
prevent	T080	C2700409
injuries	T037	C0004161
training	T065	C0220931
players	T098	C0679646
moderate	T080	C0205081
ball	T073	C1706910
moderate	T080	C0205081
moderate	T080	C0205081
match play	T056	C0150593
technique	T169	C0449851
improve	T033	C0184511
performance	T052	C1882330
training	T065	C0220931
players	T098	C0679646
ball	T073	C1706910
moderate	T080	C0205081
preventing	T080	C2700409
ball	T073	C1706910
retaining	T169	C0333118
position	T082	C0733755
moderate	T080	C0205081
match play	T056	C0150593
study	T062	C2603343
relationships	T080	C0439849
players	T098	C0679646
training attitudes	T041	C0004271
behaviour	T053	C0004927
match attitudes	T041	C0004271
behaviour	T053	C0004927
tackling	T053	C0018578
rugby union	T056	C0035945
tackle	T053	C0018578
training	T065	C0220931
prevent	T080	C2700409
injury	T037	C0004161
technique	T169	C0449851
prevent	T080	C2700409
injuries	T037	C0004161
associated with	T080	C0332281
behaviours	T053	C0004927
reduce	T080	C0392756
risk of injury	T033	C0582456
matches	T056	C0150593
Role	T077	C1705810
Oxidative Stress	T049	C0242606
Inflammatory	T169	C0333348
Factors	T169	C1521761
Diabetic Kidney Disease	T047	C0011881
Diabetic nephropathy	T047	C0011881
DN	T047	C0011881
serious	T080	C0205404
complication	T046	C0009566
diabetes mellitus	T047	C0011849
prevalence	T081	C0033106
increasing	T169	C0442808
developed countries	T080	C0282613
Diabetic nephropathy	T047	C0011881
common	T081	C0205214
single	T081	C0205171
end-stage renal disease	T047	C0022661
worldwide	T098	C2700280
Oxidative stress	T049	C0242606
inflammation	T046	C0021368
factors	T169	C1521761
hypothesized	T078	C1512571
play a role	T077	C1705810
development	T169	C1527148
late	T079	C0205087
diabetes complications	T047	C0342257
Chronic hyperglycemia	T046	C0342300
increases	T169	C0442805
oxidative stress	T049	C0242606
significantly modifies	T169	C0392747
structure	T082	C0678594
function	T039	C0031843
proteins	T116	C0033684
lipids	T109	C0023779
induces	T169	C0205263
glycoxidation	UnknownType	C0260088
peroxidation	T067	C0178796
hyperglycemia	T047	C0020456
auto-oxidation	T070	C0311405
glucose	T109	C0017725
glycation	T067	C0598528
proteins	T116	C0033684
activation	T052	C1879547
polyol mechanism	T169	C0441712
Overproduction	T057	C0033268
intracellular	T082	C0178719
reactive oxygen species	T123	C0162772
contributes	T052	C1880177
several	T081	C0443302
microvascular	T169	C0443258
macrovascular	T169	C0205245
complications	T046	C0009566
DN	T047	C0011881
reactive oxygen species	T123	C0162772
modulates	T082	C0443264
signaling cascade	T043	C2611812
immune factors	T129	C0021054
increase	T169	C0442805
reactive oxygen species	T123	C0162772
increase	T169	C0442805
production	T057	C0033268
inflammatory	T169	C0333348
cytokines	T116	C0079189
increase	T169	C0442805
inflammatory	T169	C0333348
cytokines	T116	C0079189
stimulate	T070	C1948023
production	T057	C0033268
free radicals	T104	C0016693
studies	T062	C0681814
kidney inflammation	T047	C0027697
serious	T080	C0205404
promoting	T052	C0033414
development	T169	C1527148
progression	T169	C0449258
DN	T047	C0011881
Inflammatory	T169	C0333348
factors	T169	C1521761
activated	T052	C1879547
metabolic	T169	C0311400
biochemical	T169	C0205474
hemodynamic	T042	C0019010
exist	T077	C2987476
diabetic kidney	T047	C0011881
review	T170	C0282443
oxidative stress	T049	C0242606
inflammatory	T169	C0333348
factors	T169	C1521761
DN	T047	C0011881
role	T077	C1705810
immune	T025	C0007634
inflammatory cells	T025	C0440752
inflammatory	T169	C0333348
cytokines	T116	C0079189
stress oxidative	T049	C0242606
factors	T169	C1521761
Cobalt-60 Machines	T074	C0025080
Medical Linear Accelerators	T074	C0023730
Competing Technologies	T090	C0039421
External Beam Radiotherapy	T061	C1517033
Medical linear accelerators	T074	C0023730
linacs	T074	C0023730
cobalt-60 machines	T074	C0025080
technologies	T090	C0039421
external beam radiotherapy	T061	C1517033
comparison	T052	C1707455
technologies	T090	C0039421
infrastructure	T185	C1514880
maintenance	T052	C0024501
dosimetry	T059	C0034603
shielding	T033	C0243095
requirements	T169	C1514873
staffing	T057	C0087023
costs	T081	C0010186
security	T077	C1519222
patient	T101	C0030705
throughput	T081	C2986816
clinical use	T169	C0042153
Infrastructure	T185	C1514880
maintenance	T052	C0024501
demanding	T078	C0699784
linacs	T074	C0023730
complex electric componentry	T073	C3273359
dosimetry	T059	C0034603
higher	T080	C0205250
beam energy	T081	C1442080
modulated	T082	C0443264
dose rate	T081	C1512044
smaller	T080	C0547044
focal spot size	T080	C2348694
easier	T033	C0332219
create	T052	C1706214
optimised	T052	C2698650
treatment	T061	C0087111
linac	T074	C0023730
dose	T081	C0178602
coverage	T169	C1999244
tumour	T191	C0027651
healthy organs	T023	C0178784
risk	T078	C0035647
shielding	T033	C0243095
requirements	T169	C1514873
concrete bunker	T073	C3273359
cobalt-60 machines	T074	C0025080
linacs	T074	C0023730
shielding	T033	C0243095
protection	T033	C1545588
neutrons	T167	C0027946
linacs	T074	C0023730
Staffing levels	T033	C3845726
higher	T080	C0205250
linacs	T074	C0023730
staff training	T065	C0681113
linacs	T074	C0023730
Life cycle costs	T169	C0220812
higher	T080	C0205250
linacs	T074	C0023730
multi-energy linacs	T074	C0023730
Security	T077	C1519222
complex	T080	C0439855
cobalt-60 machines	T074	C0025080
high	T080	C0205250
activity	T052	C0441655
radioactive source	T122	C0182598
Patient	T101	C0030705
throughput	T081	C2986816
affected	T169	C0392760
source	T033	C0449416
decay	T067	C2700592
cobalt-60 machines	T074	C0025080
poor	T080	C0542537
maintenance	T052	C0024501
breakdowns	T066	C0014678
affect	T169	C0392760
patient	T101	C0030705
throughput	T081	C2986816
linacs	T074	C0023730
clinical use	T169	C0042153
complex	T080	C0439855
treatment	T061	C0087111
techniques	T169	C0449851
easier	T033	C0332219
linacs	T074	C0023730
availability of	T169	C0470187
electron beams	T073	C0013840
high	T080	C0205250
energy	T081	C1442080
linacs	T074	C0023730
treatments	T061	C0087111
cobalt-60 machines	T074	C0025080
linacs	T074	C0023730
radiotherapy	T061	C1522449
low-	T033	C1331016
middle-income	T080	C0870890
countries	T083	C0454664
radiotherapy department	T093	C0587444
combination	T080	C0205195
technologies	T090	C0039421
orthovoltage X-ray units	T092	C1704729
option	T169	C1518601
Local	T082	C0205276
needs	T080	C0027552
conditions	T080	C0348080
resources	T078	C0035201
decision	T041	C0679006
technology	T090	C0039421
characteristics	T080	C1521970
teletherapy	T061	C0419095
goal	T170	C0018017
sustainability	T169	C0205245
radiotherapy service	T093	C0587559
lifetime	T079	C4071830
equipment	T073	C0014672
Design	T052	C1707689
synthesis	T052	C1883254
molecular docking	T170	C3494274
anti-Proteus mirabilis	T195	C0279516
urease	T116	C0041945
inhibition	T039	C1524081
fluoroquinolone carboxylic acid derivatives	T121	C1254351
hydroxamic acid	T109	C0020314
hydrazide	T109	C0682951
amide derivatives	T109	C0002482
ciprofloxacin	T109	C0008809
analogues	T104	C0243071
levofloxacin	T109	C0282386
spectroscopic techniques	T169	C0449851
compounds	T121	C1254351
activity	T040	C2248397
urease	T116	C0041945
bacteria	T007	C0004611
Proteus mirabilis	T007	C0033701
urease	T116	C0041945
inhibitory activity	T040	C2248397
indophenol method	T059	C1318795
tested	T170	C0392366
compounds	T121	C1254351
activity	T040	C2248397
acetohydroxamic acid	T109	C0050451
AHA	T109	C0050451
ciprofloxacin hydrazide derivative 3a	T121	C1254351
levofloxacin hydroxamic acid 7	T121	C1254351
activity	T040	C2248397
IC50	T081	C0600495
Molecular docking study	T170	C3494274
binding ability	T044	C1167622
tested	T170	C0392366
compounds	T121	C1254351
active site	T169	C0205681
urease	T116	C0041945
Interobserver	T170	C0870736
Intraobserver	T096	C0870992
Reliability	T081	C2347947
Clinical Assessments	T033	C3845884
Knee Osteoarthritis	T047	C0409959
Clinical examination	T033	C1456356
knee	T023	C0022742
measurement error	T081	C0681899
interobserver	T170	C0870736
intraobserver	T096	C0870992
reliability	T081	C2347947
patients	T101	C0030705
knee osteoarthritis	T047	C0409959
OA	T047	C0409959
subjects	T096	C0681850
symptomatic	T169	C0231220
knee OA	T047	C0409959
participants	T098	C0679646
open-label clinical trial	T062	C1709323
intraarticular steroid therapy	T061	C0585373
standardization	T062	C0038136
clinical test procedures	T059	C0022885
clinicians	T097	C0871685
assessed	T058	C0220825
subjects	T096	C0681850
visit	T058	C1512346
clinician	T097	C0871685
assessed	T058	C0220825
subjects	T096	C0681850
interval period	T079	C1272706
steroid	T061	C0149783
intervention	T061	C0184661
Clinical examination	T033	C1456356
included	T169	C0332257
assessment	T058	C0220825
bony enlargement	UnknownType	C0221610
crepitus	T046	C0277964
quadriceps wasting	T033	C0555751
knee effusion	T033	C0343166
joint-line	T029	C0446569
anserine	T023	C0224834
tenderness	T184	C0240094
knee range of movement	T033	C0576094
ROM	T033	C0576094
Intraclass correlation coefficients	T081	C0392762
ICC	T081	C0392762
estimated kappa	T081	C0392762
κ	T081	C0392762
weighted kappa	T081	C0392762
κω	T081	C0392762
Bland-Altman plots	T081	C0392762
interobserver	T170	C0870736
intraobserver	T096	C0870992
levels	T080	C0441889
agreement	T054	C0680240
Landis and Koch criteria	T081	C0871425
interobserver κ scores	T080	C0237855
moderate	T080	C0205081
patellofemoral joint	T030	C0447801
κ	T081	C0392762
anserine	T023	C0224834
tenderness	T184	C0240094
κ	T081	C0392762
good	T080	C0205170
bony enlargement	UnknownType	C0221610
κ	T081	C0392762
quadriceps wasting	T033	C0555751
κ	T081	C0392762
crepitus	T046	C0277964
κ	T081	C0392762
medial	T082	C0205098
tibiofemoral joint	T030	C0447795
tenderness	T184	C0240094
κ	T081	C0392762
effusion	T033	C0343166
ballottement	T184	C0231756
κ	T081	C0392762
bulge sign	T060	C3696902
κω	T081	C0392762
excellent	T080	C1548784
lateral	T082	C0205093
tibiofemoral joint	T030	C0447795
tenderness	T184	C0240094
κ	T081	C0392762
flexion	T042	C0231452
ICC	T081	C0392762
extension	T169	C0231448
ICC	T081	C0392762
ROM	T033	C0576094
Intraobserver κ scores	T080	C0237855
moderate	T080	C0205081
lateral	T082	C0205093
tibiofemoral joint	T030	C0447795
tenderness	T184	C0234233
κ	T081	C0392762
κ	T081	C0392762
effusion	T033	C0343166
ballottement test	T184	C0231756
κ	T081	C0392762
patellofemoral joint	T030	C0447801
κ	T081	C0392762
medial	T082	C0205098
tibiofemoral joint	T030	C0447795
κ	T081	C0392762
anserine	T023	C0224834
tenderness	T184	C0234233
κ	T081	C0392762
excellent	T080	C1548784
effusion	T033	C0343166
bulge sign	T060	C3696902
κω	T081	C0392762
bony enlargement	UnknownType	C0221610
κ	T081	C0392762
quadriceps wasting	T033	C0555751
κ	T081	C0392762
flexion	T042	C0231452
ICC	T081	C0392762
extension	T169	C0231448
ICC	T081	C0392762
ROM	T033	C0576094
individuals	T098	C0237401
symptomatic	T169	C0231220
knee OA	T047	C0409959
reliability	T081	C2347947
clinical examination	T033	C1456356
knee	T023	C0022742
clinical signs	T033	C3540840
knee OA	T047	C0409959
benefits	T081	C0814225
targeted	T169	C1521840
drug delivery	T074	C0085104
nanocarriers	T073	C1450053
partico/pharmacokinetic framework	T169	C0031328
in vivo	T082	C1515655
kinetic framework	T169	C0031328
analyze	T062	C0936012
quantitative	T081	C0392762
nanocarriers	T073	C1450053
deliver drugs	T074	C0085104
anticancer agents	T109	C0003392
compared	T052	C1707455
administering	T061	C1533734
drugs	T121	C0013227
framework	T078	C0178566
levels	T080	C0441889
kinetics	T039	C0031327
particokinetics	T070	C0022702
associated with	T080	C0332281
deposition	T169	C0333562
nanocarriers	T073	C1450053
tissues	T024	C0040300
associated with	T080	C0332281
drug effect	T169	C0728866
toxicity	T037	C0600688
residence	T082	C0237096
tissues	T024	C0040300
elimination	T040	C0683141
nanocarriers	T073	C1450053
body	T016	C0242821
release pattern	T033	C0231360
free drug	T081	C0678752
nanocarriers	T073	C1450053
pharmacokinetics	T039	C0031327
free drug	T081	C0678752
deposition	T169	C0333562
elimination processes	T040	C0683141
target	T169	C1521840
toxicity	T037	C0600688
associated	T080	C0439849
tissues	T024	C0040300
total body clearance	T034	C0087101
drug targeting index	T081	C1637833
DTI	T081	C1637833
quantitate	T081	C0392762
nanocarrier	T073	C1450053
drug delivery	T074	C0085104
effects	T080	C1280500
deposition	T169	C0333562
nanoparticles	T073	C1450054
target	T169	C1521840
tissues	T024	C0040300
tissues	T024	C0040300
associated with	T080	C0332281
drug toxicity	T037	C0013221
compared	T052	C1707455
drug	T121	C0013227
administered	T061	C1533734
methods	T170	C0025663
calculating	T052	C1441506
DTI	T081	C1637833
particokinetic	T070	C0022702
pharmacokinetic	T169	C0031328
drug release rate	T081	C1521828
result	T169	C1274040
developing	T091	C0872152
nanocarrier	T073	C1450053
formulations	T077	C1705957
populations	T098	C1257890
individuals	T098	C0237401
Recombinant	T001	C1514798
MHC Tetramers	T028	C0024518
Isolation	T061	C0204727
Virus	T005	C0042776
Specific	T080	C0205369
CD8(+) Cells	T025	C0242629
Healthy Donors	T080	C3898902
Potential	T080	C3245505
Cell Therapy	T061	C0302189
Posttransplant Cytomegalovirus Infection	T047	C0010823
Patients	T101	C0030705
allogeneic	T080	C1515895
hematopoietic stem cell transplantation	T061	C0472699
cytomegalovirus reactivation	T047	C1142560
T-cell immunity	T040	C1817907
acute inflammatory reaction	T033	C0333361
damage of internal organs	T037	C0332675
Transfusion	T061	C0086573
virus-specific	T080	C0205369
donor T-lymphocytes	T025	C0039194
highly toxic	T080	C1407029
ineffective	T078	C3242229
antiviral therapy	T061	C0280274
Potentially	T080	C3245505
cell therapy	T061	C0302189
transfusion	T061	C0086573
cytotoxic T-lymphocytes	T025	C0039195
specific	T080	C0205369
viral antigens	T129	C0003342
isolation	T061	C0204727
donor's blood circulation	T039	C0005775
in vitro expansion	T080	C1533691
Specific	T080	C0205369
T-cells	T025	C0039194
potentially	T080	C3245505
alloreactive lymphocytes	T025	C0024264
recombinant	T001	C1514798
major histocompatibility complex	T028	C0024518
MHC	T028	C0024518
multimers	T104	C1979934
synthetic viral peptides	T116	C0597551
transfusion	T061	C0086573
virus	T005	C0042776
specific	T080	C0205369
T-cells	T025	C0039194
patients	T101	C0030705
in vitro expansion	T080	C1533691
cells	T025	C0007634
hematopoietic	T169	C0229601
stem cell donors	T080	C3898902
transplant recipients	T101	C0376387
National Research Center for Hematology	T093	C1708333
HLA-A*02 allele	T028	C0555908
Russian	T098	C0337816
donors	T080	C3898902
immune response	T042	C0301872
cytomegalovirus	T005	C0010825
CMV	T005	C0010825
recombinant	T001	C1514798
HLA-A*02	T028	C0555908
multimers	T104	C1979934
immunodominant	T080	C0205556
cytomegalovirus peptide	T116	C0030956
NLV	T116	C0030956
healthy donors	T080	C3898902
T-cell immunity	T040	C1817907
antigen	T129	C0003320
transplantation	T061	C0040732
patients	T101	C0030705
specific	T080	C0205369
T-lymphocytes	T025	C0039194
donor cells	T025	C0007634
immune phenotype	T032	C0031437
memory cells	T025	C0682639
activated	T043	C2259058
proliferate	T043	C0596290
specific	T080	C0205369
antigen	T129	C0003320
Donor lymphocytes	T033	C1395724
enriched	UnknownType	C0681540
purity	T081	C1882508
magnetic separation	T059	C0599662
recombinant	T001	C1514798
MHC	T028	C0024518
multimers	T104	C1979934
activated	UnknownType	C0678666
cocultivation	T059	C0282547
antigen	T129	C0003320
cells	T025	C0007634
HLA	T116	C0019721
incompatible donors	T098	C0013018
specific	T080	C0205369
antigen	T129	C0003320
study	T062	C2603343
immune response	T042	C0301872
CMV	T005	C0010825
healthy donors	T080	C3898902
HLA-A*02 allele	T028	C0555908
Russian population	T098	C1257890
virus-specific	T080	C0205369
cells	T025	C0007634
HLA-A*02-NLV	T028	C0555908
multimers	T104	C1979934
transfusion	T061	C1879316
cells	T025	C0007634
patients	T101	C0030705
CMV	T005	C0010825
allogeneic	T080	C1515895
immune response	T042	C0301872
Outcomes	T080	C0085415
chest wall resections	T061	C0087111
pediatric	T080	C1521725
sarcoma	T191	C1261473
patients	T101	C0030705
Chest wall tumors	T191	C1290309
pediatric	T080	C1521725
patients	T101	C0030705
study	T062	C2603343
outcomes	T080	C0085415
pediatric	T080	C1521725
patients	T101	C0030705
chest wall resections	T061	C0087111
sarcomas	T191	C1261473
retrospective review	T062	C0035363
patients	T101	C0030705
chest wall resections	T061	C0087111
sarcoma	T191	C1261473
University of Texas MD Anderson Cancer Center	T093	C1519805
patients	T101	C0030705
Ewing's sarcoma	T191	C0553580
osteosarcoma	T191	C0029463
sarcomas	T191	C1261473
synovial sarcoma	T191	C0039101
chondrosarcoma	T191	C0008479
rhabdomyosarcoma	T191	C0035412
Gore-Tex	T109	C0018088
Marlex™ mesh	T122	C0005479
methyl methacrylate sandwich	T122	C0005479
patients	T101	C0030705
children	T100	C0008059
not require reconstruction	T033	C3840851
patients	T101	C0030705
normal	T080	C0205307
activity	T052	C0441655
occasional discomfort	T184	C0231218
pain impairing function	T046	C0684336
medication	T121	C0013227
physical therapy	T061	C0949766
impairment	T046	C0684336
surgery	T091	C0038894
children	T100	C0008059
scoliosis	T190	C0036439
patients	T101	C0030705
posterior	T082	C0205095
rib tumors	T191	C1290243
Median overall survival	T081	C4086681
entire cohort	T098	C0599755
months	T079	C0439231
Histology	T091	C0019638
location	T082	C0450429
tumor	T191	C0027651
ribs	T023	C0035561
surgical margins	T023	C0229985
significantly associated with	T080	C0332281
overall survival	T081	C4086681
Tumors	T191	C0027651
posterior	T082	C0205095
ribs	T023	C0035561
death	T040	C0011065
Scoliosis	T190	C0036439
posterior	T082	C0205095
rib resections	T061	C0185827
Histology	T091	C0019638
location	T082	C0450429
tumor	T191	C0027651
surgical margins	T023	C0229985
survival	T052	C0038952
Treatment Study	T062	C3161471
Tetrabromobisphenol A	T109	C0076220
activates	T052	C1879547
hepatic	T023	C0023884
interferon pathway	T044	C1512834
rats	T015	C0034721
Tetrabromobisphenol A	T109	C0076220
TBBPA	T109	C0076220
flame retardant	T120	C0016198
printed circuit boards	T073	C1707396
paper	T073	C0030351
textiles	T073	C0039717
two-year	T079	C0439234
study	T062	C2603343
TBBPA	T109	C0076220
uterine tumors	T191	C0042138
female	T032	C0086287
Wistar-Han rats	T015	C2700261
liver	T191	C0023903
colon tumors	T191	C0009375
B6C3F1 mice	T015	C2698297
gene	T028	C0017337
pathway	T044	C1704259
cancer	T191	C0027651
female	T032	C0086287
Wistar Han rats	T015	C2700261
TBBPA	T109	C0076220
oral gavage	T169	C2698653
corn oil	T109	C0010029
week	T079	C0439230
weeks	T079	C0439230
TBBPA	T109	C0076220
exposure	T080	C0332157
body weights	T032	C0005910
liver	T033	C0577053
uterus lesions	T033	C0567079
liver	T023	C0736253
uterine organ	T023	C0736936
weights	T081	C0043100
controls	T096	C0009932
dose	T081	C0178602
animals	T008	C0003062
analyzed	T062	C0936012
Analysis	T062	C0936012
hepatic	T023	C0023884
uterine	T023	C0042149
transcriptomes	T086	C3178810
TBBPA	T109	C0076220
liver	T023	C0023884
transcripts	T114	C1519595
genes	T028	C0017337
expressed	T045	C0017262
controls	T096	C0009932
Pathway analysis	T170	C0868995
activation	T052	C1879547
interferon	T116	C0021747
IFN	T116	C0021747
metabolic networks	T044	C1706062
TBBPA	T109	C0076220
uterus	T023	C0042149
Activation	T052	C1879547
interferon pathway	T044	C1512834
liver	T023	C0023884
13-weeks	T079	C0439230
TBBPA	T109	C0076220
exposure	T080	C0332157
TBBPA	T109	C0076220
exposure	T080	C0332157
immunomodulatory	T061	C1963758
changes	T169	C0392747
carcinogenic processes	T191	C0596263
Famous faces	T041	C0870537
voices	T041	C0920674
Differential	T080	C1705242
profiles	T082	C0449774
early	T079	C1279919
right	T023	C0228232
left	T023	C0228233
semantic dementia	T048	C0338462
Alzheimer's disease	T047	C0002395
Famous face	T041	C0870537
voice recognition	T041	C0920674
impaired	T169	C0221099
semantic dementia	T048	C0338462
SD	T048	C0338462
Alzheimer's Disease	T047	C0002395
AD	T047	C0002395
severely	T080	C0205082
AD	T047	C0002395
perceptual	T041	C0030971
impairment	T169	C0221099
face	T041	C0870537
voice	T041	C0920674
processing	T041	C0025361
performance	T052	C1882330
complex	T080	C0439855
semantic	T078	C0036612
tasks	T052	C0441655
SD	T048	C0338462
face	T041	C0870537
voice recognition	T041	C0920674
disorders	T047	C0012634
prevalence	T081	C0220900
atrophy	T046	C0333641
right temporal lobe	T023	C0228232
RTL	T023	C0228232
study	T062	C2603343
investigate	T169	C1292732
famous faces	T041	C0870537
voices recognition	T041	C0920674
SD	T048	C0338462
AD	T047	C0002395
diseases	T047	C0012634
differential	T080	C1705242
pattern	T082	C0449774
impairment	T169	C0221099
disruption	T169	C0332453
cognitive	T041	C0009240
mechanisms	T169	C0441712
face	T041	C0870537
voice recognition	T041	C0920674
disorders	T047	C0012634
patients	T101	C0030705
atrophy	T046	C0333641
RTL	T023	C0228232
potential	T080	C3245505
influence	T077	C4054723
primary	T080	C0205225
perceptual	T041	C0030971
problems	T033	C0033213
face	T041	C0870537
voice recognition	T041	C0920674
patients	T101	C0030705
early	T079	C1279919
SD	T048	C0338462
AD	T047	C0002395
administered	T169	C1521801
tests	T058	C2081632
face	T041	C0870537
voice	T041	C0920674
perception	T041	C0030971
SD	T048	C0338462
prevalence	T081	C0220900
right	T023	C0228232
prevalence	T081	C0220900
left temporal	T023	C0228233
atrophy	T046	C0333641
patients	T101	C0030705
visual	T169	C0234621
auditory	T169	C0439825
perceptual	T041	C0030971
impairment	T169	C0221099
administered	T169	C1521801
experimental	T080	C1517586
battery	T170	C1555716
famous face	T041	C0870537
voice recognition	T041	C0920674
naming	T170	C0392366
SD	T048	C0338462
patients	T101	C0030705
cerebral	T023	C0006104
PET imaging	T060	C0032743
right	T023	C0228232
left	T023	C0228233
SD	T048	C0338462
modality	T078	C0695347
decrease	T081	C0547047
FDG uptake	T109	C0046056
right	T023	C0228232
left temporal lobe	T023	C0228233
Correlation	T080	C1707520
PET imaging	T060	C0032743
famous face	T041	C0870537
voice recognition	T041	C0920674
Results	T169	C1274040
differential	T080	C1705242
performance	T052	C1882330
profile	T082	C0449774
diseases	T047	C0012634
AD	T047	C0002395
patients	T101	C0030705
impaired	T169	C0221099
naming tests	T170	C0392366
recognition	T041	C0524637
SD	T048	C0338462
patients	T101	C0030705
impaired	T169	C0221099
naming	T170	C0392366
recognition of famous faces	T041	C0870537
voices	T041	C0920674
face	T041	C0870537
voice recognition	T041	C0920674
disorders	T047	C0012634
SD	T048	C0338462
patients	T101	C0030705
RTL	T023	C0228232
atrophy	T046	C0333641
conceptual	T077	C1254372
impairment	T169	C0221099
Pyramids and Palm Trees test	T170	C0451399
verbal	T080	C0439824
modality	T078	C0695347
SD	T048	C0338462
patients	T101	C0030705
PET	T060	C0032743
correlation	T080	C1707520
FDG uptake	T109	C0046056
face-to-name	T080	C1708943
voice-to-name matching	T080	C1708943
data	T078	C1511726
right	T023	C0228232
left temporal lobe	T023	C0228233
data	T078	C1511726
hypothesis	T078	C1512571
cognitive	T041	C0009240
impairment	T169	C0221099
face	T041	C0870537
voice recognition	T041	C0920674
dementias	T048	C0338462
pattern	T082	C0449774
impairment	T169	C0221099
SD	T048	C0338462
semantic	T078	C0036612
representations	T052	C1882932
semantic	T078	C0036612
control	T169	C2587213
impaired	T169	C0221099
naming	T170	C0392366
preserved recognition	T041	C0524637
AD	T047	C0002395
correlation	T080	C1707520
face	T041	C0870537
voice recognition	T041	C0920674
disorders	T047	C0012634
RTL	T023	C0228232
damage	T037	C0178314
hypothesis	T078	C1512571
RTL	T023	C0228232
person	T098	C0027361
knowledge	T170	C0376554
non-verbal representations	T041	C0681317
Dry skin	T184	C0151908
related	T080	C0439849
recovery rate	T081	C1521828
skin temperature	T032	C0037294
cold	T070	C0009264
stress	T046	C0449430
blood flow	T039	C0232338
Cutaneous	T082	C0221912
blood flow	T039	C0232338
important	T080	C3898777
thermoregulation	T042	C0232416
oxygen supply	T201	C0429622
nutritional support	T061	C0242739
maintain	T052	C0024501
skin	T022	C1123023
evidence	T078	C3887511
blood flow	T039	C0232338
skin physiology	T042	C0037289
surveys	T170	C0038951
healthy volunteers	T098	C1708335
relationship	T080	C0439849
dry skin	T184	C0151908
cutaneous	T082	C0221912
vascular function	T201	C0232337
stratum corneum	T024	C0221921
transepidermal water loss	T033	C0232421
visual dryness score	T080	C1512080
investigated	T169	C1292732
dry skin	T184	C0151908
parameters	T033	C0449381
Cutaneous	T082	C0221912
blood flow	T039	C0232338
resting state	T033	C0679218
recovery rate	T081	C1521828
RR	T081	C1521828
skin temperature	T032	C0037294
hand	T023	C0018563
cold-stress test	T059	C0022885
responsiveness	T169	C0205342
facial skin	T023	C0222084
blood flow	T039	C0232338
local cooling	T061	C0419138
examined	T033	C0332128
indices	T170	C0918012
cutaneous	T082	C0221912
vascular functions	T201	C0232337
relationships	T080	C0439849
dry skin	T184	C0151908
parameters	T033	C0449381
cutaneous	T082	C0221912
vascular functions	T201	C0232337
assessed	T052	C1516048
RR	T081	C1521828
correlated	T080	C1707520
visual dryness score	T080	C1512080
skin	T022	C1123023
leg	T023	C1140621
correlated	T080	C1707520
stratum corneum	T024	C0221921
correlation	T080	C1707520
resting state	T033	C0679218
blood flow	T039	C0232338
dry skin	T184	C0151908
parameters	T033	C0449381
observed	T169	C1441672
face	T029	C0015450
body	T016	C0242821
deterioration	T067	C0868945
skin dryness	T184	C0151908
summer	T079	C0241301
winter	T079	C0241737
significant	T078	C0750502
RR	T081	C1521828
RR	T081	C1521828
correlated	T080	C1707520
responsiveness	T169	C0205342
facial skin	T023	C0222084
blood flow	T039	C0232338
local cooling	T061	C0419138
indicating	T033	C1444656
RR	T081	C1521828
dry skin	T184	C0151908
RR	T081	C1521828
blood flow	T039	C0232338
resting state	T033	C0679218
dry skin	T184	C0151908
homeostasis	T038	C0019868
seasonal	T079	C0036496
environmental changes	T033	C4060636
Molar loss	T020	C0080233
powder diet	T061	C0301569
memory deficit	T048	C0233794
mRNA expression	T045	C1515670
brain-derived neurotrophic factor	T116	C0107103
hippocampus	T023	C0019564
adult	T100	C0001675
mice	T015	C0025929
tooth loss	T020	C0080233
risk factor	T033	C0035648
Alzheimer's disease	T047	C0002395
soft diet	T061	C0301569
feeding	T052	C2987508
memory impairment	T048	C0233794
brain-derived neurotrophic factor	T116	C0107103
BDNF	T116	C0107103
associated with	T080	C0332281
tooth loss	T020	C0080233
soft diet	T061	C0301569
animal model	T008	C0599779
BDNF	T028	C1332408
expression	T045	C0017262
patients	T101	C0030705
Alzheimer's disease	T047	C0002395
effect of	T080	C1704420
tooth loss	T020	C0080233
soft diet	T061	C0301569
brain function	T042	C0678908
effect of	T080	C1704420
molar loss	T020	C0080233
powder diet	T061	C0301569
memory ability	T041	C0025260
expression	T045	C0017262
BDNF mRNA	T028	C1332408
hippocampus	T023	C0019564
adult	T100	C0001675
C57BL/6J mice	T015	C0025929
C57BL/6J mice	T015	C0025929
randomly	T062	C0034656
upper molar teeth	T023	C0927248
Solid diet	T168	C0012155
feeding	T052	C2987508
Extracted	T061	C0040440
upper molar teeth	T023	C0927248
Solid diet	T168	C0012155
feeding	T052	C2987508
upper molar teeth	T023	C0927248
Powder diet	T061	C0301569
feeding	T052	C2987508
upper molar teeth	T023	C0927248
Powder diet	T061	C0301569
feeding	T052	C2987508
analyze	T062	C0936012
memory ability	T041	C0025260
passive avoidance	T041	C0871047
BDNF-related mRNA	T028	C1332408
hippocampus	T023	C0019564
analyzed	T062	C0936012
real-time polymerase chain reaction	T063	C1709846
RT-PCR	T063	C1709846
memory test	T059	C0022885
brains	T023	C0006104
analyze	T062	C0936012
no differences	T033	C3842396
memory function	T041	C0025260
BDNF mRNA	T028	C1332408
memory impairment	T048	C0233794
BDNF mRNA	T028	C1332408
powder diet	T061	C0301569
no effect	T080	C1301751
memory function	T041	C0025260
BDNF mRNA	T028	C1332408
effect of	T080	C1704420
molar loss	T020	C0080233
powder diet	T061	C0301569
memory function	T041	C0025260
BDNF mRNA	T028	C1332408
molar loss	T020	C0080233
long-term effect	T067	C0023983
memory ability	T041	C0025260
powder diet	T061	C0301569
species	T185	C1705920
Fiorianteon Olmi	T204	C0684063
Hymenoptera	T204	C0020415
Dryinidae	T204	C1191214
Afrotropical region	T083	C0017446
Fiorianteon sulcatumsp	T204	C0684063
Fianarantsoa Province	T083	C0017446
Madagascar	T083	C0024443
species	T185	C1705920
Fiorianteon	T204	C0684063
Afrotropical region	T083	C0017446
genus	T185	C1708235
Fiorianteon	T204	C0684063
genus	T185	C1708235
Conganteon	T204	C0684063
distal	T082	C0205108
stigmal vein	T023	C0042449
long	T080	C0205166
shorter	T033	C0424641
proximal	T082	C0205107
stigmal vein	T023	C0042449
proximal	T082	C0205107
vein	T023	C0042449
Conganteon	T204	C0684063
The Daniel K. Inouye College of Pharmacy Scripts	T170	C0871893
Poha Berry	T168	C0016767
Physalis peruviana	T002	C0331245
Potential	T080	C3245505
Anti-inflammatory	T080	C1515999
Cancer Prevention	T061	C0281206
Activities	T052	C0441655
The Daniel K. Inouye College of Pharmacy	T073	C0036381
historic event	T051	C0441471
Spring	T079	C0241232
graduated	T098	C0588053
students	T098	C0038492
Pacific region	T083	C0017446
PhD	T170	C1512022
pharmaceutical sciences	T091	C0031336
University of Hawai'i	T073	C0041740
Hilo	T083	C0017446
college	T073	C0036381
PhD	T170	C1512022
programs	T169	C3484370
disciplines	T090	C1518533
Cancer Biology	T091	C1516164
Medicinal Chemistry	T091	C0008003
Pharmaceutics	T062	C4277728
Pharmacognosy	T091	C0031326
Pharmacology	T091	C0031330
Pharmacognosy	T091	C0031326
dissertations	T073	C0376645
plant-derived	T002	C0032098
natural products	T123	C1566558
potential	T080	C3245505
anti-inflammatory	T080	C1515999
cancer	T191	C0006826
chemopreventive	T080	C3273128
activities	T052	C0441655
Physalis peruviana	T002	C0331245
Pp	T002	C0331245
South America	T083	C0037713
naturalized	T169	C0205296
Island of Hawai'i	T083	C0017446
edible	T168	C0032099
fruits	T168	C0016767
cape gooseberry	T002	C0331245
poha	T002	C0331245
Hawai'i	T083	C0017446
withanolides	T109	C1955897
physaperuvin G	T121	C1254351
physaperuvins I-J	T121	C1254351
withanolides	T109	C1955897
4β-hydroxywithanolide E	T121	C1254351
withaperuvin C	T121	C1254351
physalactone	T121	C1254351
coagulin	T121	C1254351
isolated	T169	C0205409
aerial parts	T002	C1136056
P. peruviana	T002	C0331245
compounds	T103	C1706082
phyperunolide F	T121	C1254351
withanolide S	T121	C1254351
isolated	T169	C0205409
poha berry fruits	T168	C0016767
structures	T082	C0678594
absolute stereochemistry	T082	C2350023
poha	T002	C0331245
spectroscopy methods	T169	C2984732
Nuclear Magnetic Resonance (NMR) spectroscopy	T060	C0877853
X-ray diffraction	T059	C0043301
mass spectrometry	T059	C0037813
analyses	T062	C0936012
isolated	T169	C0205409
poha	T002	C0331245
compounds	T103	C1706082
aerial parts	T002	C1136056
fruits	T168	C0016767
anti-inflammatory activity	T080	C1515999
lipopolysaccharide	T109	C0023810
LPS	T109	C0023810
murine	T015	C0026809
macrophage RAW 264.7 cells	T025	C4042840
tumor necrosis factor alpha	T116	C0041368
TNF-α	T116	C0041368
nuclear factor-kappa B	T116	C0079904
NF-κB	T116	C0079904
human embryonic kidney cells 293	T025	C2936239
isolated	T169	C0205409
natural compounds	T123	C1566558
activity	T169	C0205177
assays	T059	C0005507
models	T170	C3161035
colon cancer	T191	C0007102
4β-hydroxywithanolide E	T121	C1254351
4HWE	T121	C1254351
inhibited	T080	C0311403
growth	T040	C0018270
colon cancer	T191	C0007102
monolayer	T059	C0007585
spheroid	T025	C0282501
cultures	T059	C0007585
compound	T103	C1706082
induced	T169	C0205263
cell cycle arrest	T043	C1155873
low concentrations	T081	C1446561
apoptosis	T043	C0162638
higher concentrations	T081	C1446561
data	T078	C1511726
ingestion	T038	C0232478
poha berries	T168	C0016767
colon cancer	T191	C0007102
poha	T168	C0016452
isolates compounds	T103	C1706082
growth inhibitory effects	T039	C1512280
U251MG glioblastoma	T191	C0017636
MDA-MB-231 breast cancer cells	T050	C3898556
signal transducer and activation of transcription 3 (STAT3)	T116	C0253050
NIH-3T3 mouse fibroblasts	T025	C1257739
provisional patents	T170	C0030650
University of Hawai'i Office of Technology Transfer and Economic Development	T073	C0041740
Air Pollutant	T131	C0001869
Exposure	T080	C0332157
Delivery	T061	C0011209
Placental Abruption	T046	C0000832
Japan	T083	C0022341
Placental abruption	T046	C0000832
emergency obstetric complication	T046	C0178292
etiology	T169	C1314792
abruption	T046	C0000832
acute	T079	C0205178
stimuli	T067	C0234402
ischemia	T046	C0022116
inflammation	T046	C0021368
associated with	T080	C0332281
rupture of the decidual artery	T047	C0155760
placental separation	T042	C0233170
Ischemia	T046	C0022116
inflammation	T046	C0021368
acute	T079	C0205178
biologic	T080	C0205460
effects	T080	C1280500
air pollution	T069	C0001873
case-crossover design	T062	C4288565
hypothesis	T078	C1512571
short-term	T079	C0443303
increase	T169	C0442805
exposure	T080	C0332157
air pollutants	T131	C0001869
potential	T080	C3245505
trigger	T201	C0032930
placental abruption	T046	C0000832
data	T078	C1511726
western Japan	T083	C0017446
Kyushu-Okinawa Districts	T083	C0017446
Japan Perinatal Registry Network database	T170	C0242356
singleton	T099	C1313913
pregnant women	T098	C0033011
placental abruption	T046	C0000832
daily	T079	C0332173
concentrations	T081	C1265611
air pollutants	T131	C0001869
nitrogen dioxide	T131	C0028160
NO2	T131	C0028160
suspended particulate matter	T131	C1510837
ozone	T103	C0030106
sulfur dioxide	T131	C0038777
SO2	T131	C0038777
monitoring station	T073	C1883167
delivery	T061	C0011209
hospital	T073	C0019994
woman	T098	C0043210
information	T078	C1533716
onset day	T079	C0449244
abruption	T046	C0000832
case	T169	C0868928
day	T079	C0439228
day	T079	C0439228
delivery	T061	C0011209
Exposure	T080	C0332157
NO2	T131	C0028160
associated with	T080	C0332281
placental abruption	T046	C0000832
temperature	T081	C0039476
odds ratio	T081	C0028873
increase	T169	C0442805
confidence interval	T081	C0009667
association	T080	C0439849
participants	T098	C0679646
delivered	T061	C0011209
emergency cesarean	T061	C0558380
delivered	T061	C0011209
35 weeks of gestation	T079	C0233042
no association	T033	C1513916
suspended particulate matter	T131	C1510837
ozone	T103	C0030106
SO2	T131	C0038777
association	T080	C0439849
NO2	T131	C0028160
exposure	T080	C0332157
days	T079	C0439228
day	T079	C0439228
delivery	T061	C0011209
placental abruption	T046	C0000832
pregnant Japanese women	T098	C0033011
Infusion Therapy	T061	C4316303
Standards	T081	C0034925
Practice	T041	C0237607
Infusion Nurses Society	T093	C1708333
publishes	T057	C0034037
evidence-based practice	T169	C1510541
standards	T081	C0034925
article	T170	C1706852
process	T067	C1522240
used	T169	C1524063
standards	T081	C0034925
development	T169	C1527148
format	T170	C1301627
standards	T081	C0034925
provides	T052	C1999230
summary	T170	C1706244
selected	T052	C1707391
standards	T081	C0034925
applied	T169	C4048755
home care	T058	C0019855
Standards	T081	C0034925
important	T080	C3898777
document	T170	C1301746
available	T169	C0470187
every	T080	C1948061
home care	T058	C0019855
organization	T093	C1708333
provides	T052	C1999230
home infusion therapy	T061	C0242945
Datasets	T170	C0150098
validation	T062	C1519941
in vivo	T082	C1515655
siRNA	T114	C1099354
silencing	T045	C0598496
CD40	T028	C1539081
detection	T061	C1511790
markers	T045	C0017393
atherosclerosis	T047	C0003850
progression	T046	C0242656
ApoE	T028	C1412481
deficient	T169	C0011155
mice	T015	C0025929
Data	T078	C1511726
Data	T078	C1511726
in vivo	T082	C1515655
silencing	T045	C0598496
CD40	T028	C1539081
progression	T046	C0242656
experimental	T062	C0681814
atherogenesis	T046	C1563937
NFκB	T116	C0079904
miR-125b	T114	C2352284
potential	T080	C3245505
mediators	T116	C1363844
pathogenesis	T046	C0699748
atherosclerosis	T047	C0003850
M. Hueso	T170	C1547383
L. De Ramon	T170	C1547383
E. Navarro	T170	C1547383
E. Ripoll	T170	C1547383
J.M. Cruzado	T170	C1547383
J.M. Grinyo	T170	C1547383
J. Torras	T170	C1547383
validation	T062	C1519941
silencing	T045	C0598496
CD40	T028	C1539081
expression	T045	C0017262
siRNA	T114	C1099354
ApoE(-/-)	T028	C1412481
mouse	T015	C0025929
aortas	T023	C0003483
splenic	T023	C0037993
lymphocytic subpopulations	T185	C0079720
infiltration	T046	C0332448
aortic intima	T023	C0226009
F4/80(+)	T025	C0007634
galectin-3(+) macrophages	T025	C0024432
NF-κB(+) cells	T025	C0007634
Gene Ontology	T170	C1138831
TLDA analysis	T062	C0936012
detection	T061	C1511790
potential	T080	C3245505
mediators	T116	C1363844
atherosclerosis	T047	C0003850
progression	T046	C0242656
genes	T028	C0017337
expression	T045	C0017262
increased	T081	C0205217
atherosclerosis	T047	C0003850
progression	T046	C0242656
downregulated	T044	C0013081
CD40	T028	C1539081
silencing	T045	C0598496
Investigation	T170	C1552578
evaluation	T058	C0220825
criteria	T078	C0243161
backwashing	T067	C1522240
effects	T080	C1280500
pilot-scale	T062	C0031928
BAF	T073	C0180861
treating	T169	C1522326
petrochemical	T103	C0220806
wastewater	T069	C3494254
Parameters	T077	C0549193
evaluation	T058	C0220825
criteria	T078	C0243161
air	T167	C0001861
water	T121	C0043047
backwashing	T067	C1522240
effect	T080	C1280500
pilot-scale	T062	C0031928
biological aerated filter	T073	C0180861
BAF	T073	C0180861
treating	T169	C1522326
petrochemical	T103	C0220806
wastewater	T069	C3494254
investigated	T169	C1292732
parameters	T077	C0549193
suspended	T169	C1705537
solids	T167	C0302909
SS	T167	C0302909
specific oxygen uptake rate	T033	C0429627
SOUR	T033	C0429627
backwashing	T067	C1522240
effluent	T170	C1546612
recovery	T052	C0237820
BAF	T073	C0180861
backwashing	T067	C1522240
removal	T052	C1883720
biomass	T081	C0005535
bioactivity	T080	C0205556
attached	T067	C3714578
filter	T073	C0180861
media	T167	C1705217
backwashing	T067	C1522240
Results	T169	C1274040
weight	T081	C0043100
total	T080	C0439810
sludge	T069	C0282346
backwashing	T067	C1522240
effluent	T170	C1546612
increased	T081	C0205217
increase	T169	C0442805
water	T121	C0043047
backwashing	T067	C1522240
intensity	T080	C0522510
total	T080	C0439810
SOUR	T033	C0429627
backwashing	T067	C1522240
effluent	T170	C1546612
notably	T080	C4288581
increase	T169	C0442805
air	T167	C0001861
backwashing	T067	C1522240
intensity	T080	C0522510
optimal	T080	C2698651
backwashing	T067	C1522240
intensity	T080	C0522510
air	T167	C0001861
water	T121	C0043047
obtained	T169	C1301820
BAF	T073	C0180861
backwashed	T067	C1522240
BAF	T073	C0180861
recovered	T080	C0521108
high	T080	C0205250
average	T081	C1510992
removal	T052	C1883720
chemical oxygen demand	T038	C2936287
COD	T038	C2936287
ammonia nitrogen	T197	C0368666
High	T080	C0205250
amount	T081	C1265611
biomass	T081	C0005535
removal	T052	C1883720
low	T080	C0205251
level	T080	C0441889
bioactivity	T080	C0205556
removal	T052	C1883720
attached	T067	C3714578
filter	T073	C0180861
media	T167	C1705217
Concentrations	T081	C1446561
benzene	T109	C0005036
toluene	T109	C0040383
ethylbenzene	T109	C0059792
(o-, m-, p-) xylenes	T109	C0043368
BTEX	T109	C0029224
phenol	T109	C0070570
backwashed	T067	C1522240
sludge	T069	C0282346
analyzed	T062	C0936012
backwashing	T067	C1522240
essential	T080	C0205224
remove	T052	C1883720
aromatic compounds	T109	C1510940
adsorbed	T059	C0001674
microorganisms	T001	C0445623
Implementation	T052	C1708476
infrared	T059	C0260249
Raman	T059	C0037815
modalities	T078	C0695347
glycosaminoglycan	T109	C0017973
characterization	T185	C0243175
complex	T080	C0439855
systems	T169	C0449913
Glycosaminoglycans	T109	C0017973
GAGs	T109	C0017973
natural	T169	C0205296
linear	T082	C0205132
negatively charged	T196	C0003075
heteropolysaccharides	T109	C0032594
incident	T067	C1551358
mammalian	T015	C0024660
tissue	T024	C0040300
disaccharide	T109	C0012611
units	T081	C0439148
sulfated	T109	C1954876
non-sulfated monosaccharides	T109	C0026492
tissue	T024	C0040300
types	T080	C0332307
GAGs	T109	C0017973
structural	T082	C0678594
heterogeneity	T080	C0019409
position	T082	C0733755
degree	T081	C0449286
sulfation	T067	C0597538
disaccharide	T109	C0012611
units	T081	C0439148
composition	T080	C0205556
heparin	T109	C0019134
heparan sulfate	T109	C0019143
chondroitine sulfate	T109	C0008466
dermatan sulfate	T109	C0011602
keratan sulfate	T109	C0022563
hyaluronic acid	T109	C0020196
covalently linked	T044	C1511539
core	T082	C0444669
protein	T116	C0033684
proteoglycans	T116	C0033692
free	T080	C1996904
chains	T078	C1524075
hyaluronan	T109	C0813622
GAGs	T109	C0017973
cell	T025	C0007634
properties	T080	C0871161
functions	T043	C0007613
direct	T080	C0439851
interaction	T169	C1704675
cell receptors	T116	C0034800
sequestration	T169	C0443301
growth factors	T116	C0018284
evidences of	T169	C0332120
divert	T080	C0743226
biological	T080	C0205460
roles	T077	C1705810
GAGs	T109	C0017973
characterization	T185	C0243175
cell	T025	C0007634
tissue	T024	C0040300
levels	T080	C0441889
non-invasive	T169	C0205303
techniques	T169	C0449851
investigate	T169	C1292732
qualitatively	T080	C0205556
quantitatively	T081	C0392762
GAGs	T109	C0017973
in vitro	T080	C1533691
diagnostic	T169	C0348026
biomarkers	T201	C0005516
therapeutic	T169	C0302350
targets	T074	C0085104
human	T016	C0086418
diseases	T047	C0012634
cancer	T191	C0006826
Infrared	T059	C0260249
Raman microspectroscopies	T059	C0037815
imaging	T060	C0079595
sensitive	T169	C0332324
classify	T185	C0008902
GAG	T109	C0017973
types	T080	C0332307
subtypes	T185	C0449560
molecular structures	T082	C0678594
Spectroscopic	T059	C0037812
markers	T080	C0206015
GAG	T109	C0017973
molecules	T167	C0567416
identified	T080	C0205396
investigations	T058	C1261322
GAG	T109	C0017973
infrared	T059	C0260249
Raman	T059	C0037815
GAG	T109	C0017973
complex	T080	C0439855
biological	T080	C0205460
systems	T169	C0449913
cells	T025	C0007634
implementation	T052	C1708476
vibrational spectroscopy techniques	T059	C0022885
GAG	T109	C0017973
analysis	T059	C0002778
GAG	T109	C0017973
infrared	T059	C0260249
Raman	T059	C0037815
conditioned media	T130	C0162518
live cells	T025	C0007634
Targeting	T169	C1521840
HIF2	T116	C1436532
Clear Cell Renal Cell Carcinoma	T191	C0279702
von Hippel-Lindau tumor-suppressor protein	T116	C1566585
pVHL	T116	C1566585
signature "truncal" event	T033	C0243095
clear cell renal cell carcinoma	T191	C0279702
kidney cancer	T191	C1378703
pVHL	T116	C1566585
ubiquitin ligase	T116	C0077678
targets	T169	C1521840
α subunit	T116	C0599220
hypoxia-inducible factor (HIF) transcription factor	T116	C1528322
destruction	T052	C1948029
Preclinical	T080	C1709630
studies	T062	C0008972
deregulation	T049	C1514542
HIF	T116	C1528322
HIF2	T116	C1436532
pVHL	T116	C1566585
renal carcinogenesis	T191	C1378703
HIF2α	T116	C0538487
undruggable	T080	C0205556
Rick Bruick	T170	C0805191
Kevin Gardner	T170	C0805191
University of Texas Southwestern	T073	C0041740
small molecule	T109	C1328819
HIF2α antagonists	T120	C0243076
PT2385	T109	C3896783
PT2399	T120	C0243076
Peloton Therapeutics	T093	C0815266
block	T169	C0332206
dimerization	T044	C1323327
HIF2α	T116	C0538487
protein ARNT1	T116	C1506870
inhibit clear cell renal cell carcinoma growth	T043	C1512773
preclinical models	T170	C1514292
PT2385	T109	C3896783
clinic	T073	C0442592
such compounds	T121	C1254351
clustered regularly interspaced short palindromic repeat	T114	C3658200
CRISPR	T114	C3658200
gene editing approaches	T063	C4277689
unappreciated heterogeneity	T080	C0019409
clear cell renal carcinomas	T191	C0279702
patient	T101	C0030705
xenografts	T061	C0520484
HIF2	T116	C1436532
predictive biomarkers	T123	C0041366
optimize	T052	C2698650
such agents	T121	C1254351
clinic	T073	C0442592
Prevalence	T081	C0683921
high-risk	T033	C0332167
human papillomavirus infection	T047	C0343641
women	T032	C0086287
Shaanxi	T083	C0008115
province	T083	C1514578
China	T083	C0008115
hospital	T073	C0019994
investigation	T058	C0220825
investigate	T169	C1292732
characteristics	T080	C1521970
female	T032	C0086287
high-risk human papillomavirus (HR-HPV) infection	T047	C0343641
Shaanxi	T083	C0008115
province	T083	C1514578
China	T083	C0008115
women	T032	C0086287
HPV	T005	C0021344
genotyping test	T059	C2368152
cytology	T059	C0010818
cervix biopsy	T060	C0195314
women	T032	C0086287
women	T032	C0086287
HPV infection	T047	C0343641
rate	T081	C1521828
HR-HPV	T005	C0021344
HR-HPV	T005	C0021344
genotypes	T032	C0017431
HPV-16	T005	C0999806
HPV-58	T005	C3641018
HPV-52	T005	C3641016
HPV-18	T005	C0999807
HPV-31	T005	C2936597
prevalence	T081	C0683921
HR-HPV	T005	C0021344
women	T032	C0086287
carcinogenic	T131	C0007090
genotypes	T032	C0017431
HPV-16	T005	C0999806
HPV-18	T005	C0999807
HPV-58	T005	C3641018
HPV-52	T005	C3641016
HPV-31	T005	C2936597
HPV-16	T005	C0999806
HPV-18	T005	C0999807
cervical cancer	T191	C0007847
infection	T046	C3714514
HR-HPVs	T005	C0021344
not	T033	C0205160
risk factor	T033	C0035648
cervical lesions	T046	C0235656
HPV infection	T047	C0343641
women	T032	C0086287
Shaanxi	T083	C0008115
province	T083	C1514578
Women	T032	C0086287
high-risk group	T098	C0684030
HR-HPV infection	T047	C0343641
cervical cancer	T191	C0007847
HPV-16	T005	C0999806
HPV-18	T005	C0999807
carcinogenic	T131	C0007090
genotypes	T032	C0017431
region	T083	C0017446
Novel	T080	C0205314
Lost	T169	C0745777
Forests	T070	C0086312
Upper Midwestern United States	T083	C0026081
New	T080	C0205314
Estimates	T081	C0750572
Settlement-Era	T079	C1254367
Stem	T002	C0242767
Density	T081	C0178587
Biomass	T081	C0005535
EuroAmerican	T098	C0683983
land-use	UnknownType	C0814835
legacies	T081	C0242538
transformed	T081	C0443172
forest structure	T070	C0086312
United States	T083	C0041703
US	T083	C0041703
More	T081	C0205172
accurate	T080	C0443131
reconstructions	T052	C1706853
historical states	T083	C0175169
critical	T080	C1511545
processes	T067	C1522240
governing	T080	C0243148
past	T079	C1444637
current	T079	C0521116
future	T079	C0016884
forest	T070	C0086312
dynamics	T070	C3826426
reconstructions	T052	C1706853
pre-settlement	T079	C1254367
forest	T070	C0086312
upper Midwestern US	T083	C0026081
Minnesota	T083	C0026183
Wisconsin	T083	C0043193
Michigan	T083	C1548669
Century Public Land Survey System	T170	C0038951
PLSS	T170	C0038951
estimates	T081	C0750572
relative	T080	C0205345
above-ground	T082	C1282910
biomass	T081	C0005535
stem	T002	C0242767
density	T081	C0178587
basal area	T082	C0205112
tree	T002	C0040811
types	T080	C0332307
mapping	T052	C1283195
robust	T080	C2986815
past	T079	C1444637
efforts	T051	C1516084
correction factors	T081	C3166265
sampling design	T170	C0815259
azimuthal censoring	T080	C0205556
biases	T078	C0242568
tree	T002	C0040811
selection	T052	C1707391
pre-settlement	T079	C1254367
modern	T079	C1254367
forests	T070	C0086312
US	T083	C0041703
Forest	T070	C0086312
Service	T057	C0557854
Forest Inventory and Analysis (FIA) data	T170	C0242356
prevalence	T081	C0220900
lost	T169	C0745777
forests	T070	C0086312
pre-settlement	T079	C1254367
forests	T070	C0086312
no	T169	C1518422
current	T079	C0521116
analog	T080	C0205556
novel	T080	C0205314
forests	T070	C0086312
modern	T079	C1254367
forests	T070	C0086312
no	T169	C1518422
past	T079	C1444637
analogs	T080	C0205556
pre-settlement	T079	C1254367
modern	T079	C1254367
forests	T070	C0086312
land-use	UnknownType	C0814835
impacts	T080	C4049986
ecological responses	T055	C0237534
Modern	T079	C1254367
forests	T070	C0086312
homogeneous	T080	C1881065
ecotonal	T081	C0812409
gradients	T081	C0812409
diffuse	T082	C0205219
in the past	T079	C1444637
Novel	T080	C0205314
forest	T070	C0086312
assemblages	T169	C1516698
FIA	T170	C0242356
pre-settlement	T079	C1254367
forests	T070	C0086312
no longer	T033	C0243095
exist	T077	C2987476
modern	T079	C1254367
context	T078	C0449255
Lost	T169	C0745777
forests	T070	C0086312
tamarack	T002	C0884985
forests	T070	C0086312
northeastern	T082	C1709272
Minnesota	T083	C0026183
hemlock	T002	C0242872
cedar	T002	C0949849
forests	T070	C0086312
north-central Wisconsin	T083	C0043193
Upper Peninsula of Michigan	T083	C0025939
elm	T002	C0330531
oak	T002	C0330302
basswood	T002	C1024812
ironwood	T002	C0330803
forests	T070	C0086312
forest	T070	C0086312
prairie boundary	T082	C0442534
south central Minnesota	T083	C0026183
eastern	T082	C1707877
Wisconsin	T083	C0043193
Novel	T080	C0205314
FIA	T170	C0242356
forest	T070	C0086312
assemblages	T169	C1516698
region	T083	C0017446
novelty	T080	C2700116
strong	T080	C0442821
relationship	T080	C0439849
spatial distance	T081	C0012751
remnant	T080	C1527428
forests	T070	C0086312
upper Midwest	T083	C0026081
novelty	T080	C2700116
predicted	T078	C0681842
remnants	T080	C1527428
historical	T079	C0019659
forest type	T070	C0086312
spatial	T082	C1883067
relationships	T080	C0439849
remnant	T080	C1527428
novel	T080	C0205314
forests	T070	C0086312
shifts	T169	C0333051
ecotone structure	T082	C1254362
loss	T081	C1517945
historic	T079	C0019659
forest types	T070	C0086312
significant	T078	C0750502
land	T073	C0557668
managers	T097	C0335141
landscape	T082	C0870781
priority	T079	C0549179
novelty	T080	C2700116
ecological	T070	C0162358
change	T169	C0392747
potential	T080	C3245505
modern	T079	C1254367
spatial distributions	T082	C0037775
species	T002	C0032098
communities	T070	C1253910
relationship	T080	C0439849
geophysical	T070	C2717748
climatic attributes	T070	C2350607
potential	T080	C3245505
changing	T169	C0392747
climate	T070	C0008946
signal	T067	C1710082
human	T016	C0086418
settlement	T052	C0036852
modern	T079	C1254367
forests	T070	C0086312
broad	T082	C0332464
homogenize	T080	C0205375
modern	T079	C1254367
forests	T070	C0086312
relative	T080	C0205345
historic	T079	C0019659
significant	T078	C0750502
future	T079	C0016884
management	T057	C1273870
Prevalence	T081	C0220900
Self-Reported	T062	C0681906
Prescription Drug	T121	C0304227
Use	T169	C0457083
National	T082	C0681788
Sample	T167	C0370003
U.S	T083	C0041703
Drivers	T098	C0684312
Drug	T121	C1254351
driving	T056	C0004379
increasing	T169	C0442808
concern	T078	C2699424
illegal drugs	T131	C0086190
evidence	T078	C3887511
prescribed medications	T121	C3166216
impair driving ability	T033	C0877256
determine	T059	C1148554
self-reported	T062	C0681906
prevalence	T081	C0220900
prescription drug	T121	C0304227
use	T169	C0457083
medical	T169	C0205476
nonmedical	T033	C0243095
use	T169	C0457083
nationally	T082	C0681788
representative	T052	C1882932
sample	T167	C0370003
drivers	T098	C0684312
driver	T098	C0684312
characteristics	T080	C1521970
National Roadside Survey	T062	C0242481
drivers	T098	C0684312
randomly	T080	C0439605
complete	T080	C0205197
survey	T062	C0681817
prescription drug	T121	C0304227
use	T169	C0457083
drivers	T098	C0684312
prescription drug	T121	C0304227
past	T079	C1444637
days	T079	C0439228
common drug class	T121	C1254351
sedatives	T121	C0036557
antidepressants	T121	C0003289
narcotics	T121	C0027415
stimulants	T121	C0304402
Drivers	T098	C0684312
prescription drug	T121	C0304227
use	T169	C0457083
female	T032	C0086287
older	T098	C1518563
non-Hispanic White	T098	C3843227
disability	T033	C0231170
drivers	T098	C0684312
medication	T121	C0013227
use	T169	C0457083
drug	T121	C1254351
prescribed	T058	C0278329
use	T169	C0457083
prescription	T170	C1521941
significantly higher	T081	C4055637
males	T032	C0086582
Black/African American	T098	C0085756
Hispanic	T098	C0086409
drivers	T098	C0684312
older	T098	C1518563
drivers	T098	C0684312
prescription	T170	C1521941
prescribed	T058	C0278329
narcotics	T121	C0027415
sedatives	T121	C0036557
stimulants	T121	C0304402
antidepressants	T121	C0003289
findings	T169	C2607943
drivers	T098	C0684312
potentially impairing	T169	C0221099
prescription drugs	T121	C0304227
medically	T169	C0205476
nonmedically	T033	C0243095
targeting	T169	C1521840
interventions	T058	C1273869
impaired driving	T033	C0877256
medications	T170	C4284232
Repetitive	T079	C2945760
Prolonged	T079	C0439590
Omega-3 Fatty Acid	T109	C0015689
Treatment	T061	C0087111
After	T079	C0687676
Traumatic Brain Injury	T037	C0876926
Enhances	T052	C2349975
Long-Term	T079	C0443252
Tissue	T024	C0040300
Restoration	T061	C0087111
Cognitive Recovery	T061	C0009244
Traumatic brain injury	T037	C0876926
TBI	T037	C0876926
disabling clinical conditions	T033	C4061999
lead	T169	C1522538
neurocognitive disorders	T048	C4041080
survivors	T101	C0206194
group	T098	C1705429
others	T098	C1257890
reported	T170	C0684224
prophylactic enrichment	T061	C0199176
dietary	T169	C2699635
omega-3 polyunsaturated fatty acids	T109	C0015689
n-3 PUFAs	T109	C0015689
ameliorate	T169	C0332303
cognitive deficits	T048	C0009241
after	T079	C0687676
TBI	T037	C0876926
unclear	T033	C3845108
clinically	T080	C0443178
relevant	T080	C2347946
therapeutic regimen	T061	C1276413
n-3 PUFAs	T109	C0015689
administered	T169	C1521801
after	T079	C0687676
TBI	T037	C0876926
improvement	T077	C2986411
long-term	T079	C0443252
cognitive recovery	T061	C0009244
study	T062	C2603343
decline	T080	C1511741
cognitive function	T048	C0009241
main	T080	C1542147
outcome	T169	C1274040
after	T079	C0687676
TBI	T037	C0876926
investigate	T169	C1292732
therapeutic efficacy	T080	C2348767
post	T079	C0687676
TBI	T037	C0876926
n-3 PUFA	T109	C0015689
treatment	T061	C0087111
mechanisms	T169	C0441712
Mice	T015	C0025929
sham operation	T061	C0141287
controlled	T169	C2587213
cortical	T023	C0007776
impact	T080	C4049986
random assignment	UnknownType	C0814868
receive	T080	C1514756
four	T081	C0205450
treatments	T061	C0087111
vehicle	T122	C0042444
control	T169	C2587213
daily	T079	C0332173
intraperitoneal injections	T061	C0021493
n-3 PUFAs	T109	C0015689
weeks	T079	C0439230
beginning	T079	C0439659
h	T079	C0439227
after	T079	C0687676
TBI	T037	C0876926
fish oil dietary	T168	C0556145
supplementation	T061	C0242297
study	T062	C2603343
beginning	T079	C0439659
day	T079	C0439228
after	T079	C0687676
TBI	T037	C0876926
combination	T080	C0205195
treatments	T061	C0087111
chronic	T079	C0205191
brain tissue	T023	C0459385
loss	T081	C1517945
endogenous	T169	C0205227
brain repair processes	T061	C0161849
neurogenesis	T040	C0814002
angiogenesis	T042	C0302600
oligodendrogenesis	T038	C3714634
days	T079	C0439228
after	T079	C0687676
TBI	T037	C0876926
results	T169	C1274040
revealed	T080	C0443289
cognitive deficits	T048	C0009241
massive	T080	C0522501
tissue	T023	C0459385
loss	T081	C1517945
TBI	T037	C0876926
mice	T015	C0025929
receiving	T080	C1514756
post-TBI	T037	C0876926
n-3 PUFA	T109	C0015689
treatments	T061	C0087111
combined	T080	C0205195
treatment	T061	C0087111
fish oil dietary	T168	C0556145
supplement	T168	C0242295
n-3 PUFA	T109	C0015689
injections	T122	C1272883
demonstrated	T052	C3687625
reproducible beneficial effect	UnknownType	C0683156
cognitive deficits	T048	C0009241
reducing	T080	C0392756
gross	T080	C0439806
tissue	T023	C0459385
loss	T081	C1517945
treatment	T061	C0087111
promoted	T052	C0033414
post-TBI	T037	C0876926
restorative processes	T061	C0541662
brain	T023	C0006104
including	T169	C0332257
immature neurons	T025	C0027882
microvessels	T023	C2350570
oligodendrocytes	T025	C0028944
correlated	T080	C1707520
improved	T033	C0184511
cognitive recovery	T169	C1274040
results	T169	C1274040
indicated	T033	C1444656
repetitive	T079	C2945760
prolonged	T079	C0439590
n-3 PUFA	T109	C0015689
treatments	T061	C0087111
after	T079	C0687676
TBI	T037	C0876926
enhancing	T052	C2349975
brain	T023	C0006104
remodeling	UnknownType	C0678692
potential	T080	C3245505
therapy	T061	C0087111
TBI	T037	C0876926
victims	T098	C0680681
clinic	T073	C0442592
Influence	T077	C4054723
yeast	T004	C0043393
lactic acid bacterium	T007	C1210581
constituent	T167	C0729650
profile	T059	C1979963
soy sauce	T168	C0453374
during	T079	C0347984
fermentation	T044	C0015852
Soy sauce	T168	C0453374
Japanese	T083	C0022341
traditional	T169	C0443324
seasoning	T168	C0349383
composed	T081	C0392762
various	T081	C0443302
constituents	T167	C0729650
produced	T057	C0033268
microbes	T001	C0445623
during	T079	C0347984
long-term	T079	C0443252
fermentation process	T044	C0015852
Due to	T169	C0678226
complexity	T169	C0205245
process	T067	C1522240
investigation	T062	C0242481
constituent	T167	C0729650
profile	T059	C1979963
during	T079	C0347984
fermentation	T044	C0015852
difficult	T033	C0243095
Metabolomics	T091	C1328813
comprehensive	T080	C1880156
study	T062	C2603343
low	T080	C0205251
molecular weight	T081	C0026385
compounds	T080	C0205198
biological	T080	C0205460
samples	T167	C0370003
understanding	T041	C0162340
constituent	T167	C0729650
contribution	T052	C1880177
food flavor	T080	C0596585
characteristics	T080	C1521970
metabolomics	T091	C1328813
suitable	T080	C3900053
analysis	T062	C0936012
soy sauce	T168	C0453374
fermentation	T044	C0015852
studies	T062	C2603343
soy sauce	T168	C0453374
fermentation	T044	C0015852
using	T169	C1524063
metabolomics	T091	C1328813
approach	T082	C0449445
reported	T170	C0684224
investigated	T169	C1292732
changes	T169	C0392747
low	T080	C0205251
molecular weight	T081	C0026385
hydrophilic	T081	C0392762
volatile compounds	T120	C0443769
soy sauce	T168	C0453374
gas chromatography/mass spectrometry	T059	C0024868
GC/MS	T059	C0024868
based	T169	C1527178
non-targeted	T169	C0205245
metabolic profiling	T091	C1328813
data	T078	C1511726
analyzed	T062	C0936012
statistical analysis	T062	C0871424
influences	T077	C4054723
yeast	T004	C0043393
lactic acid bacterium	T007	C1210581
constituent	T167	C0729650
profile	T059	C1979963
results	T169	C1274040
suggested	T078	C1705535
novel	T080	C0205314
finding	T033	C0243095
lactic acid bacterium	T007	C1210581
affected	T169	C0392760
production	T057	C0033268
several	T081	C0443302
constituents	T167	C0729650
cyclotene	T109	C0056829
furfural	T109	C0016849
furfuryl alcohol	T109	C0060863
methional	T109	C0066117
soy sauce	T168	C0453374
fermentation process	T044	C0015852
Low	T080	C0205251
intensity	T080	C0522510
sprint training	T061	C0454374
blood flow restriction	T065	C0220931
investigated	T169	C1292732
effects of	T080	C1704420
practical blood flow restriction	T065	C0220931
pBFR	T065	C0220931
leg muscles	T023	C0224456
sprint training	T061	C0454374
time	T079	C0040223
well-trained sport students	T098	C0038492
Participants	T098	C0679646
sprints	T056	C0035953
sprinting speed	T081	C0678536
twice a week	T079	C0556985
weeks	T079	C0439230
IG	T098	C2986530
pBFR	T065	C0220931
CG	T096	C0009932
time	T079	C0040223
decreased	T081	C0205216
IG	T098	C2986530
CG	T096	C0009932
muscle	T024	C0026845
thickness	T080	C1280412
rectus femoris	T023	C0584894
increased	T081	C0205217
IG	T098	C2986530
group	T078	C0441833
time	T079	C0040223
interactions	T169	C1704675
muscle	T024	C0026845
thickness	T080	C1280412
biceps femoris	T023	C0224449
biceps brachii	T023	C0559499
maximal isometric force	T081	C0392762
leg press	T056	C4054656
not change	T033	C0442739
group	T078	C0441833
rate of force development	T081	C0392762
IG	T098	C2986530
Growth hormone	T116	C0037663
testosterone	T109	C0039601
insulin-like growth factor 1	T116	C0021665
cortisol	T109	C0020268
concentrations	T081	C0392762
not significantly differ	T033	C0243095
groups	T078	C0441833
measurement	T169	C0242485
time point	T079	C2348792
sprints	T056	C0035953
training	T065	C0220931
session	T051	C1883016
muscle damage	T020	C0410158
marker	T201	C0005516
h-FABP	T116	C1312696
increased	T081	C0205217
CG	T096	C0009932
IG	T098	C2986530
pBFR	T065	C0220931
time	T079	C0040223
low	T080	C0205251
intensity	T080	C0522510
sprint interval training	T061	C0454374
benefits	T081	C0814225
training	T065	C0220931
pBFR	T065	C0220931
decreased	T081	C0205216
level	T080	C0441889
muscle damage	T020	C0410158
increase	T169	C0442805
rectus femoris muscle	T023	C0584894
thickness	T080	C1280412
higher	T080	C0205250
rate of force development	T081	C0392762
tested	T169	C0039593
hormones	T125	C0019932
beneficial effects	T080	C1280500
Sedation	T061	C0344106
Patients	T101	C0030705
Disorders of Consciousness	T048	C0009792
Neuroimaging	T060	C0679575
Resting State Functional Brain Connectivity	T060	C4288291
head movement	T040	C0376591
resting state functional magnetic resonance imaging	T060	C4288291
post-coma	UnknownType	C0151294
patients	T101	C0030705
disorders of consciousness	T048	C0009792
DOC	T048	C0009792
sedated	T061	C0344106
propofol	T109	C0033487
sedation	T061	C0344106
brain connectivity patterns	T082	C0449774
damaged brain	T037	C0270611
differential diagnosis	T060	C0011906
study	T062	C2603343
assess	T058	C0184514
resting state functional magnetic resonance imaging	T060	C4288291
scanning	T060	C0441633
patients	T101	C0030705
diagnostic	T169	C0348026
research	T062	C0035168
purposes	T169	C1285529
resting state connectivity	T169	C1707489
bilateral	T082	C0238767
external control	UnknownType	C0680371
auditory	T169	C0439825
sensorimotor	T040	C0237434
visual	T169	C0234621
resting state networks	T169	C1882071
connectivity	T169	C1707489
thalamus	T023	C0039729
healthy	T080	C3898900
unsedated	T033	C0243095
controls	T096	C0009932
unsedated	T033	C0243095
patients	T101	C0030705
DOC	T048	C0009792
patients	T101	C0030705
DOC	T048	C0009792
sedated	T061	C0344106
propofol	T109	C0033487
DOC	T048	C0009792
age at onset	T081	C0206132
etiology	T169	C1314792
time spent	T033	C0243095
DOC	T048	C0009792
diagnosis	T033	C0011900
standardized behavioral assessment scores	T081	C0449820
movement	T040	C0026649
intensities	T080	C0522510
structural brain injury	T037	C0270611
T1-based voxel-based morphometry	T059	C0200760
DOC	T048	C0009792
associated with	T080	C0332281
resting state network connectivity	T169	C1707489
visual	T169	C0234621
network	T169	C1882071
Thalamic	T023	C0039729
connectivity	T169	C1707489
reduced	T080	C0392756
Propofol	T109	C0033487
administration	T061	C1533734
patients	T101	C0030705
associated with	T080	C0332281
decreases	T081	C0547047
thalamic	T023	C0039729
insular	T023	C0021640
connectivity	T169	C1707489
findings	T169	C2607943
connectivity	T169	C1707489
decreases	T081	C0547047
associated with	T080	C0332281
propofol	T109	C0033487
sedation	T061	C0344106
thalamus	T023	C0039729
insula	T023	C0021640
DOC	T048	C0009792
structural brain injury	T037	C0270611
thalamus	T023	C0039729
brain arousal	T041	C0003808
disruption	T169	C0332453
diminished	T081	C0205216
movement	T040	C0026649
patients	T101	C0030705
research	T062	C0035168
research question	T078	C0681799
Potassium depletion	T047	C1971021
stimulates	T070	C1948023
Na-Cl cotransporter	T116	C0074782
phosphorylation	T044	C0031715
inactivation	T169	C0544461
ubiquitin ligase	T116	C0077678
Kelch-like 3	T116	C4042100
Kelch-like 3	T116	C4042100
KLHL3	T116	C4042100
component	T116	C1179435
E3 ubiquitin ligase complex	T116	C0077678
regulates	T038	C1327622
blood pressure	T040	C0005823
targeting	T169	C1521840
With-No-Lysine (WNK) kinases	T116	C0031727
degradation	T169	C0243125
Mutations	T045	C0026882
KLHL3	T116	C4042100
increased renal salt reabsorption	T033	C3278017
impaired	T169	C0221099
K(+)	T123	C0032821
secretion	T038	C0036536
hypertension	T047	C0020538
hyperkalemia	T033	C0020461
clinical studies	T062	C0008972
dietary K(+)	T168	C0162800
intake	T169	C1512806
affects	T169	C0392760
blood pressure	T040	C0005823
mechanisms	T169	C0441712
obscure	T033	C3845108
KLHL3	T116	C4042100
ubiquitin ligase	T116	C0077678
complex	T116	C1180347
K(+)	T123	C0032821
activation	T045	C0599177
Na-Cl cotransporter	T116	C0074782
NCC	T116	C0074782
kidney	T023	C0022646
distal convoluted tubules	T023	C0022676
mice	T015	C0025929
eating	T040	C0013470
low-K(+) diet	T061	C0948941
KLHL3	T116	C4042100
phosphorylation	T044	C0031715
S433	T082	C1254362
(KLHL3(S433-P))	T116	C4042100
modification	T033	C3840684
impairs	T169	C0221099
WNK	T116	C0031727
binding	T052	C1145667
KLHL3	T116	C4042100
levels	T080	C0441889
accumulation	T033	C4055506
target	T169	C1521840
substrate	T167	C3891814
WNK4	T116	C1452813
activation	T045	C0599177
downstream	T082	C0522506
kinases SPAK	T116	C1436950
STE20	T116	C4307920
SPS1	T116	C1436950
proline-alanine-rich protein kinase	T116	C1312482
OSR1	T116	C1438448
oxidative stress-responsive 1	T116	C1438448
NCC	T116	C0074782
phosphorylation	T044	C0031715
accumulation	T033	C4055506
plasma membrane	T026	C0007603
phosphorylation	T044	C0031715
S433	T082	C1254362
levels	T080	C0441889
active	T169	C0205177
protein kinase C	T116	C0033634
protein kinase A	T116	C0010531
phosphorylates	T044	C0031715
S433	T082	C1254362
HEK cells	T025	C2936239
expressing	T045	C1171362
KLHL3	T116	C4042100
WNK4	T116	C1452813
activation	T045	C0599177
protein kinase C	T116	C0033634
phorbol 12-myristate 13-acetate	T109	C0039654
induces	T169	C0205263
KLHL3(S433-P)	T116	C4042100
WNK4	T116	C1452813
levels	T080	C0441889
ubiquitination	T044	C1519751
data	T078	C1511726
role	T077	C1705810
KLHL3	T116	C4042100
K(+)	T123	C0032821
induction	T169	C0205263
NCC	T116	C0074782
physiologic adaptation	T040	C0001400
distal	T082	C0205108
electrogenic	T042	C0232633
Na(+) reabsorption	T039	C2610987
preventing	T169	C1292733
renal	T023	C0022646
K(+)	T123	C0032821
loss	T081	C1517945
promoting	T052	C0033414
blood pressure	T040	C0005823
relationship	T080	C0439849
thoracic	T029	C0817096
configuration	T029	C0277809
changes	T169	C0392747
volumes	T081	C0449468
hemithoraces	T029	C0934569
upright sitting	T033	C1280451
patients	T101	C0030705
respiratory disease	T047	C0035204
asymmetrical movement of the thorax	T033	C1821161
study	T062	C2603343
investigate	T169	C1292732
relationship	T080	C0439849
thoracic	T029	C0817096
configuration	T029	C0277809
changes	T169	C0392747
thoracic volume	T201	C0231961
sedentary	T080	C0205254
healthy	T080	C3898900
men	T098	C0025266
upright sitting	T033	C1280451
reflective markers	T080	C0008963
anterior	T082	C0205094
posterior	T082	C0205095
aspects	T080	C1879746
trunk	T029	C0460005
thoracic volume	T201	C0231961
quiet	T080	C0439654
volitional	T041	C0042950
deep breathing	T033	C1328799
three-dimensional motion analyzer	T074	C0025080
difference	T081	C1705241
volume	T081	C0449468
upper	T082	C1282910
lower	T082	C0441994
hemithoraces	T029	C0934569
measured	T080	C0444706
calculation	T052	C1441506
thoracic volume	T201	C0231961
imaginary hexahedra	T082	C2348964
upper	T082	C1282910
lower	T082	C0441994
thorax	T029	C0817096
reflective markers	T080	C0008963
anterior	T082	C0205094
posterior	T082	C0205095
aspects	T080	C1879746
thorax	T029	C0817096
hexahedron	T082	C2348964
imaginary triangular pyramids	T082	C1254362
calculate	T052	C1441506
positional	T033	C0240795
vectors	T082	C0442335
volume	T081	C0449468
hexahedra	T082	C2348964
triangular pyramids	T082	C1254362
calculated	T052	C1441506
thoracic volumes	T201	C0231961
findings	T169	C2607943
left	T082	C0205091
upper	T082	C1282910
right	T082	C0205090
lower	T082	C0441994
hemithorax	T029	C0934569
larger	T081	C0549177
thoracic volumes	T201	C0231961
conclusion	T078	C1707478
left	T082	C0205091
upper	T082	C1282910
right	T082	C0205090
lower	T082	C0441994
hemithoraces	T029	C0934569
expand	T082	C0205229
sides	T082	C0441987
characteristics	T080	C1521970
thoracic	T029	C0817096
excursion	T184	C0232086
quiet	T080	C0439654
volitional	T041	C0042950
deep breathing	T033	C1328799
value	T080	C0332320
assessment	T058	C0220825
instruction	T170	C1442085
breathing techniques	T065	C4040465
patients	T101	C0030705
Development	T169	C1527148
four-item Letter and Shape Drawing test	UnknownType	C0260168
LSD-4	UnknownType	C0260168
bedside test	T060	C0282662
visuospatial function	T041	C2370887
Conventional	T080	C0439858
bedside tests	T060	C0282662
visuospatial function	T041	C2370887
Clock Drawing	UnknownType	C0260168
CDT	UnknownType	C0260168
Intersecting Pentagons	UnknownType	C0260168
IPT	UnknownType	C0260168
lack	T080	C0332268
consistency	T080	C0332529
interpretation	T033	C0456377
compared	T052	C1707455
performance	T052	C1882330
visuospatial ability	T041	C0814069
LSD	UnknownType	C0260168
IPT	UnknownType	C0260168
CDT	UnknownType	C0260168
MMSE	T060	C0451306
acute	T079	C0205178
elderly	T098	C0001792
medical	T169	C0205476
inpatients	T101	C0021562
mean	T081	C0444504
age	T032	C0001779
range	T081	C1514721
females	T032	C0086287
scored	T081	C0449820
MMSE	T060	C0451306
mild	T080	C2945599
score	T081	C0449820
severe	T080	C0205082
score	T081	C0449820
impairment	T169	C0221099
scored	T081	C0449820
CDT	UnknownType	C0260168
IPT	UnknownType	C0260168
scored	T081	C0449820
CDT	UnknownType	C0260168
IPT	UnknownType	C0260168
agreed	T033	C3641827
classification	T185	C0008902
patients	T101	C0030705
strong	T080	C0442821
MMSE	T060	C0451306
categories	T170	C0683312
Correlation	T080	C1707520
LSD	UnknownType	C0260168
visuospatial tests	UnknownType	C0260168
high	T080	C0205250
four-item version	T170	C0333052
LSD	UnknownType	C0260168
items	T071	C1551338
high	T080	C0205250
correlation	T080	C1707520
LSD-15	UnknownType	C0260168
strong	T080	C0442821
association with	T080	C0332281
MMSE	T060	C0451306
categories	T170	C0683312
LSD-4	UnknownType	C0260168
easily	T033	C0332219
interpreted	T169	C1285553
bedside test	T060	C0282662
visuospatial function	T041	C2370887
high	T080	C0205250
coverage	T169	C1999244
elderly	T098	C0001792
patients	T101	C0030705
neurocognitive impairment	T048	C0338656
conventional	T080	C0439858
visuospatial ability	T041	C0814069
identify	T080	C0205396
significant	T078	C0750502
cognitive impairment	T048	C0338656
Salvage Therapy	T061	C0085405
Ceftolozane-Tazobactam	T121	C3656593
Multidrug-Resistant Pseudomonas aeruginosa	T007	C4039743
Infections	T047	C0854135
Infections	T047	C0854135
multidrug-resistant Pseudomonas aeruginosa	T007	C4039743
MDRPA	T007	C4039743
therapeutic management	T058	C0086388
patients	T101	C0030705
MDRPA	T007	C4039743
infection	T047	C0854135
pneumonia	T047	C0032285
salvage therapy	T061	C0085405
ceftolozane-tazobactam	T121	C3656593
empirical treatment	T061	C1299597
suboptimal	T080	C2984009
treatment	T061	C0087111
patients	T101	C0030705
septic shock	T046	C0036983
patients	T101	C0030705
died	T040	C0011065
follow-up	T058	C1522577
Microbiological	T059	C0025951
cure	T077	C1880198
patients	T101	C0030705
Ankaflavin	T109	C1568221
Monascin	T109	C1871155
Induce	T169	C0205263
Apoptosis	T043	C0162638
Activated	T052	C1879547
Hepatic Stellate Cells	T025	C2340138
Suppression	UnknownType	C0678671
Akt	T116	C0164786
NF-κB	T116	C0079904
p38	T116	C1451465
Signaling Pathway	T044	C0037080
increased	T081	C0205217
proliferation	T043	C0596290
activated	T052	C1879547
hepatic stellate cells	T025	C2340138
HSCs	T025	C2340138
associated with	T080	C0332281
hepatic fibrosis	T047	C0239946
excessive	T080	C0442802
extracellular matrix	T024	C0015350
ECM	T024	C0015350
protein	T116	C0033684
inhibitory	T052	C3463820
effects of	T080	C1704420
Monascus purpureus	T004	C0997449
metabolites	T123	C0870883
ankaflavin	T109	C1568221
monascin	T109	C1871155
Akt	T116	C0164786
nuclear factor (NF)-κB	T116	C0079904
p38 mitogen-activated protein kinase	T116	C1120843
MAPK	T116	C1120843
signaling pathways	T044	C0037080
HSC-T6	T025	C0682523
activated hepatic stellate cell line	T025	C0682523
Ankaflavin	T109	C1568221
monascin	T109	C1871155
induced	T169	C0205263
apoptosis	T043	C0162638
significantly	T078	C0750502
inhibited	T080	C0311403
cell growth	T043	C0007595
cell viabilities	T043	C0007620
control cells	T025	C0007634
Apoptosis	T043	C0162638
G1 phase arrest	T043	C3178834
G1 phase	T079	C0079395
percentages	T081	C0439165
control cells	T025	C0007634
correlated	T080	C1707520
increased	T081	C0205217
p53	T116	C0080055
p21	T116	C0288472
levels	T034	C0428479
caspase 3 activity	T044	C1150132
decreased	T081	C0205216
cyclin D1	T116	C0174680
Bcl-2-family protein	T026	C3269083
levels	T034	C0428479
apoptotic	T080	C1516044
effects of	T080	C1704420
ankaflavin	T109	C1568221
monascin	T109	C1871155
HSC-T6	T025	C0682523
specific	T080	C0205369
potential	T080	C3245505
treating	T169	C1522326
liver fibrosis	T047	C0239946
Low-Volume	T073	C3494217
High-Volume Centers	T073	C3494218
Management of Fournier's Gangrene	T058	C0376636
Fournier's Gangrene	T047	C0238419
Washington State	T083	C0043038
Fournier's gangrene	T047	C0238419
FG	T047	C0238419
life-threatening infection	T033	C1859430
affecting	T169	C0392760
perineum	T029	C0031066
genitals	T023	C0017420
Complex	T080	C0439855
patient management	T058	C1610129
tertiary centers	T073	C0587437
hospital transfer	T058	C2065834
patterns	T082	C0449774
morbidity	T081	C0026538
patients	T101	C0030705
FG	T047	C0238419
Washington State	T083	C0043038
Washington State	T083	C0043038
Comprehensive	T080	C1880156
Abstract Reporting	T057	C0000857
hospital discharges	UnknownType	C0541652
Washington	T083	C0043038
patients	T101	C0030705
FG	T047	C0238419
diagnosis and treatment codes	T170	C0282574
stratified	T080	C0205363
low-volume centers	T073	C3494217
LVCs	T073	C3494217
high-volume centers	T073	C3494218
HVCs	T073	C3494218
transfer status	T033	C0586512
debridements	T061	C0011079
septic shock	T046	C0036983
acute renal failure	T047	C0022660
acute respiratory failure	T047	C0264490
length of hospitalization	T058	C3694481
death	T033	C1306577
FG	T047	C0238419
patients	T101	C0030705
HVC	T073	C3494218
treated	T169	C1522326
FG	T047	C0238419
patients	T101	C0030705
Overall mortality	T081	C0205848
patients	T101	C0030705
treated	T169	C1522326
LVCs	T073	C3494217
patients	T101	C0030705
treated	T169	C1522326
HVC	T073	C3494218
LVC	T073	C3494217
High-volume center	T073	C3494218
patients	T101	C0030705
comorbidities	T078	C0009488
mortality	T081	C0205848
septic shock	T046	C0036983
respiratory failure	T047	C1145670
LVC	T073	C3494217
patients	T101	C0030705
HVC	T073	C3494218
transferred patients	T058	C0030704
immediate	T079	C0205253
delayed	T079	C0205421
associated with	T080	C0332281
debridements	T061	C0011079
septic shock	T046	C0036983
acute renal failure	T047	C0022660
Patients	T101	C0030705
treated	T169	C1522326
HVC	T073	C3494218
acutely ill	T033	C2051411
mortality	T081	C0205848
patients	T101	C0030705
treated	T169	C1522326
LVCs	T073	C3494217
acuity patients	T080	C3494263
Immediate	T079	C0205253
delayed	T079	C0205421
FG	T047	C0238419
health outcomes	T170	C1550208
disease	T047	C0012634
acuity of patients	T080	C3494263
transfer status	T033	C0586512
Pneumocystis carinii	T004	C0032276
Inositol Transporter 1	T116	C0596902
Fungi	T004	C0016832
genus Pneumocystis	T004	C0597258
lungs	T023	C0024109
mammals	T015	C0024660
fatal	T080	C1302234
pneumonia	T047	C0339961
PCP	T047	C1535939
Pneumocystis pneumonia	T047	C1535939
hosts	T001	C1167395
immune systems	T022	C0020962
in vitro	T080	C1533691
culture system	T059	C0430400
species	T185	C1705920
Pneumocystis	T004	C0597258
fungi	T004	C0016832
discovery	T052	C1880355
therapies	T061	C0087111
Pneumocystis carinii	T004	C0032276
Pneumocystis murina	T004	C1499624
Pneumocystis jirovecii	T004	C0320385
enzymes	T116	C0014442
myo-inositol biosynthesis	T044	C1156341
genes with homologies	T028	C1334043
fungal	T004	C0016832
myo-inositol	T109	C0021547
transporters	T116	C0596902
myo-inositol	T109	C0021547
eukaryotic	T025	C0015161
viability	T043	C0007620
transporter	T116	C0596902
ITR1	T116	C0596902
functionally	T169	C0205245
structurally	T082	C0678594
P. carinii	T004	C0032276
structure	T116	C1510464
P. carinii	T004	C0032276
ITR1	T116	C0596902
PcITR1	T116	C0596902
transmembrane	T026	C1167322
alpha-helices	T082	C0162805
intracellular	T082	C0178719
C	T087	C1707271
N termini	T087	C1706793
inositol	T109	C0021547
transporters	T116	C0596902
myo-inositol transport	T043	C1159756
P. carinii	T004	C0032276
transport system	T043	C0005528
sugars	T109	C0242209
inositol	T109	C0021547
stereoisomers	T104	C0376211
competitive	T044	C0005458
inhibitors	T120	C0243077
Glucose transport	T043	C0178666
transport	T043	C0005528
myo-inositol transport	T043	C1159756
mammalian	T015	C0024660
transporters	T116	C0596902
sodium dependent	T043	C1523889
cytochalasin B	T121	C0010737
resistant	T169	C0332325
Inositol transport	T043	C1159756
fungi	T004	C0016832
attractive	T080	C2346874
drug	T121	C1254351
target	T169	C1521840
fungi	T004	C0016832
transport	T043	C0005528
mammalian	T015	C0024660
fungal	T004	C0016832
transporters	T116	C0596902
host	T001	C1167395
transport	T043	C0005528
critical	T080	C1511545
nutrient	T168	C0678695
low	T080	C0205251
toxicity	T037	C0600688
potential	T080	C3245505
inhibitors	T120	C0243077
fungal	T004	C0016832
transporter	T116	C0596902
myo-Inositol	T109	C0021547
sugarlike	T109	C0242209
nutrient	T168	C0678695
essential	T080	C0205224
life	T078	C0376558
organisms	T001	C0029235
Humans	T016	C0086418
microbes	T001	C0445623
enzymes	T116	C0014442
environment	T082	C0014406
transport process	T044	C1519628
cellular	T025	C0007634
constituents	T167	C0729650
genomes	T028	C0085239
pathogenic fungi	T004	C3826297
genus Pneumocystis	T004	C0597258
pneumonia	T047	C0339961
causing	T169	C0678227
parasites	T204	C0030498
myo-inositol	T109	C0021547
enzymes	T116	C0014442
inositol	T109	C0021547
transporters	T116	C0596902
sugar	T109	C0242209
lungs	T023	C0024109
fungi	T004	C0016832
transport	T043	C0005528
myo-inositol	T109	C0021547
fungus	T004	C0016832
transporter	T116	C0596902
myo-inositol	T109	C0021547
transport	T043	C0005528
molecules	T167	C0567416
transport	T043	C0005528
mammalian cells	T025	C1512977
mammals	T015	C0024660
transport	T043	C0005528
myo-inositol	T109	C0021547
Pneumocystis fungi	T004	C0597258
transport	T043	C0005528
potential	T080	C3245505
drug	T121	C1254351
target	T169	C1521840
Worldwide	T082	C0332464
Occurrence	T079	C2745955
Mycotoxins	T109	C0026955
Cereals	T168	C0007757
Cereal	T168	C0007757
Derived	T080	C1441547
Food Products	T168	C0681562
Public	T092	C0678367
Health	T078	C0018684
Perspectives	T078	C1254370
Cereal grains	T168	C0007757
processed	T067	C1522240
food products	T168	C0681562
contaminated	T169	C0205279
mycotoxins	T109	C0026955
five	T081	C0205451
major	T080	C0205164
mycotoxins	T109	C0026955
aflatoxins	T109	C0001734
ochratoxins	T109	C0028816
fumonisins	T109	C0304082
deoxynivalenol	T109	C0057445
zearalenone	T109	C0043454
public	T092	C0678367
health	T078	C0018684
concern	T078	C2699424
cause	T169	C0015127
adverse effects	T046	C0879626
humans	T016	C0086418
airborne	T169	C3242389
soilborne	T169	C0205245
nature	T080	C0449783
mycotoxigenic fungi	T004	C0016832
worldwide	T082	C0332464
occurrence	T079	C2745955
mycotoxins	T109	C0026955
basis	T169	C1527178
global	T080	C2348867
occurrence	T079	C2745955
data	T078	C1511726
reported	T058	C0700287
incidences	T081	C0021149
maximum	T081	C0806909
levels	T080	C0441889
raw	T080	C1709843
cereal grains	T168	C0007757
aflatoxins	T109	C0001734
ochratoxin A	T109	C0069299
fumonisins	T109	C0304082
deoxynivalenol	T109	C0057445
zearalenone	T109	C0043454
concentrations	T081	C1446561
mycotoxins	T109	C0026955
lower	T080	C0205251
processed	T067	C1522240
food products	T168	C0681562
incidences	T081	C0021149
mycotoxins	T109	C0026955
due to	T169	C0678226
varying	T169	C0392747
stability	T080	C0205360
during	T079	C0347984
processing	T057	C0016487
distribution	T169	C1704711
mycotoxins	T109	C0026955
mycotoxin	T109	C0026955
produced	T169	C0678227
single	T081	C0205171
several	T081	C0443302
fungal	T004	C0016832
species	T185	C1705920
various	T081	C0439064
combinations	T080	C0205195
sample	T167	C0444315
food	T168	C0016452
studies	T062	C2603343
reported	T058	C0700287
additive	T080	C0442796
synergistic	T080	C2986495
effects	T080	C1280500
suggesting	T078	C1705535
mixtures	T167	C0439962
significant	T078	C0750502
threat	T078	C0749385
public	T092	C0678367
health	T078	C0018684
infants	T100	C0021270
young children	T100	C0728836
information	T078	C1533716
mycotoxins	T109	C0026955
interactive	T169	C1704675
toxicity	T037	C0600688
summarized	T170	C0242482
Seventh Cervical Spinous Process	T023	C0223178
Multivariate Model	T081	C0026348
Palpation	T060	C0030247
Personal Information	T077	C2983694
multivariate prediction model	T081	C0026348
palpation	T060	C0030247
personal information	T077	C2983694
seventh cervical spinous process	T023	C0223178
C7SP	T023	C0223178
single-blinded, cross-sectional study	T062	C0010362
primary to tertiary health care center	T073	C1552443
model development	T170	C0920595
temporal validation	T062	C1519941
participants	T098	C0679646
model development	T170	C0920595
time-split validation stages	T081	C0681916
C7SP	T023	C0223178
thorax-rib static method	T060	C0030247
TRSM	T060	C0030247
Participants	T098	C0679646
chest radiography	T060	C0039985
inner	T082	C0205102
body structure	T017	C0460148
TRSM	T060	C0030247
radio-opaque markers	T074	C0181741
skin	T022	C1123023
Age	T032	C0001779
sex	T032	C0079399
height	T032	C0489786
body mass	T033	C0518010
body mass index	T201	C1305855
vertex-marker distanc	T081	C0012751
DV-M	T081	C0012751
distance	T081	C0012751
C7SP	T023	C0223178
vertex	T029	C0230003
DV-C7	T081	C0012751
Multivariate linear regression modeling	T170	C0034980
histogram of residues	T170	C0870616
receiver operating characteristic curves	T081	C0035787
confusion tables	T170	C1706074
multivariate linear prediction model	T081	C0026348
DV-C7	T081	C0012751
DV-C7	T081	C0012751
Receiver operating characteristic curves	T081	C0035787
DV-C7	T081	C0012751
confidence interval	T081	C0009667
DV-M	T081	C0012751
confidence interval	T081	C0009667
sensitivity	T081	C0036667
specificity	T081	C0037791
sensitivity	T081	C0036667
specificity	T081	C0037791
C7SP	T023	C0223178
DV-C7	T081	C0012751
TRSM	T060	C0030247
C7SP	T023	C0223178
multivariate model	T081	C0026348
palpation	T060	C0030247
personal information	T077	C2983694
Comparison	T052	C1707455
Leishmania	T204	C1095819
typing	T059	C0430416
results	T034	C0456984
obtained	T169	C1301820
European	T083	C0015176
clinical laboratories	T073	C1551301
Leishmaniasis	T047	C0023281
endemic	UnknownType	C0544083
southern Europe	T083	C0037724
European	T083	C0015176
countries	T083	C0454664
cases	T081	C0021149
diagnosed	T033	C0011900
travellers	T097	C0335278
affected areas	T033	C1879646
within	T082	C0332285
continent	T083	C0454690
Prompt	T080	C0205556
accurate	T080	C0443131
diagnosis	T033	C0011900
clinical practice	T170	C2986419
Europe	T083	C0015176
Different	T080	C1705242
methods	T170	C0025663
exist	T077	C2987476
identification	T080	C0205396
infecting	T033	C0439663
Leishmania	T204	C1095819
species	T185	C1705920
clinical laboratories	T073	C1551301
European	T083	C0015176
countries	T083	C0454664
Israel	T083	C0022271
Turkey	T083	C0041400
study	T062	C2603343
genotyping	T059	C1285573
performance	T052	C1882330
DNA	T114	C0012854
promastigote cultures	T204	C0684063
species	T185	C1705920
analysed	T062	C0936012
blindly	T080	C0205556
routinely	T080	C0205547
typing	T059	C0430416
method	T170	C0025663
different	T080	C1705242
molecular targets	T104	C1513403
analysed	T062	C0936012
PCR-based	T063	C0032520
methods	T170	C0025663
Different	T080	C1705242
levels	T080	C0441889
identification	T080	C0205396
achieved	T033	C0432600
Leishmania	T204	C1095819
subgenus	T077	C1883697
species	T185	C1705920
species	T185	C1705920
reported	T170	C0684224
overall	T080	C1561607
error	T080	C0743559
rate	T081	C1521828
strains	T001	C1518614
wrong	T080	C3827420
species	T185	C1705920
reasons	T078	C0392360
incorrect	T080	C3827420
typing	T059	C0430416
identified	T080	C0205396
study	T062	C2603343
considerable	T080	C0205556
improvement	T077	C2986411
standardisation	T062	C0038136
Leishmania	T204	C1095819
typing	T059	C0430416
validated	T062	C1519941
standard operating procedures	T077	C1710183
recommended	T078	C0034866
testing	T169	C0039593
interpretation	T170	C0459471
reporting	T058	C0700287
guidelines	T170	C0162791
internal	T082	C0205102
transcribed	T080	C0205556
spacer 1	T114	C0887858
rDNA	T114	C0012931
array	T075	C0600597
restricted	T169	C0443288
Old World	T080	C0205556
samples	T077	C2347026
heat-shock protein 70 gene	T028	C1415755
mini-exon	T114	C0026163
applied	T169	C4048755
globally	T080	C2348867
Scoparone	T109	C0074191
LPS	T109	C0023810
Simulated	T169	C0205245
Inflammatory Response	T046	C1155266
Suppressing	T169	C1260953
IRF3	T116	C1510506
ERK	T116	C0600388
BV-2 Microglial Cells	T025	C0206116
Microglia	T025	C0206116
activation	T043	C1326120
inflammatory	T169	C0333348
cytokines	T116	C0079189
neurological diseases	T047	C2359473
Parkinson's	T047	C0030567
Alzheimer's	T047	C0002395
other	T080	C0205394
brain diseases	T047	C0006111
microglial cells	T025	C0206116
natural	T169	C0205296
bioactive compounds	T123	C0574031
increasingly	T169	C0442805
important	T080	C3898777
brain therapy	T061	C0872120
beneficial effect	UnknownType	C0683156
lower	T080	C0205251
toxicity	T080	C0040539
Scoparone	T109	C0074191
6,7-dimethoxycoumarin	T109	C0074191
bioactive compound	T123	C0574031
found	T033	C0150312
plant parts	T185	C2698828
shell	T080	C1948022
chestnut	T168	C0349771
Castanea crenata	T002	C1047769
lipopolysaccharide	T109	C0023810
LPS	T109	C0023810
activated	T169	C1515877
BV-2 microglia cells	T025	C0206116
results	T169	C1274040
indicated	T033	C1444656
scoparone	T109	C0074191
suppresses	T169	C1260953
LPS	T109	C0023810
stimulated	T169	C0205245
increase	T169	C0442805
neuroinflammatory responses	T046	C1155266
inhibited	T080	C0311403
pro-inflammatory	T169	C0333348
cytokine	T116	C0079189
BV-2 microglial cells	T025	C0206116
mechanistic study	T169	C0441712
scoparone	T109	C0074191
inhibited	T080	C0311403
LPS	T109	C0023810
stimulated	T169	C0205245
activation	T043	C1326120
regulation	T038	C1327622
IRF-3	T116	C1510506
regulation	T038	C1327622
ERK	T116	C0600388
phosphorylation	T044	C0031715
BV-2 microglial cells	T025	C0206116
blocked	T169	C0332206
data	T078	C1511726
suggest	T078	C1705535
scoparone	T109	C0074191
anti-neuroinflammatory effects	T080	C1515999
LPS	T109	C0023810
activated	T169	C1515877
BV-2 microglial cells	T025	C0206116
used	T169	C1524063
development	T169	C1527148
novel	T080	C0205314
drugs	T121	C0013227
prevention	T080	C1456501
treatment	T169	C1522326
neuroinflammatory diseases	T047	C2359473
genome editing	T063	C4279981
differentiated	T080	C0205615
renal	T023	C0022646
epithelial cells	T025	C0014597
genome editing technologies	T063	C4279981
manipulation of genomes	T063	C0178659
targeted introduction	T063	C4279981
alteration	T063	C4279981
removal of genomic sequences	T063	C4279981
methods	T170	C0025663
non-differentiated	T170	C0449475
haploid	T025	C1257912
cell types	T170	C0449475
Genome editing	T063	C4279981
well-differentiated	T080	C0205615
renal	T023	C0022646
epithelial cells	T025	C0014597
technological issues	T033	C0033213
optimal	T080	C2698651
design	T052	C1707689
efficient	T080	C0442799
expression of multiple genome editing constructs	T063	C4279981
attainable	T080	C0205556
mutation rates	T080	C3178846
screening strategies	T170	C0282574
workflow	T077	C1710679
rapid	T080	C0456962
generation of targeted heterozygous and homozygous genomic sequence alterations	T063	C4279981
renal	T023	C0022646
cells	T025	C0007634
transcription activator-like effector nucleases	T116	C4277678
TALENs	T116	C4277678
clustered regularly interspaced short palindromic repeat (CRISPR) system	T114	C3658200
protocols	T170	C0442711
generating	T052	C3146294
novel	T080	C0205314
cellular models	T075	C0026336
studying	T062	C2603343
autosomal dominant polycystic kidney disease	T019	C0085413
ADPKD	T019	C0085413
cell culture-validated genetic modifications	T063	C4277689
mouse embryonic stem cells	T025	C4042879
mESCs	T025	C4042879
generation	T052	C3146294
mouse	T015	C0025929
models	T008	C0599779
procedure	T169	C2700391
genome editing	T063	C4279981
cell type	T170	C0449475
study	T062	C2603343
physiological	T039	C0031845
pathophysiological functions	T046	C0030660
engineered genotypes	T028	C1516876
Right Ventricular	T023	C0225883
Response	T032	C0871261
During	T079	C0347984
Exercise	T056	C0015259
Patients	T101	C0030705
Chronic Obstructive Pulmonary Disease	T047	C0024117
Right ventricular	T023	C0225883
RV	T023	C0225883
pump function	T042	C0080311
essential	T080	C0205224
clinical	T080	C0205210
prognostic	T170	C0220901
importance	T080	C3898777
variety	T077	C2346866
heart	T047	C0018799
lung diseases	T047	C0024115
evaluation	T058	C0220825
RV	T023	C0225883
performance	T052	C1882330
rest	T056	C0035253
clinical setting	T082	C3176918
assessment	T058	C0220825
during	T079	C0347984
exercise	T056	C0015259
additional	T169	C1524062
benefit	T081	C0814225
aim	T078	C1947946
evaluated	T058	C0220825
exercise	T056	C0015259
induced	T169	C0205263
pulmonary arterial systolic pressure	T060	C1168444
PASP	T060	C1168444
increase	T169	C0442805
during	T079	C0347984
exercise	T056	C0015259
patients	T101	C0030705
severe	T080	C0392364
chronic obstructive pulmonary disease	T047	C0024117
COPD	T047	C0024117
RV	T023	C0225883
contractile reserve	T081	C0392762
Cardiopulmonary exercise testing	T060	C2959886
CPET	T060	C2959886
synchronic echocardiography	T060	C0013516
performed	T169	C0884358
patients	T101	C0030705
Patients	T101	C0030705
classified	T185	C0008902
groups	T078	C0441833
exercise	T056	C0015259
induced	T169	C0205263
PASP	T060	C1168444
increase	T169	C0442805
High	T080	C0205250
PSAP	T060	C1168444
Low	T080	C0205251
PSAP	T060	C1168444
during	T079	C0347984
maximal	T080	C0205289
exercise	T056	C0015259
Patients	T101	C0030705
followed	T079	C0332282
years	T079	C0439234
patients	T101	C0030705
low	T080	C0205251
PSAP	T060	C1168444
high	T080	C0205250
PSAP	T060	C1168444
not significant	T033	C1273937
clinical	T080	C0205210
functional	T169	C0205245
differences	T081	C1705241
Low	T080	C0205251
PSAP	T060	C1168444
associated with	T080	C0332281
significantly lower	T081	C4055638
peak	T080	C0444505
VO2	T033	C0429627
mean	T081	C0444504
SD	T081	C0871420
predicted	T078	C0681842
compared	T052	C1707455
high	T080	C0205250
PSAP	T060	C1168444
response	T032	C0871261
peak	T080	C0444505
VO2	T033	C0429627
predicted	T078	C0681842
Factors	T169	C1521761
associated with	T080	C0332281
mortality	T081	C0178686
age	T032	C0001779
exercise	T056	C0015259
induced	T169	C0205263
PASP	T060	C1168444
patients	T101	C0030705
during	T079	C0347984
years	T079	C0439234
follow-up	T058	C1522577
low	T080	C0205251
PSAP	T060	C1168444
group	T078	C0441833
high	T080	C0205250
PSAP	T060	C1168444
group	T078	C0441833
Cardiopulmonary exercise testing	T060	C2959886
synchronic echocardiography	T060	C0013516
assessment	T058	C0220825
RV	T023	C0225883
contractile reserve	T081	C0392762
severe	T080	C0392364
COPD	T047	C0024117
patients	T101	C0030705
Exercise	T056	C0015259
induced	T169	C0205263
PSAP	T060	C1168444
prognostic factor	T201	C1514474
patients	T101	C0030705
Adverse outcomes	T169	C1274040
older adults	T098	C0001792
attending	T169	C1999232
emergency departments	T073	C0562508
systematic review	T170	C1955832
meta-analysis	T062	C0920317
Identification of Seniors At Risk (ISAR) screening tool	T170	C0282574
older adults	T098	C0001792
frequent	T079	C0332183
emergency services	T058	C0013961
high	T080	C0205250
rates	T081	C1521828
adverse outcomes	T169	C1274040
emergency care	T061	C1527398
systematic review	T170	C1955832
meta-analysis	T062	C0920317
Identification of Seniors At Risk (ISAR) screening tool	T170	C0282574
predictive value	T080	C1514307
adults	T100	C0001675
years	T079	C0439234
risk	T078	C0035647
functional decline	T033	C4304688
emergency department (ED) readmission	T058	C0583237
emergency	T067	C0013956
hospitalisation	T058	C0019993
death	T033	C1306577
days	T079	C0439228
ED visit	T058	C0586082
hospitalisation	T058	C0019993
systematic	T169	C0220922
literature	T170	C0023866
search	T052	C1706202
PubMed	T170	C1138432
EMBASE	T170	C0282574
CINAHL	T170	C0282574
EBSCO	T170	C0282574
Cochrane Library	T170	C0282574
validation	T062	C1519941
impact	T080	C4049986
analysis	T062	C0936012
ISAR tool	T170	C0282574
pre-specified	T080	C2826245
ISAR	T170	C0282574
score	T081	C0449820
score	T081	C0449820
patients	T101	C0030705
high risk of	T033	C0332167
adverse outcomes	T169	C1274040
bivariate random effects model	T170	C3161035
pooled	T169	C2349200
estimates	T081	C0750572
sensitivity and specificity	T081	C0036668
Statistical heterogeneity	T080	C0019409
methodological quality	UnknownType	C0815254
validated criteria	T078	C0243161
validation studies	T062	C0681836
included	T169	C0332257
pooled	T169	C2349200
sensitivity	T081	C0036667
ISAR	T170	C0282574
ED	T073	C0562508
return	T080	C0332156
emergency	T067	C0013956
hospitalisation	T058	C0019993
mortality	T081	C0205848
months	T079	C0439231
confidence interval	T081	C0009667
CI	T081	C0009667
CI	T081	C0009667
CI	T081	C0009667
pooled	T169	C2349200
specificity	T081	C0037791
CI	T081	C0009667
CI	T081	C0009667
CI	T081	C0009667
values	T080	C0042295
days	T079	C0439228
heterogeneous	T080	C0019409
impact	T080	C4049986
analysis	T062	C0936012
examined	T033	C0332128
clinical	T080	C0205210
implementation	T052	C1708476
ISAR	T170	C0282574
mixed findings	T169	C2607943
patient	T101	C0030705
process	T067	C1522240
outcomes	T169	C1274040
ISAR	T170	C0282574
predictive	T080	C0681890
accuracy	T080	C0443131
decision-making	T041	C0011109
adjunct	T169	C1719882
older adults	T098	C0001792
discharged	T058	C0030685
Ecohydrological modeling	T062	C0870071
environmental	T082	C0014406
flow	T070	C0806140
regime	T080	C0243148
Formoso River	T070	C0337050
Minas Gerais State	T083	C0006137
Brazil	T083	C0006137
paper	T170	C1706852
determining	T080	C0521095
environmental	T082	C0014406
flow	T070	C0806140
1 km	T081	C0439198
stretch	T081	C0012751
Formoso River	T070	C0337050
MG	T083	C0006137
River2D model	T062	C0870071
ecohydrological modeling	T062	C0870071
following	T079	C0332282
information	T078	C1533716
bathymetry	T081	C0392762
physical	T169	C0205485
hydraulic	T169	C0205245
features	T080	C2348519
Habitat	T082	C0871648
Suitability Index	T080	C3900053
species	T185	C1705920
Hypostomus auroguttatus	T013	C3128443
River2D	T062	C0870071
Weighted	T081	C0439751
Usable	T080	C3827682
Areas	T082	C0205146
determined	T080	C0521095
average	T081	C1510992
long-term	T079	C0443252
streamflows	T070	C0442540
percentage	T081	C0439165
streamflows	T070	C0442540
later	T079	C0205087
construction	T169	C1881534
optimization	T052	C2698650
matrices	T082	C1704640
maximize	T081	C0806909
habitat	T082	C0871648
area	T082	C0205146
throughout	T169	C0332273
year	T079	C0439234
H. auroguttatus	T013	C3128443
Juvenile	T100	C3146221
higher	T080	C0205250
values	T080	C0042295
Weighted	T081	C0439751
Usable	T080	C3827682
Area	T082	C0205146
associated with	T080	C0332281
percentage	T081	C0439165
average	T081	C1510992
long-term	T079	C0443252
streamflows	T070	C0442540
October	T079	C3828732
September	T079	C3828193
H. auroguttatus	T013	C3128443
Adult	T100	C0001675
highest	T080	C1522410
value	T080	C0042295
Weighted	T081	C0439751
Usable	T080	C3827682
Usable	T080	C3827682
Area	T082	C0205146
associated with	T080	C0332281
percentage	T081	C0439165
average	T081	C1510992
long-term	T079	C0443252
streamflow	T070	C0442540
September	T079	C3828193
environmental	T082	C0014406
flows	T070	C0806140
found	T033	C0150312
stretch	T081	C0012751
Formoso River	T070	C0337050
varied	T169	C0392747
over	T079	C0347984
year	T079	C0439234
lowest	T080	C1708760
environmental	T082	C0014406
flow	T070	C0806140
observed	T169	C1441672
December	T080	C3830550
highest	T080	C1522410
observed	T169	C1441672
May	T079	C3812381
paper	T170	C1706852
importance	T080	C3898777
ecohydrological studies	T062	C0870071
forming	T169	C1522492
basis	T169	C1527178
water resources	T070	C3494255
management	T080	C0243148
actions	T052	C3266814
Risk factors	T033	C0035648
hepatitis C virus infection	T047	C4288963
Colombian	T098	C1553372
Caribbean coast	T083	C0206155
case-control study	T062	C0007328
million	T081	C1881839
people	T098	C0027361
infected	T033	C0439663
hepatitis C virus	T005	C0220847
Latin America	T083	C0023122
less than	T081	C0439092
antiviral treatment	T061	C2363964
Studies	T062	C2603343
Colombia	T083	C3245499
attempted	T051	C1516084
prevalence	T081	C0033106
disease	T047	C0012634
risk	T078	C0035647
groups	T098	C1257890
preventing	T169	C1292733
identification	T080	C0205396
factors	T169	C1521761
potentially	T080	C3245505
infection	T046	C3714514
identify	T080	C0205396
risk factors	T033	C0035648
chronic hepatitis C	T047	C0524910
Colombian	T098	C1553372
Caribbean coast	T083	C0206155
case-control study	T062	C0007328
health care provider	T097	C0018724
age	T032	C0001779
years	T079	C0439234
primary care level	T058	C0033137
gastroenterology	T091	C0017163
hepatology	T091	C0086403
outpatient services	T058	C0086751
patients	T101	C0030705
positive	T033	C1446409
ELISA	T059	C0014441
confirmatory	UnknownType	C0814857
viral load test	T059	C1656394
multivariate logistic regression analysis	UnknownType	C0681925
identified	T080	C0205396
independent predictors	T078	C2698872
infection	T046	C3714514
Blood transfusion	T061	C0005841
OR	T081	C0028873
CI	T081	C0009667
history of hospitalization	T201	C0551576
OR	T081	C0028873
CI	T081	C0009667
identified	T080	C0205396
independent predictors	T078	C2698872
infection	T046	C3714514
reproducibility of these results	T081	C0035149
cost-effectiveness	T081	C0010181
studies	T062	C2603343
recommending	T078	C0034866
use	T169	C0457083
design	T052	C1707689
new screening strategies	T062	C2348164
G protein-coupled receptor ligands	T044	C1149462
analysis	T062	C0936012
emergence	T078	C0750573
groups	T078	C0441833
compounds	T103	C1706082
over time	T079	C0040223
Exponential	T081	C1552645
growth	T067	C2911660
number	T081	C0237753
compounds	T103	C1706082
experimentally	T080	C1517586
verified	T169	C1711411
activity	T052	C0441655
target	T169	C1521840
emergence	T078	C0750573
databases	T170	C0242356
data	T078	C1511726
biological	T080	C0205460
activity	T052	C0441655
study	T062	C2603343
ligands	T103	C0023688
family A of the G Protein-Coupled Receptors	T116	C0682972
collected	T078	C1516695
ChEMBL database	T170	C0242356
examined	T033	C0332128
serotonin receptors	T116	C0034838
Sets	T077	C1705195
compounds	T103	C1706082
examined	T033	C0332128
appearance	T080	C0700364
over time	T079	C0040223
mapped	T052	C1283195
chemical space	T104	C1254350
drugs	T121	C1254351
DrugBank	T170	C4255544
emergence	T078	C0750573
structurally new clusters of compounds	T104	C1254350
indicated	T033	C1444656
analysis	T062	C0936012
obtained	T169	C1301820
visualizations	T170	C1704922
prepared	T033	C4082130
available	T169	C0470187
online	UnknownType	C0683828
http://chem.gmum.net/vischem	T170	C0282574
investigation	T080	C1517586
chemical structures	T170	C0220807
referring	T169	C0205543
data points	T033	C3176122
figures	UnknownType	C0683878
changes	T169	C0392747
compounds	T103	C1706082
datasets	T170	C0150098
over time	T079	C0040223
Diabetes	T047	C0011847
breast cancer	T191	C0678222
mortality	T081	C0026565
Black women	T098	C0043210
Breast cancer	T191	C0678222
mortality	T081	C0026565
Black women	T098	C0043210
White women	T098	C0043210
prevalence	T081	C0220900
type 2 diabetes mellitus	T047	C0011860
data	T078	C1511726
diabetes	T047	C0011847
affects	T080	C1280500
breast cancer	T191	C0678222
mortality	T081	C0026565
population	T098	C1257890
lacking	T080	C0332268
investigated	T169	C1292732
diabetes	T047	C0011847
breast cancer	T191	C0678222
diagnosis	T033	C0011900
breast cancer	T191	C0678222
mortality	T081	C0026565
Black Women's	T098	C0043210
Health	T058	C0086388
Study	T062	C2603343
prospective cohort study	T062	C1709709
Black women	T098	C0043210
invasive	T080	C0205281
breast cancer	T191	C0678222
diagnosed	T033	C0011900
followed by	T079	C0332283
questionnaires	T170	C0034394
National Death Index	T170	C3889680
Multivariable Cox regression analysis	T170	C0034980
hazard ratios	T081	C2985465
HRs	T081	C2985465
diabetes	T047	C0011847
breast cancer	T191	C0678222
mortality	T081	C0026565
mortality	T081	C0026565
age	T032	C0001779
stage	T201	C1300072
treatment modality	T061	C3527083
estrogen receptor	T116	C0034804
ER	T116	C0034804
status	T080	C0449438
body mass index	T201	C1305855
deaths	T033	C1306577
follow-up	T058	C1522577
breast cancer	T191	C0678222
Breast cancer	T191	C0678222
mortality	T081	C0026565
significantly increased	T081	C4055637
women	T098	C0043210
diagnosed	T033	C0011900
diabetes	T047	C0011847
breast cancer	T191	C0678222
occurrence	T079	C2745955
HR	T081	C2985465
elevations	T082	C0702240
observed	T169	C1441672
ER+	T033	C1719706
ER-	T033	C1719707
breast cancer	T191	C0678222
mortality	T081	C0026565
diabetics	T033	C0241863
HRs	T081	C2985465
overall	T080	C1561607
diabetes	T047	C0011847
relative	T080	C0205345
non-diabetics	T033	C0241863
results	T034	C0456984
present	T033	C0150312
evidence	T078	C3887511
positive	T033	C1446409
type 2 diabetes	T047	C0011860
breast cancer	T191	C0678222
mortality	T081	C0026565
Black women	T098	C0043210
prevalence	T081	C0220900
earlier onset	T033	C1833334
type 2 diabetes	T047	C0011860
Black women	T098	C0043210
diabetes	T047	C0011847
contributes	T052	C1880177
racial	T098	C0034510
disparities	T033	C1171307
breast cancer	T191	C0678222
mortality	T081	C0026565
Neuro-Behcet disease	T047	C0858762
presenting	T078	C0449450
cerebellar hemorrhagic	T046	C0149854
lesion	T033	C0221198
case report	T170	C0085973
review of the literature	T170	C0282441
Behcet's disease	T047	C0004943
heterogeneous	T033	C1858576
multisystem	T047	C0559758
inflammatory disorder	T047	C1290884
unknown etiology	T033	C0743626
oral	T047	C0149745
genital ulcerations	T047	C0151281
conjunction	T078	C2699427
uveitis	T047	C0042164
described	T078	C1552738
Turkish	T098	C0549217
dermatologist	T097	C0259831
associated symptoms	T184	C0521989
cardiovascular	T022	C0007226
central nervous	T022	C3714787
pulmonary	T022	C0884309
gastrointestinal systems	T022	C0012240
identified	T080	C0205396
Behcet's disease	T047	C0004943
neurological involvement	T047	C0027765
neuro-Behcet's disease	T047	C0858762
Patients	T101	C0030705
neuro-Behcet's disease	T047	C0858762
symptoms	T184	C1457887
most	T081	C0205393
commonly	T081	C0205214
brainstem	T023	C0006121
diencephalic	T023	C0012144
regions	T082	C0205147
report	T170	C0684224
unusual	T080	C2700116
case	T169	C0868928
neuro-Behcet's disease	T047	C0858762
patient	T101	C0030705
presented	T078	C0449450
cerebellar hemorrhage	T046	C0149854
39-year-old	T100	C0001675
Asian	T098	C0078988
woman	T098	C0043210
admitted	T058	C0809949
hospital	T073	C0019994
complaints	T033	C0277786
sudden	T080	C1276802
speech difficulty	T033	C0233715
manifested	T169	C0205319
same	T080	C0445247
morning	T079	C0332170
dizziness	T184	C0012833
mild	T080	C2945599
vomiting	T184	C0042963
over	T079	C0347984
previous	T079	C0205156
days	T079	C0439228
Magnetic resonance images	T170	C3890166
revealed	T080	C0443289
hemorrhagic	T046	C0149854
lesions	T033	C0221198
right hemisphere of the cerebellum	T023	C2335345
Risk factors	T033	C0035648
result	T169	C1274040
cerebellar hemorrhage	T046	C0149854
high blood pressure	T047	C0020538
bleeding diathesis	T046	C1458140
ruled out	T033	C1410834
subsequent	T079	C0332282
brain	T023	C0006104
angiograms	T060	C0002978
normal	T080	C0205307
findings	T033	C0243095
suggest	T078	C1705535
patient's	T101	C0030705
cerebellar hemorrhage	T046	C0149854
due to	T169	C0678226
intracranial	T029	C0524466
vasculitis	T047	C0042384
rare	T080	C0522498
complication	T046	C0009566
neuro-Behcet's disease	T047	C0858762
Intrinsic	T082	C0205102
rifamycin	T109	C0035609
resistance	T032	C0949285
Mycobacterium abscessus	T007	C0445910
ADP-ribosyltransferase	T116	C0085748
MAB_0591	T028	C0017337
Rifampicin	T109	C0035608
TB drug	T121	C0013227
rifamycin group	T109	C0035609
activity	T169	C0599112
pathogen	T001	C0450254
Mycobacterium abscessus	T007	C0445910
bacterial resistance	T046	C0151521
rifampicin	T109	C0035608
polymorphisms	T045	C0032529
gene rpoB	T028	C0017337
enzymes	T116	C0014442
rifampicin	T109	C0035608
aim	T078	C1947946
MAB_0591	T028	C0017337
arrMab	T028	C0017337
rifampicin	T109	C0035608
ADP-ribosyltransferase	T116	C0085748
Arr_Mab	T116	C0085748
rifampicin	T109	C0035608
resistance	T032	C0949285
M. abscessus	T007	C0445910
Recombinant	T001	C1514798
Escherichia coli	T007	C0014834
Mycobacterium tuberculosis	T007	C0026926
strains	T001	C1518614
expressing	T045	C0017262
MAB_0591	T028	C0017337
M. abscessus	T007	C0445910
deletion mutant	T045	C1511760
deficient	T169	C0011155
MAB_0591	T028	C0017337
MIC assays	T059	C1510438
susceptibility	T169	C1264642
rifampicin	T109	C0035608
C25 carbamate	T109	C0006948
rifamycin derivatives	T109	C0035609
Heterologous	T080	C0439860
expression	T045	C0017262
MAB_0591	T028	C0017337
rifampicin	T109	C0035608
resistance	T032	C0949285
E. coli	T007	C0014834
M. tuberculosis	T007	C0026926
Rifamycin	T109	C0035609
MIC values	T034	C1304747
M. abscessus	T007	C0445910
ΔarrMab mutant	T028	C0678941
compared	T052	C1707455
M. abscessus ATCC 19977	T007	C0445910
parental type strain	T001	C1518614
rifamycin	T109	C0035609
WT	T028	C1883559
phenotype	T032	C0031437
complementation	T045	C0178654
M. abscessus	T007	C0445910
ΔarrMab mutant	T028	C0678941
arrMab	T116	C0085748
MIC data	T034	C1304747
C25	T109	C0006948
modification	T033	C3840684
rifamycin	T109	C0035609
activity	T169	C0599112
WT	T028	C1883559
M. abscessus	T007	C0445910
MIC studies	T062	C0681814
M. abscessus	T007	C0445910
ΔarrMab mutant	T028	C0678941
C25	T109	C0006948
rifamycins	T109	C0035609
modification	T033	C3840684
Arr_Mab	T116	C0085748
Arr_Mab	T116	C0085748
rifamycin	T109	C0035609
resistance	T032	C0949285
M. abscessus	T007	C0445910
Arr_Mab	T116	C0085748
rifamycin	T109	C0035609
resistance	T032	C0949285
M. abscessus	T007	C0445910
C25 carbamate	T109	C0006948
modification	T033	C3840684
Silorane-based Resin Composites	T122	C3489777
Review	T170	C0282443
article	T170	C1706852
review	T170	C0282443
research	T062	C0035168
silorane-based resin composites	T122	C3489777
SBRC	T122	C3489777
polymerization	T067	C0314672
shrinkage	T169	C0332513
contraction stresses	T070	C0038442
methacrylate-based resin composites	T122	C0009570
MRBC	T122	C0009570
physical	T070	C0597237
mechanical properties	T070	C2350455
bond strength	T081	C0678599
marginal adaptation	T061	C0242981
cusp deflection	T070	C2350455
clinical significance	T033	C2826293
material	T167	C0520510
SBRC	T122	C3489777
tooth structure	T023	C0040426
direct restorative material	T074	C3503982
English	T171	C0376245
peer-reviewed dental literature	T170	C0282441
PubMed	T170	C1138432
MEDLINE	T170	C0025141
databases	T170	C0242356
low	T080	C0205251
shrinkage	T169	C0332513
silorane composites	T122	C3489777
articles	T170	C1706852
objectives	T170	C0018017
Endoscopic	T060	C0014245
endonasal	T029	C0225425
surgery	T061	C0543467
remission	T033	C0544452
Cushing's Disease	T047	C0010481
ectopic	T082	C0574895
intracavernous	T169	C1512919
macroadenoma	T191	C0344453
case report	T170	C0085973
literature review	T170	C0282441
surgical resection	T061	C0015252
ACTH-secreting pituitary adenoma	T191	C1306214
gold standard	T080	C0150110
treatment	T061	C0087111
Cushing's Disease	T047	C0010481
Ectopic	T082	C0574895
location	T082	C0450429
adenomas	T191	C0001430
rare	T080	C0522498
diagnosis	T033	C0011900
surgical	T061	C0543467
success	T054	C0597535
ectopic	T082	C0574895
intracavernous	T169	C1512919
ACTH-secreting macroadenoma	T191	C1306214
endoscopic	T060	C0014245
endonasal	T029	C0225425
surgery	T061	C0543467
EES	T061	C0396138
female	T032	C0086287
Cushing syndrome	T047	C0010481
Increased	T081	C0205217
ACTH	T116	C0001655
serum cortisol	T109	C0729349
free urine cortisol	T109	C1985941
levels	T080	C0441889
pituitary MRI	T060	C0412679
pituitary tumor	T191	C0032019
parasellar lesion	T033	C0221198
cavernous sinus	T030	C0007473
CS	T030	C0007473
Inferior petrosal sinus sampling	T060	C0206084
central	T082	C0205099
peripheral	T082	C0205100
ACTH	T116	C0001655
patient	T101	C0030705
EES	T061	C0396138
No tumor	T033	C0243095
sella	T023	C0036609
CS	T030	C0007473
tumor	T191	C0027651
lateral	T082	C0205093
carotid artery	T023	C0007272
no	T033	C1513916
complications	T046	C0009566
EES	T061	C0396138
Pathology	T091	C0030664
diagnosis	T033	C0011900
ACTH-secreting adenoma	T191	C1306214
postoperative	T079	C0032790
serum cortisol	T109	C0729349
levels	T080	C0441889
Postoperative	T079	C0032790
MRI	T060	C0024485
tumor resection	T061	C0015252
follow-up	T058	C1522577
patient	T101	C0030705
clinical	T080	C0205210
biochemical	T169	C0205474
remission	T033	C0544452
Cushing's Disease	T047	C0010481
ectopic	T082	C0574895
intracavernous	T169	C1512919
ACTH-secreting adenomas	T191	C1306214
microadenomas	T191	C0346306
ectopic	T082	C0574895
ACTH-secreting macroadenoma	T191	C1306214
CS	T030	C0007473
surgical	T061	C0543467
EES	T061	C0396138
resection	T061	C0015252
ectopic	T082	C0574895
intracavernous	T169	C1512919
adenomas	T191	C0001430
exploration	T061	C1280903
CS	T030	C0007473
no	T033	C1513916
surgical	T061	C0543467
complications	T046	C0009566
Randomized Controlled Trial	T062	C0206035
Habit Reversal Training	T061	C0004933
Treatment	T061	C0087111
Hair Pulling	T048	C0040953
Youth	T100	C0087178
study	T062	C2603343
evaluated	T058	C0220825
treatment	T061	C0087111
efficacy	T080	C1280519
habit reversal training	T061	C0004933
HRT	T061	C0004933
treatment as usual	T077	C2347177
TAU	T077	C2347177
children	T100	C0008059
adolescents	T100	C0205653
aged	T032	C0001779
years	T079	C0439234
diagnosis	T062	C1704656
trichotillomania	T048	C0040953
TTM	T048	C0040953
assessment	T058	C0220825
interviews	T052	C0021822
rating scales	T081	C0681889
Participants	T098	C0679646
female	T032	C0086287
diagnostic criteria	T170	C0679228
TTM	T048	C0040953
randomized	T062	C0034656
weekly	T079	C0332174
HRT	T061	C0004933
therapists	T097	C0871525
weeks	T079	C0439230
TAU	T077	C2347177
week	T079	C0439230
HRT	T061	C0004933
TAU	T077	C2347177
week	T079	C0439230
patients	T101	C0030705
posttreatment assessment	T058	C0237623
month	T079	C0439231
follow-up	T058	C1522577
assessments	T058	C0220825
assessments	T058	C0220825
rater	T097	C2697672
blinded	T062	C0150108
treatment	T061	C0087111
condition	T080	C0348080
analysis of variance	T081	C0002780
significant	T078	C0750502
National Institute of Mental Health	T093	C0027466
Trichotillomania Severity Scale Total Score	T081	C0457451
mean score	T033	C3533236
baseline	T081	C1442488
posttreatment	T058	C0237623
HRT	T061	C0004933
group	T098	C1257890
TAU	T077	C2347177
group	T098	C1257890
The Massachusetts General Hospital-Hair Pulling Scale Total Score	T081	C0457451
baseline	T081	C1442488
posttreatment	T058	C0237623
HRT	T061	C0004933
group	T098	C1257890
TAU	T077	C2347177
group	T098	C1257890
Clinical Global Impressions-Improvement	T170	C3639708
participants	T098	C0679646
treatment	T061	C0087111
responders	T098	C0282122
HRT	T061	C0004933
group	T098	C1257890
TAU	T077	C2347177
group	T098	C1257890
month	T079	C0439231
follow-up	T058	C1522577
treatment	T061	C0087111
responders	T098	C0282122
assessment	T058	C0220825
improvement	T077	C2986411
month	T079	C0439231
follow-up	T058	C1522577
improvement	T077	C2986411
HRT	T061	C0004933
treatment	T061	C0087111
TTM	T048	C0040953
youth	T100	C0087178
Fully	T080	C0443225
Endoscope	T074	C0014243
Controlled	T169	C2587213
Clipping	T061	C0189711
Bilateral Middle Cerebral Artery Aneurysm	T047	C0740385
Unilateral Supraorbital Keyhole Approach	T061	C0087111
Clipping	T061	C0189711
bilateral middle cerebral artery (bMCA) aneurysms	T047	C0740385
unilateral approach	T061	C0087111
single-stage operation	T061	C0543467
surgical management	T058	C1515089
patients	T101	C0030705
bMCA aneurysms	T047	C0740385
endoscope	T074	C0014243
controlled	T169	C2587213
techniques	T169	C0449851
patient	T101	C0030705
bMCA aneurysms	T047	C0740385
aneurysms clipping	T061	C0189711
unilateral supraorbital keyhole approach	T061	C0087111
endoscope	T074	C0014243
controlled	T169	C2587213
microneurosurgery	T061	C0524850
patient	T101	C0030705
postoperative course	T079	C0032790
without	T080	C0332288
neurologic	T080	C0205494
impairment	T046	C0684336
complication	T046	C0009566
adaptation	T170	C1706477
endoscope	T074	C0014243
controlled	T169	C2587213
clipping	T061	C0189711
bMCA aneurysms	T047	C0740385
unilateral supraorbital keyhole approach	T061	C0087111
Novel	T080	C0205314
Observations	T062	C0302523
Heteroresistant	T039	C1514892
Vancomycin-Intermediate	T116	C0042313
Methicillin-Resistant Staphylococcus aureus Strains	T007	C1265292
South India	T083	C0021201
genome sequences	T085	C2348746
heteroresistant	T039	C1514892
vancomycin-intermediate Staphylococcus aureus (hVISA) strains	T007	C1318880
bloodstream infection	T046	C2316160
strains	T001	C1518614
mutations	T045	C0026882
vraSR	T028	C0017337
graSR	T028	C0017337
walKR	T028	C0017337
tcaRAB	T028	C0017337
mutated	T045	C0026882
genes	T028	C0017337
hVISA	T007	C1318880
phenotypes	T032	C0031437
Endpoints	T080	C2349179
screening	T060	C0199230
thyroid cancer	T191	C0549473
Republic of Korea	T083	C0022773
thyroid	T023	C0040132
specialists	T097	C1611835
perspectives	T041	C0030971
Cancer screening	T060	C0199230
reducing	T080	C0392756
deaths	T033	C1306577
cancer	T191	C0006826
Thyroid-specific cancer	T191	C0549473
mortality	T081	C0681679
endpoint	T080	C2349179
estimates	T081	C0750572
screening	T058	C1710032
effect	T080	C1280500
Numerous	T081	C0439064
observations	T060	C1964257
accumulated	T033	C4055506
thyroid cancer	T191	C0549473
mortality	T081	C0681679
endpoint	T080	C2349179
difficult	T080	C0332218
population heterogeneity	T102	C0086833
provision	T058	C1283218
randomization	T062	C0034656
requirement	T169	C1514873
cohorts	T098	C0599755
long follow-up	T058	C1517942
excellent	T080	C1961136
prognosis of the cancer	T201	C1516221
important	T080	C3898777
thyroid cancer	T191	C0549473
screening	T060	C0199230
efficacy	T080	C1280519
Recommendations	T078	C0034866
thyroid cancer	T191	C0549473
screening	T060	C0199230
effectiveness	T080	C1280519
significant reduction	T080	C0392756
cancer	T191	C0549473
mortality	T081	C0681679
endpoint	T080	C2349179
endpoints	T080	C2349179
reductions in mortality	T081	C0282251
endpoint	T080	C2349179
endpoint	T080	C2349179
endpoints	T080	C2349179
thyroid cancer	T191	C0549473
incidence	T081	C0021149
proportion	T081	C1709707
early-stage	T079	C2363430
tumors	T191	C0027651
detected	T033	C0442726
treatable stage	T201	C1300072
identification	T080	C0205396
small tumors	T080	C0475277
decrease in the number of people	T058	C0509797
metastatic disease	T191	C0027627
increased	T081	C0205217
surgery	T061	C0543467
minimally invasive approaches	T169	C2711297
lifelong	T079	C4274169
thyroid replacement therapy	T061	C2242640
consistent	T078	C0332290
follow-up	T058	C1522577
low-dose	T081	C0445550
RAI administration	T060	C0203778
risk factor assessments	T170	C2983699
case findings	T058	C1444481
continuous	T078	C0549178
Korean	T098	C1556095
Korean guidelines	T170	C0162791
thyroid cancer	T191	C0549473
national-level	T082	C0681788
screening	T058	C0220908
multidisciplinary thyroid experts	T060	C0729737
evidence is insufficient	T169	C3858734
benefits	T081	C0814225
thyroid cancer	T191	C0549473
screening	T060	C0199230
research	T062	C0035168
complete	T080	C0205197
analysis	T062	C0936012
endpoints	T080	C2349179
screening	T058	C0220908
participants	T098	C0679646
information	T078	C1533716
to make decisions	T041	C0679006
thyroid cancer	T191	C0549473
identified	T080	C0205396
Zebrafish	T013	C0043457
adult pigment stem cells	T025	C1171322
multipotent	T025	C1136335
form pigment cells	T025	C0440745
progressive	T169	C0205329
fate restriction process	T043	C1160037
Clonal analysis	T060	C0796368
identifies	T080	C0205396
pigment cell types	T025	C0440745
Skin pigment	T033	C1269684
pattern formation	T040	C1160421
paradigmatic	T061	C0679667
pattern formation	T040	C1160421
zebrafish	T013	C0043457
adult	T100	C0596090
body stripes	T023	C0229962
generated	T052	C1706214
coordinated	T169	C0700114
rearrangement	T043	C0007613
three	T081	C0205449
pigment cell-types	T025	C0440745
black	T080	C0439541
melanocytes	T025	C0025201
shiny	T080	C0205556
iridophores	T025	C0007634
yellow	T080	C0221205
xanthophores	T025	C0007634
stem cell origin	T025	C0038250
melanocytes	T025	C0025201
iridophores	T025	C0007634
potency	T080	C3245505
stem cells	T025	C0038250
remained	T080	C1527428
unclear	T033	C3845108
Xanthophores	T025	C0007634
predominantly	T080	C1542147
proliferation	T043	C0596290
embryonic	T018	C0013935
xanthophores	T025	C0007634
data	T078	C1511726
three	T081	C0205449
cell-types	T025	C0007634
derive	T080	C1441547
stem cells	T025	C0038250
cells	T025	C0007634
generate	T052	C1706214
peripheral	T082	C0205100
neural cell-types	T025	C1113654
clonal	T024	C1522642
compositions	T080	C0205556
progressive	T169	C0205329
fate restriction model	T043	C1160037
generating	T052	C1706214
individual	T080	C1705242
cell-types	T025	C0007634
numbers	T081	C0237753
adult pigment stem cells	T025	C1171322
associated with	T080	C0332281
dorsal root ganglia	T023	C0017070
remain	T033	C0243095
low	T080	C0205251
progenitor	T025	C0038250
numbers	T081	C0237753
increase	T169	C0442805
during	T079	C0347984
larval development	T040	C1160209
metamorphosis	T040	C0277806
partially	T081	C0728938
restricted	T169	C0443288
progenitors	T025	C0038250
spinal nerves	T023	C0037941
Covalent Modulators	T121	C1254351
Vacuolar ATPase	T116	C0379099
vacuolar H(+) ATPase	T116	C0379099
V-ATPase	T116	C0379099
complex	T104	C1704241
machine	T169	C0449913
regulates	T038	C1327622
cellular processes	T043	C0007613
controlling	T169	C2587213
acidity	T081	C0920750
intracellular	T082	C0178719
compartments	T017	C2349967
eukaryotes	T204	C0684063
small-molecule	T109	C1328819
modulators	T121	C1254351
V-ATPase	T116	C0379099
restricted	T169	C0443288
targeting	T043	C0599894
membranous	T080	C0205287
subunit	T081	C1711351
V-ATPase	T116	C0379099
understood	T041	C0162340
mechanisms	T169	C0441712
Small molecules	T109	C1328819
novel	T080	C0205314
defined	T080	C0442825
mechanisms	T169	C0441712
inhibition	T044	C1148560
needed	T080	C0027552
functionally	T169	C0205245
characterize	T052	C1880022
V-ATPase	T116	C0379099
therapeutic	T169	C0302350
relevance	T080	C2347946
V-ATPase	T116	C0379099
human	T016	C0086418
diseases	T047	C0012634
electrophilic	T080	C0205556
quinazolines	T109	C0034407
covalently modify	T044	C3158388
soluble	T080	C1948047
catalytic subunit	T087	C0600499
V-ATPase	T116	C0379099
high	T080	C0205250
potency	T081	C3854080
proteomic selectivity	T080	C0205556
revealed	T080	C0443289
fluorescence imaging	T060	C0430876
chemical proteomic activity-based profiling	T059	C1327760
site	T082	C0205145
modification	T169	C0392747
mapped	T052	C1283195
cysteine	T116	C0010654
residue	T077	C1709915
located in	T082	C0332285
region	T087	C1514562
V-ATPase	T116	C0379099
subunit A	T116	C0599220
thought	T041	C0039869
regulate	T038	C1327622
dissociation	T044	C0301643
V-ATPase	T116	C0379099
V-ATPase inhibitor	T121	C0014432
3-bromopyruvate	T109	C0054130
targets	T169	C1521840
same	T080	C0445247
cysteine	T116	C0010654
residue	T077	C1709915
electrophilic	T080	C0205556
quinazolines	T109	C0034407
modulate	T082	C0443264
function	T169	C0542341
V-ATPase	T116	C0379099
cells	T025	C0007634
well-defined	T080	C0442825
mechanism	T169	C0441712
action	T052	C3266814
high	T080	C0205250
proteomic specificity	T081	C0037791
quinazolines	T109	C0034407
powerful	T081	C3854080
set	T077	C1705195
chemical probes	T120	C2347609
investigate	T169	C1292732
physiological	T169	C0205463
pathological	T169	C1521733
roles	T077	C1705810
V-ATPase	T116	C0379099
Association	T080	C0439849
Metabolic	T169	C0311400
Tumor Volumes	T081	C0475276
Radiation Treatment	T061	C3871222
Glioblastoma Multiforme	T191	C1621958
investigation	T058	C0220825
associations	T080	C0439849
imaging	T060	C0011923
clinical target volumes	T081	C0454198
CTVs	T081	C0454198
metabolic	T169	C0311400
tumor volumes	T081	C0475276
MTVs	T081	C0475276
features	T080	C1521970
information	T078	C1533716
CTVs	T081	C0454198
volumes	T081	C0475276
High-throughput extraction	T170	C0872047
imaging	T060	C0011923
metabolomic	T091	C1328813
quantitative	T081	C0392762
features	T080	C1521970
magnetic resonance imaging	T060	C0024485
MRI	T060	C0024485
magnetic resonance spectroscopic imaging	T060	C1522706
glioblastoma multiforme	T191	C1621958
GBM	T191	C1621958
patient	T101	C0030705
radiation therapy	T061	C3871222
GBM	T191	C1621958
relevant	T080	C2347946
metabolic	T169	C0311400
tumor volumes	T081	C0475276
MTVs	T081	C0475276
aberrant	T080	C0443127
levels	T080	C0441889
N-acetyl aspartate	T116	C0067684
NAA	T116	C0067684
choline	T109	C0008405
Cho	T109	C0008405
clinical target volumes	T081	C0454198
CTVs	T081	C0454198
radiation therapy	T061	C3871222
contrast-enhanced T1-weighted	T060	C1707501
CE-T1w	T060	C1707501
T2-weighted (T2w)/fluid-attenuated inversion recovery MRI	T060	C3897397
Necrotic portions	T033	C1334928
enhancing lesion	T033	C3830314
edema	T184	C0013604
CE-T1w	T170	C1704254
T2w images	T170	C1704254
GBM	T191	C1621958
patients	T101	C0030705
Clinical target volumes	T081	C0454198
MTVs	T081	C0475276
NAA	T116	C0067684
MTVNAA	T081	C0475276
Cho	T109	C0008405
MTVCho	T081	C0475276
Imaging	T060	C0011923
metabolic features	T201	C1864620
size	T082	C0456389
shape	T082	C0332479
signal intensities	T081	C0871362
volumes	T081	C0449468
Tumors	T191	C0027651
semantic	T078	C0036612
imaging traits	T080	C2346469
neuroradiologist	T097	C2985415
features	T080	C1521970
investigated	T169	C1292732
redundancy	T169	C1313915
Two-way correlations	T080	C1707520
imaging	T170	C1704254
CTVs	T081	C0454198
MTVs	T081	C0475276
heatmaps	T073	C2697572
Associations	T080	C0439849
MTVNAA	T081	C0475276
MTVCho	T081	C0475276
imaging features	T080	C2346469
Spearman correlation	T170	C1710141
imaging features	T080	C2346469
patient	T101	C0030705
Half	T081	C2825407
imaging traits	T080	C2346469
replaced	T169	C0559956
continuous variables	T080	C0439828
features	T080	C2346469
CTVs	T081	C0454198
MTVs	T081	C0475276
semantic	T078	C0036612
imaging traits	T080	C2346469
replaced	T169	C0559956
continuous variables	T080	C0439828
correlations	T080	C1707520
imaging measures	T080	C2346469
CTVs	T081	C0454198
MTVNAA	T081	C0475276
CTVs	T081	C0454198
MTVCho	T081	C0475276
MRI	T060	C0024485
magnetic resonance spectroscopic imaging	T060	C1522706
features	T080	C1521970
CTVs	T081	C0454198
MTVs	T081	C0475276
MTV	T081	C0475276
NAA	T116	C0067684
associated with	T080	C0332281
MRI	T060	C0024485
volumes	T081	C0449468
imaging features	T080	C2346469
MTVCho	T081	C0475276
Cho	T109	C0008405
additional information	T079	C1546922
imaging	T060	C0011923
Measurement	T169	C0242485
fidgeting	T033	C0424235
patients	T101	C0030705
anorexia nervosa	T048	C0003125
shoe	T073	C0036988
monitor	T074	C0596972
seated	T033	C4042775
non-exercise physical activity	T056	C0026606
patients	T101	C0030705
anorexia nervosa	T048	C0003125
AN	T048	C0003125
healthy controls	T080	C2986479
HCs	T080	C2986479
associations	T080	C0439849
physical activity	T056	C0026606
eating disorder	T048	C0013473
pathology	T046	C0677042
levels	T080	C0441889
anxiety	T033	C0003467
depression	T048	C0011570
inpatients	T101	C0021562
AN	T048	C0003125
HCs	T080	C2986479
shoe	T073	C0036988
accelerometer	T074	C0178951
SmartShoe	T074	C0178951
time points	T079	C1552717
while eating lunch	T079	C2362314
filling out questionnaires	T079	C2362314
watching television for 1h	T079	C2362314
tasks	T057	C3540678
patients	T101	C0030705
AN	T048	C0003125
more active	T169	C0205177
HCs	T080	C2986479
greater degree	T081	C0449286
restless	T184	C3887611
fidgeting	T033	C0424235
behavior	T053	C0004927
Degree	T081	C0449286
physical activity	T056	C0026606
positively correlated	T033	C1514241
eating disorder	T048	C0013473
psychopathology	T091	C0033927
AN	T048	C0003125
positive association	T033	C1514241
physical activity	T056	C0026606
levels	T080	C0441889
depression	T048	C0011570
anxiety	T033	C0003467
individuals	T098	C0237401
AN	T048	C0003125
physical activity	T056	C0026606
not	T033	C1513916
correlated	T080	C1707520
BMI	T201	C1305855
duration of illness	T079	C3176590
number of days	T081	C3640790
hospital admission	T058	C0184666
minimally invasive	T169	C2711297
shoe	T073	C0036988
monitor	T074	C0596972
patients	T101	C0030705
AN	T048	C0003125
greater degree	T081	C0449286
fidgeting	T033	C0424235
HCs	T080	C2986479
seated	T033	C4042775
tasks	T057	C3540678
activity	T056	C0026606
measures	T081	C0079809
pathology	T046	C0677042
Non-exercise physical activity	T056	C0026606
fidgeting	T033	C0424235
clinical	T080	C0205210
patient population	T101	C0030705
Hospital clowning	T073	C0018704
paediatrician's	T097	C0237433
view	T041	C0030971
study	T062	C0681814
investigates	T169	C1292732
current	T079	C0521116
hospital clowns	T097	C0335094
perspective	T041	C0030971
paediatricians	T097	C0237433
paediatric residents	UnknownType	C0259967
total	T080	C0439810
attending paediatricians	T097	C0237433
paediatric residents	UnknownType	C0259967
participated	T169	C0679823
focus group sessions	T077	C1883017
Data	T078	C1511726
analysed	T062	C0936012
Atlas.ti 5.0	T073	C0037585
general	T082	C0205246
physicians	T097	C0031831
reported	T170	C0684224
positive	T033	C1446409
experiences	T041	C0596545
interaction	T033	C0037420
hospital clowns	T097	C0335094
paediatric patients	T101	C0030705
ward	T073	C1305702
Physicians	T097	C0031831
interested	T041	C0543488
research	T062	C0035168
children's perception	T041	C3825851
hospital clowns	T097	C0335094
research	T062	C0035168
clinical efficacy	T080	C3850123
hospital clowning	T073	C0018704
No direct	T080	C0205556
collaboration	T054	C0282116
physicians	T097	C0031831
hospital clowns	T097	C0335094
reported	T170	C0684224
physicians	T097	C0031831
proposed	T080	C1553874
conditions	T080	C0348080
streamline	T080	C0442799
encounters	T053	C1947978
hospital clowns	T097	C0335094
clear communication	T054	C0009452
prior	T079	C0332152
hospital clown	T097	C0335094
visits	T058	C1512346
condition	T080	C0348080
visits	T053	C0545082
impede	T080	C0332454
medical interventions	T061	C0184661
Overall	T080	C1561607
paediatricians	T097	C0237433
paediatric residents	UnknownType	C0259967
view	T041	C0030971
positive	T033	C1446409
impact	T080	C4049986
paediatric patients	T101	C0030705
important	T080	C3898777
aspect	T080	C1879746
hospital clown	T097	C0335094
visits	T058	C1512346
clinical efficacy	T080	C3850123
hospital clowning	T073	C0018704
hospital clowns	T097	C0335094
worldwide	T098	C2700280
article	T170	C1706852
recommendations	T078	C0034866
encounters	T053	C1947978
paediatricians	T097	C0237433
paediatric residents	UnknownType	C0259967
maintain	T052	C0024501
optimal	T080	C2698651
health care	T058	C0086388
Previous	T079	C0205156
studies	T062	C0681814
clinically significant	T078	C0750502
pain	T184	C0030193
anxiety	T033	C0003467
reducing effect	T080	C1280500
hospital clowning	T073	C0018704
paediatric patients	T101	C0030705
admitted to hospitals	T058	C0184666
undergoing	T080	C0205556
invasive	T080	C0205281
medical procedures	T058	C0199171
paediatricians	T097	C0237433
positive	T033	C1446409
ideas	T078	C1254370
hospital clowns	T097	C0335094
personal prejudices	T055	C0033023
novel	T080	C0205314
study	T062	C0681814
insight	T041	C0233820
day-to-day	T079	C1254367
interaction	T033	C0037420
paediatricians	T097	C0237433
hospital clowns	T097	C0335094
ward	T073	C1305702
study	T062	C0681814
recommendations	T078	C0034866
clinical practice	T170	C0282451
encounters	T053	C1947978
physicians	T097	C0031831
hospital clowns	T097	C0335094
hospital clown	T097	C0335094
visits	T058	C1512346
Multiparametric estimation	T062	C1513748
brain hemodynamics	T042	C4042806
MR fingerprinting ASL	T060	C3891302
Assessment	T058	C0220825
brain hemodynamics	T042	C4042806
exogenous	T169	C0205228
contrast agents	T130	C0009924
increasing	T169	C0442808
importance	T080	C3898777
clinical applications	UnknownType	C0869019
MR perfusion technique	T060	C4287652
noncontrast	T033	C2825493
multiparametric estimation	T062	C1513748
hemodynamic	T042	C0019010
markers	T074	C2745888
arterial spin labeling	T060	C3891302
ASL	T060	C3891302
MR fingerprinting	T060	C0024485
MRF	T060	C0024485
referred	T169	C0205543
MRF-ASL	T060	C3891302
information	T078	C1533716
MRF sequence	T060	C0024485
hemodynamic	T042	C0019010
parameters	T033	C0449381
estimated	T081	C0750572
concomitantly	T079	C0521115
Feasibility demonstration	T062	C0015730
flip angle	T080	C2348681
optimization	T052	C2698650
comparison	T052	C1707455
Look-Locker ASL	T060	C3891302
reproducibility test	T080	C1514863
sensitivity	T169	C0332324
hypercapnia challenge	T033	C0020440
clinical application	UnknownType	C0869019
intracranial steno-occlusive process	T061	C0394264
Moyamoya disease	T047	C0026654
performed	T169	C0884358
technique	T169	C0449851
Magnetic resonance fingerprinting ASL	T060	C3891302
provided	T052	C1999230
parameters	T033	C0449381
B1+	T081	C0392762
tissue	T023	C0459385
T1	T081	C2697938
cerebral blood flow	T033	C0428714
CBF	T033	C0428714
tissue	T024	C0040300
bolus arrival time	T033	C0243095
BAT	T033	C0243095
arterial	T023	C0003842
BAT	T033	C0243095
blood volume	T201	C0005850
blood travel time	T060	C0919393
Coefficients	T081	C1707429
variation	T080	C0205419
estimated	T081	C0750572
parameters	T033	C0449381
Hypercapnia	T033	C0020440
increase	T169	C0442805
CBF	T033	C0428714
decrease	T081	C0547047
BAT	T033	C0243095
tissue	T024	C0040300
vessels	T023	C0005847
Patients	T101	C0030705
Moyamoya disease	T047	C0026654
diminished	T081	C0205216
CBF	T033	C0428714
lengthened	T169	C0392744
BAT	T033	C0243095
could not be detected	T033	C0442737
regular	T080	C0205272
ASL	T060	C3891302
Magnetic resonance fingerprinting ASL	T060	C3891302
technique	T169	C0449851
noncontrast	T033	C2825493
multiparametric	T062	C1513748
perfusion assessment	T058	C4038600
International Society for Magnetic Resonance in Medicine	T073	C0018720
Acute	T079	C0205178
sensitivity	T169	C0332324
vernal pool fairy shrimp	T204	C2661017
Branchinecta lynchi	T204	C2661017
Anostraca	T204	C0998204
Branchinectidae	T204	C1007142
surrogate	T099	C4053457
species	T185	C1705920
chemicals	T103	C0220806
Vernal pool fairy shrimp	T204	C2661017
Branchinecta lynchi	T204	C2661017
Branchiopoda	T204	C0596222
Anostraca	T204	C0998204
fairy shrimp	T204	C0998204
species	T185	C1705920
threatened	T098	C2717883
endangered	T098	C2717882
data	T078	C1511726
sensitivity	T169	C0332324
Branchinecta	T204	C1007143
spp.	T185	C1705920
toxic effects	T037	C0600688
contaminants	T167	C2827365
adequately protected	T204	C1031756
water quality	T080	C0597680
criteria	T078	C0243161
acute (24-h) lethality/immobilization tests	T059	C0022885
species	T185	C1705920
fairy shrimp	T204	C0998204
B. lynchi	T204	C2661017
Branchinecta lindahli	T204	C1187775
Thamnocephalus platyurus	T204	C1041123
chemicals	T103	C0220806
toxic action	T131	C1256754
ammonia	T121	C0002607
potassium	T123	C0032821
chloride	T197	C0008203
sulfate	T197	C0038720
chromium(VI)	T131	C0008574
copper	T121	C0009968
nickel	T123	C0028013
zinc	T121	C0043481
alachlor	T109	C0051051
metolachlor	T109	C0066468
chemicals	T103	C0220806
h	T079	C0439227
tests	T059	C0022885
branchiopods	T204	C0596222
cladocerans	T204	C0446344
Daphnia magna	T204	C1081963
Ceriodaphnia dubia	T204	C1089376
amphipod	T204	C0598804
Hyalella azteca	T011	C1676520
h	T079	C0439227
tests	T059	C0022885
snails	T204	C0037378
Physa gyrina	T204	C0323946
Lymnaea stagnalis	T204	C0323913
effect concentrations	T081	C1446561
EC50s	T081	C1446561
B. lynchi	T204	C2661017
correlated	T080	C1707520
EC50s	T081	C1446561
fairy shrimp	T204	C0998204
species	T185	C1705920
T. platyurus	T204	C1041123
chemicals	T103	C0220806
Comparison	T052	C1707455
EC50s	T081	C1446561
fairy shrimp	T204	C0998204
EC50s	T081	C1446561
invertebrate taxa	T204	C0021948
toxicity	T037	C0600688
data	T078	C1511726
fairy shrimp	T204	C0998204
sensitive	T169	C0332324
potassium	T123	C0032821
trace metals	T121	C0723796
compared	T052	C1707455
invertebrate taxa	T204	C0021948
cladocerans	T204	C0446344
amphipods	T204	C0598804
mussels	T204	C0026871
toxicant	T131	C0599787
sensitivity	T169	C0332324
Interspecies correlation estimation models	T170	C3161035
toxicity	T037	C0600688
fairy shrimp	T204	C0998204
surrogate	T099	C4053457
species	T185	C1705920
models	T170	C3161035
cladocerans	T204	C0446344
freshwater mussels	T204	C0026871
surrogates	T099	C4053457
sensitivity	T169	C0332324
fairy shrimp	T204	C0998204
contaminants	T167	C2827365
studies	T062	C2603343
fairy shrimp	T204	C0998204
sensitive	T169	C0332324
toxicants	T131	C0599787
fairy shrimp	T204	C0998204
genus Branchinecta	T204	C1007143
sensitive	T169	C0332324
fairy shrimp taxa	T204	C0998204
Bi-layered constructs	T122	C0005479
poly(glycerol-sebacate)	T109	C1173093
β-tricalcium phosphate	T122	C0106141
bone-soft tissue	UnknownType	C0541689
interface applications	T169	C0205245
study	T062	C2603343
protocol	T170	C2348563
preparation	T052	C1521827
bi-layered	T080	C0205556
poly(glycerol-sebacate)	T109	C1173093
PGS	T109	C1173093
β-tricalcium phosphate	T122	C0106141
β-TCP	T122	C0106141
construct	T122	C0005479
investigate	T169	C1292732
bone-soft tissue	UnknownType	C0541689
engineering	T061	C0596171
applications	T169	C0205245
layered structure	T082	C0678594
distributing	T169	C1704711
ceramic	T073	C0007742
particles	T104	C0597177
prepolymer	T104	C0597177
synthesized	T052	C1883254
microwave reactor	T073	C0336756
cross-linking	T070	C0178576
construct	T122	C0005479
vacuum	T070	C0042221
vacuum	T070	C0042221
stage	T079	C1306673
separation	UnknownType	C0678621
cross-linked	T070	C0178576
elastomer	T109	C0013766
top	T082	C1704458
ceramic	T073	C0007742
bottom	T082	C1511276
phases	T079	C0205390
β-TCP	T122	C0106141
particles	T104	C0597177
elastomer matrix	T109	C0013766
polymerization	T067	C0314672
increase	T169	C0442805
compression strength	T081	C0376507
Tensile strength	T081	C0039526
Young's modulus	T081	C2350289
elongation at break	T081	C0392762
PGS	T109	C1173093
PGS	T109	C1173093
β-TCP	T122	C0106141
bi-layered constructs	T122	C0005479
Morphology	T082	C0678594
Scanning Electron Microscopy	T059	C0026020
SEM	T059	C0026020
micro-computed tomography	T060	C2350281
μ-CT	T060	C2350281
Tomography	T060	C2350281
data	T078	C1511726
open porosity	T080	C0080037
construct	T122	C0005479
ceramic phase	T079	C0205390
elastomer	T109	C0013766
side	T082	C0441987
pore	T082	C1254362
Homogeneous	T080	C1881065
β-TCP	T122	C0106141
distribution	T169	C1704711
elastomeric structure	T082	C0678594
Cell culture studies	UnknownType	C0681854
biocompatibility	T044	C0596177
elastomer	T109	C0013766
side	T082	C0441987
bone	T024	C0391978
side	T082	C0441987
cell attachment	T026	C0887869
investigate	T169	C1292732
osteogenic	T024	C0391978
properties	T080	C0871161
construct	T122	C0005479
BMP-2	T116	C0527443
TGF-β1	T116	C1704256
PGS	T109	C1173093
β-TCP	T122	C0106141
bi-layered constructs	T122	C0005479
mechanical	T080	C0205556
biological	T080	C0205460
properties	T080	C0871161
bone-soft tissue	UnknownType	C0541689
interface applications	T169	C0205245
soft tissue	T024	C0225317
penetration	T169	C0205321
problem	T033	C0033213
Effects of	T080	C1704420
high-intensity training	T056	C4277545
cardiovascular risk factors	T047	C0850624
premenopausal	T033	C0279752
postmenopausal	T033	C0232970
women	T098	C0043210
Menopause	T039	C0025320
associated with	T080	C0332281
increased	T081	C0205217
cardiovascular disease	T047	C0007222
factors	T169	C1521761
loss	T081	C1517945
estrogen	T109	C0014939
hormonal milieu	T125	C0019932
factors	T169	C1521761
contribute	T052	C1880177
deterioration	T067	C0868945
cardiometabolic health	T042	C0596675
postmenopausal	T033	C0232970
women	T098	C0043210
menopausal	T039	C0025320
transition	T052	C2700061
associated with	T080	C0332281
increased	T081	C0205217
age	T032	C0001779
fat mass	T032	C3656665
indications	T078	C3146298
reduced	T080	C0392756
cardiometabolic	T042	C0596675
adaptations	T038	C0392673
exercise	T056	C0015259
postmenopausal	T033	C0232970
women	T098	C0043210
adverse	T046	C0877248
health profile	T080	C0018759
evaluate	T058	C0220825
risk factors	T033	C0035648
type 2 diabetes	T047	C0011860
cardiovascular disease	T047	C0007222
late	T079	C0205087
premenopausal	T033	C0279752
early	T079	C1279919
postmenopausal	T033	C0232970
women	T098	C0043210
age	T032	C0001779
body composition	T032	C0005885
investigate	T169	C1292732
high-intensity training	T056	C4277545
high-intensity aerobic training	T056	C4277545
intervention	T061	C0184661
healthy	T080	C3898900
nonobese	T033	C0243095
late	T079	C0205087
premenopausal	T033	C0279752
early	T079	C1279919
postmenopausal	T033	C0232970
women	T098	C0043210
anthropometrics	T201	C2598145
body composition	T032	C0005885
blood pressure	T040	C0005823
lipid profile	T059	C0850354
glucose tolerance	T039	C0178665
maximal oxygen consumption	T201	C0030055
baseline	T081	C1442488
intervention	T061	C0184661
baseline	T081	C1442488
groups	T098	C1257890
anthropometrics	T201	C2598145
body composition	T032	C0005885
age	T032	C0001779
confidence limits	T081	C0237530
menstrual period	T040	C0025344
postmenopausal	T033	C0232970
women	T098	C0043210
confidecnce limits	T081	C0237530
Hormonal levels	T034	C1287355
estrogen	T109	C0014939
follicle stimulation hormone	T116	C0016774
luteinizing hormone	T116	C0023607
menopausal status	T201	C1513126
baseline	T081	C1442488
postmenopausal	T033	C0232970
women	T098	C0043210
total cholesterol	T109	C0543421
low-density lipoprotein-cholesterol	T109	C0023824
high-density lipoprotein-cholesterol	T109	C0023822
premenopausal	T033	C0279752
women	T098	C0043210
intervention	T061	C0184661
reduced	T080	C0392756
body weight	T032	C0005910
waist circumference	T201	C0455829
improved	T033	C0184511
body composition	T032	C0005885
increasing	T169	C0442808
lean body mass	T201	C0424678
decreasing	T033	C0442797
fat mass	T032	C3656665
groups	T098	C1257890
lower diastolic blood pressure	T033	C0277890
resting heart rate	T033	C1821417
total cholesterol	T109	C0543421
low-density lipoprotein-cholesterol	T109	C0023824
total cholesterol	T109	C0543421
high-density lipoprotein-cholesterol	T109	C0023822
improved	T033	C0184511
plasma insulin concentration	T059	C1276042
oral glucose tolerance test	T060	C0029161
groups	T098	C1257890
Cardiovascular risk factors	T047	C0850624
late	T079	C0205087
premenopausal	T033	C0279752
early	T079	C1279919
postmenopausal	T033	C0232970
women	T098	C0043210
age	T032	C0001779
body composition	T032	C0005885
postmenopausal	T033	C0232970
women	T098	C0043210
high-	T059	C0392885
low-density lipoprotein-cholesterol levels	T059	C0202117
intervention	T061	C0184661
high-intensity aerobic training	T056	C4277545
risk factors	T033	C0035648
type 2 .diabetes	T047	C0011860
cardiovascular disease	T047	C0007222
late	T079	C0205087
premenopausal	T033	C0279752
early	T079	C1279919
postmenopausal	T033	C0232970
women	T098	C0043210
Correlation	T080	C1707520
preoperative	T079	C0445204
physical signs	T033	C0311392
functional	T169	C0205245
outcomes	T169	C1274040
laminoplasty	T061	C1535956
ossification of the posterior longitudinal ligament	T046	C0206366
Ossification of the posterior longitudinal ligament	T046	C0206366
OPLL	T046	C0206366
myelopathy	T047	C0005956
often	T079	C0332183
managed	T058	C0184516
surgically	T061	C0543467
Knowledge	T041	C0162340
predictors	T078	C2698872
surgical	T061	C0543467
outcomes	T080	C0085415
provide	T052	C1999230
decision support	T170	C3242450
surgeons	T097	C0582175
aims	T078	C1947946
study	T062	C0681814
investigate	T169	C1292732
relationships	T080	C0439849
preoperative	T079	C0445204
physical signs	T033	C0311392
postoperative	T079	C0032790
functional	T169	C0205245
outcomes	T169	C1274040
patients	T101	C0030705
OPLL	T046	C0206366
clarify	T052	C2986669
physical signs	T033	C0311392
predict	T078	C0681842
functional	T169	C0205245
outcomes	T169	C1274040
patients	T101	C0030705
OPLL	T046	C0206366
cervical laminoplasty	T061	C2026796
included	T169	C0332257
study	T062	C0681814
physical signs	T033	C0311392
hyperreflexia	T033	C0151889
Babinski sign	T033	C0034935
sensory disturbance	T047	C0152027
grip strength	T081	C0429271
10-s grip and release test	T060	C0683443
bladder dysfunction	T046	C0232841
factors	T169	C1521761
age	T032	C0001779
duration of symptoms	T079	C0436359
minor trauma	T037	C0555305
preoperative	T079	C0445204
Japanese Orthopaedic Association (JOA) score	T081	C0449820
investigated	T169	C1292732
potential	T080	C3245505
predictive	T080	C0681890
prognostic factors	T201	C1514474
univariate	T062	C0683962
multivariate analyses	T081	C0026777
mean	T081	C0444504
recovery rate	T081	C1521828
JOA score	T081	C0449820
neurological	T080	C0205494
recovery rate	T081	C1521828
negatively	T033	C0205160
associated with	T080	C0332281
age	T032	C0001779
duration of symptoms	T079	C0436359
Babinski sign	T033	C0034935
positively	T033	C1446409
correlated	T080	C1707520
grip strength	T081	C0429271
Multiple logistic regression analyses	T170	C0034980
revealed	T080	C0443289
age	T032	C0001779
Odds ratio	T081	C0028873
CI	T081	C0009667
Babinski sign	T033	C0034935
Odds ratio	T081	C0028873
CI	T081	C0009667
factors	T169	C1521761
associated with	T080	C0332281
functional	T169	C0205245
outcomes	T169	C1274040
Satisfactory	T080	C0205410
functional	T169	C0205245
outcomes	T169	C1274040
expected	T170	C1517001
patients	T101	C0030705
young	T079	C0332239
Babinski sign	T033	C0034935
Babinski sign	T033	C0034935
useful	T080	C3827682
indicator	T169	C1522602
window of opportunity	T080	C0205556
achieving	T080	C0205556
satisfactory	T080	C0205410
functional	T169	C0205245
outcomes	T169	C1274040
Bacteria	T007	C0004611
Hoverflies	T204	C1005241
Diptera	T204	C0012578
Syrphidae	T204	C1005241
Tree Hollows	T023	C0927234
Iberian Mediterranean Forest	T070	C0086312
Saproxylic insect communities	T204	C0021585
inhabiting	T082	C0337646
tree hollows	T023	C0927234
Mediterranean forests	T070	C0086312
physical characteristics	T080	C1521970
interactions	T169	C1704675
community member species	T185	C1705920
organisms	T001	C0029235
interrelationships	T080	C0439849
relationships	T080	C0439849
saproxylic insects	T204	C0021585
microbiota	T001	C3887843
microhabitats	T082	C0871648
tree hollows	T023	C0927234
Quercus rotundifolia Lamark	T002	C3457247
hold water	T169	C0205245
dead leaves	T002	C0242724
abundant microbial populations	T001	C0599840
larvae	T204	C0023047
Mallota dusmeti	T204	C3900907
Diptera	T204	C0012578
Syrphidae	T204	C1005241
vulnerable species	T185	C1705920
IUCN category	T170	C0683312
Marcos-García	T098	C0027361
Quinto	T098	C0027361
microbiota	T001	C3887843
living inside	T082	C0337646
gut	T023	C0699819
larvae	T204	C0023047
M. dusmeti	T204	C3900907
microbiota	T001	C3887843
hollow	T082	C0332484
larvae	T204	C0023047
develop	T039	C0243107
Bacteria	T007	C0004611
amplification and partial sequencing	T059	C1441475
V1-V3 regions	T028	C0598666
nucleotide sequence	T086	C0004793
16S rRNA genes	T114	C3537372
species of bacteria	T007	C0004611
living in	T082	C0337646
tree hollows	T023	C0927234
species	T185	C1705920
in the gut	T023	C0699819
M. dusmeti	T204	C3900907
larvae	T204	C0023047
Bacillus cereus	T007	C0004590
Bacillus toyonensis	T007	C3715367
Lysinibacillus sphaericus	T007	C0314884
filter-feeding mechanism characteristic	T033	C0243095
M. dusmeti	T204	C3900907
larvae	T204	C0023047
ingestion	T038	C0232478
bacteria	T007	C0004611
Impact sports	T056	C0038039
bone fractures	T037	C0016658
adolescents	T100	C0205653
study	T062	C2603343
investigate	T169	C1292732
effects of	T080	C1704420
different	T080	C1705242
sports	T056	C0038039
stress fractures	T037	C0016664
adolescents	T100	C0205653
month	T079	C0439231
follow-up	T058	C1522577
period	T079	C1948053
sample	T098	C1257890
adolescents	T100	C0205653
groups	T098	C1257890
impact sports	T056	C0038039
swimming	T056	C0039003
non-sports	T056	C0038039
occurrence	T079	C2745955
stress fracture	T037	C0016664
participants	T098	C0679646
coaches	T097	C0876909
confounders	T169	C0009673
age	T032	C0001779
sex	T032	C1522384
resistance training	T061	C0872279
body composition	T032	C0005885
variables	T080	C0439828
age	T032	C0001779
peak	T080	C0444505
height velocity	T081	C0439830
adolescents	T100	C0205653
fractures	T037	C0016658
month	T079	C0439231
period	T079	C1948053
Bone mineral density	T201	C0005938
values	T080	C0042295
adolescents	T100	C0205653
impact sports	T056	C0038039
P-value	T081	C1709380
confounders	T169	C0009673
risk	T078	C0035647
stress fracture	T037	C0016664
adolescents	T100	C0205653
impact sports	T056	C0038039
non-active adolescents	T100	C0205653
hazard ratio	T081	C2985465
HR	T081	C2985465
confidence interval	T081	C0009667
CI	T081	C0009667
swimming	T056	C0039003
practice	T041	C0032893
risk	T078	C0035647
fracture	T037	C0016658
HR	T081	C2985465
CI	T081	C0009667
findings	T033	C0243095
study	T062	C2603343
sports	T056	C0038039
participation	T169	C0679823
adolescents	T100	C0205653
reduction	T080	C0392756
stress fracture	T037	C0016664
risk	T078	C0035647
impact sports	T056	C0038039
results	T169	C1274040
relevant	T080	C2347946
adolescents	T100	C0205653
peak	T080	C0444505
bone mass	T201	C0005938
increased	T081	C0205217
risk	T078	C0035647
fractures	T037	C0016658
Business	UnknownType	C0680840
Health Physics	T091	C0018725
Jobs	T090	C0028811
Changing Market	T057	C0024825
health physics	T091	C0018725
profession	T090	C0028811
radioactive materials	T122	C0182598
commonplace	T081	C0205214
technological advancements	UnknownType	C0681519
industrial complex	T080	C0439855
World War II	T051	C0681710
radiation safety	T067	C3825766
unprecedented scale	T170	C0349674
protective measures against radiation	T068	C3494257
laboratories	T073	C0022877
health physicists	T097	C0334722
protecting people	T061	C0034533
environment	T064	C0242228
medical	T058	C0199168
research	T062	C0035168
industrial	T057	C0021267
use of radioactive materials	T033	C4060843
radiation-generating devices	T074	C2094479
prevalent today	T082	C0205391
Radiation doses	T081	C4019308
airline flights	T073	C0001881
medical procedures	T058	C0199171
Radiation	T070	C0851346
integral to numerous applications	T169	C0205245
medicine	T091	C0025118
dentistry	T091	C0011438
manufacturing	T090	C0682029
scientific research	T062	C0683933
nuclear electric power generation	T073	C0242446
oil and gas exploration	T070	C3179122
routine	T080	C0205547
scripted	T170	C0871893
higher doses	T081	C4019308
health effects	T033	C4060919
understood and avoided	T169	C0205245
Instruments for the detection and measurement of radiation	T074	C3873809
health physics	T091	C0018725
exposures to radiation	T037	C0015333
radioactive materials	T122	C0182598
effectively managed	T058	C0024679
rapid rate	T081	C1521828
creation	T052	C1706214
jobs	T090	C0028811
opportunities in the profession	T078	C1516834
recommendations	T078	C0034866
disappearing specialties	T091	C1273796
Permanence	T079	C0547050
Defended	T054	C0680227
donation	T055	C0282366
circulatory-respiratory determination of death	T060	C0079221
DCDD	T060	C0079221
dead	T040	C0011065
donor	T098	C0029206
rule	T170	C0870077
requires	T080	C0027552
donor	T098	C0029206
dead	T040	C0011065
before	T079	C0332152
organ procurement	T058	C0029210
relevant limb	T080	C2347946
Uniform Determination of Death Act 1981 (USA)	T170	C1947938
person	T098	C0027361
dead	T040	C0011065
cessation	T052	C1880019
circulatory-respiratory function	T169	C0542341
irreversible	T033	C0243095
Critics	T097	C0335034
current	T079	C0521116
practice	T041	C0237607
DCDD	T060	C0079221
argued	T054	C0680226
donor	T098	C0029206
dead	T040	C0011065
time	T079	C0040223
organs	T023	C0178784
procured	T058	C0029210
procurement of organs	T058	C0029210
donors	T098	C0029206
dead	T040	C0011065
donor	T098	C0029206
rule	T170	C0870077
offer	T033	C1444648
new	T080	C0205314
argument	T054	C0680226
defence	T054	C0680227
current	T079	C0521116
DCDD	T060	C0079221
practice	T041	C0237607
interpretation	T170	C0459471
requirement	T169	C1514873
irreversibility	T033	C0243095
permanence	T079	C0547050
Untypeable	T080	C0205370
hepatitis C virus	T005	C0220847
subtypes	T185	C0449560
Pakistan	T083	C0030211
Diagnostically	T169	C0348026
untypeable	T080	C0205370
subtypes	T185	C0449560
hepatitis C virus	T005	C0220847
HCV	T005	C0220847
subtypes	T185	C0449560
Pakistan	T083	C0030211
study	T062	C2603343
chronically infected	T047	C0151317
HCV	T005	C0220847
patients	T101	C0030705
viremia	T047	C0042749
HCV	T005	C0220847
genotyping	T059	C2368152
samples	T077	C2347026
typeable	T080	C0205309
diagnostically	T169	C0348026
untypeable	T080	C0205370
conclusion	T078	C1707478
untypeable	T080	C0205370
HCV	T005	C0220847
subtypes	T185	C0449560
type	T080	C0332307
specific	T080	C0205369
genotyping	T059	C2368152
assay	T059	C0005507
primers	T114	C0206416
rare	T080	C0522498
subtypes	T185	C0449560
minimize	T080	C0392756
untypeable	T080	C0205370
HCV	T005	C0220847
subtypes	T185	C0449560
ITPR3 gene	T028	C1416519
haplotype	T032	C0018591
cervical squamous cell carcinoma	T191	C0279671
risk	T078	C0035647
Taiwanese	T098	C1556096
women	T098	C0043210
Host immunogenetic	T091	C0021005
human papillomavirus (HPV) infection	T047	C0343641
cervical cancer development	T191	C1516170
Inositol 1,4,5-triphosphate receptor type 3	T028	C1416519
ITPR3	T028	C1416519
immune activation	T043	C1155000
cancer	T191	C0006826
pathogenesis	T046	C0699748
ITPR3	T028	C1416519
genetic polymorphisms	T045	C0032529
risk of cervical cancer	T081	C0596244
Taiwanese	T098	C1556096
women	T098	C0043210
ITPR3	T028	C1416519
rs3748079 A/G	T086	C0752046
rs2229634 C/T polymorphisms	T086	C0752046
genotyped	T032	C0017431
hospital-based study	T062	C2603343
women	T098	C0043210
cervical squamous cell carcinoma	T191	C0279671
CSCC	T191	C0279671
healthy control	T080	C2986479
women	T098	C0043210
genotypes	T032	C0017431
HPV	T005	C0021344
CSCC	T191	C0279671
ITPR3	T028	C1416519
variants	T028	C0678941
CSCC	T191	C0279671
HPV-16 positive	T034	C4288937
CSCC	T191	C0279671
haplotype AT	T032	C0018591
CSCC	T191	C0279671
OR	T081	C0028873
CI	T081	C0009667
OR	T081	C0028873
CSCC	T191	C0279671
patients infected	T101	C0030705
HPV-16	T005	C0999806
OR	T081	C0028873
CI	T081	C0009667
linkage disequilibrium analysis	T063	C1517888
ITPR3	T028	C1416519
association	T063	C2717881
CSCC	T191	C0279671
HLA-DRB1	T028	C1415576
alleles	T028	C0002085
AT haplotype	T032	C0018591
ITPR3 gene	T028	C1416519
potential marker	T045	C0017393
genetic susceptibility	T032	C0314657
CSCC	T191	C0279671
categories	T170	C0683312
actionability	T052	C0441655
secondary	T080	C0175668
findings	T033	C0243095
next-generation sequencing	T059	C0162801
Next-generation sequencing	T059	C0162801
clinical practice	T057	C0205897
diagnosis	T033	C0011900
Mendelian diseases	T047	C1285355
secondary	T080	C0175668
findings	T033	C0243095
technique	T169	C0449851
informing patients	T058	C0588446
secondary	T080	C0175668
findings	T033	C0243095
patients	T101	C0030705
research	T062	C0035168
implementation	T052	C1708476
actionability	T052	C0441655
disclosure	T055	C0012625
secondary	T080	C0175668
findings	T033	C0243095
interpretation	T170	C0459471
professionals	T097	C0679924
actionability	T052	C0441655
medical	T169	C0205476
actions	T052	C3266814
patient	T101	C0030705
health-related actions	T055	C0237121
life-plan decisions	T041	C0679006
actionability	T052	C0441655
mutation	T045	C0026882
gene	T028	C0017337
patients	T101	C0030705
secondary	T080	C0175668
findings	T033	C0243095
physician	T097	C0031831
impression	T080	C1998467
patients	T101	C0030705
variants	T028	C0678941
clinical significance	T033	C2826293
genes	T028	C0017337
autonomy	T078	C0085862
conclusions	T078	C1707478
information	T078	C1533716
Allergen	T129	C0002092
Valency	T081	C0392762
Dose	T081	C0178602
FcεRI	T116	C0162825
Occupancy	T080	C2827063
Thresholds	T080	C0449864
Secretory Responses	T043	C1327439
Pen a 1	T116	C0531911
Design	T052	C1707689
Hypoallergens	T129	C0002092
Ag	T196	C0037125
crosslinking	T070	C0178576
IgE	T116	C0020846
FcεRI	T116	C0162825
complexes	T116	C0003313
mast cells	T025	C0024880
basophils	T025	C0004827
allergic response	T046	C1527304
self-reported	T062	C0681906
shrimp allergy	T046	C1628514
shrimp-specific IgE	T116	C1270759
serum	T031	C0229671
basophil	T025	C0004827
secretory	T043	C1327616
responses	T038	C0003261
rPen a 1	T129	C2924509
shrimp	T204	C0037017
tropomyosin	T116	C0041197
FcεRI	T116	C0162825
allergen-specific IgE	T116	C0443736
dose	T081	C0178602
valency	T081	C0392762
Pen a 1	T116	C0531911
clustered regularly interspaced palindromic repeat-based gene editing	T063	C4277689
FcεRIα	T116	C0162825
Pen a 1	T116	C0531911
specific IgE	T116	C0443736
shrimp	T204	C0037017
positive	T033	C1514241
plasma	T031	C0032105
Pen a 1	T116	C0531911
specific IgE	T116	C0443736
Pen a 1	T116	C0531911
dose	T081	C0178602
response for secretion	T043	C3155125
Pen a 1	T116	C0531911
doses	T081	C0178602
Mathematical modeling	T170	C0876936
receptor aggregation	T044	C0034780
kinetics	T070	C0022702
FcεRI	T116	C0162825
IgE	T116	C0020846
allergen	T129	C0002092
dose	T081	C0178602
gE	T116	C1270759
FcεRI	T116	C0162825
complexes	T116	C0003313
specific IgE	T116	C1270759
Pen a 1	T116	C0531911
IgE	T116	C1270759
epitope	T129	C0003316
valency	T081	C0392762
FcεRI	T116	C0162825
pepsin	T116	C0030909
Pen a 1	T116	C0531911
proteolysis	T044	C0597304
gastric	T080	C1704242
digestion	T040	C0012238
secretory responses	T043	C1327439
Recombinant fragments	T116	C0599286
tropomyosin	T116	C0041197
dimerization	T044	C1323329
capacity	T081	C1516240
Pen a 1	T116	C0531911
IgE	T116	C1270759
FcεRI	T116	C0162825
complexes	T116	C0003313
hypoallergens	T129	C0002092
immunotherapy	T061	C0021083
Selected	T052	C1707391
flavonoid compounds	T109	C0596577
inhibitors	T120	C0243077
protein kinase	T116	C0108555
CK2α	T116	C1173607
CK2α'	T116	C1449828
catalytic subunits	T087	C0600499
CK2	T116	C0108555
CK2	T116	C0108555
protein kinase	T116	C0108555
cell functions	T043	C0007613
years	T079	C0439234
target	T169	C1521840
cancer research	T062	C1516225
flavonoid compounds	T109	C0596577
tested	T169	C0039593
inhibitors	T120	C0243077
protein kinase	T116	C0108555
CK2	T116	C0108555
substances	T167	C0439861
highly	T080	C0205250
active against	T078	C3858674
catalytic subunits	T087	C0600499
IC50	T081	C0600495
values	T080	C0042295
CK2α'	T116	C1449828
inhibitor	T120	C0243077
identified	T080	C0205396
chrysoeriol	T109	C0602970
IC50	T081	C0600495
values	T080	C0042295
CK2α	T116	C1173607
CK2α'	T116	C1449828
Fibrinogen	T116	C0016006
Marker	T201	C0005516
Diabetic Foot Ulcer	T047	C1456868
Severity	T080	C0392364
examine	T058	C0220825
fibrinogen levels	T034	C1318051
biomarker	T201	C0005516
assessing	T058	C0220825
disease severity	T080	C0521117
monitoring	T058	C1283169
disease progression	T046	C0242656
patients	T101	C0030705
diabetic foot ulcer	T047	C1456868
DFU	T047	C1456868
retrospective study	T062	C0035363
utility	T169	C0457083
fibrinogen	T116	C0016006
disease severity	T080	C0521117
patients	T101	C0030705
DFU	T047	C1456868
admitted	T058	C0809949
hospital	T073	C0019994
January	T080	C3829466
January	T080	C3829466
patients	T101	C0030705
DFU	T047	C1456868
study group	UnknownType	C0681860
gender	T032	C0079399
people	T101	C0030705
diabetes	T047	C0011849
DFU	T047	C1456868
control group	T096	C0009932
DFU	T047	C1456868
severity	T080	C0392364
Patients	T101	C0030705
DFU	T047	C1456868
subgroups	T185	C1515021
fibrinogen values	T034	C1318051
significantly higher	T081	C4055637
patients	T101	C0030705
DFU	T047	C1456868
grade	T185	C0441800
DFU	T047	C1456868
grades	T185	C0441800
ROC statistic	T081	C0034772
cut-off value	T081	C1522609
amputation	T061	C0002688
sensitivity	T081	C0036667
specificity	T081	C0037791
positive predictive value	T081	C1514243
PPV	T081	C1514243
negative predictive value	T081	C1513918
Fibrinogen values	T034	C1318051
CRP levels	T034	C0428528
neutrophil	T059	C0200633
WBC count	T059	C0023508
Fibrinogen levels	T034	C1318051
assessing	T058	C0220825
disease severity	T080	C0521117
monitoring	T058	C1283169
disease progression	T046	C0242656
patients	T101	C0030705
DFU	T047	C1456868
Nitrogen utilization	T044	C1158469
efficiency	T081	C0013682
prediction	T078	C0681842
nitrogen	T123	C0028158
excretion	T039	C0221102
sheep	T015	C0036945
offered	T033	C1444648
fresh perennial ryegrass	T002	C0331558
Nitrogen	T123	C0028158
excretion	T039	C0221102
sheep	T015	C0036945
production systems	T082	C0557759
nitrate	T197	C0699857
ammonia	T121	C0002607
nitrous oxide	T121	C0028215
groundwater	T082	C0596631
pollution	T069	C0392355
global warming	T069	C0206217
study	T062	C2603343
identify	T080	C0205396
key parameters	T077	C1706198
N utilization	T044	C1158469
efficiency	T081	C0013682
prediction	T078	C0681842
equations	T077	C0552449
manure	T167	C0024765
N	T123	C0028158
feces	T031	C0015733
N	T123	C0028158
urine	T031	C0042036
N	T123	C0028158
outputs	T077	C1709366
sheep	T015	C0036945
Data	T078	C1511726
sheep	T015	C0036945
offered	T033	C1444648
fresh perennial ryegrass	T002	C0331558
sole diet	T168	C0012155
metabolism	T040	C0025519
experiments	T062	C0681814
data	T078	C1511726
non-grass-only diets	T168	C0012155
not used	T169	C0445107
Sheep	T015	C0036945
breeds	T185	C1704650
Highlander	T098	C0027361
Texel	T015	C1297013
Scottish Blackface	T015	C0324108
Swaledale	T015	C1296242
age	T032	C0001779
mo	T079	C0439231
Herbage	T002	C0242775
harvested	T067	C1522240
daily	T079	C0332173
swards	T002	C2700402
harvest	T067	C1522240
dates	T079	C0011008
offering	T033	C1444648
variation	T080	C0205419
range	T081	C1514721
offered	T033	C1444648
farm situations	T082	C0557759
study	T062	C2603343
experimental	T080	C1517586
sward	T002	C2700402
harvested	T067	C1522240
residual height	T032	C0489786
grow	T040	C0018270
wk	T079	C0439230
target	T169	C1521840
sward	T002	C2700402
height	T032	C0489786
range	T081	C1514721
depending	T169	C3244310
time of year	T081	C0556970
Sheep	T015	C0036945
housed	T082	C0557759
d	T079	C0439228
transferred to	T033	C4049693
metabolism	T040	C0025519
d	T079	C0439228
feed	T052	C3853577
intake	T169	C1512806
feces	T031	C0015733
urine	T031	C0042036
outputs	T077	C1709366
Data	T078	C1511726
analyzed	T062	C0936012
linear mixed model procedure	T081	C0023732
prediction	T078	C0681842
equations	T077	C0552449
feces	T031	C0015733
urine	T031	C0042036
manure	T167	C0024765
N	T123	C0028158
outputs	T077	C1709366
N intake	T033	C0556048
herbage	T002	C0242775
chemical composition	T070	C0243176
digestibility	T067	C1522240
effects of	T080	C1704420
sex	T032	C0079399
breed	T185	C1704650
periods	T079	C1948053
removed	T080	C0849355
Nitrogen	T123	C0028158
intake	T169	C1512806
best	T080	C1522427
single predictor	T078	C2698872
N	T123	C0028158
output	T077	C1709366
feces	T031	C0015733
urine	T031	C0042036
manure	T167	C0024765
prediction	T078	C0681842
manure	T167	C0024765
N	T123	C0028158
output	T077	C1709366
greater	T081	C1704243
feces	T031	C0015733
N	T123	C0028158
urine	T031	C0042036
N	T123	C0028158
Animal	T008	C0003062
BW	T032	C0005910
herbage	T002	C0242775
DM	T167	C0439861
ether extract	T081	C0457929
NDF	T168	C0012173
ADF	T168	C0012173
water soluble carbohydrate	T059	C0201929
N	T123	C0028158
digestibility	T067	C1522240
predict	T078	C0681842
N	T123	C0028158
outputs	T077	C1709366
N	T123	C0028158
intake	T169	C1512806
not be available	T080	C0686905
commercial practice	T078	C0009433
prediction	T078	C0681842
equations	T077	C0552449
N utilizatio	T044	C1158469
efficiency	T081	C0013682
increasing	T169	C0442808
feeding	T052	C2987508
level	T080	C0441889
ME	T081	C1442080
concentration	T081	C1446561
reducing	T080	C0392756
N concentration	T033	C0456228
improve	T033	C0184511
N utilization	T044	C1158469
efficiency	T081	C0013682
N	T123	C0028158
excretion	T039	C0221102
feces	T031	C0015733
rather than	T033	C3897775
urine	T031	C0042036
equations	T077	C0552449
study	T062	C2603343
approach	T082	C0449445
sheep	T015	C0036945
producers	T098	C1709696
quantify	T081	C1709793
N	T123	C0028158
excretion	T039	C0221102
production	T057	C0033268
mitigation strategies	T062	C0035171
reduce	T080	C0392756
environmental impact	T067	C0282165
sheep	T015	C0036945
production systems	T082	C0557759
Improving	T080	C1272745
protein complex	T116	C1180347
prediction	T078	C0681842
reconstructing	T170	C0282574
high-confidence	T080	C1704725
protein-protein interaction network	T169	C3178902
Escherichia coli	T007	C0014834
physical interaction	T169	C1704675
data sources	T081	C0011001
protein-protein physical interaction	T044	C0872079
PPI	T044	C0872079
datasets	T170	C0150098
Escherichia coli	T007	C0014834
methodology	T078	C3266812
integrate	T066	C1705422
datasets	T170	C0150098
modules	T077	C1709061
biological process	T038	C3714634
protein complexes	T116	C1180347
Naïve Bayesian formula	T170	C0489829
integrate	T066	C1705422
PPI	T044	C0872079
datasets	T170	C0150098
weighted	T081	C0043100
PPI network	T169	C3178902
weights	T081	C0043100
network	T169	C1882071
methodology	T078	C3266812
integrate	T066	C1705422
physical PPI	T044	C0872079
datasets	T170	C0150098
weighted	T081	C0043100
PPI network	T169	C3178902
detected	T033	C0442726
modules	T077	C1709061
PPI network	T169	C3178902
functional	T169	C0205245
modules	T077	C1709061
co-expression	T061	C0185117
modules	T077	C1709061
functional	T169	C0205245
modules	T077	C1709061
functional	T169	C0205245
modules	T077	C1709061
detected	T033	C0442726
Gene Ontology	T170	C1138831
terms	T078	C1254370
dataset	T170	C0150098
integrating	T066	C1705422
methodology	T078	C3266812
physical PPI	T044	C0872079
datasets	T170	C0150098
orthologous	T080	C1709346
high-confidence	T080	C1704725
interactions	T169	C1704675
organism	T001	C0029235
AP-MS	T059	C0037813
PPI	T044	C0872079
datasets	T170	C0150098
gained high weights	T033	C0043094
integrated	T066	C1705422
networks	T169	C1882071
weights	T081	C0043100
AP-MS	T059	C0037813
PPI	T044	C0872079
dataset	T170	C0150098
datasets	T170	C0150098
public databases	T170	C0242356
detected	T033	C0442726
modules	T077	C1709061
hub protein(s)	T116	C3179452
protein	T116	C0033684
modules	T077	C1709061
detected	T033	C0442726
functionally	T169	C0205245
relevant	T080	C2347946
construct	T185	C2827421
protein complexes	T116	C1180347
high confidence	T080	C1704725
protein complex	T116	C1180347
prediction	T078	C0681842
functional	T169	C0205245
literature	T170	C0023866
AAV9	T005	C1564874
NPC1	T028	C1417776
significantly	T078	C0750502
ameliorates	T033	C0243095
Purkinje cell	T025	C0034143
death	T043	C0007587
behavioral abnormalities	T048	C0233514
mouse	T015	C0025929
NPC disease	T047	C0220756
Niemann-Pick type C (NPC) disease	T047	C0220756
fatal	T080	C1302234
inherited	T169	C0439660
neurodegenerative disorder	T047	C0524851
loss-of-function	T033	C0243095
mutations	T045	C0026882
NPC1	T028	C1417776
NPC2 gene	T028	C1422736
treat	T169	C1292734
NPC disease	T047	C0220756
adeno-associated virus	T005	C1564874
AAV	T005	C1564874
serotype 9	T170	C0449943
AAV9	T005	C1564874
functional	T169	C0205245
NPC1 gene	T028	C1417776
systemically	T169	C0205373
NPC1(-/-)	T028	C1417776
mice	T015	C0206745
postnatal day 4	T061	C0419611
single	T081	C0205171
AAV9-NPC1 injection	T061	C0021485
robust	T080	C2986815
NPC1	T028	C1417776
expression	T045	C0017262
tissues	T024	C0040300
brain	T023	C0006104
heart	T023	C0018787
lung	T023	C0024109
AAV9-mediated	T054	C0086597
NPC1 delivery	T077	C1524066
significantly	T078	C0750502
promoted	T052	C0033414
Purkinje cell	T025	C0034143
survival	T052	C0038952
locomotor activity	T040	C0023946
coordination	T042	C0237543
increased	T081	C0205217
lifespan	T079	C1254367
NPC1(-/-)	T028	C1417776
mice	T015	C0206745
AAV-based gene therapy	T061	C0860404
treat	T169	C1292734
NPC disease	T047	C0220756
Executive functions	T041	C0935584
deficits	T080	C2987487
impair	T169	C0221099
extinction	T041	C0015347
generalization	T041	C0017324
fear	T041	C0015726
movement-related pain	T033	C0240386
Generalization	T041	C0017324
fear	T041	C0015726
movement-related pain	T033	C0240386
movements	T040	C0026649
fear responses	T039	C1327613
movements	T040	C0026649
associated with	T080	C0332281
pain	T184	C0030193
peak-shift effect	T080	C1280500
phenomenon	T067	C1882365
movements	T040	C0026649
elicit	T080	C0449265
fear responses	T039	C1327613
pain-provoking	T184	C1960719
movement	T040	C0026649
CS+	T041	C0234404
CS+	T041	C0234404
variance	T080	C1711260
generalize	T041	C0017324
extinction learning	T041	C0237613
movements	T040	C0026649
pain	T184	C0030193
variance	T080	C1711260
associated with	T080	C0332281
executive function capacity	T041	C0935584
individuals	T098	C0237401
inhibit fear responses	T039	C3894332
examined	T033	C0332128
executive function capacity	T041	C0935584
generalization	T041	C0017324
extinction	T041	C0015347
generalization	T041	C0017324
peak-shift	T169	C0333051
conditioned fear	T041	C1510535
movement-related pain	T033	C0240386
expectancy	T078	C0679138
Healthy participants	T098	C1708335
proprioceptive	T039	C2370956
fear conditioning task	T041	C0009647
Executive function tests	T041	C0935584
updating	T079	C1519814
inhibition	T041	C0021467
extinction	T041	C0015347
fear	T041	C0015726
movement-related pain	T033	C0240386
pain	T184	C0030193
expectancy	T078	C0679138
generalization	T041	C0017324
Low inhibitory capacity	T041	C0021467
associated with	T080	C0332281
extinction	T041	C0015347
generalized fear	T041	C0015726
movement-related pain	T033	C0240386
pain	T184	C0030193
expectancy	T078	C0679138
area-shift	T169	C0333051
peak-shift effect	T080	C1280500
peak	T080	C0444505
conditioned fear response	T039	C1327613
stimulus	T067	C0234402
Participants	T098	C0679646
inhibitory capacity	T041	C0021467
fear responses	T039	C1327613
generalized fear	T041	C0015726
time	T079	C0040223
findings	T033	C0243095
treatments	T169	C1522326
Low inhibitory capacity	T041	C0021467
associated with	T080	C0332281
generalization	T041	C0017324
extinction	T041	C0015347
fear	T041	C0015726
generalization	T041	C0017324
Fear	T041	C0015726
elicited by	T080	C0449265
movement	T040	C0026649
CS+/-	T041	C0234404
CS+	T041	C0234404
stimulus	T067	C0234402
pain-onset	T033	C1507009
Robust	T080	C2986815
DLPP	T081	C0392762
Nongreedy ℓ₁$-Norm Minimization	T080	C0205556
Maximization	T080	C0205556
discriminant locality preserving projection based on L1-norm	T081	C0392762
DLPP-L1	T081	C0392762
robust	T080	C2986815
subspace learning	T041	C0023185
image	T170	C1704922
classification	T185	C0008902
projection	T082	C0348018
vectors	T082	C0442335
greedy strategy	T062	C0035171
projection	T082	C0348018
vectors	T082	C0442335
maximizing	T080	C0205556
objective	T080	C1571702
function	T169	C0542341
solution	T170	C1706817
trace ratio optimization algorithm	T170	C0002045
objective	T080	C1571702
function	T169	C0542341
dimensionality reduction	T170	C0282574
recognition	T041	C0237818
accuracy	T080	C0443131
nongreedy algorithm	T170	C0002045
trace ratio formula	T170	C0489829
DLPP-L1	T081	C0392762
convergence	T052	C2700387
databases	T170	C0242356
algorithm	T170	C0002045
Double-Blind	T062	C0013072
Randomized Controlled Trial	T062	C0206035
Maternal Postpartum	T047	C0157460
Deworming	T061	C0199859
Infant	T100	C0021270
Weight Gain	T033	C0043094
Peruvian	T098	C1553375
Nutritional interventions	T061	C0086153
critical	T080	C1511545
growth and development period	T033	C1397007
age	T032	C0001779
health	T078	C0018684
trajectories	T079	C0750729
life course	T079	C1510618
evidence	T078	C3887511
interventions	T061	C0808232
maternal health	T081	C0024921
days	T079	C0439228
life	T078	C0376558
mothers	T099	C0026591
children	T099	C0680063
intervention	T061	C0808232
deworming	T061	C0199859
maternal postpartum care	UnknownType	C0545491
areas	T082	C0205146
soil	T167	C0037592
transmitted	T169	C0332289
helminth	T204	C0018893
STH	T204	C0018893
infections	T047	C0018889
endemic	T047	C0277550
February	T080	C3830166
August	T080	C3831448
mother	T099	C0026591
infant	T100	C0021270
trial	T062	C0008976
assessing	T058	C0220825
effectiveness	T080	C1280519
maternal postpartum	T047	C0157460
deworming	T061	C0199859
infant	T100	C0021270
maternal health	T081	C0024921
outcomes	T080	C0085415
Following	T079	C0332282
delivery	T040	C0005615
mothers	T099	C0026591
dose	T081	C0178602
albendazole	T109	C0001911
placebo	T122	C1696465
Participants	T098	C0679646
followed-up	T058	C1522577
1	T079	C4082115
6 months	T079	C4082120
postpartum	T079	C0086839
no statistically significant	T033	C1273937
difference	T081	C1705241
weight gain	T033	C0043094
infants	T100	C0021270
experimental	T101	C0237950
control groups	T096	C0009932
mean difference	T081	C0392762
CI	T081	C0009667
6 months	T079	C4082120
age	T032	C0001779
deworming	T061	C0199859
no effect	T080	C1301751
infant morbidity	T046	C0848889
indicators	T081	C0018761
ad hoc analyses	T081	C0026348
mothers	T099	C0026591
positive	T033	C1514241
STHs	T204	C0018893
baseline	T081	C1442488
infants	T100	C0021270
mothers	T099	C0026591
length	T032	C0005890
gain	T081	C1517378
mean difference	T081	C0392762
CI	T081	C0009667
length-for-age z-score	T081	C0449820
mean difference	T081	C0392762
CI	T081	C0009667
6 months	T079	C4082120
age	T032	C0001779
study population	T098	C2348561
STH-infected	T047	C0018889
uninfected	T080	C3898900
mothers	T099	C0026591
maternal postpartum	T047	C0157460
deworming	T061	C0199859
insufficient	T080	C0231180
infant	T100	C0021270
growth	T040	C0018270
morbidity	T046	C0848889
indicators	T081	C0018761
6 months	T079	C4082120
postpartum	T079	C0086839
STH-infected	T047	C0018889
mothers	T099	C0026591
infant	T100	C0021270
length-for-age	T033	C0517420
maternal postpartum	T047	C0157460
deworming	T061	C0199859
study populations	T098	C2348561
prevalences	T081	C0033105
intensities	T185	C4049786
STH infections	T047	C0018889
whipworm	T047	C0040954
hookworm infections	T047	C0019911
public health concern	T058	C0034024
preliminary	T079	C0439611
comparative study	T062	C1579762
classical	T169	C0443177
interventional radiological approaches	T091	C0034602
multi-phase	T079	C0205390
post-mortem CT	T060	C3697228
angiography	T060	C0002978
Multi-phase	T079	C0205390
post-mortem computed tomography angiography	T060	C1536105
MPMCTA	T060	C1536105
new	T080	C0205314
diagnostic tool	T060	C0430022
forensic pathology	T091	C1450224
technique	T169	C0449851
direct visualization	T033	C3846514
vascular	T047	C1402315
solid organ	T023	C0440790
lesions	T033	C0221198
invasiveness	T080	C1301757
procedure	T169	C2700391
surgical denudation	T033	C0243095
inguinal	T029	C0018246
cervical	T082	C0205064
insertion	T061	C0021107
surgical cannulas	T074	C0520453
relatives	T099	C0080103
refusing	T052	C1705116
scientific autopsies	T060	C0004398
hypothesis	T078	C1512571
minimally-invasive procedure	T169	C2711297
interventional radiological techniques	T061	C0344093
MPMCTA	T060	C1536105
replacement	T169	C0559956
surgical cannulas	T074	C0520453
radiological catheters	T074	C0085590
improve	T033	C0184511
approval	T080	C0205540
rate	T081	C1521828
scientific autopsies	T060	C0004398
families	T099	C0015576
aim	T078	C1947946
study	T062	C2603343
feasibility	T062	C0015730
minimally-invasive	T169	C2711297
MPMCTA	T060	C1536105
compare	T052	C1707455
performance	T052	C1882330
current	T079	C0521116
reference-standard	T081	C0034925
consecutively	T080	C1707491
corpses	T017	C0006629
groups	T078	C0441833
contrast	T080	C1979874
enhancement	T052	C2349975
radiological catheters	T074	C0085590
surgical cannulas	T074	C0520453
Corpses	T017	C0006629
data	T078	C1511726
quality	T080	C0332306
imaging procedure	T060	C0011923
compared	T052	C1707455
global vascular	T023	C0005847
opacification	T080	C0449584
cerebral venous opacification	T080	C0449584
lower limbs	T023	C0023216
opacification	T080	C0449584
arterial	T082	C0221464
venous	T082	C0348013
minimally-invasive approach	T169	C2711297
scientific autopsies	T060	C0004398
radiological catheter	T074	C0085590
Vascular	T023	C0005847
opacification	T080	C0449584
optimal	T080	C2698651
effective	T080	C1704419
control reference group	T096	C0009932
surgical cannula	T074	C0520453
incision	T061	C0184898
associated with	T080	C0332281
non-occlusive aspects	T080	C0205556
Correlations	T080	C1707520
physical activity	T056	C0026606
neurocognitive domain functions	T041	C0392335
patients	T101	C0030705
schizophrenia	T048	C0036341
cross-sectional study	T062	C0010362
Neurocognitive dysfunction	T048	C4041080
symptom	T184	C1457887
schizophrenia	T048	C0036341
treatment	T061	C0087111
correlation	T080	C1707520
physical activity	T056	C0026606
neurocognitive function	T041	C0392335
healthy individuals	T098	C0237401
correlation	T080	C1707520
patients	T101	C0030705
schizophrenia	T048	C0036341
relationship	T080	C0439849
inpatients	T101	C0021562
outpatients	T101	C0029921
study	T062	C2603343
examine	T058	C0582103
correlations	T080	C1707520
physical activity	T056	C0026606
neurocognitive domains	T041	C0392335
inpatients	T101	C0021562
outpatients	T101	C0029921
schizophrenia	T048	C0036341
suggestions	T078	C1705535
study	T062	C2603343
patients	T101	C0030705
schizophrenia	T048	C0036341
examined	T058	C0582103
inpatients	T101	C0021562
outpatients	T101	C0029921
years	T079	C0439234
age	T032	C0001779
symptoms	T184	C1457887
assessed	T052	C1516048
Positive	T033	C1446409
Negative	T033	C0205160
Symptom Scale	T170	C0429688
neurocognitive functions	T041	C0392335
Cognitrax	T170	C0871696
neurocognitive index	T060	C0872227
NCI	T060	C0872227
scores	T081	C0449820
participants	T098	C0679646
HJA-750C accelerometer	T074	C0178951
one week	T079	C4082116
measure	T081	C0079809
physical activity	T056	C0026606
durations	T079	C0449238
Partial correlation analyses	T062	C0010101
exercise	T056	C0015259
cognitive	T041	C0009240
parameters	T033	C0449381
outpatient	T101	C0029921
higher	T080	C0205250
physical activity	T056	C0026606
Motor	T169	C1513492
Psychomotor	T041	C0033923
Speeds	T081	C0678536
outpatients	T101	C0029921
higher	T080	C0205250
physical activity	T056	C0026606
associated with	T080	C0332281
lower	T080	C0205251
NCI	T060	C0872227
Attention	T041	C0004268
score	T081	C0449820
Memory	T041	C0025260
scores	T081	C0449820
inpatients	T101	C0021562
higher	T080	C0205250
physical activity	T056	C0026606
associated with	T080	C0332281
neurocognitive functions	T041	C0392335
outpatients	T101	C0029921
inpatients	T101	C0021562
schizophrenia	T048	C0036341
higher	T080	C0205250
physical activity	T056	C0026606
associated with	T080	C0332281
cognitive domains	T041	C0392335
study	T062	C2603343
examining	T058	C0582103
relationship	T080	C0439849
physical activity	T056	C0026606
neurocognitive function	T041	C0392335
inpatients	T101	C0021562
outpatients	T101	C0029921
relationship	T080	C0439849
inpatients	T101	C0021562
outpatients	T101	C0029921
completely	T080	C0205197
calcified	T080	C0175895
prostate	T023	C0033572
Prostatic calcification	T047	C1868729
prostatic calculus	T047	C0149525
formation	T169	C1522492
adult	T100	C0001675
population	T098	C1257890
chronic prostatitis	T047	C0085696
prostatic calcification	T047	C1868729
gland	T023	C0033572
rare	T080	C0522498
presenting	T078	C0449450
case	T169	C0868928
glandular prostate	T023	C0033572
converted	T169	C0392747
stone	T031	C0006736
rare	T080	C0522498
cause	T169	C0015127
gastric obstruction	T047	C0149700
Lighters	T073	C0336770
swallowing	T040	C0011167
majority	T080	C0205164
swallowed foreign bodies	T033	C0520753
thrown	T080	C0849355
spontaneously	T169	C0205359
without	T080	C0332288
causing	T169	C0678227
complications	T046	C0009566
digestive system	T022	C0012240
Multiple	T081	C0439064
number	T081	C0237753
foreign bodies	T037	C0016542
swallowed	T040	C0011167
psychiatric patients	T101	C0748064
delay diagnosis	T080	C2718036
increase	T169	C0442805
complication	T046	C0009566
rate	T081	C1521828
Long	T080	C0205166
hard	T080	C0018599
objects	T037	C0016542
pylorus	T023	C0034196
cause	T169	C0015127
obstruction	T046	C0028778
ulceration	T046	C3887532
bleeding	T046	C0019080
perforation	T033	C0549099
Endoscopy	T060	C0014245
used	T169	C1524063
effective	T080	C1704419
method	T169	C0449851
cases	T169	C0868928
exploratory laparatomy	T060	C0085704
performed	T169	C0884358
unsuccessful	T080	C1272705
endoscopic	T082	C0442418
foreign object	T037	C0016542
removal	T061	C0015252
schizophrenic	T048	C0036341
patient	T101	C0030705
gastric outlet obstruction	T047	C0162651
due to	T169	C0678226
multiple	T081	C0439064
cigarette lighter	T073	C0336770
swallowing	T040	C0011167
lighters	T073	C0336770
removed	T080	C0849355
stomach	T023	C0038351
through	T169	C0332273
gastrotomy	T061	C0192401
lighter	T073	C0336770
removed	T080	C0849355
descending colon	T023	C0227389
milking	T061	C0185115
through	T169	C0332273
anus	T023	C0003461
difficulties	T033	C0033213
psychiatric patients	T101	C0748064
surgery	T061	C0543467
due to	T169	C0678226
intake	T169	C1512806
foreign bodies	T037	C0016542
Ceftaroline fosamil	T109	C2001525
community-acquired pneumonia	T047	C0694549
skin	T022	C1123023
skin structure infections	T046	C3714514
systematic review	T170	C1955832
Ceftaroline	T109	C2001525
administered	T169	C1621583
cephalosporin	T109	C3536856
in vitro	T080	C1533691
expanded	T082	C0205229
activity	T044	C1321418
compared	T052	C1707455
cephalosporins	T109	C3536856
data	T078	C1511726
therapy	T061	C0087111
Review	T170	C1955832
compare	T052	C1707455
efficacy	T080	C1280519
safety	T068	C0036043
ceftaroline	T109	C2001525
antibiotic	T195	C0003232
regimens	T061	C0040808
community-acquired pneumonia	T047	C0694549
CAP	T047	C0694549
complicated skin and skin structure infections	T046	C3714514
cSSSIs	T046	C3714514
databases	T170	C0242356
MEDLINE	T170	C0025141
EBSCO	T170	C0242356
Embase	T170	C0242356
Manual review of references was completed	T170	C3259354
experts	T097	C1522486
unpublished data	T170	C0887929
Randomized controlled trials	T062	C0206035
ceftaroline	T109	C2001525
CAP	T047	C0694549
cSSSI	T046	C3714514
populations	T098	C1257890
Outcomes	T169	C1274040
clinical cure	T033	C3640840
mortality	T081	C0205848
adverse events	T046	C0877248
serious adverse events	T033	C1519255
discontinuation	T061	C4288399
adverse events	T046	C0877248
Meta-analysis	T170	C0282458
outcomes	T169	C1274040
subgroup	T185	C1515021
analyses	T062	C0936012
gram positive infections	T047	C0085426
CAP	T047	C0694549
infections	T046	C3714514
methicillin-resistant Staphylococcus aureus	T007	C1265292
cSSSIs	T046	C3714514
Risk	T078	C0035647
bias	T078	C0242568
studies	T062	C2603343
trials	T062	C0681815
risk	T078	C0035647
bias	T078	C0242568
CAP	T047	C0694549
ceftaroline	T109	C2001525
efficacious	T080	C1280519
clinical cure	T033	C3640840
ceftriaxone	T109	C0007561
risk ratio	T081	C0242492
RR	T081	C0242492
confidence interval	T081	C0009667
CI	T081	C0009667
cSSSIs	T046	C3714514
clinical cure	T033	C3640840
ceftaroline	T109	C2001525
vancomycin	T116	C0042313
aztreonam	T109	C0004521
RR	T081	C0242492
CI	T081	C0009667
mortality	T081	C0205848
serious adverse events	T033	C1519255
discontinuation	T061	C4288399
adverse events	T046	C0877248
adverse events	T046	C0877248
Ceftaroline	T109	C2001525
therapeutic alternative	T061	C0949216
patients	T101	C0030705
CAP	T047	C0694549
cSSSIs	T046	C3714514
risks	T078	C0035647
bias	T078	C0242568
poor external validity	T033	C2924039
first-line agent	T195	C0003232
effects of	T080	C1704420
glucose	T109	C0017725
insulin	T116	C0021641
GLP-1	T116	C0061355
GIP	T116	C0017132
bulbospinal	T029	C0005898
neurons	T025	C0027882
rostral ventrolateral medulla	T023	C2328883
neonatal	T100	C0021289
wistar rats	T015	C0034716
patients	T101	C0030705
diabetes mellitus	T047	C0011849
DM	T047	C0011849
hypertension	T047	C0020538
mechanisms	T169	C0441712
correlation	T080	C1707520
bulbospinal	T029	C0005898
neurons	T025	C0027882
rostral ventrolateral medulla	T023	C2328883
RVLM	T023	C2328883
affected	T169	C0392760
levels	T080	C0441889
glucose	T109	C0017725
insulin	T116	C0021641
incretins	T116	C1562292
glucagon like peptide-1	T116	C0061355
GLP-1	T116	C0061355
glucose-dependent insulinotropic peptide	T116	C0017132
GIP	T116	C0017132
patients	T101	C0030705
DM	T047	C0011849
investigate	T169	C1292732
RVLM	T023	C2328883
neurons	T025	C0027882
activated	T052	C1879547
glucose	T109	C0017725
insulin	T116	C0021641
GLP-1	T116	C0061355
GIP	T116	C0017132
changes	T169	C0392747
membrane potentials	T043	C0025251
bulbospinal	T029	C0005898
RVLM	T023	C2328883
neurons	T025	C0027882
whole-cell	T025	C0007634
patch-clamp technique	T062	C0242625
superfusion	T067	C1254366
levels	T080	C0441889
glucose	T109	C0017725
hormones	T125	C0019932
neonatal	T100	C0021289
Wistar rats	T015	C0034716
brainstem	T023	C0006121
spinal cord	T023	C0037925
preparation	T052	C1521827
experiments	T062	C0681814
low	T080	C0205251
level	T080	C0441889
glucose	T109	C0017725
bulbospinal	T029	C0005898
RVLM	T023	C2328883
neurons	T025	C0027882
insulin	T116	C0021641
superfusion	T067	C1254366
RVLM	T023	C2328883
neurons	T025	C0027882
depolarized	T043	C0234081
GLP-1	T116	C0061355
GIP	T116	C0017132
superfusion	T067	C1254366
RVLM	T023	C2328883
neurons	T025	C0027882
hyperpolarized	T043	C0522208
histological examinations	T059	C0019637
transporters for glucose	T116	C0017742
receptors	T116	C0597357
insulin	T116	C0021641
GLP-1	T116	C0061355
GIP	T116	C0017132
RVLM	T023	C2328883
neurons	T025	C0027882
Low	T080	C0205251
level	T080	C0441889
glucose	T109	C0017725
depolarized	T043	C0234081
RVLM	T023	C2328883
neurons	T025	C0027882
presence	T080	C3854307
glucose transporter 3	T116	C0119484
GLUT3	T116	C0119484
insulin	T116	C0021641
depolarized	T043	C0234081
GLP-1	T116	C0061355
hyperpolarized	T043	C0522208
GIP	T116	C0017132
hyperpolarized	T043	C0522208
RVLM	T023	C2328883
neurons	T025	C0027882
specific	T080	C0205369
receptor	T116	C0597357
low	T080	C0205251
level	T080	C0441889
glucose	T109	C0017725
stimulates	T070	C1948023
bulbospinal	T029	C0005898
RVLM	T023	C2328883
neurons	T025	C0027882
specific	T080	C0205369
transporters	T116	C0017742
neurons	T025	C0027882
inducing	T169	C0205263
hypertension	T047	C0020538
increase	T169	C0442805
insulin	T116	C0021641
reduction	T080	C0392756
incretins	T116	C1562292
activate	T052	C1879547
sympathetic nervous system	T022	C0039044
induce	T169	C0205263
hypertension	T047	C0020538
activating	T052	C1879547
RVLM	T023	C2328883
neurons	T025	C0027882
receptors	T116	C0597357
Mechanisms	T169	C0441712
compensation	T058	C0001549
gait	T033	C0016928
patients	T101	C0030705
drop foot	T047	C0085684
Drop foot	T047	C0085684
syndrome	T047	C0039082
multiple	T081	C0439064
interactions	T169	C1704675
joints	T030	C0022417
muscles	T024	C0026845
Abnormalities	T033	C1704258
movement patterns	T033	C0427096
motion capture techniques	T058	C0752188
compensation	T058	C0001549
mechanisms	T169	C0441712
mechanisms	T169	C0441712
compensatory	T169	C0231186
mechanisms	T169	C0441712
patients	T101	C0030705
drop foot	T047	C0085684
study	T062	C0008972
patients	T101	C0030705
computerized	T066	C0009609
gait analysis system	T074	C3874714
healthy subjects	T098	C1708335
falling	T033	C0427122
intervals	T079	C1272706
percentage	T081	C0439165
differences	T081	C1705241
groups	T098	C1257890
study	T062	C0008972
kinematic parameters	T091	C0600169
control group	T096	C0009932
patient group	T101	C0030705
kinetic parameters	T070	C0022702
falling	T033	C0427122
interval	T079	C1272706
interval	T079	C1272706
spatiotemporal parameters	T062	C3494293
interval	T079	C1272706
kinematic	T091	C0600169
kinetic	T070	C0022702
spatiotemporal parameters	T062	C3494293
gait pattern	T033	C0016928
groups	T098	C1257890
motor deficits	T033	C0521654
compensatory	T169	C0231186
mechanisms	T169	C0441712
drop foot	T047	C0085684
patients	T101	C0030705
kinematic	T091	C0600169
kinetic	T070	C0022702
gait	T033	C0016928
compensation	T058	C0001549
change	T169	C0392747
movement	T040	C0026649
ankle joint	T030	C0003087
Inhibitory	T052	C3463820
effects of	T080	C1704420
Lactobacillus rhamnosus	T007	C0317597
Lactobacillus casei	T007	C0022940
Candida	T004	C0006837
biofilm	T007	C0081786
denture surface	T033	C0457711
Candida albicans	T004	C0006837
biofilm	T007	C0081786
associated with	T080	C0332281
denture-related stomatitis	T047	C0038364
oral candidiasis	T047	C0006849
elderly	T098	C0001792
Probiotics	T007	C0525033
bacteria	T007	C0004611
antibacterial activity	T033	C0243095
pathogenic bacteria	T007	C0004611
investigate	T169	C1292732
antifungal activity	T033	C0243095
probiotics	T007	C0525033
C. albicans	T004	C0006837
inhibitory	T052	C3463820
effects of	T080	C1704420
probiotics	T007	C0525033
Candida	T004	C0006837
biofilm	T007	C0081786
denture surface	T033	C0457711
spent culture media	T130	C0010454
probiotics	T007	C0525033
antifungal efficacy	T080	C1280519
C. albicans	T004	C0006837
Candida	T004	C0006837
biofilm	T007	C0081786
denture base resin	T074	C3503992
treated	T169	C1522326
Lactobacillus rhamnosus	T007	C0317597
Lactobacillus casei	T007	C0022940
biofilm	T007	C0081786
L. rhamnosus	T007	C0317597
L. casei	T007	C0022940
treated	T169	C1522326
C. albicans	T004	C0006837
Colony-forming units	T081	C0553561
C. albicans	T004	C0006837
denture surface	T033	C0457711
spreading	T080	C0332261
agar	T109	C0001771
plate	T074	C0180454
denture base resin	T074	C3503992
treated	T169	C1522326
spent culture media	T130	C0010454
days	T079	C0439228
denture surface	T033	C0457711
roughness	T033	C0243095
atomic force microscope	T059	C0242849
L. rhamnosus	T007	C0317597
L. casei	T007	C0022940
antifungal activity	T033	C0243095
probiotics	T007	C0525033
spent culture medium	T130	C0010454
L. rhamnosus	T007	C0317597
L. casei	T007	C0022940
antifungal activity	T033	C0243095
blastoconidia	T004	C0521050
biofilm	T007	C0081786
C. albicans	T004	C0006837
L. rhamnosus	T007	C0317597
L. casei	T007	C0022940
antifungal activity	T033	C0243095
Candida	T004	C0006837
biofilm	T007	C0081786
biofilm	T007	C0081786
L. rhamnosus	T007	C0317597
L. casei	T007	C0022940
inhibited	T052	C3463820
formation	T169	C1522492
Candida	T004	C0006837
biofilm	T007	C0081786
denture surface	T033	C0457711
probiotics	T007	C0525033
surface roughness	T033	C0243095
denture base resin	T074	C3503992
L. rhamnosus	T007	C0317597
L. casei	T007	C0022940
probiotics	T007	C0525033
prevention	T080	C2700409
treatment	T169	C0039798
denture-related stomatitis	T047	C0038364
Persistent Organic Pollutants	T131	C0001869
POPs	T131	C0001869
atmosphere	T070	C0004178
Chilean	T098	C0239045
cities	T083	C0008848
passive	T080	C3686820
air samplers	T074	C0178984
study	T062	C2603343
passive	T080	C3686820
air samplers	T074	C0178984
polyurethane foam	T109	C0071696
PUF	T109	C0071696
disks	T074	C0180459
deployed	T052	C2825812
cities	T083	C0008848
Chile	T083	C0008107
Santiago	T083	C0017446
STG	T083	C0017446
sampling sites	T082	C0449705
Concepciόn	T083	C0017446
CON	T083	C0017446
Temuco	T083	C0017446
TEM	T083	C0017446
Polychlorinated biphenyls	T109	C0032447
PCBs	T109	C0032447
indicator	T169	C1522602
congeners	T104	C0678518
chlorinated pesticides	T131	C0360424
hexachlorocyclohexanes	T109	C0005038
HCHs	T109	C0005038
dichlorodiphenyl trichloroethanes	T109	C0011041
DDTs	T109	C0011041
flame retardants	T120	C0016198
polybrominated diphenyl ethers	T109	C2350562
PBDEs	T109	C2350562
determined by	T080	C0521095
gas chromatography coupled mass spectrometry	T059	C0024868
GC/MS	T059	C0024868
sampling	T078	C0870078
rate	T081	C1521828
R	T081	C1521828
urban sites	T082	C0178876
estimate	T081	C0750572
atmospheric	T070	C0004178
concentrations	T081	C1446561
individual	T081	C1457900
compounds	T080	C0205198
PCB	T109	C0032447
concentrations	T081	C1446561
air	T167	C0001861
ranged	T081	C1514721
TEM	T083	C0017446
STG	T083	C0017446
CON	T083	C0017446
Higher molecular weight	T080	C1979900
PCBs	T109	C0032447
PCB	T109	C0032447
detected	T033	C0442726
industrial sites	T082	C0442611
Concepción	T083	C0017446
HCHs	T109	C0005038
prevalence	T081	C0683919
γ-HCH	T109	C0005038
sites	T082	C0205145
indicative	T169	C1522602
inputs	T077	C1708517
lindane	T109	C0005038
limited	T169	C0439801
technical	T081	C1553014
HCHs	T109	C0005038
Chile	T083	C0008107
DDTs	T109	C0011041
detected	T033	C0442726
prevalence	T081	C0683919
p,p'-DDE	T109	C0011038
accounting	UnknownType	C0680857
DDTs	T109	C0011041
PBDE	T109	C2350562
concentrations	T081	C1446561
air	T167	C0001861
ranged	T081	C1514721
STG	T083	C0017446
CON	T083	C0017446
TEM	T083	C0017446
similar	T080	C2348205
reported	T170	C0684224
urban areas	T082	C0178876
globally	T080	C2348867
pattern	T082	C0449774
PBDEs	T109	C2350562
cities	T083	C0008848
PBDE	T109	C2350562
dominant	T169	C1527180
sites	T082	C0205145
results	T033	C0683954
assessments	T058	C0220825
air	T167	C0001861
concentrations	T081	C1446561
POPs	T131	C0001869
urban areas	T082	C0178876
country	T083	C0454664
data	T078	C1511726
support	T077	C1521721
Chilean	T098	C0239045
commitments	T041	C0870312
signatory	T169	C4288222
Stockholm Convention	T064	C0242359
POPs	T131	C0001869
reporting	T062	C0011000
member	T097	C2698041
country	T083	C0454664
Group of Latin America and Caribbean Countries (GRULAC) region	T083	C0017446
Intraoperative	T079	C0456904
ketamine	T109	C0022614
reduces	T080	C0392756
immediate	T079	C0205253
postoperative	T079	C0032790
opioid	T109	C0002772
consumption	T169	C1512806
spinal fusion surgery	T061	C0919636
chronic pain	T184	C0150055
patients	T101	C0030705
opioid	T109	C0002772
dependency	T080	C0851827
randomized	T062	C0034656
blinded trial	T062	C2347038
Perioperative	T079	C1518988
handling	T033	C1832073
surgical patients	T101	C0871463
opioid	T109	C0002772
dependency	T080	C0851827
important	T080	C3898777
clinical	T080	C0205210
problem	T033	C0033213
Animal studies	T008	C0683949
ketamine	T109	C0022614
attenuates	T052	C0599946
central sensitization	T047	C2938905
hyperalgesia	T184	C0020429
reduces	T080	C0392756
postoperative	T079	C0032790
opioid	T109	C0002772
opioid tolerance	UnknownType	C0240601
hypothesized	T078	C1512571
intraoperative	T079	C0456904
ketamine	T109	C0022614
reduce	T080	C0392756
immediate	T079	C0205253
postoperative	T079	C0032790
opioid	T109	C0002772
consumption	T169	C1512806
placebo	T122	C1696465
chronic pain	T184	C0150055
patients	T101	C0030705
opioid	T109	C0002772
dependency	T080	C0851827
lumbar spinal fusion surgery	T061	C0186045
Primary outcome	T080	C3274433
morphine	T109	C0026549
consumption	T169	C1512806
0 to 24 hours	T079	C0439585
postoperatively	T079	C0032790
Secondary outcomes	T080	C3274440
acute pain at rest	T184	C0234253
mobilization	T061	C0185112
2 to 24 hours	T079	C0439585
postoperatively	T079	C0032790
visual analogue scale	T060	C3536884
adverse events	T046	C0877248
persistent	T079	C0205322
pain	T184	C0030193
postoperatively	T079	C0032790
patients	T101	C0030705
randomly assigned	T062	C0034656
intraoperative	T079	C0456904
S-ketamine	T109	C2825616
bolus 0.5 mg/kg and infusion	T061	C1511237
placebo	T122	C1696465
Postoperatively	T079	C0032790
patients	T101	C0030705
opioids	T109	C0002772
paracetamol	T109	C0000970
patient-controlled analgesia	T061	C0078944
morphine	T109	C0026549
final analyses	T170	C3899115
patients	T101	C0030705
Patient-controlled analgesia	T061	C0078944
morphine	T109	C0026549
consumption	T169	C1512806
postoperatively	T079	C0032790
significantly	T078	C0750502
reduced	T080	C0392756
ketamine	T109	C0022614
placebo	T122	C1696465
mean	T081	C0444504
difference	T080	C1705242
confidence interval	T081	C0009667
Sedation	T033	C0235195
significantly	T078	C0750502
reduced	T080	C0392756
ketamine	T109	C0022614
postoperatively	T079	C0032790
no significant differences	T033	C3842396
acute pain	T184	C0184567
nausea	T184	C0027497
vomiting	T184	C0042963
hallucinations	T048	C0018524
nightmares	T184	C0028084
Back pain	T184	C0004604
postoperatively	T079	C0032790
preoperative	T079	C0445204
pain	T184	C0030193
significantly	T078	C0750502
improved	T033	C0184511
ketamine	T109	C0022614
placebo	T122	C1696465
intraoperative	T079	C0456904
ketamine	T109	C0022614
significantly	T078	C0750502
reduced	T080	C0392756
morphine	T109	C0026549
consumption	T169	C1512806
0 to 24 hours	T079	C0439585
lumbar fusion surgery	T061	C0186045
opioid	T109	C0002772
dependent	T080	C0851827
patients	T101	C0030705
trend	T079	C1521798
persistent	T079	C0205322
pain	T184	C0030193
postoperatively	T079	C0032790
further	T082	C1517331
investigation	T169	C1292732
Effects of	T080	C1704420
argan oil	T109	C2975054
mitochondrial function	T043	C0007613
antioxidant system	T022	C0460002
activity	T044	C0243102
NADPH	T114	C0027303
generating	T052	C3146294
enzymes	T116	C0014442
acrylamide	T109	C0050587
treated	T061	C0332293
rat	T015	C0034715
brain	T023	C0006104
Argan oil	T109	C2975054
AO	T109	C2975054
compounds	T103	C1706082
polyphenols	T109	C0071649
tocopherols	T109	C0087096
antioxidants	T121	C0003402
Acrylamide	T109	C0050587
ACR	T109	C0050587
classified	T185	C0008902
neurotoxic agent	T131	C0260049
animals	T008	C0003062
humans	T016	C0086418
Mitochondrial	T026	C0026237
oxidative stress	T049	C0242606
dysfunction	T033	C4021734
probable	T081	C0033204
molecular mechanisms	T044	C0678659
neurodegenerative diseases	T047	C0524851
Female	T032	C0086287
Sprague Dawley rats	T015	C0034715
exposed to	T080	C0332157
ACR	T109	C0050587
AO	T109	C2975054
activities	T052	C0441655
cytosolic	T026	C1820051
enzymes	T116	C0014442
xanthine oxidase	T116	C0043317
XO	T116	C0043317
glucose 6-phosphate dehydrogenase	T116	C0017757
G6PDH	T116	C0017757
glutathione-S-transferase	T116	C0017837
GST	T116	C0017837
mitochondrial	T026	C0026237
oxidative stress	T049	C0242606
oxidative phosphorylation	T044	C0030013
OXPHOS	T044	C0030013
tricarboxylic acid cycle	T044	C0008858
TCA	T044	C0008858
enzymes	T116	C0014442
mitochondrial	T026	C0026237
metabolic function	T040	C0025519
adenosine triphosphate	T114	C0001480
ATP	T114	C0001480
level	T080	C0441889
acetylcholinesterase (AChE) activity	T044	C1149827
assessed	T052	C1516048
rat	T015	C0034715
brain	T023	C0006104
Cytosolic	T026	C1820051
mitochondrial	T026	C0026237
antioxidant enzymes	T116	C0014442
significantly	T078	C0750502
diminished	T081	C0205216
brains	T023	C0006104
rats	T015	C0034715
treated with	T061	C0332293
ACR	T109	C0050587
compared	T052	C1707455
control	T096	C0009932
ACR	T109	C0050587
treatment	T061	C0087111
resulted	T169	C1274040
significant	T078	C0750502
reduction	T080	C0392756
brain	T023	C0006104
ATP	T114	C0001480
level	T080	C0441889
mitochondrial	T026	C0026237
metabolic function	T040	C0025519
OXPHOS	T044	C0030013
TCA	T044	C0008858
enzymes	T116	C0014442
Administration	T061	C1533734
AO	T109	C2975054
cytosolic	T026	C1820051
mitochondrial	T026	C0026237
oxidative stress	T049	C0242606
normalizing	T062	C1882115
nicotinamide adenine dinucleotide phosphate	T114	C0027303
NADPH	T114	C0027303
generating	T052	C3146294
enzymes	T116	C0014442
improved	T033	C0184511
mitochondrial function	T043	C0007613
enhancing	T052	C2349975
nicotinamide adenine dinucleotide	T114	C0027270
NADH	T114	C0027270
generated	T052	C3146294
enzymes activities	T044	C0243102
ATP	T114	C0001480
level	T080	C0441889
mitochondria	T026	C0026237
reason	T078	C0392360
AO's	T109	C2975054
beneficial effects	UnknownType	C0683156
study	T062	C2603343
synergistic effects	UnknownType	C0683168
different	T080	C1705242
bioactive compounds	T167	C3714412
effective	T080	C1704419
mitochondria	T026	C0026237
Modulation	T082	C0443264
brain	T023	C0006104
mitochondrial functions	T043	C0007613
antioxidant systems	T022	C0460002
AO	T109	C2975054
development	T169	C1527148
mitochondria	T026	C0026237
targeted	T043	C0599894
antioxidants	T121	C0003402
future	T079	C0016884
Encaged	T073	C0337189
Chironomus riparius	T204	C1677085
larvae	T204	C0023047
assessment	T052	C1516048
trace metal	T121	C0723796
bioavailability	T169	C0470187
transfer	T169	C1705822
landfill leachate	T131	C1720817
collection	T169	C1516698
pond	T083	C0337048
Household	T056	C0001288
wastes	T073	C0018627
constitute	T167	C0729650
vector	T080	C0205556
environmental contamination	T069	C0014419
buried	T082	C1254362
degradation	T169	C0243125
leachates	T131	C1720817
containing	T169	C0332256
significant	T078	C0750502
trace metal	T121	C0723796
TM	T121	C0723796
concentrations	T081	C1446561
constitute	T167	C0729650
risk	T078	C0035647
biota	T070	C1253910
objectives	T170	C0018017
study	T062	C2603343
assess	T052	C1516048
bioavailability	T169	C0470187
transfer	T169	C1705822
potential	T080	C3245505
TMs	T121	C0723796
present	T033	C0150312
water	T121	C0043047
sediments	T070	C0282590
reservoir	T083	C0442537
receiving	T080	C1514756
landfill leachates	T131	C1720817
active	T169	C0205177
biomonitoring	T057	C0005517
exposing	T080	C0443289
laboratory organisms	T001	C1517710
cages	T073	C0337189
deployed	T052	C2825812
in the field	T082	C3539073
Aquatic insects	T001	C0596121
Chironomus riparius	T204	C1677085
larvae	T204	C0023047
represent	T052	C1882932
organisms	T001	C0029235
trophic	T070	C0596583
functioning	T169	C0542341
aquatic ecosystems	T067	C0563034
results	T033	C0683954
water	T121	C0043047
suspended	T169	C1553403
particles	T104	C0597177
sediments	T070	C0282590
significant	T078	C0750502
contaminated	T169	C0205279
TMs	T121	C0723796
As	T121	C0003818
Cd	T131	C0006632
Cu	T121	C0009968
Ni	T123	C0028013
Pb	T131	C0023175
Zn	T121	C0043481
contribution	T052	C1880177
transfer	T169	C1705822
TMs	T121	C0723796
specific	T080	C0205369
element	T196	C0013879
considered	T078	C0750591
Cd	T131	C0006632
sediments	T070	C0282590
Pb	T131	C0023175
suspended	T169	C1553403
particles	T104	C0597177
sediments	T070	C0282590
TMs	T121	C0723796
investigated	T169	C1292732
fractionation	T059	C0016640
insoluble	T080	C0205556
cytosolic	T026	C1820051
fraction	T081	C1264633
revealed	T080	C0443289
detoxification	T061	C0150543
strategies	T041	C0679199
preventing	T169	C1292733
induction	T169	C0205263
deleterious effects	T046	C0879626
individual	T098	C0237401
scale	T077	C1522412
accumulation	T033	C4055506
TMs	T121	C0723796
C. riparius	T204	C1677085
larvae	T204	C0023047
tissues	T024	C0040300
represent	T052	C1882932
significant	T078	C0750502
potentially	T080	C3245505
transferable	T169	C1705822
higher	T080	C0205250
trophic	T070	C0596583
levels	T080	C0441889
Binge-Like	T055	C0556346
Ethanol Exposure	UnknownType	C0814017
Adolescence	T079	C0001578
Febrile	T184	C0015967
Response	T032	C0871261
Rats	T015	C0034721
Ethanol (EtOH) exposure	UnknownType	C0814017
phases	T079	C0205390
life	T078	C0376558
risk of infections	T033	C0582147
alterations	T078	C1515926
central nervous system	T022	C3714787
binge-like	T055	C0556346
EtOH exposure	UnknownType	C0814017
adolescent	T079	C0001578
rats	T015	C0034721
febrile	T184	C0015967
response	T032	C0871261
lipopolysaccharide	T109	C0023810
LPS	T109	C0023810
interleukin-1β	T116	C0021753
IL-1β	T116	C0021753
rats	T015	C0034721
exposed to EtOH	UnknownType	C0814017
postnatal days	T079	C0443281
binge-like	T055	C0556346
Fever	T184	C0015967
LPS	T109	C0023810
intraperitoneally	T082	C0442120
postnatal days	T079	C0443281
IL-β	T116	C0021753
postnatal day	T079	C0443281
Hematological	T091	C0018943
peritoneal macrophages	T025	C0206190
plasma	T031	C0032105
cerebrospinal	T169	C0007807
IL-1β	T116	C0021753
levels	T080	C0441889
postnatal day	T079	C0443281
EtOH exposure	UnknownType	C0814017
adolescence	T079	C0001578
normal body temperature	T033	C0231262
febrile	T184	C0015967
response	T032	C0871261
LPS	T109	C0023810
postnatal	T079	C0443281
febrile	T184	C0015967
response	T032	C0871261
postnatal day	T079	C0443281
EtOH-exposed	UnknownType	C0814017
animals	T015	C0034721
febrile	T184	C0015967
response	T032	C0871261
intracerebroventricular	T082	C0595818
IL-1β	T116	C0021753
animals	T015	C0034721
binge-like	T055	C0556346
EtOH exposure	UnknownType	C0814017
adolescence	T079	C0001578
Acute oral treatment	T169	C1527415
EtOH	T109	C0001962
LPS	T109	C0023810
administration	T061	C1533734
febrile	T184	C0015967
response	T032	C0871261
LPS	T109	C0023810
Binge-like	T055	C0556346
EtOH exposure	UnknownType	C0814017
adolescence	T079	C0001578
hematological	T091	C0018943
viability	T043	C0007620
peritoneal macrophages	T025	C0206190
Binge-like	T055	C0556346
EtOH exposure	UnknownType	C0814017
plasma	T031	C0032105
IL-1β	T116	C0021753
levels	T080	C0441889
cerebrospinal fluid	T031	C0007806
levels	T080	C0441889
cytokine	T116	C0079189
binge-like	T055	C0556346
EtOH exposure	UnknownType	C0814017
adolescence	T079	C0001578
central nervous system	T022	C3714787
febrile	T184	C0015967
response	T032	C0871261
cessation	T052	C1880019
EtOH exposure	UnknownType	C0814017
LPS	T109	C0023810
IL-1β	T116	C0021753
Genital	T047	C2945680
Extragenital Gonorrhea	T047	C0018081
Chlamydia	T047	C0008149
Children	T100	C0008059
Adolescents	T100	C0205653
Evaluated	T058	C0220825
Sexual Abuse	T037	C0282350
study	T062	C2603343
nucleic acid amplification test	T059	C0200932
detecting	T061	C1511790
genital	T007	C1993250
extragenital Neisseria gonorrhoeae	T007	C1993250
NG	T007	C1993250
Chlamydia trachomatis	T007	C0008151
CT	T007	C0008151
children	T100	C0008059
adolescents	T100	C0205653
assessed	T058	C0184514
sexual abuse	T037	C0282350
assault	T048	C0237236
children	T100	C0008059
aged	T032	C0001779
years	T079	C0439234
evaluated	T058	C0220825
sexual victimization	T068	C0376695
emergency department	T073	C0562508
outpatient settings	T093	C0013966
Data	T078	C1511726
age	T032	C0001779
sex	T032	C0079399
sexual contact	T033	C2229923
anogenital	T029	C4071900
findings	T033	C0243095
previous	T079	C0205156
sexual contact	T033	C2229923
toxicology results	T033	C2348811
sites	T082	C0205145
tested	T059	C0022885
NG	T007	C1993250
CT	T007	C0008151
patients	T101	C0030705
tested	T059	C0022885
tested	T059	C0022885
site	T082	C0205145
infected	T033	C0439663
site	T082	C0205145
Chlamydia trachomatis	T007	C0008151
patients	T101	C0030705
NG	T007	C1993250
bivariate analysis	UnknownType	C0681927
associated with	T080	C0332281
female sex	T032	C0086287
age	T032	C0001779
years	T079	C0439234
previous	T079	C0205156
sexual contact	T033	C2229923
healed	T169	C0205249
genital injury	T037	C0560637
drug/alcohol intoxication	T033	C4061089
examination	T058	C0582103
hours	T079	C0439227
sexual contact	T033	C2229923
patients	T101	C0030705
positive	T033	C1514241
anal	T023	C0003461
tests	T059	C0022885
positive	T033	C1514241
oral	T082	C0442027
tests	T059	C0022885
patients	T101	C0030705
positive	T033	C1514241
extragenital tests	T059	C0022885
positive	T033	C1514241
tests	T059	C0022885
anogenital	T029	C4071900
injury	T037	C0178314
positive	T033	C1514241
anal	T023	C0003461
oral	T082	C0442027
test	T059	C0022885
genitals	T023	C0017420
site	T082	C0205145
Positive	T033	C1514241
tests	T059	C0022885
NG	T007	C1993250
CT	T007	C0008151
patients	T101	C0030705
evaluated	T058	C0220825
sexual victimization	T068	C0376695
infection	T046	C3714514
sexual contact	T033	C2229923
contiguous spread	T080	C0332261
infection	T046	C3714514
infected assailant secretions	T031	C0036537
patient	T101	C0030705
symptoms	T184	C1457887
sexual contact	T033	C2229923
NG	T047	C0948747
CT infections	T047	C0518948
patients	T101	C0030705
evaluated	T058	C0220825
sexual victimization	T068	C0376695
Longitudinal	T082	C0205127
Effects of	T080	C1704420
Parenting	T055	C0679001
Adaptive Behavior	T055	C0085880
Children	T100	C0008059
Fragile X Syndrome	T047	C0016667
studies	T062	C2603343
declines	T080	C0392756
adaptive behavior	T055	C0085880
children	T100	C0008059
fragile X syndrome	T047	C0016667
FXS	T047	C0016667
middle	T079	C1254367
childhood	T079	C0231335
examined	T033	C0332128
effects of	T080	C1704420
maternal	T099	C0026591
responsivity	T041	C2371924
adaptive behavior	T055	C0085880
children	T100	C0008059
FXS	T047	C0016667
homes	T073	C0442513
middle	T079	C1254367
childhood	T079	C0231335
analyses	T062	C0936012
sustained	T169	C0443318
maternal	T099	C0026591
responsivity	T041	C2371924
significant	T078	C0750502
positive impact	T080	C4049986
trajectories	T082	C1254362
communication	T054	C0009452
adaptive behavior	T055	C0085880
domains	T077	C1516778
middle	T079	C1254367
childhood	T079	C0231335
effects	T080	C1280500
significant	T078	C0750502
controlling	T067	C2239193
autism symptoms	T033	C4314700
developmental level	T040	C0008071
children	T100	C0008059
declines	T080	C0392756
adaptive behavior	T055	C0085880
middle	T079	C1254367
childhood	T079	C0231335
sustained	T169	C0443318
high levels	T080	C0441889
maternal	T099	C0026591
responsivity	T041	C2371924
minimized	T080	C1524031
decline	T080	C0392756
observed	T169	C1441672
communication	T054	C0009452
socialization	T065	C0037447
daily living domains	UnknownType	C0683251
Development	T169	C1527148
Validation	T062	C1519941
Method	T059	C0022885
Diagnosis	T033	C0011900
Avian	T012	C0005595
Botulism	T037	C0006057
Liver	T023	C0023884
matrix	T031	C1706515
laboratory	T059	C0022885
confirmation of	T080	C0521091
avian	T012	C0005595
botulism	T037	C0006057
real-time PCR	T063	C1709846
developed	T169	C1527148
optimized	T052	C2698650
validated	T062	C1519941
analytical	T062	C0936012
steps	T077	C1261552
preceding	T079	C0332152
PCR	T063	C0032520
detection	T033	C0442726
Clostridium botulinum group III	T007	C4303900
avian	T012	C0005595
liver	T023	C0023884
pre	T079	C0332152
PCR	T063	C0032520
steps	T077	C1261552
enrichment	T130	C0010454
incubation	T059	C1439852
liver	T023	C0023884
37°C	T059	C1545716
h	T079	C0439227
anaerobic chamber	T074	C0179876
DNA extraction	T063	C3839098
enzymatic digestion	T059	C0523169
DNA purification	T059	C0872148
sample	T077	C2347026
storage	T169	C1698986
analysis	T062	C0936012
effect	T080	C1280500
detection	T033	C0442726
group III C. botulinum strains	T007	C4304189
results	T169	C1274040
storage	T169	C1698986
temperatures	T081	C0039476
Short-term	T079	C0443303
storage	T169	C1698986
h	T079	C0439227
decrease	T081	C0547047
sensitivity	T169	C0332324
h	T079	C0439227
storage	T169	C1698986
temperature	T081	C0039476
Analysis	T062	C0936012
livers	T023	C0023884
pooling	T169	C2349200
samples	T077	C2347026
enrichment culturing	T059	C0040284
Pooling	T169	C2349200
DNA extraction	T063	C3839098
livers	T023	C0023884
enrichment medium	T130	C0010454
Pulsifier® blender	T074	C0492537
Surrey	T083	C0454877
UK	T083	C0041700
paddle blender	T074	C0492537
Spiked liver	T023	C0023884
samples	T077	C2347026
detection	T033	C0442726
spores	T007	C0038028
liver	T023	C0023884
types C	T007	C4304189
D	T007	C4304187
spores	T007	C0038028
type E	T007	C4303900
method	T059	C0022885
developed	T169	C1527148
analysis	T062	C0936012
samples	T077	C2347026
outbreaks	T081	C0021149
specificity	T081	C0037791
sensitivity	T169	C0332324
compared	T052	C1707455
PCR	T063	C0032520
methods	T059	C0022885
mosaic type C	T007	C4304189
D	T007	C4304187
neurotoxin	T131	C0027934
samples	T077	C2347026
wild	T012	C0325328
domestic birds	T012	C0324556
Quality Improvement	T057	C2936612
Liver	T023	C0023884
Ultrasound	T060	C0041618
Images	T170	C1704922
Fuzzy	T170	C0162586
Techniques	T170	C0025663
Liver	T023	C0023884
ultrasound	T060	C0041618
images	T170	C1704922
diagnose	T033	C0011900
diffuse liver diseases	T047	C0023895
fatty liver	T047	C0015695
low	T080	C0205251
quality	T080	C0332306
images	T170	C1704922
analyze	T062	C0936012
diagnose	T033	C0011900
diseases	T047	C0012634
study	T062	C2603343
contrast	T080	C1979874
quality	T080	C0332306
liver	T023	C0023884
ultrasound	T060	C0041618
images	T170	C1704922
study	T062	C2603343
image	T170	C1704922
contrast	T080	C1979874
enhancement algorithms	T170	C0002045
fuzzy logic	T170	C0162586
liver	T023	C0023884
ultrasound	T060	C0041618
images	T170	C1704922
kidney	T023	C0022646
Matlab2013b	T073	C0037585
image	T170	C1704922
contrast	T080	C1979874
quality	T080	C0332306
fuzzy	T170	C0162586
definition	T170	C1704788
image	T170	C1704922
contrast	T080	C1979874
improvement	T077	C2986411
algorithms	T170	C0002045
fuzzy	T170	C0162586
intensification operator	T074	C0181273
contrast	T080	C1979874
improvement	T077	C2986411
algorithms	T170	C0002045
fuzzy	T170	C0162586
image	T170	C1704922
histogram hyperbolization	T170	C0025663
contrast	T080	C1979874
improvement	T077	C2986411
algorithms	T170	C0002045
fuzzy	T170	C0162586
IF-THEN rules	T170	C0870077
measurement	T169	C0242485
Mean Squared Error	T080	C0743559
Peak	T080	C0444505
Signal to Noise Ratio	T081	C2986823
images	T170	C1704922
fuzzy	T170	C0162586
methods	T170	C0025663
results	T169	C1274040
implementation	T052	C1708476
compared	T052	C1707455
histogram equalization method	T170	C0025663
improvement	T077	C2986411
contrast	T080	C1979874
visual quality	T033	C0422976
images	T170	C1704922
improvement	T077	C2986411
liver	T023	C0023884
segmentation algorithms	T170	C0002045
images	T170	C1704922
Comparison	T052	C1707455
algorithms	T170	C0002045
fuzzy logic	T170	C0162586
image	T170	C1704922
contrast	T080	C1979874
compared	T052	C1707455
image processing	T066	C0178706
algorithms	T170	C0002045
contrast	T080	C1979874
improvement	T077	C2986411
fuzzy	T170	C0162586
intensification operator	T074	C0181273
algorithm	T170	C0002045
method	T170	C0025663
studies	T062	C2603343
ultrasound	T060	C0041618
images	T170	C1704922
quality improvement	T057	C2936612
image processing	T066	C0178706
analysis	T062	C0936012
applications	T169	C4048755
Development	T169	C1527148
pediatric quality of life inventory	T170	C2698752
neurofibromatosis type 1	T191	C0027831
module	T170	C3542953
items	T062	C0871509
children	T100	C0008059
adolescents	T100	C0205653
young adults	T100	C0238598
qualitative methods	T062	C0681940
Health-related quality of life	T078	C4279947
HRQOL	T078	C4279947
important	T080	C3898777
measures	T081	C0079809
evaluating	T058	C0220825
effectiveness	T080	C1280519
clinical treatments	T061	C1516635
disease	T047	C0012634
specific	T080	C0205369
outcome measure	T081	C0086749
assess	T058	C0184514
HRQOL	T078	C4279947
children	T100	C0008059
adolescents	T100	C0205653
young adults	T100	C0238598
Neurofibromatosis Type 1	T191	C0027831
NF1	T191	C0027831
study	T062	C2603343
items	T062	C0871509
content validity	T080	C1510592
Pediatric Quality of Life Inventory™	T170	C2698752
PedsQL™	T170	C2698752
NF1	T191	C0027831
Module	T170	C3542953
children	T100	C0008059
adolescents	T100	C0205653
young adults	T100	C0238598
iterative	T033	C1854293
process	T067	C1522240
multiphase qualitative methods	T062	C0681940
literature review	T170	C0282441
survey	T170	C0038951
expert opinions	T077	C0600219
semi-structured interviews	T052	C0021822
cognitive	T169	C1516691
interviews	T052	C0021822
pilot testing	T062	C0031928
domains	T169	C1880389
qualitative methods	T062	C0681940
content	T077	C0456205
items	T062	C0871509
domains	T169	C1880389
skin	T022	C1123023
pain	T184	C0030193
pain	T184	C0030193
impact	T080	C4049986
pain management	T061	C0002766
cognitive functioning	T041	C0392335
speech	T040	C0037817
fine motor	T042	C0678857
balance	T169	C0205415
vision	T040	C0042789
perceived	T041	C0030971
physical appearance	T184	C0750731
communication	T054	C0009452
worry	T033	C0233481
treatment	T061	C0087111
medicines	T121	C0013227
gastrointestinal symptoms	T184	C0426576
limited	T169	C0439801
participants	T098	C0679646
single	T081	C0205171
site	T082	C0205145
Qualitative methods	T062	C0681940
content validity	T080	C1510592
PedsQL™	T170	C2698752
NF1	T191	C0027831
Module	T170	C3542953
children	T100	C0008059
adolescents	T100	C0205653
young adults	T100	C0238598
PedsQL™	T170	C2698752
NF1	T191	C0027831
Module	T170	C3542953
national multisite field testing	T169	C0039593
psychometric	T060	C0033920
validation	T062	C1519941
instrument	T170	C0038951
development	T169	C1527148
Mimiviruses	T005	C1671055
Human	T016	C0086418
Interferon	T116	C3652465
System	T022	C0020962
Viral Evasion	T043	C1154492
Classical	T169	C0443177
Antiviral Activities	T040	C1155328
Inhibition	T052	C3463820
Interferon-β	T116	C0015980
Regulated	T038	C1327622
Immunomodulatory	T061	C1963758
Pathway	T077	C1705987
review	T170	C0282443
role	T077	C1705810
mimiviruses	T005	C1671055
potential	T080	C3245505
human	T016	C0086418
pathogens	T001	C0450254
clinical	T080	C0205210
evolutionary	T045	C0015219
evidence	T078	C3887511
propose	T080	C1553874
antiviral	T040	C1155328
immunomodulatory	T121	C0005525
pathway	T077	C1705987
controlled	T169	C2587213
interferon-β	T116	C0015980
IFN-β	T116	C0015980
immune-responsive gene 1	T116	C3253749
IRG1	T116	C3253749
itaconic acid	T109	C0064110
product	T071	C1514468
Acanthamoeba polyphaga Mimivirus	T005	C1644952
APMV	T005	C1644952
isolated	T169	C0205409
amoebae	T204	C0002642
hospital	T073	C0019994
investigating	T169	C1292732
pneumonia	T047	C0032285
outbreak	T067	C0012652
Mimivirus	T005	C1671055
ubiquity	T080	C0205556
role	T077	C1705810
protist	T001	C0597305
pathogens	T001	C0450254
putative	T082	C0205124
status	T169	C1442792
human	T016	C0086418
pathogen	T001	C0450254
gaining	T081	C1517378
strength	T078	C0808080
evidence	T078	C3887511
study	T062	C2603343
APMV	T005	C1644952
human	T016	C0086418
cells	T025	C0007634
interaction	T040	C1752856
virus	T005	C1671055
evade	T040	C1654934
IFN	T116	C0021747
system	T022	C0020962
inhibiting	T052	C3463820
regulation	T045	C0017263
interferon	T116	C3652465
genes	T028	C0017337
virus	T005	C1671055
humans	T016	C0086418
host-pathogen interactions	T040	C1752856
virus	T005	C1671055
capable	T080	C2698977
IFN-α2	T116	C2937361
IFN-β	T116	C0015980
treated	T169	C1522326
cells	T025	C0007634
exclusive	T078	C1548966
IFN-β	T116	C0015980
antiviral	T040	C1155328
pathway	T077	C1705987
hypothesis	T078	C1512571
based	T078	C1705938
preliminary data	T078	C1548161
published articles	T170	C1706852
IFN-β	T116	C0015980
preferentially	T078	C0558295
upregulates	T044	C0041904
IRG1 in human	T116	C3253749
macrophagic cells	T025	C0024432
itaconic acid	T109	C0064110
metabolite	T123	C0870883
metabolism	T040	C0025519
antiviral activity	T040	C1155328
inactivating	T169	C0544461
virus	T005	C1671055
immunomodulatory	T061	C1963758
pathway	T077	C1705987
relevant	T080	C2347946
APMV	T005	C1644952
infections	T046	C3714514
infectious diseases	T047	C0009450
Heteroprotein	T116	C0033684
Complex	T104	C1704241
Bovine Lactoferrin	T116	C1440867
Pea Protein	T116	C3535674
Isolate	T121	C1875400
Associative	T080	C0205556
electrostatic interactions	UnknownType	C0683119
oppositely	T080	C0205556
charged	T032	C1706211
globular proteins	T116	C0178663
lactoferrin	T116	C0022942
LF	T116	C0022942
pea protein	T116	C3535674
isolate	T121	C1875400
PPI	T116	C3535674
mixture	T167	C0439962
vicilin	T116	C0078228
legumin	T116	C0064738
convicilin	T116	C0056265
studied	T062	C2603343
specific	T080	C0205369
PPI	T116	C3535674
LF	T116	C0022942
molar ratio	T081	C2825550
room temperature	T033	C1822393
Structural	T082	C0678594
aspects	T080	C1879746
electrostatic	T070	C0376534
complexes	T104	C1704241
different	T080	C1705242
length	T081	C1444754
scales	T081	C0449286
investigated	T169	C1292732
function	T169	C0542341
pH	T081	C0020283
different	T080	C1705242
complementary techniques	T169	C0449851
dynamic light scattering	T059	C1882368
small-angle X-ray scattering	T059	C1537058
SAXS	T059	C1660735
turbidity measurements	T059	C2700094
atomic force microscopy	T059	C0242849
AFM	T059	C0242849
techniques	T169	C0449851
results	T034	C0456984
consistently	T078	C0332290
displayed	T169	C0870432
complexation	T104	C1704241
LF	T116	C0022942
PPI	T116	C3535674
occur	T052	C1709305
optimum	T080	C2698651
narrow	T080	C0333164
range	T081	C1514721
pH	T081	C0020283
viscous	T080	C0311419
liquid	T033	C1304698
phase	T079	C0205390
complex	T104	C1704241
coacervate	T167	C0302908
obtained	T169	C1301820
centrifugation	T059	C0007703
turbid	T080	C0311420
LF	T116	C0022942
PPI	T116	C3535674
mixture	T167	C0439962
maximum	T081	C0806909
turbidity	T080	C0301633
ζ-potential	T067	C0597697
observed	T169	C1441672
pH	T081	C0020283
SAXS	T059	C1660735
data	T078	C1511726
coacervates	T167	C0302908
densely	T080	C0439794
assembled	T052	C1706853
roughly	T080	C0205556
spherical	T082	C0332501
size	T082	C0456389
distribution	T082	C0037775
maximum	T081	C0806909
extension	T169	C0231448
pH	T081	C0020283
AFM	T059	C0242849
image analysis	T059	C0200765
size	T082	C0456389
distributions	T082	C0037775
containing	T169	C0332256
frequent	T079	C0332183
cluster	T081	C1704332
sizes	T082	C0456389
spherical	T082	C0332501
elliptical shapes	T082	C1947977
frequent	T079	C0332183
chainlike	T080	C0205556
structures	T082	C0678594
frequently	T079	C0332183
observed	T169	C1441672
complexes	T104	C1704241
LF	T116	C0022942
PPI	T116	C3535674
coacervation	T067	C1882365
frequent	T079	C0332183
chain-like aggregates	T080	C0205418
PPI	T116	C3535674
PPI	T116	C3535674
complexes	T104	C1704241
Visual	T169	C0234621
outcome	T169	C1274040
endocrine function	T039	C0678896
tumor	T191	C0027651
control	T169	C2587213
fractionated stereotactic radiation therapy	T061	C4289264
craniopharyngiomas in adults	T191	C0278875
prospective cohort	T062	C1709709
study	T062	C2603343
examine	T058	C0582103
visual	T169	C0234621
outcome	T169	C1274040
endocrine function	T039	C0678896
tumor	T191	C0027651
control	T169	C2587213
prospective cohort	T062	C1709709
craniopharyngioma	T191	C0010276
patients	T101	C0030705
treated with	T061	C0332293
fractionated stereotactic radiation therapy	T061	C4289264
FSRT	T061	C4289264
adult	T100	C0001675
patients	T101	C0030705
craniopharyngiomas	T191	C0010276
eligible	T080	C1548635
analysis	T062	C0936012
treated with	T061	C0332293
linear accelerator-based	T074	C0221878
FSRT	T061	C4289264
cases	T077	C1706256
diagnosis	T062	C1704656
histological	T169	C0205462
analysis	T062	C0936012
prescription	T058	C0033080
dose	T081	C0178602
tumor	T191	C0027651
Gy	T081	C0556636
median	T081	C0876920
range	T081	C1514721
Gy	T081	C0556636
fraction	T081	C1264633
radiation dose	T081	C4019308
optic nerves	T023	C0029130
chiasm	T023	C0029126
Gy	T081	C0556636
median	T081	C0876920
range	T081	C1514721
cohort	T098	C0599755
ophthalmological	T061	C0200149
endocrine evaluations	T058	C2960670
magnetic resonance imaging	T060	C0024485
MRI	T060	C0024485
scans	T060	C0441633
Median	T081	C0876920
follow-up	T058	C1522577
years	T079	C0439234
range	T081	C1514721
years	T079	C0439234
range	T081	C1514721
years	T079	C0439234
range	T081	C1514721
visual	T169	C0234621
outcome	T169	C1274040
endocrine function	T039	C0678896
tumor	T191	C0027651
control	T169	C2587213
Visual acuity	T201	C0042812
impairment	T169	C0221099
patients	T101	C0030705
visual field defects	T033	C3887875
patients	T101	C0030705
FSRT	T061	C4289264
patient	T101	C0030705
radiation-induced optic neuropathy	T047	C4302401
years	T079	C0439234
FSRT	T061	C4289264
patients	T101	C0030705
pituitary deficiency	T047	C0020635
FSRT	T061	C4289264
pituitary deficiency	T047	C0020635
FSRT	T061	C4289264
Mean	T081	C0444504
tumor volume	T081	C0475276
FSRT	T061	C4289264
range	T081	C1514721
FSRT	T061	C4289264
range	T081	C1514721
Tumor	T191	C0027651
control	T169	C2587213
rate	T081	C1521828
years	T079	C0439234
FSRT	T061	C4289264
FSRT	T061	C4289264
cohort	T098	C0599755
craniopharyngiomas	T191	C0010276
case	T077	C1706256
radiation-induced optic neuropathy	T047	C4302401
case	T077	C1706256
endocrinopathy	T047	C0014130
Tumor	T191	C0027651
control	T169	C2587213
rate	T081	C1521828
Scutellaria barbata D. Don extract	T123	C1999758
inhibits	T052	C3463820
tumor growth	T191	C0598934
down-regulating	T044	C0013081
Treg cells	T025	C0039198
manipulating	T040	C2584326
Th1	T043	C1155080
Th17 immune response	T040	C3156592
hepatoma H22	T025	C0677626
mice	T015	C0025929
Scutellaria barbata D. Don extract	T123	C1999758
SBE	T123	C1999758
inhibitor	T121	C0018282
hepatoma	T191	C0023903
immune function	T042	C1817756
hepatoma H22	T025	C0677626
mice	T015	C0025929
immunomodulatory function	T044	C1148560
SBE	T123	C1999758
tumor growth	T191	C0598934
hepatoma	T191	C0023903
unclear	T033	C3845108
study	T062	C2603343
investigate	T169	C1292732
anti-tumor	T080	C2986475
effects	T080	C1280500
SBE	T123	C1999758
hepatoma H22	T025	C0677626
mice	T015	C0025929
immunomodulatory function	T044	C1148560
hepatoma H22	T025	C0677626
mice	T015	C0025929
treated	T169	C1522326
SBE	T123	C1999758
days	T079	C0439228
effect of	T080	C1704420
SBE	T123	C1999758
proliferation	T043	C0596290
HepG2 cells	T025	C2717940
in vitro	T080	C1533691
growth of transplanted tumor	T191	C0598934
cytotoxicity of natural killer (NK) cells	T043	C1159807
spleen	T023	C0037993
amount	T081	C1265611
CD4(+)CD25(+)Foxp3(+) Treg cells	T121	C3830403
Th17 cells	T025	C2936411
tumor tissue	T024	C0475358
levels	T080	C0441889
IL-10	T116	C3179724
TGF-β	T116	C0076930
IL-17A	T116	C1705947
IL-2	T116	C0021756
IFN-γ	T116	C0211279
serum	T031	C0229671
hepatoma H22	T025	C0677626
mice	T015	C0025929
IL-17A	T116	C1705947
injected	T169	C0449894
SBE	T123	C1999758
treated	T169	C1522326
mice	T015	C0025929
day	T079	C0439228
post	T079	C0687676
H22	T025	C0677626
inoculation	T061	C2987620
effect	T080	C1280500
tumor growth	T191	C0598934
SBE	T123	C1999758
treatment	T169	C1522326
inhibited	T080	C0311403
proliferation	T043	C0596290
HepG2 cells	T025	C2717940
in vitro	T080	C1533691
dose-dependent manner	T169	C0205245
suppressed	T169	C1260953
tumor growth	T191	C0598934
hepatoma H22	T025	C0677626
mice	T015	C0025929
increased	T081	C0205217
NK cells' cytotoxicity	T043	C1159807
spleen	T023	C0037993
down-regulated	T044	C0013081
amount	T081	C1265611
CD4(+)CD25(+)Foxp3(+) Treg cells	T121	C3830403
Th17 cells	T025	C2936411
tumor tissue	T024	C0475358
decreased	T081	C0205216
IL-10	T116	C3179724
TGF-β	T116	C0076930
IL-17A	T116	C1705947
levels	T080	C0441889
increased	T081	C0205217
IL-2	T116	C0021756
IFN-γ	T116	C0211279
levels	T080	C0441889
serum	T031	C0229671
hepatoma H22	T025	C0677626
mice	T015	C0025929
administration	T081	C0001555
recombinant mouse	T015	C0025929
IL-17A	T116	C1705947
reversed	T169	C1555029
anti-tumor	T080	C2986475
effects	T080	C1280500
SBE	T123	C1999758
SBE	T123	C1999758
inhibit	T052	C3463820
proliferation	T043	C0596290
HepG2 cells	T025	C2717940
in vitro	T080	C1533691
SBE	T123	C1999758
inhibit	T052	C3463820
growth	T043	C0007595
H22	T025	C0677626
implanted tumor	T191	C0027651
hepatoma H22	T025	C0677626
mice	T015	C0025929
function	T169	C0542341
associated with	T080	C0332281
immunomodulatory activity	T044	C1148560
down-regulating	T044	C0013081
Treg cells	T025	C0039198
manipulating	T040	C2584326
Th1	T043	C1155080
Th17 immune response	T040	C3156592
Clinical characteristics	T201	C0683325
genital chlamydia infection	T047	C0847922
pelvic inflammatory disease	T047	C0242172
Chlamydia infection	T047	C0008149
acute pelvic inflammatory disease	T047	C0149959
PID	T047	C0242172
complications	T046	C0009566
ectopic pregnancy	T046	C0032987
tubal infertility	T047	C0156415
Fitz-Hugh-Curtis syndrome	T047	C0549148
tubo-ovarian abscess	T047	C0041343
TOA	T047	C0041343
study	T062	C2603343
clinical	T170	C1516606
laboratory data	T170	C1517709
PID	T047	C0242172
chlamydia infection	T047	C0008149
medical records	T170	C0025102
women	T098	C0043210
PID	T047	C0242172
patients	T101	C0030705
groups	T098	C1257890
PID	T047	C0242172
chlamydia infection	T047	C0008149
patients' characteristics	T201	C0815172
clinical presentation	T170	C2708283
laboratory findings	T034	C0587081
inflammatory	T169	C0333348
markers	T201	C0005516
chlamydia	T098	C1257890
non-chlamydia groups	T098	C1257890
women	T098	C0043210
patients	T101	C0030705
chlamydia group	T098	C1257890
younger	T079	C0332239
TOA	T047	C0041343
mean	T081	C0444504
hospital stay	T079	C3489408
surgeries	T061	C0543467
patients	T101	C0030705
non- chlamydia group	T098	C1257890
erythrocyte sedimentation rate	T034	C1619634
ESR	T034	C1619634
C-reactive protein	T116	C0006560
CRP	T116	C0006560
CA-125	T109	C0006610
level	T080	C0441889
chlamydia group	T098	C1257890
non-chlamydia group	T098	C1257890
significant	T078	C0750502
white blood cell count	T033	C2186576
groups	T098	C1257890
CA-125	T109	C0006610
level	T080	C0441889
predictor	T078	C2698872
chlamydia infection	T047	C0008149
ESR	T034	C1619634
CRP	T116	C0006560
level	T080	C0441889
area	T082	C0205146
receiving operating curve	T081	C0035787
CA-125	T109	C0006610
ESR	T034	C1619634
CRP	T116	C0006560
Chlamydia infection	T047	C0008149
acute PID	T047	C0149959
level	T080	C0441889
inflammatory	T169	C0333348
markers	T201	C0005516
CA-125	T109	C0006610
ESR	T034	C1619634
CRP	T116	C0006560
TOA	T047	C0041343
operation	T061	C0543467
risk	T078	C0035647
hospitalization	T058	C0019993
Incidence	T081	C0021149
effect of	T080	C1704420
variant	T080	C0205419
histology	T091	C0019638
oncological outcomes	T080	C0085415
patients	T101	C0030705
bladder cancer	T191	C0005684
treated	T169	C1522326
radical cystectomy	T061	C0194401
incidence	T081	C0021149
histological	T169	C0205462
variants	T080	C0205419
radical cystectomy	T061	C0194401
RC	T061	C0194401
bladder cancer	T191	C0005684
BCa	T191	C0005684
survival	T169	C0220921
outcomes	T080	C0085415
retrospectively	T080	C1514923
evaluated	T058	C0220825
data	T078	C1511726
patients	T101	C0030705
BCa	T191	C0005684
treated	T169	C1522326
RC	T061	C0194401
single tertiary care referral center	T073	C0587437
specimen	T167	C0370003
evaluated	T058	C0220825
uropathologists	T097	C1522486
Univariable and multivariable Cox regression analyses	T170	C0034980
effect of	T080	C1704420
histopathological	T169	C0243140
variant	T080	C0205419
recurrence	T067	C0034897
cancer-specific mortality	T081	C1516192
CSM	T081	C1516192
overall mortality	T081	C0205848
OM	T081	C0205848
confounders	T169	C0009673
patients	T101	C0030705
pure urothelial BCa	T191	C0751571
variant	T080	C0205419
variants	T080	C0205419
sarcomatoid	T191	C0205697
lymphoepitelial	T191	C0334254
small cell	T191	C0262584
squamous	T191	C0007137
micropapillary	T191	C3472608
glandular	T191	C0205854
variants	T080	C0205419
variants	T080	C0205419
median	T081	C0876920
follow-up	T058	C1522577
years	T079	C0439234
recurrence	T067	C0034897
CSM	T081	C1516192
OM	T081	C0205848
multivariable Cox regression analyses	T170	C0034980
small cell variant	T191	C0262584
associated with	T080	C0332281
recurrence	T067	C0034897
hazard ratio	T081	C2985465
HR	T081	C2985465
CSM	T081	C1516192
HR	T081	C2985465
OM	T081	C0205848
HR	T081	C2985465
urothelial cancer	T191	C0751571
no survival differences	T033	C3842396
histological	T169	C0205462
variants	T080	C0205419
study	T077	C1706256
histological	T169	C0205462
variant	T080	C0205419
RC	T061	C0194401
specimen	T167	C0370003
single-center series	T093	C1708333
patients	T101	C0030705
small cell variant	T191	C0262584
associated with	T080	C0332281
negative	T033	C0205160
effect	T080	C1280500
survival	T169	C0220921
RC	T061	C0194401
Psychometric	T060	C0033920
properties	T080	C0871161
Japanese	T171	C0376247
version	T170	C0333052
short forms	T170	C2964478
Pain Catastrophizing Scale	T170	C4273905
participants	T098	C0679646
musculoskeletal pain	T033	C0026858
cross-sectional study	T062	C0010362
Pain Catastrophizing Scale	T170	C4273905
PCS	T170	C4273905
measure	T081	C0079809
pain catastrophizing	T041	C3178745
scale	T170	C4273905
items	T062	C0871509
magnification	T060	C0430022
rumination	T038	C0232604
helplessness	T048	C0150063
screening	T058	C1710032
reduce	T080	C0392756
participant's	T098	C0679646
burden	T078	C2828008
item	T062	C0871509
item	T062	C0871509
short forms	T170	C2964478
English	T171	C0376245
version	T170	C0333052
PCS	T170	C4273905
study	T062	C2603343
evaluate	T058	C0220825
psychometric	T060	C0033920
properties	T080	C0871161
Japanese	T171	C0376247
version	T170	C0333052
short forms	T170	C2964478
PCS	T170	C4273905
approach	T169	C1292724
Rasch analysis	T062	C0242481
patients	T101	C0030705
musculoskeletal disorders	T047	C0026857
study	T062	C2603343
Participants	T098	C0679646
study	T062	C2603343
measures	T081	C0079809
pain intensity	T201	C1320357
Pain Catastrophizing Scale	T170	C4273905
PCS	T170	C4273905
Tampa Scale of Kinesiophobia	T170	C0349674
TSK	T170	C0349674
item	T062	C0871509
items	T062	C0871509
item	T062	C0871509
items	T062	C0871509
short forms	T170	C2964478
Japanese	T171	C0376247
version	T170	C0333052
PCS	T170	C4273905
Rasch analysis	T062	C0242481
analyze	T169	C1524024
psychometric	T060	C0033920
properties	T080	C0871161
item	T062	C0871509
item	T062	C0871509
short forms	T170	C2964478
PCS	T170	C4273905
Rasch analysis	T062	C0242481
short forms	T170	C2964478
PCS	T170	C4273905
consistency	T080	C0332529
unidimensionality	T082	C1707753
functional	T169	C0205245
category rating scale	T170	C0349674
item	T062	C0871509
short form	T170	C2964478
PCS	T170	C4273905
items	T062	C0871509
item	T062	C0871509
short form	T170	C2964478
PCS	T170	C4273905
psychometric	T060	C0033920
properties	T080	C0871161
participants	T098	C0679646
musculoskeletal pain	T033	C0026858
item	T062	C0871509
instruments	T074	C0348000
evaluate	T058	C0220825
pain catastrophizing	T041	C3178745
quantitative PCR	T063	C1709846
Babesia	T204	C0004572
infection	T046	C3714514
patients	T101	C0030705
non-nucleic acid amplification tests	T059	C1441475
Ticks	T204	C0040203
transmit	T169	C1444006
Babesia microti	T204	C0004574
causative agents	T033	C0449411
babesiosis	T047	C0004576
North America	T083	C0028405
Europe	T083	C0015176
Babesiosis	T047	C0004576
endemic	T047	C0277550
Northeastern	T083	C0017446
USA	T083	C0041703
people	T098	C0027361
ages	T032	C0001779
Babesia species	T204	C0004572
erythrocytes	T025	C0014792
transmitted	T046	C0242781
blood transfusion	T061	C0005841
Whole blood	T031	C0370231
blood products	T121	C0456388
Babesia	T204	C0004572
transfusion	T061	C0005841
transmitted	T046	C0242781
babesiosis	T047	C0004576
TTB	T047	C0004576
severe	T080	C0205082
consequences	T169	C0686907
immuno-compromised	T033	C0085393
patients	T101	C0030705
study	T062	C2603343
epidemiological evaluation	T062	C0002783
babesiosis	T047	C0004576
tick-infested state	T047	C0040196
examined	T033	C0332128
blood samples	T031	C0178913
patients	T101	C0030705
clinics	T073	C0442592
tick-borne diseases	T047	C0040196
season	T079	C0036497
qPCR assay	T063	C1709846
molecular beacon probe	T114	C0028630
absence	T169	C0332197
symptomology	T184	C1457887
clinical laboratories	T073	C1882331
samples	T031	C0178913
IFA	T059	C0282647
FISH	T063	C0162789
microscopic examination	T059	C0026018
Giemsa-stained	T109	C0017542
blood smears	T059	C2238079
Babesia	T204	C0004572
infection	T046	C3714514
age groups	T100	C0027362
FISH	T063	C0162789
microscopy	T059	C0026018
patients	T101	C0030705
years	T079	C0439234
age	T032	C0001779
samples	T031	C0178913
younger	T079	C0332239
patients	T101	C0030705
samples	T031	C0178913
qPCR	T063	C1709846
positive	T033	C1446409
Babesia	T204	C0004572
samples	T031	C0178913
positive	T033	C1446409
FISH	T063	C0162789
positive	T033	C1446409
qPCR	T063	C1709846
nucleic acid based tests	T059	C0200932
asymptomatic	T033	C0231221
samples	T031	C0178913
FISH	T063	C0162789
positive	T033	C1446409
qPCR	T063	C1709846
detection	T061	C1511790
Babesia	T204	C0004572
microscopic examination	T059	C0026018
patient	T101	C0030705
blood smears	T059	C2238079
clinical laboratory	T073	C1882331
examined	T033	C0332128
blood samples	T031	C0178913
counties	T083	C0454664
microscopy	T059	C0026018
individuals	T098	C0237401
positive	T033	C1446409
Babesia	T204	C0004572
infection	T046	C3714514
microscopy	T059	C0026018
FISH	T063	C0162789
serological tests	T059	C0036743
positive	T033	C1446409
qPCR	T063	C1709846
sensitive	T169	C0332324
specificity	T081	C0037791
Babesia	T204	C0004572
qPCR	T063	C1709846
probes	T130	C0026381
diagnosis	T062	C1704656
babesiosis	T047	C0004576
patients	T101	C0030705
diagnostics	T062	C1511890
blood screening	T059	C1511226
nucleic acid amplification test	T059	C0200932
screening of blood	T059	C1511226
blood products	T121	C0456388
TTB	T047	C0004576
Historical relationships	T079	C0019659
enigmatic	T080	C0205556
phasianid genera	T012	C0325635
Aves	T012	C0005595
Galliformes	T012	C0325589
phylogenomic and mitogenomic data	T170	C2346460
phylogeny	T078	C0031797
Phasianidae	T012	C0325635
pheasants	T012	C0999292
partridges	T012	C1828284
allies	T012	C3973343
enigmatic genera	T080	C0205556
scarce	T080	C0231180
DNA	T114	C0012854
source material	T033	C0449416
phylogenetic data	T170	C0872179
blood pheasants	T012	C1035898
Ithaginis	T012	C1035898
snow partridges	T012	C3684199
Lerwa	T012	C3684199
long-billed partridges	T012	C2291854
Rhizothera	T012	C2291854
phylogenetic positions	T032	C0314647
phylogeny	T078	C0031797
data	T078	C1511726
Lerwa	T012	C3684199
Ithaginis	T012	C1035898
overlapping data	T079	C1948020
relationship	T080	C0439849
Rhizothera	T012	C2291854
Perdix	T012	C0999297
true partridges	T012	C0999297
cytochrome b	T116	C0010744
CYB	T116	C0010744
sister	T077	C1546515
Pucrasia	T012	C0999301
koklass pheasant	T012	C0999301
relationships	T080	C0439849
Ithaginis	T012	C1035898
Lerwa	T012	C3684199
Rhizothera	T012	C2291854
phasianid relatives	T012	C0325635
ultra-conserved element (UCE) loci	T028	C0678933
mitogenomes	T028	C0017428
species	T185	C1705920
hypothesized	T078	C1512571
relatives	T080	C0439849
phasianid clades	T012	C0325635
DNA extracted	T114	C0012854
specimen toepads	T033	C1848515
lacked fresh tissue	T024	C2711421
museum collections	T059	C0200345
multispecies coalescent UCE analyses	T081	C0026757
Lerwa	T012	C3684199
sister	T077	C1546515
large clade	T012	C0325635
Ithaginis	T012	C1035898
turkey	T012	C3669390
grouse	T012	C0325618
pheasants	T012	C0999292
tragopans	T012	C0325686
Pucrasia	T012	C0999301
Perdix	T012	C0999297
Rhizothera	T012	C2291854
clade	T012	C0325635
sister	T077	C1546515
Perdix	T012	C0999297
pheasants	T012	C0999292
Pucrasia	T012	C0999301
turkey	T012	C3669390
grouse	T012	C0325618
Mitogenomic genealogies	T170	C0017298
UCEs topologies	T169	C0205245
sister relationship	T077	C1546515
Ithaginis	T012	C1035898
Lerwa	T012	C3684199
Rhizothera	T012	C2291854
mitogenomes	T028	C0017428
analytical choices	T062	C0936012
codon-based analyses	T059	C0162802
Rhizothera	T012	C2291854
sister	T077	C1546515
tragopan clade	T012	C0325635
DNA model	T170	C0026343
mitogenome	T028	C0017428
congruent	T080	C0439853
UCE results	T033	C0243095
mitogenome analyses	T059	C3854164
Pucrasia	T012	C0999301
sister	T077	C1546515
clade	T012	C0325635
Perdix	T012	C0999297
pheasants	T012	C0999292
published nuclear intron data	T170	C0993637
topology	T170	C0178476
UCE analyses	T170	C0178476
phylogenetic	T078	C0031797
relationships	T080	C0439849
enigmatic	T080	C0205556
phasianid taxa	T012	C0325635
novel	T080	C0205314
treatment	T169	C1522326
stimulate	T061	C1292856
bone healing	T033	C1321023
regeneration	T042	C0005972
hypoxic conditions	T046	C0242184
photobiomodulation	T061	C4019433
melatonin	T109	C0025219
Melatonin	T109	C0025219
anabolic effects	T039	C3179309
bone	T024	C0391978
hypoxia	T046	C0242184
laser irradiation	T061	C0871799
osteoblastic differentiation	T043	C1159974
aim	T078	C1947946
study	T062	C2603343
investigate	T169	C1292732
laser irradiation	T061	C0871799
melatonin	T109	C0025219
synergistic	T080	C2986495
effects	T080	C1280500
osteoblastic differentiation	T043	C1159974
mineralization	T042	C2350989
hypoxic conditions	T046	C0242184
MC3T3-E1 cells	T025	C0007634
oxygen tension	T033	C0860755
hypoxia condition	T046	C0242184
cells	T025	C0007634
groups	T078	C0441833
G1	T078	C0441833
osteoblast differentiation	T043	C1159974
medium	T130	C0010454
hypoxic condition	T046	C0242184
G2	T078	C0441833
treatment	T169	C1522326
melatonin	T109	C0025219
G3	T078	C0441833
laser irradiation	T061	C0871799
GaAlAs diode	T074	C0392255
G4	T078	C0441833
treatment	T169	C1522326
melatonin	T109	C0025219
laser irradiation	T061	C0871799
GaAlAs diode	T074	C0392255
Immunoblotting	T059	C0020985
osterix	T116	C1312518
expression	T045	C1171362
increased	T081	C0205217
melatonin	T109	C0025219
treated	T169	C1522326
laser-irradiated	T061	C0871799
cells	T025	C0007634
alkaline phosphatase	T116	C0002059
activity	T052	C0441655
increased	T081	C0205217
continued	T078	C0549178
experiment	T062	C0681814
Alizarin Red staining	T059	C1318906
increased	T081	C0205217
mineralized	T042	C2350989
nodules	T046	C0035441
melatonin	T109	C0025219
treated	T169	C1522326
laser-irradiated	T061	C0871799
cells	T025	C0007634
increased	T081	C0205217
melatonin	T109	C0025219
treated	T169	C1522326
cells	T025	C0007634
laser-irradiated	T061	C0871799
differentiation	T043	C0007589
mineralization	T042	C2350989
cells	T025	C0007634
p38 MAPK	T116	C1120843
PRKD1	T116	C2987025
signaling mechanisms	T043	C0037083
enhanced	T052	C2349975
effects of	T080	C1704420
laser irradiation	T061	C0871799
melatonin	T109	C0025219
inhibited	T080	C0311403
cells	T025	C0007634
treated	T169	C1522326
luzindole	T109	C0065275
melatonin receptor antagonist	T121	C2917356
laser irradiation	T061	C0871799
effect of	T080	C1704420
melatonin	T109	C0025219
differentiation	T043	C0007589
mineralization	T042	C2350989
MC3T3-E1 cells	T025	C0007634
hypoxic conditions	T046	C0242184
melatonin 1/2 receptors	T116	C0065911
PKRD	T116	C2987025
p38	T116	C1120843
signaling pathways	T044	C0037080
Aquaporin-2	T116	C0213238
excretion	T042	C1373187
hospitalized patients	T101	C0870668
cirrhosis	T047	C1623038
development	T169	C1527148
renal insufficiency	T047	C1565489
mortality	T081	C0205848
Urinary	T080	C1524119
aquaporin-2	T116	C0213238
AQP2	T116	C0213238
water transport	T043	C1159571
principal cells	T025	C0007634
distal part	T029	C0005898
nephron	T023	C0027713
water retention	T040	C2584327
cirrhosis	T047	C1623038
marker	T201	C0005516
renal function	T042	C0232804
aim	T078	C1947946
study	T062	C2603343
AQP2	T116	C0213238
predictor	T170	C0683956
renal insufficiency	T047	C1565489
death	T040	C0011065
patients	T101	C0030705
cirrhosis	T047	C1623038
Urine samples	T031	C1610733
patients	T101	C0030705
patients	T101	C0030705
organ failure	T184	C0349410
Group 1	UnknownType	C0681860
patients	T101	C0030705
organ failure	T184	C0349410
renal failure	T047	C0035078
Group 2	UnknownType	C0681860
patients	T101	C0030705
organ failure	T184	C0349410
renal failure	T047	C0035078
Group 3	UnknownType	C0681860
CANONIC study	T062	C2603343
urine	T031	C0042036
AQP2	T116	C0213238
urine osmolality	T201	C0086741
no difference	T033	C3842396
AQP2	T116	C0213238
groups	UnknownType	C0681860
Urine osmolality	T201	C0086741
significantly lower	T081	C4055638
patients	T101	C0030705
Group 3	UnknownType	C0681860
Group 1	UnknownType	C0681860
Group 2	UnknownType	C0681860
No relation	T033	C1513916
AQP2	T116	C0213238
glomerular filtration rate	T060	C0017654
creatinine	T109	C0010294
AQP2	T116	C0213238
predictor	T170	C0683956
development	T169	C1527148
renal insufficiency	T047	C1565489
univariate analysis	T062	C0683962
AQP2	T116	C0213238
predictor	T170	C0683956
survival	T169	C0220921
multivariate analysis	T081	C0026777
Aquaporin-2	T116	C0213238
disease severity	T080	C0521117
markers	T080	C0008963
renal function	T042	C0232804
predictor	T170	C0683956
development	T169	C1527148
renal insufficiency	T047	C1565489
death	T040	C0011065
marker	T201	C0005516
renal insufficiency	T047	C1565489
research	T062	C0035168
clinical	T080	C0205210
Decompression Surgery	T061	C0408670
Decompression	T061	C0408670
Fusion	T061	C0919636
Symptomatic	T169	C0231220
Lumbar Spinal Stenosis	T047	C0158288
Swiss	T098	C0241315
Prospective Multi-center Cohort Study	T062	C1709709
Years	T079	C0439234
Follow-up	T062	C0016441
Retrospective analysis	T062	C0035363
prospective, multicenter cohort study	T062	C1709709
effect	T080	C1280500
surgical fusion	T061	C0919636
decompression surgery	T061	C0408670
symptomatic	T169	C0231220
lumbar spinal stenosis	T047	C0158288
patients	T101	C0030705
spondylolisthesis	T047	C0038016
optimal surgical management	T058	C1515089
lumbar spinal stenosis	T047	C0158288
patients	T101	C0030705
spondylolisthesis	T047	C0038016
Patients	T101	C0030705
LSOS	T062	C0543472
DLSS	T047	C0410636
spondylolisthesis	T047	C0038016
study	T077	C1706256
outcomes	T062	C0086750
study	T077	C1706256
Spinal Stenosis	T020	C0037944
Spinal Stenosis Measure	T081	C0392762
SSM	T081	C0392762
symptoms	T184	C1457887
score range	T081	C0449820
function	T169	C0542341
over time	T079	C0040223
measured	T080	C0444706
baseline	T081	C1442488
months	T079	C0439231
follow-up	T062	C0016441
quantify	T081	C1709793
effect	T080	C1280500
fusion surgery	T061	C0919636
decompression	T061	C0408670
number of decompressed levels	T033	C0243095
effects	T080	C1280500
models	T075	C0026336
repeated observations	T062	C0302523
outcomes	T062	C0086750
SSM	T081	C0392762
symptoms	T184	C1457887
SSM	T081	C0392762
function	T169	C0542341
over time	T079	C0040223
patients	T101	C0030705
random effects	T080	C1280500
fitted random slopes	T081	C0807955
follow-up	T033	C0589120
time points	T079	C0439547
approaches	T169	C1292724
Akaike's Information Criterion	T170	C0282574
AIC	T170	C0282574
chi-squared test	T170	C0237913
Confounders	T169	C0009673
fixed effects	T080	C1280500
age	T032	C0001779
gender	T032	C0079399
BMI	T201	C1305855
diabetes	T047	C0011847
CIRS	T081	C0681889
musculoskeletal disorders	T047	C0026857
duration	T109	C2926735
symptoms	T184	C1457887
patients	T101	C0030705
decompression surgery	T061	C0408670
decompression	T061	C0408670
fusion surgery	T061	C0919636
study	T077	C1706256
multiple mixed effects	T080	C1280500
model	T075	C0026336
effect	T080	C1280500
fusion	T061	C0919636
decompression alone surgery	T061	C0408670
SSM	T081	C0392762
symptoms	T184	C1457887
confidence interval	T081	C0009667
CI	T081	C0009667
CI	T081	C0009667
SSM	T081	C0392762
function	T169	C0542341
patients	T101	C0030705
degenerative lumbar spinal stenosis	T047	C0410636
spondylolisthesis	T047	C0038016
study	T077	C1706256
groups	T078	C0441833
decompression	T061	C0408670
decompression	T061	C0408670
fusion	T061	C0919636
patients	T101	C0030705
surgical treatment	T061	C0543467
confounders	T169	C0009673
fusion surgery	T061	C0919636
associated with	T080	C0332281
outcome	T062	C0086750
SSM scores	T081	C0392762
decompression alone surgery	T061	C0408670
Muscle	T024	C0026845
synergies	T169	C1704675
stroke	T047	C0038454
perilesional	T082	C1254362
high gamma	T081	C0392762
Movements	T033	C0517907
modules	T077	C1709061
muscle	T024	C0026845
synergies	T169	C1704675
stroke	T047	C0038454
abnormal	T033	C0205161
synergies	T169	C1704675
impaired	T169	C0221099
movements	T033	C0517907
neural	T025	C0027882
basis	T169	C1527178
electrocorticography signals	T060	C0430797
perilesional	T082	C1254362
cortex	T023	C3499125
synergies	T169	C1704675
synergies	T169	C1704675
contained	T169	C0332256
normal	T080	C0205307
abnormal	T033	C0205161
patterns	T082	C0449774
normal	T080	C0205307
abnormal	T033	C0205161
synergies	T169	C1704675
perilesional	T082	C1254362
high gamma	T081	C0392762
high gamma	T081	C0392762
cortical spiking	T033	C0243095
perilesional spiking	T033	C0243095
synergies	T169	C1704675
stroke	T047	C0038454
Assessing	T058	C0184514
nitrous oxide	T121	C0028215
effect	T080	C1280500
electroencephalographically	T060	C0013819
depth of anesthesia	T033	C0474710
measures	T081	C0079809
cortical	T023	C0007776
state	T170	C0918012
cortical	T023	C0007776
input	T170	C0918012
electroencephalography	T060	C0013819
EEG	T060	C0013819
depth of anesthesia	T033	C0474710
monitors	T058	C0184514
sedative	T121	C0036557
anesthetic	T121	C0002932
states	T080	C0348080
n-methyl-D-aspartate (NMDA) receptor antagonist	T121	C3536824
anesthesia	T061	C0002903
ketamine	T109	C0022614
nitrous oxide	T121	C0028215
N2O	T121	C0028215
physiologically	T169	C0205463
depth of anesthesia	T033	C0474710
monitoring	T058	C1283169
algorithm	T170	C0002045
autoregressive-moving-average (ARMA) modeling	T170	C3161035
Cortical	T023	C0007776
State	T170	C0918012
CS	T170	C0918012
Cortical	T023	C0007776
Input	T170	C0918012
CI	T170	C0918012
retrospectively	T062	C0035363
exploratory	T169	C1292732
NMDA receptor antagonist	T121	C3536824
N2O	T121	C0028215
adjuvant anesthetic gas	T121	C0002904
clinical practice	T169	C0205245
Composite Cortical State	T170	C0918012
CCS	T170	C0918012
Composite Cortical State distance	T170	C0918012
CCSd	T170	C0918012
modifications	T033	C3840684
CS	T170	C0918012
CS	T170	C0918012
CI	T170	C0918012
evaluated	T058	C0220825
electroencephalographic	T060	C0013819
EEG	T060	C0013819
data	T078	C1511726
healthy control individuals	T080	C2986479
N2O	T121	C0028215
inhalation	T040	C0004048
equilibrated	T081	C1547026
peak gas concentrations	T081	C0457929
N2O	T121	C0028215
O2	T121	C0030054
CCSd	T170	C0918012
increasing	T081	C0205217
levels	T080	C0441889
anesthetic concentration	T033	C0474704
independent of	T169	C0332291
anesthetic's	T121	C0002932
microscopic	T080	C0205288
mode of action	T169	C1524059
N2O	T121	C0028215
propofol	T109	C0033487
effects	T080	C1280500
peak gas concentration	T081	C0457929
group	T098	C1257890
peak gas levels	T080	C0441889
individuals	T098	C0237401
statistically significant	T081	C0237881
reductions	T061	C0441610
responsiveness	T033	C3261286
compared	T052	C1707455
rest	T056	C0035253
group	T098	C1257890
CS	T170	C0918012
CCS	T170	C0918012
increased	T081	C0205217
CCSd	T170	C0918012
decrease	T081	C0547047
conclusion	T078	C1707478
CI	T170	C0918012
results	T169	C1274040
contrary	T082	C1521805
depth of anesthesia	T033	C0474710
monitoring	T058	C1283169
measures	T081	C0079809
CS	T170	C0918012
CCS	T170	C0918012
CCSd	T170	C0918012
measures	T081	C0079809
derived	T080	C1441547
frontal	T082	C0205123
EEG	T060	C0013819
potentially	T080	C3245505
gas concentration	T081	C0457929
responsiveness levels	T033	C3261286
people	T098	C0027361
N2O	T121	C0028215
utility	T169	C0457083
CI	T170	C0918012
larger	T081	C0549177
sample sizes	T081	C0242618
potentially	T080	C3245505
higher	T080	C0205250
gas concentrations	T081	C0457929
assess	T058	C0184514
sensitivity	T081	C0036667
CS	T170	C0918012
CI	T170	C0918012
measures	T081	C0079809
anesthetics	T121	C0002932
utility	T169	C0457083
clinical	T073	C0442592
environment	T082	C0014406
DT MRI	T060	C3163713
microstructural	T080	C0205556
cortical	T023	C0007776
lesion	T047	C0221505
damage	T169	C1883709
cognitive impairment	T048	C0338656
MS	T047	C0026769
double inversion recovery	T060	C0430022
DIR	T060	C0430022
diffusion tensor (DT) magnetic resonance imaging (MRI)	T060	C3163713
quantify	T081	C1709793
severity	T080	C0439793
cortical	T023	C0007776
lesion	T047	C0221505
CL	T047	C0221505
microstructural	T080	C0205556
tissue	T024	C0040300
abnormalities	T020	C0221430
large	T081	C0549177
cohort	T098	C0599755
relapse	T067	C0035020
onset	T080	C0332162
multiple sclerosis	T047	C0026769
MS	T047	C0026769
patients	T101	C0030705
contribution	T052	C1880177
cognitive dysfunction	T048	C0338656
DIR	T060	C0430022
DT	T060	C1537007
dual-echo	T060	C0011923
three-dimensional	T082	C0450363
3D	T082	C0450363
T1-weighted scans	T060	C0011923
MS	T047	C0026769
patients	T101	C0030705
controls	T096	C0009932
Cognitively impaired	T048	C0338656
CI	T048	C0338656
patients	T101	C0030705
abnormal	T033	C0205161
neuropsychological tests	T060	C0027902
Diffusivity values	T077	C3899378
CLs	T047	C0221505
cortex	T023	C0007776
white matter (WM) lesions	T033	C2752009
normal-appearing (NA) WM	T024	C0682708
assessed	T052	C1516048
Predictors	T078	C2698872
cognitive impairment	T048	C0338656
identified	T080	C0205396
random forest analysis	T062	C0936012
controls	T096	C0009932
MS	T047	C0026769
patients	T101	C0030705
lower	T080	C0205251
normalized brain volume	T081	C1113695
NBV	T081	C1113695
gray matter volume	T081	C0392762
GMV	T081	C0392762
WM volume	T033	C3278845
lower	T080	C0205251
fractional anisotropy	T081	C0392762
FA	T081	C0392762
higher	T080	C0205250
mean diffusivity	T077	C3899378
cortex	T023	C0007776
normal-appearing white matter	T024	C0682708
NAWM	T024	C0682708
patients	T101	C0030705
CI	T048	C0338656
cognitively preserved	T101	C0030705
CP	T101	C0030705
CI	T048	C0338656
patients	T101	C0030705
higher	T080	C0205250
T2 WM lesion volume	T081	C0392762
LV	T081	C0392762
lower	T080	C0205251
NBV	T081	C1113695
GMV	T081	C0392762
severe	T080	C0205082
diffusivity	T077	C3899378
abnormalities	T020	C0221430
WM lesions	T033	C2752009
cortex	T023	C0007776
NAWM	T024	C0682708
CL	T047	C0221505
measures	T081	C0079809
not differ	T033	C0243095
CI	T101	C0030705
CP patients	T101	C0030705
Cortex	T023	C0007776
FA	T081	C0392762
age	T032	C0001779
disease duration	T079	C0872146
T2 WM LV	T081	C0392762
GMV	T081	C0392762
MS	T047	C0026769
cognitive impairment	T048	C0338656
Diffuse	T082	C0205219
GM	T024	C0018220
NAWM	T024	C0682708
damage	T169	C1883709
WM lesions	T033	C2752009
intrinsic	T082	C0205102
CL	T047	C0221505
damage	T169	C1883709
cognitive impairment	T048	C0338656
MS	T047	C0026769
Correlation	T080	C1707520
histopathology	T169	C0243140
chronic urticaria	T047	C0263338
clinical picture	T201	C0683325
Chronic urticaria	T047	C0263338
transient	T079	C0205374
pruritic lesions	UnknownType	C0748813
sizes	T082	C0456389
central	T082	C0205099
pallor	T033	C0030232
disease	T047	C0012634
weeks	T079	C0439230
cellular infiltrate	T046	C1692321
neutrophils	T025	C0027950
lymphocytes	T025	C0024264
eosinophils	T025	C0014467
patients	T101	C0030705
eosinophilic	T025	C0014467
neutrophilic urticaria	T047	C1304205
treatment	T061	C0087111
antihistamines	T109	C0003360
antihistamine	T109	C0003360
drugs	T121	C0013227
infiltration	T046	C0332448
chronic urticaria	T047	C0263338
biopsies	T060	C0005558
clinical disease activity	UnknownType	C0544450
response to treatment	T201	C0521982
patients	T101	C0030705
chronic urticaria	T047	C0263338
score of severity	T081	C0457451
disease	T047	C0012634
response to treatment	T201	C0521982
perivascular infiltrate	T046	C1692321
Inflammatory infiltrates	T031	C0541629
eosinophilic	T025	C0014467
neutrophilic	T025	C0027950
association	T080	C0439849
eosinophilic infiltrate	T031	C0541629
clinical scores	T081	C0457451
severity	T080	C0439793
association	T080	C0439849
eosinophilic inflammatory infiltrates	T031	C0541629
clinical activity	T184	C0037088
severe	T080	C0205082
clinical pictures	T201	C0683325
disease	T047	C0012634
Barriers	T080	C0679881
access and uptake	T080	C0018748
antiretroviral therapy	T061	C1963724
HIV-positive	T034	C0019699
men who have sex with men	T098	C2827413
Hanoi	UnknownType	C0681784
Vietnam	T083	C0042658
HIV testing	T059	C1321876
treatment	T061	C0087111
experiences	T041	C0596545
Vietnamese	T098	C1561452
men who have sex with men	T098	C2827413
accessing	T082	C0444454
HIV testing	T059	C1321876
treatment	T061	C0087111
barriers	T080	C0679881
access and uptake	T080	C0018748
antiretroviral therapy	T061	C1963724
ART	T061	C1963724
HIV-positive	T034	C0019699
men who have sex with men	T098	C2827413
Hanoi	UnknownType	C0681784
qualitative	T080	C0205556
interviews	T052	C0021822
participants	T098	C0679646
snowball sampling	T062	C2348215
research	T062	C0035168
social networks	T098	C0150775
ART	T061	C1963724
inadequate	T080	C0205412
preparation	T052	C1521827
positive	T033	C1446409
diagnosis	T033	C0011900
stigmatisation	T078	C0038330
homosexuality	T054	C0019900
HIV	T005	C0019682
consequences	T062	C1511482
fear	T041	C0015726
disclosure	T055	C0012625
HIV status	T033	C0458074
Health system	T093	C0018696
barriers	T080	C0679881
consistency	T080	C0332529
access	T080	C0018748
ART	T061	C1963724
patient	T101	C0030705
confidentiality	T078	C0009669
providers	T169	C1138603
sexual identity	T041	C0017249
same-sex issues	T054	C0019900
HIV testing	T059	C1321876
Hanoi	UnknownType	C0681784
counselling	T058	C0010210
peer support	T061	C0679740
clear referral	T058	C0034927
barriers	T080	C0679881
men who have sex with men	T098	C2827413
benefits	T081	C0814225
routine testing	T060	C2188403
improving	T080	C1272745
access	T080	C0018748
diagnostic services	T058	C0011929
confidential	T033	C3846676
treatment	T061	C0087111
environment	T082	C0014406
HIV-positive	T034	C0019699
men	T098	C0025266
access	T080	C0018748
receive and remain in care	T052	C1947933
Cdc45	T116	C0755538
induced	T169	C0205263
loading	T052	C1708715
human RPA	T116	C0122446
single-stranded DNA	T114	C0012935
Cell division cycle protein 45	T116	C0755538
Cdc45	T116	C0755538
eukaryotic	T204	C0684063
replicative	T080	C1883725
DNA helicase	T116	C0920283
human Cdc45	T116	C0755538
complex	T104	C1704241
single-stranded DNA (ssDNA) binding protein RPA	T116	C0165675
loads	T052	C1708715
RPA	T116	C0165675
ssDNA	T114	C0012935
Pull-down assays	T059	C0022885
surface plasmon resonance studies	T063	C0597731
Cdc45	T116	C0755538
bound	T044	C1167622
RPA	T116	C0165675
complexed	T104	C1704241
ssDNA	T114	C0012935
nucleotide binding	T044	C1148916
dissociated	T044	C1148560
RPA	T116	C0165675
30-mer	T086	C0004793
Real-time analysis	T059	C0022885
RPA	T116	C0165675
ssDNA	T114	C0012935
binding	T044	C1167622
Cdc45	T116	C0755538
loaded	T052	C1708715
RPA	T116	C0165675
ssDNA	T114	C0012935
placement	T080	C1524072
reaction	T169	C0443286
physical contacts	T067	C0392367
Cdc45	T116	C0755538
RPA70A subdomain	T087	C1514562
Cdc45	T116	C0755538
stabilization	T061	C1293130
nt	T114	C0028630
RPA	T116	C0165675
binding	T044	C1167622
RPA	T116	C0165675
30-mer	T086	C0004793
mode	T169	C1513371
binding	T044	C1167622
ssDNA	T114	C0012935
Cdc45	T116	C0755538
loading	T052	C1708715
deposition	T169	C0333562
RPA	T116	C0165675
ssDNA	T114	C0012935
replication fork	T026	C1167117
antineoplastic drug	T109	C0003392
trastuzumab	T116	C0728747
dysregulates	T033	C0243095
metabolism	T040	C0025519
iPSC	T025	C2717959
cardiomyocytes	T025	C0225828
targeted ERBB2 therapy	T061	C2985566
trastuzumab	T116	C0728747
impact	T080	C4049986
management	T058	C0376636
patients	T101	C0030705
HER2+ breast cancer	T191	C1960398
development	T169	C1527148
increased	T081	C0205217
HER2	T116	C0069515
targeted therapies	T061	C2985566
clinical	T080	C0205210
side effect	T046	C0879626
cardiotoxicity	T037	C0876994
mechanism	T169	C0441712
gene expression	T045	C0017262
altered	T169	C0392747
multiple	T081	C0439064
models	T170	C0026343
heart failure	T047	C0018801
differential gene expression	T045	C1519516
iPSC	T025	C2717959
cardiomyocytes	T025	C0225828
treated	T169	C1522326
day	T079	C0439228
ERBB2	T116	C1702024
monoclonal antibody	T116	C0003250
trastuzumab	T116	C0728747
small molecule tyrosine kinase inhibitor	T121	C1268567
EGFR	T116	C0034802
ERBB2	T116	C1702024
Transcriptome sequencing	T059	C4086963
performed	T169	C0884358
replicates	T080	C1883725
group	T078	C0441833
trastuzumab	T116	C0728747
lapatinib	T109	C1506770
differential gene expression	T045	C1519516
analyses	T062	C0936012
performed	T169	C0884358
treatment	T169	C1522326
group	T078	C0441833
cardiomyocytes	T025	C0225828
genes	T028	C0017337
differentially expressed	T045	C0017262
cardiomyocytes	T025	C0225828
treated	T169	C1522326
trastuzumab	T116	C0728747
lapatinib	T109	C1506770
Gene ontology	T170	C1138831
analyses	T062	C0936012
cardiomyocytes	T025	C0225828
treated	T169	C1522326
trastuzumab	T116	C0728747
significant	T078	C0750502
down-regulation	T044	C0013081
genes	T028	C0017337
small molecule metabolism	T040	C2752534
cholesterol	T109	C0008377
sterol	T109	C0038323
measured	T080	C0444706
glucose uptake	T043	C1159527
lactate	T109	C0376261
production	T169	C0205245
iPSC	T025	C2717959
cardiomyocytes	T025	C0225828
days	T079	C0439228
treated	T169	C1522326
trastuzumab	T116	C0728747
observed	T169	C1441672
significantly	T081	C0237881
decreased	T081	C0205216
glucose uptake	T043	C1159527
media	T130	C0010454
iPSC	T025	C2717959
cardiomyocytes	T025	C0225828
treated	T169	C1522326
trastuzumab	T116	C0728747
consistently	T080	C0332529
study	T062	C2603343
dysregulation	T033	C0243095
cardiac	T023	C0018787
gene expression	T045	C0017262
metabolism	T040	C0025519
ERBB2	T028	C0242957
signaling	T044	C0037080
potentially	T080	C3245505
biomarkers	T201	C0005516
cardiotoxicity	T037	C0876994
Simvastatin	T109	C0074554
Hematoma	T046	C0018944
Absorption	T070	C0000854
Hydrocephalus	T047	C0020255
Intraventricular Hemorrhage	T046	C0240059
Upregulating	T044	C0041904
CD36	T028	C1366645
hematoma	T046	C0018944
worsens	T033	C1457868
hydrocephalus	T047	C0020255
intraventricular hemorrhage	T046	C0240059
IVH	T046	C0240059
increasing	T169	C0442808
iron deposition	T046	C0333596
ependymal	T024	C0014472
cilia	T026	C0008778
injury	T037	C3263723
hematoma	T046	C0018944
absorption	T070	C0000854
IVH	T046	C0240059
simvastatin	T109	C0074554
hematoma	T046	C0018944
absorption	T070	C0000854
efficacy	T080	C1280519
simvastatin	T109	C0074554
IVH	T046	C0240059
rats	T015	C0086893
Intracerebral hemorrhage	T046	C0475526
adult male	T032	C0086582
Sprague-Dawley rats	T015	C0034715
autologous blood injection	T061	C0849679
Simvastatin	T109	C0074554
vehicle	T122	C0042444
administered orally	T061	C0001563
IVH	T046	C0240059
MRI studies	T060	C3515983
measure	T169	C0242485
volumes	T059	C2700258
intracranial	T029	C0524466
hematoma	T046	C0018944
lateral ventricle	T030	C0152279
IVH	T046	C0240059
Motor	T038	C0234130
neurocognitive functions	T038	C3714634
assessed	T052	C1516048
Iron deposition	T046	C0333596
iron	T121	C0302583
protein expression	T045	C1171362
ependymal damage	T033	C3686783
histology	T169	C4048239
detected	T033	C0442726
Expression	T045	C0017262
CD36	T028	C1366645
scavenger receptor	T116	C0074129
phagocytosis	T043	C0031308
examined	T033	C0332128
IVH	T046	C0240059
western blotting	T059	C0005863
immunofluorescence	T059	C0079603
Simvastatin	T109	C0074554
increased	T081	C0205217
hematoma	T046	C0018944
absorption	T070	C0000854
ratio	T081	C0456603
reduced	T080	C0392756
ventricular volume	T078	C1511726
attenuated neurological dysfunction	T033	C1709219
IVH	T046	C0240059
less iron accumulation	T033	C4021076
cilia	T026	C0008778
survival	T081	C1709301
simvastatin	T109	C0074554
control	T096	C0009932
higher	T080	C0205250
expression	T045	C0017262
CD36	T028	C1366645
detected	T033	C0442726
hematoma	T046	C0018944
simvastatin	T109	C0074554
administration	T061	C1533734
Simvastatin	T109	C0074554
brain	T023	C0006104
hematoma	T046	C0018944
absorption	T070	C0000854
alleviated hydrocephalus	T047	C0020255
improved	T033	C0184511
neurological	T080	C0205494
recovery	T040	C2004454
experimental	T080	C1517586
IVH	T046	C0240059
upregulating	T044	C0041904
CD36	T028	C1366645
expression	T045	C0017262
data	T078	C1511726
simvastatin	T109	C0074554
novel	T080	C0205314
therapy	T061	C0087111
IVH	T046	C0240059
patients	T101	C0030705
AMPK	T116	C2350345
autophagy	T043	C0004391
inhibition	T052	C3463820
icaritin	T109	C1567768
induced	T169	C0205263
anti-colorectal cancer	T033	C0243095
cell activity	T043	C0007613
current	T079	C0521116
research	T062	C0035168
potential effect	T080	C1280500
autophagy	T043	C0004391
icaritin	T109	C1567768
induced	T169	C0205263
anti-colorectal cancer	T033	C0243095
CRC	T191	C1527249
cell activity	T043	C0007613
Treatment	T169	C1522326
icaritin	T109	C1567768
primary	T080	C0205225
established	T080	C0443211
HT-29	T025	C0282639
CRC	T191	C1527249
cells	T025	C0007634
induced	T169	C0205263
feedback activation	T052	C1879547
autophagy	T043	C0004391
p62	T028	C1420393
degradation	T044	C0314674
Beclin-1	T028	C1412785
autophagy-related gene-5	T028	C1825497
ATG-5	T028	C1825497
upregulation	T044	C0041904
light chain 3B	T116	C1311384
LC3B	T116	C1311384
GFP	T116	C0120285
formation	T169	C1522492
Pharmacological	T169	C0205464
inhibiting	T052	C3463820
autophagy	T043	C0004391
icaritin	T109	C1567768
induced	T169	C0205263
CRC	T191	C1527249
cell death	T043	C0007587
apoptosis	T043	C0162638
shRNA	T114	C2930586
knockdown	T063	C2350567
Beclin-1	T028	C1412785
ATG-5	T028	C1825497
icaritin	T109	C1567768
induced	T169	C0205263
CRC	T191	C1527249
cell death	T043	C0007587
apoptosis	T043	C0162638
Icaritin	T109	C1567768
activated	T052	C1879547
AMP-activated protein kinase	T116	C2350345
AMPK	T116	C2350345
signaling	T043	C0037083
CRC	T191	C1527249
cells	T025	C0007634
functioning	T169	C0542341
signaling	T043	C0037083
autophagy	T043	C0004391
activation	T052	C1879547
shRNA	T114	C2930586
siRNA	T114	C1099354
knockdown	T063	C2350567
AMPKα1	T028	C1418897
inhibited	T080	C0311403
icaritin	T109	C1567768
induced	T169	C0205263
autophagy	T043	C0004391
activation	T052	C1879547
exacerbated	T080	C1444749
CRC	T191	C1527249
cell death	T043	C0007587
AMPK	T116	C2350345
compound 13	T121	C1254351
C13	T121	C1254351
autophagy	T043	C0004391
MHY1485	T109	C3661263
attenuated	T052	C0599946
icaritin	T109	C1567768
induced	T169	C0205263
cytotoxicity	T049	C0596402
nude mice	T015	C0025932
icaritin	T109	C1567768
oral administration	T061	C0001563
induced	T169	C0205263
HT-29	T025	C0282639
tumor growth	T191	C0598934
inhibition	T052	C3463820
AMPKα1	T028	C1418897
shRNA	T114	C2930586
knockdown	T063	C2350567
tumors	T191	C0027651
feedback activation	T052	C1879547
AMPK	T116	C2350345
autophagy	T043	C0004391
pathway	T044	C0037080
resistance	T169	C4281815
factor	T169	C1521761
icaritin	T109	C1567768
Classification	T185	C0008902
Edible Oils	T168	C1517288
ATR-FTIR	T062	C0206055
Spectral Information	T078	C1533716
Long Heating Treatment	T067	C1254366
Identification	T080	C0205396
oil	T168	C1517288
type	T080	C0332307
QC	T169	C0034378
food	T168	C0016452
food control laboratories	T073	C0022877
Classifying	T185	C0008902
edible oils	T168	C1517288
unheated	T169	C0205245
vibrational spectroscopy	T059	C0037812
classification	T185	C0008902
heat-treated	T169	C0205245
oils	T168	C1517288
effect	T080	C1280500
long heating times	T079	C0040223
classification	T185	C0008902
edible oils	T168	C1517288
canola	T109	C0054599
corn	T109	C0010029
frying	T168	C1517288
sunflower	T109	C0075639
attenuated total reflectance (ATR)-FTIR spectra	T062	C0206055
surveyed	T062	C0683942
sampling	T078	C0870078
oils	T168	C1517288
heating process	T067	C1254366
ATR-FTIR spectra	T062	C0206055
samples	T167	C0370003
collected	T169	C1516698
Interval extended canonical variates analysis	T081	C0026777
ECVA	T081	C0026777
variable selection	T080	C0205556
classification	T185	C0008902
intervals	T079	C1272706
heating procedure	T067	C1254366
classification	T185	C0008902
Principal component analysis	T081	C0429865
discriminate analysis	T081	C0392762
partial least-squares discriminate analysis	T081	C0392762
ECVA	T081	C0026777
intervals	T079	C1272706
total heating time	T079	C0040223
autoscaling	T033	C0243095
mean-centering	T033	C0243095
data preprocessing methods	T170	C0025663
investigated	T169	C1292732
ECVA method	T081	C0026777
classification	T185	C0008902
cross-validated nonerror rate	T081	C0392762
heating process	T067	C1254366
times	T079	C0040223
Intravitreal	T169	C1517572
chemotherapy	T061	C3665472
management	T058	C0376636
vitreous disease	T047	C0155365
retinoblastoma	T191	C0035335
therapeutic outcome	T080	C0085415
intravitreal	T169	C1517572
melphalan	T116	C0025241
injection	T122	C1272883
management	T058	C0376636
vitreous disease	T047	C0155365
patients	T101	C0030705
retinoblastoma	T191	C0035335
higher	T080	C0205250
melphalan	T116	C0025241
dose	T081	C0178602
lower	T080	C0205251
number	T081	C0237753
injections	T122	C1272883
effective	T080	C1704419
associated with	T080	C0332281
fewer	T081	C0205388
side effects	T046	C0879626
retrospective	T062	C0035363
interventional	T062	C3274035
noncomparative	T062	C2603343
nonrandomized study	T062	C2603343
eyes	T023	C0015392
patients	T101	C0030705
Vitreous seeds	T033	C1719830
classified	T185	C0008902
dust	T191	C0027651
sphere	T191	C0027651
cloud types	T191	C0027651
Intravitreal	T169	C1517572
injections	T122	C1272883
performed	T169	C0884358
through	T169	C0332273
pars plana	T023	C0229167
visible	T080	C0205379
tumor	T191	C0027651
using	T169	C1524063
30-G needle	T074	C0027551
Response of the seeds	T040	C1817727
disappearance	T033	C0243095
conversion	T169	C0439836
inactive debris	T033	C1720491
progression	T191	C0178874
enucleation	T061	C0014392
rate	T081	C1521828
outcome	T080	C0085415
measures	T081	C0079809
patients	T101	C0030705
received	T080	C1514756
systemic	T061	C1883256
intra-arterial chemotherapy	T061	C0842399
Vitreous seeding	T033	C1719830
primary	T080	C0205225
eyes	T023	C0015392
secondary	T080	C0175668
eyes	T023	C0015392
Vitreous seeds	T033	C1719830
classified	T185	C0008902
dust	T191	C0027651
eyes	T023	C0015392
sphere	T191	C0027651
eyes	T023	C0015392
cloud	T191	C0027651
eyes	T023	C0015392
Melphalan	T116	C0025241
dose	T081	C0178602
eyes	T023	C0015392
received	T080	C1514756
total number	T081	C4288115
injections	T122	C1272883
mean	T081	C0444504
eye	T023	C0015392
Various	T081	C0439064
types	T080	C0332307
regression	T046	C0684320
obtained	T169	C1301820
eyes	T023	C0015392
Sphere-type seeds	T191	C0027651
most	T081	C0205393
responsive	T169	C0205342
melphalan	T116	C0025241
Nonresponse	T033	C3844724
disease progression	T046	C0242656
noted	T080	C4288581
eyes	T023	C0015392
mean	T081	C0444504
follow-up	T058	C1522577
months	T079	C0439231
eyes	T023	C0015392
enucleated	T037	C1396718
Vitreous hemorrhage	T046	C0042909
retinal pigment epithelial	T023	C0035322
alterations	T078	C1515926
most	T081	C0205393
common	T081	C0205214
side effects	T046	C0879626
Intravitreal	T169	C1517572
melphalan	T116	C0025241
injections	T122	C1272883
effective	T080	C1704419
eyes	T023	C0015392
vitreous disease	T047	C0155365
Fine structure	T082	C0678594
anterior median eyes	T023	C0015392
funnel	T082	C0332495
web spider	T204	C0037913
Agelena labyrinthica	T204	C1905695
Araneae	T204	C0037913
Agelenidae	T204	C0998353
electron microscopic studies	T059	C0026019
structure	T082	C0678594
eyes	T023	C0015392
anterior median eyes	T023	C0015392
AME	T023	C0015392
web spiders	T204	C0037913
anatomy	T017	C0700276
AME	T023	C0015392
spider	T204	C0037913
Agelena labyrinthica	T204	C1905695
retina	T023	C0035298
regions	T082	C0205147
photoreceptor cells	T025	C0031760
central part	T082	C0205099
sensory cells	T026	C0034837
rhabdomeres	T026	C1167266
ventral	T082	C1704448
retina	T023	C0035298
rhabdomeres	T026	C1167266
rhabdomeres	T026	C1167266
ventral	T082	C1704448
retina	T023	C0035298
ventral	T082	C1704448
long tangential rows	T082	C0454236
center	T082	C0205099
sensory cells	T026	C0034837
unpigmented	T033	C0243095
pigment cell	T025	C1179009
processes	T043	C0007613
agelenid	T204	C0998353
spiders	T204	C0037913
axons	T026	C0004461
sensory cells	T026	C0034837
cell body	T026	C2752549
fine structure	T082	C0678594
eye cup	T074	C0180233
central part	T082	C0205099
retina	T023	C0035298
nerve fibres	T026	C0027749
synapses	T030	C0039062
distal region	T082	C0205147
receptor cells	T026	C0034837
muscle	T024	C0026845
eye cup	T074	C0180233
rotational	T082	C0445237
movements	T039	C0015413
eyes	T023	C0015392
optical performance	T070	C0029141
image resolution	T077	C2699488
eyes	T023	C0015392
visual cells	T025	C0007634
Knocking down	T063	C2350567
TCF8	T028	C1420645
high glucose	T033	C0860803
angiotensin II	T116	C0003009
induced	T169	C0205263
epithelial to mesenchymal transition	T043	C1523298
podocytes	T025	C1328818
Epithelial to mesenchymal transition	T043	C1523298
EMT	T043	C1523298
physiological phenomenon	T039	C2350828
mammalian	T015	C0024660
embryogenesis	T042	C0013936
epithelial cells	T025	C0014597
mesenchymal stem cells	T025	C1257975
EMT	T043	C1523298
pathogenic	T033	C3816499
processes	T067	C1522240
embryonic development	T042	C0013936
tumor metastasis	T191	C0027627
EMT	T043	C1523298
renal fibrosis	T047	C0151650
glucose	T109	C0017725
angiotensin II	T116	C0003009
EMT	T043	C1523298
podocytes	T025	C1328818
cellular morphology	T201	C1521816
podocytes	T025	C1328818
high	T080	C0205250
concentration	T081	C1446561
glucose	T109	C0017725
angiotensin II	T116	C0003009
podocyte	T025	C1328818
movement	T040	C1621968
migration	T043	C1622501
high	T080	C0205250
concentration	T081	C1446561
glucose	T109	C0017725
angiotensin II	T116	C0003009
TCF8	T028	C1420645
expression	T045	C0017262
Inhibiting	T052	C3463820
TCF8	T028	C1420645
expression	T045	C0017262
siRNA	T114	C1099354
EMT	T043	C1523298
podocytes	T025	C1328818
high	T080	C0205250
concentration	T081	C1446561
glucose	T109	C0017725
angiotensin	T116	C0003018
Inhibiting	T052	C3463820
TCF8	T028	C1420645
expression	T045	C0017262
cellular morphology	T201	C1521816
podocyte	T025	C1328818
movement	T040	C1621968
migration	T043	C1622501
glucose	T109	C0017725
angiotensin II	T116	C0003009
EMT	T043	C1523298
podocytes	T025	C1328818
TCF8	T028	C1420645
upregulation	T044	C0041904
host surface receptors	T116	C0034800
bacterial adhesion	T040	C0004614
disease	T047	C0004623
Host surface receptors	T116	C0034800
bacteria	T007	C0004611
attach	T067	C3714578
tissue	T024	C0040300
human	T016	C0086418
disease	T047	C0012634
host receptors	T116	C0034800
cognate adhesins	T026	C0699040
bacterial	T007	C0004611
pathogenesis	T046	C0699748
elevated	T080	C3163633
expression	T045	C0597360
host surface receptors	T116	C0034800
CEACAM-1	T116	C3540477
CEACAM-6	T116	C0376900
ICAM-1	T116	C0063695
PAFR	T116	C0071234
response to specific stimuli	T039	C0542478
upregulated receptors	T044	C0949479
host	T001	C1167395
bacterial infections	T047	C0004623
respiratory tract	T022	C0035237
receptor	T116	C0597357
induction	T169	C0205263
bacterial adherence	T040	C0004614
body system	T022	C0460002
central nervous	T022	C3714787
gastrointestinal	T022	C0012240
urogenital systems	T022	C0042066
Prokaryotic	T001	C0686817
pathogens	T046	C0699748
infectivity	T046	C3714514
Streptococcus pneumoniae	T007	C0038410
Haemophilus influenzae	T007	C0018483
Neisseria meningitidis	T007	C0027575
Escherichia coli	T007	C0014834
in vitro	T062	C1515654
in vivo experimental models	T062	C1515657
bacterial attachment	T040	C0004614
expressed	T045	C0597360
host receptors	T116	C0034800
targeted	T169	C1521840
interventions	T058	C1273869
prevention	T061	C0199176
treatment	T061	C0087111
bacterial disease	T047	C0004623
Optogenetic	T063	C3494301
Demonstration	T052	C0441655
Functional	T169	C0205245
Innervation	T042	C0021516
Mouse	T015	C0025929
Colon	T023	C0009368
Neurons	T025	C0027882
Transplanted	T169	C0700106
Neural Cells	T025	C0027882
Cell therapy	T061	C0302189
treat	T169	C1522326
gastrointestinal motility disorders	T047	C0854121
diseased	T025	C0027882
absent	T169	C0332197
enteric	T082	C1304890
neurons	T025	C0027882
neurons	T025	C0027882
transplanted	T169	C0700106
enteric	T082	C1304890
neural cells	T025	C0027882
functional	T169	C0205245
innervation	T042	C0021516
bowel	T023	C0021853
smooth muscle	T024	C1267092
mice	T015	C0025929
Enteric	T082	C1304890
neural cells	T025	C0027882
light-sensitive ion channel	T116	C0022009
channelrhodopsin	T116	C0033684
isolated	T169	C0205409
fetal	T169	C0521457
postnatal	T079	C0443281
mouse	T015	C0025929
bowel	T023	C0021853
transplanted	T169	C0700106
distal colon	T024	C1517729
week	T079	C0439230
wild-type	T028	C1883559
recipient mice	T015	C0025929
Intracellular	T082	C0178719
electrophysiological recordings	T059	C0022885
responses	T169	C0205245
light stimulation	UnknownType	C0240188
transplanted	T169	C0700106
cells	T025	C0027882
colonic	T023	C0009368
smooth muscle cells	T025	C1135918
recipient mice	T015	C0025929
Electrical stimulation	T067	C1254366
endogenous	T169	C0205227
enteric	T082	C1304890
neurons	T025	C0027882
control	T096	C0009932
axons	T026	C0004461
graft	T024	C0332835
neurons	T025	C0027882
plexus	T023	C1184808
circular muscle layer	T023	C0734812
Selective stimulation	T067	C1254366
graft	T024	C0332835
cells	T025	C0027882
light	T070	C0023693
excitatory	T042	C0234121
inhibitory junction potentials	T042	C0234122
electrical	T169	C0442828
events	T051	C0441471
contraction	T039	C0026820
relaxation	T042	C0026836
colonic	T023	C0009368
muscle cells	T025	C1135918
Graft	T024	C0332835
excitatory	T025	C0026609
inhibitory motor neurons	T025	C0026609
neurotransmitters	T123	C0027908
endogenous	T169	C0205227
motor neurons	T025	C0026609
acetylcholine	T109	C0001041
adenosine triphosphate	T114	C0001480
nitric oxide	T121	C0028128
Graft	T024	C0332835
neurons	T025	C0027882
interneurons	T025	C0021792
neurons	T025	C0027882
pharmacologic properties	T080	C0871161
interneurons	T025	C0021792
age	T032	C0001779
donors	T098	C0013018
enteric	T082	C1304890
neural cells	T025	C0027882
Enteric	T082	C1304890
neural cells	T025	C0027882
transplanted	T169	C0700106
bowel	T023	C0021853
multiple	T081	C0439064
functional	T169	C0205245
types	T080	C0332307
neurons	T025	C0027882
functional	T169	C0205245
innervation	T042	C0021516
smooth muscle	T024	C1267092
bowel wall	T023	C1283694
Circuits	UnknownType	C0814033
motor neurons	T025	C0026609
interneurons	T025	C0021792
age	T032	C0001779
cells	T025	C0027882
neurotransmitter	T123	C0027908
phenotype	T032	C0031437
interneurons	T025	C0021792
Assessment	T058	C0220825
Vascular Stent	T074	C0183521
Heating	T070	C0018837
Repetitive Transcranial Magnetic Stimulation	T061	C0872259
patients	T101	C0030705
stroke	T047	C0038454
repetitive transcranial magnetic stimulation	T061	C0872259
rTMS	T061	C0872259
clinical studies	T062	C0008972
metallic stents	T074	C0441290
metal	T197	C0025552
heated	T070	C0018837
eddy currents	T070	C0013790
clinical safety data	T170	C3899555
risk	T078	C0035647
metallic stents	T074	C0441290
heating	T070	C0018837
rTMS	T061	C0872259
tested	T169	C0039593
safety	T062	C1705187
rTMS	T061	C0872259
protocols	T170	C0442711
stents	T074	C0183521
stroke	T047	C0038454
nitinol	T122	C0068790
elgiloy	T122	C0002154
stents	T074	C0183521
tested	T170	C0392366
gelled	T167	C1382104
saline	T167	C0036082
locations	T082	C0450429
at the center	T082	C0205099
lobe	T023	C0796494
coil	T074	C1705946
location	T082	C0450429
stent	T074	C0441290
heating	T070	C0018837
evaluated	T058	C0220825
orientations	T082	C1704322
parallel	T082	C1254362
long axis	T082	C0522487
coil	T074	C1705946
parallel	T082	C1254362
short axis	T082	C0522488
coil	T074	C1705946
perpendicular	T082	C1295725
coil	T074	C1705946
stents	T074	C0183521
heat	T070	C0018837
rTMS	T061	C0872259
rTMS	T061	C0872259
orientation	T082	C1704322
Heating	T070	C0018837
greater	T081	C1704243
lobe	T023	C0796494
stent	T074	C0183521
oriented	T082	C1704322
perpendicularly	T082	C1295725
ex vivo	T169	C2348480
quantification	T081	C1709793
stent	T074	C0441290
heating	T070	C0018837
heating	T070	C0018837
stents	T074	C0183521
Food and Drug Administration	T093	C1708333
standards	T170	C0038137
in vivo	T082	C1515655
testing	T169	C0039593
rTMS	T061	C0872259
implanted	T074	C0021102
magnetic resonance imaging	T060	C0024485
compatible	T080	C1524057
stents	T074	C0183521
animal studies	T008	C0683949
human	T016	C0086418
safety studies	T062	C1705187
geometry	T090	C0449829
orientation	T082	C1704322
location	T082	C0450429
coil	T074	C1705946
Clinical Observation	T058	C3889687
Treatment	T169	C1522326
Chronic Subdural Hematoma	T046	C0749095
Novel Double Needle Minimally Invasive Aspiration Technology	T074	C0025080
aim	T078	C1947946
study	T062	C2603343
clinical effects	T080	C3850123
complications	T046	C0009566
treatment	T169	C1522326
chronic subdural hematoma	T046	C0749095
double needle aspiration	T074	C0025080
clinical data	T170	C1516606
patients	T101	C0030705
chronic subdural hematoma	T046	C0749095
treated	T169	C1522326
double YL-1 needle	T074	C0025080
skull drilling	T061	C0185154
treated	T169	C1522326
drilling	T061	C0185154
drainage	T061	C0013103
YL-1 needle	T074	C0025080
group	T078	C0441833
patient	T101	C0030705
hematoma	T046	C0018944
recurrence	T046	C2825055
patient	T101	C0030705
intracranial pneumocephalus	T047	C0238376
patients	T101	C0030705
months	T079	C0439231
clinical cure	T033	C3640840
traditional drilling	T061	C0185154
drainage	T061	C0013103
group	T078	C0441833
patients	T101	C0030705
hematoma	T046	C0018944
recurrence	T046	C2825055
months	T079	C0439231
operation	T061	C0543467
patients	T101	C0030705
postoperative	T079	C0032790
intracranial pneumocephalus	T047	C0238376
method	T170	C0025663
double YL-1 needle	T074	C0025080
traditional drilling	T061	C0185154
drainage method	T061	C0013103
treatment	T169	C1522326
chronic subdural hematoma	T046	C0749095
postoperative	T079	C0032790
recurrence	T046	C2825055
complications	T046	C0009566
impact	T080	C4049986
adjunctive	T061	C0677850
guanfacine	T109	C0079466
extended release	T122	C1707968
stimulant	T121	C0304402
adherence	T169	C1510802
children	T100	C0008059
adolescents	T100	C0205653
attention-deficit	T048	C0041671
hyperactivity disorder	T048	C1263846
stimulant	T121	C0304402
adherence	T169	C1510802
children	T100	C0008059
adolescents	T100	C0205653
attention-deficit	T048	C0041671
hyperactivity disorder	T048	C1263846
ADHD	T048	C1263846
augmenting stimulants	T120	C0449986
stimulants	T121	C0304402
guanfacine extended-release	T122	C1707968
GXR	T122	C1707968
Inclusion criteria	T078	C0243161
years	T079	C0439234
ADHD	T048	C1263846
diagnosis	T033	C0011900
long-acting	T121	C0304402
short-acting stimulant	T121	C0304402
GXR	T122	C1707968
augmentation	T061	C1293122
Modified medication possession ratio	T081	C0456603
mMPR	T081	C0456603
days	T079	C0439228
medication	T058	C2081612
available	T169	C0470187
days	T079	C0439228
period	T079	C1948053
excluding	T169	C0332196
medication	T058	C2081612
holidays	T052	C0019843
mMPR	T081	C0456603
nonadherent	T033	C3845923
Regression	T170	C0034980
models	T170	C3161035
assessed	T058	C0184514
change	T169	C0392747
mMPR	T081	C0456603
adjusting	T169	C0456081
demographic	T102	C0683970
clinical characteristics	T201	C0683325
patients	T101	C0030705
nonadherent	T033	C3845923
stimulants	T121	C0304402
pre	T079	C0332152
augmentation	T061	C1293122
unadjusted	T169	C1439367
SD	T081	C0871420
pre	T079	C0332152
post	T079	C0687676
stimulant	T121	C0304402
mMPRs	T081	C0456603
Adjusted	T169	C0456081
change	T169	C0392747
mMPR	T081	C0456603
long-acting	T121	C0304402
short-acting stimulants	T121	C0304402
patients	T101	C0030705
nonadherent	T033	C3845923
stimulants	T121	C0304402
GXR	T122	C1707968
augmentation	T061	C1293122
associated with	T080	C0332281
increased	T081	C0205217
stimulant	T121	C0304402
adherence	T169	C1510802
Bxb1 phage	T005	C1071338
recombinase	T116	C0073020
genome engineering	T063	C0017387
Drosophila melanogaster	T204	C0013139
Rapid	T080	C0456962
reliable	T080	C0205556
genome modifications	T063	C4277689
in vivo	T082	C1515655
functional analysis	T058	C0558024
genomic entity	T169	C1708234
gene	T028	C0017337
regulatory DNA	T086	C2329837
non-coding RNA	T114	C0887909
CRISPR	T114	C3658200
Cas9 genome editing technology	T063	C4279981
manipulation	T063	C0178659
genomic locus	T028	C0678933
model organisms	T001	C0029235
fruit fly Drosophila melanogaster	T204	C0013139
genome engineering	T063	C0017387
phage	T005	C1071338
recombinase Bxb1	T116	C0073020
D. melanogaster	T204	C0013139
Bxb1	T005	C1071338
recombinase activity	T045	C1148744
recombinases	T116	C0073020
targeted loci	T028	C0678933
Tailor-made drug carrier	T122	C0013161
Comparison	T052	C1707455
physicochemical properties	T080	C0871161
self-assembled	T044	C0872376
aggregates	T080	C0205418
optimal	T080	C2698651
drug carrier	T122	C0013161
Self-assembled	T044	C0872376
surfactant	T122	C0038888
aggregates	T080	C0205418
micelles	T109	C0025938
vesicles	T104	C1254350
application	T169	C1524063
drug carriers	T122	C0013161
treatment	T061	C0087111
diseases	T047	C0012634
characteristics	T080	C1521970
aggregate	T080	C0205418
best	T080	C1522427
drug carrier	T122	C0013161
disease	T047	C0012634
design	T052	C1707689
optimal	T080	C2698651
drug carrier	T122	C0013161
disease	T047	C0012634
self-assembled	T044	C0872376
aggregates	T080	C0205418
spherical micelles	T109	C0025938
lens-like vesicles	T104	C1254350
tube-like vesicles	T104	C1254350
multiple techniques	T169	C0449851
dynamic light scattering	T059	C1882368
differential scanning calorimetry	T059	C0006780
nuclear magnetic resonance spectroscopy	T060	C0877853
fluorescence measurement	T059	C0037802
Laurdan	T109	C0083196
probe	T074	C0182400
studies	T062	C2603343
database	T170	C0242356
self-assembled	T044	C0872376
aggregates	T080	C0205418
relationship	T080	C0439849
physicochemical properties	T080	C0871161
self-assembled	T044	C0872376
aggregates	T080	C0205418
functions	T169	C0542341
drug carriers	T122	C0013161
database	T170	C0242356
optimal	T080	C2698651
drug carrier	T122	C0013161
tailor-made drug carrier	T122	C0013161
Uridine	T114	C0041984
laxative	T121	C0282090
effect	T080	C1280500
loperamide	T109	C0023992
induced	T169	C0205263
constipation	T184	C0009806
SD rats	T015	C2699239
regulation	T044	C1327386
mAChRs	T116	C0034826
signaling pathway	T044	C0037080
mucin	T116	C0026682
secretion	T038	C0036536
Uridine	T114	C0041984
Urd	T114	C0041984
reported	T058	C0700287
major	T080	C0205164
RNA	T114	C0035668
important	T080	C3898777
role	T077	C1705810
biological process	T038	C3714634
neuroprotection	T043	C0598958
biochemical modulation	UnknownType	C0678672
glycolysis	T044	C0017952
role	T077	C1705810
constipation	T184	C0009806
established	T080	C0443211
study	T062	C2603343
investigated	T169	C1292732
laxative	T121	C0282090
effects	T080	C1280500
Urd	T114	C0041984
chronic	T079	C0205191
constipation	T184	C0009806
constipation	T184	C0009806
phenotypes	T032	C0031437
mechanisms	T169	C0441712
investigated	T169	C1292732
transverse colons	T023	C0227386
SD rats	T015	C2699239
loperamide	T109	C0023992
Lop	T109	C0023992
induced	T169	C0205263
constipation	T184	C0009806
treatment	T061	C0087111
Urd	T114	C0041984
number	T081	C0237753
weight	T081	C0043100
water	T121	C0043047
contents	T077	C0456205
stools	T031	C0015733
significantly	T078	C0750502
higher	T080	C0205250
Lop	T109	C0023992
Urd	T114	C0041984
treated	T033	C0332154
group	T078	C0441833
Lop	T109	C0023992
Vehicle	T122	C0042444
treated	T033	C0332154
group	T078	C0441833
food intake	T040	C0013470
water consumption	T040	C0013123
group	T078	C0441833
constant	T080	C1948059
level	T080	C0441889
thickness	T080	C1280412
mucosa layer	T024	C0026724
muscle	T024	C0026845
flat luminal surface	T029	C1180160
number	T081	C0237753
goblet cells	T025	C0506994
paneth cells	T025	C0227276
lipid droplets	T026	C0230704
enhanced	T052	C2349975
Lop	T109	C0023992
Urd	T114	C0041984
treated	T033	C0332154
group	T078	C0441833
expression	T045	C1171362
muscarinic acetylcholine receptors M2	T116	C0384752
M3	T116	C0289799
mAChR M2	T116	C0384752
M3	T116	C0289799
transcriptional	T045	C1158770
translational	T045	C3537096
level	T080	C0441889
recovered	T080	C0521108
Lop	T109	C0023992
Urd	T114	C0041984
treated	T033	C0332154
group	T078	C0441833
markers	T201	C0005516
Gα	T116	C0887847
inositol triphosphate	UnknownType	C0815032
IP3	UnknownType	C0815032
downstream	T082	C0522506
signaling pathway	T044	C0037080
recovered	T080	C0521108
Urd	T114	C0041984
treatment	T061	C0087111
mucin	T116	C0026682
secretion	T038	C0036536
expression	T045	C1171362
membrane water channel	T116	C0599635
aquaporine 8	T116	C1743716
AQP8	T116	C1743716
increased	T081	C0205217
significantly	T078	C0750502
Lop	T109	C0023992
Urd	T114	C0041984
treated	T033	C0332154
group	T078	C0441833
compared	T052	C1707455
Lop	T109	C0023992
Vehicle	T122	C0042444
treated	T033	C0332154
group	T078	C0441833
activity	T052	C0441655
Urd	T114	C0041984
primary smooth muscle	T024	C1267092
rat	T015	C0086893
intestine cells	T025	C0814997
pRISMC	T025	C1135918
Gα	T116	C0887847
expression	T045	C1171362
IP3	UnknownType	C0815032
concentration	T081	C1446561
results	T033	C0683954
study	T062	C2603343
strong	T080	C0442821
evidence	T078	C3887511
Urd	T114	C0041984
important	T080	C3898777
improving	T080	C1272745
chronic	T079	C0205191
constipation	T184	C0009806
induced	T169	C0205263
Lop	T109	C0023992
treatment	T061	C0087111
animal models	T008	C0599779
Characterization	T052	C1880022
Phytochrome Interacting Factors	T123	C0574031
Moss	T002	C0282635
Physcomitrella patens	T002	C0996529
Conservation	T080	C2347858
Phytochrome Signaling Modules	T123	C0574031
Land Plants	T002	C1562025
plant kingdom	T002	C0032098
phytochrome	T116	C0031857
PHY	T116	C0031857
photoreceptors	T025	C0031760
adaptive	T169	C0231193
responses to light	T040	C2945741
Arabidopsis thaliana	T002	C0162740
PHYs	T116	C0031857
nucleus	T026	C0007610
downstream signaling components	T123	C1519315
phytochrome interacting factors	T123	C0574031
PIFs	T123	C0574031
PIFs	T123	C0574031
transcription factors	T116	C0040648
repressors	T116	C1336789
photomorphogenesis	T039	C1154971
inhibition	T040	C2265391
PHYs	T116	C0031857
gene expression	T045	C0017262
nuclear function	T043	C0007613
PHYs	T116	C0031857
non-seed plants	T002	C0032098
genes	T028	C0017337
PHY	T116	C0031857
signaling	T038	C3537152
moss	T002	C0282635
Physcomitrella patens	T002	C0996529
light-regulated genes	T028	C0017337
orthologs	T028	C1335144
PIF-controlled genes	T028	C0017337
Arabidopsis	T002	C0162741
Phylogenetic analyses	T062	C1519068
PIF-like gene	T028	C0017337
streptophyte algae	T204	C0002028
water-to-land transition	T052	C2700061
plants	T002	C0032098
PIF homologs	T123	C0574031
genome	T028	C0017428
P. patens	T002	C0996529
Arabidopsis	T002	C0162741
PIFs	T123	C0574031
protein domain structure	T116	C1510464
molecular properties	T080	C1521991
physiological effects	T039	C1254359
PHY	T116	C0031857
interaction	T082	C0596788
P. patens	T002	C0996529
PIFs	T123	C0574031
PHY	T116	C0031857
signaling	T038	C3537152
PHY-PIF signaling node	T044	C0037080
light signals	T067	C1710082
genes	T028	C0017337
land plant	T002	C1562025
evolution	T045	C0015219
lineage-specific diversification	T077	C1254372
Conditional reprogramming	T059	C4042857
long-term	T079	C0443252
expansion	T043	C0007595
normal	T025	C1268443
tumor cells	T025	C0431085
human	T016	C0086418
biospecimens	T077	C2347026
propagate	T052	C3146294
cells	T025	C0007634
in vitro	T080	C1533691
human	T016	C0086418
tumors	T191	C0027651
healthy tissue	T024	C0040300
in vitro	T080	C1533691
preclinical models	T170	C1514292
study of basic cancer biology	T091	C1516164
translational research	T062	C3494163
drug discovery	T062	C0920472
drug target identification	T074	C0085104
protocol	T059	C4042857
conditional reprogramming	T043	C3850096
CR	T043	C3850096
coculture	T059	C0282547
mouse	T015	C0025929
fibroblast feeder cells	T025	C3179110
normal	T025	C1268443
tumor	T191	C0027651
human	T016	C0086418
epithelial cells	T025	C0014597
Rho kinase	T116	C0389995
inhibitor	T121	C0014432
Y-27632	T109	C0667301
CR	T059	C4042857
cells	T025	C0007634
regenerative medicine	T091	C1257974
drug sensitivity testing	T059	C0013207
gene expression profiling	T059	C0752248
xenograft studies	T061	C0520484
method	T059	C4042857
pathologist	T097	C0334866
healthy tissue	T024	C0040300
tumor tissue	T024	C0475358
basic tissue culture	T059	C0040284
protocol	T059	C4042857
cells	T025	C0007634
fresh	T024	C1519521
cryopreserved tissue samples	T024	C1511549
cells	T025	C0007634
generated	T052	C3146294
technique	T059	C4042857
diagnostic	T130	C0358514
predictive	T080	C0681890
medicine	T121	C0013227
epithelial cells	T025	C0014597
propagated	T052	C3146294
in vitro	T080	C1533691
capacity	T081	C1516240
differentiated	T043	C0007589
conditions	T082	C0014406
natural environment	T082	C0557745
internal facilitation	T073	C0018704
activities	T052	C0441655
hospitals	T073	C0019994
implementing evidence-based interventions	T058	C0557981
Implementation	T052	C1708476
models	T170	C3161035
frameworks	T077	C1709697
theories	T078	C0871935
activities	T052	C0441655
implementation	T052	C1708476
success	T054	C0597535
internal facilitation	T073	C0018704
activities	T052	C0441655
hospital personnel	T097	C0031228
engage	T169	C1314939
implementation efforts	T052	C1708476
study	T062	C2603343
internal facilitation	T073	C0018704
activities	T052	C0441655
critical access hospitals	T073	C1552526
rural Iowa	T083	C0022037
implementation	T052	C1708476
TeamSTEPPS	T093	C0080268
patient safety	T058	C1113679
intervention	T061	C0184661
characteristics	T080	C1521970
facilitation	T073	C0018704
activities	T052	C0441655
critical access hospitals	T073	C1552526
years	T079	C0439234
onset of	T080	C0332162
implementation	T052	C1708476
quarterly	T079	C0332179
interviews	T052	C0021822
key informants	T098	C0870704
transcripts	T170	C0034869
quarters	T081	C2825406
coding template	T078	C1705542
inductive analyses	T062	C0936012
template	T078	C1705542
deductively	T080	C0205556
interview	T052	C0021822
transcripts	T170	C0034869
comparative analysis	T062	C0683941
characteristics	T080	C1521970
facilitation	T073	C0018704
facilitation	T073	C0018704
activities	T052	C0441655
Leadership	T054	C0023181
Customization	T052	C1880202
Accountability	T078	C0078889
Individuals	T098	C0237401
teams	T096	C0871489
engaged	T169	C1314939
facilitation	T073	C0018704
activities	T052	C0441655
ad hoc manner	T033	C0243095
activities	T052	C0441655
people	T098	C0027361
practices	T041	C0237607
temporal patterns	T079	C4021204
start	T079	C1301880
peak time	T079	C1254367
facilitation	T073	C0018704
activities	T052	C0441655
hospitals	T073	C0019994
engage	T169	C1314939
implementing	T052	C1708476
evidence-based practices	T091	C4042762
parsimonious	T080	C0205556
facilitation	T073	C0018704
activities	T052	C0441655
theoretical	T078	C0871935
empirical	T062	C0376367
research opportunities	T062	C0683937
facilitation	T073	C0018704
activities	T052	C0441655
characteristics	T080	C1521970
managers	T097	C0335141
planning	T169	C1301732
executing	T052	C1705848
implementations	T052	C1708476
evidence-based interventions	T091	C4042762
Directing traffic on DNA	T045	C0314627
transcription factors	T116	C0040648
relieve	T169	C1301676
induce	T169	C0205263
transcriptional interference	T045	C0598496
Transcriptional interference	T045	C0598496
TI	T045	C0598496
widespread	T082	C0205391
gene control	T045	C0017263
pervasive nature	T081	C0220900
transcription	T045	C0040649
sense	T169	C1883001
antisense	T114	C0079249
kingdoms	T185	C1708611
transcription factor	T116	C0040648
binding kinetics	T090	C0598135
influence	T077	C4054723
ability	T032	C0085732
transcription factor	T116	C0040648
relieve	T169	C1301676
induce	T169	C0205263
TI	T045	C0598496
Acoustic startle response	T040	C0038186
rats	T015	C0034693
inter-individual	T098	C0237401
variation	T080	C1705242
fear	T041	C0015726
extinction	T041	C0015347
population	T098	C1257890
traumatic	T169	C0332663
event	T051	C0441471
percentage	T081	C0439165
population	T098	C1257890
post-traumatic stress disorder	T048	C0038436
PTSD	T048	C0038436
predisposing factors	T079	C0032946
Abnormal	T033	C0205161
acoustic startle response	T040	C0038186
ASR	T040	C0038186
PTSD	T048	C0038436
potential	T080	C3245505
predictor	T078	C2698872
development	T039	C0243107
PTSD	T048	C0038436
behavior	T053	C0004927
extinction	T041	C0015347
extinction learning	T041	C0237613
PTSD	T048	C0038436
patients	T101	C0030705
abnormal	T033	C0205161
ASR	T040	C0038186
development	T039	C0243107
deficits	T080	C2987487
baseline	T081	C1442488
ASR	T040	C0038186
development	T039	C0243107
PTSD	T048	C0038436
behavior	T053	C0004927
baseline	T081	C1442488
ASR	T040	C0038186
freezing behavior	T053	C0004927
Pavlovian fear conditioning	T062	C0681797
adult	T100	C0001675
male	T032	C0086582
Sprague-Dawley rats	T015	C0034715
Baseline	T081	C1442488
acoustic startle response	T040	C0038186
ASR	T040	C0038186
Pavlovian fear conditioning paradigm	T062	C0681797
freezing behavior	T053	C0004927
fear conditioning	T062	C0681797
extinction	T041	C0015347
training	T065	C0220931
extinction	T041	C0015347
testing	T169	C0039593
baseline	T081	C1442488
ASR	T040	C0038186
fear	T041	C0015726
memory	T041	C0025260
conditioning	T062	C0681797
rats	T015	C0034715
baseline	T081	C1442488
ASR	T040	C0038186
retention	T041	C0035280
extinction	T041	C0015347
memory	T041	C0025260
rats	T015	C0034715
baseline	T081	C1442488
ASR	T040	C0038186
baseline	T081	C1442488
ASR	T040	C0038186
predictive	T080	C0681890
index	T170	C0918012
development	T039	C0243107
PTSD	T048	C0038436
phenotype	T032	C0031437
tacrolimus	T109	C0085149
blood concentrations	T081	C0699870
lung transplantation	T061	C0024128
risk	T078	C0035647
kidney injury	T037	C0160420
Lung	T023	C0024109
transplant recipients	T101	C0376387
acute kidney injury	T037	C2609414
AKI	T037	C2609414
chronic kidney disease	T047	C1561643
CKD	T047	C1561643
immunosuppressant	T121	C0021081
tacrolimus	T109	C0085149
associated with	T080	C0332281
AKI	T037	C2609414
development	T169	C1527148
recovery	T040	C2004454
kidney injury	T037	C0160420
lung transplantation	T061	C0024128
AKI	T037	C2609414
whole-blood	T031	C0370231
tacrolimus	T109	C0085149
trough concentrations	T081	C3640757
kidney injury	T037	C0160420
retrospectively studied	T062	C0035363
kidney injury	T037	C0160420
lung-transplantation	T061	C0024128
patients	T101	C0030705
UMC Utrecht	T093	C1708333
Kidney function	T042	C0232804
whole-blood	T031	C0370231
tacrolimus	T109	C0085149
trough concentrations	T081	C3640757
day	T079	C0439228
months	T079	C0439231
postoperative	T079	C0032790
Systemic inflammatory response syndrome	T047	C0242966
SIRS	T047	C0242966
septic shock	T046	C0036983
nephrotoxic	T080	C1514118
medications	T170	C4284232
covariates	UnknownType	C0814913
AKI	T037	C2609414
liver injury	T037	C0160390
drug-drug interactions	T044	C0687133
AKI	T037	C2609414
present	T033	C0150312
patients	T101	C0030705
Tacrolimus	T109	C0085149
concentrations	T081	C0699870
supra-therapeutic	T034	C4049341
patients	T101	C0030705
AKI	T037	C2609414
week	T079	C0439230
transplantation	T061	C0024128
supra-therapeutic	T034	C4049341
tacrolimus	T109	C0085149
concentrations	T081	C0699870
OR	T081	C0028873
CI	T081	C0009667
nephrotoxic drugs	T061	C3687832
OR	T081	C0028873
CI	T081	C0009667
infection	T046	C3714514
OR	T081	C0028873
CI	T081	C0009667
cystic fibrosis	T047	C0010674
OR	T081	C0028873
CI	T081	C0009667
Recovery rate	T081	C1521828
AKI	T037	C2609414
incidence	T169	C0220856
CKD	T047	C1561643
year	T079	C0439234
lung transplantation	T061	C0024128
AKI	T037	C2609414
severe	T080	C0205082
CKD	T047	C1561643
morbidity	T081	C0026538
mortality	T081	C0205848
Supra-therapeutic	T034	C4049341
whole-blood	T031	C0370231
tacrolimus	T109	C0085149
trough concentrations	T081	C3640757
AKI	T037	C2609414
Conscientious	T033	C0580939
targeting	T169	C1521840
tacrolimus	T109	C0085149
blood concentrations	T081	C0699870
vital	T080	C0442732
early phase	UnknownType	C0814494
lung transplantation	T061	C0024128
Lung	T023	C0024109
transplant recipients	T101	C0376387
acute kidney injury	T037	C2609414
chronic kidney disease	T047	C1561643
morbidity	T081	C0026538
mortality	T081	C0026566
pathophysiology	T169	C0031847
kidney injury	T037	C0160420
lung transplantation	T061	C0024128
immunosuppressant	T121	C0021081
tacrolimus	T109	C0085149
dose	T081	C0678766
unstable	T033	C0443343
clinical setting	T082	C3176918
nephrotoxic	T080	C1514118
supra-therapeutic	T034	C4049341
whole-blood	T031	C0370231
tacrolimus	T109	C0085149
trough concentrations	T081	C3640757
acute kidney injury	T037	C2609414
days	T079	C0439228
lung transplantation	T061	C0024128
Supra-therapeutic	T034	C4049341
whole-blood	T031	C0370231
tacrolimus	T109	C0085149
trough concentrations	T081	C3640757
lung transplantation	T061	C0024128
AKI	T037	C2609414
lung transplantation	T061	C0024128
low	T080	C0205251
recovery	T040	C2004454
rates	T081	C1521828
Zebrafish	T013	C0043457
akt2	T028	C0812230
essential	T080	C0205224
survival	T052	C0038952
growth	T040	C0018270
bone development	T042	C0005939
glucose homeostasis	T039	C1326961
akt	T116	C0166559
isoforms	T116	C0597298
akt2	T116	C1312419
role	T077	C1705810
regulation	T038	C1327622
cellular processes	T043	C1325880
mammals	T015	C0024660
role	T077	C1705810
mechanisms	T169	C0441712
zebrafish	T013	C0043457
unknown	T080	C0439673
function	T169	C0542341
akt2	T028	C0812230
zebrafish	T013	C0043457
generated	T080	C2346631
zebrafish	T013	C0043457
lacking	T080	C0332268
akt2 gene	T028	C0812230
CRISPR/Cas9	T044	C3658355
technology	T090	C0039421
Akt2	T028	C0812230
null	T081	C0456148
zebrafish	T013	C0043457
lethality	T033	C3151529
severe	T080	C0205082
growth	T040	C0018270
deficiency	T169	C0011155
akt2	T028	C0812230
null	T081	C0456148
mice	T015	C0025929
akt2	T028	C0812230
null	T081	C0456148
zebrafish	T013	C0043457
display	T169	C0870432
deficiency	T169	C0011155
fin ray development	T040	C2246747
cartilage	T024	C0007301
not affected	T077	C2986417
observations	T062	C0302523
akt2	T028	C0812230
null	T081	C0456148
mice	T015	C0025929
akt2	T028	C0812230
null	T081	C0456148
zebrafish	T013	C0043457
display	T169	C0870432
impaired	T169	C0221099
glucose homeostasis	T039	C1326961
akt2	T028	C0812230
null	T081	C0456148
mice	T015	C0025929
insulin level	T059	C0202098
lower	T080	C0205251
akt2	T028	C0812230
null	T081	C0456148
zebrafish	T013	C0043457
symptoms	T184	C1457887
type I diabetes	T047	C0011854
akt2	T028	C0812230
null	T081	C0456148
zebrafish	T013	C0043457
transcriptome analysis	T059	C0752248
reveals	T080	C0443289
genes	T028	C0017337
metabolism	T040	C0025519
osteogenesis	T042	C0029433
akt2	T028	C0812230
null	T081	C0456148
zebrafish	T013	C0043457
data	T078	C1511726
role	T077	C1705810
akt2	T028	C0812230
zebrafish	T013	C0043457
survival	T052	C0038952
growth	T040	C0018270
bone development	T042	C0005939
glucose homeostasis	T039	C1326961
akt2	T028	C0812230
functions	T169	C0542341
mice	T015	C0025929
zebrafish	T013	C0043457
evolutionarily	T045	C0015219
conserved	T044	C0969701
Physiological	T169	C0205463
Properties	T080	C0871161
Behavioral	T053	C0004927
Correlates	T080	C1707520
Hippocampal	T023	C0019564
Granule Cells	T025	C0007634
Mossy Cells	T025	C0007634
hippocampal	T023	C0019564
dentate gyrus	T023	C0152314
segregator	T169	C0205245
upstream information	T042	C1254358
Physiological support	T039	C0031843
function	T169	C0542341
lack	T080	C0332268
well-defined	T080	C0442825
characteristics	T080	C1521970
granule cells	T025	C0007634
mossy cells	T025	C0007634
electrophysiology	UnknownType	C0678837
classification	T185	C0008902
dentate	T023	C0152314
granule cells	T025	C0007634
mossy cells	T025	C0007634
mice	T015	C0025929
optogenetic tagging	T063	C3494301
mossy cells	T025	C0007634
Granule cells	T025	C0007634
firing	T043	C0007613
single	T081	C0205171
place field	T082	C1254362
changes	T169	C0392747
mouse	T015	C0025929
tested	T169	C0039593
mazes	T073	C0870866
room	T082	C1547703
mossy cells	T025	C0007634
active	T169	C0205177
multiple	T081	C0439064
place fields	T082	C1254362
place fields	T082	C1254362
conditions	T080	C0348080
granule cell	T025	C0007634
mossy cell	T025	C0007634
synapse	T030	C0039062
mossy cells	T025	C0007634
place fields	T082	C1254362
single	T081	C0205171
granule cells	T025	C0007634
findings	T169	C2607943
granule cells	T025	C0007634
mossy cells	T025	C0007634
modulated	T082	C0443264
action	T052	C3266814
pattern separation	T169	C0205245
intraosseous access	T169	C0595613
History	T033	C2004062
clinical considerations	T033	C0427350
current devices	T074	C0025080
Intraosseous (IO) access	T169	C0595613
method	T170	C0025663
American Heart Association	T093	C0002458
European Resuscitation Council	T093	C1708333
administer	T169	C1621583
resuscitative drugs	T121	C1254351
fluids	T167	C1704353
intravenous (IV) access	T082	C0013125
clinicians	T097	C0871685
limited knowledge	T170	C0376554
experience	T041	C0596545
IO route	T169	C0595613
review	T170	C0282443
succinct review	T170	C0282443
history	T033	C2004062
clinical considerations	T033	C0427350
devices	T074	C0025080
associated with	T080	C0332281
IO access	T169	C0595613
IO access	T169	C0595613
IO access	T169	C0595613
lifesaving bridge	T078	C1254370
definitive vascular access	T074	C0750138
IV	T082	C0348016
patient's outcome	T078	C1547647
negatively affected	T033	C0233467
prompt circulatory access	T082	C0444454
IO route	T169	C0595613
contraindications	T080	C0522473
serious complications	T046	C0009566
manual	T169	C0175674
powered devices	T074	C0025080
several anatomic sites	T082	C1513749
clinicians	T097	C0871685
acute care	T058	C0679878
cardiovascular	T029	C3887460
emergencies	T046	C2745965
training	T065	C0220931
proficiency	T080	C0205556
IO	T169	C0595613
devices	T074	C0025080
IO route	T169	C0595613
resuscitation organizations	T093	C1708333
preferred route of infusion	T169	C1827465
IV access	T082	C0013125
C-5a-substituted validamine type	T109	C0084937
glycosidase inhibitors	T116	C1960098
N-alkyl derivatives	T121	C1254351
D-galactosidase	T116	C0005220
inhibitor	T121	C0014432
1,4-di-epi-validamine	T121	C1254351
lipophilic	T081	C0598631
substituents at position C-5a	T104	C1254350
screened	T059	C0373483
glycosidase	T116	C0017976
inhibitory properties	T039	C1524081
Products	T071	C1514468
β-galactosidases	T116	C0005220
β-glucosidases	T116	C1260223
Exposure to suicidal behaviors	T033	C1760428
suicide	T033	C0038661
risk factor	T033	C0035648
personal	T032	C1519021
negative life event	T033	C1822593
Numerous	T081	C0439064
suicide	T033	C0038661
risk factors	T033	C0035648
validated for epidemiology	T080	C0042283
treatment	T061	C0087111
prevention efforts	T080	C2700409
Exposures to suicidal behaviors	T033	C1760428
ESB	T033	C1760428
family	T099	C0015576
friend	T098	C0079382
suicide attempts	T033	C0038663
completions	T033	C0038661
validity	T080	C0042283
suicidal	T033	C0038661
risk factor	T033	C0035648
measurement	T169	C0242485
adequacy	T080	C0814633
anonymous	T080	C2346787
online	T073	C0029038
survey	T170	C0038951
participants	T098	C0679646
aged	T032	C0001779
ESB	T033	C1760428
Suicidal Affect-Behavior-Cognition Scale	T170	C0282574
SABCS	T170	C0282574
variables	T080	C0439828
Tests	T170	C0392366
dimensionality	T082	C1707753
internal consistency	T081	C0870731
ESB	T033	C1760428
variables	T080	C0439828
attempts	T033	C0038663
completions	T033	C0038661
family	T099	C0015576
friends	T098	C0079382
independent	T169	C0332291
ESB	T033	C1760428
latent	T080	C0205275
trait	T032	C0599883
ESB	T033	C1760428
variables	T080	C0439828
demographic	T033	C0578829
psychiatric histories	T033	C0748059
tests	T170	C0392366
associations	T080	C0439849
ESB	T033	C1760428
suicidality	T201	C3166387
suicide	T033	C0038661
risk factors	T033	C0035648
social support	T054	C0037438
depression	T048	C0011570
anxiety	T033	C0003467
stress	T033	C0038435
satisfaction with life	T080	C0392352
emotional stability	T041	C0237105
reports	T170	C0684224
young adults	T100	C0238598
aged	T032	C0001779
increased	T081	C0205217
suicidality	T201	C3166387
ESB	T033	C1760428
Results	T169	C1274040
validity	T080	C0042283
ESB	T033	C1760428
risk factor	T033	C0035648
suicidality	T201	C3166387
psychopathology	UnknownType	C0544667
latent	T080	C0205275
trait	T032	C0599883
ESB	T033	C1760428
evidence	T078	C3887511
personal	T032	C1519021
negative life event	T033	C1822593
individual	T098	C0237401
effects	T080	C1280500
interpretations	T170	C0459471
Direct anterior approach	T082	C0205511
total hip arthroplasty	T061	C0040508
mobile traction table	T074	C0183817
prospective cohort study	T062	C1709709
prospective cohort study	T062	C1709709
total hip arthroplasty	T061	C0040508
direct anterior approach	T082	C0205511
supine position	T082	C0038846
mobile traction table	T074	C0183817
consecutive surgeries	T061	C0035110
single surgeon	T097	C0582175
direct anterior approach	T082	C0205511
traction table	T074	C0183817
follow-up	T058	C1522577
patients	T101	C0030705
patients	T101	C0030705
previous hip surgeries	T033	C3266738
severe deformity	T190	C0302142
cemented implants	T061	C0441496
groups	T078	C0441833
patients	T101	C0030705
patients	T101	C0030705
implant survival rate	T081	C0038954
follow-up	T058	C1522577
Revision surgery	T061	C0035110
periprosthetic	T037	C2609162
femoral fracture	T037	C0015802
patient	T101	C0030705
complication	T046	C0009566
rate	T081	C1521828
traction table	T074	C0183817
patients	T101	C0030705
anterior dislocations	T037	C1265658
periprosthetic	T037	C2609162
femoral fracture	T037	C0015802
intraoperative perforation	T058	C0034117
femoral rasping	T037	C0015802
complication	T046	C0009566
rate	T081	C1521828
decrease	T081	C0547047
group	T078	C0441833
Mean surgical time	T079	C3494201
rate	T081	C1521828
allogeneic blood transfusion	T061	C0005841
cup alignment	T033	C1821889
safe zone	T082	C1254362
group	T078	C0441833
group	T078	C0441833
direct anterior approach	T082	C0205511
mobile traction table	T074	C0183817
positive learning curve	T033	C0243095
surgical time	T079	C3494201
rate	T081	C1521828
allogeneic blood transfusion	T061	C0005841
cup alignment	T033	C1821889
safe zone	T082	C1254362
binding	T044	C0597358
orientations	T082	C1704322
structurally	T082	C0678594
ligands	T103	C0023688
differ	T080	C1705242
Crystal structures	T104	C0444626
ligand-receptor interactions	T044	C0597358
therapeutics	T061	C0087111
experimental	T080	C1517586
homologous proteins	T116	C1512488
Tropisetron	T109	C0063322
orthosteric ligand	T103	C0023688
5-HT3	T116	C0295352
α7 nACh receptors	T116	C0051334
binding	T044	C0597358
orientation	T082	C1704322
structural homologue	T087	C1449549
AChBP	T116	C1254349
Co-crystallisation	T070	C0010423
structurally	T082	C0678594
ligand	T103	C0023688
granisetron	T109	C0061863
identical	T080	C0205280
orientation	T082	C1704322
difference	T080	C1705242
affinity	T070	C1510827
tropisetron	T109	C0063322
5-HT3	T116	C0295352
α7 nACh receptors	T116	C0051334
α7 nACh receptors	T116	C0051334
not	T169	C1518422
bind	T044	C0597358
granisetron	T109	C0061863
pharmacological	T169	C0205464
differences	T080	C1705242
receptor	T116	C0597357
crystal structures	T104	C0444626
ligand	T103	C0023688
orientations	T082	C1704322
binding	T044	C0597358
orientation	T082	C1704322
tropisetron	T109	C0063322
granisetron	T109	C0061863
5-HT3 receptors	T116	C0295352
in silico	T066	C3489666
modelling	T090	C0013193
docking	T044	C1522290
radioligand binding	T044	C1517880
cysteine	T116	C0010654
substituted	T045	C0525038
5-HT3 receptor	T116	C0295352
mutants	T049	C0596988
expressed	T045	C0017262
HEK 293 cells	T025	C2936239
synthetic modification	T091	C0598331
ligands	T103	C0023688
cysteine	T116	C0010654
substitutions	T045	C0525038
effects	T080	C1280500
tropisetron	T109	C0063322
granisetron	T109	C0061863
Structure-activity relationships	T080	C0038477
ligands	T103	C0023688
orientations	T082	C1704322
revealing	T080	C0443289
crystallographic	T059	C0010424
evidence	T078	C3887511
AChBP	T116	C1254349
ligands	T103	C0023688
different	T080	C1705242
orientations	T082	C1704322
5-HT3 receptor	T116	C0295352
binding site	T192	C0005456
structurally	T082	C0678594
molecules	T167	C0567416
orientations	T082	C1704322
binding site	T192	C0005456
homologous proteins	T116	C1512488
ligand binding	T044	C1517880
Pancreatic	T023	C0030274
neuroendocrine cancer	T191	C0746852
liver metastases	T191	C0494165
multiple peritoneal metastases	T191	C0346989
Pancreatic	T023	C0030274
neuroendocrine tumor	T191	C0746852
pNET	T191	C0746852
pancreatic tumor	T191	C0030297
distant metastases	T201	C4297205
found	T033	C0150312
liver	T023	C0023884
male patient	T032	C0150904
pNET	T191	C0746852
liver metastasis	T191	C0494165
multiple abdominal metastases	T191	C0854198
management	T058	C0376636
tumor	T191	C0027651
advanced stage	T079	C1254367
Lignans	T109	C0064971
fruits	T168	C0016767
Schisandra chinensis (Turcz.) Baill	T002	C0696946
inhibit	T052	C3463820
proprotein convertase subtilisin/kexin type 9	T028	C1426592
expression	T045	C0017262
Bioactivity-guided fractionation	T059	C0016640
fruits	T168	C0016767
Schisandra chinensis	T002	C0696946
proprotein convertase subtilisin-kexin type 9	T028	C1426592
PCSK9	T028	C1426592
mRNA expression	T045	C1515670
screening assay	T059	C1510438
isolation	T169	C0205409
two	T081	C0205448
previously unknown	T080	C0439673
lignans	T109	C0064971
14-tigloylschinlignan D	T109	C0064971
rel-(7R, 8R, 7'R, 8'R)-manglisin E	T109	C0064971
structures	T170	C0220807
established	T080	C0443211
NMR spectroscopic	T060	C0877853
data	T078	C1511726
CD	T059	C0008813
MS	T059	C0037813
analysis	T062	C0936012
tested	T169	C0039593
inhibitory	T052	C3463820
activities	T052	C0441655
mRNA expression	T045	C1515670
PCSK9	T028	C1426592
tested	T169	C0039593
four	T081	C0205450
rel-(7R, 8R, 7'R, 8'R)-manglisin E	T109	C0064971
(-)-schisandrin C	T109	C0074176
schinlignan D	T109	C0064971
(+)-schisandrol B	T109	C0074177
inhibited	T080	C0311403
PCSK9	T028	C1426592
mRNA expression	T045	C1515670
IC50	T081	C0600495
(+)-schisandrol B	T109	C0074177
suppress	T169	C1260953
PCSK9	T116	C4255394
protein expressions	T045	C1171362
schinlignan D	T109	C0064971
low density lipoprotein receptor	T116	C0034821
expression	T045	C0597360
outcomes	T080	C0085415
morbidly obese	T047	C0028756
obese	T047	C0028754
non-obese	T032	C0005910
patients	T101	C0030705
primary total knee	T061	C0086511
total hip arthroplasty	T061	C0040508
Obesity	T047	C0028754
public	T092	C0678367
health issue	T033	C1398682
prevalence	T081	C0220900
morbid obesity, (Body Mass Index (BMI) ≥ 40 kg/m(2))	T033	C1319441
increasing	T169	C0442808
evidence	T078	C3887511
patients	T101	C0030705
peri- and post-operative complications	T047	C0280955
poorer outcomes	T080	C0085415
arthroplasty procedures	T061	C0003893
outcomes	T080	C0085415
non-obese	T032	C0005910
obese	T047	C0028754
morbidly obese	T047	C0028756
patients	T101	C0030705
arthroplasty	T061	C0003893
institution	T093	C2607850
retrospective audit	T058	C0184821
patients	T101	C0030705
institution	T093	C2607850
total knee	T061	C0086511
TKA	T061	C0086511
total hip arthroplasty	T061	C0040508
THA	T061	C0040508
Data	T078	C1511726
collected	T078	C1516695
age	T032	C0001779
gender	T032	C0079399
BMI	T201	C1305855
length of stay	T079	C0023303
LOS	T079	C0023303
Oxford knee	T201	C1997265
hip score	T201	C1998079
OKS	T201	C1997265
OHS	T201	C1998079
satisfaction	T033	C3476649
complications	T046	C0274311
years	T079	C0439234
post operation	T061	C0543467
Patients	T101	C0030705
groups	T078	C0441833
BMI < 30	T033	C0850114
BMI 30-40	T201	C1305855
BMI > 40	T033	C1561729
Outcomes	T080	C0085415
BMI	T201	C1305855
group	T078	C0441833
TKA	T061	C0086511
THA	T061	C0040508
operations	T061	C0543467
obese	T047	C0028754
non-obese	T032	C0005910
patients	T101	C0030705
morbidly obese	T047	C0028756
patients	T101	C0030705
TKA	T061	C0086511
LOS	T079	C0023303
day	T079	C0439228
mean OKS	T201	C1997265
postoperative problems	T046	C0032787
THA	T061	C0040508
patients	T101	C0030705
no difference	T033	C3842396
LOS	T079	C0023303
OHS score	T201	C1998079
increasing	T169	C0442808
BMI	T201	C1305855
category	T170	C0683312
postoperative problems	T046	C0032787
increase	T169	C0442805
non-obese	T032	C0005910
obese	T047	C0028754
morbidly obese	T047	C0028756
patients	T101	C0030705
obese	T047	C0028754
patients	T101	C0030705
outcomes	T080	C0085415
TKA	T061	C0086511
THA	T061	C0040508
patients	T101	C0030705
arthroplasty	T061	C0003893
Vitamin D Receptor Activator	T123	C0574031
Cause-specific Death	T081	C1707318
dialysis	T061	C0011946
Patients	T101	C0030705
Nationwide Cohort Study	T081	C0009247
Coarsened Exact Matching	T081	C0026348
Vitamin D receptor activators	T123	C0574031
VDRA	T123	C0574031
pleiotropic effects	T045	C2936488
cardiovascular disease	T047	C0007222
malignancy	T191	C4282132
infections	T046	C3714514
dialysis	T061	C0011946
patients	T101	C0030705
cardiovascular outcomes	T033	C0679250
patients	T101	C0030705
dialysis	T061	C0011946
who survived	T081	C0038954
Renal Data Registry	T062	C0920631
Japanese Society	T093	C1708333
Dialysis Therapy	T061	C0011946
VDRA	T123	C0574031
clinically relevant variables	T079	C0205563
coarsened exact matching procedure	T081	C0026348
deaths	T081	C0205848
cardiovascular deaths	T046	C0376297
infection-related deaths	T033	C1306577
malignancy-related deaths	T081	C1516192
Multivariable survival analyses	T062	C0038953
intra-region correlation	T080	C1707520
VDRA	T123	C0574031
lower rates	T081	C1521828
infection	T046	C3714514
malignancy	T191	C4282132
deaths	T081	C0205848
subhazard ratio	T081	C2985465
CI	T081	C0009667
CI	T081	C0009667
cardiovascular death	T046	C0376297
subhazard ratio	T081	C2985465
CI	T081	C0009667
randomized clinical trials	T062	C0206034
sample size	T081	C0242618
follow-up	T058	C1522577
clinical effectiveness	T080	C3850123
VDRA	T123	C0574031
infection	T046	C3714514
malignancy	T191	C4282132
cardiovascular disease	T047	C0007222
dialysis	T061	C0011946
patients	T101	C0030705
Burden	T078	C2828008
cervical cancer	T191	C4048328
screening	T058	C1710032
India	T083	C0021201
Cervical cancer	T191	C4048328
cancer mortality	T081	C1516192
women	T098	C0043210
quarter	T081	C2825406
global	T080	C2348867
burden	T078	C2828008
contributed	T052	C1880177
developing countries	T080	C0011750
India	T083	C0021201
government-sponsored screening program	T064	C0018109
study	T062	C2603343
conducted	T169	C0205245
assess	T052	C1516048
burden	T078	C2828008
cervical cancer	T191	C4048328
India	T083	C0021201
review	T169	C0699752
performance	T052	C1882330
characteristics	T080	C1521970
cervical cancer	T191	C4048328
screening	T058	C1710032
provide	T052	C1999230
evidence	T078	C3887511
recommendations	T078	C0034866
screening test	T060	C2717746
resource	T078	C0035201
MEDLINE	T170	C0025141
Web of Science electronic database	T170	C3841595
searched	T052	C1706202
January	T080	C3829466
December	T080	C3830550
keywords	T170	C1708608
cervical cancer	T191	C4048328
screening	T060	C2717746
early detection	T060	C0596473
cervical cytology	T059	C0856201
visual inspection	T058	C3669138
MeSH terms	T170	C1135584
combination	T080	C0205195
Boolean operators	T169	C1881439
authors	T097	C3812881
selected	T052	C1707391
studies	T062	C2603343
published	T170	C1704324
English	T171	C0376245
conducted	T169	C0205245
India	T083	C0021201
total	T080	C0439810
studies	T062	C2603343
found	T033	C0150312
relevant	T080	C2347946
eligible	T080	C1548635
included	T169	C0332257
present	T033	C0150312
study	T062	C2603343
India	T083	C0021201
cervical cancer	T191	C4048328
contributes	T052	C1880177
approximately	T080	C0332232
cancers	T191	C0006826
women	T098	C0043210
age-adjusted incidence rate	T081	C1706747
cervical cancer	T191	C4048328
registries	T170	C0034975
highest	T080	C1522410
Mizoram state	UnknownType	C0681784
lowest	T080	C1708760
Dibrugarh district	UnknownType	C0681784
estimates	T081	C0750572
sensitivity	T081	C0036667
specificity	T081	C0037791
visual inspection with acetic acid	T060	C0430022
VIA	T060	C0430022
magnified VIA	T060	C0430022
visual inspection with Lugol's iodine	T060	C1519194
VILI	T060	C1519194
cytology	T059	C1305671
Pap smear	T060	C0079104
human papillomavirus DNA	T059	C2985459
developing countries	T080	C0011750
lack	T080	C0332268
infrastructure	T185	C1998546
quality control	T169	C0034378
high-quality	T080	C0332306
cytology screening	T060	C0199230
implementation	T052	C1708476
cervical cancer	T191	C4048328
screening	T058	C1710032
program	T169	C3484370
visual screening test	T060	C2717746
VIA	T060	C0430022
VILI	T060	C1519194
health-care setup	T058	C0086388
resource	T078	C0035201
poor	T080	C2700379
countries	T083	C0454664
India	T083	C0021201
Structural and tribometric characterization	T052	C1880022
insect	T204	C0021585
adhesives	T073	C0001516
chemical analyses	T059	C3495389
insect	T204	C0021585
tarsal	T023	C1550316
adhesives	T073	C0001516
heterogeneous	T080	C0019409
synthetic	T052	C1883254
emulsions	T104	C0014020
polar/non-polar principle	T033	C0243095
microscopical structure	T082	C0678594
adhesive	T080	C0871161
frictional	T080	C0871161
rheological properties	T080	C0871161
prepared	T033	C4082130
emulsions	T104	C0014020
consistency	T080	C0332529
solid	T080	C0205208
rubber-like	T109	C0035918
soft	T080	C0205358
elastic	T073	C0450146
fluid	T167	C1704353
watery	T080	C0443350
oily	T080	C0205556
droplet sizes	T082	C0456389
emulsions	T104	C0014020
macroemulsions	T104	C0014020
emulsions	T104	C0014020
first generation	T079	C0079411
droplet-size	T082	C0456389
second generation	T079	C0079411
components	T078	C1254370
petrolatum	T109	C0031262
waxes	T122	C0043076
lipophilic	T081	C0598631
fraction	T081	C1264633
first generation	T079	C0079411
emulsions	T104	C0014020
prepared	T033	C4082130
emulsions	T104	C0014020
yield point	T033	C0243095
Bingham fluids	T120	C1254355
Tribometric adhesion	T059	C0022885
probe tack tests	T059	C0022885
second generation	T079	C0079411
viscous	T080	C0311419
components	T167	C0439861
first generation	T079	C0079411
emulsions	T104	C0014020
more adhesive	T033	C0243095
viscous	T080	C0311419
components	T167	C0439861
wax	T122	C0043076
petrolatum	T109	C0031262
gelatin	T116	C0017237
poly(vinyl alcohol)	T109	C0029224
second generation	T079	C0079411
emulsions	T104	C0014020
adhesivenesses	T070	C0001515
adhesive	T073	C0001516
performance	T052	C1882330
reduced	T080	C0392756
emulsions	T104	C0014020
albumin	T116	C0001924
protein component	T116	C0033684
protein	T116	C0033684
Tribometric shear tests	T059	C0022885
normal loads	T080	C0205556
friction forces	T070	C0162691
second generation	T079	C0079411
emulsions	T104	C0014020
Differences	T081	C1705241
shear	T070	C3825679
performance	T052	C1882330
chemical composition	T070	C0243176
emulsion	T104	C0014020
structure	T082	C0678594
chemical composition	T070	C0243176
heterogeneous	T080	C0019409
adhesive	T073	C0001516
emulsions	T104	C0014020
consistencies	T080	C0332529
rheological	T080	C0871161
tribological properties	T080	C0871161
natural	T169	C0205296
tarsal	T023	C1550316
insect	T204	C0021585
adhesives	T073	C0001516
Opioids	T109	C0242402
chronic pain	T184	C0150055
CDC's	T093	C0007670
recommendations	T078	C0034866
Centers for Disease Control and Prevention	T093	C0007670
recommendations	T078	C0034866
clinicians	T097	C0871685
prescribe	T058	C0033080
optimal	T080	C2698651
treatment	T061	C0087111
patients	T101	C0030705
Three-Dimensional	T082	C0450363
HyCoSy	T060	C0412553
Perfluoropropane-Albumin Microspheres	T109	C0389602
Contrast Agents	T130	C0009924
Saline	T167	C0036082
Injections	T061	C1533685
Pelvic Cavity	T030	C0559769
Morphological	T080	C0332437
Assessment	T058	C0220825
Fallopian Tube	T023	C0015560
Infertile	T046	C0021359
Women	T098	C0043210
three-dimensional	T082	C0450363
3D	T082	C0450363
hysterosalpingo-contrast sonography	T060	C0412553
HyCoSy	T060	C0412553
perfluoropropane-albumin microspheres	T109	C0389602
contrast agents	T130	C0009924
saline	T167	C0036082
injections	T061	C1533685
pelvic cavity	T030	C0559769
assessment of the tubal patency	T060	C0015559
adhesions of fimbrial parts	T047	C4303544
infertile	T046	C0021359
female	T032	C0086287
patients	T101	C0030705
3D	T082	C0450363
HyCoSy	T060	C0412553
saline	T167	C0036082
injected	T061	C1533685
pelvic cavity	T030	C0559769
contrast agents	T130	C0009924
fimbriae	T023	C0227912
fimbrial adhesion	T047	C4303544
finger-like projections	T082	C0348018
fimbriae	T023	C0227912
floating	T080	C0443223
moving status	T078	C1561509
patients	T101	C0030705
bilateral tubal patency	T033	C0243095
unilateral tubal patency	T033	C0243095
partial occlusion	T047	C1997620
unilateral	T082	C0205092
partial occlusion	T047	C1997620
complete occlusion	T046	C0028778
bilateral	T082	C0238767
complete occlusion	T046	C0028778
fimbrial parts	T023	C0227912
fallopian tubes	T023	C0015560
finger-like	T082	C1254362
fimbriae	T023	C0227912
floated	T080	C0443223
moved	T078	C1561509
pelvic cavity	T030	C0559769
adhesion	T047	C4303544
pelvic cavity	T030	C0559769
ovary	T023	C0029939
intestine	T023	C0021853
finger-like projection	T082	C0348018
patent	T082	C0175566
fimbrial parts	T023	C0227912
fewer	T081	C0205388
flat	T082	C0205324
finger-like projection	T082	C0348018
adhesive tubes	T047	C4303544
complications	T046	C0009566
procedure	T060	C0430022
Combination	T080	C0205195
3D	T082	C0450363
HyCoSy	T060	C0412553
saline	T167	C0036082
injected	T061	C1533685
pelvic cavity	T030	C0559769
procedure	T060	C0430022
adhesions of the fimbrial parts	T047	C4303544
Challenging	T058	C0805586
empathy	T055	C0013989
New Zealand	T083	C0027978
nursing	T065	C0013636
medical curricula	T065	C0013631
time	T079	C0040223
enhancement	T052	C2349975
empathy	T055	C0013989
empathic	T033	C0564547
important	T080	C3898777
patient care	T058	C0017313
students	T098	C0038492
students	T098	C0038492
practicum	T065	C0032929
experienced	T041	C0237607
clinicians	T097	C0871685
study	T062	C2603343
compare	T052	C1707455
self-reported	T062	C2700446
empathy	T055	C0013989
groups	T098	C1257890
medical students	T097	C0038495
cohort	T098	C0599755
nursing students	T097	C0038496
empathy	T055	C0013989
training	T065	C0220931
learning	T041	C0023185
clinical settings	T082	C3176918
patients	T101	C0030705
Jefferson Scale of Physician Empathy	T080	C0034375
JSPE	T080	C0034375
medical	T097	C0038495
nursing students	T097	C0038496
extended	T079	C0439590
periods	T079	C1948053
practicum	T065	C0032929
medical student	T097	C0038495
cohorts	T098	C0599755
brief	T079	C1879313
empathy	T055	C0013989
training	T065	C0220931
training	T065	C0220931
nursing student	T097	C0038496
cohort	T098	C0599755
no formal	T033	C0557286
empathy	T055	C0013989
training	T065	C0220931
profession	T090	C0028811
length	T079	C0023980
practicum	T065	C0032929
empathy	T055	C0013989
training	T065	C0220931
no significant differences	T033	C3842396
self-reported	T062	C2700446
JSPE scores	T080	C0034375
cohorts	T098	C0599755
students	T098	C0038492
Empathy	T055	C0013989
quality	T080	C0332306
present	T033	C0150312
students	T098	C0038492
learned by	T041	C0023185
students	T098	C0038492
practicum	T065	C0032929
DISCUSSION	T054	C2584313
empathy	T055	C0013989
caught	T055	C0679140
taught	T080	C0348054
enhance	T052	C2349975
empathy	T055	C0013989
futile	T033	C3840836
inherent empathic qualities	T033	C0564547
health professionals	T097	C1704312
consideration	T033	C0518609
empathy	T055	C0013989
influenced	T077	C4054723
practicum	T065	C0032929
experience	T041	C0237607
Surface	T082	C0205148
interactions of drugs	T044	C0687133
enhance	T052	C2349975
mechanical forces	T067	C0563538
antibiotic	T195	C0003232
action	T052	C3266814
alarming increase	T169	C0442805
pathogenic bacteria	T001	C0450254
resistant to multiple antibiotics	T046	C0860044
major health issue	T033	C4060919
demand	T061	C0441516
drugs	T121	C1254351
Bacterial resistance	T046	C0151521
molecular changes	T033	C0262496
bacterial surface	T034	C0201029
drug-target interactions	T044	C0687133
mechanism	T169	C0441712
drug-target interactions	T044	C0687133
resistant bacteria	T007	C1444090
enhanced	T052	C2349975
surface	T082	C0205148
surface	T082	C0205148
forces	T067	C0441722
antibiotics	T195	C0003232
vancomycin	T116	C0042313
ristomycin	T116	C0917879
chloroeremomycin	T116	C0674648
oritavancin	T116	C1144403
drug-susceptible	T169	C0231204
drug-resistant targets	T007	C4076168
significant	T078	C0750502
mechanical	T169	C0443254
response	T032	C0871261
drug-resistant targets	T007	C4076168
antibiotics	T195	C0003232
observed	T169	C1441672
susceptible targets	T169	C0231204
binding affinity	T039	C0678749
oritavancin	T116	C1144403
drug-resistant targets	T007	C4076168
vancomycin	T116	C0042313
antibiotic	T195	C0003232
resort treatment	T061	C0087111
streptococcal	T007	C0038402
staphylococcal bacteria	T007	C0038170
methicillin-resistant Staphylococcus aureus	T007	C1265292
MRSA	T007	C1265292
exactly solvable model	T170	C0282574
solvent	T130	C0037638
membrane	T026	C0596901
effects	T080	C1280500
drug-target interactions	T044	C0687133
pronounced polyvalent interactions	T044	C0687133
catalyzed	T070	C0007382
surface	T082	C0205148
enhance	T052	C2349975
understanding	T041	C0162340
antibiotic mode of action	T169	C1524059
development	T169	C1527148
therapies	T061	C0087111
Intra-articular	T082	C0442108
corticosteroids	T121	C3536709
intra-articular	T082	C0442108
corticosteroids	T121	C3536709
plus	T169	C0332287
methotrexate	T109	C0025677
oligoarticular juvenile idiopathic arthritis	T047	C3898105
multicentre	T062	C0206012
prospective	T062	C0033522
randomised	T062	C0206034
open-label trial	T062	C0008976
guide	T170	C2825826
treatment	T061	C0087111
oligoarticular juvenile idiopathic arthritis	T047	C3898105
investigate	T169	C1292732
oral methotrexate	T200	C1246896
increases	T169	C0442805
efficacy	T080	C1280519
intra-articular corticosteroid therapy	T061	C4054701
prospective	T062	C0033522
open-label	T062	C0008976
randomised trial	T062	C0206034
hospitals	T073	C0019994
Italy	T083	C0022277
concealed	T080	C0443189
computer-generated list	T170	C0745732
children	T100	C0008059
younger than	T033	C2237067
years	T079	C1510829
oligoarticular	T082	C0439754
onset disease	T079	C0277793
randomly	T080	C0439605
assigned	T169	C1516050
intra-articular	T082	C0442108
corticosteroids	T121	C3536709
alone	T081	C0205171
in combination with	T080	C0205195
oral methotrexate	T200	C1246896
maximum	T081	C0806909
Corticosteroids	T121	C3536709
triamcinolone hexacetonide	T109	C0077004
shoulder	T030	C0037009
elbow	T030	C0013770
wrist	T030	C1322271
knee	T030	C0022745
tibiotalar joints	T030	C0003087
methylprednisolone acetate	T109	C0600901
subtalar	T030	C0038593
tarsal joints	T030	C1527245
patients	T101	C0030705
investigators	T097	C0008961
treatment	T061	C0087111
assignments	T169	C1516050
primary outcome	T169	C1274040
proportion	T081	C1709707
patients	T101	C0030705
intention-to-treat	T062	C2718028
population	T098	C1257890
remission	T033	C0544452
arthritis	T047	C0003864
injected	T061	C0021485
joints	T030	C0022417
months	T079	C0439231
trial	T062	C0008976
registered	T058	C1514821
European Union Clinical Trials Register	T058	C1254363
EudraCT number	T170	C0282574
July	T080	C3829447
March	T079	C3829202
screened	T169	C2348582
participants	T098	C0679646
randomly	T080	C0439605
assigned	T169	C1516050
intra-articular	T082	C0442108
corticosteroids	T121	C3536709
alone	T081	C0205171
intra-articular	T082	C0442108
corticosteroids	T121	C3536709
plus	T169	C0332287
methotrexate	T109	C0025677
patients	T101	C0030705
assigned	T169	C1516050
intra-articular	T082	C0442108
corticosteroids	T121	C3536709
alone	T081	C0205171
assigned	T169	C1516050
intra-articular	T082	C0442108
corticosteroids	T121	C3536709
methotrexate	T109	C0025677
therapy	T061	C0087111
remission	T033	C0544452
arthritis	T047	C0003864
injected	T061	C0021485
joints	T030	C0022417
Adverse events	T046	C0877248
patients	T101	C0030705
methotrexate	T109	C0025677
permanent	T079	C0205355
treatment	T061	C0087111
discontinuation	T033	C1444662
patients	T101	C0030705
increased liver transaminases	T033	C1848701
gastrointestinal discomfort	T184	C1096250
No	T033	C1513916
patient	T101	C0030705
serious	T080	C0205404
adverse event	T046	C0877248
Concomitant administration	T169	C2826730
methotrexate	T109	C0025677
augment	T169	C0442805
effectiveness	T080	C1280519
intra-articular corticosteroid therapy	T061	C4054701
Future studies	T062	C2603343
optimal	T080	C2698651
therapeutic strategies	T061	C0087111
oligoarticular juvenile idiopathic arthritis	T047	C3898105
Italian Agency of Drug Evaluation	T092	C1561598
Methylation Analysis	T063	C1880239
BRCA1	T028	C0376571
APC	T028	C0162832
Breast Cancer	T191	C0006142
Relationship	T080	C0439849
Clinicopathological	T169	C1521733
Features	T080	C2348519
Promoter methylation	T044	C0376452
tumor suppressor genes	T028	C0079427
epigenetic alteration	T045	C1516924
primary	T080	C0205225
stages	T079	C1306673
human	T016	C0086418
tumors	T191	C0027651
breast cancer	T191	C0006142
methylated genes	T028	C0017337
relationship	T080	C0439849
clinical	T080	C0205210
features	T080	C2348519
prognosis	T058	C0033325
early detection	T060	C0596473
tumors	T191	C0027651
study	T062	C2603343
methylation	T044	C0376452
status	T080	C0449438
APC	T028	C0162832
BRCA1 genes	T028	C0376571
relationship	T080	C0439849
clinical	T080	C0205210
factors	T169	C1521761
breast cancer	T191	C0006142
patients	T101	C0030705
BRCA1	T028	C0376571
APC	T028	C0162832
promoter methylation	T044	C0376452
methylation	T044	C0025723
specific multiplex ligation-dependent probe amplification	T063	C3494189
MS-MLPA	T063	C3494189
assay	T059	C1510438
formalin-fixed paraffin embedded (FFPE) breast tissue	T024	C2711483
patients	T101	C0030705
APC	T028	C0162832
promoter methylation	T044	C0376452
detected	T033	C0442726
breast cancer	T191	C0006142
tissues	T024	C0040300
BRCA1	T028	C0376571
methylated	T044	C0376452
breast tumors	T191	C1458155
Methylation	T044	C0376452
APC	T028	C0162832
associated with	T080	C0332281
histological grade	T185	C0456201
methylation	T044	C0376452
BRCA1	T028	C0376571
lymph node	T023	C0024204
metastasis	T046	C4255448
findings	T033	C0243095
methylation	T044	C0376452
status	T080	C0449438
APC	T028	C0162832
BRCA1	T028	C0376571
predictive marker	T201	C0005516
early detection	T060	C0596473
management	T058	C0376636
breast cancer	T191	C0006142
patients	T101	C0030705
Recombinant	T116	C0034861
fibrinogen	T116	C0016006
differential	T080	C1705242
α-	T116	C0033684
γ-chain	T116	C0033684
cross-linking	T044	C0314675
molecular	T080	C1521991
heterogeneity	T080	C0019409
fibrin clot	T044	C3156338
strain-stiffening	T070	C0013764
Fibrinogen	T116	C0016006
circulates	T169	C0175630
human	T016	C0086418
plasma	T031	C0032105
complex	T104	C1704241
mixture	T167	C0439962
heterogeneous	T080	C0019409
molecular	T080	C1521991
variants	T080	C0205419
measured	T080	C0444706
strain-stiffening	T070	C0013764
recombinantly	T045	C0034865
fibrinogen	T116	C0016006
clotting	T042	C0005778
Factor XIII	T116	C0015528
molecular	T080	C1521991
heterogeneity	T080	C0019409
clot	T044	C3156338
elasticity	T070	C0013764
protofibril	T116	C0015982
fiber	T024	C1304649
molecular	T080	C1521991
composition	T080	C0205198
fibrin clot	T044	C3156338
mechanics	T070	C0376706
Fibrin	T116	C0015982
haemostasis	T042	C0019116
wound healing	T040	C0043240
strain-stiffening	T070	C0013764
fibrous networks	T026	C0243092
blood clots	T046	C0302148
molecular	T080	C1521991
fibrin's	T116	C0015982
strain-stiffening	T070	C0013764
plasma	T031	C0032105
fibrinogen	T116	C0016006
complex	T104	C1704241
mixture	T167	C0439962
heterogeneous	T080	C0019409
molecular	T080	C1521991
variants	T080	C0205419
plasma factors	T116	C0033684
clot	T044	C3156338
properties	T080	C0871161
mechanistic dissection	T169	C0205245
fibrin	T116	C0015982
nonlinear elasticity	T070	C0013764
homogeneous	T080	C1881065
recombinant	T116	C0034861
fibrinogen	T116	C0016006
variant	T080	C0205419
human	T016	C0086418
plasma	T031	C0032105
rFib610	T116	C0016006
structure	T082	C0678594
rFib610	T116	C0016006
clots	T044	C3156338
turbidimetry	T059	C0041394
microscopy	T059	C0026018
X-ray scattering	T059	C0043301
rheology	T059	C0599706
measure	T081	C0079809
strain-stiffening	T070	C0013764
clots	T044	C3156338
fiber	T024	C1304649
properties	T080	C0871161
modeling	T062	C0870071
clots	T044	C3156338
semi-flexible polymer networks	T169	C1882071
FXIII	T116	C0015528
rFib610	T116	C0016006
clots	T044	C3156338
dose-dependent stiffness	T080	C0018599
deformations	T169	C0333067
strain-stiffening	T070	C0013764
γ-chain	T116	C0033684
cross-linking	T044	C0314675
clot	T044	C3156338
elasticity	T070	C0013764
force-extension behavior	T169	C0205245
protofibrils	T116	C0015982
α-chain	T116	C0033684
cross-linking	T044	C0314675
fibers	T024	C1304649
tighter coupling	T169	C1948027
protofibrils	T116	C0015982
rFib610	T116	C0016006
protofibrils	T116	C0015982
bending rigidity	T080	C0018599
plasma	T031	C0032105
fibrin	T116	C0015982
protofibrils	T116	C0015982
strain-stiffening	T070	C0013764
molecular	T080	C1521991
heterogeneity	T080	C0019409
influences	T077	C4054723
clot	T044	C3156338
mechanics	T070	C0376706
protofibril scale	T116	C0015982
Fibrinogen	T116	C0016006
molecular	T080	C1521991
heterogeneity	T080	C0019409
FXIII	T116	C0015528
mechanical function	T169	C0542341
fibrin clots	T044	C3156338
nonlinear viscoelastic properties	T080	C0871161
protofibril	T026	C0230898
fiber scale	T024	C1304649
investigate	T169	C1292732
molecular	T080	C1521991
heterogeneity	T080	C0019409
plasma	T031	C0032105
fibrinogen	T116	C0016006
fibrin clot	T044	C3156338
mechanics	T070	C0376706
haemostasis	T042	C0019116
display	T169	C0870432
curvature	T082	C0205134
display	T169	C0870432
zone	T082	C1710706
task	UnknownType	C0679599
duration	T079	C0449238
legibility	T033	C0870803
visual fatigue	T047	C0004095
visual search task	UnknownType	C0679599
display	T169	C0870432
curvature	T082	C0205134
flat	T082	C0205324
display	T169	C0870432
zone	T082	C1710706
zones	T082	C1710706
task	UnknownType	C0679599
duration	T079	C0449238
legibility	T033	C0870803
visual fatigue	T047	C0004095
participant	T098	C0679646
visual search task	UnknownType	C0679599
curvature	T082	C0205134
setting	T082	C0442307
settings	T082	C0442307
flat	T082	C0205324
setting	T082	C0442307
legibility	T033	C0870803
visual fatigue	T047	C0004095
centre	T082	C0205099
zone	T082	C1710706
zones	T082	C1710706
flat	T082	C0205324
settings	T082	C0442307
legibility	T033	C0870803
flat	T082	C0205324
setting	T082	C0442307
increase	T169	C0442805
perceived	T041	C0030971
visual fatigue	T047	C0004095
curvature	T082	C0205134
legibility	T033	C0870803
decreased	T081	C0205216
perceived	T041	C0030971
visual fatigue	T047	C0004095
increased	T169	C0442805
task set	UnknownType	C0679599
task sets	UnknownType	C0679599
increase	T169	C0442805
eye complaint score	T081	C0449820
critical fusion frequency	T034	C0234697
increase	T169	C0442805
visual fatigue	T047	C0004095
curvature	T082	C0205134
central	T082	C0205099
display	T169	C0870432
zones	T082	C1710706
breaks	T082	C0449647
improve	T033	C0184511
legibility	T033	C0870803
visual fatigue	T047	C0004095
adaptive	T169	C0231193
functioning	T169	C0542341
behavioral	T053	C0004927
adjustment	T169	C0456081
treatment	T061	C0087111
pediatric brain tumor	T191	C0220603
report	T201	C4255046
Brain	T023	C0006104
Radiation Investigative Study Consortium	T097	C1880171
Children	T100	C0008059
risk	T078	C0035647
behavioral	T053	C0004927
adaptive	T169	C0231193
difficulties	T080	C0332218
pediatric brain tumor	T191	C0220603
study	T062	C2603343
familial	T169	C0241888
demographic	T090	C0011298
developmental	T080	C0458003
diagnostic	T169	C0348026
treatment	T061	C0087111
variables	T080	C0439828
posttreatment	T079	C2709088
behavioral	T053	C0004927
adaptive	T169	C0231193
functioning	T169	C0542341
Participants	T098	C0679646
children	T100	C0008059
mean	T081	C0444504
age	T032	C0001779
SD	T081	C0871420
posttreatment	T079	C2709088
mean	T081	C0444504
time	T079	C0040223
diagnosis	T033	C0011900
SD	T081	C0871420
pediatric brain tumor	T191	C0220603
Parents	T099	C0030551
children	T100	C0008059
behavioral	T053	C0004927
adjustment	T169	C0456081
adaptive	T169	C0231193
functioning	T169	C0542341
demographic	T090	C0011298
developmental	T080	C0458003
histories	T033	C0262926
Diagnostic	T033	C0011900
treatment	T061	C0087111
information	T078	C1533716
medical records	T170	C0025102
Ratings	T052	C0871208
adaptive	T169	C0231193
behavioral	T053	C0004927
functioning	T169	C0542341
postdiagnosis	T033	C0011900
average	T081	C1510992
range	T081	C1514721
percentage	T081	C0439165
children	T100	C0008059
clinical	T080	C0205210
cutoffs	T169	C1442160
impairment	T169	C0221099
adaptive	T169	C0231193
skills	T055	C0678856
expectation	T078	C0679138
skills	T055	C0678856
Premorbid behavior	T053	C4062485
problems	T078	C1546466
tumor size	T082	C0475440
posttreatment	T079	C2709088
adaptive	T169	C0231193
functioning	T169	C0542341
adaptive	T169	C0231193
functioning	T169	C0542341
diagnosis	T033	C0011900
premorbid behavior	T053	C4062485
problems	T078	C1546466
adaptive	T169	C0231193
functioning	T169	C0542341
postdiagnosis	T033	C0011900
adjustment	T169	C0456081
diagnosis	T033	C0011900
variables	T080	C0439828
behavioral	T053	C0004927
adjustment	T169	C0456081
Children	T100	C0008059
vulnerable	T169	C0231204
adaptive	T169	C0231193
functioning	T169	C0542341
pediatric brain tumor	T191	C0220603
treatment	T061	C0087111
prediagnosis	T033	C0011900
functioning	T169	C0542341
diagnostic	T033	C0011900
treatment	T061	C0087111
variables	T080	C0439828
improve	T033	C0184511
ability	T032	C0085732
risk	T078	C0035647
factors	T169	C1521761
helpful	T080	C3898897
identifying	T080	C0205396
children	T100	C0008059
behavioral	T053	C0004927
difficulties	T080	C0332218
Screening	T058	C1710032
factors	T169	C1521761
tertiary care	T058	C3494403
long-term	T079	C0443252
follow-up	T058	C1522577
improve	T033	C0184511
identification	T080	C0205396
need	T080	C0027552
support services	UnknownType	C0679879
Spine fracture	T037	C0080179
prevalence	T081	C0033105
nationally representative	T082	C0681788
US	T083	C0041703
women	T098	C0043210
men	T098	C0025266
aged	T032	C0001779
National Health and Nutrition Examination Survey	T062	C0376344
NHANES	T062	C0376344
Spine fracture	T037	C0080179
prevalence	T081	C0033105
men	T098	C0025266
women	T098	C0043210
Prevalence	T081	C0033105
higher	T080	C0205250
age	T032	C0001779
age	T032	C0001779
lower	T080	C0205251
bone mineral density	T201	C0005938
BMD	T201	C0005938
criteria	T080	C0242801
spine imaging	T060	C1532547
subjects	T062	C0178693
spine fractures	T037	C0080179
unaware	T033	C0589402
Spine fractures	T037	C0080179
medical	T169	C0205476
seldom	T080	C0522498
nationally representative	T082	C0681788
spine fracture	T037	C0080179
prevalence	T081	C0033105
Cross-sectional analysis	T062	C0010362
US	T083	C0041703
adults	T100	C0001675
aged	T032	C0001779
NHANES	T062	C0376344
Vertebral Fracture	T037	C0080179
VFA	T060	C0185141
VFA	T060	C0185141
BMD	T201	C0005938
osteoporosis	T047	C0029456
questionnaire	T170	C0034394
spine fracture	T037	C0080179
prevalence	T081	C0033105
men	T098	C0025266
women	T098	C0043210
Prevalence	T081	C0033105
age	T032	C0001779
Fractures	T037	C0016658
non-Hispanic whites	T098	C1257890
lower	T080	C0205251
body mass index	T201	C1305855
BMD	T201	C0005938
subjects	T062	C0178693
spine fracture	T037	C0080179
BMD	T201	C0005938
criteria	T080	C0242801
osteoporosis	T047	C0029456
Prevalence	T081	C0033105
higher	T080	C0205250
subjects	T062	C0178693
National Osteoporosis Foundation	UnknownType	C0679938
NOF	UnknownType	C0679938
criteria	T080	C0242801
spine imaging	T060	C1532547
spine fracture	T037	C0080179
diagnosed	T033	C0011900
VFA	T060	C0185141
self-reported	T062	C0681906
fracture	T037	C0016658
self-reported	T062	C0681906
spine fracture	T037	C0080179
diagnosed	T033	C0011900
fracture	T037	C0016658
VFA	T060	C0185141
Spine fracture	T037	C0080179
prevalence	T081	C0033105
women	T098	C0043210
men	T098	C0025266
age	T032	C0001779
lower	T080	C0205251
BMD	T201	C0005938
subjects	T062	C0178693
spine fracture	T037	C0080179
BMD	T201	C0005938
osteoporosis	T047	C0029456
individuals	T098	C0237401
unaware	T033	C0589402
spine fractures	T037	C0080179
lateral	T082	C0205093
spine imaging	T060	C1532547
women	T098	C0043210
men	T098	C0025266
Spine fracture	T037	C0080179
prevalence	T081	C0033105
higher	T080	C0205250
individuals	T098	C0237401
NOF	UnknownType	C0679938
criteria	T080	C0242801
spine imaging	T060	C1532547
VFA	T060	C0185141
spine fractures	T037	C0080179
comprehensive	T080	C1880156
risk assessment	T058	C0086930
improve	T033	C0184511
clinical decision making	T060	C4042877
Renieramycin M	T109	C1435644
Cancer Stem Cell	T025	C1956422
Phenotypes	T032	C0031437
H460	T025	C0597032
Lung	T023	C0024109
Cancer Cells	T025	C0597032
Cancer stem cells	T025	C1956422
CSCs	T025	C1956422
cancer cells	T025	C0597032
self-renewal	T043	C1155711
differentiation	T043	C0007589
CSCs	T025	C1956422
drug-resistance	T038	C0013203
cancer recurrence	T191	C0920420
metastasis	T046	C4255448
development	T169	C1527148
CSC	T025	C1956422
therapeutic strategies	T061	C0087111
cancer research	T062	C1516225
study	T062	C2603343
efficacy	T080	C1280519
renieramycin M	T109	C1435644
RM	T109	C1435644
sponge	T204	C0032699
Xestospongia species	T204	C1204055
examined	T033	C0332128
lung	T023	C0024109
CSCs	T025	C1956422
Colony and spheroid formation assays	T059	C0005507
western blotting analysis	T059	C0005863
lung	T023	C0024109
CSC	T025	C1956422
protein	T116	C0033684
markers	T123	C0041365
CSC	T025	C1956422
phenotypes	T032	C0031437
H460	T025	C0597032
lung	T023	C0024109
cancer cells	T025	C0597032
treatment	T061	C0087111
RM	T109	C1435644
non-toxic concentrations	UnknownType	C0678563
RM	T109	C1435644
treatment	T061	C0087111
colony and spheroid formation	T059	C0005507
H460 cells	T025	C0597032
CSC	T025	C1956422
markers	T123	C0041365
CD133	T116	C0673026
CD44	T116	C1097299
ALDH1A1	T116	C1721673
CSC	T025	C1956422
H460 cells	T025	C0597032
RM	T109	C1435644
treatment	T061	C0087111
RM	T109	C1435644
anti-metastatic agent	T121	C1516021
lung	T023	C0024109
CSC	T025	C1956422
phenotypes	T032	C0031437
H460 cells	T025	C0597032
chitosan	T109	C0162969
hyaluronan	T109	C0813622
lipid nanoparticles	T203	C1709148
delivery	T061	C0565867
paclitaxel	T109	C0144576
proof-of-concept study	T062	C2603343
breast cancer cells	T025	C1512505
solid lipid nanoparticles	T203	C1709148
SLN	T203	C1709148
paclitaxel	T109	C0144576
PAX	T109	C0144576
SLN loaded with PAX	T109	C3898158
high-pressure hot homogenization	T059	C3828864
Formulation parameters	T062	C0524527
high-quality delivery system	T074	C0085104
SLN	T203	C1709148
coated, layer-by-layer	T080	C1522408
chitosan	T109	C0162969
hyaluronan	T109	C0813622
HA	T109	C0813622
HA	T109	C0813622
receptors	T116	C0597357
breast cancer cell line	T025	C1512505
MCF-7	T025	C0596890
Stable and reproducible	T080	C0205556
nano-sized	T080	C0205556
negatively charged nanoparticles	T073	C1450054
chitosan	T109	C0162969
HA	T109	C0813622
SLN	T203	C1709148
targeting	T169	C1521840
cellular uptake	T043	C3888108
time-/dose-controlled delivery and release	T203	C1616334
PAX	T109	C0144576
intrinsic chemotherapeutic activities	T061	C0870057
SLN	T203	C1709148
carrier candidates	T074	C1706209
nano-oncology	T091	C0278627
cytotoxic potential	T121	C0304497
overcoming	T033	C0243095
multidrug-resistant cancer cells	T038	C0282588
Epigenetic Editing	T063	C4277689
Ascl1 Gene	T028	C1332009
Neural Stem Cells	T025	C1113654
Optogenetics	T063	C3494301
Enzymes	T116	C0014442
epigenetic processes	T045	C1516924
methyltransferases	T116	C0025831
demethylases	T116	C0014442
highly	T080	C0205250
utilized	T169	C0457083
persistent DNA	T114	C0012854
histone modifying	T044	C1156199
efficacy	T080	C1280519
optogenetic	T063	C3494301
toolbox	T170	C0282574
catalytic domain	T087	C0600499
CD	T087	C0600499
DNA-methyltransferase3A	T116	C2348048
DNMT3A	T116	C2348048
CD	T087	C0600499
Ten-Eleven Dioxygenase-1	T116	C2987138
TET1	T116	C2987138
CD	T087	C0600499
loci	T082	C1708726
specific	T080	C0205369
alteration	T045	C0026882
methylation	T044	C0376452
state	T169	C1442792
promoter	T114	C0086860
Ascl1	T028	C1332009
Mash1	T028	C1332009
candidate proneuron gene	T028	C0017337
Optogenetical protein pairs	T116	C0033684
CRY2	T116	C3813555
DNMT3A	T116	C2348048
CD	T087	C0600499
TET1	T116	C2987138
CD	T087	C0600499
CIB1	T116	C1447592
fused	T169	C0699952
Transcription Activator-Like Element	T116	C0033684
TALE	T116	C0033684
Ascl1	T028	C1332009
promoter region	T114	C0033413
site specific	T082	C0449604
epigenetic editing	T063	C4277689
differentially	T080	C0443199
methylated region	T082	C1254362
Ascl1	T028	C1332009
promoter	T114	C0086860
isolated	T169	C0205409
murine	T015	C0035804
dorsal root ganglion	T023	C0017070
hypermethylated	T044	C0376452
striated	T080	C0205364
cells	T025	C0007634
hypomethylated	T044	C0376452
targeted	T169	C1521840
optogenetic-epigenetic constructs	T116	C0033684
blue-light	T070	C0303896
illumination	T059	C0684292
triggered	T080	C1444748
co-localization	T067	C1254366
TALE constructs	T116	C0033684
DNMT3A	T116	C2348048
CD	T087	C0600499
TET1	T116	C2987138
CD	T087	C0600499
fusion proteins	T116	C0162768
targeted site	T082	C1254362
Ascl1	T028	C1332009
promoter	T114	C0086860
spatiotemporal	T080	C0205556
fusion proteins	T116	C0162768
alters	T169	C0392747
methylation	T044	C0376452
state	T169	C1442792
regulates	T045	C0017263
gene activity	T045	C0017255
concept	T078	C0178566
immense	T081	C1704243
promise	T078	C1555307
regulate	T044	C1148560
gene activity	T045	C0017255
epigenetic modulation	T063	C4277689
spatiotemporal	T080	C0205556
precision	T080	C1706245
Vaginal Infections	T047	C0404521
Albanian	T083	C0001909
women	T098	C0043210
Infected	T046	C3714514
HPV	T005	C0021344
intraepithelial cervical lesions	T191	C0206708
Pap test	T059	C3516630
Cervical cytology	T059	C0856201
screening	T060	C1710031
precancerous lesions	T191	C0940937
uterine cervix	T023	C0007874
human papillomavirus (HPV) positivity	T034	C4288937
Albanian	T083	C0001909
women	T098	C0043210
prevalence	T081	C0220900
vaginal coinfections	T047	C0404521
coinfections	T047	C0275524
HPV	T005	C0021344
metaplasia	T049	C0025568
cervical intraepithelial lesions	T191	C0206708
CIN	T191	C0206708
retrospective study	T062	C0035363
vaginal smears	T060	C0079104
Papanicolaou stain	T060	C3888892
New Bethesda System	T059	C2121268
interpretations of the smears	T059	C3526121
Statistical Package for the Social Sciences version	T081	C0010998
Prevalence	T081	C0220900
HPV positivity	T034	C4288937
Candida coinfection	T047	C0006840
HPV positive	T034	C4288937
women	T098	C0043210
Gardnerella coinfection	T047	C1622505
mixed flora	T047	C1400606
Trichomonas vaginalis	T047	C0040923
HPV positive	T034	C4288937
woman	T098	C0043210
women	T098	C0043210
positive HPV	T034	C4288937
CIN	T191	C0206708
metaplasia	T049	C0025568
metaplasia	T049	C0025568
CIN	T191	C0206708
women	T098	C0043210
HPV	T005	C0021344
CIN1	T191	C0349458
coinfections	T047	C0275524
CIN1	T191	C0349458
HPV positivity	T034	C4288937
CIN1	T191	C0349458
coinfections	T047	C0275524
HPV infection	T047	C0343641
metaplasia	T049	C0025568
bacterial coinfections	T047	C0004623
HPV positive	T034	C4288937
women	T098	C0043210
statistically significant	T081	C0237881
metaplasia	T049	C0025568
Acute	T079	C0205178
Hepatitis E Infection	T047	C2063407
Patient	T101	C0030705
Non-Hodgkin Lymphoma	T191	C0024305
Treated	T061	C0332293
Ribavirin	T114	C0035525
man	T098	C0025266
immunosuppressive treatment	T061	C0021079
non-Hodgkin lymphoma	T191	C0024305
infected	T033	C0439663
viral hepatitis E	T047	C0085293
Acute	T079	C0205178
hepatitis E virus infection	T047	C2063407
patients	T101	C0030705
deranged	T080	C0205556
liver function	T042	C0232741
haematological malignancies	T191	C0376545
immunosuppression	T047	C4048329
endemic regions	T083	C0017446
immune	T169	C0439662
competent	T080	C0086035
individuals	T098	C0237401
at-risk groups	T098	C0684030
protracted disease course	T033	C1864936
treatment	T061	C0087111
ribavirin	T114	C0035525
pegylated interferon	T109	C0907160
eradication	T058	C3178994
Commissioning	T097	C0027363
competition	T054	C0679932
cooperation	T054	C0392337
English	T098	C1556083
NHS	T058	C0027462
Health and Social Care Act 2012	T058	C1254363
qualitative study	T062	C0949415
clinical commissioning groups	T097	C0027363
Health and Social Care Act 2012	T058	C1254363
HSCA 2012	T058	C1254363
regulation	T064	C0851285
competition	T054	C0679932
National Health Service	T058	C0027462
NHS	T058	C0027462
cooperation	T054	C0392337
NHS	T058	C0027462
England's policy document	T170	C0282574
Five Year Forward View	T170	C0282574
5YFV	T170	C0282574
competition	T054	C0679932
legislation	T170	C0600657
commissioners	T062	C0949415
providers	T169	C1138603
complex	T080	C0439855
regulatory framework	T089	C0220905
competition	T054	C0679932
cooperation	T054	C0392337
case studies	T170	C0085973
clinical commissioning groups	T097	C0027363
interviews	T052	C0021822
documentary analysis	T062	C0936012
commissioners	T062	C0949415
providers	T169	C1138603
competition	T054	C0679932
cooperation	T054	C0392337
interviews	T052	C0021822
senior managers	T097	C0335141
commissioning	T097	C0027363
organisations	T094	C0033282
senior managers	T097	C0335141
NHS	T058	C0027462
independent provider organisations	T093	C1273814
acute and community services	T095	C0009482
commissioners	T062	C0949415
providers	T169	C1138603
regulatory regime	T089	C0220905
competition	T054	C0679932
NHS	T058	C0027462
regulatory authorities	T089	C0220905
guidance	T065	C0237645
HSCA 2012	T058	C1254363
promoting	T052	C0033414
competition	T054	C0679932
commissioners	T062	C0949415
collaborative strategies	T062	C0681804
service	T057	C0557854
providers	T169	C1138603
commissioners	T062	C0949415
competitive	T054	C0679932
peripheral services	T057	C0557854
quality of care	T058	C0034379
value for money	T078	C1548312
Commissioners	T062	C0949415
competition	T054	C0679932
cooperation	T054	C0392337
NHS	T058	C0027462
collaborative strategies	T062	C0681804
large-scale changes	UnknownType	C0814860
regulatory framework	T089	C0220905
HSCA 2012	T058	C1254363
publication	T073	C0034036
5YFV	T170	C0282574
guidance	T065	C0237645
regulatory authorities	T089	C0220905
Prevalence	T081	C0033105
correlates	T080	C1707520
antibiotic	T195	C0003232
sharing	T054	C0237876
Philippines	T083	C0031529
antibiotic	T195	C0003232
misconceptions	T041	C2717766
community	T096	C0009462
level	T080	C0441889
non-medical	T056	C0598464
sources	T033	C0449416
antibiotics	T195	C0003232
sociodemographic	T078	C0011292
knowledge	T170	C0376554
attitudinal	T041	C0004271
correlates	T080	C1707520
antibiotic	T195	C0003232
sharing	T054	C0237876
community-based sample	T081	C1709598
adults	T100	C0001675
low-income setting	T033	C1331016
Philippines	T083	C0031529
community	T096	C0009462
level	T080	C0441889
data	T078	C1511726
informal	T033	C0243095
antibiotic	T195	C0003232
distribution	T057	C0024826
roadside stands	T082	C1254362
sari-sari stands	T082	C1254362
Participants	T098	C0679646
completed	T080	C0205197
self-administered	T169	C1519231
surveys	T170	C0038951
Correlates	T080	C1707520
antibiotic	T195	C0003232
sharing	T054	C0237876
assessed	T052	C1516048
logistic regression	T062	C0206031
Firth's bias-adjusted estimate	T170	C0282574
staff	T097	C0851286
roadside stands	T082	C1254362
collected data	T033	C4019276
availability	T169	C0470187
antibiotics	T195	C0003232
stands	T082	C1254362
shared	T054	C0237876
antibiotics	T195	C0003232
lifetime	T079	C4071830
often	T079	C0332183
family members	T099	C0086282
multivariable analysis	T081	C0026777
agreement	T054	C0680240
belief	T078	C0004951
prematurely	T079	C1254367
stop	T052	C1947925
antibiotic	T195	C0003232
course	T079	C0750729
OR	T081	C0028873
concerns	T078	C2699424
antibiotic side effects	T037	C0850107
OR	T081	C0028873
associated with	T080	C0332281
increased	T081	C0205217
antibiotic	T195	C0003232
sharing	T054	C0237876
Antibiotic	T195	C0003232
sharing	T054	C0237876
associated with	T080	C0332281
sociodemographic characteristics	T102	C0683970
antibiotic	T195	C0003232
knowledge	T170	C0376554
Antibiotics	T195	C0003232
available	T169	C0470187
sari-sari stands	T082	C1254362
antibiotics	T195	C0003232
missing expiration dates	T033	C2609381
Amoxicillin	T109	C0002645
cephalexin	T109	C0007716
commonly	T081	C0205214
available	T169	C0470187
antibiotics	T195	C0003232
stands	T082	C1254362
Antibiotic	T195	C0003232
sharing	T054	C0237876
common	T081	C0205214
associated with	T080	C0332281
misconceptions	T041	C2717766
antibiotic	T195	C0003232
Antibiotics	T195	C0003232
available	T169	C0470187
sari-sari stands	T082	C1254362
without	T080	C0332288
expiration information	T170	C3669020
curbing	T169	C2587213
informal	T033	C0243095
antibiotic	T195	C0003232
Philippines	T083	C0031529
Southeast-Asian countries	T083	C0454709
Automated	T169	C0205554
characterization	T052	C1880022
counting	T081	C0750480
Ki-67 protein	T116	C0033684
breast cancer	T191	C0006142
prognosis	T058	C0033325
quantitative	T081	C0392762
immunohistochemistry	T060	C0021044
approach	T082	C0449445
Ki-67 protein	T116	C0033684
expression	T045	C1171362
proliferative status	T081	C1514489
tumour cell	T025	C0431085
future	T079	C0016884
course	T079	C0750729
therapy	T061	C0087111
breast cancer	T191	C0006142
Immunohistochemical (IHC) determination	T060	C0021044
Ki-67 score	T059	C4049944
labelling index	T059	C0022885
fraction of	T081	C1264633
Ki67	T116	C0033684
positively	T033	C1446409
stained	T080	C2986582
tumour cells	T025	C0431085
method	T060	C0430022
assess	T058	C0184514
tumour	T191	C0027651
proliferation	T169	C1514485
Accurate	T080	C0443131
manual counting	T059	C1441639
cells	T025	C0007634
specifically	T080	C0205369
nuclei	T026	C0007610
complex	T080	C0439855
dense	T080	C0439794
distribution	T169	C1704711
cells	T025	C0007634
critical	T080	C1511545
presents	T078	C0449450
major	T080	C0205164
pathologists	T097	C0334866
hybrid clustering algorithm	T170	C0002045
quantify	T081	C1709793
proliferative index	T081	C1514489
breast cancer cells	T025	C1512505
automated counting	T059	C1441489
Ki-67	T116	C0033684
nuclei	T026	C0007610
methodology	T060	C0430022
initially	T079	C0205265
pre-processes	T067	C1522240
IHC	T060	C0021044
images	T170	C1704254
Ki-67	T116	C0033684
stained	T080	C2986582
slides	T075	C0444330
breast cancer	T191	C0006142
grey	T080	C1269776
colour space	T170	C0876936
stained	T080	C2986582
cells	T025	C0007634
characterized	T052	C1880022
two stage segmentation process	T059	C0200768
Fuzzy C-means	T170	C0002045
quantifies	T081	C1709793
stained	T080	C2986582
cells	T025	C0007634
cluster	T081	C1704332
blue	T080	C1260957
channel	T077	C1706095
first stage	T185	C0441766
output	T077	C1709366
k-means algorithm	T062	C0009085
separate	T080	C0443299
cluster	T081	C1704332
Ki-67	T116	C0033684
positive and negative	T033	C3842923
cells	T025	C0007634
count	T081	C0750480
positive and negative	T033	C3842923
nuclei	T026	C0007610
calculate	T059	C1443182
F-measure	T081	C0079809
colour space	T170	C0876936
comparative study	T062	C1579762
expert opinion	T077	C0600219
error	T080	C0743559
rate	T081	C1521828
positive and negative	T033	C3842923
nuclei	T026	C0007610
detection	T033	C0442726
results	T169	C1274040
colour space	T170	C0876936
compared	T052	C1707455
F-measure	T081	C0079809
calculated	T059	C1443182
F-measure	T081	C0079809
colour space	T170	C0876936
statistical	T081	C2828391
result	T169	C1274040
compared	T052	C1707455
grey	T080	C1269776
colour space	T170	C0876936
study	T062	C2603343
count	T081	C0750480
nuclei	T026	C0007610
manually	T059	C1441639
automatically	T059	C1441489
algorithm	T170	C0002045
average	T081	C1510992
error	T080	C0743559
rate	T081	C1521828
significant	T078	C0750502
study	T062	C2603343
automated	T169	C0205554
count	T081	C0750480
positive and negative	T033	C3842923
nuclei	T026	C0007610
colour space	T170	C0876936
hybrid segmentation technique	T066	C2697664
Computerized evaluation	T059	C1441489
proliferation index	T081	C1514489
pathologist	T097	C0334866
breast cancer	T191	C0006142
severity	T080	C0439793
methodology	T060	C0430022
potential	T080	C3245505
assisting	T058	C0557034
manual procedure	T059	C1441639
pathological	T169	C1521733
decision support system	T068	C0023678
Multitarget	T169	C1521840
sensing of glucose	T059	C0337438
cholesterol	T059	C0201950
Janus hydrogel microparticles	T109	C0063083
visualized	T169	C0234621
sensing method for glucose	T059	C0337438
cholesterol	T059	C0201950
Janus hydrogel microparticles	T109	C0063083
Janus hydrogel microparticles	T109	C0063083
centrifugal	T080	C1301962
microfluidic chip	T075	C1449582
glucose sensing	T059	C0337438
concanavalin A	T116	C0009630
fluorescein labeled dextran	T109	C0060538
competitive binding assay	T059	C0005507
encapsulated	T080	C0205223
alginate	T109	C0002040
microparticles	T104	C0597177
fluorescence	T070	C0016315
microparticles	T104	C0597177
positively	T033	C1446409
correlated	T080	C1707520
glucose	T109	C0017725
concentration	T081	C1446561
cholesterol sensing	T059	C0201950
microparticles	T104	C0597177
γ-Fe2O3 nanoparticles	T130	C3652446
catalyst	T067	C0175921
oxidation	T044	C0030011
3,3',5,5'-Tetramethylbenzidine	T109	C0046880
H2O2	T121	C0020281
enzymatic	T116	C0014442
hydrolysis	T070	C0020291
product	T071	C1514468
cholesterol	T109	C0008377
color	T080	C0009393
transition	T052	C2700061
sensitive	T169	C0332324
microparticles	T104	C0597177
solutions	T167	C0037633
microparticles	T104	C0597177
applicable	T080	C1706839
visualized	T169	C0234621
determination	T059	C1148554
Janus microparticles	T104	C0597177
employed	T033	C0557351
multitarget	T169	C1521840
sensing	T080	C0205396
glucose	T109	C0017725
cholesterol	T109	C0008377
detected	T033	C0442726
microparticles	T104	C0597177
interference	T169	C0521102
particles	T104	C0597177
external	T082	C0205101
magnetic field	T070	C0563533
glucose	T034	C0428548
cholesterol levels	T034	C0428466
measured	T080	C0444706
human	T016	C0086418
serum	T031	C0229671
microparticles	T104	C0597177
confirmed	T033	C0750484
potential	T080	C3245505
microparticles	T104	C0597177
sample	T167	C0370003
detection	T061	C1511790
PI3K	T116	C0044602
Akt	T116	C0164786
pathway	T044	C0037080
therapeutic	T169	C0302350
target	T169	C1521840
chronic pain	T184	C0150055
Chronic pain	T184	C0150055
disabling	T047	C0596452
disorders	T047	C0012634
prevalence	T081	C0683921
ranging	T081	C1514721
therapeutic	T169	C0302350
chronic pain	T184	C0150055
unsatisfactory	T080	C0439856
poor	T080	C0542537
understanding	T041	C0162340
mechanisms	T169	C0441712
therapeutic	T169	C0302350
targets	T169	C1521840
improve	T033	C0184511
patients'	T101	C0030705
quality of life	T078	C0034380
PI3K	T116	C0044602
downstream	T082	C0522506
Akt	T116	C0164786
expressed	T045	C1171362
spinal cord	T023	C0037925
laminae I-IV	T023	C2340386
dorsal horn	T023	C0228575
nociceptive C	T026	C0501409
Aδ fibers	T026	C0027750
primary	T080	C0205225
afferents	T023	C0206309
terminate	T079	C2746065
studies	T062	C0008972
critical	T080	C1511545
roles	T077	C1705810
development	T169	C1527148
maintenance	T052	C0024501
chronic pain	T184	C0150055
review	T170	C0282443
roles	T077	C1705810
mechanisms	T169	C0441712
PI3K	T116	C0044602
Akt	T116	C0164786
pathway	T044	C0037080
progression	T046	C0242656
chronic pain	T184	C0150055
sciatic nerve injury	T037	C0161467
diabetic neuropathy	T047	C0011882
spinal cord injury	T037	C0037929
bone cancer	T191	C0279530
opioid tolerance	UnknownType	C0240601
opioid	T109	C0242402
induced	T169	C0205263
hyperalgesia	T184	C0020429
free bed	T073	C0004916
ventilator	T074	C0087153
public health specialist	T097	C0334894
author	T097	C3812881
poor	T102	C0032854
elderly father	T099	C0015671
gravely injured	T169	C0332664
young	T079	C0332239
son	T099	C0037683
government hospital	T073	C0337960
intensive care	T058	C0085559
friends	T098	C0079382
globe	T082	C1254362
euthanasia	T058	C0015187
social media	T170	C3179065
marginalised	T054	C3494319
groups of people	T098	C1257890
access	T078	C0015472
care	T052	C1947933
India	T083	C0021201
friends	T098	C0079382
developed parts of the world	T080	C0282613
choice	T052	C1707391
live	T080	C1548795
die	T040	C0011065
poor	T102	C0032854
father	T099	C0015671
battling	T048	C1407863
save	T078	C1254370
son	T099	C0037683
people	T098	C0027361
help	T080	C1269765
save	T078	C1254370
Early treatment	UnknownType	C0814494
helped	T080	C1269765
young	T079	C0332239
boy	T100	C0870221
incident	T067	C1551358
author	T097	C3812881
poor	T102	C0032854
denied	T052	C2700401
care	T052	C1947933
debate	T052	C0870392
pull the plug	T078	C1254370
patient	T101	C0030705
families	T099	C0015576
care	T052	C1947933
India	T083	C0021201
people	T098	C0027361
paying out of pocket	T081	C3815933
healthcare	T058	C0086388
below the poverty line	T102	C0860094
every year	T079	C0332181
think	T041	C0039869
universal health coverage	T078	C0376640
health	T078	C0018684
fancy term	T078	C1705313
conferences and meetings	T058	C0586182
ground reality	T078	C0871222
completely different	T080	C1705242
Quantitative	T081	C0392762
determination	T059	C1148554
metabolites	T123	C0870883
aspirin	T109	C0004057
UHPLC-MS	T059	C4053724
MS	T059	C0037813
coupled	T169	C1948027
enzymatic reaction	T044	C1511131
effects	T080	C1280500
aspirin	T109	C0004057
dosage	T081	C0178602
metabolic profile	T039	C3853758
Acetylsalicylic acid	T109	C0004057
Aspirin	T109	C0004057
ASA	T109	C0004057
drug	T121	C0013227
cardiovascular diseases	T047	C0007222
years	T079	C0439234
ASA	T109	C0004057
dosage	T081	C0178602
metabolic profile	T039	C3853758
study	T062	C2603343
rapid	T080	C0456962
reliable	T170	C3858758
method	T059	C0022885
quantify	T081	C1709793
ASA	T109	C0004057
metabolites	T123	C0870883
biological matrices	T031	C1706515
glucuronide	T109	C0812407
metabolites	T123	C0870883
method	T059	C0022885
ASA	T109	C0004057
dosage	T081	C0178602
metabolic	T039	C3853758
excretion	T039	C0221102
profile	T081	C0237801
ASA	T109	C0004057
metabolites	T123	C0870883
rat	T015	C0034721
urine	T031	C0042036
Salicylic acid	T109	C0036079
SA	T109	C0036079
gentisic acid	T109	C0045555
GA	T109	C0045555
salicyluric acid	T109	C0073984
SUA	T109	C0073984
UHPLC-MS	T059	C4053724
MS	T059	C0037813
salicyl phenolic glucuronide	T109	C0044622
SAPG	T109	C0044622
salicyluric acid phenolic glucuronide	T109	C0752086
SUAPG	T109	C0752086
quantified	T081	C1709793
SA	T109	C0036079
SUA	T109	C0073984
SAPG	T109	C0044622
SUAPG	T109	C0752086
β-glucuronidase	T116	C0017776
digestion	T040	C0012238
SUA	T109	C0073984
SUAPG	T109	C0752086
metabolites	T123	C0870883
ASA	T109	C0004057
rat	T015	C0034721
urine	T031	C0042036
h	T079	C0439227
ASA	T109	C0004057
administration	T081	C0001555
SUA	T109	C0073984
SUAPG	T109	C0752086
ASA	T109	C0004057
dosage	T081	C0178602
increased	T081	C0205217
excretion	T039	C0221102
metabolites	T123	C0870883
GA	T109	C0045555
SA	T109	C0036079
SAPG	T109	C0044622
SUA	T109	C0073984
SUAPG	T109	C0752086
excreted	T039	C0221102
time period	T079	C1948053
h	T079	C0439227
GA	T109	C0045555
excreted	T039	C0221102
time periods	T079	C1948053
h	T079	C0439227
h	T079	C0439227
SA	T109	C0036079
excreted	T039	C0221102
time period	T079	C1948053
h	T079	C0439227
h	T079	C0439227
excretion	T039	C0221102
SAPG	T109	C0044622
time periods	T079	C1948053
excretion	T039	C0221102
metabolites	T123	C0870883
rat	T015	C0034721
urine	T031	C0042036
ASA	T109	C0004057
dosage	T081	C0178602
increased	T081	C0205217
rapid	T080	C0456962
sensitive	T169	C0205342
method	T059	C0022885
ASA	T109	C0004057
metabolites	T123	C0870883
SA	T109	C0036079
GA	T109	C0045555
SUA	T109	C0073984
SAPG	T109	C0044622
SUAPG	T109	C0752086
rat	T015	C0034721
urine	T031	C0042036
ASA	T109	C0004057
dosage	T081	C0178602
influence	T077	C4054723
metabolic	T039	C3853758
excretion	T039	C0221102
profile	T081	C0237801
ASA	T109	C0004057
metabolites	T123	C0870883
rat	T015	C0034721
urine	T031	C0042036
Mismatch Repair	T045	C1155661
Incompatibilities	T054	C0679426
Diverse	T080	C1880371
Yeast	T004	C0036025
Populations	T090	C0017404
elevated	T080	C3163633
mutation rate	T080	C3178846
cells	T025	C0007634
source	T033	C0449416
mutations	T045	C0026882
changing	T169	C0392747
environments	T082	C0014406
identified	T080	C0205396
negative	T033	C0205160
epistatic interaction	T045	C0014589
involving	T169	C1314939
variants	T080	C0205419
MLH1	T028	C0879389
PMS1	T028	C0879390
mismatch repair	T045	C1155661
MMR	T045	C1155661
genes	T028	C0017337
Saccharomyces cerevisiae	T004	C0036025
MMR	T045	C1155661
incompatibility	T054	C0679426
mating	T040	C1260875
S. cerevisiae	T004	C0036025
progeny	T099	C0680063
rapidly	T080	C0456962
environmental stress	T067	C0871732
analyzed	T062	C0936012
MLH1	T028	C0879389
PMS1 genes	T028	C0879390
S. cerevisiae	T004	C0036025
natural	T169	C0205296
isolates	T123	C1764827
range	T081	C1514721
ecological	T070	C0162358
sources	T033	C0449416
tree	T002	C0040811
exudates	T031	C0015388
Drosophila	T204	C0013138
fruits	T168	C0016767
fermentation	T044	C0015852
clinical	T080	C0205210
isolates	T123	C1764827
geographical	T082	C0565935
sources	T033	C0449416
Europe	T083	C0015176
America	T083	C0002454
Africa	T083	C0001737
Asia	T083	C0003980
identified	T080	C0205396
homozygous	T032	C0019904
clinical	T080	C0205210
isolate	T123	C1764827
heterozygous	T032	C0019425
isolates	T123	C1764827
containing	T169	C0332256
MMR	T045	C1155661
genotype	T032	C0017431
MLH1	T028	C0879389
PMS1 gene	T028	C0879390
combination	T080	C0205195
isolated	T169	C0205409
homozygous	T032	C0019904
clinical	T080	C0205210
isolate	T123	C1764827
phenotype	T032	C0031437
expressed	T045	C0017262
laboratory	T073	C0022877
background	T077	C1706907
reporter	T130	C1522485
measure	T081	C0079809
mutation rates	T080	C3178846
overall	T080	C1561607
mutation rate	T080	C3178846
homozygous	T032	C0019904
background	T077	C1706907
compatible	T080	C1524057
strains	T001	C1518614
suppressor mutations	T049	C0038859
clinical	T080	C0205210
isolate	T123	C1764827
mutation rate	T080	C3178846
observation	T062	C0302523
identification	T080	C0205396
heterozygous	T032	C0019425
isolates	T123	C1764827
isolates	T123	C1764827
MMR	T045	C1155661
genotypes	T032	C0017431
offspring	T099	C0680063
consistent with	T078	C0332290
elevated	T080	C3163633
mutation rate	T080	C3178846
adaptation	T038	C0392673
long-term	T079	C0443252
fitness	T045	C2717776
costs	T081	C0010186
incompatibility	T054	C0679426
buffered	T121	C0006353
mating	T040	C1260875
suppressors	T049	C0038859
observations	T062	C0302523
effective	T080	C1704419
eukaryotes	T204	C0684063
long-term	T079	C0443252
fitness	T045	C2717776
costs	T081	C0010186
associated with	T080	C0332281
elevated	T080	C3163633
mutation rates	T080	C3178846
Mapping	T052	C1283195
circulating	T169	C0175630
serum	T031	C0229671
miRNAs	T114	C1101610
immune	T169	C0439662
related	T080	C0332281
target	T169	C1521840
mRNAs	T114	C0035696
Evidence	T078	C3887511
suggests	T078	C1705535
circulating	T169	C0175630
serum	T031	C0229671
microRNAs	T114	C1101610
miRNAs	T114	C1101610
target	T169	C1521840
immune	T169	C0439662
related	T080	C0332281
mRNAs	T114	C0035696
immune	T169	C0439662
related	T080	C0332281
mRNAs	T114	C0035696
predicted	T078	C0681842
serum	T031	C0229671
miRNA binding	T045	C1523647
sites	T082	C0205145
mRNAs	T114	C0035696
reciprocally	T080	C1882911
serum	T031	C0229671
miRNAs	T114	C1101610
immune	T169	C0439662
related	T080	C0332281
mRNA	T114	C0035696
targets	T169	C1521840
non	T169	C1518422
serum	T031	C0229671
miRNAs	T114	C1101610
developed	T169	C1527148
target	T169	C1521840
random forest framework	T169	C0205245
calculated	T169	C0444686
predicted	T078	C0681842
miRNA	T114	C1101610
mRNA	T114	C0035696
interactions	T045	C2753463
subsets	T185	C1515021
miRNAs	T114	C1101610
serum	T031	C0229671
non	T169	C1518422
serum	T031	C0229671
mRNAs	T114	C0035696
immune	T169	C0439662
related	T080	C0332281
nonimmune related	T080	C0332281
Immune	T169	C0439662
related	T080	C0332281
mRNAs	T114	C0035696
predicted	T078	C0681842
targeted	T169	C1521840
serum	T031	C0229671
miRNA	T114	C1101610
mRNAs	T114	C0035696
serum	T031	C0229671
miRNAs	T114	C1101610
predicted	T078	C0681842
target	T169	C1521840
immune	T169	C0439662
related	T080	C0332281
mRNA	T114	C0035696
targets	T169	C1521840
non	T169	C1518422
serum	T031	C0229671
miRNAs	T114	C1101610
biases	T078	C0242568
immune	T169	C0439662
related	T080	C0332281
mRNAs	T114	C0035696
serum	T031	C0229671
miRNAs	T114	C1101610
completely	T080	C0205197
independent	T078	C0085862
Immune	T169	C0439662
related	T080	C0332281
mRNAs	T114	C0035696
miRNA binding	T045	C1523647
sites	T082	C0205145
serum	T031	C0229671
miRNAs	T114	C1101610
serum	T031	C0229671
miRNAs	T114	C1101610
target	T169	C1521840
mRNAs	T114	C0035696
non	T169	C1518422
serum	T031	C0229671
miRNAs	T114	C1101610
regardless	T080	C3641650
immune	T169	C0439662
related	T080	C0332281
independent	T078	C0085862
phenomena	T067	C1882365
result	T169	C1274040
predicted	T078	C0681842
serum	T031	C0229671
miRNA	T114	C1101610
immune	T169	C0439662
mRNA	T114	C0035696
interactions	T045	C2753463
Oxidative stress	T049	C0242606
immunosenescence	T039	C0596761
spleen	T023	C0037993
obese mice	T015	C0025933
2-hydroxyoleic acid	T109	C1436659
obesity	T047	C0028754
oxidative stress	T049	C0242606
leukocyte	T025	C0023516
function	T043	C0007613
spleen	T023	C0037993
mice	T015	C0025929
supplementation	T061	C0242297
2-hydroxyoleic acid	T109	C1436659
2-OHOA	T109	C1436659
n-3 polyunsaturated fatty acids	T109	C0015689
PUFA	T109	C0015689
Female	T032	C0086287
ICR/CD1 mice	T015	C2697641
weeks	T079	C0439230
obesogenic diet	T168	C0012155
fat	T109	C0012171
weeks	T079	C0439230
fat	T109	C0012171
weeks	T079	C0439230
weeks	T079	C0439230
mice	T015	C0025929
groups	UnknownType	C0681860
group	UnknownType	C0681860
no supplementation	UnknownType	C0681860
2-OHOA supplementation	UnknownType	C0681860
n-3 PUFA supplementation	UnknownType	C0681860
EPA	T109	C0000545
DHA	T109	C0556150
mice	T015	C0025929
diet	T168	C0012155
duration	T079	C0449238
study	T062	C2603343
control group	T096	C0009932
experiment	T062	C0681814
variables	T080	C0439828
assessed	T052	C1516048
spleens	T023	C0037993
levels	T080	C0441889
reduced	T116	C0017817
GSH	T116	C0017817
oxidized (GSSG) glutathione	T116	C0061516
GSH	T116	C0017817
GSSG	T116	C0061516
xanthine oxidase (XO) activity	T044	C1151293
lipid peroxidation	T044	C0023775
lymphocyte chemotaxis	T043	C0312862
natural killer (NK) activity	T043	C1317556
mitogen	T121	C0026249
ConA	T116	C0009630
LPS	T109	C0023810
lymphocyte proliferation	T043	C0596873
Obese	T032	C0424612
animals	T008	C0003062
higher	T080	C0205250
GSSG	T116	C0061516
levels	T080	C0441889
GSSG	T116	C0061516
GSH	T116	C0017817
ratio	T081	C0456603
lipid peroxidation	T044	C0023775
XO activity	T044	C1151293
lymphocyte chemotaxis	T043	C0312862
NK activity	T043	C1317556
proliferation	T169	C1514485
ConA	T116	C0009630
controls	T096	C0009932
2-OHOA	T109	C1436659
changes	T081	C0443172
body weight	T032	C0005910
GSSG	T116	C0061516
levels	T080	C0441889
GSH	T116	C0017817
GSSG	T116	C0061516
lipid peroxidation	T044	C0023775
chemotaxis	T043	C0008018
proliferation	T043	C0596290
n-3 PUFA	T109	C0015689
increase	T169	C0442805
XO activity	T044	C1151293
2-OHOA	T109	C1436659
n-3 PUFA	T109	C0015689
oxidative stress	T049	C0242606
alteration	T078	C1515926
leukocyte	T025	C0023516
function	T043	C0007613
spleen	T023	C0037993
obese mice	T015	C0025933
findings	T033	C0243095
obesity	T047	C0028754
immunosenescence	T039	C0596761
therapeutic tool	T169	C0302350
obesity	T047	C0028754
immune dysfunction	T047	C0021053
Assembly of the outermost spore layer	T043	C2611271
endospore-forming soil dwelling bacteria	T007	C0014248
human	T016	C0086418
animal	T008	C0003062
insect	T204	C0021585
pathogens	T001	C0450254
organisms	T001	C0450254
spores	T001	C0038027
outer layer	T026	C0243092
exosporium	T026	C1623474
exosporium	T026	C1623474
site of	T080	C2945843
interactions	T169	C1704675
spore	T001	C0038027
soil	T167	C0037592
environment	T082	C0014406
spore	T001	C0038027
infected	T033	C0439663
host	T001	C1167395
initial	T079	C0205265
stages	T079	C1306673
infection	T046	C3714514
composition	T201	C0486616
assembly process of the exosporium	T043	C2611271
stability	T080	C0205360
exosporium	T026	C1623474
methods	T169	C0025664
intact	T080	C0205266
structure	T082	C0678594
component	T077	C1705248
parts	T082	C0449719
proteins	T116	C0004627
identified	T080	C0205396
exosporium	T026	C1623474
associated	T080	C0332281
abundance	T080	C2346714
relationship	T080	C0439849
proteins	T116	C0033684
processes	T067	C1522240
assembled to create the exosporium	T043	C2611271
Molecular Microbiology	T091	C0025952
laboratory	T073	C0022877
ExsY protein	T116	C0033684
structural protein	T116	C0582263
exosporium basal layer	T026	C1623474
B. cereus family	T007	C0004590
spores	T001	C0038027
self-assemble	T052	C1706853
complex	T080	C0439855
structures	T082	C0678594
structural	T082	C0678594
features	T080	C2348519
characteristic	T080	C1521970
exosporium basal layer	T026	C1623474
authors	T097	C3812881
model	T170	C3161035
exosporium assembly	T043	C2611271
findings	T033	C0243095
exosporium	T026	C1623474
formation	T169	C1522492
spore forming bacteria	T007	C0014248
Clostridium species	T007	C1264830
Skeletal muscle	T024	C0242692
adaptations	T038	C0392673
endurance	T079	C0031808
exercise training	T056	C4279936
attainable	T052	C0599946
mice	T015	C0025929
simvastatin	T109	C0074554
treatment	T061	C0087111
hypothesis	T078	C1512571
regimen	T061	C0040808
simvastatin	T109	C0074554
attenuate	T052	C0599946
skeletal muscle	T024	C0242692
adaptation	T038	C0392673
low-intensity exercise	T056	C0015259
Male	T032	C0086582
C57BL/6J wildtype mice	T015	C0025929
voluntary wheel running	T056	C0035953
cage	T073	C0179512
activities	T052	C0441655
simvastatin	T109	C0074554
treatment	T061	C0087111
Adaptations	T038	C0392673
in vivo	T062	C0681829
fatigue	T184	C0015672
resistance	T169	C4281815
treadmill running test	T060	C0087110
ankle plantarflexor	T023	C0581542
contractile	T039	C0026820
tibialis anterior	T023	C0242690
gastrocnemius	T023	C0242691
plantaris muscles	T023	C0242693
evaluated	T058	C0220825
exercised	T056	C0015259
mitochondrial	T026	C0026237
adaptations	T038	C0392673
biogenesis	T070	C0005495
function	T169	C0542341
autophagy	T043	C0004391
no difference	T033	C3842396
wheel running distance	T052	C0441655
simvastatin	T109	C0074554
treated	T169	C1522326
mice	T015	C0025929
Trained	T065	C0220931
mice	T015	C0025929
treadmill running	T056	C2712999
distance	T081	C0012751
ankle plantarflexor	T023	C0581542
contractile	T039	C0026820
fatigue	T184	C0015672
resistance	T169	C4281815
mice	T015	C0025929
simvastatin	T109	C0074554
treatment	T061	C0087111
cellular level	T025	C0007634
trained	T065	C0220931
mice	T015	C0025929
mitochondrial biogenesis	T043	C3494456
PGC1α	T116	C1570275
expression	T045	C1171362
mitochondrial	T026	C0026237
citrate synthase	T116	C0008855
activity	T044	C0243102
simvastatin	T109	C0074554
treatment	T061	C0087111
Mitochondrial	T026	C0026237
autophagy	T043	C0004391
protein	T116	C0033684
trained	T065	C0220931
mice	T015	C0025929
Bnip3	T116	C1699488
simvastatin	T109	C0074554
treatment	T061	C0087111
Drp1	T116	C1957127
marker	T201	C0005516
mitochondrial fission	T043	C0230871
simvastatin	T109	C0074554
treated	T169	C1522326
mice	T015	C0025929
exercise training	T056	C4279936
interaction	T169	C1704675
training	T065	C0220931
treatment	T061	C0087111
LC3-II protein	T116	C3711208
content	T081	C1446561
marker	T201	C0005516
autophagy	T043	C0004391
whole body	T017	C0444584
skeletal muscle	T024	C0242692
adaptations	T038	C0392673
endurance	T079	C0031808
exercise training	T056	C4279936
attainable	T052	C0599946
simvastatin	T109	C0074554
treatment	T061	C0087111
simvastatin	T109	C0074554
side effects	T046	C0879626
muscle	T024	C0026845
mitochondrial	T026	C0026237
autophagy	T043	C0004391
long-term	T079	C0443252
muscle	T024	C0026845
health	T078	C0018684
Evaluation	T058	C0220825
Treatment	T169	C0039798
Anemia	T047	C0002871
Premature Infants	T047	C0021294
Anemia	T047	C0002871
preterm infants	T100	C4048294
pathophysiological	T169	C0031847
process	T067	C1522240
decline	T081	C0282251
hemoglobin	T116	C0019046
compared	T052	C1707455
physiological	T169	C0205463
anemia	T047	C0002871
infants	T100	C0021270
transfusions	T061	C0005841
administration	T061	C1533734
human recombinant erythropoietin	T116	C0376541
determine	T078	C0205258
frequency	T079	C0439603
anemia	T047	C0002871
premature infants	T047	C0021294
Pediatric Clinic, University Clinical Center Sarajevo	T073	C3839701
parameter values	T077	C0549193
blood count	T059	C0005771
premature infants	T047	C0021294
relationship	T080	C0439849
blood transfusions	T061	C0005841
intraventricular hemorrhage	T046	C0240059
determine	T078	C0205258
treatment	T169	C0039798
preterm infants	T100	C4048294
Research	T062	C0035168
retrospective study	T062	C0035363
period	T079	C0439531
months	T079	C0439231
year	T079	C0439234
Research	T062	C0035168
patients	T101	C0030705
gestational age	T032	C0017504
weeks	T079	C0439230
premature infants	T047	C0021294
Data	T078	C1511726
collected	T078	C1516695
examining	T033	C0332128
medical records	T170	C0025102
patients	T101	C0030705
Pediatric Clinic, UCCS	T073	C3839701
first	T081	C0205435
group	T078	C0441833
patients	T101	C0030705
premature infants	T047	C0021294
gestational age	T032	C0017504
weeks	T079	C0439230
second	T081	C0205436
group	T078	C0441833
premature infants	T047	C0021294
gestational age	T032	C0017504
weeks	T079	C0439230
patients	T101	C0030705
boys	T100	C0870221
girls	T100	C0870604
significant difference	T081	C1705241
birth weight	T032	C0005612
APGAR score	T032	C0003533
groups	T078	C0441833
first	T081	C0205435
group	T078	C0441833
deaths	T033	C1306577
second	T081	C0205436
group	T078	C0441833
deaths	T033	C1306577
significant difference	T081	C1705241
treatment	T169	C0039798
statistically significant	T081	C0237881
difference	T081	C1705241
transfusion	T061	C0005841
groups	T078	C0441833
patients	T101	C0030705
first	T081	C0205435
group	T078	C0441833
transfusion	T061	C0005841
second	T081	C0205436
group	T078	C0441833
patients	T101	C0030705
Preterm infants	T100	C4048294
gestational age	T032	C0017504
weeks	T079	C0439230
candidates	T101	C0030705
blood transfusion	T061	C0005841
treatment	T169	C0039798
Preterm infants	T100	C4048294
gestational age	T032	C0017504
weeks	T079	C0439230
risk	T078	C0035647
intracranial bleeding	T047	C0151699
associated with	T080	C0332281
application	T058	C0185125
blood transfusion	T061	C0005841
week	T079	C0439230
life	T078	C0376558
Medial Patellofemoral Ligament	T023	C4254914
Reconstruction	T061	C0547071
Femoral	T023	C0015811
Tunnel	T082	C1254362
Accuracy	T080	C0443131
Disease	T047	C0012634
Specific	T080	C0205369
Quality of Life	T078	C0034380
Medial patellofemoral ligament	T023	C4254914
MPFL	T023	C4254914
reconstruction	T061	C0547071
lateral patellar translation	T037	C0559397
patients	T101	C0030705
symptomatic patellofemoral instability	T037	C0856775
femoral	T023	C0015811
tunnel	T082	C1254362
position	T082	C0733755
MPFL	T023	C4254914
reconstruction	T061	C0547071
accuracy	T080	C0443131
patient outcomes	T058	C0030698
accuracy	T080	C0443131
femoral	T023	C0015811
tunnel	T082	C1254362
placement	T058	C1533810
MPFL	T023	C4254914
reconstruction	T061	C0547071
cohort	T098	C0599755
correlation	T080	C1707520
tunnel	T082	C1254362
accuracy	T080	C0443131
validated	T062	C1519941
disease	T047	C0012634
specific	T080	C0205369
patient	T101	C0030705
quality-of-life	T078	C0034380
outcome measure	T081	C0086749
June	T079	C3829443
February	T080	C3830166
subjects	T098	C0080105
MPFL	T023	C4254914
reconstruction	T061	C0547071
Lateral	T082	C0205093
radiographs	T060	C1306645
accuracy	T080	C0443131
femoral	T023	C0015811
tunnel	T082	C1254362
femoral	T023	C0015811
tunnel	T082	C1254362
Schöttle point	T082	C1254362
Banff Patella Instability Instrument (BPII) scores	T081	C0086749
mean	T081	C0444504
months	T079	C0439231
postoperatively	T079	C0032790
postoperative	T079	C0032790
lateral	T082	C0205093
radiographs	T060	C1306645
BPII scores	T081	C0086749
mean	T081	C0444504
duration	T079	C0449238
follow-up	T058	C1522577
SD	T081	C0871420
months	T079	C0439231
months	T079	C0439231
Measurement	T169	C0242485
center	T082	C0205099
femoral	T023	C0015811
tunnel	T082	C1254362
Schöttle point	T082	C1254362
tunnel	T082	C1254362
good	T080	C0205170
ideal	T080	C1512612
failures	T046	C1262018
cohort	T098	C0599755
malpositioned	T082	C0333042
tunnels	T082	C1254362
mean	T081	C0444504
center	T082	C0205099
MPFL	T023	C4254914
tunnel	T082	C1254362
center	T082	C0205099
Schöttle point	T082	C1254362
mean	T081	C0444504
postoperative	T079	C0032790
BPII score	T081	C0086749
Pearson r correlation	T170	C1709490
no statistically significant	T033	C1273937
relationship	T080	C0439849
accuracy	T080	C0443131
femoral	T023	C0015811
tunnel	T082	C1254362
position	T082	C0733755
BPII score	T081	C0086749
no evidence of	T080	C0332125
correlation	T080	C1707520
accuracy	T080	C0443131
MPFL	T023	C4254914
reconstruction	T061	C0547071
femoral	T023	C0015811
tunnel	T082	C1254362
Schöttle point	T082	C1254362
disease	T047	C0012634
specific	T080	C0205369
quality-of-life scores	T080	C3476431
Graft failure	T046	C1262018
femoral	T023	C0015811
tunnel	T082	C1254362
placement	T058	C1533810
patellofemoral instability	T037	C0856775
patients	T101	C0030705
risk factors	T033	C0035648
accuracy	T080	C0443131
tunnel	T082	C1254362
position	T082	C0733755
quality of life	T078	C0034380
investigation	T058	C0220825
instructions	T065	C0039401
task-set representations	T061	C0039333
informed	T080	C1522154
fadeout effect	T041	C0237614
cognitive system	T041	C0392335
performance	T061	C0039333
cognitive tasks	T041	C0392335
task	T057	C3540678
switching	T169	C0392747
task	T057	C3540678
level	T080	C0441889
task	T057	C3540678
performance	T061	C0039333
research	T062	C0035168
fadeout effect	T041	C0237614
performance	T061	C0039333
improvement	T061	C0039333
task	T057	C3540678
switching	T169	C0392747
single-task	T169	C2371306
passive	T080	C3686820
learning	T041	C0023185
intentional	T080	C1283828
control	T080	C0243148
informed	T080	C1522154
fadeout	T078	C0033897
paradigm	T062	C0681797
tasks	T057	C3540678
trials	T062	C0681815
participants	T098	C0679646
informed	T080	C1522154
uninformed	T033	C0562357
task	T057	C3540678
cancelation	T080	C0205544
informed	T080	C1522154
fadeout effect	T041	C0237614
performance	T061	C0039333
informed	T080	C1522154
uninformed	T033	C0562357
fadeout	T041	C0237614
informed	T080	C1522154
trial	T062	C0681815
executed	T052	C1705848
trial	T062	C0681815
mechanisms	T169	C0441712
Metacarpophalangeal Joint Arthrodesis	T061	C0187606
Thumb	T023	C0040067
Months	T079	C0439231
Follow-up	T058	C1522577
Disorders	T047	C0012634
thumb metacarpophalangeal (MCP) joint	T030	C0224627
loss	T081	C1517945
function	T039	C1254359
pain	T184	C0030193
Thumb MCP	T030	C0224627
arthrodesis	T061	C0003881
traumatic injuries	T037	C3263723
described	T078	C1552738
studies	T062	C2603343
outcome	T169	C1274040
treatment	T061	C0087111
study	T062	C2603343
report	T058	C0700287
outcome	T169	C1274040
disability	T033	C0231170
thumb MCP joint	T030	C0224627
arthrodesis	T061	C0003881
treatment	T061	C0087111
chronic instability	T046	C0409364
traumatic injuries	T037	C3263723
retrospective	T080	C1514923
review	T061	C0451610
patients	T101	C0030705
operated	T061	C0543467
MCP joint	T030	C0224627
arthrodesis	T061	C0003881
follow-up	T058	C1522577
months	T079	C0439231
months	T079	C0439231
outcome	T169	C1274040
assessed	T052	C1516048
disabilities of the Arm, Shoulder, and Hand-questionnaire	T170	C4295796
DASH	T170	C4295796
patient satisfaction	T080	C0030702
pain	T184	C0030193
stiffness	T184	C0427008
impairment	T169	C0221099
activities of daily living	T056	C0001288
assessed	T052	C1516048
Visual Analogue Scale	T060	C3536884
VAS	T060	C3536884
procedure	T169	C2700391
patients	T101	C0030705
re-operation	T061	C0035110
nonunion	T033	C3897107
patients	T101	C0030705
hardware removal	T061	C1096445
Median	T081	C0876920
DASH	T170	C4295796
score	T081	C0449820
range	T081	C1514721
DASH	T170	C4295796
score s	T081	C0449820
Score s	T081	C0449820
gender	T032	C0079399
age	T032	C0001779
individuals	T098	C0237401
Median	T081	C0876920
VAS	T060	C3536884
pain	T184	C0030193
range	T081	C1514721
patients	T101	C0030705
mild	T033	C0278138
moderate	T184	C0278139
severe pain	T033	C0278140
patients	T101	C0030705
procedure	T169	C2700391
data	T078	C1511726
patients	T101	C0030705
post-traumatic	T079	C1254367
thumb injuries	T037	C0262649
thumb MCP joint	T030	C0224627
arthrodesis	T061	C0003881
gender	T032	C0079399
age	T032	C0001779
individuals	T098	C0237401
pain	T184	C0030193
procedure	T169	C2700391
disability scale	T170	C0451125
National Board of Industrial Injuries	T092	C1948070
patients	T101	C0030705
operated	T061	C0543467
thumb MCP	T030	C0224627
arthrodesis	T061	C0003881
Pyoderma gangrenosum	T047	C0085652
clinician's	T097	C0871685
nightmare	T184	C0028084
Pyoderma gangrenosum	T047	C0085652
PG	T047	C0085652
rare disease	T047	C0678236
sole of the foot	T029	C0230463
report	T170	C0684224
old	T079	C0580836
female	T032	C0086287
admitted	T058	C0184666
painful	T184	C0030193
ulcer	T047	C0041582
sole of the right foot	T029	C0230463
treated with	T061	C0332293
antibiotics	T195	C0003232
debridement	T061	C0011079
disease	T047	C0012634
rapidly	T080	C0456962
debridement	T061	C0011079
culture reports	T034	C2061903
negative	T033	C0205160
rheumatology	T091	C0035452
workup	T060	C0750430
Doppler study	T060	C0554756
normal limits	T033	C0442816
clinical	T080	C0205210
suspicion	T078	C0750491
PG	T047	C0085652
tissue biopsy	T060	C3864006
started on oral steroids	T061	C0419839
improved	T033	C0184511
patient	T101	C0030705
rapidly	T080	C0456962
painful	T184	C0030193
ulcer	T047	C0041582
vascular limb	T023	C0015385
refractory	T169	C0205269
antibiotic treatment	T061	C0338237
exacerbating	T080	C1444749
debridement	T061	C0011079
PG	T047	C0085652
Visualization	T060	C0178707
Uncertainty	T033	C0087130
Activation	T052	C1879547
Volumes	T081	C0449468
Deep Brain Stimulation	T061	C0394162
Neurostimulation Uncertainty Viewer (nuView or νView) tool	T170	C0282574
data	T078	C1511726
deep brain stimulation	T061	C0394162
DBS	T061	C0394162
Simulated	T062	C0679083
volume of tissue activated	T081	C0392762
VTA	T081	C0392762
clinical electrode placements	T060	C0430022
recorded	T052	C0441655
patient	T101	C0030705
outcomes	T080	C0085415
Unified Parkinson's disease rating scale	T170	C3639721
UPDRS	T170	C3639721
data	T078	C1511726
volumetric	T080	C0205556
sparse	T080	C0205556
multi-value	T080	C0205556
patient	T101	C0030705
results	T169	C1274040
activated	T052	C1879547
voxel	T077	C2700259
simulation	T062	C0679083
νView	T077	C1254372
collection	T169	C1516698
visual methods	T170	C0025663
activated	T052	C1879547
tissue	T024	C0040300
electrode	T074	C0013812
usage	T169	C0457083
therapy	T061	C0087111
DBS	T061	C0394162
conversion	T169	C0439836
5-pivaloyloxymethyluridine	T114	C0073347
present	T033	C0150312
RNA	T114	C0035668
oligomer	T087	C0599219
biologically	T080	C0205460
relevant	T080	C2347946
derivatives	T104	C0243072
5-methyluridine	T114	C0073347
reaction	T169	C0443286
5-pivaloyloxymethyluridine	T114	C0073347
present	T033	C0150312
RNA	T114	C0035668
oligomer	T087	C0599219
nucleophilic reagents	T130	C0034760
products	T071	C1514468
tRNA wobble	T045	C1817367
5-methyluridines	T114	C0073347
mnm(5)U	T114	C0073347
cmnm(5)U	T114	C0073347
τm(5)U	T114	C0073347
nm(5)U	T114	C0073347
inm(5)U	T114	C0073347
cnm(5)U	T114	C0073347
syntheses	T052	C1883254
oligoribonucleotides	T114	C0028956
modified	T169	C0392747
inm(5)U	T114	C0073347
cnm(5)U	T114	C0073347
Non-pharmacological	T169	C0205245
treatments	T061	C0087111
pain relief	T061	C0451615
TENS	T061	C0040654
acupuncture	T061	C0394664
Acupuncture	T061	C0394664
transcutaneous electrical nerve stimulation	T061	C0040654
TENS	T061	C0040654
non-pharmacological	T169	C0205245
methods	T169	C0449851
millennia	T079	C1948053
relieve pain	T061	C0451615
complementary treatments	T061	C0936077
efficacy	T080	C1280519
evaluations	T058	C0220825
double-blinding	T062	C0013072
optimal control population	T081	C0029145
treatment	T061	C0087111
good	T080	C0205170
methodological quality	UnknownType	C0815254
benefits	T081	C0814225
pain	T184	C0030193
conventional	T080	C0439858
treatment	T061	C0087111
mechanisms of action	T169	C0441712
acupuncture	T061	C0394664
TENS	T061	C0040654
increasingly	T169	C0442808
endogenous	T169	C0205227
pain control systems	T061	C1304888
cerebral plasticity	T042	C0027880
effects	T080	C1280500
expectations	T078	C0679138
placebo effect	T078	C0032041
adverse effects	T046	C0879626
data	T078	C1511726
non-pharmacological	T169	C0205245
pain management	T061	C0002766
patients	T101	C0030705
chronic pain	T184	C0150055
relieved by	T169	C0332303
medications	T121	C0013227
Synaptic	T030	C0039062
Neuronal	T025	C0027882
Autoantibody	T116	C0004358
Associated	T080	C0332281
Psychiatric Syndromes	T048	C0004936
Controversies	T054	C0680243
Hypotheses	T078	C1512571
Autoimmune encephalitis	T047	C0393639
AE	T047	C0393639
antibodies	T116	C0003241
synaptic	T030	C0039062
neuronal	T025	C0027882
surface	T082	C0205148
targets	T169	C1521840
frequently	T079	C0332183
presents	T033	C0150312
psychiatric syndrome	T048	C0004936
patients	T101	C0030705
removal of	T061	C0015252
autoantibodies	T116	C0004358
treats	T169	C1522326
disease	T047	C0012634
outcomes	T080	C0085415
intervention	T061	C0184661
discovery	T052	C1880355
autoantibodies	T116	C0004358
isolated	T169	C0205409
psychiatric syndromes	T048	C0004936
raised	T080	C0442818
patients	T101	C0030705
benefits	T081	C0814225
immunotherapy	T061	C0021083
potentially	T080	C3245505
approach	T082	C0449445
treatment	T169	C0039798
mental illness	T048	C0004936
open-label case series	T062	C3640652
therapeutic outcomes	T080	C0085415
pathological	T169	C1521733
relevance	T080	C2347946
autoantibodies	T116	C0004358
canonical presentations	T081	C0870245
diagnostic criteria	T170	C0679228
AE	T047	C0393639
attempts	T051	C1516084
identification	T080	C0205396
risks	T078	C0035647
potential	T080	C3245505
scientific	T090	C0036397
clinical significance	T033	C2826293
isolated	T169	C0205409
syndromes	T047	C0039082
syndrome	T047	C0039082
level	T080	C0441889
taxonomy	T090	C0087066
occasional	T079	C0521114
overlap	T079	C1948020
AE	T047	C0393639
synaptic	T030	C0039062
neuronal	T025	C0027882
autoantibody	T116	C0004358
associated	T080	C0332281
psychiatric syndromes	T048	C0004936
SNAps	T048	C0004936
prevent	T169	C1292733
AE	T047	C0393639
act heuristically	T170	C0597916
promote	T052	C0033414
active	T169	C0205177
investigation	T058	C0220825
rare	T080	C0522498
example	T077	C1707959
psychopathology	T091	C0033927
defined	T170	C1704788
molecular level	T081	C0596958
concept	T078	C0178566
autoantibody	T116	C0004358
associated	T080	C0332281
syndromes	T047	C0039082
including	T169	C0332257
seizure	T184	C0036572
cognitive	T169	C1516691
movement disorders	T047	C0026650
similar	T080	C2348205
issues	T033	C0033213
review	T169	C0699752
direct	T080	C1947931
indirect	T080	C0439852
mechanisms	T169	C0441712
experimentally	T080	C1517586
hypotheses	T078	C1512571
prospectively	T062	C0033522
autoantibody	T116	C0004358
detection	T061	C1511790
relevant	T080	C2347946
important	T080	C3898777
pragmatic	T054	C0871858
autoantibody	T116	C0004358
testing	T169	C0039593
management	T058	C0376636
severe	T080	C0205082
mental illness	T048	C0004936
diagnose	T033	C0011900
AE	T047	C0393639
research	T062	C0035168
orientated	T033	C0424013
experimental	T080	C1517586
medicine	T121	C0013227
paradigm	T062	C0681797
SNAps	T048	C0004936
greater	T081	C1704243
equipoise	T109	C0702057
SNAps	T048	C0004936
clinical	T080	C0205210
neuroscience	T091	C0027910
potential	T080	C3245505
ongoing	T078	C0549178
need	T080	C0027552
psychiatry	T091	C0033873
clinical research	T062	C0008972
NF-κB	T116	C0079904
TLR2	T116	C0754728
PAR1	T116	C4048327
Soluble	T080	C1948047
Immunomodulator Factor	T121	C1527392
Secretion	T038	C0036536
Human	T016	C0086418
Platelets	T025	C0005821
primary	T080	C0205225
toll-like receptor	T116	C0670896
TLR	T116	C0670896
immune cell response pathway	T043	C1511003
TLRs	T116	C0670896
MyD88	T116	C0286648
activation	T045	C0599177
NF-κB	T116	C0079904
seminal	T023	C0036628
transcription factor	T116	C0040648
chemokines	T116	C0282554
cytokines	T116	C0079189
anucleate platelets	T025	C0005821
NF-κB	T116	C0079904
platelets	T025	C0005821
investigated	T169	C1292732
contribution	T052	C1880177
NF-κB	T116	C0079904
release	T169	C0391871
cytokines	T116	C0079189
serotonin	T109	C0036751
human	T016	C0086418
platelets	T025	C0005821
following	T079	C0332282
TLR2	T116	C0754728
protease activated receptor 1	T116	C4048327
PAR1	T116	C4048327
pattern-recognition receptor	T116	C1564907
innate immune system	T032	C0020969
platelet	T025	C0005821
PAR1	T116	C4048327
activation	T045	C0599177
NF-κB	T116	C0079904
phosphorylation	T044	C0031715
TLR2	T116	C0754728
activation	T043	C1514758
induces	T169	C0205263
phosphorylation process	T044	C0031715
platelet	T025	C0005821
PAR1	T116	C4048327
TLR2	T116	C0754728
activation	T052	C1879547
induces	T169	C0205263
ERK1/2	T044	C2611094
p38	T116	C1120843
AKT	T116	C0164786
phosphorylation	T044	C0031715
platelet	T025	C0005821
TLR2	T116	C0754728
ligand	T103	C0023688
Pam3CSK4	T116	C1698795
significantly increases	T081	C4055637
release	T169	C0391871
sCD62P	T116	C0134835
RANTES	T116	C0072978
sCD40L	T116	C0167627
effect	T080	C1280500
attenuated by	T080	C0332161
incubating	T059	C1439852
platelets	T025	C0005821
blocking	T169	C0332206
anti-TLR2 antibody	T116	C3712029
effect appeared	T080	C2348382
modulation	T082	C0443264
serotonin secretion	T043	C1325900
observed	T169	C1441672
following	T079	C0332282
platelet	T025	C0005821
TLR2	T116	C0754728
activation	T043	C1514758
Platelet	T025	C0005821
release	T169	C0391871
sCD62P	T116	C0134835
RANTES	T116	C0072978
sCD40L	T116	C0167627
following	T079	C0332282
TLR2	T116	C0754728
PAR1	T116	C4048327
presence	T033	C0150312
NF-κB	T116	C0079904
inhibitor	T120	C0243077
Bay11-7082	T109	C0969281
serotonin release	T043	C1979804
following	T079	C0332282
PAR1	T116	C4048327
activation	T043	C1514758
significantly decreased	T081	C4055638
new	T080	C0205314
findings	T169	C2607943
NF-κB	T116	C0079904
platelet	T025	C0005821
immunoregulations	T040	C0678889
functions	T042	C1817756
Optical tweezers	T062	C1883721
studies	T062	C2603343
transcription	T045	C0040649
eukaryotic	T025	C0015161
RNA polymerases	T116	C0035681
Transcription	T045	C0040649
first step	T077	C1261552
expression	T045	C0017262
genetic	T169	C0314603
information	T078	C1533716
carried	T052	C0206243
macromolecular	T104	C1449655
enzymes	T116	C0014442
RNA polymerases	T116	C0035681
Transcription	T045	C0040649
studied	T062	C2603343
myriad	T170	C1881938
experimental	T080	C1517586
techniques	T169	C0449851
ranging	T081	C1514721
studies	T062	C2603343
high-resolution transcript sequencing	T059	C0917793
review	T170	C0282443
single-molecule	T167	C0872367
techniques	T169	C0449851
optical tweezers	T062	C1883721
study	T062	C2603343
transcription	T045	C0040649
dynamics	T070	C3826426
overview	T170	C0814812
results	T169	C1274040
single-molecule	T167	C0872367
transcription	T045	C0040649
field	T077	C1521738
transcription	T045	C0040649
eukaryotic	T025	C0015161
RNA polymerases	T116	C0035681
quantitative	T081	C0392762
models	T075	C0026336
describe	T078	C1552738
biophysics	T091	C0005553
RNA polymerase	T116	C0035681
translocation	T043	C0599893
dynamics	T070	C3826426
Decreased Frequencies	T080	C1561548
Peripheral Blood	T031	C0229664
CD4+CD25+CD127-Foxp3+	T025	C0039198
Patients	T101	C0030705
Graves' Disease	T047	C0018213
Graves' Orbitopathy	T047	C0339143
Enhancing Effect	T080	C1280500
Insulin Growth Factor-1	T116	C0021665
Treg Cells	T025	C0039198
Graves' orbitopathy	T047	C0339143
GO	T047	C0339143
characterized	T052	C1880022
orbital T cell	T025	C0039194
infiltration	T046	C0332448
evaluated	T058	C0220825
regulatory T (Treg) cell	T025	C0039198
fractions	T081	C1264633
induced	T169	C0205263
IGF-1	T116	C0021665
Graves' disease	T047	C0018213
GD	T047	C0018213
GO	T047	C0339143
Peripheral blood mononuclear cells	T025	C1321301
PBMCs	T025	C1321301
patients	T101	C0030705
GD	T047	C0018213
eye manifestations	T184	C0015411
patients	T101	C0030705
active	T169	C0205177
GO	T047	C0339143
patients	T101	C0030705
nodular goiter	T047	C0018023
NG	T047	C0018023
patients	T101	C0030705
GD	T047	C0018213
GO	T047	C0339143
NG	T047	C0018023
subclinical hyperthyroid	UnknownType	C0745142
analyzed	T062	C0936012
expression of Treg cell markers	T059	C0600223
CD4	T116	C0003323
CD25	T116	C0007507
CD127(-)	T116	C0083032
Foxp3	T116	C4282118
T cells	T025	C0039194
respond to	T170	C1553423
IGF-1	T116	C0021665
stimulation	T070	C1948023
patients	T101	C0030705
GD	T047	C0018213
GO	T047	C0339143
lowered percentages	T081	C0439165
CD4(+) Foxp3(+) cells	T025	C0039198
nodular goiter	T047	C0018023
significantly reduced frequencies	T080	C1561548
CD4(+)CD25(+)CD127(-)Foxp3(+)	T025	C0039198
CD4(+)CD25(+)CD127(-) cells	T025	C0039198
observed	T169	C1441672
GD	T047	C0018213
patients	T101	C0030705
nodular goiter	T047	C0018023
patients	T101	C0030705
hyperthyreosis	T047	C0020550
GO	T047	C0339143
active	T169	C0205177
GO	T047	C0339143
percentage	T081	C0439165
CD4(+)CD25(+)CD127(-) cells	T025	C0039198
decreased	T081	C0205216
nodular goiter	T047	C0018023
Stimulation	T070	C1948023
PBMC	T025	C1321301
GO	T047	C0339143
patients	T101	C0030705
IGF-1	T116	C0021665
significant increase of frequency	T080	C1561548
CD4(+) Foxp3(+)	T025	C0039198
CD4(+)CD25(+)CD127(-) Foxp3 cells	T025	C0039198
Decreased frequencies	T080	C1561548
peripheral blood	T031	C0229664
CD4(+)CD25(+)CD127(-)Foxp3(+)	T025	C0039198
patients	T101	C0030705
GD	T047	C0018213
GO	T047	C0339143
useful marker	T201	C0005516
autoimmune process	T046	C0443146
future therapies	T169	C0039798
study	T062	C2603343
Treg	T025	C0039198
enhancing effects	T080	C1280500
IGF-1	T116	C0021665
IGF-1	T116	C0021665
modulating	T082	C0443264
Treg cell	T025	C0039198
action	T052	C3266814
GO	T047	C0339143
γ-Butenolide	T123	C0574031
furanone derivatives	T123	C0574031
soil	T167	C0037592
fungus	T004	C0016832
Aspergillus sclerotiorum	T004	C0446101
PSU-RSPG178	T004	C0446101
Chromatographic separation	T059	C0008550
broth	T130	C2919900
extract	T167	C2828366
soil	T167	C0037592
fungus	T004	C0016832
Aspergillus sclerotiorum	T004	C0446101
PSU-RSPG178	T004	C0446101
isolation	T169	C0205409
γ-butenolide-furanone dimers	T123	C0574031
aspersclerotiorones A-D	T123	C0574031
furanone derivative	T123	C0574031
aspersclerotiorone E	T123	C0574031
γ-butenolide derivatives	T123	C0574031
aspersclerotiorones F	T123	C0574031
G	T123	C0574031
penicillic acid	T109	C0030821
dihydropenicillic acid	T123	C0574031
5,6-dihydro-6-hydroxypenicillic acid	T123	C0574031
6-methoxy-5,6-dihydropenicillic acid	T123	C0574031
coculnol	T123	C0574031
(4R,5R)-4,5-dihydroxy-3-methoxy-5-methylcyclohex-2-en-1-one	T123	C0574031
structures	T170	C0220807
spectroscopic evidence	T059	C0037812
aspersclerotiorones A	T123	C0574031
B	T123	C0574031
structures	T170	C0220807
single-crystal X-ray diffraction crystallography	T059	C0206755
antibacterial activity	T034	C1271650
Staphylococcus aureus	T007	C0038172
Escherichia coli	T007	C0014834
MIC values	T034	C1304747
noncytotoxic	T080	C0205556
African green monkey	T015	C0026438
kidney	T023	C0022646
fibroblast cells	T025	C0016030
E3 Ligase	T116	C0077678
RNF126	T116	C3657865
Ubiquitinates	T044	C1519751
Frataxin	T116	C0387678
Promoting	T052	C0033414
Degradation	T169	C0243125
Identification	T080	C0205396
Therapeutic	T169	C0302350
Target	T169	C1521840
Friedreich Ataxia	T047	C0016719
Friedreich ataxia	T047	C0016719
FRDA	T047	C0016719
genetic	T169	C0314603
neurodegenerative disease	T047	C0524851
expression	T045	C1171362
mitochondrial protein	T116	C0949610
frataxin	T116	C0387678
therapy	T169	C0039798
treat	T061	C0087111
condition	T080	C0348080
residual	T080	C1609982
frataxin	T116	C0387678
severity	T080	C0439793
disease	T047	C0012634
physiological	T169	C0205463
frataxin	T116	C0387678
levels	T080	C0441889
therapeutically	T169	C0302350
relevant	T080	C2347946
Frataxin	T116	C0387678
levels	T080	C0441889
controlled by	T169	C0332298
ubiquitin-proteasome system	T044	C1523807
inhibition	T052	C3463820
frataxin	T116	C0387678
E3 ligase	T116	C0077678
strategy	T062	C0035171
frataxin	T116	C0387678
levels	T080	C0441889
identification	T080	C0205396
RING E3 ligase	T116	C0077678
RNF126	T116	C3657865
enzyme	T116	C0014442
frataxin	T116	C0387678
ubiquitination	T044	C1519751
degradation	T169	C0243125
RNF126	T116	C3657865
interacts	T169	C1704675
frataxin	T116	C0387678
promotes	T052	C0033414
ubiquitination	T044	C1519751
catalytic activity	T169	C1264638
dependent	T080	C0851827
in vivo	T082	C1515655
in vitro	T080	C1533691
RNF126	T116	C3657865
depletion	T169	C0333668
frataxin	T116	C0387678
accumulation	T033	C4055506
cells	T025	C0007634
FRDA	T047	C0016719
patients	T101	C0030705
relevance	T080	C2347946
RNF126	T116	C3657865
therapeutic	T169	C0302350
target	T169	C1521840
Friedreich ataxia	T047	C0016719
Doctors'	T097	C0031831
Competencies	T080	C0008956
Communication	T054	C0009452
Activation	T052	C1879547
Older	T098	C1999167
Patients	T101	C0030705
Promoting	T052	C0033414
Active	T169	C0205177
Aging	T040	C0001811
PRACTA	T058	C3898714
Computer-Based Intervention Study	T058	C3898714
Demographic	T090	C0011298
changes	T169	C0392747
decades	T081	C2981279
promotion of health and disease prevention	UnknownType	C0677273
older	T098	C1999167
patients	T101	C0030705
independence	T078	C0085862
productivity	T081	C0033269
quality of life	T078	C0034380
computer-based educational intervention	T061	C0281163
general practitioners	T097	C0017319
GPs	T097	C0017319
active	T169	C0205177
aging	T040	C0001811
Promoting	T052	C0033414
Aging	T040	C0001811
PRACTA	T058	C3898714
baseline questionnaire	T170	C0034394
implementation	T052	C1708476
intervention	T061	C0184661
follow-up questionnaire	T170	C4054939
administered	T169	C1621583
intervention	T058	C3898714
primary care facilities	T073	C1552443
response rate	T079	C0237629
GPs	T097	C0017319
response rate	T079	C0237629
participate	T169	C0679823
baseline assessment	T062	C0282121
follow-up	T062	C0016441
GPs	T097	C0017319
questionnaires	T170	C0034394
response rate	T079	C0237629
intervention	T061	C0184661
study group	UnknownType	C0681860
GPs	T097	C0017319
e-learning	T065	C0009597
knowledge	T041	C0162340
skills	T055	C0678856
modelling	T170	C3161035
pdf article	T170	C1706852
knowledge	T041	C0162340
control	T096	C0009932
no	T080	C0332288
intervention	T058	C3898714
scores	T081	C0449820
Patients	T101	C0030705
Expectations Scale	T170	C0282574
Communication Scale	T170	C0282574
Attitude Toward Treatment and Health Scale	T170	C0282574
Self-Efficacy Scale	T170	C0282574
GPs	T097	C0017319
e-learning	T065	C0009597
significant	T078	C0750502
perception	T041	C0030971
older	T098	C1999167
patients	T101	C0030705
expectations	T078	C0679138
disease explanation	T170	C0681841
perception	T041	C0030971
motivational	T041	C0026605
older	T098	C1999167
patients	T101	C0030705
treatment	T169	C0039798
health	T078	C0018684
control	T096	C0009932
pdf article groups	UnknownType	C0681860
group	UnknownType	C0681860
level	T080	C0441889
statistical	T090	C0038215
GPs	T097	C0017319
pdf article	T170	C1706852
intervention	T061	C0184661
communication	T054	C0009452
level	T080	C0441889
global scoring	T081	C0449820
level	T080	C0441889
specific behaviors	UnknownType	C0679160
effects of	T080	C1704420
intervention	T061	C0184661
patients	T101	C0030705
GP	T097	C0017319
organizational structure	T170	C0687114
areas	T082	C0205146
conditions	T080	C0348080
pdf article	T170	C1706852
intervention	T061	C0184661
doctors	T097	C0031831
limitations	T169	C0449295
communication skills	T032	C0870313
e-learning	T065	C0009597
effective	T080	C1704419
older	T098	C1999167
patients	T101	C0030705
GPs	T097	C0017319
privately owned facilities	T073	C0033173
assigned	T169	C1516050
patients	T101	C0030705
effects of	T080	C1704420
PRACTA intervention	T058	C3898714
competencies	T080	C0008956
doctors	T097	C0031831
communication	T054	C0009452
older	T098	C1999167
patients	T101	C0030705
consummatory	T054	C0009829
motivational	T041	C0026605
behaviors	T053	C0004927
natural	T169	C0205296
rewards	T041	C0035397
withdrawal	T061	C1707825
morphine	T109	C0026549
anhedonia	T048	C0178417
maladaptive behaviors	T033	C0562443
rewards	T041	C0035397
anhedonia	T048	C0178417
abstinence	T061	C3843422
abused drugs	T131	C0086190
motivational	T041	C0026605
processes	T067	C1522240
drug craving	T033	C0556446
relapse	T067	C0035020
anhedonia	T048	C0178417
drug abstinence	T055	C0237443
anhedonia	T048	C0178417
withdrawal	T061	C1707825
behavioral	T053	C0004927
responses	T032	C0871261
natural	T169	C0205296
rewards	T041	C0035397
weeks	T079	C0439230
withdrawal	T061	C1707825
morphine	T109	C0026549
Male	T032	C0086582
rats	T015	C0034693
morphine	T109	C0026549
paradigm	T062	C0681797
daily	T079	C0332173
saline injection	T061	C0199797
days	T079	C0439228
consummatory	T054	C0009829
motivational	T041	C0026605
behaviors	T053	C0004927
natural	T169	C0205296
rewards	T041	C0035397
sucrose solutions	T109	C0038636
social	T169	C0728831
stimulus	T067	C0234402
male	T032	C0086582
rat	T015	C0034693
sexual	T054	C0036865
stimulus	T067	C0234402
estrous	T040	C0014948
female	T032	C0086287
rat	T015	C0034693
testing conditions	T080	C0449910
morphine	T109	C0026549
withdrawn	T061	C1707825
rats	T015	C0034693
sucrose solution	T109	C0038636
consumption test	T060	C0683443
operant responding	T041	C0009651
sucrose solution	T109	C0038636
progressive ratio (PR) schedule of reinforcement	T062	C0871209
reinforcer	T078	C0178826
foot	T023	C0016504
shock	T061	C0013870
PR-punishment schedule	T062	C0035008
morphine	T109	C0026549
withdrawn	T061	C1707825
rats	T015	C0034693
sucrose solution	T109	C0038636
morphine	T109	C0026549
withdrawn	T061	C1707825
rats	T015	C0034693
motivation	T041	C0026605
sexual	T054	C0036865
stimulus	T067	C0234402
free-approach test	T060	C0683443
behaviors	T053	C0004927
sexual	T054	C0036865
stimulus	T067	C0234402
conflict-based approach test	T060	C0683444
reward	T041	C0035397
aversive stimulus	T169	C1510994
No	T033	C1513916
anhedonia	T048	C0178417
behavior	T053	C0004927
sensitized	T169	C0332324
behaviors	T053	C0004927
natural	T169	C0205296
rewards	T041	C0035397
morphine	T109	C0026549
withdrawal	T061	C1707825
morphine	T109	C0026549
withdrawn	T061	C1707825
rats	T015	C0034693
motivated	T041	C0026605
behaviors	T053	C0004927
rewards	T041	C0035397
sucrose	T109	C0038636
sexual	T054	C0036865
stimulus	T067	C0234402
conflict tests	T060	C0683443
morphine	T109	C0026549
treated	T169	C1522326
rats	T015	C0034693
Extracellular	T026	C0521119
Self-Assembly	T044	C0872376
Functional	T169	C0205245
Tunable Protein Conjugates	T116	C0033684
Bacillus subtilis	T007	C0004595
stably	T080	C0205360
conjugate	T043	C1160466
recombinant proteins	T116	C0034861
engineering	T063	C0017387
multifunctional	T169	C0205245
enzymes	T116	C0014442
protein therapeutics	T121	C0872285
novel	T080	C0205314
biological materials	T122	C0005479
applications	UnknownType	C0869019
in vitro	T080	C1533691
in vivo	T082	C1515655
intracellular	T082	C0178719
protein conjugation	T043	C1160466
extracellular	T026	C0521119
self-assembly	T044	C0872376
protein conjugates	T116	C0033684
purification	T059	C0597301
reducing	T080	C0392756
toxicity	T037	C0600688
burden	T078	C2828008
tunability	T080	C0205556
SpyTag-SpyCatcher system	T059	C0022885
enzymes	T116	C0014442
structural proteins	T116	C0582263
genetically encoded	T045	C0314627
covalently	T044	C1511539
conjugate	T043	C1160466
culture media	T130	C0010454
programmable secretion	T043	C1327616
Bacillus subtilis	T007	C0004595
self-conjugation	T043	C1160466
secreted	T043	C1327616
enzyme	T116	C0014442
XynA	T116	C0149034
increases	T081	C0205217
resilience	T033	C1821534
boiling	T069	C0018851
cellular consortia	T025	C0007634
engineered	T063	C0017387
self-assemble	T044	C0872376
functional	T169	C0205245
protein-protein conjugates	T116	C0033684
novel	T080	C0205314
genetically encoded	T045	C0314627
modular system	T169	C0449913
flexible strategy	T080	C0443220
protein conjugation	T043	C1160466
extracellular	T026	C0521119
self-assembly	T044	C0872376
Vascular smooth muscle cell	T025	C4082861
peroxisome proliferator-activated receptor γ	T116	C0166417
endothelin-1	T116	C0079281
induced	T169	C0205263
oxidative stress	T049	C0242606
inflammation	T046	C0021368
Peroxisome proliferator-activated receptor γ	T116	C0166417
PPARγ	T116	C0166417
agonists	T121	C0243192
reduce	T080	C0392756
blood pressure	T040	C0005823
vascular injury	T037	C0178324
hypertensive	T033	C0857121
rodents	T015	C0035804
Pparγ	T116	C0166417
inactivation	T044	C0314679
vascular smooth muscle cells	T025	C4082861
VSMC	T025	C4082861
enhances	T052	C2349975
vascular injury	T037	C0178324
Transgenic mice	T015	C0025936
overexpressing	T045	C1171362
endothelin (ET)-1	T116	C0079281
endothelium	T024	C0014257
(eET-1)	T116	C0079281
endothelial dysfunction	T047	C0856169
increased	T081	C0205217
oxidative stress	T049	C0242606
inflammation	T046	C0021368
hypothesized	T078	C1512571
inactivation	T044	C0314679
Pparγ gene	T028	C1335238
VSMC	T025	C4082861
smPparγ	T028	C1335238
exaggerate	T080	C0442801
ET-1	T116	C0079281
induced	T169	C0205263
vascular injury	T037	C0178324
eET-1	T116	C0079281
smPparγ	T116	C0166417
eET-1	T116	C0079281
smPparγ	T116	C0166417
mice	T015	C0025929
treated	T033	C0332154
tamoxifen	T109	C0039286
studied	T062	C2603343
SBP	T201	C0871470
higher	T080	C0205250
eET-1	T116	C0079281
unaffected	T077	C2986417
smPparγ	T116	C0166417
inactivation	T044	C0314679
Mesenteric artery	T023	C0025465
vasodilatory	T042	C0042401
responses	T032	C0871261
acetylcholine	T109	C0001041
impaired	T169	C0221099
smPparγ	T116	C0166417
N-Nitro-L-arginine methyl ester	T116	C0083536
abrogated	T169	C3242341
relaxation	T052	C0035028
responses	T032	C0871261
Ednra	T028	C1414262
Ednrb	T028	C1414263
mRNA	T114	C0035696
ratio	T081	C0456603
decreased	T081	C0205216
eET-1	T116	C0079281
smPparγ	T116	C0166417
indicate	T078	C3146298
nitric oxide	T121	C0028128
production	T052	C1883254
enhanced	T052	C2349975
ET-1	T116	C0079281
stimulation	T045	C0599177
endothelin type B receptors	T116	C0218584
Mesenteric artery	T023	C0025465
media	T167	C1705217
lumen	T080	C1301906
greater	T081	C1704243
eET-1	T116	C0079281
smPparγ	T116	C0166417
Mesenteric artery	T023	C0025465
reactive oxygen species	T123	C0162772
increased	T081	C0205217
smPparγ	T116	C0166417
enhanced	T052	C2349975
eET-1	T116	C0079281
smPparγ	T116	C0166417
Perivascular	T082	C0442165
fat monocyte	T025	C0206131
macrophage	T025	C0024432
infiltration	T046	C0332448
higher	T080	C0205250
eET-1	T116	C0079281
smPparγ	T116	C0166417
increased	T081	C0205217
eET-1	T116	C0079281
smPparγ	T116	C0166417
Spleen	T023	C0037993
CD11b cells	T025	C1983879
increased	T081	C0205217
smPparγ	T116	C0166417
enhance	T052	C2349975
eET-1	T116	C0079281
smPparγ	T116	C0166417
Ly-6C monocytes	T025	C0440752
increased	T081	C0205217
eET-1	T116	C0079281
smPparγ	T116	C0166417
eET-1	T116	C0079281
smPparγ	T116	C0166417
Spleen	T023	C0037993
T regulatory lymphocytes	T025	C0039198
increased	T081	C0205217
smPparγ	T116	C0166417
decreased	T081	C0205216
eET-1	T116	C0079281
decreased	T081	C0205216
eET-1	T116	C0079281
smPparγ	T116	C0166417
VSMC	T025	C4082861
Pparγ	T116	C0166417
inactivation	T044	C0314679
exaggerates	T080	C0442801
ET-1	T116	C0079281
induced	T169	C0205263
vascular injury	T037	C0178324
role	T077	C1705810
PPARγ	T116	C0166417
hypertension	T047	C0020538
modulation	T082	C0443264
pro-oxidant	T123	C0162772
proinflammatory	T169	C0333348
pathways	T044	C1704259
ET-1	T116	C0079281
overexpression	T045	C1171362
endothelial	T024	C0014257
function	T169	C0542341
smPparγ	T116	C0166417
mice	T015	C0025929
enhancing	T052	C2349975
nitric oxide	T121	C0028128
stimulation	T045	C0599177
endothelin type B receptors	T116	C0218584
Evaluation	T058	C0220825
Opioid Consumption	T048	C0240602
Distal Radius Fracture	T037	C0435585
Repair Surgery	T061	C0543467
Pain management	T061	C0002766
opioid consumption	T048	C0240602
distal radius fracture	T037	C0435585
DRF	T037	C0435585
open reduction and internal fixation (ORIF)	T061	C0747060
optimize	T061	C1273380
postoperative	T079	C0032790
opioid	T109	C0002772
dosage	T081	C0178602
opioid consumption	T048	C0240602
DRF	T037	C0435585
ORIF	T061	C0747060
prospective study	T062	C0033522
hypothesis	T078	C1512571
opioid consumption	T048	C0240602
increase	T169	C0442805
worsening	T080	C0332271
fracture	T037	C0016658
classification	T185	C0008902
patient demographics	T078	C1548106
patients	T101	C0030705
DRF	T037	C0435585
ORIF	T061	C0747060
6-month period	T079	C0439231
patient demographics	T078	C1548106
fracture type	T080	C0457357
anesthesia type	T185	C1305863
amount	T081	C0178602
type	T080	C0332307
opioid	T109	C0002772
prescribed	T058	C0278329
number	T081	C0237753
pills	T109	C0002772
taken	T077	C1883727
reason	T078	C1550000
stopping	T061	C0850893
adverse events	T046	C0877248
Statistical analysis	T062	C0871424
patients	T101	C0030705
female	T098	C0043210
male	T098	C0025266
patients	T101	C0030705
general anesthesia	T061	C0002915
regional anesthesia	T061	C1304876
peripheral nerve block	T061	C0198807
opioid consumption	T048	C0240602
morphine	T109	C0026549
equivalence	T080	C0205163
postoperative days	T079	C0032790
no significant	T033	C1273937
opioid consumption	T048	C0240602
general	T061	C0002915
regional anesthesia	T061	C1304876
opioid consumption	T048	C0240602
fracture-type	T080	C0457357
AO/OTA [Arbeitsgemeinschaft für Osteosynthesefragen/Orthopaedic Trauma Association] classification	T170	C0559822
class A	T185	C0008902
class B	T185	C0008902
class C	T185	C0008902
Demographic analysis	T062	C0011289
inverse	T080	C0439850
relationship	T080	C0439849
age	T032	C0001779
opioid use	T048	C0240602
opioid consumption	T048	C0240602
self-pay	T033	C3530213
Medicaid	T064	C0025071
patients	T101	C0030705
Opioid consumption	T048	C0240602
DRF	T037	C0435585
ORIF	T061	C0747060
equivalent	T080	C0205163
general	T061	C0002915
regional anesthesia	T061	C1304876
relationship	T080	C0439849
increasing age	T033	C3550265
decreasing	T033	C0442797
opioid consumption	T048	C0240602
Worsening	T080	C0332271
fracture classification	T170	C0559822
self-payment	T033	C3530213
Medicaid payment	T064	C0025071
increasing	T169	C0442808
opioid consumption	T048	C0240602
opioid consumption	T048	C0240602
morphine	T109	C0026549
equivalence	T080	C0205163
pills	T122	C0994475
oxycodone/acetaminophen	T121	C0717368
Surgeons	T097	C0582175
optimizing	T061	C1273380
opioid	T109	C0002772
DRF	T037	C0435585
repair	T061	C0543467
Entrapment	T047	C0917811
posterior femoral cutaneous nerve	T023	C0228931
inferior cluneal branches	T023	C0229962
anatomical basis	T029	C0277809
surgery	T091	C1274039
inferior cluneal neuralgia	T184	C0027796
pudendal nerve	T023	C0228959
surgery	T091	C1274039
patients	T101	C0030705
entrapment	T047	C0917811
adjacent nerve structures	T024	C0027740
inferior cluneal neuralgia	T184	C0027796
collateral branches	T023	C0229962
posterior femoral cutaneous nerve	T023	C0228931
posterior surface of the thigh	T029	C0230422
infragluteal fold	T023	C0229962
skin	T022	C1123023
ischial tuberosity	T023	C0223656
lateral anal region	T029	C0005898
scrotum	T023	C0036471
labium majus	T023	C0227760
perineal branch	T023	C0739940
pathophysiological	T169	C0031847
features	T080	C1521970
cluneal neuralgia	T184	C0027796
surgical technique	T060	C0011918
preliminary results	T078	C1548161
transmuscular approach	T061	C1997294
fat	T023	C0015665
gluteal region	T029	C0282082
Exploration	T061	C1280903
piriformis	T023	C0224429
entrapments	T047	C0917811
posterior femoral cutaneous nerve	T023	C0228931
sciatic nerve	T023	C0036394
Nerve decompression	T061	C0196571
lateral surface	T029	C0230424
ischial tuberosity	T023	C0223656
anatomical finding	T029	C0277809
lateral fibrous	T024	C0225331
expansion	T061	C0196940
ischium	T023	C0223653
nerves	T024	C0027740
vessels	T023	C0005847
posterior femoral cutaneous nerve	T023	C0228931
perineal branches	T023	C0739941
patients	T101	C0030705
expansion	T061	C0196940
decompression	T061	C0196571
nerve trapped	T047	C0917811
expansion	T061	C0196940
Cluneal neuralgia	T184	C0027796
perineal pain	T184	C0240717
pudendal neuralgia	T047	C1997249
Surgery	T091	C1274039
transgluteal approach	T082	C0444462
lateral ischial	T023	C0223653
investigated	T169	C1292732
fibrous	T024	C0225331
expansion	T061	C0196940
retinaculum	T023	C0224996
nerve entrapment	T047	C0917811
Methods	T170	C0025663
Study	T062	C2603343
Autophagy	T043	C0004391
Zebrafish	T013	C0043457
Autophagy	T043	C0004391
cellular self-eating	T043	C0004391
degradation process	T044	C0314674
eukaryotic cell	T025	C0015161
cytoplasm	T026	C0010834
delivered	T169	C1705822
broken down	T080	C0443161
lysosomal compartment	T029	C0521450
elimination	T039	C0221102
cellular constituents	T026	C0243092
macromolecular	T044	C1148560
organellar turnover	T042	C1254358
cellular homeostasis	T043	C2244223
autophagy	T043	C0004391
cellular	T043	C1325880
developmental processes	T040	C0678723
degrading	T044	C0314674
regulatory proteins	T116	C0815047
intracellular	T082	C0178719
pathogens	T001	C0450254
physiological roles	T169	C0205463
pathological	T169	C1521733
autophagy	T043	C0004391
eukaryotic	T204	C0684063
model systems	T075	C0026339
yeast	T004	C0043393
mice	T015	C0026809
animal model	T008	C0599779
autophagy	T043	C0004391
zebrafish	T013	C0043457
Danio rerio	T013	C0043457
analysis	T062	C0936012
biological processes	T038	C3714634
tissue regeneration	T042	C1623047
methods and tools	T169	C0025664
autophagic structures	T026	C0243092
assay	T059	C0005507
autophagic responses	T043	C0007613
vertebrate organism	T010	C0042567
genetic (functional) approaches	T062	C0017395
cellular	T043	C1325880
developmental roles	T040	C0678723
autophagic process	T043	C0004391
Healthcare	T058	C0086388
usage	T169	C0457083
economic impact	T081	C0681024
non-treated	T033	C0332155
obesity	T047	C0028754
Italy	T083	C0022277
findings	T169	C2607943
retrospective	T080	C1514923
administrative	T033	C3845829
clinical database	T170	C1516642
analysis	T062	C0936012
Investigate	T169	C1292732
prevalence	T081	C0683921
obesity	T047	C0028754
Italy	T083	C0022277
resource	T078	C0035201
consumption	T033	C0243095
economic impact	T081	C0681024
Italian	T083	C0022277
national healthcare system	T170	C0282574
NHS	T170	C0282574
Retrospective	T080	C1514923
observational	T062	C1518527
real-life study	T062	C2603343
Data	T078	C1511726
health units	T093	C1708333
Northern	T082	C1709269
Bergamo	T083	C0017446
Lombardy	T083	C0017446
Central	T082	C0205099
Grosseto	T083	C0017446
Tuscany	T083	C0017446
Southern	T082	C1710133
Naples	T083	C0017446
Campania	T083	C0017446
Italy	T083	C0022277
patients	T101	C0030705
aged	T032	C0001779
≥18 years	T079	C0439234
body mass index	T201	C1305855
BMI	T201	C1305855
measurement	T169	C0242485
Information	T078	C1533716
databases	T170	C0242356
primary care data	T078	C1511726
medical prescriptions	T170	C1521941
specialist consultations	T058	C2090905
hospital discharge records	T170	C0743221
Costs	T081	C0010186
associated with	T080	C0332281
data	T078	C1511726
calculated	T052	C1441506
Data	T078	C1511726
time periods	T079	C1948053
1 year	T079	C0439234
BMI	T201	C1305855
measurement	T169	C0242485
Primary	T080	C0205225
estimate	T081	C0750572
health resources	T078	C0018741
consumption	T033	C0243095
economic impact	T081	C0681024
Italian	T083	C0022277
NHS	T170	C0282574
Secondary	T081	C0205436
prevalence	T081	C0683921
characteristics	T080	C1521970
subjects	T098	C0080105
BMI	T201	C1305855
category	T170	C0683312
adult	T100	C0001675
subjects	T098	C0080105
documented BMI	T033	C2724372
measurement	T169	C0242485
Subjects	T098	C0080105
BMI	T201	C1305855
obese	T047	C0028754
prevalence	T081	C0683921
obesity	T047	C0028754
increased	T081	C0205217
age	T032	C0001779
1-year	T079	C0439234
observation	T062	C0302523
period	T079	C1948053
obese	T047	C0028754
subjects	T098	C0080105
treatment	T061	C0087111
obesity	T047	C0028754
longer durations	T079	C0449238
hospitalisation	T058	C0019993
5 days	T079	C0439228
3 days	T079	C0439228
prescription drugs	T121	C0304227
specialised	T077	C1704211
outpatient	T101	C0029921
healthcare	T058	C0086388
mean number	T081	C0392762
associated with	T080	C0332281
greater costs	T081	C0010186
prescription drugs	T121	C0304227
hospital admissions	T058	C0184666
mean annual cost	T081	C0010186
year	T079	C0439234
patient	T101	C0030705
drug prescriptions	T170	C0033081
hospitalisations	T058	C0019993
outpatient care	T058	C0002423
normal weight	T033	C2712185
subjects	T098	C0080105
findings	T169	C2607943
period	T079	C1948053
data	T078	C1511726
follow-up	T058	C1522577
Untreated	T033	C0332155
obesity	T047	C0028754
economic impact	T081	C0681024
Italian	T083	C0022277
healthcare system	T170	C0282574
awareness	T041	C0004448
treat	T061	C0087111
subjects	T098	C0080105
Effects of	T080	C1704420
heat	T070	C0018837
treatment	T169	C1522326
conformation	T082	C0033625
cell growth	T043	C0007595
alpha- lactalbumin	T116	C0002287
beta-lactoglobulin	T116	C0005248
market	T083	C1318228
milk	T168	C2825079
Heat	T070	C0018837
processes	T067	C1522240
low	T080	C0205251
temperature	T081	C0039476
long	T080	C0205166
time	T079	C0040223
LTLT	T068	C3825956
pasteurization	T068	C3825956
ultra-heat treatment (UHT) sterilization	T061	C3179136
market	T083	C1318228
milk	T168	C2825079
shelf life	T070	C4279909
raw milk	T167	C1442323
milk	T168	C2825079
microbial	T001	C0599840
safety	T068	C0036043
effects of	T080	C1704420
heat	T070	C0018837
molecular	T080	C1521991
properties	T080	C0871161
α-lactalbumin	T116	C0002287
α-LA	T116	C0002287
β-lactoglobulin	T116	C0005248
β-LG	T116	C0005248
market	T083	C1318228
milk	T168	C2825079
LTLT-A	T068	C3825956
LTLT-B	T068	C3825956
UHT-I	T061	C3179136
indirect	T080	C0439852
heating	T070	C0018837
UHT-D	T061	C3179136
direct	T080	C1947931
heating	T070	C0018837
molecular conformations	T082	C0026377
circular dichroism spectrum measurement	T059	C0008813
cell growth	T043	C0007595
WST-1 method	T062	C2986858
proteins	T116	C0033684
α-LA	T116	C0002287
market	T083	C1318228
milk	T168	C2825079
no significant	T033	C1273937
structural	T116	C1510464
difference	T080	C1705242
raw milk	T167	C1442323
α-LA	T116	C0002287
α-LA	T116	C0002287
UHT-I	T061	C3179136
inhibited	T080	C0311403
cell growth	T043	C0007595
intestinal	T023	C0021853
epithelial cell line	T025	C0014597
raw milk	T167	C1442323
α-LA	T116	C0002287
β-LG	T116	C0005248
UHT-I	T061	C3179136
change	T169	C0392747
structure	T116	C1510464
did not exhibit	T033	C1513916
cytotoxicity	T049	C0596402
cell viability	T043	C0007620
effects of	T080	C1704420
α-LA	T116	C0002287
β-LG	T116	C0005248
UHT	T061	C3179136
indirect	T080	C0439852
direct	T080	C1947931
findings	T033	C0243095
effect of	T080	C1704420
heat	T070	C0018837
treatment	T169	C1522326
whey proteins	T168	C0078479
investigated	T169	C1292732
Comparison	T052	C1707455
270	T200	C0977876
320 mg I/mL of Iodixanol	T200	C0977877
Image Assessment	T058	C4076410
Renal Arteries	T023	C0035065
Veins	T023	C0042449
Dual-Energy Spectral CT Imaging	T060	C0729619
Late Arterial Phase	T079	C0205390
Influence	T077	C4054723
Renal Function	T042	C0232804
study	T062	C2603343
compare	T052	C1707455
image quality	T080	C0806487
renal arteries	T023	C0035065
veins	T023	C0042449
dual-energy spectral computed tomography (CT) imaging	T060	C0729619
late arterial phase	T079	C0205390
270	T200	C0977876
320 mg I/mL of iodixanol	T200	C0977877
influence	T077	C4054723
renal function	T042	C0232804
patients	T101	C0030705
renal CT angiography	T060	C1637292
270	T200	C0977876
320 mg I/mL of iodixanol	T200	C0977877
dual-energy spectral CT imaging	T060	C0729619
late arterial phase	T079	C0205390
Image quality	T080	C0806487
influence	T077	C4054723
renal function	T042	C0232804
compared	T052	C1707455
CT value	T081	C1522609
signal-to-noise ratio	T081	C2986823
contrast-to-noise ratio	T081	C0456603
score	T081	C0449820
renal vessels	T023	C0580863
incidence	T081	C0021149
contrast-induced nephropathy	T047	C4055183
patients	T101	C0030705
abnormal renal function	T046	C0151746
320 mg I/mL of iodixanol	T200	C0977877
270 mg I/mL of iodixanol	T200	C0977876
renal arteries	T023	C0035065
veins	T023	C0042449
late arterial phase	T079	C0205390
270 mg I/mL of iodixanol	T200	C0977876
dual-energy spectral CT scan	T060	C0177779
renal function	T042	C0232804
magnesium supplementation	T061	C1096534
depression	T048	C0011570
status	T033	C0449437
depressed	T048	C0011570
patients	T101	C0030705
magnesium deficiency	T047	C0024473
randomized	T062	C0034656
double-blind	T062	C0013072
placebo-controlled trial	T062	C1706408
effect	T169	C0728866
magnesium supplementation	T061	C1096534
depression	T048	C0011570
status	T033	C0449437
depressed	T048	C0011570
patients	T101	C0030705
suffering	T033	C0231303
magnesium deficiency	T047	C0024473
Sixty depressed people	T033	C0243095
suffering	T033	C0231303
hypomagnesemia	T033	C0151723
this trial	T062	C0008976
individuals	T098	C0237401
randomly categorized	T062	C0034656
groups	T078	C0441833
tablets of magnesium oxide	T121	C0024477
MG	T121	C0024477
placebo	T122	C1696465
PG	T122	C1696465
Beck Depression Inventory-II	T060	C4273959
serum magnesium was measured	T059	C0202125
MG	T121	C0024477
PG	T122	C1696465
normal level of magnesium	T034	C1442943
changes of serum magnesium	T033	C1826990
groups	T078	C0441833
mean Beck score	T201	C2960571
significantly declined	T081	C4055638
MG	T121	C0024477
more significant	T080	C1299395
PG	T122	C1696465
group	T078	C0441833
PG	T122	C1696465
Daily consumption	UnknownType	C0678263
magnesium oxide tablets	T121	C0024477
depressed	T048	C0011570
patients	T101	C0030705
suffering	T033	C0231303
magnesium deficiency	T047	C0024473
depression	T048	C0011570
status	T033	C0449437
magnesium levels	T034	C1442943
assessment of the magnesium serum	T059	C0202125
deficiency	T047	C0024473
treatment	T061	C0087111
depressed	T048	C0011570
patients	T101	C0030705
influence	T077	C4054723
cognitive load	T081	C0870301
metabolic	T040	C0025519
cost	T081	C0015316
transport	T078	C1554194
overground walking	T056	C0080331
healthy	T080	C3898900
young adults	T100	C0238598
cognitive processing	T041	C0025361
walking	T056	C0080331
increases	T169	C0442805
metabolic	T040	C0025519
cost	T081	C0015316
transport	T078	C1554194
healthy	T080	C3898900
young adults	T100	C0238598
healthy	T080	C3898900
young adults	T100	C0238598
conditions	T080	C0348080
walking	T056	C0080331
self	T078	C0036588
selected	T052	C1707391
speed	T081	C0678536
spontaneous	T169	C0205359
single-task	T052	C0441655
seated	T033	C4042775
resting	T056	C0035253
baseline	T081	C1442488
cognitive	T041	C0009240
task	T052	C0441655
seated	T033	C4042775
cognitive	T041	C0009240
single-task	T052	C0441655
walking	T056	C0080331
simultaneously	T079	C0521115
performing	T169	C0884358
cognitive	T041	C0009240
task	T052	C0441655
dual-task	T052	C0441655
single-task	T052	C0441655
walking	T056	C0080331
speed	T081	C0678536
matched	T080	C1708943
participant's	T098	C0679646
dual-task	T052	C0441655
gait speed	T032	C2009910
matched	T080	C1708943
single-task	T052	C0441655
Rate of oxygen consumption	T081	C1521828
V̇O2	T081	C1521828
conditions	T080	C0348080
Gait speed	T032	C2009910
cost	T081	C0015316
walking	T056	C0080331
Cw	T081	C0015316
oxygen consumed per distance traveled	T201	C0030055
walking	T056	C0080331
conditions	T080	C0348080
Reaction time	T079	C0034746
accuracy	T080	C0443131
responses	T032	C0871261
cognitive	T041	C0009240
task	T052	C0441655
cognitive	T041	C0009240
task	T052	C0441655
conditions	T080	C0348080
Data	T078	C1511726
minute	T079	C0439232
min	T079	C0439232
condition	T080	C0348080
analyzed	T062	C0936012
V̇O2	T081	C1521828
dual-task	T052	C0441655
matched	T080	C1708943
single-task	T052	C0441655
walking	T056	C0080331
conditions	T080	C0348080
V̇O2	T081	C1521828
seated	T033	C4042775
cognitive	T041	C0009240
condition	T080	C0348080
walking	T056	C0080331
conditions	T080	C0348080
Cw	T081	C0015316
matched	T080	C1708943
single-task	T052	C0441655
walking	T056	C0080331
condition	T080	C0348080
dual-task	T052	C0441655
walking	T056	C0080331
condition	T080	C0348080
Cw	T081	C0015316
clinically	T080	C0205210
significant	T078	C0750502
Cognitive processing	T041	C0025361
walking	T056	C0080331
increase	T169	C0442805
energy	T081	C1442080
walking	T056	C0080331
healthy	T080	C3898900
young adults	T100	C0238598
gait speed	T032	C2009910
matched	T080	C1708943
speed	T081	C0678536
min	T079	C0439232
attentional	T041	C0004268
resources	T078	C0035201
increase	T169	C0442805
metabolic	T040	C0025519
costs	T081	C0015316
walking	T056	C0080331
habitual	T079	C0205353
speed	T081	C0678536
Problem-based learning	T065	C0243013
patient	T101	C0030705
patient -simulated videos	T170	C3463807
daily	T079	C0332173
life	T078	C0376558
comprehensive	T080	C1880156
clinical	T080	C0205210
approach	T169	C0205245
problem-based learning	T065	C0243013
tutorials	T170	C0282574
patient	T101	C0030705
patient -simulated videos	T170	C3463807
daily	T079	C0332173
life	T078	C0376558
clinical	T080	C0205210
learning	T041	C0023185
paper-based problem-based learning	T065	C0243013
rate of psychosocial issues	T033	C0243095
recall rate	T033	C0243095
experienced learning	T041	C0023185
groups	T078	C0441833
year	T079	C0439234
students	T098	C0038492
paper-based problem-based learning	T065	C0243013
video	T170	C3463807
video -based problem-based learning	T065	C0243013
patient	T101	C0030705
patient -simulated videos	T170	C3463807
target	T169	C1521840
achievement rates	T033	C0243095
questionnaires	T170	C0034394
Wilcoxon signed-rank test	T170	C0871608
discussion	T054	C2584313
contents	T077	C0456205
diversity	T080	C1880371
Mann-Whitney U test	T081	C0242927
follow-up	T062	C0016441
survey	T170	C0038951
chi-square test	T170	C0008041
students	T098	C0038492
categories	T170	C0683312
video	T170	C3463807
paper	T073	C0030351
non-experienced	T078	C1254370
Video	T170	C3463807
Video -based problem-based learning	T065	C0243013
achievement rates	T033	C0243095
authentic patients	T101	C0030705
comprehensive	T080	C1880156
approach	T169	C0205245
psychosocial aspects	T078	C0243156
sessions	T077	C1883017
No significant differences	T033	C3842396
discussion	T054	C2584313
contents	T077	C0456205
diversity	T080	C1880371
International Classification of Primary Care Second Edition codes and chapter types	T170	C3242518
rate of psychological codes	T033	C0243095
follow-up	T062	C0016441
survey	T170	C0038951
video	T170	C3463807
paper	T073	C0030351
groups	T078	C0441833
non-experienced groups	T078	C0441833
rates	T081	C1521828
video	T170	C3463807
paper	T073	C0030351
video	T170	C3463807
rate	T081	C1521828
paper	T073	C0030351
rate	T081	C1521828
no significant difference	T033	C3842396
Patient	T101	C0030705
Patient -simulated videos	T170	C3463807
daily	T079	C0332173
life	T078	C0376558
patients	T101	C0030705
comprehensive	T080	C1880156
approach	T169	C0205245
fosters	T056	C0242298
memory	T041	C0025260
clinical	T080	C0205210
patient	T101	C0030705
patient -simulated video	T170	C3463807
method	T169	C0449851
clinical	T080	C0205210
problem-based tutorials	T170	C0282574
patient	T101	C0030705
patient -simulated videos	T170	C3463807
symptom	T184	C1457887
teaching materials	T073	C0039402
Forensic characteristics	UnknownType	C0681831
phylogenetic analyses	T062	C1519068
Chinese	T098	C0152035
Yi population	T098	C1257890
X-chromosomal	T026	C0043292
STR	T086	C0598994
loci	T028	C0678933
demographic characteristics	T102	C0683970
genetic polymorphism	T045	C0032529
data	T078	C1511726
Chinese	T098	C0152035
nationalities	T102	C0027473
administrative divisions	T092	C2919030
Chinese mainland	T083	C0008115
genetic research	T062	C0243064
hotspots	T082	C0205146
genetic studies	T062	C2827447
Chinese	T098	C0152035
populations	T098	C1257890
autosomal	T026	C0596142
Y-chromosomal	T026	C0043381
genetic markers	T045	C0017393
forensic characteristics	UnknownType	C0681831
phylogenetic analyses	T062	C1519068
Chinese	T098	C0152035
population	T098	C1257890
Yi ethnicity	T098	C0015031
X-chromosomal	T026	C0043292
genetic markers	T045	C0017393
allele frequencies	T081	C0017270
forensic statistical parameters	T033	C0449381
X-chromosomal	T026	C0043292
short tandem repeat	T086	C0598994
loci	T028	C0678933
DXS7424-DXS101	T028	C0678933
DXS6789-DXS6809	T028	C0678933
DXS7423-DXS10134	T028	C0678933
DXS10103-HPRTB-DXS10101	T028	C0678933
DXS10159-DXS10162-DXS10164	T028	C0678933
DXS10148-DXS10135-DXS8378	T028	C0678933
DXS7132-DXS10079-DXS10074-DXS10075	T028	C0678933
Chinese	T098	C0152035
Yi individuals	T098	C0237401
X-chromosomal	T026	C0043292
short tandem repeat	T086	C0598994
STR	T086	C0598994
loci	T028	C0678933
females	T098	C0043210
alleles	T028	C0002085
identified	T080	C0205396
allele frequencies	T081	C0017270
PE	T081	C0392762
PDF	T081	C0392762
PDM	T081	C0392762
MECKrüger	T081	C0392762
MECKishida	T081	C0392762
MECDesmarais	T081	C0392762
MECDesmarais Duo	T081	C0392762
findings	T033	C0243095
panel	T078	C0441833
X-STR	T086	C0598994
loci	T028	C0678933
polymorphic	T080	C1882417
informative	T080	C2986490
Yi ethnic population	T098	C0015031
tool	T073	C0336791
forensic complex kinship identification	T078	C0870773
Population differentiation analyses	T062	C0242481
populations	T098	C1257890
differences	T080	C1705242
genetic structure	T028	C1136352
Yi ethnicity	T098	C0015031
Chinese	T098	C0152035
Uyghur	T098	C1257890
Kazakh	T098	C1257890
genetic homogeneity	T080	C1881065
ethno-origin	T098	C0015031
geographic origin populations	T081	C0032659
Loss	T081	C1517945
Snf5	T028	C0812273
Induces	T169	C0205263
Formation	T169	C1522492
Aberrant	T080	C0443127
SWI/SNF Complex	T026	C1167093
SWI/SNF	T026	C1167093
chromatin remodeling complex	T026	C1167087
yeast	T004	C0043393
human	T016	C0086418
aberrant	T080	C0443127
SWI/SNF complexes	T026	C1167093
human	T016	C0086418
disease	T047	C0012634
Snf5/SMARCB1/INI1	T028	C0812273
subunit	T081	C1711351
SWI/SNF	T026	C1167093
tumor suppressor	T028	C0079427
lost	T169	C0745777
pediatric	T080	C1521725
rhabdoid cancers	T191	C0206743
effects of	T080	C1704420
Snf5	T028	C0812273
loss	T081	C1517945
composition	T033	C0243095
nucleosome binding	T045	C1623159
yeast	T004	C0043393
SWI/SNF	T026	C1167093
Snf5	T028	C0812273
subunit	T081	C1711351
crosslinking-mass spectrometry	T059	C0037813
CX-MS	T059	C0037813
subunit	T081	C1711351
deletion analysis	T059	C1294202
ATPase domain	T087	C1510701
Snf2	T116	C0246454
submodule	T044	C1959595
Snf5	T028	C0812273
Swp82	T028	C0017337
Taf14	T028	C0017337
Snf5	T028	C0812273
binding	T045	C1623159
Snf2	T116	C0246454
ATPase domain	T087	C1510701
nucleosomal DNA	T045	C1623161
SWI/SNF	T026	C1167093
Snf5	T028	C0812273
SWI/SNF	T026	C1167093
acidic transcription factors	T116	C0040648
RNA-seq analysis	T059	C0162803
Snf5	T028	C0812273
in vivo	T082	C1515655
SWI/SNF	T026	C1167093
regulation of gene expression	T045	C0017263
loss	T081	C1517945
SNF5	T028	C0812273
structure	T082	C0678594
function	T169	C0542341
SWI/SNF	T026	C1167093
presence	T033	C0150312
Parkinson's disease	T047	C0030567
low-frequency	T079	C0205213
fluctuations	T184	C0231239
BOLD signals	T060	C1705491
Parkinson's disease	T047	C0030567
PD	T047	C0030567
chronic	T079	C0205191
progressive	T169	C0205329
degenerative	T169	C1880269
neurological disorder	T047	C0027765
characterized	T052	C1880022
degeneration	T169	C1880269
dopamine neurons	T025	C1512035
substantia nigra	T023	C0038590
formation	T169	C1522492
intracellular	T082	C0178719
Lewy inclusion bodies	T026	C0085200
Resting-state functional magnetic resonance imaging	T060	C4288291
RS-fMRI	T060	C4288291
evidence	T078	C3887511
metabolic	T169	C0311400
patterns	T082	C0449774
individuals	T098	C0237401
PD	T047	C0030567
purpose	T169	C1285529
study	T062	C2603343
presence	T033	C0150312
PD	T047	C0030567
predicted	T078	C0681842
fluctuations	T184	C0231239
blood oxygenation level dependent signal	T042	C1655730
RS-fMRI	T060	C4288291
amplitude	T082	C2346753
low-frequency	T079	C0205213
fluctuation	T184	C0231239
ALFF	T184	C0231239
ALFF	T184	C0231239
fALFF	T184	C0231239
patients	T101	C0030705
PD	T047	C0030567
age	T032	C0001779
sex	T032	C1522384
healthy controls	T080	C2986479
healthy controls	T080	C2986479
individuals	T098	C0237401
PD	T047	C0030567
ALFFs	T184	C0231239
bilateral	T082	C0238767
lingual gyrus	T023	C0152308
left putamen	T023	C2334169
fALFF	T184	C0231239
right cerebellum posterior lobe	T029	C2953249
Support vector machines	T081	C2699740
SVMs	T081	C2699740
pattern recognition	T041	C1518918
method	T170	C0025663
predictions	T078	C0681842
individual	T098	C0237401
level	T080	C0441889
individuals	T098	C0237401
PD	T047	C0030567
healthy controls	T080	C2986479
ALFF	T184	C0231239
fALFF	T184	C0231239
cross-validation method	T062	C0681935
analyze	T062	C0936012
sample	T167	C0370003
participants	T098	C0679646
PD	T047	C0030567
controls	T096	C0009932
sensitivity	T080	C2349185
specificity	T081	C0037791
findings	T169	C2607943
SVM	T081	C2699740
neuroimaging	T060	C0679575
clinical	T080	C0205210
PD	T047	C0030567
individual	T098	C0237401
level	T080	C0441889
RS-fMRI	T060	C4288291
development	T169	C1527148
biomarker	T201	C0005516
evaluation	T058	C0220825
PD	T047	C0030567
Methylation	T044	C0376452
dynamics	T070	C3826426
folliculogenesis	T042	C1160267
early	T079	C1279919
embryo development	T042	C0013936
sheep	T015	C0036945
Genome	T028	C0017428
DNA methylation	T044	C0376452
mammalian	T015	C0024660
gametogenesis	T042	C0017001
early	T079	C1279919
embryogenesis	T042	C0013936
Post	T079	C0687676
fertilization	T040	C0015914
demethylation	T045	C2755352
paternal	T080	C0337493
maternal	T033	C1858460
genomes	T028	C0017428
mammals	T015	C0024660
sheep	T015	C0036945
methylation	T044	C0025723
pronucleus	T026	C1167158
Post	T079	C0687676
fertilization	T040	C0015914
methylating	T116	C0014442
demethylating enzymes	T116	C0014442
oocyte growth	T043	C1155900
re-methylation	T044	C0376452
oocyte	T025	C0029045
oocyte	T025	C0029045
reproduction technologies	T061	C0035157
environmental changes	T033	C4060636
methylation	T044	C0025723
dynamics	T070	C3826426
folliculogenesis	T042	C1160267
early	T079	C1279919
embryo development	T042	C0013936
sheep	T015	C0036945
DNA methylation	T044	C0376452
hydroxymethylation	T045	C3830412
immunofluorescence	T059	C0016318
expression	T045	C1171362
enzymes	T116	C0014442
DNA methyltransferases	T116	C0012873
DNMTs	T116	C0012873
ten-eleven translocation (TET) proteins	T116	C0033684
methyl-CpG-binding domain	T087	C4277657
MBD	T087	C4277657
proteins	T116	C0033684
hydroxymethylation	T045	C3830412
oocyte growth	T043	C1155900
methylation	T044	C0376452
hydroxymethylation	T045	C3830412
parental pronuclei	T026	C1167158
male pronucleus	T026	C1622926
demethylation	T045	C2755352
sheep	T015	C0036945
gene	T028	C0017337
dynamics	T070	C3826426
methylating	T116	C0014442
demethylating enzymes	T116	C0014442
oocyte growth	T043	C1155900
expression	T045	C1171362
developmental	T080	C0458003
competence	T080	C0086035
oocyte	T025	C0029045
methylation	T044	C0025723
dynamics	T070	C3826426
folliculogenesis	T042	C1160267
early	T079	C1279919
embryo development	T042	C0013936
early	T079	C1279919
embryo	T018	C0013935
epigenome	T028	C0017428
Network	T169	C1882071
analysis	T062	C0936012
reveals	T080	C0443289
Xylella fastidiosa	T007	C0995982
Europe	T083	C0015176
insect vector	T204	C0021573
bacterium	T007	C0004611
Xylella fastidiosa	T007	C0995982
olive trees	T002	C0996956
Southern Italy	T083	C0022277
olive quick decline syndrome	T047	C0012634
disease	T047	C0012634
Italy's	T083	C0022277
olive oil	T109	C0069449
region	T083	C0017446
epidemiology	T062	C0002783
outbreak	T067	C0012652
X. fastidiosa	T007	C0995982
hosts	T001	C1167395
vectors	T204	C0021573
Europe	T083	C0015176
humans	T016	C0086418
dispersal	T080	C0332261
unknown	T080	C0439673
knowledge	T170	C0376554
gaps	T082	C3887622
management strategies	T057	C1273870
vector control	T057	C0031249
areas	UnknownType	C0681784
destruction	T052	C1948029
infected plants	T002	C0032098
healthy	T080	C3898900
eradicate	T052	C1883720
halt	T079	C2746065
spreading	T080	C0332261
pest	T047	C0032064
epidemiological	T169	C0014508
uncertainties	T033	C0087130
olive	T002	C0996956
olive orchards	UnknownType	C0681784
Southern Italy	T083	C0022277
eradicating	T052	C1883720
X. fastidiosa	T007	C0995982
region	T083	C0017446
results	T169	C1274040
Southern Italy	T083	C0022277
reservoir	T083	C0442537
X. fastidiosa	T007	C0995982
management strategies	T057	C1273870
prevalence	T081	C0220900
X. fastidiosa	T007	C0995982
region	T083	C0017446
vector control	T057	C0031249
lest	T169	C1292733
pathogen	T001	C0450254
southern France	T083	C0016674
island of Mallorca	T083	C0454825
Spain	T083	C0037747
spreading	T080	C0332261
Italy	T083	C0022277
Europe	T083	C0015176
biomarkers	T201	C0005516
patients	T101	C0030705
idiopathic	T169	C0332240
acute anterior uveitis	T047	C0701807
neutrophil	T025	C0027950
lymphocyte	T025	C0024264
ratio	T081	C0456603
platelet	T025	C0005821
lymphocyte	T025	C0024264
ratio	T081	C0456603
assess	T052	C1516048
levels	T080	C0441889
neutrophil	T025	C0027950
lymphocyte	T025	C0024264
ratio	T081	C0456603
N	T025	C0027950
L	T025	C0024264
platelet	T025	C0005821
lymphocyte	T025	C0024264
ratio	T081	C0456603
P	T025	C0005821
L	T025	C0024264
patients	T101	C0030705
idiopathic	T169	C0332240
acute anterior uveitis	T047	C0701807
AAU	T047	C0701807
compare	T052	C1707455
healthy controls	T080	C2986479
male	T098	C0025266
patients	T101	C0030705
idiopathic	T169	C0332240
AAU	T047	C0701807
male	T098	C0025266
healthy	T080	C3898900
subjects	T098	C2349001
retrospective study	T062	C0035363
Complete	T080	C0205197
ophthalmological examination	T061	C0200149
blood count measurements	T059	C1879889
results	T033	C0683954
subjects	T098	C2349001
evaluated	T058	C0220825
significant	T078	C0750502
N	T025	C0027950
L	T025	C0024264
P	T025	C0005821
L	T025	C0024264
idiopathic	T169	C0332240
AAU	T047	C0701807
control groups	T096	C0009932
correlation analysis	T062	C0010101
significant	T078	C0750502
correlation	T080	C1707520
C-reactive protein	T116	C0006560
CRP	T116	C0006560
N	T025	C0027950
L	T025	C0024264
study	T062	C0008972
evidence of	T169	C0332120
N	T025	C0027950
L	T025	C0024264
P	T025	C0005821
L	T025	C0024264
useful	T080	C3827682
biomarkers	T201	C0005516
patients	T101	C0030705
idiopathic	T169	C0332240
AAU	T047	C0701807
N	T025	C0027950
L	T025	C0024264
correlated	T080	C1707520
CRP	T116	C0006560
useful	T080	C3827682
biomarker	T201	C0005516
prognosis	T058	C0033325
idiopathic	T169	C0332240
AAU	T047	C0701807
Comparison	T052	C1707455
magnetic resonance imaging	T060	C0024485
B-mode ultrasound	T060	C1302166
detecting	T033	C0442726
estimating	T081	C0750572
extent	T082	C0439792
human	T016	C0086418
carotid atherosclerosis	T047	C0577631
MRI studies	T060	C3515983
carotid plaques	T020	C0751633
ultrasound	T060	C1302166
find	T033	C0243095
plaques	T033	C0332461
imaged	T170	C1704254
MRI	T060	C0024485
performance	T052	C1882330
plaque	T033	C0332461
detection	T033	C0442726
compared	T052	C1707455
modalities	T169	C1275506
study	T062	C2603343
compare	T052	C1707455
performance	T052	C1882330
MRI	T060	C0024485
ultrasound	T060	C1302166
detecting	T033	C0442726
carotid artery plaques	T020	C0751633
measuring	T080	C0444706
extent	T082	C0439792
atherosclerosis	T047	C0004153
Subjects	T096	C0681850
plaque	T033	C0332461
height	T081	C0392762
ultrasound	T060	C1302166
imaged	T170	C1704254
MRI	T060	C0024485
number	T081	C0237753
plaques	T033	C0332461
height	T081	C0392762
measured	T080	C0444706
modalities	T169	C1275506
plaque	T033	C0332461
area	T082	C0205146
volume	T081	C0449468
analysed	T062	C0936012
ultrasound	T060	C1302166
MRI	T060	C0024485
Thirty-eight	T081	C0392762
subjects	T096	C0681850
included	T169	C0332257
MRI	T060	C0024485
detected	T033	C0442726
plaques	T033	C0332461
carotid arteries	T023	C0007272
plaque	T033	C0332461
height	T081	C0392762
ultrasound	T060	C1302166
carotid arteries	T023	C0007272
plaque	T033	C0332461
MRI	T060	C0024485
detected	T033	C0442726
plaques	T033	C0332461
height	T081	C0392762
plaque	T033	C0332461
height	T081	C0392762
measured	T080	C0444706
techniques	T169	C0449851
correlated	T080	C1707520
Ultrasound	T060	C1302166
plaque	T033	C0332461
height	T081	C0392762
plaque	T033	C0332461
area	T082	C0205146
correlated	T080	C1707520
similarly	T080	C2348205
MRI	T060	C0024485
plaque	T033	C0332461
volume	T081	C0449468
MRI	T060	C0024485
similar	T080	C2348205
sensitivity	T081	C1511883
ultrasound	T060	C1302166
finding	T033	C0243095
carotid artery plaques	T020	C0751633
higher	T080	C0205250
smaller	T080	C0547044
plaques	T033	C0332461
MRI	T060	C0024485
detects	T033	C0442726
fewer	T081	C0205388
plaques	T033	C0332461
Multiple carotid plaques	T020	C0751633
ultrasound	T060	C1302166
anatomy	T080	C1384516
single plaque	T033	C0332461
Plaque	T033	C0332461
height	T081	C0392762
ultrasound	T060	C1302166
plaque	T033	C0332461
height	T081	C0392762
MRI	T060	C0024485
correlates	T080	C1707520
plaque	T033	C0332461
volume	T081	C0449468
MRI	T060	C0024485
plaque	T033	C0332461
burden	T078	C2828008
Open-Cell Scaffolds	T026	C0243092
Sea Urchin	T204	C0036488
Spines	T122	C0005479
Material	T167	C0520510
Properties	T080	C0871161
Bone Defect Repair	T061	C0185364
Sea urchin	T204	C0036488
spines	T122	C0005479
Heterocentrotus mammillatus	T204	C1003462
open-cell structure	T026	C0243092
human	T016	C0086418
trabecular bone	T024	C0222660
mechanical property	T080	C0871161
compressive strength	T081	C0376507
suitable	T080	C3900053
machining	T052	C0441655
shape	T080	C0348078
potential	T080	C3245505
applications	T169	C0205245
bone defect repair	T061	C0185364
Finite element analyses	T170	C0600552
stress	T033	C0038435
concentrates	T052	C2003864
dense	T080	C0439794
growth rings	T042	C0971859
dissipates	T082	C0439742
structures of the stereoms	T017	C0700276
mesostructures	T082	C0678594
important	T080	C3898777
strength	T080	C0205556
weight	T081	C0043100
ratios	T081	C0456603
fracture	T037	C0016658
strength	T080	C0205556
magnesium	T123	C0024467
substituted tricalcium phosphate	T122	C0106141
(β-TCMP) scaffolds	T122	C0005479
hydrothermal	T067	C1254366
conversion	T169	C0439836
urchin	T204	C0036488
spines	T122	C0005479
comparable	T052	C1707455
human	T016	C0086418
trabecular bone	T024	C0222660
bone	T023	C0262950
forms	T169	C1522492
surfaces	T082	C0205148
β-TCMP scaffolds	T122	C0005479
implantation	T061	C0021107
rabbit	T015	C3887509
femoral defects	T037	C0015802
month	T079	C0439231
grows	T042	C0971859
open-cell spaces	T030	C1179886
postoperation	T079	C1882428
month	T079	C0439231
tight interface	T044	C0920352
scaffold	T122	C0005479
regenerative bone tissue	T042	C0005972
Fusion	T061	C1293131
beagle	T015	C0324306
lumbar facet joints	T030	C0507372
Ti-6Al-4V cage	T197	C0076732
β-TCMP scaffold	T122	C0005479
completed	T080	C0205197
months	T079	C0439231
biodegradation	T070	C0005482
β-TCMP scaffold	T122	C0005479
completely	T080	C0205197
degraded	T070	C0005482
replaced by	T169	C1299987
formed	T169	C0205431
bone	T023	C0262950
months	T079	C0439231
implantation	T061	C0021107
sea urchin	T204	C0036488
spines	T122	C0005479
machining	T052	C0441655
shape	T080	C0348078
biodegradable	T070	C0005482
artificial grafts	T122	C0440261
bone defect repair	T061	C0185364
Melatonin	T109	C0025219
nitric oxide	T121	C0028128
regulate	T040	C3269637
sunflower	T002	C0947381
seedling growth	T040	C3156975
salt stress	T043	C1154956
expression	T045	C1171362
Cu/Zn SOD	T116	C0010461
Mn SOD	T116	C0024708
Salinity results	T043	C1154956
significant reduction	T080	C0392756
sunflower	T002	C0947381
Helianthus annuus L.	T002	C0947381
seedling growth	T040	C3156975
reactive oxygen species	T123	C0162772
ROS	T123	C0162772
melatonin	T109	C0025219
antioxidant	T121	C0003402
nitric oxide	T121	C0028128
NO	T121	C0028128
NaCl-stress	T043	C1154956
signaling molecule	T123	C1519315
seedling	T002	C0242437
cotyledons	T002	C0242769
Exogenous	T169	C0205228
melatonin	T109	C0025219
NaCl	T121	C0037494
inhibit	T052	C3463820
seedling growth	T040	C3156975
NO	T121	C0028128
potential superoxide anion	T196	C0038836
O2(•-)	T196	C0038836
peroxynitrite anion	T123	C0136157
ONOO(-)	T123	C0136157
tyrosine-nitration	T044	C4050156
proteins	T116	C0033684
spatial localization	T169	C0475264
activity of superoxide dismutase	T044	C1151619
SOD	T116	C0038838
isoforms	T116	C0597298
NO	T121	C0028128
melatonin	T109	C0025219
seedling	T002	C0242437
cotyledons	T002	C0242769
long-distance signaling response	T044	C1514991
Modulation of superoxide anion	T040	C2246284
peroxynitrite anion	T123	C0136157
melatonin	T109	C0025219
ROS	T123	C0162772
reactive nitrogen species	T104	C0969698
melatonin	T109	C0025219
NO	T121	C0028128
seedling growth	T040	C3156975
salt stress accompanying	T043	C1154956
SOD	T116	C0038838
isoforms	T116	C0597298
Cu/Zn SOD	T116	C0010461
Mn SOD	T116	C0024708
Physiological	T169	C0205463
Regulation	T038	C1327622
Aquaporins	T116	C0599635
Teleost	T013	C0599050
Germ Cells	T025	C0017471
germ cells	T025	C0017471
gametes	T025	C2718310
oviparous	T042	C1568405
teleosts	T013	C0599050
osmoregulatory	T043	C1510659
organs	T023	C0178784
juveniles	T100	C3146221
adults	T100	C0001675
development	T039	C0243107
spawning	T032	C2826216
osmotic	T169	C0311417
challenges	T033	C0033213
external	T082	C0205101
aquatic environment	T067	C0563034
transmembrane water channels	T116	C0599635
aquaporins	T116	C0599635
mitigate	T067	C1553901
osmotic	T070	C3661513
oxidative stress	T049	C0242606
problems	T033	C0033213
developing	T039	C0243107
oocytes	T025	C0029045
embryos	T018	C0013935
spermatozoa	T025	C0037868
diversity	T080	C1880371
aquaporin	T116	C0599635
teleosts	T013	C0599050
molecular regulation	T044	C1817179
aquaporins	T116	C0599635
oogenesis	T042	C0029047
spermatogenesis	T043	C0037864
channels	T116	C0599635
egg	T025	C0029974
buoyancy	T039	C1622066
activation	T052	C1879547
detoxification	T061	C0150543
spermatozoa	T025	C0037868
marine	T083	C0036493
environment	T082	C0014406
Caribbean	T083	C0206155
massive corals	T204	C0324034
not recovering from	T080	C0521109
thermal stress	T067	C0871732
events	T051	C0441471
Massive coral	T204	C0324034
bleaching	T070	C1254365
events	T051	C0441471
sea	T083	C0036493
surface	T082	C0205148
temperatures	T081	C0039476
frequent	T079	C0332183
severe	T080	C0205082
climate change	T070	C2718051
Monitoring	T062	C0302523
colony	T096	C0596092
recovery	T052	C0237820
bleaching	T070	C1254365
multiyear time frames	T079	C0332168
coral	T204	C0324034
community	T096	C0009462
changes	T169	C0392747
multiyear studies	T062	C2603343
long-term	T079	C0443252
outcomes	T169	C1274040
coral	T204	C1063194
colonies	T096	C0596092
acute bleaching	T070	C1254365
events	T051	C0441471
colony	T096	C0596092
pigmentation	T032	C0031911
size	T082	C0456389
bleached	T078	C0441833
unbleached groups	T078	C0441833
reef-building scleractinian	T204	C0997908
corals	T204	C0324034
Orbicella franksi	T204	C1013977
Siderastrea siderea	T204	C1063194
Stephanocoenia michelini	T204	C1062911
Bocas del Toro	UnknownType	C0681784
Panama	T083	C0030266
bleaching	T070	C1254365
event	T051	C0441471
monitored	T062	C0302523
pigmentation	T032	C0031911
status	T080	C0449438
live tissue	T024	C0040300
colony	T096	C0596092
size	T082	C0456389
years	T079	C0439234
Corals	T204	C0324034
bleached	T070	C1254365
colony	T096	C0596092
groups	T078	C0441833
live tissue	T024	C0040300
loss	T081	C1517945
bleached	T070	C1254365
corals	T204	C0324034
species	T185	C1705920
bleaching	T070	C1254365
live tissue	T024	C0040300
losses	T081	C1517945
colony	T096	C0596092
months	T079	C0439231
postbleaching	T079	C1254367
O. franksi	T204	C1013977
S. michelini	T204	C1062911
S. siderea	T204	C1063194
species	T185	C1705920
O. franksi	T204	C1013977
S. michelini	T204	C1062911
positive	T033	C1446409
growth	T040	C0018270
thermal stress	T067	C0871732
event	T051	C0441471
event	T051	C0441471
species	T185	C1705920
lost	T169	C0745777
tissue	T024	C0040300
colony	T096	C0596092
species	T185	C1705920
groups	T078	C0441833
groups	T078	C0441833
bleached	T070	C1254365
acclimative response	T040	C0237446
bleached	T070	C1254365
corals	T204	C0324034
groups	T078	C0441833
tissue	T024	C0040300
loss	T081	C1517945
Caribbean	T083	C0206155
reef-building corals	T204	C0324034
tissue	T024	C0040300
loss	T081	C1517945
benthic coverage	T082	C1254362
thermal stress	T067	C0871732
region	T083	C0017446
bleaching	T070	C1254365
acclimation	T040	C0237446
Preparation	T052	C1521827
characterization	T052	C1880022
gastrointestinal	T082	C0521362
wafer	T122	C0991560
formulations	T073	C1707824
active pharmaceutical ingredients	T121	C1254351
API	T121	C1254351
variable	T080	C0439828
bioavailability	T081	C0005508
oral administration	T061	C0001563
overcome	T052	C2983310
mucoadhesive dosage forms	T122	C0013058
gastrointestinal	T082	C0521362
wafers	T122	C0991560
currently	T079	C0521116
unsolved	T077	C1710576
control	T080	C0243148
adhesion	T070	C0175633
wafer	T122	C0991560
intestinal mucus	T031	C0026727
combination	T080	C0205195
gastrointestinal	T082	C0521362
wafers	T122	C0991560
expanding systems	T169	C0205245
combination	T080	C0205195
thin and elastic wafers	T122	C0991560
characterized	T052	C1880022
unidirectional drug release	T070	C3850077
study	T062	C2603343
gastrointestinal	T082	C0521362
twolayered wafers	T122	C0991560
water-insoluble backing layer	T080	C0205556
drug-loaded	T081	C0392762
mucoadhesive layer	T080	C0205556
casting solvent technique	T169	C0449851
backing layer	T080	C0205556
Ethocel™ Standard 10 Premium	T121	C1254351
mucoadhesive layer	T080	C0205556
mixture	T167	C0439962
Methocel™ E15 Premium LV	T109	C3886467
polyvinyl alcohol	T122	C0032623
Macrogol 400	T109	C4076208
wafers	T122	C0991560
characterized	T052	C1880022
appearance	T080	C0700364
mechanical properties	T080	C0205556
dissolution profiles	T070	C3850077
influence	T077	C4054723
backing layer	T080	C0205556
thickness	T080	C1280412
drug transfer	T052	C0441655
unidirectional drug release	T070	C3850077
wafers	T122	C0991560
backing layer	T080	C0205556
thickness	T080	C1280412
500μg Ethocel	T109	C0059756
adequate	T080	C0205411
mechanical properties	T080	C0205556
drug transfer	T052	C0441655
unidirectional drug release	T070	C3850077
Discovery	T052	C1880355
<i>Neopanorpa chillcotti</i> Byers	T204	C4005338
Mecoptera	T204	C1001487
Panorpidae	T204	C1015340
Tibet	T083	C0040182
China	T083	C0008115
generic status	T078	C1254370
Neopanorpa chillcotti Byers	T204	C4005338
Kathmandu	UnknownType	C0681784
Nepal	T083	C0027689
Gyirong	UnknownType	C0681784
Tibet	T083	C0040182
China	T083	C0008115
new material	T167	C0439861
China	T083	C0008115
Nepal	T083	C0027689
generic status	T078	C1254370
species	T185	C1705920
discussed	T054	C2584313
Passive case detection	T062	C4288441
malaria	T047	C0024530
Ratanakiri Province	UnknownType	C0681784
Cambodia	UnknownType	C0681784
detect	T033	C0442726
villages	T083	C0562518
at higher risk	T033	C3843761
malaria	T047	C0024530
Cambodia	UnknownType	C0681784
reduced	T080	C0392756
malaria	T047	C0024530
incidence	T081	C0021149
target	T169	C1521840
Millennium Development Goal 6	T170	C0018017
Cambodian	UnknownType	C0681784
Government	T092	C0018104
aims	T078	C1947946
eliminate	T080	C0849355
malaria	T047	C0024530
country's	T083	C0454664
malaria	T047	C0024530
incidence	T081	C0021149
highly	T080	C0205250
variable	T080	C0439828
provincial	UnknownType	C0681784
level	T080	C0441889
village	T083	C0562518
level	T080	C0441889
study	T062	C2603343
passive case detection	T062	C4288441
PCD	T062	C4288441
village	T083	C0562518
level	T080	C0441889
Ratanakiri Province	UnknownType	C0681784
incidence	T081	C0021149
trends	T079	C1521798
identify	T080	C0205396
high-risk areas of	T033	C0332167
malaria	T047	C0024530
primarily	T080	C0205225
targeted	T169	C1521840
malaria	T047	C0024530
elimination	T080	C0849355
Cambodian	UnknownType	C0681784
malaria	T047	C0024530
programme	T170	C0376691
Malaria Information System	T170	C0021428
MIS	T170	C0021428
malaria	T047	C0024530
information	T078	C1533716
village	T083	C0562518
level	T080	C0441889
PCD	T062	C4288441
village	T083	C0562518
malaria workers	T097	C0018724
health facilities	T073	C0018704
MIS	T170	C0021428
data	T078	C1511726
Ratanakiri Province	UnknownType	C0681784
calculate	T052	C1441506
annual	T079	C0332181
incidence rates	T081	C1708485
Plasmodium species	T204	C0032148
province	UnknownType	C0681784
commune	T098	C0598781
levels	T080	C0441889
estimating	T081	C0750572
trend	T079	C1521798
provincial	UnknownType	C0681784
level	T080	C0441889
villages	T083	C0562518
reporting	T058	C0700287
year	T079	C0439234
communal	T096	C0009462
incidences	T081	C0021149
cases	T169	C0868928
per	T080	C3887962
village	T083	C0562518
map	T073	C0024779
Plasmodium species	T204	C0032148
per year	T079	C0439508
Analysis of spatial clustering	UnknownType	C0814928
village	T083	C0562518
malaria	T047	C0024530
cases	T169	C0868928
Plasmodium species	T204	C0032148
performed	T169	C0884358
year	T079	C0439234
malaria	T047	C0024530
annual	T079	C0332181
incidence rates	T081	C1708485
inhabitants	T101	C0030705
decreased	T080	C0392756
Falciparum	T204	C0032150
incidence	T081	C0021149
decreased	T080	C0392756
compared	T052	C1707455
CI	T081	C0009667
rapidly	T080	C0456962
vivax	T204	C0032154
incidence	T081	C0021149
compared	T052	C1707455
CI	T081	C0009667
significant	T078	C0750502
spatial clusters	T081	C0012641
year	T079	C0439234
Big clusters	T081	C0012641
extend	T082	C0439792
Cambodian-Vietnamese border	UnknownType	C0681784
Sesan River	T070	C0337050
clusters	T081	C0012641
years	T079	C0439234
villages	T083	C0562518
year	T079	C0439234
shrunk	T081	C0547047
progressively	T169	C0205329
split	T169	C1534709
clusters	T081	C0012641
decline	T067	C0868945
malaria	T047	C0024530
burden	T078	C2828008
intensive	T169	C0521110
malaria control activities	T052	C0441655
implemented	T052	C1708476
areas	T082	C0205146
distribution	T078	C0520511
long-lasting	T078	C0549178
insecticidal net	T074	C2717999
person	T098	C0027361
early diagnosis	T060	C0596473
prompt	T169	C0871157
treatment	T169	C1522326
Dihydro-artemisinin	T109	C0058108
piperaquine	T109	C0071105
first-line treatment	T061	C1708063
malaria	T047	C0024530
cases	T169	C0868928
radical	T080	C0439807
treatment	T169	C1522326
primaquine	T109	C0071105
Plasmodium vivax	T204	C0032154
cases	T169	C0868928
slow	T080	C0439834
decrease	T081	C0547047
P. vivax	T204	C0032154
relapses	T067	C0035020
achieve	T080	C0205197
malaria	T047	C0024530
elimination	T080	C0849355
priority	T079	C0549179
stable	T080	C0205360
malaria clusters	T081	C0012641
Interaction of lifestyle	T054	C0851537
behaviour	T053	C0004927
systemic diseases	T047	C0442893
dental caries	T047	C0011334
periodontal diseases	T047	C0031090
consensus report of group 2 of the joint EFP/ORCA workshop	T097	C0086050
caries	T047	C0011334
periodontal diseases	T047	C0031090
Periodontal diseases	T047	C0031090
dental caries	T047	C0011334
common diseases	T047	C0012634
tooth loss	T020	C0080233
diseases	T047	C0012634
nutritional compromise	T169	C0012160
self-esteem	T041	C0036597
quality of life	T078	C0034380
complex chronic diseases	T047	C0008679
common risk factors	T033	C0035648
pathogenic plaque biofilm	T001	C0599030
distinct pathophysiologies	T046	C0277785
Multiple exposures	T080	C0332157
susceptibility involves	T201	C0012655
risk factors	T033	C0035648
inherited	T169	C0439660
genetic variants	T070	C0042333
socio-economic factors	T080	C0086996
biofilm	T007	C0081786
smoking	T055	C0037369
carbohydrate intake	T201	C0489461
prevention of both diseases	T061	C0679698
their management	T058	C0376636
scientific literature	T170	C0023866
potential risk factors	T033	C0035648
caries	T047	C0011334
periodontal diseases	T047	C0031090
systematic review	T170	C1955832
genetic risk factors	T080	C0814299
narrative review	UnknownType	C0815257
role of diet and nutrition	T062	C1511900
reference documentation	T170	C0586393
modifiable acquired risk factors	T033	C0035648
genetic contribution	T033	C0243095
periodontal diseases	T047	C0031090
caries susceptibility	T032	C0011336
attributable risk	T080	C0814766
genetics literature	T169	C0017399
periodontal disease	T047	C0031090
caries	T047	C0011334
genes	T028	C0017337
associated with	T080	C0332281
chronic periodontitis	T047	C0266929
vitamin D receptor	T028	C0919430
VDR	T028	C0919430
Fc gamma receptor IIA	T028	C1414553
Fc-γRIIA	T028	C1414553
Interleukin 10 (IL10) genes	T028	C1334098
IL10	T028	C1334098
caries	T047	C0011334
genes	T028	C0017337
enamel formation	T033	C1333380
AMELX	T028	C1412382
AMBN	T028	C1412375
ENAM	T028	C1414397
TUFT	T116	C0059090
MMP20	T028	C1417208
KLK4	T028	C1416675
salivary characteristics	T033	C2219488
AQP5	T028	C1412495
immune regulation	T040	C1327458
dietary preferences	T080	C0016483
largest impact	T080	C4049986
Fermentable carbohydrates	T109	C0012170
sugars and starches	UnknownType	C0684177
risk factor for both diseases	T033	C0850664
caries	T047	C0011334
fermentation process	T044	C0015852
generation of biofilm	T043	C1325881
Glucans	T109	C0017696
periodontitis	T047	C0031099
glycaemia drives	T033	C1320980
oxidative stress	T049	C0242606
advanced glycation	T067	C0598528
hyper inflammatory	T046	C0021368
Micronutrient deficiencies	T046	C0342917
vitamin C	T109	C0003968
vitamin D	T109	C0042866
vitamin B12	T109	C0042845
onset	T079	C0277793
progression of both diseases	T046	C0242656
Functional foods	T168	C2717755
probiotics	T007	C0525033
caries prevention	T058	C1960644
periodontal disease	T047	C0031090
management	T058	C0376636
biological mechanisms	T044	C0678659
Hyposalivation	T033	C0043352
rheumatoid arthritis	T047	C0003873
smoking/tobacco use	T033	C0425291
undiagnosed	T033	C1408353
sub-optimally controlled	T033	C2911690
diabetes	T047	C0011847
obesity	T047	C0028754
risk factors	T033	C0035648
caries	T047	C0011334
periodontal diseases	T047	C0031090
Intestinal	T023	C0021853
micropatches	T074	C0991556
oral	T082	C0442027
insulin delivery	T061	C3165280
Diabetes mellitus	T047	C0011849
public health issue	T078	C1554189
epidemic proportions	T169	C0220823
Injectable insulin	UnknownType	C0544377
management	T058	C0376636
chronic disease	T047	C0008679
lack of patient compliance	T033	C0376405
injectable	T121	C0086466
formulations	T077	C1705957
oral	T082	C0442027
insulin	T116	C0021641
formulations	T077	C1705957
delivery	T061	C1533734
challenges	T058	C0805586
mucoadhesive	T073	C0001516
intestinal	T023	C0021853
patches	T074	C0991556
micrometers	T081	C0439201
dimension	T081	C0439534
micropatches	T074	C0991556
challenges	T058	C0805586
oral	T082	C0442027
insulin delivery	T061	C3165280
micropatches	T074	C0991556
adhere	T067	C3714578
intestinal mucosa	T024	C0021839
drug	T121	C1254351
rapidly	T080	C0456962
effective	T080	C1704419
lowering blood glucose levels	T033	C0595883
in vivo	T082	C1515655
insulin	T116	C0021641
micropatches	T074	C0991556
administered	T061	C1533734
permeation enhancer	T121	C1254351
protease inhibitor	T121	C0033607
peak	T080	C0444505
efficacy	T080	C1280519
drop in blood glucose levels	T033	C0595883
Efficacy	T080	C1280519
micropatches	T074	C0991556
administered	T061	C1533734
multiple doses	T201	C1960418
micropatches	T074	C0991556
oral	T082	C0442027
insulin	T116	C0021641
formulation	T077	C1705957
in vivo	T082	C1515655
efficacy	T080	C1280519
Hybrid automata models	T075	C0026339
cardiac ventricular	T023	C0018827
electrophysiology	T060	C0430467
real-time	T079	C1550177
computational applications	T169	C0205245
heart models	T075	C0026339
closed loop	T169	C0443183
validation	T062	C1519941
safety	T068	C0036043
critical	T080	C1511545
medical devices	T074	C0025080
pacemakers	T074	C0810633
models	T075	C0026339
real-time	T079	C1550177
medical devices	T074	C0025080
Real-time	T079	C1550177
performance	T052	C1882330
obtained	T169	C1301820
models	T075	C0026339
computer hardware	T073	C0009602
methods	T169	C0025664
Hybrid Automata	T075	C0026339
HA	T075	C0026339
FPGA	T074	C0025080
Models	T075	C0026339
ventricular cardiac cell	T025	C2339371
electrophysiology	T060	C0430467
described	T078	C1552738
HA	T075	C0026339
capture	T067	C1254366
behavior	T080	C1521970
biological systems	T169	C0449913
models	T075	C0026339
closed-loop	T169	C0443183
validation	T062	C1519941
pacemakers	T074	C0810633
abstract	T078	C1552863
capture	T067	C1254366
important	T080	C3898777
characteristics	T080	C1521970
dynamic	T169	C0729333
rate response	T079	C0237629
HA model	T075	C0026339
cardiac cells	T025	C0225828
captures	T067	C1254366
dynamic	T169	C0729333
behavior	T080	C1521970
model	T075	C0026339
hardware	T073	C0009602
potentially	T080	C3245505
modeling	T062	C0870071
heart	T023	C0018787
million	T081	C1881839
dynamic	T169	C0729333
cells	T025	C0007634
ideal	T080	C1512612
closed loop	T169	C0443183
testing	T169	C0039593
medical devices	T074	C0025080
Comparison	T052	C1707455
pulse wave velocity	T081	C3494431
accelerometer	T074	C0178951
reflective photo-plethysmography signals	T060	C0203341
carotid	T023	C0007272
femoral artery	T023	C0015801
Carotid	T023	C0007272
femoral	T023	C0015801
pulse wave velocity	T081	C3494431
established measure	T081	C0079809
assess	T058	C0184514
cardiovascular risk	T033	C1113685
surrogate parameter	T077	C0549193
non-invasive continuous blood pressure inference	T201	C4301970
progress	T169	C1280477
wearable wrist worn sensors	T073	C0183210
photo-plethysmography	T060	C0162599
high fidelity accelerometer s	T074	C0178951
pulse information	T058	C0034107
larger arteries	T023	C0003842
blood volume	T201	C0005850
superficial tissue	T024	C0040300
pulse wave velocities	T081	C3494431
accelerometer	T074	C0178951
reflective photo-plethysmography signals	T060	C0203341
carotid	T023	C0007272
femoral artery	T023	C0015801
physiological processes	T039	C0031845
sensing principles	T078	C1254370
experimental results	T033	C2825142
study	T062	C2603343
healthy subjects	T098	C1708335
Constructive and Unproductive Processing	T033	C0243095
Traumatic Experiences	T048	C3203533
Trauma-Focused Cognitive-Behavioral Therapy	T061	C0579049
Youth	T100	C0087178
evidence	T078	C3887511
efficacy	T080	C1280519
cognitive-behavioral treatments	T061	C0579049
CBT	T061	C0579049
posttraumatic stress disorder	T048	C0038436
PTSD	T048	C0038436
treatments	T061	C0087111
learning theory	T170	C0870794
cognitive and emotional processing theories	T170	C0282574
avoidance	T041	C0870186
constructive processing of feared experiences	T033	C0517168
inhibitory learning	T041	C0679066
unproductive and constructive processing	T033	C0243095
traumatic experiences	T048	C3203533
PTSD	T048	C0038436
symptoms	T184	C1457887
Trauma-Focused Cognitive Behavioral Therapy	T061	C0579049
TF-CBT	T061	C0579049
abuse	T033	C0237206
traumatic	T048	C3203533
interpersonal loss	UnknownType	C0679461
Sessions	T077	C1883017
trauma narrative phase	T061	C3494322
TF-CBT	T061	C0579049
unproductive processing	T033	C0243095
overgeneralization	T033	C0563151
rumination	T048	C0154575
avoidance	T041	C0870186
constructive processing	T033	C0243095
decentering	T033	C0243095
accommodation of corrective information	T033	C1832072
levels of negative emotion	T058	C3165349
previous	T079	C0205156
overgeneralization	T033	C0563151
narrative phase	T061	C3494322
internalizing symptoms	T184	C0237088
posttreatment	UnknownType	C0679865
worsening	T080	C0332271
externalizing symptoms	T184	C0237088
follow-up	T058	C1522577
accommodation predicted improvement	T033	C1832072
internalizing symptoms	T184	C0237088
moderated	T080	C1881878
negative	T033	C0205160
effects of	T080	C1704420
overgeneralization	T033	C0563151
internalizing and externalizing symptoms	T184	C0237088
overgeneralization	T033	C0563151
accommodation	T033	C1832072
Overgeneralization	T033	C0563151
associated with	T080	C0332281
rumination	T048	C0154575
negative emotion	T058	C3165349
suggesting	T078	C0038659
immersion	T058	C3714592
trauma	T048	C3203533
Accommodation	T033	C1832072
associated with	T080	C0332281
avoidance	T041	C0870186
decentering	T033	C0243095
healthy	T080	C3898900
trauma	T048	C3203533
cognitive change	T048	C1392786
predicted	T078	C0681842
improvement	T077	C2986411
externalizing symptoms	T184	C0237088
posttreatment	UnknownType	C0679865
Rumination	T048	C0154575
avoidance	T041	C0870186
overgeneralization	T033	C0563151
accommodation	T033	C1832072
treatment outcomes	T080	C0085415
overgeneralization	T033	C0563151
accommodation	T033	C1832072
unproductive and constructive processing	T033	C0243095
traumatic experiences	T048	C3203533
Giant	T025	C0017526
Antrochoanal Polyp	T191	C0008298
Rare	T080	C0522498
Presentation	T078	C0449450
Antrochoanal polyp	T191	C0008298
ACP	T191	C0008298
Killian polyp	T191	C0008298
benign lesion	T033	C0221198
maxillary	T023	C0024947
patients	T101	C0030705
antrochoanal polyp	T191	C0008298
anatomical	T080	C0220784
lateral nasal wall	T029	C0456482
middle meatus	T023	C0225401
antrum	T023	C1549092
dumbbell	T082	C0686912
problem	T033	C0033213
unusual	T080	C2700116
presentation	T078	C0449450
Effects	T080	C1280500
obesity	T047	C0028754
IL-33	T116	C2976122
ST2	T116	C3849696
system	T169	C0449913
heart	T023	C0018787
adipose tissue	T024	C0001527
liver	T023	C0023884
study	T062	C0008972
experimental model	T170	C0086272
Zucker rats	T015	C0034719
Suppression of tumorigenicity 2	T116	C3849696
ST2	T116	C3849696
effect	T080	C1280500
Interleukin-33	T116	C2976122
IL-33	T116	C2976122
relationship	T080	C0439849
IL-33	T116	C2976122
ST2	T116	C3849696
obesity	T047	C0028754
effects	T080	C1280500
obesity	T047	C0028754
IL-33	T116	C2976122
ST2	T116	C3849696
system	T169	C0449913
heart	T023	C0018787
adipose tissue	T024	C0001527
liver	T023	C0023884
rodent model	T050	C1519106
obesity	T047	C0028754
relationship	T080	C0439849
cardiac	T024	C1272575
expression	T045	C1171362
IL-33	T116	C2976122
ST2	T116	C3849696
system	T169	C0449913
natriuretic peptides	T116	C1144709
NPs	T116	C1144709
system	T169	C0449913
inflammatory mediators	T038	C3155540
mRNA expression	T045	C1515670
IL-33	T028	C1825595
ST2	T028	C1420442
system	T169	C0449913
cardiac	T060	C0189784
adipose	T024	C0001527
hepatic biopsies	T060	C0193388
obese Zucker rats	T015	C0034719
O	T015	C0034719
controls	T096	C0009932
CO	T096	C0009932
Expression	T045	C1171362
sST2	T116	C3852857
O rats	T015	C0034719
CO	T096	C0009932
tissues	T024	C0040300
mRNA	T114	C0035696
IL-33	T028	C1825595
O	T015	C0034719
CO	T096	C0009932
expression	T045	C0017262
ST2L	T028	C1416400
liver	T023	C0023884
CO	T096	C0009932
O	T015	C0034719
relationship	T080	C0439849
IL-33	T116	C2976122
ST2	T116	C3849696
NPs	T116	C1144709
inflammatory mediators	T038	C3155540
cardiac tissue	T024	C1272575
Expression	T045	C1171362
sST2	T116	C3852857
cardiac	T024	C1272575
adipose	T024	C0001527
liver tissue	T023	C0023884
O	T015	C0034719
controls	T096	C0009932
IL-33	T116	C2976122
ST2	T116	C3849696
system	T169	C0449913
molecular mechanisms	T044	C1148560
obesity	T047	C0028754
relationships	T080	C0439849
NP	T116	C1144709
systems	T169	C0449913
inflammatory mediators	T038	C3155540
IL-33	T116	C2976122
ST2	T116	C3849696
molecular pathways	T044	C1704259
cardiac dysfunction	T033	C3277906
inflammation	T046	C0021368
obesity	T047	C0028754
CXCL14	T116	C1335988
CXCR4	T116	C2352110
CXCL12	T116	C1528383
CXCR4	T116	C2352110
Invasion	T033	C1269955
Process	T067	C1522240
Endometrioid Carcinoma	T191	C0206687
MELF-Pattern	T082	C0449774
Myoinvasion	T033	C1269955
MELF-pattern	T082	C0449774
myometrial	T029	C0521387
invasion	T033	C1269955
MELF pattern	T082	C0449774
unusual	T080	C2700116
morphology	T080	C0332437
myometrial	T029	C0521387
invasion	T033	C1269955
endometrioid carcinomas	T191	C0206687
associated with	T080	C0332281
lymphovascular invasion	T033	C1708790
lymph node metastasis	T191	C0024232
tumor cells	T025	C0334227
collected	T078	C1516695
MELF pattern	T082	C0449774
laser microdissection	T059	C1113652
Comprehensive	T080	C1880156
microarray analysis	T059	C1449575
genes	T028	C0017337
expression	T045	C1171362
metastasis progression gene, CXCR4	T116	C2352110
ligands	T044	C1749457
CXCL14	T116	C1335988
CXCL12	T116	C1528383
investigated	T169	C1292732
In vitro studies	T062	C0681828
endometrioid carcinoma	T191	C0206687
cell lines	T025	C0085983
elevated	T080	C3163633
invasion	T033	C1269955
activity	T052	C0441655
CXCL14	T116	C1335988
CXCR4	T116	C2352110
CXCL12	T116	C1528383
CXCR4	T116	C2352110
Immunohistochemical analysis	T059	C1441616
MELF group	T078	C0441833
non-MELF group	T078	C0441833
CXCR4	T116	C2352110
expressed	T045	C1171362
endometrioid carcinomas	T191	C0206687
CXCL14	T116	C1335988
CXCL12	T116	C1528383
expression	T045	C1171362
score	T081	C0449820
high proportions	T081	C1709707
cells	T025	C0007634
positive	T033	C1446409
sites	T082	C0205145
MELF pattern	T082	C0449774
no significant difference	T033	C0243095
progression-free survival	T081	C0242792
overall survival	T081	C4086681
MELF group	T078	C0441833
non-MELF group	T078	C0441833
Kaplan-Meier analysis	T081	C1720943
cells	T025	C0007634
sites	T082	C0205145
MELF pattern	T082	C0449774
increased	T081	C0205217
invasiveness	T046	C0027626
function	T039	C0031843
CXCL14	T116	C1335988
CXCR4	T116	C2352110
CXCL12	T116	C1528383
CXCR4	T116	C2352110
Crude	T080	C1709843
4-methylcyclohexanemethanol	T109	C4277102
MCHM	T109	C4277102
cause	T169	C0015127
skin irritation	T033	C0152030
humans	T016	C0086418
48-h	T079	C0439586
patch test	T060	C0030646
Crude	T080	C1709843
4-methylcyclohexanemethanol	T109	C4277102
MCHM	T109	C4277102
industrial	T057	C0021267
chemical	T103	C0220806
wash	T052	C0441648
clean	T052	C1947930
coal	T109	C0009131
10,000 gallons	T081	C0560013
mixture	T167	C0439962
crude	T080	C1709843
MCHM	T109	C4277102
Elk River	T070	C0337050
Charleston	T083	C0017446
West Virginia	T083	C0043127
contaminating	T169	C0205279
local	T082	C0205276
water supply	T081	C0043062
spill	T069	C0392355
residents	T098	C2347958
reported	T058	C0700287
numerous	T081	C0439064
health complaints	T184	C0871764
medical attention	T033	C0496675
ailments	T184	C0221423
rashes	T184	C0015230
itching	T184	C0033774
relationship	T080	C0439849
complaints	T184	C0871764
spill	T069	C0392355
symptoms	T184	C1457887
reported	T058	C0700287
frequently	T079	C0332183
study	T062	C2603343
primary	T080	C0205225
irritation	T033	C0152030
potential	T080	C3245505
crude	T080	C1709843
MCHM	T109	C4277102
evaluated	T169	C1292732
individuals	T098	C0237401
48 hour	T079	C0439586
semi-occluded	T169	C1947917
patch testing	T060	C0030646
MCHM	T109	C4277102
concentrations	T081	C1446561
study	T062	C2603343
skin reactions	T201	C0221743
individuals	T098	C0237401
concentration	T081	C1446561
concentrations	T081	C1446561
evaluated	T169	C1292732
measured concentration	T081	C1446561
MCHM	T109	C4277102
tap water	T121	C2919405
residents	T098	C2347958
West Virginia	T083	C0043127
results	T169	C1274040
study	T062	C2603343
crude	T080	C1709843
MCHM	T109	C4277102
dermal	T080	C0221928
irritant	T131	C0022108
persons	T098	C0027361
concentrations	T081	C1446561
water	T121	C2919405
reported	T058	C0700287
spill	T069	C0392355
New	T080	C0205314
metabolites	T123	C0870883
sponge	T204	C0032699
fungus	T004	C0016832
Aspergillus sydowii J05B-7F-4	T004	C1085656
new	T080	C0205314
metabolites	T123	C0870883
diorcinolic acid	T123	C0870883
β-d-glucopyranosyl aspergillusene A	T109	C3253665
diphenylethers	T123	C0870883
diketopiperazine	T109	C0058171
chromone	T109	C0008594
xanthone	T109	C0078604
isolated	T169	C0205409
fungus	T004	C0016832
Aspergillus sydowii	T004	C1085656
marine sponge	T204	C0032699
Stelletta sp	T204	C2800556
configurations	T082	C0026377
1D, 2D NMR	T070	C0028580
HRESIMS	T059	C0201742
data	T078	C1511726
Compound	T103	C1706082
glycoside	T109	C0017977
phenolic	T109	C0359916
bisabolane sesquiterpenes	T109	C0036847
Compounds 1 and 8	T121	C1254351
mild	T080	C2945599
cytotoxicity	T049	C0596402
KB	T025	C0022539
human nasopharyngeal carcinoma cells	T025	C0022539
HepG2	T025	C2717940
human liver cancer cells	T025	C2717940
HCT 116	T025	C1258005
human colon cancer cells	T025	C1258005
compounds	T121	C1254351
evaluated	T058	C0220825
antibacterial activity	T052	C0441655
suppress	T169	C1260953
LPS	T109	C0023810
nitric oxide	T121	C0028128
NO	T121	C0028128
Compounds 2 and 4-7	T121	C1254351
mild	T080	C2945599
antibacterial activity	T033	C0243095
human	T016	C0086418
pathogen	T001	C0450254
Staphylococcus aureus	T007	C0038172
fish	T013	C0016163
pathogens	T001	C0450254
Streptococcus iniae	T007	C0318186
Vibrio ichthyoenteri	T007	C1265314
compounds 4 and 7	T103	C1706082
suppressed	T169	C1260953
NO	T121	C0028128
neural	T169	C3714606
legacy	T081	C0242538
concussion	T037	C0006107
hypothesized	T078	C1512571
concussions	T037	C0006107
impart	T080	C0332261
lasting	T079	C0443252
brain damage	T037	C0270611
patient	T101	C0030705
recovered	T080	C0521108
hypothesis	T078	C1512571
largely	T081	C0549177
neuropathological	T169	C1521733
studies	T062	C2603343
deceased	T040	C0011065
athletes	T097	C0238703
detected	T061	C1511790
in vivo	T062	C0681829
measured	T080	C0444706
neural	T169	C3714606
responses	T032	C0871261
speech	T040	C0037817
collegiate student	T098	C0682177
athletes	T097	C0238703
history	T033	C0683519
concussion	T037	C0006107
recovered	T080	C0521108
student	T098	C0038492
athletes	T097	C0238703
weaker	T080	C1762617
responses	T032	C0871261
speech	T040	C0037817
age	T032	C0001779
position	T082	C0733755
matched	T080	C1708943
peers	T098	C0679739
group	UnknownType	C0681860
difference	T080	C1705242
suggests	T078	C1705535
concussions	T037	C0006107
engender	T169	C0015127
small	T081	C0700321
detectable	T201	C3830527
changes	T169	C0392747
brain function	T042	C0678908
prior	T079	C0332152
emergence	T079	C0175673
frank	T080	C1947931
behavioral indications	T184	C2706099
Performance	T052	C1882330
Colorimetric	T059	C0009407
Biosensing	T059	C0005567
Paper	T073	C0030351
Microfluidic Platforms	T059	C1449576
Chemical Modification	T169	C0205245
Incorporation	T169	C0243126
Nanoparticles	T073	C1450054
methodologies	T062	C0015194
analytical performance	T052	C1882330
colorimetric	T059	C0009407
paper	T073	C0030351
biosensors	T075	C0600364
Microfluidic paper-based analytical devices	T075	C1449582
μPADs	T075	C1449582
stamping process	T067	C1254366
CO2	T123	C0007012
laser ablation	T061	C0348007
modified	T080	C0205349
oxidation	T067	C1254366
step	T077	C1261552
silica	T122	C0037098
nanoparticles	T073	C1450054
paper structure	T073	C0030351
methods	T170	C0025663
problem	T033	C0033213
associated with	T080	C0332281
colorimetric detection	T059	C0009407
heterogeneity	T080	C0019409
color	T080	C0009393
distribution	T169	C1704711
detection zones	T082	C1710706
modification	T169	C0205245
steps	T077	C1261552
interaction	T169	C1704675
paper	T073	C0030351
surface	T082	C0205148
enzymes	T116	C0014442
performance	T052	C1882330
reliability	T081	C2347947
quantitative	T081	C0392762
analysis	T062	C0936012
clinically	T080	C0205210
compounds	T103	C1706082
CXCR4	T116	C2352110
CD184	T116	C2352110
expression	T045	C1171362
stem cell harvest	T061	C0411265
CD34(+)	T116	C0054953
cells	T025	C0007634
post-transplant	T079	C1254367
CXCR4	T116	C2352110
receptor	T116	C0597357
stromal-derived factor-1	T116	C0218504
SDF-1	T116	C0218504
molecule	T167	C0567416
chemotactic	T043	C0008018
activity	T052	C0441655
lymphocytes	T025	C0024264
homing	T043	C0007613
hematopoietic stem cells	T025	C0018956
adult marrow	T024	C0005953
evaluated	T058	C0220825
CXCR4	T116	C2352110
CD184	T116	C2352110
expression	T045	C1171362
harvest cells	T025	C0038250
post-transplant	T079	C1254367
bone marrow	T024	C0005953
BM	T024	C0005953
relation	T080	C0439849
engraftment	T039	C0301944
consensus criteria	T170	C0935549
chimerism	T032	C0333678
prospective study	T062	C0033522
patients	T101	C0030705
hematopoietic stem cell transplantation	T061	C0472699
patients	T101	C0030705
received	T080	C1514756
autograft	T061	C0040736
patients	T101	C0030705
received	T080	C1514756
allograft	T061	C0040739
assessed	T052	C1516048
CD184	T116	C2352110
CXCR4	T116	C2352110
flow cytometry	T059	C0016263
harvest cells	T025	C0038250
post-transplant	T079	C1254367
BM	T024	C0005953
assessment	T058	C0220825
complete	T080	C0205197
morphologic	T082	C0543482
molecular studies	T059	C2236970
detection	T061	C1511790
CD184	T116	C2352110
expression	T045	C1171362
CD34(+)	T116	C0054953
cells	T025	C0007634
chimerism	T032	C0333678
total	T080	C0439810
peripheral blood mononuclear cells	T025	C1321301
Diagnoses	T033	C0011900
patients	T101	C0030705
acute myeloid leukemia	T191	C0023467
multiple myeloma	T191	C0026764
acute lymphoblastic leukemia	T191	C0023449
non-Hodgkin lymphoma	T191	C0024305
myelodysplastic syndromes	T191	C3463824
aplastic anemia	T047	C0002874
chronic myeloid leukemia	T191	C0023473
Hodgkin lymphoma	T191	C0019829
plasmacytomas	T191	C0032131
patient	T101	C0030705
died	T033	C1546956
excluded	T052	C2828389
study	T062	C0008972
engraftment	T039	C0301944
no	T033	C1513916
statistical significance	T081	C0237881
level	T034	C0428479
CD184	T116	C2352110
stem cell harvest	T061	C0411265
prediction	T078	C0681842
successful	T080	C1272703
engraftment	T039	C0301944
BM sample	T031	C0438737
statistical significance	T081	C0237881
level	T034	C0428479
CD184	T116	C2352110
BM sample	T031	C0438737
occurrence	T079	C2745955
successful	T080	C1272703
engraftment	T039	C0301944
SDF-1	T116	C0218504
CXCR4	T116	C2352110
engraftment	T039	C0301944
assess	T052	C1516048
expression	T045	C1171362
post-transplant	T079	C1254367
chemokine	T116	C0282554
SDF-1	T116	C0218504
receptor	T116	C0597357
CXCR4	T116	C2352110
potential	T080	C3245505
surrogate markers	T080	C0086589
assessment	T058	C0220825
engraftment	T039	C0301944
Genetic diversity	T070	C0042333
Taenia saginata	T204	C0221085
Cestoda	T204	C1706526
Cyclophyllidea	T204	C0322145
Lao People's Democratic Republic	T083	C0023034
northeastern	T083	C0017446
Thailand	T083	C0039725
mitochondrial DNA	T114	C0012929
Taenia saginata	T204	C0221085
tapeworm	T204	C1706526
cattle	T015	C0007452
Analysis	T062	C0936012
genetic diversity	T070	C0042333
geographical populations	T081	C0032659
T. saginata	T204	C0221085
origin	T079	C0439659
transmission	T070	C1521797
spread	T080	C0332261
organism	T001	C0029235
T. saginata	T204	C0221085
genetic variability	T070	C0042333
T. saginata populations	T204	C0221085
regions	T083	C0017446
world	T098	C2700280
Lao PDR	T083	C0023034
Thailand	T083	C0039725
genetic diversity	T114	C0012929
T. saginata populations	T204	C0221085
Lao PDR	T083	C0023034
northeastern	T083	C0017446
Thailand	T083	C0039725
sequences	T086	C0162326
T. saginata	T204	C0221085
countries	T083	C0454664
GenBank	T170	C0598211
Mitochondrial cox1	T028	C1537985
sequence analysis	T059	C0162802
haplotypes	T032	C0018591
T. saginata	T204	C0221085
Lao PDR	T083	C0023034
northeastern	T083	C0017446
Thailand	T083	C0039725
haplotypes	T032	C0018591
sequences	T086	C0162326
Phylogenetic tree	T062	C1519068
haplotype network analyses	T062	C0242481
global	T080	C2348867
T. saginata	T204	C0221085
groups	T078	C0441833
A	T078	C0441833
B	T078	C0441833
C1	T078	C0441833
C2	T078	C0441833
D	T078	C0441833
Taenia saginata	T204	C0221085
Lao PDR	T083	C0023034
northeastern	T083	C0017446
Thailand	T083	C0039725
Group A	T078	C0441833
B	T078	C0441833
Taenia saginata	T204	C0221085
western	T083	C0017446
Thailand	T083	C0039725
groups C1	T078	C0441833
C2	T078	C0441833
D	T078	C0441833
populations	T204	C0684063
northeast	T083	C0017446
western	T083	C0017446
Thailand	T083	C0039725
Taenia saginata	T204	C0221085
Lao PDR	T083	C0023034
Thailand	T083	C0039725
genetically diverse	T070	C0042333
genetic differentiation	T045	C0917892
Taenia saginata populations	T204	C0221085
Lao PDR	T083	C0023034
northeastern	T083	C0017446
Thailand	T083	C0039725
population	T204	C0684063
western	T083	C0017446
Thailand	T083	C0039725
T. saginata	T204	C0221085
transmission routes	T070	C1521797
Southeast Asia	T083	C0003983
novel	T080	C0205314
near-infrared	T070	C1289901
fluorescent	T070	C0016315
theranostic	T091	C4046052
combretastain A-4	T109	C0056154
analogue	T104	C0002776
YK-5-252	T121	C1254351
triple negative breast cancer	T191	C3539878
treatment	T061	C0087111
triple negative breast cancer	T191	C3539878
TNBC	T191	C3539878
cancer research	T062	C1516225
hormone receptors	T116	C0019929
treatment	T061	C0087111
patients	T101	C0030705
diagnosis	T033	C0011900
radiation	T061	C1522449
chemotherapy	T061	C3665472
Anti-angiogenesis	T061	C0281318
vasculature	T017	C3714653
tumors	T191	C0027651
Combretastatin A-4	T109	C0056154
CA-4	T109	C0056154
vasculature	T017	C3714653
cancers	T191	C0006826
inhibition	T052	C3463820
tubulin	T116	C0041348
polymerization	T067	C0314672
toxicity	T037	C0600688
analogues	T104	C0002776
CA-4	T109	C0056154
novel	T080	C0205314
CA-4	T109	C0056154
prodrug	T120	C0033262
YK-5-252	T121	C1254351
drug	T121	C1254351
disulfide bond	T044	C0813982
cleavage	T067	C0596311
mechanism	T169	C0441712
near-infrared	T070	C1289901
NIR	T070	C1289901
fluorophore	T121	C0598447
fluorescence	T070	C0016315
cleavage	T067	C0596311
disulfide linkage	T044	C0813982
CA-4	T109	C0056154
glutathione	T116	C0017817
GSH	T116	C0017817
toxicity	T037	C0600688
drug	T121	C1254351
NIR	T070	C1289901
fluorophore	T121	C0598447
prodrug	T120	C0033262
YK-5-252	T121	C1254351
novel	T080	C0205314
CA-4	T109	C0056154
analogue	T104	C0002776
toxicity	T037	C0600688
theranostics	T091	C4046052
imaging	T060	C0079595
Epidemiological	T169	C0014508
patterns	T082	C0449774
bovine	T015	C0007452
besnoitiosis	T047	C0005146
endemic	T169	C0302891
beef cattle	T015	C0175923
herd	T054	C1690528
reared	T082	C3687023
Bovine	T015	C0007452
besnoitiosis	T047	C0005146
parasitic disease	T047	C0030499
protozoan	T204	C0033739
Besnoitia besnoiti	T204	C0320701
epidemiological studies	T062	C0002783
Europe	T083	C0015176
years	T079	C0439234
epidemiological	T169	C0014508
aspects	T080	C1879746
transmission	T046	C0242781
incidence rates	T081	C1708485
risk factors	T033	C0035648
lacking	T080	C0332268
appropriate disease control	T058	C0009449
programmes	T170	C0009457
study	T062	C2603343
epidemiological	T169	C0014508
pattern	T082	C0449774
disease	T047	C0012634
endemic	T169	C0302891
herd	T054	C1690528
reared	T082	C3687023
Spanish	T083	C0037747
Pyrenees	T083	C0442533
associated with	T080	C0332281
infection	T046	C3714514
clinical disease	T047	C0012634
dynamics	T070	C3826426
study population	T062	C0681876
Brown Swiss	T015	C0324052
Pirenaica	T015	C0007452
adult animals	T008	C0596888
calves	T015	C3668829
born	T040	C0005615
weaned	T033	C0420986
farm	T082	C0557759
study	T062	C2603343
sampling	T078	C0870078
time frames	T079	C0332168
periods	T079	C0010339
mountain	T083	C0442533
valley	T082	C0563004
periods	T079	C0010339
data	T078	C1511726
animals	T008	C0003062
breed	T185	C1704650
sex	T032	C0079399
age	T032	C0001779
herd	T054	C1690528
management	T057	C1273870
animal grouping	T096	C1642385
time	T079	C0040223
housing	T073	C0020057
data collection	T062	C0010995
methodology	T078	C3266812
clinical examinations	T033	C1456356
serological	T169	C0205473
status	T080	C0449438
bovine	T015	C0007452
besnoitiosis	T047	C0005146
immunofluorescent antibody testing	T059	C0016318
blood samples	T031	C0178913
prevalence	T081	C0033105
adult animals	T008	C0596888
CI	T081	C0009667
seropositive	T080	C0521143
animals	T008	C0003062
cumulative incidence	T081	C0021149
new	T080	C0205314
infections	T046	C3714514
detected	T033	C0442726
mountain	T083	C0442533
period	T079	C0010339
valley	T082	C0563004
period	T079	C0010339
incidence density	T081	C1708485
new	T080	C0205314
infections	T046	C3714514
animal	T008	C0003062
month	T079	C0439231
mountain	T083	C0442533
valley	T082	C0563004
periods	T079	C0010339
seroepidemiological study	T062	C0036744
seroconversion	T070	C4042908
probability	T081	C0033204
B. besnoiti	T204	C0320701
infection	T046	C3714514
associated with	T080	C0332281
number	T081	C0237753
seropositive	T080	C0521143
cows	T015	C0007452
animal	T008	C0003062
housing	T073	C0020057
period	T079	C0010339
duration	T079	C0449238
horizontal transmission	T046	C4288956
disease	T047	C0012634
spread	T080	C0332261
risk	T078	C0035647
clinical course	T079	C0449259
increased	T081	C0205217
age	T032	C0001779
presence	T033	C0150312
clinical signs	T033	C3540840
higher	T080	C0205250
antibody responses	T038	C0003261
calves	T015	C3668829
months	T079	C0439231
old	T079	C0580836
weaning	T033	C0043084
seroprevalence	T062	C0600367
CI	T081	C0009667
chronic	T079	C0205191
stage	T079	C1306673
animals	T008	C0003062
B. besnoiti	T204	C0320701
infect	T046	C3714514
cause	T169	C0015127
disease	T047	C0012634
animals	T008	C0003062
months	T079	C0439231
old	T079	C0580836
risk	T078	C0035647
calf	T015	C3668829
seroconversion	T070	C4042908
serological	T169	C0205473
status	T080	C0449438
cows	T015	C0007452
postnatal	T079	C0443281
transmission	T046	C0242781
dams	T015	C0007452
offspring	T015	C3668829
suckling	T015	C0003068
period	T079	C0010339
fast small-sample kernel independence test	T170	C0237913
microbiome	T001	C1956108
community	T096	C0009462
level association analysis	T062	C0242481
role	T077	C1705810
microbiome	T001	C1956108
human	T016	C0086418
health	T078	C0018684
diseases	T047	C0012634
researchers	T097	C0035173
assessing	T052	C1516048
relationship	T080	C0439849
microbiome composition	T001	C1956108
host	T001	C1167395
genomic	T028	C0017428
data	T078	C1511726
dimensionality	T082	C1707753
data	T078	C1511726
complex	T080	C0439855
relationships	T080	C0439849
microbiota	T001	C3887843
host	T001	C1167395
genomics	T028	C0017428
challenges	T058	C0805586
analysis	T062	C0936012
kernel RV coefficient (KRV) test	T170	C0237913
overall	T080	C1561607
association	T080	C0439849
host	T001	C1167395
gene expression	T045	C0017262
microbiome composition	T001	C1956108
KRV statistic	T170	C0237913
nonlinear correlations	T080	C1707520
complex	T080	C0439855
relationships	T080	C0439849
data types	T078	C1609081
gene expression	T045	C0017262
microbiome composition	T001	C1956108
dependency	T078	C1254370
Testing	T169	C0039593
tests	T170	C0392366
RV coefficients	T081	C1707429
p-value	T081	C1709380
calculation	T052	C1441506
Strategies	T169	C0205245
confounding effects	T169	C0009673
results	T169	C1274040
problem	T033	C0033213
kernel	T170	C1881303
Simulation studies	T062	C0679083
KRV	T081	C1707429
testing	T169	C0039593
statistical independence	T078	C0085862
kernels	T170	C1881303
associations	T080	C0439849
microbiome composition	T001	C1956108
host	T001	C1167395
genomic	T028	C0017428
data	T078	C1511726
type I	T185	C0441729
error	T080	C0743559
KRV	T081	C1707429
microbiome	T001	C1956108
study	T062	C2603343
relationship	T080	C0439849
host	T001	C1167395
transcriptome	T086	C3178810
microbiome composition	T001	C1956108
context	T078	C0449255
inflammatory bowel disease	T047	C0021390
qualitative observations	T080	C0449576
Analysis	T062	C0936012
Systematic	T169	C0220922
Elemental	T196	C0013879
Changes	T081	C0443172
Decomposing Bone	T023	C0262950
aim	T078	C1947946
pilot study	T062	C0031928
investigate	T169	C1292732
compositional	T201	C0486616
changes	T081	C0443172
bone	T023	C0262950
decomposition	T067	C2700592
Elemental	T196	C0013879
concentrations	T081	C1446561
barium	T196	C0004749
calcium	T121	C0006675
iron	T121	C0302583
potassium	T123	C0032821
magnesium	T123	C0024467
zinc	T121	C0043481
phosphorus	T196	C0031705
porcine	T015	C0039005
bone	T023	C0262950
experimental	T080	C1517586
analog	T104	C0243071
human	T016	C0086418
bone	T023	C0262950
analyzed	T062	C0936012
inductively coupled plasma optical emission spectroscopy	T059	C0260252
ICP-OES	T059	C0260252
samples	UnknownType	C0444227
porcine	T015	C0039005
bone	T023	C0262950
subjected	T169	C1550501
shallow burial	T052	C0006407
surface	T029	C0825429
depositions	T169	C0333562
day	T079	C0439228
intervals	T079	C1272706
period	T079	C1948053
days	T079	C0439228
Results	T033	C0683954
indicated	T033	C1444656
ICP-OES	T059	C0260252
elemental	T196	C0013879
profiling	T169	C2003903
potential	T080	C3245505
developed	T080	C0205556
forensic test	T059	C0022885
determining	T080	C0205556
bone sample	UnknownType	C0444227
early	T079	C1279919
stages	T079	C1306673
soft tissue	T024	C0225317
putrefaction	T046	C0333532
Significant changes	T081	C0443172
iron	T121	C0302583
sodium	T123	C0037473
potassium	T123	C0032821
concentrations	T081	C1446561
found	T033	C0150312
over	T079	C0347984
days	T079	C0439228
elements	T196	C0013879
known	T080	C0205309
primarily	T080	C0205225
associated with	T080	C0332281
proteins	T116	C0033684
tissue fluids	T031	C0162367
bone	T023	C0262950
Changes	T081	C0443172
concentrations	T081	C1446561
dehydration	T033	C1963090
time	T079	C0040223
time	T079	C0040223
since	T079	C1711239
deposition	T169	C0333562
Oxyria sinensis	T002	C1066614
Polygonaceae	T002	C0524882
diploid	T032	C0012568
congener	T104	C0678518
ancestor	T099	C0870134
origin	T070	C0005495
polyploid	T049	C0032578
species	T185	C1705920
ancestor	T099	C0870134
extinct	T070	C1720991
extinct	T070	C1720991
genome	T028	C0017428
polyploid	T049	C0032578
species	T185	C1705920
existence	T081	C1547035
presence	T080	C3854307
genome	T028	C0017428
polyploid	T049	C0032578
polyploid	T049	C0032578
origin	T070	C0005495
Oxyria sinensis	T002	C1066614
congeneric	T104	C0678518
species	T185	C1705920
diploid	T032	C0012568
O. digyna	T002	C1481306
Genomic in situ hybridization	T063	C0162788
GISH	T063	C0162788
transcriptome	T059	C0752248
phylogenetic	T062	C1519068
demographic analyses	T062	C0011289
ecological niche modelling	T170	C0282574
GISH	T063	C0162788
O. sinensis	T002	C1066614
chromosomes	T026	C1135923
O. digyna	T002	C1481306
chromosomes	T026	C1135923
ancestor	T099	C0870134
Transcriptome analysis	T059	C0752248
divergence	T082	C0443204
O. digyna	T002	C1481306
genome duplication	T045	C0017261
genome duplication	T045	C0017261
O. sinensis	T002	C1066614
Oxyria sinensis	T002	C1066614
homologous gene sequences	T085	C0162774
divergent	T082	C0443204
O. digyna	T002	C1481306
clustered	T028	C0017258
O. digyna	T002	C1481306
Coalescent simulations	T170	C0876936
O. sinensis	T002	C1066614
distribution	T067	C3494413
polyploidization event	T049	C0032578
O. digyna	T002	C1481306
distributions	T067	C3494413
species	T185	C1705920
contracted and re-expanded	T169	C0205245
Pleistocene climatic oscillations	T070	C3826560
Ecological niche modelling	T170	C0282574
species	T185	C1705920
distributional	T067	C3494413
Quaternary climatic changes	T070	C3826560
extinction	T070	C1720991
tetraploid	T049	C0333694
species	T185	C1705920
origin	T070	C0005495
O. sinensis	T002	C1066614
adaptation	T040	C0000934
O. sinensis	T002	C1066614
repeated climatic changes	T070	C3826560
Primitive Neuroectodermal Tumors	T191	C0206663
Female Genital Tract	T023	C0017421
Morphologic	T080	C0332437
Immunohistochemical	T059	C1441616
Molecular	T080	C1521991
Study	T062	C2603343
Cases	T077	C1706256
Primary primitive neuroectodermal tumor	T191	C0206663
PNET	T191	C0206663
female genital tract	T023	C0017421
classification	T185	C0008902
clinical	T080	C0205210
histologic	T169	C0205462
immunophenotypic	T059	C0079611
features	T080	C2348519
EWSR1	T028	C0808901
rearrangement	T045	C0017287
gynecologic	T082	C0205480
PNETs	T191	C0206663
ovarian	T023	C0205065
uterine	T023	C0042149
vulvar	T023	C0042993
tumors	T191	C0027651
reported	T170	C0684224
Patient	T101	C0030705
age	T032	C0001779
ranged	T081	C1514721
years	T079	C0439234
age	T032	C0001779
years	T079	C0439234
ovarian	T023	C0205065
uterine	T023	C0042149
PNETs	T191	C0206663
Morphologic	T080	C0332437
features	T080	C2348519
central nervous system	T022	C3714787
CNS	T022	C3714787
tumors	T191	C0027651
PNETs	T191	C0206663
medulloblastomas	T191	C0025149
ependymomas	T191	C0014474
medulloepitheliomas	T191	C0334596
glioblastoma	T191	C0017636
central PNET	T191	C0206663
PNETs	T191	C0206663
undifferentiated	T080	C0205618
small round blue cells	T025	C0007634
Ewing sarcoma/peripheral PNET	T191	C0684337
PNETs	T191	C0206663
tumor	T191	C0027651
ovarian	T023	C0205065
mature cystic teratomas	T191	C1368910
endometrial low-grade	T080	C1282907
endometrioid carcinomas	T191	C0206687
uterine carcinosarcoma	T191	C0280630
immunohistochemistry	T060	C0021044
PNETs	T191	C0206663
marker	T123	C0041366
neuronal differentiation	T033	C1518294
synaptophysin	T116	C0085255
NSE	T116	C1880904
CD56	T116	C0108754
S100	T116	C0027758
chromogranin	T116	C0008586
tumors	T191	C0027651
GFAP	T116	C0017626
PNETs	T191	C0206663
Membranous	T024	C0025255
CD99	T116	C0058889
nuclear	T082	C0521447
Fli-1	T116	C1437505
staining	T059	C0487602
tumors	T191	C0027651
expression	T045	C1171362
markers	T123	C0041366
central	T191	C0206663
Ewing sarcoma/peripheral PNET	T191	C0684337
tumors	T191	C0027651
expressed	T045	C1171362
vimentin	T116	C0042666
keratin	T116	C0022564
CAM5.2	T116	C0910360
AE1/AE3	T116	C1545476
staining	T059	C0487602
PNETs	T191	C0206663
Fluorescence in situ hybridization	T063	C0162789
cases	T077	C1706256
EWSR1	T028	C0808901
rearrangement	T045	C0017287
tumors	T191	C0027651
morphologic	T080	C0332437
features	T080	C2348519
Ewing sarcoma/peripheral PNET	T191	C0684337
CD99	T116	C0058889
Fli-1	T116	C1437505
expression	T045	C1171362
central	T191	C0206663
Ewing sarcoma/peripheral PNETs	T191	C0684337
female genital tract	T023	C0017421
central PNETs	T191	C0206663
Central PNETs	T191	C0206663
spectrum	T077	C2827424
morphologic	T080	C0332437
features	T080	C2348519
CNS	T022	C3714787
tumors	T191	C0027651
EWSR1	T028	C0808901
rearrangement	T045	C0017287
GFAP	T116	C0017626
expression	T045	C1171362
morphologic	T080	C0332437
central PNET	T191	C0206663
sarcoma/peripheral PNET	T191	C0684337
Ewing sarcoma/peripheral PNETs	T191	C0684337
morphologic	T080	C0332437
features	T080	C2348519
CNS	T022	C3714787
tumors	T191	C0027651
Surgical Excision	T061	C0728940
Heterotopic Ossification	T046	C0029396
Re-Emergence	T079	C1254367
Mesenchymal Stem Cell Populations	T025	C1257975
Recurrence	T067	C0034897
heterotopic ossification	T046	C0029396
HO	T046	C0029396
severe	T080	C0205082
musculoskeletal injuries	T037	C0272448
burns	T037	C0562038
significant	T078	C0750502
patient	T101	C0030705
rehabilitation	T061	C0034991
incidence	T081	C0021149
HO	T046	C0029396
increases	T081	C0205217
repeated operations	T061	C0035110
resection	T061	C0728940
HO	T046	C0029396
Treatment	T061	C0087111
heterotopic ossification	T046	C0029396
surgical excision	T061	C0728940
incomplete	T080	C0205257
evidence of	T169	C0332120
persistent	T079	C0205322
heterotopic bone	T033	C4061353
patients	T101	C0030705
continue	T078	C0549178
signs or symptoms	T033	C3540840
HO	T046	C0029396
chronic pain	T184	C0150055
nonhealing	T033	C3845448
wounds	T037	C0043250
joint restriction	T033	C0231589
study	T062	C0008972
model	T050	C2986594
recurrent	T079	C2945760
HO	T046	C0029396
surgical excision	T061	C0728940
mature	T079	C0205286
HO	T046	C0029396
mouse model	T050	C2986594
hind-limb Achilles' tendon	T023	C0001074
transection	T061	C0152060
dorsal	T082	C0205095
burn injury	T037	C0006434
key	T080	C3898777
signaling	T044	C0037080
mediators	T116	C0033684
HO	T046	C0029396
bone morphogenetic protein signaling	T044	C1155364
mature bone	T024	C0682560
surgical excision	T061	C0728940
upregulation	T044	C0041904
downstream	T082	C0522506
mediators	T116	C0033684
osteogenic	T116	C0599660
differentiation	T169	C2945687
pSMAD 1	T116	C1566789
5	T116	C0529859
surgical excision	T061	C0728940
re-emergence	T079	C1254367
mesenchymal cell population	T025	C1257975
expression	T045	C0597360
platelet-derived growth factor receptor-α	T116	C0290067
PDGFRα	T116	C0290067
present	T033	C0150312
initial	T079	C0205265
HO	T046	C0029396
lesion	T033	C0221198
absent	T169	C0332197
mature	T079	C0205286
HO	T046	C0029396
recurrent	T079	C2945760
lesion	T033	C0221198
PDGFRα	T116	C0290067
mesenchymal cells	T025	C1257975
proliferative	T046	C0334094
initial	T079	C0205265
HO	T046	C0029396
lesion	T033	C0221198
surgical excision	T061	C0728940
HO	T046	C0029396
results	T033	C0683954
recurrence	T067	C0034897
mesenchymal cell populations	T025	C1257975
signaling	T044	C0037080
mechanisms	T169	C0441712
present	T033	C0150312
initial	T079	C0205265
HO	T046	C0029396
lesion	T033	C0221198
results	T033	C0683954
consistent with	T078	C0332290
findings	T033	C0243095
patients	T101	C0030705
foci	T082	C0205234
ectopic bone	T024	C1384482
excision	T061	C0728940
sites	T029	C1515974
de novo	T078	C1515568
formation	T169	C1522492
extension	T169	C0231448
unresected	T185	C2986425
bone	T024	C1384482
Extended release	T079	C0868939
flurbiprofen	T109	C0016377
tromethamine	T109	C0041175
buffered	T121	C0006353
HPMC	T109	C0063242
hydrophilic	T080	C0475370
matrix tablets	T122	C0039225
pH	T081	C0020283
dependent	T169	C3244310
solubility	T080	C0037628
drug	T121	C1254351
pH	T081	C0020283
dependent	T169	C3244310
drug release	T070	C3850077
hydrophilic	T080	C0475370
matrix tablets	T122	C0039225
buffer salts	T121	C1659042
formulation	T122	C0013058
attempt	T051	C1516084
mitigate	T067	C1553901
impair	T169	C0221099
matrix hydration	T067	C0596317
negatively	T033	C0205160
impact	T080	C4049986
drug release	T070	C3850077
evaluation	T058	C0220825
buffering	T121	C0006353
hydrophilic	T080	C0475370
matrix tablets	T122	C0039225
pH	T081	C0020283
dependent	T169	C3244310
solubility	T080	C0037628
weak acid drug	T121	C1254351
flurbiprofen	T109	C0016377
identified	T080	C0205396
possessing	T078	C3154893
deleterious effect	T080	C1280500
hydroxypropyl methylcellulose	T109	C0063242
HPMC	T109	C0063242
solubility	T080	C0037628
swelling	T067	C1522240
gelation	T067	C1522240
drug dissolution	T070	C3850077
characteristics	T080	C1521970
hydrophilic	T080	C0475370
matrix gel layer	T122	C0017243
presence	UnknownType	C0332443
tromethamine	T109	C0041175
buffer	T121	C0006353
inclusion	T080	C1512693
tromethamine	T109	C0041175
alkalizing agent	T121	C0304463
pH	T081	C0020283
independent	T169	C0332291
flurbiprofen	T109	C0016377
release	T079	C0868939
matrices	T167	C0439861
HPMC 2910 (E series)	T109	C0063242
2208 (K series)	T109	C0063242
concomitantly	T079	C0521115
decreasing	T033	C0442797
critical effect	T080	C1280500
dissolution	T070	C3850077
mediated	T054	C0086597
drug	T121	C1254351
pseudo-gel layer formation	T169	C1522492
functionality	T169	C0205245
Drug release profiles	T073	C1707824
unaffected	T077	C2986417
matrix	T167	C0439861
pH-changes	T033	C0243095
loss	T081	C1517945
tromethamine	T109	C0041175
over time	T079	C1254367
HPMC	T109	C0063242
inhibited	T080	C0311403
precipitation	T070	C0032931
drug	T121	C1254351
supersaturated solution	T167	C0037633
hydrated matrix	T067	C0596317
facilitation	T042	C0234112
diffusion-based	T070	C0012222
release	T079	C0868939
deleterious drugs	T121	C1254351
hydrophilic	T080	C0475370
matrices	T167	C0439861
buffering species	T121	C0006353
influence	T077	C4054723
slope	T082	C1254362
Spartium junceum	T002	C1014924
root system	T002	C0242726
morphological	T080	C0332437
anatomical	T080	C0220784
biomechanical	T080	C0205556
adaptation	T038	C0392673
Root systems	T002	C0242726
role	T077	C1705810
plant	T002	C0032098
anchorage	T052	C2825961
mechanical interactions	T169	C1704675
soil	T167	C0037592
soil	T167	C0037592
reinforcement	T169	C0205245
stabilization	T080	C0205360
slide-prone slopes	T082	C1254362
responses	T032	C0871261
root system	T002	C0242726
mechanical stress	T070	C0038442
induced	T169	C0205263
slope	T082	C1254362
samples	T167	C0370003
Spartium junceum L.	T002	C1014924
growing	T169	C0205245
slope	T082	C1254362
plane	T082	C1254362
natural conditions	T169	C0205296
morphology	T080	C0332437
biomechanical properties	T080	C0871161
anatomical features	T082	C0502371
Soils	T167	C0037592
sampled	T078	C0870078
slope	T082	C1254362
plane	T082	C1254362
characteristics	T080	C1521970
exception	T077	C1705847
organic matter	T167	C0439861
content	T077	C0456205
penetrometer resistance	T169	C4281815
slope	T082	C1254362
Slope	T082	C1254362
influenced	T077	C4054723
root	T002	C0242726
morphology	T080	C0332437
distribution	T169	C1704711
lateral	T082	C0205093
roots	T002	C0242726
soil	T167	C0037592
depth	T082	C0205125
first-order	T169	C1373201
lateral	T082	C0205093
roots	T002	C0242726
plants	T002	C0032098
growing	T169	C0205245
slope	T082	C1254362
condition	T080	C0348080
asymmetric	T082	C0332514
distribution	T169	C1704711
up-	T082	C1254362
down-slope	T082	C1254362
asymmetric	T082	C0332514
distribution	T169	C1704711
plants	T002	C0032098
growing	T169	C0205245
plane	T082	C1254362
tensile strength	T081	C0039526
lateral	T082	C0205093
roots	T002	C0242726
growing	T169	C0205245
up-slope	T082	C1254362
plane	T082	C1254362
conditions	T080	C0348080
growing	T169	C0205245
down-slope	T082	C1254362
Anatomical investigations	T062	C0242481
roots	T002	C0242726
up-slope	T082	C1254362
area	T082	C0205146
xylem fibers	T002	C1720877
ratio	T081	C0456603
xylem	T002	C1720877
phloem fibers	T002	C1720878
root	T002	C0242726
diameter	T081	C1301886
conditions	T080	C0348080
no differences	T033	C3842396
xylem fiber	T002	C1720877
cell wall	T026	C0007623
thickness	T080	C1280412
Roots	T002	C0242726
growing	T169	C0205245
up-slope	T082	C1254362
anchorage	T052	C2825961
properties	T080	C0871161
strength	T081	C0039526
fibers	T002	C1260603
xylematic	T002	C1720877
tissues	T025	C1514137
root	T002	C0242726
specific	T080	C0205369
morphological	T080	C0332437
anatomical	T080	C0220784
biomechanical	T080	C0205556
traits	T032	C0599883
anchorage	T052	C2825961
functions	T169	C0542341
slope	T082	C1254362
conditions	T080	C0348080
expression	T045	C0017262
Olr59	T028	C1418155
Ethe1	T028	C1428025
Slc10a2 genes	T028	C1420087
liver	T023	C1882726
F344 rats	T015	C0034703
neonatal	T100	C0021289
thyroid hormone disruption	T037	C0347610
thyroid hormone-disrupting	T037	C0347610
chemicals	T131	C0018624
environment	T082	C0014406
disruption of thyroid hormones	T037	C0347610
neonatal period	T079	C0935562
permanent effects	T080	C1280500
thyroid hormone	T116	C0040135
homeostasis	T038	C0019868
developmental disorders	T048	C0008073
thyroid hormones	T116	C0040135
regulating the growth	T040	C1160191
differentiation of many tissues	T033	C1519519
gene expressions	T045	C0017262
neonatal	T100	C0021289
administration of thyroid hormone	T061	C0199780
genes whose expression	T045	C0017262
altered	T169	C0392747
liver	T023	C1882726
thyroid hormone	T116	C0040135
neonatal	T100	C0021289
exposure to	T080	C0332157
triiodothyronine	T116	C0041014
T3	T116	C0041014
T3	T116	C0041014
administered	T061	C0199780
male F344 rats	T015	C0034703
postnatal days	T079	C0443281
cDNA microarray analysis	T062	C1609488
hepatic	T029	C0205054
genes	T028	C0017337
expression	T045	C0017262
neonatal	T100	C0021289
exposure to	T080	C0332157
T3	T116	C0041014
up-regulated genes	T044	C0041904
expression	T045	C0017262
Olr59	T028	C1418155
Ethe1	T028	C1428025
Slc10a2	T028	C1420087
rats	T015	C0034721
neonatally	T100	C0021289
exposed to	T080	C0332157
T3	T116	C0041014
hepatic	T029	C0205054
expression of these genes	T045	C0017262
hydroxylated polybrominated diphenyl ether	T109	C4086502
PBDE	T109	C4086502
OH-BDE42	T109	C4086502
binding to the TR	T044	C1323384
neonatally	T100	C0021289
neonatal	T100	C0021289
thyroid hormones	T116	C0040135
expression of the genes	T045	C0017262
neonatal effects	T047	C0856669
thyroid hormone	T116	C0040135
disrupting chemicals	T131	C0018624
Psychometric Costs	T060	C0033920
Applicants	T098	C0696628
Faking	T055	C0871743
Measurement	T169	C0242485
Retest Correlations	T062	C0237828
Response Conditions	T041	C0009647
examines the stability	T080	C0205360
response process	T041	C0009647
rank-order	T062	C0871206
respondents	T098	C0282122
responding	T041	C0009647
personality scales	T170	C0582654
response conditions	T041	C0009647
Applicants	T098	C0696628
University College of Teacher Education	T073	C0041740
Styria	T083	C0017446
personality scales	T170	C0582654
college admission process	T170	C0009352
personality scales	T170	C0582654
randomly assigned	UnknownType	C0814868
response conditions	T041	C0009647
honest	T055	C0870663
faking-good	T055	C0871743
Longitudinal means	T062	C0023981
covariance structure analyses	T081	C0814908
applicants	T098	C0696628
response processes	T041	C0009647
respondents	T098	C0282122
honest	T055	C0870663
response behavior	T041	C0009647
frame of reference	T077	C1711364
applicants	T098	C0696628
faking behavior	T055	C0871743
faking	T055	C0871743
faking-good	T055	C0871743
latent	T080	C0205275
retest correlations	T062	C0237828
measurement	T169	C0242485
latent	T080	C0205275
retest correlations	T062	C0237828
indicated	T033	C1444656
faking	T055	C0871743
distort	T169	C0700135
respondents	T098	C0282122
rank-order	T062	C0871206
fairness	T080	C2911689
selection decisions	T041	C0011109
faking behavior	T055	C0871743
faking	T055	C0871743
faking-good	T055	C0871743
measurement	T169	C0242485
applicants	T098	C0696628
faking behavior	T055	C0871743
correlations	T080	C1707520
personality scales	T170	C0582654
predictive validity	T080	C0681898
interpreted	T169	C1285553
applicants	T098	C0696628
Faking behavior	T055	C0871743
uniform bias	T078	C0242568
mean raw score	T081	C0392762
interpreted	T169	C1285553
Intraspinal meningioma	T191	C1334264
malignant transformation	T191	C1608408
distant metastasis	T185	C1269798
Meningioma	T191	C0025286
benign tumor	T191	C0086692
Malignant transformation	T191	C1608408
metastasis	T191	C0027627
meningiomas	T191	C0025286
rare	T080	C0522498
meningiomas	T191	C0025286
intracranial	T029	C0524466
reports	T170	C0684224
intraspinal meningiomas	T191	C1334264
report	T170	C0684224
clinical features	T201	C0683325
pathological	T169	C1521733
findings	T033	C0243095
case	T077	C1706256
malignant transformation	T191	C1608408
distant metastasis	T185	C1269798
intraspinal meningioma	T191	C1334264
review of	T169	C0699752
literature	T170	C0023866
man	T098	C0025266
bilateral	T082	C0238767
lower limb paresis	T184	C1836296
diagnosed	T033	C0011900
intradural extramedullary tumor of the thoracic spine	T191	C1334255
Primary	T080	C0205225
tumor resection	T061	C0472422
performed	T169	C0884358
histological findings	T033	C0449575
atypical meningioma	T191	C0431122
meningioma	T191	C0025286
recurred	T067	C0034897
years	T079	C0439234
primary	T080	C0205225
surgery	T061	C0543467
second	T081	C0205436
resection	T061	C0728940
performed	T169	C0884358
partial	T081	C0728938
resection	T061	C0728940
decreased	T081	C0205216
motor evoked potential	T042	C0282617
age	T032	C0001779
patient's	T101	C0030705
lower limb weakness	T184	C1836296
returned	T067	C0034897
third	T081	C0205437
resection	T061	C0728940
performed	T169	C0884358
histological finding	T033	C0449575
atypical meningioma	T191	C0431122
age	T032	C0001779
tumor	T191	C0027651
increased	T081	C0205217
stereotactic irradiation	T061	C0085203
performed	T169	C0884358
age	T032	C0001779
patient	T101	C0030705
diagnosed	T033	C0011900
metastatic tumors	T191	C0027627
rib	T023	C0035561
lumbar vertebra	T023	C0024091
cervical spine	T023	C0728985
sacrum	T023	C0036037
Biopsy	T060	C0005558
rib	T023	C0035561
metastatic tumor	T191	C2939420
performed	T169	C0884358
histological findings	T033	C0449575
anaplastic meningioma	T191	C0259785
case	T077	C1706256
report	T170	C0684224
intraspinal meningioma	T191	C1334264
transformed	T191	C1608408
atypical	T191	C0431122
anaplastic meningioma	T191	C0259785
distant hematogenous metastasis	T185	C1269798
hematogenous	T033	C0796572
Epidemiology	T091	C0014507
risk factors	T033	C0035648
associated with	T080	C0332281
surgical site infection	T046	C0038941
types	T080	C0332307
hepatobiliary and pancreatic surgery	T091	C1319408
Surgical site infection	T046	C0038941
SSI	T046	C0038941
healthcare-associated infections	T046	C0010356
HAIs	T046	C0010356
SSI	T046	C0038941
hepatobiliary and pancreatic surgery	T091	C1319408
HBPS	T091	C1319408
investigated	T169	C1292732
large	T081	C0549177
cohort	T098	C0599755
patients	T101	C0030705
factors	T169	C1521761
associated with	T080	C0332281
SSI	T046	C0038941
HBPS	T091	C1319408
Japan	T083	C0022341
Japanese national database	T170	C0242356
Data	T078	C1511726
HBPS	T091	C1319408
performed	T169	C0884358
extracted	T062	C1707635
national monitoring system	T170	C0282574
HAI	T046	C0010356
Japan Nosocomial Infections Surveillance	T061	C0419786
multivariate logistic regression	T062	C0206031
assessed	T052	C1516048
factors	T169	C1521761
associated with	T080	C0332281
SSI	T046	C0038941
cumulative	T080	C1511559
incidence	T081	C0021149
SSI	T046	C0038941
HBPS	T091	C1319408
incidence	T081	C0021149
SSI	T046	C0038941
pancreatoduodenectomy	T061	C0085162
significantly higher	T081	C4055637
liver resection	T061	C0019144
types	T080	C0332307
HBPS	T091	C1319408
traditional	T169	C0443324
risk factors	T033	C0035648
American Society of Anesthesiologists	T094	C2346733
score	T081	C0449820
ineffective	T078	C3242229
predicting	T078	C0681842
SSI	T046	C0038941
model	T170	C3161035
types	T080	C0332307
surgery	T061	C0543467
risk factors	T033	C0035648
identified	T080	C0205396
age	T032	C0001779
male gender	T032	C0086582
incidence	T081	C0021149
factors	T169	C1521761
associated with	T080	C0332281
SSI	T046	C0038941
types	T080	C0332307
HBPS	T091	C1319408
accurately	T080	C0443131
compare	T052	C1707455
hospital	T073	C0019994
performance	T080	C0871017
relation	T080	C0439849
SSI	T046	C0038941
HBPS	T091	C1319408
operative procedure	T061	C0543467
category	T170	C0683312
surveillance system	T058	C1254363
divided	T169	C0332849
types	T080	C0332307
Signature	T087	C1514562
aggregation	T169	C0332621
prone	T082	C0033422
tau	T116	C0085401
self-assembly	T044	C0872376
microtubule	T026	C0026046
associated	T080	C0332281
tau protein	T116	C0085401
fibrillar cell inclusions	T026	C0230674
linked	T082	C0449379
number	T081	C0237753
neurodegenerative disorders	T047	C0524851
tauopathies	T047	C0949664
mechanism	T169	C0441712
tau	T116	C0085401
self-assembles	T044	C0872376
pathological	T169	C1521733
entities	T071	C1551338
debate	T052	C0870392
largely	T081	C0549177
due to	T169	C0678226
direct	T080	C1947931
experimental	T080	C1517586
insights	T041	C0233820
earliest stages	T079	C2363430
aggregation	T169	C0332621
pulsed double electron-electron resonance	T059	C0022885
measurements	T169	C0242485
fibril	T026	C0225328
forming	T169	C1522492
regions	T082	C0205147
tau	T116	C0085401
PHF6	T116	C1608562
PHF6*	T116	C0033684
transient	T079	C0205374
aggregation	T169	C0332621
end-to-end distance	T081	C0012751
distribution	T169	C1704711
function	T169	C0542341
aggregation	T169	C0332621
time	T079	C0040223
PHF6((*))	T116	C0033684
regions	T082	C0205147
extend	T169	C0231448
distances	T081	C0012751
commensurate	T080	C0205163
extended	T082	C0231449
β-strand structures	T082	C0600383
earliest stages	T079	C2363430
aggregation	T169	C0332621
fibril	T026	C0225328
formation	T169	C1522492
Combined	T080	C0205195
simulations	T062	C0679083
experiments	T062	C0681814
extended	T082	C0231449
β-strand conformational	T082	C0600383
state	T169	C1442792
PHF6((*))	T116	C0033684
aggregating	T169	C0332621
conditions	T080	C0348080
signature	T087	C1514562
aggregation	T169	C0332621
prone	T082	C0033422
tau	T116	C0085401
target	T169	C1521840
therapeutic interventions	T061	C0808232
Design	T052	C1707689
Synthesis	T070	C0007987
Cytotoxic	T049	C0596402
Evaluation	T058	C0220825
7-Chloro-4-(piperazin-1-yl)quinoline	T109	C0034424
Derivatives	T104	C0243072
VEGFR-II	T116	C0378796
Inhibitors	T120	C0243077
Signaling pathway	T044	C0037080
inhibition	T052	C3463820
VEGFR-II	T116	C0378796
cancer	T191	C0006826
management	T058	C0376636
current study	T062	C2603343
synthesis	T070	C0007987
novel	T080	C0205314
1-4-(7-chloroquinolin-4-yl)piperazin-1-yl)-2-(N-substituted-amino)-ethanone	T109	C0034424
derivatives	T104	C0243072
4a-t	T109	C0034424
amination	T070	C0002505
2-chloro-1-(4-(7-chloroquinolin-4-yl)piperazin-1-yl)ethanone (3)	T109	C0034424
secondary amines.	T109	C0002508
structures	T085	C0026383
target	T169	C1521840
compounds	T103	C1706082
confirmed by	T080	C0521093
IR	T059	C0037807
(1) H-NMR	T060	C3850001
(13) C-NMR	T060	C3850003
HRMS	T059	C0037813
microanalysis	T059	C0013844
Compounds	T103	C1706082
4a-t	T109	C0034424
in vitro	T080	C1533691
anticancer	T061	C0920425
screening	T058	C1710032
human breast cancer	T191	C0678222
MCF-7	T025	C0596890
prostate cancer	T191	C0600139
PC3	T025	C0007634
cell lines	T025	C0007600
cytotoxicty	T049	C0596402
cell lines	T025	C0007600
2-(4-(4-bromobenzyl)piperazin-1-yl)-1-(4-(7-chloroquinolin-4-yl)piperazin-1-yl)ethanone (4q)	T109	C0034424
IC50 values	T081	C0600495
MCF-7	T025	C0596890
PC3 cells	T025	C0007634
compared	T052	C1707455
standard drug	T170	C0920479
doxorubicin	T109	C0013089
MCF-7	T025	C0596890
PC3	T025	C0007634
activity	T052	C0441655
MCF-7 cells	T025	C0596890
4q	T109	C0034424
VEGFR-II	T116	C0378796
inhibitor	T120	C0243077
IC50	T081	C0600495
sorafenib	T109	C1516119
docking	T044	C1522290
4q	T109	C0034424
binding mode	T044	C1167622
VEGFR-II	T116	C0378796
inhibitors	T120	C0243077
ErbB3 receptor tyrosine kinase	T116	C0072460
regulates	T038	C1327622
Paneth cells	T025	C0227276
PI3K	T116	C0044602
dependent	T169	C3244310
suppression	T045	C0038855
Atoh1	T028	C1412626
Paneth cells	T025	C0227276
PCs	T025	C0227276
secretory population	T025	C1519221
intestinal crypt	T023	C3686613
intestinal	T023	C0021853
stem cells	T025	C0038250
ISC	T025	C0038250
growth factors	T116	C0018284
innate immunity	T032	C0020969
antimicrobial peptides	T116	C4084937
lysozyme	T116	C3541379
defensins	T116	C0057256
PC	T025	C0227276
dysfunction	T077	C3887504
disorders	T047	C0012634
Crohn's disease	T047	C0010346
necrotizing enterocolitis	T047	C0520459
pathways	T044	C1148560
regulating	T038	C1327622
PC	T025	C0227276
development	T043	C0815089
function	T043	C0007613
neuregulin receptor ErbB3	T116	C0072460
PC	T025	C0227276
differentiation	T043	C0007589
ISC niche	T022	C2350292
Intestinal	T023	C0021853
epithelial	T080	C0221908
ErbB3	T028	C0812265
knockout	T063	C0599772
precocious	T079	C1279930
appearance	T080	C0700364
PCs	T025	C0227276
postnatal	T079	C0443281
day 7	T033	C3842672
increased	T081	C0205217
mature	T079	C0205286
PCs	T025	C0227276
adult mouse	T015	C0025929
ileum	T023	C0020885
ErbB3	T116	C0072460
secretory lineages	T078	C0282637
increased	T081	C0205217
expression	T045	C1171362
ISC	T025	C0038250
Lgr5	T116	C0762578
ErbB3	T116	C0072460
intestines	T023	C0021853
Atoh1	T028	C1412626
transcription factor	T116	C0040648
Atoh1(+)	T116	C1567779
cells	T025	C0007634
ErbB3	T028	C0812265
reciprocal	T080	C1882911
negative	T033	C0205160
regulation	T038	C1327622
ErbB3	T116	C0072460
intestinal progenitor cells	T025	C0814997
reduced	T080	C0392756
activation	T052	C1879547
PI3K-Akt	T169	C2984369
ERK MAPK pathways	T044	C1148560
pathways	T044	C1148560
HT29 cells	T025	C0007634
increased	T081	C0205217
ATOH1	T028	C1412626
PC	T025	C0227276
LYZ	T028	C1416945
ErbB3	T116	C0072460
suppressed	T045	C0038855
LYZ	T028	C1416945
ATOH1	T028	C1412626
PI3K	T116	C0044602
dependent	T169	C3244310
PC	T025	C0227276
ErbB3	T116	C0072460
intestines	T023	C0021853
ER stress	T049	C3178870
inflammation	T046	C0021368
markers	T201	C0005516
negative	T033	C0205160
regulation	T038	C1327622
PCs	T025	C0227276
ErbB3	T116	C0072460
homeostasis	T038	C0019868
data	T078	C1511726
ErbB3	T116	C0072460
PC	T025	C0227276
PI3K	T116	C0044602
suppression	T045	C0038855
Atoh1	T028	C1412626
PC	T025	C0227276
differentiation	T043	C0007589
regulation	T043	C0007613
ISC niche	T022	C2350292
CDF	T081	C3826440
quantile	T081	C1709792
distributions	T081	C0038205
modelling	T170	C3161035
random variables	T081	C1705098
unit interval	T170	C1552654
two-parameter	T077	C0549193
distributions	T081	C0038205
modelling	T170	C3161035
random variables	T081	C1705098
interval	T170	C1552654
cumulative distribution function	T081	C3826440
parent' distribution	T081	C3826440
quantile	T081	C1709792
function	T170	C1705273
probability density	T081	C2986804
functions	T170	C1705273
cumulative distribution functions	T081	C3826440
quantile	T081	C1709792
location	T082	C0450429
parameter	T077	C0549193
dispersion	T082	C0332624
parameter	T077	C0549193
variety	T077	C2346866
shapes	T082	C0332479
beta	T081	C1552649
Kumaraswamy distributions	T081	C3826440
cannot	T033	C0243095
amenable	T080	C3900053
likelihood inference	T081	C0023707
variety	T077	C2346866
quantile	T081	C1709792
regression models	T170	C0034980
predictors	T078	C2698872
location	T082	C0450429
dispersion	T082	C0332624
parameters	T077	C0549193
psychological	T091	C0033909
research problems	T062	C0242481
utility	T169	C0457083
modelling	T170	C3161035
real data	T170	C3272377
First	T081	C0205435
second	T081	C0205436
generation	T079	C0079411
DESs	T074	C1322815
reduce	T080	C0392756
diabetes	T047	C0011847
adverse effect	T046	C0879626
mortality	T081	C0205848
re-intervention	T061	C0184661
multivessel	T023	C0005847
coronary disease	T047	C0010054
Year	T079	C0439234
analysis	T062	C0936012
Diabetes	T047	C0011847
portends	T169	C0205245
increased	T081	C0205217
risk	T078	C0035647
adverse	T046	C0879626
early	T079	C1279919
late	T079	C0205087
outcomes	T169	C1274040
patients	T101	C0030705
PCI	T061	C1532338
study	T062	C2603343
investigate	T169	C1292732
adverse effect	T046	C0879626
diabetes mellitus	T047	C0011849
DM	T047	C0011849
early	T079	C1279919
late	T079	C0205087
PCI	T061	C1532338
outcomes	T169	C1274040
reduced	T080	C0392756
drug-eluting	T074	C1322815
DES	T074	C1322815
bare-metal (BMS) stents	T074	C2825200
reviewed	T078	C1552617
Mount Sinai Beth Israel Hospital	T073	C0019994
first	T081	C0205435
PCI	T061	C1532338
multivessel	T023	C0005847
coronary artery disease	T047	C0010054
CAD	T047	C0010054
Patients	T101	C0030705
excluded	T052	C2828389
single-vessel CAD	T047	C0581374
emergency	T078	C1561583
no	T033	C1513916
stent	T074	C0038257
prior	T079	C0332152
bypass graft	T061	C0185098
myocardial infarction	T047	C0027051
Diabetes	T047	C0011847
effect	T080	C1280500
year	T079	C0439234
mortality	T081	C0205848
re-intervention	T061	C0184661
risk-adjusted hazard ratios	T081	C2985465
AHR	T081	C2985465
confidence intervals	T081	C0009667
DES	T074	C1322815
three-vessel	T047	C3272265
DM	T047	C0011849
BMS	T074	C2825200
three-vessel	T047	C3272265
DM	T047	C0011849
stent	T074	C0038257
DES	T074	C1322815
BMS	T074	C2825200
vessel disease	T047	C0042373
two	T047	C0581375
three	T047	C3272265
Diabetes	T047	C0011847
effect	T080	C1280500
mortality	T081	C0205848
lower	T080	C0205556
DES	T074	C1322815
AHRDM/NoDM	T081	C2985465
BMS	T074	C2825200
AHRDM/NoDM	T081	C2985465
predominantly	T080	C1542147
two-vessel	T047	C0581375
patients	T101	C0030705
diabetes	T047	C0011847
effect	T080	C1280500
first	T081	C0205435
DES1	T074	C1322815
AHRDM/NoDM	T081	C2985465
second	T081	C0205436
DES2	T074	C1322815
AHRDM/NoDM	T081	C2985465
generation	T079	C0079411
DES	T074	C1322815
Re-intervention	T061	C0184661
comparisons	T052	C1707455
increased	T081	C0205217
diabetes	T047	C0011847
sub-cohorts	T098	C0599755
analysis	T062	C0936012
PCI	T061	C1532338
diabetes	T047	C0011847
associated with	T080	C0332281
worse	T033	C1457868
year	T079	C0439234
mortality	T081	C0205848
irrespective	T077	C1254372
stent	T074	C0038257
type	T080	C0332307
DES	T074	C1322815
DES2	T074	C1322815
2-vessel disease	T047	C0581375
complementary	T077	C1254372
stent	T074	C0038257
effect	T080	C1280500
analysis	T062	C0936012
confirmed	T033	C0750484
DES	T074	C1322815
BMS	T074	C2825200
DES2	T074	C1322815
DES1	T074	C1322815
superiority	T080	C0205556
diabetics	T033	C0241863
non-diabetics	T033	C0243095
Lycopene	T109	C0065331
risk	T078	C0035647
cardiovascular diseases	T047	C0007222
meta-analysis	T062	C0920317
observational studies	T033	C0552617
meta-analysis	T062	C0920317
investigate	T169	C1292732
lycopene	T109	C0065331
risk	T078	C0035647
cardiovascular diseases	T047	C0007222
CVD	T047	C0007222
Studies	T062	C2603343
lycopene	T109	C0065331
risk	T078	C0035647
CVD	T047	C0007222
Pubmed	T170	C1138432
Embase	T170	C0282574
Web of Science	T170	C0282574
eligible studies	T062	C2603343
identified	T080	C0205396
inverse association	T077	C1708567
risk ratio	T081	C0242492
RR	T081	C0242492
CI	T081	C0009667
lycopene	T109	C0065331
exposure	T080	C0332157
risk	T078	C0035647
CVD	T047	C0007222
Findings	T033	C0243095
dietary	T168	C0012155
studies	T062	C2603343
RR	T081	C0242492
CI	T081	C0009667
biomarker	T201	C0005516
studies	T062	C2603343
RR	T081	C0242492
CI	T081	C0009667
Dietary	T168	C0012155
lycopene	T109	C0065331
intake	T169	C1512806
statistically significant	T081	C0237881
coronary heart disease	T047	C0010068
CHD	T047	C0010068
RR	T081	C0242492
CI	T081	C0009667
stroke	T047	C0038454
RR	T081	C0242492
CI	T081	C0009667
risk estimate	T081	C1519101
lycopene	T109	C0065331
biomarker	T201	C0005516
statistically significant	T081	C0237881
stroke	T047	C0038454
RR	T081	C0242492
CI	T081	C0009667
Subgroup	T185	C1515021
analyses	T062	C0936012
retrospective	T062	C0035363
studies	T062	C2603343
statistically significant	T081	C0237881
heterogeneity	T080	C0019409
lycopene	T109	C0065331
exposure	T080	C0332157
inversely associated	T077	C1708567
risk	T078	C0035647
CVD	T047	C0007222
randomized clinical trials	T062	C0206034
lycopene	T109	C0065331
CVD	T047	C0007222
Bacteria	T007	C0004611
Wheat	T002	C1123020
Cucurbit	T002	C0446254
Plant Roots	T002	C0242726
Metabolize	T040	C0025519
PAHs	T109	C0032458
Aromatic	T109	C0020245
Root	T002	C0242726
Exudates	T167	C1720935
Implications	T078	C0392360
Rhizodegradation	T069	C1720751
chemical interaction	T070	C1537001
plants	T002	C0032098
bacteria	T007	C0004611
root	T002	C0242726
zone	T082	C1710706
soil	T167	C0037592
decontamination	T169	C0205245
Bacteria	T007	C0004611
degrade	T169	C0243125
PAHs	T109	C0032458
isolated	T169	C0205409
rhizospheres	T070	C2936389
plant	T002	C0032098
species	T185	C1705920
biological	T080	C0205460
traits	T032	C0599883
phytochemicals	T109	C0577749
contaminant	T167	C2827365
degradation	T169	C0243125
monocot	T002	C0032098
dicotyledon plants	T002	C0032098
grown	T040	C0597252
PAH	T109	C0032458
contaminated	T169	C0205279
soil	T167	C0037592
manufactured gas plant	T073	C3273359
MGP	T073	C3273359
site	T082	C0205145
phytotoxicity assay	T059	C0005507
soil	T167	C0037592
decontamination	T169	C0205245
rhizospheres	T070	C2936389
compared	T052	C1707455
soil	T167	C0037592
controls	T169	C2587213
Bacteria	T007	C0004611
isolated	T169	C0205409
plant roots	T002	C0242726
rhizobacteria	T007	C0004611
selected	T052	C1707391
growth	T040	C0018270
anthracene	T109	C0003162
chrysene	T109	C0055655
PAH	T109	C0032458
amended	T080	C1691222
plates	T074	C1139067
Rhizosphere	T070	C2936389
isolates	T123	C1764827
metabolized	T040	C0025519
PAHs	T109	C0032458
PAH	T109	C0032458
catabolic	T169	C0311402
liquid incubations	T059	C1439852
Aromatic	T109	C0020245
root	T002	C0242726
exudate compounds	T167	C1720935
flavonoids	T109	C0596577
simple phenols	T109	C0031428
substrates	T167	C3891814
isolated	T169	C0205409
rhizobacteria	T007	C0004611
phenolic compounds	T109	C0031428
morin	T109	C0066801
caffeic acid	T109	C0054433
protocatechuic acid	T109	C0072489
bacterial	T007	C0004611
degradation	T169	C0243125
PAHs	T109	C0032458
rhizosphere	T070	C2936389
Joint model imputation	T081	C2825511
estimate	T081	C0750572
treatment effect	T033	C1518681
long-term	T079	C0443252
survival	T052	C0038952
auxiliary events	T051	C0441471
Clinical trial	T062	C0008976
duration	T079	C0449238
clinical research	T062	C0008972
cancer trials	T062	C1516640
endpoint	T201	C2347784
overall survival	T081	C4086681
surrogate endpoint	T080	C0162488
auxiliary variable	T080	C0439828
analyze	T062	C0936012
treatment effect	T033	C1518681
censored	T052	C3889994
observations	T062	C0302523
compensated	T080	C0205432
imputation	T081	C2825511
unobserved	T033	C0243095
deaths	T033	C1306577
predictions	T078	C0681842
risk	T078	C0035647
death	T040	C0011065
joint model	T081	C2825511
recurrent	T079	C2945760
event	T051	C0441471
terminal	T080	C0205088
event	T051	C0441471
disease relapse	T047	C0277556
information	T078	C1533716
imputation methods	T081	C2825511
compared	T052	C1707455
sampling	T062	C0036150
estimated parametric distribution	T081	C0392762
survival time	T201	C2919552
sampling	T062	C0036150
nonparametric estimation	T081	C0242932
treatment effect	T033	C1518681
standard error	T081	C1710181
estimated	T081	C0750572
multiple imputations	T081	C2825511
performances	T052	C1882330
methods	T170	C0025663
compared	T052	C1707455
bias	T078	C0242568
estimates	T081	C0750572
standard errors	T081	C1710181
coverage	T052	C2700387
probability	T081	C0033204
methods	T170	C0025663
retrospectively	T080	C1514923
applied	T169	C4048755
randomized clinical trials	T062	C0206034
effect	T080	C1280500
adjuvant	T169	C1522673
chemotherapy	T061	C3665472
breast cancer	T191	C0006142
patients	T101	C0030705
Corneal Epithelial	T025	C1182610
Barrier	T033	C1704511
Developmental	T080	C0458003
Isolating	T169	C0205409
Corneal Epithelial	T025	C1182610
Conjunctival Cells	T025	C1182611
development	T169	C1527148
corneal epithelium	T024	C0459875
CE	T024	C0459875
conjunctiva	T023	C0009758
surface ectoderm	T018	C1515087
examined	T033	C0332128
development	T169	C1527148
cells	T025	C0007634
isolated	T169	C0205409
Epithelia	T024	C0014609
anterior eyes	T023	C0003151
chicken embryos	T018	C0008046
labeled	T130	C1522485
fluorescent	T130	C0016320
lipophilic dye	T130	C0013343
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate	T109	C2350183
DiI	T109	C2350183
DiI	T109	C2350183
epithelial surface	T026	C2327105
anterior eye	T023	C0003151
diffusion	T070	C0012222
fluorescence microscopy	T059	C0026022
morphologic	T080	C0332437
changes	T169	C0392747
surface cells of these epithelial	T026	C2327105
examined	T033	C0332128
scanning electron microscopy	T059	C0026020
Immunofluorescence	T059	C0079604
expression	T045	C1171362
cytokeratin K3	T116	C1313613
ZO-1	T116	C3503764
N-cadherin	T116	C0027215
Connexin-43	T116	C0110613
function	T039	C0031843
gap junctions	T030	C0206117
analyzed	T062	C0936012
cut-loading	T081	C0392762
fluorescent dye	T130	C0016320
rhodamine-dextran	T109	C0073196
embryonic	T042	C0013936
day	T079	C0439228
E	T042	C0013936
DiI	T109	C2350183
surface	T082	C0205148
CE	T024	C0459875
spreads	T080	C0332261
epithelial cells	T025	C0014597
anterior eye	T023	C0003151
older eyes	T023	C0015392
labeled	T130	C1522485
dye	T130	C0013343
diffusion	T070	C0012222
restricted	T169	C0443288
CE	T024	C0459875
diffusion	T070	C0012222
DiI	T109	C2350183
conjunctival	T023	C0009758
surface	T082	C0205148
E	T042	C0013936
restricted	T169	C0443288
conjunctiva	T023	C0009758
Scanning electron microscopy	T059	C0026020
developmentally	T169	C1527148
physical separations	T033	C4060664
progressively	T169	C0205329
cells	T025	C1182610
CE	T024	C0459875
conjunctiva	T023	C0009758
E	T042	C0013936
separations	T169	C0205245
ring	T023	C0229119
cornea	T023	C0010031
functional	T169	C0205245
restriction	T169	C0443288
gap junctions	T030	C0206117
tissues	T024	C0014609
occur	T052	C1709305
E	T042	C0013936
ocular development	T042	C1517080
barrier	T033	C1704511
diffusion	T070	C0012222
DiI	T109	C2350183
contiguous	T082	C0205283
CE	T024	C0459875
conjunctiva	T023	C0009758
differential	T080	C1705242
expression	T045	C1171362
gap junctions	T030	C0206117
tissues	T024	C0014609
Longitudinal study	T062	C0023981
bovine	T015	C0007452
rotavirus group A	T005	C1002306
newborn	T008	C0003065
calves	T015	C3668829
vaccinated	T033	C1519885
unvaccinated	T033	C0243095
dairy herds	T015	C0175925
rotavirus	T005	C0035870
excretion	T031	C0504085
calves	T015	C3668829
cross-sectional studies	T062	C0010362
protection	T061	C0150259
calves	T015	C3668829
born	T040	C0005615
vaccinated	T033	C1519885
dams	T015	C0007452
diarrhea	T184	C0011991
rotavirus	T005	C0035870
excretion	T031	C0504085
dairy calves	T015	C3668829
vaccinated	T033	C1519885
unvaccinated	T033	C0243095
dams	T015	C0007452
genotypes	T032	C0017431
bovine	T015	C0007452
rotavirus group A	T005	C1002306
RVA	T005	C1002306
strains	T001	C1518614
animals	T015	C3668829
disease	T047	C0012634
naturally	T169	C0205296
occurring	T052	C1709305
first month of life	T033	C3278912
fecal samples	T031	C0475362
calves	T015	C3668829
farm	T082	C0557759
vaccinated	T033	C1519885
herd	T015	C0175925
samples	T031	C0475362
calves	T015	C3668829
tested positive	T033	C1514241
RVA	T005	C1002306
unvaccinated	T033	C0243095
samples	T031	C0475362
calves	T015	C3668829
tested positive	T033	C1514241
genotyping	T059	C2368152
VP7 genes	T028	C0017337
nucleotide sequence	T086	C0004793
G6 genotype	T032	C0017431
NCDV strain	T001	C1518614
VP4 gene	T028	C0017337
strains	T001	C1518614
vaccinated	T033	C1519885
B223 strain	T001	C1518614
strains	T001	C1518614
unvaccinated	T033	C0243095
herd	T015	C0175925
P[5] genotype	T032	C0017431
UK strain	T001	C1518614
Genotypes	T032	C0017431
G6P[11]	T032	C0017431
vaccinated	T033	C1519885
herd	T015	C0175925
G6P[5]	T032	C0017431
unvaccinated	T033	C0243095
herd	T015	C0175925
calves	T015	C3668829
infected	T033	C0439663
rotavirus	T005	C0035870
diarrhea	T184	C0011991
genotypes	T032	C0017431
commercial vaccine	T121	C0042210
G6P[1]	T032	C0017431
G10P[11]	T032	C0017431
rotavirus	T005	C0035870
strains	T001	C1518614
vaccinated	T033	C1519885
unvaccinated	T033	C0243095
herds	T015	C0175925
constant	T080	C1948059
surveillance	T061	C0038842
potential	T080	C3245505
causes	T169	C0015127
vaccination	T061	C0042196
failure	T033	C0162643
Gene	T028	C0017337
genome-wide association study	T063	C2350277
identified	T080	C0205396
19p13.3	T026	C1520850
lean body mass	T201	C0424678
Lean body mass	T201	C0424678
LBM	T201	C0424678
trait	T032	C0599883
human	T016	C0086418
health	T078	C0018684
genomic loci	T028	C0678933
LBM	T201	C0424678
gene	T028	C0017337
genome-wide association study	T063	C2350277
lean mass index	T081	C0392762
LMI	T081	C0392762
unrelated	T033	C0445356
Caucasian	T098	C0043157
subjects	T098	C0080105
replicated	T169	C0205173
unrelated	T033	C0445356
Caucasians	T098	C0043157
subjects	T098	C0080105
Gene	T028	C0017337
association analyses	T063	C2350277
associations	T080	C0439849
genes	T028	C0017337
UQCR	T028	C1540163
TCF3	T028	C1336596
MBD3	T028	C1417051
single	T081	C0205171
locus	T028	C0678933
19p13.3	T026	C1520850
discovery	T080	C0205556
replication	T080	C1883725
functional	T169	C0205245
relevance	T080	C2347946
genes	T028	C0017337
LMI	T081	C0392762
19p13.3	T026	C1520850
region	T082	C0205147
UQCR	T028	C1540163
TCF3	T028	C1336596
MBD3 genes	T028	C1417051
locus	T028	C0678933
lean mass	T201	C0424678
variation	T070	C0042333
Basal	T082	C0205112
ryanodine receptor activity	T044	C1753335
suppresses	T169	C1260953
autophagic	T026	C0333781
flux	T070	C2348693
inositol 1,4,5-trisphosphate receptors	T116	C0063592
IP3Rs	T116	C0063592
intracellular Ca(2+) signaling	T043	C3158759
critically	T080	C1511545
involved	T169	C1314939
regulating	T038	C1327622
different	T080	C1705242
steps	T077	C1261552
autophagy	T043	C0004391
lysosomal	T026	C0024369
degradation pathway	T077	C1511758
ryanodine receptors	T116	C0917729
RyR	T116	C0917729
intracellular Ca(2+)-release channels	T044	C1153434
expressed	T045	C1171362
excitable	T033	C1562285
cell types	T170	C0449475
including	T169	C0332257
muscle	T024	C0026845
neurons	T025	C0027882
extensively	T080	C0205231
studied	T062	C2603343
autophagy	T043	C0004391
aberrant	T080	C0443127
expression	T045	C1171362
excessive	T080	C0442802
activity	T044	C1537044
RyRs	T116	C0917729
tissues	T024	C0040300
implicated	T033	C2945640
onset of	T080	C0332162
several	T081	C0443302
diseases	T047	C0012634
including	T169	C0332257
Alzheimer's disease	T047	C0002395
impaired	T169	C0221099
autophagy	T043	C0004391
regulation	T038	C1327622
contributes	T052	C1880177
pathology	T169	C0205469
study	T062	C2603343
determined	T059	C1148554
pharmacological	T038	C0007992
RyR	T116	C0917729
inhibition	T052	C3463820
modulate	T082	C0443264
autophagic	T026	C0333781
flux	T070	C2348693
ectopic	T082	C0574895
RyR	T116	C0917729
expressing	T045	C1171362
models	T170	C3161035
HEK293 cells	T025	C2936239
cell types	T170	C0449475
endogenously	T169	C0205227
express	T045	C1171362
RyR	T116	C0917729
C2C12 myoblasts	T025	C0596995
primary	T080	C0205225
hippocampal	T023	C0019564
neurons	T025	C0027882
Importantly	T080	C3898777
RyR3	T116	C0524964
overexpression	T045	C1171362
HEK293 cells	T025	C2936239
impaired	T169	C0221099
autophagic	T026	C0333781
flux	T070	C2348693
cell	T025	C0007634
models	T170	C3161035
tested	T169	C0039593
pharmacological	T038	C0007992
inhibition	T052	C3463820
endogenous	T169	C0205227
ectopically	T082	C0574895
expressed	T045	C1171362
RyRs	T116	C0917729
dantrolene	T109	C0010976
ryanodine	T109	C0035983
augmented	T081	C0205217
autophagic	T026	C0333781
flux	T070	C2348693
increasing	T169	C0442808
lysosomal	T026	C0024369
turn-over	T044	C0597297
number	T081	C0237753
autophagosomes	T026	C3887595
autolysosomes	T026	C0230822
measured	T080	C0444706
mCherry	T116	C3489546
LC3 punctae	T116	C3540600
cell	T025	C0007634
increased	T081	C0205217
control	T096	C0009932
HEK RyR3 cells	T025	C0007634
dantrolene	T109	C0010976
ryanodine	T109	C0035983
treatments	T061	C1533734
differentiated	T043	C1159966
C2C12 cells	T025	C0596995
transmission electron microscopy	T059	C0678118
demonstrated	T080	C0443289
dantrolene	T109	C0010976
treatment	T061	C1533734
decreased	T081	C0205216
number	T081	C0237753
autophagic	T026	C0333781
vacuoles	T026	C0042219
cellular	T025	C0007634
cross section	T082	C0552389
modulation	UnknownType	C0678672
autophagic	T026	C0333781
flux	T070	C2348693
functional	T169	C0205245
inhibition	T052	C3463820
RyR channels	T116	C0054493
RyR	T116	C0917729
inhibitors	T120	C0243077
efficiently	T080	C0442799
number	T081	C0237753
cells	T025	C0007634
spontaneous	T169	C0205359
RyR3	T116	C0524964
activity	T044	C1537044
HEK293 cell	T025	C2936239
model	T170	C3161035
control	T096	C0009932
cells	T025	C0007634
dantrolene	T109	C0010976
ryanodine	T109	C0035983
treatments	T061	C1533734
conclusion	T078	C1707478
basal	T082	C0205112
RyR	T116	C0917729
Ca(2+)-release events	T044	C1820193
suppress	T169	C1260953
autophagic	T026	C0333781
flux	T070	C2348693
level	T080	C0441889
lysosomes	T026	C0024369
Fluoride	T121	C0016327
concentration	T081	C1446561
saliva	T031	C0036087
biofilm fluid	T007	C0081786
application	T058	C0185125
fluoride varnishes	T122	C0016326
fluoride varnishes	T122	C0016326
FV	T122	C0016326
evaluated	T058	C0220825
cariostatic properties	T039	C3179394
Consequently	T033	C3845876
aim	T078	C1947946
in vivo	T082	C1515655
study	T062	C2603343
investigate	T058	C0220825
intra	T082	C0442107
oral	T082	C0442027
fluoride	T121	C0016327
retention	T169	C0333117
clearance patterns	T033	C0231360
FV	T122	C0016326
subjects	T098	C0080105
years	T079	C1510829
laboratory	T073	C0022877
analyst	T097	C0870132
blinded	T062	C0150108
randomized	T062	C0034656
crossover study	T062	C0150097
comparing	T052	C1707455
ability	T032	C0085732
sodium fluoride varnishes	T122	C0016326
CavityShield-CS	T122	C0016326
Enamel Pro-EP	T122	C0016326
Vanish-V	T122	C0016326
enhance	T052	C2349975
fluoride	T121	C0016327
concentrations	T081	C1446561
biofilm fluid	T007	C0081786
centrifuged	T031	C3897072
whole	T081	C0444667
saliva	T031	C0036087
period	T079	C1948053
FV	T122	C0016326
fluoride	T121	C0016327
concentration	T081	C1446561
time patterns	T079	C0439545
noted	T170	C1317574
investigated	T080	C0449433
FV	T122	C0016326
studied	T062	C2603343
variables	T080	C0439828
highest	T080	C1522410
fluoride	T121	C0016327
concentrations	T081	C1446561
observed	T169	C1441672
biological sample	T077	C2347026
collected	T169	C1516698
FV	T122	C0016326
Mean±SE	T081	C2348148
area under fluoride clearance curve	T081	C0376690
values	T080	C0042295
biofilm fluid	T007	C0081786
CS	T122	C0016326
EP	T122	C0016326
V	T122	C0016326
centrifuged	T031	C3897072
saliva	T031	C0036087
CS	T122	C0016326
EP	T122	C0016326
V	T122	C0016326
whole	T081	C0444667
saliva	T031	C0036087
CS	T122	C0016326
EP	T122	C0016326
V	T122	C0016326
V	T122	C0016326
fluoride	T121	C0016327
biofilm fluid	T007	C0081786
CS	T122	C0016326
EP	T122	C0016326
centrifuged	T031	C3897072
saliva	T031	C0036087
CS	T122	C0016326
V	T122	C0016326
significantly	T078	C0750502
resulted	T169	C1274040
higher	T080	C1522410
fluoride	T121	C0016327
retention	T169	C0333117
EP	T122	C0016326
significant	T078	C0750502
FV	T122	C0016326
observed	T169	C1441672
whole	T081	C0444667
saliva	T031	C0036087
present	T033	C0150312
study	T062	C2603343
FV	T122	C0016326
ability	T032	C0085732
fluoride	T121	C0016327
intra	T082	C0442107
orally	T082	C0442027
potentially	T080	C3245505
related	T080	C0439849
differences	T080	C1705242
extent	T082	C0439792
present	T033	C0150312
findings	T033	C0243095
relate	T080	C0439849
clinical efficacy	T080	C3850123
determined	T059	C1148554
Clinical research	T062	C0008972
investigates	T058	C0220825
fluoride	T121	C0016327
release	T080	C0205556
patterns	T082	C0449774
saliva	T031	C0036087
biofilm fluid	T007	C0081786
FV products	T122	C0016326
insufficient	T080	C0231180
research	T062	C0242481
investigate	T058	C0220825
FV formulations	T122	C0016326
efficacy	T080	C1280519
clinicians	T097	C0871685
better	T080	C0332272
evidence	T078	C3887511
treatment	T169	C1522326
prognostic value	T201	C1514474
extranodal extension	T033	C3899187
human papillomavirus	T005	C0021344
oropharyngeal squamous cell carcinoma	T191	C0280313
Extranodal (or extracapsular) extension	T033	C3899187
ENE	T033	C3899187
adverse prognostic factor	T201	C1514474
patients	T101	C0030705
head and neck cancers	T191	C0278996
primary surgery	T058	C2081627
ENE	T033	C3899187
human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC)	T191	C2828150
single-institution	T093	C2607850
studies	T062	C2603343
not established	T080	C0443211
ENE	T033	C3899187
predicts	T078	C0681842
inferior	T082	C0542339
outcome	T169	C1274040
prognostic value	T201	C1514474
ENE	T033	C3899187
HPV	T005	C0021344
positive	T033	C1446409
patients	T101	C0030705
primary surgery	T058	C2081627
adjuvant chemoradiation	T061	C3178761
overall survival	T081	C4086681
OS	T081	C4086681
compared	T052	C1707455
radiation alone	T070	C0851346
ENE	T033	C3899187
positive	T033	C1446409
patients	T101	C0030705
Patients	T101	C0030705
primary surgery	T058	C2081627
pathologic T1	T169	C1521733
pT1	T169	C1521733
pT4 tumors	T191	C0027651
pathologic N1	T169	C1521733
pN1	T169	C1521733
pN3 lymph node	T023	C0024204
status	T080	C0449438
HPV-positive OPSCC	T191	C2828150
identified	T080	C0205396
National Cancer Data Base	T170	C3826808
Features	T080	C1521970
associated with	T080	C0332281
ENE	T033	C3899187
analyzed	T062	C0936012
Univariable and multivariable Cox regression analyses	T170	C0034980
identified	T080	C0205396
predictors	T078	C2698872
OS	T081	C4086681
effect	T080	C1280500
adjuvant treatment	T061	C3162256
OS	T081	C4086681
ENE	T033	C3899187
positive	T033	C1446409
cohort	T081	C0009247
evaluated	T058	C0220825
patients	T101	C0030705
inclusion criteria	T080	C1512693
ENE	T033	C3899187
positive	T033	C1446409
ENE	T033	C3899187
positive	T033	C1446409
patients	T101	C0030705
treatment	T061	C0087111
received	T080	C1514756
concurrent chemoradiotherapy	T061	C3178775
received	T080	C1514756
radiotherapy	T061	C0038886
received	T080	C1514756
no	T080	C0332288
adjuvant treatment	T061	C3162256
median	T081	C0876920
follow-up	T058	C1522577
months	T079	C0439231
ENE	T033	C3899187
associated with	T080	C0332281
worse	T033	C1457868
year	T079	C0439234
OS	T081	C4086681
multivariable analysis	T170	C0034980
included	T169	C0332257
lymph nodes	T023	C0024204
ENE	T033	C3899187
lymphovascular invasion	T033	C1708790
pT3/pT4 tumors	T191	C0027651
Charlson-Deyo score	T081	C0449820
associated with	T080	C0332281
worse	T033	C1457868
OS	T081	C4086681
ENE	T033	C3899187
positive	T033	C1446409
patients	T101	C0030705
no difference	T033	C3842396
year	T079	C0439234
OS	T081	C4086681
received	T080	C1514756
adjuvant concurrent chemoradiotherapy	T061	C3178761
radiotherapy alone	T061	C0038886
Propensity score	T081	C2718044
matched comparison	T081	C0086766
revealed	T080	C0443289
results	T169	C1274040
ENE	T033	C3899187
associated with	T080	C0332281
inferior	T082	C0542339
OS	T081	C4086681
patients	T101	C0030705
HPV-positive OPSCC	T191	C2828150
OS	T081	C4086681
not better	T033	C4049139
adjuvant chemoradiotherapy	T061	C3178761
compared	T052	C1707455
radiotherapy alone	T061	C0038886
ENE	T033	C3899187
positive	T033	C1446409
patients	T101	C0030705
current findings support	T081	C0035176
prospective studies	T062	C0033522
adjuvant chemoradiation	T061	C3178761
HPV	T005	C0021344
positive	T033	C1446409
patients	T101	C0030705
ENE	T033	C3899187
Psychological Distress	T048	C0815107
Fertile	T040	C0015895
Age	T032	C0001779
Premenopausal	T039	C0206158
Women	T098	C0043210
PCOS	T047	C0032460
Symptoms	T184	C1457887
Follow-up	T058	C1522577
Polycystic ovary syndrome	T047	C0032460
PCOS	T047	C0032460
psychological distress	T048	C0815107
obesity	T047	C0028754
hyperandrogenism	T047	C0206081
promoters	T052	C0033414
investigate	T169	C1292732
prevalence	T081	C0683921
anxiety	T048	C0003469
depression	T048	C0011581
women	T098	C0043210
PCOS	T047	C0032460
PCOS	T047	C0032460
symptoms	T184	C1457887
age	T032	C0001779
obesity	T047	C0028754
hyperandrogenism	T047	C0206081
awareness	T041	C0004448
PCOS	T047	C0032460
psychological distress	T048	C0815107
assessed	T052	C1516048
Population based follow-up	T062	C1709599
Northern Finland	T083	C0016132
Birth Cohort	T081	C1706962
year	T079	C0439234
follow-up	T058	C1522577
age	T032	C0001779
questionnaire-based screening	T062	C1134635
oligoamenorrhea	T046	C0028949
OA	T046	C0028949
hirsutism	T047	C0271610
H	T047	C0271610
asymptomatic	T033	C0231221
controls	T096	C0009932
OA	T046	C0028949
H	T047	C0271610
OA	T046	C0028949
H	T047	C0271610
PCOS	T047	C0032460
year	T079	C0439234
follow-up	T058	C1522577
controls	T096	C0009932
OA	T046	C0028949
H	T047	C0271610
PCOS	T047	C0032460
Questionnaire-based screening	T062	C1134635
anxiety	T048	C0003469
depression symptoms	T184	C0086132
Hopkins Symptom Checklist-25	T170	C0451218
diagnosed	T033	C0011900
treated	T033	C0332154
depression	T048	C0011581
age	T032	C0001779
BMI	T201	C1305855
serum testosterone	T059	C4064092
free androgen index	T059	C0428629
FAI	T059	C0428629
awareness	T041	C0004448
polycystic ovaries	T047	C0032460
PCOS	T047	C0032460
psychological distress	T048	C0815107
assessed	T052	C1516048
Population-based prevalence	T081	C1709597
anxiety	T048	C0003469
depression	T048	C0011581
women	T098	C0043210
PCOS	T047	C0032460
PCOS	T047	C0032460
symptoms	T184	C1457887
age	T032	C0001779
Anxiety	T048	C0003469
depression symptoms	T184	C0086132
depression	T048	C0011581
age	T032	C0001779
women	T098	C0043210
PCOS	T047	C0032460
H	T047	C0271610
controls	T096	C0009932
BMI	T201	C1305855
hyperandrogenism	T047	C0206081
anxiety	T048	C0003469
depression symptoms	T184	C0086132
awareness	T041	C0004448
PCOS	T047	C0032460
anxiety	T048	C0003469
Women	T098	C0043210
PCOS	T047	C0032460
H	T047	C0271610
anxiety	T048	C0003469
depression symptoms	T184	C0086132
controls	T096	C0009932
BMI	T201	C1305855
hyperandrogenism	T047	C0206081
psychological distress	T048	C0815107
PCOS	T047	C0032460
awareness	T041	C0004448
PCOS	T047	C0032460
anxiety	T048	C0003469
anxiety	T048	C0003469
depression	T048	C0011581
use of	T169	C1524063
Oxford Nanopore	T092	C1561598
native	T169	C0302891
barcoding	T062	C2936547
complete	T080	C0205197
genome assembly	T085	C2348746
Oxford Nanopore Technologies	T092	C1561598
MinION(TM)	T074	C0025080
mobile	T169	C0231435
long read sequences	T086	C0162326
turn-around time	T079	C1254367
report	T170	C0684224
single contig genome assembly	T085	C2348746
using	T169	C1524063
Oxford Nanopore	T092	C1561598
native	T169	C0302891
barcoding	T062	C2936547
applied	T169	C4048755
multiplexed library	T028	C0017430
samples	T077	C2347026
combined	T080	C0205195
existing	T077	C2987476
short-read data	T170	C0950138
closure	T062	C1521802
multiple	T081	C0439064
bacterial genomes	T028	C0085238
single	T081	C0205171
MinION(TM)	T074	C0025080
sequencing	T063	C1328887
run	T169	C1704688
availability of	T169	C0470187
existing	T077	C2987476
short-read data	T170	C0950138
strain	T001	C1518614
used	T169	C1524063
MHO_001	T001	C1518614
methicillin resistant	T032	C0079830
Staphylococcus aureus	T007	C0038172
USA300	T001	C1518614
Using	T169	C1524063
assembly	T085	C2348746
existing	T077	C2987476
short read	T080	C0205556
barcoded long read sequences	T086	C0162326
multiplexed data	T078	C1547368
genome	T028	C0017428
S. aureus	T007	C0038172
USA300 strain MHO_001	T001	C1518614
long-read data	T170	C0950138
average	T081	C1510992
MinION(TM)	T074	C0025080
run	T169	C1704688
genomic	T028	C0017428
coverage	T169	C1999244
using	T169	C1524063
standard	T081	C0034925
tools	T170	C0037589
sufficient	T080	C0205410
complete	T080	C0205197
circular chromosome	T026	C0035639
S. aureus	T007	C0038172
strain MHO_001	T001	C1518614
complete	T080	C0205197
plasmids	T114	C0032136
Minor	T080	C0205165
differences	T080	C1705242
noted	T080	C4288581
compared	T052	C1707455
USA300	T001	C1518614
genome	T028	C0017428
USA300_FPR3757	T028	C0085238
including	T169	C0332257
translocation	T043	C0282583
loss	T081	C1517945
gain	T081	C1517378
mobile genetic elements	T114	C1257903
MinION(TM)	T074	C0025080
reads	T169	C1704688
multiplexed	T169	C0205245
using	T169	C1524063
native	T169	C0302891
barcoding	T062	C2936547
used	T169	C1524063
combination	T080	C0205195
short-read data	T170	C0950138
complete	T080	C0205197
bacterial genome	T028	C0085238
complete	T080	C0205197
multiple	T081	C0439064
genomes	T028	C0017428
short-read data	T170	C0950138
available	T033	C0243095
single	T081	C0205171
MinION(TM)	T074	C0025080
run	T169	C1704688
impact	T080	C4049986
understanding	T041	C0162340
accessory	T081	C1883702
genome content	T028	C0017428
plasmid	T114	C0032136
diversity	T080	C1880371
genome	T028	C0017428
rearrangements	T045	C0017287
Doxorubicin	T109	C0013089
Dose-Dependent	T081	C1512045
Toxicity	T037	C0600688
Mouse	T015	C0025929
Ovarian Follicle	T023	C0018120
Development	T039	C0243107
Hormone Secretion	T042	C0312431
Oocyte Maturation	T043	C1160520
Doxorubicin	T109	C0013089
DOX	T109	C0013089
commonly	T081	C0205214
anticancer medications	T109	C0003392
fertility	T040	C0015895
damaging	T169	C1883709
ovarian follicles	T023	C0018120
dose-dependent	T081	C1512045
toxicity	T037	C0600688
DOX	T109	C0013089
dynamic	T169	C0729333
follicle	T023	C0018120
development	T039	C0243107
oocyte maturation	T043	C1160520
objective	T170	C0018017
effects of	T080	C1704420
human	T016	C0086418
relevant	T080	C2347946
exposure	T080	C0332157
levels	T080	C0441889
DOX	T109	C0013089
follicular	T023	C0018120
functions	T169	C0542341
developmental	T039	C0243107
time	T079	C0040223
In vitro	T080	C1533691
cultured	T059	C0430400
multilayered secondary mouse follicles	T023	C0737234
treated	T169	C1522326
DOX	T109	C0013089
follicle	T023	C0018120
development	T039	C0243107
hormone secretion	T042	C0312431
oocyte maturation	T043	C1160520
DOX	T109	C0013089
dose-dependent	T081	C1512045
toxicity	T037	C0600688
follicle growth	T042	C1155902
survival	T169	C0220921
secretion	T042	C0312431
17β-estradiol	T109	C0014912
E2	T109	C0014912
DOX	T109	C0013089
induced	T169	C0205263
DNA damage	T049	C0012860
apoptosis	T043	C0162638
follicle	T023	C0018120
somatic cells	T025	C1257909
oocytes	T025	C0029045
uptake	T039	C0243144
DOX	T109	C0013089
somatic cells	T025	C1257909
germ cells	T025	C0017471
Follicles	T023	C0018120
treated	T169	C1522326
DOX	T109	C0013089
oocyte	T025	C0029045
metaphase II	T043	C1155832
MII	T043	C1155832
percentages	T081	C0439165
in vitro	T080	C1533691
oocyte maturation	T043	C1160520
DOX	T109	C0013089
increased	T081	C0205217
MII	T043	C1155832
oocytes	T025	C0029045
abnormal	T033	C0205161
spindle	T026	C1166795
morphology	T080	C0332437
chromosome	T026	C0008633
misalignment	T080	C1275957
in vitro study	T062	C0681828
in vivo	T082	C1515655
treatment	T169	C1522326
dose-dependent	T081	C1512045
toxicity	T037	C0600688
oocyte meiotic maturation	T043	C1160520
CD-1 mice	T015	C0025929
treated	T169	C1522326
DOX	T109	C0013089
consistent with	T078	C0332290
in vitro	T080	C1533691
oocyte maturation	T043	C1160520
outcomes	T169	C1274040
study	T062	C2603343
DOX	T109	C0013089
dose-dependent	T081	C1512045
toxicity	T037	C0600688
ovarian follicle	T023	C0018120
development	T039	C0243107
hormone secretion	T042	C0312431
oocyte maturation	T043	C1160520
factors	T169	C1521761
female reproductive	T040	C0278049
endocrine functions	T039	C0678896
apoptotic pathways	T043	C3269135
docosahexaenoic acid	T109	C0556150
prostate cancer	T191	C0376358
gene expression analysis	T063	C1880945
RT(2) Profile PCR Array System	T063	C3179034
apoptotic pathways	T043	C3269135
docosahexaenoic acid	T109	C0556150
DHA	T109	C0556150
apoptosis	T043	C0162638
prostate cancer	T191	C0376358
cells	T025	C0334227
Human	T016	C0086418
prostate cancer	T191	C0376358
DU145 cells	T025	C0334227
fish oil	T109	C0016157
omega-3 PUFA	T109	C0015689
DHA	T109	C0556150
Eicosapentaenoic acid	T109	C0000545
EPA	T109	C0000545
omega-6 PUFA	T109	C0133860
Arachidonic acid	T109	C0003695
AA	T109	C0003695
Cell viability	T043	C0007620
apoptosis	T043	C0162638
MTT assay	T062	C2986858
Hoechst staining	T059	C1441607
gene expression profiling	T059	C0752248
DU145 cells	T025	C0334227
real time quantitative polymerase chain reaction	T063	C3179034
RT-qPCR	T063	C3179034
AA	T109	C0003695
viability	T043	C0007620
DU145 cells	T025	C0334227
fish oil	T109	C0016157
EPA	T109	C0000545
DHA	T109	C0556150
cell viability	T043	C0007620
growth inhibition	T043	C1512773
DHA	T109	C0556150
EPA	T109	C0000545
DHA	T109	C0556150
apoptotic	T080	C1516044
genes	T028	C0017337
genes	T028	C0017337
DHA	T109	C0556150
RT-qPCR	T063	C3179034
DHA	T109	C0556150
genes	T028	C0017337
DHA	T109	C0556150
apoptosis	T043	C0162638
cancer cells	T025	C0334227
P53	T044	C2984306
MAPK	T044	C2611831
TNF	T039	C1519684
PI3K/AKT	T169	C2984369
NF-κB signaling pathways	T045	C1513838
DHA	T109	C0556150
human	T016	C0086418
prostate carcinoma	T191	C0376358
cell line DU145	T025	C0334227
DHA	T109	C0556150
DU145 cells	T025	C0334227
pathways	T044	C0037080
P53	T044	C2984306
MAPK	T044	C2611831
TNF	T039	C1519684
PI3K/AKT	T169	C2984369
NF-κB signaling pathways	T045	C1513838
Molecular mechanisms	T044	C1258062
DHA	T109	C0556150
apoptosis	T043	C0162638
cancer cells	T025	C0334227
Medication Reconciliation	T058	C2317067
Hospitalization	T058	C0019993
Hospital-Home Interface	T058	C1254363
Observational Retrospective Study	T062	C0035363
Medication errors	T080	C0025115
patient harms	T080	C3658342
Medication reconciliation	T058	C2317067
care transition	T058	C4019071
investigate	T169	C1292732
medication reconciliation	T058	C2317067
Fondazione Toscana Gabriele Monasterio hospitals	T073	C0019994
assess the quality	T080	C0332306
medication reconciliation	T058	C2317067
inpatient	T101	C0021562
outpatient	T101	C0029921
care	T052	C1947933
analyzing	T062	C0936012
medication patterns	T058	C1254363
months	T079	C0439231
admission	T058	C0184666
hospitalization	T058	C0019993
months	T079	C0439231
discharge	T058	C0030685
patients	T101	C0030705
cardiovascular diseases	T047	C0007222
retrospective observational study	T062	C0035363
Cardiothoracic Department	T093	C0587505
Fondazione Toscana Gabriele Monasterio hospitals	T073	C0019994
Medication history	T170	C1553893
reviewed	T080	C1709940
patients	T101	C0030705
admitted	T058	C0184666
discharged	T058	C0030685
community	T096	C0009462
Patients	T101	C0030705
drugs	T061	C3687832
drugs	T061	C3687832
cardiovascular system	T022	C0007226
prescription list	T170	C3533331
admission	T058	C0184666
died	T033	C4264514
follow-up	T058	C1522577
patients	T101	C0030705
clinical charts	T170	C0025102
drug prescriptions	T170	C0033081
patients	T101	C0030705
hospitalization	T058	C0019993
electronic clinical recording system	T170	C1737029
analyzed	T062	C0936012
list of prescriptions	T170	C3533331
patients	T101	C0030705
months	T079	C0439231
admission	T058	C0184666
months	T079	C0439231
discharge	T058	C0030685
regional prescription registry	T170	C0282574
prescriptions	T170	C0033081
analyzed	T062	C0936012
unintentional	T169	C1283932
discrepancies	T033	C1290905
study	T062	C2603343
patients	T101	C0030705
age	T032	C0001779
years	T079	C0439234
inclusion and exclusion criteria	T078	C0243161
prescriptions	T170	C0033081
analyzed	T062	C0936012
discrepancies	T033	C1290905
discrepancies	T033	C1290905
patient	T101	C0030705
discrepancies	T033	C1290905
unintentional	T169	C1283932
discrepancies	T033	C1290905
patient	T101	C0030705
unintentional	T169	C1283932
discrepancies	T033	C1290905
hospitalization	T058	C0019993
hospital-home interface	T058	C1254363
unintentional	T169	C1283932
discrepancies	T033	C1290905
comparison	T052	C1707455
patients	T101	C0030705
therapy	T169	C0039798
medication consumption	T058	C1254363
comparison	T052	C1707455
prescription	T170	C0033081
discharge	T058	C0030685
medication pattern	T058	C1254363
home	T082	C0442519
Medication errors	T080	C0025115
patient safety	T058	C1113679
clinical practice	T058	C1254363
comparison	T052	C1707455
medication patterns	T058	C1254363
regional prescription registry	T170	C0282574
hospitalization	T058	C0019993
medication reconciliation	T058	C2317067
medication reconciliation	T058	C2317067
hospitals	T073	C0019994
primary care services	T058	C0018747
medication discrepancies	T080	C0025115
patient safety	T058	C1113679
Autologous	T122	C0181074
Irradiated Homologous Costal Cartilage	T122	C0181074
Graft Material	T122	C0181074
Rhinoplasty	T061	C0035467
rhinoplasty	T061	C0035467
autologous costal cartilage	T122	C0181074
ACC	T122	C0181074
irradiated homologous costal cartilage	T122	C0181074
IHCC	T122	C0181074
clinical results	T034	C0456984
augmentation rhinoplasty	T061	C0176371
ACC	T122	C0181074
IHCC	T122	C0181074
histologic properties	T169	C4048239
cartilage	T024	C0007301
retrospective clinical study	T062	C0008972
patients	T101	C0030705
rhinoseptoplasty	T061	C0189054
ACC	T122	C0181074
IHCC	T122	C0181074
Patients	T101	C0030705
followed up	T058	C1522577
surgery	T061	C0543467
histologic characteristics	T169	C4048239
ACC	T122	C0181074
IHCC	T122	C0181074
compared	T052	C1707455
surgical procedures	T061	C0543467
complications	T033	C0221082
warping	T033	C0221082
infection	T046	C3714514
resorption	T040	C2985494
donor-site	T029	C1444716
morbidity	T081	C0026538
evaluated	T058	C0220825
medical records	T170	C0025102
facial photographs	T073	C0441468
Patients	T101	C0030705
subjective	T080	C0439655
satisfaction	T041	C0242428
aesthetic	T055	C0870111
functional	T169	C0205245
results	T169	C1274040
evaluated	T058	C0220825
questionnaire	T170	C0034394
surgical procedures	T061	C0543467
complications	T033	C0221082
warping	T033	C0221082
infection	T046	C3714514
resorption	T040	C2985494
donor-site	T029	C1444716
morbidity	T081	C0026538
patients	T101	C0030705
subjective	T080	C0439655
satisfaction	T041	C0242428
aesthetic	T055	C0870111
functional	T169	C0205245
results	T169	C1274040
objective	T080	C1571702
evaluation	T058	C1261322
surgical	T061	C0543467
outcomes	T169	C1274040
symmetry	T067	C2825575
dorsal	T082	C0205095
height	T032	C0489786
dorsal	T082	C0205095
length	T081	C1444754
dorsal	T082	C0205095
width	T081	C0487742
tip projection	T033	C0243095
tip rotation	T033	C0243095
tip width	T033	C0243095
overall	T080	C1561607
result	T169	C1274040
histologic	T169	C0205462
structures	T082	C0678594
Objective	T080	C1571702
evaluation	T058	C0220825
surgical	T061	C0543467
outcomes	T169	C1274040
Objective	T080	C1571702
Rhinoplasty	T061	C0035467
Outcome Score	T033	C4274403
symmetry	T067	C2825575
dorsal	T082	C0205095
height	T032	C0489786
dorsal	T082	C0205095
length	T081	C1444754
dorsal	T082	C0205095
width	T081	C0487742
tip projection	T033	C0243095
tip rotation	T033	C0243095
tip width	T033	C0243095
overall	T080	C1561607
result	T169	C1274040
Histologic structures	T169	C4048239
evaluated	T058	C0220825
hematoxylin and eosin	T059	C0523207
Masson trichrome	T059	C1294297
Alcian blue	T059	C1293946
Verhoeff elastic stains	T059	C1294321
patients	T101	C0030705
males	T032	C0086582
females	T032	C0086287
rhinoseptoplasty	T061	C0189054
ACC	T122	C0181074
males	T032	C0086582
females	T032	C0086287
rhinoseptoplasty	T061	C0189054
IHCC	T122	C0181074
observed	T169	C1441672
complications	T033	C0221082
notable	T080	C4288581
resorption	T040	C2985494
occurred	T052	C1709305
frequently	T079	C0332183
patients	T101	C0030705
IHCC	T122	C0181074
ACC	T122	C0181074
subjective	T080	C0439655
evaluations	T058	C0220825
aesthetic	T055	C0870111
satisfaction	T041	C0242428
patients	T101	C0030705
received	T080	C1514756
ACC	T122	C0181074
significantly	T078	C0750502
greater	T081	C1704243
satisfaction	T041	C0242428
patients	T101	C0030705
very satisfied	T033	C3840671
received	T080	C1514756
IHCC	T122	C0181074
subjective	T080	C0439655
functional	T169	C0205245
outcomes	T169	C1274040
patients	T101	C0030705
receiving	T080	C1514756
ACC	T122	C0181074
receiving	T080	C1514756
IHCC	T122	C0181074
satisfied	T041	C0242428
receiving	T080	C1514756
ACC	T122	C0181074
receiving	T080	C1514756
IHCC	T122	C0181074
very satisfied	T033	C3840671
objective	T080	C1571702
aesthetic	T055	C0870111
outcomes	T169	C1274040
scores	T081	C0449820
ACC	T122	C0181074
IHCC	T122	C0181074
good	T080	C0205170
excellent	T080	C1961136
Histologic analyses	T059	C0344441
larger	T081	C0549177
uniform	T080	C0205375
chondrocytes	T025	C0225369
collagens	T116	C0009325
proteoglycan	T116	C0033692
contents	T078	C1550605
ACC	T122	C0181074
IHCC	T122	C0181074
Compared	T052	C1707455
patients	T101	C0030705
receiving	T080	C1514756
IHCC	T122	C0181074
receiving	T080	C1514756
ACC	T122	C0181074
rhinoseptoplasty	T061	C0189054
superior	T080	C0205250
aesthetic	T055	C0870111
satisfaction	T041	C0242428
ACC	T122	C0181074
less	T080	C0547044
frequent	T079	C0332183
notable	T080	C4288581
resorption	T040	C2985494
Autologous costal cartilage	T122	C0181074
better	T080	C0332272
histologic properties	T169	C4048239
IHCC	T122	C0181074
ideal	T080	C1512612
graft material	T122	C0181074
less	T080	C0547044
chance	T080	C0237506
long-term	T079	C0443252
resorption	T040	C2985494
Ret	T028	C0694890
Sema3d	T028	C1419945
genetic interaction	T045	C0596610
mouse	T015	C0025929
enteric nervous system development	T042	C1522995
multigenic disorders	T047	C0567439
clinical manifestation	T080	C1280464
penetrance	T081	C0524899
presentation	T078	C0449450
expressivity	T078	C0449450
outcome	T169	C1274040
genetic interaction	T045	C0596610
susceptibility genes	T028	C0919542
gene knockouts	UnknownType	C0814039
mice	T015	C0025929
genetic interaction	T045	C0596610
Ret	T028	C0694890
Sema3d	T028	C1419945
Hirschsprung disease	T019	C0019569
susceptibility genes	T028	C0919542
Ret	T028	C0694890
Sema3d	T028	C1419945
generate mice	T169	C0205245
genotypes	T032	C0017431
assessed survival	T052	C1516048
counting various genotypes	T059	C1285573
myenteric plexus	T023	C0027028
acetylcholinesterase staining	T059	C0201829
embryonic day 12.5	UnknownType	C0815083
E12.5	UnknownType	C0815083
intestine transcriptome	T086	C3178810
RNA-sequencing	T086	C0162327
Survival rates	T081	C0038954
Ret	T028	C0694890
wildtype	T028	C0694890
mice	T015	C0025929
E12.5	UnknownType	C0815083
birth	T040	C0005615
weaning	T033	C0043084
genotypes	T032	C0017431
Sema3d	T028	C1419945
locus	T082	C1708726
myenteric plexus	T023	C0027028
Ret	T028	C0694890
genotypes	T032	C0017431
Sema3d	T028	C1419945
locus	T082	C1708726
Sema3d	T028	C1419945
heterozygote	T032	C0019425
homozygote mice	T032	C0019904
intestinal innervation	T080	C1619351
wildtype mice intestinal	T028	C1883559
gene expression	T045	C0017262
Ret	T028	C0694890
expression of ∼300 genes,	T045	C0017262
Sema3d	T028	C1419945
no evidence	T080	C0332125
interaction between the two genes	T045	C0596610
intestine transcriptome	T086	C3178810
null alleles	T049	C2985437
phenotypic assays	T059	C1285572
not find evidence	T080	C0332125
genetic interaction	T045	C0596610
Ret	T028	C0694890
Sema3d	T028	C1419945
myenteric plexus	T023	C0027028
intestine transcriptome	T086	C3178810
Pembrolizumab	T116	C3658706
treatment	T061	C0087111
non-small cell lung cancer	T191	C0007131
development	T169	C1527148
immunotherapeutic agents	T121	C0876248
PD-1	T116	C2986635
PD-L1	T129	C4300350
development	T169	C1527148
checkpoint inhibitors	T120	C0243077
treatment	T061	C0087111
lung cancer	T191	C0242379
first	T061	C1708063
second line	T061	C1710038
limited	T169	C0439801
toxicity	T037	C0013221
treat	T061	C0087111
prolonged	T079	C0439590
periods	T079	C1948053
smokers	T033	C0337664
oncologist	T097	C0259990
review	T170	C0282443
results	T169	C1274040
clinical trials	T062	C0008976
pembrolizumab	T116	C3658706
treatment	T061	C0087111
non-small cell lung cancer	T191	C0007131
authors	T097	C3812881
first	T061	C1708063
second line treatment	T061	C1710038
pembrolizumab	T116	C3658706
monotherapy	T061	C0087111
combination therapies	T061	C0013218
PD-L1	T129	C4300350
immunohistochemistry assay	T059	C0020980
22C3 antibody	T116	C0003241
use	T169	C0457083
clinical practice	T062	C0008967
trials	T062	C0008976
higher	T080	C0205250
overall response	T033	C3272903
overall survival	T081	C4086681
moderate	T080	C0205081
toxicity	T037	C0013221
use	T169	C0457083
pembrolizumab	T116	C3658706
chemotherapy	T061	C3665472
first	T061	C1708063
second line	T061	C1710038
results	T169	C1274040
registration	T058	C1514821
pembrolizumab	T116	C3658706
first	T061	C1708063
second line	T061	C1710038
patients	T101	C0030705
high	T080	C0205250
expression	T045	C1171362
PD-L1	T129	C4300350
PD-L1	T129	C4300350
staining	T059	C0487602
responders	T033	C0919876
non-responders	T033	C0919875
checkpoint inhibitors	T120	C0243077
predictive	T080	C0681890
biomarker	T201	C0005516
Synchronisms	T079	C0439580
bud	T002	C2700462
cambium	T023	C2339480
phenology	T080	C0205556
black spruce	T002	C0996604
early	T079	C1279919
flushing	T052	C1882955
provenances	T077	C1709753
early	T079	C1279919
xylem	T002	C1720877
formation	T169	C1522492
Bud	T002	C2700462
cambial	T023	C2339480
phenology	T080	C0205556
represent	T052	C1882932
adaptation	T038	C0392673
species	T185	C1705920
local	T082	C0205276
environment	T082	C0014406
growing season	T079	C0036497
maximized	T169	C0442805
minimizing	T080	C0392756
risk	T078	C0035647
frost	T197	C0020746
developing	T169	C1527148
tissues	T025	C1514137
temporal	T079	C2362314
relationship	T080	C0439849
apical	T082	C0205111
radial	T077	C0442038
meristems	T002	C0242728
tree	T002	C0040811
growth	T040	C0018270
growth	T040	C0018270
whole	T081	C0444667
process	T067	C1522240
aim	T078	C1947946
study	T062	C2603343
compare	T052	C1707455
cambial	T023	C2339480
phenology	T080	C0205556
black spruce	T002	C0996604
Picea mariana	T002	C0996604
provenances	T077	C1709753
classified	T185	C0008902
early	T079	C1279919
late	T079	C0205087
bud	T002	C2700462
flushing	T052	C1882955
different	T080	C1705242
phases	T079	C0205390
cambial	T023	C2339480
phenology	T080	C0205556
assessed	T052	C1516048
wood	T167	C0043217
microcores	T082	C0444669
sampled	T078	C0870078
weekly	T079	C0332174
trees	T002	C0040811
growing	T040	C0018270
provenance trial	T062	C0868962
Quebec	T083	C0034390
Canada	T083	C0006823
Trees	T002	C0040811
early	T079	C1279919
bud	T002	C2700462
flush	T052	C1882955
early	T079	C1279919
reactivation	T052	C4086768
xylem	T002	C1720877
differentiation	T043	C0007589
average	T081	C1510992
difference	T081	C1705241
days	T079	C0439228
buds	T002	C2700462
small	T081	C0700321
significant	T081	C0237881
differences	T081	C1705241
days	T079	C0439228
xylem	T002	C1720877
Provenances	T077	C1709753
early	T079	C1279919
bud	T002	C2700462
flush	T052	C1882955
early	T079	C1279919
bud	T002	C2700462
completed	T080	C0205197
xylem	T002	C1720877
formation	T169	C1522492
earlier	T079	C1279919
late	T079	C0205087
bud	T002	C2700462
flush	T052	C1882955
provenances	T077	C1709753
No significant	T033	C1273937
difference	T081	C1705241
period	T079	C1948053
xylem	T002	C1720877
formation	T169	C1522492
total	T080	C0439810
growth	T040	C0018270
growth	T040	C0018270
observed	T169	C1441672
flushing	T052	C1882955
results	T033	C2825142
ecotype	T032	C3178911
differentiation	T043	C0007589
black spruce	T002	C0996604
provenances	T077	C1709753
phenological	T080	C0205556
adaptation	T038	C0392673
buds	T002	C2700462
local	T082	C0205276
climate	T070	C0008946
specific	T080	C0205369
growth	T040	C0018270
dynamics	T070	C3826426
xylem	T002	C1720877
liposome	T109	C0023828
immobilization	T061	C0020944
sterically stabilized	T080	C0205556
micelles	T109	C0025938
SSMs	T109	C0025938
precursor	T078	C1709634
bio-layer interferometry	T059	C0021730
based	T169	C1527178
interaction	T169	C1704675
studies	T062	C2603343
Non-fluidic	T080	C0205556
bio-layer interferometry	T059	C0021730
BLI	T059	C0021730
rapidly	T080	C0456962
standard	T080	C1442989
monitoring	T057	C0005517
biomolecular	T080	C0205556
interactions	T169	C1704675
label-free	T080	C0205556
real-time	T079	C1550177
high-throughput	T080	C0205556
High	T080	C0205250
efficiency	T081	C0013682
screening methods	T059	C0022885
measure	T081	C0079809
kinetics	T070	C0022702
liposomes	T109	C0023828
variety	T077	C2346866
compounds	T103	C1706082
immobilization	T061	C0020944
liposomes	T109	C0023828
method	T169	C0449851
described	T078	C1552738
immobilizing	T061	C0020944
liposomes	T109	C0023828
interaction	T169	C1704675
studies	T062	C2603343
based	T169	C1527178
biophysical principles	T070	C2350452
biosensor	T075	C0600364
platform	T075	C1710360
immobilization	T061	C0020944
includes	T169	C0332257
loading	T052	C1708715
DSPE-PEG(2000)	T109	C0664515
biotin	T109	C0005575
sterically stabilized	T080	C0205556
micelles	T109	C0025938
SSMs	T109	C0025938
restructured	T080	C0205556
buffer change	T080	C0205556
resulting in	T169	C0332294
substrate	T167	C3891814
liposome	T109	C0023828
immobilization	T061	C0020944
Liposomes	T109	C0023828
concentration	T081	C1446561
composition	T201	C0486616
fluidity	T081	C0596579
immobilized	T061	C0020944
sensor	T075	C0600364
surface	T082	C0205148
hydrophobic	T080	C0598629
residues	T077	C1709915
former	T079	C0205156
SSMs	T109	C0025938
Cytochrome C	T116	C0010749
membrane-interacting	T080	C0205556
protein	T116	C0033684
binding	T044	C0033618
Cytochrome C	T116	C0010749
immobilized	T061	C0020944
liposomes	T109	C0023828
kinetic	T070	C0022702
affinity	T070	C1510827
constants	T081	C1547014
similar	T080	C2348205
values	T080	C0042295
literature	T170	C0023866
detailed	T080	C1522508
understanding	T041	C0162340
surface	T082	C0205148
integrity	T080	C1947912
liposomes	T109	C0023828
confocal fluorescence microscopy	T059	C0026022
immobilized	T061	C0020944
liposomes	T109	C0023828
containing	T169	C0332256
calcein	T109	C0060549
aqueous	T080	C0599956
core	T082	C0444669
indicated	T033	C1444656
intact	T080	C0205266
vesicles	T026	C1622418
combination	T080	C0205195
liposome	T109	C0023828
immobilization	T061	C0020944
automation	T066	C0004376
BLI	T059	C0021730
systems	T169	C0449913
high throughput	T080	C0205556
acceptable	T080	C1879533
excellent	T080	C1961136
reproducibility	T080	C1514863
assay	T059	C0005507
suitable	T080	C3900053
research	T062	C0035168
industrial	T169	C0868973
regulatory applications	T170	C2347934
Exercise	T056	C0015259
increases	T081	C0205217
lactoferrin	T116	C0022942
decreases	T081	C0547047
lysozyme	T116	C0026794
salivary	T082	C0442040
granulocytes	T025	C0018183
Intracellular lactoferrin	T116	C0022942
Lac	T116	C0022942
lysozyme	T116	C0026794
Lys	T116	C0026794
inflammation	T046	C0021368
promoting	T052	C0033414
host protection	T039	C0524828
exercise	T056	C0015259
increase	T081	C0205217
Lac	T116	C0022942
Lys	T116	C0026794
concentration	T081	C1446561
exocrine solutions	T031	C0504082
intracellular concentration changes	T081	C1446561
exercise	T056	C0015259
quantify	T081	C1709793
Lac	T116	C0022942
Lys	T116	C0026794
concentration	T081	C1446561
exercise	T056	C0015259
salivary	T082	C0442040
CD45(+)CD15(+) cells	T025	C0018183
males	T032	C0086582
years	T079	C0439234
V̇O2pk	T081	C0392762
body fat	T201	C0344335
ran	T056	C0035953
min	T079	C0439232
VO2pk	T081	C0392762
stimulated saliva	T031	C0036087
collected	T169	C1516698
pre	T079	C1439922
post exercise	T079	C1979962
Saliva	T031	C0036087
leukocytes	T025	C0023516
CD45(+)	T025	C0023516
granulocytes	T025	C0018183
CD45(+)CD15(+)	T025	C0018183
flow cytometry	T059	C0016263
Median fluorescent intensity	T081	C0392762
MFI	T081	C0392762
Lac	T116	C0022942
increased	T081	C0205217
pre	T079	C1439922
MFI	T081	C0392762
post	T079	C1979962
MFI	T081	C0392762
exercise	T056	C0015259
Lys	T116	C0026794
MFI	T081	C0392762
decreased	T081	C0205216
exercise	T056	C0015259
pre	T079	C1439922
post	T079	C1439922
Acute running	T056	C0035953
increased	T081	C0205217
Lac	T116	C0022942
concentration	T081	C1446561
decrease	T081	C0205216
inflammation	T046	C0021368
anti-inflammatory effects	T080	C1515999
exercise	T056	C0015259
exercise	T056	C0015259
decrease	T081	C0547047
intracellular Lys	T116	C0026794
cause	T169	C0015127
increased	T081	C0205217
Lys	T116	C0026794
exocrine solutions	T031	C0504082
Chronic Enzyme Replacement	T061	C0598391
Brain	T023	C0006104
Late Infantile Neuronal Ceroid Lipofuscinosis	T047	C0022340
Mouse	T015	C0025929
Effects	T080	C1280500
Phenotypes	T032	C0031437
Disease	T047	C0012634
Late infantile neuronal ceroid lipofuscinosis	T047	C0022340
LINCL	T047	C0022340
fatal	T080	C1302234
neurodegenerative disease	T047	C0524851
lysosomal protease tripeptidyl peptidase 1	T116	C1430948
TPP1	T116	C1430948
effects	T080	C1280500
chronic intrathecal (IT) administration	T169	C0677897
enzyme replacement therapy	T061	C0598391
ERT	T061	C0598391
brain	T023	C0006104
LINCL	T047	C0022340
mouse model	T050	C2986594
locomotor function	T038	C0234130
early death	T033	C1836407
lifespan	T102	C0870809
days	T079	C0439228
days	T079	C0439228
chronic IT treatment	T061	C1831734
onset	T079	C0449244
disease	T047	C0012634
animals	T008	C0003062
locomotor dysfunction	T033	C0521654
died	T040	C0011065
cerebrospinal fluid	T031	C0007806
CSF	T031	C0007806
delivery	T169	C1705822
deliver	T169	C1705822
TPP1	T116	C1530775
brain regions	T029	C1273723
Morphological	T082	C0543482
studies	T062	C2603343
delivery	T169	C1705822
TPP1	T116	C1530775
ventral	T029	C1273723
dorsal regions	T029	C1273723
IT treatment	T061	C1831734
severely	T080	C0205082
affected	T169	C0392760
LINCL	T047	C0022340
mice	T015	C0025929
lifespan	T102	C0870809
cohort	T098	C0599755
Treatment	T169	C1522326
locomotor function	T038	C0234130
animals	T008	C0003062
animals	T008	C0003062
die	T040	C0011065
pathology	T046	C0677042
LINCL	T047	C0022340
reversible	T169	C0205343
neuronal death	T043	C2754100
5-Bromo-2-aryl benzimidazole derivatives	T109	C0005050
non-cytotoxic	T121	C2827065
potential	T080	C3245505
inhibitors	T121	C0014432
α-glucosidase	T116	C0002272
urease enzymes	T116	C0041945
report	T170	C0684224
α-glucosidase	T116	C0002272
inhibitory activity	T044	C1152555
5-bromo-2-aryl benzimidazole derivatives	T109	C0005050
screened	T059	C0373483
urease	T116	C0041945
inhibitory	T044	C1152555
cytotoxicity activity	T059	C0201622
more potent	T080	C3245505
non-cytotoxic	T121	C2827065
potential	T080	C3245505
inhibitor	T121	C0014432
patients	T101	C0030705
diabetes	T047	C0011847
peptic ulcer	T047	C0030920
study	T062	C2603343
compounds	T121	C1254351
degree of potency	T038	C0678792
IC50	T081	C0600495
standard	T081	C0034925
thiourea	T109	C0039958
IC50	T081	C0600495
derivatives 7	T121	C1254351
IC50	T081	C0600495
8	T121	C1254351
IC50	T081	C0600495
11	T121	C1254351
IC50	T081	C0600495
14	T121	C1254351
IC50	T081	C0600495
22	T121	C1254351
IC50	T081	C0600495
potent inhibitors	T121	C0014432
standard	T081	C0034925
compounds	T121	C1254351
cytotoxicity	T059	C0201622
3T3	T025	C0085087
mouse fibroblast cell line	T025	C1513528
non-toxic	T033	C0243095
benzimidazole 1-25	T109	C0005050
α-glucosidase	T116	C0002272
inhibitory potential	T044	C1152555
In silico	T066	C3489666
studies	T062	C2603343
lead molecules	T121	C1254351
2	T121	C1254351
7	T121	C1254351
8	T121	C1254351
11	T121	C1254351
14	T121	C1254351
22	T121	C1254351
binding interaction	T044	C0687133
compounds	T121	C1254351
active site	T169	C0205681
urease enzyme	T116	C0041945
Intra-articular	T082	C0442108
implantation	T061	C0021107
collagen	T116	C0009325
scaffold	T073	C0337143
carriers	T074	C0025080
safe	T082	C0557723
native	T169	C0302891
arthrofibrotic	T047	C1142253
rabbit	T015	C3887509
knee joints	T030	C0022745
Sustained	T169	C0443318
intra-articular	T082	C0442108
delivery of pharmacological agents	T070	C3850077
attractive	T080	C2346874
modality	T078	C0695347
use	T169	C0457083
safe	T082	C0557723
carrier	T074	C0025080
induce	T169	C0205263
cartilage damage	T037	C0549421
fibrosis	T046	C0016059
Collagen	T116	C0009325
scaffolds	T073	C0337143
available	T169	C0470187
intra-articularly	T082	C0442108
investigation	T058	C0220825
safety	T068	C0036043
collagen	T116	C0009325
scaffolds	T073	C0337143
synovial joints	T030	C0224507
aim	T078	C1947946
study	T062	C2603343
determine	T078	C0205258
safety	T068	C0036043
collagen	T116	C0009325
scaffold	T073	C0337143
implantation	T061	C0021107
validated	T062	C1519941
in vivo	T082	C1515655
animal	T008	C0003062
knee arthrofibrosis	T047	C1142253
rabbits	T015	C3887509
randomly	T080	C0439605
equally	T080	C0205163
assigned	T169	C1516050
different	T080	C1705242
groups	T078	C0441833
arthrotomy	T061	C0185160
arthrotomy	T061	C0185160
collagen	T116	C0009325
scaffold	T073	C0337143
placement	T058	C0441587
contracture	T190	C0009918
surgery	T061	C0543467
contracture	T190	C0009918
surgery	T061	C0543467
collagen	T116	C0009325
scaffold	T073	C0337143
placement	T058	C0441587
Animals	T008	C0003062
killed	T054	C0162388
equal	T080	C0205163
hours	T079	C0439227
weeks	T079	C0439230
weeks	T079	C0439230
weeks	T079	C0439230
Joint contracture	T190	C0009918
measured	T080	C0444706
cartilage	T024	C0007301
synovial	T023	C1550315
samples	T167	C0370003
histological analysis	T059	C0002778
Animals	T008	C0003062
arthrotomy	T061	C0185160
equivalent	T080	C0205163
joint contractures	T190	C0009918
scaffold	T073	C0337143
implantation	T061	C0021107
Animals	T008	C0003062
surgery	T061	C0543467
induce	T169	C0205263
contracture	T190	C0009918
equivalent	T080	C0205163
joint contracture	T190	C0009918
joint contracture s	T190	C0009918
collagen	T116	C0009325
scaffold	T073	C0337143
implantation	T061	C0021107
Chondral	T082	C0442012
damage	T169	C1883709
damage	T169	C1883709
occurred	T052	C1709305
rates	T081	C1521828
scaffold	T073	C0337143
implantation	T061	C0021107
significant difference	T081	C1705241
synovitis	T047	C0039103
groups	T078	C0441833
Absorption	T070	C0000854
collagen	T116	C0009325
scaffold	T073	C0337143
occurred	T052	C1709305
weeks	T079	C0439230
animals	T008	C0003062
data	T078	C1511726
intra-articular	T082	C0442108
implantation	T061	C0021107
collagen	T116	C0009325
sponge	T073	C0337143
induce	T169	C0205263
synovitis	T047	C0039103
cartilage damage	T037	C0549421
Implantation	T061	C0021107
native	T169	C0302891
joint	T030	C0022745
induce	T169	C0205263
contracture	T190	C0009918
Implantation	T061	C0021107
collagen	T116	C0009325
sponge	T073	C0337143
rabbit	T015	C3887509
contracture	T190	C0009918
decrease	T081	C0547047
severity	T080	C0439793
contracture	T190	C0009918
HOST	T001	C1167395
IMMUNE RECOGNITION	T042	C0301872
EPIDEMIC	T067	C0014499
CYSTIC FIBROSIS	T047	C0010674
PATHOGEN	T001	C0450254
BURKHOLDERIA DOLOSA	T007	C1482113
Burkholderia dolosa	T007	C1482113
cystic fibrosis	T047	C0010674
CF	T047	C0010674
Boston Children's Hospital	T093	C0020017
infection	T046	C3714514
patients	T101	C0030705
died	T040	C0011065
complications	T046	C0009566
infection	T046	C3714514
organism	T007	C1482113
B. dolosa	T007	C1482113
disease	T047	C0012634
host	T001	C1167395
immune response	T042	C0301872
mice	T015	C0026809
infected	T033	C0439663
B. dolosa strain	T007	C1482113
AU0158	T007	C1482113
responses	T032	C0871261
CF	T047	C0010674
pathogen	T001	C0450254
Pseudomonas aeruginosa	T007	C0033809
mice	T015	C0026809
infected	T033	C0439663
flagellin	T026	C0016192
mutant	T049	C0596988
B. dolosa	T007	C1482113
flagella	T026	C0016192
B. dolosa	T007	C1482113
lung	T023	C0024109
colonization	T033	C4289767
higher	T080	C0205250
persistence	T041	C0546816
host	T001	C1167395
B. dolosa strains	T007	C1482113
neutrophil	T025	C0027950
cytokine	T116	C0079189
production	T169	C0005572
P. aeruginosa	T007	C0033809
host	T001	C1167395
immune cells	T025	C0007634
B. dolosa	T007	C1482113
B. dolosa	T007	C1482113
cytokine	T116	C0079189
cultured cells	T025	C0007635
flagella	T026	C0016192
bacteria	T007	C0004611
dead	T040	C0011065
B. dolosa	T007	C1482113
host cells	T026	C1819995
in vitro	T080	C1533691
suppress	T169	C1260953
host	T001	C1167395
immune response	T042	C0301872
in vivo	T082	C1515655
B. dolosa	T007	C1482113
Burkholderia species	T007	C1264855
cytokine	T116	C0079189
production	T169	C0005572
macrophages	T025	C0024432
B. cenocepacia strains	T007	C1187839
data	T078	C1511726
B. dolosa AU0158	T007	C1482113
host cells	T026	C1819995
immune systems	T022	C0020962
Burkholderia strains	T007	C0282676
species	T185	C1705920
Visualization	T033	C0243095
targeting	T169	C1521840
LGR5(+)	T028	C1537570
human	T016	C0086418
colon	T023	C0009368
cancer stem cells	T025	C1956422
cancer stem cell	T025	C1956422
CSC	T025	C1956422
theory	T078	C0871935
self-renewing	T043	C4042950
subpopulation	T185	C0449560
cancer cells	T025	C0334227
tumour growth.	T191	C0598934
existence	T081	C1547035
human	T016	C0086418
CSCs	T025	C1956422
xenotransplantation	T061	C0520484
isolated cells	T033	C3829491
clonal	T024	C1522642
dynamics	T070	C3826426
plasticity	T070	C0678558
human	T016	C0086418
LGR5(+)	T028	C1537570
colorectal cancer cells	T025	C0334227
CSCs	T025	C1956422
cancer	T191	C0006826
tissues	T024	C0040300
Lineage	T077	C1881379
tracing experiments	T059	C0022885
tamoxifen	T109	C0039286
Cre	T116	C1744318
knock-in	T063	C2350597
allele	T028	C0002085
LGR5	T116	C3640115
self-renewal	T043	C4042950
differentiation	T043	C0007589
capacity	T081	C1516240
LGR5(+)	T028	C1537570
tumour cells	T025	C0334227
ablation	T061	C0547070
LGR5(+)	T028	C1537570
CSCs	T025	C1956422
LGR5	T028	C1537570
Caspase9	T028	C1332668
knock-in	T063	C2350597
organoids	T024	C0029250
tumour regression	T201	C1718423
tumour regrowth	T191	C0598934
LGR5(+)	T028	C1537570
CSCs	T025	C1956422
KRT20	T028	C1426926
knock-in	T063	C2350597
reporter	T028	C0206414
differentiated	T043	C0007589
cancer cells	T025	C0334227
tumour tissues	T024	C0475358
LGR5(+)	T028	C1537570
CSCs	T025	C1956422
tumour regrowth	T191	C0598934
LGR5(+)	T028	C1537570
CSC	T025	C1956422
ablation	T061	C0547070
chemotherapy	T061	C3665472
targeting	T169	C1521840
LGR5(+)	T028	C1537570
CSCs	T025	C1956422
data	T078	C1511726
plasticity	T070	C0678558
CSCs	T025	C1956422
potential	T080	C3245505
therapeutic	T169	C0302350
target	T169	C1521840
human	T016	C0086418
colorectal cancer	T191	C1527249
Software	T073	C0037585
Assisted	T080	C1269765
Method	T170	C0025663
Estimate	T081	C0750572
Fetal Weight	T032	C0751992
Term	T040	C0232991
Magnetic Resonance Imaging	T060	C0024485
study	T062	C2603343
semi-automated	T169	C0205554
calculation	T052	C1441506
method	T170	C0025663
fetal	T018	C0015965
body volume	T032	C0178521
magnetic resonance-estimated fetal weight	T032	C0751992
MR-EFW	T032	C0751992
planned	T169	C1301732
delivery	T040	C0005615
evaluate	T058	C0220825
technique	T169	C0449851
measurement	T169	C0242485
simplified	T080	C0205352
remaining	T080	C1527428
accurate	T080	C0443131
MR-EFW	T032	C0751992
calculated	T169	C0444686
semi-automated	T169	C0205554
method	T170	C0025663
weeks	T079	C0439230
gestation	T040	C0032961
patients	T101	C0030705
picture archiving and communication system	T074	C0182281
PACS	T074	C0182281
patient	T101	C0030705
sequences	T169	C1519249
acquired	T080	C0439661
slice thickness	T081	C3829566
intersection gap	T082	C3887622
median	T082	C2939193
absolute	T080	C0205344
relative errors	T080	C0743559
MR-EFW	T032	C0751992
time	T079	C0040223
planimetric measurements	T169	C0242485
calculated	T169	C0444686
sequences	T169	C1519249
method	T170	C0025663
assisted	T170	C3204107
PACS	T074	C0182281
methods	T170	C0025663
calculated	T169	C0444686
median	T082	C2939193
median	T082	C2939193
relative error	T080	C0743559
MR-EFW	T032	C0751992
calculations	T052	C1441506
semi-automated	T169	C0205554
method	T170	C0025663
PACS	T074	C0182281
method	T170	C0025663
Measurements	T169	C0242485
sequences	T169	C1519249
assisted	T170	C3204107
method	T170	C0025663
PACS	T074	C0182281
time	T079	C0040223
planimetric measurement	T169	C0242485
decreased	T081	C0205216
gap	T082	C3887622
assisted	T170	C3204107
method	T170	C0025663
PACS	T074	C0182281
method	T170	C0025663
simplified	T080	C0205352
MR-EFW	T032	C0751992
measurement	T169	C0242485
dramatic decrease	T081	C0547047
time	T079	C0040223
planimetric measurement	T169	C0242485
decrease	T081	C0547047
accuracy	T080	C0598285
weight	T032	C0751992
estimates	T081	C0681916
Abiraterone	T109	C0754011
induced	T169	C0458082
rhabdomyolysis	T046	C0035410
acute kidney injury	T037	C2609414
case report	T170	C0007320
review of the literature	T170	C0282441
Abiraterone	T109	C0754011
CYP17 inhibitor	T121	C3160096
androgen biosynthesis	T044	C1157302
tissue	T024	C0040300
prednisone	T109	C0032952
first-line treatment	T061	C1708063
metastatic	T191	C2939420
castration-resistant prostate cancer	T191	C1328504
case	T077	C1706256
rhabdomyolysis	T046	C0035410
abiraterone	T109	C0754011
therapy	T061	C0087111
acute	T037	C2609414
chronic	T079	C0205191
kidney injury	T037	C0160420
patient	T101	C0030705
metastatic	T191	C2939420
castration-resistant prostate cancer	T191	C1328504
monitoring	T062	C1516647
patients	T101	C0030705
abiraterone	T109	C0754011
risk factors	T033	C0035648
rhabdomyolysis	T046	C0035410
Association	T080	C0439849
XRCC1	T028	C1366475
ERCC1	T028	C1333355
single-nucleotide polymorphisms	T086	C0752046
efficacy	T080	C1280519
concurrent radiochemotherapy	T061	C3178775
patients	T101	C0030705
esophageal squamous cell carcinoma	T191	C0279626
investigate	T169	C1292732
association	T080	C0439849
single-nucleotide polymorphisms	T086	C0752046
SNPs	T086	C0752046
X-ray repair cross-complementing 1-399	T028	C1366475
XRCC1-399	T028	C1366475
excision repair cross-complementation group 1-118	T028	C1333355
ERCC1-118	T028	C1333355
short-term	T079	C0443303
efficacy	T080	C1280519
radiochemotherapy	T061	C0436307
tumor metastasis	T191	C0027627
relapse	T067	C0035020
survival time	T201	C2919552
patients	T101	C0030705
esophageal squamous cell carcinoma	T191	C0279626
ESCC	T191	C0279626
TaqMan probe-based quantitative polymerase chain reaction	T063	C3179034
qPCR	T063	C3179034
examine	T033	C0332128
levels	T080	C0441889
XRCC1-399	T028	C1366475
ERCC1-118	T028	C1333355
SNPs	T086	C0752046
peripheral blood	T031	C0229664
patients	T101	C0030705
pathologically	T169	C1521733
confirmed	T033	C0750484
ESCC	T191	C0279626
associations	T080	C0439849
different	T080	C1705242
genotypes	T032	C0017431
short-term	T079	C0443303
therapeutic efficacy	T080	C2348767
complete remission	T033	C0677874
CR	T033	C0677874
rate	T081	C1521828
tumor metastasis	T191	C0027627
relapse	T067	C0035020
survival time	T201	C2919552
concurrent radiochemotherapy	T061	C3178775
determined	T080	C0521095
ESCC	T191	C0279626
patients	T101	C0030705
concurrent radiochemotherapy	T061	C3178775
short-term	T079	C0443303
therapeutic efficacy	T080	C2348767
CR	T033	C0677874
rate	T081	C1521828
group	T078	C0441833
patients	T101	C0030705
homozygous mutation	T045	C0026882
XRCC1-399	T028	C1366475
A	T114	C0001443
A	T114	C0001443
genotype	T032	C0017431
group	T078	C0441833
patients	T101	C0030705
XRCC1-399	T028	C1366475
mutation	T045	C0026882
G	T114	C0018330
G	T114	C0018330
genotype	T032	C0017431
CR	T033	C0677874
rate	T081	C1521828
significantly increased	T081	C4055637
patients	T101	C0030705
ERCC1-118	T028	C1333355
alleles	T028	C0002085
C	T114	C0010715
C	T114	C0010715
C	T114	C0010715
T	T114	C0040077
genotype	T032	C0017431
compared	T052	C1707455
patients	T101	C0030705
C	T114	C0010715
allele	T028	C0002085
T	T114	C0040077
T	T114	C0040077
genotype	T032	C0017431
statistically significant	T081	C0237881
A	T114	C0001443
A	T114	C0001443
G	T114	C0018330
G	T114	C0018330
T	T114	C0040077
T	T114	C0040077
C	T114	C0010715
T	T114	C0040077
C	T114	C0010715
C	T114	C0010715
follow-up period	T033	C0589120
group	T078	C0441833
patients	T101	C0030705
homozygous mutation	T045	C0026882
XRCC1-399	T028	C1366475
A	T114	C0001443
A	T114	C0001443
genotype	T032	C0017431
markedly reduced	T080	C0392756
risk	T078	C0035647
metastasis	T046	C4255448
relapse	T067	C0035020
compared	T052	C1707455
group	T078	C0441833
patients	T101	C0030705
XRCC1-399	T028	C1366475
G	T114	C0018330
G	T114	C0018330
genotype	T032	C0017431
ERCC1-118	T028	C1333355
SNP	T086	C0752046
associated with	T080	C0332281
risk	T078	C0035647
metastasis	T046	C4255448
recurrence	T067	C0034897
univariate	T062	C0683962
multivariate Cox regression analysis	T170	C0034980
SNP	T086	C0752046
ERCC1-118	T028	C1333355
associated with	T080	C0332281
survival time	T201	C2919552
mean survival time	T081	C0086595
significantly	T078	C0750502
prolonged	T079	C0439590
patients	T101	C0030705
C	T114	C0010715
alleles	T028	C0002085
C	T114	C0010715
C	T114	C0010715
C	T114	C0010715
T	T114	C0040077
genotype	T032	C0017431
compared	T052	C1707455
patients	T101	C0030705
C	T114	C0010715
allele	T028	C0002085
T	T114	C0040077
T	T114	C0040077
genotype	T032	C0017431
T	T114	C0040077
T	T114	C0040077
C	T114	C0010715
C	T114	C0010715
HR	T081	C2985465
confidence interval	T081	C0009667
CI	T081	C0009667
T	T114	C0040077
T	T114	C0040077
C	T114	C0010715
T	T114	C0040077
C	T114	C0010715
C	T114	C0010715
HR	T081	C2985465
CI	T081	C0009667
XRCC1-399	T028	C1366475
SNP	T086	C0752046
no effect	T080	C1301751
survival time	T201	C2919552
XRCCl-399	T028	C1366475
SNP	T086	C0752046
associated with	T080	C0332281
short-term	T079	C0443303
therapeutic efficacy	T080	C2348767
CR	T033	C0677874
rate	T081	C1521828
tumor metastasis	T191	C0027627
relapse	T067	C0035020
ESCC	T191	C0279626
patients	T101	C0030705
docetaxel plus cisplatin (TP) regimen	T061	C1880380
concurrent radiochemotherapy	T061	C3178775
ERCC1-118	T028	C1333355
SNP	T086	C0752046
significantly	T078	C0750502
associated with	T080	C0332281
short-term	T079	C0443303
therapeutic efficacy	T080	C2348767
CR	T033	C0677874
rate	T081	C1521828
survival time	T201	C2919552
ESCC	T191	C0279626
patients	T101	C0030705
TP regimen	T061	C1880380
concurrent radiochemotherapy	T061	C3178775
Ventricular pacing	T061	C0199648
site separation	T082	C1254362
cardiac	T082	C1522601
computed tomography	T060	C0040405
validation	T062	C1519941
prediction	T078	C0681842
clinical response	T033	C4055223
cardiac resynchronization therapy	T061	C1167956
Cardiac Resynchronization Therapy	T061	C1167956
CRT	T061	C1167956
provide	T052	C1999230
benefit	T081	C0814225
patients	T101	C0030705
geographic separation	T082	C1254362
right	T082	C1254362
left	T082	C1254362
ventricular pacing	T061	C0199648
lead sites	T029	C0442031
suggested	T078	C1705535
improve	T033	C0184511
response	T032	C0871261
Cardiac CT	T060	C0202850
provides	T052	C1999230
opportunity	T062	C0683937
3-dimensional	T082	C0450363
inter-lead distance	T082	C1254362
ILD	T082	C1254362
measures	T081	C0079809
prediction	T078	C0681842
CRT	T061	C1167956
response	T032	C0871261
objective	T170	C0018017
study	T062	C2603343
investigate	T169	C1292732
associations	T080	C0439849
standardized	T080	C1442989
measures	T081	C0079809
ILD	T082	C1254362
cardiac CT	T060	C0202850
echocardiographic	T060	C0013516
response	T032	C0871261
CRT	T061	C1167956
consecutive	T080	C1707491
patients	T101	C0030705
CRT	T061	C1167956
clinical	T058	C4084924
echocardiographic	T060	C0013516
evaluations	T058	C0220825
performed	T169	C0884358
in addition to	T169	C0332287
post-procedural	T079	C3272301
cardiac	T082	C1522601
CT	T060	C0040405
blinded	T062	C0150108
measurement	T169	C0242485
direct	T080	C1947931
circumferential	T082	C0205113
myocardium	T024	C0027061
ILD	T082	C1254362
measures	T081	C0079809
Clinical response	T033	C4055223
CRT	T061	C1167956
primary clinical outcome	T034	C0456984
reduction	T080	C0392756
LVESV	T033	C0080308
echocardiography	T060	C0013516
mean age	T032	C0001779
ejection fraction	T033	C2700378
primary outcome	T080	C3274433
occurred	T052	C1709305
patients	T101	C0030705
direct	T080	C1947931
circumferential	T082	C0205113
CT	T060	C0040405
ILD	T082	C1254362
measures	T081	C0079809
associated with	T080	C0332281
primary outcome	T080	C3274433
univariate analysis	T062	C0683962
Receiver Operator Characteristic	T081	C0034772
analysis	T062	C0936012
Circumferential	T082	C0205113
ILD	T082	C1254362
predictive	T080	C0681890
accuracy	T080	C0443131
Inter-	T081	C0021713
intra-observer	T081	C0021861
reproducibility	T080	C1514863
CT	T060	C0040405
ILD	T082	C1254362
measures	T081	C0079809
excellent	T080	C1961136
Circumferential	T082	C0205113
ILD	T082	C1254362
measures	T081	C0079809
cardiac CT	T060	C0202850
predictive	T080	C0681890
clinical response	T033	C4055223
CRT	T061	C1167956
Incorporation	T169	C0243126
measures	T081	C0079809
selection	T052	C1707391
optimal	T080	C2698651
pacing	T061	C0199640
targets	T169	C1521840
pre-procedural	T079	C3272300
CT	T060	C0040405
coronary vein	T023	C3495141
imaging	T060	C0011923
therapeutic	T169	C0302350
benefit	T081	C0814225
investigation	T058	C0220825
Iodine Storage	T196	C2348268
Metabolism	T040	C0025519
Mild to Moderate	T080	C1299392
Iodine-Deficient	T046	C0342927
Pregnant	T040	C0032961
Rats	T015	C0034693
Severe iodine deficiency	T046	C0342927
during pregnancy results	T079	C0585037
neurodevelopmental disorders	T048	C1535926
children	T100	C0008059
consequences of	T169	C0686907
mild to moderate iodine deficiency	T046	C0342927
MMID	T046	C0342927
uncertain	T033	C0087130
concentration of iodine	T059	C0523726
thyroid	T023	C0040132
iodine nutrition	T196	C2348268
iodine stores	T196	C2348268
thyroid cover	T023	C0040132
mother and the fetus	T029	C0545509
iodine	T121	C0021968
sufficient	T080	C0205410
MMID	T046	C0342927
inductively coupled plasma-mass spectrometry	T059	C1553183
female Wistar rats	T015	C0034716
MMID	T046	C0342927
low iodine intake	T033	C3714384
normal	T033	C3840145
normal iodine intake	T033	C3840145
groups	T078	C0441833
rats	T015	C0034693
fed for the next three months	T052	C2987508
after pregnancy	T079	C0086839
divided into two subgroups	T185	C1515021
low iodine	T033	C2745994
pregnancy	T040	C0032961
LP	T033	C2745994
low iodine	T033	C2745994
pregnancy	T040	C0032961
iodine supplement	T168	C3661599
LP+	T168	C3661599
normal iodine intake	T033	C3840145
pregnancy	T040	C0032961
NP	T040	C0032961
normal iodine intake	T033	C3840145
pregnancy	T040	C0032961
iodine supplement	T168	C3661599
NP+	T168	C3661599
iodine intake	T033	C4263590
pregnant	T040	C0032961
rats	T015	C0034693
NP+	T168	C3661599
LP+ groups	T168	C3661599
NP	T033	C3840145
LP groups	T033	C2745994
rats	T015	C0034693
gestational day	T079	C0439671
postnatal day	T079	C0443281
iodine concentration	T059	C0523726
thyroid	T023	C0040132
maternal	T033	C1858460
newborn	T033	C2239178
rats	T015	C0034693
maternal serum	T059	C4064645
placenta	T018	C0032043
amniotic fluid	T031	C0002638
inductively coupled plasma-mass spectrometry	T059	C1553183
concentration of iodine	T059	C0523726
thyroid	T023	C0040132
N group	T033	C3840145
significantly higher	T081	C4055637
L group	T033	C2745994
before pregnancy	T033	C3840692
concentration of iodine	T059	C0523726
maternal thyroids	T058	C2228489
LP group	T033	C2745994
during pregnancy	T079	C0585037
NP group	T033	C3840145
iodine concentration	T059	C0523726
thyroid	T023	C0040132
mothers	T099	C0026591
offspring	T099	C0680063
NP	T033	C3840145
NP+ groups	T168	C3661599
LP	T040	C0032961
LP+ groups	T168	C3661599
concentration of iodine	T059	C0523726
amniotic fluid	T031	C0002638
groups	T078	C0441833
iodine storage	T196	C2348268
thyroid	T023	C0040132
maternal	T033	C1858460
rats	T015	C0034693
normal iodine intake	T033	C4263590
during pregnancy	T079	C0585037
iodine supplementation	T058	C3661575
iodine stores	T196	C2348268
rats	T015	C0034693
MMID	T046	C0342927
Iodine supplementation	T058	C3661575
iodine concentration	T059	C0523726
thyroid	T023	C0040132
maternal	T033	C1858460
rats	T015	C0034693
MMID	T046	C0342927
offspring	T099	C0680063
amniotic fluid	T031	C0002638
during pregnancy	T079	C0585037
Omega 3 Fatty Acids	T109	C0015689
Reduce	T080	C0392756
Bone Resorption	T042	C0005974
Promoting Bone Generation	T042	C1371285
Rat	T015	C0034721
Apical Periodontitis	T047	C0031030
evaluated	T058	C0220825
effects of	T080	C1704420
dietary supplement	T168	C0242295
omega 3 polyunsaturated fatty acids	T109	C0015689
ω-3 PUFAs	T109	C0015689
pulp exposure	T047	C0011406
apical periodontitis	T047	C0031030
AP	T047	C0031030
rats	T015	C0034721
male	T032	C0086582
rats	T015	C0034721
groups	T098	C1257890
untreated	T033	C0332155
rats	T015	C0034721
rats	T015	C0034721
treated with	T169	C1522326
ω-3 PUFAs	T109	C0015689
rats	T015	C0034721
pulp exposure	T047	C0011406
AP	T047	C0031030
rats	T015	C0034721
pulp exposure	T047	C0011406
AP	T047	C0031030
treated with	T169	C1522326
ω-3 PUFAs	T109	C0015689
AP	T047	C0031030
ω-3 PUFAs	T109	C0015689
administered orally	T061	C0001563
pulp exposure	T047	C0011406
pulp exposure	T047	C0011406
Rats	T015	C0034721
killed	T054	C0162388
pulp exposure	T047	C0011406
jaws	T023	C0022359
histologic	UnknownType	C0681853
immunohistochemical	T059	C1441616
analyses	T062	C0936012
Immunohistochemical	T059	C1441616
analyses	T062	C0936012
tartrate-resistant acid phosphatase	T116	C0297331
positive	T033	C1446409
osteoclasts	T025	C0029431
osteocalcin	T116	C0029419
positive	T033	C1446409
osteoblasts	T025	C0029418
bone surface	T029	C0825429
periapical area	T082	C0729269
evaluated	T058	C0220825
analysis of variance	T081	C0002780
Tukey honestly significant difference	T081	C0392762
statistically significant	T081	C0237881
bone resorption	T042	C0005974
lesion	T033	C0221198
significantly larger	T081	C4055637
AP	T047	C0031030
AP	T047	C0031030
groups	T098	C1257890
level	T080	C0441889
inflammatory cell infiltration	T046	C0302158
tartrate-resistant acid phosphatase	T116	C0297331
positive	T033	C1446409
osteoclasts	T025	C0029431
significantly higher	T081	C4055637
periapical	T082	C0729269
lesions	T033	C0221198
AP	T047	C0031030
AP	T047	C0031030
groups	T098	C1257890
osteocalcin	T116	C0029419
positive	T033	C1446409
osteoblasts	T025	C0029418
increased	T081	C0205217
AP	T047	C0031030
AP	T047	C0031030
Supplementation	T061	C0242297
ω-3 PUFAs	T109	C0015689
suppresses	T169	C1260953
bone resorption	T042	C0005974
promotes new bone formation	T042	C1371285
periapical area	T082	C0729269
rats	T015	C0034721
AP	T047	C0031030
conjunction	T078	C2699427
downregulation	T044	C0013081
inflammatory cell infiltration	T046	C0302158
lesion	T033	C0221198
MagR	T116	C0033684
Insufficient	T080	C0231180
Cellular Calcium Responses	T043	C2754478
Magnetic	T070	C0563532
Stimulation	T061	C1292856
Magnetic	T070	C0563532
manipulation	T061	C0947647
cell activity	T043	C0007613
advantages	T081	C0814225
optical manipulation	T061	C0947647
MagR protein	T116	C0033684
interaction	T044	C0872079
cryptochrome	T116	C2717939
Cry	T116	C2717939
protein	T116	C0033684
solution	T167	C0037633
respond	T032	C0871261
magnetic	T070	C0563532
stimulation	T061	C1292856
MS	T061	C1292856
investigation	T058	C0220825
role	T077	C1705810
MagR	T116	C0033684
cellular response	T043	C2754478
MS	T061	C1292856
study	T062	C2603343
MagR	T116	C0033684
expression	T045	C1171362
cellular activation	T043	C1326120
MS	T061	C1292856
systematically	T169	C0220922
testing	T169	C0039593
measuring	T080	C0444706
intracellular	T082	C0178719
calcium	T121	C0006675
MS	T061	C1292856
protocols	T170	C0442711
detect	T033	C0442726
cellular	T025	C0007634
neuronal	T025	C0027882
responses	T032	C0871261
MS	T061	C1292856
MagR	T116	C0033684
expressing	T045	C1171362
HEK cells	T025	C2936239
primary	T080	C0205225
neurons	T025	C0027882
dorsal	T082	C0205095
root ganglion	T023	C0017070
hippocampus	T023	C0019564
neurons	T025	C0027882
co-expressing	T045	C1171362
MagR	T116	C0033684
channelrhodopin	T116	C3253054
optical	T061	C1292856
MS	T061	C1292856
increased	T081	C0205217
calcium influx	T043	C3158761
hippocampal	T023	C0019564
neurons	T025	C0027882
MagR	T116	C0033684
not sufficient	T080	C0231180
cellular	T025	C0007634
magnetic responses	T040	C2754103
Acute kidney injury	T037	C2609414
fluid overload	T047	C0546817
infants	T100	C0021270
children	T100	C0008059
cardiac surgery	T061	C0018821
Acute kidney injury	T037	C2609414
serious	T080	C0205404
complication	T046	C0009566
congenital heart surgery	T061	C2037615
infants	T100	C0021270
comorbidity	T078	C0009488
associated with	T080	C0332281
adverse outcomes	T046	C0879626
increase	T169	C0442805
mortality	T081	C0178686
Postoperative	T079	C0032790
acute kidney injury	T037	C2609414
pathophysiology	T169	C0031847
risk factors	T033	C0035648
no single medication	T033	C0746919
therapy	T033	C0746919
effective	T080	C1704419
treatment	T061	C0087111
prevention	T080	C2700409
fluid overload	T047	C0546817
determinants	T169	C1521761
morbidity	T081	C0026538
infants	T100	C0021270
cardiac surgery	T061	C0018821
absence	T169	C0332197
intervention	T061	C0184661
acute kidney injury	T037	C2609414
improve	T080	C1272747
outcomes	T080	C0085415
treating	T169	C0039798
preventing	T080	C2700409
fluid overload	T047	C0546817
Early	T079	C1279919
renal replacement therapy	T061	C0206074
peritoneal dialysis	T061	C0031139
safe	T068	C0036043
beneficial	T081	C0814225
infants	T100	C0021270
oliguria	T047	C0028961
heart surgery	T061	C0018821
pathophysiology	T169	C0031847
acute kidney injury	T037	C2609414
diagnose	T033	C0011900
preventative	T080	C2700409
therapeutic interventions	T061	C0808232
Systems	T169	C0449913
Toxicology	T091	C0040541
World	T098	C2700280
Applications	T169	C0205245
Opportunities	T078	C1254370
Systems	T169	C0449913
Toxicology	T091	C0040541
adverse biological effects	T169	C0001688
xenobiotics	T123	C0043335
characterized	T052	C1880022
empirical	T080	C1880496
end points	T080	C2349179
modes	T169	C1513371
action	T052	C3266814
adverse	T169	C0001688
outcome	T169	C1274040
pathways	T077	C1705987
perturbed networks	T169	C1882071
Systems	T169	C0449913
Toxicology	T091	C0040541
integration	T066	C1705422
in vitro	T080	C1533691
in vivo	T082	C1515655
toxicity	T037	C0600688
data	T078	C1511726
computational modeling	T066	C0009609
approach	T169	C1292724
data	T078	C1511726
reliability	T081	C2347947
relevance	T080	C2347946
quality	T080	C0332306
experimental models	T170	C0086272
bioanalysis techniques	T062	C0242481
toxicological	T169	C0205472
data	T078	C1511726
Systems	T169	C0449913
Toxicology	T091	C0040541
data streams	T170	C0150098
data	T078	C1511726
omics measurements	T062	C0242481
computational	T052	C1880157
informative	T080	C2986490
results	T169	C1274040
integrative analysis	T062	C0936012
multiple	T081	C0439064
molecular measurements	T169	C0242485
omics strategies	T059	C0022885
approach	T169	C1292724
Systems	T169	C0449913
Toxicology	T091	C0040541
in vitro	T080	C1533691
bioanalytical strategies	T059	C0022885
linking	T169	C0205245
network	T169	C1882071
perturbations	T169	C0332453
phenotypes	T032	C0031437
pathways	T077	C1705987
networks	T169	C1882071
adverse responses	T169	C0001688
summary	T170	C1552616
Systems	T169	C0449913
Toxicology	T091	C0040541
meeting	T052	C0556656
international conference	T068	C0086047
Alps	T083	C0017446
Switzerland	T083	C0039021
limitations	T169	C0449295
opportunities	T078	C1254370
applications	T169	C0205245
Systems	T169	C0449913
Toxicology	T091	C0040541
adverse biological effects	T169	C0001688
xenobiotics	T123	C0043335
characterized	T052	C1880022
empirical	T080	C1880496
end points	T080	C2349179
pathways	T077	C1705987
toxicity	T037	C0600688
integration	T066	C1705422
in vitro	T080	C1533691
in vivo	T082	C1515655
data	T078	C1511726
computational modeling	T066	C0009609
bioanalytical technologies	T059	C0022885
data	T078	C1511726
reliability	T081	C2347947
relevance	T080	C2347946
pathway	T077	C1705987
approach	T169	C1292724
link	T169	C0205245
network	T169	C1882071
perturbations	T169	C0332453
phenotypic	T032	C0031437
toxicity	T037	C0600688
Validating	T062	C1519941
Signs and Symptoms	T184	C0037088
Mass Casualty Incident	T051	C1955957
Characterize	T052	C1880022
Irritant Gas Syndrome Agent	T131	C1254354
IGSA	T131	C1254354
Development	T169	C1527148
Novel	T080	C0205314
IGSA	T131	C1254354
Triage	T061	C0040861
Algorithm	T170	C0002045
Chemical exposures	T033	C0678803
significant	T078	C0750502
threat	T078	C0749385
life	T078	C0376558
assessment	T058	C0220825
first responders	T097	C3824749
emergency nurses	T097	C0557519
required	T169	C1514873
reduce	T080	C0392756
death	T040	C0011065
disability	T033	C0231170
no	T169	C1518422
informatics tools	T170	C0037589
irritant gas syndrome agent	T131	C1254354
IGSA	T131	C1254354
exposures	T080	C0332157
exist	T077	C2987476
process	T067	C1522240
victims	T098	C0680681
efficiently	T080	C0442799
continuously	T078	C0549178
monitor	T058	C1283169
latent	T080	C0205275
signs/symptoms	T184	C0037088
triage	T061	C0040861
recommendations	T078	C0034866
study	T062	C2603343
ED	T073	C0562508
informatics tools	T170	C0037589
chemical incidents	T068	C2350599
validation	T062	C1519941
signs/symptoms	T184	C0037088
characterize	T052	C1880022
IGSA	T131	C1254354
syndrome	T047	C0039082
Data abstracted	T079	C3259344
patients	T101	C0030705
treated	T061	C0087111
chlorine exposure	T033	C0239049
emergency department	T073	C0562508
during	T079	C0347984
train derailment	T067	C0337199
patients	T101	C0030705
not	T169	C1518422
exposed to chlorine	T033	C0239049
comparison group	T096	C0009932
mapped	T170	C3858752
signs/symptoms	T184	C0037088
tools	T170	C0037589
WISER	T170	C0037589
CHEMM-IST	T170	C0037589
designed	T052	C1707689
assist	T080	C1269765
emergency responders	T097	C3178988
emergency nurses	T097	C0557519
hazardous material	T131	C0018626
exposures	T080	C0332157
Inferential statistics	T081	C0032685
Fisher's exact test	T170	C0237913
diagnostics tests	T060	C0086143
used	T169	C1524063
mapped	T170	C3858752
signs/symptoms	T184	C0037088
persons	T098	C0027361
exposed to chlorine	T033	C0239049
clusters	T081	C1704332
signs/symptoms	T184	C0037088
statistically	T081	C2828391
associated with	T080	C0332281
IGSA	T131	C1254354
syndrome	T047	C0039082
respiratory	T169	C0521346
shortness of breath	T184	C0013404
wheezing	T184	C0043144
coughing	T184	C0010200
choking	T046	C0008301
chest discomfort	T184	C0235710
tightness	T184	C0232292
pain	T184	C0008031
burning	T184	C0740396
eye	T023	C0015392
nose	T023	C0028429
throat	T023	C3665375
pain	T184	C0030193
irritation	T067	C0441723
burning	T184	C0085624
syndrome	T047	C0039082
presence	T033	C0150312
signs/symptoms	T184	C0037088
clusters	T081	C1704332
latency period	T079	C0023103
considered	T078	C0750591
exposed	T098	C1998203
potentially	T080	C3245505
exposed persons	T098	C1998203
study	T062	C2603343
uses	T169	C1524063
patient data	T170	C2707520
chemical incident	T068	C2350599
characterize	T052	C1880022
validate	T062	C1519941
signs/symptoms	T184	C0037088
IGSA	T131	C1254354
syndrome	T047	C0039082
Validating	T062	C1519941
signs/symptoms	T184	C0037088
new	T080	C0205314
ED	T073	C0562508
informatics tools	T170	C0037589
potential	T080	C3245505
process	T067	C1522240
emergency nurses	T097	C0557519
triage	T061	C0040861
victims	T098	C0680681
chemical incidents	T068	C2350599
Fyn	T116	C1442788
multipolar	T082	C1254362
bipolar	T082	C0443156
transition	T052	C2700061
neurite morphogenesis	T043	C1753129
migrating neurons	T043	C1326504
developing neocortex	T042	C1818475
Fyn	T116	C1442788
non-receptor	T033	C0243095
protein tyrosine kinase	T116	C0033681
Src family kinases	T116	C0282625
Fyn	T116	C1442788
neuronal migration	T043	C1326504
mechanism	T169	C0441712
unclear	T033	C3845108
suppression	T045	C0038855
Fyn	T116	C1442788
expression	T045	C1171362
mouse cerebral cortex	T024	C1522579
migration defects	T033	C2750249
early-born	T079	C1279919
late-born	T079	C0205087
neurons	T025	C0027882
Morphological	T082	C0543482
analysis	T062	C0936012
Fyn	T116	C1442788
multipolar	T082	C1254362
bipolar	T082	C0443156
transition	T052	C2700061
generated	T052	C3146294
neurons	T025	C0027882
neurite formation	T043	C1753129
phase	T079	C0205390
migration	T043	C1326504
Fyn	T116	C1442788
inhibition	T045	C1519619
leading process	T043	C0007613
branching	T082	C0205384
migrating cortical neurons	T043	C1326504
Fyn	T116	C1442788
controls	T169	C2587213
neuronal migration	T043	C1326504
regulating	T038	C1327622
cytoskeletal	T026	C0010853
dynamics	T070	C3826426
multipolar	T082	C1254362
bipolar	T082	C0443156
transition	T052	C2700061
newly	T078	C0750546
generated	T052	C3146294
neurons	T025	C0027882
cortical development	T042	C1818475
Closing the Loop	T169	C0443183
Adults	T100	C0001675
Children	T100	C0008059
Adolescents	T100	C0205653
Suboptimally Controlled Type 1 Diabetes	T033	C2732401
Free	T078	C0870587
Living Conditions	T080	C0337645
Psychosocial	T169	C0542298
Substudy	T062	C2603343
psychosocial experiences	T033	C1458132
closed loop technology	T074	C0181334
adults	T100	C0001675
children	T100	C0008059
adolescents	T100	C0205653
type 1 diabetes	T047	C0011854
parents	T099	C0030551
multicenter	T062	C1096776
free	T078	C0870587
living	T080	C0337645
randomized	T062	C0034656
crossover home studies	T062	C0150097
Participants	T098	C0679646
insulin pump	T074	C1140609
therapy	T061	C0087111
randomized	T062	C0034656
weeks	T079	C0439230
automated	T169	C0205554
closed-loop	T169	C0443183
glucose control	T130	C0726398
weeks	T079	C0439230
sensor	T073	C0183210
augmented	T081	C0205217
insulin pump	T074	C1140609
therapy	T061	C0087111
open loop	T169	C0559530
Closed loop	T169	C0443183
hours	T079	C0439227
adults	T100	C0001675
overnight	T079	C0439583
children	T100	C0008059
adolescents	T100	C0205653
Participants	T098	C0679646
Diabetes Technology Questionnaire	T170	C0034394
DTQ	T170	C0034394
periodically	T079	C0332182
views	T082	C0449911
semistructured interviews	UnknownType	C0681913
analysis	T062	C0936012
characterizes	T078	C3875152
impact	T080	C4049986
technology	T090	C0039421
positive	T033	C1446409
negative	T080	C3853545
living	T080	C0337645
device	T074	C0025080
participants	T098	C0679646
expectations	T078	C0679138
hopes	T041	C0392347
anxieties	T033	C0003467
Participants	T098	C0679646
adults	T100	C0001675
years	T079	C0439234
male	T032	C0086582
children	T100	C0008059
age	T032	C0001779
years	T079	C0439234
years	T079	C0439234
male	T032	C0086582
DTQ	T170	C0034394
results	T169	C1274040
moderately favorable impact	T080	C4049986
open	T169	C0559530
closed loop	T169	C0443183
interventions	T061	C0184661
evidence	T078	C3887511
comparative advantage	UnknownType	C0681074
positive themes	T033	C1446409
improved blood glucose control	T130	C1873605
improved general well-being	T033	C2939150
waking	T039	C0442696
improved sleep	T040	C0037313
reduced	T080	C0392756
burden	T078	C2828008
diabetes	T047	C0011847
visibility	T080	C0205556
data	T078	C1511726
negative themes	T080	C3853545
equipment	T073	C0014672
dislike	T041	C0870431
pump	T074	C1140609
cannula	T074	C0520453
sensor	T073	C0183210
participants	T098	C0679646
positive	T033	C1446409
experience	T055	C0683573
closed loop technology	T074	C0181334
Results	T169	C1274040
consistent with	T078	C0332290
size	T082	C0456389
equipment	T073	C0014672
problem	T033	C0033213
usability	T169	C0457083
closed-loop system	T074	C0181334
Serum	T031	C0229671
levels	T080	C0441889
genomic DNA	T114	C3272453
α1(I) collagen	T028	C1332772
elevated	T080	C3163633
scleroderma	T047	C0011644
patients	T101	C0030705
nucleic acids	T114	C0028606
human	T016	C0086418
sera	T031	C0229671
disease markers	T078	C1511983
human	T016	C0086418
diseases	T047	C0012634
DNA	T114	C0012854
RNA	T114	C0035668
collagens	T028	C1333079
human	T016	C0086418
sera	T031	C0229671
serum	T031	C0229671
levels	T080	C0441889
biomarkers	T201	C0005516
scleroderma	T047	C0011644
patients	T101	C0030705
RNA	T114	C0035668
DNA	T114	C0012854
collagens	T028	C1333079
purified	T169	C1998793
sera	T031	C0229671
detected	T033	C0442726
polymerase chain reaction	T063	C0032520
quantitated	T081	C1709793
real-time polymerase chain reaction	T063	C1709846
360 bases of full-length α1(I) collagen	T028	C1332772
DNA	T114	C0012854
regions	T028	C0017337
detected	T033	C0442726
polymerase chain reaction	T063	C0032520
human	T016	C0086418
sera	T031	C0229671
α2(I) collagen	T028	C1332773
DNA	T114	C0012854
α1(I) collagen	T028	C1332772
RNA	T114	C0035668
α2(I) collagen	T028	C1332773
RNA	T114	C0035668
not detectable	T033	C0243095
α1(I) Collagen	T028	C1332772
DNA	T114	C0012854
sera	T031	C0229671
quantitative	T081	C0392762
levels	T080	C0441889
serum	T031	C0229671
α1(I) collagen	T028	C1332772
DNA	T114	C0012854
increased	T081	C0205217
scleroderma	T047	C0011644
patients	T101	C0030705
healthy control	T080	C2986479
subjects	T098	C0080105
systemic lupus erythematosus	T047	C0024141
patients	T101	C0030705
receiver-operator curve analysis	T081	C0035787
serum	T031	C0229671
α1(I) collagen	T028	C1332772
DNA	T114	C0012854
levels	T080	C0441889
diagnostic marker	T201	C1511876
scleroderma	T047	C0011644
association	T080	C0439849
serum	T031	C0229671
α1(I) collagen	T028	C1332772
DNA	T114	C0012854
levels	T080	C0441889
clinical	T080	C0205210
laboratory	T073	C0022877
features	T080	C1521970
scleroderma	T047	C0011644
patients	T101	C0030705
elevated	T080	C3163633
α1(I) collagen	T028	C1332772
DNA	T114	C0012854
levels	T080	C0441889
prevalence	T081	C0220900
pitting scars	T047	C0012634
ulcers	T047	C0041582
elevation	T080	C3163633
serum	T031	C0229671
α1(I) collagen	T028	C1332772
DNA	T114	C0012854
levels	T080	C0441889
scleroderma	T047	C0011644
patients	T101	C0030705
diagnostic marker	T201	C1511876
vasculopathy	T047	C0042373
rna	T114	C0035668
Metabolite	T123	C0870883
mapping	T052	C1283195
nanostructure	T073	C1450053
silver-assisted mass spectrometry imaging	T059	C0037813
tissue sections	T024	C2316368
Nanostructure-based mass spectrometry imaging	T059	C0037813
MSI	T059	C0037813
molecular imaging	T060	C1537028
small molecules	T109	C1328819
matrix-assisted molecular imaging	T060	C1537028
surfaces	T082	C0205148
silver	T196	C0037125
Ag	T196	C0037125
MSI data	T170	C0282574
MSI data	T170	C0282574
application	T169	C4048755
laser desorption/ionization mass spectrometry	T059	C0282597
biological samples	UnknownType	C0444062
desorption/ionization on silicon	T067	C1254366
DIOS	T067	C1254366
substrates	T167	C3891814
analysis	T062	C0936012
ultra-thin Ag layers	T080	C1522408
MSI analysis	T059	C0037813
Ag-DIOS MSI	T059	C0282597
small molecules	T109	C1328819
environmental	T082	C0014406
contaminants	T167	C2827365
sebum	T031	C0036511
lipids	T109	C0023779
metabolites	T123	C0870883
fore-stomach sections	T024	C1517295
6-bromoisatin	T109	C3493005
chemopreventative	T080	C3273128
murine mouse model	T050	C2986594
DIOS MSI	T059	C0037813
mapping	T052	C1283195
ions	T196	C0022023
6-bromoisatin	T109	C3493005
metabolites	T123	C0870883
lipids	T109	C0023779
murine fore-stomach	T024	C1517295
DIOS MSI	T059	C0037813
Ag-DIOS MSI	T059	C0282597
Ag-adductable lipids	T109	C0023779
wax esters	T109	C0014898
cholesterol	T109	C0008377
murine fore-stomach	T024	C1517295
Gastrointestinal acid	T031	C0017119
condensation	T067	C0596312
products	T123	C0566267
6-bromoisatin	T109	C3493005
6,6'-dibromoindirubin	T123	C0574031
isolate	T059	C0220862
characterize	T052	C1880022
tissue	T024	C0040300
metabolite	T123	C0870883
DIOS	T067	C1254366
tissue-specific spatial context	T024	C1955394
lipid distributions	T043	C0007613
Ag-DIOS MSI	T059	C0282597
metabolite	T123	C0870883
lipid	T109	C0023779
tissue-specific	T024	C1955394
MSI analyses	T059	C0037813
small molecules	T109	C1328819
metabolites	T123	C0870883
undetectable	T201	C3827727
culturally competent paediatric oncology care	T058	C3850087
qualitative study	T062	C0949415
perspective	T077	C1711364
care providers	T097	C0018724
influence	T077	C4054723
ethnic	T033	C0680174
diversity	T080	C1880371
paediatric	T091	C0030755
cancer care	T061	C0920687
perspectives	T077	C1711364
care providers	T097	C0018724
Semi-structured interviews	T058	C0683518
paediatric oncologists	T097	C0279158
nurses	T097	C0028661
paediatric oncology wards	T093	C0587485
analysed	T062	C0936012
framework method	T170	C0025663
care providers	T097	C0018724
Turkish	T098	C0549217
Moroccan	T098	C1257890
parents	T099	C0030551
language barriers	T033	C0237167
care provider	T097	C0018724
parents	T099	C0030551
hindered	T169	C0205245
exchange of information	T170	C0870706
cultural barriers	T058	C0810880
care provider	T097	C0018724
parents	T099	C0030551
diagnosis	T033	C0011900
palliative	T080	C1285530
perspective	T077	C1711364
hindered	T169	C0205245
communication	T054	C0009452
Care providers	T097	C0018724
solutions	T077	C2699488
barriers	T078	C0009454
interpreter	T097	C0150646
cultural knowledge	T170	C0376554
patients	T101	C0030705
interpreters	T097	C0150646
eliciting	T048	C0474408
parents	T099	C0030551
perspectives	T077	C1711364
Communication	T054	C0009452
techniques	T169	C0449851
dilemmas	T068	C1510640
parents	T099	C0030551
care providers	T097	C0018724
care providers	T097	C0018724
stereotypes	T041	C3825635
prejudice	T055	C0033023
Care providers	T097	C0018724
cultural barriers	T058	C0810880
Training	T065	C0220931
cultural competence	T054	C0679748
manifest	T169	C0205319
barriers	T078	C0009454
Obesogenic	T047	C0028754
eating behaviors	T055	C0015745
relationships	T080	C0439849
psychological problems	T033	C0848067
BMI	T201	C1305855
children	T100	C0008059
association	T080	C0439849
psychological problems	T033	C0848067
weight	T032	C0005910
status	T080	C0449438
children	T100	C0008059
aged	T032	C0001779
years	T079	C0439234
obesogenic	T047	C0028754
eating behaviors	T055	C0015745
relationship	T080	C0439849
cross-sectional secondary analysis	T062	C0010362
data	T078	C1511726
first-time mothers	T099	C0026591
NOURISH randomized controlled trial	T062	C0206035
child	T100	C0008059
child	T100	C0008059
maternal	T099	C0026591
child	T100	C0008059
eating behaviors	T055	C0015745
psychological problems	T033	C0848067
child	T100	C0008059
weight	T032	C0005910
height	T032	C0005890
data were collected	T062	C0010995
staff	T080	C1552084
Pearson's correlations	T170	C1709490
linear regressions	T081	C0023733
associations	T080	C0439849
eating behaviors	T055	C0015745
psychological problems	T033	C0848067
BMI	T201	C1305855
z score	T081	C0871421
Multiple mediation models	UnknownType	C0814912
tested	T169	C0039593
indirect	T080	C0439852
effects	T080	C1280500
psychological problems	T033	C0848067
BMI	T201	C1305855
z score	T081	C0871421
obesogenic	T047	C0028754
eating behaviors	T055	C0015745
Peer	T098	C0679739
problems	T033	C0848067
associated with	T080	C0332281
higher	T080	C0205250
food	T168	C0016452
responsiveness	T169	C0205342
emotional overeating	T048	C0556019
directly	T080	C1947931
higher	T080	C0205250
BMI	T201	C1305855
z score	T081	C0871421
relationship	T080	C0439849
emotional overeating	T048	C0556019
emotional overeating	T048	C0556019
food	T168	C0016452
responsiveness	T169	C0205342
association	T080	C0439849
emotional problems	T048	C0677660
BMI	T201	C1305855
z score	T081	C0871421
food	T168	C0016452
responsiveness	T169	C0205342
association	T080	C0439849
conduct problems	T048	C0149654
BMI	T201	C1305855
z score	T081	C0871421
children	T100	C0008059
psychological problems	T033	C0848067
obesogenic	T047	C0028754
eating behaviors	T055	C0015745
higher	T080	C0205250
BMI	T201	C1305855
clinical management	T058	C1516615
pediatric	T080	C1521725
overweight	T184	C0497406
obesity	T047	C0028754
psychological problems	T033	C0848067
Homocysteine	T116	C0019878
peripheral	T082	C0205100
biomarker	T201	C0005516
bipolar disorder	T048	C0005586
meta-analysis	T062	C0920317
Bipolar disorder	T048	C0005586
BD	T048	C0005586
psychiatric disorder	T048	C0004936
uncertain	T033	C0087130
aetiology	T169	C1314792
homocysteine	T116	C0019878
Hcy	T116	C0019878
alterations	T078	C1515926
1-carbon metabolism	T044	C1158831
psychiatric disorders	T048	C0004936
uncertainty	T033	C0087130
alterations	T078	C1515926
peripheral	T082	C0205100
Hcy	T116	C0019878
BD	T048	C0005586
meta-analysis	T062	C0920317
serum	T059	C1278080
plasma Hcy levels	T059	C1278165
persons	T098	C0027361
BD	T048	C0005586
healthy controls	T080	C2986479
systematic	T169	C0220922
search	T052	C1706202
eligible	T080	C1548635
peer-reviewed articles	T170	C2985503
cross-sectional studies	T062	C0010362
included	T169	C0332257
meta-analyses	T062	C0920317
providing	T052	C1999230
data	T078	C1511726
participants	T098	C0679646
Random-effects	T080	C1280500
meta-analysis	T062	C0920317
serum	T059	C1278080
plasma levels of Hcy	T059	C1278165
increased	T081	C0205217
subjects	T096	C0681850
BD	T048	C0005586
mania	T048	C0338831
euthymia	T048	C0948853
compared	T052	C1707455
healthy controls	T080	C2986479
effect size	T081	C0814843
mania	T048	C0338831
group	T098	C1257890
CI	T081	C0009667
effect	T080	C1280500
euthymia	T048	C0948853
group	T098	C1257890
CI	T081	C0009667
meta-analysis	T062	C0920317
Hcy levels are elevated	T033	C0920051
persons	T098	C0027361
BD	T048	C0005586
mania	T048	C0338831
euthymia	T048	C0948853
Peripheral	T082	C0205100
Hcy	T116	C0019878
considered	T078	C0750591
potential	T080	C3245505
biomarker	T201	C0005516
BD	T048	C0005586
trait	T032	C0599883
increased	T081	C0205217
euthymia	T048	C0948853
state	T169	C1442792
increase	T169	C0442805
accentuated	T080	C1997416
mania	T048	C0338831
Longitudinal studies	T062	C0023981
relationship	T080	C0439849
bipolar disorder	T048	C0005586
Hcy	T116	C0019878
usefulness	T080	C3827682
peripheral	T082	C0205100
Hcy	T116	C0019878
trait	T032	C0599883
state	T169	C1442792
biomarker	T201	C0005516
BD	T048	C0005586
Structural Modification	T061	C0581602
Lipopolysaccharide	T109	C0023810
mcr-1	T028	C0017337
Gram-Negative ESKAPE	T007	C0018150
Pathogens	T001	C0450254
mcr-1	T028	C0017337
plasmid	T114	C0032136
colistin	T116	C0009316
resistance gene	T028	C2945710
clinical isolates	T123	C1764827
Escherichia coli	T007	C0014834
Klebsiella pneumoniae	T007	C0001699
China	T083	C0008115
species	T185	C1705920
family Enterobacteriaceae	T007	C0014346
mcr-1	T028	C0017337
phosphoethanolamine transferase	T044	C2248757
expression	T045	C0017262
phosphoethanolamine	T109	C0070939
bis-phosphorylated hexa-acylated lipid A	T109	C0023767
E. coli	T007	C0014834
effects of	T080	C1704420
mcr-1	T028	C0017337
colistin	T116	C0009316
susceptibility	T033	C0427965
lipopolysaccharide	T109	C0023810
structures	T082	C0678594
laboratory	T073	C0022877
clinical	T080	C0205210
strains	T080	C0456178
Gram-negative ESKAPE	T007	C0018150
Enterococcus faecium	T007	C0085495
Staphylococcus aureus	T007	C0038172
K. pneumoniae	T007	C0001699
K. pneumoniae	T007	C0001699
Acinetobacter baumannii	T007	C0314787
Pseudomonas aeruginosa	T007	C0033809
Enterobacter species	T007	C1295792
pathogens	T001	C0450254
treated	T169	C1522326
clinically	T080	C0205210
colistin	T116	C0009316
effects of	T080	C1704420
mcr-1	T028	C0017337
colistin	T116	C0009316
resistance	T032	C0949285
MIC assays	T059	C0427978
laboratory	T073	C0022877
clinical	T080	C0205210
strains	T080	C0456178
E. coli	T007	C0014834
K. pneumoniae	T007	C0001699
A. baumannii	T007	C0314787
P. aeruginosa	T007	C0033809
Lipid A	T109	C0023767
structural	T082	C0678594
MCR-1	T116	C4308704
mass spectrometry	T059	C0037813
mcr-1	T028	C0017337
colistin	T116	C0009316
resistance	T032	C0949285
E. coli	T007	C0014834
K. pneumoniae	T007	C0001699
A. baumannii	T007	C0314787
reduced	T080	C0392756
susceptibility	T033	C0427965
P. aeruginosa	T007	C0033809
Phosphoethanolamine	T109	C0070939
modification	T033	C3840684
lipid A	T109	C0023767
species	T185	C1705920
findings	T169	C2607943
risk	T078	C0035647
colistin	T116	C0009316
resistance	T032	C0949285
consequence of	T169	C0686907
mcr-1	T028	C0017337
expression	T045	C0017262
ESKAPE	T007	C0018150
pathogens	T001	C0450254
K. pneumoniae	T007	C0001699
A. baumannii	T007	C0314787
lipid A	T109	C0023767
structures	T082	C0678594
increases	T169	C0442805
colistin	T116	C0009316
MICs	T059	C0427978
surveillance methods	T062	C1515093
dissemination	T082	C0205221
mcr-1	T028	C0017337
plasmid	T114	C0032136
plasmid	T114	C0032136
phosphoethanolamine transferases	T044	C2248757
Effects	T080	C1280500
Transplanted	T061	C0935850
Human	T016	C0086418
Cord Blood	T031	C0162371
Mononuclear Cells	T025	C0806987
Pulmonary Hypertension	T046	C0020542
Immunodeficient Mice	T015	C0599920
Distribution	T169	C1704711
investigate	T058	C0220825
effects	T080	C1280500
human	T016	C0086418
umbilical cord blood	T031	C0162371
mononuclear cell	T025	C0806987
hUCB	T031	C0162371
MNC	T025	C0806987
transplantation	T061	C0935850
pulmonary hypertension	T046	C0020542
PH	T046	C0020542
induced	T169	C0205263
monocrotaline	T109	C0085241
MCT	T109	C0085241
immunodeficient mice	T015	C0599920
distribution	T169	C1704711
MCT	T109	C0085241
administered	T169	C1521801
BALB/c Slc-nu/nu mice	T015	C0025919
PH	T046	C0020542
induced	T169	C0205263
mice	T015	C0025919
Fresh	T080	C0443224
hUCB	T031	C0162371
MNCs	T025	C0806987
harvested	T061	C0411265
human	T016	C0086418
donor	T098	C0013018
delivery	T169	C1705822
injected intravenously	T169	C0021494
PH	T046	C0020542
mice	T015	C0025919
medial	T082	C0205098
thickness	T080	C1280412
pulmonary arterioles	T023	C4243802
ratio	T081	C0456603
right ventricular	T023	C0225883
septum	T023	C0018819
plus	T169	C0332287
left ventricular	T023	C0225897
weight	T081	C0043100
RV	T023	C0225883
S	T023	C0018819
LV	T023	C0225897
ratio	T081	C0456603
acceleration time	T081	C3655682
ejection time	T201	C0812388
pulmonary blood flow	T201	C4071554
waveform	T070	C0450448
AT	T081	C3655682
ET	T201	C0812388
determined	T080	C0521095
hUCB	T031	C0162371
MNC	T025	C0806987
transplantation	T061	C0935850
reveal	T080	C0443289
incorporation	T169	C0243126
lung	T023	C0024109
CMTMR	T109	C0761898
labeled	T130	C1522485
hUCB	T031	C0162371
MNCs	T025	C0806987
observed	T169	C1441672
lung	T023	C0024109
fluorescent microscopy	T059	C0026022
DiR-labeled	T130	C0034551
hUCB	T031	C0162371
MNCs	T025	C0806987
detected	T033	C0442726
lung	T023	C0024109
organs	T023	C0178784
bioluminescence images	T074	C2955764
Medial	T082	C0205098
thickness	T080	C1280412
RV	T023	C0225883
S	T023	C0018819
LV	T023	C0225897
AT	T081	C3655682
ET	T201	C0812388
significantly	T078	C0750502
improved	T033	C0184511
hUCB	T031	C0162371
MNC	T025	C0806987
transplantation	T061	C0935850
compared	T052	C1707455
mice	T015	C0025919
hUCB	T031	C0162371
MNC	T025	C0806987
transplantation	T061	C0935850
CMTMR	T109	C0761898
positive	T033	C1446409
hUCB	T031	C0162371
MNCs	T025	C0806987
observed	T169	C1441672
lung	T023	C0024109
transplantation	T061	C0935850
Bioluminescence	T038	C0162404
signals	T067	C1710082
detected	T033	C0442726
strongly	T080	C0442821
lung	T023	C0024109
organs	T023	C0178784
transplantation	T061	C0935850
results	T033	C0683954
indicate	T033	C1444656
hUCB	T031	C0162371
MNCs	T025	C0806987
incorporated	T169	C0243126
lung	T023	C0024109
early	T079	C1279919
hUCB	T031	C0162371
MNC	T025	C0806987
transplantation	T061	C0935850
improve	T033	C0184511
MCT	T109	C0085241
induced	T169	C0205263
PH	T046	C0020542
Interprofessional Barriers	T033	C0243095
Quality Improvement Work	T057	C2936612
Nurses	T097	C0028661
Physicians	T097	C0031831
interprofessional barriers	T033	C0243095
nurses	T097	C0028661
physicians	T097	C0031831
context	T078	C0449255
quality improvement work	T057	C2936612
nurses	T097	C0028661
physicians	T097	C0031831
interviewed	T062	C0018260
hospitals	T073	C0019994
Sweden	T083	C0038995
study uncovered	T169	C0439845
number of barriers	T033	C4296486
each group	T078	C0441833
areas of responsibility	T055	C0678341
Recovery	T052	C0237820
alcohol dependence	T048	C0001973
smoking	T055	C0037369
indicators	T169	C1522602
abstinence	T061	C3843422
inconsistent	T080	C0442809
evidence	T078	C3887511
potential	T080	C3245505
influence	T077	C4054723
smoking	T055	C0037369
recovery	T052	C0237820
alcohol dependence	T048	C0001973
study	T059	C0947630
assessing	T058	C0184514
impact	T080	C4049986
smoking-behavior	T055	C1519383
relapse	T067	C0035020
months	T079	C0439231
follow-up	T058	C1522577
period	T079	C1948053
detoxification	T061	C0150543
patients	T101	C0030705
Alcohol Use Disorder	T048	C0001956
AUD	T048	C0001956
Patients	T101	C0030705
AUD	T048	C0001956
smoking	T055	C0037369
inpatient	T101	C0021562
detoxification units	T093	C1708333
psychiatric hospitals	T073	C0020021
Germany	T083	C0017480
alcohol consumption	T055	C0001948
year	T079	C0439234
Data	T078	C1511726
indicators	T169	C1522602
smoking behavior	T055	C1519383
Cox regression model	T081	C0033489
evaluate	T058	C0220825
potential	T080	C3245505
risk factors	T033	C0035648
relapse	T067	C0035020
alcohol consumption	T055	C0001948
participants	T098	C0679646
final	T079	C3853528
analysis	T062	C0936012
Smoking	T055	C0037369
increased	T081	C0205217
risk	T078	C0035647
alcohol relapse	T067	C0035020
hazard ratio	T081	C2985465
CI	T081	C0009667
increased	T081	C0205217
risk	T078	C0035647
reduced	T080	C0392756
daily	T079	C0332173
consumed cigarettes	T033	C0459840
hazard ratio	T081	C2985465
per	T080	C3887962
cigarette	T033	C0459840
CI	T081	C0009667
Smoking reduced	T033	C1276355
probability	T081	C0033204
maintaining	T052	C0024501
alcohol abstinence	T061	C3843422
significantly	T078	C0750502
higher	T080	C0205250
cigarettes smoked	T033	C0459840
daily	T079	C0332173
diminished	T081	C0205216
increased	T081	C0205217
risk	T078	C0035647
alcohol relapse	T067	C0035020
alcohol-dependent	T048	C0001973
patients	T101	C0030705
Coordinated	T169	C0700114
psychiatric	T169	C0205487
substance abuse	T048	C0740858
interventions	T061	C0184661
subgroups	T185	C1515021
patients	T101	C0030705
AUD	T048	C0001956
post-acute treatment phase	UnknownType	C0814495
Individualized	T080	C1881197
treatment	T169	C1522326
smoking	T055	C0037369
patients	T101	C0030705
AUD	T048	C0001956
relapse to alcohol drinking	T067	C0035020
somatic	T080	C2986476
complications	T046	C0009566
findings	T033	C0243095
individualized	T080	C1881197
treatment plans	T170	C0599880
patterns	T082	C0449774
neural activity	T042	C1254358
memory function	T041	C0025260
encoding	T041	C0679058
retrieval	T041	C0679061
Neural networks	T023	C0242406
span	T081	C2700613
medial temporal lobe	T023	C0039485
MTL	T023	C0039485
prefrontal cortex	T023	C0162783
posterior cortical regions	T023	C4252868
episodic memory function	T041	C0561843
humans	T016	C0086418
Encoding	T041	C0679058
retrieval	T041	C0679061
neural pathways	T023	C0027792
cortex	T023	C0007776
structures	T082	C0678594
medial temporal lobes	T023	C0039485
memory performance	T041	C1285654
neural processing	T040	C0597043
encoding	T041	C0679058
retrieval	T041	C0679061
neural signatures	T169	C1704864
memory function	T041	C0025260
free-recall task	T057	C3540678
neurosurgical	T061	C0524850
patients	T101	C0030705
implanted	T061	C0021107
subdural	T030	C0038541
intraparenchymal	T023	C0933845
depth electrodes	T074	C0491577
multivariate classifiers	T170	C0282574
patterns	T082	C0449774
brain	T023	C0006104
episodic encoding	T041	C0679058
retrieval	T041	C0679061
encoding	T041	C0679058
retrieval	T041	C0679061
patterns	T082	C0449774
high frequency	T079	C0205212
activity	T042	C1254358
prefrontal	T023	C0162783
MTL	T023	C0039485
inferior parietal cortices	T023	C0030560
low frequency	T079	C0205213
brain	T023	C0006104
memory function	T041	C0025260
cross-decoding approach	T081	C0026777
memory function	T041	C0025260
free-recall task	T057	C3540678
classifiers	T170	C0282574
encoding	T041	C0679058
retrieval states	T041	C0679061
task-independent models	T170	C3161035
memory network	T041	C0025260
encoding	T041	C0679058
retrieval	T041	C0679061
shapes	T082	C0332479
ability to remember the past	T033	C4303539
neural interactions	T042	C1254358
encoding	T041	C0679058
retrieval	T041	C0679061
Trump's	T016	C0086418
right idea	T078	C1254370
US	T083	C0041703
nursing student	T097	C0038496
feel	T041	C0013987
Obamacare	T089	C2936611
bad idea	T078	C1254370
disappointed	T041	C0870427
President	T090	C1527114
Trump	T016	C0086418
not able to get rid of	T033	C0243095
last month	T079	C0439231
Bilirubin	T109	C0005437
atherosclerotic	T047	C0004153
diseases	T047	C0012634
Bilirubin	T109	C0005437
product	T071	C1514468
heme catabolism	T044	C1157876
systemic circulation	UnknownType	C0678860
decades	T081	C2981279
increased	T081	C0205217
serum	T031	C0229671
plasma	T031	C0032105
bilirubin	T109	C0005437
levels	T080	C0441889
sign	T033	C0311392
liver disease	T047	C0023895
data	T078	C1511726
years	T079	C0439234
elevated	T080	C3163633
bilirubin	T109	C0005437
concentrations	T081	C1446561
associated	T080	C0439849
protection	T033	C1545588
oxidative stress	T049	C0242606
diseases	T047	C0012634
diseases	T047	C0012634
atherosclerotic	T047	C0004153
clinically	T080	C0205210
relevant	T080	C2347946
data	T078	C1511726
beneficial	T081	C0086387
effects	T080	C1280500
bilirubin	T109	C0005437
published	T057	C0034037
clinical study	T062	C0008972
increased	T081	C0205217
risk	T078	C0035647
coronary heart disease	T047	C0010068
low	T080	C0205251
serum	T031	C0229671
bilirubin	T109	C0005437
levels	T080	C0441889
bilirubin	T109	C0005437
risk factor	T033	C0035648
atherosclerotic	T047	C0004153
diseases	T047	C0012634
risk factors	T033	C0035648
results	T169	C1274040
studies	T062	C2603343
mild elevation of serum levels of unconjugated bilirubin	UnknownType	C0241024
benign	T080	C0205183
hyperbilirubinemia	T047	C0020433
Gilbert syndrome	T047	C0017551
prevalence	T081	C0033105
incidence	T081	C0021149
coronary heart	T047	C0010068
peripheral vascular disease	T047	C0085096
association	T080	C0439849
serum	T031	C0229671
bilirubin	T109	C0005437
biomarker	T201	C0005516
diseases	T047	C0012634
diseases	T047	C0012634
associated	T080	C0439849
increased	T081	C0205217
risk	T078	C0035647
atherosclerosis	T047	C0004153
data	T078	C1511726
biological pathways	T044	C1704259
bilirubin	T109	C0005437
clinical	T080	C0205210
associations	T080	C0439849
Automated	T169	C0205554
Pharmacist	T097	C0031323
Initiative	T041	C0424093
Improves	T033	C0184511
Quality of Care	T058	C0034379
Staphylococcus aureus Bacteremia	T047	C1142423
Infectious diseases	T047	C0009450
ID	T047	C0009450
consultation	T058	C0009818
antimicrobial stewardship intervention	T058	C0086388
improve	T033	C0184511
management	T058	C0376636
Staphylococcus aureus bacteremia	T047	C1142423
SAB	T047	C1142423
workload	T081	C0085122
antimicrobial stewardship programs	T058	C0086388
ASPs	T058	C0086388
ASPs	T058	C0086388
efficiency of the program	T078	C0033335
patient	T101	C0030705
outcomes	T169	C1274040
study	T062	C2603343
evaluate	T058	C0220825
impact	T080	C4049986
health informatics	T091	C0008960
management	T058	C0376636
SAB	T047	C1142423
pharmacist	T097	C0031323
initiative	T041	C0424093
Retrospective	T080	C1514923
quasi-experimental	T062	C1510570
study	T062	C2603343
hospitalized patients	T101	C0030705
SAB	T047	C1142423
intervention	T061	C0184661
period	T079	C1948053
pharmacists	T097	C0031323
patients	T101	C0030705
SAB	T047	C1142423
patient	T101	C0030705
scoring tool	T074	C0025080
electronic medical record	T170	C2362543
Pharmacists	T097	C0031323
scoring tool	T074	C0025080
institution's	T093	C2607850
evidence-based practice	T169	C1510541
guideline	T170	C0162791
standardized recommendations	T078	C0034866
adherence	T169	C1510802
SAB	T047	C1142423
quality-of-care	T058	C0034379
measures	T081	C0079809
ID	T047	C0009450
consultation	T058	C0009818
primary	T080	C0205225
outcome	T169	C1274040
compliance	T033	C3714738
adherence	T169	C1510802
individual	T098	C0237401
quality-of-care	T058	C0034379
components	T077	C1705248
Secondary	T080	C0175668
outcomes	T169	C1274040
analyzed	T062	C0936012
patients	T101	C0030705
study	T062	C2603343
inclusion	T080	C1512693
intervention	T061	C0184661
intervention	T061	C0184661
group	T078	C0441833
quality-of-care	T058	C0034379
components	T077	C1705248
management	T058	C0376636
SAB	T047	C1142423
significantly	T078	C0750502
intervention	T061	C0184661
group	T078	C0441833
incidence	T081	C0021149
ID	T047	C0009450
consult	T058	C0009818
improved	T033	C0184511
significantly	T078	C0750502
intervention	T061	C0184661
group	T078	C0441833
statistically significant	T081	C0237881
differences	T080	C1705242
bacteremia	T047	C0004610
length-of-stay	T079	C0023303
infection	T046	C3714514
length-of-stay	T079	C0023303
readmission	T058	C0030700
groups	T078	C0441833
incidence	T081	C0021149
mortality	T081	C0026565
intervention	T061	C0184661
group	T078	C0441833
intervention	T061	C0184661
group	T078	C0441833
automated	T169	C0205554
pharmacist	T097	C0031323
intervention	T061	C0184661
management	T058	C0376636
patients	T101	C0030705
SAB	T047	C1142423
significant	T078	C0750502
improvement	T077	C2986411
patients	T101	C0030705
ID	T047	C0009450
consult	T058	C0009818
targeted	T169	C1521840
antimicrobial therapy	T121	C0443071
adherence	T169	C1510802
SAB	T047	C1142423
quality-of-care	T058	C0034379
measures	T081	C0079809
antimicrobial stewardship	T058	C0086388
mandatory	T169	C1514873
healthcare	T058	C0086388
hospitals	T073	C0019994
U.S.	T083	C0041703
ASPs	T058	C0086388
forced	T169	C0443221
find	T033	C0243095
efficient	T080	C0442799
impactful	T080	C4049986
disease	T047	C0012634
patient care	T058	C0017313
study	T062	C2603343
data	T078	C1511726
intervention	T061	C0184661
clinically important	T080	C0443178
infectious diseases	T047	C0009450
intracellular	T026	C0175996
Zn(2+)	T121	C0043481
signaling	T043	C4236609
LTP	T042	C0206249
perforant pathway	T023	C0524810
CA1 pyramidal cell synapse	T023	C2717851
Physiological	T169	C0205463
synaptic Zn(2+) signaling	T043	C4236609
perforant pathway	T023	C0524810
CA1 pyramidal cell synapses	T023	C2717851
In vivo	T082	C1515655
long-term potentiation	T042	C0206249
LTP	T042	C0206249
perforant pathway	T023	C0524810
CA1 pyramidal cell synapses	T023	C2717851
electrode	T074	C0013812
microdialysis	T058	C0206056
probe	T074	C0182400
perfused	T061	C0031001
artificial cerebrospinal fluid	T103	C0220806
ACSF	T103	C0220806
microdialysis	T058	C0206056
probe	T074	C0182400
Perforant pathway	T023	C0524810
LTP	T042	C0206249
perfusion	T061	C0031001
CaEDTA	T130	C0021212
extracellular	T026	C0521119
Zn(2+)	T121	C0043481
perfusion	T061	C0031001
ZnAF-2DA	T130	C0021212
intracellular	T026	C0175996
Zn(2+)	T121	C0043481
intracellular	T026	C0175996
Zn(2+)	T121	C0043481
signaling	T043	C4236609
perforant pathway	T023	C0524810
LTP	T042	C0206249
rat brain slices	T023	C1882598
CaEDTA	T130	C0021212
ACSF	T103	C0220806
intracellular	T026	C0175996
Zn(2+)	T121	C0043481
intracellular	T026	C0175996
ZnAF-2	T130	C0021212
stratum lacunosum-moleculare	T023	C3498968
perforant pathway	T023	C0524810
CA1 pyramidal cell synapses	T023	C2717851
tetanic stimulation	T061	C1292856
intracellular	T026	C0175996
Zn(2+)	T121	C0043481
signaling	T043	C4236609
proteins	T116	C0033684
LTP	T042	C0206249
perforant pathway	T023	C0524810
CA1 pyramidal cell synapses	T023	C2717851
influx	T043	C0007613
extracellular	T026	C0521119
Zn(2+)	T121	C0043481
presynaptic Zn(2+) release	T043	C0007613
LTP	T042	C0206249
Schaffer collateral	T026	C3544403
CA1 pyramidal cell synapses	T023	C2717851
synapse	T030	C0039062
Zn(2+)	T121	C0043481
plasticity	T043	C4042875
postsynaptic	UnknownType	C0682686
CA1 pyramidal cells	T025	C0206441
20S immunoproteasomes	T116	C0014442
formaldehyde	T109	C0016564
damaged	T169	C1883709
cytoplasmic proteins	T116	C1333198
suppressing	T169	C1260953
caspase-independent cell death	T043	C3820502
Immunoproteasomes	T116	C0014442
involvement	T169	C1314939
antigen presentation	T043	C0206431
broad	T082	C0332464
tissue	T024	C0040300
presence	T033	C0150312
evidence	T169	C0332120
indicative of	T078	C0392360
nonimmune functions	T039	C0031843
immunoproteasomes	T116	C0014442
cellular responses	T043	C1817908
endogenous	T169	C0205227
environmental carcinogen	T131	C0007091
formaldehyde	T109	C0016564
FA	T109	C0016564
cytosolic	T026	C1383501
nuclear proteins	T116	C0028589
proteotoxic stress	T046	C0449430
genotoxic	T049	C0598309
DNA	T114	C0012854
histone	T116	C0019652
crosslinks	T070	C0178576
immunoproteasomes	T116	C0014442
important	T080	C3898777
suppression	T169	C1260953
caspase-independent cell death	T043	C3820502
long-term	T079	C0443252
survival	T169	C0220921
FA-treated cells	T025	C0007634
genotoxic	T049	C0598309
responses	T032	C0871261
FA	T109	C0016564
replication inhibition	T045	C1511692
activation	T052	C1879547
transcription factor p53	T116	C0080055
apical	T082	C0205111
ATM	T116	C3711796
ATR kinases	T116	C3711837
unaffected	T077	C2986417
immunoproteasome	T116	C0014442
inactivity	T080	C3244312
inhibition	T052	C3463820
enhanced	T052	C2349975
activation	T052	C1879547
cytosolic	T026	C1383501
protein	T116	C0033684
damage	T169	C1883709
sensor HSF1	T116	C0121235
elevated levels	T080	C0441889
K48-polyubiquitinated	T044	C3820607
cytoplasmic proteins	T116	C1333198
increased	T081	C0205217
depletion	T169	C0333668
unconjugated	T080	C0522530
ubiquitin	T116	C0041538
FA	T109	C0016564
induced	T169	C0205263
disassembly	T052	C1707798
26S immunoproteasomes	T116	C0014442
26S proteasomes	T116	C0286330
20S catalytic immunoproteasome	T116	C0014442
FA-treated cells	T025	C0007634
higher amounts	T081	C1265611
activators PA28αβ	T116	C0753808
PA28γ	T116	C0893173
20S particles	T116	C0014442
significance	T078	C0750502
nonnuclear damage	T169	C1883709
FA	T109	C0016564
immunoproteasomes	T116	C0014442
FA-damaged	T169	C1883709
cytoplasmic proteins	T116	C1333198
ubiquitin	T116	C0041538
independent	T078	C0085862
proteolysis	T044	C0597304
Musculoskeletal pain	T033	C0026858
profile	T170	C1518848
obese	T047	C0028754
individuals	T098	C0027361
attending	T169	C1999232
multidisciplinary weight management service	T093	C0596660
Obesity	T047	C0028754
associated with	T080	C0332281
numerous	T081	C0439064
chronic diseases	T047	C0008679
including	T169	C0332257
musculoskeletal (MSK) pain	T033	C0026858
impacts	T080	C4049986
quality of life	T078	C0034380
QoL	T078	C0034380
comprehensive	T080	C1880156
MSK pain	T033	C0026858
profile	T170	C1518848
obese	T047	C0028754
cohort	T098	C0599755
retrospective study	T062	C2985505
patient	T101	C0030705
database	T170	C0242356
national weight management service	T093	C0596660
WMS	T093	C0596660
ethical	T078	C1136353
approval	T170	C2346845
anonymized	T170	C3858751
patient data	T170	C2707520
statistically analyzed	T062	C0871424
pain	T184	C0030193
profile	T170	C1518848
investigate	T169	C1292732
relationships	T080	C0439849
pain	T184	C0030193
sleep	T040	C0037313
function	T033	C0516981
variables	T080	C0439828
associated with	T080	C0332281
low back pain	T184	C0024031
LBP	T184	C0024031
knee pain	T033	C0231749
individuals	T098	C0027361
WMS	T093	C0596660
male	T098	C0025266
CI	T081	C0009667
female	T098	C0043210
CI	T081	C0009667
mean	T081	C0444504
age	T032	C0001779
Mean	T081	C0444504
BMI	T201	C1305855
obese	T047	C0028754
BMI	T201	C1305855
CI	T081	C0009667
Approximately	T080	C0332232
MSK pain	T033	C0026858
LBP	T184	C0024031
CI	T081	C0009667
mean	T081	C0444504
knee pain	T033	C0231749
CI	T081	C0009667
mean	T081	C0444504
obese	T047	C0028754
multi-site	T082	C1254362
pain	T184	C0030193
patients	T101	C0030705
lower	T052	C2003888
QoL	T078	C0034380
physical activity	T056	C0026606
levels	T080	C0441889
reduced	T080	C0392756
sleep	T040	C0037313
poorer	T080	C2700379
physical function	T033	C0516981
less	T080	C0547044
obese	T047	C0028754
patients	T101	C0030705
without	T080	C0332288
pain	T184	C0030193
Relationships	T080	C0439849
demographic	T090	C0011298
pain	T184	C0030193
self-report	T062	C0681906
psychological	T169	C0205486
functional	T169	C0205245
measures	T081	C0079809
Patients	T101	C0030705
slept fewer hours	T033	C0243095
poorer	T080	C2700379
functional outcomes	T033	C0243095
LBP	T184	C0024031
patients	T101	C0030705
divorced	T033	C0086170
lower	T052	C2003888
QoL	T078	C0034380
frequent	T079	C0332183
nocturia	T047	C0028734
knee pain	T033	C0231749
Multi-site	T082	C1254362
MSK pain	T033	C0026858
prevalent	T081	C0220900
severe	T080	C0205082
obese	T047	C0028754
patients	T101	C0030705
negatively	T033	C1513916
associated with	T080	C0332281
functional outcomes	T033	C0243095
prevalence	T081	C0220900
pain management	T061	C0002766
treating	T061	C0087111
obesity	T047	C0028754
Primary	T080	C0205225
Management	T058	C0376636
Outcome	T169	C1274040
Open Laryngotracheal Trauma	T037	C0339881
Acute	T079	C0205178
external injury	T080	C0443212
larynx	T023	C0023078
life threatening	T033	C2826244
long term	T079	C0443252
management	T170	C0680830
Otorhinolaryngologist	T097	C0334893
patients	T101	C0030705
patients	T101	C0030705
open laryngeal traumas	T037	C0339881
primary closure	T061	C0441503
patients	T101	C0030705
nature of injury	T037	C0449499
patients	T101	C0030705
nature of injury	T037	C0449499
primary closure	T061	C0441503
patients	T101	C0030705
injury	T037	C3263723
survived	T052	C0038952
patients	T101	C0030705
injury	T037	C3263723
died	T040	C0011065
experience	T033	C0557355
primary closure	T061	C0441503
nature of injury	T037	C0449499
outcome	T169	C1274040
favourable	T033	C0278250
kinematic gait analysis	T060	C0558820
young	T079	C0332239
old	T079	C0580836
Beagle dogs	T015	C1296765
Age-related	T079	C0851454
involution	T040	C0333953
dogs	T015	C1296765
loss of muscle mass	T033	C1837108
connective tissue	T024	C0009780
articular cartilage	T024	C0007303
examine	T033	C0332128
age-related	T079	C0851454
joint mobility	T033	C1820723
detected	T033	C0442726
absence	T169	C0332197
diseases	T047	C0012634
young	T079	C0332239
years	T079	C0439234
old	T079	C0580836
years	T079	C0439234
healthy	T080	C3898900
sound Beagle dogs	T015	C1296765
measured	T080	C0444706
locomotion	T040	C0023946
treadmill	T073	C0184069
computer-assisted	T059	C2362103
gait analysis	T060	C0558820
Angles	T082	C0205143
shoulder	T030	C0037009
elbow	T030	C0013770
carpal	T030	C1262468
hip	T030	C0019558
stifle	T030	C1456798
tarsal joints	T030	C1527245
analyzed	T062	C0936012
joint angle progression curves	T081	C0392762
minimum	T080	C1524031
maximum	T081	C0806909
joint	T030	C0022417
angles	T082	C0205143
range of motion	T201	C2607871
ROM	T201	C2607871
old	T079	C0580836
group	T096	C0681850
joint	T030	C0022417
angle	T082	C0205143
ROM	T201	C2607871
carpal joint	T030	C1262468
shoulder	T030	C0037009
elbow	T030	C0013770
carpal joint	T030	C1262468
descriptive analysis	T170	C0678257
progression curves	T081	C0392762
less flexion	T033	C0231455
extension	T169	C0231448
joints	T030	C0022417
forelimb	T029	C0016555
restricted	T169	C0443288
joint mobility	T033	C1820723
forelimb	T029	C0016555
carpal joint	T030	C1262468
Findings	T169	C2607943
joints	T030	C0022417
hindlimb	T023	C1522391
consistent	T078	C0332290
alterations	T078	C1515926
compensatory	T169	C0231186
mechanism	T169	C0441712
alterations	T078	C1515926
found	T033	C0150312
distal joints	T030	C0224640
particular attention	T041	C0589098
elderly dogs	T015	C1296765
Propensity Score	T081	C2718044
Comparison	T052	C1707455
Partial	T081	C0728938
Whole	T081	C0444667
Gland	T023	C0033572
Cryotherapy	T061	C3544233
Intermediate-Risk	T033	C3640764
Prostate Cancer	T191	C0376358
analysis	T062	C0936012
COLD registry data	T170	C0282574
oncological	T191	C0027651
functional	T169	C0205245
outcomes	T080	C0085415
partial	T081	C0728938
whole	T081	C0444667
gland	T023	C0033572
cryotherapy	T061	C3544233
men	T098	C0025266
intermediate-risk	T033	C3640764
prostate cancer	T191	C0376358
Men	T098	C0025266
intermediate-risk	T033	C3640764
prostate cancer	T191	C0376358
treated with	T061	C0332293
primary	T080	C0205225
prostate cryotherapy	T061	C3544233
Cryo On-Line Data Registry	T170	C0282574
matched	T062	C0150103
comparison	T052	C1707455
whole	T081	C0444667
gland	T023	C0033572
partial	T081	C0728938
prostate cryotherapy	T061	C3544233
targeted-ablation	T061	C0547070
unilateral/bilateral nerve-sparing ablations	T061	C0547070
propensity score	T081	C2718044
age	T032	C0001779
pre-biopsy serum	T031	C0229671
PSA	T116	C0138741
biopsy Gleason score	T033	C2123503
clinical stage	T079	C0205563
prostate volume	T081	C1441416
neoadjuvant androgen deprivation	T061	C1515985
status	T080	C0449438
year	T079	C0439234
surgery	T061	C0543467
pre-treatment	T079	C2709094
Outcomes	T080	C0085415
biochemical	T170	C3897727
progression-free survival	T081	C0242792
BPFS	T081	C0242792
ASTRO	T170	C0935549
Phoenix criteria	T170	C0935549
continence	T040	C0542565
sexual function	T040	C0278092
sufficient	T080	C0205410
sexual intercourse	T040	C0009253
propensity score	T081	C2718044
matching	T062	C0150103
BPFS	T081	C0242792
compared	T052	C1707455
Kaplan-Meier analysis	T081	C1720943
functional	T169	C0205245
outcomes	T080	C0085415
chi-square tests	T170	C0008041
men	T098	C0025266
identified	T080	C0205396
whole	T081	C0444667
gland	T023	C0033572
partial	T081	C0728938
Post-matching	T079	C1254367
men	T098	C0025266
analysed	T062	C0936012
follow-up	T058	C1522577
BPFS	T081	C0242792
rate	T081	C1521828
whole	T081	C0444667
gland	T023	C0033572
partial	T081	C0728938
ablation	T061	C0547070
Phoenix	T170	C0935549
whole	T081	C0444667
gland	T023	C0033572
partial	T081	C0728938
ablation	T061	C0547070
ASTRO	T170	C0935549
continence	T040	C0542565
rate	T081	C1521828
similar	T080	C2348205
successful	T080	C1272703
intercourse	T040	C0009253
whole	T081	C0444667
gland	T023	C0033572
partial	T081	C0728938
ablation	T061	C0547070
incidence	T081	C0021149
post-treatment	T079	C2709088
urinary retention	T033	C0080274
whole	T081	C0444667
gland	T023	C0033572
partial	T081	C0728938
ablation	T061	C0547070
rectourethral fistula	T047	C0268875
Partial	T081	C0728938
ablation	T061	C0547070
results	T033	C0808233
better	T080	C0332272
post-treatment	T079	C2709088
sexual function	T040	C0278092
compared	T052	C1707455
whole	T081	C0444667
gland	T023	C0033572
ablation	T061	C0547070
men	T098	C0025266
intermediate-risk	T033	C3640764
prostate cancer	T191	C0376358
early	T079	C1279919
BPFS	T081	C0242792
groups	T078	C0441833
Abnormal	T033	C0205161
metabolic	T169	C0311400
brain	T023	C0006104
network	T040	C0598941
Parkinson's disease	T047	C0030567
replication	T080	C1883725
European	T098	C0239307
sample	T077	C2347026
study	T062	C2603343
identify	T080	C0205396
metabolic	T169	C0311400
brain	T023	C0006104
pattern	T082	C0449774
characteristic	T080	C1521970
Parkinson's disease	T047	C0030567
PD	T047	C0030567
Parkinson's disease-related pattern	T081	C0449782
PDRP	T081	C0449782
network	T040	C0598941
[18F]-fluorodeoxyglucose positron emission tomography	T060	C0872169
FDG-PET	T060	C0872169
brain	T023	C0006104
images	T170	C1704254
cohort	T098	C0599755
Slovenian	T083	C0037334
PD	T047	C0030567
patients	T101	C0030705
PD	T047	C0030567
patients	T101	C0030705
age	T032	C0001779
years	T079	C0439234
Movement Disorder Society Unified Parkinson's Disease Motor Rating Scale	T170	C3639714
MDS-UPDRS-III	T170	C3639714
disease duration	T079	C0872146
years	T079	C0439234
age	T032	C0001779
matched	T080	C1708943
normal controls	T096	C0009932
NCs	T096	C0009932
FDG-PET	T060	C0872169
brain imaging	T060	C0203860
automatic voxel-based scaled subprofile model	T075	C0026336
principal component analysis	T081	C0429865
SSM	T075	C0026336
PCA	T081	C0429865
scans	T060	C0441633
PDRP	T081	C0449782
Slovenia	T083	C0037334
identification	T080	C0205396
pattern	T081	C0449782
characterized	T052	C1880022
hypermetabolism	T033	C0342952
pallidum	T023	C0017651
putamen	T023	C0034169
thalamus	T023	C0039729
brain stem	T023	C0006121
cerebellum	T023	C0007765
hypometabolism	T033	C0347938
sensorimotor cortex	T023	C3499125
posterior parietal	T023	C3853037
occipital	T029	C1184145
frontal cortices	T023	C0016733
expression	T078	C1254370
PDRP	T081	C0449782
Slovenia	T083	C0037334
PD	T047	C0030567
patients	T101	C0030705
NCs	T096	C0009932
correlated	T080	C1707520
patients	T101	C0030705
clinical	T080	C0205210
score	T081	C0449820
MDS-UPDRS-III	T170	C3639714
topography	T185	C0392918
PDRP	T081	C0449782
identified	T080	C0205396
American	T098	C0596070
cohort	T098	C0599755
PD	T047	C0030567
patients	T101	C0030705
PDRP	T081	C0449782
Slovenia	T083	C0037334
expression	T078	C1254370
FDG-PET	T060	C0872169
scans	T060	C0441633
PD	T047	C0030567
patients	T101	C0030705
NCs	T096	C0009932
patients	T101	C0030705
atypical parkinsonism	T047	C4302185
AP	T047	C4302185
expression	T078	C1254370
PDRP	T081	C0449782
Slovenia	T083	C0037334
diagnostic accuracy	T080	C0598285
specificity	T081	C1511884
sensitivity	T081	C1511883
pattern	T081	C0449782
expression	T078	C1254370
PD	T047	C0030567
patients	T101	C0030705
NCs	T096	C0009932
AP	T047	C4302185
PDRP	T081	C0449782
Slovenia	T083	C0037334
functional imaging	T060	C1517324
biomarker	T201	C0005516
patient	T101	C0030705
population	T098	C1257890
PD	T047	C0030567
patients	T101	C0030705
NCs	T096	C0009932
AP	T047	C4302185
clinical	T080	C0205210
measure	T081	C0079809
PD	T047	C0030567
progression	T046	C0242656
effects of	T080	C1704420
gestational	T079	C0439671
use of	T169	C1524063
antidepressants	T121	C0003289
antipsychotics	T121	C0040615
neonatal	T100	C0021289
outcomes	T169	C1274040
women	T098	C0043210
severe	T080	C0205082
mental illness	T048	C0004936
Psychotropic medication	T121	C0033978
use	T169	C1524063
occurs	T079	C2745955
pregnancies	T040	C0032961
rates	T033	C2359857
increasing	T169	C0442808
often	T079	C0332183
multiple	T081	C0439064
medications	T121	C0013227
prescribed	T058	C0278329
study	T062	C2603343
use of	T169	C1524063
psychotropic medication	T121	C0033978
cohort	T098	C0599755
women	T098	C0043210
severe	T080	C0205082
mental illness	T048	C0004936
increases	T169	C0442805
rates	T081	C0032975
special care nursery	T061	C0204795
admission	T058	C0184666
reports	T170	C0025102
differences	T080	C1705242
antidepressant	T121	C0003289
antipsychotic medication	T121	C0040615
use	T169	C1524063
alone	T081	C0205171
combination	T121	C0013162
retrospective database analysis from a cohort	T062	C2985505
severe	T080	C0205082
mental illness	T048	C0004936
pregnancy	T040	C0032961
identified	T080	C0205396
pregnant women	T098	C0033011
grouped	T185	C0008902
medication	T121	C0013227
type	T080	C0332307
Demographic	T080	C0681668
obstetric	T169	C0205484
neonatal	T100	C0021289
variables	T080	C0439828
analysed	T062	C0936012
using	T169	C1524063
t-tests	T170	C0871472
analysis	T062	C0936012
variance	T080	C1711260
logistic regression analysis	UnknownType	C0681925
special care nursery	T061	C0204795
admission	T058	C0184666
medication groups	T101	C0030705
women	T098	C0043210
taking no psychotropic medications	T101	C0030705
those taking antipsychotics	T101	C0030705
those taking antidepressants	T101	C0030705
those taking and a combination of antidepressants/antipsychotics	T101	C0030705
Rates	T033	C2359857
special care nursery	T061	C0204795
admission	T058	C0184666
women	T098	C0043210
psychotropic medication	T121	C0033978
compared	T052	C1707455
those who did not	T101	C0030705
significantly	T078	C0750502
raised	T080	C0442818
compared	T052	C1707455
general population	T098	C0683971
No significant difference	T033	C3842396
medication groups	T101	C0030705
significant	T078	C0750502
odds ratio	T081	C0028873
found	T033	C0150312
special care nursery	T061	C0204795
psychiatric admission	T058	C0237457
during	T079	C0347984
pregnancy	T040	C0032961
psychotropic medication	T121	C0033978
Rates	T081	C0032975
special care nursery	T061	C0204795
admission	T058	C0184666
neonates	T100	C0021289
women	T098	C0043210
severe	T080	C0205082
mental illness	T048	C0004936
psychotropic medication	T121	C0033978
monotherapy	T061	C3846440
polytherapy	T061	C0013218
prescribing	T058	C0278329
antidepressants	T121	C0003289
antipsychotic medication	T121	C0040615
vulnerability	T033	C1821973
occurs	T079	C2745955
neonates	T100	C0021289
women	T098	C0043210
mental illness	T048	C0004936
paediatric	T097	C0237433
delivery	T040	C0005615
recommended	T078	C0034866
Intrawound Vancomycin	T116	C0042313
Application	T169	C4048755
Spine Surgery	T061	C2608059
Vancomycin-Resistant	T032	C0752078
Organism	T001	C0029235
Surgical site infection	T046	C0038941
SSI	T046	C0038941
spine surgery	T061	C2608059
morbid	T080	C0205556
expensive complication	T169	C1171258
intrawound vancomycin	T116	C0042313
SSI	T046	C0038941
vancomycin-resistant	T032	C0752078
pathogens	T001	C0450254
occurrence	T079	C2745955
vancomycin-resistant	T032	C0752078
SSI	T046	C0038941
patients	T101	C0030705
intrawound vancomycin	T116	C0042313
Patients	T101	C0030705
Patients	T101	C0030705
spine surgery	T061	C2608059
dichotomized	T080	C0443299
intrawound vancomycin	T116	C0042313
occurrence	T079	C2745955
SSI	T046	C0038941
operating room	T073	C0029064
postoperative 90 days	T079	C0032790
intrawound culture	T059	C0596932
vancomycin	T116	C0042313
minimal inhibitory concentrations	T059	C0427978
MIC	T059	C0427978
pathogen profile	T001	C0450254
MIC	T059	C0427978
vancomycin	T116	C0042313
patients	T101	C0030705
vancomycin	T116	C0042313
patients	T101	C0030705
intrawound vancomycin	T116	C0042313
during the index surgery	T079	C1254367
vancomycin	T116	C0042313
significantly lower	T081	C4055638
SSI	T046	C0038941
rates	T023	C0037993
occurrence	T079	C2745955
Staphylococcus aureus	T007	C0038172
SSI	T046	C0038941
significantly lower	T081	C4055638
patients	T101	C0030705
application	T169	C4048755
intrawound vancomycin	T116	C0042313
patients	T101	C0030705
application	T169	C4048755
intrawound vancomycin powder	T116	C0042313
S aureus	T007	C0038172
SSI	T046	C0038941
pathogens	T001	C0450254
resistance to vancomycin	T033	C3265908
patients	T101	C0030705
MIC	T059	C0427978
vancomycin	T116	C0042313
occurrence	T079	C2745955
gram-negative	T047	C0085423
SSI	T046	C0038941
culture negative fluid collection	T033	C0429652
higher	T080	C0205250
vancomycin	T116	C0042313
cohort	T098	C0599755
intrawound vancomycin	T116	C0042313
spine surgery	T061	C2608059
SSI	T046	C0038941
spine surgery	T061	C2608059
application	T169	C4048755
intrawound vancomycin	T116	C0042313
during index surgery	T079	C1254367
vancomycin-resistant	T032	C0752078
organisms	T001	C0029235
SSI	T046	C0038941
Adequacy	T170	C0808073
criteria	T078	C0243161
thyroid FNA	T060	C0193787
evaluated	T058	C0220825
ThinPrep slides	T060	C0430022
Adequacy	T170	C0808073
criteria	T078	C0243161
thyroid fine-needle aspiration	T060	C0193787
FNA	T060	C0193787
recommended	T078	C0034866
Bethesda System for Reporting Thyroid Cytopathology	T059	C0022885
TBS	T059	C0022885
smears	T060	C0444186
applied	T169	C4048755
ThinPreps	T060	C0430022
TPs	T060	C0430022
evaluated	T058	C0220825
adequacy	T170	C0808073
TPs	T060	C0430022
diagnostic	T169	C0348026
thresholds	T080	C0449864
FNA procedures	T060	C0193787
performed	T169	C0884358
matched	T080	C1708943
surgical specimens	T167	C0370003
analyzed	T062	C0936012
Cell counts	T059	C0007584
cytological	T169	C0205471
features	T080	C2348519
evaluated	T058	C0220825
nondiagnostic	T033	C0686919
ND	T033	C0686919
cases	T096	C0681850
ND	T033	C0686919
cases	T096	C0681850
reclassified	T080	C0205542
TBS	T059	C0022885
categories	T170	C0683312
pathologists	T097	C0334866
results	T169	C1274040
compared	T052	C1707455
surgical outcomes	T169	C1274040
hundred forty-six	T081	C0392762
cases	T096	C0681850
classified	T185	C0008902
ND	T033	C0686919
available	T169	C0470187
review	T169	C0699752
mean	T081	C0444504
cell count	T059	C0007584
standard deviation	T081	C0871420
Interobserver agreement	T054	C0680240
reclassification	T185	C0008902
ND	T033	C0686919
cases	T096	C0681850
moderate	T080	C0205081
consensus	T054	C0376298
yielded	T081	C0392762
ND	T033	C0686919
cases	T096	C0681850
benign	T080	C0205183
cases	T096	C0681850
cases	T096	C0681850
atypia	T033	C0741302
undetermined significance	T033	C1272585
cases	T096	C0681850
suspicious for malignancy	T033	C4050405
Lowering	T052	C2003888
diagnostic	T169	C0348026
threshold	T080	C0449864
follicular	T023	C1571705
cells	T025	C0007634
yielded	T081	C0392762
sensitivity	T081	C0036667
specificity	T081	C0037791
positive predictive value	T081	C1514243
negative predictive value	T081	C1513918
false-negative	T034	C0205558
rate	T081	C1521828
diagnostic	T169	C0348026
cases	T096	C0681850
cases	T096	C0681850
cells	T025	C0007634
lacking	T080	C0332268
groups	UnknownType	C0681860
containing	T052	C2700400
cells	T025	C0007634
test performance	T060	C0871060
Nuclear enlargement	T049	C0333902
pallor	T033	C0030232
grooves	T030	C1184482
presence	T033	C0150312
histiocytoid cells	T025	C1516945
ND	T033	C0686919
FNA	T060	C0193787
correlated	T080	C1707520
malignancy	T191	C4282132
thyroid FNA	T060	C0193787
examined	T033	C0332128
TP	T060	C0430022
lowering	T052	C2003888
adequacy	T170	C0808073
threshold	T080	C0449864
requirement	T169	C1514873
groups	UnknownType	C0681860
cells	T025	C0007634
significantly	T078	C0750502
test performance	T060	C0871060
cytological	T169	C0205471
features	T080	C2348519
associated with	T080	C0332281
malignancy	T191	C4282132
absent	T169	C0332197
Silk I	T116	C0074529
Silk II	T116	C0074529
studied	T062	C2603343
fast scanning calorimetry	T059	C0006780
fast scanning calorimetry	T059	C0006780
FSC	T059	C0006780
investigated	T169	C1292732
glass transition	T052	C2700061
crystal	T104	C0444626
melting	T070	C0599882
samples	T167	C0370003
B. mori	T204	C0323309
silk fibroin	T116	C1449666
Silk I	T116	C0074529
Silk II	T116	C0074529
crystal	T104	C0444626
short	T081	C1806781
residence	T082	C0237096
times	T079	C0040223
high	T080	C0205250
temperatures	T081	C0039476
measurements	T169	C0242485
thermal	T070	C0018837
decomposition	T067	C2700592
silk protein	T116	C0074529
significantly	T078	C0750502
suppressed	T080	C0443189
FSC	T059	C0006780
performed	T169	C0884358
Mettler Flash DSC1	T059	C0006780
fibroin	T116	C0016042
films	T167	C1561572
masses	T081	C1306372
Films	T167	C1561572
different	T080	C1705242
crystalline	T104	C0444626
fractions	T081	C1264633
different	T080	C1705242
crystal structures	T104	C0444626
Silk I	T116	C0074529
Silk II	T116	C0074529
processing	T052	C1709694
conditions	T080	C0348080
water	T121	C0043047
annealing	T061	C0150247
different	T080	C1705242
temperatures	T081	C0039476
exposure to	T080	C0332157
MeOH	T109	C0001963
water	T121	C0043047
autoclaving	T074	C0179177
resulting	T169	C1274040
crystal structure	T104	C0444626
wide angle	T082	C0205143
X-ray scattering	T060	C1306645
Degree	T081	C0449286
crystallinity	T104	C0444626
evaluated	T033	C0332128
Fourier transform infrared (FTIR) spectroscopy	T062	C0206055
analysis	T062	C0936012
heat capacity	T081	C2349063
increment	T081	C1705117
glass transition temperature	T080	C1257885
Silk fibroin	T116	C1449666
films	T167	C1561572
water	T121	C0043047
annealing	T061	C0150247
crystalline	T104	C0444626
Silk I	T116	C0074529
structure	T116	C1510464
FTIR	T062	C0206055
FSC	T059	C0006780
studies	T062	C2603343
films	T167	C1561572
autoclaving	T074	C0179177
MeOH	T109	C0001963
exposure	T080	C0332157
crystalline	T104	C0444626
Silk II	T116	C0074529
structure	T116	C1510464
Intermediate	T082	C0205103
crystalline	T104	C0444626
fraction	T081	C1264633
Silk I	T116	C0074529
Silk II	T116	C0074529
structure	T116	C1510464
films	T167	C1561572
water	T121	C0043047
annealing	T061	C0150247
FSC	T059	C0006780
results	T033	C0683954
Silk I	T116	C0074529
Silk I I	T116	C0074529
crystals	T104	C0444626
endotherms	T080	C0205556
narrower width	T080	C0333164
higher	T080	C0205250
mean	T081	C0444504
melting temperature	T081	C1456458
compared	T052	C1707455
Silk I	T116	C0074529
crystals	T104	C0444626
melt	T070	C0599882
Films	T167	C1561572
Silk I	T116	C0074529
Silk II	T116	C0074529
structure	T116	C1510464
clearly	T080	C2963144
separated	T080	C0443299
endothermic	T080	C0205556
peaks	T080	C0444505
Evidence	T078	C3887511
crystal	T104	C0444626
melt	T070	C0599882
separately	T080	C0443299
thermal	T070	C0018837
interconvert	T169	C0439836
extremely	T080	C0205403
short	T081	C1806781
time scale	T079	C0040223
melting	T070	C0599882
FSC experiment	T059	C0006780
Silkworm	T204	C0037119
silk	T116	C0074529
naturally	T169	C0205296
biomaterial	T169	C1704781
fibroin component	T116	C0016042
silk forms	T116	C0074529
crystals	T104	C0444626
Silk	T116	C0074529
properties	T080	C0871161
amount	T081	C1265611
crystals	T104	C0444626
stability	T080	C0205360
measure	T081	C0079809
stability	T080	C0205360
crystal	T104	C0444626
melting temperature	T081	C1456458
Crystal	T104	C0444626
stable	T080	C0205360
higher	T080	C0205250
melting temperature	T081	C1456458
study	T062	C2603343
thermal	T070	C0018837
behavior	T053	C0004927
silk	T116	C0074529
crystal	T104	C0444626
degrade	T169	C1880269
high	T080	C0205250
temperature	T081	C0039476
degradation	T169	C0243125
study	T062	C2603343
melting	T070	C0599882
properties	T080	C0871161
silk	T116	C0074529
biomaterial	T169	C1704781
heated	T067	C1522240
silk	T116	C0074529
special calorimeter	UnknownType	C0175896
crystal	T104	C0444626
different	T080	C1705242
melting temperature	T081	C1456458
crystal	T104	C0444626
type	T080	C0332307
stable	T080	C0205360
Leonurine	T109	C0064761
Attenuates	T052	C0599946
Hyperalgesia	T184	C0020429
Mice	T015	C0026809
Induced	T169	C0205263
Adenomyosis	T047	C0341858
Adenomyosis	T047	C0341858
invasion	T046	C2699153
endometrial glands	T023	C0227848
stroma	T023	C0927195
myometrium	T023	C0027088
common	T081	C0205214
gynecological disorder	T047	C0017411
report	T170	C0684224
effect	T080	C1280500
leonurine	T109	C0064761
ICR mice	T015	C0025925
adenomyosis	T047	C0341858
induced	T169	C0205263
neonatal	T079	C2939425
tamoxifen	T109	C0039286
treated	T169	C1522326
tamoxifen	T109	C0039286
assessed	T052	C1516048
body weight	T032	C0005910
pain	T184	C0030193
mice	T015	C0026809
hotplate	T074	C0182315
tests	T059	C0022885
mice	T015	C0026809
divided	T169	C0332849
groups	T078	C0441833
low-dose	T081	C0445550
leonurine	T109	C0064761
treatment	T061	C0087111
group	T078	C0441833
high-dose	T081	C0444956
leonurine	T109	C0064761
treatment	T061	C0087111
group	T078	C0441833
valproic acid	T109	C0042291
VPA	T109	C0042291
treatment	T061	C0087111
group	T078	C0441833
vehicle	T122	C0042444
only	T081	C0205171
treatment	T061	C0087111
group	T078	C0441833
blank	T033	C0750479
control group	T096	C0009932
evaluated	T058	C0220825
body weight	T032	C0005910
hotplate	T074	C0182315
tests	T059	C0022885
depth	T082	C0205125
myometrial	T029	C0521387
infiltration	T046	C0332448
Immunoreactivity	T044	C0597879
staining	T059	C0487602
progesterone receptor	T116	C0034833
PR	T116	C0034833
nuclear factor-κB phosphorylated-p65	T116	C1567061
p-p65	T116	C1567061
cyclooxygenase-2	T116	C1447194
COX-2	T116	C1447194
oxytocin receptor	T116	C3849099
OTR	T116	C3849099
evaluated	T058	C0220825
immunohistochemistry	T060	C0021044
measurement	T169	C0242485
body weight	T032	C0005910
myometrial	T029	C0521387
infiltration	T046	C0332448
neonatal	T079	C2939425
tamoxifen	T109	C0039286
treatment	T061	C0087111
adenomyosis	T047	C0341858
Leonurine	T109	C0064761
treatment	T061	C0087111
decrease	T081	C0547047
hyperalgesia	T184	C0020429
myometrial	T029	C0521387
infiltration	T046	C0332448
Immunoreactivity	T044	C0597879
staining	T059	C0487602
decreased	T081	C0205216
p-p65	T116	C1567061
COX-2	T116	C1447194
OTR	T116	C3849099
protein expressions	T045	C1171362
leonurine	T109	C0064761
attenuates	T052	C0599946
hyperalgesia	T184	C0020429
mice	T015	C0026809
induced	T169	C0205263
adenomyosis	T047	C0341858
down-regulating	T044	C0013081
expressions	T045	C1171362
p-P65	T116	C1567061
COX-2	T116	C1447194
OTR	T116	C3849099
treating	T169	C1522326
adenomyosis	T047	C0341858
Randomized	T062	C0034656
Head-to-Head	T080	C0205556
Study	T062	C2603343
Virtual Reality Exposure Therapy	T061	C3494470
Posttraumatic Stress Disorder	T048	C0038436
Virtual reality exposure therapy	T061	C3494470
VRET	T061	C3494470
interventions	T058	C1273869
supported	T077	C1521721
randomized controlled trials	T062	C0282440
treatment	T061	C0087111
combat-related posttraumatic stress disorder	T048	C0038436
PTSD	T048	C0038436
active duty service	T033	C2135638
members	T098	C0680022
comparative effectiveness study	T062	C1579762
virtual reality	T066	C0871582
technology	T090	C0039421
improved	T033	C0184511
outcomes	T080	C0085415
similar	T080	C2348205
results	T169	C1274040
achieved	T053	C0001072
control exposure therapy	T061	C0870527
CET	T061	C0870527
condition	T080	C0348080
Service	T057	C0557854
members	T098	C0680022
combat-related PTSD	T048	C0038436
randomly	T080	C0439605
selected	T052	C1707391
receive	T080	C1514756
weeks	T079	C0439230
VRET	T061	C3494470
CET	T061	C0870527
Assessors	T097	C0401803
therapists	T097	C0871525
blinded	T062	C0150108
PTSD	T048	C0038436
symptom	T184	C1457887
improvement	T077	C2986411
assessed	T052	C1516048
week	T079	C0439230
months	T079	C0439231
conclusion	T078	C1707478
treatment	T061	C0087111
clinician-administered PTSD scale	T170	C0349674
CAPS	T170	C0349674
small	T081	C0700321
included	T169	C0332257
Results	T169	C1274040
PTSD	T048	C0038436
symptoms	T184	C1457887
improved	T033	C0184511
treatments	T061	C0087111
statistically significant	T081	C0237881
differences	T033	C3842396
groups	T078	C0441833
Dropout	T098	C0030686
rates	T081	C1521828
higher	T080	C0205250
VRET	T061	C3494470
received	T080	C1514756
VRET	T061	C3494470
improvement	T077	C2986411
CAPS	T170	C0349674
received	T080	C1514756
CET	T061	C0870527
months	T079	C0439231
treatment	T061	C0087111
improvement	T077	C2986411
VRET	T061	C3494470
participants	T098	C0679646
CET	T061	C0870527
Participants	T098	C0679646
crossed over	T033	C0243095
statistically significant	T081	C0237881
improvements	T077	C2986411
second	T081	C0205436
treatment	T061	C0087111
regardless	T080	C3641650
condition	T080	C0348080
study	T062	C2603343
supported	T077	C1521721
utility	T169	C3669222
exposure therapy	T061	C0870527
PTSD	T048	C0038436
support	T077	C1521721
additional	T169	C1524062
benefit	T081	C0814225
inclusion	T080	C1512693
virtual reality	T066	C0871582
Accounting	UnknownType	C0680857
linkage disequilibrium	T081	C0023746
genome scans	T061	C2349866
selection	T045	C0036576
without	T080	C0332288
individual	T080	C0443299
genotypes	T032	C0017431
local score approach	T062	C0036449
Detecting genomic footprints	T063	C0282579
selection	T045	C0036576
evolution	T045	C0015219
linkage disequilibrium	T081	C0023746
genome scans	T061	C2349866
detection	T061	C1511790
power	T081	C3854080
haplotype	T032	C0018591
individual	T080	C0443299
genotypes	T032	C0017431
pool-sequenced samples	T201	C1509144
local score approach	T062	C0036449
linkage disequilibrium	T081	C0023746
genome scans	T061	C2349866
selection	T045	C0036576
cumulating	T169	C1516698
signals	T044	C0037080
markers	T045	C0017393
genomic segment	T077	C1517520
selection	T045	C0036576
signal	T044	C0037080
computer simulations	T066	C0009609
detects	T033	C0442726
selection	T045	C0036576
state-of-the-art	UnknownType	C0700033
single-marker	T045	C0017393
haplotype	T032	C0018591
benchmark	T081	C0525063
data sets	T170	C0150098
individual	T080	C0443299
genotypes	T032	C0017431
local score	T062	C0036449
haplotype	T032	C0018591
local score approach	T062	C0036449
Pool-Seq data	T170	C0282574
divergent	T080	C1705242
selection	T045	C0036576
experiment	T062	C0681814
behaviour	T053	C0004927
quail	T012	C0034374
biologically	T080	C0205460
coherent	T033	C4068804
selection	T045	C0036576
signals	T044	C0037080
selection	T045	C0036576
detects	T033	C0442726
genes	T028	C0017337
social	T169	C0728831
responsiveness	T169	C0205342
autistic traits	T033	C4314654
detection	T033	C0442726
positive	T033	C1446409
selection	T045	C0036576
multiple population data	T170	C0282574
local score approach	T062	C0036449
genome scans	T061	C2349866
selection	T045	C0036576
genomewide analyses	T063	C2350277
GWAS	T063	C2350277
UV	T070	C0041625
Induced	T169	C0205263
Electron-Driven Proton Transfer	T070	C1254365
Active	T169	C0205177
Chemically Modified	T080	C0205556
A	T114	C0001407
T	T114	C0040087
DNA	T114	C0012854
Base Pair	T044	C0600436
Transient electronic and vibrational absorption spectroscopies	T059	C0037806
investigate	T169	C1292732
UV	T070	C0041625
induced	T169	C0205263
electron-driven proton transfer	T070	C1254365
EDPT	T070	C1254365
mechanisms	T169	C0441712
active	T169	C0205177
chemically modified	T080	C0205556
adenine	T114	C0001407
thymine	T114	C0040087
A	T114	C0001407
T	T114	C0040087
DNA	T114	C0012854
base pair	T044	C0600436
fraction of	T081	C1264633
biologically relevant	T080	C2347946
Watson-Crick (WC) hydrogen-bonding	T070	C0020276
motifs	T086	C3178796
Hoogsteen structures	T104	C1254350
chemically modified	T080	C0205556
derivative of A	T169	C1527240
A	T114	C0001407
synthesized	T052	C1883254
8-(tert-butyl)-9-ethyladenine	T109	C0029224
8tBA	T109	C0029224
Equimolar solutions	T167	C0037633
8tBA	T109	C0029224
silyl-protected T	T114	C0040087
nucleosides	T114	C0028621
chloroform	T109	C0008238
yield	T081	C0392762
mixture	T167	C0439962
WC pairs	T044	C0600436
reverse WC pairs	T044	C0600436
residual monomers	T104	C0596973
transient absorption studies	T059	C0037806
guanine	T114	C0018321
cytosin	T109	C0010843
G	T114	C0018321
C	T109	C0010843
pairs	T044	C0600436
spectroscopic or kinetic evidence	T078	C3887511
identified	T080	C0205396
participation	T169	C0679823
EDPT	T070	C1254365
excited-state relaxation dynamics	T070	C1254365
8tBA	T109	C0029224
T	T114	C0040087
pairs	T044	C0600436
ultrafast	T080	C0456962
EDPT	T070	C1254365
Monomer-like dynamics	T070	C3826426
8tBA	T109	C0029224
T	T114	C0040087
Monitoring	T058	C1283169
proteolytic processing	T044	C1514570
events	T051	C0441471
quantitative mass spectrometry	T059	C3525763
Protease activity	T044	C1150095
role	T170	C3871154
biological processes	T038	C3714634
including	T169	C0332257
gene expression	T045	C0017262
protein turnover	T044	C0597297
development	T040	C0678723
misregulation	T033	C0243095
proteins	T116	C0033684
associated with	T080	C0332281
cancer types	T033	C0872066
prostate	T191	C0376358
breast	T191	C0006142
skin cancer	T191	C0007114
identification	T080	C0205396
protease	T116	C0030940
substrates	T167	C3891814
provide	T052	C1999230
information	T078	C1533716
understand	T041	C0162340
proteolysis	T044	C0597304
pathologies	T091	C0030664
covered	T169	C0439844
Proteomics	T091	C0872252
methods	T170	C0025663
investigate	T169	C1292732
proteolysis activity,	T044	C0597304
substrate	T167	C3891814
identification	T080	C0205396
protease	T116	C0030940
specificity	UnknownType	C0678612
applications	T061	C0441485
systems biology	T091	C1450477
reviewed	T080	C1709940
quantification	T081	C1709793
challenges	T058	C0805586
pitfalls	T080	C0205556
biological	T080	C0205460
protease	T116	C0030940
malfunction	T169	C0231174
Expert commentary	T077	C0600219
Dysregulated	T033	C0243095
protease activity	T044	C1150095
hallmark	T080	C0205556
disease	T047	C0012634
pathologies	T091	C0030664
cancer	T191	C0006826
Current	T079	C0521116
biochemical	T169	C0205474
approaches	T169	C1292724
low	T080	C0205251
throughput	T081	C0392762
limited	T169	C0439801
amount	T081	C1265611
sample	T077	C2347026
required	T169	C1514873
obtain	T169	C1301820
results	T034	C0456984
Mass spectrometry	T059	C0037813
proteomics	T091	C0872252
provides	T052	C1999230
suitable	T080	C3900053
platform	T075	C1710360
investigate	T169	C1292732
protease activity	T044	C1150095
providing	T052	C1999230
information	T078	C1533716
substrate specificity	T081	C0038592
mapping	T059	C0030944
cleavage sites	T087	C0002518
Diabetic nephropathy	T047	C0011881
cause	T169	C1314792
end-stage kidney disease	T047	C0022661
medical evidence form	T170	C3261387
CMS2728	T170	C3261387
center	T073	C0475309
End-stage renal disease	T047	C0022661
ESRD	T047	C0022661
incidence	T081	C0021149
Type 2	T185	C0441730
diabetic nephropathy	T047	C0011881
DN	T047	C0011881
United States Renal Data System	T073	C1622900
center	T073	C0475309
retrospective cohort study	T062	C2985505
incidence	T081	C0021149
diagnostic accuracy	T080	C0598285
Type 2	T185	C0441730
DN	T047	C0011881
primary	T080	C0205225
cause	T169	C1314792
ESRD	T047	C0022661
Center for Medicare & Medicaid	T093	C0041718
CMS	T093	C0041718
Medical Evidence Report form	T170	C3261387
CMS2728	T170	C3261387
submitted	T169	C1515023
renal replacement therapy	T061	C0206074
patients	T101	C0030705
years	T079	C0439234
age	T032	C0001779
CMS2728	T170	C3261387
submitted	T169	C1515023
academic military medical center	T073	C1552471
ESRD	T047	C0022661
Medical records	T170	C0025102
diagnosis	T033	C0011900
reviewed	T080	C1709940
Kidney Disease Outcomes Quality Initiative	T093	C1708333
KDOQI	T093	C1708333
criteria	T170	C0679228
DN	T047	C0011881
ESRD	T047	C0022661
incidence	T081	C0021149
Type 2	T185	C0441730
DN	T047	C0011881
individual	T098	C0027361
CMS2728	T170	C3261387
submissions	T169	C1515022
KDOQI criteria	T170	C0679228
Type 2	T185	C0441730
DN	T047	C0011881
diabetes	T047	C0011847
not meeting criteria	T077	C3828770
disease duration	T079	C0872031
active	T169	C0205177
urine sediment	T031	C1261248
macroalbuminuria	T033	C1654921
retinopathy	T047	C0035309
ESRD	T047	C0022661
logistic regression	T062	C0206031
retinopathy	T047	C0035309
associated with	T080	C0332281
KDOQI	T093	C1708333
DN	T047	C0011881
odds ratio	T081	C0028873
confidence interval	T081	C0009667
Conclusions	T078	C1707478
center	T073	C0475309
cohort	T062	C2985505
identified	T080	C0205396
Type 2	T185	C0441730
DN	T047	C0011881
primary	T080	C0205225
cause	T169	C1314792
ESRD	T047	C0022661
assigned	T169	C1516050
KDOQI	T093	C1708333
clinical	T080	C0205210
criteria	T170	C0679228
replicated	T169	C0205173
larger	T081	C0549177
populations	T098	C1257890
epidemiology	T091	C0014507
ESRD	T047	C0022661
USA	T083	C0041703
Socioeconomic	T077	C0748878
Predictors	T078	C2698872
Adherence Behavior	T033	C0516638
HIV-Positive	T034	C0019699
Patients	T101	C0030705
Receiving	T080	C1514756
Antiretroviral Therapy	T061	C1963724
Selangor	T083	C0017446
Malaysia	T083	C0024552
Medication adherence	T033	C2364172
critical	T080	C1511545
prescribed	T058	C0278329
ART	T061	C1963724
regimen	T061	C0040808
treatment outcome	T080	C0085415
Several	T081	C0443302
factors	T169	C1521761
influence	T077	C4054723
adherence behavior	T033	C0516638
cross-sectional study	T062	C0010362
aimed	T078	C1947946
socioeconomic	T077	C0748878
predictors	T078	C2698872
adherence behavior	T033	C0516638
cohort	T098	C0599755
adult	T100	C0001675
Malaysian	T098	C0240293
patients	T101	C0030705
receiving	T080	C1514756
antiretroviral therapy	T061	C1963724
Hospital Sungai Buloh	T073	C0019994
Malaysia	T083	C0024552
single-blinded	T062	C0242570
randomized controlled trial	T062	C0206035
January	T080	C3829466
December	T080	C3830550
Statistical analysis	T062	C0871424
secondary data	UnknownType	C0683944
adherence behavior	T033	C0516638
sociodemographic characteristics	T102	C0683970
patients	T101	C0030705
revealed	T080	C0443289
mean age	T033	C0243095
years	T079	C0439234
ranged	T081	C1514721
years	T079	C0439234
males	T032	C0086582
patients	T101	C0030705
adherence assessment	T058	C1254363
included	T169	C0332257
achieved	T033	C0432600
optimal	T080	C2698651
adherence	T169	C1510802
Multivariate binary logistic regression analysis	T170	C0034980
revealed	T080	C0443289
patient's	T101	C0030705
income	T081	C0021162
ethnicity	T080	C0243103
significant	T078	C0750502
predictors	T078	C2698872
adherence behavior	T033	C0516638
targeted	T169	C1521840
programmatic interventions	T061	C0184661
enhance	T052	C2349975
successful treatment	T201	C0521982
outcomes	T169	C1274040
target population	T098	C0039309
Tobramycin Vector	T109	C0040341
Enhances	T052	C2349975
Synergy	T034	C1318081
Efficacy	T080	C0598333
Efflux Pump Inhibitors	T121	C1254351
against	T080	C0521124
Multidrug-Resistant	T032	C0242640
Gram-Negative Bacteria	T007	C0018150
Drug efflux	T044	C1512072
mechanisms	T169	C0441712
interact	T044	C0687133
synergistically	T080	C2986495
outer membrane	T026	C1167331
permeability	T043	C0007605
barrier	T046	C0028778
Gram-negative bacteria	T007	C0018150
leading	T169	C1522538
intrinsic	T082	C0205102
resistance	T169	C4281815
major	T080	C0205164
challenge	T058	C0805586
antibiotic	T195	C0003232
drug development	T062	C1512068
Efflux pump inhibitors	T121	C1254351
EPIs	T121	C1254351
block	T169	C0332206
efflux	T044	C1512072
antibiotics	T195	C0003232
synergize	T080	C0205195
antibiotics	T195	C0003232
clinical development	T062	C1512068
EPI	T121	C1254351
antibiotic	T195	C0003232
combination therapy	T061	C0013218
treat	T061	C0087111
multidrug-resistant	T032	C0242640
MDR	T032	C0242640
Gram-negative infections	T047	C0085423
challenging	T058	C0805586
caused	T169	C0015127
inefficiency	T033	C0231184
current	T079	C0521116
EPIs	T121	C1254351
penetrate	T169	C0205321
outer membrane	T026	C1167331
resist	T169	C4281815
efflux	T044	C1512072
conjugation	T043	C1160466
tobramycin	T109	C0040341
TOB	T109	C0040341
EPIs	T121	C1254351
NMP	T109	C0044097
paroxetine	T109	C0070122
DBP	T201	C0428883
enhances	T052	C2349975
synergy	T034	C1318081
efficacy	T080	C0598333
EPIs	T121	C1254351
combination	T080	C0205195
tetracycline antibiotics	T109	C1744619
MDR	T032	C0242640
Gram-negative bacteria	T007	C0018150
Pseudomonas aeruginosa	T007	C0033809
potentiating	T044	C2242637
tetracycline antibiotics	T109	C1744619
TOB	T109	C0040341
EPI	T121	C1254351
conjugates	T104	C0596313
suppress	T169	C1260953
resistance	T169	C4281815
development	T169	C1527148
tetracycline antibiotic	T109	C1744619
minocycline	T109	C0026187
providing	T052	C1999230
strategy	T041	C0679199
develop	T169	C1527148
effective	T080	C1704419
adjuvants	T120	C0001552
tetracycline antibiotics	T109	C1744619
resistance	T169	C4281815
MDR	T032	C0242640
Gram-negative bacteria	T007	C0018150
Detection	T061	C1511790
AMA-M2	T116	C0312621
human	T016	C0086418
saliva	T031	C0036087
Potentials	T080	C3245505
diagnosis	T033	C0011900
monitoring	T058	C1283169
primary biliary cholangitis	T047	C0008312
Serum	T031	C0229671
anti-mitochondrial antibody type 2	T116	C0312621
AMA-M2	T116	C0312621
biomarker	T201	C0005516
diagnosis	T033	C0011900
primary biliary cholangitis	T047	C0008312
PBC	T047	C0008312
serological tests	T059	C0036743
limitations	T169	C0449295
inconvenience	T033	C4062984
invasiveness	T080	C1301757
infection risks	T033	C0582147
less	T080	C0547044
invasive	T080	C0205281
approach	T082	C0449445
detect	T033	C0442726
AMA-M2 titer	T059	C1446191
salivary	T031	C0036087
AMA-M2	T116	C0312621
potential	T080	C3245505
PBC	T047	C0008312
patients	T101	C0030705
AMA-M2	T116	C0312621
detected	T033	C0442726
saliva	T031	C0036087
serum	T031	C0229671
AMA-M2-positive	T033	C4021051
PBC	T047	C0008312
patients	T101	C0030705
saliva	T031	C0036087
serum	T031	C0229671
AMA-M2-negative	T033	C0853205
PBC	T047	C0008312
patients	T101	C0030705
oral lichen planus	T047	C0206139
patients	T101	C0030705
OLP	T047	C0206139
patients	T101	C0030705
healthy controls	T080	C2986479
concentration	T081	C1446561
salivary	T031	C0036087
AMA-M2	T116	C0312621
positively correlated	T080	C1707520
amount	T081	C1265611
serum	T031	C0229671
AMA-M2	T116	C0312621
patients	T101	C0030705
salivary	T031	C0036087
inflammatory cytokines	T116	C0079189
increased	T081	C0205217
PBC	T047	C0008312
consistent with	T078	C0332290
results	T169	C1274040
serum	T031	C0229671
test	T059	C0022885
saliva	T031	C0036087
less	T080	C0547044
invasive	T080	C0205281
cost-effective	T057	C1511536
medium	T167	C1705217
test	T169	C0039593
AMA-M2 levels	T059	C2825862
development	T169	C1527148
diagnosis	T033	C0011900
monitoring	T058	C1283169
PBC	T047	C0008312
Mental health	T041	C0025353
associated	T080	C0332281
factors	T169	C1521761
young	T079	C0332239
offenders	T098	C0699726
Chile	T083	C0008107
cross-sectional study	T062	C0010362
Latin America	T083	C0023122
mental disorder	T048	C0004936
young	T079	C0332239
offenders	T098	C0699726
variables	T080	C0439828
associated with	T080	C0332281
associations	T080	C0439849
childhood	T079	C0231335
adversity	T077	C3900081
substance misuse	T033	C4061432
psychiatric disorders	T048	C0004936
young	T079	C0332239
offenders	T098	C0699726
Sentenced	T064	C0860081
adolescent	T100	C0205653
offenders	T098	C0699726
recruited	T052	C2949735
young	T079	C0332239
offenders'	T098	C0699726
institutions	T073	C0442681
community centres	T058	C3162245
Chilean National Service for Minors	UnknownType	C0680773
Psychiatric disorders	T048	C0004936
assessed	T052	C1516048
Mini International Neuropsychiatric Interview	T060	C0021819
trained psychologists	T097	C0033908
trained sociologist	T097	C0037467
ad hoc interview	T052	C0021822
information	T078	C1533716
childhood experiences	T201	C4298416
parenting	T033	C3836557
trauma	T037	C3714660
education	T185	C0013622
substance misuse	T033	C4061432
Multivariable logistic regressions	T062	C0206031
analyse data	T081	C0010998
psychiatric disorders	T048	C0004936
participants	T098	C0679646
marijuana dependence disorder	T048	C0006870
major depressive disorder	T048	C1269683
anxiety disorders	T048	C0003469
Substance use disorders	T048	C0038586
young	T079	C0332239
offenders	T098	C0699726
sentence	T033	C0392751
young	T079	C0332239
offenders'	T098	C0699726
institutions	T073	C0442681
community centres	T058	C3162245
frequent	T079	C0332183
started	T080	C1272689
use marijuana	T048	C0024809
earlier age	T032	C0001779
variables	T081	C1705098
childhood maltreatment	T048	C0008060
major depressive disorder	T048	C1269683
maternal death	T040	C3494405
anxiety disorders	T048	C0003469
educational status	T033	C0013658
lower frequency	T079	C0205213
depressive	T048	C0011581
anxiety disorders	T048	C0003469
findings	T033	C0243095
suggest	T078	C1705535
identify	T080	C0205396
vulnerable	T169	C0231204
young	T079	C0332239
people	T098	C0027361
earlier	T079	C1279919
Few	T081	C0205388
young	T079	C0332239
offenders	T098	C0699726
mental health	T041	C0025353
problems	T033	C0033213
adjusted	T169	C0456081
health	T078	C0018684
education	T185	C0013622
socially	T054	C0037397
period	T079	C1948053
detention	T064	C0237567
Effects of	T080	C1704420
regular	T080	C0205272
water	T056	C2712391
land-based exercise	T056	C0015259
physical function	T033	C0516981
years	T079	C0439234
long-term study	T062	C0023981
older Japanese	T098	C1556094
adults	T098	C0001792
investigate	T169	C1292732
effects	T080	C1280500
years	T079	C0439234
physical exercise	T056	C0015259
functional	T169	C0205245
parameters	T077	C0549193
older Japanese	T098	C1556094
adults	T098	C0001792
water	T056	C2712391
land-based exercise	T056	C0015259
retrospectively	T080	C1514923
investigated	T169	C1292732
data	T078	C1511726
medical examinations	T058	C0582103
enrolled	T058	C1516879
older adults	T098	C0001792
study	T062	C2603343
participants	T098	C0679646
aged	T032	C0001779
years	T079	C0439234
water-based exercise	T056	C2712391
combination	T080	C0205195
water	T056	C2712391
land-based exercise	T056	C0015259
total exercise time	T079	C0429931
years	T079	C0439234
fitness center	T073	C0600623
statistical analysis	T062	C0871424
two-way repeated-measures analysis of variance	T081	C1710497
examine	T033	C0332128
effects	T080	C1280500
time	T079	C0040223
exercise type	T033	C2708664
changes	T169	C0392747
parameter	T077	C0549193
years	T079	C0439234
compared	T052	C1707455
groups	T078	C0441833
found	T033	C0243095
significant	T078	C0750502
main	T080	C1542147
effects	T080	C1280500
interaction	T169	C1704675
time	T079	C0040223
exercise type	T033	C2708664
gait speed	T032	C2009910
early decline	T081	C0547047
combined	T080	C0205195
exercise group	T078	C0441833
significant	T078	C0750502
main	T080	C1542147
effects of	T080	C1704420
time	T079	C0040223
functional decline	T033	C4304688
grip strength	T081	C0429271
one-leg standing	T082	C0231472
time	T079	C0040223
step/height	T033	C0427127
ratio	T081	C0456603
exercise types	T033	C2708664
year	T079	C0439234
follow up	T058	C1522577
year	T079	C0439234
changes	T169	C0392747
parameter	T077	C0549193
groups	T078	C0441833
frequency of exercise	T033	C0556455
found	T033	C0243095
negative	T033	C0205160
correlation	T080	C1707520
changes	T169	C0392747
one-leg standing	T082	C0231472
time	T079	C0040223
total	T080	C0439810
amount	T081	C1265611
water-based exercise	T056	C2712391
expectations	T078	C0679138
results	T169	C1274040
suggest	T078	C1705535
regular	T080	C0205272
water-based exercise	T056	C2712391
combined	T080	C0205195
land-based exercise	T056	C0015259
long-term	T079	C0443252
benefits	T081	C0814225
maintaining	T169	C1314677
physical performance	T032	C2607857
older adults	T098	C0001792
Combined	T080	C0205195
exposures	T037	C0028798
whole-body vibration	T033	C4060689
awkward posture	T033	C2112849
cross sectional investigation	T062	C0010362
occupational	T090	C0028811
drivers	T098	C0684312
simultaneous	T079	C0521115
field measurements	T169	C0242485
Multifactorial	T033	C1837655
workloads	T081	C0085122
whole-body vibration	T033	C4060689
WBV	T033	C4060689
awkward posture	T033	C2112849
lifting	T052	C0206244
potential	T080	C3245505
predictors	T033	C0035648
low back pain	T184	C0024031
LBP	T184	C0024031
study	T062	C2603343
investigate	T169	C1292732
association	T080	C0439849
LBP	T184	C0024031
exposures	T037	C0028798
professional	T090	C0028811
drivers	T098	C0684312
combined	T080	C0205195
exposures	T037	C0028798
WBV	T033	C4060689
measured	T080	C0444706
different	T080	C1705242
workplaces	T082	C0162579
Health	T078	C0018684
data	T078	C1511726
information	T078	C1533716
lifting	T052	C0206244
tasks	T057	C3540678
collected	T169	C1516698
questionnaire	T170	C0034394
daily	T079	C0332173
vibration exposure	T037	C0677519
value	T081	C1522609
odds ratio	T081	C0028873
index	T081	C1881192
awkward posture	T033	C2112849
odds ratio	T081	C0028873
significant	T078	C0750502
association	T080	C0439849
occurence	T079	C2745955
LBP	T184	C0024031
Awkward posture	T033	C2112849
lifting	T052	C0206244
appear	T080	C0700364
associated with	T080	C0332281
sick leave	T078	C0242807
WBV	T033	C4060689
exposure	T037	C0028798
combination	T080	C0205195
measurement	T169	C0242485
results	T169	C1274040
WBV	T033	C4060689
awkward posture	T033	C2112849
quantity	T081	C1265611
significant	T078	C0750502
correlation	T080	C1707520
LBP	T184	C0024031
combined	T080	C0205195
exposure	T037	C0028798
WBV	T033	C4060689
awkward posture	T033	C2112849
described	T078	C1552738
daily	T079	C0332173
vibration exposure	T037	C0677519
index	T081	C1881192
awkward posture	T033	C2112849
work place	T082	C0162579
assessments	T052	C1516048
future	T079	C0016884
research	T062	C0035168
area	T082	C0205146
quantitative	T081	C0392762
measures	T081	C0079809
whole-body vibration	T033	C4060689
awkward posture	T033	C2112849
exposures	T037	C0028798
correlate	T080	C1707520
occurrence	T079	C2745955
low back pain	T184	C0024031
quantities	T081	C1265611
measurement	T169	C0242485
methods	T169	C0025664
workplace	T082	C0162579
assessments	T052	C1516048
assist	T080	C1269765
design	T052	C1707689
further	T079	C0016884
studies	T062	C2603343
establish	T080	C0443211
causal exposure	T037	C0274281
response	T032	C0871261
relationship	T080	C0439849
Association	T080	C0439849
CKIP-1 P21A	T028	C1826600
polymorphism	T086	C0752046
risk	T078	C0035647
chronic heart failure	T047	C0264716
Chinese population	T098	C0152035
Pathological	T169	C1521733
cardiac hypertrophy	T046	C1383860
risk factor	T033	C0035648
chronic heart failure	T047	C0264716
Casein kinase-2 interacting protein-1	T116	C1309499
CKIP-1	T116	C1309499
pathological	T169	C1521733
cardiac hypertrophy	T046	C1383860
investigated	T169	C1292732
CKIP-1	T028	C1826600
nonsynonymous polymorphism rs2306235	T086	C0752046
Pro21Ala	T045	C0026882
risk	T078	C0035647
prognosis	T058	C0033325
chronic heart failure	T047	C0264716
Chinese population	T098	C0152035
adult	T100	C0001675
patients	T101	C0030705
chronic heart failure	T047	C0264716
age	T032	C0001779
gender	T032	C0079399
healthy controls	T080	C2986479
CKIP-1 rs2306235	T028	C1826600
polymorphism	T086	C0752046
genotyped	T059	C1285573
PCR	T063	C0032520
restriction fragment length polymorphism	T059	C3714764
follow-up	T058	C1522577
data	T078	C1511726
chronic heart failure	T047	C0264716
patients	T101	C0030705
evaluated	T058	C0220825
rs2306235	T028	C1826600
G allele	T028	C0002085
increased	T081	C0205217
risk	T078	C0035647
chronic heart failure	T047	C0264716
OR	T081	C0028873
CI	T081	C0009667
p	T081	C1709380
patients	T101	C0030705
hypertension	T047	C0020538
OR	T081	C0028873
CI	T081	C0009667
coronary heart disease	T047	C0010068
OR	T081	C0028873
CI	T081	C0009667
p	T081	C1709380
multiple cardiovascular	T033	C1979763
risk factors	T033	C0035648
rs2306235	T028	C1826600
polymorphism	T086	C0752046
cardiovascular mortality	T081	C0205848
chronic heart failure	T047	C0264716
CKIP-1 rs2306235	T028	C1826600
polymorphism	T086	C0752046
risk factor	T033	C0035648
chronic heart failure	T047	C0264716
Chinese Han population	UnknownType	C0814942
phenological events	T079	C0023675
migratory passerines	T012	C0600537
changing climate	T070	C2718051
years	T079	C0439234
Laurel Highlands of Pennsylvania	T083	C0030853
Advanced timing	T079	C0449243
seasonal	T079	C0036497
reproduction	T039	C0232896
birds	T012	C0005595
associated with	T080	C0332281
warming climate	T070	C0178683
bird	T012	C0005595
species	T185	C1705920
Phenological responses	T079	C0023675
climate	T070	C0008946
stages	T079	C1306673
impact	T080	C4049986
fitness	T052	C2349186
analyzed	T062	C0936012
decades	T081	C2981279
banding data	T078	C1511726
migratory bird	T012	C0600537
species	T185	C1705920
spring	T079	C0241232
arrival	T052	C1706079
timing	T079	C0449243
breeding	T040	C0178477
interval	T079	C1272706
arrival	T052	C1706079
breeding	T040	C0178477
increasing	T169	C0442808
spring	T079	C0241232
temperatures	T081	C0039476
arrival	T052	C1706079
timing	T079	C0449243
breeding	T040	C0178477
timing	T079	C0449243
local productivity	T033	C2015882
species	T185	C1705920
mid- to long-distance migrants	T012	C0600537
hatched	T040	C0598016
years	T079	C0439234
migrants	T098	C0026093
arrived	T052	C1706079
earlier	T079	C1279919
breeding grounds	T082	C1254362
day advancement	T079	C0439228
interval	T079	C1272706
arrival	T052	C1706079
breeding grounds	T082	C1254362
appearance	T080	C0700364
juveniles	T100	C3146221
shortened	T080	C1282927
spring	T079	C0241232
temperatures	T081	C0039476
species	T185	C1705920
days	T079	C0439228
increase	T169	C0442805
species	T185	C1705920
decade	T081	C2981279
migratory passerines	T012	C0600537
climate change	T070	C2718051
laying	T040	C1622979
more quickly	T033	C4036056
arrival	T033	C0574839
reducing	T080	C0392756
time	T079	C0040223
laying	T040	C1622979
former	T078	C0750523
rate	T081	C1521828
reproductive advancement	T040	C0035150
higher	T080	C0205250
arrival	T033	C0574839
warm years	T070	C0178683
Timing	T079	C0449243
spring	T079	C0241232
arrival	T052	C1706079
breeding	T040	C0178477
poor	T080	C0542537
predictors	T078	C2698872
avian	T012	C0005595
productivity	T081	C0033269
migrants	T012	C0600537
analyzed	T062	C0936012
evidence	T078	C3887511
fitness	T045	C2717777
shifts	T067	C2347509
spring	T079	C0241232
arrival	T052	C1706079
multi-brooded Song Sparrow	T012	C0326953
results	T169	C1274040
avian	T012	C0005595
species	T185	C1705920
phenologically plastic	T079	C0023675
response	T032	C0871261
climate change	T070	C2718051
breeding grounds	T082	C1254362
migrants	T098	C0026093
weaker	T080	C1762617
response	T032	C0871261
temperatures	T081	C0039476
breeding	T040	C0178477
window	T079	C1272706
arrival	T052	C1706079
optimal breeding	T040	C0178477
shortens	T080	C1282927
plasticity	T070	C0678558
ability	T032	C0085732
species	T185	C1705920
future warming	T070	C0687712
Mucosal	T024	C0026724
IgM Antibody	T116	C1292066
d-Mannose	T109	C0024742
Affinity	T070	C1510827
Fugu Takifugu rubripes	T013	C0949586
Monogenean	T204	C0322374
Parasite	T204	C0030498
Heterobothrium okamotoi	T204	C1499594
Host Recognition	T040	C1658611
parasites	T204	C0030498
recognize	T041	C0524637
definitive	T079	C0443196
hosts	T001	C1167395
parasitism	T070	C0677482
recognition	T041	C0524637
molecules	T167	C0567416
host surfaces	T026	C2752522
Fish	T013	C0016163
ectoparasites	T204	C0562634
initial contact	T033	C1320656
hosts	T001	C1167395
body surfaces	T032	C0489451
skin	T022	C1123023
gills	T023	C0017558
covered	T169	C0439844
mucosa	T024	C0026724
mammalian guts	T023	C0699819
Fish	T013	C0016163
primitive vertebrates	T010	C0042567
immune systems	T022	C0020962
mammals	T015	C0024660
secrete	T038	C0036536
IgM	T116	C0020861
mucus	T031	C0026727
monogenean	T204	C0322374
parasite	T204	C0030498
Heterobothrium okamotoi	T204	C1499594
IgM	T116	C0020861
recognize	UnknownType	C0678894
host	T001	C1167395
fugu Takifugu rubripes Oncomiracidia	T013	C0949586
infective larvae	T204	C0686891
H. okamotoi	T204	C1499594
cilia	T026	C0008778
metamorphose	T040	C0025558
juveniles	T100	C3146221
purified	T169	C1998793
d-mannose	T109	C0024742
binding	T052	C1145667
fractions	T081	C1264633
fugu	T013	C0949586
fugu	T013	C0949586
mucus	T031	C0026727
liquid chromatography-tandem mass spectrometry analysis	T059	C4049918
proteins	T116	C0033684
fraction	T081	C1264633
identified	T080	C0205396
d-mannose	T109	C0024742
IgM	T116	C0020861
d-mannose	T109	C0024742
d-mannose -binding	T052	C1145667
lectins	T116	C0023206
deciliation	T039	C0031843
induced	T169	C0205263
IgM	T116	C0020861
inhibited	T080	C0311403
d-mannose	T109	C0024742
Ab	T116	C0003241
fugu	T013	C0949586
IgM	T116	C0020861
lectins	T116	C0023206
no effect	T080	C1301751
IgM	T116	C0020861
d-mannose	T109	C0024742
affinity	T070	C1510827
induced	T169	C0205263
deciliation	T039	C0031843
immunofluorescent staining experiments	T059	C1318793
fugu	T013	C0949586
d-mannose	T109	C0024742
IgM	T116	C0020861
binds	T052	C1145667
ciliated epidermal cells	T025	C1179149
oncomiracidium	T013	C0949586
observations	T078	C1554188
deciliation	T039	C0031843
triggered by	T080	C1444748
binding	T052	C1145667
fugu	T013	C0949586
IgM	T116	C0020861
cell surface Ags	T129	C0003339
Ag binding sites	T129	C0221114
concentrations	T081	C1446561
d-mannose	T109	C0024742
binding	T052	C1145667
IgM	T116	C0020861
gill mucus	T031	C0026727
induce	T169	C0205263
deciliation	T039	C0031843
in vitro	T080	C1533691
indicating	T078	C3146298
H. okamotoi parasites	T204	C1499594
use	T169	C0457083
host	T001	C1167395
Abs	T116	C0003241
colonize	T033	C4289767
host	T001	C1167395
gills	T023	C0017558
BALB/c mice	T015	C0025919
immunized	T061	C0020971
virus-like particles	T026	C0333785
Kaposi sarcoma-associated herpesvirus	T005	C0376526
KSHV	T005	C0376526
glycoproteins gpK8.1	T116	C0767120
gB	T116	C0761135
gH	T116	C1142879
gL	T116	C2606403
serum	T031	C0229671
neutralizing antibody	T116	C0475463
activity	T044	C1621287
UV	T070	C0041625
inactivated	T169	C0544461
KSHV	T005	C0376526
Kaposi sarcoma-associated herpesvirus	T005	C0376526
KSHV	T005	C0376526
Kaposi sarcoma	T191	C0036220
Africa	T083	C0001737
virus	T005	C0376526
prophylactic vaccine	T121	C0042210
KSHV	T005	C0376526
KSHV	T005	C0376526
gpK8.1	T116	C0767120
gB	T116	C0761135
gH	T116	C1142879
gL glycoproteins	T116	C2606403
virus	T005	C0376526
host cells	T026	C1819995
vaccine	T121	C0042210
targets	T169	C1521840
neutralizing antibodies	T116	C0475463
nAbs	T116	C0475463
virus infection	T047	C0042769
gpK8.1	T116	C0767120
gB	T116	C0761135
gB	T116	C0761135
gH	T116	C1142879
gL	T116	C2606403
virus-like particles	T026	C0333785
VLPs	T026	C0333785
VLPs	T026	C0333785
viral glycoprotein(s)	T026	C1325834
serum	T031	C0229671
nAbs	T116	C0475463
immunized	T061	C0020971
BALB/c mice	T015	C0025919
gpK8.1	T116	C0767120
gB	T116	C0761135
gH	T116	C1142879
gL	T116	C2606403
VLPs	T026	C0333785
Neutralizing antibody	T116	C0475463
mice	T015	C0025919
immunized	T061	C0020971
VLPs	T026	C0333785
KSHV	T005	C0376526
infection	T047	C0042769
HEK-293 cells	T025	C2936239
dose-dependent	T081	C1512045
immunogen	T129	C0003320
gpK8.1	T116	C0767120
VLPs	T026	C0333785
nAb	T116	C0475463
UV	T070	C0041625
inactivated	T169	C0544461
KSHV	T005	C0376526
UV-KSHV	T005	C0376526
UV-KSHV	T005	C0376526
gB	T116	C0761135
gH	T116	C1142879
gL	T116	C2606403
Mice	T015	C0025919
immunized	T061	C0020971
gB	T116	C0761135
gH	T116	C1142879
gL	T116	C2606403
VLPs	T026	C0333785
immunized	T061	C0020971
gB	T116	C0761135
gH	T116	C1142879
VLP	T026	C1325725
immunogens	T129	C0003320
Immunization	T061	C0020971
VLP	T026	C1325725
nAb	T116	C0475463
UV-KSHV	T005	C0376526
serum	T031	C0229671
KSHV	T005	C0376526
gpK8.1	T116	C0767120
gB	T116	C0761135
gH	T116	C1142879
gL glycoproteins	T116	C2606403
VLPs	T026	C0333785
prophylactic vaccine	T121	C0042210
KSHV	T005	C0376526
infection	T047	C0042769
missense	T045	C0599155
variant	T080	C0205419
rs373863828-A (p.Arg457Gln), of CREBRF	T028	C3469921
body mass index	T201	C1305855
Oceanic populations	UnknownType	C0682094
genotype	T032	C0017431
hypothesis	T078	C1512571
high prevalence	T081	C1512456
obesity	T047	C0028754
island	T083	C0022130
populations	T098	C1257890
Oceania	T083	C0282279
genome-wide association study	T063	C2350277
missense	T045	C0599155
variant	T080	C0205419
rs373863828-A (p.Arg457Gln), of the CREBRF gene	T028	C3469921
CREB3 regulatory factor	T116	C1447550
associated with	T080	C0332281
excessive	T080	C0442802
increase	T169	C0442805
body mass index	T201	C1305855
BMI	T201	C1305855
Samoans	T098	C1556103
rs373863828-A	T028	C3469921
increase	T169	C0442805
BMI	T201	C1305855
examined	T033	C0332128
Austronesian	UnknownType	C0682410
AN	UnknownType	C0682410
speaking	T056	C0234856
populations	T098	C1257890
Oceania	T083	C0282279
rs373863828-A	T028	C3469921
Tongans	T098	C0337933
Polynesians	T098	C0240790
associated with	T080	C0332281
BMI	T201	C1305855
rs373863828-A	T028	C3469921
allele	T028	C0002085
increased	T081	C0205217
BMI	T201	C1305855
age	T032	C0001779
sex	T032	C1522384
No significant	T033	C1273937
association	T080	C0439849
detected	T061	C1511790
AN	UnknownType	C0682410
speaking	T056	C0234856
populations	T098	C1257890
Melanesians	T098	C0337924
Micronesians	T098	C1556099
living	T078	C0376558
Solomon Islands	T083	C0037623
low	T080	C0205251
allele frequency	T081	C0017270
rs373863828-A	T028	C3469921
sample size	T081	C0242618
rs373863828-A	T028	C3469921
allele	T028	C0002085
AN	UnknownType	C0682410
speaking	T056	C0234856
AN	UnknownType	C0682410
speaking	T056	C0234856
Melanesians	T098	C0337924
Papua New Guinea	T083	C0030375
rs373863828-A of CREBRF	T028	C3469921
variant	T080	C0205419
ancestors	T099	C0870134
AN	UnknownType	C0682410
speaking	T056	C0234856
Polynesians	T098	C0240790
Vaccination	T061	C0042196
piglets	T015	C0039005
Ingelvac PRRSFLEX® EU	T121	C1516086
protection	T033	C1545588
heterologous	T080	C0439860
homologous	T032	C0301883
maternally derived antibodies	T116	C0729663
eradicating	T058	C3178994
porcine reproductive and respiratory syndrome	T047	C0376538
PRRS	T047	C0376538
transmission of the virus	T043	C1160716
efficient	T080	C0442799
DIVA vaccines	T121	C0887908
successful	T080	C1272703
control	T080	C0243148
PRRS	T047	C0376538
management measures	T058	C0376636
vaccination	T061	C0042196
sows	T015	C0684075
piglets	T015	C0039005
study	T062	C2603343
assess	T058	C0184514
efficacy	T080	C1280519
MLV vaccine	T121	C1516086
Ingelvac PRRSFLEX® EU	T121	C1516086
piglets	T015	C0039005
presence	T033	C0150312
homologous	T032	C0301883
maternally derived antibodies	T116	C0729663
vaccinated	T061	C0042196
vaccine strain	T121	C0042210
ReproCyc® PRRS EU	T121	C1516086
study	T062	C2603343
Hungarian farrow	T015	C1296656
farm	T082	C0557759
naturally infected	T033	C0439663
PRRSv	T005	C0376536
study	T062	C2603343
blind	T062	C2347038
placebo controlled	T062	C1706408
ORF5	T116	C0758157
sequence similarity	T081	C1710052
vaccine strain	T121	C0042210
resident field strain	T098	C1257890
PRRS	T047	C0376538
real-time quantitative PCR	T063	C3179034
serum samples	T031	C1550100
measure	T081	C0079809
viral load	T059	C1261478
virus positive	T034	C1167762
animals	T008	C0003062
natural infection	T046	C3714514
observed	T169	C1441672
control group	T096	C0009932
viraemic	T033	C0243095
animals	T008	C0003062
vaccinated	T061	C0042196
infection	T046	C3714514
dynamics	T070	C3826426
positive	T033	C1446409
PCR	T063	C0032520
samples	T167	C0370003
ORF5	T116	C0758157
data analysis	T057	C0010992
indicated	T033	C1444656
circulation	T033	C0237318
virus	T005	C0042776
data	T078	C1511726
piglets	T015	C0039005
vaccinated	T061	C0042196
Ingelvac PRRSFLEX® EU	T121	C1516086
proportion	T081	C1709707
viraemic	T033	C0243095
animals	T008	C0003062
viraemia	T047	C0042749
piglets	T015	C0039005
homologous	T032	C0301883
maternally derived antibodies	T116	C0729663
MDA	T116	C0729663
vaccination	T061	C0042196
Lung nodule	T033	C0034079
French Guiana	T083	C0016703
immunocompetent	T201	C1512656
patient	T101	C0030705
case	T077	C1706256
immunocompetent	T201	C1512656
French	T098	C1556084
soldier	T097	C0524647
French Guiana	T083	C0016703
symptomatic	T169	C0231220
pulmonary histoplasmosis	T047	C1306038
Comparison	T052	C1707455
Occlusive	T169	C1947917
Open	T082	C0175566
Application	T169	C4048755
Psoriasis Plaque Test Design	T062	C0008976
Investigations	T169	C1292732
Mapracorat	T109	C3252363
Ointment	T122	C0028912
Vehicle	T122	C0042444
Reference	T077	C1706462
Drugs	T121	C0013227
Psoriasis plaque tests	T062	C0008976
PPTs	T062	C0008976
antipsoriatic	T121	C1874314
drug development	T091	C0872152
PPT design	T062	C0008976
open	T169	C0013153
occluded drug application	T169	C0013153
antipsoriatic	T121	C1874314
mapracorat	T109	C3252363
ointment	T122	C0028912
reference	T077	C1706462
drugs	T121	C0013227
studies	T062	C2603343
open	T062	C0008976
occluded PPT designs	T062	C0008976
drug effect	T169	C0728866
sonography	T060	C0041618
thickness	T080	C1280412
chromametry	T059	C0022885
clinical assessment	T033	C3845884
Antipsoriatic	T121	C1874314
effects	T169	C0728866
study	T062	C2603343
drugs	T121	C0013227
occluded	T062	C0008976
open PPTs	T062	C0008976
potency	T038	C0678792
antipsoriatic drugs	T121	C1874314
vehicle	T122	C0042444
antipsoriatic	T121	C1874314
effect	T169	C0728866
occluded PPT	T062	C0008976
open PPT	T062	C0008976
treatment duration	T079	C0444921
weeks	T079	C0439230
Effect	T169	C0728866
dynamics	T070	C3826426
time	T079	C0040223
study	T062	C2603343
drugs	T121	C0013227
open PPT	T062	C0008976
occluded PPT	T062	C0008976
technical challenges	T067	C1710348
open PPT	T062	C0008976
occluded PPT	T062	C0008976
screening	T062	C0013206
early	T079	C1279919
drug development	T091	C0872152
drug	T121	C0013227
aspects	T080	C1879746
study	T062	C2603343
open PPT	T062	C0008976
PPT	T062	C0008976
classification	T185	C0008902
phase I studies	T062	C0920321
study	T062	C2603343
duration	T079	C0449238
compounds	T103	C1706082
concentrations	T081	C1264643
measurement	T169	C0242485
treatment response	T201	C0521982
early	T079	C1279919
clinical development	T062	C1512068
Insurance Coverage	T078	C0376629
Utilization	T169	C0042153
Sexually Transmitted Disease Clinic	T073	C0338053
Medicaid	T064	C0025071
State	T083	C1301808
Rhode Island	T083	C0035487
Patient Protection and Affordable Care Act	T089	C2936611
state's	T083	C1301808
population	T081	C0032659
insured	T170	C1548605
evaluated	T058	C0220825
insurance coverage	T078	C0376629
barriers	T033	C0243095
insurance	T058	C0021682
patients	T101	C0030705
services	T058	C1704289
Rhode Island	T083	C0035487
sexually transmitted disease (STD) clinic	T073	C0338053
analyzed	T062	C0936012
factors	T169	C1521761
associated with	T080	C0332281
insurance coverage	T078	C0376629
utilization	T169	C0042153
patients	T101	C0030705
STD	T047	C0036916
services	T058	C1704289
July	T080	C3829447
December	T080	C3830550
patients	T101	C0030705
insurance information	T078	C1548070
available	T077	C1511733
uninsured	T098	C0087134
Patients	T101	C0030705
without insurance	T098	C0087134
insurance	T058	C0021682
uninsured	T098	C0087134
insured	T170	C1548605
Hispanic	T098	C0086409
Latino/a	T098	C0086528
men	T098	C0025266
sex	T040	C0009253
men	T098	C0025266
health insurance	T058	C0021682
coverage	T078	C0376629
result	T169	C1274040
Affordable Care Act	T089	C2936611
uninsured	T098	C0087134
uninsured individuals	T098	C0087134
barriers	T033	C0243095
health insurance	T058	C0021682
cost	T081	C0087112
unemployment	T033	C0041674
with insurance	T170	C1548605
willingness	T033	C0600109
insurance	T058	C0021682
STD	T047	C0036916
services	T058	C1704289
Barriers	T033	C0243095
insurance	T058	C0021682
anonymity	T078	C0871649
out-of-pocket costs	T081	C3815933
insurance	T058	C0021682
access	T078	C0015472
individuals	T098	C0237401
Rhode Island	T083	C0035487
STD Clinic	T073	C0338053
uninsured	T098	C0087134
insured	T170	C1548605
barriers	T033	C0243095
insurance	T058	C0021682
STD clinics	T073	C0338053
safety-net	T058	C3658319
STD	T047	C0036916
services	T058	C1704289
states	T083	C1301808
uninsured	T098	C0087134
rates	T081	C1521828
public	T092	C0678367
private	T092	C0679727
insurers	T092	C0021675
financial barriers	T033	C4062976
optimize	T052	C2698650
payment	T081	C0680264
structures	T082	C0678594
services	T058	C1704289
Molecular subtyping	T059	C1294399
Treponema pallidum	T007	C0040840
associated factors	T169	C1521761
serofast	T033	C3841011
status	T080	C0449438
early syphilis	T047	C0348148
patients	T101	C0030705
Identified	T080	C0205396
genotype	T032	C0017431
cytokine	T116	C0079189
marker	T201	C0005516
Serofast	T033	C3841011
persistent	T079	C0205322
nontreponemal serological	T169	C0205473
response	T201	C0521982
observed	T169	C1441672
early syphilis	T047	C0348148
patients	T101	C0030705
conventional treatment	T061	C2945704
concern	T078	C2699424
clinicians	T097	C0871685
syphilis	T047	C0348148
patients	T101	C0030705
effective	T080	C1704419
treatment strategy	T061	C0040808
clarifies	T052	C2986669
pathogenesis	T046	C0699748
study	T062	C2603343
patients	T101	C0030705
early syphilis	T047	C0348148
enrolled	T058	C1516879
treated	T169	C1522326
months	T079	C0439231
treatment	T061	C0087111
patients	T101	C0030705
serological	T169	C0205473
cure	T077	C1880198
serofast	T033	C3841011
serological	T169	C0205473
failures	T169	C0231174
Multivariate analysis	T081	C0026777
older age	T098	C1999167
years	T079	C0439234
baseline	T081	C1442488
RPR titer	T059	C3835799
associated with	T080	C0332281
serofast	T033	C3841011
status	T080	C0449438
T. pallidum	T007	C0040840
molecular subtypes	T185	C0449560
early syphilis	T047	C0348148
patients	T101	C0030705
subtype, 14i/a	T185	C0449560
14i/a type	T185	C0449560
serofast	T033	C3841011
patients	T101	C0030705
patients	T101	C0030705
serological	T169	C0205473
cure	T077	C1880198
increasing	T169	C0442808
risk	T078	C0035647
serofast	T033	C3841011
status	T080	C0449438
status	T080	C0449438
Levels	T080	C0441889
chemerin	T116	C1312957
higher	T080	C0205250
serum	T031	C0229671
serofast	T033	C3841011
serological	T169	C0205473
cure	T077	C1880198
cytokine	T116	C0079189
marker	T201	C0005516
serofast	T033	C3841011
early syphilis	T047	C0348148
patients	T101	C0030705
therapy	T061	C0087111
results	T169	C1274040
contribute	T052	C1880177
improve	T033	C0184511
guidelines	T170	C0162791
management	T058	C0376636
syphilis	T047	C0348148
patients	T101	C0030705
serofast	T033	C3841011
Fluorescence	T070	C0016315
Fingerprinting	T073	C0016126
Pesticides	T131	C0031253
Continuous	T078	C0549178
Monitoring of Soils and Waters	T057	C0014416
creation	T052	C1706214
extension	T169	C0231448
database	T170	C0242356
Total Excitation-Emission and Total Synchronous Fluorescence Matrices	T059	C0037802
TEEMs and TSFMs	T059	C0037802
optimal Synchronous Fluorescence Spectra	T059	C0037802
SFS	T059	C0037802
fingerprint	T073	C0016126
pesticides	T131	C0031253
Morocco	T083	C0026544
spectrometric multi-component fingerprinting	T059	C0436196
detection of pesticides	T059	C0430417
persisting in soil	T131	C0037594
water	T131	C0043053
detect four pesticide	T059	C0430417
agricultural soils	T082	C0562975
spectrometric fingerprinting	T059	C0037802
insecticide Axlera 5G	T131	C0021578
carbamate	T131	C0021578
fungicide Orsalis 5% SC	T131	C0392419
triazole	T131	C0392419
insecticide Force 0,5 G	T109	C0597329
pyrethrinoid	T109	C0597329
insecticide Proclaim 05 SG	T131	C0021576
agricultural plantations monitored	T090	C0001827
great agricultural Doukkala region	T083	C0017446
western Atlantic side	T083	C0017446
Morocco	T083	C0026544
chemicals	T103	C0220806
cellular prion protein	T116	C0074202
co-chaperone	T116	C0243041
Hsp70	T116	C0243043
Hsp70 / 90 organizing protein	T116	C0018850
90	T116	C0243044
proliferation	T043	C0596290
glioblastoma	T191	C0017636
glioblastoma stem-like cells	T025	C0007634
Glioblastoma	T191	C0017636
GBM	T191	C0017636
brain tumor	T191	C0006118
glioblastoma	T191	C0017636
glioblastoma stem-like cells	T025	C0007634
GSCs	T025	C0007634
tumor	T191	C0027651
maintenance	T052	C0024501
invasion	T046	C0027626
therapeutic resistance	T038	C0013203
GSCs	T025	C0007634
target	T169	C1521840
GBM	T191	C0017636
treatment	T169	C1522326
cellular prion protein	T116	C0074202
PrP(C)	T116	C0074202
co-chaperone	T116	C0243041
Hsp70	T116	C0243043
Hsp70 / 90 organizing protein	T116	C0018850
90	T116	C0243044
HOP	T116	C0018850
target	T169	C1521840
GBM	T191	C0017636
tumorigenesis	T191	C0596263
neural stem cell	T025	C1113654
GSCs	T025	C0007634
PrP(C)	T116	C0074202
cultured	T059	C0007585
neurospheres	T025	C0007634
growth factors	T116	C0018284
stem cells	T025	C0038250
markers	T086	C0012872
adhesion molecules markers	T086	C0012872
immunofluorescence	T059	C0079603
flow cytometry	T059	C0016263
GSC	T025	C0007634
self-renewal	T043	C4042950
proliferation	T043	C0596290
clonal density assays	T059	C0005507
BrdU	T114	C0006233
BrdU incorporation	T059	C0022885
HOP	T116	C0018850
treatment	T169	C1522326
HOP	T116	C0018850
peptide	T116	C0030956
PrP(C)	T116	C0074202
binding site	T192	C0005456
silencing	T045	C0598496
HOP	T116	C0018850
PrP(C)	T116	C0074202
cell populations	T025	C0007634
proliferation	T043	C0596290
in vitro	T080	C1533691
tumor growth	T191	C0598934
in vivo	T082	C1515655
Migration assays	T059	C1513300
laminin-1	T116	C0908936
laminin-1 pre-coated glass	T073	C0017596
GBM	T191	C0017636
cells	T025	C0007634
cultured	T059	C0007585
neurospheres	T025	C0007634
stemness markers	T086	C0012872
CD133	T116	C0673026
CD15	T109	C0080188
Oct4	T116	C0069304
SOX2	T116	C0300483
PrP(C)	T116	C0074202
monolayer culture	T059	C1510803
CD133	T116	C0673026
PrP(C)	T116	C0074202
silencing	T045	C0598496
expression of molecules	T045	C0017262
cancer stem cells	T025	C1956422
markers	T086	C0012872
cell differentiation	T043	C0007589
GSC	T025	C0007634
self-renewal	T043	C4042950
PrP(C)	T116	C0074202
GSCs	T025	C0007634
HOP	T116	C0018850
treatment	T169	C1522326
proliferation	T043	C0596290
self-renewal	T043	C4042950
GSCs	T025	C0007634
PrP(C)	T116	C0074202
HOP	T116	C0018850
proliferation process	T043	C0596290
In vivo	T082	C1515655
PrP(C)	T116	C0074202
HOP	T116	C0018850
inhibits	T052	C3463820
growth	T043	C0007595
glioblastoma	T191	C0017636
cells	T025	C0007634
PrP(C)	T116	C0074202
PrP(C) - HOP complex	T116	C1180347
HOP	T116	C0018850
HOP	T116	C0018850
peptide	T116	C0030956
PrP(C)	T116	C0074202
binding site	T192	C0005456
GSC	T025	C0007634
self-renewal	T043	C4042950
proliferation	T043	C0596290
HOP	T116	C0018850
HOP - PrP(C) complex	T116	C1180347
PrP(C)	T116	C0074202
GSC	T025	C0007634
stemness	T080	C0205556
PrP(C)	T116	C0074202
GSCs	T025	C0007634
cell	T025	C0007634
adhesion-related proteins	T116	C0033684
cell migration	T043	C1622501
PrP(C)	T116	C0074202
cell surface stability	T033	C0243095
cell adhesion molecules	T116	C0007578
GBM	T191	C0017636
invasiveness	T046	C0027626
HOP	T116	C0018850
PrP(C)	T116	C0074202
PrP(C)	T116	C0074202
HOP	T116	C0018850
expression	T045	C0017262
therapeutic intervention	T061	C0808232
GBM	T191	C0017636
glioblastoma	T191	C0017636
glioblastoma stem-like cell	T025	C0007634
self-renewal	T043	C4042950
proliferation	T043	C0596290
migration	T043	C1622501
Cyclic thrombocytopenia	T047	C0272282
synchronizing	T079	C0439580
menstrual cycle	T040	C0025329
periodic	T079	C0332182
phases	T079	C0205390
thrombocytopenia	T047	C0040034
rebound	T067	C0034897
thrombocytosis	T047	C0836924
year	T079	C1510829
woman	T098	C0043210
admitted	T058	C0184666
hospital	T073	C0019994
purpura	T047	C0034150
extremities	T023	C0278454
thrombocytopenia	T047	C0040034
Prednisolone	T109	C0032950
PSL	T109	C0032950
administered	T169	C1521801
diagnosis	T033	C0011900
idiopathic thrombocytopenic purpura	T047	C0398650
ITP	T047	C0398650
not effective	T080	C1301751
maintaining	T052	C0024501
platelet count	T059	C0032181
normal range	T081	C0086715
cyclic fluctuation	UnknownType	C0681684
menstrual cycle	T040	C0025329
discontinued	T033	C1444662
PSL	T109	C0032950
cyclic thrombocytopenia	T047	C0272282
CTP	T047	C0272282
diagnosed	T033	C0011900
CTP	T047	C0272282
rare disease	T047	C0678236
treated	T169	C1522326
ITP	T047	C0398650
no response	T033	C4282382
cause	T078	C0085978
CTP	T047	C0272282
uncertain	T033	C0087130
case	T077	C1706256
hormonal mechanism	T040	C0920552
fluctuating	T079	C0231241
platelet count	T059	C0032181
Comparative evaluation	T058	C1261322
iodine-131 metaiodobenzylguanidine	T109	C0879568
18-fluorodeoxyglucose	T109	C0046056
positron emission tomography	T060	C0032743
neural crest tumors	T047	C2931189
18-Fluorodeoxyglucose	T109	C0046056
positron emission tomography	T060	C0032743
FDG-PET	T060	C0032743
malignancies	T191	C0006826
clinical role	T078	C2347795
neural crest cell tumors	T047	C2931189
iodine-131 metaiodobenzylguanidine	T109	C0879568
(131)I-MIBG	T109	C0879568
FDG-PET	T060	C0032743
patients	T101	C0030705
neural crest tumors	T047	C2931189
qualitatively	T080	C0034375
semiquantitatively	T057	C2986822
clinical utility	T033	C0422813
disease status evaluation	T033	C0243095
further management	T058	C0376636
patients	T101	C0030705
(131)I-MIBG	T109	C0879568
FDG-PET	T060	C0032743
clinicopathologically	T169	C0205469
neuroblastoma	T191	C0027819
pheochromocytoma	T191	C0031511
medullary carcinoma thyroid	T191	C0238462
patients	T101	C0030705
neuroblastoma	T191	C0027819
FDG PET	T060	C0032743
(131)I-MIBG	T109	C0879568
patient-specific sensitivity	T033	C4304945
maximum standardized uptake value	T081	C2986846
SUVmax	T081	C2986846
primary lesions	T047	C1402294
patients	T101	C0030705
unfavorable histology	T169	C4048239
favorable histology	T169	C4048239
SUVmax	T081	C2986846
posterior superior iliac spine	T023	C0223646
PSIS	T023	C0223646
greater trochanter	T023	C0223865
patients	T101	C0030705
marrow	T023	C0376152
SUVmax	T081	C2986846
contralateral normal sites	T082	C0441988
equivocal	T080	C0332241
bone marrow results	T034	C0427694
SUV	T081	C2348529
metastatic involvement	T169	C1522484
biopsy site	T201	C1301128
patients	T101	C0030705
pheochromocytoma	T191	C0031511
FDG-PET	T060	C0032743
patient-specific sensitivity	T033	C4304945
FDG-PET	T060	C0032743
metastatic foci	T082	C0205234
(131)I-MIBG	T109	C0879568
patients	T101	C0030705
medullary carcinoma thyroid	T191	C0238462
FDG-PET	T060	C0032743
recurrent	T047	C0277556
metastatic disease	T191	C0027627
metastatic foci	T082	C0205234
patient specific sensitivity	T033	C4304945
(131)I-MIBG	T109	C0879568
higher serum calcitonin levels	T059	C0863135
FDG-PET	T060	C0032743
complementary modality	T078	C0695347
neural crest cell tumors	T047	C2931189
(131)I-MIBG	T109	C0879568
nonavid tumors	T191	C0027651
Progressive Occlusion	T169	C0441597
Recanalization	T061	C0034771
Endovascular Treatment	T061	C0087111
Unruptured Small Aneurysms	T047	C0002940
Single-Center	T093	C1274109
6-Year	T079	C0439234
Experience	T041	C0596545
effect	T080	C1280500
coiling	T082	C0444764
unruptured intracranial aneurysms	T047	C0007766
UIAs	T047	C0007766
progressive occlusio	T169	C0441597
recanalization	T061	C0034771
progressive occlusion	T169	C0441597
recanalization	T061	C0034771
UIAs	T047	C0007766
occlusion	T169	C0441597
patients	T101	C0030705
UIAs	T047	C0007766
institute	T092	C0021622
UIAs	T047	C0007766
group	T078	C0441833
UIAs	T047	C0007766
occlusion	T169	C0441597
progressive	T169	C0205329
stable	T080	C0205360
recanalization	T061	C0034771
groups	T078	C0441833
Baseline	T081	C1442488
characteristics	T080	C1521970
procedure	T061	C0087111
complications	T046	C0009566
angiographic	T060	C0002978
follow-up results	T058	C1522577
clinical outcomes	T080	C0085415
statistically analyzed	T062	C0871424
aneurysms	T047	C0002940
aneurysms	T047	C0002940
intraoperative	T079	C0456904
ruptures	T037	C3203359
perioperative	T079	C1518988
thromboembolic events	T046	C0040038
Angiographic	T060	C0002978
follow-up	T058	C1522577
patients	T101	C0030705
incidence	T081	C0021149
recanalization	T061	C0034771
aneurysms	T047	C0002940
occlusion	T169	C0441597
progressive occlusion	T169	C0441597
recanalization	T061	C0034771
Anatomic results	T033	C0243095
follow-up	T058	C1522577
groups	T078	C0441833
groups	T078	C0441833
logistic regression analysis	UnknownType	C0681925
size	T082	C0456389
occlusion	T169	C0441597
recanalization	T061	C0034771
study	T062	C2603343
coil embolization	T061	C0013931
UIAs	T047	C0007766
progressive occlusion	T169	C0441597
recanalization	T061	C0034771
follow-up	T058	C1522577
Anatomic results	T033	C0243095
follow-up	T058	C1522577
groups	T078	C0441833
groups	T078	C0441833
occlusion	T169	C0441597
recanalization	T061	C0034771
Selection	T052	C1707391
Artificial	T080	C2004457
Diet	T168	C0012155
Laboratory	T073	C0022877
Rearing	T059	C1441721
Opogona sacchari	T204	C3002762
Lepidoptera	T204	C0023338
Tineidae	T204	C1009208
banana moth Opogona sacchari	T204	C3002762
Bojer	T204	C3002762
Lepidoptera	T204	C0023338
Tineidae	T204	C1009208
polyphagous pest	T204	C0684063
serious	T080	C0205404
damage	T169	C1883709
banana	T168	C0004722
crops	T002	C0242775
southern	T082	C1710133
Brazil	T083	C0006137
insect	T204	C0021585
pest	T204	C0684063
countries	T083	C0454664
Argentina	T083	C0003761
consumer	T098	C1707496
market	T083	C1318228
bananas	T168	C0004722
southern	T082	C1710133
Brazil	T083	C0006137
information	T078	C1533716
biology	T091	C0005532
ecology	T090	C0013546
moth	T204	C0026593
diet	T168	C0012155
laboratory	T073	C0022877
rearing	T059	C1441721
pest management	T057	C0031249
pest	T204	C0684063
study	T062	C2603343
data	T078	C1511726
diets	T168	C0012155
laboratory	T073	C0022877
rearing	T059	C1441721
O. sacchari	T204	C3002762
dried	T080	C1512080
beans	T168	C0004896
wheat germ	T168	C0016452
soy bran	T168	C0016452
brewer's yeast	T004	C0036025
casein	T116	C0007332
diet	T168	C0012155
wheat germ	T168	C0016452
casein	T116	C0007332
protein	T116	C0033684
sources	T033	C0449416
diets	T168	C0012155
viability	T080	C0443348
egg	T025	C0029974
adult	T100	C0001675
period	T079	C1948053
fertility	T040	C0015895
eggs	T025	C0029974
female	T098	C0043210
biotic	T070	C1253910
potential	T080	C3245505
analysis	T062	C0936012
values	T080	C0042295
diets	T168	C0012155
impact	T080	C4049986
productivity	T081	C0033269
hypothetical tax	T081	C0039371
sugar-sweetened beverages	T168	C0005329
potential	T080	C3245505
impact	T080	C4049986
additional	T169	C1524062
tax	T081	C0039371
sugar-sweetened beverages	T168	C0005329
SSBs	T168	C0005329
productivity	T081	C0033269
Australia	T083	C0004340
multi-state lifetable Markov model	T081	C0023682
examine	T033	C0332128
potential	T080	C3245505
impact	T080	C4049986
additional	T169	C1524062
tax	T081	C0039371
SSBs	T168	C0005329
total lifetime	T079	C4071830
productivity	T081	C0033269
paid and unpaid sectors	T078	C0009433
economy	T081	C0870462
study population	T098	C2348561
Australians	T098	C0238711
aged	T032	C0001779
years	T079	C0439234
older	T098	C0001792
health	T170	C1550208
relevant	T080	C2347946
outcomes	T169	C1274040
modelled	T062	C0870071
remaining	T080	C1527428
lifetime	T079	C4071830
SSBs	T168	C0005329
tax	T081	C0039371
estimated	T081	C0750572
reduce	T080	C0392756
number	T081	C0237753
people	T098	C0027361
obesity	T047	C0028754
population	T098	C1257890
persons	T098	C0027361
obesity	T047	C0028754
reduce	T080	C0392756
number	T081	C0237753
employees	T097	C0599987
obesity	T047	C0028754
persons	T098	C0027361
effects	T080	C1280500
productivity	T081	C0033269
gains	T081	C1517378
paid sector	T078	C0009433
million	T081	C1881839
working	T057	C0043227
age	T032	C0001779
population	T098	C1257890
confidence interval	T081	C0009667
million	T081	C1881839
million	T081	C1881839
human capital	T081	C0700103
approach	T082	C0449445
unpaid sector	T078	C0009433
potential	T080	C3245505
productivity	T081	C0033269
gains	T081	C1517378
amounted	T081	C1265611
million	T081	C1881839
million	T081	C1881839
million	T081	C1881839
replacement cost method	T170	C0025663
productivity	T081	C0033269
benefits	T081	C0814225
health benefits	T081	C0086387
life years	T079	C0080071
gained	T081	C1517378
reduction	T080	C0392756
healthcare costs	T081	C0085552
million	T081	C1881839
additional	T169	C1524062
tax	T081	C0039371
SSBs	T168	C0005329
improves	T033	C0184511
health outcomes	T170	C1550208
reduces	T080	C0392756
healthcare costs	T081	C0085552
productivity	T081	C0033269
gains	T081	C1517378
paid and unpaid sectors	T078	C0009433
economy	T081	C0870462
Effect	T080	C1280500
Teachers'	T097	C0221457
Parents'	T099	C0030551
Emotional Support	T058	C0600015
Children's	T100	C0008059
Working Memory	T041	C0025265
Performance	T041	C1285654
Working memory	T041	C0025265
temporarily store	T041	C0025265
information	T078	C1533716
children's	T100	C0008059
learning	T041	C0023185
factors	T169	C1521761
promote	T052	C0033414
hinder	T052	C3463820
working memory	T041	C0025265
performance	T041	C1285654
research	T062	C0035168
positive	T033	C1446409
associations	T080	C0439849
positive	T033	C1446409
parent-child	T054	C0030542
teacher-student interactions	T054	C0871486
working memory	T041	C0025265
performance	T041	C1285654
development	T169	C1527148
study	T062	C2603343
experimentally investigated	T169	C1292732
parents	T099	C0030551
teachers	T097	C0221457
working memory	T041	C0025265
performance	T041	C1285654
attachment theory	T078	C0871935
study	T062	C2603343
investigated	T169	C1292732
parent	T099	C0030551
teacher	T097	C0221457
emotional support	T058	C0600015
promoting	T052	C0033414
working memory	T041	C0025265
performance	T041	C1285654
negative	T033	C0205160
effect	T080	C1280500
social stress	T048	C0871388
Questionnaires	T170	C0034394
experimental session	T062	C0242481
children	T100	C0008059
years	T079	C0439234
months	T079	C0439231
months	T079	C0439231
Questionnaires	T170	C0034394
children's	T100	C0008059
perceptions	T041	C0030971
teacher-student	T054	C0871486
parent-child relationship	T054	C0030542
experimental session	T062	C0242481
working memory	T041	C0025265
Corsi task backward	UnknownType	C0681907
pre-	T052	C1707689
post-test design	T052	C1707689
tests	T170	C0392366
stress	T033	C0038435
induced	T169	C0205263
children	T100	C0008059
Cyberball paradigm	T062	C0681797
Emotional support	T058	C0600015
manipulated	T053	C0018578
audio	T073	C3273156
message	T170	C0470166
weather	T070	C0043085
report	T170	C0684224
supportive	T058	C0600015
message	T170	C0470166
stranger	T098	C1257890
supportive	T058	C0600015
message	T170	C0470166
parent	T099	C0030551
supportive	T058	C0600015
message	T170	C0470166
teacher	T097	C0221457
Results	T169	C1274040
repeated measures	T062	C0871881
ANOVA	T081	C0002780
effect	T080	C1280500
stress	T033	C0038435
induction	T169	C0205263
effect	T080	C1280500
parent	T099	C0030551
teacher	T097	C0221457
support	T058	C0600015
quality	T080	C0332306
parent-child relationship	T054	C0030542
children	T100	C0008059
positive	T033	C1446409
relationship	T080	C0439849
parent	T099	C0030551
support	T058	C0600015
parents	T099	C0030551
teachers	T097	C0221457
effect	T080	C1280500
working memory	T041	C0025265
performance	T041	C1285654
children	T100	C0008059
negative	T033	C0205160
relationship	T080	C0439849
parent	T099	C0030551
supportive	T058	C0600015
message	T170	C0470166
parent	T099	C0030551
working memory	T041	C0025265
performance	T041	C1285654
supportive	T058	C0600015
message	T170	C0470166
teacher	T097	C0221457
performance	T041	C1285654
study	T062	C2603343
parents	T099	C0030551
teachers	T097	C0221457
support	T058	C0600015
working memory	T041	C0025265
performance	T041	C1285654
supportive	T058	C0600015
child	T100	C0008059
Teacher	T097	C0221457
support	T058	C0600015
effective	T080	C1704419
child	T100	C0008059
negative	T033	C0205160
relationship	T080	C0439849
parent	T099	C0030551
preventing	T169	C1292733
resolving	T033	C3714811
working memory	T041	C0025265
problems	T033	C0033213
issues	T033	C0033213
Management	T057	C1273870
tachyarrhythmia	T033	C0080203
pregnancy	T040	C0032961
Maternal	T033	C1858460
tachyarrhythmia	T033	C0080203
common	T081	C0205214
complication	T046	C0009566
pregnancy	T040	C0032961
hormonal changes	T033	C1134488
enhance	T052	C2349975
pre-existing	T080	C2347662
arrhythmias	T033	C0080203
induce	T169	C0205263
arrhythmias	T033	C0080203
presence	T033	C0150312
congenital heart defects	T019	C0018798
pregnant females	T098	C0033011
Presence	T033	C0150312
tachyarrhythmia	T033	C0080203
pregnancy	T040	C0032961
risk	T078	C0035647
mother	T099	C0026591
fetus	T018	C0015965
calling	T041	C0679006
proper treatment	T061	C0087111
medications	T121	C0013227
antiarrhythmic drugs	T121	C0003195
maternal	T033	C1858460
tachyarrhythmia	T033	C0080203
consideration	T078	C0750591
potential	T080	C3245505
teratogenic side effects	T046	C0232910
Utilization	T169	C0042153
antiarrhythmic drugs	T121	C0003195
pregnancy	T040	C0032961
studied	T062	C2603343
result	T169	C1274040
minimal	T080	C0547040
fetal	T018	C0015965
harm	T037	C0005604
techniques	T169	C0449851
cardiac ablation	T061	C0162563
implemented	T052	C1708476
minimal	T080	C0547040
radiation exposure	T037	C0015333
fetus	T018	C0015965
mother	T099	C0026591
Pregnant women	T098	C0033011
tachyarrhythmia	T033	C0080203
successfully	T080	C1272703
treated	T033	C0332154
little	T081	C0700321
impact	T080	C4049986
developing fetus	T039	C3824789
result	T169	C1274040
increasing	T169	C0442808
experience	T041	C0596545
antiarrhythmic drugs	T121	C0003195
progress	T169	C1280477
procedural	T169	C2700391
techniques	T169	C0449851
Hif-1α	T116	C0965644
Overexpression	T045	C1514559
Improves	T033	C0184511
Transplanted Bone Mesenchymal Stem Cells	T061	C1257990
Survival	T043	C0007620
Rat MCAO Stroke Model	T050	C0012644
Bone mesenchymal stem cells	T025	C1257975
BMSCs	T025	C1257975
death	T043	C0007587
transplantation	T061	C1257990
cell therapy	T061	C0302189
cerebral infarction	T047	C0007785
study	T062	C0008972
aimed	T078	C1947946
investigate	T169	C1292732
modification	T169	C0392747
BMSCs	T025	C1257975
hypoxia-inducible factor 1α	T116	C0965644
Hif-1α	T116	C0965644
enhance	T052	C2349975
survival	T043	C0007620
implanted BMSCs	T061	C1257990
BMSCs	T025	C1257975
isolated	T059	C3827940
Wistar rats	T015	C0034716
infected	T046	C3714514
Hif-1α-GFP lentiviral vector	T121	C1520007
Hif-1α siRNA	T114	C1099354
modified	T169	C0392747
BMSCs	T025	C1257975
oxygen-glucose deprivation (OGD) condition	T039	C4236781
cellular viability	T043	C0007620
apoptosis	T043	C0162638
assessed	T052	C1516048
inhibitor	T121	C1254351
AMPK	T116	C2350345
compound C	T121	C1254351
detect	T061	C1511790
AMPK	T116	C2350345
mTOR	T116	C1447315
Hif-1α	T116	C0965644
BMSCs survival	T043	C0007620
BMSCs	T025	C1257975
expression of autophagy markers	T045	C1171362
modified	T169	C0392747
BMSCs	T025	C1257975
transplanted	T061	C1257990
middle cerebral artery occlusion	T020	C0740391
MCAO	T020	C0740391
model of rats	T050	C0012644
cerebral infarction	T047	C0007785
volume	T081	C0449468
neurological function	T042	C0027767
assessed	T052	C1516048
Hif-1α overexpression	T045	C1514559
OGD	T039	C4236781
induced	T169	C0205263
injury	T037	C3263723
cellular viability	T043	C0007620
inhibiting	T044	C0021469
apoptosis	T043	C0162638
AMPK	T116	C2350345
mTOR	T116	C1447315
inactivated	T169	C0544461
Hif-1α overexpression	T045	C1514559
Hif-1α	T116	C0965644
BMSCs survival	T043	C0007620
Hif-1α overexpression	T045	C1514559
autophagy	T043	C0004391
compound C	T121	C1254351
induction of Hif-1α	T045	C0014431
autophagy	T043	C0004391
Transplantation of the overexpressed Hif-1α of BMSCs	T061	C1257990
MCAO rats	T050	C0012644
brain infarct	T047	C0007785
volume	T081	C0449468
improved	T033	C0184511
neurobehavioral outcome	T080	C2986478
pro-inflammatory cytokines	T116	C0079189
neurotrophin	T116	C0132298
secretion	T043	C1159339
Hif-1α	T116	C0965644
survival of BMSCs	T043	C0007620
activation of AMPK and mTOR	T044	C0014429
autophagy	T043	C0004391
Associations	T080	C0439849
major life events	T032	C0557155
adherence	T169	C1510802
glycemic control,	T061	C3267174
psychosocial characteristics	T080	C0033963
teens	T098	C1521910
type 1 diabetes	T047	C0011854
cross-sectional study	T062	C0010362
assessed	T052	C1516048
major life events	T032	C0557155
teens	T098	C1521910
type 1 diabetes	T047	C0011854
association	T080	C0439849
event frequency	T051	C0441471
demographic	T078	C0011292
diabetes management	T061	C0948092
psychosocial characteristics	T080	C0033963
Parents	T099	C0030551
teens	T098	C1521910
Life Events	T032	C0557155
Checklist	T170	C1707357
events	T051	C0441471
teens	T098	C1521910
experienced	T067	C0023672
year	T079	C0439234
experienced	T067	C0023672
event	T051	C0441471
experienced	T067	C0023672
events	T051	C0441471
experienced	T067	C0023672
events	T051	C0441471
Teens	T098	C1521910
parents	T099	C0030551
measures	T081	C0079809
treatment adherence	T033	C0516958
diabetes	T047	C0011847
self-efficacy	T041	C0600564
quality of life	T078	C0034380
diabetes	T047	C0011847
family conflict	T033	C0233542
Parent-youth interview	T052	C0021822
chart review	T058	C0541653
demographics	T062	C0011287
diabetes management	T061	C0948092
events	T051	C0441471
teen	T098	C1521910
events	T051	C0441471
Hospitalization	T058	C0019993
family member	T099	C0086282
Getting a bad report card	T033	C0243095
arguments	T054	C0680226
parents	T099	C0030551
Serious illness	T184	C0221423
injury	T037	C3263722
family member	T099	C0086282
teens	T098	C1521910
event	T051	C0441471
teens	T098	C1521910
events	T051	C0441471
parents	T099	C0030551
parent	T099	C0030551
college degree	T170	C0542560
Teen	T098	C1521910
events	T051	C0441471
adherence	T169	C1510802
teen	T098	C1521910
parent	T099	C0030551
self-efficacy	T041	C0600564
teen	T098	C1521910
parent	T099	C0030551
quality of life	T078	C0034380
teen	T098	C1521910
parent	T099	C0030551
conflict	T033	C0233542
teen	T098	C1521910
parent	T099	C0030551
teens	T098	C1521910
events	T051	C0441471
multivariate model	T170	C3161035
demographic	T078	C0011292
diabetes management	T061	C0948092
events	T051	C0441471
A1c	T116	C0019018
major life events	T032	C0557155
associated with	T080	C0332281
diabetes care	T061	C3274787
A1c	T116	C0019018
psychosocial qualities	T078	C0243156
teens	T098	C1521910
type 1 diabetes	T047	C0011854
Metabolomics	T091	C1328813
Nutrition	T033	C0392209
Potential	T080	C3245505
Biomarkers	T201	C0005516
Food Quality	T080	C0920525
Intake	T169	C1512806
Health Status	T080	C0018759
Diet	T168	C0012155
dietary patterns	T062	C1517289
environmental factors	T080	C0686732
exposure to	T080	C0332157
toxins	T123	C0040549
role	T077	C1705810
prevention	T080	C2700409
development	T169	C1527148
diseases	T047	C0012634
obesity	T047	C0028754
type 2 diabetes	T047	C0011860
health status	T080	C0018759
individuals	T098	C0237401
identify	T080	C0205396
novel	T080	C0205314
biomarkers	T201	C0005516
detect	T033	C0442726
early	T079	C1279919
metabolic	T169	C0311400
dysfunction	T077	C3887504
predict	T078	C0681842
evolution	T169	C0205245
health status	T080	C0018759
nutritional advices	T061	C0850410
population groups	T098	C1257890
Omics technologies	T090	C0039421
genomics	T091	C0887950
proteomics	T091	C0872252
metabolomics	T091	C1328813
coupled	T169	C1948027
statistical	T170	C0037589
bioinformatics tools	T170	C0037589
potential	T080	C3245505
research field	UnknownType	C0683945
biomarkers	T201	C0005516
decades	T081	C2981279
analytical techniques	T059	C0022885
developed	T169	C0205245
detect	T033	C0442726
metabolites	T123	C0870883
human	T016	C0086418
biofluids	T031	C0005889
urine	T031	C0042036
blood	T031	C0005767
saliva	T031	C0036087
food science	T090	C0920526
nutrition	T091	C0028707
studies	T062	C2603343
food	T168	C0016452
authenticity	T080	C0205556
quality	T080	C0332306
safety	T068	C0036043
food processing	T057	C0016487
metabolomic	T091	C1328813
investigations	T169	C1292732
discover	T052	C1880355
early	T079	C1279919
biomarkers	T201	C0005516
metabolic	T169	C0311400
dysfunction	T077	C3887504
predictive	T080	C0681890
biomarkers	T201	C0005516
pathologies	T091	C0030664
obesity	T047	C0028754
metabolic syndrome	T047	C0039082
type-2 diabetes	T047	C0011860
development	T169	C1527148
methodologies	T062	C0086912
identify	T080	C0205396
biomarkers	T201	C0005516
nutrients	T168	C0678695
exposure	T080	C0332157
Draft Genome Sequence	T086	C0162326
Bacillus cereus LA2007	T007	C0004590
Human-Pathogenic Isolate	T123	C3494793
Anthrax	T204	C1254288
Anthrax -Like Plasmids	T114	C0032136
genome sequence	T086	C0162326
Bacillus cereus LA2007	T007	C0004590
strain	T001	C1518614
isolated	T169	C0205409
fatal pneumonia	T047	C0004626
case	T170	C0085973
Louisiana	T083	C0024024
Sequence-based genome analysis	T059	C3854164
revealed	T080	C0443289
LA2007	T007	C0004590
carries	T033	C0699809
plasmid	T114	C0032136
Bacillus anthracis pXO1	T007	C0004589
genes	T028	C0017337
production	T131	C0444622
regulation	T038	C1327622
anthrax toxin	T116	C0051962
elite	T080	C1522427
Neurospora crassa	T004	C0027923
strains	T001	C1518614
cellulosic	T109	C0007648
ethanol production	T040	C0678710
fungal	T169	C0521033
breeding	T040	C1260875
renewable	T169	C3178762
sustainable energy	T169	C3178763
generated	T052	C3146294
interest	T041	C0543488
conversion	T169	C0439836
cellulosic	T109	C0007648
biomass	T081	C0005535
liquid	T167	C0302908
fuels	T073	C0556991
ethanol	T109	C0001962
filamentous fungus	T004	C0016832
attempts	T051	C1516084
study	T062	C2603343
cellulose metabolism	T044	C1157836
use of	T169	C1524063
knock-out	T050	C1522225
mutants	T049	C0596988
systematic	T169	C0220922
characterize	T052	C1880022
natural	T169	C0205296
variation	T070	C0042333
cellulose metabolism	T044	C1157836
ecotypes	T032	C3178911
adapted	T070	C0001398
different	T080	C1705242
habitats	T082	C0871648
characterized	T052	C1880022
natural	T169	C0205296
variation	T070	C0042333
saccharification	T067	C1254366
cellulose	T109	C0007648
fermentation	T044	C0015852
ecotypes	T032	C3178911
laboratory	T073	C0022877
strains	T001	C1518614
model	T170	C3161035
fungus	T004	C0016832
Neurospora crassa	T004	C0027923
observed	T169	C1441672
significant	T078	C0750502
variation	T070	C0042333
traits	T032	C0599883
natural	T169	C0205296
laboratory generated	T080	C2346631
populations	T004	C0016832
elite	T080	C1522427
strains	T001	C1518614
performing	T169	C0884358
better	T080	C0332272
reference	T081	C0034925
strain	T001	C1518614
F1 population N345	T099	C0314650
population	T004	C0016832
parents	T004	C0016832
performing	T169	C0884358
strain	T001	C1518614
improvement	T077	C2986411
ethanol production	T040	C0678710
results	T034	C1254595
natural	T169	C0205296
alleles	T028	C0002085
fungal	T169	C0521033
breeding	T040	C1260875
elite	T080	C1522427
industrial	T057	C0021267
strains	T001	C1518614
bioethanol production	T040	C0678710
hippocampus	T023	C0019564
calcitonin gene-related peptide	T116	C0006669
traumatic brain injury	T037	C0876926
fracture-healing	T042	C0162542
hippocampus	T023	C0019564
fracture-healing	T042	C0162542
traumatic brain injury	T037	C0876926
calcitonin gene-related peptide	T116	C0006669
CGRP	T116	C0006669
Sprague-Dawley rats	T015	C0034715
groups	T078	C0441833
TBI	T037	C0876926
fracture	T037	C0016658
group	T078	C0441833
fracture	T037	C0016658
only	T081	C0205171
group	T078	C0441833
TBI	T037	C0876926
only	T081	C0205171
group	T078	C0441833
control group	T096	C0009932
blood specimen	T031	C0178913
rats	T015	C0034715
groups	T078	C0441833
control group	T096	C0009932
post	T079	C0687676
damage	T037	C0270611
rats	T015	C0034715
neurological	T080	C0205494
brain injury	T037	C0270611
Blood samples	T059	C1277698
control group	T096	C0009932
injury	T037	C0270611
brain tissues	T023	C0459385
injured	T169	C0332664
groups	T078	C0441833
harvested	T061	C0185110
post	T079	C0687676
injury	T037	C0270611
serum	T031	C0229671
CGRP	T116	C0006669
concentration	T081	C1446561
CGRP	T116	C0006669
CGRP	T116	C0006669
expression	T045	C1171362
expression	T045	C1171362
CGRP	T116	C0006669
hippocampus	T023	C0019564
expression	T045	C1171362
CGRP	T116	C0006669
hippocampus	T023	C0019564
expression	T045	C1171362
CGRP	T116	C0006669
hippocampus	T023	C0019564
expression	T045	C1171362
CGRP	T116	C0006669
brain	T023	C0006104
immunohistochemistry	T060	C0021044
Western blotting	T059	C0949466
RT	T045	C0035380
CGRP	T028	C0017337
RNA expression	T045	C1515670
Neurological examinations	T060	C0027853
cerebral cortex	T023	C0007776
cerebellum	T023	C0007765
brain stem	T023	C0006121
pre	T079	C0332152
post	T079	C0687676
injury	T037	C0270611
ELISA analysis	T059	C0014441
CGRP	T116	C0006669
TBI	T037	C0876926
fracture	T037	C0016658
group	T078	C0441833
TBI	T037	C0876926
fracture	T037	C0016658
group	T078	C0441833
CGRP	T116	C0006669
hippocampus	T023	C0019564
whole brain	T023	C1269537
RT-PCR	T063	C0599161
western blot analysis	T059	C0949466
post	T079	C0687676
injury	T037	C0270611
only	T081	C0205171
immunohistochemistry analysis	T060	C0021044
CGRP	T116	C0006669
hippocampus	T023	C0019564
post	T079	C0687676
injury	T037	C0270611
hippocampus	T023	C0019564
CGRP	T116	C0006669
bone-healing	T047	C3687232
hippocampus	T023	C0019564
fracture healing	T042	C0162542
CGRP	T116	C0006669
expression	T045	C1171362
IHC	T060	C0021044
groups	T078	C0441833
hippocampus	T023	C0019564
brain	T023	C0006104
big stress	T046	C0449430
Bone	T024	C0391978
extracellular matrix	T024	C0015350
hydrogel	T122	C0600484
osteogenic differentiation	T043	C0007589
C2C12 myoblasts	T025	C0596995
mouse	T015	C0025929
calvarial	T023	C0205950
cells	T025	C0007634
Hydrogel scaffolds	T122	C0600484
extracellular matrix	T024	C0015350
ECM	T024	C0015350
mammalian tissues	T024	C0040300
tissue repair	T040	C0043240
in vitro	T080	C1533691
in vivo	T082	C1515655
study	T062	C2603343
osteogenic potential	T042	C0029433
ECM	T024	C0015350
hydrogels	T122	C0600484
demineralized	T122	C1832069
decellularized bovine bone	T122	C0005479
osteogenic medium	T130	C0010454
Culture	T059	C0430400
C2C12	T025	C0596995
mouse	T015	C0025929
calvarial	T023	C0205950
cells	T025	C0007634
mPCs	T025	C0007634
decellularized bone ECM	T122	C0005479
bECM	T122	C0005479
demineralized bone matrix	T122	C1832069
DBM	T122	C1832069
gels	T122	C0600484
expression	T059	C0600223
osteogenic gene markers	T045	C0017393
osteopontin	T116	C0069676
osteocalcin	T116	C0029419
mPCs	T025	C0007634
cultured	T059	C0430400
bECM	T122	C0005479
basal	T130	C0010454
osteogenic media	T130	C0010454
bECM	T122	C0005479
hydrogels	T122	C0600484
osteogenic differentiation	T043	C0007589
C2C12	T025	C0596995
mPCs	T025	C0007634
osteogenic medium	T130	C0010454
bECM	T122	C0005479
hydrogel scaffolds	T122	C0600484
clinical	T080	C0205210
applications	T169	C4048755
bone	T024	C0391978
tissue engineering	T061	C0596171
Prostate-specific antigen	T116	C0138741
increase	T169	C0442805
dutasteride	T109	C0754659
prostate biopsy	T060	C0194804
prostatic inflammation	T047	C0033581
analyze	T062	C0936012
increase	T169	C0442805
total prostate-specific antigen (PSA) serum levels	T059	C2123607
dutasteride	T109	C0754659
treatment	T061	C0087111
predictor	T078	C2698872
prostate cancer	T191	C0376358
PC	T191	C0376358
biopsy	T060	C0005558
rate	T081	C1521828
PSA	T116	C0138741
PSA	T116	C0138741
increase	T169	C0442805
prostatic inflammation	T047	C0033581
men	T098	C0025266
prostate biopsy	T060	C0194804
elevated	T080	C3163633
PSA	T116	C0138741
PSA levels	T059	C2123607
dutasteride	T109	C0754659
treatment	T061	C0087111
population	T098	C1257890
PSA	T116	C0138741
increase	T169	C0442805
follow-up	T058	C1522577
prostate biopsy	T060	C0194804
PSA	T116	C0138741
increase	T169	C0442805
associated with	T080	C0332281
PC	T191	C0376358
re-biopsy	T060	C0005558
PSA reduction	T033	C1096147
treatment	T061	C0087111
indicator	T201	C0005516
PC	T191	C0376358
inflammatory infiltrates	T033	C3887644
prostate biopsies	T060	C0194804
PC	T191	C0376358
biopsy	T060	C0005558
increase	T169	C0442805
PSA	T116	C0138741
PSA level	T059	C2123607
dutasteride	T109	C0754659
Treatment	T061	C0087111
dutasteride	T109	C0754659
analyze	T062	C0936012
PSA	T116	C0138741
kinetic	T070	C0022702
prostatic inflammation	T047	C0033581
PSA	T116	C0138741
kinetic	T070	C0022702
dutasteride	T109	C0754659
treatment	T061	C0087111
Neurological Decline	T033	C4314692
Elderly	T098	C0001792
Repaired	T169	C0205340
Myelomeningocele	T019	C0025312
Complicated	T169	C0231242
Lumbar Canal Stenosis	T047	C0158288
case report	T170	C0085973
Tethered cord syndrome	T047	C0080218
complication	T046	C0009566
myelomeningocele	T019	C0025312
MMC	T019	C0025312
repair	T058	C1705181
childhood	T079	C0231335
complications	T046	C0009566
adults	T100	C0001675
repaired	T169	C0205340
MMC	T019	C0025312
influence	T077	C4054723
degenerative spinal deformity	T190	C0575157
sustained	T169	C0443318
tethered cord	T033	C1842369
63-year-old	T100	C0001675
man	T032	C0086582
repaired	T169	C0205340
MMC	T019	C0025312
progressive gait disturbance	T033	C0243095
numbness	T184	C0028643
lower limbs	T023	C0023216
Magnetic resonance images	T170	C1704922
tethered spinal cord	T033	C1842369
compressed	T169	C0332260
severe	T080	C0205082
canal stenosis	T047	C0158288
entire lumbar spine	T029	C1269871
multi-level lumbar decompression	T061	C0578803
surgery	T061	C0543467
patient recovered	T032	C1115804
baseline	T081	C1442488
neurological	T080	C0205494
adults	T100	C0001675
repaired	T169	C0205340
MMC	T019	C0025312
lumbar canal stenosis	T047	C0158288
investigated	T169	C1292732
neurological decline	T033	C4314692
complicated	T169	C0231242
neurological disorders	T047	C0027765
disorders	T047	C0012634
compressive myelopathy	T047	C0037926
surgical decompression	T061	C0376530
spinal cord dysfunction	T047	C0012634
Epidemiology	T091	C0014507
polyomavirus BK	T005	C0005670
BKV	T005	C0005670
emergent	T078	C0750573
African	T083	C0001737
variant	T080	C0205419
kidney	T023	C0022646
bone marrow	T024	C0005953
transplant recipients	T101	C0376387
Fundacion Valle del Lili in Cali	T093	C1708333
Colombia	T083	C3245499
epidemiology	T091	C0014507
BKV	T005	C0005670
assess	T052	C1516048
presence	T033	C0150312
African	T083	C0001737
variant	T080	C0205419
bone marrow	T024	C0005953
kidney transplant patients	T033	C4304779
suspected	T080	C0332147
BKV	T005	C0005670
reactivation	T052	C4086768
descriptive study	T062	C0002783
conducted	T033	C3844519
institutional records	T170	C0034869
Fundación Valle del Lili, Cali	T093	C1708333
Colombia	T083	C3245499
overall prevalence	T081	C0033106
BKV	T005	C0005670
African	T083	C0001737
variant	T080	C0205419
identified	T080	C0205396
samples	T167	C0370003
positive	T033	C1446409
BKV	T005	C0005670
samples	T167	C0370003
wild	T028	C1883559
strain	T080	C0456178
BKV	T005	C0005670
BKV	T005	C0005670
positive	T033	C1446409
patients	T101	C0030705
kidney transplant recipients	T033	C4304779
bone marrow	T024	C0005953
transplant recipients	T101	C0376387
epidemiological study	T062	C0002783
African	T083	C0001737
variant	T080	C0205419
BKV	T005	C0005670
Colombia	T083	C3245499
Thaw	T059	C1710378
target cells	T025	C0221284
pre-labeled	T080	C1708632
calcein AM	T130	C0016320
antibody-dependent cell-mediated cytotoxicity assays	T059	C0201624
In vitro	T080	C1533691
antibody-dependent cell-mediated cytotoxicity (ADCC) assays	T059	C0201624
therapeutic antibodies	T116	C0003241
ADCC assays	T059	C0201624
target cells	T025	C0221284
antibodies	T116	C0003241
lysed	T046	C0024348
activated	T052	C1879547
effector cells	T025	C0312740
Fc region	T116	C0021032
antibody	T116	C0003241
Fcγ receptors	T116	C0034805
effector cells	T025	C0312740
Target cell	T025	C0221284
lysis	T046	C0024348
quantification	T081	C1709793
endogenous	T169	C0205227
enzymes	T116	C0014442
lactate dehydrogenase	T116	C0022917
exogenous	T169	C0205228
labels	T130	C1522485
(51)Cr	T121	C0303212
europium	T196	C0015180
calcein	T109	C0060549
ADCC assays	T059	C0201624
exogenous	T169	C0205228
labels	T130	C1522485
lysed	T046	C0024348
target cells	T025	C0221284
incubation times	T033	C1320226
target cells	T025	C0221284
labeled	T080	C1708632
assay	T059	C1510438
assay	T059	C1510438
variations	T080	C0205419
target cell	T025	C0221284
labeling	T059	C2347885
handling processes	T059	C0037793
thaw	T059	C1710378
pre-labeled	T080	C1708632
target cells	T025	C0221284
ADCC assays	T059	C0201624
Thaw	T059	C1710378
target cells	T025	C0221284
pre-labeled	T080	C1708632
fluorescent dye calcein AM	T130	C0016320
cryopreserved	T059	C0010405
assays	T059	C1510438
thawing	T059	C2025613
thaw	T059	C1710378
pre-labeled	T080	C1708632
cells	T025	C0007634
viability	T043	C0007620
label	T130	C1522485
retention	T169	C0333118
labeled	T080	C1708632
cells	T025	C0007634
ADCC	T043	C0003272
peripheral blood mononuclear cells	T025	C1321301
engineered natural killer cells	T025	C0022688
ADCC assays	T059	C0201624
thaw	T059	C1710378
pre-labeled	T080	C1708632
target cells	T025	C0221284
ADCC assays	T059	C0201624
cell culture	T059	C0007585
dye labeling	T059	C0886517
assay	T059	C1510438
assay consistency	T080	C0332529
robustness	T080	C2986815
Pathways	T044	C1704259
Genes	T028	C0017337
Associated with	T080	C0332281
Immune	T022	C0020962
Dysfunction	T046	C0277785
Sheep	T015	C0036945
Paratuberculosis	T047	C0030524
Multibacillary	T033	C0243095
paucibacillary	T033	C0243095
paratuberculosis	T047	C0030524
Mycobacterium avium subspecies paratuberculosis	T007	C0085442
Multibacillary	T033	C0243095
lesions	T033	C0221198
infected	T033	C0439663
epithelioid macrophages	T025	C0014603
paucibacillary	T033	C0243095
lesions	T033	C0221198
T cells	T025	C0039194
bacteria	T007	C0004611
Multibacillary	T033	C0243095
disease	T047	C0012634
lepromatous leprosy	T047	C0023348
antibody	T116	C0003241
dysfunctional	T169	C0031847
immune response	T042	C0301872
Animals	T008	C0003062
paucibacillary	T033	C0243095
disease	T047	C0012634
cell-mediated immunity	T040	C0020966
variable levels	T080	C0441889
antibody	T116	C0003241
immunological dysfunction	T047	C1532237
TruSeq	T170	C0282574
analysis	T062	C0936012
ileocaecal	T082	C0700426
lymph node	T023	C0024204
disease	T047	C0012634
lesions	T033	C0221198
Immune	T022	C0020962
dysfunction	T046	C0277785
repression	T045	C0920533
TCR	T028	C0524889
CD3 genes	T028	C0017337
T cell co-receptors	T116	C0034790
co-stimulators	T116	C3203085
T cell activation	T043	C1155065
signal-transduction	T043	C0037083
genes	T028	C0017337
Inflammation	T046	C0021368
acute phase response	T046	C0001349
chronic inflammation	T046	C0021376
acute inflammation	T033	C0333361
immunoglobulin	T116	C0021027
plasma cell	T025	C0032112
transcripts	T114	C1519595
anti-MAP antibody responses	T038	C0003261
paratuberculosis	T047	C0030524
sheep	T015	C0036945
reduction	T080	C0392756
mast cell	T025	C0024880
transcripts	T114	C1519595
affecting	T169	C0392760
DC activation of the immune response	T043	C1817431
gene expression	T045	C0017262
multibacillary	T033	C0243095
paucibacillary	T033	C0243095
disease	T047	C0012634
T cell	T025	C0039194
genes	T028	C0017337
Th1	T025	C0242632
Th2	T025	C0242633
incremental	T081	C1705117
immune	T022	C0020962
dysfunction	T046	C0277785
multibacillary	T033	C0243095
pathology	T047	C0012634
Modified	T169	C0392747
frailty index	T170	C4075886
predicts	T078	C0681842
postoperative	T033	C0231287
outcomes	T081	C0086749
older	T098	C3826770
gastrointestinal cancer	T191	C0685938
patients	T101	C0030705
Frailty	T033	C0424594
disproportionately	T080	C0205556
impacts	T080	C4049986
older	T098	C3826770
patients	T101	C0030705
gastrointestinal cancer	T191	C0685938
rendering	T169	C0205245
increased risk for poor outcomes	T033	C3553618
frailty index	T170	C4075886
preoperative	T079	C0445204
risk	T078	C0035647
stratification	T062	C1514983
hypothesized	T078	C1512571
modified frailty index (mFI) scores	T033	C4075885
associated with	T080	C0332281
adverse outcomes	T033	C1705586
tumor	T191	C0027651
resection	T061	C0015252
older	T098	C3826770
gastrointestinal cancer	T191	C0685938
patients	T101	C0030705
Patients	T101	C0030705
60-90 years old	T098	C3826770
underwent	T169	C0205245
gastrointestinal tumor resection	UnknownType	C0744337
identified	T080	C0205396
NSQIP	T033	C1532051
Participant	T098	C0679646
mFI	T033	C4075885
previously	T079	C0205156
described	T078	C1552738
preoperative	T079	C0445204
variables	T080	C0439828
Frailty	T033	C0424594
mFI score	T033	C4075885
postoperative course	T058	C0032786
evaluated	T058	C0220825
univariate	T062	C0683962
multivariate analysis	T081	C0026777
patients	T101	C0030705
female	T032	C0086287
identified	T080	C0205396
prevalent form	T082	C0205391
cancer	T191	C0006826
colorectal	T191	C1527249
patients	T101	C0030705
frail	T033	C0871754
Frail	T033	C0871754
patients	T101	C0030705
significantly	T078	C0750502
more likely	T078	C0750501
increased length of stay	T079	C3840528
major	T080	C0205164
complications	T046	C0009566
mortality	T081	C0026565
Multivariate analysis	T081	C0026777
identified	T080	C0205396
mFI	T033	C4075885
independent	T078	C0085862
predictor	T078	C2698872
major	T080	C0205164
complications	T046	C0009566
mortality	T081	C0026565
mFI	T033	C4075885
associated with	T080	C0332281
incidence	T081	C0021149
postoperative	T033	C0231287
complications	T046	C0009566
mortality	T081	C0026565
older	T098	C3826770
surgical patients	T101	C0871463
gastrointestinal cancer	T191	C0685938
Spermatocytic Tumor	T191	C0334517
Sarcoma	T191	C1261473
Rare	T080	C0522498
Testicular Neoplasm	T191	C0039590
Spermatocytic tumor	T191	C0334517
spermatocytic seminoma	T191	C0334517
uncommon	T080	C0522498
testicular neoplasm	T191	C0039590
clinicopathologic entity	T169	C0205469
seminoma	T191	C0036631
tumors	T191	C0027651
germ cell neoplasia	T191	C4021985
germ cell tumors	T191	C0205851
isochromosome 12p	T049	C1515647
tumors	T191	C0027651
excellent	T080	C1961136
prognosis	T058	C0033325
occasional cases	T169	C0868928
associated with	T080	C0332281
sarcoma	T191	C1261473
very poor prognosis	T033	C0278252
case	T077	C1706256
spermatocytic tumor	T191	C0334517
sarcoma	T191	C1261473
chondrosarcomatous component	T191	C0008479
pathologic findings	T033	C1317598
differential diagnosis	T060	C0011906
follow-up	T058	C1522577
information	T078	C1533716
Remote	T082	C0205157
Ischemic Conditioning	T061	C0376466
Renal	T023	C0022646
Protection	T033	C1545588
remote	T082	C0205157
ischemic conditioning	T061	C0376466
RIC	T061	C0376466
research	T062	C0035168
interest	T041	C0543488
RIC	T061	C0376466
protecting	T033	C1545588
tissues	T024	C0040300
ischemic	T169	C0475224
damage	T037	C0010957
medical	T169	C0205476
conditions	T080	C0348080
procedures	T058	C0199171
Acute kidney injury	T037	C2609414
AKI	T037	C2609414
side effect	T169	C0001688
medical procedures	T058	C0199171
RIC	T061	C0376466
Outcomes	T169	C1274040
kidney function	T042	C0232804
studies	T062	C0079816
effects of	T080	C1704420
RIC	T061	C0376466
cardiac surgery	T061	C0018821
interventions	T061	C0184661
intravenous administration	T082	C0013125
contrast media	T130	C0009924
studies	T062	C0079816
effect of	T080	C1704420
RIC	T061	C0376466
kidney function	T042	C0232804
randomized controlled trials	T062	C0206035
patients	T101	C0030705
Effect of	T080	C1704420
Remote Ischemic Preconditioning	T061	C0376442
Cardiac Surgery	T061	C0018821
Remote Ischaemic Preconditioning	T061	C0376442
Heart Surgery	T061	C0018821
E RIC CA	T061	C0010055
RIC	T061	C0376466
negative	T033	C1513916
AKI	T037	C2609414
renal function	T042	C0232804
trials	T062	C0008976
meta-analyses	T062	C0920317
participants	T098	C0679646
results	T169	C1274040
RIC	T061	C0376466
published	T170	C1704324
studies	T062	C0079816
adversely affecting	T169	C0001688
quality	T080	C0332306
available data	T170	C0150098
review	T170	C0282443
research	T062	C0035168
authors	T097	C3812881
review	T170	C0282443
clinical trial	T062	C0008976
ischemic conditioning	T061	C0376466
studies	T062	C0079816
definitions	T170	C1704788
procedures	T169	C0025664
outcomes	T169	C1274040
goals persists	T170	C0679840
ischemic conditioning	T061	C0376466
clinical utility	T061	C0008971
Temporal	T079	C2362314
Spatial	T082	C1254362
Variability	T077	C2827666
Fungal Structures	T017	C2717804
Host Responses	T042	C0301872
Incompatible Rust-Wheat Interaction	T040	C1155325
Information	T078	C1533716
temporal	T079	C2362314
spatial	T082	C1254362
variability	T077	C2827666
fungal structures	T017	C2717804
host responses	T042	C0301872
scarce	T080	C0231180
comparison	T052	C1707455
amount	T081	C1265611
genetic	T169	C0314603
biochemical	T169	C0205474
physiological	T169	C0205463
studies	T062	C2603343
host-pathogen interactions	T040	C1752856
study	T062	C2603343
used	T169	C0457083
avirulent	T080	C0205556
wild type	T028	C1883559
virulent	T080	C1520022
mutant	T028	C0678941
isolates	T123	C1764827
Puccinia striiformis	T004	C1001443
characterize	T052	C1880022
interactions	T169	C1704675
wheat	T168	C0043137
carrying	T052	C0206243
yellow rust	T004	C1001443
Yr2	T004	C1001443
resistance	T046	C4087433
conventional	T080	C1442989
advanced	T080	C0205179
microscopic	T080	C0205288
techniques	T169	C0449851
used	T169	C0457083
detailed	T080	C1522508
study	T062	C2603343
morphology	T080	C0332437
growth	T040	C0018270
fungal	T169	C0521033
colonies	T025	C1947989
associated	T080	C0332281
host cell responses	T042	C0301872
growth	T040	C0018270
wild type	T028	C1883559
isolates	T123	C1764827
highly	T080	C0205250
restricted	T169	C0443288
hypersensitive response	T046	C0020517
HR	T046	C0020517
plant	T002	C0032098
cell death	T043	C0007587
indicated	T033	C1444656
autofluorescence	T059	C0544711
change	T169	C0392747
shape	T082	C0332479
affected	T169	C0392760
plant cells	T025	C3178867
host response	T042	C0301872
appeared	T080	C0700364
post	T079	C0687676
haustorial	T017	C2717804
large	T081	C0549177
variation	T080	C0205419
time	T079	C0040223
stage	T079	C0205390
arrest	T046	C0333951
observed	T169	C1441672
individual	T098	C0237401
fungal	T169	C0521033
colonies	T025	C1947989
probably	T078	C0750492
delay	T079	C0205421
between	T082	C0205103
detection	T061	C1511790
response	T032	C0871261
colonies	T025	C1947989
stopped	T079	C2746065
right after	T079	C0205253
formation	T169	C1522492
primary infection	T047	C0948192
hyphae	T004	C0521057
formed	T169	C0205431
highly	T080	C0205250
branched	T082	C2700384
mycelia	T004	C0949695
HR	T046	C0020517
observed	T169	C1441672
host cells	T026	C1819995
direct	T080	C1947931
contact	T067	C0392367
fungal structures	T017	C2717804
defense responses	T040	C1154988
spread	T080	C0332261
adjacent	T082	C0205117
host cells	T026	C1819995
encasement	T082	C1254362
fungal	T169	C0521033
colony	T025	C1947989
Several	T081	C0443302
cells	T025	C0007634
HR	T046	C0020517
contained	T052	C2700400
haustoria	T017	C2717804
small	T081	C0700321
underdeveloped	T080	C0205252
some	T081	C0205392
cells	T025	C0007634
contained	T052	C2700400
normal	T080	C0205307
sized	T082	C0456389
haustoria	T017	C2717804
signs	T184	C0037088
hypersensitivity	T046	C0020517
growth	T040	C0018270
virulent	T080	C1520022
mutants	T028	C0678941
resistant	T169	C0332325
plants	T002	C0032098
similar	T080	C2348205
growth	T040	C0018270
plants	T002	C0032098
Yr2	T004	C1001443
resistance	T046	C4087433
strong	T080	C0442821
indication	T078	C3146298
incompatible	T080	C1881865
phenotype	T032	C0031437
associated	T080	C0332281
Yr2	T004	C1001443
interaction	T169	C1704675
between	T082	C0205103
P. striiformis	T004	C1001443
wheat	T168	C0043137
Yr2	T004	C1001443
resistance	T046	C4087433
highly	T080	C0205250
variable	T080	C0439828
time	T079	C0040223
space	T082	C1254362
demonstrate	T080	C0443289
histological	T091	C0019638
studies	T062	C2603343
important	T080	C3898777
deeper understanding	T041	C0162340
host-pathogen interactions	T040	C1752856
plant	T002	C0032098
defense	T042	C0520990
mechanisms	T169	C0441712
general	T082	C0205246
Effects of	T080	C1704420
Messages	T170	C0470166
Causes	T169	C0015127
Obesity	T047	C0028754
Disciplinary Action	T057	C1552598
Decisions	T041	C0679006
Overweight	T047	C1561826
Employees	T097	C0599987
investigated	T169	C1292732
impact	T080	C4049986
messages	T170	C0470166
causes	T169	C0015127
obesity	T047	C0028754
controllable	T033	C2911690
uncontrollable	T080	C0205318
disciplinary action	T057	C1552598
consequences	T169	C0686907
obese	T047	C0028754
employees	T097	C0599987
response	T032	C0871261
work-related	T033	C1698590
mistake	T080	C0743559
Participants	T098	C0679646
controllable	T033	C2911690
uncontrollable	T080	C0205318
causes	T169	C0015127
obesity	T047	C0028754
reviewing	T080	C1704362
ostensible	T078	C0750489
employee	T097	C0599987
file	T057	C0016094
employee	T097	C0599987
mistake	T080	C0743559
file	T057	C0016094
photo	T073	C0441468
employee	T097	C0599987
obese	T047	C0028754
average	T081	C1510992
weight	T032	C0005910
Participants	T098	C0679646
withhold	T052	C1705116
promotion	T057	C0681129
obese	T047	C0028754
employee	T097	C0599987
average	T081	C1510992
weight	T032	C0005910
employee	T097	C0599987
evidence	T078	C3887511
messages	T170	C0470166
causes	T169	C0015127
obesity	T047	C0028754
affected	T169	C0392760
participants	T098	C0679646
perceived control	T033	C0517445
self-efficacy	T041	C0600564
healthy	T080	C3898900
behaviors	T053	C0004927
Experience	T041	C0596545
Instrumental	T081	C1704339
Tuning	T081	C0006751
Link	T052	C2986575
Language	T171	C0023008
Cognition	T041	C0009240
Evidence	T078	C3887511
6- to 7- Month-Old	T032	C0001779
Infants	T100	C0021270
Categorization	T185	C0008902
At birth	T080	C1744681
infants	T100	C0021270
listening	T041	C2584303
human	T016	C0086418
vocalizations	T054	C0009452
begun	T079	C0439659
link	T052	C2986575
vocalizations	T054	C0009452
cognition	T041	C0009240
infants	T100	C0021270
young	T079	C0332239
three months	T079	C1442461
age	T032	C0001779
listening	T041	C2584303
human	T016	C0086418
language	T171	C0023008
categorization	T185	C0008902
core	T082	C0444669
cognitive	T169	C1516691
capacity	T081	C1516240
precocious	T079	C1279930
link	T082	C0449379
initially	T079	C0205265
broad	T082	C0332464
vocalizations	T054	C0009452
both	T080	C1706086
humans	T016	C0086418
nonhuman primates	T015	C0237798
categorization	T185	C0008902
6 months	T079	C4082120
infants	T100	C0021270
narrowed	T080	C0333164
link	T052	C2986575
human	T016	C0086418
vocalizations	T054	C0009452
categorization	T185	C0008902
infants	T100	C0021270
tune	T081	C0006751
initially	T079	C0205265
broad	T082	C0332464
link	T052	C2986575
precise	T080	C2828393
vocalizations	T054	C0009452
species	T185	C1705920
studies	T062	C2603343
novel	T080	C0205314
exposure	T080	C0332157
paradigm	T062	C0681797
effects	T080	C1280500
experience	T041	C0596545
exposing	T080	C0332157
infants	T100	C0021270
nonhuman primate	T015	C0237798
vocalizations	T054	C0009452
enables	T041	C1171285
infants	T100	C0021270
early	T079	C1279919
established	T080	C0443211
link	T052	C2986575
signal	T067	C1710082
categorization	T185	C0008902
exposing	T080	C0332157
infants	T100	C0021270
backward	T169	C1555029
speech	T040	C0037817
signal	T067	C1710082
fails	T169	C0231175
support	T077	C1521721
categorization	T185	C0008902
age	T032	C0001779
findings	T033	C0243095
reveal	T080	C0443289
power	T081	C3854080
early	T079	C1279919
experience	T041	C0596545
infants	T100	C0021270
signals	T067	C1710082
initially	T079	C0205265
broad	T082	C0332464
continue	T078	C0549178
link	T052	C2986575
cognition	T041	C0009240
Bone Degeneration	T047	C1390464
SMP30/GNL	T028	C1419366
Knockout Mice	T015	C0206745
Senescence marker protein-30	T116	C1451963
SMP30	T116	C1451963
androgen	T121	C0002844
aging	T040	C0001811
lactone	T109	C0022947
hydrolyzing enzyme	T116	C0014442
gluconolactonase	T116	C0051129
GNL	T116	C0051129
vitamin C	T109	C0003968
biosynthesis	T169	C0005572
study	T062	C2603343
bone	T023	C0262950
SMP30/GNL	T028	C1419366
knockout (KO) mice	T015	C0206745
deficiency	T169	C0011155
vitamin C	T109	C0003968
synthesis	T169	C0005572
SMP30/GNL	T116	C1451963
exogenous	T169	C0205228
vitamin C	T109	C0003968
supplementation	T121	C0302837
bone formation	T042	C0029433
Mineral content	T081	C0005963
BMC	T081	C0005963
mineral density	T201	C0005938
BMD	T201	C0005938
mandible	T023	C0024687
femur	T023	C0015811
SMP30/GNL	T028	C1419366
KO	T015	C0206745
wild-type mice	T015	C1520150
months	T079	C0439231
age	T032	C0001779
vitamin C	T109	C0003968
supplementation	T121	C0302837
dual-energy X-ray absorptiometry	T060	C1510486
Body	T032	C0005910
bone	T023	C0262950
weight	T081	C0043100
age groups	T100	C0596090
wild-type mice	T015	C1520150
bones	T023	C0262950
SMP30/GNL	T028	C1419366
KO mice	T015	C0206745
BMC	T081	C0005963
BMD	T201	C0005938
wild-type	T015	C1520150
Oral	T030	C0226896
supplementation	T121	C0302837
vitamin C	T109	C0003968
body weight	T032	C0005910
bone	T023	C0262950
BMC	T081	C0005963
BMD	T201	C0005938
SMP30/GNL	T028	C1419366
KO	T015	C0206745
wild-type mice	T015	C1520150
age	T032	C0001779
bone degeneration	T047	C1390464
SMP30/GNL	T028	C1419366
KO mice	T015	C0206745
vitamin C	T109	C0003968
mouse strain	T015	C0025930
model	T008	C0599779
bone metabolism	T042	C0596204
humans	T016	C0086418
synthesize	T169	C0005572
vitamin C	T109	C0003968
Post-Mortem	T060	C0004398
Genetic Testing	T062	C1517514
Sudden Arrhythmic Death Syndrome	T047	C2721586
Sudden arrhythmic death syndrome	T047	C2721586
SADS	T047	C2721586
sudden death	T046	C0011071
autopsy	T060	C0004398
toxicological	T169	C0205472
analysis	T062	C0936012
Cardiac genetic disease	T047	C0019247
etiology	T169	C1314792
study	T062	C2603343
investigated	T169	C1292732
clinical utility	T080	C0205210
post-mortem	T060	C0004398
genetic testing	T062	C1517514
molecular autopsy	T060	C0004398
SADS	T047	C2721586
comprehensive	T080	C1880156
clinical evaluation	T058	C4084924
surviving	T052	C0038952
relatives	T099	C0080103
evaluated	T058	C0220825
SADS	T047	C2721586
DNA	T114	C0012854
age	T032	C0001779
males	T032	C0086582
next-generation	T090	C3274765
sequencing	T059	C1294197
panel	T078	C0441833
primary electrical disorder	T028	C0017337
cardiomyopathy genes	T028	C0017337
Pathogenic	T033	C3816499
pathogenic variants	T080	C0205419
American College of Medical Genetics	T093	C1708333
ACMG	T093	C1708333
consensus guidelines	T170	C0162791
molecular autopsy	T060	C0004398
clinical evaluation	T058	C4084924
surviving families	T099	C0015576
evaluated	T058	C0220825
gene-level rare variant association analysis	T063	C2350277
SADS	T047	C2721586
controls	T096	C0009932
clinically actionable	T080	C0205556
pathogenic	T033	C3816499
pathogenic variant	T080	C0205419
etiologies	T169	C1314792
catecholaminergic polymorphic ventricular tachycardia	T047	C4053736
long QT syndrome	T047	C0023976
Gene-based rare variants association analysis	T063	C2350277
deleterious variants	T080	C0205419
RYR2	T028	C1419779
molecular autopsy	T060	C0004398
clinical evaluation	T058	C4084924
surviving families	T099	C0015576
diagnostic yield	T080	C0205556
Molecular autopsy	T060	C0004398
electrical disorder	T028	C0017337
cardiomyopathy genes	T028	C0017337
ACMG	T093	C1708333
guidelines	T170	C0162791
variant classification	T185	C0008902
SADS	T047	C2721586
catecholaminergic polymorphic ventricular tachycardia	T047	C4053736
long QT syndrome	T047	C0023976
RYR2 gene	T028	C1419779
genes	T028	C0017337
clinical	T058	C4084924
genetic evaluation	T058	C0846617
Binding	T052	C1145667
DEAD-box helicase	T116	C0072382
Dhh1	T116	C1100944
5'UTR	T114	C0600493
ASH1	T028	C1426004
mRNA	T114	C0035696
represses	T045	C1519619
translation	T045	C1519614
ASH1	T028	C1426004
yeast	T004	C0043393
cells	T025	C0007634
Local translation	T045	C1519614
specific	T080	C0205369
mRNAs	T114	C0035696
regulated	T043	C1326447
subcellular	T026	C0729605
localization	T169	C0475264
changes	T169	C0392747
complex	T080	C0439855
mechanisms	T169	C0441712
controlling	T067	C2239193
cytoplasmic	T026	C0521449
mRNA transport	T043	C1523053
budding yeast	T004	C0014181
Saccharomyces cerevisiae	T004	C0036025
mechanisms	T169	C0441712
transcripts	T114	C1519595
transported	T044	C1519628
mother cell	T025	C0007634
budding	T043	C1155616
daughter cell	T025	C0007634
investigated	T169	C1292732
translational control	T043	C1157519
ASH1	T028	C1426004
mRNA	T114	C0035696
transport	T044	C1519628
localization	T169	C0475264
ASH1	T028	C1426004
ASH1	T028	C1426004
transcripts	T114	C1519595
translated	T045	C1519614
bud-tip	T026	C2263090
mRNAs	T114	C0035696
RNA-binding protein	T116	C0085177
Puf6	T116	C1453996
non-polysomal	T033	C0243095
DEAD-box helicase	T116	C0072382
Dhh1	T116	C1100944
complexed	T080	C0439855
untranslated	T114	C0600680
ASH1	T028	C1426004
mRNA	T114	C0035696
Puf6	T116	C1453996
Dhh1	T116	C1100944
local translation	T045	C1519614
ASH1	T028	C1426004
mRNA	T114	C0035696
delocalization	T169	C0475264
ASH1	T028	C1426004
transcript	T114	C1519595
bud	T002	C2700462
non-polysomal	T033	C0243095
ASH1	T028	C1426004
mRNA	T114	C0035696
polysomes	T026	C0032592
Dhh1	T116	C1100944
dissociation	T048	C0086168
Dhh1	T116	C1100944
ASH1	T028	C1426004
mRNA	T114	C0035696
co-transcriptionally	T045	C0040649
suggesting	T078	C1705535
ASH1	T028	C1426004
mRNA	T114	C0035696
cytoplasm	T026	C0010834
Dhh1	T116	C1100944
5 UTR	T114	C0600493
ASH1	T028	C1426004
mRNA	T114	C0035696
inhibited	T080	C0311403
translation	T045	C1519614
in vitro	T080	C1533691
suggest	T078	C1705535
localization	T169	C0475264
bud tip,	T026	C2263090
portion	T082	C0449719
localized	T082	C0392752
ASH1	T028	C1426004
mRNA	T114	C0035696
translationally	T045	C1519614
inactive	T080	C3244312
binding	T052	C1145667
Dhh1	T116	C1100944
Puf6	T116	C1453996
5' and 3' UTRs	T114	C0600493
ASH1	T028	C1426004
mRNA	T114	C0035696
Abundance	T080	C2346714
Endofungal Bacterium	T007	C0004611
Rhizobium radiobacter	T007	C0085472
Agrobacterium tumefaciens	T007	C0085472
Increases	T169	C0442805
Fungal	T169	C0521033
Host	T001	C1167395
Piriformospora indica	T004	C1025512
Sebacinalean	T004	C1665458
Symbiosis	T070	C0039029
Higher Plants	T002	C1562025
Rhizobium radiobacter	T007	C0085472
Agrobacterium tumefaciens	T007	C0085472
Agrobacterium fabrum	T007	C3560206
endofungal bacterium	T007	C0004611
fungal	T169	C0521033
mutualist	T070	C0599514
Piriformospora	T004	C1025512
Serendipita	T004	C1916017
indica	T004	C1025512
Basidiomycota	T004	C0004810
Sebacinalean	T004	C1665458
symbiosis	T070	C0039029
plants	T002	C0032098
R. radiobacter	T007	C0085472
strain F4	T001	C1518614
RrF4	T001	C1518614
P. indica DSM 11827	T004	C1025512
induces	T169	C0205263
growth	T040	C0018270
promotion	T052	C0033414
systemic resistance	T043	C1155264
cereal	T168	C0007757
crops	T002	C0242775
barley	T002	C0004755
wheat	T002	C0087114
R. radiobacter	T007	C0085472
symbiosis	T070	C0039029
impact	T080	C4049986
endobacteria	T007	C0004611
morphology	T080	C0332437
P. indica	T004	C1025512
interactions	T169	C1704675
plants	T002	C0032098
endobacteria	T007	C0004611
detected	T033	C0442726
axenically grown	T059	C0598869
P. indica	T004	C1025512
long term	T079	C0443252
lab-cultured	T059	C0430400
lcPiri	T004	C1025512
mycelia	T004	C0949695
colonizing	T033	C4289767
plant root	T002	C0242726
increased	T081	C0205217
bacteria	T007	C0004611
endobacteria	T007	C0004611
axenic cultures	T059	C0598869
P. indica	T004	C1025512
re-isolated	T169	C0205409
riPiri	T004	C1025512
plant roots	T002	C0242726
axenic re-cultivation	T059	C0598869
Prolonged	T079	C0439590
treatments	T061	C0087111
P. indica	T004	C1025512
cultures	T059	C0200954
antibiotics	T195	C0003232
bacterium	T007	C0004611
detectable	T201	C3830527
endobacteria	T007	C0004611
decreased	T081	C0205216
significantly	T078	C0750502
partial-cured	T033	C0243095
P. indica	T004	C1025512
pcPiri	T004	C1025512
pcPiri	T004	C1025512
reduced	T080	C0392756
growth	T040	C0018270
axenic cultures	T059	C0598869
poor	T080	C0542537
sporulation	T043	C2613267
Consistent with	T078	C0332290
pcPiri	T004	C1025512
reduced	T080	C0392756
plant growth	T040	C0597252
promotion	T052	C0033414
reduced	T080	C0392756
systemic resistanc	T043	C1155264
powdery mildew	T004	C0319635
infection	T046	C3714514
riPiri	T004	C1025512
lcPiri	T004	C1025512
results	T169	C1274040
consistent with	T078	C0332290
endobacterium	T007	C0004611
R. radiobacter	T007	C0085472
improves	T033	C0184511
P. indica's	T004	C1025512
fitness	T032	C4305181
Sebacinalean	T004	C1665458
symbiosis	T070	C0039029
Stem cell	T025	C0038250
registry	T170	C0920695
programme	T169	C3484370
patients	T101	C0030705
ischemic cardiomyopathy	T047	C0349782
coronary artery bypass grafting	T061	C0010055
benefits	T081	C0814225
Standardization	T062	C0038136
stem cell therapy	T061	C0872278
methods	T062	C2911685
evaluate	T058	C0220825
safety and efficac	T058	C0511730
long-term	T079	C0443252
pharmacovigilance	T062	C3178990
objective	T170	C0018017
long-term	T079	C0443252
registry programme	T073	C0037585
patients	T101	C0030705
ischemic cardiomyopathy	T047	C0349782
received	T080	C1514756
intramyocardial	T024	C0027061
CD133+ bone marrow mononuclear stem cell	T025	C1511246
treatment	T061	C0087111
combined	T080	C0205195
coronary artery bypass grafting	T061	C0010055
CABG	T061	C0010055
CABG	T061	C0010055
alone	T081	C0205171
mortality rate	T081	C0026565
major	T080	C0205164
adverse cerebral	T033	C0243095
cardiac events	T033	C1556247
evaluated	T058	C0220825
time period	T079	C1948053
follow-up	T058	C1522577
stratified	T080	C0205363
patient	T101	C0030705
population	T098	C1257890
patients	T101	C0030705
responders	T033	C0919876
non-responders	T033	C0919875
analysis	T062	C0936012
relevant	T080	C2347946
predictors	T078	C2698872
good response	T033	C0184785
CD133+ bone marrow mononuclear stem cell	T025	C1511246
treatment	T061	C0087111
performed	T169	C0884358
Several	T081	C0443302
stem cells transplantation	T061	C1504389
no significant	T033	C0243095
difference	T080	C1705242
major	T080	C0205164
adverse cardiovascular	T033	C0243095
cerebral events	T033	C0243095
observed	T169	C1441672
stem cell	T025	C0038250
control group	T096	C0009932
follow-up	T058	C1522577
improvement	T077	C2986411
left ventricle ejection fraction	T201	C0428772
LVEF	T201	C0428772
stem cell	T025	C0038250
group	T078	C0441833
retained	T169	C0333118
contrast	T080	C1979874
CABG	T061	C0010055
only	T081	C0205171
group	T078	C0441833
LVEF	T201	C0428772
LVEF	T201	C0428772
left ventricle end diastolic diameter	T060	C0919652
predictors	T078	C2698872
functional	T169	C0205245
CD133+ cell	T025	C0007634
therapy	T061	C0302189
Participants	T098	C0679646
overt heart failure	T047	C0018801
benefit	T081	C0814225
most	T081	C0205393
CABG	T061	C0010055
combined	T080	C0205195
intramyocardial	T024	C0027061
injection	T061	C1533685
CD133+ bone marrow mononuclear cell	T025	C1511246
group	T078	C0441833
improvement	T077	C2986411
LVEF	T201	C0428772
stem cell	T025	C0038250
group	T078	C0441833
contrast	T080	C1979874
CABG	T061	C0010055
only	T081	C0205171
group	T078	C0441833
patients	T101	C0030705
improvement	T077	C2986411
LVEF	T201	C0428772
LVED	T060	C0919652
observed	T169	C1441672
increased	T081	C0205217
life expectancy	T102	C0023671
Effects	T080	C1280500
Environmental	T082	C0014406
Factors	T169	C1521761
Metallic	T197	C0025552
Electrodes	T074	C0013812
AC	T070	C0442830
Electrical Conduction	T081	C0013777
DNA Molecule	T114	C0012854
Deoxyribonucleic acid (DNA)	T114	C0012854
device	T073	C0699733
applications	T169	C4048755
electrodes	T074	C0013812
rechargeable batteries	T073	C0337088
biosensors	T075	C0600364
molecular electronics	T074	C0025080
medical	T074	C0025080
biomedical	T074	C0025080
applications	T169	C4048755
charge transport	T070	C0563548
DNA molecule	T114	C0012854
DNA	T114	C0012854
molecular	T080	C1521991
conducting	T070	C0457405
material	T167	C0520510
wire	T073	C1705105
semiconductor	T073	C0036623
insulator	T073	C3273359
DNA	T114	C0012854
electric charges	T070	C0563548
ions	T196	C0022023
dipoles	UnknownType	C0813981
charges	T070	C0563548
electric barrier(s)	T073	C3273359
metallic	T197	C0025552
electrodes	T074	C0013812
environmental	T082	C0014406
factors	T169	C1521761
EFs	T169	C1521761
measuring	T080	C0444706
measuring	T080	C0444706
electrical conductivity	T081	C0013777
λ-double helix (DNA) molecule	T114	C0012854
metallic	T197	C0025552
electrodes	T074	C0013812
strong	T080	C0442821
frequency	T079	C0439603
AC	T070	C0442830
complex	T080	C0439855
conductivity	T081	C0013777
electrical conduction	T067	C2747877
EFs	T169	C1521761
experimental	T062	C0681814
measured	T080	C0444706
experiment	T062	C0681814
electrical conductivity	T081	C0013777
DNA molecule	T114	C0012854
electrical conduction	T081	C0013777
ions	T196	C0022023
experiment	T062	C0681814
environmental	T082	C0014406
charges	T070	C0563548
DNA molecule	T114	C0012854
experiment	T062	C0681814
measure	T081	C0079809
electrical conductivity	T081	C0013777
EFs	T169	C1521761
electrical conductivity	T081	C0013777
DNA molecule	T114	C0012854
σ DNA	T114	C0012854
measurements	T169	C0242485
DNA	T114	C0012854
lengths	T081	C1444754
measurements	T169	C0242485
frequency (f)	T079	C0376249
temperature (T)	T081	C0039476
measured	T080	C0444706
conductivity	T081	C0013777
metal	T197	C0025552
high frequencies	T079	C0205212
σ DNA	T114	C0012854
conduction	T070	C0457405
EFs	T169	C1521761
σ DNA	T114	C0012854
low frequencies	T079	C0205213
measuring	T080	C0444706
electrical conductivity	T081	C0013777
lengths	T081	C1444754
electrical conduction	T067	C2747877
DNA molecule	T114	C0012854
EFs	T169	C1521761
molecule	T114	C0012854
σ DNA	T114	C0012854
dielectric constant	UnknownType	C0813980
ε'DNA	T114	C0012854
electrical conduction	T067	C2747877
DNA molecule	T114	C0012854
DNA	T114	C0012854
semiconductor	T073	C0036623
charges	T070	C0563548
dipoles	UnknownType	C0813981
ions	T196	C0022023
localized	T169	C0475264
energy	T081	C1442080
states	T169	C1442792
energy gap	T070	C0013790
DNA molecule	T114	C0012854
charge transfer mechanism	T070	C1254365
DNA	T114	C0012854
charge transfer	T070	C1254365
DNA	T114	C0012854
insulating	T070	C0457405
semiconducting	T070	C0457405
metallic	T197	C0025552
charges	T070	C0563548
DNA	T114	C0012854
electric field	T070	C0337037
potential wells/hills	T082	C1254362
Localization	T169	C0475264
charges	T070	C0563548
DNA	T114	C0012854
intrinsic	T169	C0439674
structural	T082	C0678594
property	T080	C0871161
thermal	T070	C0018837
induced	T169	C0205263
charge	T070	C0563548
delocalization of holes	T070	C1254365
electrons	T196	C0013852
potential hills	T082	C1254362
potential wells)	T082	C1254362
electric	T081	C0392762
dielectric behavior	T081	C0596437
DNA molecule	T114	C0012854
experiment	T062	C0681814
potential hills/wells	T082	C1254362
energy	T081	C1442080
Next-Generation Sequencing	T063	C2936622
Approaches	T169	C1292724
Role	T077	C1705810
Autophagy Lysosomal Pathway	T043	C0007613
Human	T016	C0086418
Disease	T047	C0012634
Example	T077	C1707959
LysoPlex	T170	C0442711
Next-Generation Sequencing (NGS) technologies	T063	C2936622
throughput	T081	C2986816
genetic testing	T059	C0679560
DNA fragments	UnknownType	C0684192
parallel	T080	C0205556
application	T169	C0205245
genetically	T169	C0314603
heterogeneous	T033	C1858576
complex diseases	T047	C0012634
genes	T028	C0017337
control	T080	C0243148
pathways	T044	C1704259
disorders	T047	C0012634
traditional	T169	C0443324
approaches	T169	C1292724
gene-by-gene Sanger sequencing	T063	C1511897
NGS	T063	C2936622
protocol	T170	C0442711
selection	T052	C1707391
DNA regions	T114	C0012854
genes	T028	C0017337
autophagy-lysosomal (ALP) pathway	T043	C0007613
technical steps	T077	C1261552
challenges	T058	C0805586
protocol	T170	C0442711
LysoPlex	T170	C0442711
high-coverage sequencing	UnknownType	C0687728
ALP genes	T028	C0017337
LysoPlex	T170	C0442711
NGS	T063	C2936622
applications	T169	C0205245
sensitivity and specificity	T081	C0036668
variations	T070	C0042333
ALP genes	T028	C0017337
Skin Injuries	T037	C0281980
Children	T100	C0008059
Autism Spectrum Disorder	T048	C1510586
Pediatric	T080	C1521725
skin injuries	T037	C0281980
developing children	T100	C0008059
objectives	T170	C0018017
prevalence	T081	C0683921
pattern	T082	C0449774
skin injuries	T037	C0281980
children	T100	C0008059
autism spectrum disorder	T048	C1510586
ASD	T048	C1510586
skin injury	T037	C0281980
locations	T033	C0552513
developing children	T100	C0008059
differences	T080	C1705242
skin injury	T037	C0281980
frequency	T079	C0439603
locations	T033	C0552513
autistic children	T101	C0175842
self-injurious behaviors	T055	C0085271
SIBs	T055	C0085271
Children	T100	C0008059
ASD	T048	C1510586
September	T079	C3828193
September	T079	C3828193
Demographic information	T078	C0011292
caregiver	T097	C0085537
skin injuries	T037	C0281980
locations	T033	C0552513
documented	T058	C1301725
children	T100	C0008059
SIBs	T055	C0085271
skin injury	T037	C0281980
locations	T033	C0552513
legs	T023	C1140621
knees	T023	C0022742
back	T029	C0004600
Children	T100	C0008059
autism	T048	C0004352
skin injuries	T037	C0281980
locations	T033	C0552513
developing children	T100	C0008059
skin injuries	T037	C0281980
locations	T033	C0552513
accidental injuries	T037	C0151736
SIBs	T055	C0085271
Total Elbow Arthroplasty	T061	C0186781
Safe	T068	C0036043
Outpatient Procedure	T061	C1299353
Ambulatory surgery centers	T073	C1321139
preferred setting	T073	C0815184
procedures	T169	C2700391
performed	T169	C0884358
hospital	T073	C0019994
setting	T073	C0815184
study	T062	C2603343
outpatient	T101	C0029921
total elbow arthroplasty	T061	C0186781
TEA	T061	C0186781
safe	T068	C0036043
inpatient	T101	C0021562
TEA	T061	C0186781
retrospective analysis	T062	C0035363
performed	T169	C0884358
inpatient	T101	C0021562
IP	T101	C0021562
outpatient	T101	C0029921
OP	T101	C0029921
TEA	T061	C0186781
single	T081	C0205171
surgeon	T097	C0582175
years	T079	C0439234
Demographic	T062	C0011289
social	T080	C0699806
comorbidity measures	T081	C1516737
complication	T046	C0009566
rates	T081	C1521828
analyzed	T062	C0936012
stratified	T080	C0205363
IP	T101	C0021562
OP	T101	C0029921
status	T080	C0449438
Bivariate comparison	UnknownType	C0681927
increased	T081	C0205217
prevalence	T081	C0033105
coronary artery disease	T047	C1956346
OP	T101	C0029921
group	T098	C1257890
increased	T081	C0205217
age	T032	C0001779
IP	T101	C0021562
group	T098	C1257890
years	T079	C0439234
years	T079	C0439234
demographic	T062	C0011289
social	T080	C0699806
comorbidity factors	T081	C1516737
comparable	T052	C1707455
IP	T101	C0021562
OP	T101	C0029921
groups	T098	C1257890
more	T081	C0205172
infections	T046	C3714514
seen	T080	C0205397
IP	T101	C0021562
group	T098	C1257890
surgeons'	T097	C0582175
initial learning curve	T041	C2936637
occurred	T052	C1709305
IP	T101	C0021562
group	T098	C1257890
no difference	T033	C3842396
complication	T046	C0009566
rate	T081	C1521828
observed	T169	C1441672
IP	T101	C0021562
OP	T101	C0029921
groups	T098	C1257890
Developmental	T080	C0458003
Hypoxia	T046	C0242184
Negligible	T080	C0332269
Effects	T080	C1280500
Long-Term	T079	C0443252
Hypoxia	T046	C0242184
Tolerance	T080	C1704410
Aerobic Metabolism	T043	C0282636
Atlantic Salmon	T013	C0327949
Salmo salar	T013	C0327949
Exposure to	T080	C0332157
developmental	T080	C0458003
hypoxia	T046	C0242184
long-term	T079	C0443252
impacts	T080	C4049986
physiological	T039	C0031845
performance	T052	C1882330
fish	T013	C0016163
irreversible	T169	C0205245
plasticity	T070	C0678558
Wild	T170	C0445392
captive-reared	T033	C0243095
Atlantic salmon	T013	C0327949
Salmo salar	T013	C0327949
exposed to	T080	C0332157
hypoxic	T046	C0242184
conditions	T080	C0348080
development	T169	C1527148
continue	T078	C0549178
fluctuating	T079	C0231241
oxygen	T121	C0030054
levels	T080	C0441889
juveniles	T100	C3146221
adults	T100	C0001675
examine	T033	C0332128
developmental	T080	C0458003
hypoxia	T046	C0242184
impacts	T080	C4049986
subsequent	T079	C0332282
hypoxia	T046	C0242184
tolerance	T080	C1704410
aerobic	T080	C1510824
performance	T052	C1882330
Atlantic salmon	T013	C0327949
Individuals	T013	C0016163
exposed to	T080	C0332157
hypoxia	T046	C0242184
normoxia	T070	C0311411
dissolved oxygen (DO) saturation	T044	C0369768
air saturation	T070	C0522534
fertilization	T040	C3826354
raised	T080	C0442818
normoxic	T070	C0311411
conditions	T080	C0348080
fertilization	T040	C3826354
aerobic	T080	C1510824
scope	T077	C1710028
calculated	T052	C1441506
normoxia	T070	C0311411
DO	T121	C0030054
acute	T079	C0205178
hypoxia	T046	C0242184
DO	T121	C0030054
difference	T080	C1705242
minimum	T080	C1524031
maximum	T081	C0806909
oxygen consumption	T201	C0030055
rates	T081	C1521828
Hypoxia	T046	C0242184
tolerance	T080	C1704410
determined	T080	C0521095
DO	T121	C0030054
loss of equilibrium	T184	C0278126
LOE	T184	C0278126
occurred	T052	C1709305
decreasing	T033	C0442797
DO	T121	C0030054
no difference	T033	C3842396
aerobic	T080	C1510824
scope	T077	C1710028
fish	T013	C0016163
raised	T080	C0442818
hypoxia	T046	C0242184
normoxia	T070	C0311411
evidence	T078	C3887511
hypoxia	T046	C0242184
tolerance	T080	C1704410
lower	T052	C2003888
DO	T121	C0030054
LOE	T184	C0278126
hypoxia	T046	C0242184
raised	T080	C0442818
fish	T013	C0016163
raised	T080	C0442818
normoxia	T070	C0311411
magnitude	T081	C1704240
effect	T080	C1280500
small	T081	C0700321
DO	T121	C0030054
DO	T121	C0030054
LOE	T184	C0278126
Acute	T079	C0205178
hypoxia	T046	C0242184
reduced	T080	C0392756
aerobic	T080	C1510824
scope	T077	C1710028
reducing	T080	C0392756
unchanged	T033	C0442739
acute	T079	C0205178
hypoxia	T046	C0242184
individual	T013	C0016163
relationships	T080	C0439849
DO	T121	C0030054
LOE	T184	C0278126
aerobic	T080	C1510824
scope	T077	C1710028
findings	T169	C2607943
developmental	T080	C0458003
aerobic	T080	C1510824
performance	T052	C1882330
hypoxia	T046	C0242184
tolerance	T080	C1704410
LDL	T109	C0023823
particle number	T081	C0392762
size	T081	C0030608
cardiovascular	T029	C3887460
risk	T078	C0035647
potential	T080	C3245505
use	T169	C0457083
LDL	T109	C0023823
particle number	T081	C0392762
size	T081	C0030608
risk factors	T033	C0035648
cardiovascular disease	T047	C0007222
CVD	T047	C0007222
risk	T078	C0035647
clinical	T080	C0205210
Studies	T062	C0008972
significant	T078	C0750502
proportion	T081	C1709707
population	T098	C1257890
discordant	T077	C3639994
LDL	T109	C0023823
particle number	T081	C0392762
cholesterol	T109	C0008377
indices	T170	C0918012
non-HDL cholesterol	T109	C0729627
HDL-C	T109	C0023822
information	T078	C1533716
LDL	T109	C0023823
particle number	T081	C0392762
patients	T101	C0030705
discordant	T077	C3639994
particle number	T081	C0392762
cholesterol	T109	C0008377
CVD	T047	C0007222
guidelines	T170	C0282451
LDL	T109	C0023823
particle number	T081	C0392762
cholesterol	T109	C0008377
indices	T170	C0918012
non-HDL-C	T109	C0729627
concentrations	T081	C1446561
CVD	T047	C0007222
risk	T078	C0035647
LDL	T109	C0023823
particle size	T081	C0030608
associated with	T080	C0332281
CVD	T047	C0007222
risk	T078	C0035647
adjustment	T169	C0456081
risk factors	T033	C0035648
LDL cholesterol	T109	C0023824
triglycerides	T109	C0041004
HDL-C	T109	C0023822
information	T078	C1533716
particle size	T081	C0030608
patients'	T101	C0030705
risk	T078	C0035647
Additional	T169	C1524062
studies	T062	C0008972
debate	T052	C0870392
cholesterol	T109	C0008377
indices	T170	C0918012
LDL	T109	C0023823
particle number	T081	C0392762
CVD	T047	C0007222
risk	T078	C0035647
measures	T081	C0079809
clinical practice	T061	C0087111
emerging contribution	T052	C1880177
social wasps	T204	C0043041
grape rot disease	T047	C0032080
ecology	T090	C0013546
Grape sour (bunch) rot	T047	C0032080
polymicrobial disease	T047	C0598196
vineyards	T083	C4279988
millions	T081	C1881839
dollars	T081	C0562019
lost revenue	T081	C0681042
per year	T079	C0439508
decreased	T081	C0205216
quality	T080	C0332306
grapes	T168	C0018208
resultant wine	T168	C0043188
disease	T047	C0012634
associated with	T080	C0332281
damaged	T169	C1883709
berries	T168	C0005135
infected	T033	C0439663
community	T096	C0009462
acetic acid bacteria	T007	C0018150
yeasts	T004	C0043393
filamentous fungi	T004	C0369241
rotting	T067	C2700592
berries	T168	C0005135
high	T080	C0205250
amounts	T081	C1265611
volatile	T080	C1963547
acidity	T103	C0001128
insect	T204	C0021585
species	T185	C1705920
initial	T079	C0205265
grape	T168	C0018208
berry	T168	C0005135
damage	T169	C1883709
disease	T047	C0012634
studies	T062	C0681814
focused	T169	C1285542
role	T077	C1705810
fruit flies	T204	C0013138
symptoms	T184	C1457887
vectoring	T204	C0021573
microorganisms	T001	C0445623
disease	T047	C0012634
complex	T080	C0439855
fruit flies	T204	C0013138
social wasps	T204	C0043041
abundant	T080	C2346714
vineyards	T083	C4279988
ripe berries	T168	C0005135
significant	T078	C0750502
damage	T169	C1883709
dispersing	T082	C0332624
yeasts	T004	C0043393
involved	T169	C1314939
wine	T168	C0043188
fermentation	T044	C0015852
role	T077	C1705810
disease	T047	C0012634
dispersal of grape rots	T047	C0012634
tested	T169	C0039593
hypothesis	T078	C1512571
paper wasp	T204	C0446349
Polistes dominulus	T129	C1005260
grape sour rot	T047	C0012634
absence	T169	C0332197
insect vectors	T204	C0021573
marker gene sequencing	T059	C1294197
characterized	T052	C1880022
bacterial	T007	C0004611
fungal	T004	C0016832
community	T096	C0009462
wild-caught adults	T100	C0001675
foraging arena	T082	C0205146
wasps	T204	C0043041
viable	T080	C0443348
microorganisms	T001	C0445623
foraging	T055	C2752984
tested	T169	C0039593
wasps	T204	C0043041
native	T098	C0079891
microbial	T001	C0599840
community	T096	C0009462
inoculated	T061	C2987620
sour rot	T047	C0012634
effect	T080	C1280500
grape sour rot	T047	C0012634
incidence	T081	C0021149
severity	T080	C0439793
laboratory foraging arena	T083	C0017446
wasps	T204	C0043041
sour rot	T047	C0012634
microbial	T001	C0599840
community	T096	C0009462
ability	T032	C0085732
viable	T080	C0443348
microorganisms	T001	C0445623
foraging	T055	C2752984
Foraging	T055	C2752984
inoculated	T061	C2987620
uninoculated wasps	T204	C0043041
increase	T169	C0442805
berry rot disease	T047	C0032080
symptom	T184	C1457887
severity	T080	C0439793
incidence	T081	C0021149
results	T033	C0459422
paper wasps	T204	C0446349
sour rot diseases	T047	C0032080
absence	T169	C0332197
other vectors	T204	C0021573
mechanism	T169	C0441712
increasing	T169	C0442808
host	T001	C1167395
susceptibility	T201	C0012655
transmitting	T169	C0332289
microbial	T001	C0599840
communities	T096	C0009462
grapes	T168	C0018208
Social wasps	T204	C0043041
relevant players	T080	C2347946
sour rot	T047	C0012634
ecology	T090	C0013546
vineyards	T083	C4279988
Low-intensity pulsed ultrasound	T070	C4042796
periodontal atrophy	T047	C2350270
occlusal	T042	C0011382
hypofunctional	T046	C0679221
teeth	T023	C0040426
low-intensity pulsed ultrasound	T070	C4042796
LIPUS	T070	C4042796
hypofunctional	T046	C0679221
periodontal ligament	T023	C0031093
PDL	T023	C0031093
interradicular alveolar bone	T023	C0932533
IRAB	T023	C0932533
week	T079	C0439230
male	T032	C0086582
Sprague-Dawley rats	T015	C0034715
groups	T098	C1257890
normal occlusion	T042	C0011382
group	T098	C1257890
occlusal	T042	C0011382
hypofunction	T046	C0679221
group	T098	C1257890
occlusal hypofunction group	T098	C1257890
LIPUS	T070	C4042796
treatment	T061	C0087111
Hypofunctional	T046	C0679221
occlusion	T042	C0011382
maxillary first molar	T023	C4082817
M1	T023	C4082817
H	T098	C1257890
HL groups	T098	C1257890
bite-raising technique	T058	C0376583
HL group	T098	C1257890
LIPUS	T070	C4042796
days	T079	C0439228
IRAB	T023	C0932533
PDL	T023	C0031093
M1	T023	C4082817
microcomputed tomography	T060	C2350281
micro-CT	T060	C2350281
analysis	T062	C0936012
mRNA	T114	C0035696
expression	T045	C1171362
cytokines	T116	C0079189
PDL	T023	C0031093
proliferation	T169	C1514485
development	T169	C1527148
real-time reverse transcription quantitative PCR	T063	C0599161
qRT-PCR	T063	C0599161
twist family bHLH transcription factor 1	T028	C1421244
Twist1	T028	C1421244
periostin	T028	C1424662
connective tissue growth factor	T028	C1413791
CTGF	T028	C1413791
PDL	T023	C0031093
samples	T167	C0370003
Micro-CT	T060	C2350281
analysis	T062	C0936012
PDL	T023	C0031093
volume	T081	C0449468
H group	T098	C1257890
C	T098	C1257890
HL groups	T098	C1257890
bone volume	T032	C1317149
tissue volume	T081	C0449468
BV	T032	C1317149
TV	T081	C0449468
IRAB	T023	C0932533
H group	T098	C1257890
C group	T098	C1257890
LIPUS	T070	C4042796
BV	T032	C1317149
TV	T081	C0449468
IRAB	T023	C0932533
HL group	T098	C1257890
qRT-PCR	T063	C0599161
analysis	T062	C0936012
Twist1	T028	C1421244
periostin	T028	C1424662
CTGF	T028	C1413791
mRNA	T114	C0035696
levels	T080	C0441889
H group	T098	C1257890
HL group	T098	C1257890
LIPUS	T070	C4042796
atrophic	T046	C0333641
changes	T169	C0392747
alveolar bone	T023	C0932533
inducing	T169	C0205263
upregulation	T044	C0041904
periostin	T028	C1424662
CTGF	T028	C1413791
expression	T045	C1171362
PDL	T023	C0031093
healing	T040	C0043240
induction	T061	C0857127
occlusal	T042	C0011382
hypofunction	T046	C0679221
Radiologic assessment	T060	C0043299
root canal fillings	T061	C0035848
periapical status	T082	C0729269
Austrian	T098	C0337795
subpopulation	T098	C1257890
observational study	T062	C1518527
Progress	T169	C1280477
endodontic techniques	T061	C0700632
root canal therapy	T061	C0035849
periodical	T170	C0031082
documentation	T170	C0920316
observational study	T062	C1518527
prevalence	T081	C0220900
endodontic treatments,	T061	C0700632
investigated	T169	C1292732
periapical status	T082	C0729269
Austrian	T098	C0337795
subpopulation	T098	C1257890
orthopantomograms	T060	C0034579
university	T073	C0020028
patients	T101	C0030705
radiographed	T060	C1306645
outpatient clinic	T073	C0029916
evaluated	T058	C0220825
tooth	T023	C0040426
presence	T033	C0150312
periradicular pathosis	T047	C0031028
endodontic treatment	T061	C0700632
endodontic treatment	T061	C0700632
homogeneity	T080	C1881065
root canal fillings	T061	C0035848
preparation failures	T033	C2938896
posts	T074	C0183062
screws	T074	C0301559
apicoectomies	T061	C0003571
coronal restorations	T061	C0204297
evaluators	T097	C1707957
blinded	T062	C0150108
scored	T081	C0449820
teeth	T023	C0040426
score	T081	C0449820
teeth were counted	T081	C0449772
teeth	T023	C0040426
periapical pathosis	T047	C0031028
teeth	T023	C0040426
root canal treatment	T061	C0035849
endodontically treated teeth	T047	C0376699
radiographic	T070	C0444708
apical periodontitis	T047	C4082298
apical lesions	T047	C1402310
widened periodontal ligament space	T047	C1290664
root canal fillings	T061	C0035848
presence	T033	C0150312
apical	T023	C0524789
pathosis	T047	C0012634
significantly correlated	T080	C1707520
odds ratio	T081	C0028873
OR	T081	C0028873
confidence interval	T081	C0009667
CI	T081	C0009667
root canal fillings	T061	C0035848
homogeneity	T080	C1881065
Posts	T074	C0183062
screws	T074	C0301559
periapical status	T082	C0729269
OR	T081	C0028873
endodontically treated posterior teeth	T047	C0376699
restored	T061	C0565067
posts	T074	C0183062
screws	T074	C0301559
teeth	T023	C0040426
endodontic treatment	T061	C0700632
coronal restoration	T061	C0204297
high prevalence	T081	C1512456
periradicular radiolucencies	T033	C1852169
root canal filled teeth	T023	C0040426
treatment	T061	C0087111
Periapical	T082	C0729269
health	T078	C0018684
associated with	T080	C0332281
root canal obturation	T061	C0035848
postendodontic restorations	T061	C2368673
periapical	T082	C0729269
health	T078	C0018684
Chemical composition	T070	C0243176
amino acid	T116	C0002520
digestibility	T081	C0392762
soybean meal	T168	C0037733
United States	T083	C0041703
China	T083	C0008115
Argentina	T083	C0003761
Brazil	T083	C0006137
India	T083	C0021201
nutritional	T080	C1521739
composition	T070	C0243176
soybean meal	T168	C0037733
SBM	T168	C0037733
China	T083	C0008115
Argentina	T083	C0003761
Brazil	T083	C0006137
U.S	T083	C0041703
India	T083	C0021201
apparent ileal digestibility	T081	C0392762
AID	T081	C0392762
standardized ileal digestibility	T081	C0392762
SID	T081	C0392762
CP	T116	C0033684
AA	T116	C0002520
SBM	T168	C0037733
pigs	T015	C0039005
SBM	T168	C0037733
China	T083	C0008115
Argentina	T083	C0003761
Brazil	T083	C0006137
U.S	T083	C0041703
India	T083	C0021201
SBM	T168	C0037733
energy	T081	C1442080
DM	T167	C1720884
nutrients	T168	C0678695
cornstarch based diet	T109	C1384515
SBM	T168	C0037733
AA	T116	C0002520
ingredient	T120	C1550600
N-free diet	T168	C0012155
distal ileum	T029	C0227327
Youden square design	T062	C0035171
diets	T168	C0012155
periods	T079	C1948053
concentration	T081	C0457929
CP	T116	C0033684
SBM	T168	C0037733
Brazil	T083	C0006137
India	T083	C0021201
SBM	T168	C0037733
China	T083	C0008115
Argentina	T083	C0003761
U.S	T083	C0041703
concentration	T081	C0457929
AA	T116	C0002520
CP	T116	C0033684
SBM	T168	C0037733
U.S	T083	C0041703
AA	T116	C0002520
SBM	T168	C0037733
China	T083	C0008115
Argentina	T083	C0003761
SBM	T168	C0037733
India	T083	C0021201
trypsin inhibitors	T116	C0041242
SBM	T168	C0037733
countries	T083	C0454664
AID	T081	C0392762
SID	T081	C0392762
CP	T116	C0033684
AA	T116	C0002520
SBM	T168	C0037733
U.S	T083	C0041703
SBM	T168	C0037733
Brazil	T083	C0006137
Argentina	T083	C0003761
India	T083	C0021201
SBM	T168	C0037733
U.S	T083	C0041703
SBM	T168	C0037733
China	T083	C0008115
concentration	T081	C0457929
AA	T116	C0002520
SBM	T168	C0037733
China	T083	C0008115
concentration	T081	C0457929
standardized ileal digestible	T081	C0392762
AA	T116	C0002520
SBM	T168	C0037733
China	T083	C0008115
SBM	T168	C0037733
U.S	T083	C0041703
U.S	T083	C0041703
Brazil	T083	C0006137
SID	T081	C0392762
SBM	T168	C0037733
Argentina	T083	C0003761
China	T083	C0008115
India	T083	C0021201
SID	T081	C0392762
CP	T116	C0033684
AA	T116	C0002520
country	T083	C0454664
SBM	T168	C0037733
country	T083	C0454664
formulating diets	T061	C0012164
pigs	T015	C0039005
Developing	T169	C1527148
understanding	T041	C0162340
object	T072	C0347997
fall	T033	C0085639
inhibitory	T052	C3463820
processes	T067	C1522240
study	T062	C2603343
reported	T170	C0684224
participants	T098	C0679646
aged	T032	C0001779
early	T079	C1279919
trajectories	T079	C0750729
expected	T170	C1517001
objects	T072	C0347997
follow	T169	C4281991
fell	T033	C0085639
younger	T079	C0332239
participants	T098	C0679646
typically	T080	C3538928
anticipated	T033	C3840775
backward	T082	C0439781
trajectories	T079	C0750729
fall	T033	C0085639
moving	T040	C0560560
carriers	T073	C3888060
forward	T082	C0439780
non-parabolic trajectories	T079	C0750729
relatively	T080	C0205345
more	T081	C0205172
frequent	T079	C0332183
older participants	T098	C0001792
patterns	T082	C0449774
suggest	T078	C1705535
strong	T080	C0442821
sociocultural	UnknownType	C0680352
influences	T077	C4054723
implications	T078	C3146298
models	T170	C3161035
development	T169	C1527148
area	T078	C0178566
purely	T080	C2963144
inhibition	T052	C3463820
principles	UnknownType	C0678989
established	T080	C0443211
infancy	T079	C0231330
Statement	T078	C1710187
contribution	T052	C1880177
known	T080	C0205309
subject	T096	C0681850
Research	T062	C0035168
infants	T100	C0021270
demonstrates	T080	C0443289
early	T079	C1279919
established	T080	C0443211
belief	T078	C0004951
dropped	T052	C1705648
objects	T072	C0347997
fall	T033	C0085639
straight	T082	C0445291
down	T082	C0205104
erroneous	T078	C1547323
expectations	T078	C0679138
pre-schoolers	T100	C0008100
hold	T052	C1948035
object	T072	C0347997
fall	T033	C0085639
consistent with	T078	C0332290
failure	T055	C0680095
inhibit	T052	C3463820
presumption	T078	C1254370
straight	T082	C0445291
down	T082	C0205104
fall	T033	C0085639
contexts	T078	C0449255
inappropriate	T080	C1548788
study	T062	C2603343
research	T062	C0035168
replicates	T169	C0205173
extends	T169	C0231448
research	T062	C0035168
older participants	T098	C0001792
indicates	T078	C3146298
errors	T080	C0743559
explained	T058	C3526595
failed	T169	C0231175
inhibition	T052	C3463820
straight	T082	C0445291
down	T082	C0205104
fall	T033	C0085639
study	T062	C2603343
patterns	T082	C0449774
errors	T080	C0743559
late	T079	C0205087
childhood	T079	C0231335
adolescence	T079	C0001578
early	T079	C1279919
adulthood	T079	C0700597
consequence of	T169	C0686907
findings	T033	C0243095
adequate	T080	C0205411
modelling	T077	C3714583
developmental psychology	T091	C1511810
consider	T078	C0750591
multilayered	T077	C1254372
interactions	T169	C1704675
prior	T079	C0332152
representations	T052	C1882932
sociocultural	UnknownType	C0680352
experiences	T041	C0596545
Attenuation	T052	C0599946
High Glucose	T109	C0017725
Induced	T169	C0205263
Rat	T015	C0034693
Cardiomyocyte	T025	C0225828
Apoptosis	T043	C0162638
Exendin-4	T116	C0167117
Intervention	T061	C0184661
HO-1	T116	C0538674
Nrf-2	T116	C0289507
PI3K/AKT Signaling Pathway	T169	C2984369
Exendin-4	T116	C0167117
glucagon-like peptide-1 receptor agonist	T121	C2917359
cytoprotective actions	T039	C0524828
glycemic control	T033	C0522082
aims	T078	C1947946
study	T062	C2603343
investigate	T169	C1292732
effects of	T080	C1704420
exendin-4	T116	C0167117
high glucose	T109	C0017725
HG	T109	C0017725
induced	T169	C0205263
cardiomyocyte	T025	C0225828
apoptosis	T043	C0162638
mechanisms	T169	C0441712
Rat	T015	C0034693
cardiomyocytes	T025	C0225828
groups	UnknownType	C0681860
normal glucose	T109	C0017725
group	UnknownType	C0681860
NG	T109	C0017725
group	UnknownType	C0681860
HG	T109	C0017725
group	UnknownType	C0681860
HG	T109	C0017725
exendin-4	T116	C0167117
group	UnknownType	C0681860
HG	T109	C0017725
Ex	T116	C0167117
Group	UnknownType	C0681860
Cardiomyocyte	T025	C0225828
apoptosis	T043	C0162638
double-staining	T059	C0022885
annexin V-fluorescein isothiocyanate	T109	C0085216
FITC	T109	C0085216
propidium iodide	T109	C0033470
PI	T109	C0033470
flow cytometry	T059	C0016263
Intracellular	T082	C0178719
reactive oxygen species (ROS)	T123	C1537052
production	T169	C0542341
detected	T033	C0442726
2’,7’-dichlorodihydrofluorescein diacetate	T109	C0670829
DCHF-DA	T109	C0670829
incubation	T059	C1439852
fluorescence microscopy	T059	C0026022
LY294002	T109	C0251991
LY	T109	C0251991
phosphoinositide 3-kinase	T116	C0044602
PI3K	T116	C0044602
pathway	T044	C1704259
inhibitor	T080	C1999216
medium	T130	C0010454
HG	T109	C0017725
Ex	T116	C0167117
LY	T109	C0251991
Group	UnknownType	C0681860
western blot analysis	T059	C0949466
proteins	T116	C0033684
analyzed	T062	C0936012
oxidative stress	T049	C0242606
associated proteins	T116	C0033684
heme oxygenase-1	T116	C0538674
HO-1	T116	C0538674
nuclear factor E2-related factor 2	T116	C0289507
Nrf-2	T116	C0289507
apoptosis	T043	C0162638
associated proteins	T116	C0033684
caspase-3	T116	C0291573
Bax/B-cell lymphoma 2	T116	C0219474
Bcl-2	T116	C0219474
p-AKT	T116	C0164786
AKT	T116	C0164786
HG	T109	C0017725
treatment	T169	C1522326
induced	T169	C0205263
cardiomyocyte	T025	C0225828
apoptosis	T043	C0162638
upregulated	T044	C0041904
ROS	T123	C0162772
production	T169	C0542341
exendin-4	T116	C0167117
co-incubation	T059	C1439852
cardiomyocyte	T025	C0225828
apoptosis	T043	C0162638
decreased	T081	C0205216
ROS	T123	C0162772
level	T080	C0441889
significantly	T078	C0750502
HO-1	T116	C0538674
Nrf-2	T116	C0289507
protein expression	T045	C1171362
levels	T080	C0441889
decreased	T081	C0205216
significantly	T078	C0750502
HG	T109	C0017725
group	UnknownType	C0681860
levels	T080	C0441889
elevated	T080	C3163633
exendin-4	T116	C0167117
intervention	T061	C0184661
exendin-4	T116	C0167117
attenuated	T052	C0599946
HG	T109	C0017725
induced	T169	C0205263
protein expression	T045	C1171362
caspase-3	T116	C0291573
Bax	T116	C0219474
increased	T081	C0205217
expression	T045	C1171362
Bcl-2 protein	T116	C4042483
impacts	T080	C4049986
exendin-4	T116	C0167117
significantly	T078	C0750502
co-incubation	T059	C1439852
LY294002	T109	C0251991
exendin-4	T116	C0167117
HG	T109	C0017725
induced	T169	C0205263
p-AKT	T116	C0164786
AKT	T116	C0164786
lower expression	T045	C1171362
impact	T080	C4049986
suppressed	T169	C1260953
LY294002	T109	C0251991
Exendin-4	T116	C0167117
HG	T109	C0017725
induced	T169	C0205263
cardiomyocyte	T025	C0225828
apoptosis	T043	C0162638
mechanisms	T169	C0441712
anti-oxidative stress	T044	C1148560
HO-1	T116	C0538674
Nrf-2	T116	C0289507
intervention	T061	C0184661
PI3K/AKT signaling pathway	T169	C2984369
KMAP-O framework	T058	C0679897
care management	T058	C2735310
research	T062	C0035168
patients	T101	C0030705
type 2 diabetes	T047	C0011860
review	T080	C1704362
impacts	T080	C4049986
interventions	T058	C1273869
self-management education	T058	C3698325
health coaching	T065	C4255176
motivational interviewing	T061	C0683474
type 2 diabetes	T047	C0011860
review	T078	C1552617
scientific literature	T170	C0023866
diabetes	T047	C0011847
care and management	T058	C2735310
research	T062	C0035168
team	T096	C0871489
article	T170	C1706852
findings	T169	C2607943
validity	T081	C2349101
developing	T169	C0205245
comprehensive	T080	C1880156
behavioral system	T078	C1254370
framework	T058	C0679897
empirical	T080	C1880496
investigation	T058	C0220825
behavioral system	T078	C1254370
framework	T058	C0679897
patients	T101	C0030705
knowledge	T033	C0518904
K	T033	C0518904
motivation	T041	C0026605
M	T041	C0026605
attitude	T041	C0004271
A	T041	C0004271
practice	T041	C0237607
P	T041	C0237607
predictor	T078	C2698872
variables	T080	C0439828
diabetes	T047	C0011847
care outcomes	T170	C0518889
O	T170	C0518889
Care management	T058	C2735310
health education programs	T058	C0679897
intervention	T058	C1273869
variable	T080	C0439828
influences	T077	C4054723
K	T033	C0518904
M	T041	C0026605
A	T041	C0004271
P	T041	C0237607
variability	T077	C2827666
patient	T101	C0030705
care outcomes	T170	C0518889
patients	T101	C0030705
type 2 diabetes	T047	C0011860
review	T170	C0282443
KMAP-O framework	T058	C0679897
guide	T170	C0681467
care management	T058	C2735310
patients	T101	C0030705
type 2 diabetes	T047	C0011860
interventions	T058	C1273869
knowledge	T033	C0518904
enhancement	T052	C2349975
increased motivation	T041	C0520939
attitudinal	T041	C0004271
changes	T169	C0392747
improved	T033	C0184511
preventive practice	T058	C1516623
reduce	T080	C0392756
progression	T046	C0242656
type 2 diabetes	T047	C0011860
comorbidities	T078	C0009488
use of	T169	C1524063
health information technology	T066	C2936756
enhancing	T052	C2349975
changes	T169	C0392747
KMAP	T058	C0679897
communications	T054	C0009452
health promotion	T058	C0018738
development	T169	C1527148
Bayesian	T081	C0242196
Phylogenic Approaches	T062	C1519068
Relationships	T080	C0439849
Table Olive Cultivars	T002	C0996956
table olive tree	T002	C0996956
authentication	T080	C0205556
relationship	T080	C0439849
productivity	T081	C0033269
analysis	T062	C0936012
table olive cultivars	T002	C0996956
Olea europaea L.	T002	C0996956
morphological	T080	C0332437
biological	T080	C0205460
physicochemical markers	T045	C0017393
bioinformatic	T170	C0037589
biostatistic tools	T170	C0037589
relationships	T080	C0439849
varieties	T080	C0205419
productivity	T081	C0033269
quantitative	T081	C0392762
parameter	T077	C0549193
bioinformatic	T170	C0037589
analysis	T062	C0936012
graphical representation	T170	C0870616
matrix of Euclidean distances	T062	C1880593
principal components analysis	T081	C0429865
unweighted pair group method	T062	C1881045
arithmetic mean	T081	C0444504
principal coordinate analysis	T062	C0936012
PCoA	T062	C0936012
clusters	T081	C1704332
geographic	T082	C1517526
origin	T033	C0584985
statistical analysis	T062	C0871424
Spearman correlation coefficients	T081	C0242929
associations	T080	C0439849
fruit	T168	C0016767
color	T080	C0009393
pollinization	T040	C1522786
productivity	T081	C0033269
results	T169	C1274040
multiple linear regression prediction models	T081	C0023733
coefficient of determination	T081	C2827748
R (2)	T081	C2827748
model	T170	C3161035
power	T081	C3854080
pollinization	T040	C1522786
productivity	T081	C0033269
R (2)	T081	C2827748
directed acyclic graph	T170	C1706232
influences	T077	C4054723
detected	T033	C0442726
effect	T080	C1280500
tolerance	T080	C1704410
fruit	T168	C0016767
stone symmetry	T080	C0205556
effect	T080	C1280500
tolerance	T080	C1704410
stone form	T080	C0205556
oil	T109	C0028908
content	T077	C0456205
diversity	T080	C1880371
table olive cultivars	T002	C0996956
olive	T002	C0996956
breeding	T040	C0006159
authenticity	T080	C0205556
Wiedemann-Rautenstrauch Syndrome	T047	C0406586
Bilateral	T082	C0238767
Tarsal Kink	T019	C1303000
Sutures	T061	C0038968
Correction	T169	C1947976
month-old	T079	C0580836
male	T032	C0086582
infant	T100	C0021270
Wiedemann-Rautenstrauch syndrome	T047	C0406586
rare	T080	C0522498
condition	T047	C0012634
tarsal kink	T019	C1303000
upper eyelids	T023	C0585636
both eyes	T023	C0229118
treated	T169	C1522326
bilateral	T082	C0238767
tarsal kink	T019	C1303000
everting	T058	C0455231
suture	T061	C0038968
transconjunctival approach	T082	C0442347
local anesthesia	T061	C0002921
Indications	T078	C0392360
Laparoscopic Pancreatectomy	T061	C0030279
Laparoscopic pancreatectomy	T061	C0030279
routine procedure	T061	C1298805
Germany	T083	C0017480
countries	T083	C0454664
data	T078	C1511726
short- and long-term outcomes	T080	C0085415
working group	T098	C1883562
centers	T073	C0475309
centers	T073	C0475309
data	T078	C1511726
cases	T169	C0868928
laparoscopic pancreatectomy	T061	C0030279
Procedures	T061	C0087111
laparoscopy	T061	C1883297
open surgery	T061	C4283938
registry	T170	C0034975
data	T078	C1511726
cases	T169	C0868928
benign disease	T191	C0086692
malignancies	T191	C0006826
borderline tumors	T191	C0027651
procedure	T061	C0087111
laparoscopic left pancreatectomy	T061	C0030279
resection	T061	C0015252
head of the pancreas	T023	C0227579
tumor	T191	C0027651
enucleation	T061	C1283063
intraoperative complication	T046	C0021890
hemorrhage	T046	C0019080
rate	T081	C1521828
conversion	T169	C0439836
open surgery	T061	C4283938
minilaparotomies	T058	C0026168
conversion	T169	C0439836
rate	T081	C1521828
patients	T101	C0030705
pancreatic fistula	T047	C0030290
surgery	T061	C0543467
reoperation	T061	C0035110
postoperative hemorrhage	T046	C0032788
procedure-related mortality	T033	C0277599
patients	T101	C0030705
postoperative pain	T184	C0030201
diabetes mellitus	T047	C0011849
procedure	T061	C0087111
patient	T101	C0030705
cohort	T098	C0599755
registry	T170	C0034975
persons	T098	C0027361
laparoscopic pancreatectomy	T061	C0030279
hospital	T073	C0019994
teams	T096	C0871489
data	T078	C1511726
selection bias	T081	C0036577
operative procedures	T061	C0543467
laparoscopic pancreatectomy	T061	C0030279
Germany	T083	C0017480
complication	T046	C0009566
rates	T081	C1521828
open surgery	T061	C4283938
Selection bias	T081	C0036577
randomized trial	T062	C0206034
NEUROD2	T028	C1417684
polymorphisms	T045	C0678951
change	T169	C0392747
cognitive dysfunctions	T048	C0338656
schizophrenia	T048	C0036341
schizoaffective disorder	T048	C0036337
weeks	T079	C0439230
antipsychotic	T121	C0040615
treatment	T061	C0087111
NEUROD2	T028	C1417684
neurospecific helix-loop-helix	T082	C0206678
transcription factor	T116	C0040648
impact	T080	C4049986
regulation	T045	C0017263
glutamatergic	T116	C0220839
GABAergic	T116	C0016904
genes	T028	C0017337
investigated	T169	C1292732
NEUROD2	T028	C1417684
neurocognitive dysfunctions	T048	C0338656
schizophrenia	T048	C0036341
schizoaffective disorder	T048	C0036337
patients	T101	C0030705
treatment	T061	C0087111
second-generation antipsychotics	T121	C0040615
Patients	T101	C0030705
genotyped	T032	C0017431
polymorphisms	T045	C0678951
NEUROD2	T028	C1417684
gene	T028	C0017337
rs9889354(A/G	T045	C0678951
rs1877032(C/T)	T045	C0678951
rs12453682(C/T)	T045	C0678951
rs11078918(C/G)	T045	C0678951
Cognitive function	T041	C0392335
assessed	T052	C1516048
baseline	T081	C1442488
week	T079	C0439230
Results	T169	C1274040
neuropsychological tests	T060	C0027902
cognitive domains	T170	C4050130
(reaction time	T079	C0034746
quality	T080	C0332306
executive function	T041	C0935584
working	T078	C1563351
verbal	T041	C0561770
visual memory	T041	C0542316
cognitive	T169	C1516691
index	T170	C0918012
patients	T101	C0030705
study	T062	C2603343
NEUROD2	T028	C1417684
exonic polymorphism rs11078918	T045	C0678951
verbal memory	T041	C0561770
executive functions	T041	C0935584
NEUROD2	T028	C1417684
polymorphism rs12453682	T045	C0678951
working	T078	C1563351
verbal memory	T041	C0561770
executive functions	T041	C0935584
cognitive	T169	C1516691
index	T170	C0918012
baseline	T081	C1442488
weeks	T079	C0439230
change	T169	C0392747
neuropsychological test	T060	C0027902
results	T169	C1274040
antipsychotic	T121	C0040615
treatment	T061	C0087111
NEUROD2	T028	C1417684
polymorphisms	T045	C0678951
rs11078918	T045	C0678951
rs12453682	T045	C0678951
NEUROD2 gene	T028	C1417684
pathophysiology	T169	C0031847
neurocognitive dysfunctions	T048	C0338656
change	T169	C0392747
cognitive symptoms	T184	C0525041
antipsychotic	T121	C0040615
treatment	T061	C0087111
schizophrenia	T048	C0036341
schizoaffective disorder	T048	C0036337
New	T080	C0205314
Diterpenoids	T109	C0012780
Clerodendranthus spicatus	T002	C2311252
new	T080	C0205314
diterpenoids	T109	C0012780
neoorthosiphonones B	T109	C0012780
C	T109	C0012780
1	T109	C0012780
2	T109	C0012780
diterpenoid	T109	C0012780
isolated	T169	C0205409
aerial parts	T002	C1136056
Clerodendranthus spicatus	T002	C2311252
structures	T082	C0678594
absolute	T080	C0205344
configurations	T082	C0449830
determined by	T080	C0521095
spectroscopic analyses	T059	C0022885
X-ray crystallographic methods	T059	C0206755
compound	T080	C0205198
inhibit	T080	C0521111
fibronectin	T116	C0016055
production	T057	C0033268
concentration	T081	C1446561
Stalk	T017	C1947953
base	T017	C0700276
invasion	T033	C1269955
pT1	T033	C0332391
papillary cancers of the bladder	T191	C0699885
risk	T078	C0035647
progression	T046	C0242656
Pathologic stage T1	T033	C0332391
pT1	T033	C0332391
bladder cancers	T191	C0699885
clinically	T080	C0205210
heterogeneous group	T080	C0019409
staging	T185	C0178759
superficially	T082	C0205124
invasive cancers	T191	C0677898
variability	T077	C2827666
lamina propria invasion	T033	C1269980
papillary urothelial carcinomas	T191	C1368911
PUC	T191	C1368911
inter-observer variation	T081	C0021713
limited value	T169	C0439801
patient outcomes	T058	C0030698
reappraise	T058	C0184514
pT1	T033	C0332391
PUC	T191	C1368911
aiming	T078	C1947946
identify	T080	C0205396
novel	T080	C0205314
scheme	T170	C1519193
reproducible	T080	C1524057
prognostically	T170	C0220901
Stage pT1	T033	C0332391
PUC	T191	C1368911
diagnosed	T033	C0011900
years	T079	C0439234
retrospectively reviewed	T062	C0035363
characterized	T052	C1880022
focal	T082	C0205234
invasion	T046	C2699153
papillary stalk	T017	C1947953
focal	T082	C0205234
invasion	T033	C1269955
tumor	T191	C0027651
base	T017	C0700276
invasion	T033	C1269955
tumor	T191	C0027651
base	T017	C0700276
Cases	T169	C0868928
concurrent	T079	C0205420
flat carcinoma in-situ	T033	C1300924
angiolymphatic invasion	T033	C1708790
absent	T169	C0332197
muscularis propria	T024	C0225358
clinically	T080	C0205210
advanced disease	UnknownType	C0679246
excluded	T169	C0332196
cumulative	T080	C1511559
incidence	T081	C0021149
recurrence	T033	C0679254
progression	T046	C0242656
death	T040	C0011065
tumor subtype	T185	C1519691
evaluated	T058	C0220825
differential risks	T033	C0035648
log-rank tests	T170	C0237913
Kaplan-Meier curves	T081	C1720944
stratified	T080	C0205363
type	T080	C0332307
extent of invasion	T201	C1269793
patients	T101	C0030705
inclusion	T080	C1512693
criteria	T078	C0243161
patients	T101	C0030705
base	T017	C0700276
extensive	T080	C0205231
invasion	T033	C1269955
progressed	T169	C1280477
base	T017	C0700276
focal	T082	C0205234
stalk	T017	C1947953
invasion	T033	C1269955
progressed	T169	C1280477
base	T017	C0700276
patients	T101	C0030705
risk	T078	C0035647
progression	T046	C0242656
death	T040	C0011065
bladder cancer	T191	C0699885
base	T017	C0700276
focal	T082	C0205234
stalk	T017	C1947953
tumor subtype	T185	C1519691
risk	T078	C0035647
recurrence	T033	C0679254
lamina propria invasion	T033	C1269980
patients	T101	C0030705
pT1	T033	C0332391
PUC	T191	C1368911
patient	T101	C0030705
stratification	T080	C0205363
risk	T078	C0035647
progression	T046	C0242656
Basic science	T062	C0681833
pathogenesis	T046	C0699748
ageing	T040	C0001811
HIV	T047	C0019693
mechanisms	T169	C0441712
biomarkers	T201	C0005516
prevalence	T081	C0220900
age	T032	C0001779
comorbidities	T078	C0009488
mortality	T081	C0178686
worrisome	T033	C0233481
ageing	T040	C0001811
HIV-infected	T047	C0019693
patients	T101	C0030705
aim	T078	C1947946
analyse	T062	C0936012
ageing	T040	C0001811
mechanisms	T169	C0441712
HIV infection	T047	C0019693
Ageing	T040	C0001811
time	T079	C0040223
dependent	T169	C3244310
accumulation	T033	C4055506
cellular damage	T049	C0599732
Epigenetic modifications	T045	C1516924
mitochondrial DNA	T114	C0012929
haplogroups	T032	C0018591
modulate	T082	C0443264
ageing	T040	C0001811
antiretroviral treatment	T061	C1963724
patients	T101	C0030705
epigenetic clock	T040	C0085759
haplogroups	T032	C0018591
HIV infection	T047	C0019693
severity	T080	C0439793
Telomere shortening	T049	C1515263
HIV-infected	T047	C0019693
patients	T101	C0030705
HIV	T005	C0019682
nucleoside analogue	T114	C1579410
reverse transcriptase inhibitors	T121	C0282519
Mitochondria	T026	C0026237
oxidative stress	T049	C0242606
mitochondrial DNA	T114	C0012929
mutations	T045	C0026882
ageing	T040	C0001811
nucleoside analogue	T114	C1579410
reverse transcriptase inhibitors	T121	C0282519
inflammation	T046	C0021368
inflammageing	T046	C0021368
ageing	T040	C0001811
cell senescence	T043	C0007581
proinflammatory mediators	T121	C0243042
gut microbiota	T001	C2985398
coinfections	T047	C0275524
HIV-infected	T047	C0019693
patients	T101	C0030705
level	T080	C0441889
inflammation	T046	C0021368
innate immunity	T032	C0020969
activation	T052	C1879547
comorbidities	T078	C0009488
mortality	T081	C0178686
age	T032	C0001779
virus	T005	C0042776
viral protein	T116	C0042736
reservoirs	T078	C0012653
HIV	T005	C0019682
gut	T023	C0699819
permeability	T070	C0031164
dysbiosis	T046	C3658208
antiretroviral treatment	T061	C1963724
cytomegalovirus	T005	C0010825
hepatitis C virus	T005	C0220847
coinfections	T047	C0275524
environmental factors	T169	C1516998
fat accumulation	T033	C0333574
smoking	T055	C0037369
Adaptive immune	T039	C0678209
activation	T052	C1879547
immunosenescence	T039	C0596761
comorbidities	T078	C0009488
mortality	T081	C0178686
general population	T098	C0683971
predictive	T080	C0681890
HIV-infected	T047	C0019693
patients	T101	C0030705
Biomarkers	T201	C0005516
evaluate	T058	C0220825
ageing	T040	C0001811
HIV-infected	T047	C0019693
patients	T101	C0030705
systemic	T169	C0205373
cellular inflammatory	T025	C0440752
immune	T169	C0439662
activation	T052	C1879547
oxidative stress	T049	C0242606
markers	T201	C0005516
tested	T169	C0039593
serum	T031	C0229671
peripheral blood mononuclear cells	T025	C1321301
European	T083	C0015176
Study	T062	C2603343
Biomarkers	T201	C0005516
Human Ageing MARK-AGE algorithm	T170	C0002045
evaluating	T058	C0220825
biological	T080	C0205460
age	T032	C0001779
HIV-infected	T047	C0019693
patients	T101	C0030705
biological	T080	C0205460
age	T032	C0001779
inflammatory	T169	C0333348
innate immune	T032	C0020969
activation	T052	C1879547
markers	T201	C0005516
patient's	T101	C0030705
follow-up	T058	C1522577
patients	T101	C0030705
biological	T080	C0205460
age	T032	C0001779
healthspan	T078	C0018684
MESOTHELIAL CELL	T025	C0225335
ADHERENCE	T169	C0334154
VASCULAR PROSTHESES	T074	C0005846
SUBSEQUENT	T079	C0332282
GROWTH	T040	C0018270
IN VITRO	T080	C1533691
Cell	T025	C0007634
seeding	T059	C1705192
decrease	T081	C0547047
thrombogenicity	T046	C0040053
implanted	T074	C0021102
vascular grafts	T074	C0879126
availability of	T169	C0470187
autologous	T080	C0439859
endothelial cells	T025	C0225336
Human	T016	C0086418
peritoneal	T029	C0442034
mesothelial cells	T025	C0225335
blood flow	T039	C0232338
supporting qualities	T080	C0332306
readily available	T169	C0470187
investigated	T169	C1292732
adherence	T169	C0334154
mesothelial cells	T025	C0225335
vascular prostheses	T074	C0005846
subsequent	T079	C0332282
growth	T040	C0018270
in vitro	T080	C1533691
Circular	T082	C1282913
pieces	T081	C2982836
vascular	T080	C1801960
prosthetic materials	T122	C0444752
seeded	T059	C1705192
51Chromium-labeled	T121	C0303212
mesothelial	T025	C0225335
endothelial cells	T025	C0225336
minutes	T079	C0439232
unattached	T033	C3841381
cells	T025	C0007634
removed	T080	C0849355
degree	T081	C0449286
cell	T025	C0007634
attachment	T052	C1947904
measured	T080	C0444706
number	T081	C0237753
mesothelial cells	T025	C0225335
Dacron	T109	C0947693
increased	T081	C0205217
min	T079	C0439232
seeded	T059	C1705192
inoculum	T167	C0439861
plateau	T081	C2964353
reached	T033	C0243095
Scanning electron microscopy	T059	C0026020
spreaded	T080	C0332261
mesothelial cells	T025	C0225335
adherent	T169	C0334154
Dacron fibers	T109	C0947693
significant	T078	C0750502
increase	T169	C0442805
adherence	T169	C0334154
observed	T169	C1441672
preincubation	T059	C0022885
Dacron	T109	C0947693
fibronectin	T116	C0016055
no improvement	T033	C3844714
found	T033	C0150312
preincubation	T059	C0022885
human	T016	C0086418
serum albumin	T116	C0036773
gelatin	T116	C0017237
Mesothelial cells	T025	C0225335
adhered	T067	C3714578
Gelcoated	T080	C1522408
Gelsealed	T080	C0205556
plain Dacron	T109	C0947693
adherence	T169	C0334154
mesothelial cells	T025	C0225335
ePTFE	T109	C0015312
Teflon	T109	C0699518
significantly	T078	C0750502
poorer	T080	C2700379
No significant	T033	C1273937
differences	T080	C1705242
adherence	T169	C0334154
found	T033	C0150312
mesothelial	T025	C0225335
endothelial cells	T025	C0225336
Mesothelial cell	T025	C0225335
growth	T040	C0018270
Dacron	T109	C0947693
resulted	T169	C1274040
modest increase	T169	C0442805
number	T081	C0237753
viable cells	T025	C1441322
days	T079	C0439228
biocompatibility	T044	C0596177
Dacron	T109	C0947693
mesothelial cells	T025	C0225335
in vitro	T080	C1533691
Anterolateral	T082	C0332194
entorhinal cortex	T023	C0175196
volume	T081	C0449468
intra-item configural processing	T170	C0449335
imaging studies	T060	C1881134
human	T016	C0086418
entorhinal cortex	T023	C0175196
anterolateral	T082	C0332194
alERC	T023	C0175196
posteromedial	T082	C1179848
pmERC	T023	C0175196
subregions	T029	C0005898
alERC	T023	C0175196
Alzheimer's disease	T047	C0002395
pathology	T046	C0677042
cognitive function	T041	C0392335
human	T016	C0086418
fMRI studies	T060	C0376335
object	T072	C0347997
memory	T041	C0025260
rodent	T015	C0035804
studies	T008	C0683949
entorhinal cortex	T023	C0175196
spatial properties	T082	C0012727
objects	T072	C0347997
cognitive effects	T033	C0935657
human	T016	C0086418
alERC	T023	C0175196
volume	T081	C0449468
evaluate	T058	C0220825
intra-item configural processing	T170	C0449335
processing	T052	C1709694
arrangement	T082	C0449830
object's	T072	C0347997
manual segmentation	T058	C0700381
developed protocol	T170	C2348563
alERC	T023	C0175196
pmERC	T023	C0175196
medial temporal lobe	T023	C0039485
MTL	T023	C0039485
subregions	T029	C0005898
adult	T100	C0001675
men	T098	C0025266
women	T098	C0043210
stages	T079	C1306673
brain atrophy	T047	C0235946
cognitive decline	T046	C0234985
intra-item configural processing	T170	C0449335
object's	T072	C0347997
alERC	T023	C0175196
volume	T081	C0449468
volume	T081	C0449468
MTL subregion	T023	C0039485
human	T016	C0086418
alERC	T023	C0175196
object	T072	C0347997
processing	T052	C1709694
arrangement	T082	C0449830
object's	T072	C0347997
Alzheimer's disease	T047	C0002395
pathology	T046	C0677042
brain regions	T029	C1273723
anterolateral	T082	C0332194
entorhinal cortex	T023	C0175196
alERC	T023	C0175196
cognitive role	T041	C0009240
alERC	T023	C0175196
human studies	T062	C0178693
treat	T061	C0087111
alERC	T023	C0175196
perirhinal cortex	T029	C2326929
object	T072	C0347997
memory	T041	C0025260
Animal studies	T008	C0683949
alERC	T023	C0175196
spatial properties	T082	C0012727
objects	T072	C0347997
adult	T100	C0001675
humans	T016	C0086418
earliest stages	T079	C2363430
cognitive decline	T046	C0234985
alERC	T023	C0175196
volume	T081	C0449468
configural processing	T170	C0449335
attention	T041	C0004268
spatial arrangement	T082	C0449830
object's	T072	C0347997
cognitive role	T041	C0009240
alERC	T023	C0175196
volume	T081	C0449468
humans	T016	C0086418
early detection method	T170	C0449335
Alzheimer's disease	T047	C0002395
pathology	T046	C0677042
Alcohol brief intervention	T058	C3494740
primary care	T058	C0033137
Blood pressure	T040	C0005823
outcomes	T033	C2015879
hypertensive	T047	C0020538
patients	T101	C0030705
clinical trials	T062	C0008976
alcohol brief intervention	T058	C3494740
BI	T058	C3494740
adult	T100	C0001675
primary care	T058	C0033137
efficacious	T080	C1704419
reducing	T080	C0392756
alcohol consumption	T055	C0001948
impact	T080	C4049986
health outcomes	T080	C0085415
Hypertension	T047	C0020538
chronic condition	T033	C4315615
U.S.	T083	C0041703
worldwide	T080	C2348867
alcohol use	T055	C0001948
hypertension	T047	C0020538
risk factor	T033	C0035648
effect	T080	C1280500
BI	T058	C3494740
unhealthy drinking	T055	C4303858
blood pressure (BP) control	T040	C1753303
adult	T100	C0001675
hypertensive	T047	C0020538
patients	T101	C0030705
analyzing secondary data	UnknownType	C0683944
clustered	T062	C0009085
randomized controlled trial	T062	C0206035
alcohol screening	T058	C0420032
brief intervention	T058	C0814459
referral to treatment	UnknownType	C0814457
SBIRT	T058	C1254363
implementation	T052	C1708476
primary care physicians	T097	C0033131
PCP intervention arm	T097	C0033131
non-physician providers	T097	C0027363
medical assistants	T097	C0334914
NPP	T097	C0027363
MA intervention arm	T097	C0334914
integrated health care delivery system	T093	C0282599
Observational	T062	C1518527
prospective cohort study	T062	C1709709
adult	T100	C0001675
hypertensive	T047	C0020538
primary care patients	T101	C0030705
screening	T058	C1710032
past-year	T079	C4086728
heavy drinking	T048	C0687132
baseline	T081	C1442488
electronic health record	T170	C2362543
BP	T040	C0005823
baseline	T081	C1442488
18-month	T079	C0439231
follow-up	T058	C1522577
Change in BP	T033	C1268766
controlled BP	T040	C1753303
systolic/diastolic BP	T032	C2704328
mmHg	T081	C0439475
associations	T080	C0439849
alcohol BI	T058	C3494740
BP change	T033	C1268766
18-month	T079	C0439231
follow-up	T058	C1522577
subjects	T098	C0080105
intervention arms	T097	C0027363
BI	T058	C3494740
past-year	T079	C4086728
unhealthy drinking	T055	C4303858
associated with	T080	C0332281
BP control	T040	C1753303
18months	T079	C0439231
PCP intervention arm	T097	C0033131
heavy drinking	T048	C0687132
frequency	T079	C0439603
BP control	T040	C1753303
index screening	T058	C1710032
hypertensive	T047	C0020538
patients	T101	C0030705
benefit	T081	C0814225
physician	T097	C0031831
brief intervention	T058	C0814459
unhealthy alcohol use	T055	C4303858
primary care	T058	C0033137
population-level benefits	T081	C0814225
alcohol BI	T058	C3494740
SBIRT delivery	T058	C1254363
primary care	T058	C0033137
Unusual	T080	C2700116
asymptomatic presentation	T047	C0275522
bladder cancer	T191	C0005695
metastatic to the penis	T191	C0347002
Penile metastasis	T191	C0347002
extremely rare event	T047	C0678236
pelvic	T023	C0030797
tumor sites	T082	C0475445
urinary bladder	T023	C0005682
gastro-intestinal tract	T022	C0017189
prostate	T023	C0033572
respiratory system	T022	C0035237
bone tumors	T191	C0005967
melanoma	T191	C0025202
unusual	T080	C2700116
presentation	T078	C0449450
bladder urothelial cancer	T191	C0751571
metastatic to	T169	C0036525
penis	T023	C0030851
no relevant clinical symptoms	T033	C0231221
lesions	T033	C0221198
foreskin and the glans	UnknownType	C0545925
condylomata	T047	C0302180
histological	T059	C0019637
immunohistochemical analysis	T059	C1441616
bladder urothelial carcinoma	T191	C2145472
reddish	T080	C1260956
skin lesion of the glans	T033	C2168434
history of bladder	T033	C0567322
urethral carcinoma	T191	C2145472
histological pagetoid spread	T033	C1335292
urothelial cancer	T191	C2145472
to the glans	T023	C0227948
Recurrent bladder urothelial carcinoma	T191	C0278827
visceral	T023	C0042779
disease	T047	C0012634
asymptomatic	T033	C0231221
skin lesion	T047	C0037284
cases were asymptomatic	T033	C0231221
superficial penis metastases	T191	C0347002
fairy good prognosis	T033	C0278250
conservative surgical approach	T169	C0449446
clinical examination of the penis is mandatory for males	T064	C0242803
history of bladder cancer	T033	C0567322
Female	T032	C0086287
Siamese fighting fish	T013	C0599049
avoid	T169	C0443288
males	T032	C0086582
exposed to	T080	C0332157
estrogen	T109	C0014939
mimic	T169	C0205245
improper	T080	C3827420
disposal	T052	C1707797
lack	T080	C0332268
removal	T052	C1883720
wastewater	T069	C3494254
treatment process	T169	C1522326
endocrine	T169	C0521425
disrupting	T080	C0332454
chemicals	T103	C0220806
aquatic ecosystems	T067	C0563034
effects	T080	C1280500
fish	T013	C0016163
behavior	T053	C0004927
physiology	T039	C0031843
prevalent	T081	C0220900
EDC	T103	C0220806
17α-ethinylestradiol	T109	C0015011
EE2	T109	C0015011
ingredient	T120	C1550600
oral contraceptives	T121	C0009905
reductions	T080	C0392756
male	T032	C0086582
behaviors	T053	C0004927
alterations	T078	C1515926
male	T032	C0086582
courtship	T054	C0237548
behavior	T053	C0004927
decrease	T081	C0547047
reproductive fitness	T045	C2717777
EE2	T109	C0015011
exposure	T080	C0332157
reduces	T080	C0392756
male	T032	C0086582
attractiveness	T032	C0871078
female	T032	C0086287
Siamese fighting fish	T013	C0599049
Betta splendens	T013	C0599049
investigated	T169	C1292732
females	T032	C0086287
video	T170	C3463807
images	T170	C1704922
exposed	T098	C2348484
unexposed	T098	C2349018
males	T032	C0086582
Females	T032	C0086287
exposure	T080	C0332157
conditions	T080	C0348080
exposed to	T080	C0332157
EE2	T109	C0015011
control	T096	C0009932
subject	T096	C0681850
four	T081	C0205450
different	T080	C1705242
video	T170	C3463807
combinations	T080	C0205195
male	T032	C0086582
conspecifics	T078	C1510537
courting	T054	C0237548
exposed	T098	C2348484
exposed	T098	C2348484
courting	T054	C0237548
unexposed	T098	C2349018
unexposed	T098	C2349018
courting	T054	C0237548
unexposed	T098	C2349018
exposed	T098	C2348484
swimming	T056	C0039003
unexposed	T098	C2349018
exposed	T098	C2348484
Females	T032	C0086287
exposed to	T080	C0332157
EE2	T109	C0015011
behavior	T053	C0004927
exposed	T098	C2348484
males	T032	C0086582
exposed	T098	C2348484
male	T032	C0086582
unexposed	T098	C2349018
male	T032	C0086582
simultaneously	T079	C0521115
EE2	T109	C0015011
significant	T078	C0750502
individual	T081	C0205171
population-level	T098	C1257890
consequences	T169	C0686907
fitness	T078	C0031812
disrupting	T080	C0332454
sexual selection	T054	C0024909
success	T054	C0597535
exposed	T098	C2348484
males	T032	C0086582
males	T032	C0086582
Targeting	T169	C1521840
accuracy	T080	C0443131
single-isocenter	T082	C1881275
intensity-modulated	T061	C1512814
radiosurgery	T061	C0085203
lesions	T033	C0221198
investigate	T169	C1292732
targeting	T169	C1521840
accuracy	T080	C0443131
intensity-modulated	T061	C1512814
SRS	T061	C0085203
IMRS	T061	C0085203
plans	T170	C0599880
brain	T023	C0006104
metastases	T046	C4255448
single isocenter	T082	C1881275
home-made acrylic	T122	C0001222
phantom	T073	C0282611
film	T167	C1561572
EBT3	T167	C1561572
coronal plane	T082	C0205123
phantom	T073	C0282611
CT scanned	T060	C0040405
targets	T169	C1521840
central	T082	C0205099
peripheral	T082	C0205100
Eclipse system	T061	C2363849
Peripheral	T082	C0205100
targets	T169	C1521840
central	T082	C0205099
IMRS	T061	C0085203
plan	T170	C0599880
targets	T169	C1521840
single isocenter	T082	C1881275
central	T082	C0205099
target	T169	C1521840
positioning	T082	C1550045
phantom	T073	C0282611
linac	T074	C0023730
room	T082	C1547703
lasers	T073	C0023089
CBCT scan	T060	C0040405
plan	T170	C0599880
mapped	T052	C1283195
isocenter	T082	C1881275
intersection	T078	C1555443
film	T167	C1561572
linac	T074	C0023730
isocenter	T082	C1881275
mapped	T052	C1283195
plan	T170	C0599880
recalculated	T052	C1441506
delivered	T169	C1705822
film	T167	C1561572
dose distribution	T061	C0087111
cloud computing application	T170	C3873720
www.radiochromic.com	T170	C3873720
dosimetry	T059	C0016103
algorithm	T170	C0002045
dose distributions	T061	C0087111
gamma index	T081	C1708185
target	T169	C1521840
2D shifts	T169	C0333051
gamma	T070	C0017011
peripheral	T082	C0205100
target	T169	C1521840
central	T082	C0205099
target	T169	C1521840
experiment	T062	C0681814
sessions	T061	C0481503
2D shifts	T169	C0333051
gamma	T070	C0017011
central	T082	C0205099
peripheral	T082	C0205100
targets	T169	C1521840
targeting	T169	C1521840
accuracy	T080	C0443131
central	T082	C0205099
peripheral	T082	C0205100
targets	T169	C1521840
study	T062	C2603343
targeting	T169	C1521840
accuracy	T080	C0443131
isocenter	T082	C1881275
targets	T169	C1521840
linac	T074	C0023730
isocenter	T082	C1881275
single-isocenter	T082	C1881275
IMRS	T061	C0085203
plan	T170	C0599880
Physical activity	T056	C0026606
limits	T169	C0439801
effects of	T080	C1704420
age	T032	C0001779
Alzheimer's disease	T047	C0002395
postural control	T042	C0683212
aim	T078	C1947946
influence	T077	C4054723
physical activity	T056	C0026606
postural	T169	C0205278
performance	T052	C1882330
subjects	T098	C2349001
Alzheimer's disease	T047	C0002395
AD	T047	C0002395
postural	T169	C0205278
performance	T052	C1882330
surface area	T081	C4263416
center of foot pressure displacement	T082	C0012727
groups	T078	C0441833
compared	T052	C1707455
Alzheimer active group	T078	C0441833
AA	T078	C0441833
Alzheimer non-active group	T078	C0441833
ANA	T078	C0441833
healthy non-active group	T078	C0441833
HNA	T078	C0441833
AA group's	T098	C1257890
postural	T169	C0205278
performance	T052	C1882330
superior	T082	C1282910
ANA	T078	C0441833
HNA groups	T078	C0441833
AD	T047	C0002395
postural	T169	C0205278
performance	T052	C1882330
participation	T169	C0679823
regular	T080	C0205272
physical activity	T056	C0026606
limit	T169	C0439801
disturbing effects	T080	C1280500
AD	T047	C0002395
postural	T169	C0205278
performance	T052	C1882330
active AD subjects	T098	C0080105
superior	T082	C1282910
healthy subjects	T098	C1708335
LAMP-2	T116	C1563373
oxidative stress	T049	C0242606
cell death	T043	C0007587
Zn(2+)	T121	C2346521
treated	T061	C0087111
lung	T023	C0024109
epithelium cells	T025	C0014597
Zinc	T121	C0043481
element	T196	C0013879
biological system	T022	C0460002
exogenous	T169	C0205228
Zn(2+)	T121	C2346521
cellular Zn(2+) homeostasis	T043	C2263139
cause toxicity	T037	C0600688
Zinc salts	T121	C0351669
ZnO	T121	C0043491
nanoparticles	T073	C1450054
respiratory injury	T037	C0560313
organelle	T026	C0029219
damage	T049	C0599732
mitochondria	T026	C0026237
lysosomes	T026	C0024369
reactive oxygen species	T123	C0162772
ROS	T123	C0162772
Zn(2+)	T121	C2346521
toxicity	T037	C0600688
mitochondria	T026	C0026237
lysosomes	T026	C0024369
damage	T049	C0599732
ROS	T123	C0162772
Zn(2+)	T121	C2346521
deglycosylation	T044	C1157972
lysosome-associated membrane protein 1	T116	C3539735
2	T116	C1563373
LAMP-1	T116	C3539735
LAMP-2	T116	C1563373
endosomes	T026	C0034850
lysosomes	T026	C0024369
A549 lung epithelium cells	T025	C0014597
LAMP-2	T028	C1416790
knockdown	T063	C2350567
aggravated	T080	C1444749
Zn(2+)	T121	C2346521
ROS	T123	C0162772
cell death	T043	C0007587
LAMP-2	T116	C1563373
LAMP-1	T116	C3539735
Zn(2+)	T121	C2346521
toxicity	T037	C0600688
LAMP-2	T116	C1563373
ROS	T123	C0162772
cell death	T043	C0007587
Zn(2+)	T121	C2346521
treatment	T061	C0087111
Zn(2+)	T121	C2346521
toxicity	T037	C0600688
respiratory system	T022	C0035237
Fluorescence hyperspectral imaging	T060	C0430022
fHSI	T060	C0430022
spectrally	T080	C0205556
resolved	T033	C3714811
detector array	T074	C0025080
resolve	T077	C2699488
multiple	T081	C0439064
fluorescent emissions	T067	C1522240
different	T080	C1705242
biological	T080	C0205460
targets	T169	C1521840
video rate applications	UnknownType	C0869019
endoscopy	T060	C0014245
intraoperative imaging	T060	C3898703
limited	T169	C0439801
filter-based	T080	C0205556
imaging systems.	T074	C0025080
Hyperspectral imaging	T060	C0430022
HSI	T060	C0430022
detection	T061	C1511790
spatial	T082	C0037775
spectral	T081	C1883073
information	T078	C1533716
single data acquisition	T052	C0441655
instrumentation	T080	C0021632
HSI	T060	C0430022
complex	T080	C0439855
bulky	T081	C0392762
expensive	T080	C0205556
overcome	T052	C2983310
limitations	T169	C0449295
novel	T080	C0205314
robust	T080	C2986815
low cost	T081	C0392762
HSI	T060	C0430022
camera	T074	C0179533
spectrally resolved detector array	T074	C0025080
SRDA	T074	C0025080
integrated	T066	C1705422
HSI	T060	C0430022
camera	T074	C0179533
wide-field	T033	C0243095
reflectance-based	T059	C1514813
imaging system	T073	C2697665
operating	T169	C0205245
near-infrared	T080	C1532326
range	T081	C1514721
assess	T058	C0184514
in vivo imaging	T059	C1708481
exogenous	T169	C0205228
fluorescent contrast agents	T130	C0009924
fluorescence HSI	T060	C0430022
fHSI	T060	C0430022
system	T169	C0449913
accurately	T080	C0443131
resolve	T077	C2699488
presence	T080	C3854307
concentration	T081	C1446561
fluorescent dyes	T130	C0016320
solution	T167	C0037633
high	T080	C0205250
spectral unmixing	T066	C2827423
precision	T080	C1706245
signal	T067	C1710082
linearity	T080	C0205556
dye	T130	C0013343
concentration	T081	C1446561
depth	T082	C0205125
tissue	T024	C0040300
mimicking	T070	C4042849
phantoms	T073	C0282611
delineate	T033	C0243095
fluorescent dyes	T130	C0016320
in vivo	T082	C1515655
including	T169	C0332257
statistical	T080	C0205556
background	T077	C1706907
directly	T080	C1947931
generalised	T082	C0205246
broader spectral	T074	C1138667
ranges	T081	C1514721
resolve	T077	C2699488
tissue	T024	C0040300
reflectance	T059	C1514813
autofluorescence	T059	C0544711
future	T079	C0016884
video rate applications	UnknownType	C0869019
HSI	T060	C0430022
data acquisition	T052	C0441655
Biochemical	T169	C0205474
studies	T062	C2603343
amylase	T116	C0002712
lipase	T116	C0023764
protease	T116	C0030940
Callosobruchus maculatus	T204	C1024702
Coleoptera	T204	C0009276
Chrysomelidae	T204	C1001499
populations	T098	C1257890
Vigna unguiculata	T002	C0996865
grain	T168	C0007757
cultivated	T062	C0242481
diazotrophic bacteria strains	T007	C0004611
study	T062	C2603343
enzymatic activity	T044	C0243102
homogenates	T072	C3829671
insects	T204	C0021585
grain	T168	C0007757
cowpea	T002	C0996865
Vigna unguiculata (L.)	T002	C0996865
cultivars	T002	C0032098
nitrogen	T123	C0028158
homogenate	T072	C3829671
adult	T100	C0001675
insects	T204	C0021585
grain	T168	C0007757
cowpea	T002	C0996865
cultivars	T002	C0032098
BRS Acauã	T002	C0032098
BRS Carijó	T002	C0032098
BRS Pujante	T002	C0032098
BRS Tapaihum	T002	C0032098
nitrogen	T123	C0028158
mineral	T197	C0026162
fertilizer	T073	C0015919
inoculation	T059	C0022885
strains of diazotrophs	T007	C0004611
BR 3267	T007	C3917457
BR 3262	T007	C3917456
BR 3299	T007	C0004611
INPA 03-11B	T007	C0004611
03-84 UFLA	T007	C0004611
control	T096	C0009932
soil	T167	C0037592
nitrogen	T123	C0028158
enzymatic activities	T044	C0243102
insect	T204	C0021585
protease	T116	C0030940
amylase	T116	C0002712
lipase	T116	C0023764
starch	T109	C0038179
grains	T168	C0007757
enzymatic activity	T044	C0243102
amylase	T116	C0002712
lipase	T116	C0023764
protease	T116	C0030940
insect	T204	C0021585
homogenate	T072	C3829671
food	T168	C0016452
activity of the enzyme	T044	C0243102
amylase	T116	C0002712
C. maculatus	T204	C1024702
homogenate	T072	C3829671
insects	T204	C0021585
grain	T168	C0007757
cultivar BRS Carijó	T002	C0032098
activity of lipase enzyme	T044	C1149836
C. maculatus	T204	C1024702
homogenate	T072	C3829671
insects	T204	C0021585
grain	T168	C0007757
cultivar Tapaihum	T002	C0032098
BR 3262 diazotrophs	T007	C3917456
proteolytic activity	T044	C0597304
homogenate	T072	C3829671
insects	T204	C0021585
BRS Carijó	T002	C0032098
BR 3262 diazotroph	T007	C3917456
Starch	T109	C0038179
amylase activity	T044	C1150038
C. maculatus	T204	C1024702
homogenate	T072	C3829671
cultivar BRS Carijó	T002	C0032098
cultivars	T002	C0032098
cluster analysis	T062	C0009085
correlation of the results	T081	C0010100
survey SNOT-20	T170	C0038951
objective studies	T078	C2985627
nasal obstruction	T033	C0027429
nasal cavities	T030	C0027423
correlation between the results	T081	C0010100
survey SNOT-20	T170	C0038951
results of the objective tests	T033	C0243095
nasal obstruction	T033	C0027429
rhinomanometry	T060	C0430615
acoustic rhinometry	T060	C0430619
surgical treatment	T061	C0543467
septoplasty	T061	C0844334
septoconchoplasty	T060	C0430022
ethmoidectomy	T061	C0189149
septoethmoidectomy	T060	C0430022
patients	T101	C0030705
diagnosed	T033	C0011900
Rhinomanometry	T060	C0430615
Laboratory	T073	C0022877
Department of Otolaryngology	T093	C4047590
Medical University	T073	C0000872
Warsaw	UnknownType	C0681784
rhinological problems	T047	C0029896
Data	T078	C1511726
women	T098	C0043210
men	T098	C0025266
RhinoMetrics SRE 2100	T074	C0025080
Rhinomanometer	T074	C0183043
RhinoStream	T074	C0183043
Acoustic Rhinometer	T074	C3881541
RhinoScan	T074	C3881541
Interacoustics AS	T074	C0025080
Denmark	T083	C0011318
Survey SNOT-20	T170	C0038951
Sino-Nasal Outcome Test-20	T170	C0038951
Polish	UnknownType	C0681784
patients	T101	C0030705
before surgery	T079	C1254367
during the postoperative control visits	T079	C0032790
objective parameter	T033	C0449381
resistance	T169	C4281815
flow of air through the nasal cavity	T033	C0429203
subjective feelings of respondents	T033	C0243095
survey SNOT-20	T170	C0038951
generally weak	T080	C1762617
statistical significance	T081	C0237881
first question survey	T062	C0038949
severity of the nose obstruction	T033	C0027429
resistance flow	T169	C4281815
nasal obstruction	T033	C0027429
patient	T101	C0030705
rhinological problems	T047	C0029896
Emergency department	T073	C0562508
use	T169	C0457083
barriers	T080	C0679881
wellness	T078	C0018684
survey	T170	C0038951
emergency department	T073	C0562508
frequent	T079	C0332183
users	T098	C1706077
needs	T080	C0027552
emergency department	T073	C0562508
ED	T073	C0562508
frequent	T079	C0332183
users	T098	C1706077
patients	T101	C0030705
study	T062	C2603343
population	T098	C1257890
Examinations	T058	C0582103
ED	T073	C0562508
frequent	T079	C0332183
users	T098	C1706077
present	T033	C0150312
ED	T073	C0562508
barriers	T080	C0679881
care	T058	C0017313
exist	T077	C2987476
service	T057	C0557854
patients	T101	C0030705
optimal	T080	C2698651
level	T080	C0441889
health	T078	C0018684
prospective study	T062	C0033522
frequent	T079	C0332183
ED	T073	C0562508
users	T098	C1706077
adult	T100	C0001675
level 1 trauma center	T073	C0040786
approximately	T080	C0332232
visits	T058	C1512346
per year	T079	C0439508
Frequent	T079	C0332183
ED	T073	C0562508
users	T098	C1706077
ED visits	T058	C0586082
month	T079	C0439231
period	T079	C1948053
Participants	T098	C0679646
administered	T169	C1521801
piloted structured interview	UnknownType	C0681913
trained researcher	T097	C0035173
querying	T170	C1522634
demographics	T090	C0011298
ED	T073	C0562508
usage	T169	C0457083
perceived barriers	T080	C0205556
care	T058	C0017313
aids	T080	C0205556
maintaining health	T055	C2371475
screened	T058	C1710032
patients	T101	C0030705
identified	T080	C0205396
frequent	T079	C0332183
ED	T073	C0562508
users	T098	C1706077
frequent	T079	C0332183
ED	T073	C0562508
users	T098	C1706077
mean age	T032	C0001779
years	T079	C1510829
CI	T081	C0009667
subjects	T098	C0080105
female	T098	C0043210
CI	T081	C0009667
white	T098	C1257890
CI	T081	C0009667
insured	T170	C1548605
Medicaid	T064	C0025071
CI	T081	C0009667
Medicare	T064	C0018717
CI	T081	C0009667
Subjects	T098	C0080105
median	T081	C0439536
ED visits	T058	C0586082
inpatient admissions	T169	C0420512
past	T079	C1444637
months	T079	C0439231
hospital	T073	C0019994
frequent	T079	C0332183
ED	T073	C0562508
users	T098	C1706077
CI	T081	C0009667
primary reason	T078	C1549995
visit	T058	C1512346
health problem	T033	C1398682
treated	T169	C1522326
ED	T073	C0562508
Transportation	T078	C1554194
major	T080	C0205164
barrier	T080	C0205556
few	T081	C0205388
patients	T101	C0030705
CI	T081	C0009667
Subjects	T098	C0080105
after-hours options	T058	C1136313
ED	T073	C0562508
minor	T080	C0205165
health issues	T078	C2362508
CI	T081	C0009667
nurse	T097	C0028661
work	T057	C0043227
one-on-one	T061	C0557987
manage	T058	C0184516
health care	T058	C0086388
needs	T080	C0027552
CI	T081	C0009667
optimal	T080	C2698651
health	T078	C0018684
study	T062	C2603343
characterized	T052	C1880022
ED	T073	C0562508
frequent	T079	C0332183
users	T098	C1706077
identified	T080	C0205396
several	T081	C0443302
opportunities	T062	C0683937
population	T098	C1257890
barriers	T080	C0205556
care	T058	C0017313
patient	T101	C0030705
health systems	T064	C1456613
needs	T080	C0027552
prevent	T080	C2700409
wellness	T078	C0018684
population	T098	C1257890
Contralateral	T082	C0441988
Superior Cerebellar Artery Syndrome	T046	C1384733
Consequence of	T169	C0686907
Brain Herniation	T190	C0553686
Vascular	T023	C0005847
compromise	T033	C2945640
consequence of	T169	C0686907
brain herniation	T190	C0553686
syndromes	T047	C0039082
Transtentorial	T082	C0522519
brain herniation	T190	C0553686
posterior cerebral arteries	T023	C0149576
isolated	T169	C0205409
involvement	T169	C1314939
contralateral	T082	C0441988
superior cerebellar artery	T023	C0149575
SCA	T023	C0149575
unilateral	T082	C0205092
impending	T079	C0332190
brain herniation	T190	C0553686
reported	T058	C0700287
rare	T080	C0522498
entity	T071	C1551338
man	T098	C0025266
impending	T079	C0332190
herniation	T190	C0019270
multiloculated	T082	C0205293
hydrocephalus	T047	C0020255
course of illness	T046	C0242656
isolated	T169	C0205409
SCA	T023	C0149575
ischemia	T046	C0022116
dilated	T033	C0700124
horn	T023	C0019939
article	T170	C1706852
pathophysiologic	T169	C0031847
mechanisms	T169	C0441712
phenomenon	T067	C1882365
inclusive	T169	C0332257
brain	T023	C0006104
suspected	T078	C0750491
Kernohan-Woltman notch phenomenon	T046	C0030660
unilateral	T082	C0205092
brain herniation	T190	C0553686
rationale	T078	C2699007
commentary	T170	C0282411
contralateral	T082	C0441988
SCA	T023	C0149575
transient ischemia	T047	C0022118
infarct	T046	C0021308
underdiagnosed	T033	C0243095
pathomechanism	T046	C0030660
ipsilateral	T082	C0441989
hemiparesis	T184	C0018989
vague	T080	C0205408
phenomenon	T067	C1882365
effects of	T080	C1704420
clinical supervision	T057	C0870294
supervisees	T098	C1257890
patients	T101	C0030705
cognitive-behavioral therapy	T061	C0009244
study protocol	T170	C2348563
systematic review	T170	C1955832
Clinical supervision	T057	C0870294
senior therapist	T097	C0871525
practice	T041	C0032893
psychotherapist	T097	C0557555
training	T065	C0220931
psychiatric care	T061	C0597312
clinical supervision	T057	C0870294
educational and governing institutions	UnknownType	C0681325
clinical supervision	T057	C0870294
supervisees	T098	C1257890
competence	T080	C0086035
attitudes	T041	C0004271
behaviors	T053	C0004927
skills	T055	C0678856
treatment outcomes	T080	C0085415
patient	T101	C0030705
Evidence-based practice	T169	C1510541
clinical settings	T082	C3176918
systematic review	T170	C1955832
empirical literature	T170	C0023866
clinical supervision	T057	C0870294
cognitive-behavioral therapy	T061	C0009244
systematic review	T170	C1955832
literature	T170	C0023866
supervised psychotherapists	T097	C0557555
patients	T101	C0030705
indexed	T170	C0918012
MEDLINE	T170	C0025141
EMBASE	T170	C0282574
PsycINFO	T170	C1140129
Cochrane Library databases	T170	C0282574
Data	T078	C1511726
psychotherapists	T097	C0557555
patients	T101	C0030705
reported	T170	C0684224
systematic review	T170	C1955832
guidelines	T170	C0162791
systematic reviews	T170	C1955832
clinical supervision	T057	C0870294
cognitive-behavioral therapy	T061	C0009244
research	T062	C0035168
Higher risk of	T033	C0332167
revision	T079	C0439617
infection	T046	C3714514
systemic	T169	C0205373
clindamycin	T109	C0008947
prophylaxis	T061	C0282638
cloxacillin	T109	C0009077
Clindamycin	T109	C0008947
antibiotics	T195	C0003232
prophylaxis	T061	C0282638
arthroplasty	T061	C0003893
Swedish Knee Arthroplasty Register	T170	C0034975
Knee Arthroplasty	T061	C0086511
SKAR	T170	C0034975
collecting	T169	C1516698
information	T078	C1533716
prophylactic antibiotic regime	T061	C0282638
individual	T098	C0237401
operation	T169	C0038895
Sweden	T083	C0038995
allergy	T046	C0020517
penicillin	T109	C0220892
clindamycin	T109	C0008947
recommended	T078	C0034866
alternative	T077	C1523987
revision	T079	C0439617
infection	T046	C3714514
antibiotic	T195	C0003232
systemic	T169	C0205373
prophylaxis	T061	C0282638
Patients	T101	C0030705
Patients	T101	C0030705
total knee arthroplasty	T061	C0086511
TKA	T061	C0086511
osteoarthritis	T047	C0029408
OA	T047	C0029408
antibiotic	T195	C0003232
operations	T169	C0038895
patients	T101	C0030705
Survival statistics	T170	C0600673
revision	T079	C0439617
infection	T046	C3714514
patients	T101	C0030705
cloxacillin	T109	C0009077
clindamycin	T109	C0008947
systemic	T169	C0205373
prophylaxis	T061	C0282638
Cloxacillin	T109	C0009077
clindamycin	T109	C0008947
cephalosporins	T109	C3536856
infection	T046	C3714514
clindamycin	T109	C0008947
cloxacillin	T109	C0009077
revision	T079	C0439617
causes	T169	C0015127
Interpretation	T170	C0459471
patients	T101	C0030705
allergic reaction	T046	C1527304
penicillin	T109	C0220892
allergic history	T184	C2106654
history	T184	C2106654
type-I allergic reaction	T046	C1527304
urticaria	T047	C0042109
anaphylaxis	T047	C0850803
bronchospasm	T047	C0006266
third-generation cephalosporin	T109	C0304320
clindamycin	T109	C0008947
perioperative	T079	C1518988
prophylaxis	T061	C0282638
TKR	T061	C0086511
recommendation	T078	C0034866
patients	T101	C0030705
type-1 allergy	T046	C0020517
PCVMZM	T062	C1516769
Probabilistic Classification Vector Machines Model Combined with a Zernike Moments	T062	C1516769
Predict	T078	C0681842
Protein-Protein Interactions	T044	C0872079
Protein Sequences	T087	C0002518
Protein-protein interactions	T044	C0872079
PPIs	T044	C0872079
living organisms	T001	C0029235
PPIs	T044	C0872079
molecular	T080	C1521991
mechanisms	T169	C0441712
biological systems	T169	C0449913
PPIs	T044	C0872079
high-throughput technologies	T170	C0872047
organisms	T001	C0029235
high-throughput technologies	T170	C0872047
PPIs	T044	C0872079
unavoidable defects	T169	C1457869
time consumption	T079	C0040223
cost	T081	C0010186
error rate	T081	C0392762
machine learning	T066	C0376284
computational methods	T062	C1516769
PPIs	T044	C0872079
prediction	T078	C0681842
PCVMZM	T062	C1516769
computational method	T062	C1516769
Probabilistic Classification Vector Machines (PCVM) model	T081	C2699740
Zernike moments (ZM) descriptor	T081	C0026346
predicting	T078	C0681842
PPIs	T044	C0872079
protein	T116	C0033684
amino acids sequences	T087	C0002518
Zernike moments (ZM) descriptor	T081	C0026346
protein	T116	C0033684
information	T078	C1533716
Position-Specific Scoring Matrix	T081	C2717845
PSSM	T081	C2717845
Position-Specific Iterated Basic Local Alignment Search Tool (PSI-BLAST)	T170	C2698333
PCVM classifier	T081	C2699740
interactions	T044	C0872079
protein	T116	C0033684
PPIs	T044	C0872079
Yeast	T004	C0043393
H. Pylori	T007	C0079488
prediction	T078	C0681842
accuracy	T080	C0443131
state-of-the-art	T170	C0038199
support vector machines	T081	C2699740
SVM) classifier	T081	C2699740
PCVM model	T081	C2699740
Experimental results	T033	C2825142
Yeast	T004	C0043393
PCVM classifier	T081	C2699740
SVM classifier	T081	C2699740
experimental results	T033	C2825142
proteomics research	T062	C0035168
Conditional	T080	C1701901
Knockdown	T063	C2350567
Endogenous	T169	C0205227
MicroRNAs	T114	C1101610
CHO Cells	T025	C0085080
TET-ON-SanDI Sponge Vectors	T114	C0017397
MicroRNAs	T114	C1101610
miRNAs	T114	C1101610
noncoding RNAs	T114	C0887909
nucleotides	T114	C0028630
targets	T169	C1521840
genetic modifications	T063	C4277689
phenotype	T032	C0031437
biotech	T091	C0005574
industry	T057	C0021267
miRNA sponge" vectors	T114	C0017397
tandem miRNA	T114	C1101610
binding sites	T192	C0005456
transcripts	T114	C1519595
transcriptionally regulated	T045	C1158770
promoter	T114	C0086860
down regulating	T044	C0013081
endogenous	T169	C0205227
microRNAs	T114	C1101610
Chinese hamster ovary (CHO) cells	T025	C0085080
antisense oligonucleotides	T114	C0079925
miRNA sponges	T114	C0599566
biotechnological	T091	C0005574
processes	T067	C1522240
effective	T080	C1704419
expression	T045	C0017262
miRNA sponges	T114	C0599566
CHO cell lines	T025	C0085080
expressing	T045	C0017262
TET-ON-SanDI-miRNA-sponge	T114	C0599566
inducer	T167	C3898767
Forest	T070	C0086312
protected areas	T083	C0017446
governance	T080	C0243148
Zimbabwe	T083	C0043476
Shift	T067	C2347509
long history	T033	C3714536
local	T082	C0205276
community	T096	C0009462
exclusion	T052	C2828389
concept	T078	C0178566
exclusion	T052	C2828389
local	T082	C0205276
communities	T096	C0009462
accessing	T078	C0015472
resources	T078	C0027492
forest	T070	C0086312
protected areas	T083	C0017446
FPAs	T083	C0017446
Zimbabwe	T083	C0043476
colonial	T170	C0870077
post	T079	C0687676
colonial forms	T170	C0870077
mechanisms	T169	C0441712
exclusion	T052	C2828389
social	T078	C0037403
economic	T081	C0013551
ecological outcomes	T077	C0870460
examined	T033	C0332128
range	T081	C1514721
powers	T068	C0037430
processes	T067	C1522240
social relations	T054	C0037397
impact	T080	C4049986
local	T082	C0205276
communities	T096	C0009462
access	T078	C0015472
FPA	T083	C0017446
resources	T078	C0027492
benefits	T081	C0814225
historical	T079	C0681698
trajectory	T169	C0392747
forest	T070	C0086312
governance	T080	C0243148
Zimbabwe	T083	C0043476
forms	T080	C0348078
extent	T082	C0439792
exclusion	T052	C2828389
changed	T081	C0443172
over	T079	C0347984
time	T079	C0040223
shifting	T169	C0333051
political	T078	C0032381
economic landscape	T064	C0282159
colonial period	T079	C1254367
exclusion	T052	C2828389
people	T098	C0027361
evicted	T052	C2828389
forest	T070	C0086312
land	T073	C0557668
denied	T080	C0332319
access	T078	C0015472
basic	T169	C1527178
resources	T078	C0027492
Local	T082	C0205276
communities	T096	C0009462
access	T078	C0015472
low	T080	C0205251
value	T081	C1522609
FPA	T083	C0017446
resources	T078	C0027492
improved	T033	C0184511
post-colonial period	T079	C1254367
access	T078	C0015472
high	T080	C0205250
value	T081	C1522609
resources	T078	C0027492
commercial timber	T167	C0043217
sharing	T054	C0237876
income	T081	C0021162
benefits	T081	C0814225
derived	T080	C1441547
FPA	T083	C0017446
commercial activities	T052	C0441655
pipe dream	T077	C1254372
Regulation	T064	C0851285
legitimation	T064	C0023637
FPA	T083	C0017446
governing	T080	C0243148
authorities	T054	C0599437
exclude	T052	C2828389
local	T082	C0205276
communities	T096	C0009462
intact	T080	C0205266
collaborative	T054	C0282116
governance	T080	C0243148
local	T082	C0205276
communities	T096	C0009462
expressed	T055	C0455212
dissatisfaction	T041	C0870433
centralised exclusionary governance system	T064	C0034982
FPAs	T083	C0017446
ungovernable	T033	C0243095
policy	T170	C0242456
reform	T169	C0392747
FPA	T083	C0017446
sector	T083	C1708237
improve	T033	C0184511
current	T079	C0521116
dire situation	T067	C0013956
Renal arterial mycotic aneurysm	T047	C0085808
kidney transplantation	T061	C0022671
Mycotic aneurysm	T047	C0085808
attributable	T078	C0449234
Candida	T004	C0006836
Aspergillus species	T004	C0004034
Candida	T004	C0006836
arteritis	T046	C0003860
kidney transplant	T061	C0022671
patients	T101	C0030705
report	T170	C0684224
kidney	T023	C0022646
donor	T098	C0013018
accidental	T169	C0521129
digestive wound	T037	C0850041
organ retrieval	T058	C0162438
anuria	T047	C0003460
renal transplantation	T061	C0022671
mycotic aneurysm	T047	C0085808
kidney graft	T024	C1720289
renal artery	T023	C0035065
Organs	T023	C0178784
donors	T098	C0013018
digestive breach	T037	C0850041
used with caution	T169	C1710588
Risk of cancer	T081	C0596244
patients	T101	C0030705
heart failure	T047	C0018801
digoxin	T109	C0012265
follow-up study	T062	C0016441
cell	T025	C0007634
verification	T169	C1711411
Heart failure	T047	C0018801
HF	T047	C0018801
cause of death	T033	C0007465
world	T098	C2700280
digoxin	T109	C0012265
therapies	T061	C0087111
HF	T047	C0018801
safety	T068	C0036043
efficacy	T080	C1280519
use	T169	C0457083
uncertainty	T033	C0087130
long-term	T079	C0443252
efficacy	T080	C1280519
safety	T068	C0036043
repositioning	T061	C0556030
cardiac glycosides	T109	C0007158
function	T169	C0542341
anti-tumor activity	T061	C0920425
multiple	T081	C0439064
working pathways	T077	C1705987
compare	T052	C1707455
potential	T080	C3245505
effects	T080	C1280500
digoxin	T109	C0012265
clinical	T080	C0205210
patients	T101	C0030705
cell lines	T025	C0085983
patient information	T170	C1955348
National Health Insurance Research database	T170	C0242356
Taiwan	T083	C0039260
retrospective study	T062	C0035363
cohort	T098	C0599755
patients	T101	C0030705
comparison	T052	C1707455
cohort	T098	C0599755
analytical data	T078	C1511726
patients	T101	C0030705
digoxin	T109	C0012265
increased	T081	C0205217
risk of cancers	T081	C0596244
breast	T191	C0006142
liver	T191	C0345904
lung cancers	T191	C0684249
follow-up period	T058	C1522577
anti-tumor function	T061	C0920425
digoxin	T109	C0012265
potential	T080	C3245505
pathway	T169	C1291081
digoxin	T109	C0012265
cell	T025	C0007634
strategy	T041	C0679199
breast cancer	T191	C0678222
cell lines	T025	C0085983
MCF-7	T025	C0596890
BT-474	T025	C0085983
MAD-MB-231	T025	C0085983
ZR-75-1	T025	C0085983
Digoxin	T109	C0012265
cytotoxicity	T049	C0596402
cell lines	T025	C0085983
concentration	T081	C1446561
proliferation	T169	C1514485
ZR-75-1 cells	T025	C0085983
cell lines	T025	C0085983
digoxin	T109	C0012265
suppressed	T169	C1260953
digoxin	T109	C0012265
responsiveness	T169	C0205342
SRSF3	T028	C1419994
digoxin	T109	C0012265
cell-type	T170	C0449475
differences	T080	C1705242
cohort study	T081	C0009247
digoxin	T109	C0012265
treatment	T061	C0087111
HF	T047	C0018801
patients	T101	C0030705
cell	T025	C0007634
strategy	T041	C0679199
complexity	T080	C0439855
personalized medicine	T061	C2718059
Analysis of Patients	T058	C0679830
Takotsubo Cardiomyopathy	T047	C1739395
Triggered by	T080	C1444748
Emotional Stress	T048	C0086209
Physical Stress	T046	C0231302
takotsubo cardiomyopathy	T047	C1739395
TTC	T047	C1739395
triggered by	T080	C1444748
physical	T046	C0231302
emotional stresses	T048	C0086209
short-	T079	C0443303
long-term	T079	C0443252
emotional-	T048	C0086209
physical stress	T046	C0231302
associated with	T080	C0332281
TTC	T047	C1739395
institutional database	T170	C0242356
patients	T101	C0030705
diagnosed	T033	C0011900
TTC	T047	C1739395
patients	T101	C0030705
groups	T078	C0441833
emotional stress	T048	C0086209
physical stress	T046	C0231302
endpoint	T080	C2349179
composite	T080	C0205199
in-hospital events	T033	C0243095
thromboembolic events	T046	C0040038
life-threatening	T033	C2826244
arrhythmias	T033	C0003811
myocardial infarction	T047	C0027051
cause of mortality	T033	C1408525
re-hospitalization	T058	C1254363
heart failure	T047	C0018801
stroke	T047	C0038454
recurrence	T067	C0034897
TTC	T047	C1739395
Kaplan-Meier analysis	T081	C1720943
survival rate	T081	C0038954
follow-up	T058	C1522577
emotional	T048	C0086209
group	T078	C0441833
physical stress	T046	C0231302
group	T078	C0441833
Multivariate Cox regression analysis	T170	C0034980
emotional stress	T048	C0086209
negative independent predictor	T033	C0243095
endpoint	T080	C2349179
in-hospital events	T033	C0243095
short-	T079	C0443303
long-term	T079	C0443252
TTC	T047	C1739395
patients	T101	C0030705
suffering	T048	C0683278
emotional stress	T048	C0086209
patients	T101	C0030705
physical stress	T046	C0231302
Surviving	T169	C0220921
moment	T079	C0040223
moment	T079	C0040223
experience	T041	C0596545
living	T078	C0376558
state	T033	C0278060
ambivalence	T041	C0233495
recurrent	T079	C2945760
suicide attempts	T033	C0038663
qualitative study	T062	C0949415
experience	T041	C0596545
living	T078	C0376558
ambivalent space	T041	C0233495
life	T078	C0376558
death	T078	C1546949
adults	T100	C0001675
recurrent	T079	C2945760
suicide attempts	T033	C0038663
RSA	T033	C0038663
expand	T082	C0205229
study	T062	C2603343
processes	T041	C0025361
involved	T169	C1314939
transitioning	T052	C2700061
RSA	T033	C0038663
adults	T100	C0001675
revealed	T080	C0443289
ambivalent space	T041	C0233495
process	T067	C1522240
Interpretive phenomenological analysis	T062	C0936012
IPA	T062	C0936012
methodology	T078	C3266812
designed	T052	C1707689
lived experiences	T041	C0596545
meaning making	T041	C0025361
interpretation	T062	C0871180
multidimensional	T082	C2347299
subjective	T080	C0439655
experiences	T041	C0596545
RSA	T033	C0038663
participants	T098	C0679646
semi-structured interviews	UnknownType	C0681913
conducted	T052	C0441655
adult women	T098	C0043210
history	T169	C0019665
RSA	T033	C0038663
participated	T169	C0679823
therapeutic intervention	T061	C0808232
research	T062	C0035168
site	T082	C0205145
Skills	T055	C0678856
Safer Living	T078	C0376558
Psychosocial	T169	C0542298
Psychoeducational Intervention	T065	C0871175
People	T098	C0027361
Recurrent	T079	C2945760
Suicide Attempts	T033	C0038663
SfSL	T078	C0376558
PISA	T033	C0038663
stages	T079	C1306673
IPA	T062	C0936012
analyse	T062	C0936012
interview	T058	C0683518
data	T078	C1511726
Analysis	T062	C0936012
revealed	T080	C0443289
superordinate theme	UnknownType	C0869035
surviving	T169	C0220921
moment	T079	C0040223
moment	T079	C0040223
precarious state	T033	C0278060
making decisions	T041	C0011109
life	T078	C0376558
destiny	T079	C0016884
moment	T079	C0040223
moment	T079	C0040223
commitment	T041	C0870312
life	T078	C0376558
death	T078	C1546949
subordinate themes	UnknownType	C0869035
identified	T080	C0205396
deciding	T080	C0205556
die	T033	C4061184
moment	T079	C0040223
participants	T098	C0679646
invested	T169	C0205245
dying	T033	C4061184
living	T078	C0376558
deciding	T080	C0205556
live	T078	C0376558
moment	T079	C0040223
invested	T169	C0205245
living	T078	C0376558
dying	T033	C4061184
study	T062	C2603343
complex	T080	C0439855
process	T067	C1522240
making decisions	T041	C0011109
destiny	T079	C0016884
moment	T079	C0040223
moment	T079	C0040223
revealed	T080	C0443289
experienced	T041	C0596545
state	T033	C0278060
paradoxically	T080	C0205310
indecision	T033	C0423908
life	T078	C0376558
death	T078	C1546949
provided	T052	C1999230
lifeline	T078	C0376558
opportunity	T080	C0205556
RSA	T033	C0038663
Clinicians	T097	C0871685
associated with	T080	C0332281
state	T033	C0278060
interventions	T061	C0184661
Surviving	T169	C0220921
moment	T079	C0040223
moment	T079	C0040223
characterized	T052	C1880022
state	T033	C0278060
emotional flux	T033	C0849912
uncertainty	T033	C0087130
destiny	T079	C0016884
person	T098	C0027361
life	T078	C0376558
death	T078	C1546949
state	T033	C0278060
interlinked subprocesses	T041	C0025361
person	T098	C0027361
leaning	T078	C0558295
death	T078	C1546949
life	T078	C0376558
feature	T080	C2348519
working	T057	C0043227
client group	T096	C0008942
ambiguity	T080	C2346729
fragility	T033	C3553489
temporality	T041	C0040226
decisions	T041	C0679006
destiny	T079	C0016884
practitioner	T097	C1709627
opportunity	T080	C0205556
life	T078	C0376558
understanding	T041	C0162340
survival	T169	C0220921
struggle	T033	C0243095
tailoring intervention	T061	C0184661
nuanced processes	T041	C0025361
state	T033	C0278060
policy	T170	C0242456
earlier induction	T061	C3710446
labour	T040	C0022864
outcomes	T169	C1274040
women	T098	C0033011
induced	T169	C0205263
postmaturity	T047	C0221007
retrospective	T080	C1514923
analysis	T062	C0936012
tertiary hospital	T073	C0337954
North	T082	C1709269
England	T083	C0014282
investigate	T169	C1292732
change	T169	C0392747
management	T057	C1273870
postmature pregnancy	T046	C0032993
earlier induction	T061	C3710446
length of labour	T201	C0566679
induction process	T061	C0259787
assess	T052	C1516048
feasibility	T062	C0015730
research process	T062	C0242481
future	T079	C0016884
larger study	T062	C2603343
change	T169	C0392747
management	T057	C1273870
postmature pregnancy	T046	C0032993
NHS	T058	C0027462
hospital	T073	C0019994
October	T079	C3828732
induction	T061	C0259787
weeks	T079	C0439230
gestation	T040	C0032961
induction	T061	C0259787
weeks	T079	C0439230
provided	T052	C1999230
opportunity	T062	C0683937
retrospective	T080	C1514923
analysis	T062	C0936012
Pre-existing	T080	C2347662
data	T078	C1511726
maternity	T054	C0681108
database	T170	C0242356
casenotes	T170	C3842891
collected	T169	C1516698
primary outcomes	T062	C0086750
analysed	T062	C0936012
Mann-Whitney test	T170	C1708930
Hodges-Lehman confidence interval	T081	C0009667
differences	T080	C1705242
medians	T081	C0876920
large city	T083	C0008848
tertiary referral hospital	T073	C0587437
North	T082	C1709269
England	T083	C0014282
women	T098	C0033011
induced	T169	C0205263
change	T169	C0392747
policy	T170	C0242456
compared	T052	C1707455
women	T098	C0033011
induced	T169	C0205263
change	T169	C0392747
primary outcomes	T062	C0086750
length	T081	C1444754
1st	T079	C0022871
2nd stage of labour	T079	C0022872
length of labour	T201	C0566679
length	T081	C1444754
induction	T061	C0259787
established	T080	C0443211
labour	T040	C0022864
length	T081	C1444754
induction	T061	C0259787
birth	T040	C0005615
median	T081	C0876920
length of labour	T201	C0566679
women	T098	C0033011
induced	T169	C0205263
weeks	T079	C0439230
hours	T079	C0439227
women	T098	C0033011
induced	T169	C0205263
weeks	T079	C0439230
hours	T079	C0439227
difference	T080	C1705242
statistically significant	T081	C0237881
CI	T081	C0009667
median	T081	C0876920
difference	T080	C1705242
hours	T079	C0439227
small effect size	T081	C0814843
Pearson's	T081	C0871052
median	T081	C0876920
length	T081	C1444754
induction	T061	C0259787
birth	T040	C0005615
hours	T079	C0439227
women	T098	C0033011
induced	T169	C0205263
weeks	T079	C0439230
hours	T079	C0439227
women	T098	C0033011
induced	T169	C0205263
weeks	T079	C0439230
difference	T080	C1705242
statistically significant	T081	C0237881
CI	T081	C0009667
median	T081	C0876920
difference	T080	C1705242
hours	T079	C0439227
small effect size	T081	C0814843
Pearson's	T081	C0871052
study	T062	C2603343
statistically significant	T081	C0237881
difference	T080	C1705242
length of labour	T201	C0566679
induction	T061	C0259787
change	T169	C0392747
management	T057	C1273870
postmature pregnancy	T046	C0032993
earlier induction	T061	C3710446
large study	T062	C2603343
establish	T080	C0443211
effects of	T080	C1704420
earlier induction	T061	C3710446
labour	T040	C0022864
outcomes	T169	C1274040
Liquid chromatography-mass spectrometry	T059	C0872318
quantitative proteomics analysis	T059	C0022885
proteomics	T091	C0872252
chondroprotective effects	T033	C0243095
astragaloside IV	T109	C0378018
interleukin-1β	T116	C0021753
induced	T169	C0205263
SW1353 chondrocyte-like cells	T025	C1516497
Chondrocyte	T025	C0225369
apoptosis	T043	C0162638
progression	T046	C0242656
Osteoarthritis	T047	C0029408
OA	T047	C0029408
drugs	T061	C3687832
treatment	T169	C1522326
OA	T047	C0029408
study	T077	C1706256
Astragaloside IV	T109	C0378018
ASG-IV	T109	C0378018
protective effect	UnknownType	C0678771
articular cartilage degeneration	T047	C1394964
proliferation	T169	C1514485
chondrocyte	T025	C0225369
study	T077	C1706256
effects	T169	C0728866
mechanisms	T169	C0441712
ASG-IV	T109	C0378018
chondrocyte	T025	C0225369
apoptosis	T043	C0162638
Isobaric Tags For Relative And Absolute Quantitation (iTRAQ)-based quantitative proteomics	T059	C0022885
proteomics	T091	C0872252
detect	T033	C0442726
map	T052	C1283195
proteins	T116	C0033684
SW1353 chondrocyte-like cells	T025	C1516497
pre-treated	T169	C1522326
ASG-IV	T109	C0378018
interleukin-1β	T116	C0021753
IL-1β	T116	C0021753
ASG-IV	T109	C0378018
IL-1β	T116	C0021753
iTRAQ-labeled peptides	T116	C0030956
fractionated	T080	C1979893
high-accuracy liquid chromatography-mass spectrometry	T059	C0872318
LC-MS	T059	C0872318
Cell apoptosis	T043	C0162638
differentially expressed proteins	T116	C0033684
detected	T033	C0442726
flow cytometry	T059	C0016263
FCM	T059	C0016263
quantitative real-time polymerase chain reaction	T063	C3179034
qRT-PCR	T063	C3179034
western blotting	T059	C0005863
apoptosis	T043	C0162638
IL-1β	T116	C0021753
induced	T169	C0205263
SW1353 cells	T025	C1516497
treated	T169	C1522326
ASG-IV	T109	C0378018
inhibited	T080	C0311403
Bioinformatics	T091	C1140694
Bioinformatics analysis	T059	C0022885
gamma actin 1	T116	C3884655
ACTG1	T116	C3884655
Yes Associated Protein 1	T116	C1318127
YAP1	T116	C1318127
Hippo signaling pathway	T043	C3158583
Vitronectin	T116	C4281807
VTN	T116	C4281807
Collagen Type I Alpha 1 Chain	T116	C0972255
COL1A1	T116	C0972255
extracellular matrix (ECM)-receptor interaction signaling pathway	T169	C2984324
up-regulated	T044	C0041904
IL-1β	T116	C0021753
induced	T169	C0205263
SW1353 cells	T025	C1516497
treatment	T169	C1522326
ASG-IV	T109	C0378018
qRT-PCR	T063	C3179034
Western blotting	T059	C0005863
up-regulation	T044	C0041904
genes	T028	C0017337
ASG-IV	T109	C0378018
positive role	T033	C1446409
human	T016	C0086418
osteoarthritic chondrocyte apoptosis	T043	C0162638
chondrocyte	T025	C0225369
modulation	UnknownType	C0544633
Hippo signaling pathway	T043	C3158583
up-regulating	T044	C0041904
YAP1	T116	C1318127
ACTG1	T116	C3884655
expression	T045	C0017262
up-regulating	T044	C0041904
VTN	T116	C4281807
COL1A1	T116	C0972255
ECM-receptor interaction pathway	T169	C2984324
ASG-IV	T109	C0378018
therapeutic	T169	C0302350
potential	T080	C3245505
treatment	T169	C1522326
OA	T047	C0029408
Open-label, multicentre safety study	T062	C1709323
vemurafenib	T109	C3192263
patients	T101	C0030705
BRAF(V600) mutation	T049	C3811884
positive	T033	C1514241
metastatic melanoma	T191	C0278883
follow-up	T058	C1522577
data	T078	C1511726
long-term	T079	C0443252
responders' analysis	T062	C0936012
orally	T082	C0442027
BRAF kinase inhibitor	T116	C3838813
vemurafenib	T109	C3192263
effective	T080	C1704419
tolerable	T080	C4053931
treatment option	T061	C0683525
patients	T101	C0030705
metastatic melanoma	T191	C0278883
BRAF(V600) mutations	T049	C3811884
assessed	T052	C1516048
safety	T080	C0678800
vemurafenib	T109	C3192263
large	T081	C0549177
population	T098	C1257890
patients	T101	C0030705
alternative	T077	C1523987
treatment options	T061	C0683525
safety	T080	C0678800
open-label, multicentre study	T062	C1709323
vemurafenib	T109	C3192263
patients	T101	C0030705
treated	T169	C1522326
untreated	T033	C0332155
BRAF mutation	T049	C3811884
positive	T033	C1514241
metastatic melanoma	T191	C0278883
cobas(®) 4800	T074	C0025080
BRAF V600 Mutation Test	T059	C1504359
primary	T080	C0205225
end-point	T080	C2349179
safety	T080	C0678800
end-points	T080	C2349179
secondary	T080	C0175668
exploratory analysis	T062	C0936012
assess	T058	C0184514
safety	T080	C0678800
outcomes	T080	C0085415
patients	T101	C0030705
long	T080	C0205166
duration of response	T079	C0237585
DOR	T079	C0237585
months	T079	C0439231
median	T082	C0549183
follow-up	T058	C1522577
months	T079	C0439231
months	T079	C0439231
patients	T101	C0030705
discontinued treatment	T033	C0558681
Adverse events	T046	C0877248
AEs	T046	C0877248
consistent with	T078	C0332290
treatment	T169	C0039798
AEs	T046	C0877248
arthralgia	T184	C0003862
alopecia	T047	C0002170
hyperkeratosis	T047	C0870082
treatment	T169	C0039798
AEs	T046	C0877248
squamous cell carcinoma of the skin	T191	C0553723
keratoacanthoma	T191	C0022572
exploratory analysis	T062	C0936012
patients	T101	C0030705
DOR	T079	C0237585
months	T079	C0439231
months	T079	C0439231
AEs	T046	C0877248
overall	T080	C1561607
population	T098	C1257890
specific	T080	C0205369
safety signals	T073	C0183301
vemurafenib	T109	C3192263
vemurafenib exposure	T033	C0743284
follow-up	T058	C1522577
safety	T080	C0678800
large group	UnknownType	C0679991
patients	T101	C0030705
BRAF(V600) mutation	T049	C3811884
positive	T033	C1514241
metastatic melanoma	T191	C0278883
clinical practice	T057	C0205897
clinical trial	T062	C0008976
populations	T098	C1257890
long-term	T079	C0443252
vemurafenib	T109	C3192263
treatment	T169	C0039798
effective	T080	C1704419
tolerable	T080	C4053931
safety signals	T073	C0183301
Collecting	T062	C0010995
Reporting Safety Data	T062	C0011000
Monitoring Trial Conduct	T062	C1516647
Pragmatic Trials	T062	C3658215
Pragmatic trials	T062	C3658215
opportunity	T062	C0683937
real-life	T078	C0376558
data	T078	C1511726
effectiveness	T080	C1280519
safety	T068	C0036043
treatment	T061	C0087111
market authorisation	T064	C2981648
penultimate paper	T078	C1547566
design	T090	C0013171
choices	T052	C1707391
implementation	T052	C1708476
pragmatic trials	T062	C3658215
paper	T078	C1547566
collecting	T062	C0010995
reporting safety data	T062	C0011000
monitoring trial conduct	T062	C1516647
clinical care practice	T061	C0695275
ICH	T170	C0282574
serious adverse events	T033	C1519255
SAEs	T033	C1519255
drug	T121	C1254351
interventional	T061	C0184661
trial	T062	C0008976
risk	T078	C0035647
approach	T082	C0449445
collection	T062	C0010995
non	T033	C1513916
drug	T121	C1254351
non-serious AEs	T033	C1518404
serious events	T080	C2826307
treatment	T061	C0087111
risk	T078	C0035647
profile	T169	C2003903
medicine	T121	C0013227
patient	T101	C0030705
population	T098	C1257890
collection	T062	C0010995
reporting of safety data	T062	C0011000
study	T062	C2603343
follow-up visits	T058	C0589121
risk	T078	C0035647
approach	T082	C0449445
monitoring trial conduct	T062	C1516647
risks	T078	C0035647
pragmatic trial	T062	C3658215
clinical trials	T062	C0008976
mitigation	T067	C1553901
management of these risks	T058	C0035649
care	T052	C1947933
pilot study	T062	C0031928
intraocular lens explantation	T061	C1096279
eyes	T023	C0015392
Chinese patients	T101	C0030705
intraocular lens (IOL) explantation	T061	C1096279
demographic characteristics	T102	C0683970
Retrospective	T080	C1514923
non-comparative case series	T062	C0150093
Clinical data	T170	C1516606
patient charts	T073	C1268547
demographic	T102	C0683970
preoperative	T058	C0205908
postoperative	T079	C0032790
characteristics	T080	C1521970
complications	T046	C0009566
surgical methods	UnknownType	C0683469
visual acuity	T060	C0200150
eyes	T023	C0015392
Chinese	T098	C0152035
patients	T101	C0030705
IOL explants	T061	C1096279
patients	T101	C0030705
age	T032	C0001779
time of explantation	T079	C1254367
patients were female	T032	C0150905
employment	T080	C0014003
farmers	T097	C0221460
retired	T097	C4076599
students	T098	C0038492
unemployed	T033	C0041674
workers	T098	C1527116
staff members	T097	C1552089
teachers	T097	C0221457
officers	T078	C1549461
explantation	T061	C0561946
dislocation	T037	C0012691
decentration	T033	C2609312
retinal detachment	T047	C0035305
prevalent cause	T169	C0015127
incorrect lens power	T033	C1627355
eyes	T023	C0015392
endophthalmitis	T047	C0014236
posterior capsular opacity	T047	C1444680
eyes	T023	C0015392
impacting	T080	C4049986
retinal surgery operation	T061	C0197770
comorbidities	T078	C0009488
high myopia	T047	C0271183
eyes	T023	C0015392
trauma	T037	C3714660
eyes	T023	C0015392
retinal detachment	T047	C0035305
eyes	T023	C0015392
congenital cataracts	T019	C0009691
eyes	T023	C0015392
Marfan's syndrome	T047	C0024796
eyes	T023	C0015392
mean time from implantation to explantation	T079	C1254367
Treatment after explantation	T058	C0032786
posterior chamber IOL implantation	T061	C1298763
eyes	T023	C0015392
aphakia	T190	C0003534
eyes	T023	C0015392
After surgery	T033	C0241311
best corrected visual ability	T033	C1690532
BCVA	T033	C1690532
patients	T101	C0030705
visual ability	T201	C0042812
Dislocation	T037	C0012691
decentration	T033	C2609312
main cause	T169	C0015127
explantation	T061	C0561946
high myopia	T047	C0271183
main risk factor	T033	C0035648
Posterior chamber IOL implantation	T061	C1298763
treatment after explantation	T058	C0032786
Improvement	T077	C2986411
older	T098	C0001792
person	T098	C0027361
specific	T080	C0205369
QOL	T078	C0034380
hearing aid	T074	C0018768
fitting	T061	C0185023
relation	T080	C0439849
social interaction	T033	C0037420
study	T062	C2603343
aimed	T078	C1947946
investigate	T169	C1292732
hearing aids	T074	C0018768
associated with	T080	C0332281
improvement	T077	C2986411
older	T098	C0001792
person	T098	C0027361
specific	T080	C0205369
QOL	T078	C0034380
social interactions	T033	C0037420
modify	T169	C0392747
association	T080	C0439849
WHOQOL-OLD questionnaire	T170	C0034394
answered	T170	C1706817
older adults	T098	C0001792
aged	T032	C0001779
newly	T078	C0750546
fitted	T061	C0185023
hearing aids	T074	C0018768
fitting	T061	C0185023
afterward	T079	C0205087
associations	T080	C0439849
hearing aid	T074	C0018768
usage	T169	C0457083
social relations	UnknownType	C0683633
changes	T169	C0392747
WHOQOL-OLD	T170	C0034394
total score	T081	C2964552
hearing aids	T074	C0018768
fitting	T061	C0185023
estimated	T081	C0750572
adjusting	T061	C0849719
possible	T033	C0332149
confounders	T169	C0009673
Older	T098	C0001792
persons	T098	C0027361
hearing loss	T033	C3887873
experienced	T052	C1709305
significant	T078	C0750502
increases	T169	C0442805
WHOQOL-OLD	T170	C0034394
total score	T081	C2964552
hearing aid	T074	C0018768
fitting	T061	C0185023
Regular	T080	C0205272
use of	T169	C1524063
hearing aid	T074	C0018768
associated with	T080	C0332281
greater	T081	C1704243
increase	T169	C0442805
total score	T081	C2964552
combined	T080	C0205195
categorical	T170	C0683312
variable	T080	C0439828
social relations	UnknownType	C0683633
hearing aid	T074	C0018768
usage	T169	C0457083
revealed	T080	C0443289
separate	T080	C0443299
effects	T080	C1280500
variables	T080	C0439828
combined	T080	C0205195
effect	T080	C1280500
frequent	T079	C0332183
social interactions	T033	C0037420
hearing aid	T074	C0018768
regularly	T080	C0205272
significantly	T078	C0750502
greater	T081	C1704243
increase	T169	C0442805
WHOQOL-OLD	T170	C0034394
total score	T081	C2964552
study's	T062	C2603343
findings	T169	C2607943
indicate	T080	C1521902
hearing aid	T074	C0018768
fitting	T061	C0185023
associated with	T080	C0332281
subsequent	T079	C0332282
improvement	T077	C2986411
older	T098	C0001792
person	T098	C0027361
specific	T080	C0205369
QOL	T078	C0034380
improvements	T077	C2986411
hearing	T039	C0018767
hearing aid	T074	C0018768
possibly	T033	C0332149
enhanced	T052	C2349975
communication	T054	C0009452
opportunities	T080	C0237506
Comparative Effectiveness Research	T062	C2718022
Automated	T169	C0205554
Pediatric	T080	C1521725
Pneumonia	T047	C0032285
Detection	T061	C1511790
Multi-Institutional	T093	C0026738
Clinical	T080	C0205210
Repository	T073	C3847505
PHIS	T170	C0679918
Pilot Study	T062	C0031928
Community-acquired pneumonia	T047	C0694549
pediatric	T080	C1521725
morbidity	T081	C0026538
Administrative	T169	C1292785
data	T078	C1511726
comparative effectiveness research	T062	C2718022
CER	T062	C2718022
sample sizes	T081	C0242618
detection	T033	C0442726
important	T080	C3898777
outcomes	T169	C1274040
misclassification errors	T080	C0743559
variable	T080	C0439828
accuracy	T080	C0443131
discharge diagnosis	T033	C1555319
codes	T170	C0805701
automated	T169	C0205554
scalable	T169	C1513040
accurate	T080	C0443131
method	T170	C0025663
determine	T080	C0521095
presence	T033	C0150312
absence	T169	C0332197
pneumonia	T047	C0032285
children	T100	C0008059
chest imaging	T060	C1531652
reports	T170	C4274373
multi-institutional	T093	C0026738
PHIS	T170	C0679918
clinical	T080	C0205210
repository	T073	C3847505
pediatric	T080	C1521725
CER	T062	C2718022
administrative	T169	C1292785
database	T170	C0242356
children's hospitals	T093	C0020017
clinical	T080	C0205210
data	T078	C1511726
scalable	T169	C1513040
find	T033	C0243095
patients	T101	C0030705
bacterial pneumonia	T047	C0004626
Natural Language Processing	T066	C0027489
NLP	T066	C0027489
application	T080	C0205556
relevant	T080	C2347946
information	T078	C1533716
chest diagnostic imaging	T060	C1531652
reports	T170	C4274373
Domain	T169	C1880389
experts	T097	C0009817
established	T080	C0443211
reference standard	T081	C0034925
manually	T033	C3842330
annotating	T169	C0205245
reports	T170	C4274373
NLP	T066	C0027489
application	T080	C0205556
pleural effusion	T047	C0032227
pulmonary infiltrate	T033	C0235896
pneumonia	T047	C0032285
automatically	T033	C3842331
reports	T170	C4274373
automatically	T033	C3842331
classify	T185	C0008902
report	T170	C4274373
consistent with	T078	C0332290
bacterial pneumonia	T047	C0004626
Compared	T052	C1707455
diagnostic imaging	T060	C0011923
reports	T170	C4274373
reference standard	T081	C0034925
accurate	T080	C0443131
implementation	T052	C1708476
machine learning	T066	C0376284
algorithms	T170	C0002045
NLP	T066	C0027489
application	T080	C0205556
relevant	T080	C2347946
findings	T169	C2607943
sensitivity	T081	C0036667
positive	T033	C1446409
predictive value	T080	C1514307
classifying	T185	C0008902
reports	T170	C4274373
sensitivity	T081	C0036667
positive	T033	C1446409
predictive value	T080	C1514307
specificity	T081	C0037791
compared	T052	C1707455
domain	T169	C1880389
experts	T097	C0009817
manually	T033	C3842330
annotating	T169	C0205245
reports	T170	C0025102
NLP	T066	C0027489
application	T080	C0205556
significantly higher	T081	C4055637
sensitivity	T081	C0036667
positive	T033	C1446409
predictive value	T080	C1514307
specificity	T081	C0037791
NLP	T066	C0027489
pneumonia	T047	C0032285
information	T078	C1533716
pediatric	T080	C1521725
diagnostic imaging	T060	C0011923
reports	T170	C4274373
performed	T169	C0884358
domain	T169	C1880389
experts	T097	C0009817
pilot study	T062	C0031928
NLP	T066	C0027489
information	T078	C1533716
collection	T169	C1516698
imaging reports	T170	C4274373
CER	T062	C2718022
Determination	T058	C1254363
volatile organic compounds	T109	C2350439
exhaled	T040	C0231800
cell lines	T025	C0682523
derived	T080	C1441547
hematological malignancies	T191	C0376545
gas	T104	C0017110
human	T016	C0086418
exhaled	T040	C0231800
volatile organic compounds	T109	C2350439
VOCs	T109	C2350439
health status	T080	C0018759
body	T016	C0242821
Analysis	T062	C0936012
VOCs	T109	C2350439
noninvasive	T185	C2986496
diagnostic tool	T060	C0430022
cancers	T191	C0027651
VOCs	T109	C2350439
gas	T104	C0017110
exhaled	T040	C0231800
cell	T025	C0007634
cell type	T170	C0449475
metabolites	T123	C0870883
cancer markers	T123	C0041366
clinical practice	T057	C0205897
Solid phase microextraction	T059	C1720881
gas chromatography	T059	C0008555
mass spectrometry	T059	C0037813
VOCs	T109	C2350439
tissue culture flask	T074	C0492793
non-Hodgkin's lymphoma	T191	C0024305
cell line JEKO	T025	C0085983
acute mononuclear leukemia	T191	C0085669
cell line SHI-1	T025	C0085983
gaseous	T104	C0017110
biomarkers	T123	C0041366
hematological malignancies	T191	C0376545
macrophage cells	T025	C0024432
lymphocytic cells	T025	C0024264
control	T096	C0009932
blank group	T078	C0441833
RPMI 1640 medium	T130	C0010454
fetal calf serum	T130	C3812213
cells	T025	C0007634
control group	T096	C0009932
concentration	T081	C1446561
dimethyl sulphide	T123	C0574031
2,4-dimethyl-heptane	T123	C0574031
methylbenzene	T109	C0040383
o-xylene	T109	C0046596
dodecane	T109	C0067942
1,3-ditert-butylbenzene	T123	C0574031
JEKO cells	T025	C0085983
ethanol	T109	C0001962
hexanal	T109	C0068007
benzaldehyde	T109	C0005023
SHI-1 cells	T025	C0085983
2,4-dimethyl-heptane	T123	C0574031
benzene	T109	C0005036
4-methyldecane	T123	C0574031
chloroform	T109	C0008238
3,7-dimethyl dodecane	T123	C0574031
hexadecane	T109	C0068005
hexanol	T109	C0001978
cyclohexanol	T109	C0010569
pilot study	T062	C0031928
malignant hematological	T191	C0376545
cells	T025	C0007634
VOCs	T109	C2350439
cell culture flask	T059	C3830103
cell type	T170	C0449475
VOCs	T109	C2350439
hematological malignancies	T191	C0376545
biomarkers	T123	C0041366
diagnosis	T033	C0011900
malignant	T080	C0205282
hematological diseases	T047	C0018939
Intratympanic steroid delivery	T169	C1517566
steroid	T109	C0038317
indwelling catheter	T074	C0007439
refractory severe sudden sensorineural hearing loss	T047	C4275242
decade	T081	C2981279
outcomes	T080	C0085415
intratympanic	T169	C1517566
IT	T169	C1517566
steroid	T109	C0038317
steroid treatment	T061	C0149783
salvage treatment	T061	C0085405
systemic therapy	T061	C1515119
ST	T061	C1515119
sensorineural hearing loss	T047	C4275242
resistant	T169	C0332325
ST	T061	C1515119
infusion mode	T061	C0574032
type	T080	C0332307
concentration	T081	C0392762
solution	T167	C0037633
drug	T121	C1254351
total amount	T081	C1265611
duration	T079	C0444921
fractionation	T061	C0524811
treatment	T061	C0087111
investigate	T169	C1292732
outcomes	T080	C0085415
direct and constant IT delivery	T169	C1517566
dexamethasone	T109	C0011777
DEX	T109	C0011777
indwelling catheter	T074	C0007439
prospective case-control study	T062	C0007328
tertiary referral university hospital	T073	C0020028
subjects	T098	C0080105
treated	T169	C1522326
ST	T061	C1515119
IT	T169	C1517566
DEX	T109	C0011777
4 Fr catheter	T074	C0085590
inserted	T058	C0441587
sub-annular fashion	T080	C0205556
postero-inferior	T082	C1179852
tympanotomy	T061	C0087123
endocanalar approach	T082	C0444470
local anesthesia	T061	C0002921
DEX	T109	C0011777
days	T079	C0439228
bone and air-conducted pure tone	T060	C0200273
speech audiometry	T060	C0004293
months	T079	C0439231
treatment	T061	C0087111
patients	T101	C0030705
refractory	T169	C0205269
ST	T061	C1515119
HL	T033	C0175841
IT	T169	C1517566
DEX	T109	C0011777
HL	T033	C0175841
ST	T061	C1515119
side effects	T046	C0879626
sudden deafness	T184	C1148477
refractory	T169	C0205269
ST	T061	C1515119
perfusion	T061	C0031001
DEX	T109	C0011777
intratympanic	T169	C1517566
catheter	T074	C0085590
patients	T101	C0030705
drug	T121	C1254351
middle ear	T030	C0013455
repeatable	T061	C0087111
sustained form	T122	C1710261
discomfort and a partial rescue	T062	C3661486
speech recognition	T041	C0597498
Design	T052	C1707689
synthesis	T052	C1883254
anti-tumor activity	T044	C1148560
study	T062	C2603343
histone deacetylase inhibitors	T116	C1512474
isatin	T109	C0022115
caps	T104	C1254350
o-phenylenediamine	T109	C0043796
zinc binding groups	T104	C1254350
epigenetic studies	T091	C1655731
histone deacetylases	T116	C0019643
HDACs	T116	C0019643
diseases	T047	C0012634
cancer	T191	C0027651
researches	T062	C0035168
different	T080	C1705242
HDAC isoforms	T116	C0019643
roles	T077	C1705810
tumor types	T033	C4263544
series	T081	C0205549
HDAC inhibitors	T116	C1512474
isatin	T109	C0022115
caps	T104	C1254350
o-phenylenediamine	T109	C0043796
zinc binding groups	T104	C1254350
designed	T052	C1707689
synthesized	T052	C1883254
through	T169	C0332273
scaffold hopping strategy	T059	C0022885
compounds	T103	C1706082
compound 9n	T103	C1706082
better	T080	C0332272
HDAC	T116	C0019643
inhibition	T039	C1524081
antiproliferative activities	T044	C1148560
multiple	T081	C0439064
tumor cell lines	T025	C0085983
compared	T052	C1707455
positive control	T077	C1883676
entinostat	T109	C2743752
MS-275	T109	C1510480
compared	T052	C1707455
MS-275	T109	C1510480
IC50	T081	C0600495
values	T081	C1522609
HDAC1	T116	C2718309
2	T116	C0768528
3	T116	C1098658
compound 9n	T103	C1706082
IC50	T081	C0600495
values	T081	C1522609
HDAC1	T116	C2718309
2	T116	C0768528
3	T116	C1098658
HDAC1	T116	C2718309
selectivity	T080	C0205556
Efficacy	T080	C1280519
Pharmacologic	T121	C1254351
Cotreatment	T061	C0087111
Antipsychotic	T121	C0040615
Monotherapy	T061	C0087111
Schizophrenia	T048	C0036341
Quality	T080	C0332306
Meta-analytic	T062	C0920317
Evidence	T078	C3887511
treatment	T061	C0087111
responses	T032	C0871261
schizophrenia	T048	C0036341
antipsychotic drug	T121	C0040615
treatment	T061	C0087111
psychotropic	T121	C0033978
medication	T121	C0013227
evaluation	T058	C0220825
efficacy	T080	C1280519
medication	T121	C0013227
combinations	T121	C0013162
meta-analytically	T062	C0920317
efficacy	T080	C1280519
pharmacologic	T121	C1254351
combination	T121	C0013162
antipsychotic drugs	T121	C0040615
adults	T100	C0001675
schizophrenia	T048	C0036341
PubMed	T170	C1138432
PsycInfo	T170	C1140129
Meta-analyses	T062	C0920317
randomized clinical trials	T062	C0206034
efficacy	T080	C1280519
antipsychotic drugs	T121	C0040615
antipsychotic	T121	C0040615
nonantipsychotic medications	T121	C0013227
placebos	T122	C1696465
antipsychotic	T121	C0040615
monotherapy	T061	C0087111
adults	T100	C0001675
schizophrenia	T048	C0036341
reviewers	T098	C1882950
data	T078	C1511726
quality	T080	C0332306
methods	T170	C0025663
meta-analyses	T062	C0920317
Measurement Tool to Assess Systematic Reviews	T170	C1955832
AMSTAR	T170	C1955832
quality	T080	C0332306
Effect sizes	T081	C0814843
standardized mean difference	T201	C1828170
risk ratio	T081	C0028873
combinations	T121	C0013162
antipsychotic drug	T121	C0040615
combinations	T121	C0013162
clozapine	T109	C0009079
symptom	T184	C1457887
reduction	T080	C0392756
positive	T033	C1446409
negative	T033	C0205160
symptoms	T184	C1457887
treatment recommendations	T058	C0582427
inefficacies	T033	C0231184
cognitive	T169	C1516691
depressive symptoms	T184	C0086132
discontinuation	T058	C0457454
treatment	T061	C0087111
inefficacies	T033	C0231184
meta-analyses	T062	C0920317
combination	T121	C0013162
individual	T098	C0237401
participants	T098	C0679646
symptom	T184	C1457887
reductions	T061	C0441610
antipsychotic drug	T121	C0040615
clozapine	T109	C0009079
combination	T121	C0013162
treatments	T061	C0087111
standard mean difference	T201	C1828170
CI	T081	C0009667
CI	T081	C0009667
combination	T121	C0013162
clozapine	T109	C0009079
quality	T080	C0332306
methods	T170	C0025663
meta-analyses	T062	C0920317
high	T080	C0205250
mean score	T033	C3533236
maximum score	T081	C0449820
quality	T080	C0332306
meta-analyzed studies	T062	C0920317
low	T080	C0205251
mean score	T033	C3533236
maximum score	T081	C0449820
Treatment recommendations	T058	C0582427
effect size	T081	C0814843
correlation coefficient	T081	C0392762
CI	T081	C0009667
effect sizes	T081	C0814843
quality	T080	C0332306
correlation coefficient	T081	C0392762
CI	T081	C0009667
Meta-analyses	T062	C0920317
recommendations	T078	C0034866
positively	T033	C1446409
effect sizes	T081	C0814843
effect sizes	T081	C0814843
meta-analyzed study	T062	C0920317
quality	T080	C0332306
reducing	T080	C0392756
confidence	T041	C1704726
recommendations	T078	C0034866
Higher	T080	C0205250
quality	T080	C0332306
patient	T101	C0030705
meta-analyses	T062	C0920317
subpopulations	T098	C1257890
combination	T121	C0013162
treatment	T061	C0087111
patients	T101	C0030705
schizophrenia	T048	C0036341
meta-analytic	T062	C0920317
literature	T170	C0023866
Involvement	T169	C1314939
Vascular	T023	C0005847
Aldosterone Synthase	T116	C0075233
Phosphate	T121	C1601799
Induced	T169	C0205263
Osteogenic Transformation	T033	C0243095
Vascular	T023	C0005847
Smooth Muscle Cells	T025	C1135918
Vascular calcification	T046	C0342649
hyperphosphatemia	T047	C0085681
mortality	T081	C0178686
chronic kidney disease	T047	C1561643
CKD	T047	C1561643
Vascular calcification	T046	C0342649
aldosterone	T109	C0002006
osteogenic transformation	T033	C0243095
vascular	T023	C0005847
smooth muscle cells	T025	C1135918
VSMCs	T025	C1135918
absence	T169	C0332197
exogenous	T169	C0205228
aldosterone	T109	C0002006
silencing	T044	C1148560
pharmacological inhibition	T044	C1148560
spironolactone	T109	C0037982
eplerenone	T109	C0961485
mineralocorticoid receptor	T116	C0066563
MR	T116	C0066563
phosphate	T121	C1601799
induced	T169	C0205263
osteo-	T033	C0243095
chondrogenic transformation	T033	C0243095
primary	T080	C0205225
human	T016	C0086418
aortic	T023	C0003483
smooth muscle cells	T025	C1135918
HAoSMCs	T025	C1135918
phosphate	T121	C1601799
concentrations	T081	C0392762
up-regulated	T044	C0041904
aldosterone synthase	T116	C0075233
CYP11B2	T116	C1527416
expression	T045	C1171362
HAoSMCs	T025	C1135918
Silencing	T044	C1148560
deficiency	T047	C0033626
CYP11B2	T116	C1527416
VSMCs	T025	C1135918
phosphate	T121	C1601799
induced	T169	C0205263
osteogenic reprogramming	T042	C1254358
calcification	T042	C1533591
Phosphate	T121	C1601799
treatment	T169	C1522326
nuclear export	T043	C0887840
APEX1	T116	C0140145
CYP11B2	T028	C1413857
transcriptional repressor	T116	C1336789
APEX1	T116	C0140145
silencing	T044	C1148560
up-regulated	T044	C0041904
CYP11B2	T028	C1413857
expression	T045	C0017262
osteo-	T033	C0243095
chondrogenic transformation	T033	C0243095
APEX1	T116	C0140145
overexpression	T045	C1514559
phosphate	T121	C1601799
induced	T169	C0205263
osteo-	T033	C0243095
chondrogenic transformation	T033	C0243095
calcification	T042	C1533591
HAoSMCs	T025	C1135918
Cyp11b2	T028	C1413857
expression	T045	C0017262
aortic	T023	C0003483
tissue	T024	C0040300
hyperphosphatemic	T047	C0085681
klotho-hypomorphic (kl/kl) mice	T015	C0025929
wild-type	T028	C1883559
mice	T015	C0025929
adrenalectomized kl/kl mice	T015	C0025929
spironolactone	T109	C0037982
treatment	T169	C1522326
aortic	T023	C0003483
osteoinductive reprogramming	T042	C1254358
findings	T169	C2607943
VSMCs	T025	C1135918
aldosterone synthase	T116	C0075233
up-regulated	T044	C0041904
phosphate	T121	C1601799
induced	T169	C0205263
disruption	T169	C0332453
APEX1	T116	C0140145
gene suppression	T045	C0038855
Vascular	T023	C0005847
CYP11B2	T116	C1527416
VSMCs	T025	C1135918
osteo-	T033	C0243095
chondrogenic transformation	T033	C0243095
hyperphosphatemia	T047	C0085681
Fairness	T080	C2911689
challenge	T058	C0805586
competency-based postgraduate medical education programs	T065	C0150562
Competency-based medical education systems	UnknownType	C0681326
institutions	UnknownType	C0681325
individualize	T169	C0205245
teaching practices	T065	C0039403
meet	T067	C1550543
needs	T080	C0027552
diverse learners	T098	C0038492
improvement	T077	C2986411
individualization	T169	C0205245
curricula	T170	C0010478
programs	T169	C3484370
learners	T098	C0038492
fair manner	T033	C0243095
learners	T098	C0038492
competencies	T080	C0086035
probation	T089	C0687758
dismissed	T052	C2348301
training programs	T065	C0040607
issues	T033	C0033213
fairness	T080	C2911689
legal claims	T170	C0282574
examination	T057	C0033336
fairness	T080	C2911689
examine	T033	C0332128
fairness	T080	C2911689
postgraduate medical education	T065	C0013633
contexts	T078	C0449255
educational opportunities	T033	C0243095
assessment practices	T058	C0220825
decision-making processes	T057	C0011111
fairness	T080	C2911689
legal standpoint	T169	C1301860
fairness	T080	C2911689
context	T078	C0449255
learning environment	T082	C1510556
fairness	T080	C2911689
issues	T033	C0033213
US	T083	C0041703
training programs	T065	C0040607
fairness	T080	C2911689
medical education system	UnknownType	C0681326
competency-based education framework	T078	C1254370
Assessment	T057	C0033336
committees	T097	C1522486
annual programmatic evaluations	T057	C0033336
fairness	T080	C2911689
postgraduate medical education programs	T065	C0150562
fairness	T080	C2911689
training experiences	T065	C0220931
assessment practices	T058	C0220825
examined	T033	C0332128
committees	T097	C1522486
programs	T169	C3484370
fairness	T080	C2911689
educational program	T065	C0150562
conversations	T054	C0871703
issues	T033	C0033213
Us3	T116	C0033684
Us9	T116	C2001544
proteins	T116	C0033684
stromal invasion	T033	C1336515
bovine herpesvirus 1	T005	C0021335
respiratory mucosa	T024	C0751974
Bovine herpesvirus 1 (BHV-1) infection	T047	C3687301
conjunctivitis	T047	C0009763
upper respiratory tract	T023	C0458578
problems	T033	C0033213
pneumonia	T047	C0032285
genital disorders	T047	C0178829
abortion	T033	C0156543
BHV-1	T005	C0021335
spread	T080	C0332261
plaque	T033	C0332461
manner	T169	C0205245
invade	T169	C0205245
breaching	T037	C3203359
basement membrane	T024	C0004799
(BM)	T024	C0004799
barrier	UnknownType	C0682585
respiratory mucosa	T024	C0751974
BHV-1	T005	C0021335
Us3	T116	C0033684
serine/threonine kinase	T116	C0072402
induces	T169	C0205263
cytoskeletal reorganization	T043	C1511632
BHV-1	T005	C0021335
Us9	T116	C2001544
tail-anchored membrane protein	T116	C0025252
axonal transport	T043	C0004462
viruses	T005	C0042776
neurons	T025	C0027882
study	T062	C2603343
investigated	T169	C1292732
role	T077	C1705810
Us3	T116	C0033684
Us9	T116	C2001544
BHV-1 infection	T047	C3687301
respiratory mucosa	T024	C0751974
characterized	T052	C1880022
BHV-1	T005	C0021335
Us3	T028	C0017337
null	T005	C0042776
Us9	T028	C0017337
null	T005	C0042776
revertant viruses	T005	C0042776
analysed	T062	C0936012
viral replication	T043	C0042774
plaque	T033	C0332461
size	T082	C0456389
Madin-Darby bovine kidney	T025	C0598829
MDBK	T025	C0598829
cells	T025	C0598829
respiratory mucosa	T024	C0751974
viral penetration	T043	C1656555
BM	T024	C0004799
respiratory mucosa	T024	C0751974
inoculated	T061	C2987620
recombinant viruses	T005	C0085391
Knockout	T050	C1522225
Us3	T028	C0017337
reduction	T080	C0392756
viral titre	T081	C2713348
plaque	T033	C0332461
size	T082	C0456389
latitude	T081	C1627936
MDBK cells	T025	C0598829
trachea mucosa	T023	C0225584
no	T033	C1513916
defects	T169	C1457869
cell-to-cell spread	T040	C1160712
observed	T169	C1441672
BHV-1	T005	C0021335
Us9	T028	C0017337
null virus	T005	C0042776
BHV-1	T005	C0021335
Us3	T028	C0017337
null	T005	C0042776
Us9	T028	C0017337
null viruses	T005	C0042776
significant	T078	C0750502
reduction	T080	C0392756
plaque	T033	C0332461
penetration	T169	C0205321
BM	T024	C0004799
penetration	T169	C0205321
inhibited	T052	C3463820
conclusion	T078	C1707478
findings	T062	C0035168
Us3	T028	C0017337
Us9	T028	C0017337
role	T077	C1705810
invasion	T033	C1336515
BHV-1	T005	C0021335
BM	T024	C0004799
respiratory mucosa	T024	C0751974
research	T062	C0035168
attenuation	T052	C0599946
viruses	T005	C0042776
better	T080	C0332272
performing	T169	C0884358
vaccines	T121	C0042210
Traumatic Brain Injury	T037	C0876926
Depression	T048	C0011570
Community	T096	C0009462
Based	T169	C1527178
Cohort Study	T081	C0009247
Adult	T100	C0001675
Life Span	T102	C0870809
traumatic brain injuries	T037	C0876926
TBIs	T037	C0876926
associated with	T080	C0332281
cases	T077	C1706256
clinically significant	T033	C2826293
depression	T048	C0011570
general community	T096	C0009462
interactions	T169	C1704675
variables	T081	C1705098
depression	T048	C0011570
TBI	T037	C0876926
Population	T098	C1257890
community	T096	C0009462
study	T062	C2603343
Canberra	T083	C0454764
Queanbeyan	UnknownType	C0681784
Australia	T083	C0004340
Three	T081	C0205449
age cohorts	T098	C2348001
young	T079	C0332239
middle-aged	T100	C0205847
older	T098	C0001792
adults	T100	C0001675
aged	T032	C0001779
60-64 years	T100	C4035747
baseline	T081	C1442488
randomly	T080	C0439605
selected	T052	C1707391
followed	T079	C0332283
years apart	T079	C0439234
people	T098	C0027361
TBI	T037	C0876926
Lifetime	T079	C4071830
sustained	T169	C0443318
time	T079	C0040223
since	T079	C1711239
birth	T040	C0005615
recent	T079	C0332185
preceding	T079	C0332152
years	T079	C0439234
multiple	T081	C0439064
TBIs	T037	C0876926
current	T079	C0521116
depression	T048	C0011570
risk factors	T033	C0035648
depression	T048	C0011570
age	T032	C0001779
sex	T032	C0079399
marital	T102	C0024819
employment status	T033	C0242271
prior history	T033	C2133631
depression	T048	C0011570
medical conditions	T033	C0243095
life events	T051	C0441471
alcohol consumption	T055	C0001948
social support	T054	C0037438
physical activity	T056	C0026606
equations	T077	C0552449
association	T080	C0439849
TBI	T037	C0876926
clinically significant	T033	C2826293
depression	T048	C0011570
cases	T077	C1706256
controlling	T067	C2239193
multiple	T081	C0439064
demographic	T078	C0011292
health	T078	C0018684
lifestyle	T054	C0023676
factors	T169	C1521761
association	T080	C0439849
depression	T048	C0011570
TBI	T037	C0876926
TBI	T037	C0876926
individuals	T098	C0237401
monitored	T097	C1521743
long-term	T079	C0443252
psychological health	T041	C0025353
CS	T109	C0162969
PEG	T109	C0032483
PLGA nano-prototype	T109	C0071599
delivery	T070	C3850077
bioactive compounds	T123	C0574031
novel	T080	C0205314
approach	T082	C0449445
induction	T169	C0205263
apoptosis	T043	C0162638
HepG2 cell line	T025	C2717940
Polymer	T104	C0032521
based	T169	C1527178
nanoparticles	T073	C1450054
used	T169	C1524063
vectors	T082	C0442335
cancer	T191	C0007097
drug delivery	T169	C0039798
bioactive compounds	T123	C0574031
quercetin	T109	C0034392
ellagic acid	T109	C0013900
gallic acid	T109	C0016979
antioxidants	T121	C0003402
chemopreventive candidates	T121	C1516463
against	T080	C0521124
various	T081	C0439064
types	T080	C0332307
cancers	T191	C0007097
low	T080	C0205251
bioavailability	T081	C0005508
short	T081	C1806781
half-life	T079	C0018517
time	T079	C0040223
obstacles	T169	C0332206
novel	T080	C0205314
PLGA nano-platform	T109	C0071599
functionalized	T169	C0205245
CS	T109	C0162969
PEG	T109	C0032483
encapsulate	T080	C0205223
phytochemicals	T109	C0577749
encapsulation	T067	C2348438
protect	T033	C1545588
compounds	T121	C1254351
phagocytic uptake	T043	C3888108
deliver	T070	C3850077
PLGA-CS-PEG nano-prototype	T121	C1254351
biodegradability	T080	C0205556
biosafety	T080	C0205556
types	T080	C0332307
PLGA-based nanocomposites	T121	C1254351
prepared	T052	C1521827
characterized	T052	C1880022
investigated	T169	C1292732
synthesized	T052	C1883254
nano-formulations	T073	C1707824
against	T080	C0521124
human	T016	C0086418
hepatocellular carcinoma	T191	C2239176
HepG2	T025	C2717940
colorectal cancer	T191	C1527249
HCT 116	T025	C1258005
cell lines	T025	C0682523
using	T169	C1524063
cell growth inhibition	T043	C1512773
assays	T059	C1510438
followed by	T079	C0332283
apoptosis	T043	C0162638
necrosis	T042	C0027540
assays	T059	C1510438
using	T169	C1524063
flow cytometry	T059	C0016263
detect	T059	C0022885
mechanism	T169	C0441712
HepG2	T025	C2717940
cell death	T043	C0007587
average	T081	C1510992
diameters	T081	C1301886
nano-prototypes	T073	C1450054
cytotoxic activity	T059	C1551412
quercetin	T109	C0034392
ellagic acid	T109	C0013900
gallic acid	T109	C0016979
encapsulated	T080	C0205223
PLGA	T109	C0071599
PLGA-CS	T121	C1254351
PLGA-CS-PEG nano-prototypes	T121	C1254351
found	T033	C0150312
reduce	T080	C0392756
IC50s	T081	C0600495
HepG2 cells	T025	C2717940
values	T081	C1522609
folds	T081	C1880833
folds	T081	C1880833
folds	T081	C1880833
quercetin	T109	C0034392
dependent	T080	C0851827
apoptosis	T043	C0162638
necrosis	T042	C0027540
ellagic acid	T109	C0013900
gallic acid	T109	C0016979
dependent	T080	C0851827
apoptosis	T043	C0162638
CS	T109	C0162969
PEG	T109	C0032483
PLGA	T109	C0071599
nano-delivery system	T169	C0449914
quercetin	T109	C0034392
ellagic acid	T109	C0013900
gallic acid	T109	C0016979
potentiate	T052	C2349975
apoptosis-mediated	T043	C0162638
cell death	T043	C0007587
HepG2 cell line	T025	C2717940
Fingerprint	T073	C0016126
background checks	T033	C0243095
personal care workers	T097	C1522486
Stakeholder	T098	C0027361
views	T078	C1254370
policy	T170	C0242456
criteria	T078	C0243161
Decision makers	T098	C1257890
implementing	T052	C1708476
mechanisms	T169	C0441712
protecting	T033	C0516529
elderly	T098	C0001792
vulnerable adults	T033	C1562367
abuse	T051	C1546935
pilot project	T062	C0031928
fingerprint	T073	C0016126
criminal	T098	C2607966
background checks	T033	C0243095
personal care workers	T097	C1522486
Michigan	T083	C1548669
opportunity	T062	C0683937
mechanism	T169	C0441712
conjunction	T078	C2699427
pilot project	T062	C0031928
stakeholder	T097	C1522486
analysis	T062	C0936012
decision makers	T098	C1257890
stakeholder	T098	C0027361
perceptions	T041	C0030971
standard	T170	C3244099
policy	T170	C0242456
criteria	T078	C0243161
effectiveness	T080	C1280519
efficiency	T081	C0013682
equity	T080	C0237597
focus groups	UnknownType	C0681860
web-based survey	T170	C0038951
collect	T062	C0010995
data	T078	C1511726
stakeholders	T098	C0027361
stakeholders	T098	C0027361
fingerprint	T073	C0016126
background checks	T033	C0243095
personal care workers	T097	C1522486
effective	T080	C1704419
net benefit	T081	C0814225
contingencies	T051	C0441471
difficulties	T033	C0425101
constraints	T169	C0443288
government	T092	C0018104
involvement	T169	C1314939
preliminary analysis	T062	C0936012
foundational information	T078	C1533716
decision makers	T098	C1257890
benefit-cost analysis	T057	C0010174
Penetrating	T169	C0205321
Craniomaxillofacial Injury	T037	C0024961
Craniomaxillofacial Injury Caused by a Pneumatic Nail Gun	T037	C0418073
Pneumatic Nail Gun	T073	C3273359
treatment	T169	C1522326
penetrating	T169	C0205321
oral	T030	C0226896
nasal cavities	T030	C0027423
treatment	T169	C1522326
enhanced	T052	C2349975
lingual nerve	T061	C0394805
inferior alveolar nerve blocks	T061	C0394801
maintain	T052	C0024501
spontaneous respiration	T033	C0412771
tongue	T023	C0040408
distracted	T033	C0243095
palate	T023	C0700374
upper airway	T023	C0458827
vibrational signal	T067	C1710082
mating	T040	C1260875
disruption	T169	C0332453
glassy-winged sharpshooter	T204	C0600235
Homalodisca vitripennis	T204	C1218186
glassy-winged sharpshooter	T204	C0600235
GWSS	T204	C0600235
Homalodisca vitripennis	T204	C1218186
pest	T204	C0021585
grapevines	T002	C0682492
transmit	T169	C0332289
Xylella fastidiosa	T007	C0995982
causal agent	T001	C0314732
Pierce's disease	T047	C0032080
GWSS	T204	C0600235
mating	T040	C1260875
communication	T054	C0003046
vibrational signals	T067	C1710082
vibrational	T080	C0205556
mating	T040	C1260875
disruption	T169	C0332453
alternative	T077	C1523987
insecticides	T131	C0021576
suppression	UnknownType	C0678671
GWSS	T204	C0600235
population	T098	C1257890
objectives	T170	C0018017
spectral	T081	C1883073
features	T080	C2348519
female	T032	C0086287
signal	T067	C1710082
male	T032	C0086582
signaling	T040	C3158821
disruptive	T080	C0332454
signals	T067	C1710082
alter	T169	C0392747
male	T032	C0086582
perception	T041	C0030971
acceptance	T055	C0000899
female	T032	C0086287
signal intensity	T081	C0871362
Results	T033	C0683954
male	T032	C0086582
responses	T032	C0871261
playback	T052	C0441655
modified	T169	C0392747
female	T032	C0086287
signals	T067	C1710082
significantly	T078	C0750502
reduced	T080	C0392756
female	T032	C0086287
signal spectral components	T077	C1705248
Playback	T052	C0441655
bioassays	T059	C0005507
transmission	T070	C1521797
frequency tone	T079	C0237917
plants	T002	C0032098
suppressed	T169	C1260953
male	T032	C0086582
signaling	T040	C3158821
female	T032	C0086287
signal playback	T052	C0441655
disruptive	T080	C0332454
signal amplitude	T082	C3828024
female	T032	C0086287
signal playback	T052	C0441655
mechanism	T169	C0441712
cessation	T052	C1880019
male	T032	C0086582
signaling	T040	C3158821
presence	T033	C0150312
disruption	T169	C0332453
results	T033	C0683954
vibrational signal	T067	C1710082
laboratory	T073	C0022877
field experiments	T062	C0868962
assess	T052	C1516048
efficacy	T080	C1280519
mating	T040	C1260875
GWSS	T204	C0600235
Barriers	T080	C0205556
facilitators	T080	C0205556
smoking cessation	T055	C0085134
cancer	T191	C0006826
context	T078	C0449255
qualitative study	T062	C0949415
patient	T101	C0030705
family	T099	C0015576
professional	T097	C0679924
views	T080	C0205556
Continued	T078	C0549178
smoking	T055	C0037369
cancer	T191	C0006826
adversely affects	T046	C0879626
quality of life	T184	C0518214
survival	T169	C0220921
cancer	T191	C0006826
survivors	T101	C0206194
smoke	T055	C0037369
cancer	T191	C0006826
positive	T033	C1446409
behaviour change	T055	C0542299
Smoking	T055	C0037369
social groups	T098	C0687744
interventions	T061	C0184661
target	T169	C1521840
families	T099	C0015576
individuals	T098	C0027361
successful	T080	C1272703
qualitative study	T062	C0949415
patients	T101	C0030705
family members	T099	C0086282
health professionals	T097	C1704312
views	T080	C0205556
experiences	T041	C0596545
smoking	T055	C0037369
smoking cessation	T055	C0085134
cancer	T191	C0006826
interventions	T061	C0184661
In-depth qualitative interviews	T058	C0683518
patients	T101	C0030705
family members	T099	C0086282
health professionals	T097	C1704312
Data	T078	C1511726
'Framework' method	T169	C0449851
patient	T101	C0030705
family members	T099	C0086282
National Health Service	T058	C0027462
NHS	T058	C0027462
smoking cessation	T055	C0085134
services	T058	C0018747
smoked	T055	C0037369
smoking	T055	C0037369
discussion	T061	C0557050
clinicians	T097	C0871685
Clinicians	T097	C0871685
barriers	T080	C0205556
discussion	T061	C0557050
Participants	T098	C0679646
continued	T078	C0549178
smoking	T055	C0037369
stress	T033	C0038435
diagnosis	T060	C0920688
personal	T032	C1519021
control	T080	C0243148
lack	T080	C0332268
smoking	T055	C0037369
cancer	T191	C0006826
health	T078	C0018684
barriers	T080	C0205556
smoking cessation	T055	C0085134
patients	T101	C0030705
family members	T099	C0086282
insufficiently	T080	C0231180
assessed	T052	C1516048
clinicians	T097	C0871685
Interventions	T061	C0184661
Improving	T080	C1272745
Sexual Health	T032	C2362326
Young People	T100	C0087178
Mobility Impairments	T033	C0518456
Challenges	T058	C0805586
Recommendations	T078	C0034866
mixed-method study	T062	C0681814
challenges	T058	C0805586
providing	T052	C1999230
sexual health	T032	C2362326
services	T058	C0018747
youth	T100	C0087178
mobility impairments	T033	C0518456
perspective	T082	C0449911
health care providers	T097	C0018724
experts	T097	C0009817
compares	T052	C1707455
sexual health	T032	C2362326
experiences	T041	C0596545
youth	T100	C0087178
mobility impairments	T033	C0518456
Secondary data analysis of My Path	UnknownType	C0683944
study	T062	C0681814
focused	T169	C1285542
transition	T052	C2700061
adulthood	T079	C0700597
youth	T100	C0087178
mobility impairments	T033	C0518456
exploratory sequential design	T062	C0035171
qualitative data	UnknownType	C0681942
analyzed	T062	C0936012
systematic	T169	C0220922
content analysis	T062	C0681915
quantitative analysis of survey data	UnknownType	C0681919
Challenges	T058	C0805586
included	T169	C0332257
not talking	T080	C0205556
sex	T032	C1522384
sexual development	T040	C0233896
adaptation	T040	C0000934
instruction	T170	C1442085
parent roles	T054	C0680075
safety	T068	C0036043
Survey	T170	C0038951
data	T078	C1511726
youth	T100	C0087178
mobility impairments	T033	C0518456
diverse	T080	C1880371
experiences	T041	C0596545
sexual behavior	T053	C0036864
sources	T033	C0449416
sexual health	T032	C2362326
information	T078	C1533716
connected	T052	C2986575
primary care providers	T097	C0018724
received	T080	C1514756
information	T078	C1533716
sexual health	T032	C2362326
Interventions	T058	C1273869
improve	T033	C0184511
youths	T100	C0087178
well-being	T078	C0018684
include	T052	C2700399
comprehensive care	T058	C0009586
education	T065	C0018701
promotes	T052	C0033414
supports	T077	C1521721
healthy	T080	C3898900
sexual development	T040	C0233896
Understanding	T041	C0162340
interrelationship	T080	C0439849
synthesis	T038	C0220781
urea	T109	C0041942
gluconeogenesis	T044	C0017715
overall	T080	C1561607
balanced equation	T077	C0552449
metabolic	T169	C0311400
interrelationship	T080	C0439849
ureagenesis	T044	C0597619
gluconeogenesis	T044	C0017715
overall	T080	C1561607
equation	T077	C0552449
metabolic	T169	C0311400
link	T082	C0449379
ureagenesis	T044	C0597619
gluconeogenesis	T044	C0017715
guided approach	T082	C0449445
students	T098	C0038492
problem	T033	C0033213
obtaining	T052	C1706701
overall	T080	C1561607
equation	T077	C0552449
metabolic pathway	T169	C1291081
atoms	T196	C0567415
charges	T032	C1706211
reactions	T169	C0443286
cellular localizations	T043	C1660642
substrates	T167	C3891814
transport	T044	C1519628
systems	T169	C0449913
balanced	T169	C0205415
overall	T080	C1561607
equation	T077	C0552449
metabolic pathway	T169	C1291081
physiological	T169	C0205463
textbooks	T073	C0039712
report	T170	C0684224
overall	T080	C1561607
equations	T077	C0552449
metabolic pathways	T169	C1291081
ureagenesis	T044	C0597619
gluconeogenesis	T044	C0017715
metabolism	T040	C0025519
enzymology	T169	C0014445
molecular biology	T091	C0026376
molecular genetics	T091	C0086345
paper	T170	C1706852
students	T098	C0038492
overall	T080	C1561607
reaction	T169	C0443286
metabolic pathway	T169	C1291081
reactions	T169	C0443286
balanced	T169	C0205415
atoms	T196	C0567415
charges	T032	C1706211
suggestion	T078	C1705535
overall	T080	C1561607
equation	T077	C0552449
metabolic	T169	C0311400
interrelationship	T080	C0439849
ureagenesis	T044	C0597619
gluconeogenesis	T044	C0017715
urea	T109	C0041942
glucose	T109	C0017725
final	T079	C3853528
products	T071	C1514468
rationalize	T169	C1552821
topic	T078	C1706203
students	T098	C0038492
teachers	T097	C0221457
metabolism	T040	C0025519
chapter	T078	C1552857
human physiology	T091	C3826168
B-cell	T025	C0004561
Epitopes	T129	C0003316
Salmonella enterica serovar Typhi	T007	C0036125
Hemolysin E	T116	C2603981
Potential	T080	C3245505
antibody	T116	C0003241
therapeutic	T061	C0087111
target	T169	C1521840
Hemolysin E	T116	C2603981
HlyE	T116	C2603981
immunogenic	T169	C0872192
novel	T080	C0205314
pore	T026	C1325742
toxin	T109	C0073997
pathogenesis	T046	C0699748
typhoid fever	T047	C0041466
mapping	T052	C1283195
B-cell	T025	C0004561
epitopes	T129	C0003316
Salmonella enterica serovar Typhi	T007	C0036125
S. Typhi	T007	C0036125
critical	T080	C1511545
immunogenic regions	T082	C1254362
HlyE	T116	C2603981
peptide library	T116	C0376436
anti-HlyE polyclonal antibodies	T116	C0312586
typhoid	T047	C0041466
patient	T101	C0030705
sera	T031	C0229671
Bioinformatic	T091	C1140694
tools	T170	C0037589
analyze	T062	C0936012
map	T052	C1283195
peptide sequences	T087	C0920679
protein	T116	C0033684
epitopes	T129	C0003316
analysis	T062	C0936012
linear	T082	C0205132
conformational	T082	C1254362
epitopes	T129	C0003316
HlyE protein	T116	C2603981
predicted	T078	C0681842
linear	T082	C0205132
GAAAGIVAG	T087	C0002518
conformational	T082	C1254362
epitope	T129	C0003316
PYSQESVLSADSQNQK	T087	C0002518
sera	T031	C0229671
epitopes	T129	C0003316
isolate	T061	C0204727
epitope	T129	C0003316
monoclonal antibodies	T116	C0003250
antibody	T116	C0003241
phage display	T063	C1519025
Monoclonal scFv	T116	C1432679
antibodies	T116	C0003241
linear	T082	C0205132
conformational	T082	C1254362
epitopes	T129	C0003316
Molecular docking	T170	C3494274
antigen-antibody interaction	T039	C1268869
monoclonal antibodies	T116	C0003250
epitopes	T129	C0003316
HlyE	T116	C2603981
monomer	T116	C0312811
oligomer structure	T087	C0599219
positional	T033	C0240795
characteristics	T080	C1521970
antibodies	T116	C0003241
epitope	T129	C0003316
HlyE	T116	C2603981
combination	T080	C0205195
phage display	T063	C1519025
bioinformatic	T091	C1140694
analysis	T062	C0936012
predicted	T078	C0681842
function	T169	C0542341
structure	T082	C0678594
antibodies	T116	C0003241
antibodies	T116	C0003241
neutralizing agents	T121	C1254351
typhoid fever	T047	C0041466
Comparison	T052	C1707455
electrospun	T067	C1254366
solvent cast	T067	C1254366
polylactic acid	T109	C0071443
PLA	T109	C0071443
poly(vinyl alcohol)	T122	C0032623
PVA	T122	C0032623
inserts	T122	C0005479
ocular	T023	C0015392
drug delivery vehicles	T122	C0042444
electrospun nanofiber	T073	C1881960
inserts	T122	C0005479
ENIs	T073	C1881960
solvent cast	T067	C1254366
polymeric	T104	C0032521
inserts	T122	C0005479
SCIs	T104	C0032521
ocular	T023	C0015392
drug delivery	T074	C0085104
ENI	T073	C1881960
SCI	T104	C0032521
dexamethasone	T109	C0011777
fabricated	T067	C1254366
blend	T068	C0678946
poly-lactic acid	T109	C0071443
PLA	T109	C0071443
poly-vinyl alcohol	T122	C0032623
PVA	T122	C0032623
Inserts	T122	C0005479
morphology	T080	C0332437
thickness	T080	C1280412
pH	T081	C0020283
drug content	T077	C0456205
drug crystallinity	T080	C0205556
in vitro	T080	C1533691
drug release	T070	C3850077
sterility	T080	C0232920
dimethylformamide	T109	C0012426
DMF	T109	C0012426
chloroform	T109	C0008238
content	T077	C0456205
cytotoxicity	T049	C0596402
thickness	T080	C1280412
dexamethasone	T109	C0011777
ENIs	T073	C1881960
folding endurance	T033	C0518031
SCIs	T104	C0032521
brittle	T033	C3810845
thickness	T080	C1280412
Drug release	T070	C3850077
rates	T081	C1521828
ENIs	T073	C1881960
SCIs	T104	C0032521
DMF	T109	C0012426
content	T077	C0456205
ENIs	T073	C1881960
SCIs	T104	C0032521
chloroform	T109	C0008238
not detected	T033	C0442737
No	T033	C1513916
cytotoxicity	T049	C0596402
ENIs	T073	C1881960
cultured	T025	C0007635
bovine	T015	C3667982
corneal endothelial cells	T025	C0225336
ENIs	T073	C1881960
SCIs	T104	C0032521
delivery system	T074	C0085104
treating	T169	C1522326
anterior segment	T082	C0348014
ocular diseases	T047	C0015397
Quantitative	T081	C0392762
regulation	T038	C1327622
histone variant H2A.Z	T116	C4284633
during	T079	C0347984
cell cycle	T043	C0007586
ubiquitin proteasome system	T044	C1523807
SUMO-targeted ubiquitin ligases	T026	C2247240
Quantitative	T081	C0392762
control	T169	C2587213
histones	T116	C0019652
histone variants	T116	C1529369
during	T079	C0347984
cell cycle	T043	C0007586
relevant	T080	C2347946
epigenetic functions	T043	C1160465
level	T080	C0441889
yeast histone variant H2A.Z	T116	C4284633
G2/M-phase	T043	C3824600
actively	T169	C0205177
ubiquitin proteasome system	T044	C1523807
SUMO-targeted ubiquitin ligases	T026	C2247240
Overexpression	T045	C1514559
H2A.Z	T116	C4284633
induced defects in mitotic progression	T043	C1155864
suggesting	T078	C1705535
functional	T169	C0205245
importance	T080	C3898777
quantitative	T081	C0392762
control	T169	C2587213
Tyrphostin AG-related compounds	T121	C1254351
H2O2	T121	C0020281
induced	T169	C0205263
TRPM2	T116	C1505166
dependent	T080	C0851827
independent	T169	C0332291
cellular	T025	C0007634
responses	T032	C0871261
TRPM2	T116	C1505166
Ca(2+)-permeable channel	T116	C0006685
activated	T052	C1879547
H2O2	T121	C0020281
TRPM2	T116	C1505166
Ca(2+) signaling	T043	C0600431
aggravation	T033	C0541889
inflammatory diseases	T047	C1290884
development	T169	C1527148
TRPM2	T116	C1505166
inhibitors	T121	C0033671
aggravation	T033	C0541889
diseases	T047	C0012634
Tyrphostin AG-related compounds	T121	C1254351
inhibited	T080	C0311403
H2O2	T121	C0020281
induced	T169	C0205263
activation	T052	C1879547
TRPM2	T116	C1505166
scavenging the intracellular hydroxyl radical	T044	C3537124
effects of	T080	C1704420
AG-related compounds	T121	C1254351
H2O2	T121	C0020281
induced	T169	C0205263
cellular	T025	C0007634
responses	T032	C0871261
human	T016	C0086418
monocytic	T025	C0026473
U937 cells	T025	C0600531
functionally	T169	C0205245
express	T045	C1171362
TRPM2	T116	C1505166
effects of	T080	C1704420
AG-related compounds	T121	C1254351
H2O2	T121	C0020281
induced	T169	C0205263
changes	T169	C0392747
intracellular	T082	C0178719
Ca(2+)	T121	C0596235
concentrations	T081	C1446561
extracellular signal-regulated kinase	T116	C0600388
ERK	T116	C0600388
activation	T052	C1879547
CXCL8	T116	C1698756
secretion	T043	C1159339
U937 cells	T025	C0600531
Ca(2+) influxes	T043	C3158761
TRPM2	T116	C1505166
H2O2	T121	C0020281
blocked	T046	C0028778
AG-related compounds	T121	C1254351
AG-related compounds	T121	C1254351
inhibited	T080	C0311403
H2O2	T121	C0020281
induced	T169	C0205263
activation	T052	C1879547
ERK	T116	C0600388
secretion	T043	C1159339
CXCL8	T116	C1698756
TRPM2	T116	C1505166
dependent	T080	C0851827
independent	T169	C0332291
mechanisms	T169	C0441712
AG-related compounds	T121	C1254351
inhibit	T080	C0311403
H2O2	T121	C0020281
induced	T169	C0205263
CXCL8	T116	C1698756
secretion	T043	C1159339
ERK	T116	C0600388
activation	T052	C1879547
TRPM2	T116	C1505166
dependent	T080	C0851827
independent	T169	C0332291
mechanisms	T169	C0441712
U937 cells	T025	C0600531
AG-related compounds	T121	C1254351
blocked	T046	C0028778
H2O2	T121	C0020281
induced	T169	C0205263
TRPM2	T116	C1505166
activation	T052	C1879547
scavenging the hydroxyl radical	T044	C3537124
inhibitory	T052	C3463820
effects	T080	C1280500
AG-related compounds	T121	C1254351
TRPM2	T116	C1505166
independent	T169	C0332291
responses	T032	C0871261
scavenging of the hydroxyl radical	T044	C3537124
Shared decision making	T041	C3179495
UK	T083	C0041700
Shared decision making	T041	C3179495
SDM	T041	C3179495
policy	T170	C0242456
agenda	T170	C0681473
UK	T083	C0041700
legal	T169	C1301860
ruling	T064	C0022424
Policymakers	T097	C0242170
ethicists	T097	C0086267
professional regulators	T097	C1522486
societies	T092	C0037455
patient organisations	T092	C1561598
courts	T092	C0178572
SDM	T041	C3179495
norm	T080	C0205307
NHS	T058	C0027462
economic climate	UnknownType	C0683773
progress	T169	C1280477
years	T079	C0439234
learning	T041	C0023185
demonstration	T054	C0237560
sites	T082	C0205145
initiatives	T041	C0424093
capacity building	T058	C2718026
training	T065	C0220931
patient	T101	C0030705
decision aids	T170	C0086104
leadership	T054	C0023181
initiatives	T041	C0424093
Enthusiasm	T041	C0424090
working	T057	C0043227
clinicians	T097	C0871685
patients	T101	C0030705
managers	T097	C0335141
SDM	T041	C3179495
means	T077	C1704970
cost control	T064	C0010176
Lactate	T109	C0022924
osteoblast differentiation	T043	C1159974
stabilization	T044	C1152620
HIF1α	T116	C0965644
Aerobic glycolysis	T044	C0598754
osteoblast differentiation	T043	C1159974
Wnt signaling	T044	C1520113
PTH	T116	C0030520
treatment	T169	C1522326
lactate	T109	C0022924
aerobic glycolysis	T044	C0598754
osteoblast differentiation	T043	C1159974
cultures	T059	C0007585
osteoblast-lineage cells	T025	C0029418
lactate	T109	C0022924
alkaline phosphatase	T116	C0002059
cell formation	T043	C0007613
activity	T044	C0243102
alkaline phosphatase	T116	C0002059
expression	T045	C1171362
osteocalcin	T116	C0029419
osteoblast differentiation	T043	C1159974
lactate	T109	C0022924
inhibited	T080	C0311403
blocking	T169	C0332206
cells	T025	C0007634
MCT1	T116	C3812715
siRNA	T114	C1099354
inhibitors	T121	C0033671
metabolism	T040	C0025519
siRNAs	T114	C1099354
LDHB	T116	C0022918
PDH	T116	C0034343
lactate	T109	C0022924
HIF1α	T116	C0965644
expression	T045	C1171362
inhibited	T080	C0311403
HIF1α	T116	C0965644
activity	T044	C1537044
BAY87-2243	T121	C0033671
osteoblast differentiation	T043	C1159974
lactate	T109	C0022924
findings	T033	C0243095
aerobic glycolysis	T044	C0598754
osteoblast differentiation	T043	C1159974
lactate	T109	C0022924
Committee	T096	C2699414
Route	T082	C0449444
Hysterectomy	T061	C0020699
Benign	T080	C0205183
Disease	T047	C0012634
Hysterectomy	T061	C0020699
surgical procedures	T061	C0543467
United States	T083	C0041703
Selection	T052	C1707391
route	T082	C0449444
hysterectomy	T061	C0020699
benign	T080	C0205183
size	T082	C0456389
shape	T082	C0332479
vagina	T023	C0042232
uterus	T023	C0042149
uterus	T023	C0042149
extrauterine disease	T047	C0012634
surgeon	T097	C0582175
training	T065	C0220931
experience	T041	C0596545
case volume	T081	C0392762
hospital	T073	C0019994
technology	T058	C0752189
devices	T074	C0025080
patient	T101	C0030705
Vaginal	T061	C0195117
laparoscopic procedures	T061	C0751429
minimally invasive	T169	C2711297
surgical approaches	T169	C0449446
abdominal incision	T061	C0198488
hospitalization	T058	C0019993
postoperative recovery times	T033	C4061108
abdominal hysterectomy	T061	C0404077
Minimally invasive approaches	T169	C2711297
hysterectomy	T061	C0020699
abdominal hysterectomy	T061	C0404077
vaginal approach	T082	C0175672
minimally invasive approaches	T169	C2711297
Laparoscopic hysterectomy	T061	C0404089
abdominal hysterectomy	T061	C0404077
patients	T101	C0030705
vaginal hysterectomy	T061	C0020700
minimally invasive approaches	T169	C2711297
hysterectomy	T061	C0020699
route	T082	C0449444
open	T061	C4283938
abdominal hysterectomy	T061	C0404077
patients	T101	C0030705
obstetrician	T097	C0334897
gynecologist	T097	C0237419
patients	T101	C0030705
route	T082	C0449444
hysterectomy	T061	C0020699
benefits	T081	C0814225
risks	T078	C0035647
approaches	T169	C1292724
hysterectomy	T061	C0020699
patient	T101	C0030705
preferences	T080	C0376409
patient	T101	C0030705
health care provider	T097	C0018724
Measuring	T080	C0444706
nonlinear	T080	C0205556
signal	T067	C1710082
combination	T080	C0205195
EEG	T060	C0013819
Relatively	T080	C0205345
processes	T067	C1522240
linear	T082	C0205132
nonlinear	T080	C0205556
signals	T067	C1710082
combined	T080	C0205195
V1	T029	C0038446
stimulus	T067	C0234402
components	T077	C1705248
simultaneously	T079	C0521115
flickering	T033	C0243095
different	T080	C1705242
temporal frequencies	T079	C0871500
frequency	T081	C0871396
tagging	T074	C0183825
measuring	T080	C0444706
steady-state	T070	C0678587
visual evoked potentials	T042	C0015217
assess	T058	C0184514
responses	T032	C0871261
components	T077	C1705248
direct	T080	C1947931
measurements	T169	C0242485
suppression	T046	C0221103
nonlinear	T080	C0205556
responses	T032	C0871261
combination	T080	C0205195
intermodulation	T080	C0205556
frequencies	T081	C0871396
result	T034	C0456984
dataset	T170	C0150098
frequencies	T081	C0871396
responses	T032	C0871261
pairs	T080	C1709450
sinusoidal gratings	T082	C1254362
different	T080	C1705242
temporal frequencies	T079	C0871500
plaid patterns	T033	C0243095
coherent	T033	C4068804
looking like a checkerboar	T082	C0456340
noncoherent	T033	C0243095
pair	T080	C1709450
transparently	T080	C0522503
overlaid gratings	T082	C0456341
intermodulation	T080	C0205556
responses	T032	C0871261
compound	T080	C0205198
stimuli	T067	C0234402
nonlinear	T080	C0205556
summation	T042	C0234109
cross-orientation	T082	C1704322
suppression	T046	C0221103
pattern	T082	C0449774
intermodulation	T080	C0205556
responses	T032	C0871261
differed	T080	C0205556
coherent	T033	C4068804
noncoherent	T033	C0243095
patterns	T082	C0449774
effects of	T080	C1704420
suppression	T046	C0221103
component	T077	C1705248
frequencies	T081	C0871396
two-stage model	T170	C3161035
nonlinear	T080	C0205556
summation	T042	C0234109
conjunction	T078	C2699427
detection	T061	C1511790
logical	T077	C1705253
AND gate	T170	C0282574
data	T078	C1511726
difference	T081	C1705241
coherent	T033	C4068804
noncoherent	T033	C0243095
plaids	T082	C1254362
array	T082	C1510941
possible	T033	C0332149
response frequencies	T079	C0237629
Multistimulus	T080	C0205556
frequency	T081	C0871396
EEG	T060	C0013819
combination	T080	C0205195
computational modeling	T066	C3850009
conjunction	T078	C2699427
signals	T067	C1710082
study	T062	C2603343
results	T034	C0456984
second-order mechanism	T042	C0597439
selectively	T080	C0205556
coherent	T033	C4068804
plaid patterns	T033	C0243095
Sleep Loss	T033	C0235161
Promotes	T052	C0033414
Astrocytic	T029	C0521395
Phagocytosis	T043	C0031308
Microglial Activation	T043	C1326169
Mouse Cerebral Cortex	T024	C1522579
Mertk	T116	C1259418
ligand Gas6	T116	C1567829
astrocytic	T029	C0521395
genes	T028	C0017337
phagocytosis	T043	C0031308
upregulated	T044	C0041904
after	T079	C0687676
acute	T079	C0205178
sleep deprivation	T033	C0037316
astrocytes	T025	C0004112
phagocytic activity	T043	C0031308
during	T079	C0347984
extended	T082	C0231449
wake	T039	C0442696
direct	T080	C1947931
evidence	T078	C3887511
lacking	T080	C0332268
Studies	T062	C2603343
humans	T016	C0086418
rodents	T015	C0035804
found	T033	C0150312
sleep loss	T033	C0235161
increases	T169	C0442805
peripheral	T082	C0205100
markers	T201	C0005516
inflammation	T046	C0021368
changes	T169	C0392747
associated with	T080	C0332281
neuroinflammation	UnknownType	C0683396
activation	T043	C1326120
microglia	T025	C0206116
brain's	T023	C0006104
innate immune cells	T025	C0312740
unknown	T080	C0439673
used	T169	C1524063
serial block-face scanning electron microscopy	T059	C0026020
volume	T081	C0449468
measurements	T169	C0242485
synapses	T030	C0039062
surrounding	T082	C1282914
astrocytic	T029	C0521395
processes	T038	C3714634
mouse	T015	C0025929
frontal cortex	T023	C0016733
after	T079	C0687676
sleep	T040	C0037313
spontaneous	T169	C0205359
wake	T039	C0442696
sleep deprivation	T033	C0037316
SD	T033	C0037316
after	T079	C0687676
chronic (∼5 d) sleep restriction	T169	C0443288
CSR	T169	C0443288
Astrocytic	T029	C0521395
phagocytosis	T043	C0031308
presynaptic components of large synapses	T026	C1179895
increased	T081	C0205217
after	T079	C0687676
both	T080	C1706086
acute	T079	C0205178
chronic	T079	C0205191
sleep loss	T033	C0235161
relative	T080	C0205345
sleep	T040	C0037313
wake	T039	C0442696
MERTK	T116	C1259417
expression	T045	C1171362
lipid peroxidation	T044	C0023775
synaptoneurosomes	T026	C0039067
increased	T081	C0205217
similar	T080	C2348205
extent	T082	C0439792
after	T079	C0687676
short	T081	C1806781
long	T080	C0205166
sleep loss	T033	C0235161
astrocytic	T029	C0521395
phagocytosis	T043	C0031308
represent	T052	C1882932
brain's	T023	C0006104
response	T032	C0871261
increase	T169	C0442805
synaptic activity	T043	C0027793
associated with	T080	C0332281
prolonged	T079	C0439590
wake	T039	C0442696
clearing	T080	C2963144
used	T169	C1524063
synapses	T030	C0039062
Using	T169	C1524063
confocal microscopy	T059	C0242842
found	T033	C0150312
CSR	T169	C0443288
not	T169	C1518422
SD	T033	C0037316
mice	T015	C0025929
morphological	T082	C0543482
signs	T184	C0037088
microglial activation	T043	C1326169
enhanced	T052	C2349975
microglial	T029	C0521398
phagocytosis	T043	C0031308
synaptic elements	T026	C3893360
without	T080	C0332288
signs	T184	C0037088
neuroinflammation	UnknownType	C0683396
CSF	T031	C0007806
low	T080	C0205251
level	T080	C0441889
sustained	T169	C0443318
microglia activation	T043	C1326169
abnormal	T033	C0205161
responses	T032	C0871261
secondary	T080	C0175668
insult	T037	C0598698
results	T169	C1274040
suggest	T078	C1705535
chronic	T079	C0205191
sleep loss	T033	C0235161
through	T169	C0332273
microglia	T025	C0206116
priming	T043	C0007613
brain	T023	C0006104
further	T082	C1517331
damage	T169	C1883709
find	T033	C0243095
astrocytic	T029	C0521395
phagocytosis	T043	C0031308
synaptic elements	T026	C3893360
presynaptic origin	T026	C3893360
large	T081	C0549177
synapses	T030	C0039062
upregulated	T044	C0041904
after	T079	C0687676
few	T081	C0205388
hours	T079	C0439227
sleep deprivation	T033	C0037316
further	T082	C1517331
significant	T078	C0750502
increase	T169	C0442805
after	T079	C0687676
prolonged	T079	C0439590
severe	T080	C0205082
sleep loss	T033	C0235161
promote	T052	C0033414
housekeeping	T057	C0020053
used	T169	C1524063
strong	T080	C0442821
synapses	T030	C0039062
response	T032	C0871261
increased	T081	C0205217
neuronal	T025	C0027882
activity	T043	C0007613
extended	T082	C0231449
wake	T039	C0442696
contrast	T080	C1979874
chronic sleep restriction	T169	C0443288
not	T169	C1518422
acute	T079	C0205178
sleep loss	T033	C0235161
activates	T043	C1326120
microglia	T025	C0206116
promotes	T052	C0033414
phagocytic activity	T043	C0031308
absence	T169	C0332197
signs	T184	C0037088
neuroinflammation	UnknownType	C0683396
other	T080	C0205394
stressors	T078	C0597530
extended	T082	C0231449
sleep disruption	T033	C1821308
state	T169	C1442792
sustained	T169	C0443318
microglia activation	T043	C1326169
increasing	T169	C0442808
brain's	T023	C0006104
susceptibility	T169	C1264642
other	T080	C0205394
forms	T169	C1522492
damage	T169	C1883709
Reflections	T062	C2603343
Hip Fracture Recovery	T061	C0744924
Older Adults	T098	C0001792
Clinical Trial	T062	C0008976
study	T062	C2603343
patients'	T101	C0030705
perspectives	UnknownType	C0678958
recovery	T052	C0237820
participation	T169	C0679823
randomized controlled trial	T062	C0206035
tested	T170	C0392366
postoperative	T079	C0032790
hip fracture	T037	C0019557
management program	T169	C0039798
B4 Clinic	T073	C0442592
compared	T052	C1707455
usual care	T058	C0511425
mobility	T080	C0449580
Semistructured	T082	C0678594
qualitative	T080	C0205556
interviews	T052	C0021822
older adults	T098	C0001792
hip fracture	T037	C0019557
groups	T098	C1257890
total	T080	C0439810
women	T098	C0043210
men	T098	C0025266
participated	T169	C0679823
study	T062	C2603343
mean	T081	C0444504
age	T032	C0001779
baseline	T081	C1442488
range	T081	C1514721
total	T080	C0439810
participants	T098	C0679646
reported	T058	C0700287
recovery	T052	C0237820
goals	T170	C0018017
recovery	T052	C0237820
hip fracture	T037	C0019557
participants	T098	C0679646
realized	T078	C4304473
goals	T170	C0018017
Recovering	T040	C2004454
mobility	T080	C0449580
returning	T080	C0332156
prefracture activities	T052	C0441655
obtaining	T169	C1301820
stable	T080	C0205360
health	T078	C0018684
most	T081	C0205393
commonly	T081	C0205214
reported	T058	C0700287
goals	T170	C0018017
Participants	T098	C0679646
good	T080	C0205170
social support	T058	C1540833
access	T082	C0444454
physiotherapy	T061	C0949766
positive	T033	C1446409
perspective	UnknownType	C0678958
most	T081	C0205393
important	T080	C3898777
recovery	T052	C0237820
factors	T169	C1521761
influenced	T077	C4054723
participants	T098	C0679646
knowledge	T170	C0376554
resources	T078	C0035201
contact	T078	C1705415
study	T062	C2603343
staff	T097	C0851286
perceived	T041	C0030971
social support	T058	C1540833
most	T081	C0205393
frequently	T079	C0332183
reported	T058	C0700287
barriers	T080	C0679881
participants	T098	C0679646
recovery	T052	C0237820
onset of	T080	C0332162
complications	T046	C0009566
pain	T184	C0030193
limited access	T033	C1948144
physiotherapy	T061	C0949766
Potential	T080	C3245505
implications	T078	C0392360
findings	T033	C0243095
include	T052	C2700399
design	T052	C1707689
modification	T033	C3840684
preexisting	T080	C2347662
fracture	T037	C0016658
programs	T169	C3484370
prioritizing	T079	C0549179
patient engagement	T058	C0030675
enhanced	T052	C2349975
knowledge	T170	C0376554
future	T079	C0016884
clinical research	T062	C0008972
hip fracture recovery	T061	C0744924
learn	T041	C0023185
Physical activity	T056	C0026606
improves	T033	C0184511
learning	T041	C0023185
second language	T033	C0557074
studies	T062	C2603343
concurrent	T079	C0205420
physical activity	T056	C0026606
enhances	T052	C2349975
learning	T041	C0023185
L2	T033	C0557074
vocabulary	T170	C0042926
learning	T041	C0023185
static	T080	C0441463
condition	T080	C0348080
study	T062	C2603343
possible	T033	C0332149
positive	T033	C1446409
effects of	T080	C1704420
physical activity	T056	C0026606
L2	T033	C0557074
learning	T041	C0023185
level	T080	C0441889
proficiency	T080	C0678997
better	T080	C0332272
performance	T052	C1882330
physical activity	T056	C0026606
linguistic	T090	C0023741
level	T080	C0441889
training	T080	C2673163
L2	T033	C0557074
vocabulary	T170	C0042926
tested	T169	C0039593
Word-Picture Verification task	T062	C0242481
sentence	T170	C0876929
level	T080	C0441889
tested	T169	C0039593
Sentence Semantic Judgment Task	T062	C0242481
Chinese speakers	T098	C0152035
basic knowledge	T033	C4036283
English	T171	C0376245
benefited	T081	C0814225
physical activity	T056	C0026606
learning	T041	C0023185
words	T170	C0042926
better	T080	C0332272
performance	T052	C1882330
sentential	T170	C0876929
level,	T080	C0441889
performance	T052	C1882330
Semantic Judgment task	T062	C0242481
lexical	T078	C1705313
sentential	T170	C0876929
level	T080	C0441889
experimental	T078	C0441833
control group	T096	C0009932
testing session	T051	C1883016
lexical	T078	C1705313
level	T080	C0441889
sentential	T170	C0876929
level	T080	C0441889
added	T169	C1524062
value	T081	C1522609
cardiac index	T033	C0428776
pulse pressure	T040	C0949236
variation	T080	C0205419
monitoring	T058	C1283169
mean arterial pressure	T033	C0428886
guided volume therapy	T061	C0087111
moderate-risk abdominal surgery	T061	C2066139
COGUIDE	T061	C0087111
pragmatic	T062	C3658312
multicentre	T062	C0206012
randomised controlled trial	T062	C0206035
disagreement	UnknownType	C0681800
benefits	T081	C0814225
goal-directed therapy	T061	C1271494
moderate-risk abdominal surgery	T061	C2066139
tested	T170	C0392366
hypothesis	T078	C1512571
addition	T169	C0332287
non-invasive	T169	C0205303
cardiac index	T033	C0428776
pulse pressure	T040	C0949236
variation	T080	C0205419
monitoring	T058	C1283169
mean arterial pressure	T033	C0428886
goal-directed therapy	T061	C1271494
reduce	T080	C0392756
incidence	T081	C0021149
postoperative complications	T046	C0032787
patients	T101	C0030705
moderate-risk abdominal surgery	T061	C2066139
pragmatic	T062	C3658312
multicentre	T062	C0206012
randomised controlled trial	T062	C0206035
randomly allocated	T062	C0034656
patients	T101	C0030705
envelope drawing	T170	C0013113
stratified	T080	C0205363
patients	T101	C0030705
mean arterial pressure	T033	C0428886
cardiac index	T033	C0428776
pulse pressure	T040	C0949236
variation	T080	C0205419
measured	T080	C0444706
continuously	T078	C0549178
group	T078	C0441833
healthcare professionals	T097	C0018724
blinded	T062	C0150108
cardiac index	T033	C0428776
pulse pressure	T040	C0949236
variation	T080	C0205419
values	T081	C1522609
haemodynamic therapy	T061	C0087111
mean arterial pressure	T033	C0428886
control group	T096	C0009932
group	T078	C0441833
cardiac index	T033	C0428776
pulse pressure	T040	C0949236
variation	T080	C0205419
values	T081	C1522609
displayed	T169	C0870432
target	T169	C1521840
ranges	T081	C1514721
pre-defined algorithm	T170	C0002045
CI-PPV group	T078	C0441833
primary endpoint	T130	C2986535
incidence	T081	C0021149
postoperative complications	T046	C0032787
within 30 days	T033	C3845590
patients	T101	C0030705
eligible	T080	C1548635
final	T079	C3853528
analysis	T062	C0936012
Overall	T080	C1561607
complication rates	T046	C0009566
control	T096	C0009932
CI-PPV groups	T078	C0441833
CI-PPV group	T078	C0441833
lower	T080	C0205251
mean	T081	C0444504
SD	T081	C0871420
pulse pressure	T040	C0949236
variation	T080	C0205419
values	T081	C1522609
higher	T080	C0205250
mean	T081	C0444504
SD	T081	C0871420
cardiac indices	T033	C0428776
control group	T096	C0009932
moderate-risk abdominal surgery	T061	C2066139
observed	T169	C1441672
additional value	T170	C0439062
cardiac index	T033	C0428776
pulse pressure	T040	C0949236
variation	T080	C0205419
guided haemodynamic therapy	T061	C0087111
mean arterial pressure	T033	C0428886
guided volume therapy	T061	C0087111
postoperative complications	T046	C0032787
Anterior single implants	T074	C0376511
neck	T082	C1254362
designs	T052	C1707689
Year	T079	C0439234
randomized clinical trial	T062	C0206034
design	T052	C1707689
implant neck	T074	C0376511
preservation	T059	C1514402
marginal	T082	C0205284
bone	T024	C0005931
5-year	T079	C0439234
radiographic	T070	C0444708
clinical	T080	C0205210
outcome	T169	C1274040
single anterior implants	T074	C0376511
smooth	T080	C0205357
smooth neck	T082	C1254362
rough neck	T082	C1254362
rough neck	T082	C1254362
Patients	T101	C0030705
anterior	T082	C0205094
tooth	T023	C0040426
maxilla	T023	C0024947
patients	T101	C0030705
implant	T074	C0376511
smooth	T080	C0205357
neck	T082	C1254362
smooth group	T078	C0441833
rough neck	T082	C1254362
rough group	T078	C0441833
rough neck	T082	C1254362
scalloped group	T078	C0441833
Implants	T074	C0376511
healed sites	T029	C1515974
Follow-up visits	T058	C0589121
crown delivery	T169	C1705822
year	T079	C0439234
years	T079	C0439234
implants	T074	C0376511
marginal	T082	C0205284
bone resorption	T042	C0005974
bone loss	T042	C0005974
smooth group	T078	C0441833
rough group	T078	C0441833
scalloped group	T078	C0441833
Survival rates	T081	C0038954
smooth	T078	C0441833
scalloped group	T078	C0441833
rough group	T078	C0441833
implants	T074	C0376511
deeper pocket depths	T082	C0205125
bleeding	T046	C0019080
complications	T078	C2362589
esthetic outcome	T169	C1274040
patient satisfaction	T080	C0030702
anterior	T082	C0205094
tooth replacements	T042	C3893426
implants	T074	C0376511
radiographic	T070	C0444708
clinical	T080	C0205210
outcome	T169	C1274040
implants	T074	C0376511
smooth	T080	C0205357
neck	T082	C1254362
rough neck	T082	C1254362
Recessive mutations	T045	C0026882
MSTO1	T116	C1957185
mitochondrial dynamics	T043	C3494415
impairment	T169	C0221099
myopathy	T047	C0026848
ataxia	T184	C0004134
families	T099	C0015576
variants	T080	C0205419
MSTO1 gene	T028	C1826310
compound heterozygous	T033	C4264438
mutations	T045	C0026882
mutations	T045	C0026882
identified	T080	C0205396
sisters	T099	C0337514
unrelated	T033	C0445356
singleton	T099	C1313913
presented	T078	C0449450
complex	T080	C0439855
phenotype	T032	C0031437
characterized	T052	C1880022
myopathy	T047	C0026848
cerebellar ataxia	T184	C0007758
Human MSTO1	T116	C1957185
suggested	T078	C1705535
mitochondrial localization	T038	C1657244
regulate	T038	C1327622
morphology	T080	C0332437
distribution of mitochondria	T043	C1522855
mutations	T045	C0026882
affecting	T169	C0392760
genes	T028	C0017337
mitochondrial dynamics	T043	C3494415
biochemical	T169	C0205474
defects	T169	C0243067
mitochondrial disorders	T047	C0751651
reported	T058	C0700287
patients	T101	C0030705
fibroblasts	T025	C0016030
revealed	T080	C0443289
MSTO1 protein	T116	C1957185
levels	T080	C0441889
reduced	T080	C0392756
mitochondrial network was fragmented	T033	C3809602
fusion	T169	C0332466
mitochondria	T026	C0026237
decreased	T081	C0205216
deleterious effect	T049	C2985436
identified	T080	C0205396
variants	T080	C0205419
MSTO1	T116	C1957185
modulating	T082	C0443264
mitochondrial dynamics	T043	C3494415
cytosolic protein	T116	C0033684
recessive mutations	T045	C0026882
MSTO1	T116	C1957185
inherited	T169	C0439660
neuromuscular disorders	T047	C0027868
bird	T012	C0005595
passive air sampler	T074	C0178984
monitoring	T058	C1283169
halogenated flame retardants	T120	C0016198
Birds	T012	C0005595
biomonitors	T074	C0025080
halogenated flame retardants	T120	C0016198
HFRs	T120	C0016198
studies	T062	C2603343
tissue	T024	C0040300
concentrations	T081	C1446561
individual	T098	C0237401
variability	T077	C2827666
contaminants	T167	C2827365
diet	T168	C0012155
exposure	T080	C0332157
pathway	T077	C1705987
HFRs	T120	C0016198
birds	T012	C0005595
suggested	T078	C1705535
exposure	T080	C0332157
air	T167	C0001861
represent	T052	C1882932
source	T033	C0449416
HFRs	T120	C0016198
species	T185	C1705920
method	T170	C0025663
not available	T080	C0686905
measuring	T080	C0444706
atmospheric	T070	C0004178
exposure	T080	C0332157
individual	T098	C0237401
birds	T012	C0005595
HFRs	T120	C0016198
semi-volatile	T080	C1963547
contaminants	T167	C2827365
goal	T170	C0018017
study	T062	C2603343
bird	T012	C0005595
passive air sampler	T074	C0178984
PAS	T074	C0178984
determination	T059	C1148554
individual	T098	C0237401
atmospheric	T070	C0004178
exposure	T080	C0332157
gas	T104	C0017110
particle-phase	T104	C0597177
HFRs	T120	C0016198
ring-billed gull	T012	C1061035
Larus delawarensis	T012	C1061035
nesting	T053	C0870949
Montreal area	UnknownType	C0681784
QC	T083	C0034390
Canada	T083	C0006823
elliptical-shaped	T082	C1947977
PAS	T074	C0178984
mean weight	T081	C0043100
tested	T169	C0039593
two sorbent types	T059	C0022885
exposure periods	T079	C2826764
Results	T169	C1274040
PAS	T074	C0178984
polyurethane foam	T109	C0071696
PUF	T109	C0071696
glass fiber	T122	C0060317
filter collected	UnknownType	C0545227
polybrominated diphenyl ethers	T109	C2350562
PBDEs	T109	C2350562
better performance	T052	C1882330
collecting	T169	C1516698
highly hydrophobic	T080	C0598629
DecaBDE	T109	C2350562
mixture	T167	C0439962
congeners	T104	C0678518
compared to	T052	C1707455
PAS	T074	C0178984
polydimethylsiloxane	T109	C0137758
PDMS	T109	C0137758
HFRs	T120	C0016198
hexabromobenzene	T109	C0062598
Dechlorane 604 Component B	T109	C3180256
Dechlorane plus	T109	C2351195
DP	T109	C2351195
isomers	T070	C0022203
sampled	T060	C0441621
PUF	T109	C0071696
PAS	T074	C0178984
Sampling	T060	C0441621
rates	T081	C1521828
HFRs	T120	C0016198
comparable	T052	C1707455
exposure periods	T079	C2826764
bird	T012	C0005595
PAS	T074	C0178984
valuable information	T078	C1533716
non-dietary exposure	T080	C0332157
free-ranging	T033	C3845292
birds	T012	C0005595
HFRs	T120	C0016198
Post	T079	C0032790
endodontic pain	T184	C0030193
root canal preparation	T061	C0282543
rotary	T074	C0011377
reciprocating instruments	T074	C0011377
meta-analysis	T062	C0920317
randomized clinical trials	T062	C0206034
endodontic therapy	T061	C0035849
rotary instrumentation	UnknownType	C0587378
debris	T167	C0440266
reciprocal instrumentation	UnknownType	C0587378
incidence	T081	C0021149
post-endodontic pain	T184	C0030193
PP	T184	C0030193
study	T062	C2603343
PP	T184	C0030193
incidence	T081	C0021149
rotary	T074	C0011377
reciprocal instruments	T074	C0011377
meta-analysis	T062	C0920317
Pubmed	T170	C1138432
EM databases	T170	C0242356
clinical randomized trials	T062	C0206034
root canal preparation	T061	C0282543
instrumentation	UnknownType	C0587378
treatment	T061	C0087111
therapy	T061	C0087111
post-operative	T079	C0032790
endodontic pain	T184	C0030193
reciprocal	T074	C0011377
rotary instruments	T074	C0011377
studies	T062	C2603343
patients	T101	C0030705
reciprocating instruments	T074	C0011377
rotary instruments	T074	C0011377
PP	T184	C0030193
patients	T101	C0030705
reciprocating group	T098	C1257890
rotary group	T098	C1257890
PP	T184	C0030193
incidence	T081	C0021149
confidence interval	T081	C0009667
CI	T081	C0009667
rotary instruments	T074	C0011377
mild	T080	C2945599
moderate	T080	C0205081
severe	T080	C0205082
PP	T184	C0030193
Rotary instrument	T074	C0011377
endodontic therapy	T061	C0035849
associated with	T080	C0332281
incidence	T081	C0021149
PP	T184	C0030193
reciprocating instruments	T074	C0011377
reciprocating instruments	T074	C0011377
associated with	T080	C0332281
PP	T184	C0030193
incidence	T081	C0021149
resistance	T039	C1514892
profiling	T169	C2003903
Plasmodium falciparum	T204	C0032150
Plasmodium falciparum infections	T046	C3714514
custom dual indexing	T062	C0017395
Illumina next generation sequencing-technology	T062	C0017395
Genetic polymorphisms	T045	C0032529
P. falciparum	T204	C0032150
parasite's	T204	C0030498
susceptibility	T033	C0243095
antimalarial drugs	T121	C0003374
geographical origin	T082	C0565935
monitoring	T058	C1283169
development	T169	C1527148
spread	T080	C0332261
antimalarial	T121	C0003374
antimalarial drug resistance	T038	C0013203
multiplex PCR	T059	C2732533
custom designed dual indexing	T062	C0017395
Miseq	T170	C3898361
sequencing	T059	C1294197
SNP	T086	C0752046
profiling	T169	C2003903
malaria	T047	C0024530
infections	T046	C3714514
Guinea-Bissau	T083	C0018387
cost	T081	C0010186
amplifying	T045	C0017256
sequencing	T059	C1294197
genetic	T169	C0314603
fragments	T080	C1708096
resistance	T039	C1514892
SNPs	T086	C0752046
pfcrt	T028	C0017337
pfmdr1	T028	C0017337
pfdhfr	T028	C0017337
pfdhps	T028	C0017337
length	T081	C1444754
pfK13	T028	C0017337
mitochondrial	T026	C0026237
barcode	T170	C0004738
parasite	T204	C0030498
origin	T033	C0584985
SNPs	T086	C0752046
average	T081	C1510992
SNP	T086	C0752046
positions	T082	C0733755
SNP	T086	C0752046
artemisinin	T109	C0052430
artemisinin resistance	T038	C0013203
SNPs	T086	C0752046
pfK13	T028	C0017337
absent	T169	C0332197
Guinea-Bissau	T083	C0018387
pfmdr1	T028	C0017337
prevalence	T081	C0220900
mitochondrial	T026	C0026237
barcodes	T170	C0004738
West African	T098	C0238606
West African origin	T033	C0584985
parasites	T204	C0030498
method	T170	C0025663
reliable	T170	C3858758
surveillance	T061	C0038842
antimalarial	T121	C0003374
antimalarial drug resistance	T038	C0013203
systematic review	T170	C1955832
investigating	T169	C1292732
psychosocial aspects	T078	C0243156
egg sharing	T061	C4053456
United Kingdom	T083	C0041700
potential	T080	C3245505
effects	T080	C1280500
egg donation	T061	C4053456
numbers	T081	C0237753
review	T170	C0282443
knowledge	T170	C0376554
psychosocial aspects	T078	C0243156
egg donation	T061	C4053456
egg share donor	T098	C0029975
recipient	T098	C1709854
motives	UnknownType	C0869035
experiences	T041	C0596545
attitudes	T041	C0004271
egg sharers	T098	C0029975
donor	T098	C0029975
anonymity	T078	C0871649
disclosure	T055	C0012625
Conclusions	T078	C1707478
findings	T033	C0243095
guide clinical practice	T170	C0282451
egg sharing	T061	C4053456
numbers	T081	C0237753
systematic	T169	C0220922
search	T052	C1706202
peer-reviewed journals	T170	C2985503
computerized databases	T170	C0871696
studies	T062	C2603343
review	T170	C0282443
Psychosocial aspects	T078	C0243156
donation	T061	C4053456
positive	T033	C1446409
egg share donor	T098	C0029975
recipient	T098	C1709854
Concerns	T078	C2699424
raised	T080	C0442818
participating	T169	C0679823
egg sharing	T061	C4053456
scheme	T170	C1519193
impact	T080	C4049986
success	T080	C0679864
rates	T081	C1521828
frustration	T041	C0016770
expressed	T078	C1551042
minority	T098	C0026192
lack of knowledge	T033	C1998986
egg sharing	T061	C4053456
fertility	T040	C0015895
clinics	T073	C0442592
legislative	T170	C2937257
changes	T169	C0392747
UK	T083	C0041700
decrease	T081	C0547047
egg donation	T061	C4053456
oocyte donation	T061	C0242813
demand	T061	C0441516
Egg sharing	T061	C4053456
practical option	T169	C1518601
patients	T101	C0030705
access	T169	C1554204
IVF	T061	C0015915
donor oocytes	T098	C3267027
information provision	UnknownType	C0681319
result	T169	C1274040
awareness	T041	C0004448
egg sharing	T061	C4053456
potential	T080	C3245505
recruit	T052	C2949735
meet	T067	C1550543
recipients	T098	C1709854
currently	T079	C0521116
waiting lists	T170	C0043010
Medication regimen	T061	C0237125
complexity	T078	C0237522
prevalence	T081	C0033105
potentially inappropriate medicines	T080	C4042848
older	T098	C0001792
patients	T101	C0030705
hospitalisation	T058	C0019993
relative	T080	C0205345
information	T078	C1533716
potential	T080	C3245505
changes	T169	C0392747
medication regimen	T061	C0237125
complexity	T078	C0237522
prevalence	T081	C0033105
prescribing	T058	C2239117
potentially inappropriate medications	T080	C4042848
hospitalisation	T058	C0019993
Australia	T083	C0004340
Objective	T170	C0018017
evaluate	T058	C0220825
medication regimen	T061	C0237125
complexity	T078	C0237522
prevalence	T081	C0033105
potentially inappropriate medications	T080	C4042848
before	T079	C0332152
admission to hospital	T058	C0184666
General medical units	T093	C1708333
tertiary care hospital	T073	C0337954
Australia	T083	C0004340
Retrospective cohort study	T062	C2985505
patients	T101	C0030705
aged	T032	C0001779
Medication	T058	C2081612
complexity	T078	C0237522
measured	T080	C0444706
Medication Regimen Complexity Index	T170	C0282574
MRCI	T170	C0282574
Main outcome measure	T080	C3274433
primary outcome	T080	C3274433
change	T169	C0392747
Medication Regimen Complexity Index	T170	C0282574
prescribed medications	T121	C3166216
hospitalization	T058	C0019993
Results	T034	C0456984
convenience sample	T062	C0150095
patients	T101	C0030705
included	T169	C0332257
study	T062	C2603343
significant	T078	C0750502
change	T169	C0392747
mean	T081	C0444504
medication	T058	C2081612
complexity	T078	C0237522
score	T081	C0449820
measured	T080	C0444706
MRCI	T170	C0282574
increasing	T081	C0205217
time of admission	T079	C3854259
time of discharge	T079	C3864299
Factors	T169	C1521761
baseline	T081	C1442488
medication regimen	T061	C0237125
complexity	T078	C0237522
pre-admission	T079	C0559269
MRCI	T170	C0282574
length of stay in the hospitals	T079	C0023303
appear	T080	C0700364
influence	T077	C4054723
change	T169	C0392747
medication	T058	C2081612
complexity	T078	C0237522
proportion	T081	C1709707
patients	T101	C0030705
prescribed	T058	C0278329
potentially inappropriate medicine	T080	C4042848
PIM	T080	C4042848
decreased significantly	T081	C4055638
pre-hospitalization	T058	C0019993
at discharge	T079	C3871203
Relative	T080	C0205345
time of admission	T079	C3854259
overall	T080	C1561607
medication	T058	C2081612
complexity	T078	C0237522
increased	T081	C0205217
proportion	T081	C1709707
patients	T101	C0030705
prescribed	T058	C0278329
PIMs	T080	C4042848
decreased	T081	C0205216
hospitalisation	T058	C0019993
